{"id": "8908396_3", "context": "To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["tumor necrosis factor (TNF)-alpha"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["TNF-alpha"]], "entity_id": [["T1"]] , "Trigger": { "text": [["may mediate"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["may mediate"]], "entity_id": [["T2"]] }, "Disorder": { "text": [["the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies"]], "entity_id": [["T3"]] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Drug": null } , "Subject": { "text": [["a diabetic patient who presented extensive lesions"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["a diabetic patient who presented extensive lesions"]], "entity_id": [["T4"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["diabetic"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["diabetic"]], "entity_id": [["T5"]] } } , "Negated": null, "Speculated": null, "Severity": null , "Effect": { "text": [["the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies"]], "entity_id": [["T3"]] } , "Trigger": { "text": [["may mediate"]], "start": [["To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions."], ["may mediate"]], "entity_id": [["T2"]] }}]}
{"id": "10891991_1","context": "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["evaluation"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["valproate"]],"start": [[ "55" ]],"entity_id": [ ],"Disorder": {"text": [["epilepsy"]],"start": [[ "32" ]],"entity_id": [ ]},"Dosage": {"text": [["being treated"]],"start": [[ "44" ]],"entity_id": [ ]},"Route": {"text": [["treated"]],"start": [[ "44" ]],"entity_id": [ ]},"Duration": {"text": [["treated"]],"start": [[ "44" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["during treatment"]],"start": [[ "79" ]],"entity_id": [ ]},"Freq": {"text": [["during treatment"]],"start": [[ "79" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["valproate"]],"start": [[ "55" ]],"entity_id": [ ]},"Trigger": {"text": [["treated"]],"start": [[ "44" ]],"entity_id": [ ]},"event_id": "C1","event_type": "null"} ],"Trigger": {"text": [["menstrual cycle disturbances"]],"start": [[ "109" ]],"entity_id": [ ]},"Drug": {"text": [["valproate"]],"start": [[ "55" ]],"entity_id": [ ]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Subject": {"text": [["women"]],"start": [[ "19" ]],"entity_id": [ ],"Age": {"text": [["reproductive age"]],"start": [[ "25" ]],"entity_id": [ ]},"Gender": {"text": [["women"]],"start": [[ "19" ]],"entity_id": [ ]},"Disorder": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["evaluation"]],"start": [[ "0" ]],"entity_id": []}} ]}
{"id": "2332596_1","context": "Phenobarbital hepatotoxicity in an 8-month-old infant","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Phenobarbital"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Phenobarbital"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["8-month-old"]],"start": [["9"]],"entity_id": [["T2"]]},"Dosage": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Route": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Freq": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Combination": null,"Trigger": null},"Subject": {"text": [["an"]],"start": [["6"]],"entity_id": [["T3"]],"Age": {"text": [["8-month-old"]],"start": [["9"]],"entity_id": [["T2"]]},"Gender": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Population": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]},"Disorder": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]]}},"Negated": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[ "null" ]],"entity_id": [["null"]],"value": false},"Severity": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "12552054_1", "context": "The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Balint syndrome"]], "start": [["0"]], "entity_id": [["T1"]]},"Treatment": {"text": [["intrathecal methotrexate and cytarabine"]],"start": [["81"]],"entity_id": [["T3"]],"Drug": {"text": [["methotrexate", "cytarabine"]],"start": [["81", "95"]],"entity_id": [["T4", "T5"]]} ,"Disorder": {"text": [["Balint syndrome"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["79"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["following"]],"start": [["79"]],"entity_id": [["T2"]]} ,"Combination": [{"event_id": "C1", "Drug": {"text": [["methotrexate"]], "start": [["81"]], "entity_id": [["T4"]]}, "Trigger": {"text": [["intrathecal"]], "start": [["81"]], "entity_id": [["T3"]]}, "event_type": "Treatment"}] ,"Trigger": {"text": [["Balint syndrome"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["intrathecal"]],"start": [["81"]],"entity_id": [["T3"]]} ,"Route": {"text": [["intrathecal"]],"start": [["81"]],"entity_id": [["T3"]]} ,"Duration": {"text": [[]],"start": [[], [], []],"entity_id": [[]]}} ,"Effect": {"text": [["irreversible posterior leukoencephalopathy"]],"start": [["42"]],"entity_id": [["T6"]]},"Negated": {"text": [[]],"start": [[], [], []],"entity_id": [[]] ,"value": false},"Speculated": {"text": [[]],"start": [[], [], []],"entity_id": [[]] ,"value": false} ,"Severity": {"text": [["irreversible"]],"start": [["42"]],"entity_id": [["T6"]],"value": "high"} ,"Subject": {"text": [[]],"start": [[], [], []],"entity_id": [[]],"Age": {"text": [[]],"start": [[], [], []],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[], [], []],"entity_id": [[]]},"Race": {"text": [[]],"start": [[], [], []],"entity_id": [[]]},"Disorder": {"text": [["Balint syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Population": {"text": [[]],"start": [[], [], []],"entity_id": [[]]} }}]}
{"id": "8002140_2", "context": "Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]}, "Treatment": {"text": [["budesonide"]], "start": [[ "38" ]], "entity_id": [ ], "Drug": {"text": [["budesonide"]], "start": [[ "38" ]], "entity_id": [ ]} ,"Disorder": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]} ,"Time_elapsed": {"text": [["report of five cases"]], "start": [[ "41" ]], "entity_id": [ ]} ,"Freq": {"text": [["review of the Japanese literature"]], "start": [[ "66" ]], "entity_id": [ ]} ,"Trigger": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]} ,"Route": {"text": [["topical"]], "start": [[ "15" ]], "entity_id": [ ]} ,"Dosage": {"text": [["0.05-0.1%"]], "start": [[ "41" ]], "entity_id": [ ]} ,"Duration": {"text": [["chronic use"]], "start": [[ "66" ]], "entity_id": [ ]} ,"Combination": [ {"Drug": {"text": [["budesonide"]], "start": [[ "38" ]], "entity_id": [ ]} ,"Trigger": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]} ,"event_id": "C1" ,"event_type": "Adverse_event" } ] } , "Effect": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]} , "Subject": {"Age": null, "Disorder": {"text": [["Contact dermatitis"]], "start": [[ "0" ]], "entity_id": [ ]} ,"Gender": null ,"Population": null ,"Race": null ,"text": [["report of five cases"]], "start": [[ "41" ]], "entity_id": [ ]} ,"Negated": null ,"Speculated": null ,"Severity": null } ]}
{"id": "8586895_3","context": "Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Prolongation of the QT interval"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["a Japanese patient"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ],"Age": null,"Gender": {"text": [["Japanese"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ]},"Population": null,"Race": {"text": [["Japanese"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ]},"Disorder": {"text": [["vivax malaria"]],"start": [[ "40" ]],"entity_id": [ ["T3"] ]}},"Treatment": {"text": [["treatment with halofantrine"]],"start": [[ "63" ]],"entity_id": [ ["T4"] ],"Drug": {"text": [["halofantrine"]],"start": [[ "63" ]],"entity_id": [ ["T5"] ]},"Dosage": null,"Duration": null,"Disorder": {"text": [["vivax malaria"]],"start": [[ "40" ]],"entity_id": [ ["T3"] ]},"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [["Prolongation of the QT interval"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"value": "medium"} ,"Effect": {"text": [["Prolongation of the QT interval"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}}]}
{"id": "7776854_3","context": "We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Effect": {"text": [["severe hepatotoxicity"]],"start": [["18"]],"entity_id": [["E1_Effect"]]},"Treatment": {"text": [["benzarone"]],"start": [["54"]],"entity_id": [["E1_Treatment"]],"Drug": {"text": [["benzarone"]],"start": [["54"]],"entity_id": [["E1_Drug"]]},"Disorder": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [["E1_Disorder"]]},"Dosage": {"text": [["three cases"]],"start": [["7"]],"entity_id": [["E1_Dosage"]]},"Freq": {"text": [["three cases"]],"start": [["7"]],"entity_id": [["E1_Freq"]]},"Time_elapsed": {"text": [["related"]],"start": [["27"]],"entity_id": [["E1_Time_elapsed"]]},"Trigger": {"text": [["report"]],"start": [["0"]],"entity_id": [["E1_Trigger"]]},"Combination": null,"Route": null,"Duration": null},"Subject": null,"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["E1_Severity"]],"value": "severe"},"Negated": null,"Speculated": null,"Trigger": null}]}
{"id": "8024670_1","context": "Four patients who manifested symptoms of the antiepileptic drug (AED) hypersensitivity syndrome during therapy with carbamazepine are reported","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["antiepileptic drug (AED) hypersensitivity syndrome"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Subject": {"text": [["Four patients"]],"start": [["0"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["carbamazepine"]],"start": [["78", "79"]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"]],"start": [["78", "79"]],"entity_id": [["T2"]]},"Disorder": {"text": [["AED hypersensitivity syndrome"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null }]}
{"id": "11026106_1", "context": "Minocycline as a cause of drug-induced autoimmune hepatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["drug-induced autoimmune hepatitis"]], "start": [["28"]], "entity_id": []}, "Treatment": {"text": [["Minocycline"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Minocycline"]], "start": [["0"]], "entity_id": []},"Disorder": {"text": [["autoimmune hepatitis"]], "start": [["28"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null}, "Effect": null, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{ "id": "19434733_1", "context": "Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Adverse_event", "Trigger": { "text": [["secondary acute myeloid leukemia"]], "start": [[ "0" ]] , "entity_id": [ ["T1"] ] }, "Treatment": { "text": [["etoposide therapy"]], "start": [["42"]], "entity_id": [["T2"]], "Drug": { "text": [["etoposide"]], "start": [["42"]], "entity_id": [["T3"]] } , "Disorder": { "text": [["haemophagocytic lymphohistiocytosis"]], "start": [["71"]], "entity_id": [["T4"]] } , "Time_elapsed": { "text": [["after"]], "start": [["41"]], "entity_id": [["T5"]] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": { "text": [["etoposide therapy"]], "start": [["42"]], "entity_id": [["T2"]] } }, "Effect": { "text": [["secondary acute myeloid leukemia"]], "start": [["0"]], "entity_id": [["T1"]] } , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [] , "Age": { "text": [], "start": [], "entity_id": [] } , "Gender": { "text": [], "start": [], "entity_id": [] } , "Disorder": { "text": [], "start": [], "entity_id": [] } , "Population": { "text": [], "start": [], "entity_id": [] } , "Race": { "text": [], "start": [], "entity_id": [] } } } ] }
{"id": "16882109_1", "context": "Allergic contact angioedema to benzoyl peroxide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Allergic contact angioedema"]], "start": [["0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["benzoyl peroxide"]], "start": [[ "49" ]], "entity_id": [ ["T2"] ] ,"Drug": { "text": [["benzoyl peroxide"]], "start": [[ "49" ]], "entity_id": [ ["T2"] ]} ,"Disorder": { "text": [["Allergic contact angioedema"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["benzoyl peroxide"]], "start": [[ "49" ]], "entity_id": [ ["T2"] ]} } ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["Allergic contact angioedema"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] }} ]}
{"id": "1244265_1", "context": "A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem._", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["methazolamide"]],"start": [["started on methazolamide (Neptazane)" ,"Neptazane" ] ],"entity_id": [["T2"],["T3"]]},"Disorder": {"text": [["an ophthalmologic problem"]],"start": [["] for an ophthalmologic problem."]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["four days after"]],"start": [["] was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T5"]]},"Trigger": {"text": [["develop"]],"start": [["] was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"entity_id": [["E1"]],"text": [["develop acute respiratory failure and metabolic acidosis"]],"start": [["] was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]]},"Subject": {"text": [["A 60-year-old white man with chronic bronchitis"]],"start": [["] was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T1"]],"Age": {"text": [["60-year-old"]],"start": [["] A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T7"]]},"Gender": {"text": [["man"]],"start": [["] A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T8"]]},"Population": null,"Race": {"text": [["white"]],"start": [["] A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T9"]]},"Disorder": {"text": [["chronic bronchitis"]],"start": [["] A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem."]],"entity_id": [["T10"]]}},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null,"Effect": null}]}
{"id": "14557583_2", "context": "L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["L-DOPA-induced excessive daytime sleepiness"]], "start": [[ "0" ]], "entity_id": [ ]}, "Treatment": {"text": [["L-DOPA"]], "start": [[ "19" ]], "entity_id": [ ], "Drug": {"text": [["L-DOPA"]], "start": [[ "19" ]], "entity_id": [ ]} ,"Disorder": {"text": [["PD"]], "start": [[ "52" ]], "entity_id": [ ]} ,"Duration": {"text": [["induced"]], "start": [[ "9" ]], "entity_id": [ ]} ,"Time_elapsed": {"text": [["daytime"]], "start": [[ "41" ]], "entity_id": [ ]} ,"Route": {"text": [["oral"]], "start": [[ "69" ]], "entity_id": [ ]} ,"Dosage": {"text": [["-" ]], "start": [[ "19" ]], "entity_id": [ ]} ,"Freq": {"text": [["-" ]], "start": [[ "19" ]], "entity_id": [ ]} ,"Combination": null ,"Trigger": null }, "Effect": {"text": [["excessive daytime sleepiness"]], "start": [[ "41" ]], "entity_id": [ ]} ,"Subject": {"text": [["PD"]], "start": [[ "34" ]], "entity_id": [ ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["PD"]], "start": [[ "34" ]], "entity_id": [ ]} }, "Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "8384030_1","context": "It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["foscarnet"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 0"]],"entity_id": [["T1"]]},"Effect": {"text": [["electrolyte disorders and symptomatology"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 47"]],"entity_id": [["T2"]]},"Treatment": {"text": [["foscarnet"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 0"]],"entity_id": [["T1"]],"Drug": {"text": [["foscarnet"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 0"]],"entity_id": [["T1"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["electrolyte disorders and symptomatology"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 47"]],"entity_id": [["T2"]]} ,"Freq": null ,"Combination": null ,"Trigger": null } ,"Negated": null,"Speculated": {"text": [["probable"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 9"]],"entity_id": [["T3"]] ,"value": true },"Severity": null,"Subject": {"text": [["this patient"]],"start": [["It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. : 82"]],"entity_id": [["T4"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "17228132_1","context": "Acute drug induced hepatitis due to erlotinib","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute drug induced hepatitis"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["erlotinib"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["erlotinib"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": null ,"Dosage": null ,"Duration": null ,"Disorder": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Trigger": {"text": [["Acute drug induced hepatitis"]],"start": [[ ]],"entity_id": [ ]}},"Subject": null,"Effect": {"text": [["Acute drug induced hepatitis"]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9804082_2","context": "We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["intolerable dizziness", "nausea", "vomiting"]],"start": [["35-39", "44-47", "48-51"]],"entity_id": []},"Subject": {"text": [["3 diabetic patients"]],"start": [["12-16"]],"entity_id": [],"Disorder": {"text": [["diabetic"]],"start": [["13-19"]],"entity_id": []},"Population": {"text": [["3"]],"start": [["12-13"]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["initial administration", "the alpha-glucosidase inhibitor, voglibose"]],"start": [["55-63","67-83"]],"entity_id": [],"Drug": {"text": [["voglibose"]],"start": [["79-83"]],"entity_id": []},"Disorder": {"text": [["alpha-glucosidase inhibitor"]],"start": [["67-83"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["immediately after"]],"start": [["64-69"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [["initial administration"]],"start": [[ "55-63"]],"entity_id": []}},"Effect": {"text": [["dizziness","nausea","vomiting"]],"start": [[ "35-39","44-47","48-51"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["intolerable"]],"start": [[ "35"]],"entity_id": [],"value": "high"}}]}
{"id": "8936932_1","context": "Acute esmolol toxicity may be self-limiting because of its extremely short half-life","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute esmolol toxicity"]],"start": [[ "0"]],"entity_id": [ ]} ,"Treatment": {"text": [["its extremely short half-life"]],"start": [[ "52" ]],"entity_id": [ ],"Drug": {"text": [["esmolol"]],"start": [[ "12" ]],"entity_id": [ ]} ,"Trigger": {"text": [["its extremely short half-life"]],"start": [[ "52" ]],"entity_id": [ ]} ,"Time_elapsed": { "text": [["Acute"]],"start": [[ "0" ]],"entity_id": [ ]} ,"Duration": { "text": [["its extremely short half-life"]],"start": [[ "52" ]],"entity_id": [ ]} ,"Disorder": { "text": [["toxicity"]],"start": [[ "8" ]],"entity_id": [ ]} ,"Freq": { "text": [["may be self-limiting"]],"start": [[ "44" ]],"entity_id": [ ]} ,"Route": { "text": [["toxicity"]],"start": [[ "8" ]],"entity_id": [ ]} ,"Dosage": { "text": [["Acute"]],"start": [[ "0" ]],"entity_id": [ ]} ,"Combination": null },"Subject": { "text": [["Acute esmolol toxicity"]],"start": [[ "0" ]],"entity_id": [ ],"Age": null, "Disorder": { "text": [["toxicity"]],"start": [[ "8" ]],"entity_id": [ ]}, "Gender": null, "Population": null, "Race": null },"Negated": null, "Speculated": null, "Severity": null ,"Effect": null }] }
{"id": "7835785_2","context": "The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["prolonged unopposed estrogen-like stimulation with tamoxifen"]],"start": [[ ]], "entity_id": []},"Treatment": {"text": [["tamoxifen"]],"start": [[ ]], "entity_id": [],"Disorder": {"text": [["ovarian endometrioid carcinoma"]],"start": [[ ]], "entity_id": []},"Dosage": {"text": [["prolonged unopposed"]],"start": [[ ]], "entity_id": []},"Duration": {"text": [["prolonged"]],"start": [[ ]], "entity_id": []},"Route": {"text": [["stimulation"]],"start": [[ ]], "entity_id": []},"Time_elapsed": {"text": [["in the development"]],"start": [[ ]], "entity_id": []},"Freq": {"text": [["possible factor"]],"start": [[ ]], "entity_id": []},"Combination": [{"Drug": {"text": [["tamoxifen"]],"start": [[ ]], "entity_id": []},"Trigger": {"text": [["prolonged unopposed estrogen-like stimulation"]],"start": [[ ]], "entity_id": []},"event_id": "E1-1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["estrogen-like stimulation"]],"start": [[ ]], "entity_id": []},"Drug": {"text": [["tamoxifen"]],"start": [[ ]], "entity_id": []}},"Subject": {"text": [["The association"]],"start": [[ ]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["ovarian endometrioid carcinoma"]],"start": [[ ]], "entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["development"]],"start": [[ ]], "entity_id": []}}]}
{"id": "7019786_2","context": "The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["gentamicin"]],"start": [["47"]],"entity_id": [["T1"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["21"]],"entity_id": [["T2"]]},"Trigger": {"text": [["treatment"]],"start": [["41"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after"]],"start": [["53"]],"entity_id": [["T4"]]},"Freq": {"text": [["acute"]],"start": [["55"]],"entity_id": [["T5"]]},"Dosage": {"text": [["tubular necrosis"]],"start": [["62"]],"entity_id": [["T6"]]},"Duration": {"text": [["acute"]],"start": [["55"]],"entity_id": [["T5"]]},"Route": {"text": [["after treatment with"]],"start": [["41"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["gentamicin"]],"start": [["47"]],"entity_id": [["T1"]]},"Trigger": {"text": [["and"]],"start": [["50"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["cefoxitin"]],"start": [["65"]],"entity_id": [["T8"]]},"Trigger": {"text": [["after treatment with"]],"start": [["41"]],"entity_id": [["T3"]]},"event_id": "C2","event_type": "Combination"}],"entity_id": [["T1","T2","T3","T4","T5","T6","T7","T8"]],"start": [["21","47","41","53","55","62","50","65"]],"text": [["rheumatoid arthritis","gentamicin","treatment","after","acute","tubular necrosis","and","cefoxitin"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["The other woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["21"]],"entity_id": [["T2"]]}},"Effect": {"text": [["acute tubular necrosis"]],"start": [["62"]],"entity_id": [["T6"]]},"Trigger": {"text": [["developed"]],"start": [["34"]],"entity_id": [["T9"]]}}]}
{"id": "8053440_2","context": "One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["marked cholestasis", "portal inflammation", "bile duct injury", "bile duct paucity (ductopenia)"]],"start": [["33", "44", "58", "71"]],"entity_id": [["T1", "T2", "T3", "T4"]]},"Treatment": {"text": [["clindamycin"]],"start": [["15"]],"entity_id": [["T5"]],"Drug": {"text": [["clindamycin"]],"start": [["15"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["liver biopsy findings"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["had"]],"start": [["20"]],"entity_id": [["T8"]]} ,"Freq": {"text": [["One patient who received"]],"start": [["0"]],"entity_id": [["T9"]]} ,"Combination": [{"Drug": {"text": [["clindamycin"]],"start": [["15"]],"entity_id": [["T6"]]},"Trigger": {"text": [["received"]],"start": [["25"]],"entity_id": [["T10"]]} ,"event_id": "E1-D1T1" ,"event_type": "Treatment"}] ,"Trigger": {"text": [["had"]],"start": [["20"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} ,"Duration": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} ,"Route": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} },"Subject": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T9"]],"Age": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} ,"Gender": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} ,"Population": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T9"]]},"Race": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]} ,"Disorder": {"text": [["liver biopsy findings"]],"start": [["0"]],"entity_id": [["T7"]]} },"Negated": {"value": false,"text": [],"start": [],"entity_id": []} ,"Speculated": {"value": false,"text": [],"start": [],"entity_id": []} ,"Severity": {"value": "high","text": [],"start": [],"entity_id": []} ,"Effect": {"text": [["marked cholestasis", "portal inflammation", "bile duct injury and bile duct paucity (ductopenia)"]],"start": [[ "33","44","58"]],"entity_id": [["T1","T2","T3"]]} }]}
{"id": "11250985_1","context": "As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["close monitoring"]],"start": [["As these cases revealed,"], ["close monitoring"]],"entity_id": []},"Treatment": {"text": [["starting spironolactone"]],"start": [[", and patients should be advised to stop spironolactone immediately if diarrhoea develops."], ["starting spironolactone"]],"entity_id": [],"Drug": {"text": [["spironolactone"]],"start": [[", and patients should be advised to stop spironolactone immediately if diarrhoea develops."], ["starting spironolactone"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["diarrhoea"]],"start": [[", and patients should be advised to stop spironolactone immediately if diarrhoea develops."]],"entity_id": []}}]}
{"id": "15107195_1","context": "A case of heatstroke is reported in a 32-year-old man diagnosed with schizophrenia and on clozapine monotherapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["heatstroke"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ] }, "Subject": { "text": [["32-year-old man diagnosed with schizophrenia"]], "start": [[ "12" ]], "entity_id": [ ["T2"] ], "Age": { "text": [["32"]], "start": [[ "12" ]], "entity_id": [ ["A1"] ] }, "Disorder": { "text": [["schizophrenia"]], "start": [[ "23" ]], "entity_id": [ ["D1"] ]} ,"Gender": { "text": [["man"]], "start": [[ "29" ]], "entity_id": [ ["G1"] ] }, "Race": null ,"Population": null }, "Treatment": { "text": [["clozapine monotherapy"]], "start": [[ "69" ]], "entity_id": [ ["T3"] ], "Drug": { "text": [["clozapine"]], "start": [[ "69" ]], "entity_id": [ ["D2"] ] }, "Dosage": null ,"Duration": null , "Disorder": { "text": [["schizophrenia"]], "start": [[ "69" ]], "entity_id": [ ["D2"] ] }, "Trigger": null ,"Route": null , "Time_elapsed": null , "Freq": null , "Combination": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "6733633_1", "context": "Cimetidine-induced fever", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Cimetidine-induced"]], "start": [[ "]], ","entity_id"], ["T1"]],"entity_id":[]},"Treatment":{"text": [["Cimetidine"]], "start": [["0"]], "entity_id":[], "Drug": {"text": [["Cimetidine"]], "start": [["0"]], "entity_id":[]},"Disorder": {"text": [["fever"]], "start": [["13"]], "entity_id":[]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null,"Trigger": null},"Negated": null, "Speculated": null, "Severity": null, "Subject": null,"Effect": null}]}
{"id": "3470173_5", "context": "This case report illustrates the neurotoxicity unique to HDARAC", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["neurotoxicity"]], "start": [["18"]], "entity_id": []}, "Subject": {"text": [["this case report"]], "start": [["0"]], "entity_id": [], "Disorder": {"text": [["HDARAC"]], "start": [["44"]], "entity_id": []},"Age":{"text":[],"start":[[]],"entity_id":[]},"Gender":{"text":[],"start":[[]],"entity_id":[]},"Population":{"text":[],"start":[[]],"entity_id":[]},"Race":{"text":[],"start":[[]],"entity_id":[]}},"Effect":{"text":[["neurotoxicity"]], "start":[[ "18"]], "entity_id": []},"Negated":{"text":[],"start":[[]],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[[]],"entity_id":[],"value":false},"Severity":{"text":[],"start":[[]],"entity_id":[],"value":"not specified" },"Treatment":{"text":[],"start":[[]],"entity_id":[],"Drug":{"text":[["HDARAC"]], "start":[[ "44"]], "entity_id": []},"Disorder":{"text":[],"start":[[]],"entity_id":[]},"Dosage":{"text":[],"start":[[]],"entity_id":[]},"Duration":{"text":[],"start":[[]],"entity_id":[]},"Trigger":{"text":[],"start":[[]],"entity_id":[]},"Route":{"text":[],"start":[[]],"entity_id":[]},"Time_elapsed":{"text":[],"start":[[]],"entity_id":[]},"Freq":{"text":[],"start":[[]],"entity_id":[]},"Combination":null} }]}
{"id": "9433539_2","context": "Agranulocytosis associated with ticlopidine: a possible benefit with filgastim","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Agranulocytosis"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["ticlopidine"]],"start": [[ "33"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["ticlopidine"]],"start": [[ "33"]],"entity_id": [ ["T2"] ]},"Disorder": {"text": [["Agranulocytosis"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Time_elapsed": {"text": [["associated with"]],"start": [[ "18"]],"entity_id": [ ["T3"] ]},"Trigger": null,"Freq": null,"Route": null,"Dosage": null,"Duration": null,"Combination": null},"Effect": {"text": [["a possible benefit"]],"start": [[ "50"]],"entity_id": [ ["T4"] ]},"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16005413_10","context": "Since SS is a clinical diagnosis, heightened clinician awareness of the possibility of SS among patients receiving SSRI or mirtazapine in combination with opioids may lead to earlier detection and avoidance of potentially lethal consequences","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["SS"]],"start": [[], []],"entity_id": []},"Subject": {"text": [["patients"]],"start": [[], []],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["SSRI", "mirtazapine in combination with opioids"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["SSRI", "mirtazapine", "opioids"]],"start": [[], [], []],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["SS"]],"start": [[], []],"entity_id": []},"Combination": [{"Drug": {"text": [["SSRI"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["or"]],"start": [[], []],"entity_id": []},"event_id": "E2","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["mirtazapine"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["in combination with"]],"start": [[], []],"entity_id": []},"event_id": "E3","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["opioids"]],"start": [[], []],"entity_id": []},"Trigger": null,"event_id": "E4","event_type": "Potential_therapeutic_effect"}],"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["lethal"]],"start": [[], []],"entity_id": [],"value": "high"}}]}
{"id": "19499966_4","context": "The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gynaecomastia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sunitinib"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["sunitinib"]],"start": [["5"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["an unknown direct action on breast hormonal receptors"]],"start": [["61"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["an unknown direct action"]],"start": [["61"]],"entity_id": [["T3"]]} ,"Route": {"text": [["on breast hormonal receptors"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["induces"]],"start": [["25"]],"entity_id": [["T5"]]},"Freq": {"text": [["induces"]],"start": [["25"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["induces"]],"start": [["25"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["induces"]],"start": [["25"]],"entity_id": [["T5"]]} ,"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "18676387_2","context": "To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin toxicity"]],"start": [["31","38"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["paroxetine"]],"start": [["81","89"]],"entity_id": [["T2"]]},"text": [["an interaction between paroxetine"]],"start": [["81","96"]],"entity_id": [["T2"]],"Trigger": {"text": [["interaction"]],"start": [["97","103"]],"entity_id": [["T3"]]},"Dosage": {"text": [["a selective serotonin reuptake inhibitor"]],"start": [["104","130"]],"entity_id": [["T4"]]},"Route": {"text": [["SSRI"]],"start": [["129","130"]],"entity_id": [["T5"]]},"Duration": {"text": [["and fentanyl"]],"start": [["139","146"]],"entity_id": [["T6"]]},"Disorder": {"text": [["a phenylpiperidine opioid"]],"start": [["147","163"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["caused by an interaction between"]],"start": [["97","114"]],"entity_id": [["T3"]]},"Freq": {"text": [["interaction between paroxetine"]],"start": [["81","96"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["paroxetine"]],"start": [["81","89"]],"entity_id": [["T2"]]},"Trigger": {"text": [["interaction"]],"start": [["97","103"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["fentanyl"]],"start": [["140","146"]],"entity_id": [["T6"]]},"Trigger": {"text": [["interaction"]],"start": [["97","103"]],"entity_id": [["T3"]]},"event_id": "C2","event_type": "Adverse_event"}]},"Subject": {"text": [["To report a case"]],"start": [["0","10"]],"entity_id": [["T8"]],"Disorder": {"text": [["serotonin toxicity"]],"start": [["31","38"]],"entity_id": [["T1"]]},"Population": {"text": [["a case"]],"start": [["11","15"]],"entity_id": [["T9"]]},"Age": {"text": [["postoperative period"]],"start": [["44","60"]],"entity_id": [["T10"]]},"Gender": {"text": [["To report a case"]],"start": [["0","10"]],"entity_id": [["T8"]]},"Race": {"text": [["To report a case"]],"start": [["0","10"]],"entity_id": [["T8"]]}},"Effect": {"text": [["serotonin toxicity"]],"start": [["31","38"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [["To report a case"]],"start": [["0","10"]],"entity_id": [["T8"]]},"Speculated": {"value": false,"text": [["To report a case"]],"start": [["0","10"]],"entity_id": [["T8"]]},"Severity": {"value": "high","text": [["serotonin toxicity"]],"start": [["31","38"]],"entity_id": [["T1"]]}}]}
{"id": "20367573_1","context": "However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["thrombocytosis"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["enoxaparin"]],"start": [["74"]],"entity_id": [["T2"]],"Disorder": {"text": [["induced"]],"start": [["68"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Drug": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["newborns"]],"start": [["15"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": null,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": true },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }}]}
{"id": "9846036_7","context": "The case presented here documents adverse cardiac effects in a 28-year-old man who intentionally ingested 24 mg of risperidone--4 times the recommended dose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse cardiac effects"]],"start": [["16"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 28-year-old man"]],"start": [["33"]],"entity_id": [["T2"]],"Age": {"text": [["28"]],"start": [["33"]],"entity_id": [["A1"]]},"Gender": {"text": [["man"]],"start": [["39"]],"entity_id": [["G1"]]},"Population": {"text": [["a"]],"start": [["33"]],"entity_id": [["P1"]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [[]],"start": [[],[]],"entity_id": [[]]}},"Treatment": {"text": [["risperidone"]],"start": [["84"]],"entity_id": [["T3"]],"Drug": {"text": [["risperidone"]],"start": [["84"]],"entity_id": [["D1"]]},"Dosage": {"text": [["24 mg"]],"start": [["84"]],"entity_id": [["Do1"]]},"Duration": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [["adverse cardiac effects"]],"start": [["16"]],"entity_id": [["T1"]]},"Trigger": {"text": [["ingested"]],"start": [["63"]],"entity_id": [["T4"]]},"Route": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Time_elapsed": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Freq": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Combination": null},"Effect": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Negated": null,"Speculated": null,"Severity": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": "high"}}]}
{"id": "14746605_3","context": "To the best of the authors' knowledge, this is the first reported case of Propecia-associated cataract","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Propecia-associated cataract"]],"start": [["42"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Propecia"]],"start": [["18"]],"entity_id": [["T2"]],"Drug": {"text": [["Propecia"]],"start": [["18"]],"entity_id": [["T2"]]},"Disorder": {"text": [["cataract"]],"start": [["42"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]]},"Freq": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["Propecia"]],"start": [["18"]],"entity_id": [["T2"]]},"Trigger": {"text": [["associated"]],"start": [["34"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["reported"]],"start": [["37"]],"entity_id": [["T5"]]},"Route": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]]},"Dosage": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]]},"Duration": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]]}},"Subject": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]],"Population": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]]},"Gender": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]]},"Age": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]]},"Race": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]]},"Disorder": {"text": [["this"]],"start": [["5"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["first reported case"]],"start": [["21"]],"entity_id": [["T3"]],"value": "low"},"Effect": {"text": [["cataract"]],"start": [["42"]],"entity_id": [["T1"]]}}]}
{"id": "11757641_3","context": "This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute lung injury"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["mefloquine"]],"start": [["63"]],"entity_id": [["T2"]],"Drug": {"text": [["mefloquine"]],"start": [["63"]],"entity_id": [["T3"]]},"Disorder": {"text": [["low-level Plasmodium falciparum malaria"]],"start": [["82"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["hours"]],"start": [["41"]],"entity_id": [["T5"]]},"Freq": {"text": [["was persistent"]],"start": [["93"]],"entity_id": [["T6"]]},"Trigger": {"text": [["halofantrine therapy"]],"start": [["127"]],"entity_id": [["T7"]]},"Route": {"text": [["administration"]],"start": [["55"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["mefloquine"]],"start": [["63"]],"entity_id": [["T3"]]},"Trigger": {"text": [["halofantrine therapy"]],"start": [["127"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Concomitant_therapy"}],"Dosage": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T9"]]},"Duration": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T10"]]}},"Negated": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T11"]],"value": false},"Speculated": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T12"]],"value": false},"Severity": {"text": [["acute"]],"start": [["16"]],"entity_id": [["T13"]],"value": "high"},"Subject": {"text": [["This report"]],"start": [[""],[""]],"entity_id": [["T14"]],"Age": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T15"]]},"Gender": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T16"]]},"Population": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T17"]]},"Race": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T18"]]},"Disorder": {"text": [["low-level Plasmodium falciparum malaria"]],"start": [["82"]],"entity_id": [["T4"]]}},"Effect": {"text": [["acute lung injury"]],"start": [["16"]],"entity_id": [["T1"]]}}]}
{"id": "11837564_3","context": "Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Warfarin-associated bleeding"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["Warfarin"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Warfarin"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["colon cancer"]],"start": [["82"]],"entity_id": []},"Time_elapsed": {"text": [["it"]],"start": [["54"]],"entity_id": []},"Freq": {"text": [["generally"]],"start": [["6"]],"entity_id": []},"Trigger": {"text": [["it"]],"start": [["54"]],"entity_id": []},"Combination": [{"event_id": "E1a","Drug": {"text": [["Warfarin"]],"start": [["0"]],"entity_id": []},"Trigger": {"text": [["Warfarin-associated bleeding"]],"start": [["0"]],"entity_id": []},"event_type": "Adverse_event"}],"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Route": {"text": [[]],"start": [],"entity_id": []}},"Subject": {"text": [["our patient"]],"start": [["42"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["colon cancer"]],"start": [["82"]],"entity_id": []}},"Effect": {"text": [["unmasked an early stage of colon cancer"]],"start": [["74"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "6251941_2","context": "Three cases of gold-related neuropathy are reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gold-related neuropathy"]],"start": [["22"]],"entity_id": [["T1"]]},"Subject": {"text": [["Three cases"]],"start": [["0"]],"entity_id": [["T2"]] ,"Population": {"text": [["Three cases"]],"start": [["0"]],"entity_id": [["T2"]]},"Disorder": {"text": [["gold-related neuropathy"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} ,"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [["gold"]],"start": [["7"]],"entity_id": [["T3"]]},"Disorder": {"text": [["gold-related neuropathy"]],"start": [["22"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false },"Severity": {"text": [],"start": [],"entity_id": [],"value": "" }}]}
{"id": "11483161_3", "context": "We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["spontaneous intracranial bleeding"]], "start": [["32","42"]], "entity_id": [["T1"]]}, "Subject": {"text": [["an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A"]], "start": [["9","75"]], "entity_id": [["T2"]], "Disorder": {"text": [["hemophilia A"]], "start": [["57","64"]], "entity_id": [["T3"]]},"Age": {"text": [["adolescent"]], "start": [["18","26"]], "entity_id": [["T4"]]},"Gender": {"text": [["adolescent"]], "start": [["18","26"]], "entity_id": [["T4"]]},"Race": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["amprenavir (APV)"]], "start": [["113","119"]], "entity_id": [["T5"]], "Drug": {"text": [["amprenavir"]], "start": [["113","119"]], "entity_id": [["T6"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null, "Disorder": {"text": [["human immunodeficiency virus (HIV)"]], "start": [["45","71"]], "entity_id": [["T7"]]}},"Effect": {"text": [["spontaneous intracranial bleeding"]], "start": [["32","42"]], "entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17352036_3","context": "Under the suspicion of amiodarone-induced acute pancreatitis, amiodarone was substituted by propafenone","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["amiodarone-induced acute pancreatitis"]],"start": [["Under the suspicion of amiodarone-induced acute pancreatitis,","amiodarone-induced acute pancreatitis"]],"entity_id": []},"Treatment": {"text": [["amiodarone"]],"start": [["amiodarone"]],"entity_id": [],"Drug": {"text": [["amiodarone"]],"start": [["amiodarone"]],"entity_id": []},"Disorder": {"text": [["amiodarone-induced acute pancreatitis"]],"start": [["amiodarone-induced acute pancreatitis"]],"entity_id": []},"Trigger": {"text": [["amiodarone"]],"start": [["amiodarone"]],"entity_id": []},"Route": {"text": [["was substituted"]],"start": [["was substituted"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": null,"Effect": null,"Negated": null,"Speculated": null,"Severity": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": null,"Treatment": {"text": [["propafenone"]],"start": [["propafenone"]],"entity_id": [],"Drug": {"text": [["propafenone"]],"start": [["propafenone"]],"entity_id": []},"Disorder": {"text": [["amiodarone-induced acute pancreatitis"]],"start": [["amiodarone-induced acute pancreatitis"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": null,"Effect": {"text": [["amiodarone-induced acute pancreatitis"]],"start": [["amiodarone-induced acute pancreatitis"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "acute"}}]}
{"id": "7661076_1","context": "Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["associated"]],"start": [["30"]],"entity_id": []},"Treatment": {"text": [["adenosine"]],"start": [["10"]],"entity_id": [],"Drug": {"text": [["adenosine"]],"start": [["10"]],"entity_id": []},"Disorder": {"text": [["arrhythmia"]],"start": [["44"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["dangerous worsening"]],"start": [["52"]],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["patients with atrial flutter"]],"start": [["65"]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "dangerous"}}]}
{"id": "15866658_1","context": "Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neutropenia"]],"start": [["55"]],"entity_id": [["T1"]]},"Subject": {"text": [["four patients"]],"start": [["23"]],"entity_id": [["T2"]],"Population": {"text": [["four patients"]],"start": [["23"]],"entity_id": [["T2"]]},"Disorder": {"text": [["liver transplantation"]],"start": [["14"]],"entity_id": [["T3"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["MMF"]],"start": [["86"]],"entity_id": [["T4"]],"Drug": {"text": [["MMF"]],"start": [["86"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["liver transplantation"]],"start": [["14"]],"entity_id": [["T3"]]},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["neutropenia"]],"start": [["55"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2931445_2","context": "A study of in vitro reactivity to L-T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L-T4","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["leukopenia"]],"start": [["59"]],"entity_id": [["T2"]]},"Treatment": {"text": [["treatment with L-T4"]],"start": [["103"]],"entity_id": [["T3"]],"Drug": {"text": [["L-T4"]],"start": [["103"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["Hashimoto's disease"]],"start": [["43"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["100"]],"entity_id": [["T5"]]},"Freq": {"text": [["developed"]],"start": [["59"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["treatment with L-T4"]],"start": [["103"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["L-T4"]],"start": [["103"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment with L-T4"]],"start": [["103"]],"entity_id": [["T3"]]} ,"event_id": "E1","event_type": "Adverse_event"}] ,"Duration": {"text": [["study"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Route": {"text": [["in vitro reactivity"]],"start": [["6"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["assessed by peripheral blood lymphocyte transformation"]],"start": [["28"]],"entity_id": [["T8"]]} },"Subject": {"text": [["patient"]],"start": [["43"]],"entity_id": [["T9"]],"Disorder": {"text": [["Hashimoto's disease"]],"start": [["43"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [["leukopenia"]],"start": [["59"]],"entity_id": [["T2"]]} }] }
{"id": "3470173_3", "context": "During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["dysarthria", "ataxia"]], "start": [["7","21"]], "entity_id": []}, "Treatment": {"text": [["first treatment"]], "start": [["0"]], "entity_id": [], "Duration": {"text": [["eighth and final dose"]], "start": [["41"]], "entity_id": []}, "Drug": {"text": [["HDARAC"]], "start": [["51"]], "entity_id": []},"Route": {"text": [["oral"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [["after"]], "start": [[],[]], "entity_id": []},"Freq": {"text": [["once"]], "start": [[],[]], "entity_id": []}, "Trigger":{"text":[["completion"]], "start":[[],[]], "entity_id": []},"Dosage":{"text":[["the patient's"]], "start":[[],[]], "entity_id": []},"Disorder":{"text":[["during"]], "start":[[],[]], "entity_id": []},"Combination":[{"Drug":{"text":[["HDARAC"]], "start":[[],[]], "entity_id": []},"Trigger":{"text":[["and"]], "start":[[],[]], "entity_id": []},"event_id":"E1","event_type":"Adverse_event"}]},"Subject":{"Age":{"text":[["the patient's"]], "start":[[],[]], "entity_id": []},"Gender":{"text":[[]], "start":[[],[]], "entity_id": []},"Race":{"text":[[]], "start":[[],[]], "entity_id": []},"Population":{"text":[["the patient"]], "start":[[],[]], "entity_id": []},"Disorder":{"text":[["During the first treatment"]], "start":[[],[]], "entity_id": []},"text":[["During the first treatment"]],"start":[[],[]],"entity_id": []},"Effect":{"text":[["dysarthria","ataxia"]], "start":[[],[]], "entity_id": []},"Negated":{"text":[[]], "start":[[],[]], "entity_id": [],"value":false},"Speculated":{"text":[[]], "start":[[],[]], "entity_id": [],"value":false},"Severity":{"text":[["seen"]], "start":[[],[]], "entity_id": [],"value":"low"}}]}
{"id": "3143551_4","context": "Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hepatopathy"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["carbamazepine", "lynestrenol and sodium valproate"]],"start": [["43"]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"], ["lynestrenol"], ["sodium valproate"]],"start": [[ "43" ], ["58"], ["67"]],"entity_id": [["T3"], ["T4"], ["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [["Four weeks earlier"]],"start": [[ "0" ]],"entity_id": [["T6"]]} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [{"Drug": {"text": [["carbamazepine"], ["lynestrenol"], ["sodium valproate"]],"start": [[ "43" ], ["58"], ["67"]],"entity_id": [["T3"], ["T4"], ["T5"]]} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["regimen"]],"start": [["43"]],"entity_id": [["T7"]]} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [["she"]],"start": [["8"]],"entity_id": [["T8"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["hepatopathy"]],"start": [["23"]],"entity_id": [["T1"]]}} }] }
{"id": "20178709_3","context": "We report here a rare case of pleuropericarditis due to methotrexate","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["pleuropericarditis"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate"]],"start": [["58"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["58"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["pleuropericarditis"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["a rare case"]],"start": [["0"]],"entity_id": [["F1"]]} ,"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["58"]],"entity_id": [["T2"]]},"Trigger": {"text": [["due"]],"start": [["45"]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ],"Time_elapsed": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Route": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["report"]],"start": [["0"]],"entity_id": [["S1"]]},"Gender": {"text": [["report"]],"start": [["0"]],"entity_id": [["S1"]]},"Population": {"text": [["report"]],"start": [["0"]],"entity_id": [["S1"]]},"Race": {"text": [["report"]],"start": [["0"]],"entity_id": [["S1"]]},"Disorder": {"text": [["report"]],"start": [["0"]],"entity_id": [["S1"]]} },"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["N1"]],"value": false} ,"Speculated": {"text": [["report"]],"start": [["0"]],"entity_id": [["Spec1"]],"value": false} ,"Severity": {"text": [["rare"]],"start": [["16"]],"entity_id": [["Sev1"]],"value": "low"} ,"Effect": {"text": [["pleuropericarditis"]],"start": [["16"]],"entity_id": [["T1"]]} } ]}
{"id": "10099659_14","context": "We also discuss whether screening for DPD deficiency is warranted to identify patients at risk for severe toxicities from 5-FU treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["screening for DPD deficiency"]],"start": [["screening for DPD deficiency appears first in the text"]],"entity_id": [["T1"]]},"Treatment": {"text": [["5-FU treatment"]],"start": [["; appears after the word 'for' in the phrase 'for severe toxicities from 5-FU treatment'"]],"entity_id": [["T2"]],"Disorder": {"text": [["severe toxicities"]],"start": [["; appears right before 'from 5-FU treatment'"]],"entity_id": [["T3"]]},"Dosage": {"text": [["5-FU"]],"start": [["; appears right before 'treatment'"]],"entity_id": [["T4"]]},"Freq": {"text": [["screening"]],"start": [["; appears at the beginning of the phrase"]],"entity_id": [["T5"]]},"Route": {"text": [["screening"]],"start": [["; appears at the beginning of the phrase"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["screening"]],"start": [["; appears at the beginning of the phrase"]],"entity_id": [["T7"]]},"Duration": {"text": [["screening"]],"start": [["; appears at the beginning of the phrase"]],"entity_id": [["T8"]]},"Combination": null,"Drug": {"text": [["5-FU"]],"start": [["; appears right before 'treatment'"]],"entity_id": [["T9"]]},"Trigger": {"text": [["severe toxicities"]],"start": [["; appears right before 'from 5-FU treatment'"]],"entity_id": [["T10"]]}},"Subject": {"text": [["We"]],"start": [["; appears at the beginning of the text"]],"entity_id": [["T11"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["DPD deficiency"]],"start": [["; appears in the phrase 'screening for DPD deficiency'"]],"entity_id": [["T12"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["severe toxicities"]],"start": [["; appears right before 'from 5-FU treatment'"]],"entity_id": [["T13"]],"value": "high"},"Effect": null}]}
{"id": "10102531_2","context": "We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["reversible encephalopathy syndrome"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 16-year-old girl"]],"start": [["5"]],"entity_id": [["T2"]],"Age": {"text": [["16"]],"start": [["10"]],"entity_id": [["T3"]]},"Gender": {"text": [["girl"]],"start": [["7"]],"entity_id": [["T4"]]},"Disorder": {"text": [["acute myelogenous leukemia (AML)"]],"start": [["24"]],"entity_id": [["T5"]]},"Population": {"text": [["a"]],"start": [["5"]],"entity_id": [["T7"]]},"Race": {"text": [["a"]],"start": [["5"]],"entity_id": [["T8"]]}},"Treatment": {"text": [["consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin"]],"start": [["73"]],"entity_id": [["T6"]],"Drug": {"text": [["BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin"]],"start": [["81"]],"entity_id": [["T9"],["T10"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Trigger": {"text": [["undergoing"]],"start": [["68"]],"entity_id": [["T11"]]},"Route": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Time_elapsed": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Freq": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": [{"Drug": {"text": [["BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine)"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Trigger": {"text": [["and"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"event_type": "Treatment","event_id": "C1"},{"Drug": {"text": [["idarubicin"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Trigger": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"event_type": "Treatment","event_id": "C2"}],"Disorder": {"text": [["consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin"]],"start": [[""],[""]],"entity_id": [[""],[""]]}},"Effect": {"text": [["reversible encephalopathy syndrome"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11834188_2","context": "Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Captopril"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["Captopril"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": { "text": [["angiotensin-converting enzyme (ACE) inhibitor"]], "start": [[ "start"], ["entity_id"] ], "entity_id": [ ]} ,"Freq": { "text": [["when they occur"]], "start": [[ "start"]], "entity_id": [ ]} ,"Duration": { "text": [["documented"]], "start": [[ "start"]], "entity_id": [ ]} ,"Route": { "text": [["occur"]], "start": [[ "start"]], "entity_id": [ ]} ,"Trigger": { "text": [["cutaneous side-effects"]], "start": [[ "start"]], "entity_id": [ ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Trigger": null }] }
{"id": "18784429_3", "context": "High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["High-dose methylprednisolone"]], "start": [[ "entity_id"]],"Drug":{"text":[["methylprednisolone"]],"start":[[ ]],"entity_id":[["T1"]]},"Disorder":{"text":[["Crohn's disease"]],"start":[[ ]],"entity_id":[["T2"]]},"Route":{"text":[["in a pregnant woman"]],"start":[[ ]],"entity_id":[["T3"]]},"Freq":{"text":[["High-dose"]],"start":[[ ]],"entity_id":[["T1"]]},"Dosage":{"text":[["High-dose"]],"start":[[ ]],"entity_id":[["T1"]]}, "Trigger": {"text": [["in"]], "start": [[ ]], "entity_id": [["T3"]]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"entity_id":[["T1"],["T2"],["T3"]],"Combination":[{"Drug":{"text":[["methylprednisolone"]],"start":[[ ]],"entity_id":[["T1"]]},"Trigger":{"text":[["in"]],"start":[[ ]],"entity_id":[["T3"]]},"event_id":"E1-1","event_type":"Potential_therapeutic_effect"}]},"Subject":{"text":[["a pregnant woman"]],"start":[[ ]],"entity_id":[["T3"]],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[["woman"]],"start":[[ ]],"entity_id":[["T3"]]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["Crohn's disease"]],"start":[[ ]],"entity_id":[["T2"]]}},"Effect":{"text":[],"start":[],"entity_id":[]},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":""},"Trigger":{"text":[["and adrenal suppression in her newborn"]],"start":[[ ]],"entity_id":[["T4"]]}}]}
{"id": "17224428_1","context": "Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cardiac hypersensitivity", "myopericarditis"]],"start": [["0"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["long-term treatment with mesalazine"]],"start": [["53"]],"entity_id": [["T3"]],"Drug": {"text": [["mesalazine"]],"start": [["53"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["long-term"]],"start": [["37"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["Cardiac hypersensitivity", "myopericarditis"]],"start": [["0"]],"entity_id": [["T1","T2"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["28"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["during"]],"start": [["28"]],"entity_id": [["T6"]]} ,"Route": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["long-term"]],"start": [["37"]],"entity_id": [["T5"]]} ,"Combination": null ,"Dosage": null} , "Subject": {"text": [["Cardiac hypersensitivity", "myopericarditis"]],"start": [["0"]],"entity_id": [["T1","T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["Cardiac hypersensitivity", "myopericarditis"]],"start": [["0"]],"entity_id": [["T1","T2"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6311654_6","context": "It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["accumulative effect"]],"start": [["52"]],"entity_id": [["T1"]]},"Subject": {"text": [["cerebral atrophy"]],"start": [["14"]],"entity_id": [["T2"]],"Disorder": {"text": [["cerebral atrophy"]],"start": [["14"]],"entity_id": [["T2"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["ACTH"]],"start": [["71"]],"entity_id": [["T3"]],"Drug": {"text": [["ACTH"]],"start": [["71"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["cerebral atrophy"]],"start": [["14"]],"entity_id": [["T2"]]},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "12135176_1","context": "Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["polymorphic ventricular tachycardia"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["verapamil"]],"start": [["62"]],"entity_id": [ ["T2"]],"Drug": {"text": [["verapamil"]],"start": [["62"]],"entity_id": [ ["T2"]]},"Disorder": {"text": [["paroxysmal supraventricular tachycardia"]],"start": [["43"]],"entity_id": [ ["T3"]]} ,"Time_elapsed": {"text": [["administration"]],"start": [["22"]],"entity_id": [ ["T4"]]} ,"Route": {"text": [["administration"]],"start": [["22"]],"entity_id": [ ["T4"]]} ,"Freq": {"text": [["induced"]],"start": [["52"]],"entity_id": [ ["T5"]]} ,"Combination": [{"Drug": {"text": [["verapamil"]],"start": [["62"]],"entity_id": [ ["T2"]]},"Trigger": {"text": [["administration"]],"start": [["22"]],"entity_id": [ ["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["administration"]],"start": [["22"]],"entity_id": [ ["T4"]]} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["paroxysmal supraventricular tachycardia"]],"start": [["43"]],"entity_id": [ ["T3"]] }} }]}
{"id": "18465737_2","context": "The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["incomplete posterior hyaloid detachment"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravitreal pegaptanib"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["pegaptanib"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["DME"]],"start": [["81"]],"entity_id": [["T4"]]} ,"Route": {"text": [["intravitreal"]],"start": [["45"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["following"]],"start": [["25"]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["25"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["one case"]],"start": [["11"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["one case"]],"start": [["11"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["one case"]],"start": [["11"]],"entity_id": [["T7"]]} ,"Combination": []} ,"Subject": {"text": [["The authors"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["one case"]],"start": [["11"]],"entity_id": [["T7"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []}} ]}
{"id": "3612639_1", "context": "Pulmonary edema as a delayed complication of ritodrine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Pulmonary edema"]], "start": [[ ]],"entity_id": [ ["T1"] ]}, "Treatment": {"text": [["ritodrine therapy"]], "start": [[ ]],"entity_id": [ ["T2"] ],"Dosage": {"text": [[]], "start": [], "entity_id": []},"Duration": {"text": [[]], "start": [], "entity_id": []},"Disorder": {"text": [[]], "start": [], "entity_id": []},"Route": {"text": [[]], "start": [], "entity_id": []},"Time_elapsed": {"text": [["delayed"]], "start": [[ ]],"entity_id": [ ["T3"] ]},"Freq": {"text": [[]], "start": [], "entity_id": []},"Combination": null ,"Drug": {"text": [["ritodrine"]], "start": [[ ]],"entity_id": [ ["T4"] ]} ,"Trigger": null } ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "18633310_1", "context": "Multiple seizures after bupropion overdose in a small child", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Multiple seizures"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]},"Treatment": { "text": [["bupropion overdose"]], "start": [[ "31" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["bupropion"]], "start": [[ "31" ]], "entity_id": [ ["T3"] ]} ,"Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["overdose"]], "start": [[ "40" ]], "entity_id": [ ["T4"] ]} },"Effect": null, "Subject": { "text": [["a small child"]], "start": [[ "51" ]], "entity_id": [ ["T5"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null },"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "19537383_2", "context": "Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["Sorafenib"]], "start": [[ ]], "entity_id": [ ["T1"] ], "Drug": { "text": [["Sorafenib"]], "start": [[ ]], "entity_id": [ ["T1"] ] }, "Disorder": { "text": [["the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas"]], "start": [[ ]], "entity_id": [ ["T2"] ] } , "Freq": { "text": [["FDA approval"]], "start": [[ ]], "entity_id": [ ["T3"] ] } , "Trigger": { "text": [["received"]], "start": [[ ]], "entity_id": [ ["T4"] ] } , "Time_elapsed": { "text": [["in 2005"]], "start": [[ ]], "entity_id": [ ["T5"] ] } , "Dosage": { "text": [["FDA approval"]], "start": [[ ]], "entity_id": [ ["T3"] ] } , "Route": { "text": [["oral"]], "start": [[ ]], "entity_id": [["T6"] ] } , "Duration": { "text": [["lifetime"]], "start": [[ ]], "entity_id": [ ["T7"] ] } , "Combination": null } , "Subject": { "text": [["Sorafenib"]], "start": [[ ]], "entity_id": [["T1"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } , "Negated": null, "Speculated": null, "Severity": null , "Effect": null , "Trigger": { "text": [["received"]], "start": [[ ]], "entity_id": [ ["T4"] ] } }]}
{"id": "1174301_2", "context": "Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Triiodothyronine-induced thyrotoxicosis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": { "text": [[ "Triiodothyronine" ]], "start": [[ "0" ]], "entity_id": [ ["T2" ]], "Disorder": { "text": [[ "thyrotoxicosis in ophthalmic Graves disease" ]], "start": [[ "21" ]], "entity_id": [ ["D1" ]] } ,"Drug": { "text": [[ "Triiodothyronine" ]], "start": [[ "0" ]], "entity_id": [ ["T2" ]] } ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Combination": null ,"Trigger": { "text": [[ "Triiodothyronine-induced" ]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] } }, "Effect": { "text": [[ "thyrotoxicosis" ]], "start": [[ "21" ]], "entity_id": [ ["E1" ]] } ,"Subject": null, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "17526968_1", "context": "Bleomycin induced hyperpigmentation with yolk sac tumor", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Bleomycin induced hyperpigmentation"]], "start": [[ ]],"entity_id": [ ]}, "Treatment": {"text": [["Bleomycin"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["Bleomycin"]], "start": [[ ]], "entity_id": [ ] },"Disorder": { "text": [["yolk sac tumor"]], "start": [[ ]], "entity_id": [ ["T2"] ] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": { "text": [], "start": [], "entity_id": [] } },"Effect": { "text": [["hyperpigmentation"]], "start": [[ ]], "entity_id": [ ["T1"] ] }, "Negated": null, "Speculated": null, "Severity": null , "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": null, "Population": null, "Race": null } }]}
{"id": "19034138_5", "context": "To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a patient with Parkinson disease"]], "start": [["25","29"]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Parkinson disease"]], "start": [["32","44"]], "entity_id": []}}, "Treatment": {"text": [["amantadine"]], "start": [["92","99"]], "entity_id": [],"Drug": {"text": [["amantadine"]], "start": [["92","99"]], "entity_id": []},"Dosage": null,"Duration": {"text": [["long-term"]], "start": [["88","92"]], "entity_id": []},"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Disorder": null}, "Effect": {"text": [["bilateral corneal endothelial dysfunction"]], "start": [["5","24"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "2140997_1","context": "A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe acute hepatitis"]],"start": [["13","14","15","16","17","18","19","20","21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cyproterone acetate"]],"start": [["33","34","35","36","37","38"]],"entity_id": [["T2"]],"Drug": {"text": [["cyproterone acetate"]],"start": [["33","34","35","36","37","38"]],"entity_id": [["T3"]]},"Disorder": {"text": [["prostatic carcinoma"]],"start": [["53","54","55","56"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["a 71 year old man"]],"start": [["40","41","42","43","44","45","46","47"]],"entity_id": [["T5"]],"Age": {"text": [[""],["71"]],"start": [[],["40"]],"entity_id": []},"Gender": {"text": [[""],["man"]],"start": [[],["44"]],"entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [["prostatic carcinoma"]],"start": [["53","54","55","56"]],"entity_id": [["T4"]]}},"Effect": {"text": [["severe acute hepatitis"]],"start": [["13","14","15","16","17","18","19","20","21"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [[""],["severe"]],"start": [[],["13"]],"entity_id": [],"value": "severe"}},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["hepatic reactions"]],"start": [["111","112","113","114","115","116"]],"entity_id": [["T6"]]},"Treatment": {"text": [["cyproterone acetate"]],"start": [["33","34","35","36","37","38"]],"entity_id": [["T2"]],"Drug": {"text": [["cyproterone acetate"]],"start": [["33","34","35","36","37","38"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null,"Disorder": null},"Subject": null,"Effect": {"text": [["hepatic reactions"]],"start": [["111","112","113","114","115","116"]],"entity_id": [["T6"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2309833_2", "context": "Insulin-dependent diabetes mellitus associated with danazol", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Insulin-dependent diabetes mellitus"]], "start": [[ "0" ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["danazol"]], "start": [[ "42" ]], "entity_id": [["T2"]],"Drug": {"text": [["danazol"]], "start": [[ "42" ]], "entity_id": [["T3"]] },"Disorder": { "text": [["Insulin-dependent diabetes mellitus"]], "start": [[ "0" ]], "entity_id": [["T1"]] },"Time_elapsed": { "text": [["associated with"]], "start": [[ "31" ]], "entity_id": [["T4"]] },"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null, "Trigger": { "text": [], "start": [], "entity_id": [] }},"Effect": { "text": [], "start": [], "entity_id": []},"Negated": { "text": [], "start": [], "entity_id": [],"value": false }, "Speculated": { "text": [], "start": [], "entity_id": [],"value": false },"Severity": { "text": [], "start": [], "entity_id": [],"value": "" },"Subject": { "text": [], "start": [], "entity_id": [],"Age": { "text": [], "start": [], "entity_id": [] },"Gender": { "text": [], "start": [], "entity_id": [] },"Population": { "text": [], "start": [], "entity_id": [] },"Race": { "text": [], "start": [], "entity_id": [] },"Disorder": { "text": [["Insulin-dependent diabetes mellitus"]], "start": [[ "0" ]], "entity_id": [["T1"]] }}}]}
{"id": "10458196_4","context": "Topical brimonidine may be associated with central nervous system depression in infants","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["central nervous system depression"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Topical brimonidine"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["brimonidine"]],"start": [["8"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["central nervous system depression"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Route": {"text": [["Topical"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["Topical brimonidine"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"event_type": "Potential_therapeutic_effect" ,"event_id": "E2"}] ,"Time_elapsed": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["Topical"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} },"Subject": {"text": [["infants"]],"start": [["70"]],"entity_id": [["T5"]],"Age": {"text": [["infants"]],"start": [["70"]],"entity_id": [["T5"]]} ,"Population": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Race": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["may be associated"]],"start": [["13"]],"entity_id": [["T4"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Effect": {"text": [["central nervous system depression"]],"start": [["33"]],"entity_id": [["T1"]]} }] }
{"id": "10707759_1", "context": "Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a patient"]], "start": [["a patient'.length"]], "entity_id": [],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":{"text":[["LEOPARD syndrome"]], "start": [[],["LEOPARD syndrome''.length"]], "entity_id": []}}, "Treatment": {"text": [["Flecainide"]], "start": [[],["Flecainide''.length"]], "entity_id": [],"Drug":{"text":[["Flecainide"]], "start": [[],["Flecainide''.length"]], "entity_id": []},"Disorder":null,"Dosage":null,"Duration":null,"Trigger":null,"Route":null,"Time_elapsed":null,"Freq":null,"Combination":null}, "Effect": {"text": [["pneumonitis with acute respiratory failure"]], "start": [[],["pneumonitis with acute respiratory failure''.length"]], "entity_id": []},"Negated":null,"Speculated":null,"Severity":null,"Trigger":{"text":[["Flecainide-associated"]], "start": [[],["Flecainide-associated''.length"]], "entity_id": []}}]}
{"id": "1433432_1", "context": "Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Seizure", "hyponatremia"]], "start": [[ ]], "entity_id": [["T1", "T2"]]}, "Subject": {"text": [["a child"]], "start": [[ ]], "entity_id": [["T3"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["desmopressin"]], "start": [[ ]], "entity_id": [["T4"]], "Drug": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null, "Combination": null, "Trigger": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "23624139_10","context": "Risks and benefits of co-treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["co-treatment"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["therapeutic alternatives to NSAIDs"]],"start": [["40"]],"entity_id": [],"Drug": {"text": [["NSAIDs"]],"start": [["52"]],"entity_id": []},"Disorder": {"text": [["central DI"]],"start": [["31"]],"entity_id": []},"Freq": {"text": [["should be recommended"]],"start": [["40"]],"entity_id": []},"Combination": [{"Drug": {"text": [["co-treatment"]],"start": [["0"]],"entity_id": []},"Trigger": {"text": [["co-treatment"]],"start": [["0"]],"entity_id": []},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["in order to improve DDAVP safety"]],"start": [["76"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["co-treatment"]],"start": [["0"]],"entity_id": []}},"Subject": {"text": [["patients"]],"start": [["68"]],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["central DI"]],"start": [["31"]],"entity_id": []}},"Effect": {"text": [["improve DDAVP safety"]],"start": [["76"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "15685264_6","context": "She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity._","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["Carbamazepine"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Carbamazepine"]],"start": [["16"]],"entity_id": [["T1"]],"Dosage": {"text": [["1000 mg/day"]],"start": [["30"]],"entity_id": [["T2"]]},"Duration": {"text": [["2 years"]],"start": [["46"]],"entity_id": [["T3"]]},"Disorder": {"text": [["neuropathic pain"]],"start": [["62"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treated"]],"start": [["10"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["for 2 years"]],"start": [["54"]],"entity_id": [["T6"]]},"Freq": {"text": [["/day"]],"start": [["30"]],"entity_id": [["T7"]]},"Route": {"text": [["treated"]],"start": [["10"]],"entity_id": [["T5"]]},"Combination": [],"Drug": {"text": [["Carbamazepine"]],"start": [["16"]],"entity_id": [["T1"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["She"]],"start": [["0"]],"entity_id": [["T8"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "11816261_1","context": "After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["these symptoms"]],"start": [["After a second dose of metoclopramide," ,"recurred and were associated with"]],"entity_id": []},"Treatment": {"text": [["a second dose of metoclopramide"]],"start": [[ "After a second dose of metoclopramide,"]],"entity_id": [],"Drug": {"text": [["metoclopramide"]],"start": [[ "After a second dose of metoclopramide,"]],"entity_id": []},"Dosage": {"text": [["a second dose"]],"start": [[ "After a second dose of metoclopramide,"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["confusion","agitation","fever","diaphoresis","tachypnea","tachycardia","hypertension"]],"start": [[ "confusion","agitation","fever","diaphoresis","tachypnea","tachycardia","hypertension"]],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17364199_4", "context": "We report the first case of tuberculous uveitis due to etanercept", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["tuberculous uveitis"]], "start": [[ "22" ]], "entity_id": [["T1"] ]}, "Treatment": { "text": [["etanercept"]], "start": [[ "54" ]], "entity_id": [ ["T2"] ] ,"Drug": { "text": [["etanercept"]], "start": [[ "54" ]], "entity_id": [ ["T2"] ] }, "Disorder": { "text": [["tuberculous uveitis"]], "start": [[ "22" ]], "entity_id": [["T1"] ] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Subject": { "text": [["We"]], "start": [[ "0" ]], "entity_id": [["T0"] ] ,"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["tuberculous uveitis"]], "start": [[ "22" ]], "entity_id": [["T1"] ] }}]}
{"id": "10516999_1","context": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute hyperphosphatemia"]],"start": [["0"]] ,"entity_id": [ ]},"Treatment": {"text": [["sodium phosphate enema"]],"start": [["48"]] ,"entity_id": [ ],"Drug": {"text": [["sodium phosphate"]],"start": [["48"]] ,"entity_id": [ ]} ,"Route": {"text": [["enema"]],"start": [["64"]] ,"entity_id": [ ]} ,"Disorder": {"text": [["liver dysfunction", "chronic renal failure"]],"start": [["100"]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["caused"]],"start": [["25"]] ,"entity_id": [ ]} ,"Freq": {"text": [["Acute"]],"start": [["0"]] ,"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": null },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["liver dysfunction", "chronic renal failure"]],"start": [["100"]] ,"entity_id": [ ]} }} ]}
{"id": "16882112_7","context": "Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["serotonin syndrome'."]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with lithium and venlafaxine"]],"start": [["treatment with lithium and venlafaxine"]],"entity_id": [["T2"]],"Drug": {"text": [["lithium"]],"start": [["lithium"]],"entity_id": [["T3"]]},"Dosage": {"text": [["venlafaxine"]],"start": [["venlafaxine"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["probable"]],"start": [["probable"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["lithium"]],"start": [[""], ["lithium"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [[""], ["and"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["indicated"]],"start": [[""], ["indicated"]],"entity_id": [["T8"]]} ,"Disorder": {"text": [["Naranjo adverse drug reaction probability algorithm"]],"start": [[""], ["Naranjo adverse drug reaction probability algorithm"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["Use"]],"start": [[""], ["Use"]],"entity_id": [["T9"]]} ,"Trigger": {"text": [["Use"]],"start": [[""], ["Use"]],"entity_id": [["T9"]]} ,"Route": {"text": [["a"]],"start": [[""], ["a"]],"entity_id": [["T10"]]}} ,"Effect": {"text": [["probable relationship"]],"start": [[""], ["probable relationship"]],"entity_id": [["T11"]]} ,"Negated": {"text": [[]],"start": [[], []],"entity_id": [["T12"]],"value": false},"Speculated": {"text": [["indicated"]],"start": [[""], ["indicated"]],"entity_id": [["T8"]],"value": false} ,"Subject": {"text": [[]],"start": [[], []],"entity_id": [["T13"]],"Age": {"text": [[]],"start": [[], []],"entity_id": [["T14"]]},"Gender": {"text": [[]],"start": [[], []],"entity_id": [["T15"]]},"Population": {"text": [[]],"start": [[], []],"entity_id": [["T16"]]},"Race": {"text": [[]],"start": [[], []],"entity_id": [["T17"]]},"Disorder": {"text": [[]],"start": [[], []],"entity_id": [["T18"]]}} ,"Severity": {"text": [["probable"]],"start": [[""], ["probable"]],"entity_id": [["T5"]],"value": "Medium"}}]}
{"id": "19203515_3", "context": "The exact mechanism of IVIG-associated acute renal failure remains unclear", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["IVIG-associated acute renal failure"]], "start": [[ ]],"entity_id": []}, "Negated": {"value": false, "text": [], "start": [], "entity_id": []}, "Speculated": {"value": false, "text": [], "start": [], "entity_id": []}, "Severity": {"value": "", "text": [], "start": [], "entity_id": []}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["IVIG"]], "start": [[]], "entity_id": []}},"Treatment": {"text": [], "start": [], "entity_id": [], "Drug": {"text": [["IVIG"]], "start": [[]], "entity_id": []}, "Disorder": {"text": [["acute renal failure"]], "start": [[]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null}, "Effect": null}]}
{"id": "1849334_2","context": "We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal neuromyeloencephalopathy"]],"start": [[ "developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy" ]],"entity_id": [["T1"]]},"Subject": {"text": [["7 patients"]],"start": [[ "We report on 7 patients" ]],"entity_id": [["T2"]],"Age": {"text": [["5 men", "2 women"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic renal failure"]],"start": [[ "We report on 7 patients (2 women, 5 men) with chronic renal failure" ]],"entity_id": [["T4"]]},"Population": {"text": [["7 patients"]],"start": [[ "We report on 7 patients" ]],"entity_id": [["T2"]]},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [["2 women", "5 men"]],"start": [[ "We report on 7 patients (2 women, 5 men)" ]],"entity_id": [["T3"]]}},"Treatment": {"text": [["muzolimine"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)" ]],"entity_id": [["T5"]],"Drug": {"text": [["muzolimine"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)" ]],"entity_id": [["T5"]]},"Dosage": {"text": [["240 to 1440 mg per day"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)" ]],"entity_id": [["T6"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["diuretic"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["fatal neuromyeloencephalopathy"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy" ]],"entity_id": [["T1"]]} ,"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []},"Severity": {"value": "high" ,"text": [["fatal"]],"start": [[ "who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy" ]],"entity_id": [["T1"]]}}]}
{"id": "1580986_2","context": "Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["Two renal transplant patients"]],"start": [[ "0" ]],"entity_id": [["S1"]],"Disorder": {"text": [["hypertension"]],"start": [["43"]],"entity_id": [["S2"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["enalapril medication"]],"start": [["61"]],"entity_id": [["T1"]],"Drug": {"text": [["enalapril"]],"start": [["61"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["hypertension"]],"start": [["43"]],"entity_id": [["S2"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["anemia"]],"start": [["24"]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["developed"]],"start": [["18"]],"entity_id": [["T3"]]}}]}
{"id": "7787496_1","context": "Sotalol-induced bradycardia reversed by glucagon","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Sotalol-induced bradycardia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": {"text": [["glucagon"]],"start": [[ "44" ]],"entity_id": [ ["T2" ]],"Drug": {"text": [["glucagon"]],"start": [[ "44" ]],"entity_id": [ ["T2" ]]} ,"Combination": null ,"Route": null ,"Dosage": null ,"Duration": null ,"Freq": null ,"Time_elapsed": null ,"Trigger": {"text": [["Sotalol-induced bradycardia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]} ,"Disorder": null },"Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null } ]}
{"id": "9892272_4","context": "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cutaneous ecchymosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["alteplase"]],"start": [["97"]],"entity_id": [["T3"]]} ,"text": [["administration"]],"start": [["76"]],"entity_id": [["T2"]] ,"Time_elapsed": {"text": [["after"]],"start": [["87"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["a sudden fall in hemoglobin"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Route": {"text": [["administration"]],"start": [["76"]],"entity_id": [["T2"]]},"Freq": {"text": [["the administration"]],"start": [["76"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["the development"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["alteplase"]],"start": [["97"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["the administration"]],"start": [["76"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["alteplase"]],"start": [["97"]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [["76"]],"entity_id": [["T2"]]} ,"event_id": "E2","event_type": "Therapeutic_effect"} ]} ,"Effect": {"text": [["diffuse subfascial hematoma"]],"start": [["118"]],"entity_id": [["T6"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [["The development"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": {"text": [["a sudden fall in hemoglobin"]],"start": [["42"]],"entity_id": [["T4"]]},"Gender": null,"Population": null,"Race": null }} ]}
{"id": "11545487_7","context": "We report a case of papillary necrosis in a patient treated with indinavir","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["papillary necrosis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["indinavir"]],"start": [["66"]],"entity_id": [["T2"]],"Drug": {"text": [["indinavir"]],"start": [["66"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["papillary necrosis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["treated"]],"start": [["43"]],"entity_id": [["T3"]]},"Duration": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Route": {"text": [["treated"]],"start": [["43"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T4"]]} ,"Freq": {"text": [["not mentioned"]],"start": [[""],[""]],"entity_id": [["T5"]]},"Combination": null ,"Trigger": null },"Effect": {"text": [["papillary necrosis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["patient"]],"start": [["11"]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["papillary necrosis"]],"start": [["18"]],"entity_id": [["T1"]]} }} ]}
{"id": "9247841_3","context": "Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide-induced reactions","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Generalized maculopapular", "papular purpuric eruptions"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["thionamide-induced"]],"start": [["43"]],"entity_id": [ ["T2"]],"Disorder": {"text": [["thionamide"]],"start": [["43"]],"entity_id": [ ["T3"]]} ,"Dosage": {"text": [["common"]],"start": [["62"]],"entity_id": [ ["T4"]]} ,"Freq": {"text": [["reactions"]],"start": [["70"]],"entity_id": [ ["T5"]]} ,"Combination": null ,"Drug": null ,"Route": null ,"Time_elapsed": null ,"Duration": null ,"Trigger": {"text": [["induced"]],"start": [["52"]],"entity_id": [ ["T6"]]} }, "Subject": null ,"Effect": null ,"Severity": null ,"Speculated": null ,"Negated": null} ]}
{"id": "8276031_6","context": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Imidazoline intoxication"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["overdose", "accidental ingestion", "normal therapeutic usage"]],"start": [[ "33", "46", "60" ]],"entity_id": [ ["T2"], ["T3"], ["T4"] ],"Drug": {"text": [["Imidazoline"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Freq": { "text": [["frequent"]], "start": [[ "112" ]], "entity_id": [ ["T5"] ]} ,"Disorder": { "text": [["children"]], "start": [[ "118" ]], "entity_id": [ ["T6"] ]} ,"Route": { "text": [["ingestion"]], "start": [[ "46" ]], "entity_id": [ ["T3"] ]} ,"Time_elapsed": { "text": [["after normal therapeutic usage"]], "start": [[ "60" ]], "entity_id": [ ["T4"] ]} ,"Dosage": { "text": [["overdose"]], "start": [[ "33" ]], "entity_id": [ ["T2"] ]} ,"Duration": { "text": [["frequent"]], "start": [[ "112" ]], "entity_id": [ ["T5"] ]} ,"Combination": null ,"Trigger": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null} ]}
{"id": "12121061_2","context": "A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ticlopidine-induced marrow aplasia"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 50-year-old diabetic and hypertensive male patient"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["50-year-old"]],"start": [["0"]],"entity_id": [["S1A"]]},"Disorder": {"text": [["diabetic", "hypertensive"]],"start": [["3","11"]],"entity_id": [["S1D1","S1D2"]]},"Gender": {"text": [["male"]],"start": [["16"]],"entity_id": [["S1G"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["S1P"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["partially responsive"]],"start": [["82"]],"entity_id": [["E1S1"]],"value": "low"},"Treatment": {"text": [["colony-stimulating factors and corticosteroids"]],"start": [["62"]],"entity_id": [["T2"]],"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"Combination": null,"Drug": {"text": [["colony-stimulating factors"]],"start": [["62"]],"entity_id": [["T2D1"]]},"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []}},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["complete recovery"]],"start": [["124"]],"entity_id": [["E2T1"]]},"Subject": {"text": [["A 50-year-old diabetic and hypertensive male patient"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["50-year-old"]],"start": [["0"]],"entity_id": [["S1A"]]},"Disorder": {"text": [["diabetic", "hypertensive"]],"start": [["3","11"]],"entity_id": [["S1D1","S1D2"]]},"Gender": {"text": [["male"]],"start": [["16"]],"entity_id": [["S1G"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["S1P"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Treatment": {"text": [["cyclosporine"]],"start": [["97"]],"entity_id": [["T3"]],"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"Combination": null,"Drug": {"text": [["cyclosporine"]],"start": [["97"]],"entity_id": [["T3D"]]},"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17522786_1", "context": "We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["neurointensive care (NIC) management"]], "start": [["0"]], "entity_id": [],"Drug": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["severe cerebral swelling", "raised intracranial pressure (ICP)"]], "start": [["49","61"]], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["sodium valproic acid (VPA)"]], "start": [["138"]], "entity_id": []},"Trigger": {"text": [["intoxication"]], "start": [["150"]], "entity_id": []},"event_id": "E1-1","event_type": "Adverse_event"} ],"Trigger": {"text": [], "start": [], "entity_id": []}},"Subject": {"text": [["patient"]], "start": [["32"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["severe cerebral swelling", "raised intracranial pressure (ICP)"]], "start": [["49","61"]], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []}},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Effect": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []}}]}
{"id": "8313300_7","context": "Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["poor compliance"]],"start": [["18"]],"entity_id": []},"Treatment": {"text": [["Lithium therapy"]],"start": [["0"]],"entity_id": [],"Disorder": {"text": [["intolerable polyuria"]],"start": [["56"]],"entity_id": []},"Drug": {"text": [["Lithium"]],"start": [["0"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": []},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "7594371_2", "context": "Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[ ], []],"entity_id": [["T3"], ["T4"]]}, "Treatment": null, "Effect": {"text": [["sensorineural hearing loss"]], "start": [[]],"entity_id": [["T5"]]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "19667003_14","context": "A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hyperammonemia"]],"start": [["33"]],"entity_id": [["T2"]]},"Treatment": {"text": [["carbamazepine therapy"]],"start": [["53"]],"entity_id": [["T3"]],"Drug": {"text": [["carbamazepine"]],"start": [["53"]],"entity_id": [["T4"]]},"Duration": {"text": [["three weeks"]],"start": [["44"]],"entity_id": [["T5"]]},"Disorder": {"text": [["bipolar disorder"]],"start": [["18"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger" : {"text" : [["initiating"]],"start":[[ "60" ]],"entity_id" : []}},"Effect": null,"Subject": {"text": [["A 26-year-old man"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["26"]],"start": [["2"]],"entity_id": [["T6"]]},"Gender": {"text": [["man"]],"start": [["13"]],"entity_id": [["T7"]]},"Population": null,"Race": null,"Disorder": {"text": [["bipolar disorder"]],"start": [["18"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11034877_2","context": "We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["gabapentin"]],"start": [["(GBP) + 34"]],"entity_id": [["T1"]]} ,"entity_id": [["T1"]],"text": [["gabapentin"]],"start": [["(GBP) + 34"]] ,"Trigger": {"text": [["received"]],"start": [["(GBP) + 7"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["behavioural side effects"]],"start": [["subsequently + 11"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["two"]],"start": [["We + 0"]],"entity_id": [["T4"]]} ,"Route": {"text": [["who"]],"start": [["We + 2"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["who"]],"start": [["We + 2"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["who"]],"start": [["We + 2"]],"entity_id": [["T5"]]},"Dosage": {"text": [["who"]],"start": [["We + 2"]],"entity_id": [["T5"]]} ,"Combination": null },"Subject": {"text": [["We"]],"start": [["We + 0"]],"entity_id": [["T4"]],"Gender": null,"Population": {"text": [["two"]],"start": [["We + 0"]],"entity_id": [["T4"]]},"Race": null,"Disorder": null,"Age": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["developed"]],"start": [["subsequently + 11"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["developed"]],"start": [["subsequently + 11"]],"entity_id": [["T3"]]} }] }
{"id": "21448111_6","context": "We can conclude that in this case, as in many others, akathisia as a possible adverse effect of psychopharmacs was very hard to identify","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["akathisia"]],"start": [["10"]],"entity_id": [["T1"]]},"Treatment": {"text": [["psychopharmacs"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["psychopharmacs"]],"start": [["51"]],"entity_id": [["T2"]]},"Disorder": {"text": [["akathisia"]],"start": [["10"]],"entity_id": [["T1"]]},"Freq": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["psychopharmacs"]],"start": [["51"]],"entity_id": [["T2"]]},"Trigger": {"text": [["psychopharmacs"]],"start": [["51"]],"entity_id": [["T2"]]},"event_id": "E1-1","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["this case"]],"start": [["41"]],"entity_id": [["T4"]]},"Duration": {"text": [["in many others"]],"start": [["48"]],"entity_id": [["T5"]]},"Dosage": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]]},"Route": {"text": [["psychopharmacs"]],"start": [["51"]],"entity_id": [["T2"]]},"Trigger": {"text": [["akathisia"]],"start": [["10"]],"entity_id": [["T1"]]}},"Effect": {"text": [["akathisia"]],"start": [["10"]],"entity_id": [["T1"]]},"Subject": {"text": [["this case"]],"start": [["41"]],"entity_id": [["T4"]],"Population": {"text": [["in many others"]],"start": [["48"]],"entity_id": [["T5"]]},"Age": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]]},"Gender": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]]},"Race": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]]},"Disorder": {"text": [["akathisia"]],"start": [["10"]],"entity_id": [["T1"]]}},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T6"]],"value": true},"Speculated": {"text": [["can conclude"]],"start": [["0"]],"entity_id": [["T7"]],"value": false},"Severity": {"text": [["very hard to identify"]],"start": [["70"]],"entity_id": [["T3"]],"value": "medium"}}]}
{"id": "7668127_2","context": "A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute subdural haematoma"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["patient"]],"start": [["86"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["angiomatous meningioma"]],"start": [["30"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["prophylactic aspirin therapy"]],"start": [["68"]],"entity_id": [["T4"]],"Drug": {"text": [["aspirin"]],"start": [["68"]],"entity_id": [["T5"]]},"Disorder": {"text": [["prophylactic"]],"start": [["68"]],"entity_id": [["T4"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16529136_4","context": "Monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["hypertensive crisis"]],"start": [["65"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Monoamine oxidase inhibitors (MAOIs)"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["complications"]],"start": [["32"]],"entity_id": [["T2"]]},"Trigger": {"text": [["unwittingly precipitate"]],"start": [["48"]],"entity_id": [["T3"]]},"Dosage": {"text": [["their use"]],"start": [["33"]],"entity_id": [["T2"]]},"Route": {"text": [["Monoamine oxidase inhibitors (MAOIs)"]],"start": [["0"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["unwittingly precipitate"]],"start": [["48"]],"entity_id": [["T3"]]},"Freq": {"text": [["may be unfamiliar"]],"start": [["40"]],"entity_id": [["T4"]]},"Combination": [{"event_type": "Potential_therapeutic_effect","event_id": "E2","Trigger": {"text": [["serotonin syndrome"]],"start": [["86"]],"entity_id": [["T5"]]},"Drug": {"text": [["Monoamine oxidase inhibitors (MAOIs)"]],"start": [["0"]],"entity_id": [["T0"]]}}],"Drug": {"text": [["Monoamine oxidase inhibitors (MAOIs)"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["may be unfamiliar"]],"start": [["40"]],"entity_id": [["T4"]]}},"Negated": {"text": [["may be unfamiliar"]],"start": [["40"]],"entity_id": [["T4"]],"value": false},"Speculated": {"text": [["may be unfamiliar"]],"start": [["40"]],"entity_id": [["T4"]],"value": false},"Severity": {"text": [["hypertensive crisis"]],"start": [["65"]],"entity_id": [["T1"]],"value": "high"},"Subject": {"text": [["medical and surgical practitioners"]],"start": [["49"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["complications"]],"start": [["32"]],"entity_id": [["T2"]]}},"Effect": {"text": [["hypertensive crisis"]],"start": [["65"]],"entity_id": [["T1"]]}}]}
{"id": "18294121_1","context": "According to the Naranjo adverse drug reaction probability scale, the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable (score of 6).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse drug reaction"]],"start": [["35"]],"entity_id": [["T4"]]},"Treatment": {"Drug": {"text": [["temozolomide"]],"start": [["68"]],"entity_id": [["T5"]]} ,"entity_id": [["T5"]] ,"Trigger": {"text": [["fever"]],"start": [["101"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["probable"]],"start": [["130"]],"entity_id": [["T7"]]},"Dosage": {"text": [["score of 6"]],"start": [["132"]],"entity_id": [["T8"]]} ,"Time_elapsed": {"text": [["probable"]],"start": [["130"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["adverse drug reaction"]],"start": [["35"]],"entity_id": [["T4"]]} ,"Route": {"text": [["oral"]],"start": [["68"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["long-term"]],"start": [["68"]],"entity_id": [["T5"]]} ,"Combination": [] ,"text": [["temozolomide"]],"start": [["68"]] },"Effect": {"text": [["fever"]],"start": [["101"]],"entity_id": [["T6"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T1"]] ,"Age": {"text": [["45"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Gender": {"text": [["male"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Population": {"text": [["1000"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Race": {"text": [["Caucasian"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["glioblastoma"]],"start": [["0"]],"entity_id": [["T2"]]}}} ]}
{"id": "10891991_4", "context": "To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["valproate-related reproductive endocrine disorders"]], "start": [["52-80"]], "entity_id": []}, "Subject": {"text": [["women"]], "start": [["15-20"]], "entity_id": [], "Gender": {"text": [["women"]], "start": [["15-20"]], "entity_id": []}, "Population": {"text": [["women"]], "start": [["15-20"]], "entity_id": []}, "Disorder": {"text": [["epilepsy"]], "start": [["42-45"]], "entity_id": []}, "Age": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["valproate"]], "start": [["5-11"]], "entity_id": [], "Drug": {"text": [["valproate"]], "start": [["5-11"]], "entity_id": []}, "Disorder": {"text": [["valproate-related reproductive endocrine disorders"]], "start": [["52-80"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": [],"Trigger":{"text":[], "start":[], "entity_id": []}},"Effect":{"text":[["development"]], "start":[["21-27"]], "entity_id": []},"Negated":{"text":[], "start":[], "entity_id": [],"value":false},"Speculated":{"text":[], "start":[], "entity_id": [],"value":false},"Severity":{"text":[], "start":[], "entity_id": [],"value":""}}]}
{"id": "2857534_1", "context": "Alprazolam-induced mania: two clinical cases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null,"Subject": null,"Treatment": {"text": [["Alprazolam"]], "start": [[ "0"]], "entity_id": [ ],"Drug": {"text": [["Alprazolam"]], "start": [[ "0"]], "entity_id": [ ] },"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": {"text": [["mania"]], "start": [[ "15"]], "entity_id": [ ] },"Combination": null ,"Trigger": {"text": [["Alprazolam-induced"]], "start": [[ "0"]], "entity_id": [ ] } },"Effect": {"text": [["mania"]], "start": [[ "15"]], "entity_id": [ ] } ,"Trigger": {"text": [["Alprazolam-induced"]], "start": [[ "0"]], "entity_id": [ ] } }]}
{"id": "6692713_3", "context": "To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": {"value": true, "text": [["has not been reported"]], "start": [[ "not been reported"]], "entity_id": []},"Trigger": {"text": [["recurrence", "amiodarone pulmonary toxicity"]], "start": [[ "recurrence", "amiodarone pulmonary toxicity"]], "entity_id": []}, "Subject": {"text": [["to our knowledge"]], "start": [[ "to our knowledge"]], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}, "Treatment": {"text": [["amiodarone"]], "start": [[ "amiodarone"]], "entity_id": [],"Drug": {"text": [["amiodarone"]], "start": [[ "amiodarone"]], "entity_id": []},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null , "Trigger": null},"Effect": {"text": [["recurrence of pulmonary toxicity"]], "start": [[ "recurrence"]], "entity_id": []},"Severity": null,"Speculated": null}]}
{"id": "10660641_2", "context": "A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["itraconazole"]], "start": [["21"]], "entity_id": [["T1"]]},"Disorder": {"text": [["Aspergillus flavus-induced chronic hypertrophic pachymeningitis"]], "start": [["72"]], "entity_id": [["T2"]]}, "Dosage": {"text": [["itraconazole (ITCZ)"]],"start": [["21"]],"entity_id": [["T1"]]}, "Route": {"text": [["treated"]],"start": [["13"]],"entity_id": [["T0"]]}, "Duration": {"text": [["is presented"]],"start": [["106"]],"entity_id": [["T3"]]}, "Trigger": {"text": [["treated"]],"start": [["13"]],"entity_id": [["T0"]]}, "entity_id": [["T0"], ["T1"], ["T2"], ["T3"]],"Time_elapsed": null,"Freq": null,"Combination": null,"text": [["itraconazole"], ["under"], ["the"], ["diagnosis"], ["of"], ["Aspergillus"], ["flavus-induced"], ["chronic"], ["hypertrophic"], ["pachymeningitis"], ["is"], ["presented"]],"start": [["21"], ["51"], ["54"], ["57"], ["60"], ["65"], ["72"], ["78"], ["85"], ["92"], ["98"], ["106"]]},"Subject": {"text": [["A", "patient"]],"start": [["0"]],"entity_id": [["T4"]],"Age": null,"Disorder": null,"Gender": null,"Race": null,"Population": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": {"text": [["treated"]],"start": [["13"]],"entity_id": [["T0"]]}}]}
{"id": "12802933_1","context": "Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["autoimmune hemolytic anemia"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rituximab therapy"]],"start": [["43"]],"entity_id": [["T2"]],"Drug": {"text": [["rituximab"]],"start": [["43"]],"entity_id": [["T3"]]},"Disorder": {"text": [["lymphoproliferative disorder"]],"start": [["71"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following"]],"start": [["22"]],"entity_id": [["T5"]]},"Freq": {"text": [["severe"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["rituximab"]],"start": [["43"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["43"]],"entity_id": [["T2"]]},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["therapy"]],"start": [["43"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["lymphoproliferative disorder"]],"start": [["71"]],"entity_id": [["T4"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["severe"]],"start": [["0"]],"entity_id": [["T0"]],"value": "severe"}}]}
{"id": "7428724_2", "context": "Oesophageal ulceration due to emepronium bromide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Oesophageal ulceration"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Treatment": { "text": [["emepronium bromide"]], "start": [[ "47" ]], "entity_id": [ ["T2" ]], "Drug": { "text": [["emepronium bromide"]], "start": [[ "47" ]], "entity_id": [ ["T3" ]] } ,"Combination": null ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Trigger": null, "Disorder": null } ,"Effect": { "text": [["Oesophageal ulceration"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "16432996_1", "context": "Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sarcoidosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["interferon alpha 2b and ribavirin combination therapy"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["interferon alpha 2b", "ribavirin"]],"start": [["42", "63"]],"entity_id": [["T3","T4"]]},"Combination": [{"Drug":{"text":[["interferon alpha 2b"]],"start":[[ "42" ]],"entity_id":[["T3"]]},"Trigger":{"text":[["and"]],"start":[[ "54" ]],"entity_id":[["T5"]]},"event_type":"Adverse_event","event_id":"E2"}],"Disorder": {"text": [["chronic hepatitis C"]],"start": [["83"]],"entity_id": [["T6"]]},"Duration": {"text": [["during"]],"start": [["41"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "9022114_2","context": "The findings in these two patients suggest that colchicine may delay corneal wound healing","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["colchicine"]],"start": [[ "0" ]],"entity_id": [ ] ,"Drug": null ,"Disorder": {"text": [["corneal wound healing"]],"start": [[ "43"]],"entity_id": [ ["T1"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["may delay"]],"start": [[ "21"]],"entity_id": [ ["T2"]]}},"Effect": null,"Negated": null,"Speculated": {"text": [["suggests"]],"start": [[ "48"]],"entity_id": [ ["T3"]] ,"value": false} ,"Severity": null,"Subject": null ,"Trigger": null}]}
{"id": "12324937_3", "context": "Gemcitabine-associated hemolytic-uremic syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Gemcitabine-associated hemolytic-uremic syndrome"]], "start": [[ "Start" ]], "entity_id": [ ]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[ "Start" ]], "entity_id": [ ],"Drug": null , "Disorder": { "text": [["hemolytic-uremic syndrome"]], "start": [[ "Start" ]], "entity_id": [ ] } , "Dosage": null , "Duration": null , "Trigger": null , "Route": null , "Time_elapsed": null , "Freq": null , "Combination": null } , "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": { "text": [[ ]], "start": [[ ]], "entity_id": [ ] , "Age": null , "Disorder": { "text": [[ ]], "start": [[ ]], "entity_id": [ ] }, "Gender": null , "Population": null , "Race": null } }]}
{"id": "9100429_1", "context": "Case study: adverse response to clonidine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse response"]], "start": [["18","19"]], "entity_id": []}, "Treatment": {"text": [["clonidine"]], "start": [["43"]], "entity_id": [], "Drug": {"text": [["clonidine"]], "start": [["43"]], "entity_id": [] } , "Disorder": {"text": [["adverse response"]], "start": [["18","19"]], "entity_id": [] } , "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null , "Trigger": null } , "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [], "start": [], "entity_id": []} } }]}
{"id": "17163271_2","context": "In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["thrombosis"]],"start": [["developed thrombosis of the central retinal vein 5 years following the transplantation" , "transplantation" ]],"entity_id": [ ]},"Treatment": {"text": [["renal transplantation"]],"start": [["In this report,"]],"entity_id": [ ] ,"Drug": {"text": [["cyclosporin"]],"start": [[""]],"entity_id": [ ] }, "Dosage": null,"Duration": null,"Disorder": {"text": [["malignant hypertension"]],"start": [["In this report,"]],"entity_id": [ ] },"Route": null,"Time_elapsed": {"text": [["5 years"]],"start": [[""]],"entity_id": [ ] } ,"Freq": null ,"Combination": null ,"Trigger": null},"Effect": {"text": [["thrombosis of the central retinal vein"]],"start": [["developed thrombosis of the central retinal vein 5 years following the transplantation"]],"entity_id": [ ] } ,"Subject": {"text": [["a patient"]],"start": [["In this report,"]],"entity_id": [ ] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["malignant hypertension"]],"start": [["In this report,"]],"entity_id": [ ] } } ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16629074_1", "context": "To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["traumatic flap dehiscence"]], "start": [["12"]], "entity_id": [ ["T1"]]},"Subject": {"text": [["To report a case"]], "start": [[ "0"]], "entity_id": [ ["T0"]] ,"Age": { "text": [["34 months after LASIK"]], "start": [[ "67"]], "entity_id": [ ["T3"]]} ,"Disorder": { "text": [["Enterobacter keratitis"]], "start": [[ "43"]], "entity_id": [ ["T2"]]} ,"Gender": null, "Population": null, "Race": null }, "Treatment": null ,"Effect": { "text": [["traumatic flap dehiscence"]], "start": [[ "12"]], "entity_id": [ ["T1"]]} ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "9220046_2","context": "The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["lovastatin"]],"start": [[ "lovastatin" ]],"entity_id": [ ["T1"]] ,"Drug": {"text": [["lovastatin"]],"start": [[ "lovastatin" ]],"entity_id": [ ["T1"]] },"Trigger": {"text": [["concomitant use"]],"start": [[ "concomitant use" ]],"entity_id": [ ["T2"]] },"Disorder": {"text": [["drug-induced rhabdomyolysis"]],"start": [[ "drug-induced rhabdomyolysis" ]],"entity_id": [ ["T3"]] },"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["azithromycin"]],"start": [[ "azithromycin" ]],"entity_id": [ ["T4"]] },"Trigger": {"text": [["or clarithromycin"]],"start": [[ "or clarithromycin" ]],"entity_id": [ ["T5"]] },"event_id": "E1-1" ,"event_type": "Potential_therapeutic_effect" }] },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }] }
{"id": "1509179_2","context": "Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["phenobarbital"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenobarbital"]],"start": [["23"]],"entity_id": [["T1"]],"Drug": {"text": [["phenobarbital"]],"start": [["23"]],"entity_id": [["T1"]]},"Disorder": {"text": [["exacerbating maladaptive behaviors"]],"start": [["53"]],"entity_id": [["T2"]]},"Trigger": {"text": [["exacerbating maladaptive behaviors"]],"start": [["53"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["Ten years of behavioral data"]],"start": [["0"]],"entity_id": [["T3"]]},"Freq": {"text": [["Ten years"]],"start": [["0"]],"entity_id": [["T3"]]},"Duration": {"text": [["Ten years"]],"start": [["0"]],"entity_id": [["T3"]]},"Route": {"text": [["presented"]],"start": [["10"]],"entity_id": [["T4"]]},"Dosage": {"text": [["Ten years of behavioral data"]],"start": [["0"]],"entity_id": [["T3"]]},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "8835752_2","context": "Terbinafine-induced cholestatic liver disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Terbinafine-induced"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["Terbinafine"]],"start": [[ "0" ]],"entity_id": [["T2"]],"Drug": {"text": [["Terbinafine"]],"start": [[ "0" ]],"entity_id": [["T2"]]},"Disorder": {"text": [["cholestatic liver disease"]],"start": [[ "16" ]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["cholestatic liver disease"]],"start": [[ "16" ]],"entity_id": [["T3"]]}}]}
{"id": "21789791_2","context": "The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["Bortezomib"]],"start": [["13"]],"entity_id": [["T1"]]},"text": [["The proteasome inhibitor Bortezomib"]],"start": [["0"]],"entity_id": [["T2"]] ,"Trigger": {"text": [["enhancer"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Time_elapsed": null,"Freq": null,"Route": null,"Dosage": null,"Duration": null ,"Disorder": {"text": [["human cancers"]],"start": [["93"]],"entity_id": [["T4"]]} ,"Combination": null } ,"Effect": {"text": [["apoptosis"]],"start": [["79"]],"entity_id": [["T5"]] } ,"Subject": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null } ] }
{"id": "19116715_2","context": "A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["gemcitabine-related HUS"]],"start": [["23"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["43"]],"entity_id": [["T2"]],"Disorder": {"text": [["metastatic pancreatic adenocarcinoma"]],"start": [["51"]],"entity_id": [["T3"]]},"Age": {"text": [[" "]],"start": [[""], ["43"]],"entity_id": [["A1"]]},"Gender": {"text": [[" "]],"start": [[""], ["43"]],"entity_id": [["G1"]]},"Population": {"text": [[" "]],"start": [[""], ["43"]],"entity_id": [["P1"]]},"Race": {"text": [[" "]],"start": [[""], ["43"]],"entity_id": [["R1"]]}},"Treatment": {"text": [["rituximab"]],"start": [["109"]],"entity_id": [["T4"]],"Drug": {"text": [["rituximab"]],"start": [["109"]],"entity_id": [["D1"]]},"Dosage": {"text": [[" "]],"start": [[""], ["109"]],"entity_id": [["Dg1"]]},"Duration": {"text": [[" "]],"start": [[""], ["109"]],"entity_id": [["Du1"]]},"Trigger": {"text": [["in addition to"]],"start": [["93"]],"entity_id": [["T5"]]},"Route": {"text": [[" "]],"start": [[""], ["109"]],"entity_id": [["Rt1"]]},"Time_elapsed": {"text": [[" "]],"start": [[""], ["109"]],"entity_id": [["Te1"]]},"Freq": {"text": [[" "]],"start": [[""], ["109"]],"entity_id": [["F1"]]},"Disorder": {"text": [["to treat metastatic pancreatic adenocarcinoma"]],"start": [["76"]],"entity_id": [["D2"]]},"Combination": [{"Drug": {"text": [["standard therapies"]],"start": [["65"]],"entity_id": [["D3"]]},"Trigger": {"text": [["in addition to"]],"start": [["93"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Treatment"}]},"Effect": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["Ef1"]]},"Negated": {"text": [["not"]],"start": [[""], ["0"]],"entity_id": [["N1"]],"value": false},"Speculated": {"text": [["is presented"]],"start": [["138"]],"entity_id": [["Sp1"]],"value": false},"Severity": {"text": [[" "]],"start": [[""], ["0"]],"entity_id": [["S1"]],"value": "Low"}}]}
{"id": "2595431_3","context": "Their parkinsonism improved on discontinuation of metoclopramide therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["improved"]],"start": [["15"]],"entity_id": []},"Treatment": {"text": [["discontinuation of metoclopramide therapy"]],"start": [["33"]],"entity_id": [],"Drug": {"text": [["metoclopramide"]],"start": [["50"]],"entity_id": []} ,"Disorder": {"text": [["parkinsonism"]],"start": [["0"]],"entity_id": []} ,"Trigger": {"text": [["discontinuation"]],"start": [["33"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"text": [["Their"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["parkinsonism"]],"start": [["0"]],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18453852_4", "context": "A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1-5", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["600 mg rifampicin once daily"]], "start": [["32"]], "entity_id": [],"Drug": {"text": [["rifampicin"]], "start": [["32"]], "entity_id": []}, "Dosage": {"text": [["600 mg"]], "start": [["32"]], "entity_id": []}, "Duration": {"text": [["once daily from days 1-5"]], "start": [["42"]], "entity_id": []}, "Route": {"text": [["daily"]], "start": [["32"]], "entity_id": []}, "Freq": {"text": [["once"]], "start": [["32"]], "entity_id": []}, "Disorder": {"text": [["planned to start"]], "start": [["15"]], "entity_id": []}, "Time_elapsed": {"text": [["start"]], "start": [["28"]], "entity_id": []}, "Trigger": {"text": [["planned"]], "start": [["15"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["rifampicin"]], "start": [["32"]], "entity_id": []},"Trigger": {"text": [["planned to start"]], "start": [["15"]], "entity_id": []}, "event_id": "C1", "event_type": "Potential_therapeutic_effect"}]}, "Subject": {"text": [["40 healthy volunteers"]], "start": [["0"]], "entity_id": [],"Age": {"text": [[]], "start": [[],[]], "entity_id": []}, "Gender": {"text": [[]], "start": [[],[]], "entity_id": []}, "Population": {"text": [[ "40"]], "start": [["0"]], "entity_id": []}, "Race": {"text": [[]], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [[]], "start": [[],[]], "entity_id": []}}, "Effect": {"text": [], "start": [[],[]], "entity_id": []}, "Negated": {"text": [], "start": [[],[]], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [[],[]], "entity_id": [],"value": false},"Severity": {"text": [], "start": [[],[]], "entity_id": [],"value": ""}, "Trigger": {"text": [["planned"]], "start": [["15"]], "entity_id": []}}]}
{"id": "20098333_1", "context": "Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["anthracycline-induced early chronic cardiomyopathy"]], "start": [[ "0" ]], "entity_id": [ ["S1"] ] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["cardiomyopathy"]], "start": [[ "32" ]], "entity_id": [ ["S2"] ] }},"Treatment": {"text": [["ATRA"]], "start": [[ "61" ]], "entity_id": [ ["T1"] ],"Drug": {"text": [["ATRA"]], "start": [[ "61" ]], "entity_id": [ ["T1"] ] },"Disorder": {"text": [["cardiomyopathy"]], "start": [[ "32" ]], "entity_id": [["S2"] ] },"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null },"Effect": {"text": [["Exacerbation"]], "start": [[ "0" ]], "entity_id": [ ["E1"] ] }, "Trigger": {"text": [["Exacerbation"]], "start": [[ "0" ]], "entity_id": [ ["E1"] ] }} ]}
{"id": "10395123_2","context": "Fixed drug eruption in hands caused by omeprazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Fixed drug eruption"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["omeprazole"]],"start": [[ ]],"entity_id": [ ],"Drug": { "text": [["omeprazole"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": null ,"Combination": null ,"Trigger": { "text": [["caused by"]],"start": [[ ]],"entity_id": [ ]} },"Subject": { "text": [["in hands"]],"start": [[ ]],"entity_id": [ ],"Age": null,"Gender": null,"Disorder": null,"Population": null,"Race": null },"Effect": { "text": [["Fixed drug eruption"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "12699871_1", "context": "FK506, which began to be administered 12 days earlier, rose to a level of 44 ng//mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["FK506"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]],"Dosage": {"text": [["began to be administered 12 days earlier"]], "start": [["26" ]], "entity_id": [ ["T2" ]]},"Drug": {"text": [["FK506"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]},"Time_elapsed": {"text": [["1 day before neurologic abnormalities began"]], "start": [[ "87" ]], "entity_id": [ ["T3" ]]},"Trigger": {"text": [["rose to a level"]], "start": [[ "51" ]], "entity_id": [ ["T4" ]]},"Freq": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Combination": null},"Effect": null,"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Subject": null,"Trigger": null}]}
{"id": "2016556_1","context": "We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["chronic nausea", "an episode of confusion"]],"start": [[ ], []],"entity_id": [["T1"],["T2"]]},"Treatment": {"text": [["oral morphine"]],"start": [[ ]],"entity_id": [["T3"]],"Dosage": {"text": [["small, stable dose"]],"start": [[ ]],"entity_id": [["T4"]]},"Route": {"text": [["oral"]],"start": [[ ]],"entity_id": [["T4"]]},"Disorder": {"text": [["mild renal insufficiency"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Drug": {"text": [["morphine"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Freq": {"text": [["while treated"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["while treated"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["treated"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Duration": {"text": [["chronic"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["oral morphine"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["treated"]],"start": [[ ]],"entity_id": [["T4"]]} ,"event_type": "Adverse_event" ,"event_id": "E1" }] }, "Subject": { "text": [["a patient"]],"start": [[ ]],"entity_id": [["T0"]],"Age": {"text": [[" "]],"start": [[ ]],"entity_id": [["T0"]]},"Gender": {"text": [[" "]],"start": [[ ]],"entity_id": [["T0"]]},"Race": {"text": [[" "]],"start": [[ ]],"entity_id": [["T0"]]},"Population": {"text": [[" "]],"start": [[ ]],"entity_id": [["T0"]]},"Disorder": {"text": [["mild renal insufficiency"]],"start": [[ ]],"entity_id": [["T5"]]} }, "Effect": { "text": [["chronic nausea", "an episode of confusion"]],"start": [[ ], []],"entity_id": [["T1"], ["T2"]] }, "Negated": null,"Speculated": null,"Severity": null }]}
{"id": "2011096_1", "context": "Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Bulbar and pseudobulbar palsy"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["therapy with high-dose cytosine arabinoside"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["high-dose cytosine arabinoside"]], "start": [[ ]], "entity_id": [ ]},"Dosage": { "text": [["high-dose"]], "start": [[ ]], "entity_id": [ ] },"Disorder": { "text": [["leukemia"]], "start": [[ ]], "entity_id": [ ] },"Route": { "text": [["therapy"]], "start": [[ ] ], "entity_id": [ ] },"Time_elapsed": { "text": [["complicating"]], "start": [[ ]], "entity_id": [ ] },"Freq": { "text": [["therapy with"]], "start": [[ ]], "entity_id": [ ] },"Combination": [{ "Drug": { "text": [["high-dose cytosine arabinoside"]], "start": [[ ]] , "entity_id": [ ]} , "Trigger": { "text": [["therapy"]], "start": [[ ]], "entity_id": [ ]} , "event_type": "Adverse_event" , "event_id": "E2" } ] , "Trigger": { "text": [["Bulbar and pseudobulbar palsy"]], "start": [[ ]], "entity_id": [ ]},"Duration": { "text": [["therapy with high-dose cytosine arabinoside"]], "start": [[ ]], "entity_id": [ ] } } ,"Subject": { "text": [["children with leukemia"]], "start": [[ ]], "entity_id": [ ],"Age": { "text": [["children"]], "start": [[ ]], "entity_id": [ ] },"Disorder": { "text": [["leukemia"]], "start": [[ ]], "entity_id": [ ] },"Population": { "text": [["children with leukemia"]], "start": [[ ]], "entity_id": [ ] } ,"Gender": { "text": [], "start": [[ ]], "entity_id": [] },"Race": { "text": [], "start": [[ ]], "entity_id": [] } }, "Negated": null, "Speculated": null, "Severity": null , "Effect": { "text": [["Bulbar and pseudobulbar palsy"]], "start": [[ ]], "entity_id": [ ]}}]}
{"id": "25538343_3","context": "Administration of thiazide diuretics also has been the cause of hyponatremia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Administration", "has been the cause"]],"start": [[ ], []],"entity_id": []},"Treatment": {"text": [["thiazide diuretics"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["thiazide diuretics"]],"start": [[ ]],"entity_id": []}, "Disorder": {"text": [["hyponatremia"]],"start": [[ ]],"entity_id": []}, "Freq": {"text": [["also"]],"start": [[ ]],"entity_id": []}, "Route": {"text": [["Administration"]],"start": [[ ]],"entity_id": []}, "Time_elapsed": {"text": [["has been the cause"]],"start": [[ ]],"entity_id": []}, "Trigger": {"text": [["Administration", "has been the cause"]],"start": [[ ], []],"entity_id": []}, "Dosage": {"text": [["thiazide diuretics"]],"start": [[ ]],"entity_id": []}, "Duration": {"text": [["thiazide diuretics"]],"start": [[ ]],"entity_id": []}, "Combination": null}, "Negated": null,"Speculated": null,"Severity": null,"Subject": null, "Effect": {"text": [["hyponatremia"]],"start": [[ ]],"entity_id": []}}]}
{"id": "7519913_1","context": "However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["may be associated"]],"start": [["However, there remain questions concerning whether these drugs,","especially methimazole (MMI)"," may be associated with aplasia cutis congenita (ACC)"]],"entity_id": []},"Treatment": {"text": [["methimazole (MMI)"]],"start": [[",especially methimazole (MMI),"]],"entity_id": [],"Disorder": {"text": [["aplasia cutis congenita (ACC)"]],"start": [[", especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC)"]],"entity_id": []},"Freq": {"text": [["how best to avoid"]],"start": [[", and how best to avoid impairment of fetal thyroid function during their use"]],"entity_id": []},"Time_elapsed": {"text": [["during"]],"start": [[", and how best to avoid impairment of fetal thyroid function during their use"]],"entity_id": []},"Drug": {"text": [["their use"]],"start": [[", and how best to avoid impairment of fetal thyroid function during their use"]],"entity_id": []},"Duration": {"text": [["during their use"]],"start": [[", and how best to avoid impairment of fetal thyroid function during their use"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["impairment of fetal thyroid function"]],"start": [[", and how best to avoid impairment of fetal thyroid function during their use"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "10357715_3", "context": "The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.","is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["help"]], "start": [[ "58" ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["treatment with calcipotriol"]], "start": [[ "118" ]], "entity_id": [["T2"]], "Drug": {"text": [["calcipotriol"]], "start": [[ "118" ]], "entity_id": [["T3"]]},"Disorder": {"text": [["contact dermatitis"]], "start": [[ "85" ]], "entity_id": [["T4"]]},"Dosage": {"text": [["different testing doses", "lower testing doses"]], "start": [[ "50" ]], "entity_id": [["T5"]]}, "Freq": {"text": [["differentiate"]], "start": [[ "71" ]], "entity_id": [["T6"]]}, "Route": {"text": [["after treatment"]], "start": [[ "106" ]], "entity_id": [["T7"]]}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": null}]}
{"id": "1068531_1","context": "Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute erythroid leukemia"]],"start": [[ ], [ ]],"entity_id": [ ]},"Treatment": {"text": [["cyclophosphamide therapy"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["cyclophosphamide"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["multiple myeloma"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": null} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high"} ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "1642627_1","context": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["behavioural", "cognitive adverse effects"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["triazolam"]],"start": [[ "38" ]],"entity_id": [["T2"]],"Drug": {"text": [["triazolam"]],"start": [[ "38" ]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["triazolam"]],"start": [[ "38" ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["behavioural", "cognitive adverse effects"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["eating disorder"]],"start": [[ "94" ]],"entity_id": [["T4"]]},"Dosage": null,"Freq": null,"Route": null,"Trigger": null }, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": {"text": [["behavioural", "cognitive adverse effects"]],"start": [[ "0" ]],"entity_id": [["T1"]]} }]}
{"id": "8908396_2", "context": "Insulin-induced lipoatrophy in type I diabetes", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Insulin-induced lipoatrophy"]], "start": [["0"]],"entity_id": [ ]},"Treatment": {"text": [["Insulin"]], "start": [["0"]], "entity_id": [ ],"Disorder": {"text": [["type I diabetes"]], "start": [["24"]], "entity_id": [ ]} ,"Dosage": null, "Freq": null, "Route": null, "Time_elapsed": null, "Duration": null ,"Combination": null ,"Drug": null ,"Trigger": null }, "Effect": {"text": [["Insulin-induced lipoatrophy"]], "start": [["0"]], "entity_id": [ ]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["patient(s)"]], "start": [[ "-1" ]], "entity_id": [ ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["type I diabetes"]], "start": [[ "24" ]], "entity_id": [ ]} } }]}
{"id": "2327115_4","context": "This article describes a patient with suspected ciprofloxacin-induced interstitial nephritis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["suspected ciprofloxacin-induced interstitial nephritis"]],"start": [[ "0" ] ],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["ciprofloxacin"]],"start": [[ "52" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["interstitial nephritis"]],"start": [[ "32" ]],"entity_id": [["T3"]]} ,"entity_id": [["T4"]] ,"text": [["ciprofloxacin-induced interstitial nephritis"]],"start": [[ "44" ]],"Dosage": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} ,"Route": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} ,"Duration": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} ,"Freq": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} ,"Combination": null ,"Trigger": {"text": [["induced"]],"start": [[ "51" ]],"entity_id": [["T5"]]} },"Subject": {"text": [["patient"]],"start": [[ "9" ]],"entity_id": [["T6"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patient"]],"start": [[ "9" ]],"entity_id": [["T6"]]} },"Effect": {"text": [["interstitial nephritis"]],"start": [[ "32" ]],"entity_id": [["T3"]]} ,"Negated": null,"Speculated": {"text": [["suspected"]],"start": [[ "0" ]],"entity_id": [["T0"]] ,"value": true },"Severity": null }]}
{"id": "10607332_1","context": "We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["3 cases of HIV-1 infected patients"]],"start": [["0"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["HIV-1 infected"]],"start": [["15"]],"entity_id": [["S2"]]}},"Treatment": {"text": [["antiretroviral therapy including the protease inhibitor indinavir"]],"start": [["48"]],"entity_id": [["T1"]],"Drug": {"text": [["indinavir"]],"start": [["91"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["antiretroviral therapy"]],"start": [["48"]],"entity_id": [["T3"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["starting"]],"start": [["66"]],"entity_id": [["T4"]]}},"Effect": {"text": [["symptomatic angiolipomas"]],"start": [["101"]],"entity_id": [["E1"]]},"Trigger": {"text": [["shortly after"]],"start": [["74"]],"entity_id": [["T5"]]}}]}
{"id": "11093071_1","context": "Depressive symptoms disappeared after interferon therapy was stopped","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Depressive symptoms"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["interferon therapy"]],"start": [["52"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["interferon"]],"start": [["52"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["Depressive symptoms"]],"start": [["0"]],"entity_id": [["T1"] ]},"Time_elapsed": {"text": [["after"]],"start": [["30"]],"entity_id": [ ["T4"] ]} ,"Freq": {"text": [["was stopped"]],"start": [["49"]],"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [],"value": false },"Severity": {"text": [],"start": [],"entity_id": [],"value": "" },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Depressive symptoms"]],"start": [["0"]],"entity_id": [ ["T1"] ]} },"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "12776809_2","context": "Coumarin is reported to elevate liver function tests (LFT) values","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Coumarin"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["Coumarin"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["Coumarin"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["elevate liver function tests (LFT) values"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": { "text": [["reported"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": { "text": [],"start": [[ ]],"entity_id": []} ,"Duration": { "text": [],"start": [[ ]],"entity_id": []} ,"Route": { "text": [],"start": [[ ]],"entity_id": []} ,"Freq": { "text": [],"start": [[ ]],"entity_id": []} ,"Combination": null ,"Trigger": { "text": [["Coumarin"]],"start": [[ ]],"entity_id": [ ]} } ,"Subject": { "text": [],"start": [[ ]],"entity_id": [] ,"Age": { "text": [],"start": [[ ]],"entity_id": []} ,"Gender": { "text": [],"start": [[ ]],"entity_id": []} ,"Population": { "text": [],"start": [[ ]],"entity_id": []} ,"Race": { "text": [],"start": [[ ]],"entity_id": []} ,"Disorder": { "text": [],"start": [[ ]],"entity_id": []}} ,"Effect": { "text": [["elevate liver function tests (LFT) values"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": null } ] }
{"id": "6837655_3","context": "Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["continuous daily isoniazid and rifampin therapy"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["isoniazid", "rifampin"]],"start": [[ "4", "36"]],"entity_id": [["T2", "T3"]]},"Disorder": {"text": [["pulmonary tuberculosis"]],"start": [["56"]],"entity_id": [["T4"]]},"Duration": {"text": [["3 weeks"]],"start": [["1"]],"entity_id": [["T5"]]},"Route": {"text": [["therapy"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["daily"]],"start": [["3"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["acute renal failure"]],"start": [["84"]],"entity_id": [["T7"]]},"Trigger": {"text": [["developed"]],"start": [["80"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["isoniazid"]],"start": [[ "4"]],"entity_id": [["T2"]]},"Trigger": {"text": [["therapy"]],"start": [["0"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]}},"Subject": {"text": [["a patient"]],"start": [["74"]],"entity_id": [["T9"]],"Population": {"text": [["a patient"]],"start": [["74"]],"entity_id": [["T9"]]},"Age": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Disorder": {"text": [["pulmonary tuberculosis"]],"start": [["56"]],"entity_id": [["T4"]]}},"Effect": {"text": [["acute renal failure"]],"start": [["84"]],"entity_id": [["T7"]]},"Negated": {"text": [["not"]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": false},"Speculated": {"text": [["not"]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": false},"Severity": {"text": [["acute"]],"start": [["84"]],"entity_id": [["T7"]],"value": "high"},"Trigger": {"text": [["developed"]],"start": [["80"]],"entity_id": [["T8"]]}}]}
{"id": "8862924_5","context": "We report four cases of severe corneal ulceration in methamphetamine abusers","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe corneal ulceration"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methamphetamine"]],"start": [["53"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["abusers"]],"start": [["59"]],"entity_id": [["T3"]]},"Duration": null,"Dosage": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["abusers"]],"start": [["59"]],"entity_id": [["T3"]]}},"Subject": {"text": [["four cases"]],"start": [["6"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["T4"]] ,"value": "high"}}]}
{"id": "7375145_1","context": "Diagnosis: practolol induced sclerosing peritonitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["practolol induced sclerosing peritonitis"]],"start": [[""], []],"entity_id": []},"Treatment": {"text": [["practolol"]],"start": [[""], []],"entity_id": [] ,"Drug": {"text": [["practolol"]],"start": [[""], []],"entity_id": []} ,"Disorder": {"text": [["practolol induced sclerosing peritonitis"]],"start": [[""], []],"entity_id": []} ,"Freq": {"text": [["induced"]],"start": [[""], []],"entity_id": []} ,"Route": {"text": [["induced"]],"start": [[""], []],"entity_id": []} ,"Duration": {"text": [["practolol induced sclerosing peritonitis"]],"start": [[""], []],"entity_id": []} ,"Time_elapsed": {"text": [["induced"]],"start": [[""], []],"entity_id": []} ,"Trigger": {"text": [["induced"]],"start": [[""], []],"entity_id": []} ,"Dosage": {"text": [["practolol induced sclerosing peritonitis"]],"start": [[""], []],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [["practolol induced sclerosing peritonitis"]],"start": [[""], []],"entity_id": []} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "19039026_2","context": "We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute interstitial nephritis"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with Sunitinib"]],"start": [["84"]],"entity_id": [["T2"]],"Drug": {"text": [["Sunitinib"]],"start": [["84"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["metastatic renal cell cancer"]],"start": [["109"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["first"]],"start": [["33"]],"entity_id": [["F1"]]} ,"Combination": [{"Drug": {"text": [["Sunitinib"]],"start": [["84"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["84"]],"entity_id": [["T2"]]} ,"event_id": "C1","event_type": "Treatment"}] ,"Time_elapsed": {"text": [["first"]],"start": [["33"]],"entity_id": [["F1"]]} ,"Duration": {"text": [["occurrence"]],"start": [["33"]],"entity_id": [["D1"]]} ,"Dosage": {"text": [["biopsy confirmed"]],"start": [["33"]],"entity_id": [["D1"]]} ,"Route": {"text": [["treatment"]],"start": [["84"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["occurrence"]],"start": [["33"]],"entity_id": [["D1"]]} },"Subject": {"text": [["patient"]],"start": [["55"]],"entity_id": [["S1"]],"Age": {"text": [["first"]],"start": [["33"]],"entity_id": [["F1"]]} ,"Disorder": {"text": [["metastatic renal cell cancer"]],"start": [["109"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["-"]],"start": [["-"]],"entity_id": [["G1"]]} ,"Population": {"text": [["-"]],"start": [["-"]],"entity_id": [["P1"]]} ,"Race": {"text": [["-"]],"start": [["-"]],"entity_id": [["R1"]]} },"Speculated": {"text": [["first"]],"start": [["33"]],"entity_id": [["F1"]],"value": false} ,"Negated": {"text": [["-"]],"start": [["-"]],"entity_id": [["N1"]],"value": false} ,"Severity": {"text": [["acute"]],"start": [["33"]],"entity_id": [["S2"]],"value": "High"} ,"Effect": {"text": [["acute interstitial nephritis"]],"start": [["33"]],"entity_id": [["T1"]]} }]}
{"id": "12111771_3", "context": "Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fludarabine pulmonary toxicity"]], "start": [["51"]], "entity_id": [["T1"]]}, "Subject": {"text": [["Multiple pulmonary nodules"]], "start": [["0"]], "entity_id": [["T0"]], "Disorder": {"text": [["Multiple pulmonary nodules"]], "start": [["0"]], "entity_id": [["T0"]]},"Population": {"text": [["an unusual presentation"]], "start": [["22"]], "entity_id": [["T2"]]},"Gender": {"text": [[""]], "start": [[""]], "entity_id": [["T3"]]},"Race": {"text": [[""]], "start": [[""]], "entity_id": [["T4"]]},"Age": {"text": [[""]], "start": [[""]], "entity_id": [["T5"]]}}, "Treatment": {"text": [["fludarabine"]], "start": [["51"]], "entity_id": [["T1"]], "Drug": {"text": [["fludarabine"]], "start": [["51"]], "entity_id": [["T1"]]},"Disorder": {"text": [["fludarabine pulmonary toxicity"]], "start": [["51"]], "entity_id": [["T1"]]},"Dosage": {"text": [[""]], "start": [[""]], "entity_id": [["T6"]]},"Duration": {"text": [[""]], "start": [[""]], "entity_id": [["T7"]]},"Route": {"text": [[""]], "start": [[""]], "entity_id": [["T8"]]},"Time_elapsed": {"text": [[""]], "start": [[""]], "entity_id": [["T9"]]},"Freq": {"text": [[""]], "start": [[""]], "entity_id": [["T10"]]},"Combination": null,"Trigger": null}, "Effect": {"text": [["Multiple pulmonary nodules"]], "start": [["0"]], "entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["an unusual presentation"]], "start": [["22"]], "entity_id": [["T2"]],"value": "low"}}]}
{"id": "19995222_1","context": "Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tardive dyskinesia"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clozapine"]],"start": [["8"]],"entity_id": [["T2"]],"Drug": {"text": [["clozapine"]],"start": [["8"]],"entity_id": [["T2"]]},"Disorder": {"text": [["schizophrenic patients"]],"start": [["42"]],"entity_id": [["T3"]]},"Route": {"text": [["as a first-line antipsychotic drug"]],"start": [["55"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["taking"]],"start": [["47"]],"entity_id": [["T5"]]},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["schizophrenic patients"]],"start": [["42"]],"entity_id": [["T3"]],"Age": null,"Gender": null,"Population": {"text": [],"start": [],"entity_id": []},"Race": null,"Disorder": {"text": [["schizophrenic patients"]],"start": [["42"]],"entity_id": [["T3"]]}}}]}
{"id": "9701106_4","context": "Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["increased"]],"start": [["31"]],"entity_id": []},"Treatment": {"text": [["the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del)"]],"start": [["55"]],"entity_id": [],"Drug": {"text": [["zafirlukast"]],"start": [["55"]],"entity_id": []},"Disorder": {"text": [["her regimen"]],"start": [["88"]],"entity_id": []},"Dosage": {"text": [["133.2 micromol/L [24 microg/mL]"]],"start": [["25"]],"entity_id": []},"Route": {"text": [["the addition"]],"start": [["55"]],"entity_id": []},"Time_elapsed": {"text": [["shortly after"]],"start": [["40"]],"entity_id": []},"Trigger": {"text": [["Recently"]],"start": [["0"]],"entity_id": []},"Freq": {"text": [["the addition"]],"start": [["55"]],"entity_id": []},"Duration": {"text": [["Recently"]],"start": [["0"]],"entity_id": []},"Combination": []},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["toxic range"]],"start": [["35"]],"entity_id": [],"value": "high"},"Subject": {"text": [["her"]],"start": [["12"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "2738729_2", "context": "Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Withdrawal emergent syndrome"]], "start": [[ "0" ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["haloperidol therapy"]], "start": [[ "51" ]], "entity_id": [ ["T2"]], "Drug": {"text": [["haloperidol"]], "start": [[ "51" ]], "entity_id": [ ["T3"]]}, "Combination": [{"Drug": {"text": [["haloperidol"]], "start": [[ "51" ]], "entity_id": [ ["T3"]]}, "Trigger": {"text": [["therapy"]], "start": [[ "56" ]], "entity_id": [ ["T4"]]}, "event_type": "Combination", "event_id": "C1"}], "Freq": {"text": [["maternal"]], "start": [[ "13" ]], "entity_id": [ ["T5"]]}, "Disorder": {"text": [["infant"]], "start": [[ "18" ]], "entity_id": [ ["T6"]]}, "Time_elapsed": {"text": [["associated with"]], "start": [[ "40" ]], "entity_id": [ ["T7"]]}, "Duration": {"text": [["Withdrawal emergent syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1"]]}, "Dosage": {"text": [[]], "start": [[]], "entity_id": []}, "Route": {"text": [[]], "start": [[]], "entity_id": []}, "Trigger": {"text": [["therapy"]], "start": [[ "56" ]], "entity_id": [ ["T4"]]}}, "Subject": {"text": [["infant"]], "start": [[ "18" ]], "entity_id": [ ["T6"]], "Age": {"text": [[]], "start": [[]], "entity_id": []}, "Disorder": {"text": [[]], "start": [[]], "entity_id": []}, "Gender": {"text": [[]], "start": [[]], "entity_id": []}, "Population": {"text": [[]], "start": [[]], "entity_id": []}, "Race": {"text": [[]], "start": [[]], "entity_id": []}} , "Negated": {"text": [[]], "start": [[]], "entity_id": [] , "value": false}, "Speculated": {"text": [[]], "start": [[]], "entity_id": [] , "value": false}, "Severity": {"text": [[]], "start": [[]], "entity_id": [] , "value": ""} , "Effect": {"text": [["Withdrawal emergent syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1"]]} }]}
{"id": "812008_1","context": "Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["apparently adversely affected"]],"start": [["18"]],"entity_id": []},"Treatment": {"text": [["Diphenylhydantoin"]],"start": [["0"]],"entity_id": [] ,"Drug": {"text": [["Diphenylhydantoin"]],"start": [["0"]],"entity_id": []} ,"Disorder": {"text": [["acute intermittent porphyria"]],"start": [["71"]],"entity_id": []} ,"Freq": {"text": [["both"]],"start": [["32"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["Diphenylhydantoin"]],"start": [["0"]],"entity_id": []},"Trigger": {"text": [["apparently adversely affected"]],"start": [["18"]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["clinical"]],"start": [["42"]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["acute intermittent porphyria"]],"start": [["71"]],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} }] }
{"id": "15852680_1","context": "Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["interstitial pneumonitis"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["bicalutamide", "and", "leuprorelin acetate"]],"start": [["61"], [ "66"], ["69"]],"entity_id": [ ["T2"], ["T3"]],"Drug": {"text": [["bicalutamide", "leuprorelin acetate"]],"start": [["61"], ["69"]],"entity_id": [ ["T4"], ["T5"]]},"Disorder": {"text": [["treatment for prostate cancer"]],"start": [["84"]],"entity_id": [ ["T6"]]},"Duration": {"text": [["Successful recovery"]],"start": [["0"]],"entity_id": [ ["T0"]]},"Trigger": {"text": [["induced by"]],"start": [["37"]],"entity_id": [ ["T7"]]},"Route": {"text": [["given as treatment"]],"start": [["71"]],"entity_id": [ ["T8"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "3438585_1", "context": "Gold-induced pneumonitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event","Trigger": {"text": [["Gold-induced pneumonitis"]], "start": [[ ]], "entity_id": [ ]},"Subject": {"text": [[ ]], "start": [[ ]], "entity_id": [ ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [[ ]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Gold"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": null},"Effect": {"text": [["Gold-induced pneumonitis"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11215836_1","context": "He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["clomipramine"]],"start": [["22"]],"entity_id": [["T2"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["16"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["eight days later"]],"start": [["52"]],"entity_id": [["T3"]]},"Trigger": {"text": [["clozapine"]],"start": [["76"]],"entity_id": [["T4"]]},"Route": {"text": [["was stopped"]],"start": [["31"]],"entity_id": [["T5"]]},"entity_id": [["T1","T2","T3","T4","T5"]],"text": [["diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later"]],"start": [[""],["16"],["31"],["52"],["76"]],"Freq": {"text": [["eight days later"]],"start": [["52"]],"entity_id": [["T3"]]},"Dosage": {"text": [["stopped"]],"start": [["31"]],"entity_id": [["T5"]]},"Duration": {"text": [["eight days later"]],"start": [["52"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["clomipramine"]],"start": [["22"]],"entity_id": [["T2"]]},"Trigger": {"text": [["was stopped"]],"start": [["31"]],"entity_id": [["T5"]]},"event_id": "E1","event_type": "Adverse_event"},{"Drug": {"text": [["clozapine"]],"start": [["76"]],"entity_id": [["T4"]]},"Trigger": {"text": [["was restarted"]],"start": [["72"]],"entity_id": [["T6"]]},"event_id": "E1","event_type": "Adverse_event"}]},"Subject": {"text": [["He"]],"start": [[""]],"entity_id": [["T0"]],"Gender": {"text": [["He"]],"start": [[""]],"entity_id": [["T0"]]},"Age": {"text": [[""]],"start": [[""]],"entity_id": [["T0"]]},"Population": {"text": [[""]],"start": [[""]],"entity_id": [["T0"]]},"Race": {"text": [[""]],"start": [[""]],"entity_id": [["T0"]]},"Disorder": {"text": [[""]],"start": [[""]],"entity_id": [["T0"]]}},"Negated": {"text": [["possible"]],"start": [["12"]],"entity_id": [["T1"]],"value": true},"Speculated": {"text": [["possible"]],"start": [["12"]],"entity_id": [["T1"]],"value": true},"Severity": {"text": [["serotonin syndrome"]],"start": [["16"]],"entity_id": [["T1"]],"value": "High"},"Effect": {"text": [["serotonin syndrome"]],"start": [["16"]],"entity_id": [["T1"]]}}]}
{"id": "6484655_3","context": "Two patients had ampicillin-associated seizures","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ampicillin-associated seizures"]],"start": [[ ]],"entity_id": [ ["T1"] ] }, "Subject": { "text": [["Two patients"]], "start": [[ ]] ,"entity_id": [ ["T2" ]] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Treatment": { "text": [["ampicillin"]], "start": [[ ]] ,"entity_id": [ ["T3" ]], "Drug": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null, "Combination": null }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["seizures"]], "start": [[ ]] ,"entity_id": [ ["T4" ]] } }] }
{"id": "15197722_1","context": "A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["restless legs symptoms"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["interferon-alpha (IFN alpha) therapy"]],"start": [["52"]],"entity_id": [ ["T2"]],"Drug": {"text": [["interferon-alpha"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic hepatitis C"]],"start": [["81"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": {"text": [["paralleling the course"]],"start": [["21"]],"entity_id": [ ["T5"]]} ,"Duration": {"text": [["therapy"]],"start": [["52"]],"entity_id": [ ["T2"]]} ,"Route": {"text": [["therapy"]],"start": [["52"]],"entity_id": [ ["T2"]]} ,"Freq": {"text": [["symptoms"]],"start": [["0"]],"entity_id": [ ["T1"]]} ,"Dosage": {"text": [["interferon-alpha (IFN alpha) therapy"]],"start": [["52"]],"entity_id": [ ["T2"]]} ,"Trigger": {"text": [["therapy"]],"start": [["52"]],"entity_id": [ ["T2"]]} ,"Combination": []} ,"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [ ["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [["restless legs symptoms"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["symptoms"]],"start": [["0"]],"entity_id": [ ["T1"]],"value": "Low"} }]}
{"id": "16005413_9","context": "While many can benefit from coadministration of serotonergic antidepressants and opioids, it appears that some individuals are at increased risk for SS","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["coadministration of serotonergic antidepressants and opioids"]],"start": [[ "coadministration of serotonergic antidepressants and opioids" ]],"entity_id": [ ["T1"] ], "Drug": { "text": [["serotonergic antidepressants", "opioids"]], "start": [[ "serotonergic antidepressants" , "opioids" ]], "entity_id": [ ["T2","T3"] ]} ,"Disorder": { "text": [["benefit"]], "start": [[ "benefit" ]], "entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": null, "Negated": null, "Speculated": { "text": [["it appears that some individuals are at increased risk for SS"]], "start": [[ "it appears that some individuals are at increased risk for SS" ]], "entity_id": [ ["T5"] ], "value": true }, "Severity": null, "Subject": null ,"Trigger": { "text": [["SS"]], "start": [[ "SS" ]], "entity_id": [ ["T6"] ]} }] }
{"id": "11487721_3","context": "We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["difficulty walking", "marked pain in the lower extremities", "loss of proprioception"]],"start": [["18", "42", "57"]],"entity_id": [["T1", "T2", "T3"]]},"Subject": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["advanced ovarian carcinoma"]],"start": [["5"]],"entity_id": [["T4"]]},"Age": {"text": [["25 days"]],"start": [["67"]],"entity_id": [["T5"]]},"Gender": {"text": [["who"]],"start": [["15"]],"entity_id": [["T6"]]},"Race": {"text": [["We describe"]],"start": [["0"]],"entity_id": [["T7"]]},"Population": {"text": [["case"]],"start": [["0"]],"entity_id": [["T8"]]}},"Treatment": {"text": [["treatment with weekly taxol (80 mg/m(2)x3)"]],"start": [["104"]],"entity_id": [["T9"]],"Drug": {"text": [["taxol"]],"start": [["114"]],"entity_id": [["T10"]]},"Dosage": {"text": [["80 mg/m(2)x3"]],"start": [["130"]],"entity_id": [["T11"]]},"Time_elapsed": {"text": [["25 days"]],"start": [["67"]],"entity_id": [["T12"]]},"Duration": {"text": [["weekly"]],"start": [["92"]],"entity_id": [["T13"]]},"Disorder": {"text": [["treatment"]],"start": [["91"]],"entity_id": [["T14"]]},"Route": {"text": [["with"]],"start": [["98"]],"entity_id": [["T15"]]},"Freq": {"text": [["weekly"]],"start": [["92"]],"entity_id": [["T16"]]},"Trigger": {"text": [["treatment with weekly taxol (80 mg/m(2)x3)"]],"start": [["104"]],"entity_id": [["T17"]]},"Combination": [{"Drug": {"text": [["taxol"]],"start": [["114"]],"entity_id": [["T18"]]},"Trigger": {"text": [["treatment with weekly taxol (80 mg/m(2)x3)"]],"start": [["104"]],"entity_id": [["T19"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["developed difficulty walking because of marked pain in the lower extremities and loss of proprioception"]],"start": [["18","42","57"]],"entity_id": [["T20"]]}}]}
{"id": "11722307_1", "context": "Agranulocytosis and granulocytopenia associated with quetiapine", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Agranulocytosis", "granulocytopenia"]], "start": [[],[]], "entity_id": [["T1"], ["T2"]]},"Treatment": {"text": [["quetiapine"]], "start": [[]], "entity_id": [["T3"]],"Drug": {"text": [["quetiapine"]], "start": [[]], "entity_id": [["T4"]]}, "Disorder": {"text": [["Agranulocytosis", "granulocytopenia"]], "start": [[],[]], "entity_id": [["T1"], ["T2"]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Effect": null}]}
{"id": "12932249_1", "context": "Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Hyperpigmentation"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Treatment": { "text": [["interferon-alpha therapy"]], "start": [[ "42" ]], "entity_id": [ ["T2" ] ], "Drug": { "text": [["interferon-alpha"]], "start": [[ "42" ]], "entity_id": [ ["T3" ] ]}, "Disorder": { "text": [["chronic hepatitis C virus infection"]], "start": [[ "66" ]], "entity_id": [ ["T4" ] ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null , "Trigger": null },"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null },"Effect": { "text": [["Hyperpigmentation"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "6142995_1","context": "Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Chlorambucil-induced chromosome damage"]],"start": [[ "0"]] ,"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Chlorambucil"]],"start": [[ "22" ]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"Dosage": {"text": [["dose-dependent"]],"start": [[ "41" ]],"entity_id": [["T3"]]},"Duration": {"text": [["cumulative"]],"start": [[ "58" ]],"entity_id": [["T4"]]},"Disorder": {"text": [["chromosome damage to human lymphocytes"]],"start": [[ "28" ]],"entity_id": [["T5"]]},"Route": {"text": [["-induced"]],"start": [[ "23" ]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"text": [],"start": [],"Trigger": null},"Effect": {"text": [["chromosome damage to human lymphocytes"]],"start": [[ "28" ]],"entity_id": [["T5"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "17705565_1","context": "Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Carbamazepine hypersensitivity syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] },"Effect": {"text": [["Carbamazepine hypersensitivity syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] },"Negated": null,"Speculated": null,"Severity": {"text": [["rare, life-threatening"]],"start": [[ "21" ]],"entity_id": [ ["V1" ]],"value": "high" }, "Subject": null, "Treatment": null }] }
{"id": "3195622_3","context": "Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["dapsone hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment"]],"start": [["48"]],"entity_id": [["T2"]],"Drug": {"text": [["dapsone"]],"start": [["48"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment of the bite of a brown recluse spider"]],"start": [["26"]],"entity_id": [["T4"]]} ,"Route": {"text": [["treatment"]],"start": [["48"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["associated with"]],"start": [["39"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["dapsone"]],"start": [["48"]],"entity_id": [["T3"]]},"Trigger": {"text": [["associated with"]],"start": [["39"]],"entity_id": [["T5"]]},"event_type": "Adverse_event" ,"event_id": "E2" }],"Freq": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} },"Subject": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["treatment of the bite of a brown recluse spider"]],"start": [["26"]],"entity_id": [["T4"]]} ,"Age": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Gender": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Race": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]} },"Effect": {"text": [["dapsone hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["dapsone hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"} }] }
{"id": "11706664_1","context": "Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute asymptomatic hepatitis"]],"start": [[ ]],"entity_id": []},"Subject": {"text": [["a healthy normal volunteer"]],"start": [[]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["amodiaquine and artesunate"]],"start": [[]],"entity_id": [],"Drug": {"text": [["amodiaquine"]],"start": [[]],"entity_id": []},"Dosage": {"text": [["2 oral doses"]],"start": [[]],"entity_id": []},"Route": {"text": [["oral"]],"start": [[]],"entity_id": []},"Duration": null,"Disorder": {"text": [["hepatitis"]],"start": [[]],"entity_id": []},"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "3753891_3","context": "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["focal myocardial necrosis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["amsacrine"]],"start": [[ "139" ]],"entity_id": [ ["T3"] ],"Drug": {"text": [["amsacrine"]],"start": [[ "139" ]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["acute myocardial infarction"]],"start": [[ "65" ]],"entity_id": [ ["T2"] ]},"Time_elapsed": {"text": [["during"]],"start": [[ "101" ]],"entity_id": [ ["T5"] ]} ,"Trigger": {"text": [["administration"]],"start": [[ "126" ]],"entity_id": [ ["T6"] ]} ,"Duration": {"text": [["during"]],"start": [[ "126" ]],"entity_id": [ ["T6"] ]} ,"Freq": {"text": [["during"]],"start": [[ "126" ]],"entity_id": [ ["T6"] ]} ,"Route": {"text": [["administration"]],"start": [[ "126" ]],"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [["administration"]],"start": [[ "126" ]],"entity_id": [ ["T6"] ]} ,"Combination": []},"Subject": {"text": [["patient"]],"start": [[ "213" ]],"entity_id": [ ["T7"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["coronary artery disease"]],"start": [[ "239" ]],"entity_id": [ ["T8"] ]} },"Severity": {"text": [["focal myocardial necrosis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"value": "High"} ,"Negated": null,"Speculated": null ,"Effect": {"text": [["acute myocardial infarction"]],"start": [[ "65" ]],"entity_id": [ ["T2"] ]} }]}
{"id": "17420198_8","context": "Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["Baclofen"]],"start": [[ ], [ ]],"entity_id": [["T1"]]},"text": [["Baclofen"]],"start": [[ ], [ ]],"entity_id": [["T1"]],"Disorder": {"text": [["right-sided hemiparesis contractures"]],"start": [[ ], [ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["prescribed"]],"start": [[ ], [ ]],"entity_id": [["T2"]]},"Freq": {"text": [["secondary"]],"start": [[ ], [ ]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Combination": null},"Effect": null,"Speculated": null,"Negated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "11918514_2", "context": "A review of the cases of SS with implication of mirtazapine as the cause was performed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["mirtazapine"]], "start": [[ "51"]], "entity_id": [ ] ,"Drug": { "text": [["mirtazapine"]], "start": [[ "51"]], "entity_id": [ ] } ,"Disorder": { "text": [["SS"]], "start": [[ "0"]], "entity_id": [ ] } ,"Trigger": { "text": [["implication"]], "start": [[ "33"]], "entity_id": [ ] } ,"Time_elapsed": { "text": [["performed"]], "start": [[ "46"]], "entity_id": [ ] } , "Freq": { "text": [["performed"]], "start": [[ "46"]], "entity_id": [ ] } , "Duration": { "text": [["performed"]], "start": [[ "46"]], "entity_id": [ ] } , "Dosage": { "text": [["performed"]], "start": [[ "46"]], "entity_id": [ ] } , "Route": { "text": [["performed"]], "start": [[ "46"]], "entity_id": [ ] } , "Combination": null } , "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["SS"]], "start": [[ "0"]], "entity_id": [] } } , "Negated": null, "Speculated": null, "Severity": null ,"Effect": null ,"Trigger": { "text": [["implication"]], "start": [[ "33"]], "entity_id": [ ] } } ]}
{"id": "16968538_3", "context": "A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null, "Effect": {"text": [["hemolytic", "thrombocytopenic"]], "start": [["32", "46"]], "entity_id": [["T1", "T2"]]}, "Trigger": {"text": [["oxaliplatin-related"]], "start": [["11"]], "entity_id": [["T3"]]}}]}
{"id": "10410183_3","context": "A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["elevated serum CK concentration"]],"start": [["36"]],"entity_id": [["T1"]]},"Severity": {"value": "high","text": [["elevated serum CK concentration"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["olanzapine"]],"start": [["89"]],"entity_id": [["T3"]],"Drug": {"text": [["olanzapine"]],"start": [["89"]],"entity_id": [["T3"]]},"Disorder": {"text": [["schizophrenic"]],"start": [["47"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T0"]]},"Dosage": {"text": [["not specified"]],"start": [[], []],"entity_id": [[]]},"Duration": {"text": [["not specified"]],"start": [[], []],"entity_id": [[]]},"Route": {"text": [["not specified"]],"start": [[], []],"entity_id": [[]]},"Freq": {"text": [["not specified"]],"start": [[], []],"entity_id": [[]]},"Combination": null,"Trigger": null},"Subject": {"text": [["A 39-year-old white Jewish man"]],"start": [[], [], [], []],"entity_id": [[]],"Age": {"text": [["39"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["man"]],"start": [["22"]],"entity_id": [["T0"]]},"Population": {"text": [["not specified"]],"start": [[], []],"entity_id": [[]]},"Race": {"text": [["white Jewish"]],"start": [["11"]],"entity_id": [["T0"]]},"Disorder": {"text": [["schizophrenic"]],"start": [["47"]],"entity_id": [["T2"]]}},"Effect": {"text": [["elevated serum CK concentration"]],"start": [["36"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null}]}
{"id": "23624139_1", "context": "Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["water intoxication"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["non-steroidal anti-inflammatory drugs", "desmopressin"]], "start": [["52","65"]], "entity_id": [],"Combination": [{"Drug": {"text": [["non-steroidal anti-inflammatory drugs"]], "start": [["52"]], "entity_id": []},"Trigger": {"text": [["concomitant intake"]], "start": [["42"]], "entity_id": []},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["desmopressin"]], "start": [["65"]], "entity_id": []},"Trigger": {"text": [["concomitant intake"]], "start": [["42"]], "entity_id": []},"event_id": "C2","event_type": "Adverse_event"}],"Drug": {"text": [["non-steroidal anti-inflammatory drugs", "desmopressin"]], "start": [["52","65"]], "entity_id": []},"Disorder": {"text": [["water intoxication"]], "start": [["18"]], "entity_id": []},"Time_elapsed": {"text": [["secondary"]], "start": [["19"]], "entity_id": []},"Trigger": {"text": [["concomitant intake"]], "start": [["42"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []}},"Effect": {"text": [["Severe"]], "start": [["8"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["Severe"]], "start": [["8"]], "entity_id": [],"value": "High"},"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Severe water intoxication"]], "start": [["8"]], "entity_id": []}}}]}
{"id": "10755579_3","context": "This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fluoxetine-related death"]],"start": [["17"]],"entity_id": [["T1"]]},"Subject": {"text": [["a child"]],"start": [["40"]],"entity_id": [["T2"]],"Age": {"text": [["child"]],"start": [["40"]],"entity_id": [["T2"]]},"Disorder": {"text": [["genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism"]],"start": [["55"]],"entity_id": [["T3"]]},"Gender": {"text": [["child"]],"start": [["40"]],"entity_id": [["T2"]]},"Race": {"text": [["child"]],"start": [["40"]],"entity_id": [["T2"]]},"Population": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T0"]]}},"Treatment": {"text": [["fluoxetine"]],"start": [["13"]],"entity_id": [["T1"]],"Drug": {"text": [["fluoxetine"]],"start": [["13"]],"entity_id": [["T1"]]},"Disorder": {"text": [["fluoxetine-related death"]],"start": [["17"]],"entity_id": [["T1"]]},"Dosage": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]},"Duration": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]},"Route": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]},"Time_elapsed": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]},"Freq": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]},"Combination": null,"Trigger": {"text": [["fluoxetine-related death"]],"start": [["17"]],"entity_id": [["T1"]]}} ,"Effect": { "text": [["fluoxetine-related death"]], "start": [[ "17" ]], "entity_id": [["T1"]] }, "Negated": null, "Speculated": null, "Severity": { "text": [["death"]], "start": [[ "25" ]], "entity_id": [["T4"]], "value": "High" }}]}
{"id": "17298107_1","context": "The patient's arthritis flared after the second infusion of infliximab, which was discontinued","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["flared"]],"start": [["30"]],"entity_id": []},"Subject": {"text": [["The patient's arthritis"]],"start": [["0"]],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["arthritis"]],"start": [["5"]],"entity_id": []}} ,"Treatment": {"text": [["the second infusion of infliximab"]],"start": [["19"]],"entity_id": [] ,"Drug": {"text": [["infliximab"]],"start": [["36"]],"entity_id": []} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": {"text": [["second"]],"start": [["19"]],"entity_id": []} ,"Disorder": {"text": [["arthritis"]],"start": [["5"]],"entity_id": []} ,"Trigger": {"text": [["the second infusion"]],"start": [["19"]],"entity_id": []},"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null} ,{"event_id": "E2","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["discontinued"]],"start": [["73"]],"entity_id": []},"Subject": {"text": [["The patient's arthritis"]],"start": [["0"]],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["arthritis"]],"start": [["5"]],"entity_id": []}} ,"Treatment": {"text": [["the second infusion of infliximab"]],"start": [["19"]],"entity_id": [] ,"Drug": {"text": [["infliximab"]],"start": [["36"]],"entity_id": []} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": {"text": [["second"]],"start": [["19"]],"entity_id": []} ,"Disorder": {"text": [["arthritis"]],"start": [["5"]],"entity_id": []} ,"Trigger": {"text": [["the second infusion"]],"start": [["19"]],"entity_id": []},"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null} ]}
{"id": "11077455_1","context": "Marked visual field constriction appears to be associated with vigabatrin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Marked visual field constriction"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["vigabatrin therapy"]],"start": [["55"]],"entity_id": [["T2"]],"Drug": {"text": [["vigabatrin"]],"start": [["55"]],"entity_id": [["T3"]]},"Freq": {"text": [["appears"]],"start": [["41"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["vigabatrin"]],"start": [["55"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["62"]],"entity_id": [["T2"]]},"event_id": "E2","event_type": "Treatment"}],"Disorder": {"text": [["Marked visual field constriction"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["associated"]],"start": [["36"]],"entity_id": [["T5"]]},"Route": {"text": [["therapy"]],"start": [["62"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["therapy"]],"start": [["62"]],"entity_id": [["T2"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["Marked"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Marked visual field constriction"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "11215836_3","context": "Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clomipramine"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["clomipramine"]],"start": [["5"]],"entity_id": [["T2"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["18"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after withdrawal"]],"start": [["44"]],"entity_id": [["T3"]]},"Trigger": {"text": [["withdrawal"]],"start": [["44"]],"entity_id": [["T3"]]},"Route": {"text": [["after withdrawal"]],"start": [["44"]],"entity_id": [["T3"]]}, "Dosage": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Duration": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Freq": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Combination": null}, "Effect": {"text": [["serotonin syndrome"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]], "value" : false},"Speculated": {"text": [["possible"]],"start": [["0"]],"entity_id": [["T0"]],"value" : true},"Severity": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]],"value" : ""}, "Subject": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]],"Age": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Disorder": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Gender": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Population": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}, "Race": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}}}]}
{"id": "1295628_2","context": "A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["systemic lupus erythematosus (SLE)-like symptoms"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["carbamazepine (CBZ; Tegretol)"]],"start": [["93"]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"]],"start": [["93"]],"entity_id": [["T3"]]},"Disorder": {"text": [["benign Rolandic epilepsy"]],"start": [["114"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["two weeks"]],"start": [["68"]],"entity_id": [["T5"]]},"Trigger": {"text": [["administration"]],"start": [["79"]],"entity_id": [["T6"]]},"Freq": {"text": [["after"]],"start": [["68"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["carbamazepine (CBZ; Tegretol)"]],"start": [["93"]],"entity_id": [["T2"]]},"Trigger": {"text": [["administration"]],"start": [["79"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Route": {"text": [["used against"]],"start": [["102"]],"entity_id": [["T8"]]},"Dosage": {"text": [["systemic lupus erythematosus (SLE)-like symptoms"]],"start": [["18"]],"entity_id": [["T1"]]},"Duration": {"text": [["developed"]],"start": [["0"]],"entity_id": [["T9"]]}},"Effect": {"text": [["rash"]],"start": [["28"]],"entity_id": [["T10"]]},"Severity": {"text": [["SLE-like symptoms"]],"start": [["18"]],"entity_id": [["T1"]],"value": "High"},"Subject": {"text": [["A 14-year-old female"]],"start": [["0"]],"entity_id": [["T11"]],"Age": {"text": [["14"]],"start": [["5"]],"entity_id": [["T12"]]},"Gender": {"text": [["female"]],"start": [["12"]],"entity_id": [["T13"]]},"Disorder": {"text": [["developed"]],"start": [["0"]],"entity_id": [["T9"]]},"Race": {"text": [["A"]],"start": [["0"]],"entity_id": [["T14"]]},"Population": {"text": [["A"]],"start": [["0"]],"entity_id": [["T14"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "7718983_3","context": "Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Graves' hyperthyroidism", "transient thyrotoxicosis"]],"start": [[ ], [ ]],"entity_id": [["T1", "T2"]]},"Treatment": {"text": [["interferon therapy"]],"start": [[ ]],"entity_id": [["T3"]],"Disorder": {"text": [["chronic hepatitis type C"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Drug": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Dosage": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Duration": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Route": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Freq": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Combination": null ,"Trigger": {"text": [["during"]],"start": [[ ]],"entity_id": [["T3"]]}} ,"Subject": {"text": [[]],"start": [[]],"entity_id": [[]],"Age": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Gender": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Population": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Race": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Disorder": {"text": [["Graves' hyperthyroidism"]],"start": [[ ]],"entity_id": [["T1"]]}},"Effect": {"text": [[]],"start": [[]],"entity_id": [[]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"}}]}
{"id": "12324937_2", "context": "There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": {"value": false, "text": [["only a few confirmed cases"]], "start": [[],[]],"entity_id": [["N1"]]},"Trigger": {"text": [["HUS"]], "start": [[],[]],"entity_id": [["T1"]]},"Treatment": {"text": [["gemcitabine"]], "start": [[],[]],"entity_id": [["T2"]], "Drug": {"text": [["gemcitabine"]], "start": [[],[]],"entity_id": [["T3"]]}, "Disorder": {"text": [["HUS"]], "start": [[],[]],"entity_id": [["T1"]]}, "Dosage": {"text": [["widespread use"]], "start": [[],[]],"entity_id": [["T4"]]}, "Freq": {"text": [["few confirmed cases"]], "start": [[],[]],"entity_id": [["N1"]]}, "Combination": null, "Time_elapsed": null, "Duration": null, "Route": null, "Trigger": null},"Severity": null, "Subject": {"text": [["There are"]], "start": [[],[]],"entity_id": [["N2"]],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["HUS"]], "start": [[],[]],"entity_id": [["T1"]]}},"Speculated": null,"Effect": null}]}
{"id": "19365885_3","context": "In these patients, long-acting octreotide may trigger serious hypoglycemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serious hypoglycemia"]],"start": [["32"]],"entity_id": [["T2"]]},"Treatment": {"text": [["long-acting octreotide"]],"start": [["8"]],"entity_id": [["T1"]],"Trigger": {"text": [["trigger"]],"start": [["22"]],"entity_id": [["T3"]]} ,"Drug": {"text": [["octreotide"]],"start": [["8"]],"entity_id": [["T4"]]},"Disorder": {"text": [["hypoglycemia"]],"start": [["32"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["these patients"]],"start": [["0"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["serious"]],"start": [["32"]],"entity_id": [["T6"]],"value": "High"}}]}
{"id": "17039658_1", "context": "An intertrigo-like eruption from pegylated liposomal doxorubicin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intertrigo-like eruption"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["pegylated liposomal doxorubicin"]], "start": [["52"]], "entity_id": [["T2"]],"Drug": {"text": [["doxorubicin"]], "start": [["52"]], "entity_id": [["T3"]]}, "Disorder": {"text": [["intertrigo-like eruption"]], "start": [["0"]], "entity_id": [["T1"]]},"Dosage": {"text": [["pegylated"]], "start": [["52"]], "entity_id": [["T2"]]} ,"Route": {"text": [["from"]], "start": [["42"]], "entity_id": [["T4"]]} ,"Time_elapsed": { "text":[["eruption"]], "start":[[ "31" ]], "entity_id":[["T5"]]} ,"Freq": { "text":[["like"]], "start":[[ "17" ]], "entity_id":[["T6"]]} ,"Combination": [{"event_type":"Adverse_event","event_id":"E1","Drug":{"text":[["doxorubicin"]],"start":[[ "52" ]], "entity_id":[["T3"]]},"Trigger":{"text":[["intertrigo-like eruption"]],"start":[[ "0" ]], "entity_id":[["T1"]]} }] ,"Trigger":{"text":[["from"]], "start":[[ "42" ]], "entity_id":[["T4"]]} ,"Duration": { "text":[], "start":[], "entity_id":[]} },"Subject": { "text": [], "start": [], "entity_id": [], "Age": { "text":[], "start":[], "entity_id":[]}, "Disorder": { "text":[["intertrigo-like eruption"]], "start":[[ "0" ]], "entity_id":[["T1"]]}, "Gender": { "text":[], "start":[], "entity_id":[]}, "Population": { "text":[], "start":[], "entity_id":[]}, "Race": { "text":[], "start":[], "entity_id":[]} },"Negated": { "text":[], "start":[], "entity_id":[],"value":false}, "Speculated": { "text":[], "start":[], "entity_id":[],"value":false}, "Severity": { "text":[], "start":[], "entity_id":[],"value":""} ,"Effect": { "text": [], "start": [], "entity_id": [] }}]}
{"id": "14514135_2","context": "We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["NEH masquerading as cutaneous vasculitis"]],"start": [["28"]],"entity_id": [["T1"]]},"Subject": {"text": [["a woman"]],"start": [["13"]],"entity_id": [["T2"]],"Age": null,"Gender": {"text": [["woman"]],"start": [["18"]],"entity_id": [["T3"]]},"Population": null,"Race": null,"Disorder": {"text": [["lupus nephritis"]],"start": [["71"]],"entity_id": [["T4"]]}},"Treatment": {"text": [["cyclophosphamide"]],"start": [["52"]],"entity_id": [["T5"]],"Drug": {"text": [["cyclophosphamide"]],"start": [["52"]],"entity_id": [["T6"]]},"Disorder": {"text": [["lupus nephritis"]],"start": [["71"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["receiving"]],"start": [["36"]],"entity_id": [["T7"]]}} ,"Effect": {"text": [["NEH"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10048291_2","context": "Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe hypercalcemia"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["dihydrotachysterol"]],"start": [["71"]],"entity_id": [["T2"]],"Drug": {"text": [["dihydrotachysterol"]],"start": [["71"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["hypoparathyroidism"]],"start": [["32"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["treated"]],"start": [["23"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["treated"]],"start": [["23"]],"entity_id": [["T4"]]} ,"Route": {"text": [["with"]],"start": [["67"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["Unaccountable"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["severe"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["dihydrotachysterol"]],"start": [["71"]],"entity_id": [["T2"]]},"Trigger": {"text": [["with"]],"start": [["67"]],"entity_id": [["T5"]]},"event_type": "Adverse_event" ,"event_id": "E1" }] ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "severe" },"Subject": {"text": [["a patient"]],"start": [["8"]],"entity_id": [["T6"]],"Disorder": {"text": [["hypoparathyroidism"]],"start": [["44"]],"entity_id": [["T3"]]} ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["hypercalcemia"]],"start": [["11"]],"entity_id": [["T7"]] }} ]}
{"id": "11022272_1", "context": "Anaphylaxis to calcitonin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Anaphylaxis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Treatment": {"text": [["calcitonin"]], "start": [[ "25" ]], "entity_id": [ ["T2" ] ], "Drug": null ,"Disorder": { "text": [["Anaphylaxis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null } , "Effect": { "text": [["Anaphylaxis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ] } , "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "17983451_1", "context": "Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Mycobacterium marinum infection"]], "start": [[ ]], "entity_id": [["E1"]]},"Effect": {"text": [], "start": [], "entity_id": []},"Subject": {"text": [["Crohn's disease"]], "start": [[ ]], "entity_id": [["E2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["infliximab"]], "start": [[ ]], "entity_id": [["E3"]],"Drug": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["Crohn's disease"]], "start": [[ ]], "entity_id": [["E2"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "16649344_2","context": "Current immunosuppressive therapies are effective but can be associated with significant adverse reactions","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["immunosuppressive therapies"]],"start": [["0"]],"entity_id": [["T1"]]},"Effect": {"text": [["effective"]],"start": [["21"]],"entity_id": [["T2"]]},"Negated": {"value": false,"text": [["effective"]],"start": [["21"]],"entity_id": [["T2"]]},"Speculated": {"value": false,"text": [["effective"]],"start": [["21"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["immunosuppressive therapies"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"text": [["immunosuppressive therapies"]],"start": [["0"]],"entity_id": [["T1"]],"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"value": "significant","text": [["significant"]],"start": [["65"]],"entity_id": [["T3"]]}}]}
{"id": "14632592_3","context": "Colchicine, the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Colchicine"]],"start": [[ "0" ]] ,"entity_id": [["T1" ]] ,"Drug": {"text": [["Colchicine"]],"start": [[ "0" ]],"entity_id": [["T2"]]},"Disorder": {"text": [["FMF"]],"start": [[ "47" ]] ,"entity_id": [["T3"]]},"Trigger": {"text": [["can cause"]],"start": [[ "32" ]] ,"entity_id": [["T4"]]},"Freq": {"text": [["most important"]],"start": [[ "9" ]],"entity_id": [["T5"]]},"Route": {"text": [["in treatment"]],"start": [[ "23" ]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patients with impaired renal and hepatic function"]],"start": [[ "73" ]],"entity_id": [["T7"]]}},"Effect": {"text": [["myopathy"]],"start": [[ "95" ]],"entity_id": [["T8"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["can cause"]],"start": [[ "32" ]],"entity_id": [["T4"]]}}]}
{"id": "7673653_4","context": "In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["fluvoxamine-induced akathisia"]],"start": [[" "]],"entity_id": [["T1"]]},"Subject": {"text": [["an OCD patient"]],"start": [[", in"]],"entity_id": [["T2"]],"Disorder": {"text": [["OCD"]],"start": [[","]],"entity_id": [["T3"]]},"Population": {"text": [["the patient"]],"start": [[""], ["in"]],"entity_id": [["T4"]]},"Age": {"text": [[]],"start": [[],[]],"entity_id": []},"Gender": {"text": [[]],"start": [[],[]],"entity_id": []},"Race": {"text": [[]],"start": [[],[]],"entity_id": []}},"Treatment": {"text": [["fluvoxamine"]],"start": [[""], ["induced"]],"entity_id": [["T5"]],"Drug": {"text": [["fluvoxamine"]],"start": [[""], ["induced"]],"entity_id": [["T5"]]},"Disorder": {"text": [["akathisia"]],"start": [[],["induced"]],"entity_id": [["T6"]]},"Dosage": {"text": [[]],"start": [[],[]],"entity_id": []},"Duration": {"text": [[]],"start": [[],[]],"entity_id": []},"Trigger": {"text": [["biperiden"]],"start": [[", and was partially resistant to the anticholinergic agent"]],"entity_id": [["T7"]]},"Route": {"text": [["anticholinergic agent"]],"start": [[", partially resistant to the"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [[]],"start": [[],[]],"entity_id": []},"Freq": {"text": [[]],"start": [[],[]],"entity_id": []},"Combination": [{"Drug": {"text": [["mianserin"]],"start": [[", and was successfully treated with"]],"entity_id": [["T9"]]},"Trigger": {"text": [["5-HT2A/5-HT2C antagonist"]],"start": [[],[]],"entity_id": []},"event_id": "E2","event_type": "Treatment"}]},"Negated": {"text": [[]],"start": [[],[]],"entity_id": [],"value": false},"Speculated": {"text": [[]],"start": [[],[]],"entity_id": [],"value": false},"Severity": {"text": [[]],"start": [[],[]],"entity_id": [],"value": ""},"Effect": {"text": [[]],"start": [[],[]],"entity_id": []}}]}
{"id": "16225183_7","context": "SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["interferon"]],"start": [["33"]],"entity_id": [["T1"]]},"entity_id": [["T1"]],"text": [["the interferon"]],"start": [["33"]],"Duration": {"text": [["once the interferon was stopped"]],"start": [["33"]],"entity_id": [["T2"]]},"Trigger": {"text": [["once"]],"start": [["33"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["after immunosuppressive treatment"]],"start": [["55"]],"entity_id": [["T3"]]},"Route": {"text": [["stopped"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": {"text": [["the nephrosis"]],"start": [["9"]],"entity_id": [["T4"]]},"Freq": {"text": [["almost completely"]],"start": [["29"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": {"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["the nephrosis"]],"start": [["9"]],"entity_id": [["T4"]]},"Age": {"text": [],"start": [],"entity_id": []},"entity_id": [["T4"]],"text": [["the nephrosis"]],"start": [["9"]],"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [["once"]],"start": [["33"]],"entity_id": [["T2"]]}}]}
{"id": "8149366_1","context": "In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ],"Drug": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Disorder": {"text": [["dyskinesias"]],"start": [[ "72" ]],"entity_id": [ ]},"Duration": {"text": [["in the morning"]],"start": [[ "9" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["in the afternoon"]],"start": [[ "93" ]],"entity_id": [ ]},"Freq": {"text": [["remained effective"]],"start": [[ "25" ]],"entity_id": [ ]},"Trigger": {"text": [["increased"]],"start": [[ "63" ]],"entity_id": [ ]},"Dosage": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Route": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Trigger": {"text": [["in the morning"]],"start": [[ "9" ]],"entity_id": [ ]},"event_id": "C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["apomorphine"]],"start": [[ "0" ]],"entity_id": [ ]},"Trigger": {"text": [["in the afternoon"]],"start": [[ "93" ]],"entity_id": [ ]},"event_id": "C2","event_type": "Adverse_event"}]},"Negated": {"text": [ ],"start": [ ],"entity_id": [ ],"value": false},"Speculated": {"text": [ ],"start": [ ],"entity_id": [ ],"value": false},"Severity": {"text": [ ],"start": [ ],"entity_id": [ ],"value": ""},"Subject": {"text": [["two patients"]],"start": [[ "0" ]],"entity_id": [ ],"Age": {"text": [ ],"start": [ ],"entity_id": [ ]},"Disorder": {"text": [["dyskinesias"]],"start": [[ "72" ]],"entity_id": [ ]},"Gender": {"text": [ ],"start": [ ],"entity_id": [ ]},"Population": {"text": [["two patients"]],"start": [[ "0" ]],"entity_id": [ ]},"Race": {"text": [ ],"start": [ ],"entity_id": [ ]}},"Effect": {"text": [["remained effective"]],"start": [[ "25" ]],"entity_id": [ ]}}]}
{"id": "25515435_6", "context": "In 2006, he was diagnosed with deep vein thrombosis and pulmonary embolism and was started on warfarin.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["deep vein thrombosis", "pulmonary embolism"]], "start": [["12","25"]], "entity_id": []}, "Treatment": {"text": [["warfarin"]], "start": [["114"]], "entity_id": [], "Drug": {"text": [["warfarin"]], "start": [["114"]], "entity_id": []},"Disorder": {"text": [["deep vein thrombosis", "pulmonary embolism"]], "start": [["12","25"]], "entity_id": []},"Time_elapsed": {"text": [["2006"]], "start": [["0"]], "entity_id": []},"Route": {"text": [["oral"]], "start": [["111"]], "entity_id": []},"Trigger": {"text": [["was started on"]], "start": [["93"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"event_type":"Adverse_event","event_id":"E1","Drug":{"text":[["warfarin"]],"start":[[""],["114"]],"entity_id":[[]]},"Trigger":{"text":[["was started on"]],"start":[[""],["93"]],"entity_id":[[]]}}]},"Subject": {"text": [["he"]], "start": [["5"]], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["deep vein thrombosis", "pulmonary embolism"]], "start": [["12","25"]], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value":false},"Speculated": {"text": [], "start": [], "entity_id": [],"value":false},"Severity": {"text": [], "start": [], "entity_id": [],"value":"Low"}}]}
{"id": "10467499_1","context": "A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fever"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["minocycline therapy"]],"start": [["88"]],"entity_id": [["T2"]],"Drug": {"text": [["minocycline"]],"start": [["88"]],"entity_id": [["T3"]]},"Duration": {"text": [["3 weeks"]],"start": [["69"]],"entity_id": [["T4"]]},"Dosage": {"text": [["therapy"]],"start": [["88"]],"entity_id": [["T2"]]},"Disorder": {"text": [["acne"]],"start": [["106"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["3 weeks"]],"start": [["69"]],"entity_id": [["T4"]]},"Route": {"text": [["therapy"]],"start": [["88"]],"entity_id": [["T2"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["fever","chills","fatigue","night sweats","tender lymphadenopathy","a generalized, pruritic, macular eruption"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A 22-year-old black man"]],"start": [[ "0" ]],"entity_id": [],"Age": {"text": [["22"]],"start": [[ "2" ]],"entity_id": []},"Gender": {"text": [["man"]],"start": [[ "19" ]],"entity_id": []},"Population": null,"Race": {"text": [["black"]],"start": [[ "11" ]],"entity_id": []},"Disorder": null}}]}
{"id": "12221670_4", "context": "Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["two new case reports"]], "start": [["Ticlopidine-induced aplastic anemia: two new case reports,"], [""], []],"entity_id": [["new case reports"], ["review"], ["meta-analysis"]],"Age": null, "Disorder": {"text": [["Ticlopidine-induced aplastic anemia"]], "start": [[ "Ticlopidine-induced aplastic anemia:"], [""]], "entity_id": [["T1"]]},"Gender": null, "Population": null, "Race": null},"Treatment": {"text": [["Ticlopidine"]], "start": [[ "Ticlopidine-induced" ]], "entity_id": [["T2"]],"Drug": {"text": [["Ticlopidine"]], "start": [[ "Ticlopidine-induced" ]], "entity_id": [["T2"]]},"Disorder": {"text": [["aplastic anemia"]], "start": [[ "aplastic anemia:"], [""]], "entity_id": [["T1"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null,"Combination": null ,"Trigger": {"text": [["Ticlopidine-induced"]], "start": [[ "Ticlopidine-induced" ]], "entity_id": [["T2"]]}},"Effect": {"text": [["aplastic anemia"]], "start": [[ "aplastic anemia:"], [""]], "entity_id": [["T1"]]} ,"Trigger": {"text": [["Ticlopidine-induced"]], "start": [[ "Ticlopidine-induced" ]], "entity_id": [["T2"]]}} ,{"event_id": "E2", "event_type": "Potential_therapeutic_effect", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["55 additional cases"]], "start": [[ "of 55 additional cases."]], "entity_id": [["55 additional cases."]],"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null},"Treatment": {"text": [["Ticlopidine"]], "start": [[ "" ]], "entity_id": [["T2"]],"Drug": {"text": [["Ticlopidine"]], "start": [[ "" ]], "entity_id": [["T2"]]},"Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null,"Combination": null ,"Trigger": null},"Effect": {"text": [["Ticlopidine-induced"]], "start": [[ "" ]], "entity_id": [["T2"]]} ,"Trigger": null} ]}
{"id": "480917_1", "context": "A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Erythema Multiforme Bullosum"]], "start": [["0"]], "entity_id": [["T1"]]}, "Subject": {"text": [["patient"]], "start": [["52"]], "entity_id": [["T2"]], "Disorder": {"text": [["lepromatous leprosy with pulmonary tuberculosis"]], "start": [["53"]], "entity_id": [["T3"]]} ,"Age": null, "Gender": null, "Population": null, "Race": null},"Treatment": {"text": [["Rifampicin"]], "start": [["122"]], "entity_id": [["T4"]], "Drug": {"text": [["Rifampicin"]], "start": [["122"]], "entity_id": [["T5"]]},"Disorder": {"text": [["lepromatous leprosy with pulmonary tuberculosis"]], "start": [["53"]], "entity_id": [["T3"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": {"text": [["due to Rifampicin"]], "start": [["108"]], "entity_id": [["T6"]]}},"Effect": null ,"Negated": null, "Speculated": null, "Severity": null}]}
{"id": "7661076_2","context": "Life-threatening alterations in heart rate after the use of adenosine in atrial flutter","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Life-threatening alterations in heart rate"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["adenosine"]],"start": [[ "58" ]],"entity_id": [ ],"Drug": {"text": [["adenosine"]],"start": [[ "58" ]],"entity_id": [ ]} ,"Disorder": {"text": [["atrial flutter"]],"start": [[ "74" ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["after"]],"start": [[ "48" ]],"entity_id": [ ]} ,"Freq": {"text": [["use"]],"start": [[ "53" ]],"entity_id": [ ]} ,"Route": {"text": [["use"]],"start": [[ "53" ]],"entity_id": [ ]} ,"Duration": {"text": [["use"]],"start": [[ "53" ]],"entity_id": [ ]} ,"Dosage": {"text": [["use"]],"start": [[ "53" ]],"entity_id": [ ]} ,"Combination": null ,"Trigger": {"text": [["Life-threatening alterations in heart rate"]],"start": [[ "0" ]],"entity_id": [ ]}} ,"Effect": {"text": [["Life-threatening alterations in heart rate"]],"start": [[ "0" ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["Life-threatening"]],"start": [[ "0" ]],"entity_id": [ ],"value": "high"} ,"Subject": null } ] }
{"id": "9719245_4","context": "We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pancytopenia"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 23-year-old man"]],"start": [["7"]],"entity_id": [["T2"]],"Age": {"text": [["23"]],"start": [["9"]],"entity_id": [["T3"]]},"Gender": {"text": [["man"]],"start": [["14"]],"entity_id": [["T4"]]},"Disorder": {"text": [["Crohn's disease"]],"start": [["33"]],"entity_id": [["T5"]]},"Race": {"text": [["Nisshin, Tokyo, Japan"]],"start": [["58"]],"entity_id": [["T6"]]},"Population": {"text": [["1"]],"start": [["7"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["5-aminosalicylic acid (Pentasa)"]],"start": [["51"]],"entity_id": [["T7"]],"Drug": {"text": [["5-aminosalicylic acid"]],"start": [["51"]],"entity_id": [["T8"]]},"Dosage": {"text": [["3.0 g/day"]],"start": [["66"]],"entity_id": [["T9"]]},"Route": {"text": [["was treated"]],"start": [["41"]],"entity_id": [["T10"]]},"Duration": {"text": [["was treated"]],"start": [["41"]],"entity_id": [["T10"]]},"Disorder": {"text": [["Crohn's disease"]],"start": [["33"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["case of pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["day"]],"start": [["65"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["5-aminosalicylic acid"]],"start": [["51"]],"entity_id": [["T8"]]},"Trigger": {"text": [["was treated"]],"start": [["41"]],"entity_id": [["T10"]]},"event_id": "C1","event_type": "Treatment"}],"Trigger": {"text": [["pancytopenia"]],"start": [["18"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["pancytopenia"]],"start": [["18"]],"entity_id": [["T1"]],"value": "High"},"Effect": {"text": [["pancytopenia"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "9169264_2","context": "The ampicillin rash occurring in cases of infectious mononucleosis is well documented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ampicillin rash"]],"start": [[ "0", "5" ]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["ampicillin"]],"start": [[ "0", "8" ]],"entity_id": [ ["T2"]],"Drug": null,"Disorder": {"text": [["infectious mononucleosis"]],"start": [[ "23", "36" ]],"entity_id": [ ["T3"]]},"Freq": {"text": [["occurring"]],"start": [[ "13", "19" ]],"entity_id": [ ["T4"]]},"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Trigger": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16204273_1","context": "The major side effect of infliximab is infection","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["major side effect"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["infliximab"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["infliximab"]],"start": [["41"]],"entity_id": [["T2"]]},"Disorder": {"text": [["infection"]],"start": [["50"]],"entity_id": [["T3"]]},"Freq": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["infliximab"]], "start": [["41"]], "entity_id": [["T2"]]},"Trigger": { "text": [["side effect"]], "start": [["12"]], "entity_id": [["T1"]]},"event_id": "E2","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]},"Route": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]},"Duration": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]]}},"Subject": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]]},"Population": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]]},"Race": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]]},"Age": {"text": [["The"]],"start": [[""], ["0"]],"entity_id": [["T0"]]}},"Effect": {"text": [["infection"]],"start": [["50"]],"entity_id": [["T3"]]},"Negated": {"text": [["not"]],"start": [[""], ["0"]],"entity_id": [["T0"]],"value": false},"Speculated": {"text": [["not"]],"start": [[""], ["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [["major"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"}}]}
{"id": "6233326_3","context": "The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["optic neuropathy"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["penicillamine"]],"start": [["70"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Wilson's disease"]],"start": [["43"]],"entity_id": [["T2"]]},"text": [["receiving"]],"start": [["53"]],"entity_id": [["T4"]],"Time_elapsed": {"text": [["occurred"]],"start": [["13"]],"entity_id": [["T0"]]},"Freq": {"text": [["previously reported cases"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["penicillamine"]],"start": [["70"]],"entity_id": [["T3"]]},"Trigger": {"text": [["receiving"]],"start": [["53"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Therapy"}],"Trigger": {"text": [["occurred"]],"start": [["13"]],"entity_id": [["T0"]]},"Duration": {"text": [["previously reported cases"]],"start": [["0"]],"entity_id": [["T5"]]},"Dosage": {"text": [["penicillamine"]],"start": [["70"]],"entity_id": [["T3"]]},"Route": {"text": [["receiving"]],"start": [["53"]],"entity_id": [["T4"]]}},"Subject": {"text": [["patients with Wilson's disease"]],"start": [["43"]],"entity_id": [["T2"]],"Population": {"text": [["two previously reported cases"]],"start": [["0"]],"entity_id": [["T5"]]},"Age": {"text": [["patients"]],"start": [["43"]],"entity_id": [["T2"]]},"Gender": {"text": [["patients"]],"start": [["43"]],"entity_id": [["T2"]]},"Race": {"text": [["patients"]],"start": [["43"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Wilson's disease"]],"start": [["43"]],"entity_id": [["T2"]]}},"Effect": {"text": [["optic neuropathy"]],"start": [["16"]],"entity_id": [["T1"]]},"Severity": {"text": [["occurred"]],"start": [["13"]],"entity_id": [["T0"]],"value": "low"},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T6"]],"value": false},"Speculated": {"text": [["resembles"]],"start": [["0"]],"entity_id": [["T7"]],"value": false}}]}
{"id": "1743388_1","context": "Cutaneous ulceration: an unusual complication of intravenous pentamidine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cutaneous ulceration"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["intravenous pentamidine therapy"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["pentamidine"]],"start": [[ "45" ]],"entity_id": [ ["T3"] ]},"Route": {"text": [["intravenous"]],"start": [[ "32" ]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["cutaneous ulceration"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["an unusual complication"]],"start": [[ "13" ]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["an unusual complication"]],"start": [[ "13" ]],"entity_id": [ ["T5"] ]} ,"Duration": {"text": [["an unusual complication"]],"start": [[ "13" ]],"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [["intravenous pentamidine therapy"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ]} ,"Combination": null ,"Trigger": null },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": {"text": [["cutaneous ulceration"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} }]}
{"id": "6414095_4","context": "The episode appeared to have been precipitated by toxicity due to ingestion of a large amount of phenytoin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["phenytoin"]],"start": [["54"]],"entity_id": [["T2"]]} ,"text": [["a large amount of phenytoin"]],"start": [["43"]],"entity_id": [["T3"]] ,"Route": {"text": [["ingestion"]],"start": [["36"]],"entity_id": [["T4"]] },"Time_elapsed": {"text": [["episode"]],"start": [["0"]],"entity_id": [["T5"]] },"Dosage": {"text": [["a large amount of"]],"start": [["43"]],"entity_id": [["T6"]] },"Duration": {"text": [["episode"]],"start": [["0"]],"entity_id": [["T7"]] },"Disorder": {"text": [["episode"]],"start": [["0"]],"entity_id": [["T8"]] },"Freq": {"text": [["episode"]],"start": [["0"]],"entity_id": [["T9"]] },"Combination": null ,"Trigger": {"text": [["toxicity"]],"start": [["18"]],"entity_id": [["T10"]] }} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null }]}
{"id": "3370103_1", "context": "Cardiopulmonary arrest following intravenous phenytoin loading", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Cardiopulmonary arrest"]], "start": [[ ]] , "entity_id": [ ["T1"]]}, "Treatment": {"text": [["intravenous phenytoin loading"]], "start": [[]] , "entity_id": [ ["T2"]], "Drug": {"text": [["phenytoin"]], "start": [[ ]] , "entity_id": [ ["T3"]] }, "Route": {"text": [["intravenous"]], "start": [[ ]] , "entity_id": [ ["T4"]] }, "Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Disorder": {"text": [], "start": [], "entity_id": []} ,"Combination": null ,"Trigger": null }, "Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "3438585_5","context": "Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Corticosteroid therapy"]],"start": [[ "0" ]],"entity_id": [ ],"Drug": {"text": [["Corticosteroid"]],"start": [[ "0" ]],"entity_id": [ ]},"Duration": {"text": [["8 months"]],"start": [[ "27" ]],"entity_id": [ ]} ,"Trigger": {"text": [["continued"]],"start": [[ "16" ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["still improvement"]],"start": [[ "48" ]],"entity_id": [ ]},"Disorder": {"text": [["improvement of pulmonary function studies"]],"start": [[ "55" ]],"entity_id": [ ]} ,"Freq": {"text": [["continued"]],"start": [[ "16" ]],"entity_id": [ ]} ,"Route": {"text": [["therapy"]],"start": [[ "9" ]],"entity_id": [ ]} ,"Dosage": {"text": [["continued"]],"start": [[ "16" ]],"entity_id": [ ]} ,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "19567656_3", "context": "To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["sertraline-induced rhabdomyolysis"]], "start": [["15","16"]], "entity_id": []}, "Subject": {"text": [["an elderly patient"]], "start": [["46"]], "entity_id": [], "Age": {"text": [["elderly"]], "start": [["46"]], "entity_id": []}, "Disorder": {"text": [["dementia"]], "start": [["37"]], "entity_id": []}, "Population": {"text": [["patient"]], "start": [["46"]], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["sertraline"]], "start": [["15"]], "entity_id": [], "Drug": {"text": [["sertraline"]], "start": [["15"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null , "Disorder": {"text": [["dementia"]], "start": [["37"]], "entity_id": []}},"Effect": {"text": [["rhabdomyolysis"]], "start": [["15","16"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [], "start": [], "entity_id": [] , "value": "high" } }]}
{"id": "15028964_3","context": "Beyond the predictable pharmacokinetic drug-drug interaction requiring a significant warfarin dose reduction, the iodine-rich amiodarone affects the thyroid gland, causing overt hypothyroidism or thyrotoxicosis in 14%-18% of cases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["pharmacokinetic drug-drug interaction"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["warfarin"]],"start": [["64"]],"entity_id": [["T2"]],"Dosage": {"text": [["significant"]],"start": [["81"]],"entity_id": [["T3"]]},"Freq": {"text": [["requiring"]],"start": [["75"]],"entity_id": [["T4"]]},"Duration": {"text": [["dose reduction"]],"start": [["89"]],"entity_id": [["T5"]]},"Disorder": {"text": [["cases"]],"start": [["132"]],"entity_id": [["T6"]]},"Route": {"text": [["Beyond"]],"start": [["0"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["the predictable"]],"start": [["4"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["amiodarone"]],"start": [["110"]],"entity_id": [["T8"]]},"Trigger": {"text": [["affects"]],"start": [["106"]],"entity_id": [["T9"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["the thyroid gland"]],"start": [["101"]],"entity_id": [["T10"]]},"Drug": {"text": [["amiodarone"]],"start": [["110"]],"entity_id": [["T8"]]}},"Effect": {"text": [["overt hypothyroidism", "thyrotoxicosis"]],"start": [["127"]],"entity_id": [["T11"],["T12"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["14%-18%"]],"start": [["135"]],"entity_id": [["T13"]],"value": "medium"},"Subject": {"text": [["cases"]],"start": [["132"]],"entity_id": [["T6"]],"Population": {"text": [["14%-18%"]],"start": [["135"]],"entity_id": [["T13"]]},"Disorder": {"text": [["overt hypothyroidism or thyrotoxicosis"]],"start": [["127"]],"entity_id": [["T11"],["T12"]]},"Age": null,"Gender": null,"Race": null}}]}
{"id": "12086549_4", "context": "Toxic epidermal necrolysis associated with interleukin-2", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Toxic epidermal necrolysis"]], "start": [["0"]], "entity_id":[["T1"]]}, "Treatment": {"text": [["interleukin-2"]], "start": [["41"]], "entity_id":[["T2"]],"Drug": {"text": [["interleukin-2"]], "start": [["41"]], "entity_id":[["T2"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["Toxic epidermal necrolysis"]],"start": [["0"]],"entity_id":[["T1"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "9840249_2","context": "The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pulmonary toxicity"]],"start": [[ "entity_id"]], "entity_id": [["T1"]]},"Treatment": {"text": [["gold salts"]],"start": [[ "entity_id"]], "entity_id": [["T2"]],"Drug": {"text": [["gold salts"]],"start": [[ "entity_id"]], "entity_id": [["T2"]]}, "Disorder": {"text": [["life-threatening respiratory failure"]],"start": [[ "entity_id"]], "entity_id": [["T3"]]},"Freq": {"text": [["uncommon"]],"start": [[ "entity_id"]], "entity_id": [["F1"]]},"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Trigger": {"text": [["pulmonary toxicity"]],"start": [[ "entity_id"]], "entity_id": [["T1"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "15383642_14", "context": "With its characteristics, tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin-converting enzyme inhibitor use", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["compromise hemodynamic stability"]], "start": [["44"]], "entity_id": []}, "Treatment": {"text": [["tizanidine"]], "start": [["15"]], "entity_id": [], "Drug": {"text": [["tizanidine"]], "start": [["15"]], "entity_id": []},"Disorder":{"text":[["hemodynamic stability"]], "start":[[ "44"]], "entity_id":[]},"Trigger":{"text":[["concomitant"]], "start":[[ "35"]], "entity_id":[]},"Time_elapsed":{"text":[["during"]], "start":[[ "35"]], "entity_id":[]},"Freq":{"text":[["its characteristics"]], "start":[[ "0"]], "entity_id":[]},"Combination":[{"Drug":{"text":[["tizanidine"]], "start":[[ "15"]], "entity_id":[]},"Trigger":{"text":[["during"]], "start":[[ "35"]], "entity_id":[]},"event_id":"C1","event_type":"Combination"} ,{"Drug":{"text":[["angiotensin-converting enzyme inhibitor"]], "start":[[ "65"]], "entity_id":[]},"Trigger":{"text":[["concomitant"]], "start":[[ "35"]], "entity_id":[]},"event_id":"C2","event_type":"Combination"} ] ,"Dosage":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Duration":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Route":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]} } ,"Negated":{"value":false,"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Speculated":{"value":false,"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Severity":{"value":"","text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Subject":{"text":[["With its characteristics"]], "start":[[ "0"]], "entity_id":[],"Age":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Gender":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Population":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Race":{"text":[[""]], "start":[[ ""],[""]], "entity_id":[]},"Disorder":{"text":[["hemodynamic stability"]], "start":[[ "44"]], "entity_id":[]}} ,"Effect":{"text":[["compromise hemodynamic stability"]], "start":[[ "44"]], "entity_id":[]} }]}
{"id": "17060191_1","context": "Premature closure of the ductus arteriosus: variable response among monozygotic twins after in utero exposure to indomethacin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["premature closure of the ductus arteriosus"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["variable response among monozygotic twins"]],"start": [[ "49"]],"entity_id": [ ["T2"]] ,"Age": null,"Gender": null,"Population": {"text": [["twins"]],"start": [[ "61"]],"entity_id": [ ["T3"]]},"Race": null,"Disorder": null},"Treatment": {"text": [["in utero exposure to indomethacin"]],"start": [[ "95"]],"entity_id": [ ["T4"]],"Drug": {"text": [["indomethacin"]],"start": [[ "106"]],"entity_id": [ ["T5"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Disorder": {"text": [["premature closure of the ductus arteriosus"]],"start": [[ "0"]],"entity_id": [ ["T1"]]}} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null}]}
{"id": "10475726_3","context": "This is the first report of a possible association between an acute cardiovascular event and venlafaxine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["acute cardiovascular event"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["venlafaxine"]],"start": [["72"]],"entity_id": [["T2"]] ,"Drug": {"text": [["venlafaxine"]],"start": [["72"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["acute cardiovascular event"]],"start": [["32"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["between"]],"start": [["52"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["venlafaxine"]],"start": [["72"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["62"]],"entity_id": [["T6"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Freq": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["possible association"]],"start": [["33"]],"entity_id": [["T8"]]} ,"Route": {"text": [["report"]],"start": [["0"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []}} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": true} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "6830388_1","context": "Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["toxic effects"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cimetidine"]],"start": [["52"]],"entity_id": [["T2"]],"Disorder": {"text": [["peptic ulcer disease"]],"start": [["23"]],"entity_id": [["T3"]]},"Dosage": {"text": [["might be prescribed"]],"start": [["52"]],"entity_id": [["T4"]]},"Route": {"text": [["for the gastrointestinal symptoms"]],"start": [["52"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["subsequent worsening"]],"start": [["69"]],"entity_id": [["T6"]]},"Drug": {"text": [["theophylline"]],"start": [["13"]],"entity_id": [["T1"]]},"Trigger": {"text": [["poisoning"]],"start": [["84"]],"entity_id": [["T7"]]},"Freq": {"text": [["early symptoms"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["the toxic effects"]],"start": [["13"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["cimetidine"]],"start": [["52"]],"entity_id": [["T2"]]},"Trigger": {"text": [["poisoning"]],"start": [["84"]],"entity_id": [["T7"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["peptic ulcer disease"]],"start": [["23"]],"entity_id": [["T3"]]}},"Effect": {"text": [["worsening"]],"start": [["69"]],"entity_id": [["T6"]]}}]}
{"id": "8222875_2", "context": "Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Pulmonary hemorrhage"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["mitomycin C therapy"]], "start": [[ ]], "entity_id": [["T3"]],"Drug": {"text": [["mitomycin C"]], "start": [[ ]], "entity_id": [["T4"]] } , "Disorder": {"text": [["hemolytic-uremic syndrome"]], "start": [[ ]], "entity_id": [["T2"]]} , "Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null, "Combination": null, "Trigger": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9111724_1","context": "Discontinuation of the itraconazole caused resolution of the drug eruption","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["discontinuation", "drug eruption"]],"start": [["0","42"]],"entity_id": []},"Treatment": {"text": [["itraconazole"]],"start": [["12"]],"entity_id": [],"Drug": {"text": [["itraconazole"]],"start": [["12"]],"entity_id": []},"Freq": {"text": [["discontinuation"]],"start": [["0"]],"entity_id": []},"Duration": {"text": [["discontinuation"]],"start": [["0"]],"entity_id": []},"Route": {"text": [["discontinuation"]],"start": [["0"]],"entity_id": []},"Time_elapsed": {"text": [["discontinuation"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["drug eruption"]],"start": [["42"]],"entity_id": []},"Dosage": {"text": [["discontinuation"]],"start": [["0"]],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["resolution"]],"start": [["32"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19307676_2","context": "The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["intrathecal methotrexate"]],"start": [["22"]],"entity_id": [["T1"]] ,"Drug": {"text": [["methotrexate"]],"start": [["22"]],"entity_id": [["T2"]] },"Disorder": {"text": [["treatment protocols"]],"start": [["0"]],"entity_id": [["T3"]] },"Duration": {"text": [["to treatment protocols"]],"start": [["0"]],"entity_id": [["T3"]] },"Route": {"text": [["intrathecal"]],"start": [["22"]],"entity_id": [["T4"]] },"Time_elapsed": {"text": [["increased survival rates"]],"start": [["43"]],"entity_id": [["T5"]] },"Freq": {"text": [["has increased"]],"start": [["43"]],"entity_id": [["T6"]] },"Combination": null ,"Trigger": null ,"Dosage": null },"Effect": {"text": [["neurotoxicity"]],"start": [["103"]],"entity_id": [["T7"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["varying degrees"]],"start": [["95"]],"entity_id": [["T8"]] ,"value": "medium" },"Subject": null ,"Trigger": null }]}
{"id": "10473079_1","context": "We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug._","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"value": "high","text": [["life-threatening"]],"start": [["56"]],"entity_id": [["T4"]]},"Subject": null,"Treatment": {"text": [["topical 5-FU"]],"start": [["47"]],"entity_id": [["T2"]],"Drug": {"text": [["5-FU"]],"start": [["47"]],"entity_id": [["T3"]]},"Dosage": null,"Freq": null,"Duration": null,"Route": {"text": [["topical"]],"start": [["47"]],"entity_id": [["T1"]]},"Time_elapsed": null,"Disorder": {"text": [["this metabolic defect"]],"start": [["11"]],"entity_id": [["T0"]]},"Combination": null,"Trigger": null},"Effect": {"text": [["toxicity"]],"start": [["73"]],"entity_id": [["T5"]]},"Trigger": {"text": [["treatment"]],"start": [["92"]],"entity_id": [["T6"]]}}]}
{"id": "6958210_1","context": "Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["syndrome resembling lupus erythematosus"]],"start": [["32"]],"entity_id": [["T1"]]},"Subject": {"text": [["Six patients with rheumatoid arthritis"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": {"text": [["Six"]], "start": [["0"]], "entity_id": [["T0"]]},"Race": null,"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["9"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["penicillamine"]],"start": [["73"]],"entity_id": [["T3"]],"Drug": {"text": [["penicillamine"]],"start": [["73"]],"entity_id": [["T3"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["6"]],"entity_id": [["T2"]]} ,"Combination": null ,"Trigger": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["syndrome resembling lupus erythematosus"]],"start": [["32"]],"entity_id": [["T1"]]}}]}
{"id": "12590235_3", "context": "This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["6-TG"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["thiopurine-induced hepatic injury"]],"start": [["100"]],"entity_id": [["T2"]]} ,"entity_id": [["T1"], ["T2"]],"text": [["6-TG"], ["thiopurine-induced hepatic injury"]],"start": [["32"], ["100"]] ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [["treated with"]],"start": [["24"]],"entity_id": [] },"Combination": [] },"Subject": {"text": [["patients"]],"start": [["11"]],"entity_id": [["T3"]],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": {"text": [["need"]],"start": [["0"]],"entity_id": [] ,"value": true },"Severity": null ,"Effect": {"text": [["monitor liver enzymes"]],"start": [["5"]],"entity_id": [["T4"]] },"Trigger": {"text": [["highlights"]],"start": [["0"]],"entity_id": [] }}]}
{"id": "9347384_2","context": "During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Treatment": {"text": [["clarithromycin coadministration"]],"start": [[ "During clarithromycin coadministration," ,"clarithromycin coadministration" ]],"entity_id": [["T1"]],"Trigger": {"text": [["developed"]],"start": [[ "developed" ]],"entity_id": [["T2"]]},"Drug": {"text": [["carbamazepine"]],"start": [[ "carbamazepine" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["toxic symptoms"]],"start": [[ "toxic symptoms" ]],"entity_id": [["T4"]]},"Freq": {"text": [["four out of the seven patients"]],"start": [[ "four out of the seven patients" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["5 days"]],"start": [[ "5 days" ]],"entity_id": [["T6"]]},"Duration": {"text": [["resolved within"]],"start": [[ "resolved within" ]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [[ "clarithromycin coadministration" ]],"entity_id": [["T8"]]},"Trigger": {"text": [["discontinuation"]],"start": [[ "discontinuation" ]],"entity_id": [["T9"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Route": {"text": [["of clarithromycin"]],"start": [[ "of clarithromycin" ]],"entity_id": [["T10"]]},"Dosage": {"text": [["clarithromycin coadministration"]],"start": [[ "During clarithromycin coadministration," ]],"entity_id": [["T1"]]}},"Effect": {"text": [["drowsiness","dizziness","ataxia"]],"start": [[ "drowsiness","dizziness","ataxia" ]],"entity_id": [["T11","T12","T13"]]},"Subject": {"text": [["four out of the seven patients"]],"start": [[ "four out of the seven patients" ]],"entity_id": [["T5"]],"Population": {"text": [["four out of the seven patients"]],"start": [[ "four out of the seven patients" ]],"entity_id": [["T5"]]},"Age": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T14"]]},"Gender": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T15"]]},"Race": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T16"]]},"Disorder": {"text": [["toxic symptoms"]],"start": [[ "toxic symptoms" ]],"entity_id": [["T4"]]}},"Negated": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T17"]],"value": false},"Speculated": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T18"]],"value": false},"Severity": {"text": [["moderate-to-severe"]],"start": [[ "moderate-to-severe" ]],"entity_id": [["T19"]],"value": "moderate-to-severe"},"Trigger": {"text": [["developed"]],"start": [[ "developed" ]],"entity_id": [["T2"]]}}]}
{"id": "10099659_2", "context": "5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["5-Fluorouracil (5-FU)"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] ,"Drug": {"text": [["5-Fluorouracil"]],"start": [[ "0" ]],"entity_id": [ ["T2" ]] },"Disorder": {"text": [["head and neck cancer"]],"start": [[ "81" ]],"entity_id": [ ["T3" ]] },"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null }, "Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": null, "Population": null, "Race": null }, "Trigger": null }] }
{"id": "19782276_1", "context": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cardiotoxicity"]], "start": [["15"]], "entity_id": []}, "Treatment": {"text": [["cyclophosphamide therapy"]], "start": [["41"]], "entity_id": [], "Drug": {"text": [["cyclophosphamide"]], "start": [["41"]], "entity_id": [] } ,"Disorder": {"text": [["cardiotoxicity"]], "start": [["15"]], "entity_id": [] } ,"Time_elapsed": {"text": [["following"]], "start": [["34"]], "entity_id": [] } ,"Freq": {"text": [["fulminant fatal"]], "start": [["0"]], "entity_id": [] } ,"Combination": [] ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Route": {"text": [], "start": [], "entity_id": [] } ,"Trigger": {"text": [], "start": [], "entity_id": [] } } ,"Effect": {"text": [], "start": [], "entity_id": [] } ,"Negated": null, "Speculated": null, "Severity": {"text": [["fulminant fatal"]], "start": [["0"]], "entity_id": [], "value": "high" },"Subject": { "text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": [] } ,"Disorder": {"text": [], "start": [], "entity_id": [] } ,"Gender": {"text": [], "start": [], "entity_id": [] } ,"Population": {"text": [], "start": [], "entity_id": [] } ,"Race": {"text": [], "start": [], "entity_id": [] }} }]}
{"id": "11142491_2","context": "We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["exceptional development"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["26"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["previously diagnosed CLL in minimal residual disease status"]],"start": [["9"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["fludarabine treatment followed by autologous peripheral blood stem-cell transplantation"]],"start": [["72"]],"entity_id": [["T4"]],"Drug": {"text": [["fludarabine"]],"start": [["72"]],"entity_id": [["T5"]]},"Disorder": {"text": [["AML"]],"start": [["41"]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["lung cancer"]],"start": [["50"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6353252_3","context": "We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug-resistant hypertension","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute reversible renal failure"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with captopril"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["captopril"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["severe drug-resistant hypertension"]],"start": [["75"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["5 cases"]],"start": [["4"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["coinciding with the onset"]],"start": [["32"]],"entity_id": [["T5"]]} ,"Route": {"text": [["treatment"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [[]],"start": [],"entity_id": []} ,"Duration": {"text": [[]],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [["acute reversible"]],"start": [["18"]],"entity_id": [["T1"]] ,"value": "Low"} ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }} ]}
{"id": "9375469_3","context": "We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["contact dermatitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Tathion eye drops"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["sodium bisulfite"]],"start": [["35"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["contact dermatitis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Route": {"text": [["eye drops"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["due to"]],"start": [["34"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["report a case"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["report a case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": null ,"Dosage": {"text": [["contact dermatitis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["Tathion eye drops"]],"start": [["52"]],"entity_id": [["T2"]]} },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }} ]}
{"id": "19815480_1","context": "The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["responding"]],"start": [["35"]],"entity_id": []},"Treatment": {"text": [["sunitinib"]],"start": [["53"]],"entity_id": [],"Drug": {"text": [["sunitinib"]],"start": [["53"]],"entity_id": []},"Disorder": {"text": [["significant fatigue"]],"start": [["63"]],"entity_id": []},"Time_elapsed": {"text": [["responding"]],"start": [["35"]],"entity_id": []},"Freq": {"text": [["responding"]],"start": [["35"]],"entity_id": []},"Combination": [{"Drug": {"text": [["hemodialysis"]],"start": [["13"]],"entity_id": []},"Trigger": {"text": [["undergoing"]],"start": [["13"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E2"}],"Trigger": {"text": [["hypertension"]],"start": [["82"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["The first patient"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["undergoing hemodialysis"]],"start": [["13"]],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["significant fatigue"]],"start": [["63"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "17536204_4", "context": "CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["CCBs"]], "start": [[]],"entity_id":[],"Disorder": {"text": [["5-FU or capecitabine-induced headaches"]], "start": [[]],"entity_id":[]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null,"Drug": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "9337441_8","context": "Furosemide, spironolactone, allopurinol, and hydroxyurea were considered possible causes of the reaction and were discontinued","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Furosemide"]],"start": [[ ]],"entity_id": [ ]},"text": [["Furosemide"]],"start": [[ ]],"entity_id": [ ] ,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": null,"Combination": [{"Drug": {"text": [["spironolactone"]],"start": [[ ]],"entity_id": [ ]},"Trigger": null , "event_id": "E2" ,"event_type": "Potential_therapeutic_effect"}]}, "Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null , "Trigger": null}]}
{"id": "11414270_5","context": "One patient with mucositis secondary to chemotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["mucositis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["chemotherapy"]],"start": [["46"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"Trigger": {"text": [["secondary"]],"start": [["30"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["mucositis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["secondary"]],"start": [["30"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["One"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["One"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["One"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Route": {"text": [["chemotherapy"]],"start": [["46"]],"entity_id": [["T2"]]} ,"text": [["One patient with mucositis secondary to chemotherapy"]],"start": [["0"]],"Combination": [{"Drug": {"text": [["chemotherapy"]],"start": [["46"]],"entity_id": [["T2"]]},"Trigger": {"text": [["secondary"]],"start": [["30"]],"entity_id": [["T3"]]},"event_id": "E1","event_type": "Adverse_event"}] } ,"Subject": {"text": [["One patient"]],"start": [["0"]],"Age": {"text": [["One"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["One"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} ,"entity_id": [["T0"]]} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Effect": {"text": [["mucositis"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "15266150_1","context": "A patient with monocular open-angle glaucoma had trichiasis, a condition associated with the use of a prostaglandin analog","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["trichiasis"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["prostaglandin analog"]],"start": [["72"]],"entity_id": [["T2"]]},"text": [["use"]],"start": [["53"]],"entity_id": [["T3"]],"Disorder": {"text": [["monocular open-angle glaucoma"]],"start": [["9"]],"entity_id": [["T4"]]},"Route": {"text": [["use"]],"start": [["53"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["had"]],"start": [["15"]],"entity_id": [["T5"]]},"Freq": {"text": [["use"]],"start": [["53"]],"entity_id": [["T3"]]},"Trigger": {"text": [["associated"]],"start": [["44"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["prostaglandin analog"]],"start": [["72"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use"]],"start": [["53"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [["use"]],"start": [["53"]],"entity_id": [["T3"]]},"Duration": {"text": [["had"]],"start": [["15"]],"entity_id": [["T5"]]}},"Effect": {"text": [["trichiasis"]],"start": [["19"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["condition"]],"start": [["19"]],"entity_id": [["T1"]],"value": "low"},"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["monocular open-angle glaucoma"]],"start": [["9"]],"entity_id": [["T4"]]},"Age": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "21189363_3","context": "A 53-year-old African American male with HIV was prescribed warfarin 5 mg/day for 12 months after diagnosis of idiopathic deep vein thrombosis and bilateral pulmonary emboli (target INR 2.5 [range 2.0-3.0])","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["warfarin"]],"start": [["9"]],"entity_id": [["T1"]]},"Dosage": {"text": [["5 mg/day"]],"start": [["21"]],"entity_id": [["T2"]]},"Duration": {"text": [["12 months"]],"start": [["37"]],"entity_id": [["T3"]]},"Trigger": {"text": [["prescribed"]],"start": [["44"]],"entity_id": [["T4"]]},"Disorder": {"text": [["HIV"]],"start": [["18"]],"entity_id": [["T5"]]},"Route": {"text": [["oral"]],"start": [["72"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["diagnosis"]],"start": [["58"]],"entity_id": [["T7"]]},"Freq": {"text": [["daily"]],"start": [["21"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["warfarin"]],"start": [["9"]],"entity_id": [["T1"]]},"Trigger": {"text": [["prescribed"]],"start": [["44"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"entity_id": [["T1"],["T2"],["T3"],["T4"],["T5"],["T6"],["T7"]],"start": [["9"],["21"],["37"],["44"],["18"],["72"],["58"]],"text": [["warfarin"],["5 mg/day"],["12 months"],["prescribed"],["HIV"],["oral"],["diagnosis"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A 53-year-old African American male"]],"start": [["0"]],"entity_id": [["T9"]],"Age": {"text": [["53"]],"start": [["2"]],"entity_id": [["T10"]]},"Gender": {"text": [["male"]],"start": [["16"]],"entity_id": [["T11"]]},"Population": null,"Race": {"text": [["African American"]],"start": [["10"]],"entity_id": [["T12"]]},"Disorder": {"text": [["HIV"],["idiopathic deep vein thrombosis"],["bilateral pulmonary emboli"]],"start": [["18"],["48"],["68"],["78"]],"entity_id": [["T5"],["T13"],["T14"]]}},"Effect": {"text": [["anticoagulation effect"]],"start": [["74"]],"entity_id": [["T15"]]},"Trigger": {"text": [["idiopathic deep vein thrombosis and bilateral pulmonary emboli"]],"start": [["48"]],"entity_id": [["T13"],["T14"]]}}]}
{"id": "18836269_1","context": "After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["beta-sympathomimetic drug", "Partusisten"]],"start": [["After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof(" ] , [ "After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof(" ] ],"entity_id": [ [ "18836269_1_T1", "18836269_1_T2" ] ],"Trigger": {"text": [["developed"]],"start": [["After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof(" ] ],"entity_id": [ [ "18836269_1_T3" ] ]},"Drug": {"text": [["beta-sympathomimetic drug", "Partusisten"]],"start": [["After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof(" ] ],"entity_id": [ [ "18836269_1_T1", "18836269_1_T2" ] ]},"Disorder": {"text": [["supraventricular tachycardia"]],"start": [["After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof([" ] ],"entity_id": [ [ "18836269_1_T4" ] ]},"Freq": null,"Duration": null,"Route": null,"Time_elapsed": null,"Dosage": null,"Combination": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["supraventricular tachycardia"]],"start": [["After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia].indexof([" ] ],"entity_id": [ [ "18836269_1_T4" ] ]},"Trigger": null}]}
{"id": "18533420_2","context": "A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["sexual dysfunction"]],"start": [["41"]],"entity_id": [["T1"]]},"Subject": {"text": [["a male and a female patient with spasticity"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": {"text": [["male"]],"start": [["4"]],"entity_id": [["T2"]]},"Population": null,"Race": null,"Disorder": {"text": [["spasticity"]],"start": [["22"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["intrathecal baclofen"]],"start": [["54"]],"entity_id": [["T4"]],"Drug": {"text": [["baclofen"]],"start": [["59"]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Disorder": {"text": [["spasticity"]],"start": [["22"]],"entity_id": [["T3"]]}},"Effect": {"text": [["sexual dysfunction"]],"start": [["41"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17448102_2","context": "Flecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Flecainide overdose"]],"start": [[ "0" ]],"entity_id": []},"Effect": {"text": [["profound cardiovascular collapse"]],"start": [[ "47" ]],"entity_id": []},"Negated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Severity": {"value": "high","text": [],"start": [],"entity_id": [] },"Subject": {"text": [],"start": [],"entity_id": [] ,"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Age": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }},"Treatment": {"text": [],"start": [],"entity_id": [] ,"Drug": {"text": [["Flecainide"]],"start": [[ "0" ]],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": [] }} ,"Speculated": {"value": false,"text": [],"start": [],"entity_id": [] }} ]}
{"id": "2894766_4", "context": "Sulfasalazine-induced lupus erythematosus", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Sulfasalazine-induced lupus erythematosus"]], "start": [[],[]], "entity_id": []}, "Treatment": { "text": [["Sulfasalazine"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["Sulfasalazine"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [["lupus erythematosus"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [["induced"]], "start": [[],[]], "entity_id": []},"Duration": { "text": [], "start": [], "entity_id": []},"Dosage": { "text": [], "start": [], "entity_id": []},"Route": { "text": [], "start": [], "entity_id": []},"Freq": { "text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": { "text": [], "start": [], "entity_id": []}},"Effect": { "text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": { "text": [], "start": [], "entity_id": [],"value": "medium" },"Subject": { "text": [], "start": [], "entity_id": [],"Age": { "text": [], "start": [], "entity_id": []},"Disorder": { "text": [], "start": [], "entity_id": []},"Gender": { "text": [], "start": [], "entity_id": []},"Population": { "text": [], "start": [], "entity_id": []},"Race": { "text": [], "start": [], "entity_id": []}}}]}
{"id": "4036917_2","context": "Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Reye syndrome"]],"start": [[ ]] ,"entity_id": [ ]},"Treatment": {"text": [["long-term aspirin therapy"]],"start": [[ ]] ,"entity_id": [ ],"Drug": {"text": [["aspirin"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["long-term"]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["long-term"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["children"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["occur"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["receiving"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": null ,"Trigger": null } ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": {"text": [["children"]],"start": [[ ]],"entity_id": [ ],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": {"text": [["children"]],"start": [[ ]],"entity_id": [ ]} } } ] }
{"id": "14746605_2", "context": "Propecia-associated bilateral cataract", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Propecia-associated"]], "start": [["0"]], "entity_id": [ ["T1"]]}, "Effect": {"text": [["bilateral cataract"]], "start": [["18"]], "entity_id": [ ["T2"]]}, "Treatment": { "text": [], "start": [], "entity_id": [] , "Drug": { "text": [["Propecia"]], "start": [[ "0" ]], "entity_id": [ ["T0" ] ] } , "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Disorder": { "text": [], "start": [], "entity_id": [] }},"Subject": { "text": [], "start": [], "entity_id": [] , "Age": null , "Gender": null , "Population": null , "Race": null , "Disorder": { "text": [], "start": [], "entity_id": [] }},"Negated": null,"Speculated": null,"Severity": { "text": [], "start": [], "entity_id": [] , "value": "low"}}]}
{"id": "12921505_1","context": "After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["minor bleeding"]],"start": [["minor bleeding observed" ] ],"entity_id": [["T1"]]},"Treatment": {"text": [["argatroban"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]],"Dosage": {"text": [["39 hours"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]},"Duration": {"text": [["39 hours"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]},"Route": {"text": [["on"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["when minor bleeding was observed"]],"start": [[ "when minor bleeding was observed" ]],"entity_id": [["T1"]]},"Disorder": {"text": [["minor bleeding"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]]},"Trigger": {"text": [["minor bleeding was observed"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]]},"Freq": {"text": [["39 hours"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["argatroban"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]},"Trigger": {"text": [["minor bleeding was observed"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Drug": {"text": [["argatroban"]],"start": [[ "39 hours on argatroban" ]],"entity_id": [["T2"]]}},"Effect": {"text": [["minor bleeding"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["minor"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]],"value": "minor"},"Subject": {"text": [["the infusion"]],"start": [[ "the infusion was stopped" ]],"entity_id": [["T0"]],"Population": {"text": [["the infusion"]],"start": [[ "the infusion was stopped" ]],"entity_id": [["T0"]]},"Gender": null,"Disorder": {"text": [["minor bleeding"]],"start": [[ "minor bleeding observed" ]],"entity_id": [["T1"]]},"Age": null,"Race": null}}]}
{"id": "6540393_2", "context": "Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Anaphylactoid reaction"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["methylprednisolone pulsed therapy"]], "start": [["22"]], "entity_id": [], "Drug": {"text": [["methylprednisolone"]], "start": [["22"]], "entity_id": []}, "Duration": {"text": [["pulsed"]], "start": [["32"]], "entity_id": []}, "Disorder": {"text": [["multiple sclerosis"]], "start": [["52"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Dosage": {"text": [], "start": [], "entity_id": []}, "Trigger": null}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "18020545_1","context": "Surprisingly, we found that three patients appeared to develop tardive OGC while taking clozapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tardive OGC"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["three patients"]],"start": [["11"]],"entity_id": [["T2"]],"Population": {"text": [["three patients"]],"start": [["11"]],"entity_id": [["T2"]]},"Disorder": {"text": [["tardive OGC"]],"start": [["33"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["clozapine"]],"start": [["65"]],"entity_id": [["T3"]],"Drug": {"text": [["clozapine"]],"start": [["65"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["tardive OGC"]],"start": [["33"]],"entity_id": [["T1"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["tardive OGC"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11207969_4","context": "We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [["0"]],"entity_id": [] ,"value":"fatal"},"Subject": null,"Treatment": {"text": [["high dose"]],"start": [["23"]],"entity_id": [] ,"Drug": { "text": [["cytosine arabinoside (ARA-C)"]], "start": [["35"]], "entity_id": [] },"Dosage": { "text": [["high dose"]], "start": [["23"]], "entity_id": [] },"Route": null, "Time_elapsed": null, "Duration": null, "Disorder": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [["resulting"]], "start": [["19"]], "entity_id": [] }},"Effect": {"text": [["toxic epidermal necrolysis (TEN)"]],"start": [["6"]],"entity_id": [] },"Trigger": null}]}
{"id": "11207969_2","context": "On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bullous lesions", "hands", "soles"]],"start": [["On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed "], [", that disseminated,"], []],"entity_id": [[],[],[]]},"Treatment": {"text": [["ARA-C"]],"start": [[ "On the fifth day after administration of a high dose of " ]],"entity_id": [[]],"Dosage": {"text": [["a high dose"]],"start": [[ "On the fifth day after administration of a high dose of " ]],"entity_id": [[]]},"Route": {"text": [["intravenously"]],"start": [[ "On the fifth day after administration of a high dose of ARA-C (2 g/m2 " ]],"entity_id": [[]]},"Freq": {"text": [["every 12 hours"]],"start": [[ "On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously " ]],"entity_id": [[]]},"Drug": {"text": [["ARA-C"]],"start": [[ "On the fifth day after administration of a high dose of " ]],"entity_id": [[]]},"Time_elapsed": {"text": [["5 days"]],"start": [[ "On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed " ]],"entity_id": [[]]},"Disorder": {"text": [["necrosis", "sepsis", "death"]],"start": [[ ", evolving to necrosis,"], [", sepsis,"], [", and death on the 22nd day"]],"entity_id": [[],[],[]]},"Trigger": {"text": [["developed"]],"start": [[ "she developed" ]],"entity_id": [[]]},"Combination": [{"Drug": {"text": [["ARA-C"]],"start": [[ "On the fifth day after administration of a high dose of " ]],"entity_id": [[]]},"Trigger": {"text": [["developed"]],"start": [[ "she developed" ]],"entity_id": [[]]},"event_id": "E1","event_type": "Adverse_event"}],"Duration": {"text": [["22 days"]],"start": [[ "death on the 22nd day"]],"entity_id": [[]]}},"Effect": {"text": [["bullous lesions", "hands", "soles"]],"start": [[ "On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed "]],"entity_id": [[]]},"Severity": {"text": [["disseminated", "evolving to necrosis", "sepsis", "death"]],"start": [[ ", that disseminated,"], [ ", evolving to necrosis,"], [ ", sepsis,"], [ "death on the 22nd day"]],"entity_id": [[],[],[],[]],"value": "High"},"Negated": {"value": false,"text": [[]],"start": [[ ]],"entity_id": [[]]},"Speculated": {"value": false,"text": [[]],"start": [[ ]],"entity_id": [[]]},"Subject": {"text": [["she"]],"start": [[ "she developed" ]],"entity_id": [[]],"Age": {"text": [],"start": [[ ]],"entity_id": [[]]},"Gender": {"text": [],"start": [[ ]],"entity_id": [[]]},"Population": {"text": [],"start": [[ ]],"entity_id": [[]]},"Race": {"text": [],"start": [[ ]],"entity_id": [[]]},"Disorder": {"text": [],"start": [[ ]],"entity_id": [[]]}}}]}
{"id": "8730143_3","context": "We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe dapsone reaction"]],"start": [["31"]],"entity_id": [["T1"]]},"Subject": {"text": [["2 patients with cutaneous lupus erythematosus"]],"start": [["0"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["cutaneous lupus erythematosus"]],"start": [["4"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["dapsone therapy"]],"start": [["55"]],"entity_id": [["T4"]],"Drug": {"text": [["dapsone"]],"start": [["55"]],"entity_id": [["T5"]]},"Dosage": {"text": [["low dose"]],"start": [["60"]],"entity_id": [["T6"]]},"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["fatal outcome"]],"start": [["83"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["31"]],"entity_id": [["T1"]],"value": "High"}}]}
{"id": "1359782_1","context": "A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["skin pigmentation", "diffuse pulmonary shadowing"]],"start": [["16", "45"]],"entity_id": [["T1", "T2"]]},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["ulcerative colitis"]],"start": [["5"]],"entity_id": [["T3"]]} ,"Age": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]},"Gender": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]},"Population": {"text": [["1"]],"start": [[""], []],"entity_id": [["NA"]]},"Race": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]} },"Treatment": {"text": [["sulfasalazine"]],"start": [["81"]],"entity_id": [["T4"]],"Drug": {"text": [["sulfasalazine"]],"start": [["81"]],"entity_id": [["T5"]]},"Dosage": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]},"Duration": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]},"Trigger": {"text": [["while taking"]],"start": [["70"]],"entity_id": [["T6"]]},"Route": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]},"Time_elapsed": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]} ,"Freq": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]]} ,"Disorder": {"text": [["ulcerative colitis"]],"start": [["5"]],"entity_id": [["T3"]]} ,"Combination": null} ,"Effect": {"text": [["skin pigmentation", "diffuse pulmonary shadowing"]],"start": [["16", "45"]],"entity_id": [["T1", "T2"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["NA"]] ,"value": "low"} }]}
{"id": "23552010_2","context": "This is a case report involving a patient who was treated with topical 5-FU cream and subsequently developed a severe case of angioedema","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["subsequently developed"]],"start": [["51"]],"entity_id": []},"Effect": {"text": [["severe case of angioedema"]],"start": [["36"]],"entity_id": []},"Treatment": {"text": [["topical 5-FU cream"]],"start": [["22"]],"entity_id": [] ,"Drug": {"text": [["5-FU"]],"start": [["30"]],"entity_id": []} ,"Route": {"text": [["topical"]],"start": [["22"]],"entity_id": []} ,"Freq": {"text": [["cream"]],"start": [["28"]],"entity_id": []} ,"Time_elapsed": {"text": [["subsequently"]],"start": [["51"]],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["42"]],"entity_id": [] ,"value": "high"}}]}
{"id": "10555917_2","context": "Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["D-Pen"]],"start": [[ ],[ ]],"entity_id": [ ]},"Trigger": {"text": [["cessation"]],"start": [[ ],[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["start of corticosteroid therapy"]],"start": [[ ],[ ]],"entity_id": [ ]},"Disorder": {"text": [["recovery from bicytopenia"]],"start": [[ ],[ ]],"entity_id": [ ]},"entity_id": [ ],"text": [["Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia"]],"start": [[ ],[ ]],"Dosage": {"text": [[" "]],"start": [[ ],[ ]],"entity_id": [ ]},"Duration": {"text": [[" "]],"start": [[ ],[ ]],"entity_id": [ ]},"Route": {"text": [[" "]],"start": [[ ],[ ]],"entity_id": [ ]},"Freq": {"text": [[" "]],"start": [[ ],[ ]],"entity_id": [ ]},"Combination": null},"Effect": {"text": [["recovery from bicytopenia"]],"start": [[ ],[ ]],"entity_id": [ ]},"Trigger": {"text": [["start of corticosteroid therapy"]],"start": [[ ],[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "16411025_3","context": "A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia. {OBJECTIVES}.","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["delayed stroke-like leukoencephalopathy"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Subject": {"text": [["patients"]],"start": [["23"]],"entity_id": [["T2"]],"Age": {"text": [["childhood"]],"start": [["43"]],"entity_id": [["T3"]]},"Disorder": {"text": [["leukemia"]],"start": [["58"]],"entity_id": [["T4"]]},"Race": null,"Gender": null,"Population": null},"Treatment": {"text": [["methotrexate (MTX)"]],"start": [["13"]],"entity_id": [["T5"]],"Drug": {"text": [["methotrexate"]],"start": [["13"]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["leukemia"]],"start": [["58"]],"entity_id": [["T4"]]},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "25538343_1","context": "Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Duloxetine-induced hyponatremia"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["thiazide diuretics"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["thiazide"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["hyponatremia"]],"start": [[ ]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["an elderly patient"]],"start": [[ ]],"entity_id": [],"Age": {"text": [[ "elderly"]],"start": [[ ]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16623611_2","context": "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the need for better care coordination"]],"start": [[], []],"entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [["olanzapine"]],"start": [[], []],"entity_id": [] ,"Drug": { "text": [["olanzapine"]], "start": [[], []], "entity_id": []} ,"Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null},"Effect": {"text": [["metabolic changes manifested as uncontrolled diabetes mellitus and weight gain"]],"start": [[], []],"entity_id": [] },"Trigger": { "text": [["the observed relationship of olanzapine to"]], "start": [[], []], "entity_id": []} }]}
{"id": "10466445_2", "context": "Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Arsenic trioxide"]], "start": [[]],"entity_id":[["T1"]],"Dosage":{"text":[["recently introduced"]], "start": [[]],"entity_id":[["T2"]]},"Route":{"text":[["as a promising new agent"]], "start": [[]],"entity_id":[["T3"]]},"Disorder":{"text":[["to treat refractory acute promyelocytic leukemia (APL)"]], "start": [[]],"entity_id":[["T4"]]},"Trigger":{"text":[["promising"]], "start": [[]],"entity_id":[["T5"]]},"Time_elapsed":{"text":[["recently introduced"]], "start": [[]],"entity_id":[["T2"]]},"Freq":{"text":[["new agent"]], "start": [[]],"entity_id":[["T3"]]},"Duration":{"text":[["treat refractory acute promyelocytic leukemia (APL)"]], "start": [[]],"entity_id":[["T4"]]},"Combination":null,"Drug":{"text":[["Arsenic trioxide"]], "start": [[]],"entity_id":[["T1"]]}},"Severity":null,"Speculated":null,"Negated":null,"Subject":null,"Effect":null,"Trigger":null}]}
{"id": "10779995_1", "context": "Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["t-AML"]], "start": [["13"]], "entity_id": []}, "Treatment": {"text": [["oral etoposide therapy"]], "start": [["48"]], "entity_id": [], "Drug": {"text": [["etoposide"]], "start": [["48"]], "entity_id": [] } , "Route": {"text": [["oral"]], "start": [["48"]], "entity_id": []} , "Duration": {"text": [["following"]], "start": [["48"]], "entity_id": []} , "Freq": {"text": [["oral etoposide therapy"]], "start": [["48"]], "entity_id": []} , "Time_elapsed": {"text": [["developed"]], "start": [["13"]], "entity_id": []} , "Dosage": { "text": [ ["high-dose"] ], "start": [["20"]], "entity_id": [] } , "Combination": [{"Drug": {"text": [["etoposide"]], "start": [["48"]], "entity_id": []}, "Trigger": {"text": [["multiagent chemotherapy"]], "start": [["63"]], "entity_id": []}, "event_type": "Potential_therapeutic_effect" , "event_id": "E2"}] , "Disorder": { "text": [ ["t-AML"] ], "start": [["13"]], "entity_id": [] } , "Trigger": { "text": [ ["developed"] ], "start": [["13"]], "entity_id": [] } } , "Effect": { "text": [], "start": [], "entity_id": [] } , "Negated": { "text": [], "start": [], "entity_id": [], "value": false } , "Speculated": { "text": [], "start": [], "entity_id": [], "value": false } , "Severity": { "text": [], "start": [], "entity_id": [], "value": "" } , "Subject": { "text": [["the child"]], "start": [["55"]], "entity_id": [], "Age": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [["t-AML"]], "start": [["13"]], "entity_id": [] } }}]}
{"id": "15107195_2", "context": "Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Heat stroke"]], "start": [[ ]],"entity_id": [ ]}, "Treatment": {"text": [["clozapine treatment"]], "start": [[ ]],"entity_id": [ ], "Drug": {"text": [["clozapine"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["treatment"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["schizophrenia"]], "start": [[ ]], "entity_id": [ ]}, "Freq": {"text": [["during"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [["stroke"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["treatment"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": {"text": [[]], "start": [[ ]], "entity_id": []}, "Duration": {"text": [[]], "start": [[ ]], "entity_id": []}, "Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "25957434_4", "context": "The same symptoms recurred few days after taking nitrendipine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurred"]], "start": [["13"]], "entity_id": []}, "Treatment": {"text": [["taking nitrendipine"]], "start": [["42"]], "entity_id": [], "Drug": {"text": [["nitrendipine"]], "start": [["42"]], "entity_id": []},"Time_elapsed": {"text":[["few days"]], "start": [["20"]], "entity_id": []},"Disorder":{"text":[["The same symptoms"]], "start": [["0"]], "entity_id": []},"Freq":{"text":[["taking"]], "start": [["42"]], "entity_id": []},"Route":{"text":[["taking"]], "start": [["42"]], "entity_id": []},"Combination":[{"Drug":{"text":[["nitrendipine"]], "start": [["42"]], "entity_id": []},"Trigger":{"text":[["taking"]], "start": [["42"]], "entity_id": []},"event_type":"Treatment","event_id":"E1-T"}],"Trigger":{"text":[["recurred"]], "start": [["13"]], "entity_id": []},"Dosage":{"text":[], "start": [], "entity_id": []},"Duration":{"text":[], "start": [], "entity_id": []}},"Subject":{"Age":{"text":[], "start": [], "entity_id": []},"Gender":{"text":[], "start": [], "entity_id": []},"Population":{"text":[], "start": [], "entity_id": []},"Race":{"text":[], "start": [], "entity_id": []},"Disorder":{"text":[["The same symptoms"]], "start": [["0"]], "entity_id": []},"entity_id":[],"text":[["The same symptoms recurred"]], "start": [["0"]]},"Severity":{"text":[], "start": [], "entity_id": [],"value":"Low"},"Negated":{"text":[], "start": [], "entity_id": [],"value":false},"Speculated":{"text":[], "start": [], "entity_id": [],"value":false},"Effect":{"text":[["recurred"]], "start": [["13"]], "entity_id": []}}]}
{"id": "16062101_3","context": "The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute dystonic reactions"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lamivudine"]],"start": [["85"]],"entity_id": [["T3"]],"Drug": {"text": [["lamivudine"]],"start": [["85"]],"entity_id": [["T4"]]},"Freq": {"text": [["two cases"]],"start": [["6"]],"entity_id": [["T2"]]},"Disorder": {"text": [["acute dystonic reactions"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Route": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Time_elapsed": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Trigger": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Combination": null},"Effect": {"text": [["acute dystonic reactions"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]],"value": false},"Severity": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]],"value": "null"},"Subject": {"text": [["The authors"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Population": {"text": [["two cases"]],"start": [["6"]],"entity_id": [["T2"]]},"Race": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]},"Disorder": {"text": [["null"]],"start": [[""],[""]],"entity_id": [["null"]]}}}]}
{"id": "18067642_3", "context": "Histopathology of the thyroid in amiodarone-induced hypothyroidism", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null,"Subject": null,"Treatment": {"text": [["amiodarone"]], "start": [[ "amiodarone" ] ], "entity_id": [ ["T1"]], "Drug": {"text": [["amiodarone"]], "start": [[ "amiodarone" ]], "entity_id": [ ["T1"]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": {"text": [["hypothyroidism"]], "start": [[ "hypothyroidism" ]], "entity_id": [ ["T2"]]} ,"Combination": null ,"Trigger": {"text": [["amiodarone-induced"]], "start": [[ "amiodarone-induced" ]], "entity_id": [ ["T3"]]} },"Effect": {"text": [["hypothyroidism"]], "start": [[ "hypothyroidism" ]], "entity_id": [ ["T2"]]} ,"Trigger": {"text": [["amiodarone-induced"]], "start": [[ "amiodarone-induced" ]], "entity_id": [ ["T3"]]} }]}
{"id": "15300114_1","context": "Deepening of lid sulcus from topical bimatoprost therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Deepening of lid sulcus"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["bimatoprost"]],"start": [[ "42" ]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Route": {"text": [["topical"]],"start": [[ "42" ]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["Deepening of lid sulcus"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Duration": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Dosage": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["topical bimatoprost therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Combination": null }, "Subject": null ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "2979256_2", "context": "Gastro-oesophageal reflux associated with nifedipine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Gastro-oesophageal reflux"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["nifedipine"]], "start": [[ "45" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["nifedipine"]], "start": [[ "45" ]], "entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Gastro-oesophageal reflux"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Time_elapsed": null ,"Freq": null ,"Dosage": null ,"Duration": null ,"Route": null ,"Combination": null ,"Trigger": null }, "Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "7919557_1","context": "A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["dry", "irritating", "cough"]],"start": [["6","7","8"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["68-year-old woman"]],"start": [["0","1","2","3","4","5","6"]],"entity_id": [ ["T2"]],"Age": {"text": [["68"]],"start": [["0"]],"entity_id": [ ["T3"]]},"Gender": {"text": [["woman"]],"start": [["5"]],"entity_id": [ ["T4"]]},"Disorder": {"text": [["essential hypertension"]],"start": [["53","54","55","56","57","58"]],"entity_id": [ ["T5"]]},"Population": {"text": [["one"]],"start": [["3"]],"entity_id": [ ["T6"]]},"Race": null},"Treatment": {"text": [["quinapril therapy"]],"start": [["33","34","35","36","37","38","39"]],"entity_id": [ ["T7"]],"Drug": {"text": [["quinapril"]],"start": [["33","34","35","36","37"]],"entity_id": [ ["T8"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["essential hypertension"]],"start": [["53","54","55","56","57","58"]],"entity_id": [ ["T9"]]},"Time_elapsed": {"text": [["one month"]],"start": [["27","28","29","30"]],"entity_id": [ ["T10"]]},"Freq": null,"Route": null,"Combination": null,"Trigger": {"text": [["starting quinapril therapy"]],"start": [["30","31","32","33","34","35","36"]],"entity_id": [ ["T11"]]}},"Effect": {"text": [["a dry", "irritating cough"]],"start": [["6","7","8","9","10","11"]],"entity_id": [ ["T12"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19567656_4","context": "Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rhabdomyolysis"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Sertraline"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["dementia"]],"start": [["31"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["induced"]],"start": [["10"]],"entity_id": [["T3"]]} ,"entity_id": [["T0","T3"]] ,"text": [["Sertraline-induced"]],"start": [["0","10"]], "Dosage": {"text": [],"start": [],"entity_id": []}, "Duration": {"text": [],"start": [],"entity_id": []}, "Route": {"text": [],"start": [],"entity_id": []}, "Time_elapsed": {"text": [],"start": [],"entity_id": []}, "Freq": {"text": [],"start": [],"entity_id": []},"Combination": null} ,"Subject": {"text": [["an elderly patient"]],"start": [["21"]],"entity_id": [["T4"]],"Age": {"text": [[""],["elderly"]],"start": [[],["21"]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["dementia"]],"start": [["31"]],"entity_id": [["T2"]]}} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Effect": null} ]}
{"id": "11431864_1","context": "After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["psychotic reaction"]],"start": [[ ]],"entity_id": [["T5"]]},"Treatment": {"text": [["methylprednisolone","40 mg"],["methylprednisolone","20 mg"],["procaterol metered dose inhaler via spacer"]],"start": [[ ]],"entity_id": [["T1","T2"],["T3","T4"],["T6"]],"Drug": {"text": [["methylprednisolone"]],"start": [[ ]],"entity_id": [["T1"]]},"Dosage": {"text": [["40 mg"], ["20 mg"]],"start": [[ ]],"entity_id": [["T2"], ["T4"]]},"Route": {"text": [["i.v."]],"start": [[ ]],"entity_id": [["T2"]]},"Trigger": {"text": [["shifted"]],"start": [[ ]],"entity_id": [["T5"]]},"Freq": {"text": [["q6h"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["anti-asthma treatment"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["a few hours later"]],"start": [[ ]],"entity_id": [["T7"]]} ,"Duration": {"text": [["the dose was reduced"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["methylprednisolone"]],"start": [[ ]],"entity_id": [["T1"]]},"Trigger": {"text": [["reduced"]],"start": [[ ]],"entity_id": [["T5"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ,{"Drug": {"text": [["procaterol metered dose inhaler via spacer"]],"start": [[ ]],"entity_id": [["T6"]]},"Trigger": {"text": [["shifted"]],"start": [[ ]],"entity_id": [["T5"]]} ,"event_id": "C2" ,"event_type": "Adverse_event"}]} ,"Effect": {"text": [["psychotic reaction"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [["the dose"]],"start": [[ ]],"entity_id": [["T5"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["anti-asthma treatment"]],"start": [[ ]],"entity_id": [["T6"]]}}}]}
{"id": "21512888_7", "context": "Patient was on warfarin for a prior deep venous thrombosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["warfarin"]], "start": [["21"]], "entity_id": [],"Drug": {"text": [["warfarin"]], "start": [["21"]], "entity_id": []}, "Disorder":{"text":[["deep venous thrombosis"]], "start":[["54"]], "entity_id":[]},"Duration":{"text":[["for"]], "start":[["42"]], "entity_id":[]} ,"Trigger":{"text":[["on"]], "start":[["20"]], "entity_id":[]} ,"Time_elapsed":{"text":[], "start":[], "entity_id":[]} ,"Dosage":{"text":[], "start":[], "entity_id":[]} ,"Freq":{"text":[], "start":[], "entity_id":[]} ,"Route":{"text":[], "start":[], "entity_id":[]} ,"Combination":null},"Effect":{"text":[], "start":[], "entity_id":[]},"Negated":null,"Speculated":null,"Severity":null,"Subject":{"text":[["Patient"]], "start":[["0"]], "entity_id":[],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":{"text":[["deep venous thrombosis"]], "start":[["36"]], "entity_id":[]}} , "Trigger":{"text":[["on"]], "start":[["20"]], "entity_id":[]} }]}
{"id": "7496198_6","context": "The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Treatment": {"Drug": {"text": [["melarsoprol"]],"start": [["32"]],"entity_id": [["T1"]]},"text": [["treated by melarsoprol"]],"start": [["22"]],"entity_id": [["T2"]] ,"Trigger": {"text": [["exceeded"]],"start": [["12"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["10%"]],"start": [["8"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["August 1992 and September 1993"]],"start": [["0"]],"entity_id": [["T5"]]},"Disorder": {"text": [["ARE"]],"start": [["0"]],"entity_id": [["T6"]]},"Freq": {"text": [["suddenly"]],"start": [["6"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["during August 1992 and September 1993"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Route": {"text": [["treated by melarsoprol"]],"start": [["22"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["melarsoprol"]],"start": [["32"]],"entity_id": [["T1"]]},"Trigger": {"text": [["exceeded"]],"start": [["12"]],"entity_id": [["T3"]]},"event_id": "C1" ,"event_type": "Adverse_event" }]} ,"Subject": {"Population": {"text": [["10%"]],"start": [["8"]],"entity_id": [["T4"]]},"Disorder": {"text": [["ARE"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Age": {"text": [["August 1992 and September 1993"]],"start": [["0"]],"entity_id": [["T5"]]},"Gender": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T9"]]},"Race": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T10"]]} ,"text": [["The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol"]],"start": [[ "0" ]],"entity_id": [["T11"]]} ,"Negated": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T12"]] ,"value": false},"Speculated": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T13"]] ,"value": false},"Severity": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [["T14"]] ,"value": "N/A"} ,"Effect": {"text": [["exceeded"]],"start": [["12"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["exceeded"]],"start": [["12"]],"entity_id": [["T3"]]} }]}
{"id": "426502_1", "context": "A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["syndrome of inappropriate antidiuretic hormone", "profound hyponatremia"]], "start": [["33", "52"]], "entity_id": []}, "Treatment": {"text": [["adenine arabinoside"]], "start": [["106"]], "entity_id": [],"Drug": {"text": [["adenine arabinoside"]], "start": [["106"]], "entity_id": []},"Disorder": {"text": [["disseminated herpes zoster"]], "start": [["4"]], "entity_id": []},"Time_elapsed": {"text": [["developed"]], "start": [["22"]], "entity_id": []},"Duration":{"text":[], "start": [], "entity_id": []},"Dosage":{"text":[], "start": [], "entity_id": []},"Freq":{"text":[], "start": [], "entity_id": []},"Route":{"text":[], "start": [], "entity_id": []},"Combination": null,"Trigger":{"text":[["the administration"]], "start":[["90"]], "entity_id":[]}},"Effect": {"text": [["syndrome of inappropriate antidiuretic hormone", "profound hyponatremia"]], "start": [["33", "52"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity":{"text":[["severe"]], "start":[["48"]], "entity_id":[],"value":"severe"},"Subject":{"text":[["A patient"]], "start":[[ "0"]], "entity_id":[],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":{"text":[["disseminated herpes zoster"]], "start":[[ "4"]], "entity_id":[]}}}] }
{"id": "2147700_1","context": "One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["erythema multiforme"]],"start": [["38"]],"entity_id": [["T2"]]},"Treatment": {"text": [["griseofulvin"]],"start": [["74"]],"entity_id": [["T3"]],"Drug": {"text": [["griseofulvin"]],"start": [["74"]],"entity_id": [["T3"]]},"Disorder": {"text": [["systemic lupus erythematosus"]],"start": [["17"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after taking"]],"start": [["56"]],"entity_id": [["T4"]]},"Trigger": {"text": [["took"]],"start": [["66"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["systemic lupus erythematosus"]],"start": [["17"]],"entity_id": [["T1"]]}},"Effect": {"text": [["erythema multiforme"]],"start": [["38"]],"entity_id": [["T2"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19949685_4","context": "We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["colonic mucosal necrosis"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Kalimate (calcium polystryrene sulfonate)"]],"start": [["16"]],"entity_id": [["T2"]],"Drug": {"text": [["Kalimate"]],"start": [["16"]],"entity_id": [["T3"]]},"Route": {"text": [["following"]],"start": [["32"]],"entity_id": [["T4"]]},"Disorder": {"text": [["a rare case"]],"start": [["0"]],"entity_id": [["T5"]]},"Dosage": {"text": [["Kalimate (calcium polystryrene sulfonate)"]],"start": [["16"]],"entity_id": [["T2"]]},"Duration": {"text": [["following"]],"start": [["32"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following"]],"start": [["32"]],"entity_id": [["T4"]]},"Freq": {"text": [["a rare case"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["Kalimate"]],"start": [["16"]],"entity_id": [["T3"]]},"Trigger": {"text": [["following"]],"start": [["32"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E1"}],"Trigger": {"text": [["following"]],"start": [["32"]],"entity_id": [["T4"]]}},"Subject": {"text": [["a 34-yr-old man"]],"start": [["58"]],"entity_id": [["T6"]],"Age": {"text": [["34-yr-old"]],"start": [["58"]],"entity_id": [["T6"]]},"Gender": {"text": [["man"]],"start": [["62"]],"entity_id": [["T6"]]},"Population": {"text": [["a rare case"]],"start": [["0"]],"entity_id": [["T5"]]},"Race": {"text": [["man"]],"start": [["62"]],"entity_id": [["T6"]]},"Disorder": {"text": [["a rare case"]],"start": [["0"]],"entity_id": [["T5"]]}},"Effect": {"text": [["colonic mucosal necrosis"]],"start": [["36"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["rare case"]],"start": [["0"]],"entity_id": [["T5"]],"value": "low"}}]}
{"id": "18379937_1","context": "Bilateral anterior uveitis associated with clomiphene citrate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Bilateral anterior uveitis"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["clomiphene citrate"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["clomiphene citrate"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["Bilateral anterior uveitis"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "8461228_1","context": "A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["intravenous adenosine"]],"start": [["26"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravenous adenosine"]],"start": [["26"]],"entity_id": [["T1"]],"Drug": {"text": [["adenosine"]],"start": [["26"]],"entity_id": [["T2"]]},"Disorder": {"text": [["atrial flutter"]],"start": [["11"]],"entity_id": [["T3"]]},"Trigger": {"text": [["acceleration of the heart rate to a potentially dangerous arrhythmia"]],"start": [["65"]],"entity_id": [["T4"]]},"Freq": {"text": [["followed by"]],"start": [["40"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["followed by"]],"start": [["40"]],"entity_id": [["T5"]]},"Dosage": {"text": [["intravenous"]],"start": [["26"]],"entity_id": [["T1"]]},"Route": {"text": [["intravenous"]],"start": [["26"]],"entity_id": [["T1"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["A 12 year old patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["12"]],"start": [["4"]],"entity_id": [["A1"]]},"Gender": {"text": [["patient"]],"start": [["18"]],"entity_id": [["T0"]]},"Disorder": {"text": [["atrial flutter"]],"start": [["11"]],"entity_id": [["T3"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["potentially dangerous"]],"start": [["71"]],"entity_id": [["S1"]],"value": "high"},"Effect": null}]}
{"id": "17873198_3","context": "Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["erlotinib pulmonary toxicity"]],"start": [["87"]],"entity_id": [["T3"]]},"Treatment": {"text": [["erlotinib"]],"start": [["65"]],"entity_id": [["T2"]],"Drug": {"text": [["erlotinib"]],"start": [["65"]],"entity_id": [["T2"]]},"Disorder": {"text": [["pulmonary toxicity"]],"start": [["87"]],"entity_id": [["T3"]]},"Trigger": {"text": [["those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis"]],"start": [["22"]],"entity_id": [["T1"]]},"Route": {"text": [["oral"]],"start": [["55"]],"entity_id": [["T4"]]},"Freq": {"text": [["once daily"]],"start": [["58"]],"entity_id": [["T5"]]},"Dosage": {"text": [["150 mg"]],"start": [["47"]],"entity_id": [["T6"]]},"Duration": {"text": [["until disease progression"]],"start": [["61"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["following administration"]],"start": [["64"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["gefitinib"]],"start": [["10"]],"entity_id": [["T9"]]},"Trigger": {"text": [["reports in patients receiving gefitinib"]],"start": [["0"]],"entity_id": [["T10"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["those"]],"start": [["22"]],"entity_id": [["T1"]],"Population": {"text": [["those"]],"start": [["22"]],"entity_id": [["T1"]]},"Disorder": {"text": [["pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis"]],"start": [["22"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["erlotinib pulmonary toxicity"]],"start": [["87"]],"entity_id": [["T3"]]}}]}
{"id": "11144696_4","context": "Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["trimipramine"]],"start": [["11"]],"entity_id": [["T1"]]},"Dosage": {"text": [["100 mg/d"]],"start": [["41"]],"entity_id": [["T2"]]},"start": [["23"]],"entity_id": [["T3"]],"Disorder": {"text": [["seizures"]],"start": [["81"]],"entity_id": [["T4"]]},"Trigger": {"text": [["increase"]],"start": [["14"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["eleven days after"]],"start": [["0"]],"entity_id": [["T6"]]},"Freq": null,"Route": null,"Duration": null,"Combination": null,"text": [["increase of the trimipramine dosage"]]},"Subject": {"text": [["she"]],"start": [["66"]],"entity_id": [["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["seizures suggesting a secondary generalized grand-mal episode"]],"start": [["81"]],"entity_id": [["T8"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "19707032_3","context": "To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute retinal ischemic change", "stroke"]],"start": [["41","75"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["intravitreal injection of bevacizumab"]],"start": [["95","125"]],"entity_id": [["T3"]],"Route": {"text": [["intravitreal injection"]],"start": [["95","107"]],"entity_id": [["T4"]]},"Drug": {"text": [["bevacizumab"]],"start": [["114","125"]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["diabetic rubeosis"]],"start": [["14","29"]],"entity_id": [["T0"]]},"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [["a patient"]],"start": [["4","8"]],"entity_id": [["T6"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["diabetic rubeosis"]],"start": [["14","29"]],"entity_id": [["T0"]]}},"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "11174414_1","context": "Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Stevens-Johnson syndrome"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["the antiretroviral drug nevirapine"]],"start": [[ "42" ]] ,"entity_id": [ ["T2"] ],"Drug": {"text": [["nevirapine"]],"start": [[ "56" ]] ,"entity_id": [ ["T3"] ]} ,"Combination": null ,"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Disorder": null ,"Trigger": null },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null,"Subject": null }] }
{"id": "9476721_2", "context": "From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute generalized dystonia with brainstem and thalamic lesions"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["an initial d-penicillamine therapy"]], "start": [["102"]], "entity_id": [], "Drug": {"text": [["d-penicillamine"]], "start": [["102"]], "entity_id": []},"Disorder": {"text": [["WD"]], "start": [["43"]], "entity_id": []},"Duration": {"text": [["initial"]], "start": [["102"]], "entity_id": []},"Time_elapsed": {"text": [["after"]], "start": [["90"]], "entity_id": []},"Route": {"text": [["therapy"]], "start": [["102"]], "entity_id": []},"Freq": {"text": [["an"]], "start": [["102"]], "entity_id": []},"Combination": [{"Drug": {"text": [["d-penicillamine"]], "start": [["102"]], "entity_id": []},"Trigger": {"text": [["therapy"]], "start": [["102"]], "entity_id": []},"event_id": "C1","event_type": "Treatment"} ],"Trigger": {"text": [["acute generalized dystonia with brainstem and thalamic lesions"]], "start": [["0"]], "entity_id": []},"Dosage": {"text": [["initial"]], "start": [["102"]], "entity_id": []}},"Effect": {"text": [["occur"]], "start": [["76"]], "entity_id": []},"Subject": {"text": [["WD patients"]], "start": [["56"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [["WD patients"]], "start": [["56"]], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["WD"]], "start": [["43"]], "entity_id": []}},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [["acute generalized dystonia with brainstem and thalamic lesions"]], "start": [["0"]], "entity_id": [],"value": "High"}}] }
{"id": "21728158_4","context": "Drug resistant tuberculosis requires more complex and longer treatment with alternative substances","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment's start index"]],"entity_id": [["T1"]] ,"Drug": {"text": [["alternative substances"]],"start": [["alternative substances' start index"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["Drug resistant tuberculosis"]],"start": [["Drug resistant tuberculosis' start index"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment' start index"]],"entity_id": [["T1"]]} ,"Route": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment' start index"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment' start index"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment' start index"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["complex and longer treatment"]],"start": [["complex and longer treatment' start index"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["alternative substances"]],"start": [[""],["alternative substances' start index"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["alternative substances"]],"start": [[""],["alternative substances' start index"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Trigger": {"text": [["Drug resistant tuberculosis"]],"start": [["Drug resistant tuberculosis' start index"]],"entity_id": [["T5"]]}} ,"Subject": {"text": [["Drug resistant tuberculosis"]],"start": [["Drug resistant tuberculosis' start index"]],"entity_id": [["T3"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": {"text": [["Drug resistant tuberculosis"]],"start": [["Drug resistant tuberculosis' start index"]],"entity_id": [["T5"]]}}]}
{"id": "7668127_1", "context": "Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Intracranial haemorrhage"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["56"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["meningioma"]],"start": [["21"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["aspirin prophylaxis"]],"start": [["64"]],"entity_id": [["T4"]],"Drug": {"text": [["aspirin"]],"start": [["64"]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["prophylaxis"]],"start": [["76"]],"entity_id": [["T6"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["Intracranial haemorrhage"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["Intracranial haemorrhage"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "High"}}]}
{"id": "10395123_3","context": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fixed drug eruption"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["omeprazole treatment"]],"start": [["60"]],"entity_id": [["T2"]],"Drug": {"text": [["omeprazole"]],"start": [["60"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["occurred during"]],"start": [["37"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["fixed drug eruption"]],"start": [["17"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["occurred"]],"start": [["17"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["occurred"]],"start": [["17"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["occurred"]],"start": [["17"]],"entity_id": [["T4"]]} ,"Route": {"text": [["occurred during"]],"start": [["37"]],"entity_id": [["T4"]]},"Combination": null ,"Trigger": null },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "9042097_1", "context": "Delayed hypersensitivity to flurbiprofen", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["hypersensitivity"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["flurbiprofen"]], "start": [["52"]], "entity_id": [], "Drug": {"text": [["flurbiprofen"]], "start": [["52"]], "entity_id": []},"Disorder": {"text": [["hypersensitivity"]], "start": [["18"]], "entity_id": []},"Time_elapsed": {"text": [["Delayed"]], "start": [["0"]], "entity_id": []},"Route":{"text":[["to"]],"start":[["36"]],"entity_id":[]},"Dosage":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Duration":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Freq":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Combination":null,"Trigger":null},"Effect":{"text":[["hypersensitivity"]],"start":[["18"]],"entity_id":[]},"Negated":{"text":[["N/A"]],"start":[["0"]],"entity_id":[],"value":false},"Speculated":{"text":[["N/A"]],"start":[["0"]],"entity_id":[],"value":false},"Severity":{"text":[["N/A"]],"start":[["0"]],"entity_id":[],"value":"Not Specified"},"Subject":{"text":[["N/A"]],"start":[["0"]],"entity_id":[],"Age":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Gender":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Population":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Race":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]},"Disorder":{"text":[["N/A"]],"start":[["0"]],"entity_id":[]}}}]}
{"id": "10981493_3", "context": "Propafenone-induced ataxia: report of three cases", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Propafenone-induced ataxia"]], "start": [[ "entity_id"]], "entity_id": [["T1"]]}, "Subject": {"text": [["three cases"]], "start": [[ "entity_id"]], "entity_id": [["T2"]] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Treatment": { "text": [["Propafenone"]], "start": [[ ], ["T3"]], "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Disorder": {"text": [["ataxia"]], "start": [[ ], ["T4"]], "entity_id": [["T5"]] }, "Time_elapsed": null, "Trigger": null , "entity_id": [["T6"]] , "Drug": {"text": [["Propafenone"]], "start": [[ ], ["T3"]], "entity_id": [["T7"]] }, "Combination": null }, "Negated": null, "Speculated": null, "Severity": null , "Effect": null }]}
{"id": "11225565_6","context": "Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Delavirdine"]],"start": [[ ]],"entity_id": []},"text": [["strong inhibitors of CYP3A"]],"start": [[]],"entity_id": [],"Trigger": {"text": [["these drugs"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [["initial cotreatment"]],"start": [[]],"entity_id": []},"Freq": {"text": [["cotreatment"]],"start": [[]],"entity_id": []},"Route": {"text": [["with"]],"start": [[]],"entity_id": []},"Combination": [{"Drug": {"text": [["efavirenz"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["these drugs"]],"start": [[]],"entity_id": []},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Disorder": {"text": [["substrates of CYP3A"]],"start": [[]],"entity_id": []},"Dosage": {"text": [["strong inhibitors"]],"start": [[]],"entity_id": []},"Duration": {"text": [["cotreatment"]],"start": [[]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["clinical hazards"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["consistent"]],"start": [[]],"entity_id": []}}]}
{"id": "10688731_2", "context": "This is the first report of UFT-induced scleroderma-like reaction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["UFT-induced scleroderma-like reaction"]], "start": [["36"]], "entity_id": []}, "Treatment": {"text": [["UFT"]], "start": [["11"]], "entity_id": [], "Drug": {"text": [["UFT"]], "start": [["11"]], "entity_id": []} ,"Disorder": {"text": [["scleroderma-like reaction"]], "start": [["36"]], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["UFT-induced"]], "start": [["11"]], "entity_id": []}},"Effect": {"text": [["UFT-induced scleroderma-like reaction"]], "start": [["36"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "12923827_1", "context": "Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["fluvoxamine treatment"]], "start": [[], []], "entity_id": []}, "Treatment": {"text": [["fluvoxamine"]], "start": [[], []], "entity_id": [],"Drug": {"text": [["fluvoxamine"]], "start": [[], []], "entity_id": []},"Disorder": {"text": [["Schneiderian first-rank symptoms"]], "start": [[], []], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": [] ,"Trigger":{"text":[[]], "start":[[],[]], "entity_id":[]}},"Effect":{"text":[["Schneiderian first-rank symptoms"]], "start":[[],[]], "entity_id":[]},"Negated":{"value":false,"text":[[]], "start":[[],[]], "entity_id":[]}, "Speculated":{"value":false,"text":[[]], "start":[[],[]], "entity_id":[]}, "Severity":{"value":"low","text":[[]], "start":[[],[]], "entity_id":[]},"Subject":{"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["Schneiderian first-rank symptoms"]], "start":[[],[]], "entity_id":[]},"text":[["patient"]], "start":[[],[]], "entity_id":[]}}]}
{"id": "1849334_1", "context": "Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["seven cases"]], "start": [["report of seven cases"]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["Muzolimine"]], "start": [[ "Muzolimine-induced" ]], "entity_id": [],"Drug": {"text": [["Muzolimine"]], "start": [[ "Muzolimine-induced" ]], "entity_id": []},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["neuromyeloencephalopathy"]], "start": [[ "neuromyeloencephalopathy" ]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [[ "severe" ]], "entity_id": [],"value":"severe"},"Trigger": null}]}
{"id": "15494638_16","context": "We conclude peripheral neuropathy with 5-FU is rare","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["peripheral neuropathy"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["5-FU"]],"start": [["32"]],"entity_id": [["T2"]],"Drug": {"text": [["5-FU"]],"start": [["32"]],"entity_id": [["T2"]]},"Disorder": {"text": [["peripheral neuropathy"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["rare"]],"start": [["40"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger" : {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "7962394_2","context": "Additionally, danazol produces hepatocellular damage in approximately 10% of women","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hepatocellular damage"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["danazol"]],"start": [["10"]],"entity_id": [["T2"]],"Drug": {"text": [["danazol"]],"start": [["10"]],"entity_id": [["T2"]]},"Freq": {"text": [["approximately 10%"]],"start": [["31"]],"entity_id": [["T3"]]},"Disorder": {"text": [["women"]],"start": [["52"]],"entity_id": [["T4"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Route": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Time_elapsed": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Trigger": {"text": [["danazol"]],"start": [["10"]],"entity_id": [["T2"]]},"Combination": null},"Effect": {"text": [["hepatocellular damage"]],"start": [["21"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "17188061_1","context": "We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["typical symptoms"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["patients with severe AMD"]],"start": [["32"]],"entity_id": [["T2"]],"Disorder": {"text": [["severe AMD"]],"start": [["32"]],"entity_id": [["T2"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["Charles-Bonnet syndrome (CBS)"]],"start": [["11"]],"entity_id": [["T3"]]},"Treatment": {"text": [["intravitreal Avastin-injections"]],"start": [["62"]],"entity_id": [["T4"]],"Drug": {"text": [["Avastin"]],"start": [["62"]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["intravitreal Avastin-injections"]],"start": [["62"]],"entity_id": [["T4"]]},"Trigger": null,"Combination": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11033734_3","context": "Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Proconvulsive tendency"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["imipenem/cilastatin"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["imipenem"]],"start": [[ "42" ]],"entity_id": [ ["T3"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["side effects"]],"start": [[ "66" ]],"entity_id": [ ["T4"] ]}},"Effect": {"text": [["Proconvulsive tendency"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "9013348_1","context": "A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["prednisone"]],"start": [[ "7" ]],"entity_id": [ ]},"Disorder": {"text": [["Crohn's disease"]],"start": [[ "23" ]],"entity_id": [ ]},"entity_id": [ ],"start": [[ "7" ]],"text": [["prednisone", "and mesalamine (5-ASA)"]],"Dosage": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["treated"]],"start": [[ "37" ]],"entity_id": [ ]},"Route": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Combination": null},"Effect": {"text": [["worsening respiratory distress and fever"]],"start": [[ "77" ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A 49-year-old man"]],"start": [[ "0" ]],"entity_id": [ ],"Age": {"text": [["49"]],"start": [[ "2" ]],"entity_id": [ ]},"Gender": {"text": [["man"]],"start": [[ "22" ]],"entity_id": [ ]},"Disorder": {"text": [["Crohn's disease"]],"start": [[ "23" ]],"entity_id": [ ]},"Population": null,"Race": null},"Trigger": null}]}
{"id": "18721173_3", "context": "This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["significant type of morbidity"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["gabapentin"]],"start": [["88"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["gabapentin"]],"start": [["88"]],"entity_id": [ ["T2"] ]},"Duration": {"text": [["continued use"]],"start": [["64"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["acute renal failure"]],"start": [["124"]],"entity_id": [["T4"] ]} ,"Time_elapsed": {"text": [["continued use"]],"start": [["64"]],"entity_id": [ ["T3"] ]} ,"Route": {"text": [["use"]],"start": [["88"]],"entity_id": [ ["T2"] ]} ,"Dosage": {"text": [["continued use"]],"start": [["64"]],"entity_id": [ ["T3"] ]} ,"Freq": {"text": [["continued use"]],"start": [["64"]],"entity_id": [ ["T3"] ]} ,"Combination": null ,"Trigger": {"text": [["gabapentin"]],"start": [["88"]],"entity_id": [ ["T2"] ]} },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["acute renal failure"]],"start": [["124"]],"entity_id": [ ["T4"] ]} },"Effect": {"text": [["significant type of morbidity"]],"start": [["0"]],"entity_id": [ ["T1"] ]} , "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "17473493_1", "context": "Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["raloxifene-associated aggravation"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["Selective estrogen receptor modulator raloxifene"]], "start": [["0"]], "entity_id": [],"Drug": {"text": [["raloxifene"]], "start": [["50"]], "entity_id": []},"Disorder": {"text": [["nonalcoholic steatohepatitis"]], "start": [["71"]], "entity_id": []},"Route": {"text": [["Selective estrogen receptor modulator"]], "start": [["0"]], "entity_id": []},"Time_elapsed": {"text": [["-associated"]], "start": [["32"]], "entity_id": []},"Duration": {"text": [["-associated"]], "start": [["32"]], "entity_id": []},"Freq": {"text": [["-associated"]], "start": [["32"]], "entity_id": []},"Combination": [{"Drug": {"text": [["raloxifene"]], "start": [["50"]], "entity_id": []},"Trigger": {"text": [["-associated"]], "start": [["32"]], "entity_id": []},"event_id": "C1","event_type": "null"} ],"Dosage": {"text": [["-associated"]], "start": [["32"]], "entity_id": []},"Trigger": {"text": [["-associated"]], "start": [["32"]], "entity_id": []}}, "Effect": {"text": [["aggravation"]], "start": [["32"]], "entity_id": []},"Negated": {"text": [["null"]], "start": [["null"]], "entity_id": [],"value": false},"Speculated": {"text": [["null"]], "start": [["null"]], "entity_id": [],"value": false},"Severity": {"text": [["null"]], "start": [["null"]], "entity_id": [],"value": "null" },"Subject":{"text": [["Selective estrogen receptor modulator raloxifene"]], "start": [["0"]], "entity_id": [],"Age":{"text": [["null"]], "start": [["null"]], "entity_id": []},"Gender":{"text": [["null"]], "start": [["null"]], "entity_id": []},"Population":{"text": [["null"]], "start": [["null"]], "entity_id": []},"Race":{"text": [["null"]], "start": [["null"]], "entity_id": []},"Disorder":{"text": [["nonalcoholic steatohepatitis"]], "start": [["71"]], "entity_id": []}} } ]}
{"id": "15162903_4","context": "The day after methotrexate administration, the patient complained of severe back pain and urinary retention","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["methotrexate administration"]],"start": [["The day after", "methotrexate administration" ] ] ,"entity_id": []},"Treatment": {"text": [["methotrexate administration"]],"start": [[ "The day after" ]],"entity_id": [],"Drug": {"text": [["methotrexate"]],"start": [[ "The day after" ]],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["the patient"]],"start": [[ "the patient" ]],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["severe back pain"]],"start": [[ "severe back pain" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [[ "severe" ]],"entity_id": [],"value": "high"}},{"event_id": "E2","event_type": "Adverse_event","Trigger": {"text": [["urinary retention"]],"start": [[ "urinary retention" ]],"entity_id": []},"Treatment": null,"Effect": {"text": [["urinary retention"]],"start": [[ "urinary retention" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patient"]],"start": [[ "the patient" ]],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null}}]}
{"id": "58443_1","context": "In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["secondary changes"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["irradiation", "Bleomycin treatment"]],"start": [["53","66"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["Bleomycin"]],"start": [["66"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["damaged"]],"start": [["16"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["47"]],"entity_id": [["T6"]]} ,"Route": {"text": [["treatment"]],"start": [["66"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["irradiation"]],"start": [["53"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["Bleomycin"]],"start": [["66"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment"]],"start": [["66"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Freq": {"text": [["following"]],"start": [["47"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["secondary changes"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["irradiation"]],"start": [["53"]],"entity_id": [["T2"]]} },"Subject": {"text": [["aortic wall"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [["this case"]],"start": [["23"]],"entity_id": [["T7"]]},"Disorder": {"text": [["damaged"]],"start": [["16"]],"entity_id": [["T5"]]},"Gender": {"text": [["this case"]],"start": [["23"]],"entity_id": [["T7"]]},"Population": {"text": [["this case"]],"start": [["23"]],"entity_id": [["T7"]]},"Race": {"text": [["this case"]],"start": [["23"]],"entity_id": [["T7"]]}} ,"Negated": null,"Speculated": null,"Severity": {"text": [["damaged"]],"start": [["16"]],"entity_id": [["T5"]] ,"value": "High"} ,"Effect": {"text": [["damaged"]],"start": [["16"]],"entity_id": [["T5"]] }} ]}
{"id": "426502_2", "context": "Inappropriate antidiuretic hormone following adenine arabinoside administration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Inappropriate antidiuretic hormone"]], "start": [[ "0" ]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["adenine arabinoside"]], "start": [[ "46" ]], "entity_id": [ ["T2"]] , "Drug": {"text": [["adenine arabinoside"]], "start": [[ "46" ]], "entity_id": [ ["T2"]]} , "Disorder": {"text": [["Inappropriate antidiuretic hormone"]], "start": [[ "0" ]], "entity_id": [ ["T1"]]} , "Time_elapsed": {"text": [["following"]], "start": [[ "39" ]], "entity_id": [ ["T3"]]} , "Trigger": {"text": [["adenine arabinoside administration"]], "start": [[ "40" ]], "entity_id": [ ["T4"]]} , "Route": {"text": [["administration"]], "start": [[ "60" ]], "entity_id": [ ["T5"]]} , "Freq": {"text": [], "start": [], "entity_id": []} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Combination": null }, "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": null }]}
{"id": "6484655_2", "context": "Ampicillin-associated seizures", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ampicillin-associated seizures"]], "start": [[ "Start"]],"entity_id":[["T1"]]}, "Treatment":{"text":[["Ampicillin"]], "start": [[ "Start"]], "entity_id":[["T2"]],"Drug":{"text":[["Ampicillin"]], "start": [[ "Start"]], "entity_id":[["T3"]] } ,"Disorder":{"text":[["seizures"]], "start": [[ "Start"]], "entity_id":[["T4"]]} , "Freq":{"text":[["associated"]], "start": [[ "Start"]], "entity_id":[["T5"]]} ,"Combination":[{"Drug":{"text":[["Ampicillin"]], "start": [[ "Start"]], "entity_id":[["T6"]]},"Trigger":{"text":[["seizures"]], "start": [[ "Start"]], "entity_id":[["T7"]]}, "event_id":"C1", "event_type":"Adverse_event"} ] ,"Time_elapsed":{"text":[["-elapsed"]], "start": [[ "Start"]], "entity_id":[["T8"]]} ,"Dosage":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T9"]]} ,"Duration":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T10"]]} ,"Route":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T11"]]} ,"Trigger":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T12"]]} }, "Negated":{"value":false,"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T13"]]} ,"Speculated":{"value":false,"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T14"]]} ,"Severity":{"value":"-","text":[["-"]], "start": [[ "Start"]], "entity_id":[["T15"]]} ,"Subject":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T16"]], "Age":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T17"]]},"Gender":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T18"]]},"Population":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T19"]]},"Race":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T20"]]},"Disorder":{"text":[["-"]], "start": [[ "Start"]], "entity_id":[["T21"]]}} ,"Effect":{"text":[["seizures"]], "start": [[ "Start"]], "entity_id":[["T22"]]} }]}
{"id": "6692713_4","context": "We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fibrosing alveolitis"]],"start": [[ "3" ]] ,"entity_id": [ ["T1"] ] },"Treatment": { "text": [["amiodarone"]], "start": [["35"]], "entity_id": [ ["T2"] ], "Drug": { "text": [["amiodarone"]], "start": [["35"]], "entity_id": [ ["T3"] ]} ,"Time_elapsed": { "text": [["diagnosed by lung biopsy"]], "start": [["15"]], "entity_id": [ ]} ,"Trigger": { "text": [["which responded to corticosteroid therapy"]], "start": [["43"]], "entity_id": [ ]} ,"Disorder": { "text": [["fibrosing alveolitis"]], "start": [["3"]], "entity_id": [ ["T1"] ]} ,"Freq": { "text": [["responded"]], "start": [["43"]], "entity_id": [ ]} ,"Route": { "text": [["therapy"]], "start": [["48"]], "entity_id": [ ]} ,"Duration": { "text": [["responded"]], "start": [["43"]], "entity_id": [ ]} ,"Dosage": { "text": [["diagnosed by lung biopsy"]], "start": [["15"]], "entity_id": [ ]} ,"Combination": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "7752014_1", "context": "Furosemide-associated fever", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Furosemide-associated fever"]], "start": [[ "]], " ,"entity_id" ]],"entity_id" : [["T1"]]},"Treatment" : {"text" : [["Furosemide"]], "start" : [[ ]],"entity_id" : [["T2"]] , "Drug" : {"text" : [["Furosemide"]], "start" : [[ ]],"entity_id" : [["T2"]]} ,"Time_elapsed" : {"text" : [["associated"]], "start" : [[ ]],"entity_id" : [["T3"]]} ,"Disorder" : {"text" : [["fever"]], "start" : [[ ]],"entity_id" : [["T4"]]} ,"Dosage" : {"text" : [[]], "start" : [[ ]], "entity_id" : [[]]} ,"Duration" : {"text" : [[]], "start" : [[ ]], "entity_id" : [[]]} ,"Route" : {"text" : [[]], "start" : [[ ]], "entity_id" : [[]]} ,"Freq" : {"text" : [[]], "start" : [[ ]], "entity_id" : [[]]} ,"Combination" : null ,"Trigger" : null } ,"Negated" : null ,"Speculated" : null ,"Severity" : null ,"Subject" : null ,"Effect" : null }]}
{"id": "18810448_2","context": "Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thymic enlargement"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["a patient with juvenile idiopathic arthritis"]],"start": [[ "22" ]],"entity_id": [ ["T2"] ],"Disorder": { "text": [["juvenile idiopathic arthritis"]], "start": [[ "22" ]], "entity_id": [ ["T2.1"] ]} ,"Age": null, "Gender": null, "Population": null, "Race": null},"Treatment": {"text": [["etanercept therapy"]],"start": [[ "63" ]],"entity_id": [ ["T3"] ], "Drug": { "text": [["etanercept"]], "start": [[ "63" ]], "entity_id": [ ["T3.1"] ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": null, "Freq": null, "Combination": null ,"Trigger": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "24846936_1", "context": "Fatal methylene blue associated serotonin toxicity", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Negated": null, "Speculated": null, "Severity": {"value": "high", "text": [["high"]], "start": [["18"]], "entity_id": []}, "Subject": null, "Treatment": null, "Effect": {"text": [["Fatal methylene blue associated serotonin toxicity"]], "start": [[""], ["0"]], "entity_id": []}, "Trigger": {"text": [["Fatal", "methylene blue associated serotonin toxicity"]], "start": [[""], ["0"]], "entity_id": []}}]}
{"id": "18665833_3","context": "We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["recurrent (stuttering) priapism"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["32"]],"entity_id": [["T2"]],"Disorder": {"text": [["protein C deficiency"]],"start": [["43"]],"entity_id": [["T3"]]},"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}},"Treatment": {"text": [["Warfarin therapy"]],"start": [["79"]],"entity_id": [["T4"]],"Drug": {"text": [["Warfarin"]],"start": [["79"]],"entity_id": [["T5"]]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"Combination": null,"Disorder": {"text": [["protein C deficiency"]],"start": [["43"]],"entity_id": [["T3"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value":"rare"}}]}
{"id": "16641839_1","context": "Angioedema and maculopapular eruptions associated with carbamazepine administration","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["carbamazepine administration"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["associated with"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["carbamazepine"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"}] ,"Freq": {"text": [["associated with"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["carbamazepine"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Duration": {"text": [["carbamazepine administration"]],"start": [[ ]],"entity_id": [["T2"]]} ,"Route": {"text": [["carbamazepine administration"]],"start": [[ ]],"entity_id": [["T2"]]} }, "Effect": {"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} ,"text": [["Angioedema"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""}}]}
{"id": "9195619_2","context": "Mental nerve neuropathy as a result of hepatitis B vaccination","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Mental nerve neuropathy"]],"start": [[ ], ["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"]]},"Treatment": {"text": [["hepatitis B vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T2"]],"Drug": {"text": [["hepatitis B vaccine"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Mental nerve neuropathy"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"]]} ,"Route": {"text": [["vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"],["T2"],["T3"]]} ,"Freq": {"text": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"],["T2"],["T3"]]} ,"Duration": {"text": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"],["T2"],["T3"]]} ,"Dosage": {"text": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"],["T2"],["T3"]]} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["Mental nerve neuropathy"]],"start": [["Mental nerve neuropathy as a result of hepatitis B vaccination"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "12860350_2","context": "We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["tamoxifen"]],"start": [["while having tamoxifen due to a diagnosis of in situ ductal carcinoma,"],[","]],"entity_id": []},"Subject": {"text": [["a premenopausal woman"]],"start": [[ "We describe a"]],"entity_id": [],"Age":{"text":[["premenopausal"]], "start":[[ "premenopausal"]], "entity_id":[]},"Gender":{"text":[["woman"]], "start":[[ "woman"]], "entity_id":[]},"Disorder": {"text": [["in situ ductal carcinoma"]],"start": [[", due to a diagnosis of in situ ductal carcinoma,"]],"entity_id": []},"Population":{"text":[["1"]], "start":[[ "We describe a"]], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]}},"Treatment": {"text": [["tamoxifen"]],"start": [[ "while having tamoxifen due to a diagnosis of in situ ductal carcinoma,"]],"entity_id": [],"Drug":{"text":[["tamoxifen"]], "start":[[ "tamoxifen"]], "entity_id":[]},"Dosage":{"text":[], "start":[], "entity_id":[]},"Duration":{"text":[], "start":[], "entity_id":[]},"Trigger":{"text":[["tamoxifen"]], "start":[[ "while having tamoxifen due to a diagnosis of in situ ductal carcinoma,"]], "entity_id":[]},"Route":{"text":[], "start":[], "entity_id":[]},"Time_elapsed":{"text":[], "start":[], "entity_id":[]},"Freq":{"text":[], "start":[], "entity_id":[]},"Disorder":{"text":[["in situ ductal carcinoma"]], "start":[[", due to a diagnosis of in situ ductal carcinoma,"]], "entity_id":[]},"Combination":[{"Drug":{"text":[["tamoxifen"]], "start":[[ "tamoxifen"]], "entity_id":[]},"Trigger":{"text":[["tamoxifen"]], "start":[[ "while having tamoxifen due to a diagnosis of in situ ductal carcinoma,"]], "entity_id":[]},"event_id":"E1-1","event_type":"Treatment"}]},"Effect": {"text": [["endometriosis"]],"start": [[ "developed endometriosis requiring surgery"]],"entity_id": []},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[], "start":[], "entity_id":[],"value":false},"Severity":{"text":[], "start":[], "entity_id":[],"value":"low"}}]}
{"id": "12773807_1", "context": "Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["disseminated cellulitic cryptococcosis"]], "start": [[ ]], "entity_id": [ ["T1" ]]}, "Treatment": { "text": [ ["prednisone monotherapy" ]], "start": [[ ]], "entity_id": [ ["T2" ]], "Drug": { "text": [ ["prednisone" ]], "start": [[ ]], "entity_id": [ ["T3" ]] } , "Disorder": { "text": [ ["pemphigus vulgaris" ]], "start": [[ ]], "entity_id": [ ["T4" ]] } , "Time_elapsed": { "text": [ ["in the setting of" ]], "start": [[ ]], "entity_id": [ ["T5" ]] } ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Combination": null, "Trigger": null } , "Effect": null, "Negated": null, "Speculated": null, "Severity": null , "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } }]}
{"id": "3417739_2","context": "We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous PI irrigation who developed an acute oliguric renal failure","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["PI"]],"start": [["65"]],"entity_id": [["T1"]]},"text": [["continuous PI irrigation"]],"start": [["52"]],"entity_id": [["T2"]],"Disorder": {"text": [["suppurative mediastinitis"]],"start": [["15"]],"entity_id": [["T3"]]},"Duration": {"text": [["continuous"]],"start": [["52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treated"]],"start": [["48"]],"entity_id": [["T5"]]},"Route": {"text": [["irrigation"]],"start": [["59"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"Age": {"text": [["63"]],"start": [["10"]],"entity_id": [["T7"]]},"Gender": {"text": [["woman"]],"start": [["17"]],"entity_id": [["T8"]]},"Population": null,"Race": null,"Disorder": {"text": [["a suppurative mediastinitis"]],"start": [["15"]],"entity_id": [["T9"]]},"text": [["a 63 year old woman"]],"start": [["0"]],"entity_id": [["T10"]]},"Effect": {"text": [["acute oliguric renal failure"]],"start": [["86"]],"entity_id": [["T11"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["developed"]],"start": [["82"]],"entity_id": [["T12"]]}}]}
{"id": "3128415_1","context": "A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tonic-clonic seizures"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["young woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["young"]],"start": [["0"]],"entity_id": [["A0"]]},"Disorder": {"text": [["epilepsy"]],"start": [["5"]],"entity_id": [["T2"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["P0"]]},"Race": {"text": [["woman"]],"start": [["5"]],"entity_id": [["R0"]]},"Gender": {"text": [["woman"]],"start": [["5"]],"entity_id": [["G0"]]}},"Treatment": {"text": [["antineoplastic therapy"]],"start": [["44"]],"entity_id": [["T3"]],"Drug": {"text": [["adriamycin"]],"start": [["44"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Trigger": {"text": [["antineoplastic therapy"]],"start": [["44"]],"entity_id": [["T3"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["antineoplastic therapy"]],"start": [["44"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["adriamycin"]],"start": [["44"]],"entity_id": [["T4"]]},"Trigger": {"text": [["antineoplastic therapy"]],"start": [["44"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "null"},{"Drug": {"text": [["cisplatin"]],"start": [["52"]],"entity_id": [["T5"]]},"Trigger": {"text": [["antineoplastic therapy"]],"start": [["44"]],"entity_id": [["T3"]]},"event_id": "C2","event_type": "null"}]},"Effect": {"text": [["tonic-clonic seizures"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19567656_1","context": "This patient's rhabdomyolysis was probably induced by sertraline therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rhabdomyolysis"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sertraline therapy"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T2"]],"Drug": {"text": [["sertraline"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["rhabdomyolysis"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["probably induced"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["probably induced"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T4"]]} ,"Route": {"text": [["therapy"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["sertraline"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["probably induced"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["sertraline"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["probably induced"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["rhabdomyolysis"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T1"]]}} ,"Effect": {"text": [["rhabdomyolysis"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": {"text": [["probably"]],"start": [["This patient's rhabdomyolysis was probably induced by sertraline therapy"]],"entity_id": [["T4"]] ,"value": true} ,"Severity": null,"Subject": null}]}
{"id": "16225183_1", "context": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Nephrotic syndrome"]],"start": [["0"]] , "entity_id": [ ]},"Subject": {"text": [["a multiple sclerosis patient"]],"start": [["21"]] , "entity_id": [ ], "Disorder": { "text": [["multiple sclerosis"]], "start": [["21"]], "entity_id": [ ]} , "Age": null, "Gender": null, "Population": null, "Race": null },"Treatment": {"text": [["interferon beta 1a"]],"start": [["62"]] , "entity_id": [ ], "Drug": { "text": [["interferon beta 1a"]], "start": [["62"]], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": { "text": [["multiple sclerosis"]], "start": [[ ]], "entity_id": [ ]} , "Combination": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "10772434_1","context": "A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["carboplatin"]],"start": [["51"]],"entity_id": [["T1"]]},"entity_id": [["T1"]],"text": [["hypersensitivity reaction to carboplatin"]],"start": [["36"]] ,"Trigger": {"text": [["developed"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["bilateral optic glioma"]],"start": [["17"]],"entity_id": [["T3"]]},"Dosage": {"text": [["nine courses"]],"start": [["76"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["after nine courses"]],"start": [["76"]],"entity_id": [["T5"]]},"Freq": {"text": [["nine courses"]],"start": [["76"]],"entity_id": [["T5"]]} ,"Route": {"text": [["to carboplatin"]],"start": [["51"]],"entity_id": [["T1"]]} ,"Combination": null ,"Duration": null } ,"Subject": {"text": [["A 10-year-old white girl"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["10-year-old"]],"start": [["0"]],"entity_id": [["T0a"]]},"Gender": {"text": [["girl"]],"start": [["8"]],"entity_id": [["T0b"]]},"Race": {"text": [["white"]],"start": [["12"]],"entity_id": [["T0c"]]},"Population": null,"Disorder": {"text": [["bilateral optic glioma"]],"start": [["17"]],"entity_id": [["T3"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "18453852_16","context": "Liver function should be carefully monitored when rifampicin and lopinavir/ritonavir are combined in patients","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["combined"]],"start": [[ "52" ],["53"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"text": [["rifampicin"], ["lopinavir/ritonavir"]],"start": [["22"],["41"]],"entity_id": [["T3"],["T4"]],"Combination": [{"Drug": {"text": [["rifampicin"]],"start": [["22"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["31"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["lopinavir/ritonavir"]],"start": [["41"]],"entity_id": [["T4"]]},"Trigger": {"text": [["are combined"]],"start": [["50"]],"entity_id": [["T6"]]},"event_id": "C2","event_type": "Combination"}],"Trigger": {"text": [["carefully monitored"]],"start": [["10"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["when"]],"start": [["8"]],"entity_id": [["T8"]]},"Disorder": {"text": [["Liver function"]],"start": [["0"]],"entity_id": [["T9"]]},"Dosage": {"text": [["should be"]],"start": [["7"]],"entity_id": [["T10"]]},"Duration": {"text": [["carefully monitored"]],"start": [["10"]],"entity_id": [["T7"]]},"Route": {"text": [["in patients"]],"start": [["54"]],"entity_id": [["T11"]]},"Freq": {"text": [["carefully monitored"]],"start": [["10"]],"entity_id": [["T7"]]},"Drug": {"text": [["rifampicin"], ["lopinavir/ritonavir"]],"start": [["22"],["41"]],"entity_id": [["T3"],["T4"]]}},"Subject": {"text": [["patients"]],"start": [["54"]],"entity_id": [["T11"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "15504988_2","context": "We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["rosiglitazone therapy"]],"start": [["the initiation of rosiglitazone therapy"]],"entity_id": [],"Drug": {"text": [["rosiglitazone"]],"start": [[ "the initiation of rosiglitazone therapy" ]],"entity_id": []},"Trigger": {"text": [["showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["diabetic dyslipidemia"]],"start": [[ "had preexisting diabetic dyslipidemia"]],"entity_id": []},"Time_elapsed": {"text": [["soon after"]],"start": [[ "soon after"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels"]],"start": [[ "showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels" ]],"entity_id": []},"Subject": {"text": [[ "We report three patients"]],"start": [[ "We report three patients" ]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["diabetic dyslipidemia"]],"start": [[ "had preexisting diabetic dyslipidemia" ]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "12923827_4","context": "This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["fluvoxamine"]],"start": [["0"]],"entity_id": [["T1"]] ,"Drug": {"text": [["fluvoxamine"]],"start": [["0"]],"entity_id": [["T2"]] },"Disorder": {"text": [["Schneiderian first-rank symptoms"]],"start": [["42"]],"entity_id": [["T3"]] },"Trigger": {"text": [["precipitate"]],"start": [["22"]],"entity_id": [["T4"]] },"Time_elapsed": {"text": [["can"]],"start": [["7"]],"entity_id": [["T5"]] },"Freq": {"text": [["can"]],"start": [["7"]],"entity_id": [["T6"]] },"Route": {"text": [["can"]],"start": [["7"]],"entity_id": [["T7"]] },"Duration": {"text": [["can"]],"start": [["7"]],"entity_id": [["T8"]] },"Dosage": {"text": [["can"]],"start": [["7"]],"entity_id": [["T9"]] },"Combination": null },"Subject": {"text": [["some susceptible patients"]],"start": [["60"]],"entity_id": [["T10"]],"Disorder": {"text": [["Schneiderian first-rank symptoms"]],"start": [["42"]],"entity_id": [["T3"]] },"Gender": null,"Race": null,"Age": null,"Population": null },"Severity": null,"Negated": null,"Speculated": null ,"Effect": {"text": [["Schneiderian first-rank symptoms"]],"start": [["42"]],"entity_id": [["T3"]] },"Trigger": {"text": [["can precipitate"]],"start": [["22"]],"entity_id": [["T4"]] }} ]}
{"id": "10774758_2","context": "This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse effect"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["nimesulide"]],"start": [["70"]],"entity_id": [["T2"]]},"Disorder": {"text": [["fetal renal circulation"]],"start": [["33"]],"entity_id": [["T3"]]},"Trigger": {"text": [["maternal ingestion"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T5"]]},"Freq": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T5"]]},"entity_id": [["E1"]] ,"text": [["adverse effect"]],"start": [["17"]],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": [] } ,"Effect": {"text": [["fetal renal circulation"]],"start": [["33"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": null,"Severity": null} ,{"event_id": "","event_type": "","Trigger": null,"Treatment": null,"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": [] } } ]}
{"id": "11111942_1", "context": "Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Diarrhea-associated over-anticoagulation"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["warfarin"]], "start": [[],[]], "entity_id": [] ,"Drug": { "text": [["warfarin"]], "start": [[],[]], "entity_id": [] } ,"Disorder": { "text": [["over-anticoagulation"]], "start": [[],[]], "entity_id": [] } ,"Time_elapsed": { "text": [["Diarrhea-associated"]], "start": [[],[]], "entity_id": [] } ,"Route": { "text": [["taking"]], "start": [[],[]], "entity_id": [] } ,"Combination": [ { "Drug": { "text": [["cholestyramine"]], "start": [[],[]], "entity_id": [] } , "Trigger": { "text": [["therapeutic role"]], "start": [[],[]], "entity_id": [] } , "event_id": "E2" , "event_type": "Potential_therapeutic_effect" } ] ,"Freq": { "text": [["the therapeutic role"]], "start": [[],[]], "entity_id": [] } ,"Trigger": { "text": [["Diarrhea-associated over-anticoagulation"]], "start": [[],[]], "entity_id": [] } ,"Dosage": { "text": [["the therapeutic role"]], "start": [[],[]], "entity_id": [] } ,"Duration": { "text": [["the therapeutic role"]], "start": [[],[]], "entity_id": [] }},"Subject": { "Age": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [["over-anticoagulation"]], "start": [[],[]], "entity_id": [] } ,"text": [["a patient"]], "start": [[],[]], "entity_id": [] } ,"Effect": { "text": [["over-anticoagulation"]], "start": [[],[]], "entity_id": [] } ,"Negated": null, "Speculated": null, "Severity": { "text": [["Diarrhea-associated"]], "start": [[],[]], "entity_id": [] ,"value": "low" } }]}
{"id": "9876809_3", "context": "A 72-year-old white man suddenly developed combative behavior, refused to leave his room, stopped eating, and began falling to the floor 6 weeks after being given ticlopidine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["combative behavior"]], "start": [["7-17"]], "entity_id": [["T1"]]}, "Subject": {"text": [["A 72-year-old white man"]], "start": [["0-9"]], "entity_id": [["T2"]], "Age": {"text": [["72"]], "start": [["0-2"]], "entity_id": [["T3"]]}, "Race": {"text": [["white"]], "start": [["18-21"]], "entity_id": [["T4"]]}, "Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [["man"]], "start": [["22-24"]], "entity_id": [["T5"]]},"Population": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["ticlopidine"]],"start": [["127-133"]],"entity_id": [["T6"]],"Drug": {"text": [["ticlopidine"]], "start": [["127-133"]], "entity_id": [["T7"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [["6 weeks"]], "start": [["105-111"]], "entity_id": [["T8"]]},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Combination": null},"Effect": {"text": [["developed combative behavior", "refused to leave his room", "stopped eating", "began falling to the floor"]],"start": [["7-17","42-55","56-63","70-78"],["42-55"],["64-71"],["88-98"]],"entity_id": [["T1"], [], [], []]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8828999_3", "context": "Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Lithium neurotoxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Effect": { "text": [ [ "considered" ], [ "in" ], [ "Creutzfeldt-Jakob" ], [ "disease" ], [ "differential" ], [ "diagnosis" ] ], "start": [[ "43" ], [ "46" ], [ "49" ], [ "52" ], [ "55" ], [ "58" ] ], "entity_id": [ ["T2"] ] } ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [ [ "Creutzfeldt-Jakob" ], [ "disease" ] ], "start": [[ "49" ], [ "52" ]], "entity_id": [ ["T2-1"] ] } } ,"Treatment": { "text": [], "start": [], "entity_id": [], "Drug": null, "Disorder": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null } ,"Negated": null, "Speculated": null, "Severity": null }] }
{"id": "7647084_1","context": "The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["neuroleptic malignant syndrome"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["amitriptyline", "lithium carbonate"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["amitriptyline"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["neuroleptic malignant syndrome"]],"start": [[ ]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["amitriptyline"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["lithium carbonate"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C2","event_type": "Adverse_event"}],"Trigger": {"text": [["occurred"]],"start": [[ ]],"entity_id": []}},"Subject": {"text": [["patient"]],"start": [[ ]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["neuroleptic malignant syndrome"]],"start": [[ ]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["occurred"]],"start": [[ ]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "15239684_2","context": "The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["soft-tissue injury"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravenous administration of phenytoin"]],"start": [["44"]],"entity_id": [["T2"]],"Drug": {"text": [["phenytoin"]],"start": [["44"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["purple glove syndrome"]],"start": [["91"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["associated with"]],"start": [["54"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["consistent with"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Route": {"text": [["intravenous"]],"start": [["44"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["findings"]],"start": [["5"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["isoniazid"]],"start": [["64"]],"entity_id": [["T6"]]},"Trigger": {"text": [["therapy"]],"start": [["64"]],"entity_id": [["T9"]]} ,"event_id": "C1","event_type": "Therapy"}] ,"Duration": {"text": [["findings"]],"start": [["5"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [["findings"]],"start": [["5"]],"entity_id": [["T8"]]}} ,"Subject": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]],"Population": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Age": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Gender": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Race": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Disorder": {"text": [["The"]],"start": [["0"]],"entity_id": [["T10"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["soft-tissue injury"]],"start": [["13"]],"entity_id": [["T1"]],"value": "medium"} ,"Effect": {"text": [["soft-tissue injury"]],"start": [["13"]],"entity_id": [["T1"]]}} ]}
{"id": "2887555_1","context": "Soon after its introduction in 1952, chlorpromazine was noted to induce symptoms resembling Parkinson's disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["induce"]],"start": [["Soon after its introduction in 1952, chlorpromazine was noted to induce"]],"entity_id": []},"Treatment": {"text": [["chlorpromazine"]],"start": [["chlorpromazine"]],"entity_id": [],"Drug": {"text": [["chlorpromazine"]],"start": [["chlorpromazine"]],"entity_id": []},"Disorder": {"text": [["symptoms resembling Parkinson's disease"]],"start": [["symptoms resembling Parkinson's disease"]],"entity_id": []},"Time_elapsed": {"text": [["Soon after its introduction in 1952"]],"start": [["Soon after its introduction in 1952"]],"entity_id": []},"Freq": {"text": [["noted"]],"start": [["noted"]],"entity_id": []},"Combination": [{"Drug": {"text": [["chlorpromazine"]],"start": [["chlorpromazine"]],"entity_id": []},"Trigger": {"text": [["induce"]],"start": [["Soon after its introduction in 1952, chlorpromazine was noted to induce"]],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["induce"]],"start": [["Soon after its introduction in 1952, chlorpromazine was noted to induce"]],"entity_id": []},"Dosage": {"text": [["noted"]],"start": [["noted"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["symptoms resembling Parkinson's disease"]],"start": [["symptoms resembling Parkinson's disease"]],"entity_id": []}}]}
{"id": "9220046_4","context": "Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Erythromycin"]],"start": [[ ]],"entity_id": [ ] ,"Drug": {"text": [["Erythromycin"]],"start": [[ ]],"entity_id": [ ] } ,"Trigger": {"text": [["may increase the risk"]],"start": [[ ]],"entity_id": [ ] } ,"Disorder": {"text": [["lovastatin-induced rhabdomyolysis"]],"start": [[ ]],"entity_id": [ ] } ,"Freq": {"text": [["may increase"]],"start": [[ ]],"entity_id": [ ] } ,"Dosage": {"text": [["may increase"]],"start": [[ ]],"entity_id": [ ] } ,"Route": {"text": [["antibiotic"]],"start": [[ ]],"entity_id": [ ] } ,"Time_elapsed": {"text": [["may increase"]],"start": [[ ]],"entity_id": [ ] } ,"Duration": {"text": [["may increase"]],"start": [[ ]],"entity_id": [ ] } ,"Combination": null} ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null ,"Trigger": null } ] }
{"id": "2768785_2","context": "We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["leukoencephalopathy"]],"start": [["48"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ara = C", "methotrexate"]],"start": [["83","105"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["ara = C","methotrexate"]],"start": [["83","105"]],"entity_id": [["T4","T5"]]} ,"Combination": [{"Drug": {"text": [["ara = C"]],"start": [[""],["83"]],"entity_id": [["T4"]]},"Trigger": {"text": [["and"]],"start": [[""],["95"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["methotrexate"]],"start": [[""],["105"]],"entity_id": [["T5"]]},"Trigger": {"text": [["and"]],"start": [[""],["95"]],"entity_id": [["T6"]]},"event_id": "C2","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["following administration"]],"start": [[""],["24"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["acute lymphocytic leukemia"]],"start": [[""],["14"]],"entity_id": [["T8"]]} ,"Trigger": {"text": [["developed"]],"start": [[""],["42"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [["a combination"]],"start": [[""],["82"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["during the consolidation phase of chemotherapy"]],"start": [[""],["108"]],"entity_id": [["T10"]]} ,"Route": {"text": [["intravenous"]],"start": [[""],["83"]],"entity_id": [["T11"]]} ,"Freq": {"text": [["two children"]],"start": [[""],["5"]],"entity_id": [["T12"]]}} ,"Subject": {"text": [["two children"]],"start": [[""],["5"]],"entity_id": [["T12"]],"Age": {"text": [[""]],"start": [[""],["5"]],"entity_id": [["T13"]]},"Gender": {"text": [[""]],"start": [[""],["5"]],"entity_id": [["T14"]]},"Population": {"text": [["two children"]],"start": [[""],["5"]],"entity_id": [["T12"]]},"Race": {"text": [[""]],"start": [[""],["5"]],"entity_id": [["T15"]]},"Disorder": {"text": [["acute lymphocytic leukemia"]],"start": [[""],["14"]],"entity_id": [["T8"]]}} ,"Negated": {"text": [["not"]],"start": [[""],[""]],"entity_id": [["T16"]],"value": false},"Speculated": {"text": [["present","developed"]],"start": [[""],["2","42"]],"entity_id": [["T17","T9"]],"value": false},"Severity": {"text": [["leukoencephalopathy"]],"start": [[""],["48"]],"entity_id": [["T1"]],"value": "high"} ,"Effect": {"text": [["leukoencephalopathy"]],"start": [[""],["48"]],"entity_id": [["T1"]]}}]}
{"id": "2320800_1","context": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lethal anuria"]],"start": [[ "0" ]] ,"entity_id": [ ]},"Treatment": {"text": [["high dose ifosfamide chemotherapy"]],"start": [[ "26" ]],"entity_id": [],"Drug": {"text": [["ifosfamide"]],"start": [[ "33" ]],"entity_id": []} ,"Disorder": {"text": [["breast cancer"]],"start": [[ "66" ]],"entity_id": []} ,"Route": { "text": [], "start": [], "entity_id": [] },"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [], "start": [], "entity_id": [] },"Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Disorder": { "text": [[ "breast cancer" ]], "start": [[ "66" ]], "entity_id": [] }, "Gender": null, "Population": null, "Race": null }, "Negated": null, "Speculated": null, "Severity": { "text": [[ "lethal" ]], "start": [[ "0" ]], "entity_id": [] ,"value": "high" }, "Effect": null }] }
{"id": "19018868_3","context": "We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe aplastic anemia"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lenalidomide"]],"start": [["84"]],"entity_id": [["T2"]],"Drug": {"text": [["lenalidomide"]],"start": [["84"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["severe aplastic anemia (AA)"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["induced"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["probably"]],"start": [["51"]],"entity_id": [["T4"]]},"Dosage": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Duration": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Freq": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Route": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Combination": null} ,"Effect": null,"Negated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] ,"value": false },"Speculated": {"text": [["probably"]],"start": [["51"]],"entity_id": [["T4"]],"value": true },"Severity": {"text": [["severe"]],"start": [["13"]],"entity_id": [["T0"]],"value": "high" },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] },"Gender": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] },"Population": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] },"Disorder": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] }} } ]}
{"id": "3310776_3","context": "This confirmed the history of captopril-related asthma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["captopril-related asthma"]],"start": [["26"]],"entity_id": [["T1"]]},"Subject": {"text": [["This"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["captopril-related asthma"]],"start": [["26"]],"entity_id": [["T1"]]} ,"Age": { "text": [["This"]], "start": [["0"]], "entity_id": [["T0"]]}, "Gender": { "text": [["This"]], "start": [["0"]], "entity_id": [["T0"]]}, "Population": { "text": [["This"]], "start": [["0"]], "entity_id": [["T0"]]}, "Race": { "text": [["This"]], "start": [["0"]], "entity_id": [["T0"]]}},"Treatment": {"text": [["captopril"]],"start": [["9"]],"entity_id": [["T2"]],"Drug": {"text": [["captopril"]],"start": [["9"]],"entity_id": [["T2"]]},"Disorder": {"text": [["captopril-related asthma"]],"start": [["26"]],"entity_id": [["T1"]]},"Dosage": { "text": [["captopril"]], "start": [["9"]], "entity_id": [["T2"]]},"Duration": { "text": [["captopril"]], "start": [["9"]], "entity_id": [["T2"]]},"Route": { "text": [["captopril"]], "start": [["9"]], "entity_id": [["T2"]]},"Time_elapsed": { "text": [["captopril"]], "start": [["9"]], "entity_id": [["T2"]]},"Freq": { "text": [["captopril"]], "start": [["9"]], "entity_id": [["T2"]]} ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [["asthma"]],"start": [["37"]],"entity_id": [["T3"]]} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "9100429_3", "context": "Four cases of adverse experiences with clonidine are described", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse experiences"]], "start": [["0-15"]], "entity_id": []}, "Subject": {"text": [["Four cases"]], "start": [["0-5"]], "entity_id": [],"Age": {"text": [[]], "start": [[]], "entity_id": []},"Gender": {"text": [[]], "start": [[]], "entity_id": []},"Population": {"text": [["Four cases"]], "start": [["0-5"]], "entity_id": []},"Race": {"text": [[]], "start": [[]], "entity_id": []},"Disorder": {"text": [[]], "start": [[]], "entity_id": []}}, "Treatment": {"text": [["clonidine"]], "start": [["46-52"]], "entity_id": [],"Drug": {"text": [["clonidine"]], "start": [["46-52"]], "entity_id": []},"Dosage": {"text": [[]], "start": [[]], "entity_id": []},"Duration": {"text": [[]], "start": [[]], "entity_id": []},"Trigger": {"text": [[]], "start": [[]], "entity_id": []},"Route": {"text": [[]], "start": [[]], "entity_id": []},"Time_elapsed": {"text": [[]], "start": [[]], "entity_id": []},"Freq": {"text": [[]], "start": [[]], "entity_id": []},"Combination": null, "Disorder": {"text": [[]], "start": [[]], "entity_id": []}} , "Negated": null, "Speculated": null, "Severity": null , "Effect": null}]}
{"id": "9972383_2", "context": "To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reversible nonthrombocytopenic palpable purpura"]], "start": [["6"]], "entity_id": []}, "Treatment": {"text": [["metoclopramide"]], "start": [["73"]], "entity_id": [], "Drug": {"text": [["metoclopramide"]], "start": [["73"]], "entity_id": [] } ,"Disorder": {"text": [["reversible nonthrombocytopenic palpable purpura"]], "start": [["6"]], "entity_id": [] } ,"Time_elapsed": {"text": [["associated with"]], "start": [["47"]], "entity_id": [] } ,"Freq": {"text": [["a case of"]], "start": [["0"]], "entity_id": [] } ,"Combination": [{"Drug": {"text": [["metoclopramide"]], "start": [["73"]], "entity_id": [] }, "Trigger": {"text": [["associated with"]], "start": [["47"]], "entity_id": [] },"event_id": "E1","event_type": "Adverse_event"}] ,"Trigger": {"text": [["reversible nonthrombocytopenic palpable purpura"]], "start": [["6"]], "entity_id": [] } ,"Dosage":{"text":[["None"]],"start":[["0"]],"entity_id":[]} ,"Duration":{"text":[["None"]],"start":[["0"]],"entity_id":[]} ,"Route":{"text":[["None"]],"start":[["0"]],"entity_id":[]} },"Subject":{"text":[["None"]],"start":[["0"]],"entity_id":[],"Age":{"text":[["None"]],"start":[["0"]],"entity_id":[]},"Gender":{"text":[["None"]],"start":[["0"]],"entity_id":[]},"Population":{"text":[["None"]],"start":[["0"]],"entity_id":[]},"Race":{"text":[["None"]],"start":[["0"]],"entity_id":[]},"Disorder":{"text":[["None"]],"start":[["0"]],"entity_id":[]}} ,"Severity":{"text":[["reversible"]],"start":[["6"]],"entity_id":[],"value": "Low"} ,"Negated":{"text":[["None"]],"start":[["0"]],"entity_id":[],"value":false} ,"Speculated":{"text":[["None"]],"start":[["0"]],"entity_id":[],"value":false} ,"Effect":{"text":[["None"]],"start":[["0"]],"entity_id":[]} }]}
{"id": "9876812_1","context": "Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["SIADH"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["vinorelbine"]],"start": [["11"]],"entity_id": [["T2"]],"Drug": {"text": [["vinorelbine"]],"start": [["11"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["SIADH"]],"start": [["23"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["vinorelbine"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["hypokalemia"]],"start": [["42"]],"entity_id": [["T4"]]} ,"event_id": "E2","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Route": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]]} }, "Negated": null,"Speculated": {"text": [["possibly"]],"start": [["37"]],"entity_id": [["T5"]] ,"value": true} ,"Severity": {"text": [["may cause"]],"start": [["17"]],"entity_id": [["T3"]],"value": "low"} ,"Subject": {"text": [["Clinicians"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["Clinicians"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Age": null,"Gender": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["SIADH"]],"start": [["23"]],"entity_id": [["T1"]]}}]}
{"id": "19995690_4","context": "We report a case of a 34-year-old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute liver and renal failure"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["carbamazepine"]],"start": [["20"]],"entity_id": [["T2"]],"Disorder": {"text": [["complex partial seizures"]],"start": [["36"]],"entity_id": [["T3"]]},"Drug": {"text": [["acetaminophen"]],"start": [["88"]],"entity_id": [["T4"]]},"Dosage": {"text": [["2.5 grams a day"]],"start": [["104"]],"entity_id": [["T5"]]},"Duration": {"text": [["less than"]],"start": [["97"]],"entity_id": [["T6"]]},"Route": {"text": [["on"]],"start": [["91"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["developed"]],"start": [["46"]],"entity_id": [["T8"]]},"Freq": {"text": [["a day"]],"start": [["108"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["carbamazepine"]],"start": [["20"]],"entity_id": [["T10"]]},"Trigger": {"text": [["for"]],"start": [["25"]],"entity_id": [["T11"]]},"event_type": "Treatment_of","event_id": "E2"}],"Trigger": {"text": [["developed"]],"start": [["46"]],"entity_id": [["T12"]]}},"Subject": {"text": [["a 34-year-old man"]],"start": [["7"]],"entity_id": [["T13"]],"Age": {"text": [["34"]],"start": [["11"]],"entity_id": [["T14"]]},"Gender": {"text": [["man"]],"start": [["16"]],"entity_id": [["T15"]]},"Population": {"text": [["We report a case"]],"start": [["0"]],"entity_id": [["T16"]]},"Race": {"text": [["a case"]],"start": [["5"]],"entity_id": [["T17"]]},"Disorder": {"text": [["complex partial seizures"]],"start": [["36"]],"entity_id": [["T18"]]}},"Effect": {"text": [["acute liver and renal failure"]],"start": [["52"]],"entity_id": [["T19"]]},"Severity": {"text": [["acute"]],"start": [["52"]],"entity_id": [["T20"]],"value": "high"},"Negated": {"text": [["not"]],"start": [[""], []],"entity_id": [["T21"]],"value": false},"Speculated": {"text": [["We report"]],"start": [[""], []],"entity_id": [["T22"]],"value": false}}]}
{"id": "15628319_4","context": "We report AZA-induced drug eruption that developed in two cases of systemic scleroderma with polymyositis","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["AZA-induced drug eruption"]],"start": [["12"]],"entity_id": [["T1"]]},"Treatment": {"text": [["AZA"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["AZA"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["systemic scleroderma with polymyositis"]],"start": [["38"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["that developed"]],"start": [["17"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Freq": null,"Combination": null,"Trigger": null},"Subject": {"text": [["two cases"]],"start": [["28"]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["systemic scleroderma with polymyositis"]],"start": [["38"]],"entity_id": [["T2"]]}},"Effect": {"text": [["drug eruption"]],"start": [["12"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12776809_1", "context": "Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["coumarin-troxerutin combination"]],"start": [["0"]],"entity_id": [["T1"]] ,"Drug": { "text": [["coumarin"]], "start": [["0"]], "entity_id": [["T2"]] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Combination": [{ "event_type": "", "event_id": "", "Drug": { "text": [["coumarin-troxerutin combination"]], "start": [["0"]], "entity_id": [["T1"]] }, "Trigger": { "text": [], "start": [], "entity_id": [] }}]},"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }}, "Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": { "text": [], "start": [], "entity_id": [] ,"value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false }, "Severity": { "text": [], "start": [], "entity_id": [] ,"value": "" }, "Trigger": { "text": [], "start": [], "entity_id": [] }}]}
{"id": "15580406_3","context": "Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["interferon alpha therapy"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["interferon alpha"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["chronic hepatitis C"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Duration": {"text": [["chronic"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["during"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["occurring"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]} ,"Freq": {"text": [["during"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["interferon alpha"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["isoniazid"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]} ,"event_id": "C1","event_type": "Adverse_event"}]} ,"Subject": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]],"Age": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]]},"Gender": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]]},"Population": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]]},"Race": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]]},"Disorder": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [[ ]],"entity_id": [["T1"]]}} ,"Severity": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [[ ]],"entity_id": [["T1"]],"value": "high"} ,"Negated": {"text": [["occurring"]],"start": [[ ]],"entity_id": [["T6"]],"value": false} ,"Speculated": {"text": [["occurring"]],"start": [[ ]],"entity_id": [["T6"]],"value": false} ,"Effect": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [[ ]],"entity_id": [["T1"]]}}]}
{"id": "11206417_1","context": "Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Glucose"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Disorder": {"text": [["healthy humans"]],"start": [[ "51" ]],"entity_id": [ ["T2"] ]},"Trigger": {"text": [["vasodilator effects"]],"start": [[ "35" ]],"entity_id": [ ["T3"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"entity_id": [ ["T1","T2","T3"] ],"text": [["Glucose"],["healthy humans"],["vasodilator effects"]],"start": [[ "0" ],[ "51" ],[ "35" ]]} ,"Effect": null ,"Subject": null ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null }] }
{"id": "4025011_2","context": "Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reversible cholestatic jaundice"]],"start": [["28", "34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment"]],"start": [["77", "83"]],"entity_id": [["T2"]],"Drug": {"text": [["oxacillin derivatives"]],"start": [["90", "102"]],"entity_id": [["T3"]]},"Duration": {"text": [["during"]],"start": [["35", "39"]],"entity_id": [["T4"]]},"Disorder": {"text": [["osteomyelitis"]],"start": [["7", "15"]],"entity_id": [["T5"]]},"Freq": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["developed"]],"start": [["22", "27"]],"entity_id": [["T7"]]},"Route": {"text": [["treatment"]],"start": [["77", "83"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["oxacillin derivatives"]],"start": [["90", "102"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["77", "83"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["reversible cholestatic jaundice"]],"start": [["28", "34"]],"entity_id": [["T1"]]},"Dosage": {"text": [["during"]],"start": [["35", "39"]],"entity_id": [["T4"]]}},"Subject": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]],"Disorder": {"text": [["osteomyelitis"]],"start": [["7", "15"]],"entity_id": [["T5"]]},"Gender": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]]},"Age": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]]},"Population": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]]},"Race": {"text": [["Two patients"]],"start": [["0", "4"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["reversible"]],"start": [["28", "34"]],"entity_id": [["T1"]],"value": "Low"},"Effect": {"text": [["reversible cholestatic jaundice"]],"start": [["28", "34"]],"entity_id": [["T1"]]}}]}
{"id": "1504404_3","context": "A 49-year-old man developed symptoms of severe psychosis concomitant with ciprofloxacin (250 mg bid) treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe psychosis"]],"start": [["19","26"]],"entity_id": []},"Treatment": {"text": [["ciprofloxacin (250 mg bid)"]],"start": [["66","77"]],"entity_id": [],"Drug": {"text": [["ciprofloxacin"]],"start": [["66","72"]],"entity_id": []},"Dosage": {"text": [["250 mg bid"]],"start": [["73","77"]],"entity_id": []},"Route": {"text": [["treatment"]],"start": [["89","96"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [["concomitant"]],"start": [["38","45"]],"entity_id": []}},"Subject": {"text": [["A 49-year-old man"]],"start": [["0","9"]],"entity_id": [],"Age": {"text": [["49"]],"start": [["2","4"]],"entity_id": []},"Gender": {"text": [["man"]],"start": [["10","13"]],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["developed symptoms"]],"start": [["14","25"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["20","24"]],"entity_id": [],"value": "severe"}}]}
{"id": "7673653_1","context": "Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["low-dose mianserin"]],"start": [[ "0" ]] ,"entity_id": [ [ "T1" ]],"Drug": {"text": [["mianserin"]],"start": [[ "0" ]],"entity_id": [ [ "T3" ]]},"Disorder": {"text": [["fluvoxamine-induced akathisia"]],"start": [[ "23" ]],"entity_id": [ [ "T2" ]]},"Dosage": {"text": [["low-dose"]],"start": [["0" ]],"entity_id": [["T1"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["an obsessive-compulsive patient"]],"start": [[ "80" ]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["obsessive-compulsive"]],"start": [[ "80" ]],"entity_id": [["T4"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "2028358_2", "context": "Pulmonary oedema after hexoprenaline administration in preterm labour", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Pulmonary oedema"]], "start": [["0"]], "entity_id":[ ["T1"]]}, "Treatment": {"text": [["hexoprenaline administration"]], "start": [[ "21"]], "entity_id": [ ["T2"]], "Drug": {"text": [["hexoprenaline"]], "start": [[ "21"]], "entity_id": [ ["T3"]]}, "Route": {"text": [["administration"]], "start": [[ "21"]], "entity_id": [ ["T4"]]},"Time_elapsed": {"text": [[ "after"]], "start": [[ "12"]], "entity_id": [ ["T5"]]}, "Disorder": {"text": [[ "preterm labour"]], "start": [[ "41"]], "entity_id": [ ["T6"]]}, "Freq": {"text": [[ "administration"]], "start": [[ "21"]], "entity_id": [ ["T4"]]},"Trigger": {"text": [[ "hexoprenaline administration"]], "start": [[ "21"]], "entity_id": [ ["T2"]]},"Dosage": {"text": [[ "hexoprenaline"]], "start": [[ "21"]], "entity_id": [ ["T3"]]} ,"Duration": {"text": [[ "preterm labour"]], "start": [[ "41"]], "entity_id": [ ["T6"]]} ,"Combination": []} ,"Subject": {"text": [[ "Pulmonary oedema"]], "start": [[ "0"]], "entity_id": [ ["T1"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null} ,"Severity": null, "Negated": null, "Speculated": null, "Effect": {"text": [[ "Pulmonary oedema"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}}]}
{"id": "11144696_10","context": "Venlafaxine-associated seizures at therapeutic doses have not been reported in the literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": {"value": true,"text": [["not"]],"start": [[ "16"]],"entity_id": []},"Trigger": {"text": [["seizures"]],"start": [["11"]],"entity_id": []},"Treatment": {"text": [["Venlafaxine"]],"start": [["0"]],"entity_id": [],"Dosage": {"text": [["therapeutic doses"]],"start": [["33"]],"entity_id": []},"Disorder": {"text": [["seizures"]],"start": [["11"]],"entity_id": []},"Freq": {"text": [["not reported"]],"start": [["44"]],"entity_id": []},"Time_elapsed": {"text": [["not reported"]],"start": [["44"]],"entity_id": []},"Duration": {"text": [["not reported"]],"start": [["44"]],"entity_id": []},"Route": {"text": [["not reported"]],"start": [["44"]],"entity_id": []},"Drug": {"text": [["Venlafaxine"]],"start": [["0"]],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["seizures"]],"start": [["11"]],"entity_id": []},"Subject": null,"Speculated": null,"Severity": null}]}
{"id": "9211543_4","context": "Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fibrotic lesions"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["bleomycin"], ["cyclophosphamide"]],"start": [["55"], ["63"]],"entity_id": [["T2"], ["T3"]]} ,"entity_id": [["T2"], ["T3"]] ,"text": [["bleomycin"], ["cyclophosphamide"]],"start": [["55"], ["63"]], "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Trigger": {"text": [[" attributable "]],"start": [["47"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["metastasis"]],"start": [["11"]],"entity_id": [["T5"]]} ,"Combination": null }, "Effect": {"text": [["Thoracoscopic biopsy"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Subject": null, "Negated": null, "Speculated": null, "Severity": null }] }
{"id": "16968538_4", "context": "We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hemolytic-uremic syndrome"]], "start": [["33"]], "entity_id": []}, "Treatment": {"text": [["combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin"]], "start": [["11"]], "entity_id": [], "Combination": [{"Drug": {"text": [["oxaliplatin"]], "start": [["55"]], "entity_id": []}, "Trigger": {"text": [["combination chemotherapy"]], "start": [["11"]], "entity_id": []}, "event_id": "C1", "event_type": "null"}],"Trigger": {"text": [["5-fluorouracil"]], "start": [["72"]], "entity_id": []}, "Drug": {"text": [["leucovorin"]], "start": [["84"]], "entity_id": []}, "Dosage": {"text": [["4th cycle"]], "start": [["36"]], "entity_id": []}, "Route": {"text": [["combination chemotherapy"]], "start": [["11"]], "entity_id": []} ,"Time_elapsed":{"text":[["developed"]],"start":[["33"]],"entity_id":[]} ,"Disorder":{"text":[["hemolytic-uremic syndrome"]],"start":[["33"]],"entity_id":[]} ,"Duration":{"text":[["4th cycle"]],"start":[["36"]],"entity_id":[]} ,"Freq":{"text":[["combination chemotherapy"]],"start":[["11"]],"entity_id":[]} }, "Subject":{"text":[["We"]],"start":[["0"]],"entity_id":[],"Age":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Gender":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Population":{"text":[["case"]],"start":[["0"]],"entity_id":[]},"Race":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Disorder":{"text":[["hemolytic-uremic syndrome"]],"start":[["33"]],"entity_id":[]}} ,"Effect":{"text":[["developed"]],"start":[["33"]],"entity_id":[]} ,"Negated":{"text":[["not"]],"start":[["0"]],"entity_id":[],"value":false} ,"Speculated":{"text":[["We present"]],"start":[["0"]],"entity_id":[],"value":false} ,"Severity":{"text":[[" "]],"start":[["0"]],"entity_id":[],"value":"Low"}}]}
{"id": "16632429_1","context": "We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. ","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["chemotherapy with docetaxel and gemcitabine"]],"start": [["31"]],"entity_id": [["T1"]],"Drug": {"text": [["docetaxel"]],"start": [["31"]],"entity_id": [["T2"]]},"Disorder": {"text": [["lung cancer"]],"start": [["6"]],"entity_id": [["T3"]]},"Duration": {"text": [["after"]],"start": [["27"]],"entity_id": [["T4"]]},"Trigger": {"text": [["presenting with BOOP"]],"start": [["57"]],"entity_id": [["T5"]]},"Freq": {"text": [["severe respiratory insufficiency"]],"start": [["87"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["producing"]],"start": [["81"]],"entity_id": [["T7"]]},"Route": {"text": [["after"]],"start": [["27"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["docetaxel"]],"start": [["31"]],"entity_id": [["T2"]]},"Trigger": {"text": [["presenting with BOOP"]],"start": [["57"]],"entity_id": [["T5"]]},"event_type": "Potential_therapeutic_effect","event_id": "E1-1"},{"Drug": {"text": [["gemcitabine"]],"start": [["44"]],"entity_id": [["T8"]]},"Trigger": {"text": [["presenting with BOOP"]],"start": [["57"]],"entity_id": [["T5"]]},"event_type": "Potential_therapeutic_effect","event_id": "E1-2"}],"Dosage": {"text": [["chemotherapy with docetaxel and gemcitabine"]],"start": [["31"]],"entity_id": [["T1"]]}},"Subject": {"text": [["a lung cancer patient with bronquiloalveolar carcinoma (BAC)"]],"start": [["6"]],"entity_id": [["T3"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["lung cancer"]],"start": [["6"]],"entity_id": [["T3"]]}},"Effect": {"text": [["BOOP"]],"start": [["57"]],"entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["87"]],"entity_id": [["T6"]],"value": "high"},"Trigger": {"text": [["presenting with BOOP"]],"start": [["57"]],"entity_id": [["T5"]]}}]}
{"id": "15840734_1", "context": "Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Fluphenazine-induced neuroleptic malignant syndrome"]],"start": [[ ]],"entity_id": []},"Subject": {"text": [["a schizophrenic patient"]],"start": [[ ]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["schizophrenic"]],"start": [[ ]],"entity_id": []}},"Treatment": {"text": [["Fluphenazine"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["Fluphenazine"]],"start": [[ ]],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["neuroleptic malignant syndrome"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Freq": null,"Combination": null},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "19039026_1", "context": "Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["acute interstitial nephritis"]], "start": [["22"]], "entity_id": []}, "Treatment": {"text": [["tyrosine kinase inhibitor sunitinib"]], "start": [["50"]], "entity_id": [],"Drug": {"text": [["sunitinib"]], "start": [["50"]], "entity_id": []}, "Disorder": {"text": [["acute interstitial nephritis"]], "start": [["22"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6529939_2", "context": "Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["propranolol"]], "start": [["propranolol", "daily" ] ], "entity_id": [ ]}, "Dosage": {"text": [["80 mg"]], "start": [["80"]], "entity_id": [ ]}, "Route": {"text": [["daily"]], "start": [["daily"]], "entity_id": [ ]}, "Disorder": {"text": [["angina"]], "start": [["angina"]], "entity_id": [ ]} ,"Trigger": {"text": [["treatment"]], "start": [[ "treatment"]], "entity_id": [ ]},"Time_elapsed": {"text": [["observed"]], "start": [["observed"]], "entity_id": [ ]},"Freq": {"text": [["daily"]], "start": [["daily"]], "entity_id": [ ]} ,"Duration": {"text": [["under treatment"]], "start": [["under treatment"]], "entity_id": [ ]} ,"entity_id": [ ] ,"text": [["Alternating sinus rhythm and intermittent sinoatrial (S-A) block"]], "start": [[ "Alternating sinus rhythm and intermittent sinoatrial (S-A) block"]], "Combination" : null} ,"Subject": {"text": [["a" , "57-year-old" , "woman"]], "start": [["a"]], "Age": {"text": [["57-year-old"]], "start": [["57-year-old"]], "entity_id": [ ]},"Gender": {"text": [["woman"]], "start": [["woman"]], "entity_id": [ ]},"Disorder": {"text": [["angina"]], "start": [["angina"]], "entity_id": [ ]},"entity_id": [ ] ,"Race" : null ,"Population" : null},"Negated" : null ,"Speculated" : null ,"Severity" : null ,"Effect" : null ,"Trigger" : null}]}
{"id": "9375469_2","context": "Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["contact dermatitis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sodium bisulfite"]],"start": [["64"]],"entity_id": [["T2"]],"Drug": {"text": [["sodium bisulfite"]],"start": [["64"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["contact dermatitis"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["her"]],"start": [["15"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["eruption"]],"start": [["21"]],"entity_id": [["T3"]]} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11876387_2","context": "Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["tamoxifen therapy"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["tamoxifen therapy"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["induce endometrial disorders"]],"start": [["21"]],"entity_id": [["T2"]]},"Dosage": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Duration": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Route": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Time_elapsed": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Freq": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Trigger": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Drug": {"text": [["tamoxifen"]],"start": [["0"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Trigger": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"event_id": "E1","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["women taking tamoxifen"]],"start": [["71"]],"entity_id": [["T4"]],"Age": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Disorder": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Gender": {"text": [["women"]],"start": [["71"]],"entity_id": [["T4"]]},"Population": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]},"Race": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]]}},"Effect": {"text": [["surveillance schemes"]],"start": [["102"]],"entity_id": [["T5"]]},"Negated": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]],"value": false},"Speculated": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]],"value": false},"Severity": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["N/A"]],"value": "N/A"}}]}
{"id": "11837564_2", "context": "Warfarin-associated bleeding complication saved life", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bleeding complication"]], "start": [["Warfarin-associated bleeding complication saved life" ]], "entity_id": []}, "Treatment": null, "Effect": {"text": [["saved life"]], "start": [[], []], "entity_id": []}, "Subject": {"text": [["Warfarin-associated bleeding complication"]], "start": [[], []], "entity_id": [],"Age":null,"Disorder":{"text":[["bleeding complication"]], "start":[[],[]],"entity_id":[]},"Gender":null,"Population":null,"Race":null}, "Negated": null, "Speculated": null, "Severity": null} ]}
{"id": "8979664_1", "context": "This paper presents a new case of rifabutin uveitis and a review of the various published reports to date", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["rifabutin uveitis"]],"start": [["METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date"]],"entity_id": [["ENT1"]]},"Subject": {"text": [["this paper"]],"start": [["METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date"]],"entity_id": [["SUB1"]],"Disorder": {"text": [["rifabutin uveitis"]],"start": [["METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date"]],"entity_id": [["ENT1"]]},"Population": {"text": [["a new case"]],"start": [["METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date"]],"entity_id": [["ENT2"]]},"Age": null,"Gender": null,"Race": null},"Treatment": null,"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12860350_1","context": "Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute abdomen"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Subject": {"text": [["a premenopausal woman"]],"start": [[ "45"]] ,"entity_id": [ ["T2"] ],"Age": null,"Gender": {"text": [["woman"]],"start": [[ "54"]] ,"entity_id": [ ["T3"] ]},"Population": null,"Race": null,"Disorder": {"text": [["endometriosis"]],"start": [[ "20"]] ,"entity_id": [ ["T4"] ]}},"Treatment": {"text": [["tamoxifen"]],"start": [[ "73"]] ,"entity_id": [ ["T5"] ],"Drug": {"text": [["tamoxifen"]],"start": [[ "73"]] ,"entity_id": [ ["T5"] ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Disorder": {"text": [["endometriosis"]],"start": [[ "20"]] ,"entity_id": [ ["T4"] ]} ,"Combination": null} ,"Effect": {"text": [["acute abdomen"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18094347_3", "context": "Methotrexate-induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases. ", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Methotrexate-induced papular eruption"]], "start": [[ "0" ]], "entity_id": [ ]}, "Treatment": {"text": [["methotrexate therapy"]], "start": [[ "46" ]], "entity_id": [ ], "Drug": {"text": [["methotrexate"]], "start": [[ "46" ]], "entity_id": [ ]} , "Time_elapsed": {"text": [["shortly after beginning"]], "start": [[ "13" ]], "entity_id": [ ]} , "Disorder": {"text": [["acute exacerbation of collagen vascular diseases"]], "start": [[ "80" ]], "entity_id": [ ]} , "Freq": {"text": [["rarely reported"]], "start": [[ "4" ]], "entity_id": [ ]} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Route": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": null }, "Negated": null , "Speculated": null , "Severity": null , "Subject": null , "Effect": null}]}
{"id": "15028964_5","context": "We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone-induced thyrotoxicosis heralded by a significant decrease in warfarin requirements","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["amiodarone-induced thyrotoxicosis"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["amiodarone", "warfarin"]],"start": [["10","22"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["amiodarone"]],"start": [["10"]],"entity_id": [["T4"]]},"Disorder": {"text": [["thyrotoxicosis"]],"start": [["33"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [["a significant decrease in warfarin requirements"]],"start": [["55"]],"entity_id": [["T6"]]}},"Subject": {"text": [["3 patients"]],"start": [["0"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "25157214_3", "context": "The aim of this post-hoc analysis of data from a Phase III clinical trial (VISTA; NCT00298831) was to investigate the impact of antibiotics on recovery from rocuronium-induced NMB after administration of sugammadex for reversal, and compared the neuromuscular recovery in patients who received antibiotics preoperatively with those who did not", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["antibiotics"]], "start": [["55"]], "entity_id": [["T1"]]},"Disorder": {"text": [["recovery from rocuronium-induced NMB"]], "start": [["102"]], "entity_id": [["T2"]]},"Trigger": {"text": [["impact"]], "start": [["72"]], "entity_id": [["T3"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"entity_id": [ ], "text": [ ], "start": [ ]} ,"Effect": { "text": [["recovery"]], "start": [["102"]], "entity_id": [["T2"]] }, "Subject": { "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["patients"]], "start": [["145"]], "entity_id": [["T4"]] }, "text": [ ], "start": [ ], "entity_id": [ ]} ,"Negated": null, "Speculated": null, "Severity": null ,"Trigger": { "text": [["impact"]], "start": [["72"]], "entity_id": [["T3"]] }} ]}
{"id": "9754850_3","context": "One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["possible extrapyramidal side effects"]],"start": [["28", "37"]],"entity_id": []},"Treatment": {"text": [["olanzapine"]],"start": [["57"]],"entity_id": [],"Drug": {"text": [["olanzapine"]],"start": [["57"]],"entity_id": []} ,"Disorder": {"text": [["extrapyramidal side effects"]],"start": [["28", "37"]],"entity_id": []} ,"Time_elapsed": {"text": [["reduced"]],"start": [["68"]],"entity_id": []} ,"Freq": {"text": [["not completely eliminated"]],"start": [["90"]],"entity_id": []} ,"Route": {"text": [["with"]],"start": [["55"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["classical neuroleptic drugs"]],"start": [["85"]],"entity_id": []},"Trigger": {"text": [["compared"]],"start": [["77"]],"entity_id": []} ,"event_type": "Adverse_event","event_id": "E2"}] ,"Trigger": {"text": [["be aware"]],"start": [["0"]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["One"]],"start": [[""], []],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []} ,"Effect": {"text": [["possible extrapyramidal side effects"]],"start": [["28", "37"]],"entity_id": []} }]}
{"id": "122410_1","context": "A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["large doses of thyroid hormone"]],"start": [["12", "13"]],"entity_id": [] ,"Drug": {"text": [["thyroid hormone"]],"start": [["4", "5"]],"entity_id": [] },"Duration": {"text": [["several years"]],"start": [["31", "32"]],"entity_id": [] },"Trigger": {"text": [["after thyroid hormone withdrawal"]],"start": [["70", "71"]],"entity_id": [] },"Disorder": {"text": [["secondary hypothyroidism"]],"start": [["49", "50"]],"entity_id": [] },"Freq": {"text": [["large doses"]],"start": [["0", "1"]],"entity_id": [] },"Time_elapsed": {"text": [["after thyroid hormone withdrawal"]],"start": [["70", "71"]],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [["large doses"]],"start": [["0", "1"]],"entity_id": [] },"Combination": null },"Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Trigger": {"text": [["developed features"]],"start": [["45", "46"]],"entity_id": [] }} ] }
{"id": "984862_2","context": "A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with betamethasone valerate cream 0.1%","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["postprandial hyperglycemia"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["betamethasone valerate cream 0.1%"]],"start": [["88"]],"entity_id": [["T2"]],"Drug": {"text": [["betamethasone valerate"]],"start": [["88"]],"entity_id": [["T3"]]},"Route": {"text": [["cream"]],"start": [["101"]],"entity_id": [["T4"]]},"Dosage": {"text": [["0.1%"]],"start": [["108"]],"entity_id": [["T5"]]},"Disorder": {"text": [["similar glucose tolerance test result"]],"start": [["15"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["treated similarly"]],"start": [["44"]],"entity_id": [["T7"]]},"Trigger": null,"Freq": null,"Duration": null,"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A second patient"]],"start": [["0"]],"entity_id": [["T8"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "3677571_1", "context": "Phenytoin-induced hypersensitivity reactions", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Phenytoin-induced hypersensitivity reactions"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Phenytoin"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Phenytoin"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["hypersensitivity reactions"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [["induced"]], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [["reactions"]], "start": [[ ]], "entity_id": [ ]},"Combination": [{"Drug": {"text": [["Phenytoin"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["induced"]], "start": [[ ]], "entity_id": [ ]},"event_id": "C1","event_type": "null"} ] ,"Trigger" :{"text": [["Phenytoin-induced hypersensitivity reactions"]], "start": [[ ]], "entity_id": []}, "Dosage" : {"text": [], "start": [], "entity_id": []}, "Duration" : {"text": [], "start": [], "entity_id": []}, "Route" : {"text": [], "start": [], "entity_id": []} }, "Effect" : {"text": [["hypersensitivity reactions"]], "start": [[ ]], "entity_id": []} ,"Negated" : {"text": [], "start": [], "entity_id": [] ,"value" :false }, "Speculated" : {"text": [], "start": [], "entity_id": [] ,"value" :false }, "Severity" : {"text": [], "start": [], "entity_id": [] ,"value" :"moderate" }, "Subject" : {"text": [], "start": [], "entity_id": [] ,"Age" :{"text": [], "start": [], "entity_id": []}, "Gender" :{"text": [], "start": [], "entity_id": []}, "Population" :{"text": [], "start": [], "entity_id": []}, "Race" :{"text": [], "start": [], "entity_id": []}, "Disorder" :{"text": [], "start": [], "entity_id": []} }} ]}
{"id": "9545161_1","context": "A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["TEN"]],"start": [["19"]],"entity_id": [["T2"]]},"Treatment": {"text": [["lamotrigine"]],"start": [["52"]],"entity_id": [["T3"]],"Drug": {"text": [["lamotrigine"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["complex partial seizures"]],"start": [["34"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["4 weeks"]],"start": [["22"]],"entity_id": [["T1"]]},"Dosage": {"text": [["beginning"]],"start": [["51"]],"entity_id": [["T0"]]} ,"Route": {"text": [["after"]],"start": [["49"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["beginning"]],"start": [["51"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["lamotrigine"]],"start": [["52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["beginning"]],"start": [["51"]],"entity_id": [["T0"]]} ,"event_id": "C1" ,"event_type": "Treatment" }],"Trigger": {"text": [["4 weeks"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["4 weeks"]],"start": [["22"]],"entity_id": [["T1"]]} },"Subject": {"text": [["A 54-year-old man"]],"start": [["0"]],"entity_id": [["T6"]],"Age": {"text": [["54"]],"start": [["3"]],"entity_id": [["T7"]]},"Gender": {"text": [["man"]],"start": [["26"]],"entity_id": [["T8"]]} ,"Disorder": {"text": [["glioblastoma multiforme brain tumor"]],"start": [["69"]],"entity_id": [["T9"]]} ,"Population": {"text": [["A 54-year-old man"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Race": {"text": [["A 54-year-old man"]],"start": [["0"]],"entity_id": [["T6"]]}} ,"Negated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Speculated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Severity": {"value": "","text": [],"start": [],"entity_id": [] },"Effect": {"text": [["TEN"]],"start": [["19"]],"entity_id": [["T2"]]} }]}
{"id": "11881322_5", "context": "The occurrence of acute hepatitis is best known for ketoconazole", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute hepatitis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["ketoconazole"]], "start": [[ "49" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["ketoconazole"]], "start": [[ "49" ]], "entity_id": [ ["T2"] ]} , "Disorder": {"text": [["acute hepatitis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} , "Time_elapsed": null , "Duration": null , "Dosage": null , "Route": null , "Freq": null , "Combination": null , "Trigger": null }, "Subject": null , "Negated": null , "Speculated": null , "Severity": null , "Effect": null }]}
{"id": "6233326_2","context": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D-penicillamine for about 1 year","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Optic neuropathy"]],"start": [[ "0" ]],"entity_id": [ ]},"Subject": {"text": [["a patient with rheumatoid arthritis"]],"start": [[ "41" ]],"entity_id": [ ],"Disorder": {"text": [["rheumatoid arthritis"]],"start": [[ "57" ]],"entity_id": [ ]},"Age": {"text": [["about 1 year"]],"start": [[ "83" ]],"entity_id": [ ]},"Gender": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Race": {"text": [ ],"start": [[ ]],"entity_id": [ ]}},"Treatment": {"text": [["D-penicillamine"]],"start": [[ "68" ]],"entity_id": [ ],"Dosage": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["for about 1 year"]],"start": [[ "83" ]],"entity_id": [ ]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [[ "41" ]],"entity_id": [ ]},"Drug": {"text": [["D-penicillamine"]],"start": [[ "68" ]],"entity_id": [ ]},"Freq": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Combination": null,"Trigger": {"text": [["developed"]],"start": [[ "19" ]],"entity_id": [ ]}},"Effect": {"text": [["Optic neuropathy"]],"start": [[ "0" ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19520277_1", "context": "Stupor and fast activity on electroencephalography in a child treated with valproate", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["stupor"]], "start": [[ ], ["fast activity on electroencephalography"]], "entity_id": [["T1"], ["T2"]]},"Treatment": {"text": [["valproate"]], "start": [[ ]], "entity_id": [["T3"]], "Drug": {"text": [["valproate"]], "start": [[ ]], "entity_id": [["T4"]] },"Disorder": {"text": [["stupor"]], "start": [[ ]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["treated"]], "start": [[ ]], "entity_id": [["T6"]] },"Trigger": {"text": [["treated"]], "start": [[ ]], "entity_id": [["T6"]] },"Freq": {"text": [["on electroencephalography"]], "start": [[ ]], "entity_id": [["T7"]]},"Route": {"text": [["treated"]], "start": [[ ]], "entity_id": [["T6"]]},"Dosage": {"text": [["valproate"]], "start": [[ ]], "entity_id": [["T4"]]},"Duration": {"text": [["treated"]], "start": [[ ]], "entity_id": [["T6"]]},"Combination": null},"Subject": null,"Severity": null,"Negated": null,"Speculated": null,"Effect": null}]}
{"id": "7606071_5","context": "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["cisplatin"]],"start": [["During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] ,"Drug": {"text": [["cisplatin"]],"start": [[ "During her third cycle, she again received cisplatin" ]],"entity_id": [ ] } ,"Dosage": {"text": [["100 mg/m2"]],"start": [[ "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] } ,"Duration": {"text": [["over 30 minutes"]],"start": [[ "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] } ,"Trigger": {"text": [["developed"]],"start": [[ "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] } ,"Route": {"text": [["over"]],"start": [[ "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] } ,"Time_elapsed": {"text": [["her third cycle"]],"start": [[ "During her third cycle" ]],"entity_id": [ ] } ,"Disorder": {"text": [["palmar pruritus, urticaria, and edema"]],"start": [[ "palmar pruritus, urticaria, and edema." ]],"entity_id": [ ] } ,"Freq": {"text": [["again"]],"start": [[ "During her third cycle, she again received cisplatin" ]],"entity_id": [ ] } ,"Combination": [ {"Drug": {"text": [["cisplatin"]],"start": [[ "During her third cycle, she again received cisplatin" ]],"entity_id": [ ] } ,"Trigger": {"text": [["developed"]],"start": [[ "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. " ]],"entity_id": [ ] } ,"event_type": "Potential_therapeutic_effect","event_id": "E1" } ]} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Effect": null , "Trigger": null } ] }
{"id": "9169264_3", "context": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed.\n", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["treated"]], "start": [["treated'.length"]], "entity_id": []}, "Treatment": {"text": [["cephalexin"]], "start": [["cephalexin'.length"]], "entity_id": [],"Drug": {"text": [["cephalexin"]], "start": [["cephalexin'.length"]], "entity_id": []} ,"Disorder": {"text": [["infectious mononucleosis"]], "start": [[ "infectious mononucleosis'.length"]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [["showed"]], "start": [[ "showed'.length"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["patient"]], "start": [[ "patient'.length"]], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["infectious mononucleosis"]], "start": [[ "infectious mononucleosis'.length"]], "entity_id": [] } }}]}
{"id": "8771575_4", "context": "Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a case"]], "start": [[ "0"]], "entity_id": [ ["S1"]], "Disorder": {"text": [["Nitrofurantoin-induced pulmonary toxicity"]], "start": [[ "22"]], "entity_id": [ ["S2"]]} ,"Age": {"text": [["during pregnancy"]], "start": [[ "61"]], "entity_id": [ ["S3"]]} , "Population": {"text": [["a case"]], "start": [[ "0"]], "entity_id": [ ["S1"]]} , "Race": {"text": [], "start": [], "entity_id": []} , "Gender": {"text": [["during pregnancy"]], "start": [[ "61"]], "entity_id": [ ["S3"]]} },"Trigger": {"text": [["Nitrofurantoin-induced pulmonary toxicity"]], "start": [[ "22"]], "entity_id": [ ["T1"]]},"Effect": {"text": [], "start": [], "entity_id": []},"Severity": {"text": [], "start": [], "entity_id": [],"value":""},"Negated": {"text": [], "start": [], "entity_id": [],"value":false},"Speculated": {"text": [], "start": [], "entity_id": [],"value":false},"Treatment": {"text": [], "start": [], "entity_id": [],"Drug": {"text": [["Nitrofurantoin"]], "start": [[ "0"]], "entity_id": [ ["T2"]]} ,"Disorder": {"text": [["Nitrofurantoin-induced pulmonary toxicity"]], "start": [[ "22"]], "entity_id": [ ["T1"]]} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Combination": [{"Drug": {"text": [["Nitrofurantoin"]], "start": [[ "0"]], "entity_id": [ ["T2"]]},"Trigger": {"text": [], "start": [], "entity_id": []},"event_id": "C1","event_type": "Drug"} ] ,"Trigger": {"text": [], "start": [], "entity_id": []}}}]}
{"id": "18644535_1", "context": "Methylphenidate-associated enuresis in attention deficit hyperactivity disorder", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["enuresis"]], "start": [["22"]], "entity_id": []}, "Treatment": {"text": [["Methylphenidate"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Methylphenidate"]], "start": [["0"]], "entity_id": [] },"Disorder": {"text": [["attention deficit hyperactivity disorder"]], "start": [["42"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["enuresis"]], "start": [["22"]], "entity_id": []}},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["attention deficit hyperactivity disorder"]], "start": [["42"]], "entity_id": []}}}]}
{"id": "14740795_4", "context": "To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["amifostine"]], "start": [["43"]], "entity_id": [["T1"]]}, "Dosage": {"text": [["low-dose"]], "start": [["24"]], "entity_id": [["T2"]]},"Route": null, "Time_elapsed": null, "Duration": null, "Disorder": null, "entity_id": [["T3"]],"text": [["amifostine therapy"]], "start": [["43"]], "Freq": null, "Combination": null, "Trigger": null}, "Effect": {"text": [["fever"]], "start": [["10"]], "entity_id": [["T4"]]}, "Trigger": null}]}
{"id": "17122225_5","context": "In both cases, symptoms of autonomic instability and severe agitation started within hours of initiation of cyclobenzaprine and fully resolved within 3 days after discontinuing the proserotoninergic drugs","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["autonomic instability", "severe agitation"]],"start": [[", 23", ", 34"]],"entity_id": []},"Treatment": {"text": [["cyclobenzaprine"]],"start": [[", 8"]],"entity_id": [],"Drug": {"text": [["cyclobenzaprine"]],"start": [[", 8"]],"entity_id": []} ,"Duration": {"text": [["hours"]],"start": [[", 37"]],"entity_id": []} ,"Time_elapsed": {"text": [["3 days"]],"start": [[", 55"]],"entity_id": []} ,"Disorder": {"text": [["proserotoninergic drugs"]],"start": [[", 64"]],"entity_id": []} ,"Route": {"text": [["initiation"]],"start": [[", 42"]],"entity_id": []} ,"Trigger": {"text": [["discontinuing"]],"start": [[", 52"]],"entity_id": []} ,"Freq": {"text": [["fully resolved"]],"start": [[", 47"]],"entity_id": []} ,"Dosage": {"text": [["initiation"]],"start": [[", 42"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["cyclobenzaprine"]],"start": [[", 8"]],"entity_id": []},"Trigger": {"text": [["initiation"]],"start": [[", 42"]],"entity_id": []},"event_type": "Adverse_event" ,"event_id": "E1" }] }, "Negated": {"text": [],"start": [],"entity_id": [] ,"value": false }, "Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false }, "Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }, "Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] }, "Disorder": {"text": [],"start": [],"entity_id": [] }, "Gender": {"text": [],"start": [],"entity_id": [] }, "Population": {"text": [],"start": [],"entity_id": [] }, "Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["autonomic instability and severe agitation"]],"start": [[", 23"]],"entity_id": [] }} ]}
{"id": "10779995_2", "context": "Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["child"]], "start": [["Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?"],[ "0" ],["12"]],"entity_id": [ ["S1"] ] ,"Age":{"text":[],"start":[],"entity_id":[]} ,"Gender":{"text":[],"start":[],"entity_id":[]} ,"Population":{"text":[],"start":[],"entity_id":[]} ,"Race":{"text":[],"start":[],"entity_id":[]} ,"Disorder":{"text":[["neuroblastoma"]], "start": [["Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?"],[ "24" ],["38"]],"entity_id":[ ["D1"] ]}},"Treatment": {"text": [["oral etoposide"]], "start": [["Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?"],["69" ],["82"]],"entity_id":[ ["T1"] ],"Drug":{"text":[["etoposide"]], "start": [["69" ],["76"]],"entity_id":[ ["D2"] ]},"Dosage":{"text":[],"start":[],"entity_id":[]} ,"Duration":{"text":[],"start":[],"entity_id":[]} ,"Disorder":{"text":[["neuroblastoma"]], "start": [["Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?"],["24" ],["38"]],"entity_id":[ ["D1"] ]},"Route":{"text":[],"start":[],"entity_id":[]} ,"Time_elapsed":{"text":[],"start":[],"entity_id":[]} ,"Freq":{"text":[],"start":[],"entity_id":[]} ,"Combination":[{"Drug":{"text":[["etoposide"]], "start": [["69" ],["76"]],"entity_id":[ ["D2"] ]},"Trigger":{"text":[["oral"]], "start": [["69" ],["72"]],"entity_id":[ ["T5"] ]}, "event_id": "C1", "event_type":"Drug"}] ,"Trigger":{"text":[["on"]], "start": [["69" ],["71"]],"entity_id":[ ["T3"] ]}} , "Trigger":{"text":[["while"]], "start": [["69" ],["74"]],"entity_id":[ ["T2"] ]} , "Negated":{"text":[],"start":[],"entity_id":[],"value":false} , "Speculated":{"text":[],"start":[],"entity_id":[],"value":false} , "Severity":{"text":[["Secondary leukemia"]], "start": [["0" ],["15"]],"entity_id":[ ["E1"] ],"value":"high" },"Effect":{"text":[["Secondary leukemia"]], "start": [["0" ],["15"]],"entity_id":[ ["E1"] ]} }] }
{"id": "20666169_1", "context": "Atorvastatin induced multiple organ failure", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Atorvastatin induced multiple organ failure"]], "start": [[ ]], "entity_id": []}, "Treatment": {"text": [["Atorvastatin"]], "start": [[ ]], "entity_id": [],"Drug": {"text": [["Atorvastatin"]], "start": [[ ]], "entity_id": []},"Disorder": {"text": [["multiple organ failure"]], "start": [[ ]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Combination": null ,"Trigger": null},"Effect": {"text": [["multiple organ failure"]], "start": [[ ]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19697589_3", "context": "While serotonin syndrome has become more frequent in an overdose situation and when an interacting drug is given, the toxicity of SSIRs is less than that of most other psychiatric drugs.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["serotonin syndrome"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["overdose situation", "an interacting drug is given"]], "start": [["45","86"]], "entity_id": [["T2","T3"]], "Drug": {"text": [["interacting drug"]], "start": [["86"]], "entity_id": [["T3"]]},"Freq":{"text":[["given"]],"start":[["86"]],"entity_id":[["T3"]]},"Time_elapsed":{"text":[["has become more frequent"]],"start":[["45"]],"entity_id":[["T2"]]},"Route":{"text":[["given"]],"start":[["86"]],"entity_id":[["T3"]]},"Dosage":{"text":[["overdose situation"]],"start":[["45"]],"entity_id":[["T2"]]},"Duration":{"text":[["has become more frequent"]],"start":[["45"]],"entity_id":[["T2"]]},"Disorder":{"text":[["serotonin syndrome"]],"start":[["0"]],"entity_id":[["T1"]]},"Combination":[{"Drug":{"text":[["interacting drug"]],"start":[["86"]],"entity_id":[["T3"]]},"Trigger":{"text":[["given"]],"start":[["86"]],"entity_id":[["T3"]]},"event_type":"Combination","event_id":"C1"}],"Trigger":{"text":[["serotonin syndrome"]],"start":[["0"]],"entity_id":[["T1"]]}},"Effect":{"text":[["the toxicity"]], "start": [["101"]], "entity_id": [["T4"]]},"Negated":{"value":false,"text":[["less than that"]],"start":[["124"]],"entity_id":[["T5"]]},"Speculated":{"value":false,"text":[["has become more frequent"]],"start":[["45"]],"entity_id":[["T2"]]},"Severity":{"value":"Low","text":[["less than that"]],"start":[["124"]],"entity_id":[["T5"]]},"Subject":{"text":[["While"]],"start":[["0"]],"entity_id":[["T0"]],"Age":{"text":[["While"]],"start":[["0"]],"entity_id":[["T0"]]},"Disorder":{"text":[["serotonin syndrome"]],"start":[["0"]],"entity_id":[["T1"]]},"Gender":{"text":[["While"]],"start":[["0"]],"entity_id":[["T0"]]},"Population":{"text":[["While"]],"start":[["0"]],"entity_id":[["T0"]]},"Race":{"text":[["While"]],"start":[["0"]],"entity_id":[["T0"]]}}}]}
{"id": "7272895_1","context": "A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, sensori-neural hearing loss after vincristine therapy","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["two episodes of severe, bilateral, sensori-neural hearing loss"]],"start": [["22"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 73-year-old woman"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["73"]],"start": [["5"]],"entity_id": [["A1"]]},"Disorder": {"text": [["non-Hodgkin's lymphoma"]],"start": [["33"]],"entity_id": [["T3"]]},"Population": {"text": [["two episodes"]],"start": [["22"]],"entity_id": [["P1"]]},"Race": {"text": [["A 73-year-old woman"]],"start": [["0"]],"entity_id": [["R1"]]},"Gender": {"text": [["A 73-year-old woman"]],"start": [["0"]],"entity_id": [["G1"]]}},"Treatment": {"text": [["vincristine therapy"]],"start": [["114"]],"entity_id": [["T4"]],"Drug": {"text": [["vincristine"]],"start": [["114"]],"entity_id": [["D1"]]},"Route": {"text": [["vincristine therapy"]],"start": [["114"]],"entity_id": [["R2"]]},"Time_elapsed": {"text": [["two episodes"]],"start": [["22"]],"entity_id": [["T2"]]},"Freq": {"text": [["two episodes"]],"start": [["22"]],"entity_id": [["F1"]]},"Dosage": {"text": [["vincristine therapy"]],"start": [["114"]],"entity_id": [["D2"]]},"Duration": {"text": [["therapy"]],"start": [["114"]],"entity_id": [["D3"]]},"Disorder": {"text": [["non-Hodgkin's lymphoma"]],"start": [["33"]],"entity_id": [["D4"]]},"Combination": [],"Trigger": {"text": [["after"]],"start": [["107"]],"entity_id": [["T5"]]}},"Severity": {"text": [["severe"]],"start": [["22"]],"entity_id": [["S1"]],"value":"High"},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Effect": {"text": [["severe, bilateral, sensori-neural hearing loss"]],"start": [["22"]],"entity_id": [["E1"]]}}]}
{"id": "2746565_2","context": "Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ulcerative proctitis"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["juvenile systemic lupus erythematosus"]],"start": [["22"]],"entity_id": [ ["T2"] ], "Disorder": { "text": [["Ulcerative proctitis"]], "start": [[ "0" ]] ,"entity_id": [ ["T1" ]] }, "Age": null, "Gender": null, "Population": null, "Race": null },"Treatment": {"text": [["ibuprofen treatment"]],"start": [["66"]],"entity_id": [ ["T3"] ], "Drug": { "text": [["ibuprofen"]], "start": [[ "66" ]] ,"entity_id": [ ["T4" ]] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Disorder": { "text": [["Ulcerative proctitis"]], "start": [[ "0" ]] ,"entity_id": [ ["T1" ]] }, "Combination": null }, "Effect": { "text": [["Ulcerative proctitis"]], "start": [[ "0" ]] ,"entity_id": [ ["T1" ]] }, "Negated": null, "Speculated": null, "Severity": null }] }
{"id": "9161656_1", "context": "Acute asthma associated with sustained-release verapamil", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute asthma"]], "start": [[ ]] , "entity_id": [ ]}, "Treatment": {"text": [["sustained-release verapamil"]], "start": [[ ]] , "entity_id": [ ], "Drug": {"text": [["verapamil"]], "start": [[ ]] , "entity_id": [ ] } ,"Disorder": { "text": [["acute asthma"]], "start": [[ ]] ,"entity_id": [ ]} ,"Route": { "text": [["sustained-release"]], "start": [[ ]] ,"entity_id": [ ]} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Freq": null ,"Combination": null ,"Trigger": null }, "Subject": { "text": [["patient"]], "start": [[ ]] ,"entity_id": [ ], "Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "8749646_3","context": "The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["renal insufficiency"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["three patients"]],"start": [[ "18"]],"entity_id": [ ["T2"]],"Population": {"text": [["three patients"]],"start": [[ "18"]],"entity_id": [ ["T2"]]} ,"Disorder": {"text": [["renal insufficiency"]],"start": [[ "0"]],"entity_id": [ ["T1"]]} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []}}, "Treatment": {"text": [["ofloxacin"]],"start": [[ "82"]],"entity_id": [ ["T3"]],"Drug": {"text": [["ofloxacin"]],"start": [[ "82"]],"entity_id": [ ["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["renal insufficiency"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["the timing of the seizures"]],"start": [[ "41"]],"entity_id": [ ["T4"]]},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["accumulation"]],"start": [[ "52"]],"entity_id": [ ["T5"]]}} ,"Effect": {"text": [["contributing factor"]],"start": [[ "94"]],"entity_id": [ ["T6"]]} ,"Severity": null ,"Negated": null ,"Speculated": null} ]}
{"id": "15878975_1","context": "A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute hemoglobinemia", "hemoglobinuria"]],"start": [["34", "47"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"text": [["anti-D IGIV administration"]],"start": [["79"]],"entity_id": [["T3"]],"Drug": {"text": [["anti-D"]],"start": [["79"]],"entity_id": [["T4"]]},"Route": {"text": [["administration"]],"start": [["79"]],"entity_id": [["T5"]]},"Disorder": {"text": [["ITP or secondary thrombocytopenia"]],"start": [["101"]],"entity_id": [["T6"]]},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Freq": {"text": [[]],"start": [],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [],"entity_id": []},"Trigger": {"text": [[]],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["15 patients"]],"start": [["1"]],"entity_id": [["T7"]],"Age": null,"Disorder": {"text": [["ITP or secondary thrombocytopenia"]],"start": [["101"]],"entity_id": [["T6"]]},"Gender": null,"Population": {"text": [["15 patients"]],"start": [["1"]],"entity_id": [["T7"]]},"Race": null},"Effect": {"text": [["acute hemoglobinemia or hemoglobinuria"]],"start": [["34", "47"]],"entity_id": [["T1"],["T2"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "2042691_1","context": "Amiodarone was discontinued, and thyrotoxicosis gradually abated","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Amiodarone"]],"start": [[ "0" ]],"entity_id": [ ["T1" ] ] },"Disorder": {"text": [["thyrotoxicosis"]],"start": [[ "42" ]],"entity_id": [ ["T2" ] ] },"Trigger": { "text": [["discontinued"]], "start": [[ "8" ]], "entity_id": [ ["T3" ] ] }, "entity_id": [ ["T1" ] ] ,"text": [["Amiodarone"]], "start": [[ "0" ]], "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Combination": null }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Disorder": null, "Race": null }, "Effect": { "text": [["thyrotoxicosis"]], "start": [[ "42" ]], "entity_id": [ ["T2" ] ] }, "Trigger": { "text": [["gradually abated"]], "start": [[ "20" ]], "entity_id": [ ["T4" ] ] }} ]}
{"id": "19183077_1", "context": "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["nephrotoxicity"]], "start": [["Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["Tenofovir"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "0" ]], "entity_id": [ ["T2"] ], "Drug": null , "Disorder": {"text": [["HIV-infected"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "17" ]], "entity_id": [ ["T3"] ]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null , "Trigger": null } , "Subject": { "text": [["two HIV-infected adolescent males"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "30" ]], "entity_id": [ ["T5"] ], "Age": null, "Gender": { "text": [["males"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "44" ]], "entity_id": [ ["T6"] ] }, "Population": null, "Race": null, "Disorder": { "text": [["HIV-infected"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "17" ]], "entity_id": [ ["T3"] ]} } , "Effect": { "text": [["nephrotoxicity"]], "start": [[ "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males" , "11" ]], "entity_id": [ ["T4"] ]} , "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "17965530_1","context": "Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["colonic perforation"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the administration of calcium polystyrene sulfonate and sorbitol"]],"start": [["63"]],"entity_id": [["T2"]],"Drug": {"text": [["calcium polystyrene sulfonate", "sorbitol"]],"start": [["63"]],"entity_id": [["T3","T4"]]} ,"Disorder": {"text": [["colonic perforation"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["rare"]],"start": [["106"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["calcium polystyrene sulfonate"]],"start": [["63"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["80"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["the administration"]],"start": [["63"]],"entity_id": [["T2"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} } ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []} } ] }
{"id": "8749646_1","context": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["neurotoxic effects"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ofloxacin"]],"start": [["43"]],"entity_id": [["T2"]] ,"Drug": {"text": [["ofloxacin"]],"start": [["43"]],"entity_id": [["T2"]]},"Disorder": {"text": [["neurotoxic effects"]],"start": [["18"]],"entity_id": [["T1"]]},"Freq": {"text": [["enhance its safe use"]],"start": [["52"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["ofloxacin"]],"start": [["43"]],"entity_id": [["T2"]]},"Trigger": {"text": [["neurotoxic effects"]],"start": [["18"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]},"Trigger": {"text": [["awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]},"Route": {"text": [["use"]],"start": [["64"]],"entity_id": [["T3"]]},"Dosage": {"text": [["enhance its safe use"]],"start": [["52"]],"entity_id": [["T3"]]},"Duration": {"text": [["awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]}},"Subject": {"text": [["Improved awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]],"Population": {"text": [["enhance its safe use"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Improved awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]},"Gender": {"text": [["Improved awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]},"Age": {"text": [["Improved awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]},"Race": {"text": [["Improved awareness of and further investigation into"]],"start": [["0"]],"entity_id": [["T4"]]}},"Effect": {"text": [["enhance its safe use"]],"start": [["52"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["neurotoxic effects"]],"start": [["18"]],"entity_id": [["T1"]],"value": "low"}}]}
{"id": "12013364_2", "context": "Atypical neuroleptic malignant syndrome associated with olanzapine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Atypical neuroleptic malignant syndrome"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["olanzapine"]], "start": [[ ]], "entity_id": [],"Drug": {"text": [["olanzapine"]], "start": [[ ]], "entity_id": []},"Disorder": {"text": [["neuroleptic malignant syndrome"]], "start": [[ ]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Trigger": null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "1495728_4", "context": "We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy, but suggest that it be used with caution in view of possible systemic toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["methotrexate"]], "start": [["22"]], "entity_id": [],"Drug": {"text": [["methotrexate"]], "start": [["22"]], "entity_id": []},"Disorder":{"text":[["surgery"]], "start":[["64"]], "entity_id":[]},"Dosage":{"text":[["a relatively effective"]], "start":[["22"]], "entity_id":[]},"Duration":{"text":[["alternative"]], "start":[["34"]], "entity_id":[]},"Trigger":{"text":[["represents"]], "start":[["30"]], "entity_id":[]},"Freq":{"text":[["caution"]], "start":[["95"]], "entity_id":[]},"Time_elapsed":{"text":[["in view of possible systemic toxicity"]], "start":[["88"]], "entity_id":[]},"Route":{"text":[], "start":[], "entity_id":[]},"Combination":[{"Drug":{"text":[["methotrexate"]], "start":[["22"]], "entity_id":[]},"Trigger":{"text":[["and"]], "start":[["107"]], "entity_id":[]},"event_type":"Adverse_event","event_id":"E2"}]},"Subject":{"Age":{"text":[], "start":[], "entity_id":[]},"Gender":{"text":[], "start":[], "entity_id":[]},"Population":{"text":[["patients"]], "start":[["59"]], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]},"Disorder":{"text":[["early unruptured tubal pregnancy"]], "start":[["67"]], "entity_id":[]},"text":[["We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy, but suggest that it be used with caution in view of possible systemic toxicity"]],"start":[[],[],[],[],[]],"entity_id":[]},"Effect":{"text":[["effective"]], "start":[["22"]], "entity_id":[]},"Trigger":{"text":[["alternative"]], "start":[["34"]], "entity_id":[]},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[["believe"]], "start":[["0"]], "entity_id":[],"value":false},"Severity":{"text":[["possible systemic toxicity"]], "start":[["88"]], "entity_id":[],"value":"low"}}]}
{"id": "1775411_2","context": "Pulmonary fibrosis associated with nabumetone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pulmonary fibrosis"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["nabumetone"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["nabumetone"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["Pulmonary fibrosis"]],"start": [[ ]],"entity_id": [["T1"]]} ,"Freq": null,"Combination": null ,"Trigger": null },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "19660974_2", "context": "The ability of tumor necrosis factor (TNF)-alpha inhibitors to impair pivotal pro-inflammatory host defenses may facilitate the development of disseminated cryptococcosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [["3","8"]], "entity_id": [],"Drug": { "text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [["3","8"]], "entity_id": [] },"Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["impair"]], "start": [["37"]], "entity_id": [] }}, "Effect": { "text": [["disseminated cryptococcosis"]], "start": [["130"]], "entity_id": [] },"Trigger": { "text": [["development"]], "start": [["116"]], "entity_id": [] }} ]}
{"id": "6529939_4","context": "This was accepted as evidence for propranolol being the cause of this conduction disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["propranolol"]],"start": [["25"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["this conduction disorder"]],"start": [["64"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["being the cause"]],"start": [["44"]],"entity_id": [["T3"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Drug": {"text": [["propranolol"]],"start": [["25"]],"entity_id": [["T1"]]} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Subject": null ,"Trigger": {"text": [["being the cause"]],"start": [["44"]],"entity_id": [["T3"]]} }]}
{"id": "1517501_4","context": "We report a third case of a 6-week-old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["TEN"]],"start": [["61"]],"entity_id": [["T7"]]},"Subject": {"text": [["a 6-week-old infant"]],"start": [["9"]],"entity_id": [["T1"]],"Age": {"text": [["6-week-old"]],"start": [["9"]],"entity_id": [["A1"]]},"Disorder": {"text": [["Escherichia coli sepsis"]],"start": [["21"]],"entity_id": [["T2"]]},"Gender": {"text": [["infant"]],"start": [["9"]],"entity_id": [["G1"]]},"Race": {"text": [["infant"]],"start": [["9"]],"entity_id": [["R1"]]},"Population": {"text": [["a"]],"start": [["9"]],"entity_id": [["P1"]]}},"Treatment": {"text": [["ampicillin"]],"start": [["51"]],"entity_id": [["T3"]],"Drug": {"text": [["ampicillin"]],"start": [["51"]],"entity_id": [["D1"]]},"Disorder": {"text": [["antibiotics"]],"start": [["57"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["received"]],"start": [["44"]],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18379937_2", "context": "To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bilateral anterior uveitis"]], "start": [["13"]], "entity_id":[ ]},"Treatment": {"text": [["ovulation induction therapy using clomiphene citrate"]], "start": [["41"]], "entity_id": [ ],"Drug": {"text": [["clomiphene citrate"]], "start": [["56"]], "entity_id": [ ]} , "Disorder" :{"text":[["bilateral anterior uveitis"]], "start":[[ "13"]], "entity_id":[]} , "Time_elapsed" :{"text":[["associated with"]], "start":[[ "22"]], "entity_id":[]} , "Trigger" :{"text":[["ovulation induction therapy"]], "start":[[ "41"]], "entity_id":[]} , "Route" :{"text":[["using"]], "start":[[ "48"]], "entity_id":[]} , "Combination" :[{"Drug":{"text":[["clomiphene citrate"]], "start":[["56"]], "entity_id":[]},"Trigger":{"text":[["ovulation induction therapy"]], "start":[["41"]], "entity_id":[]},"event_type":"Treatment" , "event_id":"C1"}] , "Freq" :{"text":[["using"]], "start":[[ "48"]], "entity_id":[]} , "Duration" :{"text":[["report a case"]], "start":[[ "0"]], "entity_id":[]} , "Dosage" :{"text":[[]], "start":[[]], "entity_id":[]} } , "Subject" :{"text":[["To report"]], "start":[["0"]], "entity_id":[],"Age":{"text":[[]], "start":[[]], "entity_id":[]},"Gender":{"text":[[]], "start":[[]], "entity_id":[]},"Population":{"text":[[]], "start":[[]], "entity_id":[]},"Race":{"text":[[]], "start":[[]], "entity_id":[]},"Disorder":{"text":[["bilateral anterior uveitis"]], "start":[[ "13"]], "entity_id":[]}} , "Effect" :{"text":[["report a case"]], "start":[[ "0"]], "entity_id":[]} , "Negated" :{"text":[[]], "start":[[]], "entity_id":[],"value":false} , "Speculated" :{"text":[[]], "start":[[]], "entity_id":[],"value":false} , "Severity" :{"text":[[]], "start":[[]], "entity_id":[],"value":"Low"} } ]}
{"id": "2979256_1", "context": "A 57-year-old woman presented with a 3-week history of dysphagia for solids, 6 months after starting treatment with nifedipine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["presented"]], "start": [["0"]], "entity_id": []}, "Subject": {"text": [["A 57-year-old woman"]], "start": [[],[]], "entity_id": [],"Age":{"text":[["57"]],"start":[[],[]],"entity_id":[]},"Gender":{"text":[["woman"]],"start":[[],[]],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}, "Treatment": {"text": [["nifedipine"]], "start": [["98"]], "entity_id": [],"Drug":{"text":[["nifedipine"]],"start":[[],[]],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null}, "Effect":{"text":[["dysphagia for solids"]],"start":[[],[]],"entity_id":[]}, "Negated":null,"Speculated":null,"Severity":null}]}
{"id": "2728526_2","context": "Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe adverse effects"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Rifampin"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["Rifampin"]],"start": [["41"]],"entity_id": [["T3"]]},"Disorder": {"text": [["adverse effects"]],"start": [["18"]],"entity_id": [["T4"]]},"Dosage": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Route": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Time_elapsed": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Freq": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Combination": null,"Trigger": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]}},"Effect": {"text": [["hepatitis","acute renal failure","hemolytic anemia","thrombocytopenia"]],"start": [["66","75","90","101"]],"entity_id": [["T5","T6","T7","T8"]]},"Negated": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]],"value": false},"Severity": {"text": [["severe"]],"start": [["21"]],"entity_id": [["T9"]],"value": "high"},"Subject": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]],"Age": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Disorder": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Population": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [["null"]],"entity_id": [["null"]]}}}]}
{"id": "2051906_2","context": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["azathioprine"]],"start": [["22"]],"entity_id": [["T1"]]},"entity_id": [["T1"]],"text": [["azathioprine-induced cholestasis"]],"start": [["22"]],"Trigger": {"text": [["cholestasis"]],"start": [["40"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["associated with histological evidence"]],"start": [["53"]],"entity_id": [["T3"]]},"Freq": {"text": [["reversible"]],"start": [["7"]],"entity_id": [["T4"]]},"Disorder": {"text": [["first reported case"]],"start": [["17"]],"entity_id": [["T5"]]},"Dosage": {"text": [["this"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["this"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Route": {"text": [["this"]],"start": [["0"]],"entity_id": [["T6"]]},"Combination": null} ,"Subject": {"Gender": null,"Population": null,"Race": null,"Age": null,"Disorder": null,"text": [["It"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Negated": null,"Speculated": {"text": [["It is believed that"]],"start": [["0"]],"entity_id": [["T8"]],"value": true},"Severity": null ,"Effect": {"text": [["injury"]],"start": [["94"]],"entity_id": [["T9"]]} ,"Trigger": {"text": [["injury"]],"start": [["94"]],"entity_id": [["T9"]]} }]}
{"id": "9554064_4","context": "We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["subacute methanol toxicity"]],"start": [[" "]],"entity_id": [["T1"]]},"Severity": {"value": "high","text": [["fatal"]],"start": [[" "]],"entity_id": [["T2"]]},"Subject": {"text": [["We"]],"start": [[""],[]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["subacute methanol toxicity"]],"start": [[""],[]],"entity_id": [["T1"]]}},"Effect": {"text": [["diffuse brain involvement", "bilateral putaminal necrosis", "cerebral edema with ventricular compression"]],"start": [[" "],[" "],[" "]],"entity_id": [["T3"],["T4"],["T5"]]},"Treatment": null,"Negated": null,"Speculated": null}]}
{"id": "9653495_6","context": "Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days, or FU alone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["FU"]],"start": [["39"]],"entity_id": []},"Disorder": {"text": [["colorectal cancer"]],"start": [["12"]],"entity_id": []},"Dosage": {"text": [["400 mg/m2/day"]],"start": [["40"]],"entity_id": []},"Duration": {"text": [["monthly"]],"start": [["37"]],"entity_id": []},"Route": {"text": [["intravenous push daily for five days"]],"start": [["50"]],"entity_id": []},"Trigger": {"text": [["randomized"]],"start": [["21"]],"entity_id": []},"entity_id": [],"text": [["Patients with inoperable or metastatic colorectal cancer were randomized to receive"]],"start": [["0"]],"Freq": {"text": [["daily for five days"]],"start": [["50"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Patients with inoperable or metastatic colorectal cancer"]],"start": [["0"]],"Age": null,"Gender": null,"Disorder": {"text": [["colorectal cancer"]],"start": [["12"]],"entity_id": []},"Population": null,"Race": null,"entity_id": []},"Trigger": {"text": [["randomized"]],"start": [["21"]],"entity_id": []}}]}
{"id": "9347384_3","context": "The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["clarithromycin coadministration"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clarithromycin coadministration"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["clarithromycin"]],"start": [["0"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["induces"]],"start": [["23"]],"entity_id": [["T3"]]},"Duration": {"text": [["induces"]],"start": [["23"]],"entity_id": [["T3"]]},"Disorder": {"text": [["increased plasma carbamazepine concentrations"]],"start": [["40"]],"entity_id": [["T4"]]},"Freq": {"text": [["induces"]],"start": [["23"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["carbamazepine"]],"start": [["67"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "null"}],"Trigger": {"text": [["increased plasma carbamazepine concentrations"]],"start": [["40"]],"entity_id": [["T4"]]},"Route": {"text": [["administration"]],"start": [["23"]],"entity_id": [["T3"]]},"Dosage": {"text": [["clarithromycin coadministration"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["carbamazepine toxicity"]],"start": [["110"]],"entity_id": [["T6"]]},"Severity": {"text": [["toxicity"]],"start": [["110"]],"entity_id": [["T6"]],"value": "high"},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["N1"]],"value": false},"Speculated": {"text": [["suggests"]],"start": [["0"]],"entity_id": [["S1"]],"value": false},"Subject": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]],"Population": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]]},"Age": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]]},"Race": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]]},"Gender": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]]},"Disorder": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["S2"]]}}}]}
{"id": "16005413_2","context": "To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome (SS), mechanism of the interaction, and the spectrum of SS in elderly residents of a long-term care facility","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["opioids"]],"start": [[ "0" ]],"entity_id": [ ["T1"]],"Drug": {"text": [["opioids"]],"start": [[ "0" ]],"entity_id": [ ["T3"]]},"Trigger": {"text": [["interaction"]],"start": [[ "40" ]],"entity_id": [ ["T4"]]},"Time_elapsed": null,"Freq": null,"Route": null,"Dosage": null,"Duration": null,"Disorder": {"text": [["serotonin syndrome (SS)"]],"start": [[ "45" ]],"entity_id": [ ["T5"]]},"Combination": [{"Drug": {"text": [["serotonergic antidepressants"]],"start": [[ "54" ]],"entity_id": [ ["T6"]]},"Trigger": {"text": [["interaction"]],"start": [[ "40" ]],"entity_id": [ ["T4"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}]},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "480917_2","context": "Erythema multiforme bullosum due to rifampicin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Erythema multiforme bullosum"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rifampicin"]],"start": [["53"]],"entity_id": [["T2"]],"Drug": {"text": [["rifampicin"]],"start": [["53"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["Erythema multiforme bullosum"]],"start": [["0"]],"entity_id": [["T1"]] },"Time_elapsed": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] },"Freq": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] },"Duration": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] },"Dosage": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] },"Route": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] },"Combination": null ,"Trigger": {"text": [["due"]],"start": [["27"]],"entity_id": [["T3"]] }} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low" },"Effect": {"text": [["Erythema multiforme bullosum"]],"start": [["0"]],"entity_id": [["T1"]] }} ]}
{"id": "1509179_3","context": "This profile should trigger a 'red flag' as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["phenobarbital behavioral side effects"]],"start": [["38"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [["phenobarbital behavioral side effects"]],"start": [["38"]],"entity_id": [["T1"]]},"Effect": {"text": [["phenobarbital behavioral side effects"]],"start": [["38"]],"entity_id": [["T1"]]},"Subject": {"text": [["This profile"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["phenobarbital"]],"start": [["23"]],"entity_id": [["T2"]],"Drug": {"text": [["phenobarbital"]],"start": [["23"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Speculated": {"value": true,"text": [["This profile should trigger a 'red flag' as to the possibility"]],"start": [["0"]],"entity_id": [["T0"]]},"Severity": {"value": "low","text": [],"start": [],"entity_id": []}}]}
{"id": "12581772_2","context": "Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pneumonitis"]],"start": [["12","19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Rapamycin/sirolimus"]],"start": [["0","7"]],"entity_id": [["T2"]],"Drug": {"text": [["Rapamycin","sirolimus"]],"start": [["0","7"]],"entity_id": [["T3","T4"]]} ,"Disorder": {"text": [["pneumonitis"]],"start": [["12","19"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["that reversed after ceasing SR therapy"]],"start": [["59"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["this report"]],"start": [["31","38"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["previously"]],"start": [["12"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["Rapamycin","sirolimus"]],"start": [["0","7"]],"entity_id": [["T3","T4"]]},"Trigger": {"text": [["induced"]],"start": [["8","11"]],"entity_id": [["T7"]]} ,"event_id": "E1-1","event_type": "Adverse_event"}] ,"Route": {"text": [["therapy"]],"start": [["43","47"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [["SR"]],"start": [["48","49"]],"entity_id": [["T9"]]} ,"Duration": {"text": [["developed"]],"start": [["40"]],"entity_id": [["T10"]]} },"Subject": {"text": [["a stable heart-lung transplant recipient"]],"start": [["21","40"]],"entity_id": [["T11"]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Population": {"text": [["a"]],"start": [["21"]],"entity_id": [["T11"]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Disorder": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]} },"Severity": {"text": [[]],"start": [[],[]],"entity_id": [[],[]] ,"value": "low" },"Negated": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"value": false },"Speculated": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"value": false },"Effect": {"text": [["a pulmonary infiltrate"]],"start": [["50","62"]],"entity_id": [["T12"]] }} ]}
{"id": "19104709_1", "context": "IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["IFNalpha"]], "start": [["0"]], "entity_id": [ ["S1"]],"Disorder": {"text": [["Graves' disease"]], "start": [["19"]], "entity_id": [ ["S2"]]},"Age": {"text": [["ten years"]], "start": [["40"]], "entity_id": [ ["S3"]]},"Gender": null,"Population": null,"Race": null},"Treatment": null,"Effect": {"text": [["recurrence"]], "start": [["21"]], "entity_id": [ ["E1"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "11918514_4","context": "Severe serotonin syndrome induced by mirtazapine monotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe serotonin syndrome"]],"start": [[ ],["Severe serotonin syndrome"],["induced by"],["mirtazapine monotherapy"]],"entity_id": [["T1"],["T2"],["T3"],["T4"]]},"Treatment": {"text": [["mirtazapine monotherapy"]],"start": [["induced by"],["mirtazapine monotherapy"]],"entity_id": [["T3"],["T4"]],"Drug": {"text": [["mirtazapine"]],"start": [["induced by"],["mirtazapine monotherapy"]],"entity_id": [["T3"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["Severe serotonin syndrome"],["induced by"]],"entity_id": [["T1"]]},"Duration": {"text": [["monotherapy"]],"start": [["mirtazapine monotherapy"]],"entity_id": [["T4"]]},"Route": {"text": [["monotherapy"]],"start": [["mirtazapine monotherapy"]],"entity_id": [["T4"]]},"Dosage": {"text": [["mirtazapine"]],"start": [["mirtazapine monotherapy"]],"entity_id": [["T3"]]},"Freq": {"text": [["monotherapy"]],"start": [["mirtazapine monotherapy"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["induced by"]],"start": [["induced by"]],"entity_id": [["T3"]]},"Combination": null,"Trigger": {"text": [["induced by"]],"start": [["induced by"]],"entity_id": [["T3"]]}},"Effect": {"text": [["Severe serotonin syndrome"]],"start": [["Severe serotonin syndrome"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["Severe"]],"start": [["Severe serotonin syndrome"]],"entity_id": [["T1"]],"value": "High"},"Subject": {"text": [["Severe serotonin syndrome induced"]],"start": [["Severe serotonin syndrome"],["induced by"]],"entity_id": [["T1"],["T3"]],"Age": null,"Gender": null,"Disorder": null,"Population": null,"Race": null}}]}
{"id": "7854541_3","context": "Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["leukoencephalopathy"]],"start": [[ ]] , "entity_id": [["T1"]]},"Treatment": {"text": [["5-fluorouracil and levamisole"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["5-fluorouracil"]],"start": [[ ]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"event_type": "Adverse_event","event_id": "C1","Drug": {"text": [["levamisole"]],"start": [[ ]],"entity_id": [["T4"]]},"Trigger": {"text": [],"start": [],"entity_id": []}}],"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": true},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "10589077_6","context": "We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Subject": {"text": [["five patients"]],"start": [["21"]],"entity_id": [["S1"]] ,"Population": {"text": [["five patients"]],"start": [["21"]],"entity_id": [["S1"]]} ,"Disorder": {"text": [["thalassemia intermedia"]],"start": [["46"]],"entity_id": [["S2"]]} ,"Age": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A1"],["A2"]]} ,"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A3"],["A4"]]} ,"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A5"],["A6"]]}},"Treatment": {"text": [["HU alone or in combination with SPB"]],"start": [["82"]],"entity_id": [["T1"]],"Drug": {"text": [["HU"]],"start": [["82"]],"entity_id": [["T2"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A7"],["A8"]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A9"],["A10"]]},"Route": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A11"],["A12"]]},"Time_elapsed": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A13"],["A14"]]},"Freq": {"text": [[""]],"start": [[""],[""]],"entity_id": [["A15"],["A16"]]},"Combination": [{"Drug": {"text": [["HU"]],"start": [["82"]],"entity_id": [["T2"]]},"Trigger": {"text": [["alone"]],"start": [["87"]],"entity_id": [["T3"]]},"event_id": "E2" ,"event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["SPB"]],"start": [["94"]],"entity_id": [["T4"]]},"Trigger": {"text": [["in combination"]],"start": [["90"]],"entity_id": [["T5"]]},"event_id": "E3" ,"event_type": "Potential_therapeutic_effect"}] ,"Trigger": {"text": [["clinical response"]],"start": [["15"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["thalassemia intermedia"]],"start": [["46"]],"entity_id": [["S2"]]} },"Effect": {"text": [["increases in total Hb and decreased transfusion needs"]],"start": [["54"]],"entity_id": [["E2"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["clinical response"]],"start": [["15"]],"entity_id": [["T6"]]} }]}
{"id": "19299370_1","context": "According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse-reaction"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["enoxaparin"]],"start": [["57"]],"entity_id": [["T2"]] ,"Drug": {"text": [["enoxaparin"]],"start": [["57"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["hepatotoxicity"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["probable cause"]],"start": [["45"]],"entity_id": [["T5"]]} ,"Combination": null ,"Freq": null ,"Dosage": null ,"Duration": null ,"Route": null ,"Trigger": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": {"text": [["this patient"]],"start": [["97"]],"entity_id": [["T6"]],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }} ]}
{"id": "2781955_2","context": "Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["thionamide"]],"start": [["16"]],"entity_id": [["T1"]] ,"Trigger": {"text": [["ineffective"]],"start": [["81"]],"entity_id": [["T3"]] },"Disorder": {"text": [["amiodarone-induced thyrotoxicosis"]],"start": [["0"]],"entity_id": [["T2"]] },"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Drug": null },"Subject": null ,"Effect": null ,"Negated": {"text": [["ineffective"]],"start": [["81"]],"entity_id": [["T3"]],"value": true },"Speculated": null,"Severity": null ,"Trigger": null }]}
{"id": "2292051_2","context": "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute coronary ischemia/infarction"]],"start": [[ ]], "entity_id": [["T1"]]},"Subject": {"text": [["Six patients"]],"start": [[ ]], "entity_id": [["T2"]],"Age": null,"Gender": null,"Population": {"text": [["Six patients"]],"start": [[ ]], "entity_id": [["T2"]]},"Race": null,"Disorder": {"text": [["no previous signs or symptoms suggestive of coronary artery disease"]],"start": [[ ]], "entity_id": [["T3"]]}},"Treatment": {"text": [["cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy"]],"start": [[ ]], "entity_id": [["T4"]],"Drug": {"text": [["cisplatin"]],"start": [[ ]], "entity_id": [["T5"]]},"Disorder": {"text": [["coronary artery disease"]],"start": [[ ]], "entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": {"text": [["shortly after"]],"start": [[ ]], "entity_id": [["T7"]]},"Freq": null ,"Combination": null ,"Trigger" : null }, "Effect" : { "text": [["acute coronary ischemia/infarction"]],"start": [[ ]], "entity_id": [["T1"]]} ,"Negated" : null ,"Speculated" : null ,"Severity" : null }]}
{"id": "1879988_3","context": "After the first oral dose of propranolol, syncope developed together with atrioventricular block","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["syncope"]],"start": [["After the first oral dose of propranolol," , "developed together with atrioventricular block."] ],"entity_id": []},"Treatment": {"text": [["propranolol"]],"start": [[ "After the first oral dose of" ]],"entity_id": [],"Drug": {"text": [["propranolol"]],"start": [[ "After the first oral dose of" ]],"entity_id": []},"Disorder": {"text": [["syncope"]],"start": [[ "syncope" ]],"entity_id": []} ,"Time_elapsed": {"text": [["the first oral dose"]],"start": [[ "After" ]],"entity_id": []} ,"Trigger": {"text": [["developed together with atrioventricular block."]],"start": [[ "developed together with atrioventricular block." ]],"entity_id": []} ,"Route": {"text": [["oral"]],"start": [[ "After the first oral dose of" ]],"entity_id": []} ,"Dosage": {"text": [["the first dose"]],"start": [[ "After the first oral dose of" ]],"entity_id": []} ,"Freq": {"text": [["first"]],"start": [[ "After the first oral dose of" ]],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [["syncope"]],"start": [[ "syncope" ]],"entity_id": []} }]}
{"id": "19764104_2","context": "Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tumor lysis syndrome"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Sorafenib"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["Sorafenib"]],"start": [["5"]],"entity_id": [["T2"]]},"Disorder": {"text": [["advanced hepatocellular carcinoma"]],"start": [["48"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["induced"]],"start": [["19"]],"entity_id": [["T4"]]},"Trigger": null,"Freq": null,"Route": null,"Dosage": null,"Duration": null,"Combination": null},"Subject": {"text": [["a patient"]],"start": [["70"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["advanced hepatocellular carcinoma"]],"start": [["48"]],"entity_id": [["T3"]]}},"Effect": null,"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "10660641_9","context": "The symptoms did not recur during the 36 months of itraconazole treatment after discharge, and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["itraconazole treatment"]],"start": [[ "36" ]],"entity_id": [ ] ,"Dosage": {"text": [["36 months"]],"start": [[ "0" ]],"entity_id": [ ] } ,"Trigger": {"text": [["after discharge"]],"start": [[ "48" ]],"entity_id": [ ] } ,"Disorder": {"text": [["A. flavus hypertrophic pachymeningitis"]],"start": [[ "77" ]],"entity_id": [ ] } ,"Time_elapsed": {"text": [["after discharge"]],"start": [[ "48" ]],"entity_id": [ ] } ,"Freq": {"text": [["during"]],"start": [[ "6" ]],"entity_id": [ ] } ,"Route": {"text": [["of"]],"start": [[ "23" ]],"entity_id": [ ] } ,"Combination": [{"Drug": {"text": [["itraconazole"]],"start": [[ "9" ]],"entity_id": [ ] },"Trigger": {"text": [["treatment"]],"start": [[ "36" ]],"entity_id": [ ] } ,"event_id": "C1","event_type": "null"}] ,"Duration": {"text": [["36 months"]],"start": [[ "0" ]],"entity_id": [ ] } ,"Drug": {"text": [["itraconazole"]],"start": [[ "9" ]],"entity_id": [ ] } },"Effect": {"text": [["effective"]],"start": [[ "104" ]],"entity_id": [ ] },"Negated": {"value": false ,"text": [["did not recur"]],"start": [[ "6" ]],"entity_id": [ ] } ,"Speculated": {"value": false ,"text": [["it was concluded"]],"start": [[ "87" ]],"entity_id": [ ] } ,"Severity": {"value": "null" ,"text": [ ],"start": [],"entity_id": [] } ,"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["A. flavus hypertrophic pachymeningitis"]],"start": [[ "77" ]],"entity_id": [ ] }} ,"Trigger": {"text": [["effective"]],"start": [[ "104" ]],"entity_id": [ ] } }]}
{"id": "14679124_3", "context": "A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["tamoxifen to chemotherapy"]], "start": [["52","59"]], "entity_id": [],"Drug": {"text": [["tamoxifen"]], "start": [["52","56"]], "entity_id": []},"Disorder": {"text": [["chemotherapy"]], "start": [["57","65"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": []}, "Effect": { "text": [["improved clinical benefit"]], "start": [["84","101"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": { "text": [["postmenopausal patients"]], "start": [["104","117"]], "entity_id": [],"Age": null,"Gender": {"text": [["patients"]], "start": [["114","117"]], "entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [["breast cancer"]], "start": [["77","88"]], "entity_id": []}},"Trigger": null}] }
{"id": "11328247_2", "context": "Increased libido in a woman treated with fluvoxamine: a case report", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["increased libido"]], "start": [["0"]], "entity_id": []},"Treatment": {"text": [["fluvoxamine"]], "start": [["45"]], "entity_id": [],"Drug": {"text": [["fluvoxamine"]], "start": [["45"]], "entity_id": []},"Disorder": {"text": [["treatment"]], "start": [["20"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null, "Trigger": null}, "Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a woman"]], "start": [["12"]], "entity_id": [],"Age": null,"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [["woman"]], "start": [["12"]], "entity_id": []},"Population": null,"Race": null}}]}
{"id": "2935070_3","context": "In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute interstitial nephritis", "renal failure", "exfoliative dermatitis"]],"start": [[ ], [], []],"entity_id": [["T1"],["T2"],["T3"]]},"Treatment": {"text": [["ampicillin therapy"]],"start": [[ ]],"entity_id": [["T4"]],"Drug": {"text": [["ampicillin"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["acute interstitial nephritis", "renal failure"]],"start": [[ ], []],"entity_id": [["T1"],["T2"]]} ,"Time_elapsed": {"text": [["following"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Freq": {"text": [["acute"]],"start": [[ ]],"entity_id": [["T7"]]} ,"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T8"]]} ,"Dosage": {"text": [[]],"start": [[ ]],"entity_id": [[]]} ,"Duration": {"text": [[]],"start": [[ ]],"entity_id": [[]]} ,"Combination": null ,"Trigger": {"text": [["following"]],"start": [[ ]],"entity_id": [["T6"]]} },"Severity": {"text": [["acute interstitial nephritis", "renal failure", "exfoliative dermatitis"]],"start": [[ ], [], []],"entity_id": [["T1"],["T2"],["T3"]] ,"value": "high"} ,"Negated": null,"Speculated": null ,"Subject": {"text": [["a patient"]],"start": [[ ]],"entity_id": [["T9"]],"Age": {"text": [[]],"start": [[ ]],"entity_id": [[]]} ,"Disorder": {"text": [],"start": [[ ]],"entity_id": []} ,"Gender": {"text": [[]],"start": [[ ]],"entity_id": [[]]} ,"Race": {"text": [[]],"start": [[ ]],"entity_id": [[]]} ,"Population": {"text": [[]],"start": [[ ]],"entity_id": [[]]} },"Effect": {"text": [["developed"]],"start": [[ ]],"entity_id": [["T10"]]} }]}
{"id": "16623611_3","context": "The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted. Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["weight-loss clinic"]],"start": [[ ], ["weight-loss clinic"]] ,"entity_id": [["T1"]],"Disorder": {"text": [["diabetes medications"]],"start": [[ ], ["diabetes medications"]] ,"entity_id": [["T2"]]},"Trigger": {"text": [["adjusted"]],"start": [[ ], ["adjusted"]] ,"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Drug": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["discontinued"]],"start": [[ ], ["discontinued"]] ,"entity_id": [["T4"]]}},{"event_id": "E2","event_type": "Adverse_event","Treatment": {"text": [["olanzapine"]],"start": [[ ], ["olanzapine"]] ,"entity_id": [["T5"]],"Disorder": {"text": [["weight gain"]],"start": [[ ], ["weight gain"]] ,"entity_id": [["T6"]]},"Trigger": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Drug": null},"Effect": {"text": [["uncontrolled diabetes"]],"start": [[ ], ["uncontrolled diabetes"]] ,"entity_id": [["T7"]]},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "16176119_2", "context": "Gefitinib (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has been approved in several countries for the treatment of advanced non-small-cell lung cancer", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Gefitinib"]],"start": [[ "Gefitinib (IRESSA, ZD1839)" , "an epidermal growth factor receptor tyrosine kinase inhibitor" ]],"entity_id": [ ["T1"],["T2"] ],"Drug": {"text": [["Gefitinib"]],"start": [[ "Gefitinib (IRESSA, ZD1839)" ]],"entity_id": [ ["T1"] ]},"Disorder": {"text": [["the treatment of advanced non-small-cell lung cancer"]],"start": [[ "treatment" , "of advanced non-small-cell lung cancer" ]],"entity_id": [ ["T3"] ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [["approved"]], "start": [[ "approved" ]], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null} ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null },"Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null }]}
{"id": "19520277_2","context": "The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["valproate-induced stupor"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Treatment": {"Drug": {"text": [["valproate"]],"start": [["4"]],"entity_id": [["T2"]]} ,"entity_id": [["T3"]],"text": [["valproate"]],"start": [["4"]],"Dosage": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]} ,"Route": {"text": [["oral"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["reported"]],"start": [["0"]],"entity_id": [["T5"]]},"Duration": {"text": [["4-year-old"]],"start": [["5"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["stupor"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["a"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["valproate"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Trigger": {"text": [["reported"]],"start": [["0"]],"entity_id": [["T5"]]} },"Subject": {"text": [["a"]],"start": [["5"]],"entity_id": [["T6"]],"Age": {"text": [["4"]],"start": [["5"]],"entity_id": [["T6"]]} ,"Gender": {"text": [["girl"]],"start": [["7"]],"entity_id": [["T7"]]} ,"Race": {"text": [["reported"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Population": {"text": [["a"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["stupor"]],"start": [["15"]],"entity_id": [["T1"]]} },"Effect": {"text": [["stupor"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["increased fast activity"]],"start": [["60"]],"entity_id": [["T8"]],"value": "medium"} }]}
{"id": "16421117_2", "context": "Prior to surgery, levodopa induced dyskinesia had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["treatment with amantadine"]], "start": [["49"]], "entity_id": [],"Drug": {"text": [["amantadine"]], "start": [["49"]], "entity_id": []},"Dosage": {"text": [["400 mg/day"]], "start": [["59"]], "entity_id": []},"Route": {"text": [["po"]], "start": [["67"]], "entity_id": []},"Trigger": {"text": [["under treatment with amantadine"]], "start": [["49"]], "entity_id": []},"Disorder": {"text": [["levodopa induced dyskinesia"]], "start": [["10"]], "entity_id": []},"Time_elapsed": {"text": [["improved (< or = 50%) prior to surgery"]], "start": [["0"]], "entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Duration": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": {"text": [["all three patients"]], "start": [["77"]], "entity_id": []},"Race": null},"Trigger": null}] }
{"id": "8384030_3","context": "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Foscarnet-induced"]],"start": [["0"]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["Foscarnet"]],"start": [[ "0" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["Foscarnet"]],"start": [[ "0" ]],"entity_id": [ ["T3"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": { "text": [["severe hypomagnesemia", "other electrolyte disorders"]],"start": [[ "16" ]],"entity_id": [ ["T4"] ]} ,"Combination": null ,"Trigger": { "text": [["Foscarnet"]],"start": [[ "0" ]],"entity_id": [ ["T2"] ]} }, "Subject": null, "Negated": null, "Speculated": null, "Severity": { "text": [["severe"]],"start": [[ "16" ]],"entity_id": [ ["T4"] ], "value": "high" }, "Effect": { "text": [["hypomagnesemia"]],"start": [[ "16" ]],"entity_id": [ ["T4"] ]} }] }
{"id": "667809_1", "context": "A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fatal pulmonary fibrosis"]], "start": [["51", "52"]], "entity_id": []}, "Treatment": {"text": [["BCNU therapy"]], "start": [["24", "25"]], "entity_id": [],"Drug": {"text": [["BCNU"]], "start": [["24", "25"]], "entity_id": []},"Disorder": {"text": [["pulmonary fibrosis"]], "start": [["51", "52"]], "entity_id": []},"Time_elapsed": {"text": [["following"]], "start": [["46"]], "entity_id": []},"Freq": {"text": [["a"]], "start": [["4"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["BCNU"]], "start": [["24", "25"]], "entity_id": []}, "Trigger": {"text": [["therapy"]], "start": [["26"]], "entity_id": []},"event_id": "T1","event_type": "Treatment"} ],"Trigger": {"text": [["reported"]], "start": [["6"]], "entity_id": []}, "Route": {"text": [["of"]], "start": [["12"]], "entity_id": []}, "Dosage": {"text": [["a"]], "start": [["4"]], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}},"Subject": { "text": [["a"]], "start": [["4"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["child"]], "start": [["8"]], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []} },"Negated":{"text": [], "start": [], "entity_id": [] ,"value": false},"Speculated":{"text": [], "start": [], "entity_id": [] ,"value": false},"Severity":{"text": [], "start": [], "entity_id": [] ,"value": "fatal"},"Effect": {"text": [["fatal pulmonary fibrosis"]], "start": [["51", "52"]], "entity_id": []}} ]}
{"id": "15729090_3", "context": "A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 64-year-old man"]], "start": [[ "0" ]], "entity_id": [ ],"Age":{"text":[["64"]],"start":[[ "3" ]],"entity_id":[ ]},"Disorder":{"text":[["schizophrenia"]], "start": [[ "22" ]], "entity_id": [ ]},"Gender":{"text":[["man"]], "start": [[ "35" ]], "entity_id": [ ]},"Race":{"text":[ ],"start":[[ ]],"entity_id":[ ]},"Population":{"text":[ ],"start":[[ ]],"entity_id":[ ]}}, "Treatment": {"text": [["higher doses of quetiapine"]], "start": [[ "80" ]], "entity_id": [ ],"Drug":{"text":[["quetiapine"]], "start": [[ "100" ]], "entity_id": [ ]},"Dosage":{"text":[["higher doses"]], "start": [[ "80" ]], "entity_id": [ ]},"Duration":{"text":[ ],"start":[[ ]],"entity_id":[ ]},"Route":{"text":[ ],"start":[[ ]],"entity_id":[ ]},"Time_elapsed":{"text":[ ],"start":[[ ]],"entity_id":[ ]},"Freq":{"text":[ ],"start":[[ ]],"entity_id":[ ]},"Combination":null,"Trigger":{"text":[["myoclonic jerks"]], "start": [[ "40" ]], "entity_id": [ ]},"Disorder":{"text":[ ],"start":[[ ]],"entity_id":[ ]}},"Negated":null,"Speculated":null,"Severity":null,"Trigger":null,"Effect":{"text":[["developed"]], "start": [[ "40" ]], "entity_id": [ ]}}]}
{"id": "15494638_18","context": "The etiology of neurotoxicity in our two patients remains unclear; however, as CAP is rapidly metabolized to 5-FU in patients with normal liver function, it is likely that 5-FU or its active metabolites (fluoro-beta-alanine) were contributing factors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["our two patients"]],"start": [["15","16"]],"entity_id": [["S1"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["neurotoxicity"]],"start": [["0"]],"entity_id": [["S2"]]}},"Treatment": {"text": [["CAP"]],"start": [["44"]],"entity_id": [["T1"]],"Drug": {"text": [["CAP"]],"start": [["44"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Trigger": {"text": [["is rapidly metabolized"]],"start": [["25","26"]],"entity_id": [["T2"]]},"Route": null,"Time_elapsed": null,"Freq": null ,"Disorder": {"text": [["normal liver function"]],"start": [["32","33"]],"entity_id": [["T3"]]} ,"Combination": null},"Effect": {"text": [["5-FU","fluoro-beta-alanine"]],"start": [["69","70"],["84","85"]],"entity_id": [["E1"],["E2"]]} ,"Trigger": null}]}
{"id": "1635565_1","context": "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["gastric-outlet obstruction"]],"start": [["After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."], [ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."], [ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."], [ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."], [ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."]],"entity_id": []},"Treatment": {"text": [["prostaglandin E1"]],"start": [[ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."]],"entity_id": [],"Drug": {"text": [["prostaglandin E1"]],"start": [[ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."]],"entity_id": []},"Disorder": {"text": [["gastric-outlet obstruction"]],"start": [[ "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication."]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Severity": null,"Speculated": null,"Negated": null,"Subject": null}]}
{"id": "10981493_2","context": "A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse central nervous system effects"]],"start": [["31-49"]],"entity_id": [["T1"]]},"Treatment": {"text": [["propafenone"]],"start": [["73-79"]],"entity_id": [["T2"]],"Drug": {"text": [["propafenone"]],"start": [["73-79"]],"entity_id": [["T3"]]},"Disorder": {"text": [["adverse central nervous system effects"]],"start": [["31-49"]],"entity_id": [["T1"]]},"Freq": {"text": [["most common"]],"start": [["80-87"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["propafenone"]],"start": [["73-79"]],"entity_id": [["T3"]]},"Trigger": {"text": [["adverse central nervous system effects"]],"start": [["31-49"]],"entity_id": [["T1"]]},"event_id": "E1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["have been reported"]],"start": [["1-16"]],"entity_id": [["T5"]]},"Trigger": {"text": [["adverse central nervous system effects"]],"start": [["31-49"]],"entity_id": [["T1"]]},"Dosage": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Duration": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Route": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]}},"Negated": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"value": false},"Speculated": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"value": false},"Severity": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"value": ""},"Subject": {"text": [[]],"start": [[],[]],"entity_id": [[],[]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Population": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]},"Disorder": {"text": [[]],"start": [[],[]],"entity_id": [[],[]]}},"Effect": {"text": [["dizziness"]],"start": [["97-103"]],"entity_id": [["T6"]]}}]}
{"id": "1765991_1","context": "Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Induction of systemic lupus erythematosus"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["interferon-gamma"]],"start": [["52"]],"entity_id": [],"Drug": {"text": [["interferon-gamma"]],"start": [["52"]],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["73"]],"entity_id": []},"Freq": {"text": [["induction"]],"start": [["0"]],"entity_id": []},"Combination": [{"Drug": {"text": [["interferon-gamma"]],"start": [["52"]],"entity_id": []},"Trigger": {"text": [["Induction"]],"start": [["0"]],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["by"]],"start": [["51"]],"entity_id": []},"Duration": {"text": [["by"]],"start": [["51"]],"entity_id": []},"Trigger": {"text": [["Induction"]],"start": [["0"]],"entity_id": []},"Route": {"text": [["by"]],"start": [["51"]],"entity_id": []},"Dosage": {"text": [["induction"]],"start": [["0"]],"entity_id": []}},"Subject": {"text": [["a patient"]],"start": [["45"]],"entity_id": [],"Population": {"text": [["a patient"]],"start": [["45"]],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["65"]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["systemic lupus erythematosus"]],"start": [["18"]],"entity_id": [],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["systemic lupus erythematosus"]],"start": [["18"]],"entity_id": []}}]}
{"id": "16997047_2","context": "In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hyponatremia"]],"start": [[ ], ["recurred"], ["switching"], ["mirtazapine"]], "entity_id": []},"Treatment": {"Drug": {"text": [["citalopram"]],"start": [["previously reported"], ["switching"]],"entity_id": []},"text": [["citalopram to mirtazapine"]],"start": [["switching"]],"entity_id": [],"Disorder": {"text": [["hyponatremia"]],"start": [["hyponatremia"]],"entity_id": []},"Time_elapsed": {"text": [["5 months"]],"start": [["recurred"]],"entity_id": []},"Trigger": {"text": [["switching"]],"start": [["switching"]],"entity_id": []},"Route": {"text": [["oral"]],"start": [["believed"]],"entity_id": []},"Freq": {"text": [["once"]],"start": [["recurred"]],"entity_id": []},"Dosage": {"text": [["standard"]],"start": [["believed"]],"entity_id": []},"Duration": {"text": [["chronic"]],"start": [["believed"]],"entity_id": []},"Combination": [{"Drug": {"text": [["citalopram"]],"start": [["previously reported"], ["switching"]],"entity_id": []},"Trigger": {"text": [["switching"]],"start": [["switching"]],"entity_id": []},"event_id": "C1","event_type": "Treatment"},{"Drug": {"text": [["mirtazapine"]],"start": [["switching"]],"entity_id": []},"Trigger": {"text": [["switching"]],"start": [["switching"]],"entity_id": []},"event_id": "C2","event_type": "Treatment"}]},"Effect": {"text": [["hyponatremia"]],"start": [["hyponatremia"]],"entity_id": []},"Negated": null,"Speculated": {"text": [["believed"]],"start": [["believed"]],"entity_id": [],"value": false},"Severity": {"text": [["severe"]],"start": [["recurred"]],"entity_id": [],"value": "severe"},"Subject": {"text": [["patient"]],"start": [["In"]],"entity_id": [],"Age": {"text": [["50"]],"start": [["In"]],"entity_id": []},"Gender": {"text": [["male"]],"start": [["In"]],"entity_id": []},"Population": {"text": [["single"]],"start": [["In"]],"entity_id": []},"Race": {"text": [["Caucasian"]],"start": [["In"]],"entity_id": []},"Disorder": {"text": [["depression"]],"start": [["previously reported"]],"entity_id": []}}}]}
{"id": "16945058_2","context": "This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["a 7-year-old boy"]],"start": [["33"]],"entity_id": [["T1"]],"Age": {"text": [["7-year-old"]],"start": [["33"]],"entity_id": [["T2"]]},"Gender": {"text": [["boy"]],"start": [["36"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute compromise of renal function"]],"start": [["5"]],"entity_id": [["T4"]]},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["the ACE inhibitor lisinopril and the ARB losartan"]],"start": [["69"]],"entity_id": [["T5"]],"Drug": {"text": [["lisinopril"]],"start": [["69"]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["lisinopril"]],"start": [["69"]],"entity_id": [["T6"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C1","event_type": "null"},{"Drug": {"text": [["losartan"]],"start": [["83"]],"entity_id": [["T7"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C2","event_type": "null"}],"Disorder": {"text": [["acute compromise of renal function"]],"start": [["5"]],"entity_id": [["T4"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [["associated with hypotension"]],"start": [["40"]],"entity_id": [["T8"]]}}]}
{"id": "9302445_4","context": "We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["male patient"]],"start": [[" "], [""], []],"entity_id": [] ,"Age": null,"Gender": {"text": [["male"]],"start": [[""], []],"entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [["advanced AIDS"]],"start": [[","]],"entity_id": []}},"Treatment": {"text": [["rhGH therapy"]],"start": [[","]],"entity_id": [] ,"Drug": {"text": [["rhGH"]],"start": [[","]],"entity_id": []},"Disorder": null,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": {"text": [["2 weeks"]],"start": [[","]],"entity_id": []} ,"Freq": null,"Combination": null },"Effect": {"text": [["hypercalcemia"]],"start": [[","]],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null }]}
{"id": "1592841_2","context": "Both patients experienced a previously unreported side effect--falling backward--associated with bupropion use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["previously unreported side effect--falling backward"]],"start": [["23","31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["bupropion use"]],"start": [["76","84"]],"entity_id": [["T2"]],"Drug": {"text": [["bupropion"]],"start": [["76","83"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["falling backward"]],"start": [["23","31"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["Both patients experienced"]],"start": [["0","8"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["experienced"]],"start": [["32","38"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["bupropion"]],"start": [["76","83"]],"entity_id": [["T3"]]},"Trigger": {"text": [["associated with"]],"start": [["85","95"]],"entity_id": [["T5"]]} ,"event_type": "Adverse_event","event_id": "E2"} ],"Dosage": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T6"]]},"Duration": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T7"]]},"Route": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T8"]]} ,"Trigger": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T9"]]}},"Subject": {"text": [["Both patients"]],"start": [[],[]],"entity_id": [["T0"]],"Age": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T10"]]},"Gender": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T11"]]},"Population": {"text": [["Both patients"]],"start": [[],[]],"entity_id": [["T0"]]},"Race": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T12"]]},"Disorder": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T13"]]}},"Effect": {"text": [["falling backward"]],"start": [["23","31"]],"entity_id": [["T1"]]},"Negated": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T14"]] ,"value": false },"Speculated": {"text": [["not mentioned"]],"start": [[],[]],"entity_id": [["T15"]],"value": false },"Severity": {"text": [["previously unreported side effect"]],"start": [["23","38"]],"entity_id": [["T16"]],"value": "medium" }} ]}
{"id": "150825_2","context": "A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["second episode of jaundice"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["furazolidone and nifuroxime"]],"start": [[]],"entity_id": [],"Drug": {"text": [["furazolidone"]],"start": [[]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["intravaginal administration"]],"start": [[]],"entity_id": []},"Route": {"text": [["intravaginal"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"event_id": "C1","Drug": {"text": [["furazolidone"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["furazolidone and nifuroxime"]],"start": [[]],"entity_id": []},"event_type": "Adverse_event"}]},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "18294121_2","context": "Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["erythematous and exfoliative rash"]],"start": [["35", "35"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["temozolomide"]],"start": [["61"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["may be induced"]],"start": [["35"]],"entity_id": [["T3"]]},"entity_id": [["T4"]],"text": [["temozolomide"]],"start": [["61"]],"Dosage": {"text": [["may be induced"]],"start": [["35"]],"entity_id": [["T3"]]},"Route": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T5"]]},"Freq": {"text": [["be familiar"]],"start": [["89"]],"entity_id": [["T6"]]},"Duration": {"text": [["be familiar"]],"start": [["89"]],"entity_id": [["T6"]]},"Disorder": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["temozolomide"]],"start": [["61"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may be induced"]],"start": [["35"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["may be induced"]],"start": [["35"]],"entity_id": [["T3"]]}},"Subject": {"text": [["clinicians"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T5"]]},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "Low","text": [],"start": [],"entity_id": []}}]}
{"id": "9796135_1", "context": "A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate (5 mg).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["isosorbide dinitrate"]], "start": [[ "64" ]], "entity_id": [ ["T1"] ], "Dosage": { "text": [["5 mg"]], "start": [[ "84" ]], "entity_id": [ ["T2"] ]}, "Route": { "text": [["sublingual"]], "start": [[ "45" ]], "entity_id": [ ["T3"] ]}, "Disorder": { "text": [["angina pectoris"]], "start": [[ "15" ]], "entity_id": [ ["T4"] ]} ,"Trigger": { "text": [["after"]], "start": [[ "56" ]], "entity_id": [ ["T5"] ]} ,"Time_elapsed": { "text": [["presented with syncope"]], "start": [[ "57" ]], "entity_id": [ ["T6"] ]} ,"Freq": null, "Duration": null, "Drug": null, "Combination": null } ,"Subject": { "text": [["A 65-year-old woman"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ], "Age": { "text": [["65"]], "start": [[ "7" ]], "entity_id": [ ["T7"] ]}, "Gender": null, "Race": null, "Disorder": { "text": [["angina pectoris"]], "start": [[ "15" ]], "entity_id": [ ["T4"] ]}, "Population": null }, "Effect": { "text": [["syncope"]], "start": [[ "57" ]], "entity_id": [ ["T8"] ]} ,"Negated": null, "Speculated": null, "Severity": null ,"Trigger": { "text": [["after"]], "start": [[ "56" ]], "entity_id": [ ["T5"] ]} }]}
{"id": "1860779_1","context": "The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, obsessional-like suicidal ideas and images after ingestion of the anti-fungal drug ketoconazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["suicidal ideas and images"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the anti-fungal drug ketoconazole"]],"start": [["86"]],"entity_id": [["T2"]],"Drug": {"text": [["ketoconazole"]],"start": [["86"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["mentally healthy"]],"start": [["27"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["after ingestion"]],"start": [["97"]],"entity_id": [["T5"]]} ,"Route": {"text": [["ingestion"]],"start": [["97"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["ingestion"]],"start": [["97"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["repeatedly experienced", "short-lived"]],"start": [["43","50"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["repeatedly experienced"]],"start": [["43"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": []} ,"Effect": {"text": [["suicidal ideas and images"]],"start": [["52"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Subject": {"text": [["a mentally healthy man"]],"start": [["27"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["mentally healthy"]],"start": [["27"]],"entity_id": [["T4"]]} }}]}
{"id": "1356045_2","context": "Flaccid quadriparesis was noted after discontinuation of vecuronium","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Flaccid quadriparesis"]],"start": [[ ], []], "entity_id": []},"Treatment": {"text": [["vecuronium"]],"start": [[]], "entity_id": [], "Disorder": {"text": [["Flaccid quadriparesis"]],"start": [[]], "entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": {"text": [["after discontinuation"]],"start": [[]], "entity_id": []},"Freq": null,"Combination": null, "Trigger": null, "Drug": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "17444802_2","context": "The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["topical interferon (INF) alpha 2-beta"]],"start": [["31"]],"entity_id": [["T1"]],"Drug": {"text": [["interferon (INF)"]],"start": [["31"]],"entity_id": [["T2"]]},"Disorder": {"text": [["conjunctiva-cornea intraepithelial neoplasia (CIN)"]],"start": [["77"]],"entity_id": [["T3"]]},"Duration": {"text": [["a case"]],"start": [["68"]],"entity_id": [["T4"]]},"Trigger": {"text": [["effectiveness"]],"start": [["44"]],"entity_id": [["T5"]]},"Freq": {"text": [["report"]],"start": [["23"]],"entity_id": [["T6"]]},"Route": {"text": [["topical"]],"start": [["31"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["of this study"]],"start": [["2"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["interferon (INF)"]],"start": [["31"]],"entity_id": [["T2"]]},"Trigger": {"text": [["side effects"]],"start": [["56"]],"entity_id": [["T9"]]},"event_id": "E2","event_type":"Adverse_event"}],"Dosage": {"text": [["topical"]],"start": [["31"]],"entity_id": [["T7"]]}},"Subject": {"text": [["a patient"]],"start": [["108"]],"entity_id": [["T10"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17044380_1","context": "Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["warfarin-induced skin necrosis"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["mitral valve replacement"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["warfarin"]],"start": [["11"]],"entity_id": [["T3"]]},"Disorder": {"text": [["thromboembolic phenomena"]],"start": [["68"]],"entity_id": [["T4"]]},"Trigger": {"text": [["following"]],"start": [["43"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["following"]],"start": [["43"]],"entity_id": [["T5"]]},"Duration": {"text": [["following"]],"start": [["43"]],"entity_id": [["T5"]]},"Freq": {"text": [["following"]],"start": [["43"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["heparin"]],"start": [["102"]],"entity_id": [["T7"]]},"Trigger": {"text": [["heparin-induced thrombocytopenia"]],"start": [["102"]],"entity_id": [["T8"]]},"event_id": "E2","event_type": "Adverse_event"}],"Dosage": {"text": [["mitral valve replacement"]],"start": [["52"]],"entity_id": [["T2"]]},"Route": {"text": [["mitral valve replacement"]],"start": [["52"]],"entity_id": [["T2"]]}},"Subject": {"text": [["Herein"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["marantic endocarditis", "bronchial adenocarcinoma"]],"start": [["83"]],"entity_id": [["T9"]]}},"Severity": {"text": [],"start": [],"entity_id": [],"value": "High"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17026827_2","context": "We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe unilateral posterior scleritis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["zoledronic acid administration"]],"start": [["53"]],"entity_id": [["T2"]],"Drug": {"text": [["zoledronic acid"]],"start": [["53"]],"entity_id": [["T3"]]},"Route": {"text": [["administration"]],"start": [[ "53" ]],"entity_id": [["T4"]]},"Freq": {"text": [["was recognized and treated"]],"start": [[ "64" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["that was recognized and treated"]],"start": [[ "64" ]],"entity_id": [["T5"]]},"Trigger": {"text": [["administration"]],"start": [[ "53" ]],"entity_id": [["T4"]]},"Disorder": {"text": [["severe unilateral posterior scleritis"]],"start": [["18"]],"entity_id": [["T1"]]},"Dosage": {"text": [["was recognized and treated"]],"start": [[ "64" ]],"entity_id": [["T5"]]},"Duration": {"text": [["was recognized and treated"]],"start": [[ "64" ]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["zoledronic acid"]],"start": [[ "53" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [[ "53" ]],"entity_id": [["T4"]]},"event_id": "E1","event_type": "Adverse_event"}]},"Subject": {"text": [["We"]],"start": [[ "0" ]],"entity_id": [["T0"]],"Population": {"text": [["a case"]],"start": [[ "10" ]],"entity_id": [["T6"]]},"Disorder": {"text": [["severe unilateral posterior scleritis"]],"start": [["18"]],"entity_id": [["T1"]]},"Age": {"text": [["a case"]],"start": [[ "10" ]],"entity_id": [["T6"]]},"Gender": {"text": [["We"]],"start": [[ "0" ]],"entity_id": [["T0"]]},"Race": {"text": [["We"]],"start": [[ "0" ]],"entity_id": [["T0"]]}},"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["T7"]],"value":"high"},"Speculated": {"text": [["We present"]],"start": [[ "0" ]],"entity_id": [["T0"]],"value":false},"Negated": {"text": [["was recognized and treated"]],"start": [[ "64" ]],"entity_id": [["T5"]],"value":false},"Effect": {"text": [["severe unilateral posterior scleritis"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "19567656_5","context": "The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Negated": {"value": true,"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Trigger": {"text": [["interactions"]],"start": [["48"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sertraline"]],"start": [["33"]],"entity_id": [["T2"]],"Drug": {"text": [["sertraline"]],"start": [["33"]],"entity_id": [["T3"]]},"Disorder": {"text": [["rhabdomyolysis"]],"start": [["71"]],"entity_id": [["T4"]]},"Freq": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Combination": [{"Drug": {"text": [["sertraline"]],"start": [["33"]],"entity_id": [["T3"]]},"Trigger": {"text": [["interactions"]],"start": [["48"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Duration": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Dosage": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Route": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Trigger": {"text": [["interactions"]],"start": [["48"]],"entity_id": [["T1"]]}},"Subject": {"text": [["The patient"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Gender": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Population": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]},"Disorder": {"text": [["The patient's other comorbidities"]],"start": [["0"]],"entity_id": [["S2"]]},"Race": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]]}},"Severity": {"text": [["can cause"]],"start": [["58"]],"entity_id": [["N2"]],"value": "High"},"Speculated": {"text": [["have not been suggested"]],"start": [["0"]],"entity_id": [["N1"]],"value": false},"Effect": {"text": [["rhabdomyolysis"]],"start": [["71"]],"entity_id": [["T4"]]}}]}
{"id": "11030530_1", "context": "L-asparaginase-provoked seizures as singular expression of central nervous toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seizures"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["L-asparaginase"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["L-asparaginase"]], "start": [["0"]], "entity_id": [] } ,"Disorder": {"text": [["central nervous toxicity"]], "start": [["42"]], "entity_id": [] } ,"Route": {"text": [["provoked"]], "start": [["11"]], "entity_id": [] } ,"Time_elapsed": {"text": [], "start": [], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination": null ,"Trigger": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "7351000_1", "context": "Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute non-lymphocytic leukemia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["Treosulfan (= dihydroxybusulfan)"]], "start": [[ "91" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["Treosulfan"]], "start": [[ "91" ]], "entity_id": [ ["T3"] ]} ,"Duration": {"text": [["long-term"]], "start": [[ "56" ]], "entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["patients with ovarian carcinoma"]], "start": [[ "26" ]], "entity_id": [ ["T5"] ]} ,"Time_elapsed": null ,"Freq": null ,"Route": null ,"Combination": null ,"Dosage": null ,"Trigger": null },"Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "17260498_4","context": "The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["weekly administration"]],"start": [["46"]],"entity_id": [["T1"]]},"Treatment": {"text": [["30 mg/m2 docetaxel"]],"start": [["59"]],"entity_id": [["T2"]],"Drug": {"text": [["docetaxel"]],"start": [["59"]],"entity_id": [["T3"]]},"Disorder": {"text": [["hormone-refractory prostate cancer"]],"start": [["26"]],"entity_id": [["T4"]]},"Dosage": {"text": [["30 mg/m2"]],"start": [["46"]],"entity_id": [["T5"]]},"Duration": {"text": [["seven doses"]],"start": [["67"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after seven doses"]],"start": [["67"]],"entity_id": [["T6"]]},"Trigger": {"text": [["who developed subacute interstitial pneumonitis-related pulmonary fibrosis"]],"start": [["82"]],"entity_id": [["T7"]]},"Freq": {"text": [["weekly administration"]],"start": [["46"]],"entity_id": [["T1"]]},"Route": {"text": [["administration"]],"start": [["46"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["docetaxel"]],"start": [["59"]],"entity_id": [["T3"]]},"Trigger": {"text": [["weekly administration"]],"start": [["46"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["a 72-year-old man"]],"start": [["11"]],"entity_id": [["T8"]],"Age": {"text": [["72"]],"start": [["11"]],"entity_id": [["T9"]]},"Gender": {"text": [["man"]],"start": [["14"]],"entity_id": [["T10"]]},"Population": {"text": [["a"]],"start": [["11"]],"entity_id": [["T8"]]},"Disorder": {"text": [["hormone-refractory prostate cancer"]],"start": [["26"]],"entity_id": [["T4"]]},"Race": {"text": [["a"]],"start": [["11"]],"entity_id": [["T8"]]}},"Effect": {"text": [["died"]],"start": [["144"]],"entity_id": [["T11"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["subacute interstitial pneumonitis-related pulmonary fibrosis"]],"start": [["82"]],"entity_id": [["T7"]],"value": "High"}}]}
{"id": "10732843_5","context": "In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["promoted"]],"start": [["53"]],"entity_id": []},"Treatment": {"text": [["cigarette smoking", "low-dose methotrexate therapy"]],"start": [["22", "62"]],"entity_id": [],"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["62"]],"entity_id": []},"Trigger": {"text": [["therapy"]],"start": [["66"]],"entity_id": []},"event_id": "T1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["cigarette smoking"]],"start": [["22"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "T2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["combination"]],"start": [["22"]],"entity_id": []},"Disorder": {"text": [["lung cancer"]],"start": [["92"]],"entity_id": []},"Freq": {"text": [["a combination"]],"start": [["22"]],"entity_id": []},"Duration": {"text": [["promoted"]],"start": [["53"]],"entity_id": []},"Dosage": {"text": [["low-dose"]],"start": [["44"]],"entity_id": []},"Route": {"text": [["therapy"]],"start": [["66"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [["cigarette smoking", "methotrexate"]],"start": [["22", "62"]],"entity_id": []}},"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["pulmonary fibrosis"]],"start": [["32"]],"entity_id": []},"text": [["In this case", "it was suspected"]],"start": [["0"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [["was suspected"]],"start": [["28"]],"entity_id": [],"value": true},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["promoted"]],"start": [["53"]],"entity_id": []}}]}
{"id": "21712512_1","context": "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a patient"]],"start": [["23"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["cystic fibrosis-related liver disease"]],"start": [["42"]],"entity_id": [["S2"]]}},"Treatment": {"text": [["inhaled corticosteroids", "a moderate CYP3A4 inhibitor"]],"start": [["86","101"]],"entity_id": [["T1","T2"]],"Drug": {"text": [["inhaled corticosteroids"]],"start": [["86"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["inhaled corticosteroids"]], "start": [[ "86" ]], "entity_id": [["T1"]]},"Trigger": {"text": [["and"]], "start": [["98"]], "entity_id": [["T7"]]},"event_id": "E1-C1","event_type": "Treatment"}],"Disorder": {"text": [["iatrogenic adrenal insufficiency"]],"start": [["15"]],"entity_id": [["D1"]]}},"Effect": {"text": [["iatrogenic adrenal insufficiency"]],"start": [["15"]],"entity_id": [["D1"]]},"Trigger": {"text": [["treated"]],"start": [["64"]],"entity_id": [["T3"]]}}]}
{"id": "10891991_7","context": "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["valproate"]],"start": [["valproate therapy was discontinued,"],[", the 2 women who had gained weight and developed amenorrhea while being treated with valproate,"]],"entity_id": [["T1"],["T2"]]},"Trigger": {"text": [["disappeared"]],"start": [[ "disappeared from the ovaries in" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["polycystic changes"]],"start": [[ "The polycystic changes" ]],"entity_id": [["T4"]]},"entity_id": [["T1"],["T2"],["T3"],["T4"]],"Dosage": {"text": [["discontinued"]],"start": [[ "valproate therapy was discontinued,"]],"entity_id": [["T1"]]},"Duration": {"text": [["after"]],"start": [[ "after valproate therapy was discontinued,"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after"]],"start": [[ "after valproate therapy was discontinued,"]],"entity_id": [["T1"]]},"Route": {"text": [["therapy"]],"start": [[ "valproate therapy was discontinued,"]],"entity_id": [["T1"]]},"Freq": {"text": [["the 2 women"]],"start": [[ "The polycystic changes disappeared from the ovaries in 2 of the women" ]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["valproate"]],"start": [[", the 2 women who had gained weight and developed amenorrhea while being treated with valproate,"]],"entity_id": [["T2"]]},"Trigger": {"text": [["lost weight and resumed menstruating"]],"start": [[ "lost weight and resumed menstruating after the change in medication."]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"text": [["The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued,"]],"start": [[ "The polycystic changes disappeared from the ovaries in" ]]},"Trigger": {"text": [["after the change in medication."]],"start": [[ "lost weight and resumed menstruating after the change in medication."]],"entity_id": [["T6"]]},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Subject": {"text": [["2 of the women"]],"start": [[ "2 of the women" ]],"entity_id": [["T3"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["polycystic changes"]],"start": [[ "The polycystic changes" ]],"entity_id": [["T4"]]}},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Effect": {"text": [["disappeared"]],"start": [[ "disappeared from the ovaries in" ]],"entity_id": [["T3"]]}}]}
{"id": "11225532_2","context": "The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe thrombocytopoaenia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["quinine"]],"start": [["53"]],"entity_id": [["T2"]],"Dosage": {"text": [["chronic ingestion"]],"start": [["40"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["bleeding"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": [{"event_type": "Adverse_event","event_id": "E1","Drug": {"text": [["quinine"]],"start": [["53"]],"entity_id": [["T2"]]},"Trigger": {"text": [["severe thrombocytopoaenia"]],"start": [["18"]],"entity_id": [["T1"]]}}] ,"Time_elapsed": {"text": [["induced"]],"start": [["31"]],"entity_id": [["T4"]]},"Freq": {"text": [["chronic ingestion"]],"start": [["40"]],"entity_id": [["T3"]]} ,"Drug": {"text": [["quinine"]],"start": [["53"]],"entity_id": [["T2"]]} ,"Route": {"text": [["ingestion"]],"start": [["46"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["chronic"]],"start": [["40"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["severe thrombocytopoaenia"]],"start": [["18"]],"entity_id": [["T1"]]} },"Subject": {"text": [["his"]],"start": [["6"]],"entity_id": [["T6"]],"Gender": {"text": [["his"]],"start": [["6"]],"entity_id": [["T6"]]},"Population": {"text": [["his"]],"start": [["6"]],"entity_id": [["T6"]]} ,"Age": {"text": [["his"]],"start": [["6"]],"entity_id": [["T6"]]},"Race": {"text": [["his"]],"start": [["6"]],"entity_id": [["T6"]]},"Disorder": {"text": [["bleeding"]],"start": [["0"]],"entity_id": [["T0"]]} },"Severity": {"text": [["severe"]],"start": [["14"]],"entity_id": [["T7"]] ,"value": "High"} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Effect": {"text": [["severe thrombocytopoaenia"]],"start": [["18"]],"entity_id": [["T1"]]} }]}
{"id": "16882112_3","context": "The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["this adverse reaction"]],"start": [[ ], [ ]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["antidepressant drugs"]],"start": [[ ], [ ]],"entity_id": [["T2"]]},"Disorder": {"text": [["lithium"]],"start": [[ ], [ ]],"entity_id": [["T3"]]},"Route": {"text": [["co-adjuvant"]],"start": [[ ], [ ]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Time_elapsed": null,"Freq": null,"Combination": null,"entity_id": [],"text": [["increase the risk"]],"start": [[ ], [ ]],"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "2554727_3","context": "Peripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Peripheral nervous system disturbances"]],"start": [[ "0"]] , "entity_id": [ ]},"Treatment": {"text": [["cytosine arabinoside"]],"start": [[ "53"]],"entity_id": [] ,"Drug": {"text": [["cytosine arabinoside"]],"start": [[ "53"]],"entity_id": [] },"Disorder": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": { "text": [["Peripheral nervous system disturbances"]], "start": [[ "0" ]], "entity_id": [] }, "Severity": null ,"Negated": null ,"Speculated": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null ,"Disorder": null ,"Gender": null ,"Population": null ,"Race": null }} ]}
{"id": "9315405_1","context": "We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["unusually short lived", "asymptomatic", "severe", "cisplatin-induced renal tubular salt wasting"]],"start": [[ "3", "33", "41", "50" ]],"entity_id": [ ["T1", "T2", "T3", "T4"] ]},"Subject": {"text": [["a fit 41-year-old patient"]],"start": [["103"]],"entity_id": [["T5"]],"Age": {"text": [["41"]],"start": [[ "106" ]],"entity_id": [["A1"]]},"Gender": {"text": [["fit"]],"start": [[ "103" ]],"entity_id": [["G1"]]},"Disorder": {"text": [["malignant teratoma"]],"start": [["114"]],"entity_id": [["D1"]]} ,"Race": null, "Population": null }, "Treatment": { "text": [["cisplatin-induced"]], "start": [[ "42" ]], "entity_id": [["T6"]], "Drug": { "text": [["cisplatin"]], "start": [[ "42" ]], "entity_id": [["D1"]] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": { "text": [["renal tubular salt wasting"]], "start": [[ "50" ]], "entity_id": [["D2"]] }, "Combination": null }, "Effect": { "text": [["unusually short lived", "asymptomatic"]], "start": [[ "3", "33" ]], "entity_id": [["E1", "E2"]] }, "Negated": null, "Speculated": null, "Severity": { "text": [["severe"]], "start": [[ "41" ]], "entity_id": [["S1"]] ,"value": "High" }} ] }
{"id": "10102531_1","context": "This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["BH-AC"]],"start": [["12"]],"entity_id": [["T1"]]},"Treatment": {"text": [["a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine)"]],"start": [["30"]],"entity_id": [["T2"]],"Drug": {"text": [["cytosine arabinoside"]],"start": [["30"]],"entity_id": [["T3"]]},"Disorder": {"text": [["reversible encephalopathy syndrome"]],"start": [["85"]],"entity_id": [["T4"]]},"Trigger": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Dosage": {"text": [["a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine)"]],"start": [["30"]],"entity_id": [["T2"]]},"Route": {"text": [["a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine)"]],"start": [["30"]],"entity_id": [["T2"]]},"Duration": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Freq": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["cytosine arabinoside"]],"start": [["30"]],"entity_id": [["T3"]]},"Trigger": {"text": [["a derivative of"]],"start": [["30"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Common"}],"Time_elapsed": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]}},"Subject": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Gender": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Population": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Race": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]},"Disorder": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]]}},"Effect": {"text": [["reversible encephalopathy syndrome"]],"start": [["85"]],"entity_id": [["T4"]]},"Negated": {"text": [["reversible"]],"start": [["85"]],"entity_id": [["T4"]],"value": false},"Speculated": {"text": [["this case suggests"]],"start": [["0"]],"entity_id": [["T5"]],"value": false},"Severity": {"text": [["reversible"]],"start": [["85"]],"entity_id": [["T4"]],"value": "Low"}}]}
{"id": "448845_4","context": "This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["aplastic anemia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methazolamide"]],"start": [["92"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["aplastic anemia"]],"start": [["0"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["almost certainly induced"]],"start": [["53"]],"entity_id": [["T4"]]},"Freq": {"text": [["two cases"]],"start": [["5"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["methazolamide"]],"start": [["92"]],"entity_id": [["T2"]]},"Trigger": {"text": [["related"]],"start": [["152"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["use"]],"start": [["80"]],"entity_id": [["T7"]]},"Route": null,"Dosage": null,"Duration": null},"Effect": {"text": [["aplastic anemia"]],"start": [["0"]],"entity_id": [["T3"]]},"Subject": {"text": [["two cases"]],"start": [["5"]],"entity_id": [["T5"]],"Population": null,"Gender": null,"Race": null,"Age": null,"Disorder": {"text": [["aplastic anemia"]],"start": [["0"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12584153_3", "context": "Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Amprenavir"]], "start": [[ ]], "entity_id": [], "Time_elapsed": null, "Duration": null, "Disorder": {"text": [["HIV-infected children"]], "start": [[]], "entity_id": []}, "Drug": {"text": [["Amprenavir"]], "start": [[]], "entity_id": []}, "Freq": null, "Combination": null, "Trigger": {"text": [["intended"]], "start": [[]], "entity_id": []}, "Route": {"text": [["to treat"]], "start": [[]], "entity_id": []}, "Dosage": null},"Effect": null, "Subject": null, "Negated": null, "Speculated": null, "Severity": null, "Trigger": null}]}
{"id": "19733945_2","context": "On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["linezolid treatment"]],"start": [["On day 7 of linezolid treatment,"]],"entity_id": []},"Treatment": {"text": [["linezolid treatment"]],"start": [["On day 7 of linezolid treatment,"]],"entity_id": [],"Drug": {"text": [["linezolid"]],"start": [["On day 7 of linezolid treatment,"]],"entity_id": []},"Duration": {"text": [["day 7"]],"start": [["On day 7"]],"entity_id": []},"Disorder": {"text": [["treatment"]],"start": [["linezolid treatment"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe pruritus","macular rash","facial edema","eosinophilia","marked increase in serum creatinine level","mild hepatitis"]],"start": [[],[],[],[],[],[]],"entity_id": []},"Severity": {"text": [["severe"]],"start": [[],[],[],[],[],[]],"entity_id": [],"value": "high"},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Subject": {"text": [["the patient"]],"start": [[", the patient"]],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "8181372_2","context": "We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal case", "acute interstitial pneumonitis"]],"start": [["12", "42"]],"entity_id": []},"Treatment": {"text": [["carmustine (BCNU)"]],"start": [["64"]],"entity_id": [],"Drug": {"text": [["carmustine", "BCNU"]],"start": [["64"]],"entity_id": []},"Disorder": {"text": [["brain tumor"]],"start": [["90"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["patient"]],"start": [["23"]],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "fatal"}}]}
{"id": "10749332_4","context": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["troglitazone is an idiosyncratic hepatotoxin"]],"start": [["33"]],"entity_id": [["T1"]]},"Effect": {"text": [["irreversible liver injury"]],"start": [["85"]],"entity_id": [["T2"]]},"Treatment": {"text": [["troglitazone"]],"start": [["33"]],"entity_id": [["T1"]],"Drug": {"text": [["troglitazone"]],"start": [["33"]],"entity_id": [["T1"]]},"Disorder": {"text": [["liver injury"]],"start": [["76"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["that can lead to"]],"start": [["64"]],"entity_id": [["T3"]]},"Duration": {"text": [["reported cases demonstrate"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}}]}
{"id": "7814182_1", "context": "High-grade atrioventricular block during dipyridamole stress testing", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["High-grade atrioventricular block"]], "start": [["0"]], "entity_id":[["T1"]]}, "Treatment": {"text": [["dipyridamole stress testing"]], "start": [["41"]], "entity_id":[["T2"]], "Drug": {"text": [["dipyridamole"]], "start": [["41"]], "entity_id":[["T3"]]}, "Disorder": {"text": [["atrioventricular block"]], "start": [["0"]], "entity_id":[["T4"]]}, "Time_elapsed": {"text": [["during"]], "start": [["15"]], "entity_id":[["T5"]]}, "Trigger": {"text": [["testing"]], "start": [["37"]], "entity_id":[["T6"]]}, "Route": {"text": [["stress"]], "start": [["28"]], "entity_id":[["T7"]]}, "Duration": null, "Dosage": null, "Freq": null, "Combination": null}, "Negated": null, "Speculated": null, "Severity": {"text": [["High-grade"]], "start": [["0"]], "entity_id":[["T8"]], "value": "High"}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Effect": {"text": [], "start": [], "entity_id": []}}]}
{"id": "2406680_3","context": "The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reversible hearing loss"]],"start": [["39"]],"entity_id": [["T3"]]},"Treatment": {"text": [["quinine therapy"]],"start": [["65"]],"entity_id": [["T4"]],"Drug": {"text": [["quinine"]],"start": [["65"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["falciparum malaria disease"]],"start": [["18"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["reversible"]],"start": [["39"]],"entity_id": [["T3"]]} ,"Route": {"text": [["from"]],"start": [["59"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["quinine"]],"start": [["65"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["therapy"]],"start": [["60"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["from"]],"start": [["59"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["reversible"]],"start": [["39"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["therapy"]],"start": [["60"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["therapy"]],"start": [["60"]],"entity_id": [["T4"]]} },"Subject": {"text": [["a 29-year-old man"]],"start": [["0"]],"entity_id": [["T1"]],"Age": {"text": [["29"]],"start": [["2"]],"entity_id": [["T1"]]} ,"Gender": {"text": [["man"]],"start": [["5"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["falciparum malaria disease"]],"start": [["18"]],"entity_id": [["T2"]]} ,"Population": {"text": [["a"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Race": {"text": [["man"]],"start": [["5"]],"entity_id": [["T1"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["reversible"]],"start": [["39"]],"entity_id": [["T3"]],"value": "low"} ,"Effect": {"text": [["hearing loss"]],"start": [["44"]],"entity_id": [["T3"]]}}]}
{"id": "7893301_3","context": "The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["became hypokalemic"]],"start": [["28"]],"entity_id": [["E3"]]},"Subject": {"text": [["two asthmatic patients"]],"start": [["5"]],"entity_id": [["E2"]],"Population": {"text": [["two"]], "start": [[ "5" ]], "entity_id": [["E7"]]},"Disorder": {"text": [["asthmatic"]],"start": [[ "6" ]],"entity_id": [["E8"]]},"Age": {"text": [["-"]], "start": [[ "5" ]], "entity_id": [["E9"]]},"Gender": {"text": [["-"]], "start": [[ "5" ]], "entity_id": [["E10"]]},"Race": {"text": [["-"]], "start": [[ "5" ]], "entity_id": [["E11"]]}},"Treatment": {"text": [["normal doses of albuterol"]],"start": [["41"]],"entity_id": [["E4"]],"Drug": {"text": [["albuterol"]], "start": [["41"]], "entity_id": [["E5"]]},"Dosage": {"text": [["normal doses"]], "start": [["41"]], "entity_id": [["E6"]]},"Duration": {"text": [["-"]], "start": [["41"]], "entity_id": [["E12"]]},"Route": {"text": [["inhalation"]], "start": [["33"]], "entity_id": [["E13"]]},"Time_elapsed": {"text": [["after inhalation"]], "start": [["33"]], "entity_id": [["E14"]]},"Trigger": {"text": [["after inhalation"]], "start": [["33"]], "entity_id": [["E15"]]},"Freq": {"text": [["-"]], "start": [["41"]], "entity_id": [["E16"]]},"Combination": null,"Disorder": {"text": [["-"]],"start": [["41"]],"entity_id": [["E17"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["-"]],"start": [["28"]],"entity_id": [["E18"]],"value": "low"},"Effect": {"text": [["hypokalemic"]],"start": [["28"]],"entity_id": [["E3"]]}}]}
{"id": "19537383_4","context": "This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["atypical localized cutaneous eruption"]],"start": [["12"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sorafenib therapy"]],"start": [["82"]],"entity_id": [["T2"]],"Drug": {"text": [["sorafenib"]],"start": [["82"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["protracted resolution time"]],"start": [["63"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["sorafenib"]],"start": [["82"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["sorafenib therapy"]],"start": [["82"]],"entity_id": [["T2"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Time_elapsed": {"text": [["unusual course"]],"start": [["35"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["protracted resolution time"]],"start": [["63"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["sorafenib therapy"]],"start": [["82"]],"entity_id": [["T2"]]} ,"Route": {"text": [["sorafenib therapy"]],"start": [["82"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["atypical localized cutaneous eruption"]],"start": [["12"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["atypical localized cutaneous eruption"]],"start": [["12"]],"entity_id": [["T1"]]} },"Negated": null ,"Speculated": null ,"Severity": {"text": [["atypical"]],"start": [["0"]],"entity_id": [["T0"]] ,"value": "low" },"Subject": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Age": null ,"Gender": null ,"Disorder": {"text": [["atypical localized cutaneous eruption"]],"start": [["12"]],"entity_id": [["T1"]]} ,"Race": null },"Effect": {"text": [["atypical localized cutaneous eruption"]],"start": [["12"]],"entity_id": [["T1"]]} }] }
{"id": "16480245_1", "context": "We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["quetiapine"]], "start": [["36"]], "entity_id": [["T1"]]},"Disorder": {"text": [["diabetic ketoacidosis"]], "start": [["12"]], "entity_id": [["T2"]]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null , "start": [[ "36" ]], "entity_id": [["T1"]] ,"text": [["quetiapine"]] ,"Trigger": { "text": [["after treatment with quetiapine"]], "start": [[ "30" ]], "entity_id": [["T3"]] }},"Effect": {"text": [["diabetic ketoacidosis"]], "start": [[ "12" ]], "entity_id": [["T2"]] },"Trigger": { "text": [["presented with"]], "start": [[ "10" ]], "entity_id": [["T4"]] }},{"event_id": "E2", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["risperidone"]], "start": [["61"]], "entity_id": [["T5"]]},"Disorder": {"text": [["diabetic ketoacidosis"]], "start": [["12"]], "entity_id": [["T2"]]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null , "start": [[ "61" ]], "entity_id": [["T5"]] ,"text": [["risperidone"]] ,"Trigger": { "text": [["after treatment with risperidone"]], "start": [[ "55" ]], "entity_id": [["T6"]] }},"Effect": {"text": [["diabetic ketoacidosis"]], "start": [[ "12" ]], "entity_id": [["T2"]] },"Trigger": { "text": [["presented with"]], "start": [[ "10" ]], "entity_id": [["T4"]] }}]}
{"id": "9855339_4","context": "We suspect that nefazodone inhibits metabolism of tacrolimus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["nefazodone"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["inhibits metabolism of tacrolimus"]],"start": [["21"]],"entity_id": [["T2"]]} ,"entity_id": [["T1"], ["T2"]] ,"text": [["nefazodone", "inhibits metabolism of tacrolimus"]],"start": [[ "0" ], ["21"]], "Trigger": {"text": [["inhibits"]],"start": [["21"]],"entity_id": [["T3"]] },"Time_elapsed": null,"Duration": null,"Dosage": null,"Route": null,"Freq": null,"Combination": null },"Effect": null,"Negated": null,"Speculated": {"value": true,"text": [["We suspect"]],"start": [[ "0" ]],"entity_id": [["T4"]] },"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "9184269_4","context": "Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["MTX-induced pneumonitis"]],"start": [["36","47"]],"entity_id": [["T1"]]},"Subject": {"text": [["RA patients","PsA patients"]],"start": [["8","9","30","31"]],"entity_id": [["T2","T3"]],"Population": {"text": [[ "194","38"]],"start": [["14","24"]],"entity_id": [["T4","T5"]]},"Age": null,"Gender": null,"Race": null,"Disorder": {"text": [["RA","PsA"]],"start": [["8","30"]],"entity_id": [["T2","T3"]]}},"Treatment": {"text": [["MTX"]],"start": [["18"]],"entity_id": [["T6"]],"Drug": {"text": [["MTX"]],"start": [["18"]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Trigger": {"text": [["receiving"]],"start": [["17"]],"entity_id": [["T7"]]},"Disorder": {"text": [["RA","PsA"]],"start": [["8","30"]],"entity_id": [["T2","T3"]]},"Combination": null},"Effect": {"text": [["pneumonitis"]],"start": [["47"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16498048_1","context": "Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["common side-effect"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["interferon-alpha (IFN-alpha) treatment"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["interferon-alpha"]],"start": [["42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["viral hepatitis C"]],"start": [["76"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["Autoimmune thyroid disease"]],"start": [["0"]],"entity_id": [["T5"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Autoimmune thyroid disease"]],"start": [["0"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "15866658_4", "context": "The side effects of MMF, such as bone marrow toxicity, have been reported", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects", "bone marrow toxicity"]], "start": [["0", "42"]], "entity_id": []}, "Treatment": {"text": [["MMF"]], "start": [["7"]], "entity_id": [], "Drug": {"text": [["MMF"]], "start": [["7"]], "entity_id": []},"Disorder": {"text": [["bone marrow toxicity"]], "start": [["42"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null}, "Effect": {"text": [], "start": [], "entity_id": []}, "Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "15727358_1","context": "He developed a late secondary infection in some sites treated with imiquimod","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["late secondary infection"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["imiquimod"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["imiquimod"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["late secondary infection"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Route": {"text": [["treated"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["late"]],"start": [["16"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["late secondary infection"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["treated"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["late secondary infection"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["imiquimod"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["treated"]],"start": [["40"]],"entity_id": [["T4"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["He"]],"start": [[""],[]],"entity_id": [[],[]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["late secondary infection"]],"start": [["16"]],"entity_id": [["T1"]]},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false }}]}
{"id": "19104709_3","context": "We report the case of a 51-year-old man in whom IFN-alpha treatment was followed by recurrence of Graves' disease 10 years after thyroidectomy was performed and the patient was declared cured","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["IFN-alpha treatment"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["IFN-alpha treatment"]],"start": [["32"]],"entity_id": [["T1"]],"Drug": {"text": [["IFN-alpha"]],"start": [["32"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Graves' disease"]],"start": [["52"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["10 years"]],"start": [["49"]],"entity_id": [["T4"]]},"Trigger": {"text": [["thyroidectomy"]],"start": [["72"]],"entity_id": [["T5"]]},"Freq": {"text": [["followed by recurrence"]],"start": [["24"]],"entity_id": [["T6"]]},"Route": {"text": [["treatment"]],"start": [["32"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["a 51-year-old man"]],"start": [["4"]],"entity_id": [["T0"]],"Age": {"text": [["51-year-old"]],"start": [["4"]],"entity_id": [["T0"]]},"Gender": {"text": [["man"]],"start": [["10"]],"entity_id": [["T0"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["recurrence"]],"start": [["66"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6733633_2","context": "Cimetidine is a rare cause of drug-induced fever","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["drug-induced fever"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Cimetidine"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Cimetidine"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["drug-induced fever"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["rare"]],"start": [["7"]],"entity_id": [["T0"]]} ,"Route": {"text": [["oral"]],"start": [["28"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["200-400 mg/day"]],"start": [["37"]],"entity_id": [["T3"]]},"Duration": {"text": [["short-term"]],"start": [["56"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["onset within 2 hours"]],"start": [["16"]],"entity_id": [["T5"]]} ,"Combination": null ,"Trigger": null} ,"Subject": null,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null}]}
{"id": "19745701_2","context": "Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["methotrexate-associated lymphoproliferative disorder"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate"]],"start": [["25"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["25"]],"entity_id": [["T3"]]},"Disorder": {"text": [["lymphoproliferative disorder"]],"start": [["11"]],"entity_id": [["T4"]]},"Duration": {"text": [["reversible"]],"start": [["0"]],"entity_id": [["T5"]]},"Dosage": {"text": [["methotrexate-associated"]],"start": [["1"]],"entity_id": [["T6"]]},"Trigger": {"text": [["resembling"]],"start": [["53"]],"entity_id": [["T7"]]},"Freq": {"text": [["advanced gastric cancer"]],"start": [["54"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["25"]],"entity_id": [["T3"]]},"Trigger": {"text": [["resembling"]],"start": [["53"]],"entity_id": [["T7"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["associated"]],"start": [["1"]],"entity_id": [["T6"]]},"Route": {"text": [["in a patient with rheumatoid arthritis"]],"start": [["72"]],"entity_id": [["T9"]]}},"Subject": {"text": [["a patient"]],"start": [["72"]],"entity_id": [["T10"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["80"]],"entity_id": [["T11"]]}},"Effect": {"text": [["lymphoproliferative disorder"]],"start": [["11"]],"entity_id": [["T4"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["reversible"]],"start": [["0"]],"entity_id": [["T5"]],"value": "low"}}]}
{"id": "11077455_5","context": "The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["field defects", "electrophysiological abnormalities"]],"start": [["0","42"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["vigabatrin therapy"]],"start": [["46"]],"entity_id": [["T3"]],"Duration": {"text": [["when vigabatrin therapy is withdrawn"]],"start": [["56"]],"entity_id": [["T4"]]} ,"Drug": {"text": [["vigabatrin"]],"start": [["46"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["field defects", "some electrophysiological abnormalities"]],"start": [["0","42"]],"entity_id": [["T1","T2"]]} ,"Trigger": {"text": [["when vigabatrin therapy is withdrawn"]],"start": [["56"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["persist"]],"start": [["32"]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["when vigabatrin therapy is withdrawn"]],"start": [["56"]],"entity_id": [["T4"]]} ,"Route": {"text": [["therapy"]],"start": [["46"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["therapy"]],"start": [["46"]],"entity_id": [["T3"]]} ,"Combination": null} ,"Subject": {"text": [["The patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["field defects", "some electrophysiological abnormalities"]],"start": [["0","42"]],"entity_id": [["T1","T2"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["persist"]],"start": [["32"]],"entity_id": [["T6"]] ,"value": "low"} ,"Effect": {"text": [["field defects", "some electrophysiological abnormalities"]],"start": [["0","42"]],"entity_id": [["T1","T2"]]} }] }
{"id": "9177620_1", "context": "A possible case of carbamazepine induced pancreatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["carbamazepine induced pancreatitis"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["carbamazepine"]], "start": [["22"]], "entity_id": [["T2"]],"Drug": null, "Disorder": {"text": [["pancreatitis"]], "start": [["31"]], "entity_id": [["T3"]]},"Duration": null,"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null, "Trigger": null, "Combination": null}, "Effect": null, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "18665833_1", "context": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Stuttering priapism"]], "start": [[],[ ]], "entity_id": []}, "Treatment": {"text": [["warfarin therapy"]], "start": [[],[ ]], "entity_id": [], "Drug": {"text": [["warfarin"]], "start": [[],[ ]], "entity_id": []}, "Disorder": {"text": [["protein C deficiency"]], "start": [[],[ ]], "entity_id": []}, "Time_elapsed": {"text": [["complicating"]], "start": [[],[]], "entity_id": []}, "Combination": [{"Drug": {"text": [["warfarin"]], "start": [[],[ ]], "entity_id": []}, "Trigger": {"text": [["therapy"]], "start": [[],[ ]], "entity_id": []} , "event_id":"C1" , "event_type":"Treatment" },{"Drug": null ,"Trigger": {"text": [["complicating"]], "start": [[],[ ]], "entity_id": []} ,"event_id":"C2" ,"event_type":"Trigger" }] , "Trigger": {"text": [["complicating"]], "start": [[],[ ]], "entity_id": []}, "Freq": null , "Dosage": null , "Duration": null , "Route": null }, "Subject": { "Age": null ,"Disorder": {"text": [["protein C deficiency"]], "start": [[],[ ]], "entity_id": []}, "entity_id": [], "Gender": null ,"Population": null ,"Race": null ,"text": [["patient"]], "start": [[ ],[ ]] }, "Severity": null , "Speculated": null , "Negated": null , "Effect": {"text": [["Stuttering priapism"]], "start": [[],[ ]], "entity_id": []} }]}
{"id": "24791374_2","context": "We describe a rare case of severe drug-drug interaction between propafenone and mirtazapine leading to propafenone toxicity","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe drug-drug interaction"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["propafenone", "mirtazapine"]],"start": [["52"], ["64"]],"entity_id": [["T2"], ["T3"]],"Drug": {"text": [["propafenone"], ["mirtazapine"]],"start": [["52"], ["64"]],"entity_id": [["T4"], ["T5"]]},"Disorder": {"text": [["propafenone toxicity"]],"start": [["88"]],"entity_id": [["T6"]]},"Freq": {"text": [["interaction"]],"start": [["33"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["propafenone"]],"start": [["52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["and"]],"start": [["62"]],"entity_id": [["T7"]]},"event_type": "null","event_id": "null"},{"Drug": {"text": [["mirtazapine"]],"start": [["64"]],"entity_id": [["T5"]]},"Trigger": {"text": [["leading"]],"start": [["73"]],"entity_id": [["T8"]]},"event_type": "null","event_id": "null"}],"Time_elapsed": {"text": [["between"]],"start": [["60"]],"entity_id": [["T9"]]},"Duration": {"text": [["describe"]],"start": [["0"]],"entity_id": [["T10"]]},"Dosage": {"text": [["a"]],"start": [["0"]],"entity_id": [["T10"]]},"Route": {"text": [["rare case"]],"start": [["6"]],"entity_id": [["T11"]]},"Trigger": {"text": [["case"]],"start": [["44"]],"entity_id": [["T12"]]}},"Severity": {"text": [["severe"]],"start": [["29"]],"entity_id": [["T13"]],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T10"]],"Population": {"text": [["a"]],"start": [["0"]],"entity_id": [["T10"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["propafenone toxicity"]],"start": [["88"]],"entity_id": [["T6"]]}}]}
{"id": "12875956_3","context": "The psychotic behavior resolved completely soon after the discontinuation of levetiracetam","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["psychotic behavior"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["levetiracetam"]],"start": [[ "86" ]] ,"entity_id": [ ["T2"] ]},"Disorder": {"text": [["psychotic behavior"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Trigger": {"text": [["discontinuation"]],"start": [[ "48" ]] ,"entity_id": [["T3"] ]} ,"Time_elapsed": { "text": [["soon after"]],"start": [[ "54" ]] ,"entity_id": [ ["T4"] ]} ,"Duration": { "text": [["completely"]],"start": [[ "31" ]] ,"entity_id": [ ["T5"] ]} ,"entity_id": [ ], "text": [ ["The psychotic behavior resolved completely soon after the discontinuation of levetiracetam" ]], "start": [ ["0" ]], "Dosage": { "text": [],"start": [],"entity_id": []}, "Route": { "text": [],"start": [],"entity_id": []}, "Freq": { "text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Effect": null} ]}
{"id": "15034704_3","context": "Male volunteers (n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["rifampicin"]],"start": [[ ],[ ]],"entity_id": [["T1"]]},"Dosage": {"text": [["600 mg"]],"start": [[ ],[ ]],"entity_id": [["T2"]]},"Duration": {"text": [["once daily for 7 days"]],"start": [[ ],[ ],[ ],[ ],[ ],[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["effect"]],"start": [[ ],[ ]],"entity_id": [["T4"]]},"Freq": {"text": [["multiple doses"]],"start": [[ ],[ ]],"entity_id": [["T5"]]},"Disorder": {"text": [["repaglinide metabolism"]],"start": [[ ],[ ],[ ],[ ],[ ],[ ]],"entity_id": [["T6"]]},"entity_id": [["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"]],"text": [["rifampicin"], ["600 mg"], ["once daily for 7 days"], ["effect"], ["multiple doses"], ["repaglinide metabolism"]],"start": [[ ],[ ],[ ],[ ],[ ],[ ]],"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"Gender": {"text": [["Male"]],"start": [[ ],[ ]],"entity_id": [["T7"]]},"Population": {"text": [["12"]],"start": [[ ],[ ]],"entity_id": [["T8"]]},"Age": null,"Disorder": null,"Race": null,"text": [["Male"], ["12"]],"start": [[ ],[ ]],"entity_id": [["T7"], ["T8"]]},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "17671884_9","context": "This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anemia"]],"start": [[ "3" ]],"entity_id": [ ]},"Treatment": {"text": [["MMF"]],"start": [["21"]],"entity_id": [ ],"Drug": {"text": [["MMF"]],"start": [["21"]],"entity_id": [ ]},"Disorder": {"text": [["anemia"]],"start": [["3"]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["prednisone"]],"start": [["53"]],"entity_id": []},"Trigger": {"text": [["given"]],"start": [["47"]],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Freq": {"text": [["well documented"]],"start": [[ "87" ]],"entity_id": []},"Time_elapsed": {"text": [["occur"]],"start": [["15"]],"entity_id": []},"Trigger": {"text": [["can occur"]],"start": [["12"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "16432996_4","context": "We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed sarcoidosis"]],"start": [["39"]],"entity_id": []},"Treatment": {"text": [["treatment by interferon alpha and ribavirin"]],"start": [["28"]],"entity_id": [],"Drug": {"text": [["interferon alpha", "ribavirin"]],"start": [["28"]],"entity_id": []},"Disorder": {"text": [["chronic hepatitis C (CHC)"]],"start": [["8"]],"entity_id": []},"Time_elapsed": {"text": [["after"]],"start": [["30"]],"entity_id": []},"Combination": [{"Drug": {"text": [["interferon alpha"]],"start": [["28"]],"entity_id": []},"Trigger": {"text": [["treatment"]],"start": [["28"]],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["ribavirin"]],"start": [["28"]],"entity_id": []},"Trigger": {"text": [["treatment"]],"start": [["28"]],"entity_id": []},"event_id": "C2","event_type": "Adverse_event"}],"Freq": {"text": [["the treatment"]],"start": [["28"]],"entity_id": []},"Duration": {"text": [["chronic"]],"start": [["8"]],"entity_id": []},"Trigger": {"text": [["report"]],"start": [["0"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["treatment by"]],"start": [["28"]],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["chronic"]],"start": [["8"]],"entity_id": [],"value": "High"},"Subject": {"text": [["a case"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["chronic hepatitis C (CHC)"]],"start": [["8"]],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["sarcoidosis"]],"start": [["39"]],"entity_id": []}}]}
{"id": "8239963_3","context": "Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hypotension"], ["dry mouth"], ["constipation"]],"start": [[ ], [ ], []],"entity_id": [["T1"], ["T2"], ["T3"]]},"Treatment": {"Drug": {"text": [["clonidine"]],"start": [[ ], [ ], []],"entity_id": [["T5"]]},"entity_id": [["T5"]] ,"Disorder": {"text": [["bradycardia"]],"start": [[ ], [ ], []],"entity_id": [["T4"]]} ,"Freq": {"text": [["rare"]],"start": [[ ], [ ], []],"entity_id": [["T6"]]} ,"Trigger": {"text": [["clonidine-induced"]],"start": [[ ], [ ], []],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["well-documented"]],"start": [[ ], [ ], []],"entity_id": [["T7"]]} ,"Dosage": {"text": [["possible adverse effects"]],"start": [[ ], [ ], []],"entity_id": [["T8"]]} ,"Route": {"text": [["effects"]],"start": [[ ], [ ], []],"entity_id": [["T8"]]} ,"Duration": {"text": [["less well recognized"]],"start": [[ ], [ ], []],"entity_id": [["T9"]]} ,"Combination": null ,"text": [["clonidine-induced bradycardia"]],"start": [[ ], [ ], []] },"Severity": null,"Negated": null,"Speculated": null,"Subject": null ,"Effect": null }]}
{"id": "17547624_1", "context": "Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Brugada type electrocardiographic changes"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["lithium", "propafenone"]], "start": [["53"], ["60"]], "entity_id": [],"Drug": {"text": [["lithium"], ["propafenone"]], "start": [["53"], ["60"]], "entity_id": [] },"Disorder": {"text": [["Wolff-Parkinson-White syndrome"]], "start": [["93"]], "entity_id": [] },"Route": {"text": [["concomitant use"]], "start": [["51"]], "entity_id": [] } ,"Time_elapsed": {"text": [["induced"]], "start": [["44"]], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination":[{"Drug": {"text": [["lithium"]], "start": [["53"]], "entity_id": []},"Trigger": {"text":[["concomitant use"]], "start": [["51"]], "entity_id": []},"event_id":"C1","event_type":"Concomitant" },{"Drug": {"text": [["propafenone"]], "start": [["60"]], "entity_id": []},"Trigger": {"text":[["concomitant use"]], "start": [["51"]], "entity_id": []},"event_id":"C2","event_type":"Concomitant" }] ,"Trigger": {"text":[["Brugada type electrocardiographic changes"]], "start": [["0"]], "entity_id": []} },"Effect": {"text": [], "start": [], "entity_id": [] },"Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": [] },"Gender": {"text": [], "start": [], "entity_id": [] },"Population": {"text": [], "start": [], "entity_id": [] },"Race": {"text": [], "start": [], "entity_id": [] },"Disorder": {"text": [["patient with Wolff-Parkinson-White syndrome"]], "start": [["82"]], "entity_id": [] } },"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"Low"}}]}
{"id": "17404582_2", "context": "Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Docetaxel-induced"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Effect": {"text": [["Meibomian duct inflammation and blockage leading to chalazion formation"]], "start": [[ ]], "entity_id": [[ "T2" ]]}, "Treatment": {"text": [["Docetaxel"]], "start": [[ ]], "entity_id": [[ "T1" ]], "Drug": null, "Disorder": {"text": [["Docetaxel"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Combination": null}, "Subject": {"text": [["Docetaxel-induced"]], "start": [[ ]], "entity_id": [[ "T1" ]], "Age": null, "Disorder": {"text": [["Docetaxel-induced"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Gender": null, "Population": null, "Race": null}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "11212595_1", "context": "Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Quetiapine"]], "start": [[ "0" ]], "entity_id": [ ] ,"Drug": { "text": [["Quetiapine"]], "start": [[ "0" ]], "entity_id": [ ] }, "Disorder": { "text": [["obsessive-compulsive symptoms (OCS)"]], "start": [[ "16" ]], "entity_id": [ ] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }}, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "665845_1","context": "A case history of a 15-year-old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["incapacitating tardive dyskinesia"]],"start": [["31"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 15-year-old boy"]],"start": [["6"]],"entity_id": [["T2"]],"Age": {"text": [["15"]],"start": [["10"]],"entity_id": [["T3"]]},"Gender": {"text": [["boy"]],"start": [["7"]],"entity_id": [["T4"]]},"Disorder": {"text": [["incapacitating tardive dyskinesia"]],"start": [["31"]],"entity_id": [["T1"]]},"Population": {"text": [["a 15-year-old boy"]],"start": [["6"]],"entity_id": [["T2"]]},"Race": {"text": [["a 15-year-old boy"]],"start": [["6"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["deanol"]],"start": [["102"]],"entity_id": [["T5"]],"Drug": {"text": [["deanol"]],"start": [["102"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["that resolved during treatment"]],"start": [["86"]],"entity_id": [["T6"]]},"Duration": {"text": [["treatment"]],"start": [["98"]],"entity_id": [["T7"]]},"Disorder": {"text": [["incapacitating tardive dyskinesia"]],"start": [["31"]],"entity_id": [["T1"]]},"Freq": {"text": [["treatment"]],"start": [["98"]],"entity_id": [["T7"]]},"Route": {"text": [["treatment"]],"start": [["98"]],"entity_id": [["T7"]]},"Dosage": {"text": [["deanol"]],"start": [["102"]],"entity_id": [["T5"]]},"Combination": null,"Trigger": {"text": [["deanol"]],"start": [["102"]],"entity_id": [["T5"]]}},"Effect": {"text": [["incapacitating tardive dyskinesia"]],"start": [["31"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["incapacitating"]],"start": [["31"]],"entity_id": [["T1"]],"value": "High"}}]}
{"id": "12187348_2","context": "Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Drug-induced mammary hyperplasias"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["D-penicillamine", "Neothetazone"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["D-penicillamine"]],"start": [[ ]],"entity_id": [ ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Disorder": null} ,"Effect": {"text": [["Drug-induced mammary hyperplasias"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["rare complications"]],"start": [[ ]],"entity_id": [ ],"value": "low"} ,"Subject": null}]}
{"id": "10482872_2", "context": "The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["in utero CP exposure"]],"start": [["15"]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["this report"]],"start": [["0"]],"entity_id": [ ["T0"] ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["multiple congenital anomalies"]], "start": [["55"]], "entity_id": [ ]} },"Effect": {"text": [["CP embryopathy phenotype"]],"start": [["83"]],"entity_id": [ ["T2"] ]} ,"Severity": null, "Negated": null, "Speculated": null ,"Treatment": null }]}
{"id": "18176653_2", "context": "The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["oral adverse effect"]], "start": [["56", "57"]], "entity_id": []}, "Treatment": {"text": [["the antiretroviral medication Nevirapine (NVP)"]], "start": [["115", "116"]], "entity_id": [], "Drug": {"text": [["Nevirapine"]], "start": [["119", "122"]], "entity_id": []},"Route":{"text":[["oral"]],"start":[[ "53","54"]],"entity_id":[]},"Time_elapsed":{"text":[["stemming from the use"]],"start":[["81","97"]],"entity_id":[]},"Disorder":{"text":[["the antiretroviral medication Nevirapine (NVP)"]],"start":[["115","116"]],"entity_id":[]},"Freq":{"text":[["the use"]],"start":[["98","101"]],"entity_id":[]},"Dosage":{"text":[["the antiretroviral medication Nevirapine (NVP)"]],"start":[["115","116"]],"entity_id":[]},"Duration":{"text":[["the clinical characteristics and management"]],"start":[["22","49"]],"entity_id":[]},"Combination":[{"Drug":{"text":[["Nevirapine"]],"start":[["119","122"]],"entity_id":[]},"Trigger":{"text":[["the use"]],"start":[["98","101"]],"entity_id":[]},"event_id":"C1","event_type":"Treatment"}],"Trigger":{"text":[["oral adverse effect"]],"start":[["56","57"]],"entity_id":[]}} , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["The aim"]], "start": [[ "0","1"]], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } , "Effect": { "text": [["clinical characteristics and management"]], "start": [[ "22","49"]], "entity_id": [] }}]}
{"id": "14674674_4","context": "Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["increase"]],"start": [["36"]],"entity_id": []},"Treatment": {"text": [["Treatment with infliximab"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["infliximab"]],"start": [["18"]],"entity_id": []},"Disorder": {"text": [["autoantibodies"]],"start": [["30"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": []},"Effect": {"text": [["antinuclear antibodies","anti-double-stranded DNA"]],"start": [["45","61"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "16882112_2","context": "Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Serotonin syndrome"]],"start": [[ ]] ,"entity_id": [ ]},"Effect": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["serotonin-active medications"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["serotonin-active"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["enhanced serotonin concentration in the central nervous system"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["well-known"]],"start": [[ ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["serotonin-active medications"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["enhanced serotonin concentration in the central nervous system"]],"start": [[ ]],"entity_id": [ ]},"event_id": "E1-1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["occurs"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["occurs"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [["serotonin-active medications"]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["occurs"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["occurs"]],"start": [[ ]],"entity_id": [ ]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [ ]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "11424102_5","context": "Despite the risk of needle-track seeding, PEI remains useful in the treatment of HCC","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["PEI"]],"start": [["15"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["HCC"]],"start": [["52"]],"entity_id": [["T2"]] },"Trigger": {"text": [["useful"]],"start": [["23"]],"entity_id": [["T3"]] },"Freq": {"text": [["remains"]],"start": [["19"]],"entity_id": [["T4"]] },"Dosage": {"text": [["Despite the risk of needle-track seeding"]],"start": [["0"]],"entity_id": [["T5"]] },"Duration": {"text": [["in the treatment"]],"start": [["29"]],"entity_id": [["T6"]] },"Route": {"text": [["of"]],"start": [["42"]],"entity_id": [["T7"]] },"Combination": [{"Drug": {"text": [["PEI"]],"start": [["15"]],"entity_id": [["T1"]] },"Trigger": {"text": [["useful"]],"start": [["23"]],"entity_id": [["T3"]] },"event_id": "C1" ,"event_type": "Potential_therapeutic_effect" }] ,"Time_elapsed": {"text": [["Despite the risk of needle-track seeding"]],"start": [["0"]],"entity_id": [["T5"]] },"Drug": {"text": [["PEI"]],"start": [["15"]],"entity_id": [["T1"]] }} ,"Negated": {"text": [["Despite"]],"start": [["0"]],"entity_id": [["T5"]],"value": false },"Speculated": {"text": [],"start": [],"entity_id": [],"value": false },"Severity": {"text": [],"start": [],"entity_id": [],"value": "" },"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["HCC"]],"start": [["52"]],"entity_id": [["T2"]] }} ,"Effect": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [["useful"]],"start": [["23"]],"entity_id": [["T3"]] }} ]}
{"id": "20412003_4", "context": "Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Trimethoprim-sulfamethoxazole-induced hepatotoxicity"]], "start": [[ ]], "entity_id": [ ]}, "Subject": {"text": [["a pediatric patient"]], "start": [[ ]], "entity_id": [ ],"Age": {"text": [["pediatric"]], "start": [[ ]], "entity_id": [ ]}, "Gender": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Population": {"text": [["a pediatric patient"]], "start": [[ ]], "entity_id": [ ]},"Race": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]}},"Treatment": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Dosage": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Duration": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["Trimethoprim-sulfamethoxazole-induced"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [["null"]], "start": [[ ]], "entity_id": [ ]},"Combination": null},"Effect": {"text": [["hepatotoxicity"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10589077_3","context": "Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["low doses of HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ],"Drug": {"text": [["HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Dosage": {"text": [["3-10 mg/kg/day"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Disorder": {"text": [["Prolonged responses"]],"start": [[ "Prolonged responses were achieved" ]],"entity_id": [ ]},"Duration": {"text": [["low doses of HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["Prolonged responses"]],"start": [[ "Prolonged responses were achieved" ]],"entity_id": [ ]},"Freq": {"text": [["low doses of HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Trigger": {"text": [["achieved"]],"start": [[ "Prolonged responses were achieved" ]],"entity_id": [ ]},"Route": {"text": [["low doses of HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["HU"]],"start": [[ "3-10 mg/kg/day" ]],"entity_id": [ ]},"Trigger": {"text": [["achieved"]],"start": [[ "Prolonged responses were achieved" ]],"entity_id": [ ]},"event_id": "E1","event_type": "Potential_therapeutic_effect"}]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null,"Trigger": {"text": [["achieved"]],"start": [[ "Prolonged responses were achieved" ]],"entity_id": []}}]}
{"id": "8276031_1", "context": "Imidazoline intoxication in children", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Imidazoline intoxication"]], "start": [[ ]],"entity_id": [ ["T1"]]}, "Subject": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] ,"Age": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] },"Gender": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] },"Race": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] },"Population": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] },"Disorder": { "text": [["children"]], "start": [[ "start"]], "entity_id": [ ["T2"]] }} ,"Severity": { "text": [["intoxication"]], "start": [[ "start"]], "entity_id": [ ["T1"]] ,"value": "high" },"Negated": null ,"Speculated": null ,"Effect": null ,"Treatment": null }]}
{"id": "7351000_4", "context": "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": {"value": true, "text": [["not significantly correlated"]], "start": [[ "32" ]], "entity_id": [ ["N1"] ]},"Treatment": {"text": [["Treosulfan"]], "start": [[ "77" ]], "entity_id": [ ["T2"] ], "Dosage": {"text": [["total cumulative dosage"]], "start": [[ "47" ]], "entity_id": [ ["T1"] ]},"Trigger": {"text": [["correlated"]], "start": [[ "38" ]], "entity_id": [ ["N2"] ]},"Disorder": {"text": [["acute leukemia"]], "start": [[ "13" ]], "entity_id": [ ["D1"] ]},"Time_elapsed": null,"Freq": null,"Route": null,"Duration": null,"Drug": null,"Combination": null} ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["acute leukemia"]], "start": [[ "13" ]], "entity_id": [ ["D1"] ]} },"Effect": { "text": [], "start": [], "entity_id": [] },"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "11443640_1", "context": "Massive plasmocytosis due to methimazole-induced bone marrow toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["massive plasmocytosis"]], "start": [["0"]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["methimazole"]], "start": [[ "41"]], "entity_id": [ ["T2"]], "Drug": {"text": [["methimazole"]], "start": [[ "41"]], "entity_id": [ ["T3"]]},"Combination": [{"Drug": {"text": [["methimazole"]], "start": [[ "41"]], "entity_id": [ ["T3"]]},"Trigger": {"text": [["bone marrow toxicity"]], "start": [[ "61"]], "entity_id": [ ["T4"]]}, "event_type": "Adverse_event", "event_id": "E2"}],"Disorder": {"text": [["plasmocytosis"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}, "Dosage": {"text": [["massive"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}, "Route": {"text": [["due to"]], "start": [[ "41"]], "entity_id": [ ["T5"]]},"Time_elapsed": {"text": [["induced"]], "start": [[ "41"]], "entity_id": [ ["T6"]]}, "Freq": {"text": [["massive"]], "start": [[ "0"]], "entity_id": [ ["T1"]]},"Trigger": {"text": [["bone marrow toxicity"]], "start": [[ "61"]], "entity_id": [ ["T4"]]}, "Duration": {"text": [["massive"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}}, "Severity": {"text": [["massive"]], "start": [["0"]], "entity_id": [ ["T1"]],"value": "High"},"Subject": {"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["plasmocytosis"]], "start": [[ "0"]], "entity_id": [ ["T1"]]},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"text": [["Patient"]], "start": [[ "0"]], "entity_id": [ ["T0"]]}, "Negated": null, "Speculated": null , "Effect": {"text": [["plasmocytosis"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}}]}
{"id": "15331204_4","context": "After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["indapamide"]],"start": [["22"]],"entity_id": [["T1"]]},"Dosage": {"text": [["2.5 mg/day"]],"start": [["27"]],"entity_id": [["T2"]]},"Duration": {"text": [["4- to 14-month period"]],"start": [["4"]],"entity_id": [["T3"]]},"Route": {"text": [["therapy"]],"start": [["20"]],"entity_id": [["T4"]]},"Trigger": {"text": [["therapy"]],"start": [["20"]],"entity_id": [["T4"]]},"Freq": {"text": [["daily"]],"start": [["27"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["fosinopril"]],"start": [["41"]],"entity_id": [["T6"]]},"Trigger": {"text": [["combination"]],"start": [["35"]],"entity_id": [["T7"]]},"event_id": "E2","event_type":"Potential_therapeutic_effect"}],"Disorder": {"text": [["diabetes diagnoses"]],"start": [["96"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [["after"]],"start": [["4"]],"entity_id": [["T9"]]},"entity_id": [["T1"],["T2"],["T3"],["T4"],["T5"],["T6"],["T7"],["T8"]],"start": [["22"],["27"],["4"],["20"],["27"],["41"],["35"],["96"]],"text": [["indapamide"],["2.5 mg/day"],["4- to 14-month period"],["therapy"],["daily"],["fosinopril"],["combination"],["diabetes diagnoses"]]},"Effect": {"text": [["increased"]],"start": [["79"]],"entity_id": [["T10"]]},"Subject": {"text": [["three patients"]],"start": [["53"]],"entity_id": [["T11"]],"Population": {"text": [["three patients"]],"start": [["53"]],"entity_id": [["T11"]]},"Age": {"text": [["four-month period"]],"start": [["5"]],"entity_id": [["T12"]]},"Gender": {"text": [["three patients"]],"start": [["53"]],"entity_id": [["T11"]]},"Race": {"text": [["three patients"]],"start": [["53"]],"entity_id": [["T11"]]},"Disorder": {"text": [["diabetes diagnoses"]],"start": [["96"]],"entity_id": [["T8"]]}},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["increased"]],"start": [["79"]],"entity_id": [["T10"]]}}]}
{"id": "6453500_1","context": "A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reversible toxic liver damage"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["disulfiram"]],"start": [["78"]],"entity_id": [["T2"]],"Drug": {"text": [["disulfiram"]],"start": [["78"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["toxic liver damage"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["treated"]],"start": [["53"]],"entity_id": [["T3"]]},"Duration": {"text": [["was observed"]],"start": [["0"]],"entity_id": [["T4"]]},"Route": {"text": [["treated"]],"start": [["53"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []}, "Freq": {"text": [],"start": [],"entity_id": []}, "Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} }, "Subject": {"text": [["A non-alcoholic woman"]],"start": [["17"]],"entity_id": [["T5"]], "Age": {"text": [],"start": [],"entity_id": []}, "Gender": {"text": [["woman"]],"start": [["32"]],"entity_id": [["T6"]]}, "Population": {"text": [],"start": [],"entity_id": []}, "Race": {"text": [["non-alcoholic"]],"start": [["17"]],"entity_id": [["T5"]]}, "Disorder": {"text": [],"start": [],"entity_id": []} }, "Effect": {"text": [["reversible toxic liver damage"]],"start": [["0"]],"entity_id": [["T1"]]}, "Negated": {"text": [],"start": [],"entity_id": [] ,"value": false }, "Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false }, "Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }}]}
{"id": "10904571_1","context": "A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute proximal muscle weakness"]],"start": [["48"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 60 year-old woman"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["60"]],"start": [["5"]],"entity_id": [["T3"]]},"Gender": {"text": [["woman"]],"start": [["20"]],"entity_id": [["T4"]]},"Disorder": {"text": [["chronic renal failure"]],"start": [["25"]],"entity_id": [["T5"]]},"Population": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]},"Race": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]}},"Treatment": {"text": [["colchicine"]],"start": [["115"]],"entity_id": [["T6"]],"Drug": {"text": [["colchicine"]],"start": [["115"]],"entity_id": [["T6"]]},"Dosage": {"text": [["regular dosage"]],"start": [["101"]],"entity_id": [["T7"]]},"Duration": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]},"Disorder": {"text": [["chronic renal failure"]],"start": [[""],[]],"entity_id": [["T5"]]},"Route": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]},"Freq": {"text": [["A 60 year-old woman"]],"start": [[""],[]],"entity_id": [["T2"]]},"Combination": null,"Trigger": {"text": [["after receiving"]],"start": [["92"]],"entity_id": [["T8"]]}},"Effect": {"text": [["acute proximal muscle weakness"]],"start": [[""],[]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [[""],[]],"entity_id": [["T1"]],"value": "high"}}]}
{"id": "9824032_2","context": "The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth._","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["side effects"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["niacin therapy"]],"start": [["4"]],"entity_id": [["T2"]],"Drug": {"text": [["niacin"]],"start": [["4"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["side effects"]],"start": [["13"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["unreported"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]]} ,"Route": {"text": [["therapy"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["unreported"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["niacin"]],"start": [["4"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["niacin"]],"start": [["4"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["4"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["side effects"]],"start": [["13"]],"entity_id": [["T1"]]}} ,"Subject": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]],"Disorder": {"text": [["side effects"]],"start": [["13"]],"entity_id": [["T1"]]} ,"Age": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]]},"Population": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]]},"Gender": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]]},"Race": {"text": [["these"]],"start": [["10"]],"entity_id": [["T0"]]} },"Effect": {"text": [["side effects"]],"start": [["13"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": {"text": [["uncertain"]],"start": [["25"]],"entity_id": [["T4"]] ,"value": true} ,"Severity": null }]}
{"id": "16404563_4", "context": "Nocardia is an important opportunistic infectious agent in immunocompromised hosts, i.e. in patients taking corticosteroids", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["corticosteroids"]], "start": [["patients taking corticosteroids" ] ], "entity_id": [],"Disorder": {"text": [["immunocompromised hosts"]], "start": [[ "immunocompromised hosts" ]], "entity_id": []},"Trigger": {"text": [["patients taking corticosteroids"]], "start": [[ "patients taking corticosteroids" ]], "entity_id": []},"Freq": {"text": [["taking"]], "start": [["taking"]], "entity_id": []},"Drug": {"text": [["corticosteroids"]], "start": [["corticosteroids"]], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Combination": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "3790438_2","context": "We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["provoked"]],"start": [["37"]],"entity_id": []},"Treatment": {"text": [["the anti-depressant trazodone hydrochloride (Molipaxin, Roussel)"]],"start": [["11"]],"entity_id": [],"Drug": {"text": [["trazodone hydrochloride"]],"start": [["23"]],"entity_id": []},"Disorder": {"text": [["generalized pustular psoriasis (GPP)"]],"start": [["71"]],"entity_id": []},"Route": {"text": [["a serotonin antagonist"]],"start": [["47"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null,"Dosage": {"text": [],"start": [],"entity_id": []},"Trigger": null},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11703329_1","context": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["early recognition"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["hereditary motor and sensory neuropathy type 1"]],"start": [["23"]],"entity_id": [],"Disorder": {"text": [["hereditary motor and sensory neuropathy type 1"]],"start": [["23"]],"entity_id": []},"Time_elapsed": {"text": [["can avoid"]],"start": [["44"]],"entity_id": []},"Trigger": {"text": [["life-threatening vincristine neurotoxicity"]],"start": [["55"]],"entity_id": []},"Drug": {"text": [["vincristine"]],"start": [["55"]],"entity_id": []},"Freq": {"text": [["early recognition"]],"start": [["0"]],"entity_id": []},"Combination": [{"Drug": {"text": [["hereditary motor and sensory neuropathy type 1"]],"start": [["23"]],"entity_id": []},"Trigger": {"text": [["life-threatening vincristine neurotoxicity"]],"start": [["55"]],"entity_id": []},"event_type": "Potential_therapeutic_effect","event_id": "E2"}],"Duration": {"text": [["early recognition"]],"start": [["0"]],"entity_id": []},"Route": {"text": [["early recognition"]],"start": [["0"]],"entity_id": []},"Dosage": {"text": [["early recognition"]],"start": [["0"]],"entity_id": []}},"Subject": {"text": [["patient with hereditary motor and sensory neuropathy type 1"]],"start": [["0"]],"entity_id": [],"Age": {"text": [["patient"]],"start": [["0"]],"entity_id": []},"Gender": {"text": [["patient"]],"start": [["0"]],"entity_id": []},"Population": {"text": [["patient"]],"start": [["0"]],"entity_id": []},"Race": {"text": [["patient"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["patient with hereditary motor and sensory neuropathy type 1"]],"start": [["0"]],"entity_id": []}},"Negated": {"text": [["avoid"]],"start": [["44"]],"entity_id": [],"value": false},"Speculated": {"text": [["early recognition"]],"start": [["0"]],"entity_id": [],"value": false},"Severity": {"text": [["life-threatening"]],"start": [["55"]],"entity_id": [],"value": "High"},"Effect": {"text": [["avoid life-threatening vincristine neurotoxicity"]],"start": [["44"]],"entity_id": []}}]}
{"id": "19299370_3", "context": "Probable enoxaparin-induced hepatotoxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["enoxaparin-induced hepatotoxicity"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["enoxaparin"]], "start": [["12"]], "entity_id": [], "Drug": {"text": [["enoxaparin"]], "start": [["12"]], "entity_id": []},"Disorder": {"text": [["hepatotoxicity"]], "start": [["19"]], "entity_id": []},"Route": {"text": [["-induced"]], "start": [["13"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["enoxaparin-induced hepatotoxicity"]], "start": [["0"]], "entity_id": []}},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": {"text": [["Probable"]], "start": [["0"]], "entity_id": [],"value": true},"Severity": null,"Subject": null}]}
{"id": "12581772_1", "context": "Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null, "Effect": {"text": [["Interstitial pneumonitis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Trigger": {"text": [["associated with"]], "start": [[ "22" ]], "entity_id": [ ["T2"] ]}}]}
{"id": "19667003_15","context": "He had also developed elevated serum ammonia levels while on valproic acid","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["elevated serum ammonia levels"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["valproic acid"]],"start": [["72"]],"entity_id": [["T2"]],"Drug": {"text": [["valproic acid"]],"start": [["72"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["while on"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Route": {"text": [["on"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["had also developed"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["elevated serum ammonia levels"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["null"]],"start": [[""]],"entity_id": [["T6"]]} ,"Freq": {"text": [["null"]],"start": [[""]],"entity_id": [["T7"]]} ,"Combination": null ,"Trigger": {"text": [["on"]],"start": [["71"]],"entity_id": [["T4"]]} },"Subject": {"text": [["He"]],"start": [[""]],"entity_id": [["T8"]],"Age": {"text": [["null"]],"start": [[""]],"entity_id": [["T9"]]},"Gender": {"text": [["null"]],"start": [[""]],"entity_id": [["T10"]]},"Population": {"text": [["null"]],"start": [[""]],"entity_id": [["T11"]]},"Race": {"text": [["null"]],"start": [[""]],"entity_id": [["T12"]]},"Disorder": {"text": [["null"]],"start": [[""]],"entity_id": [["T13"]]}},"Effect": {"text": [["elevated serum ammonia levels"]],"start": [["28"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""]],"entity_id": [["T14"]] ,"value": false },"Speculated": {"text": [["null"]],"start": [[""]],"entity_id": [["T15"]],"value": false },"Severity": {"text": [["null"]],"start": [[""]],"entity_id": [["T16"]],"value": "null" }} ]}
{"id": "16641839_4","context": "Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Cutaneous rashes and eruptions"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]}, "Treatment": null, "Effect": { "text": [["Cutaneous rashes and eruptions"]], "start": [[ "0" ]] ,"entity_id": [ ["T1"] ]} ,"Subject": null ,"Severity": null ,"Negated": null ,"Speculated": null }] }
{"id": "19897274_4","context": "Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["sorafenib"]],"start": [[ "27" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["sorafenib"]],"start": [[ "27" ]],"entity_id": [ ["T1"] ]} ,"Disorder": {"text": [["serious interstitial lung disease"]],"start": [[ "74" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["induce"]],"start": [[ "55" ]],"entity_id": [ ["T3"] ]} ,"Freq": {"text": [["can potentially"]],"start": [[ "43" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }},"Negated": null,"Speculated": {"text": [["might"]],"start": [[ "107" ]],"entity_id": [ ["T5"] ],"value": true },"Severity": {"text": [["serious"]],"start": [[ "75" ]],"entity_id": [ ["T6"] ],"value": "high" },"Effect": {"text": [],"start": [],"entity_id": [] },"Trigger": null }] }
{"id": "19667003_3", "context": "A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["carbamazepine"]],"start": [["68"]],"entity_id": [["T1"]]},"Disorder": {"text": [["aggression", "seizure control"]],"start": [["113", "134"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["began treatment"]],"start": [["102"]],"entity_id": [["T3"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"text": [[ "began treatment with carbamazepine for aggression and seizure control"]], "start": [[ "102" ]], "entity_id": [[ "T3" ]]} ,"Subject": {"text": [["A 26-year-old man"]],"start": [[ "0" ]],"entity_id": [[ "S1" ]],"Age": {"text": [[ "26" ]],"start": [[ "5" ]],"entity_id": [[ "A1" ]]}, "Gender": {"text": [[ "man" ]],"start": [[ "25" ]],"entity_id": [[ "G1" ]]}, "Population": {"text": [],"start": [],"entity_id": []}, "Race": {"text": [],"start": [],"entity_id": []}, "Disorder": {"text": [["bipolar disorder", "seizures", "mild mental retardation secondary to a traumatic brain injury"]],"start": [[ "25", "32", "54" ]],"entity_id": [[ "D1" ]]}}, "Effect": {"text": [],"start": [],"entity_id": []}, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "18676387_3","context": "Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Serotonin toxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["fentanyl"]],"start": [[ "35" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["fentanyl"]],"start": [[ "35" ]],"entity_id": [ ["T2"] ]} ,"entity_id": [ ["T2"] ],"text": [["fentanyl"]],"start": [[ "35" ]],"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["Serotonin toxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Route": null ,"Dosage": null ,"Freq": null ,"Combination": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "16889287_1","context": "It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": {"text": [["may"]],"start": [[ "0" ]],"entity_id": [["N1" ]] ,"value": true },"Trigger": {"text": [["severe adverse drug reaction"]],"start": [[ "21" ]],"entity_id": [["T1"]] },"Treatment": {"text": [["dapsone"]],"start": [[ "68" ]],"entity_id": [["T2"]],"Drug": {"text": [["dapsone"]],"start": [[ "68" ]],"entity_id": [["T3"]] },"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Disorder": {"text": [["multiorgan involvement known as dapsone hypersensitivity syndrome"]],"start": [[ "48" ]],"entity_id": [["T4"]] },"Trigger": null },"Effect": {"text": [["severe adverse drug reaction"]],"start": [[ "21" ]],"entity_id": [["E1-Effect"]] },"Severity": {"text": [["severe"]],"start": [[ "21" ]],"entity_id": [["S1"]],"value": "severe" },"Subject": {"text": [["It"]],"start": [[ "0" ]],"entity_id": [["S2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }} ]}
{"id": "1124417_2","context": "Renal failure associated with acetazolamide therapy for glaucoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["renal failure"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["acetazolamide therapy"]],"start": [[ "29" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["acetazolamide"]],"start": [[ "29" ]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["glaucoma"]],"start": [[ "56" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["associated with"]],"start": [[ "22" ]],"entity_id": [ ["T5"] ]} ,"Duration": {"text": [["therapy"]],"start": [[ "30" ]],"entity_id": [ ["T6"] ]} ,"Freq": {"text": [["therapy"]],"start": [[ "30" ]],"entity_id": [ ["T6"] ]} ,"Route": {"text": [["therapy"]],"start": [[ "30" ]],"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [["therapy"]],"start": [[ "30" ]],"entity_id": [ ["T6"] ]} ,"Combination": null ,"Trigger": {"text": [["acetazolamide therapy"]],"start": [[ "29" ]],"entity_id": [ ["T2"] ]}} ,"Effect": null ,"Subject": {"text": [["patient"]],"start": [[ "-1" ]],"entity_id": [[ "-1" ]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12424571_1", "context": "Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute onset", "nephrotic syndrome"]], "start": [[ "acute onset" , "nephrotic syndrome" ]], "entity_id": [ ["T1"] , ["T2"] ]} ,"Subject": { "text": [["patient"]], "start": [[ "patient" ]], "entity_id": [ ["T0"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["chronic active hepatitis C"]], "start": [[ "chronic active hepatitis C" ]], "entity_id": [ ["T3"] ] } }, "Treatment": { "text": [["interferon-alpha retreatment"]], "start": [[ "interferon-alpha retreatment" ]], "entity_id": [ ["T4"] ], "Drug": { "text": [["interferon-alpha"]], "start": [[ "interferon-alpha" ]], "entity_id": [ ["T5"] ] }, "Disorder": { "text": [["chronic active hepatitis C"]], "start": [[ "chronic active hepatitis C" ]], "entity_id": [ ["T3"] ] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null , "Trigger": { "text": [["acute onset"]], "start": [[ "acute onset" ]], "entity_id": [ ["T1"] ] } } , "Effect": { "text": [["nephrotic syndrome"]], "start": [[ "nephrotic syndrome" ]], "entity_id": [ ["T2"] ] } , "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "12587815_1", "context": "A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. ", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 16-year-old boy"]], "start": [[ ]], "entity_id": [ ],"Age": {"text": [["16"]], "start": [[ ]], "entity_id": [ ]},"Gender": {"text": [["boy"]], "start": [[ ]], "entity_id": [ ]},"Population": {"text": [["A 16-year-old boy"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Race": {"text": [ ], "start": [[ ]], "entity_id": [ ]}},"Treatment": {"text": [["treatment with olanzapine and lithium"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["olanzapine"]], "start": [[ ]], "entity_id": [ ]},"Dosage": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Duration": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [ ], "start": [[ ]], "entity_id": [ ]},"Combination": [{"Drug": {"text": [["olanzapine"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["treatment with olanzapine and lithium"]], "start": [[ ]], "entity_id": [ ]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["lithium"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["treatment with olanzapine and lithium"]], "start": [[ ]], "entity_id": [ ]},"event_id": "C2","event_type": "Combination"}] ,"Disorder": {"text": [ ], "start": [[ ]], "entity_id": [ ]}},"Effect": {"text": [["fever"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["developed"]], "start": [[ ]], "entity_id": [ ]}}]}
{"id": "2295443_1", "context": "Bowel perforation associated with intraperitoneal chromic phosphate instillation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Bowel perforation"]], "start": [[ ]], "entity_id": [ ]},"Treatment": {"text": [["intraperitoneal chromic phosphate instillation"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["chromic phosphate"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["intraperitoneal"]], "start": [[ ]], "entity_id": [ ]},"Freq": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"Dosage": null,"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "2224786_1","context": "A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["chemotherapy-related hemolytic-uremic syndrome"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Treatment": {"text": [["neoadjuvant chemotherapy"]],"start": [["62"]],"entity_id": [["T2"]],"Disorder": {"text": [["squamous cell carcinoma of the head and neck"]],"start": [["17"]],"entity_id": [["T3"]]},"Drug": {"text": [["cisplatin", "bleomycin", "methotrexate"]],"start": [["88", "90", "100"]],"entity_id": [["T4", "T5", "T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [["second cycle"]],"start": [["52"]],"entity_id": [["T7"]]},"Route": {"text": [["neoadjuvant chemotherapy"]],"start": [["62"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [["chemotherapy-related hemolytic-uremic syndrome"]],"start": [["31"]],"entity_id": [["T1"]]} },"Subject": {"text": [["A 62-year-old woman"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [["62"]],"start": [["3"]],"entity_id": [["T9"]]},"Gender": {"text": [["woman"]],"start": [["12"]],"entity_id": [["T10"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["squamous cell carcinoma of the head and neck"]],"start": [["17"]],"entity_id": [["T3"]]} },"Effect": {"text": [["hemolytic-uremic syndrome"]],"start": [["43"]],"entity_id": [["T11"]]},"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "11243427_4","context": "Ectropion secondary to bolus injection of 5-fluorouracil","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bolus injection"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["5-fluorouracil"]],"start": [["33"]],"entity_id": [["T2"]],"Drug": {"text": [["5-fluorouracil"]],"start": [["33"]],"entity_id": [["T2"]]},"Route": {"text": [["bolus injection"]],"start": [["18"]],"entity_id": [["T1"]]},"Freq": {"text": [["1"]],"start": [["18"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["5-fluorouracil"]],"start": [["33"]],"entity_id": [["T2"]]},"Trigger": {"text": [["bolus injection"]],"start": [["18"]],"entity_id": [["T1"]]},"event_id": "E1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["secondary to"]],"start": [["10"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Ectropion"]],"start": [["0"]],"entity_id": [["T4"]]},"Dosage": {"text": [["5-fluorouracil"]],"start": [["33"]],"entity_id": [["T2"]]},"Duration": {"text": [["1"]],"start": [["18"]],"entity_id": [["T1"]]},"Trigger": {"text": [["bolus injection"]],"start": [["18"]],"entity_id": [["T1"]]}},"Subject": {"text": [["patient"]],"start": [[""], []],"entity_id": [["T0"]],"Age": {"text": [["age"]],"start": [[""], []],"entity_id": [["T0"]]},"Disorder": {"text": [["Ectropion"]],"start": [[""], []],"entity_id": [["T4"]]},"Gender": {"text": [["gender"]],"start": [[""], []],"entity_id": [["T0"]]},"Population": {"text": [["population"]],"start": [[""], []],"entity_id": [["T0"]]},"Race": {"text": [["race"]],"start": [[""], []],"entity_id": [["T0"]]}},"Severity": {"text": [["severe"]],"start": [[""], []],"entity_id": [["T4"]],"value": "high"},"Negated": {"text": [["not"]],"start": [[""], []],"entity_id": [["T0"]],"value": false},"Speculated": {"text": [["likely"]],"start": [[""], []],"entity_id": [["T0"]],"value": true},"Effect": {"text": [["Ectropion"]],"start": [[""], []],"entity_id": [["T4"]]}}]}
{"id": "25407257_4", "context": "A 6-year-old boy (weight: 16 kg, at the start of treatment) began sodium valproate (valproate syrup 5%) treatment for epilepsy in February 2012", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["sodium valproate (valproate syrup 5%)"]], "start": [["17","28"]], "entity_id": [["T1"]],"Dosage": {"text": [["5%"]], "start": [["43"]], "entity_id": [["T2"]]},"Route": {"text": [["syrup"]], "start": [["36"]], "entity_id": [["T3"]]},"Disorder": {"text": [["epilepsy"]], "start": [["55"]], "entity_id": [["T4"]]},"Duration": {"text": [["February 2012"]], "start": [["75","84"]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["began"]], "start": [["11"]], "entity_id": [["T6"]]},"Freq": {"text": [["start of treatment"]], "start": [["29","38"]], "entity_id": [["T7"]]},"Trigger": {"text": [["A 6-year-old boy (weight: 16 kg)"]], "start": [[""],["0","5"]], "entity_id": [["T8"]] },"Combination": [{"Drug":{"text":[["sodium valproate"]],"start":[["17"]],"entity_id":[["T9"]]},"Trigger":{"text":[["began"]],"start":[["11"]],"entity_id":[["T10"]]},"event_type":"Potential_therapeutic_effect","event_id":"E2"} ] ,"Drug":{"text":[["valproate syrup 5%"]],"start":[["28"]],"entity_id":[["T11"]]}},"Subject":{"text":[["A 6-year-old boy (weight: 16 kg)"]],"start":[[""],["0","5"]],"entity_id":[["T12"]],"Age":{"text":[["6-year-old"]],"start":[["0","5"]],"entity_id":[["T13"]]},"Gender":{"text":[["boy"]],"start":[["6"]],"entity_id":[["T14"]]},"Population":{"text":[["A 6-year-old boy"]],"start":[[""],["0","5"]],"entity_id":[["T15"]]},"Disorder":{"text":[["epilepsy"]],"start":[["55"]],"entity_id":[["T16"]]},"Race":{"text":[["A 6-year-old boy"]],"start":[[""],["0","5"]],"entity_id":[["T17"]]} },"Negated":null,"Speculated":null,"Severity":null,"Effect":null,"Trigger":{"text":[["began"]],"start":[["11"]],"entity_id":[["T18"]]}}]}
{"id": "3465489_1", "context": "Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["6-mercaptopurine"]], "start": [["4"]], "entity_id": [ ["T1"] ] ,"Drug": { "text": [["6-mercaptopurine"]], "start": [["4"]], "entity_id": [ ["T1"] ] } ,"Disorder": { "text": [["myelotoxicity"]], "start": [["22"]], "entity_id": [ ["T2"] ] } ,"Freq": { "text": [["children with acute lymphoblastic leukemia"]], "start": [["52"]], "entity_id": [ ["T3"] ] } ,"Duration": { "text": [["children with acute lymphoblastic leukemia"]], "start": [["52"]], "entity_id": [ ["T3"] ] } ,"Trigger": { "text": [["pharmacokinetic determinants"]], "start": [["0"]], "entity_id": [ ["T0"] ] } ,"Time_elapsed": { "text": [["pharmacokinetic determinants"]], "start": [["0"]], "entity_id": [ ["T0"] ] } ,"Route": { "text": [["6-mercaptopurine"]], "start": [["4"]], "entity_id": [ ["T1"] ] } ,"Dosage": { "text": [["6-mercaptopurine"]], "start": [["4"]], "entity_id": [ ["T1"] ] } ,"Combination": [] }, "Subject": { "text": [["children with acute lymphoblastic leukemia"]], "start": [["52"]], "entity_id": [ ["T3"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["acute lymphoblastic leukemia"]], "start": [["60"]], "entity_id": [ ["T4"] ] } } , "Severity": { "text": [["myelotoxicity"]], "start": [["22"]], "entity_id": [ ["T2"] ], "value": "medium" } , "Negated": null, "Speculated": null , "Effect": { "text": [["therapeutic failure"]], "start": [["73"]], "entity_id": [ ["T5"] ] } , "Trigger": { "text": [["pharmacokinetic determinants"]], "start": [["0"]], "entity_id": [ ["T0"] ] } }]}
{"id": "15735923_8","context": "Considering the increasing use of TMZ, which is regarded as a drug with moderate toxicity, careful follow-up with routine blood testing is vital","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["TMZ"]],"start": [["11"]],"entity_id": [["T1"]]},"text": [["the increasing use of TMZ"]],"start": [["0"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["moderate toxicity"]],"start": [["21"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["increasing use"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["use"]],"start": [["10"]],"entity_id": [["T1"]]} ,"Route": {"text": [["oral"]],"start": [[],[],[]],"entity_id": [[]]} ,"Dosage": {"text": [["standard doses"]],"start": [[],[],[]],"entity_id": [[]]} ,"Time_elapsed": {"text": [[]],"start": [[],[],[]],"entity_id": [[]]} ,"Freq": {"text": [["as needed"]],"start": [[],[],[]],"entity_id": [[]]} ,"Combination": [{"Drug": {"text": [["drug A"]],"start": [[],[],[]],"entity_id": [[]]},"Trigger": {"text": [["and"]],"start": [[],[],[]],"entity_id": [[]]},"event_id": "E2" ,"event_type": "Potential_therapeutic_effect"} ]} ,"Effect": {"text": [["careful follow-up with routine blood testing"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Negated": {"text": [],"start": [[],[],[]],"entity_id": [[]] ,"value": false },"Speculated": {"text": [],"start": [[],[],[]],"entity_id": [[]] ,"value": false },"Severity": {"text": [],"start": [[],[],[]],"entity_id": [[]] ,"value": "moderate" },"Subject": {"text": [["the patient"]],"start": [[],[],[]],"entity_id": [[]] ,"Age": {"text": [],"start": [[],[],[]],"entity_id": [[]] },"Gender": {"text": [],"start": [[],[],[]],"entity_id": [[]] },"Population": {"text": [],"start": [[],[],[]],"entity_id": [[]] },"Race": {"text": [],"start": [[],[],[]],"entity_id": [[]] },"Disorder": {"text": [],"start": [[],[],[]],"entity_id": [[]] }} ,"Trigger": {"text": [["the increasing use"]],"start": [["0"]],"entity_id": [["T1"]] }} ] }
{"id": "11093071_3","context": "While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["antidepressants"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["prevent"]],"start": [["43"]],"entity_id": [["T2"]],"Trigger": {"text": [["changes in serotonergic or noradrenergic neurotransmission"]],"start": [["55"]],"entity_id": [["T3"]]},"Disorder": {"text": [["caused by IFN-alpha"]],"start": [["83"]],"entity_id": [["T4"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Drug": {"text": [["ribavirin"]],"start": [["0"]],"entity_id": [["T0"]] }},"Negated": {"text": [["not known"]],"start": [["10"]],"entity_id": [["T5"]],"value": false},"Speculated": {"text": [["we suppose that"]],"start": [["5"]],"entity_id": [["T6"]],"value": true},"Severity": null,"Subject": null ,"Effect": null } ]}
{"id": "17381671_2","context": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["11"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fentanyl", "citalopram"]],"start": [["42","63"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["fentanyl","citalopram"]],"start": [["42","63"]],"entity_id": [["T4","T5"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["11"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["interaction between"]],"start": [["29","38"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["fentanyl"]],"start": [["42"]],"entity_id": [["T4"]]},"Trigger": {"text": [["interaction between"]],"start": [["29","38"]],"entity_id": [["T6"]]},"event_id": "C1","event_type":"Adverse_event"},{"Drug": {"text": [["citalopram"]],"start": [["63"]],"entity_id": [["T5"]]},"Trigger": {"text": [["interaction between"]],"start": [["29","38"]],"entity_id": [["T6"]]},"event_id": "C2","event_type":"Adverse_event"}],"Freq": {"text": [["associated with"]],"start": [["1","10"]],"entity_id": [["T7"]]},"Duration": {"text": [["following discontinuation"]],"start": [["82"]],"entity_id": [["T8"]]},"Trigger": {"text": [["interaction between"]],"start": [["29","38"]],"entity_id": [["T6"]]},"Route": {"text": [["following discontinuation"]],"start": [["82"]],"entity_id": [["T8"]]},"Dosage": {"text": [["following discontinuation"]],"start": [["82"]],"entity_id": [["T8"]]}},"Subject": {"text": [["To report a case"]],"start": [["0"]],"entity_id": [["T9"]],"Population": {"text": [["a case"]],"start": [["5"]],"entity_id": [["T10"]]},"Age": {"text": [["To report a case"]],"start": [["0"]],"entity_id": [["T9"]]},"Gender": {"text": [["To report a case"]],"start": [["0"]],"entity_id": [["T9"]]},"Race": {"text": [["To report a case"]],"start": [["0"]],"entity_id": [["T9"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["11"]],"entity_id": [["T1"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"},"Effect": {"text": [["serotonin syndrome"]],"start": [["11"]],"entity_id": [["T1"]]}}]}
{"id": "2586773_2","context": "We report a case of ibuprofen-induced meningitis in an otherwise healthy individual","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ibuprofen-induced meningitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ibuprofen"]],"start": [["5"]],"entity_id": [["T2"]] ,"Drug": {"text": [["ibuprofen"]],"start": [["5"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["meningitis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Route": {"text": [["oral"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["null"]],"start": [[""]],"entity_id": [["T4"]]} ,"Freq": {"text": [["once"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["null"]],"start": [[""]],"entity_id": [["T6"]]} ,"Duration": {"text": [["null"]],"start": [[""]],"entity_id": [["T7"]]} ,"Combination": null ,"Trigger": null} ,"Subject": {"text": [["an otherwise healthy individual"]],"start": [["44"]],"entity_id": [["T8"]],"Age": {"text": [["null"]],"start": [[""]],"entity_id": [["T9"]]} ,"Gender": {"text": [["null"]],"start": [[""]],"entity_id": [["T10"]]} ,"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T11"]]} ,"Race": {"text": [["null"]],"start": [[""]],"entity_id": [["T12"]]} ,"Disorder": {"text": [["null"]],"start": [[""]],"entity_id": [["T13"]]}} ,"Negated": {"text": [["null"]],"start": [[""]],"entity_id": [["T14"]],"value": false} ,"Speculated": {"text": [["null"]],"start": [[""]],"entity_id": [["T15"]],"value": false} ,"Severity": {"text": [["null"]],"start": [[""]],"entity_id": [["T16"]],"value": "null"} ,"Effect": {"text": [["meningitis"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "10482872_3","context": "The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["in utero exposure to cyclosposphamide"]],"start": [[ "in utero exposure to cyclosposphamide" ]],"entity_id": [ ["T1"] ]},"Effect": {"text": [["growth deficiency"]],"start": [[ "growth deficiency" ]],"entity_id": [ ["T2"] ]},"Subject": {"text": [["our patient"]],"start": [[ "our patient" ]],"entity_id": [ ["T3"] ],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":null },"Treatment": {"text": [["in utero exposure to cyclosposphamide"]],"start": [[ "in utero exposure to cyclosposphamide" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["cyclosposphamide"]],"start": [[ "cyclosposphamide" ]],"entity_id": [ ["T4"] ]},"Dosage":null,"Duration":null,"Disorder": {"text": [["in utero exposure"]],"start": [[ "in utero exposure" ]],"entity_id": [ ["T1"] ]},"Route":null,"Time_elapsed":null,"Freq":null ,"Combination":null ,"Trigger": {"text": [["manifestations"]],"start": [[ "manifestations" ]],"entity_id": [ ["T5"] ]} }, "Negated":null, "Speculated":null, "Severity":null }] }
{"id": "1295628_1", "context": "Carbamazepine-induced systemic lupus erythematosus-like disease", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Carbamazepine-induced systemic lupus erythematosus-like disease"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ], "Drug": null ,"Disorder": {"text": [["systemic lupus erythematosus-like disease"]], "start": [[ "27" ]], "entity_id": [ ["T3"] ]} ,"Duration": null ,"Dosage": null ,"Route": null ,"Freq": null ,"Time_elapsed": null ,"Trigger": null ,"Combination": null }, "Subject": { "text": [[ "Carbamazepine-induced systemic lupus erythematosus-like disease" ]], "start": [[ "0" ]], "entity_id": [[ "T1" ]], "Age": null, "Disorder": {"text": [[ "systemic lupus erythematosus-like disease" ]], "start": [[ "27" ]], "entity_id": [[ "T3" ]] }, "Population": null, "Race": null, "Gender": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "7653281_8","context": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hepatoxicity"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ethanol"]],"start": [["34"]],"entity_id": [["T2"]],"Drug": {"text": [["ethanol"]],"start": [["34"]],"entity_id": [["T2"]]},"Disorder": {"text": [["liver damage"]],"start": [["104"]],"entity_id": [["T3"]]},"Trigger": {"text": [["interaction"]],"start": [["57"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["ethanol"]],"start": [["34"]],"entity_id": [["T2"]]},"Trigger": {"text": [["interaction"]],"start": [["57"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "C1"}],"Freq": {"text": [["alcoholic beverages"]],"start": [["81"]],"entity_id": [["T5"]]},"Duration": {"text": [["alcoholic beverages"]],"start": [["81"]],"entity_id": [["T5"]]},"Route": {"text": [["in alcoholic beverages"]],"start": [["81"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["interaction"]],"start": [["57"]],"entity_id": [["T4"]]},"Dosage": {"text": [["ethanol"]],"start": [["34"]],"entity_id": [["T2"]]}},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "high","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["hepatoxicity"]],"start": [["13"]],"entity_id": [["T1"]]}}]}
{"id": "17671884_8","context": "The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anemia"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["patients taking MMF"]],"start": [["50"]],"entity_id": [["T2"]],"Drug": {"text": [["MMF"]],"start": [["50"]],"entity_id": [["T3"]]},"Disorder": {"text": [["pemphigus"]],"start": [["75"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["has not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["side effect"]],"start": [["24"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["MMF"]],"start": [["50"]],"entity_id": [["T3"]]},"Trigger": {"text": [["taking"]],"start": [["50"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["patients taking MMF"]],"start": [["50"]],"entity_id": [["T2"]]},"Dosage": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]],"value": true},"Speculated": {"text": [["has not noted"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [["anemia"]],"start": [["31"]],"entity_id": [["T1"]],"value": "Low"},"Subject": {"text": [["patients"]],"start": [["50"]],"entity_id": [["T2"]],"Age": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["not noted"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["pemphigus"]],"start": [["75"]],"entity_id": [["T4"]]}},"Effect": {"text": [["anemia"]],"start": [["31"]],"entity_id": [["T1"]]}}]}
{"id": "3430507_4","context": "The 9 other reported cases of D-penicillamine induced rapidly progressive glomerulonephritis have been reviewed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["D-penicillamine induced rapidly progressive glomerulonephritis"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["D-penicillamine"]],"start": [["9"]],"entity_id": [["T2"]] ,"Drug": {"text": [["D-penicillamine"]],"start": [["9"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["rapidly progressive glomerulonephritis"]],"start": [["33"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["9"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["D-penicillamine"]],"start": [["9"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["24"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["have been reviewed"]],"start": [["46"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["reported cases"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["have been reviewed"]],"start": [["46"]],"entity_id": [["T6"]]} ,"Route": {"text": [["induced"]],"start": [["24"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["D-penicillamine"]],"start": [["9"]],"entity_id": [["T2"]]} } ,"Subject": {"text": [["The 9 other reported cases"]],"start": [["0"]],"entity_id": [["T8"]],"Population": {"text": [["The 9 other reported cases"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["cases"]],"start": [["3"]],"entity_id": [["T9"]]} } ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [["rapidly progressive glomerulonephritis"]],"start": [["33"]],"entity_id": [["T3"]],"value": "high"} ,"Effect": {"text": [],"start": [],"entity_id": []} } ]}
{"id": "15203443_2", "context": "We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant.$", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Adverse_event", "Trigger": { "text": [["clinical and laboratory manifestations"]], "start": [["22"]], "entity_id": [ ["T1"] ] }, "Subject": { "text": [["a heroin abuser"]], "start": [["7"]], "entity_id": [ ["T2" ]], "Disorder": { "text": [["heroin abuser"]], "start": [["7"]], "entity_id": [ ["T2" ]] } , "Population": { "text": [["a"]], "start": [["7"]], "entity_id": [ ["T2" ]] } , "Age": { "text": [], "start": [], "entity_id": [] } , "Gender": { "text": [], "start": [], "entity_id": [] } , "Race": { "text": [], "start": [], "entity_id": [] } }, "Treatment": { "text": [["naltrexone implant"]], "start": [["82"]], "entity_id": [ ["T3" ]], "Drug": { "text": [["naltrexone"]], "start": [["82"]], "entity_id": [ ["T4" ]] }, "Route": { "text": [["subcutaneous"]], "start": [["72"]], "entity_id": [ ["T5" ]] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] } , "Disorder": { "text": [["acute hepatitis B and C"]], "start": [["35"]], "entity_id": [ ["T6" ]] } , "Time_elapsed": { "text": [["a few days after"]], "start": [["55"]], "entity_id": [ ["T7" ]] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": { "text": [["the insertion"]], "start": [["65"]], "entity_id": [ ["T8" ]] } } , "Negated": null, "Speculated": null, "Severity": { "text": [["acute"]], "start": [["35"]], "entity_id": [ ["T6" ]], "value": "high" } , "Effect": { "text": [["clinical and laboratory manifestations"]], "start": [["22"]], "entity_id": [ ["T1" ]] } }]}
{"id": "1504404_2", "context": "Ciprofloxacin-induced psychosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ciprofloxacin-induced psychosis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "text": [["Ciprofloxacin"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["Ciprofloxacin"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ] }, "Disorder": { "text": [["psychosis"]], "start": [[ "16" ]], "entity_id": [ ["T4"] ] }, "Time_elapsed": null, "Duration": null, "Freq": null, "Dosage": null, "Route": null, "Combination": null , "Trigger": { "text": [["Ciprofloxacin-induced psychosis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] } } , "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } , "Effect": { "text": [["psychosis"]], "start": [[ "16" ]], "entity_id": [ ["T4"] ] } , "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "15694139_2","context": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["teratogenic effects"]],"start": [["58"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Thalidomide"]],"start": [["9"]],"entity_id": [["T2"]]},"entity_id": [["T2"]] ,"Disorder": {"text": [["teratogenic effects"]],"start": [["58"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["1961"]],"start": [["35"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["recognition"]],"start": [["44"]],"entity_id": [["T4"]]} ,"Route": {"text": [["withdrawn from world markets"]],"start": [["9"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["1961"]],"start": [["35"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["withdrawn"]],"start": [["9"]],"entity_id": [["T5"]]} ,"Combination": null ,"Dosage": null ,"text": [["Thalidomide"]],"start": [["9"]]} ,"Subject": null ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["teratogenic effects"]],"start": [["58"]],"entity_id": [["T1"]]}}]}
{"id": "1688693_5","context": "We suggest the use of esmolol for treatment of dysrhythmias secondary to caffeine toxicity; to the best of our knowledge, the use of esmolol has not been reported for this purpose","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["esmolol"]],"start": [["12"]],"entity_id": [["T1"]]},"text": [["use of esmolol"]],"start": [["0"]],"entity_id": [["T2"]],"Disorder": {"text": [["dysrhythmias"]],"start": [["42"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["35"]],"entity_id": [["T4"]]},"Duration": {"text": [["reported for this purpose"]],"start": [["110"]],"entity_id": [["T5"]]},"Route": {"text": [["use"]],"start": [["0"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["secondary to caffeine toxicity"]],"start": [["42"]],"entity_id": [["T3"]]},"Freq": {"text": [["use"]],"start": [["0"]],"entity_id": [["T2"]]},"Combination": null,"Dosage": {"text": [["esmolol"]],"start": [["12"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null,"Trigger": {"text": [["suggest"]],"start": [["0"]],"entity_id": [["T6"]]}}]}
{"id": "15806568_2","context": "To date, there have been few reports of visual disturbances associated with BTX-B use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["visual disturbances"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["BTX-B use"]],"start": [["65"]],"entity_id": [["T2"]],"Drug": {"text": [["BTX-B"]],"start": [["65"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["visual disturbances"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["few reports"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["associated with"]],"start": [["49"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["BTX-B"]],"start": [["65"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["use"]],"start": [["71"]],"entity_id": [["T6"]]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Trigger": {"text": [["associated with"]],"start": [["49"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["few reports"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Route": {"text": [["use"]],"start": [["71"]],"entity_id": [["T6"]]} },"Subject": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T7"]],"Population": {"text": [["few reports"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["visual disturbances"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Age": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Gender": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Race": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T7"]]} },"Severity": {"text": [["few reports"]],"start": [["11"]],"entity_id": [["T4"]],"value": "low"} ,"Negated": null,"Speculated": null ,"Effect": {"text": [["visual disturbances"]],"start": [["31"]],"entity_id": [["T1"]]} }]}
{"id": "19116715_1","context": "Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.\n","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Gemcitabine"]],"start": [[ ] , [ ]],"entity_id": [ ]},"Effect": {"text": [["hemolytic uremic syndrome (HUS)"]],"start": [[ ], [], [], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["rapidly fatal clinical course"]],"start": [[ ], []],"entity_id": [],"value": "high"},"Subject": {"text": [["a patient taking Gemcitabine"]],"start": [[ ], []],"entity_id": [],"Disorder": {"text": [["hemolytic uremic syndrome (HUS)"]],"start": [[ ], []],"entity_id": []},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["steroids", "plasmapheresis and hemodialysis"]],"start": [[ ], []],"entity_id": [],"Drug": null,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["intervention"]],"start": [[ ]],"entity_id": []}}}]}
{"id": "16411025_4", "context": "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["four patients"]], "start": [["43"]], "entity_id": [],"Age": null, "Gender": null, "Population": {"text": [["four patients"]], "start": [["43"]], "entity_id": []}, "Race": null, "Disorder": null}, "Treatment": {"text": [["intrathecal MTX"]], "start": [["83"]], "entity_id": [],"Drug": {"text": [["MTX"]], "start": [["83"]], "entity_id": []}, "Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": {"text": [["subacute neurotoxicity"]], "start": [["56"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Trigger": null}]}
{"id": "17547624_2","context": "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ST elevation in right precordial leads compatible with type 1 Brugada syndrome"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["propafenone"]],"start": [["118"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Wolff-Parkinson-White syndrome"]],"start": [["74"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["following administration"]],"start": [["106"]],"entity_id": [["T4"]]},"Freq": {"text": [["who was receiving"]],"start": [["129"]],"entity_id": [["T5"]]},"Dosage": {"text": [["lithium at concentrations within therapeutic levels"]],"start": [["146"]],"entity_id": [["T6"]]},"Route": {"text": [["administration"]],"start": [["106"]],"entity_id": [["T4"]]},"Duration": {"text": [["who was receiving"]],"start": [["129"]],"entity_id": [["T5"]]},"entity_id": [["T2"]],"text": [["administration"]],"start": [["106"]],"Trigger": {"text": [["following administration"]],"start": [["106"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["propafenone"]],"start": [["118"]],"entity_id": [["T2"]]},"Trigger": {"text": [["following administration"]],"start": [["106"]],"entity_id": [["T4"]]},"event_id": "E1","event_type": "Adverse_event"}]},"Effect": {"text": [["ST elevation in right precordial leads compatible with type 1 Brugada syndrome"]],"start": [["36"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "25957434_2","context": "The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe adverse events"]],"start": [["58"]],"entity_id": [["T2"]]},"Treatment": {"text": [["dihydropyridines"]],"start": [["12"]],"entity_id": [["T1"]],"Drug": {"text": [["dihydropyridines"]],"start": [["12"]],"entity_id": [["T1"]]},"Disorder": {"text": [["cutaneous eruptions"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["extensive"]],"start": [["22"]],"entity_id": [["T3"]]},"Duration": {"text": [["varying"]],"start": [["32"]],"entity_id": [["T4"]]},"Freq": {"text": [["extensive"]],"start": [["22"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["dihydropyridines"]],"start": [["12"]],"entity_id": [["T1"]]},"Trigger": {"text": [["cutaneous eruptions"]],"start": [["0"]],"entity_id": [["T0"]]},"event_id": "E2","event_type": "Adverse_event"}],"Route": {"text": [["associated with"]],"start": [["12"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["varying"]],"start": [["32"]],"entity_id": [["T4"]]},"Trigger": {"text": [["cutaneous eruptions"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe adverse events"]],"start": [["58"]],"entity_id": [["T2"]]}}]}
{"id": "3365032_2","context": "Polymyositis after propylthiouracil treatment for hyperthyroidism","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Polymyositis"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["propylthiouracil treatment"]],"start": [["21"]],"entity_id": [],"Drug": {"text": [["propylthiouracil"]],"start": [["21"]],"entity_id": []},"Disorder": {"text": [["hyperthyroidism"]],"start": [["49"]],"entity_id": []},"Time_elapsed": {"text": [["after"]],"start": [["13"]],"entity_id": []},"Freq": {"text": [["treatment"]],"start": [["21"]],"entity_id": []},"Trigger": {"text": [["treatment"]],"start": [["21"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "8862924_2", "context": "Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["injury"]], "start": [["82"]], "entity_id": []}, "Subject": {"text": [["cornea"]], "start": [["100"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": null, "Effect": {"text": [["injury"]], "start": [["82"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "2956288_4","context": "Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["ethambutol"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ethambutol"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["ethambutol"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["renal tuberculosis"]],"start": [["93"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["serum concentration elevations"]],"start": [["115"]],"entity_id": [["T4"]]},"Trigger": {"text": [["compromise of renal function such as due to"]],"start": [["18"]],"entity_id": [["T2"]]},"Freq": {"text": [["may lead to"]],"start": [["72"]],"entity_id": [["T5"]]},"Dosage": {"text": [["serum concentration elevations"]],"start": [["115"]],"entity_id": [["T4"]]},"Duration": {"text": [["produce optic neuropathy"]],"start": [["164"]],"entity_id": [["T6"]]},"Route": {"text": [["via the renal system"]],"start": [["24"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["ethambutol"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["compromise of renal function such as due to"]],"start": [["18"]],"entity_id": [["T2"]]},"event_type": "Potential_therapeutic_effect","event_id": "E1"}]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["renal tuberculosis"]],"start": [["93"]],"entity_id": [["T3"]]}},"Effect": {"text": [["optic neuropathy"]],"start": [["186"]],"entity_id": [["T7"]]}}]}
{"id": "11424102_1", "context": "Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cutaneous seeding"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["ultrasound-guided percutaneous ethanol injection"]], "start": [["23"]], "entity_id": [],"Disorder": {"text": [["treatment of hepatocellular carcinoma"]], "start": [["52"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [["ultrasound-guided percutaneous"]], "start": [["23"]], "entity_id": []}, "Time_elapsed": {"text": [["after"]], "start": [["14"]], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null ,"Trigger": null ,"Drug": null} ,"Effect":{"text": [], "start": [], "entity_id": []} ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null} ]}
{"id": "9972383_1","context": "Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reversible nonthrombocytopenic vascular-type palpable purpura"]],"start": [["42"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Metoclopramide"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["Metoclopramide"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["reversible nonthrombocytopenic vascular-type palpable purpura"]],"start": [["42"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["Metoclopramide"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["reversible"]],"start": [["42"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Route": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]}} ,"Subject": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]],"Population": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["reversible nonthrombocytopenic vascular-type palpable purpura"]],"start": [["42"]],"entity_id": [["T1"]]} ,"Age": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Gender": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Race": {"text": [["may cause"]],"start": [["11"]],"entity_id": [["T3"]]}} ,"Negated": null,"Speculated": null,"Severity": {"text": [["reversible"]],"start": [["42"]],"entity_id": [["T1"]],"value": "Low"} ,"Effect": {"text": [["reversible nonthrombocytopenic vascular-type palpable purpura"]],"start": [["42"]],"entity_id": [["T1"]]}} ]}
{"id": "18784429_2","context": "Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose methylprednisolone in late pregnancy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"text": [["Life-threatening"]],"start": [[ "0" ]] ,"entity_id": [ ["V1"] ] , "value": "High" },"Subject": {"text": [["a newborn"]],"start": [[ "41" ]],"entity_id": [ ["S1"] ] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null },"Treatment": {"text": [["hydrocortisone supplementation"]],"start": [[ "55" ]],"entity_id": [ ["T1"] ], "Drug": { "text": [["hydrocortisone"]], "start": [[ "55" ]], "entity_id": [ ["T2"] ] } , "Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null },"Effect": {"text": [["adrenal suppression"]],"start": [[ "14" ]],"entity_id": [ ["E1"] ] } , "Trigger": { "text": [["was observed"]],"start": [[ "24" ]],"entity_id": [ ["T3"] ] } } ] }
{"id": "17420198_2","context": "A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["extrapyramidal symptoms (EPS)"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["aripiprazole"]],"start": [["49"]],"entity_id": [ ],"Drug": {"text": [["aripiprazole"]],"start": [["49"]],"entity_id": [ ]},"Disorder": {"text": [["developmental disabilities"]],"start": [["25"]],"entity_id": [ ]},"Freq": {"text": [["following administration"]],"start": [["20"]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["aripiprazole"]],"start": [["49"]],"entity_id": []},"Trigger": {"text": [["following administration"]],"start": [["20"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E1"}],"Time_elapsed": {"text": [["following administration"]],"start": [["20"]],"entity_id": []},"Route": {"text": [["administration"]],"start": [["40"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [[]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["administration"]],"start": [["40"]],"entity_id": []}},"Subject": {"text": [["a man"]],"start": [["9"]],"entity_id": [],"Age": {"text": [[]],"start": [[ ]],"entity_id": []},"Gender": {"text": [["man"]],"start": [["9"]],"entity_id": []},"Population": {"text": [["a man"]],"start": [["9"]],"entity_id": []},"Race": {"text": [[]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["developmental disabilities"]],"start": [["25"]],"entity_id": []}},"Severity": {"text": [[]],"start": [[ ]],"entity_id": [],"value": "Low"},"Negated": {"text": [[]],"start": [[ ]],"entity_id": [],"value": false},"Speculated": {"text": [[]],"start": [[ ]],"entity_id": [],"value": false},"Effect": {"text": [["extrapyramidal symptoms (EPS)"]],"start": [[ "0" ]],"entity_id": []}}]}
{"id": "2378415_1","context": "Although high-dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["high-dose methotrexate"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["treatment"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["methotrexate"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["primary osteogenic sarcoma"]],"start": [[ ]],"entity_id": []},"Freq": {"text": [["high-dose"]],"start": [[ ]],"entity_id": []},"Dosage": {"text": [["useful"]],"start": [[ ]],"entity_id": []},"Time_elapsed": {"text": [["caused"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["tumoricidal effects"]],"start": [[ ]],"entity_id": []},"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": []},"Duration": {"text": [["treatment"]],"start": [[ ]],"entity_id": []},"Combination": null},"Effect": {"text": [["a fatal rise in intracranial pressure"]],"start": [[ ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [[ ]],"entity_id": [],"value": "High"},"Subject": null}]}
{"id": "20298401_11","context": "This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["radiation fibrosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Effect": {"text": [["occurrence of ILD"]],"start": [["71"]],"entity_id": [["T2"]]},"Treatment": {"text": [["taking erlotinib"]],"start": [["100"]],"entity_id": [["T3"]],"Disorder": {"text": [["ILD"]],"start": [["71"]],"entity_id": [["T2"]]},"Trigger": {"text": [["radiation fibrosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Drug": {"text": [["erlotinib"]],"start": [["100"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["may be another contributor"]],"start": [["21"]],"entity_id": [["T4"]]},"Freq": {"text": [["taking"]],"start": [["100"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["erlotinib"]],"start": [["100"]],"entity_id": [["T3"]]},"Trigger": {"text": [["taking"]],"start": [["100"]],"entity_id": [["T3"]]},"event_type": "Adverse_event","event_id": "E2"}],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["This case"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["radiation fibrosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [["may be another contributor"]],"start": [["21"]],"entity_id": [["T4"]],"value": true},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "8363533_3","context": "Lithium-associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Lithium-associated transient thyrotoxicosis"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]},"Subject": {"text": [["4 Chinese women"]],"start": [[ "32"]] ,"entity_id": [ ["T2"] ],"Age": {"text": [["4"]],"start": [[ "32"]] ,"entity_id": [ ["T3"] ]},"Race": {"text": [["Chinese"]],"start": [[ "36"]] ,"entity_id": [ ["T4"] ]},"Disorder": {"text": [["autoimmune thyroiditis"]],"start": [[ "56"]] ,"entity_id": [ ["T5"] ]} ,"Population": {"text": [["4"]],"start": [[ "32"]] ,"entity_id": [ ["T3"] ]} ,"Gender": {"text": [["women"]],"start": [[ "34"]] ,"entity_id": [ ["T4"] ]}},"Treatment": {"text": [["Lithium"]],"start": [[ "8"]] ,"entity_id": [ ["T6"] ],"Drug": {"text": [["Lithium"]],"start": [[ "8"]] ,"entity_id": [ ["T6"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Disorder": {"text": [["transient thyrotoxicosis"]],"start": [[ "42"]] ,"entity_id": [ ["T1"] ]} ,"Time_elapsed": null,"Freq": null ,"Trigger": null,"Combination": null} ,"Effect": {"text": [["transient thyrotoxicosis"]],"start": [[ "42"]] ,"entity_id": [ ["T1"] ]} ,"Severity": null,"Negated": null,"Speculated": null }]}
{"id": "2006943_2", "context": "A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["episode of acute chest pain"]], "start": [[ ]], "entity_id": [["T2"]]}, "Treatment": {"text": [["intravenous ritodrine therapy"]], "start": [[ ]], "entity_id": [["T1"]], "Drug": {"text": [["ritodrine"]], "start": [[ ]], "entity_id": [["T3"]]}, "Route": {"text": [["intravenous"]], "start": [[ ]], "entity_id": [["T4"]]},"Disorder": {"text": [["preterm labor"]], "start": [[ ]], "entity_id": [["T5"]]}, "Time_elapsed": {"text": [["experienced"]], "start": [[ ]], "entity_id": [["T6"]]}, "Freq": {"text": [["while on"]], "start": [[ ]], "entity_id": [["T7"]]}, "Duration": {"text": [["for preterm labor"]], "start": [[ ]], "entity_id": [["T5"]]} , "Dosage": null, "Trigger": {"text": [["episode of acute chest pain"]], "start": [[ ]], "entity_id": [["T2"]]}, "Combination": null} ,"Subject": null ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": {"text": [["episode of acute chest pain"]], "start": [[ ]], "entity_id": [["T2"]]} }]}
{"id": "4095247_2","context": "Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["synergistic action", "fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems"]],"start": [["35", "106"]],"entity_id": [["T1", "T2"]]},"Treatment": {"text": [["desferrioxamine", "prochlorperazine"]],"start": [["18", "55"]],"entity_id": [["T3", "T4"]],"Combination": [{"Drug": {"text": [["desferrioxamine"]],"start": [["18"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["49"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["prochlorperazine"]],"start": [["55"]],"entity_id": [["T4"]]},"Trigger": {"text": [["and"]],"start": [["49"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["Subsequent studies"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["in vivo/vitro"]],"start": [["7"]],"entity_id": [["T5"]]},"Disorder": {"text": [["neurological effects"]],"start": [["31"]],"entity_id": [["T1"]]},"Freq": {"text": [["probably resulting"]],"start": [["60"]],"entity_id": [["T6"]]},"Route": {"text": [["action"]],"start": [["60"]],"entity_id": [["T6"]]},"Dosage": {"text": [["synergistic"]],"start": [["35"]],"entity_id": [["T1"]]},"Trigger": {"text": [["action"]],"start": [["60"]],"entity_id": [["T6"]]},"Drug": {"text": [["desferrioxamine", "prochlorperazine"]],"start": [["18", "55"]],"entity_id": [["T3", "T4"]]}},"Effect": {"text": [["neurological effects"]],"start": [["31"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the studies"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["Subsequent studies"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": null,"Disorder": null,"Gender": null,"Race": null}}]}
{"id": "19725909_1","context": "Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["lamivudine"]],"start": [["46"]],"entity_id": [["T1"]]},"Dosage": {"text": [["de novo hepatitis B infection after liver transplantation with"]],"start": [["0"]],"entity_id": [["T2"]]},"Duration": {"text": [["lamivudine and adefovir therapy"]],"start": [["56"]],"entity_id": [["T3"]]},"entity_id": [["T1","T2","T3"]],"Trigger": {"text": [["favorable outcome"]],"start": [["0"]],"entity_id": [["T4"]]},"Disorder": {"text": [["de novo hepatitis B infection"]],"start": [["17"]],"entity_id": [["T5"]]},"Freq": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T3"]]},"Route": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after liver transplantation"]],"start": [["23"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["lamivudine"]],"start": [["46"]],"entity_id": [["T1"]]},"Trigger": {"text": [["and"]],"start": [["53"]],"entity_id": [["T7"]]},"event_id": "E1_C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["adefovir"]],"start": [["60"]],"entity_id": [["T8"]]},"Trigger": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T3"]]},"event_id": "E1_C2","event_type": "Potential_therapeutic_effect"}],"text": [["favorable outcome"]],"start": [["0"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["favorable"]],"start": [["0"]],"entity_id": [["T4"]],"value": "Low"},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T9"]],"Population": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T9"]]},"Disorder": {"text": [["de novo hepatitis B infection"]],"start": [["17"]],"entity_id": [["T5"]]},"Gender": null,"Age": null,"Race": null},"Effect": {"text": [["outcome"]],"start": [["0"]],"entity_id": [["T10"]]},"Trigger": {"text": [["favorable outcome"]],"start": [["0"]],"entity_id": [["T4"]]}}]}
{"id": "6498095_3", "context": "Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy.$", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Pemphigus foliaceus"]], "start": [[ "0" ] ], "entity_id": [ ["T1"] ]},"Subject": { "text": [["a patient with pulmonary tuberculosis"]], "start": [[ "26" ]], "entity_id": [ ["T2"] ], "Disorder": { "text": [["pulmonary tuberculosis"]], "start": [[ "35" ]], "entity_id": [ ["T3"] ]} ,"Age": null, "Gender": null, "Population": null, "Race": null }, "Treatment": { "text": [["rifampicin therapy"]], "start": [[ "78" ]], "entity_id": [ ["T4"] ], "Drug": { "text": [["rifampicin"]], "start": [[ "78" ]], "entity_id": [ ["T5"] ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Disorder": null }, "Effect": { "text": [["Pemphigus foliaceus"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "9260733_2","context": "We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed polyserositis"]],"start": [["25"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clozapine"]],"start": [["92"]],"entity_id": [["T2"]],"Drug": {"text": [["clozapine"]],"start": [["92"]],"entity_id": [["T3"]]},"Route": {"text": [["started on"]],"start": [["71"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after being started on"]],"start": [["71"]],"entity_id": [["T4"]]},"Duration": {"text": [["whose symptoms remitted upon discontinuation of clozapine"]],"start": [["115"]],"entity_id": [["T5"]]},"Disorder": {"text": [["polyserositis"]],"start": [["25"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["clozapine"]],"start": [["92"]],"entity_id": [["T3"]]},"Trigger": {"text": [["started on"]],"start": [["71"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Freq": {"text": [["whose symptoms remitted upon discontinuation"]],"start": [["115"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [["25"]],"entity_id": [["T1"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]}},"Subject": {"text": [["a patient"]],"start": [["1"]],"entity_id": [["T0"]],"Age": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Population": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]]},"Disorder": {"text": [["polyserositis"]],"start": [["25"]],"entity_id": [["T1"]]}},"Effect": {"text": [["polyserositis"]],"start": [["25"]],"entity_id": [["T1"]]},"Negated": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]],"value": false},"Speculated": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]],"value": false},"Severity": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""]],"value": ""}}]}
{"id": "8053440_5","context": "Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["treatment with ampicillin"]],"start": [["Three years later,"], [", treatment with ampicillin caused"]],"entity_id": []},"Effect": {"text": [["another episode of cholestatic hepatitis with cholestasis and duct paucity"]],"start": [[], ["caused"]],"entity_id": []},"Treatment": {"text": [["ampicillin"]],"start": [[", treatment with"]],"entity_id": [],"Drug": {"text": [["ampicillin"]],"start": [[", treatment with"]],"entity_id": []} ,"Time_elapsed": {"text": [["Three years later"]],"start": [[], []],"entity_id": []} ,"Trigger": {"text": [["cholestatic hepatitis"]],"start": [[], []],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8071504_5","context": "A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["dramatic", "permanent vision loss"]],"start": [[ "0"],["14"]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["ethambutol", "isoniazid"]],"start": [["58"],["68"]],"entity_id": [ ["T3","T4"] ]},"Duration": {"text": [["9-month"]],"start": [["50"]],"entity_id": [ ["T2"] ]},"Disorder": {"text": [["pulmonary tuberculosis"]],"start": [["81"]],"entity_id": [ ["T5"] ]} ,"entity_id":[ ["T1","T2","T3","T4","T5"] ],"text": [["developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented"]],"start": [["0"]] ,"Time_elapsed":null,"Dosage":null,"Freq":null,"Route":null ,"Trigger":null,"Combination":null },"Subject": {"text":[["A patient"]],"start":[["0"]],"entity_id":[ ["T6"] ],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":null },"Severity": {"text":[["dramatic", "permanent"]],"start":[["0"],["14"]],"entity_id":[ ["T7","T8"] ],"value":"high" },"Speculated":null,"Negated":null ,"Effect":null }]}
{"id": "16239768_2","context": "The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["urinary incontinence"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["venlafaxine"]],"start": [["82"]],"entity_id": [["T2"]],"Drug": {"text": [["venlafaxine"]],"start": [["82"]],"entity_id": [["T3"]]},"Disorder": {"text": [["urinary incontinence (UI)"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after administration"]],"start": [["58"]],"entity_id": [["T4"]]},"Trigger": {"text": [["administration"]],"start": [["58"]],"entity_id": [["T4"]]},"Freq": {"text": [["occurred"]],"start": [["17"]],"entity_id": [["T5"]]},"Route": {"text": [["administration"]],"start": [["58"]],"entity_id": [["T4"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": null},"Subject": {"text": [["a woman"]],"start": [["44"]],"entity_id": [["T6"]],"Age": null,"Gender": {"text": [["woman"]],"start": [["44"]],"entity_id": [["T6"]]},"Population": null,"Race": null,"Disorder": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8651254_3","context": "The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["M-CSF"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ], "Drug": { "text": [["M-CSF"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Disorder": { "text": [["renal disease"]], "start": [[ "51" ]], "entity_id": [ ["T2" ]] }, "Duration": null, "Dosage": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["accelerated"]], "start": [[ "30" ]], "entity_id": [ ["T3" ]] }}, "Effect": { "text": [["development of nephrotic syndrome"]], "start": [[ "121" ]], "entity_id": [ ["T4" ]] }, "Negated": null, "Speculated": { "text": [["can be raised"]], "start": [[ "1" ]], "entity_id": [ ["T5" ]] ,"value": true }, "Severity": null, "Subject": null ,"Trigger": { "text": [["underlying renal disease"]], "start": [[ "57" ]], "entity_id": [ ["T7" ]] }} ]}
{"id": "14996269_2","context": "We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants. ","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hyperkalaemia"]],"start": [["21"]],"entity_id": [ ["T1"] ] },"Treatment": {"text": [["Kayexalate"]],"start": [["53"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["Kayexalate"]],"start": [["53"]],"entity_id": [ ["T2"] ] }, "Disorder": { "text": [["hyperkalaemia"]], "start": [["21"]], "entity_id": [ ["T1"] ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": { "text": [["serious hypernatraemia"]], "start": [["74"]], "entity_id": [ ["T3"] ]} ,"Negated": null, "Speculated": null, "Severity": { "text": [], "start": [], "entity_id": [] ,"value": "serious" }, "Subject": null }] }
{"id": "8384030_2", "context": "Electrolyte disorders associated with foscarnet are reviewed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Electrolyte disorders"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Treatment": { "text": [["foscarnet"]], "start": [[ "51" ]], "entity_id": [ ["T2" ] ] ,"Drug":{"text":[["foscarnet"]],"start":[[ "51" ]], "entity_id": [ ["T2" ] ]} ,"Disorder":{"text":[["Electrolyte disorders"]],"start":[[ "0" ]], "entity_id": [ ["T1" ] ]} ,"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Combination":null ,"Trigger":null},"Effect":null,"Subject":null,"Negated":null,"Speculated":null,"Severity":null}]}
{"id": "1440123_1","context": "This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["SIADH"]],"start": [["10"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Tegretol therapy"]],"start": [["40"]],"entity_id": [["T2"]],"Drug": {"text": [["Tegretol"]],"start": [["40"]],"entity_id": [["T3"]]},"Disorder": {"text": [["seizure disorder"]],"start": [["58"]],"entity_id": [["T4"]]},"Freq": {"text": [["to control"]],"start": [["47"]],"entity_id": [["T5"]]},"Route": {"text": [["therapy"]],"start": [["40"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["secondary"]],"start": [["32"]],"entity_id": [["T6"]]},"Duration": {"text": [["describes"]],"start": [["0"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["a 38-year-old male"]],"start": [["5"]],"entity_id": [["T8"]],"Age": {"text": [["38"]],"start": [["6"]],"entity_id": [["T9"]]},"Gender": {"text": [["male"]],"start": [["14"]],"entity_id": [["T10"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["strongly suspected"]],"start": [["24"]],"entity_id": [["T11"]],"value": "medium"},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17199845_1","context": "However, cyclosporine dependency is associated with the risk of nephrotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["cyclosporine dependency"]],"start": [[ ],[ ]],"entity_id": [ ]},"Treatment": {"text": [["cyclosporine dependency"]],"start": [[ ]],"entity_id": [ ] ,"Disorder": {"text": [["dependency"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["dependency"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["dependency"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["dependency"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["dependency"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": null ,"Drug": null ,"Time_elapsed": null ,"Trigger": null },"Effect": {"text": [["nephrotoxicity"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "3335488_1","context": "The observations suggest that testicular swelling and pain are side effects of desipramine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["testicular swelling and pain"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["desipramine"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["desipramine"]],"start": [["56"]],"entity_id": [["T2"]]},"Disorder": {"text": [["side effects"]],"start": [["42"]],"entity_id": [["T3"]]},"Freq": {"text": [["side effects"]],"start": [["42"]],"entity_id": [["T3"]]},"Route": {"text": [["observations suggest"]],"start": [["0"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["side effects"]],"start": [["42"]],"entity_id": [["T3"]]},"Duration": {"text": [["observations suggest"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["observations suggest"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["testicular swelling and pain"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "11722307_3", "context": "We describe three case-reports concerning haematological adverse effects of quetiapine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["quetiapine"]], "start": [["64"]], "entity_id": [["T1"]]},"Disorder": {"text": [["haematological adverse effects"]], "start": [["42"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "text": [["quetiapine"]], "start": [["64"]], "entity_id": [["T1"]] ,"Trigger": null}, "Effect": {"text": [["haematological adverse effects"]], "start": [["42"]], "entity_id": [["T2"]]}, "Trigger": {"text": [["haematological adverse effects"]], "start": [["42"]], "entity_id": [["T2"]]} }]}
{"id": "1575118_1","context": "Typically, drug-induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["drug-induced neutropenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["a semisynthetic penicillin"]],"start": [["54"]],"entity_id": [["T2"]],"Dosage": {"text": [["two weeks or more"]],"start": [["72"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["neutropenia"]],"start": [["19"]],"entity_id": [["T4"]]},"Duration": {"text": [["two weeks or more"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Drug": {"text": [["a semisynthetic penicillin"]],"start": [["54"]],"entity_id": [["T2"]]} ,"Route": {"text": [["a semisynthetic penicillin"]],"start": [["54"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["occurs"]],"start": [["12"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["occurs"]],"start": [["12"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["a semisynthetic penicillin"]],"start": [["54"]],"entity_id": [["T2"]]},"Trigger": {"text": [["receiving"]],"start": [["33"]],"entity_id": [["T6"]]} ,"event_id": "E2" ,"event_type": "Treatment" }] ,"Trigger": {"text": [["occurs"]],"start": [["12"]],"entity_id": [["T5"]]} },"Subject": {"text": [["a patient"]],"start": [["22"]],"entity_id": [["T7"]],"Population": {"text": [["a patient"]],"start": [["22"]],"entity_id": [["T7"]]} ,"Age": {"text": [["a patient"]],"start": [["22"]],"entity_id": [["T7"]]} ,"Gender": {"text": [["a patient"]],"start": [["22"]],"entity_id": [["T7"]]} ,"Race": {"text": [["a patient"]],"start": [["22"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["neutropenia"]],"start": [["19"]],"entity_id": [["T4"]]}},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [["drug-induced neutropenia"]],"start": [["0"]],"entity_id": [["T1"]]} }]}
{"id": "17444802_1","context": "Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Tumor-volume increase"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Subject": {"text": [["a case of conjunctiva-cornea intraepithelial neoplasia"]],"start": [[ "88" ]],"entity_id": [ ["T2"] ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["conjunctiva-cornea intraepithelial neoplasia"]], "start": [[ "88" ]], "entity_id": [ ["T2"] ]} }, "Treatment": { "text": [["topical interferon alpha 2-beta"]], "start": [[ "58" ]], "entity_id": [ ["T3"] ], "Drug": { "text": [["interferon alpha 2-beta"]], "start": [[ "58" ]], "entity_id": [ ["T3"] ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": { "text": [["conjunctiva-cornea intraepithelial neoplasia"]], "start": [[ "88" ]], "entity_id": [ ["T2"] ]} ,"Combination": null }, "Effect": null ,"Negated": null, "Speculated": null, "Severity": null}]}
{"id": "18504683_1", "context": "L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["posterior reversible encephalopathy syndrome"]],"start": [["30"]],"entity_id": [["T1"]]},"Treatment": {"text": [["L-asparaginase"]],"start": [["5"]],"entity_id": [["T2"]],"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["50"]],"entity_id": [["T3"]]},"Dosage": {"text": [["during treatment"]],"start": [["41"]],"entity_id": [["T4"]]},"Route": {"text": [["during"]],"start": [["41"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["induced"]],"start": [["5"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["during"]],"start": [["41"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["L-asparaginase"]],"start": [["5"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["5"]],"entity_id": [["T2"]]} ,"event_id": "E2","event_type": "Potential_therapeutic_effect"} ] ,"Trigger": {"text": [["L-asparaginase-induced"]],"start": [["5"]],"entity_id": [["T2"]]} ,"Drug": {"text": [["L-asparaginase"]],"start": [["5"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["during treatment"]],"start": [["41"]],"entity_id": [["T4"]]}} ,"Subject": {"text": [["children"]],"start": [["80"]],"entity_id": [["T5"]],"Age": {"text": [["children"]],"start": [["80"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["50"]],"entity_id": [["T3"]]} ,"Population": {"text": [["children"]],"start": [["80"]],"entity_id": [["T5"]]} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [["posterior reversible encephalopathy syndrome"]],"start": [["30"]],"entity_id": [["T1"]]} } ]}
{"id": "9184269_3","context": "On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["MTX-induced pneumonitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"value": true,"text": [["very rare"]],"start": [["42"]],"entity_id": [["T2"]]},"Subject": {"text": [["psoriatic arthritis (PsA)"]],"start": [["52"]],"entity_id": [["T3"]],"Disorder": {"text": [["psoriatic arthritis"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Population": {"text": [["very rare"]],"start": [["42"]],"entity_id": [["T2"]]},"Gender": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Age": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Race": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} },"Treatment": {"text": [["MTX"]],"start": [["7"]],"entity_id": [["T0"]],"Drug": {"text": [["MTX"]],"start": [["7"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["MTX-induced pneumonitis"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Duration": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Route": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Time_elapsed": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Freq": {"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Combination": null ,"Trigger": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]} },"Effect": {"text": [["pneumonitis"]],"start": [["14"]],"entity_id": [["T5"]]} ,"Speculated": {"value": false,"text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} ,"Severity": {"value": "NA","text": [["NA"]],"start": [[""],[]],"entity_id": [["NA"]]} } ]}
{"id": "3899068_1","context": "Ototoxicity as a result of cis-platinum administration is well documented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ototoxicity"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["cis-platinum administration"]],"start": [[ "33" ]],"entity_id": [["T2"]],"Drug": {"text": [["cis-platinum"]],"start": [[ "33" ]],"entity_id": [["T3"]]} ,"Route": {"text": [["administration"]],"start": [[ "42" ]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["as a result"]],"start": [[ "22" ]],"entity_id": [["T5"]]} ,"Freq": {"text": [["well documented"]],"start": [[ "51" ]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["cis-platinum"]],"start": [[ "33" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [[ "42" ]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E2"}] ,"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""},"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "11881322_7","context": "We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["itraconazole"]],"start": [["18"]],"entity_id": [["T1"]] ,"Drug": {"text": [["itraconazole"]],"start": [["18"]],"entity_id": [["T1"]] },"Disorder": {"text": [["vanishing bile duct syndrome"]],"start": [["85"]],"entity_id": [["T2"]] },"Trigger": {"text": [["responsible for"]],"start": [["56"]],"entity_id": [["T3"]] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": {"text": [],"start": [],"entity_id": [] },"Subject": null ,"Negated": null ,"Speculated": {"text": [["should be added"]],"start": [["28"]],"entity_id": [["T4"]] ,"value": true },"Severity": null ,"Trigger": null }] }
{"id": "1295628_4", "context": "The cases of CBZ-induced SLE reported in the literature were reviewed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["CBZ-induced SLE"]], "start": [["3","4"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["CBZ"]], "start": [["0","1"]], "entity_id": [["T2"]], "Drug": {"text": [["CBZ"]], "start": [["0","1"]], "entity_id": [["T3"]]},"Disorder": {"text": [["SLE"]], "start": [["5","6"]], "entity_id": [["T4"]]}, "Dosage": {"text": [["induced"]], "start": [["3"]], "entity_id": [["T5"]]},"Duration": {"text": [["reported in the literature"]], "start": [["12","13","14","15","16","17","18","19","20"]], "entity_id": [["T6"]]}, "Route": {"text": [["reported"]], "start": [["12"]], "entity_id": [["T7"]]}, "Time_elapsed": {"text": [["reported"]], "start": [["12"]], "entity_id": [["T8"]]}, "Freq": {"text": [["reported"]], "start": [["12"]], "entity_id": [["T9"]]},"Combination": null, "Trigger": null } ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null}]}
{"id": "19892516_1", "context": "Ciprofloxacin-induced hemorrhagic vasculitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ciprofloxacin-induced hemorrhagic vasculitis"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["Ciprofloxacin"]], "start": [[ ]], "entity_id": [ ] } ,"Disorder": {"text": [["hemorrhagic vasculitis"]], "start": [[ ]], "entity_id": [ ]} ,"Dosage": {"text": [[""]], "start": [[ ]], "entity_id": [ ]} ,"Duration": {"text": [[""]], "start": [[ ]], "entity_id": [ ]} ,"Trigger": {"text": [["induced"]], "start": [[ ]], "entity_id": [ ]} ,"Route": {"text": [[""]], "start": [[ ]], "entity_id": [ ]} ,"Time_elapsed": {"text": [[""]], "start": [[ ]], "entity_id": [ ]} ,"Freq": {"text": [[""]], "start": [[ ]], "entity_id": [ ]} ,"Combination": null }, "Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "8691927_4","context": "When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["high doses"]],"start": [["When high doses of fluticasone propionate are used,"], [""], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": []},"Treatment": {"text": [["fluticasone propionate"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": [],"Drug": {"text": [["fluticasone propionate"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Dosage": {"text": [["high doses"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Disorder": {"text": [["retarded growth"]],"start": [[""], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": []},"Freq": {"text": [["may occur"]],"start": [[""], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": []},"Time_elapsed": {"text": [["when used"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Trigger": {"text": [["when used"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Route": {"text": [["used"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Duration": {"text": [["high doses"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], []],"entity_id": []},"Combination": null},"Subject": {"text": [["patient"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patient"]],"start": [[""], ["When high doses of fluticasone propionate are used,"], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": []}},"Effect": {"text": [["retarded growth"]],"start": [[""], ["growth may be retarded and adrenal suppression may occur."]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10614572_2", "context": "To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["significant hypotension"]], "start": [["32", "33"]], "entity_id": []}, "Treatment": {"text": [["intravenous valproate"]], "start": [["51", "52"]], "entity_id": [], "Drug": {"text": [["valproate"]], "start": [["51", "52"]], "entity_id": []},"Disorder": {"text": [["status epilepticus"]], "start": [["60", "61"]], "entity_id": []},"Route": {"text": [["intravenous"]], "start": [["51", "52"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [],"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []}}, "Effect": {"text": [], "start": [], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": "Significant" },"Subject": {"text": [["our knowledge"]], "start": [["0","1"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [["pediatric population"]], "start": [["93","94","95","96"]], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []}}}] }
{"id": "17655517_1", "context": "Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Linezolid-associated peripheral and optic neuropathy"]], "start": [[ ]], "entity_id": []}, "Effect": {"text": [["Linezolid-associated peripheral and optic neuropathy"]], "start": [[ ]], "entity_id": []},"Treatment": {"text": [["Linezolid"]],"start": [[]],"entity_id": [],"Drug": {"text": [["Linezolid"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["peripheral and optic neuropathy"]],"start": [[]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["serotonin syndrome"]],"start": [[]],"entity_id": [],"value": "high"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": {"text": [],"start": [],"entity_id": []},"Race": null}},{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["lactic acidosis"]], "start": [[]], "entity_id": []}, "Effect": {"text": [["lactic acidosis"]], "start": [[]], "entity_id": []},"Treatment": {"text": [["Linezolid"]],"start": [[]],"entity_id": [],"Drug": {"text": [["Linezolid"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["lactic acidosis"]],"start": [[]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "medium"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": {"text": [],"start": [],"entity_id": []},"Race": null}}]}
{"id": "3124393_1","context": "A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo-Medrol, developed a spastic paraparesis at the lower limbs","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Subject": {"text": [["A woman 38-year-old"]],"start": [[ "0" ]],"entity_id": [["S1"]],"Age": {"text": [["38-year-old"]],"start": [[ "6" ]],"entity_id": [["A1"]]},"Disorder": {"text": [["multiple sclerosis"]],"start": [[ "42" ]],"entity_id": [["D1"]]} ,"Gender": {"text": [["A woman"]],"start": [[ "0" ]],"entity_id": [["G1"]]} ,"Population": {"text": [["repeated therapy cycles"]],"start": [[ "72" ]],"entity_id": [["P1"]]} ,"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["intrathecal Depo-Medrol"]],"start": [[ "103" ]],"entity_id": [["T1"]],"Drug": {"text": [["Depo-Medrol"]],"start": [[ "103" ]],"entity_id": [["D2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["multiple sclerosis"]],"start": [[ "42" ]],"entity_id": [["D1"]]} ,"Combination": null},"Effect": {"text": [["spastic paraparesis"]],"start": [[ "148" ]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "8513656_10","context": "The efficacy of single-dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1-activated toxins.\n","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["disulfiram"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"text": [["single-dose disulfiram"]],"start": [[ "16" ]],"entity_id": [ ["T2"] ],"Disorder": {"text": [["treatment"]],"start": [[ "89" ]],"entity_id": [ ["T3"] ]},"Dosage": {"text": [["single-dose"]],"start": [[ "16" ]],"entity_id": [ ["T4"] ]},"Route": {"text": [["ingestion"]],"start": [[ "57" ]],"entity_id": [ ["T5"] ]},"Freq": {"text": [["single-dose"]],"start": [[ "16" ]],"entity_id": [ ["T6"] ]},"Time_elapsed": {"text": [["this modality for manipulating clinical P450 2E1 activity"]],"start": [[ "57" ]],"entity_id": [ ["T7"] ]},"Duration": {"text": [["this modality for manipulating clinical P450 2E1 activity"]],"start": [[ "57" ]],"entity_id": [ ["T7"] ]},"Trigger": {"text": [["efficacy"]],"start": [[ "0" ]],"entity_id": [ ["T8"] ]},"Combination": [{"Drug": {"text": [["disulfiram"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Trigger": {"text": [["ingredient"]],"start": [[ "37" ]],"entity_id": [ ["T9"] ]},"event_type": "Potential_therapeutic_effect","event_id": "E2"}]},"Effect": {"text": [["a useful probe for delineating P450 2E1 participation in human drug biotransformation"]],"start": [[ "142" ]],"entity_id": [ ["T10"] ]},"Trigger": {"text": [["probe"]],"start": [[ "142" ]],"entity_id": [ ["T11"] ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["The efficacy"]],"start": [[ "0" ]],"entity_id": [ ["T12"] ],"Gender": null,"Population": null,"Race": null,"Age": null,"Disorder": {"text": [["poisoning by P450 2E1-activated toxins"]],"start": [[ "263" ]],"entity_id": [ ["T13"] ]}}}]}
{"id": "3579660_2","context": "To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["penicillamine therapy"]],"start": [["134"]],"entity_id": [["T1"]],"Disorder": {"text": [["neurologic disease"]],"start": [["93"]],"entity_id": [["T2"]]},"Dosage": {"text": [["25"]],"start": [["83"]],"entity_id": [["T3"]]},"Duration": {"text": [["additional patients"]],"start": [["54"]],"entity_id": [["T4"]]},"Freq": {"text": [["relative rarity or frequency"]],"start": [["18"]],"entity_id": [["T5"]]},"Trigger": {"text": [["worsening"]],"start": [["101"]],"entity_id": [["T6"]]},"Route": {"text": [["initiation"]],"start": [["126"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["develop information"]],"start": [["0"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["penicillamine"]],"start": [["134"]],"entity_id": [["T1"]]},"Trigger": {"text": [["therapy"]],"start": [["134"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_effect"}],"Drug": {"text": [["penicillamine"]],"start": [["134"]],"entity_id": [["T1"]]}},"Subject": {"text": [["25 additional patients with Wilson's disease"]],"start": [["54"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["25"]],"start": [["54"]],"entity_id": [["T4"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["Wilson's disease"]],"start": [["63"]],"entity_id": [["T9"]]}},"Effect": {"text": [["neurologic worsening"]],"start": [["101"]],"entity_id": [["T6"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [["initiation"]],"start": [["126"]],"entity_id": [["T7"]]}}]}
{"id": "10779995_3","context": "The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a child"]],"start": [["13"]],"entity_id": [["S1"]] ,"Age": {"text": [["18 months"]],"start": [["24"]],"entity_id": [["S2"]]} ,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["metastatic neuroblastoma"]],"start": [["4"]],"entity_id": [["S3"]]} },"Treatment": {"text": [["oral etoposide"]],"start": [["76"]],"entity_id": [["T1"]],"Drug": {"text": [["etoposide"]],"start": [["76"]],"entity_id": [["T2"]]} ,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Disorder": {"text": [["palliation purpose"]],"start": [["101"]],"entity_id": [["T3"]]} ,"Combination": null },"Effect": {"text": [["t-AML"]],"start": [["6"]],"entity_id": [["E1"]]} ,"Trigger": null }]}
{"id": "7781845_10", "context": "Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypoglycaemia"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["mefloquine"]], "start": [["51"]], "entity_id": [],"Drug": {"text": [["mefloquine"]], "start": [["51"]], "entity_id": []},"Disorder": {"text": [["hypoglycaemia"]], "start": [["0"]], "entity_id": []},"Route": {"text": [["induced"]], "start": [["45"]], "entity_id": []},"Time_elapsed": {"text": [["some other anti-malarial quinine analogues"]], "start": [["58"]], "entity_id": []},"Duration": {"text": [["are discussed"]], "start": [["80"]], "entity_id": []},"Freq": {"text": [["discussed"]], "start": [["80"]], "entity_id": []},"Combination": [{"Drug": {"text": [["mefloquine"]], "start": [["51"]], "entity_id": []},"Trigger": {"text": [["induced"]], "start": [["45"]], "entity_id": []},"event_id": "E1","event_type": "Adverse_event"} ,{"Drug": {"text": [["some other anti-malarial quinine analogues"]], "start": [["58"]], "entity_id": []},"Trigger": {"text": [["induced"]], "start": [["45"]], "entity_id": []},"event_id": "E2","event_type": "Adverse_event"} ] ,"Trigger": {"text": [["induced"]], "start": [["45"]], "entity_id": []},"Dosage": {"text": [], "start": [[],[]], "entity_id": []} }, "Effect": {"text": [["hypoglycaemia"]], "start": [["0"]], "entity_id": []},"Negated": {"text": [], "start": [[],[]], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [[],[]], "entity_id": [],"value": false},"Severity": {"text": [], "start": [[],[]], "entity_id": [],"value": ""} ,"Subject": { "Age": {"text": [], "start": [[],[]], "entity_id": []}, "Gender": {"text": [], "start": [[],[]], "entity_id": []}, "Population": {"text": [], "start": [[],[]], "entity_id": []}, "Race": {"text": [], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [["hypoglycaemia"]], "start": [["0"]], "entity_id": []} ,"text": [], "start": [[],[]], "entity_id": []} }]}
{"id": "11414270_15","context": "Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["nondepolarizing muscle relaxants"]],"start": [["0"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["patients who are at risk for mucositis"]],"start": [["41"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["should be used"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["should be used"]],"start": [["11"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["nondepolarizing muscle relaxants"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["should be used"]],"start": [["11"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Potential_therapeutic_effect"} ],"Time_elapsed": null,"Route": null,"Duration": null ,"Dosage": null ,"Drug": {"text": [["nondepolarizing muscle relaxants"]],"start": [["0"]],"entity_id": [["T1"]]} },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "15685264_11", "context": "A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["pharmacokinetic interaction"]], "start": [["10"]], "entity_id": []}, "Treatment": {"text": [["Dantrolene", "Oxybutynin", "Carbamazepine"]], "start": [["3", "24", "53"]], "entity_id": [],"Drug": {"text": [["Dantrolene"], ["Oxybutynin"], ["Carbamazepine"]], "start": [["3"], ["24"], ["53"]], "entity_id": []}, "Disorder": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Dosage": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Duration": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Route": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Time_elapsed": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Freq": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Combination": [{"Drug": {"text": [["Dantrolene"], ["Oxybutynin"]], "start": [[], []], "entity_id": []}, "Trigger": {"text": [["pharmacokinetic interaction"]], "start": [[ "10"]], "entity_id": []},"event_type":"Potential_therapeutic_effect","event_id":"E1-1"}], "Trigger": {"text": [["Carbamazepine medication"]], "start": [["53"]], "entity_id": []}}, "Subject": {"text": [["a patient with a spinal cord lesion"]], "start": [["82"]], "entity_id": [],"Age": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Gender": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Population": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Race": {"text": [[]], "start": [[], [], []], "entity_id": []}, "Disorder": {"text": [["spinal cord lesion"]], "start": [["87"]], "entity_id": []}}, "Negated": null, "Speculated": null, "Severity": null, "Effect": null}]}
{"id": "19307676_3","context": "We describe a 15-year-old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["15-year-old female patient"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["15"]],"start": [["0"]],"entity_id": [["A1"]]},"Gender": {"text": [["female"]],"start": [["3"]],"entity_id": [["G1"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["22"]],"entity_id": [["D1"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["P1"]]},"Race": {"text": [["N/A"]],"start": [[""],["0"]],"entity_id": [["R1"]]}},"Treatment": {"text": [["intrathecal methotrexate"]],"start": [["103"]],"entity_id": [["T1"]],"Drug": {"text": [["methotrexate"]],"start": [["103"]],"entity_id": [["T2"]]},"Dosage": {"text": [["intrathecal"]],"start": [["103"]],"entity_id": [["D1"]]},"Duration": {"text": [["N/A"]],"start": [[""],["0"]],"entity_id": [["Du1"]]},"Trigger": {"text": [["presenting with status epilepticus after receiving"]],"start": [["50"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after receiving"]],"start": [["98"]],"entity_id": [["Te1"]]},"Route": {"text": [["intrathecal"]],"start": [["103"]],"entity_id": [["R1"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["22"]],"entity_id": [["D1"]]},"Freq": {"text": [["N/A"]],"start": [[""],["0"]],"entity_id": [["Fr1"]]},"Combination": null},"Effect": {"text": [["status epilepticus"]],"start": [["50"]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["N/A"]],"start": [[""],["0"]],"entity_id": [["Se1"]],"value": "N/A"},"Trigger": {"text": [["presenting with status epilepticus after receiving"]],"start": [["50"]],"entity_id": [["T3"]]}}]}
{"id": "3767790_1","context": "Duodenal ulceration: a complication of tolazoline therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["duodenal ulceration"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["tolazoline therapy"]],"start": [[ ]],"entity_id": [] ,"Drug": {"text": [["tolazoline"]],"start": [[ ]],"entity_id": []} ,"Disorder": {"text": [["duodenal ulceration"]],"start": [[ ]],"entity_id": []} ,"Time_elapsed": null,"Duration": null,"Dosage": null,"Freq": null,"Route": null,"Combination": null,"Trigger": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Subject": null}]}
{"id": "10461415_2","context": "Hepato-biliary abnormalities secondary to ceftriaxone use: a case report","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hepato-biliary abnormalities"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]} ,"Treatment": { "text": [["ceftriaxone use"]], "start": [[ "32"]] , "entity_id": [ ["T2"] ],"Drug": { "text": [["ceftriaxone"]], "start": [[ "32"]] , "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["Hepato-biliary abnormalities"]], "start": [[ "0"]] , "entity_id": [ ["T1"] ]} ,"Time_elapsed": { "text": [["secondary"]], "start": [[ "16"]] , "entity_id": [ ["T4"] ]} ,"Duration": { "text": [], "start": [], "entity_id": [] },"Dosage": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null ,"Trigger": { "text": [["ceftriaxone use"]], "start": [[ "32"]] , "entity_id": [ ["T2"] ]} },"Effect": { "text": [["Hepato-biliary abnormalities"]], "start": [[ "0"]] , "entity_id": [ ["T1"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "7900744_1", "context": "Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mannitol nephrotoxicity syndrome"]], "start": [[ "Case report: mannitol nephrotoxicity syndrome" ]],"entity_id": [ ["T1"] ] }, "Subject": { "text": [["man"]], "start": [[ "man" ]],"entity_id": [ ["T2"] ] ,"Age": null, "Gender": { "text": [["man"]], "start": [[ "man" ]],"entity_id": [ ["T2"] ] }, "Population": null, "Race": null, "Disorder": { "text": [["nephrotoxicity syndrome"]], "start": [[ "nephrotoxicity syndrome" ]],"entity_id": [ ["T1"] ] } }, "Treatment": { "text": [["mannitol"]], "start": [[ "mannitol" ]],"entity_id": [ ["T3"] ], "Drug": { "text": [["mannitol"]], "start": [[ "mannitol" ]],"entity_id": [ ["T3"] ] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null , "Disorder": { "text": [["nephrotoxicity syndrome"]], "start": [[ "nephrotoxicity syndrome" ]],"entity_id": [ ["T1"] ] } }, "Effect": { "text": [["nephrotoxicity syndrome"]], "start": [[ "nephrotoxicity syndrome" ]],"entity_id": [ ["T1"] ] } ,"Negated": null, "Speculated": null, "Severity": { "text": [["syndrome"]], "start": [[ "syndrome" ]],"entity_id": [ ["T1"] ], "value": "moderate" } }] }
{"id": "8710040_1", "context": "Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Uveitis"]], "start": [[ ]], "entity_id": []}, "Treatment": {"text": [["treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol"]], "start": [[ ]], "entity_id": [], "Drug": {"text": [["rifabutin","clarithromycin","ethambutol"]], "start": [[ ]], "entity_id": []}, "Combination": [{"Drug": {"text": [["rifabutin"]], "start": [[ ]], "entity_id": []}, "Trigger": {"text": [["and"]], "start": [[ ]], "entity_id": []}, "event_id": "C1", "event_type": "Combination"} ,{"Drug": {"text": [["clarithromycin"]], "start": [[ ]], "entity_id": []}, "Trigger": {"text": [["and"]], "start": [[ ]], "entity_id": []}, "event_id": "C2", "event_type": "Combination"} ] , "Disorder": {"text": [["disseminated Mycobacterium avium-intracellulare complex infection"]], "start": [[ ]], "entity_id": []}, "Time_elapsed": {"text": [["during"]], "start": [[ ]], "entity_id": []}, "Freq":{"text": [["the combination"]], "start": [[ ]], "entity_id": []} , "Duration":{"text": [["of"]], "start": [[ ]], "entity_id": []}, "Route":{"text": [["treatment"]], "start": [[ ]], "entity_id": []}, "Dosage":{"text": [], "start": [], "entity_id": []}, "Trigger":{"text": [["with"]], "start": [[ ]], "entity_id": []}} , "Subject":{"text": [], "start": [], "entity_id": [] , "Age":{"text": [], "start": [], "entity_id": []},"Disorder":{"text": [["disseminated Mycobacterium avium-intracellulare complex infection"]], "start": [[ ]], "entity_id": []}, "Gender":{"text": [], "start": [], "entity_id": []},"Population":{"text": [], "start": [], "entity_id": []},"Race":{"text": [], "start": [], "entity_id": []} }, "Effect":{"text": [["Uveitis"]], "start": [[ ]], "entity_id": []}, "Negated":{"text": [], "start": [], "entity_id": [] ,"value": false},"Speculated":{"text": [], "start": [], "entity_id": [] ,"value": false},"Severity":{"text": [], "start": [], "entity_id": [] ,"value": ""} }]}
{"id": "16527771_2","context": "The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["phenol neurotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Effect": {"text": [["visual loss"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": true,"text": [["seems"]],"start": [["5"]],"entity_id": []} ,"Subject": {"text": [["this patient"]],"start": [["9"]],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []}} ,"Severity": {"value": "","text": [],"start": [],"entity_id": []}}]}
{"id": "16200540_1", "context": "Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["levodopa"]], "start": [["23"]], "entity_id": [],"Drug": {"text": [["levodopa"]], "start": [["23"]], "entity_id": []},"Trigger": {"text": [["augmentation"]], "start": [["55"]], "entity_id": []},"Disorder": {"text": [["restless legs syndrome"]], "start": [["67"]], "entity_id": []},"Time_elapsed": {"text": [["induced"]], "start": [["50"]], "entity_id": []},"Freq": {"text": [["induced"]], "start": [["50"]], "entity_id": []},"Route": {"text": [["pharmacokinetic"]], "start": [["33"]], "entity_id": []},"Duration": {"text": [["Polysomnographic"]], "start": [["0"]], "entity_id": []},"Dosage": {"text": [["levodopa"]], "start": [["23"]], "entity_id": []},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": {"text": [["restless legs syndrome"]], "start": [["67"]], "entity_id": []},"Gender": null,"Population": null,"Race": null},"Effect": null,"Trigger": {"text": [["augmentation"]], "start": [["55"]], "entity_id": []}}]}
{"id": "16109609_2","context": "Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["radiation recall reactions"]],"start": [["35"]],"entity_id": []},"Treatment": {"text": [["Gemcitabine therapy"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Gemcitabine"]],"start": [["0"]],"entity_id": []} ,"Disorder": {"text": [["carcinoma"]],"start": [["75"]],"entity_id": []} ,"Route": {"text": [["therapy"]],"start": [["7"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "15266150_2","context": "Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Increased lash length", "thickness", "and pigmentation"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["prostaglandin analog glaucoma drops"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["prostaglandin analog"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["side effects"]],"start": [[ ]],"entity_id": [ ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null},"Effect": {"text": [["Increased lash length", "thickness", "and pigmentation"]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "17083900_1","context": "Acute generalized exanthematous pustulosis induced by nimesulide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute generalized exanthematous pustulosis"]],"start": [[ "0"]] ,"entity_id": [ ["T1" ]] },"Treatment": {"text": [["nimesulide"]],"start": [[ "53"]] ,"entity_id": [ ["T2" ]],"Drug": {"text": [["nimesulide"]],"start": [[ "53"]] ,"entity_id": [ ["T2" ]] } ,"Combination": null ,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": {"text": [["induced by"]],"start": [[ "18"]] ,"entity_id": [ ["T3" ]] } },"Effect": {"text": [["Acute generalized exanthematous pustulosis"]],"start": [[ "0"]] ,"entity_id": [ ["T1" ]] } ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["induced by"]],"start": [[ "18"]] ,"entity_id": [ ["T3" ]] } ,"Treatment": {"text": [["nimesulide"]],"start": [[ "53"]] ,"entity_id": [ ["T2" ]],"Drug": {"text": [["nimesulide"]],"start": [[ "53"]] ,"entity_id": [ ["T2" ]] } ,"Combination": null,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null } ]}
{"id": "11225532_1","context": "Quinine induced coagulopathy--a near fatal experience","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Quinine induced coagulopathy"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["Quinine"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Quinine"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["coagulopathy"]],"start": [["12"]],"entity_id": []},"Freq": {"text": [["induced"]],"start": [["7"]],"entity_id": []},"Time_elapsed": {"text": [["near fatal experience"]],"start": [["31"]],"entity_id": []},"Trigger": {"text": [["Quinine induced coagulopathy"]],"start": [["0"]],"entity_id": []},"Combination": [{"Drug": {"text": [["Quinine"]],"start": [["0"]],"entity_id": []},"Trigger": {"text": [["Quinine induced coagulopathy"]],"start": [["0"]],"entity_id": []},"event_id": "E1","event_type": "Adverse_event"}],"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []}},"Subject": {"text": [["a near fatal experience"]],"start": [["31"]],"entity_id": [],"Age": {"text": [[]],"start": [[]],"entity_id": []},"Gender": {"text": [[]],"start": [[]],"entity_id": []},"Race": {"text": [[]],"start": [[]],"entity_id": []},"Disorder": {"text": [["coagulopathy"]],"start": [["12"]],"entity_id": []},"Population": {"text": [[]],"start": [[]],"entity_id": []}},"Effect": {"text": [["Quinine induced coagulopathy"]],"start": [["0"]],"entity_id": []},"Negated": {"text": [[]],"start": [[]],"entity_id": [],"value": false},"Speculated": {"text": [[]],"start": [[]],"entity_id": [],"value": false},"Severity": {"text": [["near fatal experience"]],"start": [["31"]],"entity_id": [],"value": "high"}}]}
{"id": "71813_1","context": "A 58-year-old man with rheumatoid arthritis developed lichen planus during treatment with gold","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed lichen planus"]],"start": [[" "], [""], [""], [""], [""], [""], [""], [""], [""], [""], [""], [""], [""], [""], ["d"]],"entity_id": []},"Subject": {"text": [["A 58-year-old man"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": [],"Age": {"text": [["58"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": []},"Gender": {"text": [["man"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["treatment with gold"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": [],"Drug": {"text": [["gold"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["lichen planus"]],"start": [[""], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], [" "], ["A"], ["5"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2347102_1", "context": "Atenolol-induced pseudolymphoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Atenolol-induced"]], "start": [[], []], "entity_id": []}, "Treatment": { "Drug": {"text": [["Atenolol"]], "start": [[], []], "entity_id": []} , "Disorder": {"text": [["pseudolymphoma"]], "start": [[], []], "entity_id": []} , "entity_id": [] , "text": [["Atenolol"]], "start": [[], []], "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": { "text": [["Atenolol-induced"]], "start": [[], []], "entity_id": [] }} , "Effect": { "text": [["pseudolymphoma"]], "start": [[], []], "entity_id": [] } , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null , "Disorder": null , "Gender": null , "Population": null , "Race": null }}]}
{"id": "25407257_1","context": "First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["convulsive seizures"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["valproic acid and tebipenem"]],"start": [["53"]],"entity_id": [["T2", "T3"]],"Combination": [{"Drug": {"text": [["valproic acid"]],"start": [[ "53"]],"entity_id": [["T2"]]},"Trigger": {"text": [["co-administration"]],"start": [[ "5"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["tebipenem"]],"start": [[ "69"]],"entity_id": [["T3"]]},"Trigger": {"text": [["co-administration"]],"start": [[ "5"]],"entity_id": [["T4"]]},"event_id": "C2","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["onset"]],"start": [[ "1"]],"entity_id": [["T5"]]},"Disorder": {"text": [["convulsive seizures"]],"start": [[ "22"]],"entity_id": [["T1"]]},"Dosage": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Duration": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Freq": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Route": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Trigger": {"text": [["co-administration"]],"start": [[ "5"]],"entity_id": [["T4"]]},"Drug": {"text": [["valproic acid and tebipenem"]],"start": [[ "53"]],"entity_id": [["T2","T3"]]}},"Negated": {"value": false,"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Speculated": {"value": true,"text": [["suspected"]],"start": [[ "0"]],"entity_id": [["T6"]]},"Severity": {"value": "low","text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Subject": {"text": [["First case report"]],"start": [[ "0"]],"entity_id": [["T0"]],"Age": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Gender": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Population": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Race": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]},"Disorder": {"text": [["NA"]],"start": [[ "NA"]],"entity_id": [["NA"]]}},"Effect": {"text": [["convulsive seizures"]],"start": [[ "22"]],"entity_id": [["T1"]]}}]}
{"id": "10755579_1", "context": "Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Fluoxetine-related death"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Subject": {"text": [["a child"]], "start": [[ "30" ]], "entity_id": [ ["T2"] ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["cytochrome P-450 2D6 genetic deficiency"]], "start": [[ "53" ]], "entity_id": [ ["T3"] ]}}, "Treatment": {"text": [["Fluoxetine"]], "start": [[ "8" ]], "entity_id": [ ["T1"] ], "Drug": {"text": [["Fluoxetine"]], "start": [[ "8" ]], "entity_id": [ ["T1"] ]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Freq": null, "Combination": null, "Disorder": null}, "Severity": {"text": [["death"]], "start": [[ "17" ]], "entity_id": [ ["T4"] ], "value": "high" },"Negated": null, "Speculated": null ,"Effect": null}] }
{"id": "15735923_3","context": "We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["t-MDS"]],"start": [["35"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 44-year-old woman"]],"start": [["8"]],"entity_id": [["T2"]],"Age": {"text": [["44"]],"start": [["8"]],"entity_id": [["T3"]]},"Gender": {"text": [["woman"]],"start": [["19"]],"entity_id": [["T4"]]},"Disorder": {"text": [["t-MDS (refractory anemia with excess blasts)"]],"start": [["35"]],"entity_id": [["T1"]]},"Population": {"text": [["1"]],"start": [["8"]],"entity_id": [["T5"]]},"Race": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T6"]]}},"Treatment": {"text": [["treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)"]],"start": [["51"]],"entity_id": [["T7"]],"Drug": {"text": [["temozolomide"]],"start": [["70"]],"entity_id": [["T8"]]},"Disorder": {"text": [["treatment of recurrent anaplastic astrocytoma"]],"start": [["51"]],"entity_id": [["T9"]]},"Dosage": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T10"]]},"Duration": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T11"]]},"Route": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T12"]]},"Time_elapsed": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T13"]]},"Freq": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T14"]]},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11332679_1","context": "An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pancreatitis"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["meglumine antimoniate"]],"start": [["44"]],"entity_id": [["T2"]],"Drug": {"text": [["meglumine antimoniate"]],"start": [["44"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["visceral leishmaniasis"]],"start": [["65"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["during"]],"start": [["18"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["18"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["during"]],"start": [["18"]],"entity_id": [["T0"]]} ,"Route": {"text": [["treatment"]],"start": [["37"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["allopurinol"]],"start": [["111"]],"entity_id": [["T7"]]},"Trigger": {"text": [["and"]],"start": [["106"]],"entity_id": [["T6"]]} ,"event_id": "E2" ,"event_type": "Treatment" },{"Drug": {"text": [["ketoconazole"]],"start": [["125"]],"entity_id": [["T8"]]},"event_id": "E3" ,"event_type": "Treatment" ,"Trigger": {"text": [["combination"]],"start": [["100"]],"entity_id": [["T6"]]}}] ,"Trigger": {"text": [["reported"]],"start": [["137"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["infant"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["pancreatitis"]],"start": [["22"]],"entity_id": [["T1"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "8641617_6","context": "The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin-based combination chemotherapy in ovarian cancer patients","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["cisplatin-based combination chemotherapy"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cisplatin-based combination chemotherapy"]],"start": [["32"]],"entity_id": [["T1"]],"Drug": {"text": [["cisplatin"]],"start": [["32"]],"entity_id": [["T2"]]},"Route": {"text": [["combination chemotherapy"]],"start": [["43"]],"entity_id": [["T3"]]},"Disorder": {"text": [["ovarian cancer"]],"start": [["71"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["occurring"]],"start": [["63"]],"entity_id": [["T5"]]},"Trigger": {"text": [["Clostridium difficile colitis"]],"start": [["13"]],"entity_id": [["T0"]]},"Freq": {"text": [["incidence"]],"start": [["5"]],"entity_id": [["T6"]]},"Duration": {"text": [["examine"]],"start": [["0"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["cisplatin"]],"start": [["32"]],"entity_id": [["T2"]]},"Trigger": {"text": [["combination chemotherapy"]],"start": [["43"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Dosage": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Clostridium difficile colitis"]],"start": [["13"]],"entity_id": [["T0"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["ovarian cancer patients"]],"start": [["82"]],"entity_id": [["T8"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["ovarian cancer"]],"start": [["71"]],"entity_id": [["T4"]]}}}]}
{"id": "7854541_1","context": "Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cerebral demyelinating disease"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["adjuvant therapy with levamisole"]], "start": [[ "42" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["levamisole"]], "start": [[ "65" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["malignant melanoma"]], "start": [[ "95" ]], "entity_id": [ ["T4"] ]} ,"Duration": null ,"Dosage": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Combination": null ,"Trigger": null }, "Subject": { "text": [["a patient"]], "start": [[ "21" ]], "entity_id": [ ["T5"] ], "Age": null ,"Disorder": null ,"Gender": null ,"Population": null ,"Race": null },"Effect": { "text": [["Cerebral demyelinating disease"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "3558331_1","context": "Amoxapine-induced cognitive impairment in two patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Amoxapine-induced cognitive impairment"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Subject": {"text": [["two patients"]],"start": [[ "41" ]],"entity_id": [["T2"]],"Population": {"text": [["two patients"]],"start": [[ "41" ]],"entity_id": [["T2"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["Amoxapine"]],"start": [[ "0" ]],"entity_id": [["T3"]],"Drug": {"text": [["Amoxapine"]],"start": [[ "0" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["cognitive impairment"]],"start": [[ "18" ]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["cognitive impairment"]],"start": [[ "18" ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6245286_3", "context": "Visceral herpesvirus infections in leukemic patients receiving cytarabine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Visceral herpesvirus infections"]], "start": [[ ]], "entity_id": [ ]}, "Subject": {"text": [["leukemic patients"]], "start": [[ ]], "entity_id": [ ],"Disorder":{"text":[["leukemic"]], "start":[[ ]], "entity_id":[ ]},"Population":{"text":[["patients"]], "start":[[ ]], "entity_id":[ ]},"Age":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Gender":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Race":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]}},"Treatment": {"text": [["cytarabine"]], "start": [[ ]], "entity_id": [ ],"Drug":{"text":[["cytarabine"]], "start":[[ ]], "entity_id":[ ]},"Disorder":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Dosage":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Duration":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Trigger":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Route":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Time_elapsed":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Freq":{"text":[[" "]], "start":[[ ]], "entity_id":[ ]},"Combination": null} ,"Severity": null,"Negated": null,"Speculated": null ,"Effect": null}]}
{"id": "10431414_1","context": "One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["priapism"]],"start": [["6"]],"entity_id": [["T1"]]},"Treatment": {"text": [["heparin therapy"]],"start": [["21"]],"entity_id": [["T2"]],"Drug": {"text": [["heparin"]],"start": [["21"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["a previous surgical operation to the knee"]],"start": [["47"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["during"]],"start": [["17"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["occurred"]],"start": [["6"]],"entity_id": [["T6"]]},"Trigger": {"text": [["during"]],"start": [["17"]],"entity_id": [["T7"]]} ,"Route": {"text": [["therapy"]],"start": [["21"]],"entity_id": [["T8"]]} ,"Freq": {"text": [["One case"]],"start": [["0"]],"entity_id": [["T9"]]} ,"Combination": [{"Drug": {"text": [["heparin"]],"start": [["21"]],"entity_id": [["T3"]]},"Trigger": {"text": [["during"]],"start": [["17"]],"entity_id": [["T5"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["priapism"]],"start": [["6"]],"entity_id": [["T1"]]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "12365708_5","context": "While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["permanent visual changes"]],"start": [["While both amiodarone and digoxin can cause permanent visual changes,"]],"entity_id": []},"Treatment": {"text": [["amiodarone", "digoxin"]],"start": [],"entity_id": [],"Drug": {"text": [["amiodarone"]],"start": [[", amiodarone"]],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Disorder": null,"Time_elapsed": null,"Freq": null,"Trigger": null,"Combination": null},"Effect": {"text": [["permanent visual changes"]],"start": [[", digoxin can cause permanent visual changes"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"value": "high","text": [],"start": [],"entity_id": []},"Subject": {"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null,"text": [],"start": [],"entity_id": []}}]}
{"id": "15543388_1","context": "Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed celiac disease"]],"start": [["41"]],"entity_id": [["T1"]]},"Subject": {"text": [["a woman patient"]],"start": [["12"]],"entity_id": [["T2"]],"Gender": {"text": [["woman"]],"start": [["12"]],"entity_id": [["T2"]]},"Age": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T2"]]},"Population": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T2"]]},"Race": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T2"]]},"Disorder": {"text": [["chronic hepatitis C"]],"start": [["93"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["pegylated interferon alpha-2a and ribavirin use"]],"start": [["66"]],"entity_id": [["T4"]],"Drug": {"text": [["pegylated interferon alpha-2a"]],"start": [["66"]],"entity_id": [["T5"]]},"Dosage": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T4"]]},"Duration": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T4"]]},"Route": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T4"]]},"Freq": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["pegylated interferon alpha-2a"]],"start": [["66"]],"entity_id": [["T5"]]},"Trigger": {"text": [["and"]],"start": [["79"]],"entity_id": [["T7"]]},"event_id": "E1-1","event_type": "Treatment"},{"Drug": {"text": [["ribavirin"]],"start": [["85"]],"entity_id": [["T8"]]},"Trigger": {"text": [["use"]],"start": [["91"]],"entity_id": [["T9"]]},"event_id": "E1-2","event_type": "Treatment"}],"Disorder": {"text": [["celiac disease"]],"start": [["41"]],"entity_id": [["T1"]]},"Trigger": {"text": [["after"]],"start": [["30"]],"entity_id": [["T10"]]}},"Effect": {"text": [["celiac disease"]],"start": [["41"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["E1"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["E1"]],"value": false},"Severity": {"text": [["null"]],"start": [[""], ["null"]],"entity_id": [["E1"]],"value": "null"}}]}
{"id": "11243427_2", "context": "Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["5-FU-induced ectropion"]], "start": [[ ], [ "36" ] ],"entity_id": [ ]}, "Treatment": { "text": [], "start": [], "entity_id": [] , "Drug": {"text": [["5-FU"]], "start": [[ ], [ "21" ] ],"entity_id": [ ] } , "Disorder": {"text": [["ectropion"]], "start": [[ ], [ "41" ] ],"entity_id": [ ] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Trigger": { "text": [], "start": [], "entity_id": [] } },"Effect": { "text": [["ectropion"]], "start": [[ ], [ "41" ] ],"entity_id": [ ] } , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null, "Disorder": { "text": [["ocular rosacea with cicatrizing conjunctivitis"]], "start": [[ ], [ "12" ] ],"entity_id": [ ] } , "Gender": null, "Population": null, "Race": null } }]}
{"id": "12699871_4", "context": "Tacrolimus (FK506)-induced mutism after liver transplant", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Tacrolimus (FK506)-induced"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Tacrolimus (FK506)"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Tacrolimus"]], "start": [[ ]], "entity_id": [ ]}, "Disorder": {"text": [["mutism"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]},"Trigger": {"text": [["liver transplant"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": null, "Duration": null, "Route": null, "Freq": null, "Combination": null} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Effect": {"text": [["mutism"]], "start": [[ ]], "entity_id": [ ]}}]}
{"id": "17009081_4","context": "Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["proteinuria and nephrotic syndrome"]],"start": [["0", "48"]],"entity_id": [["T1"]]},"Treatment": {"text": [["IFN-beta-1b therapy"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["IFN-beta-1b"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["rare adverse effect"]],"start": [["49"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["rare"]],"start": [["49"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["new clinical symptoms and laboratory findings"]],"start": [["100"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["this agent"]],"start": [["82"]],"entity_id": [["T6"]]} ,"Route": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["treating MS patients"]],"start": [["68"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["IFN-beta-1b"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T7"]]} ,"event_id": "C1","event_type": "Therapy"}],"Trigger": {"text": [["treating MS patients"]],"start": [["68"]],"entity_id": [["T8"]]} },"Subject": {"text": [["physicians"]],"start": [["87"]],"entity_id": [["T9"]],"Population": {"text": [["MS patients"]],"start": [["76"]],"entity_id": [["T10"]]},"Disorder": {"text": [["treating"]],"start": [["87"]],"entity_id": [["T9"]]} ,"Age": {"text": [["this agent"]],"start": [["82"]],"entity_id": [["T6"]]} ,"Race": {"text": [["physicians"]],"start": [["87"]],"entity_id": [["T9"]]} ,"Gender": {"text": [["physicians"]],"start": [["87"]],"entity_id": [["T9"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["rare adverse effect"]],"start": [["49"]],"entity_id": [["T4"]] ,"value": "Low" },"Effect": {"text": [["proteinuria and nephrotic syndrome"]],"start": [["0"]],"entity_id": [["T1"]] }}]}
{"id": "2894766_1","context": "It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sulfasalazine-induced lupus"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["sulfasalazine"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["sulfasalazine"]],"start": [[ ]],"entity_id": [["T2"]]},"Disorder": {"text": [["lupus"]],"start": [[ ]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["manifested"]],"start": [[ ]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["sulfasalazine"]],"start": [[ ]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [[ ]],"entity_id": [["T2"]]},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["manifested"]],"start": [[ ]],"entity_id": [["T4"]]},"Freq": {"text": [["in the absence of joint symptoms"]],"start": [[ ]],"entity_id": [["T5"]]},"Dosage": {"text": [["-"]],"start": [[ ]],"entity_id": [["T2"]]},"Duration": {"text": [["-"]],"start": [[ ]],"entity_id": [["T2"]]},"Route": {"text": [["-"]],"start": [[ ]],"entity_id": [["T2"]]}},"Effect": {"text": [["serositis and pulmonary parenchymal involvement"]],"start": [[ ]],"entity_id": [["T6"]]},"Subject": {"text": [["the patient"]],"start": [[ ]],"entity_id": [["T7"]],"Age": {"text": [["-"]],"start": [[ ]],"entity_id": [["T7"]]},"Gender": {"text": [["-"]],"start": [[ ]],"entity_id": [["T7"]]},"Population": {"text": [["-"]],"start": [[ ]],"entity_id": [["T7"]]},"Race": {"text": [["-"]],"start": [[ ]],"entity_id": [["T7"]]},"Disorder": {"text": [["lupus"]],"start": [[ ]],"entity_id": [["T3"]]}},"Negated": {"text": [["not"]],"start": [[ ]],"entity_id": [["T5"]],"value": false},"Speculated": {"text": [["it is suggested"]],"start": [[ ]],"entity_id": [["T1"]],"value": true},"Severity": {"text": [["-"]],"start": [[ ]],"entity_id": [["T3"]],"value": "low"}}]}
{"id": "19357764_2","context": "This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["zidovudine"]],"start": [["switching to zidovudine].indexOf(" ] ] ,"entity_id": [ ["T1"] ] } ,"Trigger": {"text": [["potentially"]],"start": [[ "switching to zidovudine].indexOf(" ] , [ "switching to zidovudine].indexOf(" ] ],"entity_id": [ ["T2"] ] } ,"Time_elapsed": {"text": [["a hyperlactatemia relapse"]],"start": [[ "DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse." ] ] ,"entity_id": [ ["T3"] ] } ,"entity_id": [ ["E1"] ] ,"text": [["switching to zidovudine potentially can lead to a hyperlactatemia relapse"]],"start": [[ "DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse." ] ] ,"Disorder": {"text": [["hyperlactatemia"]],"start": [[ "DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse." ] ] , "entity_id": [ ["T3"] ] } ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Combination": null } , "Subject": null , "Negated": null , "Speculated": {"text": [["potentially"]],"start": [[ "switching to zidovudine].indexOf(" ] ],"entity_id": [ ["T2"] ] ,"value": true },"Severity": null ,"Effect": null ,"Trigger": null } ] }
{"id": "9232614_1","context": "Acute leukaemia during tamoxifen therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute leukaemia"]],"start": [[ ],[ ]],"entity_id": [ ]},"Treatment": {"text": [["tamoxifen therapy"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["tamoxifen"]],"start": [[ ]],"entity_id": [ ]},"Duration": null,"Disorder": null,"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Combination": null,"Trigger": null},"Effect": {"text": [["Acute leukaemia"]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "1310879_3", "context": "Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["a patient"]], "start": [["a patient's starting index here"]], "entity_id": [["S1"]] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["Heparin-associated thrombocytopenia"]], "start": [[ "Heparin-associated thrombocytopenia's starting index here" ]], "entity_id": [["S2"]] }},"Trigger": {"text": [["Heparin-associated thrombocytopenia"]], "start": [[ "Heparin-associated thrombocytopenia's starting index here" ]], "entity_id": [["T1"]]},"Effect": null,"Treatment": {"text": [["successful therapy with the heparinoid Org 10172"]], "start": [[ "therapy's starting index here" ]], "entity_id": [["T2"]],"Drug": {"text": [["Org 10172"]], "start": [[ "Org 10172's starting index here" ]], "entity_id": [["T3"]]},"Dosage": null, "Duration": null, "Disorder": {"text": [["Heparin-associated thrombocytopenia"]], "start": [[ "Heparin-associated thrombocytopenia's starting index here" ]], "entity_id": [["T4"]]},"Route": null, "Time_elapsed": null, "Freq": null , "Combination": null ,"Trigger": { "text": [["showing cross-reaction to LMW heparins"]], "start": [[ "showing cross-reaction to LMW heparins' starting index here" ]], "entity_id": [["T5"]] }} }]}
{"id": "9509511_2","context": "We conclude that vincristine and actinomycin D were the cause of this rare form of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["vincristine", "actinomycin D"]],"start": [[ ], []],"entity_id": [["T1"], ["T2"]]},"Effect": {"text": [["hepatotoxicity"]],"start": [[ ]],"entity_id": [["T3"]]},"Treatment": {"text": [["chemotherapy"]],"start": [[ ]],"entity_id": [["T4"]],"Drug": {"text": [["vincristine", "actinomycin D"]],"start": [[], []],"entity_id": [["T1"], ["T2"]]},"Disorder": {"text": [["malignant disease"]],"start": [[ ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["clinical recovery"]],"start": [[ ]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["We"]],"start": [[ ]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["malignant disease"]],"start": [[ ]],"entity_id": [["T5"]]}},"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "6702890_2", "context": "Pure red cell aplasia associated with fenoprofen", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Pure red cell aplasia"]], "start": [[ ]],"entity_id": [["T1"]]}, "Treatment": {"text": [["fenoprofen"]], "start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["fenoprofen"]], "start": [[ ]],"entity_id": [["T3"]] } ,"Disorder": {"text": [["Pure red cell aplasia"]], "start": [[ ]],"entity_id": [["T1"]]} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Freq": null ,"Route": null ,"Trigger": null ,"Combination": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "10891991_5","context": "Three patients developed a reproductive endocrine disorder during treatment with valproate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Three patients"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["Three patients"]],"start": [["0"]],"entity_id": [ ["T1"] ],"Age": null,"Gender": null,"Population": {"text": [["Three patients"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Race": null,"Disorder": null },"Treatment": {"text": [["valproate"]],"start": [["90"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["valproate"]],"start": [["90"]],"entity_id": [ ["T2"] ]},"Dosage": null,"Duration": null,"Disorder": {"text": [["a reproductive endocrine disorder"]],"start": [["35"]],"entity_id": [ ["T3"] ]},"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": {"text": [["a reproductive endocrine disorder"]],"start": [["35"]],"entity_id": [ ["T3"] ]} ,"Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "3430507_6","context": "A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["rapidly progressive glomerulonephritis", "hemoptysis"]],"start": [["22", "51"]],"entity_id": [["T1", "T2"]]},"Subject": {"text": [["A 56-year-old woman"]],"start": [["0"]],"entity_id": [["T3"]],"Age": {"text": [["56"]],"start": [["2"]],"entity_id": [["T4"]]},"Gender": {"text": [["woman"]],"start": [["10"]],"entity_id": [["T5"]]},"Disorder": {"text": [["scleroderma"]],"start": [["7"]],"entity_id": [["T6"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T3"]]},"Race": null},"Treatment": {"text": [["D-penicillamine therapy"]],"start": [["76"]],"entity_id": [["T7"]],"Drug": {"text": [["D-penicillamine"]],"start": [["76"]],"entity_id": [["T8"]]},"Dosage": {"text": [["1,200 g"]],"start": [["92"]],"entity_id": [["T9"]]},"Duration": {"text": [["27 months"]],"start": [["81"]],"entity_id": [["T10"]]},"Trigger": {"text": [["after"]],"start": [["80"]],"entity_id": [["T11"]]},"Route": null,"Time_elapsed": {"text": [["27 months"]],"start": [["81"]],"entity_id": [["T10"]]},"Disorder": {"text": [["rapidly progressive glomerulonephritis"]],"start": [["22"]],"entity_id": [["T1"]]},"Freq": null,"Combination": null},"Effect": {"text": [["epithelial crescents"]],"start": [["42"]],"entity_id": [["T12"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2212262_2","context": "We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["heparin associated thrombocytopenia"]],"start": [["31"]],"entity_id": [["T1"]]},"Subject": {"text": [["patient"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["heparin"]],"start": [["64"]],"entity_id": [["T3"]],"Drug": {"text": [["heparin"]],"start": [["64"]],"entity_id": [["T3"]]},"Disorder": {"text": [["thrombocytopenia"]],"start": [["31"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Route": {"text": [["continuous arteriovenous haemofiltration"]],"start": [["42"]],"entity_id": [["T4"]]},"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["thrombocytopenia"]],"start": [["31"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17133571_2", "context": "We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fulminant hepatitis"]], "start": [["33"]], "entity_id": [["T1"]]},"Treatment": {"text": [["liver transplantation"]], "start": [["83"]], "entity_id": [["T3"]] ,"Disorder": {"text": [["fulminant hepatitis"]], "start": [["33"]], "entity_id": [["T1"]]} ,"Drug": {"text": [["nevirapine (Viramune)"]], "start": [["46"]], "entity_id": [["T2"]]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null },"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "7900744_5", "context": "The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["ARF"]], "start": [["32-33"]], "entity_id": []}, "Treatment": {"text": [["mannitol infusion"]], "start": [["12-17"]], "entity_id": [], "Drug": {"text": [["mannitol"]], "start": [["12-17"]], "entity_id": []}, "Route": {"text": [["infusion"]], "start": [["15"]], "entity_id": []}, "Trigger": {"text": [["infusion"]], "start": [["15"]], "entity_id": []}, "Time_elapsed": {"text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Disorder": {"text": [["ARF"]], "start": [["32-33"]], "entity_id": []}, "Freq": {"text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Duration": {"text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Dosage": {"text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Combination": []}, "Subject": {"text": [["patients who received dialysis and those who did not receive dialysis"]], "start": [["46-72"]], "entity_id": [], "Age": {"text": [["-"]], "start": [["46-72"]], "entity_id": []}, "Gender": {"text": [["-"]], "start": [["46-72"]], "entity_id": []}, "Population": {"text": [["all patients"]], "start": [["46-72"]], "entity_id": []}, "Race": {"text": [["-"]], "start": [["46-72"]], "entity_id": []}, "Disorder": {"text": [["-"]], "start": [["46-72"]], "entity_id": []}}, "Effect": {"text": [["ARF"]], "start": [["32-33"]], "entity_id": []}, "Negated": {"value": false, "text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Speculated": {"value": false, "text": [["-"]], "start": [["32-33"]], "entity_id": []}, "Severity": {"value": "low", "text": [["-"]], "start": [["32-33"]], "entity_id": []}}]}
{"id": "15190230_2","context": "In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute dystonia"]],"start": [["39"]],"entity_id": [["T1"]]},"Treatment": {"text": [["pegylated interferon alpha"]],"start": [["82"]],"entity_id": [["T2"]],"Drug": {"text": [["pegylated interferon"]],"start": [["82"]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic hepatitis B"]],"start": [["24"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["soon after the first dose"]],"start": [["64"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [["49"]],"entity_id": [["T6"]]},"Freq": {"text": [["first dose"]],"start": [["64"]],"entity_id": [["T7"]]},"Dosage": {"text": [["pegylated interferon alpha"]],"start": [["82"]],"entity_id": [["T2"]]},"Route": {"text": [["dose"]],"start": [["64"]],"entity_id": [["T5"]]},"Duration": {"text": [["chronic"]],"start": [["24"]],"entity_id": [["T4"]]},"Combination": null},"Subject": {"text": [["a case"]],"start": [["12"]],"entity_id": [["T8"]],"Age": null,"Disorder": {"text": [["chronic hepatitis B"]],"start": [["24"]],"entity_id": [["T4"]]},"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["acute dystonia"]],"start": [["39"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15266150_3", "context": "Trichiasis associated with prostaglandin analog use", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Trichiasis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["prostaglandin analog use"]], "start": [[ ]], "entity_id": [["T2"]], "Drug": {"text": [["prostaglandin analog"]], "start": [[ ]], "entity_id": [["T3"]]}, "Disorder": {"text": [["Trichiasis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null} , "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [], "start": [], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Effect": {"text": [], "start": [], "entity_id": []} }]}
{"id": "2937155_2","context": "The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["drug-induced vasculitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["vancomycin"]],"start": [["67"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["rare toxic effects"]],"start": [["54"]],"entity_id": [["T3"]]} ,"entity_id": [["T2"]] ,"Freq": {"text": [["possible development"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["should be added"]],"start": [["44"]],"entity_id": [["T5"]]} ,"text": [["vancomycin"]],"start": [["67"]],"Dosage": {"text": [["development"]],"start": [["18"]],"entity_id": [["T1"]]},"Duration": {"text": [["toxic effects"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Route": {"text": [["induced vasculitis or lupus-like syndrome"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["possible development"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["vancomycin"]],"start": [["67"]],"entity_id": [["T2"]]},"Trigger": {"text": [["possible development"]],"start": [["0"]],"entity_id": [["T4"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] } ,"Negated": null,"Speculated": null,"Severity": {"text": [["rare"]],"start": [["54"]],"entity_id": [["T3"]] ,"value": "low" },"Subject": {"text": [["should be added"]],"start": [["44"]],"entity_id": [["T5"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["rare toxic effects"]],"start": [["54"]],"entity_id": [["T3"]]} },"Effect": {"text": [["drug-induced vasculitis"]],"start": [["18"]],"entity_id": [["T1"]]} }] }
{"id": "17381671_8","context": "Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["serotonin syndrome"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["initiation of fentanyl and other phenylpiperidine opioids"]],"start": [["55"]],"entity_id": [["T2"]],"Drug": {"text": [["fentanyl"]],"start": [["55"]],"entity_id": [["T3"]]},"Route": {"text": [["initiation"]],"start": [["55"]],"entity_id": [["T3"]]},"Trigger": {"text": [["initiation"]],"start": [["55"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment with SSRIs"]],"start": [["104"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["of initiation"]],"start": [["55"]],"entity_id": [["T5"]]},"Freq": {"text": [["possible development"]],"start": [["21"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["fentanyl"]],"start": [["55"]],"entity_id": [["T3"]]},"Trigger": {"text": [["initiation"]],"start": [["55"]],"entity_id": [["T3"]]},"event_type": "Adverse_event","event_id": "E2"}],"Dosage": {"text": [["initiation"]],"start": [["55"]],"entity_id": [["T5"]]},"Duration": {"text": [["treatment with SSRIs"]],"start": [["104"]],"entity_id": [["T4"]]}},"Subject": {"text": [["Healthcare professionals"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["-"]],"start": [["]],"]],"entity_id": [["T7"]]},"Disorder": {"text": [["treatment with SSRIs"]],"start": [["104"]],"entity_id": [["T4"]]},"Gender": {"text": [["-"]],"start": [["]],"]],"entity_id": [["T7"]]},"Population": {"text": [["-"]],"start": [["]],"]],"entity_id": [["T7"]]},"Race": {"text": [["-"]],"start": [["]],"]],"entity_id": [["T7"]]}},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T8"]],"value": false},"Speculated": {"text": [["should be aware"]],"start": [["0"]],"entity_id": [["T9"]],"value": false},"Severity": {"text": [["possible development"]],"start": [["21"]],"entity_id": [["T6"]],"value": "Low"},"Effect": {"text": [["serotonin syndrome"]],"start": [["21"]],"entity_id": [["T1"]]}}]}
{"id": "2299784_2", "context": "Bromide intoxication secondary to pyridostigmine bromide therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bromide intoxication"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["pyridostigmine bromide therapy"]], "start": [["31"]], "entity_id": [], "Drug": {"text": [["pyridostigmine bromide"]], "start": [["31"]], "entity_id": []},"Route":{"text":[["therapy"]], "start":[[ "31" ]], "entity_id": [] },"Disorder":{"text":[["bromide intoxication"]], "start":[[ "0" ]], "entity_id": [] },"Time_elapsed":{"text":[["secondary"]], "start":[[ "11" ]], "entity_id": [] },"Trigger":{"text":[["to"]], "start":[[ "30" ]], "entity_id": [] }, "Freq":{"text":[["therapy"]], "start":[[ "31" ]], "entity_id": [] },"Duration":{"text":[["to"]], "start":[[ "30" ]], "entity_id": [] },"Dosage":{"text":[["bromide intoxication"]], "start":[[ "0" ]], "entity_id": [] },"Combination": [] },"Effect": { "text": [], "start": [], "entity_id": [] },"Negated": { "text": [], "start": [], "entity_id": [],"value":false },"Speculated": { "text": [], "start": [], "entity_id": [],"value":false },"Severity": { "text": [], "start": [], "entity_id": [],"value":"Not Specified" },"Subject": { "Age": { "text": [], "start": [], "entity_id": [] },"Disorder": { "text": [["bromide intoxication"]], "start": [[ "0" ]], "entity_id": [] },"Gender": { "text": [], "start": [], "entity_id": [] },"Population": { "text": [], "start": [], "entity_id": [] },"Race": { "text": [], "start": [], "entity_id": [] },"text": [], "start": [], "entity_id": [] } } ] }
{"id": "22735246_4","context": "We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["this medicine"]],"start": [["53"]],"entity_id": [["T2"]],"Drug": {"text": [["this medicine"]],"start": [["53"]],"entity_id": [["T2"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["which was precipitated by"]],"start": [["22"]],"entity_id": [["T3"]]},"Trigger": {"text": [["long-term treatment with sertraline"]],"start": [["67"]],"entity_id": [["T4"]]},"Dosage": {"text": [["long-term"]],"start": [["67"]],"entity_id": [["T4"]]},"Duration": {"text": [["long-term"]],"start": [["67"]],"entity_id": [["T4"]]},"Freq": {"text": [["treatment"]],"start": [["67"]],"entity_id": [["T4"]]},"Route": {"text": [["treatment"]],"start": [["67"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["sertraline"]],"start": [["88"]],"entity_id": [["T6"]]},"Trigger": {"text": [["long-term treatment with"]],"start": [["67"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["a patient"]],"start": [["42"]],"entity_id": [["T5"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["predisposed by long-term treatment with sertraline"]],"start": [["42"]],"entity_id": [["T5"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "19789372_6","context": "Of the 15 patients treated with tizanidine and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and dry mouth in the retrospective survey","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["the 15 patients"]],"start": [[ "Of the" , "15" ]],"entity_id": [["T1"], ["T2"]],"Age": null,"Gender": null,"Population": {"text": [["15"]],"start": [[ "15" ]],"entity_id": [["T2"]]},"Race": null,"Disorder": {"text": [["tizanidine-induced adverse effects"]],"start": [[ "suffered", "such as" ]],"entity_id": [["T4"]]}},"Treatment": {"text": [["tizanidine and mexiletine"]],"start": [[ "treated with" ]],"entity_id": [["T3"]],"Drug": {"text": [["tizanidine"]],"start": [[ "tizanidine" ]],"entity_id": [["T5"]]},"Disorder": {"text": [["tizanidine-induced adverse effects"]],"start": [[ "suffered", "such as" ]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Trigger": {"text": [["tizanidine-induced"]],"start": [[ "suffered" ]],"entity_id": [["T4"]]},"Freq": null,"Combination": [{"event_type": "Adverse_event","event_id": "E1_C1","Drug": {"text": [["tizanidine"]],"start": [[ "tizanidine" ]],"entity_id": [["T5"]]},"Trigger": {"text": [["drowsiness"]],"start": [[ "such as" ]],"entity_id": [["T6"]]}},{"event_type": "Adverse_event","event_id": "E1_C2","Drug": {"text": [["tizanidine"]],"start": [[ "tizanidine" ]],"entity_id": [["T5"]]},"Trigger": {"text": [["dry mouth"]],"start": [[ "dry mouth" ]],"entity_id": [["T7"]]}}]},"Effect": {"text": [["tizanidine-induced adverse effects"]],"start": [[ "suffered", "such as" ]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["tizanidine-induced"]],"start": [[ "suffered" ]],"entity_id": [["T4"]]}}]}
{"id": "2006943_1","context": "Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Type I second-degree AV block (Mobitz type I, Wenckebach AV block)"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["ritodrine therapy"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["ritodrine"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["preterm labor"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": null,"Freq": null,"Combination": null,"Route": null,"Dosage": null,"Duration": null,"Trigger": {"text": [["during"]],"start": [[ ]],"entity_id": [ ]}},"Subject": {"text": [["patient"]],"start": [[ ]],"entity_id": [ ],"Age": null,"Disorder": {"text": [["preterm labor"]],"start": [[ ]],"entity_id": [ ]},"Gender": null,"Population": null,"Race": null},"Effect": null,"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "20412003_1","context": "After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["TMP-SMX"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["TMP-SMX"]],"start": [["28"]],"entity_id": [["T1"]],"Drug": {"text": [["TMP-SMX"]],"start": [["28"]],"entity_id": [["T1"]]},"Disorder": {"text": [["liver toxicity"]],"start": [["7"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["was determined"]],"start": [["41"]],"entity_id": [["T3"]]},"Freq": {"text": [["acute"]],"start": [["33"]],"entity_id": [["T4"]]},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Route": {"text": [[]],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [[]],"start": [],"entity_id": []}},"Effect": {"text": [["liver toxicity"]],"start": [["7"]],"entity_id": [["T2"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["his"]],"start": [["51"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Disorder": null,"Race": null}}]}
{"id": "6149250_3", "context": "One of the patients had a dexamethasone dependent brain metastatic condition", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["dexamethasone"]], "start": [["32","38"]], "entity_id": [],"Drug": {"text": [["dexamethasone"]], "start": [["32","38"]], "entity_id": []},"Disorder": {"text": [["brain metastatic condition"]], "start": [["45","73"]], "entity_id": []}, "Duration": { "text": [["dexamethasone dependent"]], "start": [["29","44"]], "entity_id": []}, "Trigger": { "text": [], "start": [], "entity_id": []},"Route": { "text": [], "start": [], "entity_id": []}, "Time_elapsed": { "text": [], "start": [], "entity_id": []}, "Freq": { "text": [], "start": [], "entity_id": []}, "Dosage": { "text": [], "start": [], "entity_id": []}, "Combination": []} , "Subject": { "text": [["One of the patients"]], "start": [[ "0","19" ]], "entity_id": [], "Age": { "text": [], "start": [], "entity_id": []}, "Disorder": { "text": [], "start": [], "entity_id": []}, "Gender": { "text": [], "start": [], "entity_id": []}, "Population": { "text": [], "start": [], "entity_id": []}, "Race": { "text": [], "start": [], "entity_id": []}} ,"Negated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Severity": { "text": [], "start": [], "entity_id": [] , "value": "" } ,"Effect": { "text": [["brain metastatic condition"]], "start": [[ "45","73" ]], "entity_id": []} ,"Trigger": { "text": [], "start": [], "entity_id": []} }]}
{"id": "12365708_2","context": "Biomicroscopy revealed amiodarone corneal deposits","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["amiodarone corneal deposits"]],"start": [["26"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["amiodarone"]],"start": [["18"]],"entity_id": [["T2"]]},"entity_id": [["T1"]] ,"Disorder": {"text": [["amiodarone corneal deposits"]],"start": [["26"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["Biomicroscopy revealed"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Route": {"text": [["revealed"]],"start": [["17"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["N/A"]],"start": [[""]],"entity_id": [["T4"]]} ,"Duration": {"text": [["N/A"]],"start": [[""]],"entity_id": [["T5"]]} ,"Freq": {"text": [["N/A"]],"start": [[""]],"entity_id": [["T6"]]} ,"Combination": null ,"Trigger": {"text": [["amiodarone corneal deposits"]],"start": [["26"]],"entity_id": [["T1"]]} ,"text": [["Biomicroscopy revealed amiodarone corneal deposits"]],"start": [["0"]] },"Subject": {"text": [["N/A"]],"start": [[""]],"entity_id": [["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["amiodarone corneal deposits"]],"start": [["26"]],"entity_id": [["T1"]]} }]}
{"id": "14601701_5","context": "This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe", "unpredictable", "nature", "ethambutol", "toxicity", "irreversible", "vision", "loss"]],"start": [[ ],[ ],[ ],[ ],[ ],[ ],[ ],[ ]],"entity_id": [ ]},"Effect": {"text": [["ethambutol toxicity"]],"start": [[ ]],"entity_id": [ ]},"Severity": {"value": "high" ,"text": [["severe"]],"start": [[ ]],"entity_id": [ ]},"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []} ,"Treatment": {"Drug": {"text": [["ethambutol"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["ethambutol toxicity"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["oral"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"text": [["ethambutol therapy"]],"start": [[ ]],"entity_id": [ ],"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Subject": {"text": [["This case"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} }} ]}
{"id": "15790469_4","context": "Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Methotrexate (MTX)"]],"start": [["54"]],"entity_id": [["T1"]],"Disorder": {"text": [["juvenile rheumatoid arthritis (JRA)"]],"start": [["35"]],"entity_id": [["T2"]]},"Trigger": {"text": [["developing"]],"start": [["89"]],"entity_id": [["T3"]]},"Dosage": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T4"]]},"Duration": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T5"]]},"Route": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T7"]]},"Freq": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["Methotrexate (MTX)"]],"start": [["54"]],"entity_id": [["T1"]]},"Trigger": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T9"]]},"event_id": "E2","event_type": "Adverse_event"}],"Drug": {"text": [["Methotrexate (MTX)"]],"start": [["54"]],"entity_id": [["T1"]]}},"Subject": {"text": [["patients with juvenile rheumatoid arthritis (JRA)"]],"start": [["35"]],"entity_id": [["T10"]],"Age": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T11"]]},"Gender": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T12"]]},"Population": {"text": [["some studies have also reported association"]],"start": [[],[]],"entity_id": [["T13"]]},"Race": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T14"]]},"Disorder": {"text": [["juvenile rheumatoid arthritis (JRA)"]],"start": [["35"]],"entity_id": [["T15"]]}},"Effect": {"text": [["malignant lymphoma"]],"start": [["72"]],"entity_id": [["T16"]]},"Negated": {"text": [["Not specified"]],"start": [[],[]],"entity_id": [["T17"]],"value": false},"Speculated": {"text": [["some studies have also reported association"]],"start": [[],[]],"entity_id": [["T18"]],"value": true},"Severity": {"text": [["malignant"]],"start": [["72"]],"entity_id": [["T19"]],"value": "high"},"Trigger": {"text": [["developing"]],"start": [["89"]],"entity_id": [["T20"]]}}]}
{"id": "10679548_6","context": "The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["respiratory symptoms"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["prolonged treatment with nitrofurantoin"]],"start": [["61"]],"entity_id": [["T2"]],"Drug": {"text": [["nitrofurantoin"]],"start": [["61"]],"entity_id": [["T3"]]},"Duration": {"text": [["prolonged"]],"start": [["48"]],"entity_id": [["T4"]]},"Dosage": {"text": [["prolonged"]],"start": [["48"]],"entity_id": [["T4"]]},"Route": {"text": [["treatment"]],"start": [["56"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["after"]],"start": [["41"]],"entity_id": [["T6"]]},"Trigger": {"text": [["presented"]],"start": [["13"]],"entity_id": [["T7"]]},"Disorder": {"text": [["respiratory symptoms"]],"start": [["18"]],"entity_id": [["T1"]]},"Freq": {"text": [["prolonged"]],"start": [["48"]],"entity_id": [["T4"]]},"Combination": null},"Subject": {"text": [["two middle aged women"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [["middle aged"]],"start": [["2"]],"entity_id": [["T9"]]},"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "20378385_1","context": "To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fever"]],"start": [["To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever," , "fever"]],"entity_id": []},"Subject": {"text": [["a patient with rheumatoid arthritis"]],"start": [[ "To describe" , "a patient with rheumatoid arthritis" ]],"entity_id": [] ,"Disorder": {"text": [["rheumatoid arthritis"]],"start": [[ "a patient with rheumatoid arthritis" ]],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["adalimumab"]],"start": [[ "receiving adalimumab" ]],"entity_id": [],"Drug": {"text": [["adalimumab"]],"start": [[ "receiving adalimumab" ]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Disorder": {"text": [["rheumatoid arthritis"]],"start": [[ "a patient with rheumatoid arthritis" ]],"entity_id": []}},"Effect": {"text": [["fever"]],"start": [[ "fever" ]],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""}}]}
{"id": "12523465_2", "context": "Visual hallucinations associated with zonisamide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Visual hallucinations"]], "start": [[ "0" ]], "entity_id": []}, "Treatment": {"text": [["zonisamide"]], "start": [[ "43" ]], "entity_id": [],"Drug": {"text": [["zonisamide"]], "start": [[ "43" ]], "entity_id": [] },"Disorder": {"text": [["Visual hallucinations"]], "start": [[ "0" ]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["associated with"]], "start": [[ "22" ]], "entity_id": []}} ,"Negated": null, "Speculated": null, "Severity": null ,"Subject": null ,"Effect": null }]}
{"id": "10494874_1","context": "We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["multiple hepatic adenomas"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["danazol treatment"]],"start": [["78"]],"entity_id": [["T2"]],"Drug": {"text": [["danazol"]],"start": [["78"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["uterine fibromatosis"]],"start": [["93"]],"entity_id": [["T4"]]} ,"Route": {"text": [["treatment"]],"start": [["78"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["soon after"]],"start": [["64"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["multiple hepatic adenomas"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["soon after"]],"start": [["64"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["danazol treatment"]],"start": [["78"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["danazol treatment"]],"start": [["78"]],"entity_id": [["T2"]]} ,"Combination": null} ,"Subject": {"text": [["a female acromegalic patient"]],"start": [["15"]],"entity_id": [["T0"]],"Age": null,"Gender": {"text": [["a female"]],"start": [["15"]],"entity_id": [["T0"]]},"Population": null,"Race": null,"Disorder": {"text": [["acromegalic patient"]],"start": [["15"]],"entity_id": [["T0"]]} },"Effect": {"text": [["multiple hepatic adenomas"]],"start": [["38"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9347384_1","context": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Carbamazepine toxicity"]],"start": [[ ]] ,"entity_id": [ ]},"Treatment": {"text": [["clarithromycin coadministration"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["clarithromycin"]],"start": [[ ]],"entity_id": []},"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["psychiatric"]],"start": [[ ]],"entity_id": []},"Freq": null,"Combination": [{"event_type": "Adverse_event","event_id": "C1","Drug": {"text": [["Carbamazepine"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["toxicity"]],"start": [[ ]],"entity_id": []}}],"Trigger": {"text": [["induced"]],"start": [[ ]],"entity_id": []},"Dosage": null,"Route": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["psychiatric"]],"start": [[ ]],"entity_id": []},"text": [],"start": [],"entity_id": []}}]}
{"id": "2116935_2","context": "Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["acute myocardial infarction"]],"start": [["54"]],"entity_id": [["T2"]]},"Drug": {"text": [["tissue plasminogen activator (tPA)"]],"start": [["13"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["thrombolytic therapy"]],"start": [["0"]],"entity_id": [["T4"]]},"Trigger": {"text": [["result in"]],"start": [["86"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["may result in"]],"start": [["86"]],"entity_id": [["T5"]]},"Freq": {"text": [["may"]],"start": [["86"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["may result in"]],"start": [["86"]],"entity_id": [["T5"]]},"Route": {"text": [["thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction"]],"start": [["0"]],"entity_id": [["T1"]]},"Duration": {"text": [["thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["major bleeding complications such as gastrointestinal or intracranial bleeding"]],"start": [["112"]],"entity_id": [["T6"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Trigger": {"text": [["may result in"]],"start": [["86"]],"entity_id": [["T5"]]}}]}
{"id": "10897389_1","context": "However, recurrent staphylococcus aureus sepsis developed during CyA therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["recurrent staphylococcus aureus sepsis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["CyA therapy"]],"start": [["72"]],"entity_id": [["T2"]],"Drug": {"text": [["CyA"]],"start": [["72"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["during"]],"start": [["54"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["recurrent"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["developed"]],"start": [["32"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["staphylococcus aureus sepsis"]],"start": [["11"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null} }]}
{"id": "8570441_1", "context": "Nabumetone-associated interstitial nephritis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Nabumetone-associated interstitial nephritis"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]]}, "Treatment": {"text": [["Nabumetone"]], "start": [[ "0" ]], "entity_id": [[ "T2" ]],"Drug": { "text": [[ "Nabumetone" ]], "start": [[ "0" ]], "entity_id": [[ "T2" ]] } , "Disorder": { "text": [[ "interstitial nephritis" ]], "start": [[ "18" ]], "entity_id": [[ "T3" ]] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": []}, "Combination": null , "Trigger": { "text": [["Nabumetone-associated interstitial nephritis"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]] } }, "Subject": null , "Effect": { "text": [[ "interstitial nephritis" ]], "start": [[ "18" ]], "entity_id": [[ "T3" ]] } , "Severity": null , "Speculated": null , "Negated": null }]}
{"id": "18362995_1", "context": "A short review on imatinib-related hepatotoxicity is also presented.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["imatinib-related hepatotoxicity"]], "start": [[ ], ["T1"]], "entity_id": [ ["E1"]]} ,"Treatment": { "text": [ ], "start": [[ ], ["T2"]], "entity_id": [ ], "Drug": { "text": [["imatinib"]], "start": [[ ], ["T3"]], "entity_id": [ ["E1"]]} ,"Disorder": { "text": [["hepatotoxicity"]], "start": [[ ], ["T4"]], "entity_id": [ ["E1"]]} ,"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null } ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } ,"Effect": { "text": [["hepatotoxicity"]], "start": [[ ], ["T4"]], "entity_id": [ ["E1"]]} ,"Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "3379435_2", "context": "Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Reye-like syndrome"]], "start": [[], []], "entity_id": [["T1"]]}, "Treatment": {"text": [["treatment with the pantothenic acid antagonist, calcium hopantenate"]], "start": [[], []], "entity_id": [["T2"]], "Drug": {"text": [["calcium hopantenate"]], "start": [[], []], "entity_id": [["T3"]]}, "Dosage": {"text": [["the pantothenic acid antagonist"]], "start": [[], []], "entity_id": [["T4"]]} , "Disorder": {"text": [["Reye-like syndrome"]], "start": [[], []], "entity_id": [["T1"]]} , "Time_elapsed": {"text": [["following"]], "start": [[], []], "entity_id": [["T5"]]} , "Freq": {"text": [["treatment"]], "start": [[], []], "entity_id": [["T2"]]} , "Route": {"text": [["with"]], "start": [[], []], "entity_id": [["T6"]]} , "Duration": {"text": [[]], "start": [[], []], "entity_id": [["T7"]]} , "Combination": null , "Trigger": null } , "Negated": null , "Speculated": null , "Severity": null , "Subject": null , "Effect": null }]}
{"id": "8691927_2","context": "Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["growth retardation"]],"start": [["13","19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with high-dose fluticasone propionate"]],"start": [["51","64"]],"entity_id": [["T2"]],"Drug": {"text": [["fluticasone propionate"]],"start": [["58","74"]],"entity_id": [["T3"]]},"Dosage": {"text": [["high-dose"]],"start": [["51","56"]],"entity_id": [["T4"]]},"Disorder": {"text": [["adrenal suppression"]],"start": [["81","99"]],"entity_id": [["T5"]]},"Duration": {"text": [["after treatment"]],"start": [["45","50"]],"entity_id": [["T6"]]},"Freq": {"text": [["Six children"]],"start": [["0","4"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["noted after treatment"]],"start": [["19","34"]],"entity_id": [["T8"]]},"Route": {"text": [["treatment"]],"start": [["51","56"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["fluticasone propionate"]],"start": [["58","74"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment with"]],"start": [["51","56"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["after treatment with"]],"start": [["45","56"]],"entity_id": [["T10"]]}},"Subject": {"text": [["Six children"]],"start": [["0","4"]],"entity_id": [["T11"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["growth retardation"]],"start": [["13","19"]],"entity_id": [["T12"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "16326413_3","context": "Methotrexate-associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Methotrexate-associated nephropathy"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["Methotrexate"]],"start": [[ "12" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["nephropathy"]],"start": [[ "31" ]],"entity_id": [ ["T3"] ]} ,"entity_id": [ ["T1"] ] ,"text": [["Methotrexate-associated nephropathy"]],"start": [[ "0" ]], "Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null },"Subject": {"Population": {"text": [["pediatric oncology"]],"start": [[ "62" ]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["complication"]],"start": [[ "35" ]],"entity_id": [ ["T5"] ]} ,"text": [["Methotrexate-associated nephropathy is a rare complication in pediatric oncology"]],"start": [[ "0" ]],"Age": null,"Gender": null,"Race": null ,"entity_id": [ ["T1"] ] },"Effect": {"text": [["risk factor"]],"start": [[ "180" ]],"entity_id": [ ["T6"] ]} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "10555917_1","context": "A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed"]],"start": [[" "],[""],[""],[""],[""],[""],["d"],["e"],["v"],["e"],["l"],["o"],["p"],["e"],["d"]],"entity_id": []},"Subject": {"text": [["A 66-year-old Japanese woman"]],"start": [[],[],[""],[""],[""],[""],[""],[""],[""],[""],[""],[""],[""],[""],["J"],["a"],["p"],["a"],["n"],["e"],["s","e"],["e"],[" "],["w"],["o"],["m","a","n"]],"Age": {"text": [["66"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["6"],["6"]],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["w"],["o"],["m","a","n"]],"entity_id": []},"Race": {"text": [["Japanese"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["J"],["a"],["p","a","n","e","s","e"]],"entity_id": []},"Disorder": {"text": [["severe scleroderma"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["s"],["e"],["v","e","r","e"],[" "],["s"],["c"],["l"],["e"],["r","o"],["d"],["e"],["r","m","a"]],"entity_id": []},"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["D-penicillamine (D-Pen) treatment"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["D","-"],["p","e","n"],["i","c","i","l","l","a","m","i","n","e"],[" "],["("],["D","-","P","e","n"],[")"],[" treatment"]],"Drug": {"text": [["D-penicillamine"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],["D","-"],["p","e","n"],["i","c","i","l","l","a","m","i","n","e"],[" "],["("],["D","-","P","e","n"],[")"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"entity_id": [],"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["anemia","thrombocytopenia"]],"start": [[],[],["a"],["n"],["e"],["m","i","a"],[" "],["t","h"],["r","o"],["m","b","o"],["c","y"],["t","o"],["p"],["e","n","i","a"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["not markedly severe"]],"start": [[],[],[],[],["l"],["e"],["u"],["k"],["o"],["w"],["p"],["e","n","i","a"]],"entity_id": [],"value": "low"}}]}
{"id": "20456080_4","context": "Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Corticosteroid injections"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ],"Drug": {"text": [["Corticosteroid"]],"start": [[ "0"]] ,"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["effective treatments"]],"start": [[ "44"]] ,"entity_id": [ ["T3"] ]} ,"Duration": {"text": [["commonly used"]],"start": [[ "11"]] ,"entity_id": [ ["T4"] ]} ,"Route": {"text": [["injections"]],"start": [[ "22"]] ,"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["commonly used"]],"start": [[ "11"]] ,"entity_id": [ ["T4"] ]} ,"Trigger": {"text": [["used"]],"start": [[ "40"]] ,"entity_id": [ ["T6"] ]} ,"Time_elapsed": {"text": [["used"]],"start": [[ "40"]] ,"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [["Corticosteroid injections"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]} ,"Combination": [] },"Effect": {"text": [["effective treatments"]],"start": [[ "44"]] ,"entity_id": [ ["T3"] ]} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "15549981_1","context": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anaphylaxis"]],"start": [["13"]],"entity_id": [["T1"]]},"Subject": {"text": [["two cases"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["two cases"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["anaphylaxis"]],"start": [["13"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["epinephrine"]],"start": [["86"]],"entity_id": [["T4"]],"Drug": {"text": [["epinephrine"]],"start": [["86"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["the administration of the alpha-agonist metaraminol"]],"start": [["105"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["metaraminol"]],"start": [["114"]],"entity_id": [["T6"]]},"Trigger": {"text": [["the administration"]],"start": [["105"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Disorder": {"text": [["return of spontaneous circulation"]],"start": [["45"]],"entity_id": [["T2"]]}},"Effect": {"text": [["occurred"]],"start": [["122"]],"entity_id": [["T3"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "3310776_1","context": "A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["attacks of asthma"]],"start": [[ "26"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["captopril"]],"start": [["57"]],"entity_id": [ ["T2"]],"Drug": {"text": [["captopril"]],"start": [[ "57" ]],"entity_id": [ ["T2"]]} ,"Disorder": {"text": [["asthma"]],"start": [["26"]],"entity_id": [ ["T1"]]} ,"Trigger": {"text": [["when captopril was added"]],"start": [[ "45" ]],"entity_id": [ ["T3"]]} ,"Route": {"text": [["treatment"]],"start": [["61"]],"entity_id": [ ["T4"]]} ,"Duration": {"text": [["high blood pressure"]],"start": [["85"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Subject": {"text": [["A 51-yr-old nonsmoking male patient"]],"start": [[ "0" ]],"entity_id": [ ["T0"]],"Age": {"text": [["51-yr-old"]],"start": [[ "2" ]],"entity_id": [ ["T0"]]},"Gender": {"text": [["male"]],"start": [[ "24" ]],"entity_id": [ ["T0"]]},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []} ,"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "8672829_1","context": "After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["ifosfamide/mesna"]],"start": [["0", "3"]],"entity_id": [["T1"]]},"Dosage": {"text": [["3"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["unresponsive"]],"start": [["48"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["3 doses"]],"start": [["5"]],"entity_id": [["T4"]]},"Disorder": {"text": [["unresponsive"]],"start": [["48"]],"entity_id": [["T3"]]},"entity_id": [["T1"],["T2"],["T3"],["T4"]],"text": [["After receiving"],["3 doses of"],["ifosfamide/mesna"],["she was found to be"],["unresponsive"]],"start": [["0"],["5"],["11"],["41"],["48"]],"Freq": {"text": [["3"]],"start": [["5"]],"entity_id": [["T2"]]},"Route": {"text": [["ifosfamide/mesna"]],"start": [["11"]],"entity_id": [["T1"]]},"Duration": {"text": [["3 doses"]],"start": [["5"]],"entity_id": [["T4"]]},"Combination": null},"Subject": {"text": [["she"]],"start": [["41"]],"entity_id": [["T5"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["unresponsive"]],"start": [["48"]],"entity_id": [["T3"]]},"Trigger": null}]}
{"id": "2316232_2", "context": "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptomatic hypoglycemia"]], "start": [[], []], "entity_id": []}, "Treatment": {"text": [["glipizide-trimethoprim/sulfamethoxazole"]], "start": [[], []], "entity_id": [], "Drug": {"text": [["glipizide"]], "start": [[], []], "entity_id": []}, "Combination": [{"Drug": {"text": [["trimethoprim"]], "start": [[], []], "entity_id": []}, "Trigger": {"text": [["sulfamethoxazole"]], "start": [[], []], "entity_id": []}, "event_id": "E2" , "event_type": "Adverse_event"}] ,"Dosage": {"text": [], "start": [[], []], "entity_id": []}, "Duration": {"text": [], "start": [[], []], "entity_id": []}, "Route": {"text": [], "start": [[], []], "entity_id": []}, "Time_elapsed": {"text": [], "start": [[], []], "entity_id": []}, "Disorder": {"text": [], "start": [[], []], "entity_id": []}, "Freq": {"text": [], "start": [[], []], "entity_id": []} ,"Trigger": {"text": [], "start": [[], []], "entity_id": []} },"Effect": {"text": [["hypoglycemia"]], "start": [[], []], "entity_id": []} ,"Subject":{"text":[], "start": [[], []], "entity_id": [] ,"Age":{"text":[], "start": [[], []], "entity_id": []} ,"Gender":{"text":[], "start": [[], []], "entity_id": []} ,"Population":{"text":[], "start": [[], []], "entity_id": []} ,"Race":{"text":[], "start": [[], []], "entity_id": []} ,"Disorder":{"text":[], "start": [[], []], "entity_id": []} },"Negated":{"value":false, "text":[], "start": [[], []], "entity_id": []} ,"Speculated":{"value":false, "text":[], "start": [[], []], "entity_id": []} ,"Severity":{"value":"Low", "text":[], "start": [[], []], "entity_id": []} }]}
{"id": "18421192_1","context": "A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["developed"]],"start": [[" "],[ "d" ],[ "e" ],[ "v" ],[ "e" ],[ "l" ],[ "o" ],[ "p" ],[ "e" ],[ "d" ]],"entity_id": []},"Subject": {"text": [["A 51-year-old man"]],"start": [[ "A" ],[ " " ],[ "5" ],[ "1" ],[ "-" ],[ "y" ],[ "e" ],[ "a" ],[ "r" ],[ "-" ],[ "o" ],[ "l" ],[ "d" ]],"Age": {"text": [["51"]],"start": [[ "5" ],[ "1" ]],"entity_id": []},"Gender": {"text": [["man"]],"start": [[ "m" ],[ "a" ],[ "n" ]],"entity_id": []},"Disorder": {"text": [["type 1 diabetes mellitus"]],"start": [[ "t" ],[ "y" ],[ "p" ],[ "e" ]],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"entity_id": []},"Treatment": {"text": [["treatment"]],"start": [[ "t" ],[ "r" ],[ "e" ],[ "a" ],[ "t" ],[ "m" ],[ "e" ],[ "n" ],[ "t" ]],"entity_id": [],"Drug": {"text": [["recombinant alpha-2b peginterferon", "ribavirin"]],"start": [[ "r" ],[ "e" ],[ "c" ],[ "o" ],[ "m" ],[ "b" ],[ "i" ],[ "n" ],[ "a" ],[ "n" ],[ "t"],[ " "],[ "a" ],[ "l" ],[ "p" ],[ "h" ],[ "a" ]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [["24 weeks"]],"start": [[ "2" ],[ "4" ]],"entity_id": []},"Disorder": {"text": [["chronic hepatitis C"]],"start": [[ "c" ],[ "h" ],[ "r" ],[ "o" ],[ "n" ],[ "i" ],[ "c" ]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [["following"]],"start": [[ "f" ],[ "o" ],[ "l" ],[ "l" ],[ "o" ],[ "w" ],[ "i" ],[ "n" ]],"entity_id": []}},"Effect": {"text": [["developed"]],"start": [[ "d" ],[ "e" ],[ "v" ],[ "e" ],[ "l" ],[ "o" ],[ "p" ],[ "e" ],[ "d" ]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "8832451_1", "context": "A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient.","is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["differential diagnosis"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["vecuronium-induced and magnesium-induced protracted neuromuscular block"]], "start": [["43"]], "entity_id": [],"Drug": {"text": [["vecuronium"]], "start": [["43"]], "entity_id": []}, "Dosage": {"text": [["induced"]], "start": [["43"]], "entity_id": []}, "Duration": {"text": [["protracted"]], "start": [["55"]], "entity_id": []}, "Route": {"text": [["neuromuscular block"]], "start": [["64"]], "entity_id": []}, "Disorder": {"text": [["severely preeclamptic patient"]], "start": [["106"]], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": [] ,"Trigger": { "text": [["vecuronium-induced"]], "start": [[ "43"]], "entity_id": [] }}, "Subject": { "text": [["a severely preeclamptic patient"]], "start": [[ "106"]], "entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["severely preeclamptic"]], "start": [["106"]], "entity_id": []} },"Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "424824_1","context": "Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate"]],"start": [["83"]],"entity_id": [["T2"]] ,"Disorder": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["methotrexate"]],"start": [["83"]],"entity_id": [["T2"]]} ,"Route": {"text": [["seen on chest roentgenograms"]],"start": [["106"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["develop"]],"start": [["60"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["receiving"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["who develop"]],"start": [["60"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["83"]],"entity_id": [["T2"]]},"Trigger": {"text": [["seen on chest roentgenograms"]],"start": [["106"]],"entity_id": [["T3"]]} ,"event_type": "Adverse_event","event_id": "E2"} ] ,"Trigger": {"text": [["develop"]],"start": [["60"]],"entity_id": [["T4"]]},"Drug": {"text": [["methotrexate"]],"start": [["83"]],"entity_id": [["T2"]]} } ,"Subject": {"text": [["patients"]],"start": [["46"]],"entity_id": [["T6"]] ,"Population": {"text": [["patients"]],"start": [["46"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} } ,"Negated": null,"Speculated": null,"Severity": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [["18"]],"entity_id": [["T1"]] ,"value": "high"} ,"Effect": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [["18"]],"entity_id": [["T1"]]} } ]}
{"id": "2316232_1","context": "An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["developed"]],"start": [["33"]],"entity_id": []},"Treatment": {"text": [["glipizide 10 mg bid"]],"start": [["8"]],"entity_id": [],"Drug": {"text": [["glipizide"]],"start": [["8"]],"entity_id": []},"Dosage": {"text": [["10 mg bid"]],"start": [["15"]],"entity_id": []},"Disorder": {"text": [["hypoglycemia"]],"start": [["56"]],"entity_id": []},"Duration": {"text": [["three days"]],"start": [["43"]],"entity_id": []},"Trigger": {"text": [["adding"]],"start": [["24"]],"entity_id": []},"Time_elapsed": {"text": [["three days"]],"start": [["43"]],"entity_id": []},"Route": {"text": [["to his regimen"]],"start": [["63"]],"entity_id": []},"Freq": {"text": [["bid"]],"start": [["18"]],"entity_id": []},"Combination": [{"Drug": {"text": [["trimethoprim/sulfamethoxazole"]],"start": [["24"]],"entity_id": []},"Trigger": {"text": [["adding"]],"start": [["24"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E2"}]},"Effect": {"text": [["symptomatic hypoglycemia"]],"start": [["56"]],"entity_id": []},"Subject": {"text": [["An 83-year-old man"]],"start": [["0"]],"entity_id": [],"Age": {"text": [["83-year-old"]],"start": [["0"]],"entity_id": []},"Gender": {"text": [["man"]],"start": [["16"]],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "12598508_4","context": "Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["lisinopril"]],"start": [[],[]],"entity_id": []} ,"Disorder": {"text": [["multiorgan failure"]],"start": [[],[]],"entity_id": []},"Time_elapsed": {"text": [["not previously been reported"]],"start": [[],[]],"entity_id": []} ,"entity_id": [] ,"text": [["lisinopril induced multiorgan failure"]],"start": [[],[]],"Trigger": {"text": [["reported"]],"start": [[],[]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [["peritoneal dialysis"]],"start": [[],[]],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": []} ,"Subject": {"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"text": [["Early peritoneal dialysis"]],"start": [[],[]],"entity_id": []} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"value": true ,"text": [["not previously been reported"]],"start": [[],[]],"entity_id": []} ,"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []} ,"Severity": {"value": "" ,"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["reported"]],"start": [[],[]],"entity_id": []} }]}
{"id": "12862258_3","context": "Various case reports concerning dapsone-induced agranulocytosis are reviewed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["dapsone-induced agranulocytosis"]],"start": [["23"]],"entity_id": [["T1"]]} ,"Treatment": {"Drug": {"text": [["dapsone"]],"start": [["5"]],"entity_id": [["T2"]]} ,"entity_id": [["T3"]] ,"text": [["dapsone"]],"start": [["5"]] ,"Trigger": {"text": [["dapsone-induced"]],"start": [["5"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["agranulocytosis"]],"start": [["19"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["15"]],"entity_id": [["T6"]]},"Route": {"text": [["concerning"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["Various case reports"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["are reviewed"]],"start": [["32"]],"entity_id": [["T9"]]},"Combination": null ,"Dosage": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": {"text": [["agranulocytosis"]],"start": [["19"]],"entity_id": [["T10"]] ,"value": "high" },"Subject": {"Age": null ,"Gender": null ,"Population": {"text": [["Various case reports"]],"start": [["0"]],"entity_id": [["T11"]] },"Race": null ,"Disorder": {"text": [["agranulocytosis"]],"start": [["19"]],"entity_id": [["T12"]] },"text": [["dapsone-induced agranulocytosis"]],"start": [["23"]],"entity_id": [["T13"]] }} ]}
{"id": "18717612_3", "context": "We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"Age": {"text": [["54"]], "start": [["54-year-old"]], "entity_id": []}, "Gender": {"text": [["woman"]], "start": [[""], ["woman"]], "entity_id": []}, "Race": {"text": [["Turkish"]], "start": [[""], ["Turkish"]], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "text": [["first case"]], "start": [[], ["first"], ["case"]], "entity_id": [] , "Population": {"text": [], "start": [], "entity_id": []} } , "Trigger": {"text": [["ceftriaxone-induced"]], "start": [["ceftriaxone-induced"]], "entity_id": []}, "Effect": {"text": [["FDE"]], "start": [[], ["FDE"]], "entity_id": []} , "Negated": null, "Speculated": null, "Severity": null , "Treatment": { "text": [["ceftriaxone"]], "start": [[], ["ceftriaxone"]], "entity_id": [], "Drug": {"text": [["ceftriaxone"]], "start": [[], ["ceftriaxone"]], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null } }]}
{"id": "15379082_3", "context": "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fulminant hepatic failure"]], "start": [["This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]], "entity_id": [ ]},"Subject": {"text": [["a patient"]], "start": [["This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]],"entity_id": [ ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["no previous liver disease"]], "start": [["This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]], "entity_id": [ ]}},"Treatment": {"text": [["disulfiram"]],"start": [[ "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]],"entity_id": [ ],"Drug": {"text": [["disulfiram"]], "start": [[ "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]],"entity_id": [ ]} ,"Dosage": null,"Duration": null,"Disorder": {"text": [["fulminant hepatic failure"]], "start": [[ "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]], "entity_id": [ ]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger" : {"text" : [["taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence"]],"start" : [[ "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence" ]],"entity_id" : [] }} ,"Effect": null, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "8438851_2", "context": "Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["idiosyncratic factors involving vasopressin receptor affinity and distribution", "vasopressin-associated vasodilation in some vascular beds", "the effect of vasopressin on the renin-angiotensin system"]], "start": [[], [], []], "entity_id": []}, "Treatment": {"text": [], "start": [], "entity_id": [],"Drug": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["vasopressin"]], "start": [[], [], []], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [["vasopressin receptor affinity and distribution", "vasopressin-associated vasodilation in some vascular beds", "the effect of vasopressin on the renin-angiotensin system"]], "start": [[], [], []], "entity_id": []}, "Combination": null, "Dosage": null}, "Effect": {"text": [["impaired tissue perfusion"]], "start": [[], []], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "16765687_2", "context": "Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["methylprednisolone"]], "start": [["51"]], "entity_id": [["T1"]],"Drug": {"text": [["methylprednisolone"]], "start": [["51"]], "entity_id": [["T2"]]},"Route": {"text": [["with"]], "start": [["42"]], "entity_id": [["T3"]]},"Dosage": {"text": [["topiramate-induced angle-closure glaucoma"]], "start": [["10"]], "entity_id": [["T4"]]},"Duration": {"text": [["Rapid resolution"]], "start": [["0"]], "entity_id": [["T5"]]},"Trigger": {"text": [["Rapid resolution"]], "start": [["0"]], "entity_id": [["T6"]]}, "Time_elapsed": {"text": [["topiramate-induced angle-closure glaucoma"]], "start": [["10"]], "entity_id": [["T7"]]},"Combination":[{"Drug": {"text": [["methylprednisolone"]], "start": [["51"]], "entity_id": [["T2"]]},"Trigger": {"text": [["with"]], "start": [["42"]], "entity_id": [["T3"]]},"event_id": "E2","event_type":"Potential_therapeutic_effect"}],"Disorder": {"text": [["topiramate-induced angle-closure glaucoma"]], "start": [["10"]], "entity_id": [["T4"]]}, "Freq":{"text":[["Rapid resolution"]],"start":[["0"]],"entity_id":[["T5"]]}},"Subject":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]],"Disorder":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]}, "Population":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]}, "Age":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]}, "Gender":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]}, "Race":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]} },"Severity":{"text":[["Rapid resolution"]],"start":[[ "0"]],"entity_id":[["T5"]],"value":"Low"},"Negated":{"text":[["Rapid resolution"]],"start":[[ "0"]],"entity_id":[["T5"]],"value":false},"Speculated":{"text":[["Rapid resolution"]],"start":[[ "0"]],"entity_id":[["T5"]],"value":false},"Effect":{"text":[["topiramate-induced angle-closure glaucoma"]],"start":[[ "10"]],"entity_id":[["T4"]]},"Trigger":{"text":[["Rapid resolution"]],"start":[[ "0"]],"entity_id":[["T5"]]}}] }
{"id": "7098384_1", "context": "A 66-year-old man suffering from severe coronary heart disease took digoxin with suicidal intent and was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments.\n", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["took digoxin with suicidal intent"]], "start": [[" "], [""], [], ["took"], ["digoxin"], ["with"], ["suicidal"], ["intent"]], "entity_id": []}, "Treatment": {"text": [["was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments"]], "start": [[], [], [], [], ["was"], ["treated"], ["for"], ["the"], ["ensuing"], ["complete"], ["atrioventricular"], ["block"], ["with"], ["digoxin-specific"], ["antibody"], ["fragments"]], "Drug": {"text": [["digoxin"]], "start": [[], [], [], ["treated"], ["with"], ["digoxin"], []], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["severe coronary heart disease"]], "start": [[], ["A"], ["66-year-old"], ["man"], ["suffering"], ["from"], ["severe"], ["coronary"], ["heart"], ["disease"]], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null ,"entity_id": [] ,"Trigger": null ,"Route": null }, "Subject": { "text": [["A 66-year-old man"]], "start": [[], ["A"], ["66-year-old"], ["man"]], "entity_id": [], "Age": { "text": [["66-year-old"]], "start": [[], ["66-year-old"]], "entity_id": [] }, "Gender": { "text": [["man"]], "start": [[], ["man"]], "entity_id": [] }, "Disorder": { "text": [["severe coronary heart disease"]], "start": [[], ["A"], ["66-year-old"], ["man"], ["suffering"], ["from"], ["severe"], ["coronary"], ["heart"], ["disease"]], "entity_id": [] }, "Race": null ,"Population": null }, "Negated": null, "Speculated": null, "Severity": null, "Effect": { "text": [["complete atrioventricular block"]], "start": [[], [], [], ["treated"], ["for"], ["the"], ["ensuing"], ["complete"], ["atrioventricular"], ["block"]], "entity_id": [] } }]}
{"id": "15533031_2","context": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["increased cerebral cortical excitability"]],"start": [["31"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["flupirtine"]],"start": [["89"]],"entity_id": [["T2"]],"Drug": {"text": [["flupirtine"]],"start": [["89"]],"entity_id": [ ["T2"]]},"Disorder": {"text": [["intoxication"]],"start": [["71"]],"entity_id": [["T3"]]},"Route": {"text": [["orally"]],"start": [["102"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["31"]],"entity_id": [ ["T5"]]} ,"Duration": {"text": [["long-term"]],"start": [["110"]],"entity_id": [ ["T6"]]} ,"Dosage": {"text": [["daily doses of 600mg"]],"start": [["106"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["twice daily"]],"start": [["115"]],"entity_id": [ ["T8"]]} ,"Combination": null ,"Trigger": {"text": [["intoxication with"]],"start": [["71"]],"entity_id": [ ["T3"]]} } ,"Subject": {"text": [["a patient"]],"start": [["0"]],"entity_id": [ ["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patient with"]],"start": [["0"]],"entity_id": [ ["T0"]]}} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["increased cerebral cortical excitability"]],"start": [["31"]],"entity_id": [ ["T1"]]}}]}
{"id": "6702890_3","context": "This case represents the third example of erythroid aplasia associated with an anti-inflammatory agent and the first instance due to fenoprofen","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["erythroid aplasia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["an anti-inflammatory agent"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["anti-inflammatory agent"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": {"text": [["erythroid aplasia"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["the third example"]],"start": [["6"]],"entity_id": [["F1"]]},"Combination": [{"Drug": {"text": [["fenoprofen"]],"start": [["95"]],"entity_id": [["T3"]]},"Trigger": {"text": [["the first instance"]],"start": [["78"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["associated with"]],"start": [["40"]],"entity_id": [["T5"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11568758_1", "context": "Lichenoid drug eruption to salsalate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Lichenoid drug eruption"]], "start": [[ ]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["salsalate"]], "start": [[ "36" ]], "entity_id": [ ["T2" ]], "Drug": { "text": [["salsalate"]], "start": [[ "36" ]], "entity_id": [ ["T2" ]] } ,"Disorder": { "text": [["Lichenoid drug eruption"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] } ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Combination": null ,"Trigger": null }, "Effect": { "text": [["Lichenoid drug eruption"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] } ,"Negated": null, "Speculated": null, "Severity": null ,"Subject": null }]}
{"id": "9211543_2","context": "Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor were treated with drug regimens that included bleomycin or cyclophosphamide","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["drug regimens that included bleomycin"]],"start": [["53"]],"entity_id": [["T1"]],"Drug": {"text": [["bleomycin"]],"start": [["72"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["pediatric oncology patients with Ewing's sarcoma"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["treated"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Route": {"text": [["drug regimens"]],"start": [["30"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["bleomycin"]],"start": [["72"]],"entity_id": [["T2"]]},"Trigger": {"text": [["or"]],"start": [["83"]],"entity_id": [["T5"]]},"event_type": "Potential_therapeutic_effect","event_id": "E2"}] ,"Freq": {"text": [["that included"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["drug regimens that included bleomycin or cyclophosphamide"]],"start": [["53"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["treated"]],"start": [["30"]],"entity_id": [["T4"]]},"Dosage": {"text": [["drug regimens that included"]],"start": [["42"]],"entity_id": [["T4"]]} },"Subject": {"text": [["Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor"]],"start": [["0"]],"entity_id": [["T3"]],"Age": {"text": [["pediatric"]],"start": [["0"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Ewing's sarcoma"]],"start": [["13"]],"entity_id": [["T6"]]},"Population": {"text": [["Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor"]],"start": [["0"]],"entity_id": [["T3"]]},"Race": {"text": [["Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor"]],"start": [["0"]],"entity_id": [["T3"]]},"Gender": {"text": [["Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor"]],"start": [["0"]],"entity_id": [["T3"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["treated with drug regimens that included bleomycin or cyclophosphamide"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Effect": null }]}
{"id": "2011096_2", "context": "Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Three"]], "start": [[]],"entity_id": [],"Population": {"text": [["3"]], "start": [[]],"entity_id": []},"Disorder": {"text": [["complication"]], "start": [[]],"entity_id": []},"Age": null,"Gender": null,"Race": null},"Treatment": {"text": [["high-dose cytosine arabinoside therapy"]], "start": [[]],"entity_id": [],"Drug": {"text": [["cytosine arabinoside"]], "start": [[]],"entity_id": []},"Dosage": {"text": [["high-dose"]], "start": [[]],"entity_id": []},"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null}, "Effect": {"text": [["developed"]], "start": [[]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "20178709_1","context": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["aseptic pleuropericarditis"]],"start": [["0"]],"entity_id": []},"Subject": {"text": [["a patient with chronic plaque psoriasis"]],"start": [["26"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["chronic plaque psoriasis"]],"start": [["32"]],"entity_id": []}},"Treatment": {"text": [["methotrexate therapy"]],"start": [["72"]],"entity_id": [],"Drug": {"text": [["methotrexate"]],"start": [["72"]],"entity_id": []},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null ,"Disorder": {"text": [["aseptic pleuropericarditis"]],"start": [["0"]],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["aseptic pleuropericarditis"]],"start": [["0"]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "11328247_1","context": "The present findings suggest that fluvoxamine can cause increased libido in some patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["increased libido"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fluvoxamine"]],"start": [["12"]],"entity_id": [["T2"]],"Drug": {"text": [["fluvoxamine"]],"start": [["12"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["increased libido"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["can cause"]],"start": [["25"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["fluvoxamine"]],"start": [["12"]],"entity_id": [["T2"]]},"Trigger": {"text": [["can cause"]],"start": [["25"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["cause"]],"start": [["25"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["some patients"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Route": {"text": [["in"]],"start": [["41"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["can cause"]],"start": [["25"]],"entity_id": [["T3"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Subject": {"text": [["patients"]],"start": [["45"]],"entity_id": [["T4"]],"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["increased libido"]],"start": [["38"]],"entity_id": [["T1"]]} }] }
{"id": "2144305_1", "context": "A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["transient, nonpigmenting fixed drug eruption"]], "start": [["13","18"]], "entity_id": []}, "Treatment": {"text": [["the radiopaque contrast medium iothalamate"]], "start": [["52","71"]], "entity_id": [], "Drug": {"text": [["iothalamate"]], "start": [["66","71"]], "entity_id": [] },"Route": {"text": [["the radiopaque contrast medium"]], "start": [["52","65"]], "entity_id": [] }, "Time_elapsed": {"text": [["caused"]], "start": [["35","39"]], "entity_id": [] }, "Disorder": {"text": [["a unique case"]], "start": [["0","5"]], "entity_id": [] }, "Freq": {"text": [["is reported"]], "start": [["72","81"]], "entity_id": [] }, "Dosage": {"text": [], "start": [], "entity_id": [] }, "Duration": {"text": [], "start": [], "entity_id": [] }, "Trigger": {"text": [], "start": [], "entity_id": [] }, "Combination": [{"Drug": {"text": [["iothalamate"]], "start": [["66","71"]], "entity_id": [] },"Trigger": {"text": [["caused"]], "start": [["35","39"]], "entity_id": [] },"event_id": "E1-1", "event_type": "Adverse_event" }]},"Subject": {"text": [["A unique case"]], "start": [["0","5"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": [] },"Gender": {"text": [], "start": [], "entity_id": [] },"Population": {"text": [], "start": [], "entity_id": [] },"Race": {"text": [], "start": [], "entity_id": [] },"Disorder": {"text": [["a unique case"]], "start": [["0","5"]], "entity_id": [] }},"Negated": {"text": [], "start": [], "entity_id": [],"value": false },"Speculated": {"text": [], "start": [], "entity_id": [],"value": false },"Severity": {"text": [["transient, nonpigmenting fixed drug eruption"]], "start": [["13","18"]], "entity_id": [],"value": "low" },"Effect": {"text": [["transient, nonpigmenting fixed drug eruption"]], "start": [["13","18"]], "entity_id": []}}]}
{"id": "15785053_1", "context": "Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mucosal pigmentation"]], "start": [["0"]], "entity_id": []}, "Subject": {"text": [["oral lichen planus"]], "start": [["22"]], "entity_id": [],"Disorder":{"text":[["oral lichen planus"]], "start": [["22"]], "entity_id": []}, "Population":{"text":[["after"]], "start": [["16"]], "entity_id": []}, "Age":{"text":[["after"]], "start": [["16"]], "entity_id": []}, "Gender":{"text":[["after"]], "start": [["16"]], "entity_id": []}, "Race":{"text":[["after"]], "start": [["16"]], "entity_id": []}}, "Treatment": {"text": [["topical tacrolimus"]], "start": [["52"]], "entity_id": [],"Drug":{"text":[["topical tacrolimus"]], "start": [["52"]], "entity_id": []}, "Dosage":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": []}, "Route":{"text":[["topical"]], "start": [["49"]], "entity_id": []}, "Freq":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": []}, "Time_elapsed":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": []}, "Duration":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": []}, "Disorder":{"text":[["oral lichen planus"]], "start": [["22"]], "entity_id": []},"Trigger":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": []},"Combination":[{"Drug":{"text":[["topical tacrolimus"]], "start": [["52"]], "entity_id": []},"Trigger":{"text":[["oral lichen planus treatment"]], "start": [["22"]], "entity_id": []},"event_id":"C1","event_type":"Combination"}]} ,"Effect": {"text": [["mucosal pigmentation"]], "start": [["0"]], "entity_id": []},"Negated":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": [],"value":false},"Speculated":{"text":[["after oral lichen planus treatment"]], "start": [["22"]], "entity_id": [],"value":false},"Severity":{"text":[["mucosal pigmentation"]], "start": [["0"]], "entity_id": [],"value":"Low"}}]}
{"id": "10473079_2","context": "We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["life-threatening complications"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with topical 5-FU"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["topical 5-FU"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["cancer"]],"start": [["7"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["after"]],"start": [["31"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["31"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["after"]],"start": [["31"]],"entity_id": [["T5"]]} ,"Route": {"text": [["topical"]],"start": [["52"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["treatment with"]],"start": [["52"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["topical 5-FU"]],"start": [["52"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment with"]],"start": [["52"]],"entity_id": [["T7"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ],"Trigger": {"text": [["after"]],"start": [["31"]],"entity_id": [["T5"]]} },"Subject": {"text": [["the first known cancer patient"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["cancer"]],"start": [["7"]],"entity_id": [["T4"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["life-threatening complications"]],"start": [["31"]],"entity_id": [["T1"]],"value": "high"} ,"Effect": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T5"]]}} ]}
{"id": "110153_2","context": "When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["increased vulnerability"]],"start": [["55"]],"entity_id": []},"Treatment": {"text": [["lithium"]],"start": [["93"]],"entity_id": [],"Disorder": {"text": [["severe lithium neurotoxicity"]],"start": [["101"]],"entity_id": []},"Dosage": {"text": [["increased"]],"start": [["55"]],"entity_id": []},"Time_elapsed": {"text": [["development"]],"start": [["69"]],"entity_id": []},"Trigger": {"text": [["characterized"]],"start": [["22"]],"entity_id": []},"Freq": {"text": [["may be associated"]],"start": [["50"]],"entity_id": []},"Route": {"text": [["acute manic state"]],"start": [["0"]],"entity_id": []},"Combination": [{"Drug": {"text": [["lithium"]],"start": [["93"]],"entity_id": []},"Trigger": {"text": [["increased vulnerability"]],"start": [["55"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E2"}],"Drug": {"text": [["lithium"]],"start": [["93"]],"entity_id": []},"Duration": {"text": [["acute manic state"]],"start": [["0"]],"entity_id": []}},"Subject": {"text": [["the acute manic state"]],"start": [["0"]],"entity_id": [],"Gender": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["marked psychotic symptoms and intense anxiety"]],"start": [["22"]],"entity_id": []}},"Effect": {"text": [["increased vulnerability"]],"start": [["55"]],"entity_id": []},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["severe"]],"start": [["101"]],"entity_id": [],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "7781845_11","context": "Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including mefloquine, should be aware of the risk of severe hypoglycaemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["risk"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["manage"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["anti-malarial drugs"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["cachectic patients"]],"start": [[ ]],"entity_id": []},"Duration": {"text": [["protracted diarrhoea"]],"start": [[ ]],"entity_id": []},"Freq": {"text": [["including mefloquine"]],"start": [[ ]],"entity_id": []},"Route": {"text": [["manage"]],"start": [[ ]],"entity_id": []},"Time_elapsed": {"text": [["aware"]],"start": [[ ]],"entity_id": []},"Dosage": {"text": [["aware"]],"start": [[ ]],"entity_id": []},"Combination": [{"Drug": {"text": [["anti-malarial drugs"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["including mefloquine"]],"start": [[ ]],"entity_id": []},"event_id": "C1","event_type": "Treatment"}],"Trigger": {"text": [["aware"]],"start": [[ ]],"entity_id": []}},"Effect": {"text": [["severe hypoglycaemia"]],"start": [[ ]],"entity_id": []},"Subject": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": [],"Population": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": []},"Gender": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": []},"Age": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": []},"Race": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["cachectic patients"]],"start": [[ ]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [[ ]],"entity_id": [],"value": "high"}}]}
{"id": "15383642_15","context": "Based upon the literature review, the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["interaction"]],"start": [["35"]],"entity_id": []},"Treatment": {"text": [["tizanidine", "lisinopril"]],"start": [["6", "39"]],"entity_id": [],"Drug": {"text": [["tizanidine"], ["lisinopril"]],"start": [["6"], ["39"]],"entity_id": []},"Disorder": {"text": [["hypotension"]],"start": [["15"]],"entity_id": []},"Combination": [{"Drug": {"text": [["tizanidine"]],"start": [["6"]],"entity_id": []},"Trigger": {"text": [["and"]],"start": [["26"]],"entity_id": []},"event_id": "C1","event_type": "null"},{"Drug": {"text": [["lisinopril"]],"start": [["39"]],"entity_id": []},"Trigger": {"text": [["interaction"]],"start": [["35"]],"entity_id": []},"event_id": "C2","event_type": "null"}],"Freq": {"text": [["possibly"]],"start": [["8"]],"entity_id": []},"Time_elapsed": {"text": [["due"]],"start": [["40"]],"entity_id": []},"Trigger": {"text": [["Based upon the literature review", "the hypotension in this patient was"]],"start": [[], ["0"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["this patient"]],"start": [["22"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["hypotension"]],"start": [["15"]],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [["possibly"]],"start": [["8"]],"entity_id": [],"value": true},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "16119501_1", "context": "Baclofen withdrawal: a cause of prolonged fever in the intensive care unit", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Baclofen withdrawal"]], "start": [[ "0" ]], "entity_id": [["T1"] ]}, "Effect": { "text": [["prolonged fever"]], "start": [[ "35" ]], "entity_id": [["T2"] ] }, "Subject": { "text": [["the intensive care unit"]], "start": [[ "76" ]], "entity_id": [["T3"] ], "Disorder": { "text": [["Baclofen withdrawal"]], "start": [[ "0" ]], "entity_id": [["T1"] ]} ,"Population": { "text": [["a cause"]], "start": [[ "15" ]], "entity_id": [["T4"] ]} ,"Age": null, "Gender": null, "Race": null } ,"Negated": null, "Speculated": null, "Severity": { "text": [["prolonged"]], "start": [[ "35" ]], "entity_id": [["T5"] ], "value":"high" } ,"Treatment": null }]}
{"id": "11022272_4","context": "We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["rhinitis", "conjunctivitis and perspiration immediately after the administration"]],"start": [[ "37", "58"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["salmon calcitonin"]],"start": [["11"]],"entity_id": [["T3"]],"Disorder": {"text": [["rhinitis", "conjunctivitis"]],"start": [["37","39"]],"entity_id": [["T1"]]},"Route": {"text": [["nasal spray or intramuscular administration"]],"start": [["65"]],"entity_id": [["T4"]]},"Drug": {"text": [["salmon calcitonin"]],"start": [["11"]],"entity_id": [["T3"]]},"Freq": {"text": [["immediately after the administration"]],"start": [["58"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["immediately after the administration"]],"start": [["58"]],"entity_id": [["T2"]]},"Duration": {"text": [["several previous episodes"]],"start": [["37"]],"entity_id": [["T1"]]},"Dosage": {"text": [["salmon calcitonin"]],"start": [["11"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["salmon calcitonin"]],"start": [["11"]],"entity_id": [["T3"]]},"Trigger": {"text": [["nasal spray or intramuscular administration"]],"start": [["65"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["rhinitis", "conjunctivitis and perspiration immediately after the administration"]],"start": [["37","58"]],"entity_id": [["T1","T2"]]}},"Subject": {"text": [["a sixty years old woman"]],"start": [["15"]],"entity_id": [["T5"]],"Age": {"text": [["sixty years old"]],"start": [["15"]],"entity_id": [["T5"]]},"Gender": {"text": [["woman"]],"start": [["22"]],"entity_id": [["T5"]]},"Race": {"text": [["a sixty years old woman"]],"start": [["15"]],"entity_id": [["T5"]]},"Disorder": {"text": [["several previous episodes of rhinitis", "conjunctivitis"]],"start": [["37","39"]],"entity_id": [["T1"]]},"Population": {"text": [["a sixty years old woman"]],"start": [["15"]],"entity_id": [["T5"]]}},"Effect": {"text": [["rhinitis", "conjunctivitis and perspiration immediately after the administration"]],"start": [["37","58"]],"entity_id": [["T1","T2"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15554737_1","context": "In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.', ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [[ "a 46-year-old female patient" ]],"start": [[ ]],"entity_id": [ ],"Age": {"text": [[ "46" ]],"start": [[ ]],"entity_id": [ ]},"Gender": {"text": [[ "female" ]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Race": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]}},"Treatment": {"text": [[ "glatiramer acetate" ]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [[ "glatiramer acetate" ]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [[ "18 months" ]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [[ "injection" ]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [[ "subcutaneous changes" ]],"start": [[ ]],"entity_id": [ ]},"Combination": null},"Effect": {"text": [[ "localized panniculitis in the area around the injection sites" ]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "11033734_1","context": "Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["imipenem/cilastatin"]],"start": [["33"]],"entity_id": [["T1"]] ,"Drug": {"text": [["imipenem"]],"start": [["33"]],"entity_id": [["T2"]]},"Disorder": {"text": [["neutropenic fever"]],"start": [["71"]],"entity_id": [["T3"]]},"Freq": {"text": [["143"]],"start": [["56"]],"entity_id": [["T4"]]},"Duration": {"text": [["March 1994 and October 1999"]],"start": [["62"]],"entity_id": [["T5"]]},"Route": {"text": [["Department of Pediatric Oncology, Gazi University"]],"start": [["96"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["received"]],"start": [["42"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["between"]],"start": [["53"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["cilastatin"]],"start": [["33"]],"entity_id": [["T9"]]} ,"Trigger": {"text": [["received"]],"start": [["42"]],"entity_id": [["T10"]]} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect"} ] ,"Dosage": {"text": [],"start": [],"entity_id": []} } ,"Subject": {"text": [["Eighty-two patients with various malignancies"]],"start": [["0"]],"entity_id": [["T11"]] ,"Population": {"text": [["Eighty-two"]],"start": [["0"]],"entity_id": [["T12"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["various malignancies"]],"start": [["21"]],"entity_id": [["T13"]]} } ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} }]}
{"id": "16623611_1","context": "Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["therapy with olanzapine"]],"start": [["53"]],"entity_id": [["T1"]],"Drug": {"text": [["olanzapine"]],"start": [["53"]],"entity_id": [["T2"]]},"Disorder": {"text": [["lack of control of diabetes"]],"start": [["15"]],"entity_id": [["T3"]]},"Duration": {"text": [["on initiation and rechallenge"]],"start": [["15"]],"entity_id": [["T4"]]},"Freq": {"text": [["on initiation and rechallenge"]],"start": [["15"]],"entity_id": [["T4"]]},"Trigger": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["on initiation and rechallenge"]],"start": [["15"]],"entity_id": [["T4"]]},"Route": {"text": [["therapy with olanzapine"]],"start": [["53"]],"entity_id": [["T1"]]},"Dosage": {"text": [["therapy with olanzapine"]],"start": [["53"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["olanzapine"]],"start": [["53"]],"entity_id": [["T2"]]},"Trigger": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Effect": {"text": [["weight gain"]],"start": [["82"]],"entity_id": [["T5"]]},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [["a patient"]],"start": [["30"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["lack of control of diabetes"]],"start": [["15"]],"entity_id": [["T3"]]}},"Trigger": {"text": [["Case report"]],"start": [["0"]],"entity_id": [["T0"]]}}]}
{"id": "10030778_1","context": "Intravenous azithromycin-induced ototoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Intravenous azithromycin-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Effect": {"text": [["ototoxicity"]],"start": [[ "56" ]],"entity_id": [ ["T2"] ]},"Treatment": {"text": [["Intravenous azithromycin"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["azithromycin"]],"start": [[ "21" ]],"entity_id": [ ["T3"] ]},"Route": {"text": [["Intravenous"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Time_elapsed": {"text": [["induced"]],"start": [[ "43" ]],"entity_id": [ ["T4"] ]},"Duration": null,"Disorder": null,"Dosage": null,"Freq": null,"Combination": null,"Trigger": {"text": [["Intravenous azithromycin-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}},"Subject": {"text": [[""]],"start": [[ "0" ]],"entity_id": [ ["T0"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "18079582_3","context": "We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5-FU","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["transient asymptomatic bradycardia"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["continuous infusion 5-FU"]],"start": [["84"]],"entity_id": [["T2"]],"Drug": {"text": [["5-FU"]],"start": [["84"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["bradycardia"]],"start": [["36"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after"]],"start": [["57"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["transient"]],"start": [["36"]],"entity_id": [["T1"]]} ,"Route": {"text": [["infusion"]],"start": [["64"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["continuous"]],"start": [["50"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["such a series of patients"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "18854289_1", "context": "Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["consolidation therapy with bortezomib/lenalidomide/dexamethasone"]],"start": [[ "0"]],"entity_id": [ ] ,"Drug": { "text": [["bortezomib", "lenalidomide", "dexamethasone"]], "start": [[ "30","43","55"]],"entity_id": [ ] } ,"Disorder": { "text": [["multiple myeloma"]], "start": [[ "125"]],"entity_id": [ ] } ,"Trigger": { "text": [["versus"]], "start": [[ "92"]],"entity_id": [ ] } ,"Duration": { "text": [["after a dexamethasone-based induction regimen"]], "start": [[ "63"]],"entity_id": [ ] } ,"Route": { "text": [["oral"]], "start": [[ "0"]],"entity_id": [ ] } ,"Dosage": { "text": [], "start": [], "entity_id": [] } ,"Time_elapsed": { "text": [], "start": [], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": null } ,"Subject": { "text": [["patients with multiple myeloma"]], "start": [[ "124"]],"entity_id": [ ] ,"Age": null ,"Gender": null ,"Population": { "text": [], "start": [], "entity_id": [] } ,"Disorder": { "text": [["multiple myeloma"]], "start": [[ "125"]],"entity_id": [ ] } ,"Race": null } ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "24318743_3", "context": "Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["phenoxodiol (PXD)"]], "start": [["31"]], "entity_id": [["T1"]],"Dosage": {"text": [["shown to have chemoresistance reversing potential"]], "start": [["49"]], "entity_id": [["T2"]]},"Disorder": {"text": [["potential therapeutic benefit"]], "start": [["26"]], "entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["weekly AUC2-carboplatin"]], "start": [["82"]], "entity_id": [["T4"]]},"Trigger": {"text": [["combined"]], "start": [["78"]], "entity_id": [["T5"]]}, "event_id": "E2", "event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["assess"]], "start": [["72"]], "entity_id": [["T6"]]},"Route": {"text": [["in PROC patients"]], "start": [["105"]], "entity_id": [["T7"]]}, "Time_elapsed": {"text": [["based on prior data suggesting that scheduling alterations of platinum would increase activity"]], "start": [["0"]], "entity_id": [["T8"]]}, "Freq": {"text": [["weekly"]], "start": [["80"]], "entity_id": [["T9"]]}, "Duration": {"text": [["scheduling alterations of platinum"]], "start": [["6"]], "entity_id": [["T10"]]},"Drug": {"text": [["platinum"]], "start": [["6"]], "entity_id": [["T11"]]}}, "Subject": {"text": [["PROC patients"]],"start": [["105"]],"entity_id": [["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}, "Severity": null,"Negated": null,"Speculated": null, "Effect": null, "Trigger": null}]}
{"id": "1378497_2","context": "Our series of 3 patients supports a causal connection between bleomycin and scleroderma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["bleomycin"]],"start": [["33"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["scleroderma"]],"start": [["55"]],"entity_id": [["T2"]] },"Trigger": {"text": [["a causal connection between"]],"start": [["15"]],"entity_id": [["T3"]] },"Dosage": {"text": [["3 patients"]],"start": [["4"]],"entity_id": [["T4"]] },"Combination": [{"Drug": {"text": [["bleomycin"]],"start": [["33"]],"entity_id": [["T1"]] },"Trigger": {"text": [["a causal connection between"]],"start": [["15"]],"entity_id": [["T3"]] },"event_type": "Potential_therapeutic_effect","event_id": "E1" }] ,"Freq": {"text": [["3 patients"]],"start": [["4"]],"entity_id": [["T4"]] },"Duration": {"text": [["3 patients"]],"start": [["4"]],"entity_id": [["T4"]] },"Route": {"text": [["between"]],"start": [["40"]],"entity_id": [["T5"]] },"Time_elapsed": {"text": [["supports"]],"start": [["0"]],"entity_id": [["T6"]]},"Drug": {"text": [["bleomycin"]],"start": [["33"]],"entity_id": [["T1"]] }} ,"Subject": {"text": [["Our series"]],"start": [["0"]],"entity_id": [["T7"]] ,"Age": {"text": [["3 patients"]],"start": [["4"]],"entity_id": [["T4"]] },"Gender": {"text": [["Our series"]],"start": [["0"]],"entity_id": [["T7"]] },"Race": {"text": [["Our series"]],"start": [["0"]],"entity_id": [["T7"]] },"Population": {"text": [["3 patients"]],"start": [["4"]],"entity_id": [["T4"]]},"Disorder": {"text": [["Our series"]],"start": [["0"]],"entity_id": [["T7"]] }} ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null ,"Effect": null }]}
{"id": "16404563_6","context": "In this paper, we report a patient with primary anti-phospholipid syndrome treated by corticosteroid, who developed disseminated nocardiosis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["corticosteroid"]],"start": [[ ]], "entity_id": [["T1"]]},"Disorder": {"text": [["primary anti-phospholipid syndrome"]],"start": [[ ]], "entity_id": [["T2"]]},"entity_id": [["T1"]],"text": [["treated"]],"start": [[ ]],"Trigger": {"text": [["by"]],"start": [[ ]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_type": "null","event_id": "null"}]},"Effect": {"text": [["developed"]],"start": [[ ]],"entity_id": [["T4"]]},"Trigger": {"text": [["disseminated nocardiosis"]],"start": [[ ]],"entity_id": [["T5"]]},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "null","text": [],"start": [],"entity_id": []},"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["primary anti-phospholipid syndrome"]],"start": [[ ]],"entity_id": [["T2"]]},"text": [],"start": [],"entity_id": []}}]}
{"id": "4025011_1","context": "Prolonged severe cholestasis induced by oxacillin derivatives","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Prolonged severe cholestasis"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ] }, "Treatment": { "text": [["oxacillin derivatives"]], "start": [[ "53" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["oxacillin"]], "start": [[ "53" ]], "entity_id": [ ["T3"] ]} ,"Dosage": null, "Duration": null, "Disorder": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Effect": { "text": [["Prolonged severe cholestasis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Negated": null, "Speculated": null, "Severity": { "text": [["severe"]], "start": [[ "13" ]], "entity_id": [ ["T4"] ], "value": "high" }, "Subject": null }] }
{"id": "21881031_11","context": "Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Cisplatin"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"text": [["Cisplatin"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ], "Trigger": {"text": [["related"]],"start": [[ "45" ]],"entity_id": [ ["T2"] ]} ,"Time_elapsed": null, "Freq": null, "Duration": null, "Disorder": null ,"Dosage": null ,"Route": null ,"Combination": null} ,"Effect": { "text": [["elevations"]], "start": [[ "86" ]], "entity_id": [ ["T3"] ]}, "Negated": null, "Speculated": null, "Severity": null ,"Subject": null ,"Trigger": null }] }
{"id": "17624096_1", "context": "5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cardiotoxicity"]], "start": [["13"]], "entity_id": []}, "Treatment": {"text": [["treatment"]], "start": [["44"]], "entity_id": [], "Drug": {"text": [["5-Fluorouracil"]], "start": [["5"]], "entity_id": []},"Disorder": {"text": [["treatment of stage IIB cervical cancer"]], "start": [["44"]], "entity_id": []},"Route": {"text": [["complicating"]], "start": [["12"]], "entity_id": []} , "Combination": [{"Drug": {"text": [["5-Fluorouracil"]], "start": [["5"]], "entity_id": []},"Trigger": {"text": [["complicating"]], "start": [["12"]], "entity_id": []},"event_id": "C1","event_type": "null"}], "Freq": {"text": [["treatment"]], "start": [["44"]], "entity_id": []},"Time_elapsed": {"text": [["complicating"]], "start": [["12"]], "entity_id": []} , "Duration": {"text": [["treatment of stage IIB cervical cancer"]], "start": [["44"]], "entity_id": []},"Dosage": {"text": [["5-Fluorouracil"]], "start": [["5"]], "entity_id": []} , "Trigger": {"text": [["cardiotoxicity"]], "start": [["13"]], "entity_id": []} },"Subject": {"text": [["case report"]], "start": [["82"]], "entity_id": [],"Age": {"text": [["case report"]], "start": [["82"]], "entity_id": []},"Gender": {"text": [["case report"]], "start": [["82"]], "entity_id": []},"Population": {"text": [["case report"]], "start": [["82"]], "entity_id": []},"Race": {"text": [["case report"]], "start": [["82"]], "entity_id": []},"Disorder": {"text": [["treatment of stage IIB cervical cancer"]], "start": [["44"]], "entity_id": []} },"Effect": {"text": [["cardiotoxicity"]], "start": [["13"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17241588_1","context": "A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fixed drug eruption"]],"start": [["12"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the PDE5 inhibitor tadalafil (Cialis)"]],"start": [["46"]],"entity_id": [["T2"]],"Drug": {"text": [["tadalafil"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["fixed drug eruption"]],"start": [["12"]],"entity_id": [["T1"]]} ,"Route": {"text": [["use"]],"start": [["33"]],"entity_id": [["T4"]]} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Freq": null ,"Combination": null ,"Trigger": null },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "12111771_2","context": "Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lung toxicity"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Fludarabine"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Fludarabine"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["lung disease"]],"start": [["41"]],"entity_id": [["T2"]]},"Route": {"text": [["while receiving"]],"start": [["36"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["all patients"]],"start": [["18"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["lung disease"]],"start": [["41"]],"entity_id": [["T2"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "15694139_5","context": "We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Treatment": {"Drug": {"text": [["thalidomide"]],"start": [["treated with thalidomide for myxopapillary ependymoma,"], ["treated with thalidomide for Crohn's disease and"], ["treated with thalidomide for recurrent giant"]],"entity_id": [["T1"], ["T2"], ["T3"]]},"Disorder": {"text": [["myxopapillary ependymoma"], ["Crohn's disease"], ["recurrent giant aphthous ulceration"]],"start": [[", treated with thalidomide for myxopapillary ependymoma,"], [", Crohn's disease and"], ["recurrent giant"]],"entity_id": [["T4"], ["T5"], ["T6"]]},"entity_id": [["T1"], ["T2"], ["T3"]],"text": [["thalidomide"]],"start": [["treated with thalidomide for myxopapillary ependymoma,"], ["treated with thalidomide for Crohn's disease and"], ["treated with thalidomide for recurrent giant"]],"Trigger": {"text": [["sensorimotor axonal neuropathy"]],"start": [[], [], []],"entity_id": [["T7"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "E1-C1","event_type": "Adverse_event"}]},"Subject": {"Age": {"text": [[], ["10-15 years,"]],"start": [[], [", 10-15 years,"]],"entity_id": [["T8"], ["T9"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [[], [], []],"start": [[], [], []],"entity_id": [["T10"], ["T11"], ["T12"]]},"Race": {"text": [],"start": [],"entity_id": []},"text": [[], ["children"], ["report four cases"]],"start": [[], [", children"], ["report four cases"]],"entity_id": [["T13"], ["T14"], ["T15"]]},"Effect": {"text": [["sensorimotor axonal neuropathy"]],"start": [[], [], []],"entity_id": [["T7"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "20298401_9","context": "The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"text": [["high"]],"start": [[], []],"entity_id": [] ,"value": "high" } ,"Subject": { "text": [["The patient"]], "start": [[], []], "entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["respiratory failure"]], "start": [[], []], "entity_id": [] }} , "Treatment": { "text": [["steroid infusion"]], "start": [[], []], "entity_id": [] ,"Drug": { "text": [["steroid"]], "start": [[], []], "entity_id": [] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": { "text": [["8 days"]], "start": [[], []], "entity_id": [] }, "Freq": null , "Disorder": { "text": [["respiratory failure"]], "start": [[], []], "entity_id": [] }, "Combination": null }, "Effect": { "text": [["died"]], "start": [[], []], "entity_id": [] }, "Trigger": { "text": [["respiratory failure"]], "start": [[], []], "entity_id": [] }} ]}
{"id": "10656221_9","context": "We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["this"]],"start": [["15"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["acute hepatitis"]],"start": [["31"]],"entity_id": [["S2"]]}},"Treatment": {"text": [["gliclazide"]],"start": [["68"]],"entity_id": [["T1"]],"Drug": {"text": [["gliclazide"]],"start": [["68"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["acute hepatitis"]],"start": [["31"]],"entity_id": [["S2"]]},"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null},"Effect": {"text": [["acute hepatitis"]],"start": [["31"]],"entity_id": [["S2"]]},"Trigger": {"text": [["an idiosyncratic adverse reaction"]],"start": [["44"]],"entity_id": [["T2"]]}}]}
{"id": "17352036_4","context": "We report a patient who developed acute pancreatitis during amiodarone therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute pancreatitis"]],"start": [["developed acute pancreatitis" ]] ,"entity_id": [ ] } ,"Treatment": {"text": [["amiodarone therapy"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] ,"Drug": {"text": [["amiodarone"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Disorder": {"text": [["acute pancreatitis"]],"start": [["developed acute pancreatitis"]],"entity_id": [ ] } ,"Time_elapsed": {"text": [["during"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Freq": {"text": [["during"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Route": {"text": [["therapy"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Duration": {"text": [["during"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Dosage": {"text": [["amiodarone"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Trigger": {"text": [["during"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"Combination": [{"Drug": {"text": [["amiodarone"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] },"Trigger": {"text": [["during"]],"start": [["during amiodarone therapy"]],"entity_id": [ ] } ,"event_id": "E1" ,"event_type": "Adverse_event" } ] } ,"Subject": {"text": [["patient"]],"start": [["patient"]],"entity_id": [ ] ,"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["acute pancreatitis"]],"start": [["developed acute pancreatitis"]],"entity_id": [ ] } ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""}}]}
{"id": "9602881_1", "context": "We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a 76-year-old man"]], "start": [["a", "76-year-old", "man"]], "entity_id": [],"Age":{"text":[["76"]],"start":[[ "76"]],"entity_id":[]},"Gender":{"text":[["man"]],"start":[[ "man"]],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]}},"Trigger": {"text": [["acute blistering eruption"]], "start": [["acute", "blistering", "eruption"]], "entity_id": []},"Treatment": {"text": [["high-dose penicillin treatment"]], "start": [[ "high-dose", "penicillin", "treatment"]], "entity_id": [],"Drug":{"text":[["penicillin"]],"start":[[ "penicillin"]],"entity_id":[]},"Dosage":{"text":[["high-dose"]],"start":[[ "high-dose"]],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["pneumococcal septicaemia"]],"start":[[ "pneumococcal septicaemia"]],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null, "Trigger":null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"moderate"}}]}
{"id": "14632592_5","context": "To report a case of colchicine-induced myopathy in a teenager with familial Mediterranean fever (FMF).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["colchicine-induced myopathy"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["colchicine"]],"start": [["8"]],"entity_id": [["T2"]],"Drug": {"text": [["colchicine"]],"start": [["8"]],"entity_id": [["T3"]]},"Disorder": {"text": [["familial Mediterranean fever (FMF)"]],"start": [["59"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["induced"]],"start": [["25"]],"entity_id": [["T5"]]},"Duration": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T6"]]},"Route": {"text": [["oral"]],"start": [["15"]],"entity_id": [["T7"]]},"Dosage": {"text": [["the standard dosage"]],"start": [["20"]],"entity_id": [["T8"]]},"Freq": {"text": [["daily"]],"start": [["19"]],"entity_id": [["T9"]]},"Trigger": {"text": [["To report"]],"start": [["0"]],"entity_id": [["T10"]]},"Combination": [{"Drug": {"text": [["colchicine"]],"start": [["8"]],"entity_id": [["T3"]]},"Trigger": {"text": [["To report"]],"start": [["0"]],"entity_id": [["T10"]]},"event_type": "Potential_therapeutic_effect","event_id": "E2"}]},"Subject": {"text": [["a teenager"]],"start": [["38"]],"entity_id": [["T11"]],"Age": {"text": [["a teenager"]],"start": [["38"]],"entity_id": [["T11"]]},"Gender": {"text": [["-"]],"start": [[""], ["-"]],"entity_id": [["T12"]]},"Population": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T6"]]},"Race": {"text": [["Mediterranean"]],"start": [["67"]],"entity_id": [["T13"]]},"Disorder": {"text": [["familial Mediterranean fever (FMF)"]],"start": [["59"]],"entity_id": [["T4"]]}},"Severity": {"text": [["severe"]],"start": [["75"]],"entity_id": [["T14"]],"value": "severe"},"Negated": {"text": [["-"]],"start": [[""], ["-"]],"entity_id": [["T15"]],"value": false},"Speculated": {"text": [["-"]],"start": [[""], ["-"]],"entity_id": [["T16"]],"value": false},"Effect": {"text": [["myopathy"]],"start": [["33"]],"entity_id": [["T17"]]}}]}
{"id": "11414270_14","context": "We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.', extttps://clinicaltrials.gov/ct2/show/NCT00368016","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"value": "high" ,"text": [["high"]] ,"start": [[],[]] ,"entity_id": []},"Trigger": {"text": [["mucositis"]],"start": [[],[]],"entity_id": []},"Treatment": null,"Subject": {"text": [["this case"]],"start": [[],[]],"entity_id": [] ,"Age": null, "Disorder": {"text": [["fatal hyperkalemia"]],"start": [[],[]],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["fatal hyperkalemia"]],"start": [[],[]],"entity_id": []}},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["administration"]],"start": [[],[]],"entity_id": []},"Treatment": {"text": [["succinylcholine"]],"start": [[],[]],"entity_id": [] ,"Drug": {"text": [["succinylcholine"]],"start": [[],[]],"entity_id": []} ,"Dosage": null, "Freq": null, "Duration": null, "Disorder": {"text": [["fatal hyperkalemia"]],"start": [[],[]],"entity_id": []},"Route": null, "Time_elapsed": null ,"Combination": null ,"Trigger": null},"Effect": null,"Subject": null}]}
{"id": "3628148_1","context": "Rupture of a cerebral aneurysm associated with nifedipine treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Rupture"]],"start": [[ "0"]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["nifedipine treatment"]],"start": [[ "47"]] ,"entity_id": [["T2"]],"Drug": {"text": [["nifedipine"]],"start": [[ "47"]],"entity_id": [["T3"]]},"Disorder": {"text": [["cerebral aneurysm"]],"start": [[ "17"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["associated with"]],"start": [[ "34"]],"entity_id": [["T5"]]},"Freq": {"text": [["Rupture"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["nifedipine"]],"start": [[ "47"]],"entity_id": [["T3"]]},"Trigger": {"text": [["associated with"]],"start": [[ "34"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["Rupture"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["nifedipine"]],"start": [[ "47"]],"entity_id": [["T3"]]},"Route": {"text": [["nifedipine treatment"]],"start": [[ "47"]],"entity_id": [["T2"]]},"Duration": {"text": [["nifedipine treatment"]],"start": [[ "47"]],"entity_id": [["T2"]]}},"Effect": {"text": [["Rupture"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Subject": {"text": [["Rupture"]],"start": [[ "0"]],"entity_id": [["T1"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["cerebral aneurysm"]],"start": [[ "17"]],"entity_id": [["T4"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "15157248_1", "context": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["immediate hemolytic reaction"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["repeated administration of oxaliplatin"]], "start": [["55"]], "entity_id": [], "Drug": {"text": [["oxaliplatin"]], "start": [["55"]], "entity_id": [] }, "Route": {"text": [["administration"]], "start": [["55"]], "entity_id": []}, "Freq": {"text": [["repeated"]], "start": [["55"]], "entity_id": []}, "Time_elapsed": {"text": [["induced"]], "start": [["33"]], "entity_id": []}, "Disorder": {"text": [["hemolytic reaction"]], "start": [["1"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": {"text": [[ "repeated administration of oxaliplatin"]],"start": [[ "55"]],"entity_id": []}}, "Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [], "start": [], "entity_id": []}}, "Effect": {"text": [[ "hemolytic reaction"]],"start": [[ "1"]],"entity_id": []}, "Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "15494638_8","context": "Patient B developed perioral and upper extremity paresthesias during the fourth cycle of CAP alone (2500 mg/m2).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["perioral and upper extremity paresthesias"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["CAP alone"]],"start": [["52"]],"entity_id": [["T2"]],"Dosage": {"text": [["2500 mg/m2"]],"start": [["62"]],"entity_id": [["T3"]]} ,"Route": {"text": [["alone"]],"start": [[ "52" ]],"entity_id": [["T4"]]} ,"Duration": {"text": [["fourth cycle"]],"start": [[ "17" ]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["Patient B"]],"start": [[ "0" ]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Drug": {"text": [["CAP"]],"start": [[ "17" ]],"entity_id": [["T7"]]} ,"Trigger": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low"} ,"Subject": {"text": [["Patient B"]],"start": [[ "0" ]],"entity_id": [["T6"]],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null}}]}
{"id": "8749646_4","context": "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["seizures"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["four patients"]],"start": [["5"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": {"text": [["four"]],"start": [["5"]],"entity_id": [["T2"]]},"Race": null,"Disorder": null},"Treatment": {"text": [["ofloxacin"]],"start": [["52"]],"entity_id": [["T3"]],"Drug": {"text": [["ofloxacin"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["receiving"]],"start": [["32"]],"entity_id": [["T4"]]}},"Effect": {"text": [["seizures"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9701106_1", "context": "A drug interaction between zafirlukast and theophylline", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["drug interaction"]], "start": [["0"]], "entity_id": []}, "Treatment": { "Drug": {"text": [["zafirlukast"]], "start": [["22"]], "entity_id": []}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "text": [["zafirlukast"]], "start": [["22"]], "entity_id": [] ,"Disorder": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "16503727_1","context": "Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Dipyrone"]],"start": [[ "0" ]],"entity_id": [ ["T1" ] ] ,"Drug": {"text": [["Dipyrone"]],"start": [[ "0" ]],"entity_id": [ ["T1" ] ] },"Disorder": {"text": [["agranulocytosis"]],"start": [[ "152" ]],"entity_id": [ ["T5" ] ] },"Trigger": {"text": [["association with"]],"start": [[ "136" ]],"entity_id": [ ["T4" ] ] },"Time_elapsed": { "text": [["association with"]], "start": [[ "136" ]], "entity_id": [ ["T4" ] ] }, "Dosage": null, "Duration": null, "Route": null, "Freq": null ,"Combination": null }, "Effect": null ,"Negated": null, "Speculated": null ,"Severity": null ,"Subject": null ,"Trigger": null }] }
{"id": "12503933_7","context": "The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["clarithromycin"]],"start": [["39"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["clarithromycin"]],"start": [["39"]],"entity_id": [["T1"]]},"Disorder": {"text": [["liver failure"]],"start": [["7"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["has been reported"]],"start": [["60"]],"entity_id": [["T3"]]},"Freq": {"text": [["most likely cause"]],"start": [["0"]],"entity_id": [["T4"]]},"entity_id": [["T1","T2","T3","T4"]],"text": [["clarithromycin"]],"start": [["39"]],"Dosage": {"text": [["undergoes hepatic metabolism"]],"start": [["42"]],"entity_id": [["T5"]]},"Duration": {"text": [["has been reported"]],"start": [["60"]],"entity_id": [["T3"]]},"Route": {"text": [["therapy"]],"start": [["51"]],"entity_id": [["T6"]]},"Trigger": {"text": [["liver failure"]],"start": [["7"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [["39"]],"entity_id": [["T1"]]},"Trigger": {"text": [["liver failure"]],"start": [["7"]],"entity_id": [["T2"]]},"event_id": "E1-1","event_type": "Adverse_event"}]},"Subject": {"text": [["this patient"]],"start": [["17"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["liver failure"]],"start": [["7"]],"entity_id": [["T2"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["fulminant hepatic failure"]],"start": [["70"]],"entity_id": [["T8"]],"value": "High"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["liver failure"]],"start": [["7"]],"entity_id": [["T2"]]}}]}
{"id": "10084639_2", "context": "The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["olanzapine"]], "start": [["34"]], "entity_id": [["T1"]]},"Disorder": {"text": [["treating patients with clozapine-induced granulocytopenia"]], "start": [["53"]], "entity_id": [["T2"]]} ,"Dosage": {"text": [["may be useful"]], "start": [["34"]], "entity_id": [["T1"]]},"Freq": {"text": [[""]], "start": [[""], []], "entity_id": [[""], []]},"Route": {"text": [[""]], "start": [[""], []], "entity_id": [[""], []]},"Duration": {"text": [[""]], "start": [[""], []], "entity_id": [[""], []]} ,"Time_elapsed": {"text": [[""]], "start": [[""], []], "entity_id": [[""], []]} ,"Combination": null ,"entity_id": [["T1"], ["T2"]] ,"text": [["olanzapine"], ["treating patients with clozapine-induced granulocytopenia"]],"start": [["34"], ["53"]] ,"Trigger": null },"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "10452772_1","context": "Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["insulin allergy"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Effect": {"text": [["complete resolution of their symptoms"]],"start": [[ "47" ]],"entity_id": [ ["T2"] ]},"Negated": {"value": true ,"text": [["may not have"]],"start": [[ "22" ]],"entity_id": [ ["T3"] ]} ,"Subject": {"text": [["Patients"]],"start": [[ "0" ]],"entity_id": [ ["T0"] ],"Disorder": {"text": [["insulin allergy"]],"start": [[ "17" ]],"entity_id": [ ["T1"] ]},"Population": {"text": [["Patients"]],"start": [[ "0" ]],"entity_id": [ ["T0"] ]} ,"Age": null,"Gender": null,"Race": null} ,"Treatment": {"text": [["standard desensitization"]],"start": [[ "63" ]],"entity_id": [ ["T4"] ],"Drug": null,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": {"text": [["after"]],"start": [[ "51" ]],"entity_id": [ ["T5"] ]} ,"Combination": null }, "Speculated": null ,"Severity": null }] }
{"id": "3485422_2","context": "We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["retinal toxic effect"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gentamicin"]],"start": [["65"]],"entity_id": [["T2"]],"Dosage": {"text": [["massive doses"]],"start": [["90"]],"entity_id": [["T3"]]} ,"Route": {"text": [["intraocular injection"]],"start": [["74"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["macular lesion"]],"start": [["4"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["recent description"]],"start": [["20"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["occurring after"]],"start": [["52"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["after the inadvertent injection"]],"start": [["52"]],"entity_id": [["T6"]]} ,"Drug": {"text": [["gentamicin"]],"start": [["65"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["massive doses"]],"start": [["90"]],"entity_id": [["T3"]]} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": {"text": [["concerned"]],"start": [["0"]],"entity_id": [["T7"]] ,"value": true },"Severity": null,"Subject": null}]}
{"id": "17675030_4", "context": "We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced angioedema during treatment with oxcarbazepine.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["oxcarbazepine"]], "start": [[ "63" ]], "entity_id": [ ["T1" ]] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"text": [ ["oxcarbazepine"] ], "start": [[ "63" ]], "entity_id": [ ["T1" ]] ,"Disorder": null }, "Effect": { "text": [ ["angioedema"] ], "start": [[ "41" ]], "entity_id": [ ["T2" ]] } ,"Trigger": { "text": [ ["treatment"] ], "start": [[ "45" ]], "entity_id": [ ["T3" ]] } }]}
{"id": "17381671_7", "context": "SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["SSRIs"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["underlying depression"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["co-administered"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["fentanyl"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["and"]],"start": [[ ]],"entity_id": [ ]} ,"event_id": "E2","event_type": "Potential_therapeutic_effect"}] ,"entity_id": [ ],"text": [["SSRIs and fentanyl"]],"start": [[ ]] ,"Freq": {"text": [["commonly"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["administered"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["chronic or malignant pain"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Trigger": {"text": [],"start": [],"entity_id": []} }]}
{"id": "458006_1", "context": "Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["5-fluorouracil"]], "start": [["62"]], "entity_id": [],"Drug": {"text": [["5-fluorouracil"]], "start": [["62"]], "entity_id": []},"Disorder": {"text": [["Squamous-cell carcinoma arising in a basal-cell epithelioma"]], "start": [["0"]], "entity_id": []},"Duration": {"text": [["treated"]], "start": [["42"]], "entity_id": []},"Trigger": {"text": [["treated"]], "start": [["42"]], "entity_id": []},"Route": {"text": [["with"]], "start": [["55"]], "entity_id": []},"Time_elapsed": {"text": [["arising"]], "start": [["21"]], "entity_id": []},"Freq": {"text": [["treated"]], "start": [["42"]], "entity_id": []},"Combination": [],"Dosage": {"text": [], "start": [], "entity_id": []}},"Subject": {"text": [["Squamous-cell carcinoma arising in a basal-cell epithelioma"]], "start": [["0"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["Squamous-cell carcinoma arising in a basal-cell epithelioma"]], "start": [["0"]], "entity_id": []}},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Trigger": {"text": [], "start": [], "entity_id": []}}]}
{"id": "8313300_2","context": "The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["thyrotoxicosis", "severe exophthalmos"]],"start": [["developed thyrotoxicosis with severe exophthalmos" ]],"entity_id": [ ]},"Treatment": {"text": [["lithium therapy"]],"start": [["on lithium therapy" ]],"entity_id": [ ],"Drug": {"text": [["lithium"]],"start": [[ "on lithium therapy" ]],"entity_id": [ ]} ,"Disorder": {"text": [["bipolar"]],"start": [[ "a bipolar patient" ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Subject": {"text": [["a bipolar patient"]],"start": [[ "a bipolar patient" ]],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["bipolar"]],"start": [[ "a bipolar patient" ]],"entity_id": []} },"Effect": {"text": [["thyrotoxicosis", "severe exophthalmos"]],"start": [[ "developed thyrotoxicosis with severe exophthalmos" ]],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["severe"]],"start": [[ "severe exophthalmos" ]],"entity_id": [] ,"value": "severe" }} ]}
{"id": "8360712_1","context": "A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["IL-2"]],"start": [[ ]],"entity_id": [["T2"]]},"Disorder": {"text": [["leptomeningeal disease"]],"start": [[ ]],"entity_id": [["T3"]]},"Route": {"text": [["intraventricular"]],"start": [[ ]],"entity_id": [["T1"]]},"entity_id": [["T1","T2","T3"]],"text": [["treated with intraventricular IL-2 for leptomeningeal disease"]],"start": [[ ]],"Dosage": null,"Duration": null,"Trigger": null,"Time_elapsed": null,"Freq": null,"Combination": null},"Effect": {"text": [["progressive cognitive dysfunction"]],"start": [[ ]],"entity_id": [["T4"]]},"Subject": {"Age": {"text": [["40 year old"]],"start": [[ ]],"entity_id": [["T5"]]},"Gender": {"text": [["woman"]],"start": [[ ]],"entity_id": [["T6"]]},"Population": null,"Race": null,"Disorder": null,"text": [["A case is reported of a 40 year old woman"]],"start": [[ ]],"entity_id": [["T5","T6"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "15289139_3","context": "We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open-angle glaucoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["abrupt development", "choroidal detachment"]],"start": [["13","32"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["dorzolamide therapy"]],"start": [["59"]],"entity_id": [["T3"]],"Drug": {"text": [["dorzolamide"]],"start": [["59"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["primary open-angle glaucoma"]],"start": [["82"]],"entity_id": [["T5"]]} ,"Route": {"text": [["therapy"]],"start": [["59"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["after initiation"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["after initiation"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["after initiation"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["after initiation"]],"start": [["51"]],"entity_id": [["T3"]]}, "Combination": null ,"Dosage": null },"Subject": {"text": [["We"]],"start": [[""],[]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null,"Effect": null} ]}
{"id": "19226083_1", "context": "Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Serotonin toxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["linezolid use"]], "start": [[ "42" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["linezolid"]], "start": [[ "42" ]], "entity_id": [ ["T3"] ]} , "Disorder": {"text": [["Serotonin toxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Route": null ,"Freq": null ,"Combination": null ,"Trigger": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "11788010_2","context": "Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Gallstones", "bile sludge"]],"start": [["0","24"]],"entity_id": []},"Treatment": {"text": [["octreotide therapy"]],"start": [["51"]],"entity_id": [],"Drug": {"text": [["octreotide"]],"start": [["51"]],"entity_id": []},"Disorder": {"text": [["side effects"]],"start": [["25"]],"entity_id": []},"Freq": {"text": [["common"]],"start": [["4"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": []},"Trigger": {"text": [[]],"start": [[]],"entity_id": []},"Combination": null},"Effect": {"text": [["symptomatic"]],"start": [["79"]],"entity_id": []},"Negated": {"value": false,"text": [["rarely"]],"start": [["79"]],"entity_id": []},"Speculated": null,"Severity": {"value": "Low","text": [["rarely"]],"start": [["79"]],"entity_id": []},"Subject": null}]}
{"id": "14557583_3","context": "The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["L-dopa"]],"start": [[ "0" ]],"entity_id": []},"Treatment": {"text": [["L-dopa"]],"start": [[ "0" ]],"entity_id": [],"Drug": {"text": [["L-dopa"]],"start": [[ "0" ]],"entity_id": []},"Disorder": {"text": [["daytime somnolence"]],"start": [[ "40" ]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": []},"Freq": {"text": [[]],"start": [[]],"entity_id": []},"Combination": null,"Trigger": {"text": [["may cause"]],"start": [["36"]],"entity_id": []}},"Subject": {"text": [["some patients with Parkinson's disease"]],"start": [[ "52" ]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "70" ]],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": {"text": [["suggest"]],"start": [[ "3" ]],"entity_id": [],"value": true},"Severity": null}]}
{"id": "16284443_1","context": "Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["insulin-induced lipohypertrophy"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Subject": {"text": [["the patient"]],"start": [["0"],["5"]],"entity_id": [["S1"],["S2"]] ,"Age": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["A1"]]},"Gender": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["G1"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["P1"]]},"Race": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["R1"]]},"Disorder": {"text": [["insulin-induced lipohypertrophy"]],"start": [["31"]],"entity_id": [["D1"]]}} ,"Treatment": {"text": [["insulin"]],"start": [["12"]],"entity_id": [["T2"]] ,"Drug": {"text": [["insulin"]],"start": [["12"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["insulin-induced lipohypertrophy"]],"start": [["31"]],"entity_id": [["D1"]]} ,"Route": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["R2"]]} ,"Dosage": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["D2"]]} ,"Duration": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["D3"]]} ,"Time_elapsed": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["F1"]]} ,"Combination": null ,"Trigger": {"text": [["diagnosis"]],"start": [["16"]],"entity_id": [["T5"]]}} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null} ]}
{"id": "16637972_2", "context": "An unusual presentation of spontaneous sub-conjunctival haematoma in a patient receiving warfarin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["spontaneous sub-conjunctival haematoma"]], "start": [["33","37"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["warfarin"]], "start": [["81","85"]], "entity_id": [["T2"]], "Drug": {"text": [["warfarin"]], "start": [["81","85"]], "entity_id": [["T3"]] } ,"Disorder": {"text": [["spontaneous sub-conjunctival haematoma"]], "start": [["33","37"]], "entity_id": [["T1"]]},"Route": {"text": [["in a patient receiving"]], "start": [["51","67"]], "entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["an unusual presentation"]], "start": [["0","17"]], "entity_id": [["T5"]]} ,"Freq": {"text": [["spontaneous"]], "start": [["33"]], "entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["warfarin"]], "start": [["81","85"]], "entity_id": [["T3"]]},"Trigger": {"text": [["receiving"]], "start": [["68","75"]], "entity_id": [["T7"]]}, "event_id": "E2", "event_type": "Potential_therapeutic_effect"} ] ,"Trigger": {"text": [["patient receiving warfarin"]], "start": [["51","85"]], "entity_id": [["T8"]]} ,"Duration": {"text": [["an unusual presentation"]], "start": [["0","17"]], "entity_id": [["T5"]]} ,"Dosage": {"text": [["an unusual presentation"]], "start": [["0","17"]], "entity_id": [["T5"]]} } ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": {"text": [["spontaneous sub-conjunctival haematoma"]], "start": [["33","37"]], "entity_id": [["T1"]]} }]}
{"id": "19782276_4","context": "He developed congestive heart failure 5 days after administration of cyclophosphamide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["congestive heart failure"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["cyclophosphamide"]],"start": [["86"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["5 days"]],"start": [["54"]],"entity_id": [["T3"]]},"text": [["administration"]],"start": [["73"]],"entity_id": [["T4"]],"Trigger": {"text": [["administration"]],"start": [["73"]],"entity_id": [["T4"]]},"Disorder": {"text": [["congestive heart failure"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["He"]],"start": [[""],[]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["congestive heart failure"]],"start": [[""],[]],"entity_id": []}}]}
{"id": "12503933_5", "context": "Fulminant liver failure associated with clarithromycin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Fulminant liver failure"]], "start": [[ "0"]], "entity_id": []}, "Treatment": {"text": [["clarithromycin"]], "start": [[ "52"]], "entity_id": [],"Drug": {"text": [["clarithromycin"]], "start": [[ "52"]], "entity_id": []} ,"Disorder": {"text": [["Fulminant liver failure"]], "start": [[ "0"]], "entity_id": []} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Freq": null ,"Route": null ,"Combination": null ,"Trigger": null },"Effect": {"text": [["Fulminant liver failure"]], "start": [[ "0"]], "entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "2979256_3","context": "Nifedipine may induce, or aggravate, pre-existing, gastro-oesophageal reflux","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["induce", "aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]},"Treatment": {"text": [["Nifedipine"]],"start": [[ "0"]],"entity_id": [ ["T0"]],"Drug": {"text": [["Nifedipine"]],"start": [[ "0"]],"entity_id": [ ["T0"]]} ,"Disorder": {"text": [["pre-existing, gastro-oesophageal reflux"]],"start": [[ "36"]],"entity_id": [ ["T3"]]} ,"Time_elapsed": {"text": [["may induce", "or aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} ,"Freq": {"text": [["may induce", "or aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} ,"Dosage": {"text": [["may induce", "or aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} ,"Duration": {"text": [["may induce", "or aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} ,"Route": {"text": [["may induce", "or aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} ,"Combination": null ,"Trigger": {"text": [["induce", "aggravate"]],"start": [[ "3", "25"]],"entity_id": [ ["T1", "T2"]]} }, "Effect": {"text": [["pre-existing", "gastro-oesophageal reflux"]],"start": [[ "36"]],"entity_id": [ ["T3"]]} ,"Negated": null ,"Speculated": null ,"Severity": {"text": [["pre-existing"]],"start": [[ "36"]],"entity_id": [ ["T3"]],"value": "Low"} ,"Subject": null }]}
{"id": "7416268_3","context": "Although useful in the management of chronic alcoholism, disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include catatonia","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["disulfiram"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["useful", "in", "the", "management", "of", "chronic", "alcoholism"]],"start": [["0"]],"entity_id": [["T2"]],"Disorder": {"text": [["chronic alcoholism"]],"start": [["26"]],"entity_id": [["T3"]]},"Drug": {"text": [["disulfiram"]],"start": [["35"]],"entity_id": [["T1"]]},"Freq": {"text": [["increasingly"]],"start": [["42"]],"entity_id": [["T4"]]},"Duration": {"text": [["management"]],"start": [["14"]],"entity_id": [["T5"]]},"Route": {"text": [["management"]],"start": [["14"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["increasingly"]],"start": [["42"]],"entity_id": [["T4"]]},"Dosage": {"text": [["useful"]],"start": [["0"]],"entity_id": [["T2"]]},"Combination": null,"Trigger": {"text": [["disulfiram"]],"start": [["35"]],"entity_id": [["T1"]]}},"Effect": {"text": [["side effects", "untoward medical sequelae", "catatonia"]],"start": [["52","63","92"]],"entity_id": [["T6","T7","T8"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19567656_2","context": "The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["sertraline treatment"]],"start": [["0"]],"entity_id": [["T1"]] ,"Drug": {"text": [["sertraline"]],"start": [["0"]],"entity_id": [["T2"]] },"Disorder": {"text": [["rhabdomyolysis"]],"start": [["102"]],"entity_id": [["T3"]] },"Trigger": {"text": [["the onset"]],"start": [["68"]],"entity_id": [["T4"]] },"Freq": {"text": [["probable relationship"]],"start": [["31"]],"entity_id": [["T5"]] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "14677199_1","context": "Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe Raynaud's phenomenon"]],"start": [["0"]] ,"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["yohimbine therapy"]], "start": [["41" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["yohimbine"]], "start": [["41" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["erectile dysfunction"]], "start": [["72" ]], "entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Combination": null }, "Negated": null, "Speculated": null, "Severity": { "text": [["Severe"]], "start": [["0" ]], "entity_id": [ ["E1"] ], "value": "Severe" }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Effect": null }]}
{"id": "10323129_1", "context": "Possible theophylline toxicity during anesthesia", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["theophylline toxicity"]], "start": [["16"]], "entity_id": []}, "Treatment": {"text": [["anesthesia"]], "start": [["38"]], "entity_id": [], "Drug": {"text": [["theophylline"]], "start": [["16"]], "entity_id": []}, "Route": {"text": [["during"]], "start": [["30"]], "entity_id": []}, "Time_elapsed": {"text": [["during"]], "start": [["30"]], "entity_id": []},"Dosage": {"text": [["possible"]], "start": [["0"]], "entity_id": []} ,"Disorder": {"text": [["theophylline toxicity"]], "start": [["16"]], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Combination": null ,"Trigger": null } ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null } ]}
{"id": "3124393_2", "context": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Calcification and ossification"]], "start": [[ ]],"entity_id": [ ]}, "Treatment": {"text": [["intrathecal administration of Depo-Medrol"]], "start": [[ ]],"entity_id": [ ],"Drug": {"text": [["Depo-Medrol"]], "start": [[ ]], "entity_id": [ ] } , "Disorder": {"text": [["spinal arachnoid"]], "start": [[ ]], "entity_id": [ ] } , "Route": {"text": [["intrathecal administration"]], "start": [[ ]], "entity_id": [ ] } , "Time_elapsed": {"text": [["after"]], "start": [[ ]], "entity_id": [ ] } , "Duration": {"text": [[]], "start": [[ ]], "entity_id": [ ] } , "Dosage": {"text": [[]], "start": [[ ]], "entity_id": [ ] } , "Freq": {"text": [[]], "start": [[ ]], "entity_id": [ ] } , "Combination": null , "Trigger": null } , "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": null }]}
{"id": "921427_2", "context": "Circulating anticoagulant in the procainamide-induced lupus syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["procainamide-induced lupus syndrome"]], "start": [["36"]], "entity_id": []}, "Effect": {"text": [["Circulating anticoagulant"]], "start": [["0"]], "entity_id": []}, "Negated": {"value": false, "text": [], "start": [], "entity_id": []}, "Speculated": {"value": false, "text": [], "start": [], "entity_id": []}, "Treatment": null, "Subject": null, "Severity": null}]}
{"id": "16405935_3","context": "This report describes a case of bilateral ptosis induced by chloroquine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bilateral ptosis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["chloroquine"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["chloroquine"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["bilateral ptosis"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Route": {"text": [["induced"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["report"]],"start": [["1"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["describes"]],"start": [["7"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["a case"]],"start": [["8"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["a case"]],"start": [["8"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["a case"]],"start": [["8"]],"entity_id": [["T7"]]} ,"Combination": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "12221670_5","context": "When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reversible direct cytotoxic effect"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ticlopidine"]],"start": [["53", "54"]],"entity_id": [["T2"]] ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Drug": {"text": [["ticlopidine"]],"start": [["53", "54"]],"entity_id": [["T2"]]} },"Effect": {"text": [["a reversible direct cytotoxic effect"]],"start": [["0"]],"entity_id": [["T1"]] },"Negated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Speculated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Severity": {"value": "","text": [],"start": [],"entity_id": [] },"Subject": {"text": [["the data of the 57 patients"]],"start": [["0"]],"entity_id": [["T0"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [["57 patients"]],"start": [["13", "14"]],"entity_id": [["T0"] ]},"Race": {"text": [],"start": [],"entity_id": [] }} } ]}
{"id": "17526968_3","context": "We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["localized pigmentation"]],"start": [["56"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["cisplatin", "etoposide", "bleomycin"]],"start": [["88"]],"entity_id": [["T2"], ["T3"], ["T4"]]},"Disorder": {"text": [["yolk sac tumor"]],"start": [["12"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["after the first course"]],"start": [["32"]],"entity_id": [["T6"]]},"Trigger": {"text": [["chemotherapy regimen"]],"start": [["42"]],"entity_id": [["T7"]]},"text": [["who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin"]],"start": [["18"]],"entity_id": [["T8"]],"Dosage": null,"Duration": null,"Route": null,"Freq": null,"Combination": null},"Effect": {"text": [["localized pigmentation"]],"start": [["56"]],"entity_id": [["T1"]]},"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16791713_2","context": "Except hypothyroidism after radioiodine treatment (euthyroid under substitutional therapy), she suffered from no other diseases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypothyroidism"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["radioiodine treatment"]],"start": [["32"]],"entity_id": [["T2"]],"Drug": {"text": [["radioiodine"]],"start": [["32"]],"entity_id": [["T3"]]},"Disorder": {"text": [["hypothyroidism"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after"]],"start": [["22"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment"]],"start": [["32"]],"entity_id": [["T2"]]},"Route": {"text": [["treatment"]],"start": [["32"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["radioiodine"]],"start": [["32"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["32"]],"entity_id": [["T2"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["after"]],"start": [["22"]],"entity_id": [["T4"]]},"Duration": {"text": [["under substitutional therapy"]],"start": [["41"]],"entity_id": [["T5"]]},"Dosage": {"text": [["substitutional therapy"]],"start": [["41"]],"entity_id": [["T5"]]}},"Subject": {"text": [["she"]],"start": [["67"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "17034541_1", "context": "Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hepatitis B virus reactivation"]], "start": [["33"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["rituximab"]], "start": [["84"]], "entity_id": [["T2"]], "Drug": {"text": [["rituximab"]], "start": [["84"]], "entity_id": [["T3"]]},"Disorder": { "text": [["low-grade cutaneous B-cell lymphoma"]], "start": [["58"]], "entity_id": [["T4"]]},"Time_elapsed": { "text": [["Late"]], "start": [["0"]], "entity_id": [["T0"]]},"Freq": { "text": [["lethal"]], "start": [["1"]], "entity_id": [["T5"]]},"Combination": [{ "Drug": { "text": [["isoniazid"]], "start": [[],[]], "entity_id": [["T6"]]},"Trigger": { "text": [["therapy"]], "start": [[],[]], "entity_id": [["T7"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": { "text": [["treatment"]], "start": [["65"]], "entity_id": [["T8"]]},"Route": { "text": [["of"]], "start": [[],[]], "entity_id": [["T9"]]},"Dosage": { "text": [["low-grade"]], "start": [[],[]], "entity_id": [["T10"]]},"Duration": { "text": [["cutaneous B-cell lymphoma"]], "start": [[],[]], "entity_id": [["T11"]]}},"Effect": { "text": [[]], "start": [], "entity_id": []},"Subject": { "text": [[]], "start": [], "entity_id": [],"Age": { "text": [[]], "start": [], "entity_id": []},"Gender": { "text": [[]], "start": [], "entity_id": []},"Population": { "text": [[]], "start": [], "entity_id": []},"Race": { "text": [[]], "start": [], "entity_id": []},"Disorder": { "text": [["low-grade cutaneous B-cell lymphoma"]], "start": [[],[]], "entity_id": [["T4"]]}},"Negated": { "text": [[]], "start": [], "entity_id": [],"value": false},"Speculated": { "text": [[]], "start": [], "entity_id": [],"value": false},"Severity": { "text": [["lethal"]], "start": [[],[]], "entity_id": [["T5"]],"value": "high"}}]}
{"id": "3815268_2", "context": "The possible role of interferon beta in the pathogenesis of sarcoidosis in this patient is discussed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["interferon beta"]], "start": [["3"]], "entity_id": [],"Drug": {"text": [["interferon beta"]], "start": [["3"]], "entity_id": [] },"Disorder":{"text":[["sarcoidosis"]],"start":[["46"]],"entity_id":[]},"Trigger":{"text":[["role"]],"start":[["9"]],"entity_id":[]},"Time_elapsed":{"text":[["in this patient"]],"start":[["53"]],"entity_id":[]},"Route":{"text":[["in the pathogenesis"]],"start":[["24"]],"entity_id":[]},"Freq":{"text":[["possible"]],"start":[["0"]],"entity_id":[]},"Combination":[{"Drug":{"text":[["interferon beta"]], "start": [["3"]], "entity_id": []},"Trigger":{"text":[["role"]],"start":[["9"]],"entity_id":[]},"event_id":"C1","event_type":"Potential_therapeutic_effect"} ],"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]}} ,"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":true},"Severity":{"text":[],"start":[],"entity_id":[],"value":"low" },"Subject":{"text":[["this patient"]],"start":[["53"]],"entity_id":[],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["sarcoidosis"]],"start":[["46"]],"entity_id":[]}} ,"Effect":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[["role"]],"start":[["9"]],"entity_id":[]}}]}
{"id": "15383642_6", "context": "Three weeks later, the decerebrate rigidity and high BP remained, and tizanidine was initiated to see whether the decrease in muscle tone could facilitate hypertension control and motor recovery.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["tizanidine"]], "start": [["76"]], "entity_id": [],"Drug":{"text":[["tizanidine"]],"start":[["76"]],"entity_id":[]},"Disorder":{"text":[["hypertension control and motor recovery"]], "start": [["101"]], "entity_id": []},"Route":{"text":[["initiated"]], "start": [["76"]], "entity_id": []},"Trigger":{"text":[["see whether"]], "start": [["90"]], "entity_id": []},"Time_elapsed":{"text":[["Three weeks later","the decerebrate rigidity and high BP remained"]], "start": [[],["0"]], "entity_id": []},"Freq":{"text":[["initiated"]], "start": [["76"]], "entity_id": []},"Dosage":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Duration":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Combination":null}, "Subject":{"text":[["the decerebrate rigidity and high BP remained"]], "start": [[],["0"]], "entity_id": [],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":{"text":[["decerebrate rigidity"]], "start": [[""],["0"]], "entity_id": []}},"Effect":{"text":[["decrease in muscle tone"]], "start": [["88"]], "entity_id": []},"Negated":null,"Speculated":null,"Severity":null,"Trigger":{"text":[["see whether"]], "start": [["90"]], "entity_id": []}}]}
{"id": "1635565_2","context": "The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gastric-outlet obstruction"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the administration of prostaglandin E1"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["prostaglandin E1"]],"start": [["18"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["gastric-outlet obstruction"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Route": {"text": [["to neonates"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["prostaglandin E1"]],"start": [["18"]],"entity_id": [["T3"]]},"Trigger": {"text": [["antral hyperplasia"]],"start": [["70"]],"entity_id": [["T5"]]} ,"event_type": "Adverse_event" ,"event_id": "E2"} ],"Time_elapsed": {"text": [["can cause"]],"start": [["36"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["can cause"]],"start": [["36"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["the administration"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["the administration"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["gastric-outlet obstruction"]],"start": [["32"]],"entity_id": [["T1"]]} },"Subject": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]],"Age": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Population": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Race": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["neonates"]],"start": [["45"]],"entity_id": [["T4"]]} },"Severity": {"text": [["gastric-outlet obstruction"]],"start": [["32"]],"entity_id": [["T1"]],"value": "high"} ,"Speculated": {"text": [["can cause"]],"start": [["36"]],"entity_id": [["T6"]],"value": false} ,"Negated": {"text": [["not cause"]],"start": [["36"]],"entity_id": [["T6"]],"value": false} ,"Effect": {"text": [["gastric-outlet obstruction"]],"start": [["32"]],"entity_id": [["T1"]]} }]}
{"id": "8013261_1","context": "During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["occurrence"]],"start": [["38"]],"entity_id": []},"Treatment": {"text": [["IFN therapy"]],"start": [["11"]],"entity_id": [],"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["IDDM"]],"start": [["24"]],"entity_id": []}, "Duration": {"text": [],"start": [],"entity_id": []}, "Time_elapsed": {"text": [],"start": [],"entity_id": []}, "Freq": {"text": [],"start": [],"entity_id": []}, "Route": {"text": [],"start": [],"entity_id": []}, "Combination": null, "Dosage": {"text": [],"start": [],"entity_id": []}, "Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": {"text": [["should consider"]],"start": [["11"]],"entity_id": [], "value": true},"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [], "Age": null, "Gender": null, "Disorder": {"text": [["autoimmune diseases"]],"start": [["50"]],"entity_id": []}, "Population": {"text": [],"start": [],"entity_id": []}, "Race": null}}]}
{"id": "3310776_2", "context": "Captopril-related (and -induced?) asthma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Captopril-related asthma"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["Captopril"]], "start": [[ "12" ]], "entity_id": [ ["T2" ]],"Drug": {"text": [["Captopril"]], "start": [[ "12" ]], "entity_id": [ ["T2" ]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": {"text": [["asthma"]], "start": [[ "25" ]], "entity_id": [ ["T3" ]]}, "Freq": null, "Combination": null,"Trigger": {"text": [["Captopril-related", "Captopril-induced?"]], "start": [[ "0","21" ]], "entity_id": [ ["T1","T4" ]]}} ,"Negated": null, "Speculated": {"text": [["-induced?"]], "start": [[ "21" ]], "entity_id": [ ["T4" ]],"value": true }, "Severity": null, "Subject": null , "Effect": {"text": [["asthma"]], "start": [[ "25" ]], "entity_id": [ ["T3" ]]}}]}
{"id": "18094347_1","context": "According to the Naranjo probability scale, the papular eruption was probably caused by methotrexate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["papular eruption"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["methotrexate"]],"start": [["74"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"entity_id": [["T3"]] ,"text": [["methotrexate"]],"start": [["74"]], "Dosage": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Route": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["was probably caused"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Combination": null} ,"Negated": null,"Speculated": {"text": [["probably"]],"start": [["42"]],"entity_id": [["T4"]] ,"value": true },"Severity": null,"Subject": {"text": [["the papular eruption"]],"start": [["18"]],"entity_id": [["T1"]],"Age": null,"Disorder": {"text": [["According to the Naranjo probability scale"]],"start": [["0"]],"entity_id": [["T5"]] },"Gender": null,"Population": null,"Race": null },"Effect": {"text": [["papular eruption"]],"start": [["18"]],"entity_id": [["T1"]] }} ] }
{"id": "3688031_3","context": "The patient's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["methimazole"]],"start": [[ "3" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["methimazole"]],"start": [[ "3" ]],"entity_id": [ ["T1"] ]} ,"Disorder": {"text": [["methimazole teratogenicity"]],"start": [[ "31" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["methimazole teratogenicity"]],"start": [[ "31" ]],"entity_id": [ ["T2"] ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": {"text": [["could represent"]],"start": [[ "54" ]],"entity_id": [ ["T3"] ],"value": true },"Severity": null,"Subject": {"text": [["The patient's defects"]],"start": [[ "0" ]],"entity_id": [ ["T0"] ],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": null,"Population": null,"Race": null },"Trigger": null }] }
{"id": "11881322_2", "context": "Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Itraconazole-induced liver injury"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Effect": {"text": [["damage to the interlobular bile ducts", "ductopenia"]], "start": [[ "46" ],[ "101" ]], "entity_id": [ ["T2", "T3"] ]}, "Severity": {"value": "high", "text": [["Itraconazole-induced liver injury"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Negated": null, "Speculated": null, "Subject": null, "Treatment": null}]}
{"id": "12243603_8","context": "Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG-CoA reductase inhibitors has been described in the literature","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["drug interaction"]],"start": [["32", "33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["diltiazem"]],"start": [["12", "13"]],"entity_id": [["T2"]],"Drug": {"text": [["diltiazem"]],"start": [["12", "13"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["other HMG-CoA reductase inhibitors"]],"start": [["51", "52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["between"]],"start": [["42", "43"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "null"}],"Time_elapsed": {"text": [["has been described"]],"start": [["68", "69"]],"entity_id": [["T6"]]},"Disorder": {"text": [["Rhabdomyolysis"]],"start": [["0", "1"]],"entity_id": [["T7"]]},"Freq": {"text": [["resulting"]],"start": [["29", "30"]],"entity_id": [["T8"]]},"Dosage": {"text": [["from the"]],"start": [["40", "41"]],"entity_id": [["T9"]]},"Duration": {"text": [["in the literature"]],"start": [["70", "71"]],"entity_id": [["T10"]]},"Trigger": {"text": [["between"]],"start": [["42", "43"]],"entity_id": [["T5"]]},"Route": {"text": [["from the"]],"start": [["40", "41"]],"entity_id": [["T9"]]}},"Subject": {"text": [["Rhabdomyolysis"]],"start": [["0", "1"]],"entity_id": [["T7"]],"Population": {"text": [["has been described"]],"start": [["68", "69"]],"entity_id": [["T6"]]},"Disorder": {"text": [["Rhabdomyolysis"]],"start": [["0", "1"]],"entity_id": [["T7"]]},"Age": {"text": [["has been described"]],"start": [["68", "69"]],"entity_id": [["T6"]]},"Gender": {"text": [["has been described"]],"start": [["68", "69"]],"entity_id": [["T6"]]},"Race": {"text": [["has been described"]],"start": [["68", "69"]],"entity_id": [["T6"]]}},"Negated": {"text": [["not"]],"start": [["0", "1"]],"entity_id": [["T11"]],"value": false},"Speculated": {"text": [["described"]],"start": [["68", "69"]],"entity_id": [["T6"]],"value": false},"Severity": {"text": [["resulting"]],"start": [["29", "30"]],"entity_id": [["T8"]],"value": "High"},"Effect": {"text": [["Rhabdomyolysis"]],"start": [["0", "1"]],"entity_id": [["T7"]]}}]}
{"id": "18515982_3","context": "Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Diagnosis", "occurred"]],"start": [[ ] , [ ]],"entity_id": [["T1"],["T2"]]},"Subject": {"text": [["this patient"]],"start": [[ ]],"entity_id": [["T3"]],"Disorder": {"text": [["sclerosing glomerulonephritis"]],"start": [[ ]],"entity_id": [["T4"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["anastrozole use"]],"start": [[ ]],"entity_id": [["T5"]],"Drug": {"text": [["anastrozole"]],"start": [[ ]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["a newly defined side effect"]],"start": [[ ]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "582099_1", "context": "A patient with coccidioidal meningitis was treated with intrathetcally administered amphotericin B, and an acute toxic delirium with EEG abnormalities developed", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["amphotericin B"]], "start": [["39"]], "entity_id": [["T2"]]},"Disorder": {"text": [["coccidioidal meningitis"]], "start": [["13"]], "entity_id": [["T1"]]},"Route": {"text": [["intrathecally administered"]], "start": [["24"]], "entity_id": [["T3"]]} ,"Dosage": null, "Duration": null, "Time_elapsed": null, "Freq": null ,"start": [[ "39" ]], "entity_id": [["T2"]] ,"text": [["amphotericin B"]] ,"Trigger": null ,"Combination": null }, "Effect": { "text": [["acute toxic delirium with EEG abnormalities"]], "start": [[ "71" ]], "entity_id": [["T4"]] }, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Trigger": { "text": [["developed"]], "start": [[ "118" ]], "entity_id": [["T5"]] } } ]}
{"id": "18801826_5","context": "This case raises important questions about non-ketotic, hyperosmolar diabetic coma with antipsychotics, the possible association between hyperglycaemia and hyperthermia, and the direction of causality in this, the recognition of either syndrome when they co-exist and management issues in such patients","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["non-ketotic, hyperosmolar diabetic coma"]],"start": [["18","23"]],"entity_id": [ ]},"Treatment": {"text": [["antipsychotics"]],"start": [["61","67"]],"entity_id": [ ] ,"Drug": {"text": [["antipsychotics"]],"start": [["61","67"]],"entity_id": [ ]} ,"Disorder": {"text": [["non-ketotic, hyperosmolar diabetic coma"]],"start": [["18","23"]],"entity_id": [ ]} ,"Freq": {"text": [["the possible association"]],"start": [["40","56"]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["antipsychotics"]],"start": [["61","67"]],"entity_id": [ ]},"Trigger": {"text": [["hyperglycaemia"]],"start": [["100","108"]],"entity_id": [ ]} ,"event_id": "E2" ,"event_type": "Adverse_event"} ] ,"Time_elapsed": {"text": [["and the direction of causality in this"]],"start": [["91","105"]],"entity_id": [ ]} ,"Trigger": {"text": [["hyperthermia"]],"start": [["57","63"]],"entity_id": [ ]} ,"Route": {"text": [["the recognition"]],"start": [["134","141"]],"entity_id": [ ]} ,"Duration": {"text": [["management issues"]],"start": [["164","175"]],"entity_id": [ ]} ,"Dosage": {"text": [["important questions"]],"start": [["0","14"]],"entity_id": [ ]}} , "Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "267281_1","context": "A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["treated with busulphan"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["busulphan"]],"start": [["17"]],"entity_id": [["T2"]],"Dosage": {"text": [["4-5 years"]],"start": [["26"]],"entity_id": [["T3"]]},"Duration": {"text": [["4-5 years"]],"start": [["26"]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic myeloid leukaemia"]],"start": [["6"]],"entity_id": [["T4"]]},"Drug": {"text": [["busulphan"]],"start": [["17"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["developed"]],"start": [["63"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice"]],"start": [["63"]],"entity_id": [["T6"]]},"Freq": {"text": [["4-5 years"]],"start": [["26"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["busulphan"]],"start": [["17"]],"entity_id": [["T2"]]},"Trigger": {"text": [["developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice"]],"start": [["63"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"}],"Route": {"text": [["treated with busulphan"]],"start": [["17"]],"entity_id": [["T1"]]}},"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T0"]]},"Disorder": {"text": [["chronic myeloid leukaemia"]],"start": [["6"]],"entity_id": [["T4"]]},"Gender": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T0"]]},"Population": {"text": [["1"]],"start": [[""], []],"entity_id": [["T0"]]},"Race": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T0"]]}},"Severity": {"text": [["developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice"]],"start": [["63"]],"entity_id": [["T6"]],"value": "high"},"Negated": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T0"]],"value": false},"Speculated": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T0"]],"value": false},"Effect": {"text": [["portal hypertension with ascites, oesophageal varices and jaundice"]],"start": [["72"]],"entity_id": [["T7"]]}}]}
{"id": "8445549_2","context": "Pemphigus vulgaris precipitated by glibenclamide therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pemphigus vulgaris"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["glibenclamide therapy"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["glibenclamide"]],"start": [[ ]],"entity_id": []} ,"Disorder": {"text": [["Pemphigus vulgaris"]],"start": [[ ]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": []} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "3804181_1", "context": "Methimazole-associated cholestatic liver injury: case report and brief literature review", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Methimazole"]], "start": [[ "7" ]], "entity_id": [ ["T1"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["cholestatic liver injury"]], "start": [[ "33" ]], "entity_id": [ ["T2"] ]} },"Treatment": {"text": [["Methimazole"]], "start": [[ "7" ]], "entity_id": [ ["T1"] ],"Drug": {"text": [["Methimazole"]], "start": [[ "7" ]], "entity_id": [ ["T1"] ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Disorder": { "text": [["cholestatic liver injury"]], "start": [[ "33" ]], "entity_id": [ ["T2"] ]} ,"Combination": null }, "Effect": { "text": [["cholestatic liver injury"]], "start": [[ "33" ]], "entity_id": [ ["T2"] ]} ,"Negated": null, "Speculated": null, "Severity": null ,"Trigger": null }]}
{"id": "2452936_2","context": "The most likely cause of such hyponatremic episode is vinblastine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["vinblastine"]],"start": [["32"]],"entity_id": [["T1"]] ,"Drug": {"text": [["vinblastine"]],"start": [["32"]],"entity_id": [["T2"]] }, "Disorder": {"text": [["such hyponatremic episode"]],"start": [["12"]],"entity_id": [["T3"]] }, "Trigger": {"text": [["most likely cause"]],"start": [["0"]],"entity_id": [["T4"]] }, "Time_elapsed": null,"Dosage": null,"Duration": null,"Route": null,"Freq": null ,"Combination": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [["such hyponatremic episode"]], "start": [["12"]], "entity_id": [["T3"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Trigger": null }] }
{"id": "15770343_1","context": "Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["development"]],"start": [["31"]],"entity_id": []},"Treatment": {"text": [["Anti-tuberculous drugs"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["ethambutol"]],"start": [["72"]],"entity_id": []},"Disorder": {"text": [["optic neuritis"]],"start": [["42"]],"entity_id": []},"Time_elapsed": {"text": [["2nd day"]],"start": [["18"]],"entity_id": []},"Trigger": {"text": [["administration"]],"start": [["65"]],"entity_id": []},"Route": {"text": [["at another hospital"]],"start": [["98"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "21751692_5", "context": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["low-dose ketamine added to propofol"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ],"Drug": { "text": [["low-dose ketamine"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ]},"Disorder": { "text": [["prevention of EA"]], "start": [[ "55" ]], "entity_id": [ ["T3"] ]},"Dosage": { "text": [["low-dose"]], "start": [[ "0" ]], "entity_id": [ ["T4"] ]},"Route": { "text": [["added to propofol"]], "start": [[ "19" ]], "entity_id": [ ["T5"] ]} ,"Duration": { "text": [["low-dose"]], "start": [[ "0" ]], "entity_id": [ ["T4"] ]} ,"Time_elapsed": null ,"Freq": null ,"Combination": null ,"Trigger": null },"Subject": {"text": [["children with a history of EA with propofol TIVA"]], "start": [[ "70" ]], "entity_id": [ ["T6"] ],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": { "text": [["EA"]], "start": [[ "91" ]], "entity_id": [ ["T7"] ]} }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "8903300_2", "context": "Tetany in a child with AIDS receiving intravenous tobramycin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Tetany"]], "start": [[ ]], "entity_id": [["T1"]]}, "Subject": {"text": [["a child"]], "start": [[ ]], "entity_id": [["T2"]], "Age": {"text": [["child"]], "start": [[ ]], "entity_id": [["T2"]]}, "Disorder": {"text": [["AIDS"]], "start": [[ ]], "entity_id": [["T3"]]} , "Population": {"text": [["a child"]], "start": [[ ]], "entity_id": [["T2"]]} , "Race": {"text": [], "start": [], "entity_id": []} , "Gender": {"text": [], "start": [], "entity_id": []} }, "Treatment": {"text": [["intravenous tobramycin"]], "start": [[ ]], "entity_id": [["T4"]], "Drug": {"text": [["tobramycin"]], "start": [[ ]], "entity_id": [["T6"]]} , "Dosage": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [["intravenous"]], "start": [[ ]], "entity_id": [["T5"]]}, "Duration": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["AIDS"]], "start": [[ ]], "entity_id": [["T3"]]} , "Time_elapsed": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": {"text": [], "start": [], "entity_id": []} }, "Effect": {"text": [["Tetany"]], "start": [[ ]], "entity_id": [["T1"]]} , "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "10458196_5", "context": "To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["topical brimonidine"]], "start": [["13"]], "entity_id": []}, "Effect": {"text": [["central nervous system depression and unresponsiveness"]], "start": [["52"]], "entity_id": []}, "Subject": {"text": [["an infant"]], "start": [["92"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}} , "Severity": {"text": [], "start": [], "entity_id": [],"value": "high" } , "Negated": {"text": [], "start": [], "entity_id": [],"value": false } , "Speculated": {"text": [], "start": [], "entity_id": [],"value": false } , "Treatment": { "text": [], "start": [], "entity_id": [] ,"Drug": {"text": [], "start": [], "entity_id": []} ,"Disorder": {"text": [], "start": [], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Trigger": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Combination": [] } }]}
{"id": "16225183_2", "context": "Interferon beta has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Interferon beta"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]],"Disorder": { "text": [["reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS)" ]], "start": [[ "43" ]], "entity_id": [ ["T2" ]] } ,"Drug": { "text": [["Interferon beta"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] } ,"Trigger": { "text": [["standard therapy"]], "start": [[ "33" ]], "entity_id": [ ["T3" ]] } ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null ,"Trigger": { "text": [["standard therapy"]], "start": [[ "33" ]], "entity_id": [ ["T3" ]] } }]}
{"id": "10099659_7","context": "Cancer patients who are receiving 5-FU treatment and are DPD deficient can develop severe side effects","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["develop"]],"start": [["58"]],"entity_id": []},"Treatment": {"text": [["5-FU treatment"]],"start": [["24"]],"entity_id": [],"Disorder": {"text": [["Cancer"]],"start": [["0"]],"entity_id": []},"Drug": {"text": [["5-FU"]],"start": [["24"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Dosage": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["Cancer patients"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Cancer"]],"start": [["0"]],"entity_id": []}},"Effect": {"text": [["severe side effects"]],"start": [["71"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}}]}
{"id": "876914_1","context": "A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["poorly differentiated sarcoma"]],"start": [["27"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cyclophosphamide"]],"start": [["91"]],"entity_id": [["T2"]],"Drug": {"text": [["cyclophosphamide"]],"start": [["91"]],"entity_id": [["T3"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["51"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after"]],"start": [["82"]],"entity_id": [["T5"]]},"Trigger": {"text": [["was used"]],"start": [["85"]],"entity_id": [["T6"]]},"Dosage": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Duration": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Route": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Freq": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Combination": null},"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Gender": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["not provided"]],"start": [["not provided"]],"entity_id": [["not provided"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["43"]],"entity_id": [["T4"]]}},"Effect": {"text": [["developed"]],"start": [["20"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["poorly differentiated sarcoma"]],"start": [["27"]],"entity_id": [["T1"]],"value": "high"}}]}
{"id": "7606071_7","context": "We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating anaphylactoid reactions with cisplatin","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["5 reactions"]],"start": [["0"]],"entity_id": []},"Subject": {"text": [["3 patients"]],"start": [["23"]],"entity_id": [] ,"Population": {"text": [["3 patients"]],"start": [["23"]],"entity_id": []} ,"Disorder": {"text": [["anaphylactoid reactions"]],"start": [["73"]],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [],"start": [],"entity_id": [] ,"Drug": {"text": [["cisplatin"]],"start": [["112"]],"entity_id": []} ,"Dosage": {"text": [["high dose"]],"start": [["15"]],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [["high dose-infusion time ratio"]],"start": [["29"]],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} }]}
{"id": "6460590_1","context": "One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acrodermatitis enteropathica"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["administration of clioquinol"]],"start": [["92"]],"entity_id": [["T2"]],"Drug": {"text": [["clioquinol"]],"start": [["92"]],"entity_id": [["T3"]]},"Freq": {"text": [["very high frequency"]],"start": [["59"]],"entity_id": [["T4"]]},"Disorder": {"text": [["SMON"]],"start": [["1"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["association"]],"start": [["65"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["clioquinol"]],"start": [["92"]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [["92"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["administration"]],"start": [["92"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["SMON"]],"start": [["1"]],"entity_id": [["T5"]]}}}]}
{"id": "8949576_3", "context": "We report a case of amiodarone-induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions.', " , "is_mult_event": false, "annotations": [{ "event_id": "E1", "event_type": "Adverse_event", "Treatment": { "text": [["amiodarone"]], "start": [["9"]], "entity_id": [["T1"]], "Drug": { "text": [["amiodarone"]], "start": [["9"]], "entity_id": [["T2"]] }, "Duration": { "text": [["protracted duration"]], "start": [["31"]], "entity_id": [["T3"]] } , "Disorder": { "text": [["thyrotoxicosis"]], "start": [["13"]], "entity_id": [["T4"]] } , "Trigger": { "text": [["severe adverse drug reactions"]], "start": [["89"]], "entity_id": [["T5"]] } , "Freq": { "text": [["unresponsive"]], "start": [["61"]], "entity_id": [["T6"]] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Combination": null } , "Effect": null , "Negated": null , "Speculated": null , "Severity": { "text": [], "start": [], "entity_id": [] , "value": "severe" } , "Subject": { "text": [["We"]], "start": [["0"]], "entity_id": [["T0"]], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } , "Trigger": null }]}
{"id": "19151423_3","context": "The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["the development of rhabdomyolysis"]],"start": [["39"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the addition of ciprofloxacin to chronic simvastatin therapy"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["ciprofloxacin"]],"start": [["17"]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic simvastatin therapy"]],"start": [["25"]],"entity_id": [["T4"]]} , "Route": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": null } , "Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": { "text": [], "start": [], "entity_id": [] , "value": "High" }, "Subject": null } ] }
{"id": "941054_1", "context": "Nephropathy caused by methicillin therapy for staphylococcal septicemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Nephropathy"]], "start": [[ "start" ], [ "Nephropathy" ]],"entity_id": [ ["T1"] ]}, "Treatment": {"text": [["methicillin therapy"]], "start": [[ "start" ], [ "methicillin therapy" ]],"entity_id": [ ["T2"] ],"Disorder": {"text": [["staphylococcal septicemia"]], "start": [[ "start" ], [ "staphylococcal septicemia" ]],"entity_id": [ ["T3"] ]},"Drug": {"text": [["methicillin"]], "start": [[ "start" ], [ "methicillin" ]],"entity_id": [ ["T4"] ]},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Combination": [] ,"Trigger": null },"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null }]}
{"id": "16637972_1","context": "A 65-year-old man on warfarin therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["warfarin therapy"]],"start": [[ "24" ]] ,"entity_id": [ ]},"Treatment": {"text": [["warfarin"]],"start": [[ "24" ]],"entity_id": [ ],"Drug": {"text": [["warfarin"]],"start": [[ "24" ]],"entity_id": [ ]},"Disorder": {"text": [["sub-conjunctival haematoma associated with bloody tears"]],"start": [[ "40" ]],"entity_id": [ ]},"Trigger": {"text": [["sub-conjunctival haematoma associated with bloody tears"]],"start": [[ "40" ]],"entity_id": [ ]},"Freq": {"text": [["sudden spontaneous onset"]],"start": [[ "32" ]],"entity_id": [ ]},"Route": {"text": [["therapy"]],"start": [[ "24" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["following a referral from an optometrist"]],"start": [[ "101" ]],"entity_id": [ ]},"Duration": {"text": [["on warfarin therapy"]],"start": [[ "24" ]],"entity_id": [ ]},"Dosage": {"text": [["warfarin"]],"start": [[ "24" ]],"entity_id": [ ]},"Combination": null},"Subject": {"Age": {"text": [["A 65-year-old man"]],"start": [[ "1" ]],"entity_id": [ ]},"Gender": {"text": [["man"]],"start": [[ "13" ]],"entity_id": [ ]},"Disorder": {"text": [["sub-conjunctival haematoma associated with bloody tears"]],"start": [[ "40" ]],"entity_id": [ ]},"Population": null,"Race": null,"text": [["A 65-year-old man"]],"start": [[ "1" ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["sub-conjunctival haematoma associated with bloody tears"]],"start": [[ "40" ]],"entity_id": [ ]}}]}
{"id": "11749112_2","context": "This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["development"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["psychiatric patient"]],"start": [[ "28" ]],"entity_id": [ ["T2"] ],"Disorder": {"text": [["bipolar disorder"]],"start": [[ "54" ]],"entity_id": [ ["T3"] ]} ,"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["tiagabine treatment"]],"start": [[ "102" ]],"entity_id": [ ["T4"] ],"Drug": {"text": [["tiagabine"]],"start": [[ "102" ]],"entity_id": [ ["T5"] ]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["bipolar disorder"]],"start": [[ "54" ]],"entity_id": [ ["T3"] ]} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["asymptomatic visual field defects (VFDs)"]],"start": [[ "48" ]],"entity_id": [ ["T6"] ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "7436161_1","context": "Cardiorespiratory toxicity due to miconazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cardiorespiratory toxicity"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["miconazole"]],"start": [[ ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["miconazole"]],"start": [[ ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Cardiorespiratory toxicity"]],"start": [[ ]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["miconazole"]],"start": [[ ]],"entity_id": [ ["T2"] ]} },"Effect": {"text": [["Cardiorespiratory toxicity"]],"start": [[ ]],"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "9220046_5","context": "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Lovastatin-induced rhabdomyolysis"]],"start": [[ "0"]] ,"entity_id": [ ["T1"]]},"Treatment": {"text": [["Lovastatin"]],"start": [[ "0"]] ,"entity_id": [ ["T2"]],"Drug": {"text": [["Lovastatin"]],"start": [[ "0"]] ,"entity_id": [ ["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [[ "54"]] ,"entity_id": [ ["T3"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "E2","event_type": "Adverse_event"},{"Drug": {"text": [["azithromycin"]],"start": [[ "63"]] ,"entity_id": [ ["T4"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "E3","event_type": "Adverse_event"}],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": true},"Severity": {"text": [],"start": [],"entity_id": [],"value": "Medium"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "19789166_2", "context": "Nitrofurantoin-induced acute liver damage in pregnancy", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Nitrofurantoin-induced acute liver damage"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Subject": {"text": [["pregnancy"]], "start": [[ "59" ]], "entity_id": [ ["T2"] ] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null}, "Treatment": {"text": [["Nitrofurantoin"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ] ,"Drug": {"text": [["Nitrofurantoin"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ]} ,"Disorder": {"text": [["acute liver damage"]], "start": [[ "13" ]], "entity_id": [ ["T1"] ]} ,"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Combination": null , "Trigger": null} ,"Effect": {"text": [["acute liver damage"]], "start": [[ "13" ]], "entity_id": [ ["T1"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "12656748_1","context": "A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr." ,"is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["hydroxyurea"]],"start": [["36"]],"entity_id": [["T1"]] ,"Drug": {"text": [["hydroxyurea"]],"start": [["36"]],"entity_id": [["T2"]] },"Duration": {"text": [["18 yr"]],"start": [["55"]],"entity_id": [["T3"]] },"Disorder": {"text": [["essential thrombocythaemia (ET)"]],"start": [["14"]],"entity_id": [["T4"]] },"Trigger": {"text": [["treatment"]],"start": [["30"]],"entity_id": [["T5"]] },"Route": {"text": [["uneventful"]],"start": [["42"]],"entity_id": [["T6"]] },"Time_elapsed": {"text": [["continuous"]],"start": [["36"]],"entity_id": [["T7"]] } ,"Freq": {"text": [["continuous"]],"start": [["36"]],"entity_id": [["T8"]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Combination": [{"Drug": {"text": [["hydroxyurea"]],"start": [["36"]],"entity_id": [["T2"]] },"Trigger": {"text": [["treatment"]],"start": [["30"]],"entity_id": [["T5"]] },"event_id": "C1" ,"event_type": "Combination" } ]} ,"Effect": {"text": [["developed"]],"start": [["10"]],"entity_id": [["T9"]] },"Trigger": {"text": [["developed"]],"start": [["10"]],"entity_id": [["T10"]] },"Subject": {"text": [["patient"]],"start": [["8"]],"entity_id": [["T11"]] ,"Age": {"text": [["58-yr-old"]],"start": [["8"]],"entity_id": [["T12"]] },"Gender": {"text": [["male"]],"start": [["12"]],"entity_id": [["T13"]] },"Race": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["essential thrombocythaemia (ET)"]],"start": [["14"]],"entity_id": [["T4"]] }},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "unknown" }} ]}
{"id": "8862924_1", "context": "Keratitis in methamphetamine abusers", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Keratitis"]], "start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["methamphetamine"]], "start": [[ ]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["Keratitis"]], "start": [[ ]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Subject": {"text": [["methamphetamine abusers"]], "start": [[ ]],"entity_id": [["T3"]],"Age": null,"Gender": null,"Population": {"text": [["abusers"]], "start": [[ ]],"entity_id": [["T3"]]},"Race": null,"Disorder": null},"Effect": {"text": [["Keratitis"]], "start": [[ ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8197046_1", "context": "Central nervous system toxicity associated with meperidine use in hepatic disease", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Central nervous system toxicity"]], "start": [[ ]],"entity_id": [["T1"]]}, "Treatment": {"text": [["meperidine use"]], "start": [[ ]],"entity_id": [["T2"]], "Drug": {"text": [["meperidine"]], "start": [[ ]], "entity_id": [["T3"]] },"Route": {"text": [["use"]], "start": [[ ]], "entity_id": [["T4"]] },"Disorder": {"text": [["hepatic disease"]], "start": [[ ]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["associated with"]], "start": [[ ]], "entity_id": [["T6"]]}, "Dosage": null, "Duration": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "12066972_2", "context": "To our knowledge, this case is the first published report of levofloxacin-induced TEN", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["levofloxacin"]], "start": [["33"]], "entity_id": [["T1"]]},"Disorder": {"text": [["TEN"]], "start": [["53"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "text": [["levofloxacin"]], "start": [["33"]], "entity_id": [["T1"]], "Trigger": {"text": [["induced"]], "start": [["44"]], "entity_id": [["T3"]]}},"Effect": {"text": [["TEN"]], "start": [["53"]], "entity_id": [["T2"]]}, "Trigger": {"text": [["induced"]], "start": [["44"]], "entity_id": [["T3"]]}}]}
{"id": "19423610_9", "context": "Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Methylene blue"]], "start": [[ ]], "entity_id":[ ["T1"]] ,"Disorder" : { "text" : [["various types of hypotensive shock"]], "start" : [[ "start" ], ["start" ]], "entity_id" : [[ "T2" ], ["T3" ]] }, "Dosage" : { "text" : [["a variety of surgical settings"]], "start" : [[ "start" ]], "entity_id" : [[ "T4" ]] }, "Duration" : { "text" : [], "start" : [], "entity_id" : [] }, "Trigger" : { "text" : [], "start" : [], "entity_id" : [] }, "Route" : { "text" : [], "start" : [], "entity_id" : [] }, "Time_elapsed" : { "text" : [], "start" : [], "entity_id" : [] }, "Freq" : { "text" : [], "start" : [], "entity_id" : [] }, "Drug" : { "text" : [["Methylene blue"]], "start" : [[ "start" ]], "entity_id" : [[ "T1" ]] }, "Combination" : null }, "Effect" : null ,"Negated" : null ,"Speculated" : null ,"Severity" : null ,"Subject" : null ,"Trigger" : null }]}
{"id": "9554064_1","context": "Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Methanol toxicity"]],"start": [[ "0"]],"entity_id": [ ]} ,"Effect": {"text": [["severe central nervous system insult"]],"start": [[ "47"]],"entity_id": [ ]} ,"Negated": null,"Speculated": null ,"Severity": {"text": [["severe"]],"start": [[ "47"]],"entity_id": [ ],"value": "high" } ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null } ,"Treatment": null}]}
{"id": "11737689_5","context": "We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["skin eruptions"]],"start": [["these skin eruptions" , "these skin eruptions" ] , [ "these skin eruptions" ]] , "entity_id": [ ["T1" ]] } , "Treatment": {"text": [["G-CSF therapy"]],"start": [[ "G-CSF therapy" ]] , "entity_id": [ ["T2" ]] ,"Drug": { "text": [["G-CSF"]], "start": [[ "G-CSF" ]], "entity_id": [ ["T3" ]] },"Disorder": { "text": [["spectrum of neutrophilic dermatoses"]], "start": [[ "spectrum of neutrophilic dermatoses" ]], "entity_id": [ ["T4" ]] },"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Trigger": null ,"Combination": null },"Effect": null ,"Subject": { "text": [["We believe"]], "start": [[ "We believe" ]], "entity_id": [ ["T0" ]] ,"Age": null ,"Disorder": null ,"Gender": null ,"Population": null ,"Race": null },"Negated": null ,"Speculated": { "text": [["believe"]], "start": [[ "believe" ]], "entity_id": [ ["T0" ]] ,"value": true },"Severity": null }] }
{"id": "2595431_4","context": "We have reported six cases of metoclopramide-induced parkinsonism seen in consultation over a two-year period","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["metoclopramide-induced parkinsonism"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["metoclopramide"]],"start": [["33"]],"entity_id": [ ["T2"]],"Drug": {"text": [["metoclopramide"]],"start": [["33"]],"entity_id": [ ["T2"]]},"Dosage": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Route": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Freq": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Duration": {"text": [["over a two-year period"]],"start": [["52"]],"entity_id": [ ["T3"]]},"Disorder": {"text": [["parkinsonism"]],"start": [["20"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Combination": null,"Trigger": {"text": [["seen in consultation"]],"start": [["44"]],"entity_id": [ ["T5"]]}},"Subject": {"text": [["We"]],"start": [[""], [""]],"entity_id": [[""], [""]],"Age": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Gender": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Population": {"text": [["six cases"]],"start": [["7"]],"entity_id": [ ["T6"]]},"Race": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Disorder": {"text": [["not specified"]],"start": [[""], [""]],"entity_id": [[""], [""]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10656221_1", "context": "Gliclazide-induced acute hepatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Gliclazide-induced"]], "start": [[],[ "start" ]] , "entity_id": [["T1"]]}, "Treatment": {"text": [["Gliclazide"]], "start": [[],[ "start" ]] , "entity_id": [["T2"]],"Drug": {"text": [["Gliclazide"]], "start": [[],[ "start" ]] , "entity_id": [["T2"]]},"Disorder": {"text": [["acute hepatitis"]], "start": [[],[ "start" ]] , "entity_id": [["T3"]]},"Time_elapsed": {"text": [["induced"]], "start": [[],[ "start" ]] , "entity_id": [["T1"]]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null,"Trigger": null} ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null}]}
{"id": "8435665_1","context": "A 16-year-old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation. ","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["eosinophilia myalgia syndrome"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["total parenteral nutritional support with solutions containing tryptophan"]],"start": [["15"]],"entity_id": [["T2"]],"Drug": {"text": [["tryptophan"]],"start": [["53"]],"entity_id": [["T3"]]},"Route": {"text": [["total parenteral nutritional support"]],"start": [["15"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["developed evidence"]],"start": [["35"]],"entity_id": [["T5"]]},"Disorder": {"text": [["acute biphenotypic leukemia"]],"start": [["7"]],"entity_id": [["T6"]]},"Duration": {"text": [["during his initial induction chemotherapy and also after autologous marrow transplantation"]],"start": [["68"]],"entity_id": [["T7"]]},"Freq": {"text": [["total parenteral nutritional support with solutions containing tryptophan"]],"start": [["15"]],"entity_id": [["T2"]]},"Trigger": {"text": [["total parenteral nutritional support with solutions containing tryptophan"]],"start": [["15"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["tryptophan"]],"start": [["53"]],"entity_id": [["T3"]]},"Trigger": {"text": [["total parenteral nutritional support with solutions containing tryptophan"]],"start": [["15"]],"entity_id": [["T2"]]},"event_type": "Adverse_event","event_id": "E2"}],"Dosage": {"text": [["total parenteral nutritional support with solutions containing tryptophan"]],"start": [["15"]],"entity_id": [["T2"]]}},"Subject": {"text": [["A 16-year-old white male"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [["16"]],"start": [["1"]],"entity_id": [["T9"]]},"Gender": {"text": [["male"]],"start": [["12"]],"entity_id": [["T10"]]},"Race": {"text": [["white"]],"start": [["10"]],"entity_id": [["T11"]]},"Disorder": {"text": [["acute biphenotypic leukemia"]],"start": [["7"]],"entity_id": [["T6"]]},"Population": {"text": [["A 16-year-old white male"]],"start": [["0"]],"entity_id": [["T8"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["eosinophilia myalgia syndrome"]],"start": [["35"]],"entity_id": [["T1"]],"value": "high severity"},"Effect": {"text": [["eosinophilia myalgia syndrome"]],"start": [["35"]],"entity_id": [["T1"]]}}]}
{"id": "16268429_2","context": "Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Subacute cholestatic hepatitis"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["senna"]],"start": [[]],"entity_id": [],"Disorder": {"text": [["chronic constipation"]],"start": [[]],"entity_id": []},"Dosage": {"text": [["null"]],"start": [[]],"entity_id": []},"Duration": {"text": [["null"]],"start": [[]],"entity_id": []},"Route": {"text": [["null"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [["null"]],"start": [[]],"entity_id": []},"Freq": {"text": [["null"]],"start": [[]],"entity_id": []},"Combination": [{"Drug": {"text": [["senna"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["use"]],"start": [[]],"entity_id": []},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["null"]],"start": [[]],"entity_id": []},"Drug": {"text": [["null"]],"start": [[]],"entity_id": []}},"Effect": {"text": [["Subacute cholestatic hepatitis"]],"start": [[]],"entity_id": []},"Subject": {"text": [["null"]],"start": [[]],"entity_id": [],"Age": {"text": [["null"]],"start": [[]],"entity_id": []},"Gender": {"text": [["null"]],"start": [[]],"entity_id": []},"Population": {"text": [["null"]],"start": [[]],"entity_id": []},"Race": {"text": [["null"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["chronic constipation"]],"start": [[]],"entity_id": []}},"Negated": {"text": [["null"]],"start": [[]],"entity_id": [],"value": false},"Speculated": {"text": [["likely related"]],"start": [[]],"entity_id": [],"value": true},"Severity": {"text": [["null"]],"start": [[]],"entity_id": [],"value": "low"}}]}
{"id": "19363904_2","context": "We report a case of an 11-year-old boy who experienced an anaphylactic reaction after administration of bacitracin ointment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anaphylactic reaction"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["an 11-year-old boy"]],"start": [["14"]],"entity_id": [["T2"]],"Age": {"text": [["11"]],"start": [["18"]],"entity_id": [["T3"]]},"Gender": {"text": [["boy"]],"start": [["21"]],"entity_id": [["T4"]]},"Population": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T5"]]},"Race": {"text": [["boy"]],"start": [["21"]],"entity_id": [["T4"]]},"Disorder": {"text": [["anaphylactic reaction"]],"start": [["33"]],"entity_id": [["T1"]]}},"Treatment": {"text": [["bacitracin ointment"]],"start": [["75"]],"entity_id": [["T6"]],"Drug": {"text": [["bacitracin"]],"start": [["75"]],"entity_id": [["T7"]]},"Disorder": {"text": [["anaphylactic reaction"]],"start": [["33"]],"entity_id": [["T1"]]},"Route": {"text": [["administration"]],"start": [["62"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [["after"]],"start": [["67"]],"entity_id": [["T9"]]},"Freq": {"text": [["administration"]],"start": [["62"]],"entity_id": [["T8"]]},"Dosage": {"text": [["bacitracin ointment"]],"start": [["75"]],"entity_id": [["T6"]]},"Duration": {"text": [["case"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": null,"Trigger": null},"Effect": {"text": [["anaphylactic reaction"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["anaphylactic reaction"]],"start": [["33"]],"entity_id": [["T1"]],"value": "High"}}]}
{"id": "15661067_2","context": "The patient was found to have no motile sperm with a normal sperm count, while taking a dose of 400 mg/day of carbamazepine","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["carbamazepine"]],"start": [["82"]],"entity_id": [["T1"]],"Dosage": {"text": [["400 mg/day"]],"start": [["72"]],"entity_id": [["T2"]]} ,"Route": {"text": [["while taking"]],"start": [["67"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["no motile sperm with a normal sperm count"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["while taking"]],"start": [["67"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["taking a dose"]],"start": [["67"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["day"]],"start": [["79"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["taking a dose"]],"start": [["67"]],"entity_id": [["T3"]]},"Drug": {"text": [["carbamazepine"]],"start": [["82"]],"entity_id": [["T1"]]} ,"Combination": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "990658_2","context": "A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["fatal pancytopenia"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["a patient"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ],"Disorder": {"text": [["an history of depression with hypomanic rebounds"]],"start": [[ "22" ]],"entity_id": [ ["T3"] ]} ,"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["levomepromazine", "diazepam", "lithium carbonate"]],"start": [[ "92" ]],"entity_id": [ ["T4","T5","T6"] ],"Drug": {"text": [["levomepromazine", "diazepam", "lithium carbonate"]],"start": [[ "92" ]],"entity_id": [ ["T4","T5","T6"] ]},"Dosage": null,"Duration": null,"Disorder": {"text": [["a manic episode"]],"start": [[ "74" ]],"entity_id": [ ["T7"] ]},"Freq": null,"Route": null,"Time_elapsed": null ,"Trigger": null ,"Combination": null }, "Negated": null ,"Speculated": null ,"Severity": { "text": [["fatal"]], "start": [[ "1" ]], "entity_id": [ ["T0"] ], "value": "fatal" }, "Effect": { "text": [["fatal pancytopenia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} }] }
{"id": "15133245_2", "context": "Oxatomide is an antiallergic drug used for the treatment of diseases mediated by type I allergy", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Oxatomide"]],"start": [[ ]] ,"entity_id": []},"text": [["used"]],"start": [[ ]] ,"entity_id": [],"Time_elapsed": {"text": [["treatment"]],"start": [[ ]] ,"entity_id": []},"Disorder": {"text": [["the treatment of diseases mediated by type I allergy"]],"start": [[ ]] ,"entity_id": []},"Trigger": {"text": [["used"]],"start": [[ ]] ,"entity_id": []},"Dosage": {"text": [["an"]],"start": [[ ]] ,"entity_id": []},"Duration": {"text": [["treatment"]],"start": [[ ]] ,"entity_id": []},"Route": {"text": [["used"]],"start": [[ ]] ,"entity_id": []},"Freq": {"text": [["used"]],"start": [[ ]] ,"entity_id": []},"Combination": null},"Effect": null,"Subject": {"text": [["Oxatomide"]],"start": [[ ]] ,"entity_id": [],"Age": null,"Population": null,"Race": null,"Disorder": null,"Gender": null},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "17381671_9","context": "A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.CASE SUMMARY","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["65-year-old patient"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["65-year-old"]],"start": [["0"]],"entity_id": [["A1"]]},"Disorder": {"text": [["citalopram treated"]],"start": [["16"]],"entity_id": [["D1"]]},"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["fentanyl"]],"start": [["146"]],"entity_id": [["T2"]],"Drug": {"text": [["fentanyl"]],"start": [["146"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["citalopram"]],"start": [["95"]],"entity_id": [["T1"]]},"Combination": null},"Effect": {"text": [["confusion","agitation","tachycardia","tremors","myoclonic jerks","unsteady gait","serotonin syndrome"]],"start": [[ "35","38","45","53","61","70","81"]],"entity_id": [["E1"]]},"Trigger": {"text": [["initiation"]],"start": [["118"]],"entity_id": [["T4"]]}}]}
{"id": "3941210_2", "context": "Such a case induced by hypothyroidism complicating long-term therapy with amiodarone in a 45 year old woman with pre-excitation is presented", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["a 45 year old woman"]],"start": [["36"]],"entity_id": [["S1"]],"Age": {"text": [["45"]],"start": [["36"]],"entity_id": [["A1"]]},"Gender": {"text": [["woman"]],"start": [["42"]],"entity_id": [["G1"]]} ,"Disorder": {"text": [["hypothyroidism"]],"start": [["16"]],"entity_id": [["D1"]]} ,"Population": null ,"Race": null }, "Treatment": {"text": [["long-term therapy with amiodarone"]],"start": [["54"]],"entity_id": [["T1"]],"Drug": {"text": [["amiodarone"]],"start": [["62"]],"entity_id": [["D2"]]},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Trigger": {"text": [["complicating"]],"start": [["28"]],"entity_id": [["T2"]]} ,"Combination": null }, "Effect": {"text": [["induced"]],"start": [["9"]],"entity_id": [["E2"]]} ,"Trigger": {"text": [["case"]],"start": [["0"]],"entity_id": [["C1"]]} }] }
{"id": "2935070_4","context": "The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rapid onset of renal failure"]],"start": [[ "0" ]],"entity_id": [[ "T1" ]]},"Treatment": {"text": [["ampicillin"]],"start": [[ "125" ]],"entity_id": [[ "T2" ]] ,"Drug": {"text": [["ampicillin"]],"start": [[ "125" ]],"entity_id": [[ "T2" ]]},"Disorder": {"text": [["renal failure"]],"start": [[ "11" ]],"entity_id": [[ "T3" ]]} ,"Time_elapsed": {"text": [["following the administration"]],"start": [[ "87" ]],"entity_id": [[ "T4" ]]} ,"Trigger": {"text": [["following the administration"]],"start": [[ "87" ]],"entity_id": [[ "T4" ]]} ,"Route": {"text": [["administration"]],"start": [[ "108" ]],"entity_id": [[ "T5" ]]} ,"Combination": [{"Drug": {"text": [["ampicillin"]],"start": [[ "125" ]],"entity_id": [[ "T2" ]]} ,"Trigger": {"text": [["following the administration"]],"start": [[ "87" ]],"entity_id": [[ "T4" ]]} ,"event_id": "E1" ,"event_type": "Adverse_event" }] ,"Freq": {"text": [["following the administration"]],"start": [[ "87" ]],"entity_id": [[ "T4" ]]} ,"Duration": {"text": [["rapid onset"]],"start": [[ "0" ]],"entity_id": [[ "T1" ]]} ,"Dosage": {"text": [["administration"]],"start": [[ "108" ]],"entity_id": [[ "T5" ]]} },"Effect": {"text": [["renal failure"]],"start": [[ "11" ]],"entity_id": [[ "T3" ]]} ,"Subject": {"text": [["The diagnosis"]],"start": [[ "0" ]],"entity_id": [[ "T0" ] ],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": {"text": [["rapid onset"]],"start": [[ "0" ]],"entity_id": [[ "T1" ] ],"value": "high" }} ]}
{"id": "16008658_1","context": "46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["painful ulcers"]],"start": [["developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis" ]],"entity_id": []},"Subject": {"text": [["46-year-old woman"]],"start": [[], [], [], [], [], []],"Age": {"text": [["46"]],"start": [[], [], [], [], [], []],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[], [], [], [], [], []],"entity_id": []},"Disorder": {"text": [["multiple sclerosis"]],"start": [[], [], [], [], [], []],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"entity_id": []},"Treatment": {"text": [["interferon beta-1b"]],"start": [[], [], [], [], [], []],"Drug": {"text": [["interferon beta-1b"]],"start": [[], [], [], [], [], []],"entity_id": []},"Disorder": {"text": [["multiple sclerosis"]],"start": [[], [], [], [], [], []],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["subcutaneously"]],"start": [[], [], [], [], [], []],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"entity_id": [],"Trigger": {"text": [["after injecting interferon beta-1b subcutaneously for multiple sclerosis"]],"start": [[], [], [], [], [], []],"entity_id": []},"Combination": []},"Effect": {"text": [["painful ulcers"]],"start": [[], [], [], [], [], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12792223_2", "context": "A lupus-like syndrome associated with infliximab therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lupus-like syndrome"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["infliximab therapy"]], "start": [["41"]], "entity_id": [],"Drug": {"text": [["infliximab"]], "start": [["41"]], "entity_id": []},"Disorder": {"text": [["lupus-like syndrome"]], "start": [["0"]], "entity_id": []},"Time_elapsed":{"text":[["associated"]], "start":[["18"]], "entity_id":[]} ,"Duration":{"text":[["-"]], "start":[["41"]], "entity_id":[]} ,"Dosage":{"text":[["-"]], "start":[["41"]], "entity_id":[]} ,"Freq":{"text":[["-"]], "start":[["41"]], "entity_id":[]} ,"Route":{"text":[["-"]], "start":[["41"]], "entity_id":[]} ,"Trigger":{"text":[["associated"]], "start":[["18"]], "entity_id":[]} ,"Combination":null },"Effect":null ,"Negated":null ,"Speculated":null ,"Severity":null ,"Subject":null }]}
{"id": "2669373_1","context": "A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cisplatin and bleomycin-induced TMA"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T2"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["TMA"]],"start": [["42"]],"entity_id": [["T3"]]},"entity_id": [["T1"]],"Trigger": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T2"]]},"text": [["cisplatin"]],"start": [["0"]],"Combination": [{"Drug": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["bleomycin-induced TMA"]],"start": [["25"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Effect": {"text": [["TMA"]],"start": [["42"]],"entity_id": [["T3"]]},"Subject": {"Population": null,"Age": null,"Gender": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10458196_3","context": "Apparent central nervous system depression in infants after the use of topical brimonidine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["central nervous system depression"]],"start": [["21-29"]],"entity_id": []},"Treatment": {"text": [["topical brimonidine"]],"start": [["50-59"]],"entity_id": [],"Drug": {"text": [["brimonidine"]],"start": [["50-59"]],"entity_id": []},"Disorder": {"text": [["depression"]],"start": [["21-29"]],"entity_id": []},"Time_elapsed": {"text": [["after"]],"start": [["42"]],"entity_id": []},"Route": {"text": [["topical"]],"start": [["42-49"]],"entity_id": []},"Trigger": {"text": [["use"]],"start": [["31-34"]],"entity_id": []},"Freq": {"text": [["in infants"]],"start": [["10-18"]],"entity_id": []},"Combination": [],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["depression"]],"start": [["21-29"]],"entity_id": []}}}]}
{"id": "16284443_4", "context": "To our knowledge, this is the first report of insulin-induced lipohypertrophy with detailed histological examinations", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["insulin-induced lipohypertrophy"]], "start": [["28"]], "entity_id": []}, "Treatment": {"text": [["insulin"]], "start": [["4"]], "entity_id": [], "Drug": {"text": [["insulin"]], "start": [["4"]], "entity_id": [] },"Disorder":{"text":[["lipohypertrophy"]],"start":[["28"]],"entity_id":[] },"Route":{"text":[["induced"]],"start":[["22"]],"entity_id":[] },"Duration":{"text":[["first report"]],"start":[["6"]],"entity_id":[] },"Freq":{"text":[["first report"]],"start":[["6"]],"entity_id":[] },"Combination":[{"Drug":{"text":[["insulin"]],"start":[["4"]],"entity_id":[]},"Trigger":{"text":[["induced"]],"start":[["22"]],"entity_id":[]},"event_id":"C1","event_type":"Combination"}],"Time_elapsed":{"text":[["report"]],"start":[["6"]],"entity_id":[]},"Trigger":{"text":[["report"]],"start":[["6"]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]} },"Effect":{"text":[["lipohypertrophy"]],"start":[["28"]],"entity_id":[] },"Subject":{"text":[["our knowledge"]],"start":[["0"]],"entity_id":[],"Population":{"text":[["first report"]],"start":[["6"]],"entity_id":[] },"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]} },"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"low"}}]}
{"id": "19540093_4", "context": "Tigecycline-induced acute pancreatitis: case report and literature review", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Tigecycline"]], "start": [[],[]], "entity_id": [],"Gender": {"text":[["-"]], "start": [[],[]], "entity_id": []}, "Age": {"text":[["-"]], "start": [[],[]], "entity_id": []}, "Population": {"text":[["-"]], "start": [[],[]], "entity_id": []}, "Race": {"text":[["-"]], "start": [[],[]], "entity_id": []}, "Disorder": {"text":[["induced acute pancreatitis"]], "start": [[],[]], "entity_id": []}}, "Treatment": {"text": [["Tigecycline"]], "start": [[],[]], "entity_id": [],"Drug": {"text":[["Tigecycline"]], "start": [[],[]], "entity_id": []},"Dosage": {"text":[["-"]], "start": [[],[]], "entity_id": []},"Duration": {"text":[["-"]], "start": [[],[]], "entity_id": []},"Route": {"text":[["-"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text":[["induced"]], "start": [[],[]], "entity_id": []},"Freq": {"text":[["-"]], "start": [[],[]], "entity_id": []},"Combination": null, "Trigger": {"text": [["Tigecycline-induced acute pancreatitis"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [["acute pancreatitis"]], "start": [[],[]], "entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "7679525_1","context": "Severe bleomycin lung toxicity: reversal with high dose corticosteroids","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Effect": {"text": [["bleomycin lung toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Severity": {"text": [["Severe"]],"start": [["0"]],"entity_id": [["T2"]],"value": "High"},"Negated": null,"Speculated": null,"Trigger": {"text": [["reversal"]],"start": [["45"]],"entity_id": [["T3"]]},"Treatment": {"text": [["high dose corticosteroids"]],"start": [["48"]],"entity_id": [["T4"]],"Drug": {"text": [["corticosteroids"]],"start": [["48"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["high dose"]],"start": [["48"]],"entity_id": [["T6"]]} ,"Time_elapsed": null,"Duration": null ,"Disorder": null ,"Route": null ,"Freq": null ,"Combination": null ,"Trigger": null} ,"Subject": null }] }
{"id": "11918514_1", "context": "Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.","is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["strong efficacy", "good safety"]], "start": [[ "21", "33" ]], "entity_id": [ [ "T1" ], [ "T2" ] ]}, "Treatment": {"text": [["mirtazapine"]], "start": [[ "54" ]], "entity_id": [ [ "T3" ] ], "Drug": {"text": [["mirtazapine"]], "start": [[ "54" ]], "entity_id": [ [ "T4" ] ]}, "Freq": {"text": [["when prescribing this drug"]], "start": [[ "88" ]], "entity_id": [ [ "T5" ] ]}, "Combination": [{"Drug": {"text": [["mirtazapine"]], "start": [[ "54" ]], "entity_id": [ [ "T4" ] ]}, "Trigger": {"text": [["combination"]], "start": [[ "18" ]], "entity_id": [ [ "T0" ] ]}, "event_id": "C1", "event_type": "Adverse_event"}], "Time_elapsed": null, "Duration": null, "Disorder": {"text": [["frail, elderly patients with underlying chronic conditions"]], "start": [[ "114" ]], "entity_id": [ [ "T6" ] ]}, "Dosage": null, "Route": null, "Trigger": null} , "Negated": null, "Speculated": null, "Severity": null , "Subject": { "text": [["clinicians"]], "start": [[ "4" ]], "entity_id": [[ "T7" ]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } , "Effect": null}]}
{"id": "536461_1","context": "Five cases of clindamycin-associated pseudomembranous colitis in leukaemic patients are reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["clindamycin-associated pseudomembranous colitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["Five cases"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["Five cases"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["leukaemic patients"]],"start": [["46"]],"entity_id": [["T2"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["clindamycin"]],"start": [["13"]],"entity_id": [["T3"]],"Drug": {"text": [["clindamycin"]],"start": [["13"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Disorder": { "text": [["leukaemic patients"]], "start": [["46"]], "entity_id": [["T2"]] }} ,"Negated": { "value": false ,"text": [], "start": [], "entity_id": [] },"Speculated": { "value": false ,"text": [], "start": [], "entity_id": [] },"Severity": { "value": "" ,"text": [], "start": [], "entity_id": [] },"Effect": { "text": [["clindamycin-associated pseudomembranous colitis"]], "start": [["0"]], "entity_id": [["T1"]] }} ]}
{"id": "19707032_6","context": "Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["intravitreal injection of bevacizumab"]],"start": [[ "35"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["intravitreal injection of bevacizumab (1.25 mg in 0.1 ml)"]],"start": [[ "35"]],"entity_id": [ ["T1"]],"Drug": {"text": [["bevacizumab"]],"start": [[ "35"]],"entity_id": [ ["T3"]]},"Dosage": {"text": [["1.25 mg"]],"start": [[ "59"]],"entity_id": [ ["T4"]]},"Route": {"text": [["intravitreal injection"]],"start": [[ "35"]],"entity_id": [ ["T2"]]} ,"Time_elapsed": {"text": [["three days after receiving"]],"start": [[ "0"]],"entity_id": [ ["T0"]]} ,"Disorder": {"text": [["acute vision loss and change of consciousness"]],"start": [[ "73"]],"entity_id": [ ["T5"]]} ,"Freq": null,"Combination": null ,"Trigger": null ,"Duration": null } ,"Effect": {"text": [["acute vision loss and change of consciousness"]],"start": [[ "73"]],"entity_id": [ ["T5"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": null }]}
{"id": "23868369_7","context": "The proposed cause of the nausea and anorexia was digoxin toxicity secondary to a drug-drug interaction with ciprofloxacin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["digoxin toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ciprofloxacin"]],"start": [["85"]],"entity_id": [["T2"]],"Drug": {"text": [["ciprofloxacin"]],"start": [["85"]],"entity_id": [["T2"]]},"Trigger": {"text": [["a drug-drug interaction"]],"start": [["45"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["nausea and anorexia"]],"start": [["5"]],"entity_id": [["T0"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["digoxin toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Drug": {"text": [["digoxin"]],"start": [["14"]],"entity_id": [["T1"]]}}]},"Subject": {"text": [["The proposed cause"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["nausea and anorexia"]],"start": [["5"]],"entity_id": [["T0"]]}},"Effect": {"text": [["digoxin toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8222875_1","context": "Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Mitomycin C (MMC)"]],"start": [[ "0"]],"entity_id": [ ] ,"Drug": { "text": [["Mitomycin C"]], "start": [[ "0"]], "entity_id": [ ] } ,"Disorder": { "text": [["hemolytic-uremic syndrome (HUS)"]], "start": [[ "43"]], "entity_id": [ ] } ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null , "Trigger": { "text": [["has been recently associated"]], "start": [[ "21"]], "entity_id": [ ] } } ,"Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Trigger": null } ] }
{"id": "10904571_3","context": "Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["colchicine-induced myopathy"]],"start": [["63"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["colchicine"]],"start": [["35"]],"entity_id": [["T2"]]} ,"entity_id": [["T2"]] ,"text": [["colchicine"]],"start": [["35"]] ,"Disorder": {"text": [["colchicine-induced myopathy"]],"start": [["63"]],"entity_id": [["T1"]] },"Route": {"text": [["Muscle biopsy revealed"]],"start": [[""], ["0"]],"entity_id": [["T0"]] },"Time_elapsed": {"text": [["which were features"]],"start": [[""], ["46"]],"entity_id": [["T0"]] },"Duration": {"text": [["Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers"]],"start": [[""], ["0"]],"entity_id": [["T0"]] },"Freq": {"text": [["Muscle biopsy revealed"]],"start": [[""], ["0"]],"entity_id": [["T0"]] },"Combination": [] ,"Dosage": {"text": [["Muscle biopsy revealed"]],"start": [[""], ["0"]],"entity_id": [["T0"]] },"Trigger": {"text": [["Muscle biopsy revealed"]],"start": [[""], ["0"]],"entity_id": [["T0"]] }} ,"Effect": {"text": [["variation in muscle fiber size and few vacuolated fibers"]],"start": [[""], ["23"]],"entity_id": [["T0"]] },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "medium" },"Speculated": null,"Negated": null }]}
{"id": "1467295_1","context": "We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and mitoxantrone","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["NEH"]],"start": [["17"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["5"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["cytarabine"]],"start": [["69"]],"entity_id": [["T4"]],"Drug": null,"Disorder": null,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["mitoxantrone"]],"start": [["94"]],"entity_id": [["T5"]]},"Trigger": {"text": [["provoked"]],"start": [["85"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "22791547_4","context": "Orofacial dyskinesia appeared 5 hours after methylphenidate administration, persisted for 10 hours, and had completely resolved within 2 days","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Orofacial dyskinesia"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["methylphenidate administration"]],"start": [[ "46" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["methylphenidate"]],"start": [[ "46" ]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": {"text": [["5 hours"]],"start": [[ "32" ]],"entity_id": [ ["T4"] ]} ,"Duration": {"text": [["10 hours"]],"start": [[ "60" ]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["had completely resolved within 2 days"]],"start": [[ "72" ]],"entity_id": [ ["T6"] ]} ,"Trigger": {"text": [["after"]],"start": [[ "42" ]],"entity_id": [ ["T7"] ]} ,"Route": {"text": [["administration"]],"start": [[ "46" ]],"entity_id": [ ["T8"] ]} ,"Disorder": {"text": [["Orofacial dyskinesia"]],"start": [[ "0" ]],"entity_id": [ ["T9"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} }]}
{"id": "19789372_7","context": "Present results suggested that coadministration of mexiletine increased blood tizanidine concentrations and enhanced tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["coadministration of mexiletine"]],"start": [[], [], []],"entity_id": [],"Drug": {"text": [["mexiletine"]],"start": [[], [], []],"entity_id": []},"Trigger": {"text": [["coadministration"]],"start": [[], []],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["enhanced tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms"]],"start": [[], [], [], [], []],"entity_id": []},"Trigger": {"text": [["enhanced"]],"start": [[], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["increased blood tizanidine concentrations"]],"start": [[], [], []],"entity_id": []},"Trigger": {"text": [["increased"]],"start": [[], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["blood tizanidine concentrations"]],"start": [[], []],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "633424_1","context": "Acute leukopenia associated with silver sulfadiazine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute leukopenia"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["silver sulfadiazine therapy"]],"start": [["42"]],"entity_id": [ ["T2"]],"Drug": {"text": [["silver sulfadiazine"]],"start": [["42"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["Acute leukopenia"]],"start": [["0"]],"entity_id": [ ["T1"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null }]}
{"id": "8301877_4","context": "We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["L-dopa-induced myoclonus", "seizures"]],"start": [[], []],"entity_id": []},"Treatment": {"text": [["L-dopa"]],"start": [[], []],"entity_id": [] ,"Drug": {"text": [["L-dopa"]],"start": [[], []],"entity_id": []} ,"Disorder": {"text": [["parkinsonism"]],"start": [[], []],"entity_id": []} ,"Time_elapsed": {"text": [["occurrence"]],"start": [[], []],"entity_id": []} ,"Trigger": {"text": [["occurrence"]],"start": [[], []],"entity_id": []} ,"Freq": {"text": [["induced"]],"start": [[], []],"entity_id": []} ,"Combination": [{"Drug": {"text": [["L-dopa"]],"start": [[], []],"entity_id": []} ,"Trigger": {"text": [["induced"]],"start": [[], []],"entity_id": []} ,"event_type": "Adverse_event","event_id": "E2"} ],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["parkinsonism"]],"start": [[], []],"entity_id": []}}}]}
{"id": "12187348_8","context": "Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["giant hypertrophy"]],"start": [["26"]],"entity_id": [["T1"]]},"Treatment": {"text": [["bucillamine"]],"start": [["11"]],"entity_id": [["T2"]],"Drug": {"text": [["bucillamine"]],"start": [["11"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["retrospectively"]],"start": [["0"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["D-penicillamine"]],"start": [["55"]],"entity_id": [["T4"]]},"Trigger": {"text": [["reports"]],"start": [["76"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["abundance"]],"start": [["71"]],"entity_id": [["T6"]]},"Route": {"text": [["structural similarity"]],"start": [["37"]],"entity_id": [["T7"]]},"Disorder": {"text": [["mammary hyperplasia"]],"start": [["90"]],"entity_id": [["T8"]]},"Trigger": {"text": [["cause"]],"start": [["22"]],"entity_id": [["T9"]]},"Dosage": {"text": [["believed"]],"start": [["18"]],"entity_id": [["T10"]]},"Duration": {"text": [["retrospectively"]],"start": [["0"]],"entity_id": [["T3"]]}},"Subject": {"text": [["bucillamine"]],"start": [["11"]],"entity_id": [["T2"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["giant hypertrophy"]],"start": [["26"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "11181395_1", "context": "Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["antiresistance determinant gene transfer"]], "start": [[ "42" ]],"entity_id": [ ["T1"] ], "Trigger": { "text": [["restoration"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ] } ,"Disorder": { "text": [["vancomycin susceptibility"]], "start": [[ "12" ]], "entity_id": [ ["T3"] ] } ,"Drug": { "text": [["vancomycin"]], "start": [[ "7" ]], "entity_id": [ ["T4"] ] } ,"Duration": { "text": [["Enterococcus faecalis"]], "start": [[ "33" ]], "entity_id": [ ["T5"] ] } ,"Route": { "text": [["gene transfer"]], "start": [[ "42" ]], "entity_id": [ ["T1"] ] } ,"Time_elapsed": { "text": [], "start": [[ ]], "entity_id": [] } ,"Freq": { "text": [], "start": [[ ]], "entity_id": [] } ,"Dosage": { "text": [], "start": [[ ]], "entity_id": [] } ,"Combination": null } ,"Effect": { "text": [], "start": [[ ]], "entity_id": [] } ,"Negated": null ,"Speculated": null ,"Severity": { "text": [], "start": [[ ]], "entity_id": [] ,"value": "Low" } ,"Subject": null ,"Trigger": null } ]}
{"id": "9824032_1","context": "Dental and gingival pain as side effects of niacin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Dental and gingival pain"]],"start": [[ ] ],"entity_id": []},"Treatment": {"text": [["niacin therapy"]],"start": [[ ]],"entity_id": [], "Drug": {"text": [["niacin"]],"start": [[ ]],"entity_id": []}, "Disorder": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}, "Freq": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}, "Combination": [{"event_type": "Adverse_event","event_id": "E1-1","Drug": {"text": [["Dental"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["Dental"]],"start": [[ ]],"entity_id": []}},{"event_type": "Adverse_event","event_id": "E1-2","Drug": {"text": [["gingival pain"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["gingival pain"]],"start": [[ ]],"entity_id": []}}],"Time_elapsed": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}, "Duration": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}, "Route": {"text": [["of"]],"start": [[ ]],"entity_id": []},"Dosage": {"text": [["niacin therapy"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}}, "Effect": {"text": [["Dental and gingival pain"]],"start": [[ ]],"entity_id": []}, "Negated": null,"Speculated": null,"Severity": {"text": [["side effects"]],"start": [[ ]],"entity_id": [], "value": "Low"},"Subject": {"text": [["Dental and gingival pain"]],"start": [[ ]],"entity_id": [], "Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["side effects"]],"start": [[ ]],"entity_id": []}}}]}
{"id": "12590235_5","context": "We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["significant elevation of serum transaminases"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["6-TG"]],"start": [["85"]],"entity_id": [["T2"]],"Drug": {"text": [["6-TG"]],"start": [["85"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["Crohn's disease"]],"start": [["106"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["treated"]],"start": [["76"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["a flare"]],"start": [["90"]],"entity_id": [["T5"]]},"Trigger": {"text": [["treated"]],"start": [["76"]],"entity_id": [["T4"]]} ,"Route": {"text": [["oral"]],"start": [[""], []],"entity_id": [["T4"]]} ,"Duration": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": null} ,"Subject": {"text": [["a patient"]],"start": [["59"]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Crohn's disease"]],"start": [["106"]],"entity_id": [["T3"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["significant elevation"]],"start": [["22"]],"entity_id": [["T1"]] ,"value": "high"} ,"Effect": {"text": [["elevation of serum transaminases"]],"start": [["22"]],"entity_id": [["T1"]]} }] }
{"id": "18094347_2", "context": "The pathogenesis of methotrexate-induced papular eruption in collagen vascular diseases may suggest cutaneous small-vessel vasculitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["methotrexate-induced papular eruption"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["methotrexate"]], "start": [["12"]], "entity_id": [],"Drug": {"text": [["methotrexate"]], "start": [["12"]], "entity_id": []} ,"Disorder": { "text": [["collagen vascular diseases"]], "start": [["43"]], "entity_id": [] } ,"Route": { "text": [["induced"]], "start": [["18"]], "entity_id": [] } ,"Time_elapsed": { "text": [["induced"]], "start": [["18"]], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": [] ,"Dosage": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] } ,"Trigger": { "text": [], "start": [], "entity_id": [] }},"Effect": { "text": [["papular eruption"]], "start": [["32"]], "entity_id": [] }, "Severity": { "text": [], "start": [], "entity_id": [] ,"value": "" }, "Negated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false } ,"Subject": { "text": [], "start": [], "entity_id": [],"Age": { "text": [], "start": [], "entity_id": []},"Disorder": { "text": [], "start": [], "entity_id": []},"Gender": { "text": [], "start": [], "entity_id": []},"Population": { "text": [], "start": [], "entity_id": []},"Race": { "text": [], "start": [], "entity_id": []}}}]}
{"id": "9719245_1","context": "Excluding other causes, Pentasa-associated pancytopenia was considered","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pentasa-associated pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Pentasa"]],"start": [["16"]],"entity_id": [["T2"]]} ,"entity_id": [["T2"]],"Disorder": {"text": [["pancytopenia"]],"start": [["35"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["associated"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Route": {"text": [["Pentasa-associated pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["considered"]],"start": [["55"]],"entity_id": [["T5"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["Pentasa-associated pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]} ,"text": [["Pentasa-associated pancytopenia"]],"start": [["0"]] },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": [] }} }]}
{"id": "15013892_3","context": "A patient developed a bilaterally symmetric bull's-eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bilaterally symmetric bull's-eye maculopathy"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["quinacrine"]],"start": [["72"]],"entity_id": [["T2"]]},"Duration": {"text": [["18 months"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": {"text": [["prophylaxis against malaria"]],"start": [["92"]],"entity_id": [["T4"]]} , "Time_elapsed": { "text": [["45 years"]], "start": [["42"]], "entity_id": [["T5"]] } , "Trigger": { "text": [["took"]], "start": [["37"]], "entity_id": [["T6"]] } ,"entity_id": [["T1"],["T2"],["T3"],["T4"],["T5"],["T6"]],"start": [["0"],["72"],["52"],["92"],["42"],["37"]],"text": [["bilaterally symmetric bull's-eye maculopathy"],["quinacrine"],["18 months"],["prophylaxis against malaria"],["45 years"],["took"]],"Dosage": null,"Freq": null,"Route": null,"Combination": null},"Subject": {"Age": {"text": [["45 years"]],"start": [["42"]],"entity_id": [["T5"]]},"Gender": null,"Population": null,"Race": null,"Disorder": null,"text": [["A patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["A patient developed"]],"start": [["0"]],"entity_id": [["T0"]]}}]}
{"id": "23868369_1","context": "Possible digoxin toxicity associated with concomitant ciprofloxacin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["digoxin toxicity"]],"start": [[ "0"]] ,"entity_id": [ ]},"Treatment": {"text": [["concomitant ciprofloxacin therapy"]],"start": [[ "46"]],"entity_id": [ ],"Drug": {"text": [["ciprofloxacin"]],"start": [[ "69"]],"entity_id": [ ]} ,"Disorder": {"text": [["digoxin toxicity"]],"start": [[ "0"]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["associated with"]],"start": [[ "46"]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["digoxin"]],"start": [[ "0"]],"entity_id": [ ]},"Trigger": {"text": [["concomitant"]],"start": [[ "46"]],"entity_id": [ ]} ,"event_id": "E2","event_type": "Potential_therapeutic_effect"} ],"Freq": {"text": [["concomitant"]],"start": [[ "46"]],"entity_id": [ ]} ,"Route": {"text": [["therapy"]],"start": [[ "69"]],"entity_id": [ ]} ,"Trigger": {"text": [["therapy"]],"start": [[ "69"]],"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["digoxin toxicity"]],"start": [[ "0"]],"entity_id": [ ]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} }]}
{"id": "8313300_9","context": "The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["improved"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["withdrawal of lithium"]],"start": [["48"]],"entity_id": [],"Drug": {"text": [["lithium"]],"start": [["63"]],"entity_id": []},"Time_elapsed": {"text": [["72 hours"]],"start": [["34"]],"entity_id": []},"Disorder": {"text": [["exophthalmos"]],"start": [["0"]],"entity_id": []},"Freq": {"text": [["dramatically"]],"start": [["13"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger" : {"text": [],"start": [],"entity_id": []},"Combination" : null},"Effect" : {"text": [],"start": [],"entity_id": []},"Negated" : null,"Speculated" : null,"Severity" : null,"Subject" : null}]}
{"id": "8255797_3","context": "We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["neutropenia"]],"start": [["16"]],"entity_id": [["T1"]]},"Subject": {"text": [["two cases"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["two cases"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["cardiac patients with trisomy 21"]],"start": [["42"]],"entity_id": [["T3"]]},"Age": null,"Gender": null,"Race": null},"Treatment": {"text": [["captopril use"]],"start": [["24"]],"entity_id": [["T2"]],"Drug": {"text": [["captopril"]],"start": [["24"]],"entity_id": [["T2"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"Combination": null ,"Trigger": null},"Effect": {"text": [["neutropenia"]],"start": [["16"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "1433432_2","context": "We report a case of hyponatremia associated with a grand mal seizure in a 28 month-old child after intra-nasal desmopressin administration for high fluid intake with nocturnal enuresis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hyponatremia"]],"start": [["16"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 28 month-old child"]],"start": [["42"]],"entity_id": [["T2"]],"Age": {"text": [["28 month-old"]],"start": [["42"]],"entity_id": [["A1"]]},"Gender": {"text": [["child"]],"start": [["42"]],"entity_id": [["G1"]]},"Race": {"text": [["child"]],"start": [["42"]],"entity_id": [["R1"]]},"Disorder": {"text": [["grand mal seizure"]],"start": [["10"]],"entity_id": [["D1"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["P1"]]}},"Treatment": {"text": [["intra-nasal desmopressin administration"]],"start": [["75"]],"entity_id": [["T3"]],"Drug": {"text": [["desmopressin"]],"start": [["75"]],"entity_id": [["D1"]]},"Disorder": {"text": [["high fluid intake with nocturnal enuresis"]],"start": [["53"]],"entity_id": [["D2"]]},"Route": {"text": [["intra-nasal"]],"start": [["75"]],"entity_id": [["R1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "1348483_3", "context": "Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["cabergoline"]], "start": [[ "13" ]], "entity_id": [ ["T1"] ] ,"Drug": { "text": [["cabergoline"]], "start": [[ "13" ]], "entity_id": [ ["T1"] ] }, "Trigger": { "text": [["cause"]], "start": [[ "40" ]], "entity_id": [ ["T2"] ] }, "Disorder": { "text": [["similar pleuropulmonary abnormalities"]], "start": [[ "45" ]], "entity_id": [ ["T3"] ] }, "Time_elapsed": { "text": [["may cause"]], "start": [[ "31" ]], "entity_id": [ ["T4"] ] }, "Freq": { "text": [["may cause"]], "start": [[ "31" ]], "entity_id": [ ["T4"] ] }, "Route": { "text": [["cause"]], "start": [[ "40" ]], "entity_id": [ ["T2"] ] }, "Dosage": { "text": [["cabergoline"]], "start": [[ "13" ]], "entity_id": [ ["T1"] ] }, "Duration": { "text": [["cause"]], "start": [[ "40" ]], "entity_id": [ ["T2"] ] }, "Combination": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Trigger": null }]}
{"id": "7067510_1","context": "Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient coronary vasoconstriction induced by the dopamine infusion","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["dopamine infusion"]],"start": [["128"]],"entity_id": [["T1"]],"Trigger": {"text": [["transient coronary vasoconstriction"]],"start": [["113"]],"entity_id": [["T2"]]},"Drug": {"text": [["dopamine"]],"start": [["128"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute ischemic event"]],"start": [["86"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["transient"]],"start": [["113"]],"entity_id": [["T5"]]},"Freq": {"text": [["transient"]],"start": [["113"]],"entity_id": [["T5"]]},"Route": {"text": [["infusion"]],"start": [["128"]],"entity_id": [["T6"]]},"Duration": {"text": [["brief duration"]],"start": [["104"]],"entity_id": [["T7"]]},"Dosage": {"text": [["the dopamine infusion"]],"start": [["121"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["dopamine"]],"start": [["128"]],"entity_id": [["T3"]]},"Trigger": {"text": [["transient coronary vasoconstriction"]],"start": [["113"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}]},"Effect": {"text": [["acute pericarditis or an acute myocarditis"]],"start": [["11"]],"entity_id": [["T9"]]},"Negated": {"text": [["cannot be fully ruled out"]],"start": [["46"]],"entity_id": [["T10"]],"value": false},"Subject": {"text": [["the existence"]],"start": [["0"]],"entity_id": [["T11"]],"Disorder": {"text": [["an acute pericarditis or an acute myocarditis"]],"start": [["11"]],"entity_id": [["T9"]]},"Population": {"text": [["the existence"]],"start": [["0"]],"entity_id": [["T11"]]},"Age": {"text": [["the existence"]],"start": [["0"]],"entity_id": [["T11"]]},"Gender": {"text": [["the existence"]],"start": [["0"]],"entity_id": [["T11"]]},"Race": {"text": [["the existence"]],"start": [["0"]],"entity_id": [["T11"]]}},"Trigger": {"text": [["the sudden onset"]],"start": [["86"]],"entity_id": [["T12"]]},"Severity": {"text": [["acute"]],"start": [["86"]],"entity_id": [["T12"]],"value": "high"},"Speculated": {"text": [["perhaps more indicative"]],"start": [["104"]],"entity_id": [["T13"]],"value": true}}]}
{"id": "7594371_1", "context": "Acute sensorineural hearing loss following intravenous ketoralac administration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Acute sensorineural hearing loss"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [[ "intravenous ketoralac administration" ]], "start": [[ "48" ]],"entity_id": [ ["T2"] ], "Drug": { "text": [[ "ketoralac" ]], "start": [[ "60" ]],"entity_id": [ ["T3"] ] }, "Route": { "text": [[ "intravenous" ]], "start": [[ "48" ]],"entity_id": [ ["T4"] ] }, "Disorder": { "text": [[ "Acute sensorineural hearing loss" ]], "start": [[ "0" ]],"entity_id": [ ["T1"] ] }, "Time_elapsed": { "text": [[ "following" ]], "start": [[ "48" ]],"entity_id": [ ["T5"] ] }, "Dosage": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": null ,"Trigger": null }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [], "start": [], "entity_id": [] } }, "Effect": { "text": [[ "Acute sensorineural hearing loss" ]], "start": [[ "0" ]],"entity_id": [ ["T1"] ] }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "16484748_3","context": "Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity syndrome"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Trimethoprim-sulfamethoxazole"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Trimethoprim-sulfamethoxazole"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["hypersensitivity syndrome"]],"start": [["19"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["associated with"]],"start": [["25"]],"entity_id": [["T2"]]},"Trigger": {"text": [["reactivation"]],"start": [["47"]],"entity_id": [["T3"]]},"Dosage": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["N/A"]]},"Duration": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["N/A"]]},"Freq": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["N/A"]]},"Route": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["N/A"]]},"Combination": null},"Effect": {"text": [["human herpesvirus-6"]],"start": [["40"]],"entity_id": [["T4"]]},"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "1775411_1", "context": "A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non-steroidal anti-inflammatory drug, nabumetone", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["rapid onset of pulmonary fibrosis"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["treatment with a new non-steroidal anti-inflammatory drug, nabumetone"]], "start": [["63"]], "entity_id": [], "Drug": {"text": [["nabumetone"]], "start": [["98"]], "entity_id": []}, "Disorder": {"text": [["new non-steroidal anti-inflammatory drug"]], "start": [["63"]], "entity_id": []}, "Route": {"text": [["treatment"]], "start": [["63"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [["rapid onset"]], "start": [["32"]], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Combination": null,"Trigger": null},"Effect": {"text": [["developed"]], "start": [["16"]], "entity_id": []},"Subject": {"text": [["A patient"]], "start": [["0"]], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11675845_2", "context": "To report a case of increased international normalized ratio (INR) in a geriatric patient receiving warfarin and ropinirole", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased international normalized ratio (INR)"]], "start": [["33","33","37"]], "entity_id": []}, "Subject": {"text": [["geriatric patient"]], "start": [["7","8"]], "entity_id": [],"Age":{"text":[["geriatric"]], "start":[[ "7","7" ]], "entity_id":[]},"Disorder":{"text":[["receiving warfarin and ropinirole"]], "start":[[ "40","40","44" ]], "entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}, "Treatment": {"text": [["warfarin and ropinirole"]], "start": [["40","40","44"]], "entity_id": [],"Drug":{"text":[["warfarin","ropinirole"]], "start":[[ "40","44" ]], "entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":[{"Drug":{"text":[["warfarin"]], "start":[[ "40" ]], "entity_id":[]},"Trigger":{"text":[["and"]], "start":[[ "43" ]], "entity_id":[]},"event_id":"C1","event_type":"Combination"},{"Drug":{"text":[["ropinirole"]], "start":[[ "44" ]], "entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"event_id":"C2","event_type":"Combination"}],"Trigger":{"text":[],"start":[],"entity_id":[]}},"Effect": {"text": [["increased international normalized ratio (INR)"]], "start": [["33","33","37"]], "entity_id": []},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"High"}}]}
{"id": "8071504_8","context": "There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ocular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ethambutol"]],"start": [["44"]],"entity_id": [["T2"]],"Dosage": {"text": [["dosages generally pronounced as being safe"]],"start": [["61"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["ocular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["when administered"]],"start": [["22"]],"entity_id": [["T4"]]} ,"Route": {"text": [["with"]],"start": [["37"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["with"]],"start": [["37"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["when administered"]],"start": [["22"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["ethambutol"]],"start": [["44"]],"entity_id": [["T2"]]},"Trigger": {"text": [["when administered"]],"start": [["22"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event" }] ,"Drug": {"text": [["ethambutol"]],"start": [["44"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["when administered"]],"start": [["22"]],"entity_id": [["T4"]]} }, "Effect": {"text": [["ocular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Severity": {"text": [["ocular toxicity"]],"start": [["0"]],"entity_id": [["T1"]] ,"value": "high" }, "Negated": null, "Speculated": {"text": [["is"]],"start": [["5"]],"entity_id": [["T6"]] ,"value": false }, "Subject": {"text": [["There is documentation"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }} ]}
{"id": "6329575_1", "context": "k bipolar manic-depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["akathisia"]], "start": [["developed while on lithium prophylaxis,"], [""], ["akathisia"]], "entity_id": []}, "Treatment": {"text": [["lithium prophylaxis"]], "start": [["developed while on lithium prophylaxis,"]], "entity_id": [],"Dosage": {"text": [["therapeutic serum lithium levels"]], "start": [[""], ["akathisia at therapeutic serum lithium levels"]], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Disorder": {"text": [["bipolar manic-depressive patient"]], "start": [[""], ["k bipolar manic-depressive patient,"]], "entity_id": []} , "Drug": {"text": [["lithium"]], "start": [[""], ["lithium prophylaxis"]], "entity_id": []} , "Route": {"text": [], "start": [], "entity_id": []} , "Time_elapsed": {"text": [], "start": [], "entity_id": []} , "Freq": {"text": [], "start": [], "entity_id": []} , "Combination": [] , "Trigger": {"text": [], "start": [], "entity_id": []} }, "Effect": {"text": [["akathisia"]], "start": [["developed while on lithium prophylaxis,"], [""], ["akathisia"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["k bipolar manic-depressive patient"]], "start": [[""], ["k bipolar manic-depressive patient,"]], "entity_id": [] , "Age": null , "Disorder": {"text": [["bipolar manic-depressive"]], "start": [[""], ["k bipolar manic-depressive patient,"]], "entity_id": []} , "Gender": null , "Population": null , "Race": null } } ,{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["bucco-linguo-masticatory dyskinesia"]], "start": [[""], ["subsequently bucco-linguo-masticatory dyskinesia."]], "entity_id": []}, "Treatment": null, "Effect": {"text": [["bucco-linguo-masticatory dyskinesia"]], "start": [[""], ["subsequently bucco-linguo-masticatory dyskinesia."]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["k bipolar manic-depressive patient"]], "start": [[""], ["k bipolar manic-depressive patient,"]], "entity_id": [] , "Age": null , "Disorder": {"text": [["bipolar manic-depressive"]], "start": [[""], ["k bipolar manic-depressive patient,"]], "entity_id": []} , "Gender": null , "Population": null , "Race": null }}]}
{"id": "11712064_2","context": "We describe a patient who had a systemic allergic contact dermatitis to 8-MOP develop during her second course of PUVA treatment for psoriasis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["systemic allergic contact dermatitis to 8-MOP"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["psoriasis"]],"start": [["95"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["PUVA treatment"]],"start": [["66"]],"entity_id": [["T2"]],"Drug": {"text": [["8-MOP"]],"start": [["33"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": {"text": [["second course"]],"start": [["49"]],"entity_id": [["T1"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Disorder": {"text": [["psoriasis"]],"start": [["95"]],"entity_id": [["T3"]]},"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "3677571_8","context": "Seizures were treated with diazepam","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["diazepam"]],"start": [["28"]],"entity_id": [["T1"]] ,"Drug": {"text": [["diazepam"]],"start": [["28"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Seizures"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treated"]],"start": [["11"]],"entity_id": [["T4"]]},"Time_elapsed": null,"Freq": null,"Duration": null,"Dosage": null,"Route": null,"Combination": null},"Subject": {"text": [["Seizures"]],"start": [["0"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Seizures"]],"start": [["0"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": null}]}
{"id": "10487084_2", "context": "Paradoxical seizures in phenytoin toxicity", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["paradoxical seizures"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["phenytoin"]], "start": [[ "33" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["phenytoin"]], "start": [[ "33" ]], "entity_id": [ ["T3"] ]},"Time_elapsed": {"text": [["toxicity"]], "start": [[ "19" ]], "entity_id": [ ["T4"] ]},"Disorder": {"text": [["phenytoin toxicity"]], "start": [[ "19" ]], "entity_id": [ ["T4"] ]}, "Freq": {"text": [["paradoxical"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Combination": null , "Dosage": null, "Duration": null, "Route": null, "Trigger": null} , "Effect": {"text": [["paradoxical seizures"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} , "Negated": null , "Speculated": null , "Severity": null , "Subject": null}]}
{"id": "1477441_1","context": "Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fixed drug eruption"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methylphenidate"]],"start": [["31"]],"entity_id": [["T2"]],"Drug": {"text": [["methylphenidate"]],"start": [["31"]],"entity_id": [["T3"]]},"Disorder": {"text": [["attention deficit disorder"]],"start": [["10"]],"entity_id": [["T4"]]},"Route": {"text": [["simple drug"]],"start": [["25"]],"entity_id": [["T5"]]},"Dosage": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Time_elapsed": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Freq": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Combination": null,"Trigger": null},"Subject": {"text": [["Two children"]],"start": [[""], [""]],"entity_id": [["null"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["attention deficit disorder"]],"start": [["10"]],"entity_id": [["T4"]]}},"Effect": {"text": [["fixed drug eruption"]],"start": [["52"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9846036_6","context": "To date, only 1 death attributable to risperidone overdose has been reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["risperidone overdose"]],"start": [["31", "32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["risperidone"]],"start": [["22"]],"entity_id": [["T2"]],"Drug": {"text": [["risperidone"]],"start": [["22"]],"entity_id": [["T2"]]},"Disorder": {"text": [["overdose"]],"start": [["31"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["risperidone"]],"start": [["22"]],"entity_id": [["T2"]]},"Trigger": {"text": [["overdose"]],"start": [["31"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Freq": {"text": [["only 1"]],"start": [["7"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["reported"]],"start": [["53"]],"entity_id": [["T4"]]},"Dosage": {"text": [["overdose"]],"start": [["31"]],"entity_id": [["T1"]]},"Duration": {"text": [["reported"]],"start": [["53"]],"entity_id": [["T4"]]},"Route": {"text": [["risperidone"]],"start": [["22"]],"entity_id": [["T2"]]},"Trigger": {"text": [["risperidone overdose"]],"start": [["31"]],"entity_id": [["T1"]]}},"Subject": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"value": false,"text": [["death"]],"start": [["44"]],"entity_id": [["T5"]]},"Speculated": {"value": false,"text": [["To date"]],"start": [["0"]],"entity_id": [["T0"]]},"Severity": {"value": "High","text": [["death"]],"start": [["44"]],"entity_id": [["T5"]]},"Effect": {"text": [["death"]],"start": [["44"]],"entity_id": [["T5"]]}}]}
{"id": "11712064_1", "context": "Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["systemic allergic contact dermatitis"]], "start": [[ ]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["8-methoxypsoralen (8-MOP)"]], "start": [[ ]], "entity_id": [ ["T2"]],"Drug": {"text": [["8-methoxypsoralen"]], "start": [[ ]], "entity_id": [ ["T3"]]}, "Dosage": {"text": [["8-MOP"]], "start": [[ ]], "entity_id": [ ["T4"]]} ,"Route": {"text": [["Systemic"]], "start": [[ ]], "entity_id": [ ["T5"]]} ,"Duration": {"text": [["to"]], "start": [[ ]], "entity_id": [ ["T6"]]} ,"Disorder": {"text": [["8-methoxypsoralen (8-MOP)"]], "start": [[ ]], "entity_id": [ ["T2"]]} ,"Freq": {"text": [["Systemic allergic contact dermatitis"]], "start": [[ ]], "entity_id": [ ["T1"]]} ,"Time_elapsed": {"text": [["to"]], "start": [[ ]], "entity_id": [ ["T6"]]} ,"Combination": null ,"Trigger":{"text":[["8-methoxypsoralen (8-MOP)"]], "start": [[ ]], "entity_id": [ ["T2"]]} }, "Effect":{"text":[["Systemic allergic contact dermatitis"]], "start": [[ ]], "entity_id": [ ["T1"]]} ,"Negated":null, "Speculated":null, "Severity": null ,"Subject":null }]}
{"id": "3301251_1","context": "A case of a 21-year-old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["mild hepatotoxicity"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["choline magnesium trisalicylate therapy"]],"start": [["78"]],"entity_id": [["T2"]],"Drug": {"text": [["choline magnesium trisalicylate"]],"start": [["78"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["while receiving"]],"start": [["50"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["hepatotoxicity"]],"start": [["36"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": null} ,"Subject": {"text": [["a 21-year-old woman"]],"start": [["6"]],"entity_id": [["T5"]],"Age": {"text": [["21"]],"start": [["9"]],"entity_id": [["T6"]]},"Gender": {"text": [["woman"]],"start": [["14"]],"entity_id": [["T7"]]},"Population": null,"Race": null,"Disorder": null} ,"Severity": {"text": [["mild"]],"start": [["36"]],"entity_id": [["T1"]] ,"value": "low"},"Negated": null,"Speculated": null ,"Effect": {"text": [],"start": [],"entity_id": []}} ]}
{"id": "9407188_1", "context": "Early ritonavir-induced maculopapular eruption", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["ritonavir-induced maculopapular eruption"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["ritonavir"]], "start": [[ ]], "entity_id": [["T2"]],"Drug": {"text": [["ritonavir"]], "start": [[ ]], "entity_id": [["T3"]]}, "Time_elapsed": {"text": [["Early"]], "start": [[ ]], "entity_id": [["T4"]]}, "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Freq": null, "Combination": null, "Trigger": null} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Effect": null}]}
{"id": "14632592_4","context": "In our patient, an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy, even though his renal and hepatic function were normal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["colchicine"]],"start": [["10"]],"entity_id": [["T1"]] ,"Drug": { "text": [["colchicine"]], "start": [["10"]], "entity_id": [["T1"]] },"Disorder": { "text": [["myopathy"]], "start": [["52"]], "entity_id": [["T2"]] },"Dosage": { "text": [["therapeutic doses"]], "start": [["16"]], "entity_id": [["T3"]] },"Duration": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null },"Effect": { "text": [["myopathy"]], "start": [["52"]], "entity_id": [["T2"]] },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null}]}
{"id": "20367573_3","context": "Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thrombocytosis induced by enoxaparin"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["this medication"]],"start": [[ "76" ]],"entity_id": [["T3"]],"Drug": {"text": [["enoxaparin"]],"start": [[ "34" ]],"entity_id": [["T2"]]},"Disorder": {"text": [["adverse effect"]],"start": [[ "53" ]],"entity_id": [["T4"]]},"Freq": {"text": [["a rare"]],"start": [[ "57" ]],"entity_id": [["T5"]]},"Route": {"text": [["of this medication"]],"start": [[ "68" ]],"entity_id": [["T6"]]},"Dosage": {"text": [["induced"]],"start": [[ "17" ]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["has been reported"]],"start": [[ "30" ]],"entity_id": [["T8"]]},"Duration": {"text": [["in adults"]],"start": [[ "82" ]],"entity_id": [["T9"]]},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": {"text": [["rare"]],"start": [[ "57" ]],"entity_id": [["T5"]],"value": "low"},"Subject": null,"Effect": {"text": [["Thrombocytosis"]],"start": [[ "0" ]],"entity_id": [["T1"]]}}]}
{"id": "3493797_1","context": "A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a B-cell lymphoma of the lip following 4 1/2 years of treatment with razoxane","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["razoxane"]],"start": [[" "], [")"]],"entity_id": [["T1"]] ,"Dosage": {"text": [["4 1/2 years"]],"start": [[","]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["acral pustular psoriasis of Hallopeau", "pustular lesions of the forearms and lower legs", "B-cell lymphoma of the lip"]],"start": [[], [], ["following"]],"entity_id": [["T3"], ["T4"], ["T5"]]} ,"Time_elapsed": {"text": [["following"]],"start": [[], [], ["following"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["developed"]],"start": [[], [], ["developed"]],"entity_id": [["T5"]]} ,"Route": {"text": [["treatment"]],"start": [[], [")"]],"entity_id": [["T1"]]} ,"Freq": {"text": [[]],"start": [[], [], ["following"]],"entity_id": [[]]} ,"Duration": {"text": [["4 1/2 years"]],"start": [[","]],"entity_id": [["T2"]]} ,"Combination": null ,"Drug": {"text": [["razoxane"]],"start": [[], []],"entity_id": [["T1"]]}} ,"Subject": {"text": [["A woman"]],"start": [[], []],"entity_id": [["T0"]],"Age": {"text": [["20-year history"]],"start": [[], []],"entity_id": [["T3"]]},"Gender": {"text": [["woman"]],"start": [[], []],"entity_id": [["T0"]]},"Population": {"text": [[]],"start": [[], []],"entity_id": [[], []]},"Race": {"text": [[]],"start": [[], []],"entity_id": [[], []]},"Disorder": {"text": [["acral pustular psoriasis of Hallopeau", "recurrent pustular lesions of the forearms and lower legs"]],"start": [[], []],"entity_id": [["T3"], ["T4"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "9177620_3","context": "The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating factor of the episode of acute pancreatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["overdose"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["CBZ"]],"start": [["11"]],"entity_id": [["T2"]],"Drug": {"text": [["CBZ"]],"start": [["11"]],"entity_id": [["T2"]]},"Dosage": {"text": [["high plasmatic levels"]],"start": [["0"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute pancreatitis"]],"start": [["72"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["could have represented the precipitating factor"]],"start": [["51"]],"entity_id": [["T5"]]},"Trigger": {"text": [["the absence of other aetiologic factors"]],"start": [["23"]],"entity_id": [["T6"]]},"Freq": {"text": [["overdose"]],"start": [["34"]],"entity_id": [["T1"]]},"Route": {"text": [["overdose"]],"start": [["34"]],"entity_id": [["T1"]]},"Duration": {"text": [["overdose"]],"start": [["34"]],"entity_id": [["T1"]]},"Combination": null},"Effect": {"text": [["acute pancreatitis"]],"start": [["72"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["72"]],"entity_id": [["T4"]],"value": "high"},"Subject": {"text": [["The evidence"]],"start": [["0"]],"entity_id": [["T3"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["other aetiologic factors"]],"start": [["23"]],"entity_id": [["T6"]]}}}]}
{"id": "19904536_3","context": "In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["fatal", "pulmonary toxicity"]],"start": [["31","43"]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["gemcitabine"]],"start": [["12","20"]],"entity_id": [["T3"]],"Drug": {"text": [["gemcitabine"]],"start": [["12","20"]],"entity_id": [["T4"]]},"Disorder": {"text": [["gallbladder metastatic adenocarcinoma"]],"start": [["66","89"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["this report"]],"start": [["0","6"]],"entity_id": [["T6"]]},"Freq": {"text": [["a"]],"start": [["31"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["gemcitabine"]],"start": [["12","20"]],"entity_id": [["T4"]]},"Trigger": {"text": [["induced"]],"start": [["21","25"]],"entity_id": [["T8"]]},"event_type": "Adverse_event","event_id": "E2"}],"Trigger": {"text": [["gemcitabine"]],"start": [["12","20"]],"entity_id": [["T4"]]},"Route": {"text": [["induced"]],"start": [["21","25"]],"entity_id": [["T8"]]},"Dosage": {"text": [["a"]],"start": [["31"]],"entity_id": [["T7"]]},"Duration": {"text": [["this report"]],"start": [["0","6"]],"entity_id": [["T6"]]}},"Subject": {"text": [["a patient"]],"start": [["5","11"]],"entity_id": [["T9"]],"Age": {"text": [[""]],"start": [[""],[""]],"entity_id": [["T10"],["T11"]]},"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [["T12"],["T13"]]},"Population": {"text": [["a"]],"start": [["31"]],"entity_id": [["T7"]]},"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [["T14"],["T15"]]},"Disorder": {"text": [["gallbladder metastatic adenocarcinoma"]],"start": [["66","89"]],"entity_id": [["T5"]]}},"Severity": {"text": [["fatal"]],"start": [["31"]],"entity_id": [["T1"]],"value": "high"},"Negated": {"text": [["not"]],"start": [[""],[""]],"entity_id": [["T16"],["T17"]],"value": false},"Speculated": {"text": [["we describe"]],"start": [["0","6"]],"entity_id": [["T18"]],"value": false},"Effect": {"text": [["fatal gemcitabine-induced pulmonary toxicity"]],"start": [["31","52"]],"entity_id": [["T1"]]}}]}
{"id": "736591_2", "context": "Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a psoriatic patient"]], "start": [["case of a psoriatic patient"]], "entity_id": [],"Age":{"text":[["18 years"]],"start":[[ "had been on a regimen of methotrexate for 18 years"]],"entity_id":[]},"Disorder":{"text":[["psoriatic"]],"start":[["psoriatic patient"]],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}, "Treatment": {"text": [["methotrexate"]], "start": [[ "on a regimen of methotrexate for"]], "entity_id": [],"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[["18 years"]],"start":[[ "had been on a regimen of methotrexate for 18 years"]],"entity_id":[]},"Drug":{"text":[["methotrexate"]], "start": [[ "on a regimen of methotrexate for"]], "entity_id": []},"Disorder":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"Combination":null},"Effect": {"text": [["Progressive interstitial fibrosis with roentgenographic honeycombing"]], "start": [[ "Progressive interstitial fibrosis with roentgenographic honeycombing developed"]], "entity_id": []},"Negated":null,"Speculated":null,"Severity":null,"Trigger": null}]}
{"id": "20412003_3","context": "Due to the increasing use of TMP-SMX in children, clinicians should be aware of this potentially life-threatening, immunemediated hypersensitivity reaction","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["increasing use"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["TMP-SMX"]],"start": [["22"]],"entity_id": [],"Drug": {"text": [["TMP-SMX"]],"start": [["22"]],"entity_id": []} ,"Disorder": {"text": [["children"]],"start": [["15"]],"entity_id": []} ,"Route": {"text": [["in"]],"start": [["20"]],"entity_id": []} ,"Freq": {"text": [["increasing"]],"start": [["0"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["TMP-SMX"]],"start": [["22"]],"entity_id": []} ,"Trigger": {"text": [["children"]],"start": [["15"]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["hypersensitivity reaction"]],"start": [["62"]],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [["children"]],"start": [["15"]],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["life-threatening"]],"start": [["47"]],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "life-threatening" }} ]}
{"id": "12235444_3","context": "Therefore there is the potential for significant concentration-related adverse effects when phenytoin is coadministered with other CYP2C9 substrates","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["significant concentration-related adverse effects"]],"start": [["46"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenytoin"]],"start": [["24"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["CYP2C9 substrates"]],"start": [["76"]],"entity_id": [["T3"]]},"Freq": null,"Route": null,"Dosage": null,"Duration": null,"Time_elapsed": null,"Combination": null,"Trigger": {"text": [["co-administered"]],"start": [["58"]],"entity_id": [["T4"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "9554064_2", "context": "Putaminal infarct in methanol intoxication: case report and role of brain imaging studies", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Putaminal infarct"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["methanol intoxication"]], "start": [[],[]], "entity_id": [], "Disorder": {"text": [["methanol intoxication"]], "start": [[],[]], "entity_id": []}, "Time_elapsed": {"text": [[],[]], "start": [[],[]], "entity_id": []}, "Freq": {"text": [[],[]], "start": [[],[]], "entity_id": []}, "Combination": [{"Drug": {"text": [["methanol"]], "start": [[],[]], "entity_id": []},"Trigger": {"text": [["Putaminal infarct"]], "start": [[],[]], "entity_id": []},"event_id": "C1","event_type": "null"}], "Trigger": {"text": [["Putaminal infarct"]], "start": [[],[]], "entity_id": []}, "Drug": {"text": [["methanol"]], "start": [[],[]], "entity_id": []},"Route": {"text": [[],[]], "start": [[],[]], "entity_id": []}, "Duration": {"text": [[],[]], "start": [[],[]], "entity_id": []}, "Dosage": {"text": [[],[]], "start": [[],[]], "entity_id": []}},"Subject": {"text": [["case report"]], "start": [[],[]], "entity_id": [],"Age":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["methanol intoxication"]], "start": [[],[]], "entity_id": []},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[["Putaminal infarct"]], "start": [[],[]], "entity_id": [],"value":"High" },"Effect":{"text":[["Putaminal infarct"]], "start": [[],[]], "entity_id": []}}]}
{"id": "736591_3","context": "Progressive interstitial lung disease from prolonged methotrexate therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Progressive interstitial lung disease"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["methotrexate therapy"]],"start": [[ "53" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["methotrexate"]],"start": [[ "53" ]],"entity_id": [ ["T3"] ]},"Duration": {"text": [["prolonged"]],"start": [[ "38" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Severity": null,"Negated": null,"Speculated": null ,"Effect": {"text": [["Progressive interstitial lung disease"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} }] }
{"id": "16044093_2", "context": "The case reported here is of a child given a large dose of intravenous iron sucrose (16 mg/kg) over 3 hours, who subsequently developed features of systemic iron toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["iron sucrose"]], "start": [["32","39"]], "entity_id": []}, "Dosage": {"text": [["16 mg/kg"]], "start": [["18","23"]], "entity_id": []}, "Duration": null, "Route": {"text": [["intravenous"]], "start": [["8","15"]], "entity_id": []}, "Time_elapsed": null, "Disorder": null, "Freq": null, "Combination": null, "text": [["a large dose"]], "start": [["10","17"]], "entity_id": [] ,"Trigger": {"text": [["features"]], "start": [["113","118"]], "entity_id": []}},"Effect": {"text": [["features of systemic iron toxicity"]], "start": [["110","125"]], "entity_id": []} ,"Trigger": {"text": [["developed"]], "start": [["98","106"]], "entity_id": []}}]}
{"id": "11292139_1","context": "We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["oxaliplatin"]],"start": [["102","109"]],"entity_id": [["T1"]]},"Disorder": {"text": [["concomitant chemoirradiation with oxaliplatin"]],"start": [["31","61"]],"entity_id": [["T2"]]},"Trigger": {"text": [["treated"]],"start": [["31"]],"entity_id": [["T3"]]},"entity_id": [["T2"]],"text": [["treated"]],"start": [["31"]],"Time_elapsed": {"text": [["subsequent"]],"start": [["93"]],"entity_id": [["T4"]]},"Dosage": {"text": [["oxaliplatin"]],"start": [["102","109"]],"entity_id": [["T1"]]},"Duration": {"text": [["advanced colonic carcinoma"]],"start": [["6","26"]],"entity_id": [["T5"]]},"Freq": {"text": [["subsequent chemotherapy"]],"start": [["80","101"]],"entity_id": [["T6"]]},"Route": {"text": [["concomitant chemoirradiation with oxaliplatin"]],"start": [["31","61"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["oxaliplatin"]],"start": [["102","109"]],"entity_id": [["T1"]]},"Trigger": {"text": [["subsequent chemotherapy"]],"start": [["80","101"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Subject": {"text": [["patient"]],"start": [["0","5"]],"entity_id": [["T7"]],"Age": {"text": [["advanced"]],"start": [["6"]],"entity_id": [["T8"]]},"Disorder": {"text": [["colon carcinoma"]],"start": [["16","26"]],"entity_id": [["T9"]]},"Population": {"text": [["1"]],"start": [[],[]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["developed"]],"start": [["70"]],"entity_id": [["T10"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["dermatitis"]],"start": [["112","119"]],"entity_id": [["T11"]]}}]}
{"id": "1751354_2","context": "Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Recombinant human interferon-alpha"]],"start": [[ "0" ]],"entity_id": [["T1" ] ],"Disorder": {"text": [["several cancers"]],"start": [[ "42" ]],"entity_id": [["T2"] ]},"Dosage": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ]},"Route": {"text":[["in the treatment"]],"start": [["31"]],"entity_id": [["T0"] ]},"Duration": {"text":[["has been used"]],"start": [["27"]],"entity_id": [["T0"] ]},"Freq": {"text":[["may exacerbate"]],"start": [["81"]],"entity_id": [["T3"] ]},"Combination": [{"Drug": {"text": [["Recombinant human interferon-alpha"]],"start": [["0"]],"entity_id": [["T1"] ]},"Trigger": {"text": [["may exacerbate"]],"start": [["81"]],"entity_id": [["T3"] ]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["may exacerbate"]],"start": [["81"]],"entity_id": [["T3"] ]},"Time_elapsed": {"text":[["may exacerbate"]],"start": [["81"]],"entity_id": [["T3"] ]},"Drug": {"text": [["Recombinant human interferon-alpha"]],"start": [["0"]],"entity_id": [["T1"] ]}},"Negated": {"text":[["may not"]],"start": [["81"]],"entity_id": [["T3"] ],"value": false},"Speculated": {"text":[["may"]],"start": [["81"]],"entity_id": [["T3"] ],"value": false},"Subject": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ],"Gender": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ]},"Age": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ]},"Population": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ]},"Race": {"text":[["it"]],"start": [["37"]],"entity_id": [["T0"] ]},"Disorder": {"text": [["several cancers"]],"start": [["42"]],"entity_id": [["T2"] ]}},"Severity": {"text":[["may exacerbate"]],"start": [["81"]],"entity_id": [["T3"] ],"value": "low"},"Effect": {"text": [["psoriasis"]],"start": [["106"]],"entity_id": [["T4"] ]},"Trigger": {"text": [["or trigger off its onset"]],"start": [["120"]],"entity_id": [["T5"] ]}}]}
{"id": "17034541_3","context": "This is the first case of HBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["HBV reactivation"]],"start": [["This is the first case of HBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rituximab monotherapy"]],"start": [[""]],"entity_id": [["T2"]],"Drug": {"text": [["rituximab"]],"start": [[""]],"entity_id": [["T3"]]} ,"Duration": {"text": [["the year following"]],"start": [[""]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["in the absence of any other immunosuppressive factor"]],"start": [[""]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["occurring during"]],"start": [[""]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["rituximab"]],"start": [[""]],"entity_id": [["T3"]]},"Trigger": {"text": [["monotherapy"]],"start": [[""]],"entity_id": [["T7"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Freq": {"text": [["the first case"]],"start": [[""]],"entity_id": [["T8"]]} ,"Trigger": {"text": [["This"]],"start": [[""]],"entity_id": [["T9"]]} ,"Dosage": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]]} ,"Route": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]]} },"Subject": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] ,"Age": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] },"Population": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] },"Gender": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] },"Race": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] },"Disorder": {"text": [[""]],"start": [[""]],"entity_id": [[""],["T10"]] }} ,"Effect": {"text": [["HBV reactivation"]],"start": [[""]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "6958210_2", "context": "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Systemic lupus erythematosus"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "text": [["penicillamine therapy"]], "start": [[ "52" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["penicillamine"]], "start": [[ "52" ]], "entity_id": [ ["T3"] ]}, "Disorder": { "text": [["rheumatoid arthritis"]], "start": [[ "78" ]], "entity_id": [ ["T4"] ]}, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null , "Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": { "text": [], "start": [], "entity_id": [] , "Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "3346128_2", "context": "Erosion of psoriatic plaques after chronic methotrexate administration", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Erosion of psoriatic plaques"]], "start": [[ ], []], "entity_id": [ ]},"Treatment": {"text": [["chronic methotrexate administration"]], "start": [[]],"entity_id": [ ],"Drug": {"text": [["methotrexate"]], "start": [[]],"entity_id": [ ]},"Dosage": null, "Duration": {"text": [["chronic"]], "start": [[]], "entity_id": [ ]},"Route": null,"Time_elapsed": null,"Disorder": {"text": [["psoriatic plaques"]], "start": [[]], "entity_id": [ ]},"Freq": null,"Combination": null,"Trigger": {"text": [["after"]], "start": [[]], "entity_id": [ ]}},"Effect": {"text": [[]], "start": [[]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [[]], "start": [[]], "entity_id": [], "Age": null, "Disorder": {"text": [["psoriatic plaques"]], "start": [[]], "entity_id": [ ]},"Gender": null,"Population": null,"Race": null} }]}
{"id": "3982906_1","context": "Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cardiac decompensation"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["verapamil therapy"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["verapamil"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["supraventricular tachycardia"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": []} ,"Subject": {"text": [["infants"]],"start": [[ ]],"entity_id": [ ] ,"Age": {"text": [["infants"]],"start": [[ ]],"entity_id": [ ]} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [["infants"]],"start": [[ ]],"entity_id": [ ]} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["supraventricular tachycardia"]],"start": [[ ]],"entity_id": [ ]}} ,"Effect": {"text": [["Cardiac decompensation"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""}}]}
{"id": "19183077_3","context": "We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tenofovir (TDF)-associated nephrotoxicity"]],"start": [["33"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["two cases"]],"start": [[ "4"]],"entity_id": [ ["T2"]],"Age": null,"Gender": null,"Population": {"text": [["perinatally HIV-infected adolescents"]],"start": [["58"]],"entity_id": [ ["T3"]]},"Race": null,"Disorder": {"text": [["HIV-infected"]],"start": [["50"]],"entity_id": [ ["T4"]]}},"Treatment": {"text": [["tenofovir (TDF)"]],"start": [["33"]],"entity_id": [ ["T1"]],"Drug": {"text": [["tenofovir"]],"start": [[ "33"]],"entity_id": [ ["T5"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["TDF-associated nephrotoxicity"]],"start": [[ "19"]],"entity_id": [ ["T6"]]} ,"Combination": null ,"Trigger": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "12324937_6", "context": "Including our own patient, a total of 26 cases of gemcitabine-associated HUS were identified", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Treatment": {"text": [["gemcitabine-associated HUS"]], "start": [["a total of 26 cases of gemcitabine-associated HUS were identified" ], ["Including our own patient,"]], "entity_id": [] ,"Drug": {"text": [["gemcitabine"]], "start": [[ "a total of 26 cases of gemcitabine-associated HUS were identified" ]], "entity_id": []} ,"Disorder": {"text": [["HUS"]], "start": [[ "a total of 26 cases of gemcitabine-associated HUS were identified" ]], "entity_id": []} ,"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Subject": null ,"Severity": null ,"Negated": null ,"Speculated": null ,"Effect": null ,"Trigger": null }]}
{"id": "17260498_5","context": "Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel-induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["adverse event"]],"start": [["Even though only a few cases of this "]],"entity_id": [ ["T1"]]},"Effect": {"text": [["severe docetaxel-induced pulmonary toxicity"]],"start": [["severe docetaxel-induced pulmonary toxicity"]],"entity_id": [ ["T2"]]} ,"Negated": {"value": false ,"text": [["have been reported"]],"start": [[", only a few cases of this "]],"entity_id": [ ["T3"]]} ,"Severity": {"value": "severe" ,"text": [["severe"]],"start": [["severe"]],"entity_id": [ ["T4"]]} ,"Subject": {"text": [["such patients"]],"start": [["such patients present with"]],"entity_id": [ ["T5"]] ,"Disorder": {"text": [["respiratory symptoms"]],"start": [[", when such patients present with"]],"entity_id": [ ["T6"]]} ,"Population": {"text": [["a few cases"]],"start": [[", only a few cases of this "]],"entity_id": [ ["T7"]]} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["docetaxel"]],"start": [["docetaxel-induced"]],"entity_id": [ ["T8"]] ,"Drug": {"text": [["docetaxel"]],"start": [["docetaxel-induced"]],"entity_id": [["T9"]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["pulmonary toxicity"]],"start": [["pulmonary toxicity"]],"entity_id": [ ["T10"]] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": [] ,"Trigger": {"text": [["induced"]],"start": [["induced"]],"entity_id": [ ["T11"]]} },"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []} }]}
{"id": "12221670_1","context": "The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed severe aplastic anemia"]],"start": [["22"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["a 70-year-old man"]],"start": [["0"]],"entity_id": [ ["T2"]],"Age": {"text": [["70"]],"start": [["3"]],"entity_id": [ ["T3"]]},"Gender": {"text": [["man"]],"start": [["13"]],"entity_id": [ ["T4"]]},"Disorder": {"text": [["severe aplastic anemia"]],"start": [["22"]],"entity_id": [ ["T1"]]},"Population": {"text": [["a 70-year-old man"]],"start": [["0"]],"entity_id": [ ["T2"]]},"Race": {"text": [["a 70-year-old man"]],"start": [["0"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["treatment with 500 mg of ticlopidine daily"]],"start": [["54"]],"entity_id": [ ["T5"]],"Drug": {"text": [["ticlopidine"]],"start": [["61"]],"entity_id": [ ["T6"]]},"Dosage": {"text": [["500 mg"]],"start": [["57"]],"entity_id": [ ["T7"]]},"Duration": {"text": [["daily"]],"start": [["74"]],"entity_id": [ ["T8"]]},"Route": {"text": [["treatment with"]],"start": [["54"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["7 weeks after"]],"start": [["33"]],"entity_id": [ ["T9"]]},"Disorder": {"text": [["severe aplastic anemia"]],"start": [["22"]],"entity_id": [ ["T1"]]},"Freq": {"text": [["daily"]],"start": [["74"]],"entity_id": [ ["T8"]]},"Combination": [{"Drug": {"text": [["ticlopidine"]],"start": [["61"]],"entity_id": [ ["T6"]]},"Trigger": {"text": [["treatment with"]],"start": [["54"]],"entity_id": [ ["T5"]]},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["developed severe aplastic anemia"]],"start": [["22"]],"entity_id": [ ["T1"]]}},"Effect": {"text": [["developed severe aplastic anemia"]],"start": [["22"]],"entity_id": [ ["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["22"]],"entity_id": [ ["T10"]],"value": "high"}}]}
{"id": "17931455_1","context": "A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["unilateral hearing loss"]],"start": [["28"]],"entity_id": [["T1"]]},"Subject": {"text": [["a six-year-old boy"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["six-year-old"]],"start": [["0"]],"entity_id": [["A1"]]},"Disorder": {"text": [["transfusion-dependent beta-thalassaemia"]],"start": [["12"]],"entity_id": [["T3"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["P1"]]},"Gender": {"text": [["boy"]],"start": [["0"]],"entity_id": [["G1"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["desferrioxamine therapy"]],"start": [["69"]],"entity_id": [["T4"]],"Drug": {"text": [["desferrioxamine"]],"start": [["69"]],"entity_id": [["D1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9796135_4","context": "Syncope in a 65-year-old woman after nitrate ingestion","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Syncope"]],"start": [["0"]] ,"entity_id": [ ["T1"] ] },"Subject": {"text": [["a 65-year-old woman"]],"start": [["10"]],"entity_id": [["T2"] ],"Age": {"text": [["65"]],"start": [["10"]],"entity_id": [ ["Age1"] ] },"Gender": {"text": [["woman"]],"start": [["15"]],"entity_id": [ ["Gender1"] ] } ,"Race": { "text":[[]], "start":[], "entity_id": [] } ,"Disorder": { "text":[[]], "start":[], "entity_id": [] } ,"Population": { "text":[[]], "start":[], "entity_id": [] } },"Treatment": {"text": [["nitrate ingestion"]],"start": [["40"]],"entity_id": [ ["T3"] ],"Drug": {"text": [["nitrate"]],"start": [["40"]],"entity_id": [ ["Drug1"] ] },"Dosage": {"text": [[]],"start": [],"entity_id": [] },"Duration": {"text": [[]],"start": [],"entity_id": [] },"Disorder": {"text": [[]],"start": [],"entity_id": [] },"Route": {"text": [["ingestion"]],"start": [["44"]],"entity_id": [ ["Route1"] ] },"Time_elapsed": {"text": [[]],"start": [],"entity_id": [] },"Freq": {"text": [[]],"start": [],"entity_id": [] },"Combination": null ,"Trigger": { "text":[[]], "start":[], "entity_id": [] } },"Effect": {"text": [["Syncope"]],"start": [["0"]],"entity_id": [ ["Effect1"] ] } ,"Negated": { "text":[[]], "start":[], "entity_id": [] ,"value": false } ,"Speculated": { "text":[[]], "start":[], "entity_id": [] ,"value": false } ,"Severity": { "text":[[]], "start":[], "entity_id": [] ,"value": "" } } ]}
{"id": "9247841_5","context": "The observation of cutaneous vasculitis during administration of propylthiouracil suggested that clinical awareness of this complication should be of considerable importance","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cutaneous vasculitis"]],"start": [["13", "20"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["propylthiouracil"]],"start": [["42", "55"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"Trigger": {"text": [["administration"]],"start": [["42", "49"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["during"]],"start": [["13", "18"]],"entity_id": [["T4"]]},"Freq": {"text": [["should be"]],"start": [["63", "71"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["propylthiouracil"]],"start": [["42", "55"]],"entity_id": [["T6"]]},"Trigger": {"text": [["administration"]],"start": [["42", "49"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"text": [["cutaneous vasculitis"]],"start": [["13", "20"]],"Disorder": {"text": [["this complication"]],"start": [["72", "83"]],"entity_id": [["T8"]]},"Route": {"text": [["during administration"]],"start": [["42", "49"]],"entity_id": [["T9"]]},"Duration": {"text": [["of considerable importance"]],"start": [["85", "97"]],"entity_id": [["T10"]]},"Dosage": {"text": [["clinical awareness"]],"start": [["21", "34"]],"entity_id": [["T11"]]}},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["this complication"]],"start": [["72", "83"]],"entity_id": [["T12"]]}},"Effect": {"text": [["cutaneous vasculitis"]],"start": [["13", "20"]],"entity_id": [["T13"]]}}]}
{"id": "16109609_3","context": "Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["gemcitabine-induced radiation recall reaction"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gemcitabine"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["gemcitabine"]],"start": [["56"]],"entity_id": [["T2"]]},"Disorder": {"text": [["radiation recall reaction"]],"start": [["16"]],"entity_id": [["T3"]]},"Route": {"text": [["induced"]],"start": [["54"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["resulting"]],"start": [["42"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developing"]],"start": [["8"]],"entity_id": [["T6"]]},"Freq": {"text": [["potential"]],"start": [["0"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["gemcitabine"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["gemcitabine-induced radiation recall reaction"]],"start": [["0"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["hemodynamically significant pericardial effusion"]],"start": [["84"]],"entity_id": [["T8"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["significant"]],"start": [["94"]],"entity_id": [["T9"]],"value": "high"},"Subject": null}]}
{"id": "6149250_4","context": "The second patient suffered from high blood pressure, which was controlled with beta-blocker drugs","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["high blood pressure"]],"start": [["16"]],"entity_id": [["T1"]]},"Subject": {"text": [["The second patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["high blood pressure"]],"start": [["16"]],"entity_id": [["T1"]]}},"Treatment": {"text": [["beta-blocker drugs"]],"start": [["62"]],"entity_id": [["T2"]],"Drug": {"text": [["beta-blocker"]],"start": [["62"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["high blood pressure"]],"start": [["16"]],"entity_id": [["T1"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null }] }
{"id": "11999915_3","context": "The female patient received clozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["clozapine"]],"start": [["The female patient received clozapine in a daily dose of 400 mg,"], ["which induced agranulocytosis after 2 months."]],"entity_id": []},"Treatment": {"text": [["clozapine"]],"start": [[ "received clozapine" ]],"entity_id": [],"Drug": {"text": [["clozapine"]],"start": [[ "received clozapine" ]],"entity_id": []},"Disorder": {"text": [["clozapine"]],"start": [[ "received clozapine" ]],"entity_id": []},"Dosage": {"text": [["400 mg"]],"start": [[ "daily dose of 400 mg," ]],"entity_id": []},"Duration": {"text": [["2 months"]],"start": [[ "after 2 months" ]],"entity_id": []},"Freq": {"text": [["daily"]],"start": [[ "daily dose of" ]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": []},"Effect": {"text": [["agranulocytosis"]],"start": [[ "induced agranulocytosis" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["The female patient"]],"start": [[ "The female patient" ]],"entity_id": [],"Age": null,"Disorder": null,"Gender": {"text": [["female"]],"start": [[ "The female patient" ]],"entity_id": []},"Population": null,"Race": null}}]}
{"id": "11399735_4","context": "We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["interstitial pulmonary disease"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with ticlopidine"]],"start": [["88"]],"entity_id": [["T2"]],"Drug": {"text": [["ticlopidine"]],"start": [["88"]],"entity_id": [["T3"]]} , "Disorder" : { "text" : [["interstitial pulmonary disease"]], "start" : [[ "33" ]], "entity_id" : [["T1"]] } , "Time_elapsed" : { "text" : [["occurred together"]], "start" : [[ "47" ]], "entity_id" : [["T4"]] } , "Combination" : [ { "Drug" : { "text" : [["ticlopidine"]], "start" : [[ "88" ]], "entity_id" : [["T3"]] } , "Trigger" : { "text" : [["occurred together"]], "start" : [[ "47" ]], "entity_id" : [["T4"]] } , "event_id" : "E2" , "event_type" : "Adverse_event" } ] , "Freq" : { "text" : [["during treatment"]], "start" : [[ "74" ]], "entity_id" : [["T5"]] } , "Duration" : { "text" : [["during treatment"]], "start" : [[ "74" ]], "entity_id" : [["T5"]] } , "Route" : { "text" : [["treatment with"]], "start" : [[ "74" ]], "entity_id" : [["T5"]] } , "Dosage" : { "text" : [["treatment with"]], "start" : [[ "74" ]], "entity_id" : [["T5"]] } , "Trigger" : { "text" : [["occurred together"]], "start" : [[ "47" ]], "entity_id" : [["T4"]] } } , "Negated" : { "value" : false , "entity_id" : [["T4"]] , "start" : [[ "47" ]], "text" : [["occurred together"]] } , "Speculated" : { "value" : false , "entity_id" : [["T4"]] , "start" : [[ "47" ]], "text" : [["occurred together"]] } , "Severity" : { "value" : "Low" , "entity_id" : [["T1"]] , "start" : [[ "33" ]], "text" : [["interstitial pulmonary disease"]] } , "Subject" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]], "Age" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]] } , "Gender" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]] } , "Population" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]] } , "Race" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]] } , "Disorder" : { "text" : [["We"]], "start" : [[ "0" ]], "entity_id" : [["T0"]] } } , "Effect" : { "text" : [["interstitial pulmonary disease"]], "start" : [[ "33" ]], "entity_id" : [["T1"]] } } ]}
{"id": "9579301_1","context": "Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Increased ocular pressure"]],"start": [[ "0" ]],"entity_id": [[ "T1" ]]},"Subject": {"text": [["two patients with narrow angle glaucoma"]],"start": [[ "32" ]],"entity_id": [[ "T2" ]],"Disorder": {"text": [["narrow angle glaucoma"]],"start": [[ "32" ]],"entity_id": [[ "T3" ]]},"Age": null,"Gender": null,"Population": {"text": [["two"]],"start": [[ "32" ]],"entity_id": [[ "T4" ]]},"Race": null},"Treatment": {"text": [["venlafaxine"]],"start": [[ "83" ]],"entity_id": [[ "T5" ]],"Drug": {"text": [["venlafaxine"]],"start": [[ "83" ]],"entity_id": [[ "T6" ]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Disorder": {"text": [["narrow angle glaucoma"]],"start": [[ "32" ]],"entity_id": [[ "T3" ]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6484655_1","context": "Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ampicillin therapy"]],"start": [["91"]],"entity_id": [["T2"]],"Drug": {"text": [["ampicillin"]],"start": [["91"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["at the time of seizures"]],"start": [["54"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["high serum concentrations"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["without their recurrence after discontinuing the antibiotic"]],"start": [["66"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["complex medical problems"]],"start": [["5"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["their"]],"start": [["46"]],"entity_id": [["T8"]]} ,"Route": {"text": [["the antibiotic"]],"start": [["102"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["ampicillin"]],"start": [["91"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["high serum concentrations"]],"start": [["18"]],"entity_id": [["T5"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Dosage": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T1"]]} ,"Subject": {"text": [["they"]],"start": [["4"]],"entity_id": [["T10"]],"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["complex medical problems"]],"start": [["5"]],"entity_id": [["T7"]]} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "medium"} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} }]}
{"id": "17319250_1","context": "Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of methadone, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fluctuation"]],"start": [["33"]],"entity_id": []},"Treatment": {"text": [["methadone"]],"start": [["56"]],"entity_id": [],"Drug": {"text": [["methadone"]],"start": [["56"]],"entity_id": []} ,"Dosage": {"text": [["stable dose"]],"start": [["50"]],"entity_id": []} ,"Route": {"text": [["at"]],"start": [["47"]],"entity_id": []} ,"Duration": {"text": [["stable"]],"start": [["48"]],"entity_id": []} ,"Time_elapsed": {"text": [["at"]],"start": [["47"]],"entity_id": []} ,"Trigger": {"text": [["this patient"]],"start": [["15"]],"entity_id": []} ,"Freq": {"text": [["a single"]],"start": [["22"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["methadone"]],"start": [["56"]],"entity_id": []} ,"Trigger": {"text": [["at"]],"start": [["47"]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Disorder": {"text": [["ventricular arrhythmias"]],"start": [["105"]],"entity_id": []} },"Effect": {"text": [["fluctuation"]],"start": [["33"]],"entity_id": []} ,"Subject": {"text": [["this patient"]],"start": [["15"]],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [["of particular interest"]],"start": [["0"]],"entity_id": [] ,"value": false },"Severity": {"text": [["fluctuation"]],"start": [["33"]],"entity_id": [] ,"value": "" }} ]}
{"id": "1393348_2","context": "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of carbamazepine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["SLE"]],"start": [["33"]],"entity_id": [["T1"]] ,"Age": null,"Disorder": {"text": [["SLE"]],"start": [["0"]],"entity_id": [["T2"]] },"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["carbamazepine"]],"start": [["114"]],"entity_id": [["T3"]],"Drug": {"text": [["carbamazepine"]],"start": [["114"]],"entity_id": [["T4"]] },"Dosage": null,"Duration": null,"Disorder": {"text": [["SLE"]],"start": [["33"]],"entity_id": [["T1"]] },"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null },"Effect": {"text": [["SLE"]],"start": [["33"]],"entity_id": [["T1"]] },"Trigger": {"text": [["adverse effect"]],"start": [["101"]],"entity_id": [["T5"]] }} ]}
{"id": "10803790_1","context": "Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["induce"]],"start": [["33"]],"entity_id": []},"Treatment": {"text": [["Cyanamide"]],"start": [["6"]],"entity_id": [],"Drug": {"text": [["Cyanamide"]],"start": [["6"]],"entity_id": []},"Disorder": {"text": [["hepatic lesion"]],"start": [["43"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["induce"]],"start": [["33"]],"entity_id": []}},"Effect": {"text": [["various degrees of hepatic lesion with ground-glass inclusion bodies"]],"start": [["43"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": null}]}
{"id": "17675030_3","context": "Oxcarbazepine-associated angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Oxcarbazepine-associated angioedema"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Effect": {"text": [["swelling of the face", "swelling of the eyes", "swelling of the lips", "swelling of the tongue", "difficulty swallowing", "difficulty breathing"]],"start": [["38"],["60"],["65"],["71"],["85"],["100"]],"entity_id": [["T2"],["T3"],["T4"],["T5"],["T6"],["T7"] ]},"Severity": {"value": "high" ,"text": [["life-threatening"]],"start": [["115"]],"entity_id": [ ["T8"] ]},"Negated": null,"Speculated": null ,"Subject": { "Population": { "text": [["a patient"]],"start": [["0"]],"entity_id": [ ["T0"] ]},"Disorder": null,"Age": null,"Gender": null,"Race": null ,"text": [["patient"]],"start": [["0"]],"entity_id": [ ["T0"] ]} ,"Treatment": { "Drug": { "text": [["Oxcarbazepine"]],"start": [["15"]],"entity_id": [ ["T1"] ]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"text": [["Oxcarbazepine"]],"start": [["15"]],"entity_id": [["T1"] ],"Combination": null ,"Trigger": null }} ]}
{"id": "15494638_1","context": "Peripheral neuropathy associated with capecitabine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Peripheral neuropathy"]],"start": [["0"]],"entity_id": [ ["T1"] ] },"Treatment": { "text": [["capecitabine"]], "start": [[ "48" ]] ,"entity_id": [ ["T2" ]] ,"Drug": { "text": [["capecitabine"]], "start": [[ "48" ]] ,"entity_id": [ ["T2" ]] } ,"Disorder": { "text": [["Peripheral neuropathy"]], "start": [[ "0" ]] ,"entity_id": [ ["T1" ]] } ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [["associated with"]], "start": [[ "25" ]] ,"entity_id": [ ["T3" ]] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": { "text": [["Peripheral neuropathy"]], "start": [[ "0" ]] ,"entity_id": [ ["T1" ]] } ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "16411025_1", "context": "We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX.\n", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["central neurological syndrome"]], "start": [["56"]], "entity_id": []}, "Treatment": {"text": [["intrathecal MTX"]], "start": [["111"]], "entity_id": [], "Drug": {"text": [["MTX"]], "start": [["111"]], "entity_id": []}, "Route": {"text": [["intrathecal"]], "start": [["105"]], "entity_id": []}, "Time_elapsed": {"text": [["days"]], "start": [["89"]], "entity_id": []}, "Trigger": null, "Dosage": null, "Duration": null, "Disorder": null, "Freq": null, "Combination": null},"Subject": {"text": [["four patients"]], "start": [["23"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "9497597_1", "context": "Prothipendylhydrochloride-induced priapism: case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Prothipendylhydrochloride-induced priapism"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]},"Subject": { "text": [["case report"]], "start": [[ "48" ]], "entity_id": [ ["T2"] ],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }, "Treatment": { "text": [["Prothipendylhydrochloride"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ],"Drug": { "text": [["Prothipendylhydrochloride"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ]} ,"Dosage": null ,"Duration": null ,"Trigger": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Disorder": null ,"Combination": null },"Effect": { "text": [["priapism"]], "start": [[ "30" ]], "entity_id": [ ["T4"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "20412003_5","context": "Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of hepatotoxicity and the TMP-SMX therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse drug reaction"]],"start": [[ "39" ]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["TMP-SMX therapy"]],"start": [[ "86" ]],"entity_id": [ ["T2"]],"Drug": {"text": [["TMP-SMX"]],"start": [[ "86" ]],"entity_id": [ ["T3"]]} ,"Trigger": {"text": [["TMP-SMX therapy"]],"start": [[ "86" ]],"entity_id": [ ["T2"]]},"Disorder": {"text": [["hepatotoxicity"]],"start": [[ "54" ]],"entity_id": [ ["T4"]]} ,"Freq": {"text": [["probable relationship (score of 5)"]],"start": [[ "18" ]],"entity_id": [ ["T5"]]},"Time_elapsed": {"text": [["development"]],"start": [[ "54" ]],"entity_id": [ ["T6"]]} ,"Combination": null ,"Dosage": null ,"Duration": null ,"Route": null },"Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "24429012_9","context": "Since its introduction in 2012, vismodegib has been implicated as a possible factor in seven reports of patient deaths","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["possible factor in patient deaths"]],"start": [["possible factor in patient deaths" , "patient deaths" ]],"entity_id": []},"Treatment": {"text": [["vismodegib"]],"start": [[ "vismodegib" ]],"entity_id": [] ,"Drug": {"text": [["vismodegib"]],"start": [[ "vismodegib" ]],"entity_id": [] },"Disorder": {"text": [["patient deaths"]],"start": [[ "patient deaths" ]],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": [] },"Effect": {"text": [],"start": [],"entity_id": [] },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high" }} ]}
{"id": "8461228_2", "context": "Acceleration of ventricular response to atrial flutter after intravenous adenosine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acceleration of ventricular response"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["intravenous adenosine"]], "start": [[ "58" ]], "entity_id": [ ["T2" ]],"Drug": {"text": [["adenosine"]], "start": [[ "58" ]], "entity_id": [ ["T3" ]]}, "Disorder": {"text": [["atrial flutter"]], "start": [[ "15" ]], "entity_id": [ ["T4" ]]}, "Time_elapsed": {"text": [["after"]], "start": [[ "45" ]], "entity_id": [ ["T5" ]]}, "Freq": {"text": [["after"]], "start": [[ "45" ]], "entity_id": [ ["T5" ]]} , "Route": {"text": [["intravenous"]], "start": [[ "50" ]], "entity_id": [ ["T6" ]]} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": null }, "Negated": null , "Speculated": null , "Severity": null , "Subject": null , "Effect": null}]}
{"id": "4036917_1","context": "Physicians should be aware of the potential for the development of RS among children who are receiving long-term aspirin therapy for the treatment of systemic inflammatory illnesses","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["aspirin"]],"start": [["46"]],"entity_id": [["T1"]]},"text": [["long-term aspirin therapy"]],"start": [["28"]],"entity_id": [["T2"]],"Disorder": {"text": [["systemic inflammatory illnesses"]],"start": [["102"]],"entity_id": [["T3"]]},"Duration": {"text": [["long-term"]],"start": [["28"]],"entity_id": [["T4"]]},"Route": {"text": [["therapy"]],"start": [["43"]],"entity_id": [["T5"]]},"Trigger": {"text": [["development"]],"start": [["15"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["for"]],"start": [["11"]],"entity_id": [["T7"]]},"Freq": {"text": [["the"]],"start": [["7"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["aspirin"]],"start": [["46"]],"entity_id": [["T1"]]},"Trigger": {"text": [["development"]],"start": [["15"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [["therapy"]],"start": [["43"]],"entity_id": [["T5"]]}},"Subject": {"text": [["children"]],"start": [["69"]],"entity_id": [["T9"]],"Population": {"text": [["children"]],"start": [["69"]],"entity_id": [["T9"]]},"Age": {"text": [["children"]],"start": [["69"]],"entity_id": [["T9"]]},"Gender": {"text": [["children"]],"start": [["69"]],"entity_id": [["T9"]]},"Race": {"text": [["children"]],"start": [["69"]],"entity_id": [["T9"]]},"Disorder": {"text": [["systemic inflammatory illnesses"]],"start": [["102"]],"entity_id": [["T3"]]}},"Effect": {"text": [["RS"]],"start": [["75"]],"entity_id": [["T10"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["potential"]],"start": [["1"]],"entity_id": [["T11"]]}}]}
{"id": "889156_7","context": "While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction to oleic acid, a dispersing agent in the aerosol freon vehicle, is a strong possibility","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse reaction"]],"start": [["While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction to oleic acid,"], ["strong possibility"]],"entity_id": [["T1"], ["T3"]]},"Treatment": {"Drug": {"text": [["oleic acid"]],"start": [["adverse reaction to oleic acid"]],"entity_id": [["T2"]]} ,"entity_id": [["T2"]] ,"Trigger": {"text": [["dispersing agent in the aerosol freon vehicle"]],"start": [["adverse reaction to oleic acid"]],"entity_id": [["T4"]]} ,"Route": {"text": [["aerosol freon vehicle"]],"start": [["adverse reaction to oleic acid"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["a lower systemic steroid dosage"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["strong possibility"]],"start": [["strong possibility"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["a lower systemic steroid dosage"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["Gynaecomastia"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["a lower systemic steroid dosage"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor"]],"entity_id": [["T5"]]} ,"text": [["adverse reaction"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction"]],"Combination": [{"Drug": {"text": [["oleic acid"]], "start": [["adverse reaction to oleic acid"]], "entity_id": [["T2"]]} , "Trigger": {"text": [["dispersing agent in the aerosol freon vehicle"]], "start": [["adverse reaction to oleic acid"]], "entity_id": [["T4"]]}, "event_id": "E2" , "event_type": "Adverse_event" }] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["we"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor, we feel that"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Gynaecomastia"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor"]],"entity_id": [["T6"]]} ,"entity_id": [["T6"]] },"Effect": {"text": [["adverse reaction"]],"start": [[ "While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction"]],"entity_id": [["T1"]]} }] }
{"id": "7787496_2","context": "We present a case of sotalol-induced bradycardia reversed by glucagon","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sotalol-induced bradycardia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["glucagon"]],"start": [["59"]],"entity_id": [["T2"]],"Drug": {"text": [["glucagon"]],"start": [["59"]],"entity_id": [["T3"]]} ,"Route": {"text": [["reversed"]],"start": [["48"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["reversed"]],"start": [["48"]],"entity_id": [["T4"]]},"Trigger": {"text": [["reversed"]],"start": [["48"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["glucagon"]],"start": [["59"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["sotalol-induced bradycardia"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["glucagon"]],"start": [["59"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["reversed"]],"start": [["48"]],"entity_id": [["T4"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] },"Severity": {"text": [["bradycardia"]],"start": [["26"]],"entity_id": [["T6"]],"value": "medium"} ,"Negated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["reversed"]],"start": [["48"]],"entity_id": [["T4"]]} }] }
{"id": "19423610_7","context": "Methylene blue has been found to be a potent inhibitor of monoamine oxidase (MAO), and several cases of serotonin toxicity have been reported recently following its administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Methylene blue"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["Methylene blue"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["Methylene blue"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["recently"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["serotonin toxicity"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["administration"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [["a potent inhibitor"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["of monoamine oxidase (MAO)"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["several cases"]],"start": [[ ]],"entity_id": [ ]},"Combination": null,"Duration": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "8903300_1","context": "She had just finished a 3-week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["3-week course of intravenous tobramycin"]],"start": [[ ]],"entity_id": [["T1"]] ,"Disorder": {"text": [["bronchiectasis"]],"start": [[ ]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["3-week"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Duration": {"text": [["3-week"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Route": {"text": [["intravenous"]],"start": [[ ]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["1 week"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["elevated serum tobramycin trough level"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Freq": {"text": [["before the onset of tetany"]],"start": [[ ]],"entity_id": [["T7"]]} ,"Drug": {"text": [["tobramycin"]],"start": [[ ]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["tobramycin"]],"start": [[ ]],"entity_id": [["T8"]]} ,"Trigger": {"text": [["elevated serum tobramycin trough level"]],"start": [[ ]],"entity_id": [["T6"]]} ,"event_id": "C1","event_type": "Adverse_event"} ] } , "Subject": {"text": [["She"]],"start": [[ ]],"entity_id": [["T0"]] ,"Age": {"text": [[""]],"start": [[ ]],"entity_id": [["T0"]]} ,"Gender": {"text": [[""]],"start": [[ ]],"entity_id": [["T0"]]} ,"Population": {"text": [[""]],"start": [[ ]],"entity_id": [["T0"]]} ,"Race": {"text": [[""]],"start": [[ ]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["bronchiectasis"]],"start": [[ ]],"entity_id": [["T2"]]} } , "Effect": {"text": [["tetany"]],"start": [[ ]],"entity_id": [["T9"]]} , "Severity": {"text": [[""]],"start": [[ ]],"entity_id": [["T9"]] ,"value": "low"} , "Negated": {"text": [[""]],"start": [[ ]],"entity_id": [["T9"]] ,"value": false} , "Speculated": {"text": [[""]],"start": [[ ]],"entity_id": [["T9"]] ,"value": false} , "Trigger": {"text": [["onset of tetany"]],"start": [[ ]],"entity_id": [["T10"]]} } ] }
{"id": "9796135_3", "context": "In a postural challenge test after administration of isosorbide dinitrate (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["isosorbide dinitrate"]], "start": [["36"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["isosorbide dinitrate (5 mg)"], ["isosorbide dinitrate"]], "start": [["21"]], "entity_id": [["T1"], ["T2"]], "Dosage": {"text": [["5 mg"]], "start": [["26"]], "entity_id": [["T3"]]},"Route":{"text":[["administration"]], "start":[["22"]], "entity_id":[["T4"]]},"Time_elapsed":{"text":[["postural challenge test"]], "start":[["4"]], "entity_id":[["T5"]]},"Freq":{"text":[["followed by syncope with a sudden decrease in pulse rate from"]], "start":[["58"]], "entity_id":[["T6"]]}, "Trigger":{"text":[["decreased"]], "start":[["40"]], "entity_id":[["T7"]]},"Drug":{"text":[["isosorbide dinitrate"]], "start":[["36"]], "entity_id":[["T8"]]},"Disorder":{"text":[["syncope"]], "start":[["60"]], "entity_id":[["T9"]]},"Duration":{"text":[["decreased from"]], "start":[["40"]], "entity_id":[["T10"]]},"Combination":[{"Drug":{"text":[["isosorbide dinitrate"]], "start":[["36"]], "entity_id":[["T11"]]},"Trigger":{"text":[["decreased"]], "start":[["40"]], "entity_id":[["T12"]]},"event_id":"C1","event_type":"Potential_therapeutic_effect"}]},"Effect": {"text": [["blood pressure decreased from 120/67 to 65/35 mmHg"]],"start": [[ "40" ]],"entity_id": [["T13"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["In"]],"start": [[ "0" ]],"entity_id": [["T14"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "19122478_7","context": "The condition improved slowly after stopping medication and systemic steroids","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["improved"]],"start": [["0"]],"entity_id": []},"Treatment": {"Drug": {"text": [["medication"]],"start": [["30"]],"entity_id": []},"Trigger": {"text": [["stopping"]],"start": [["18"]],"entity_id": []},"entity_id": [],"Disorder": {"text": [["condition"]],"start": [["0"]],"entity_id": []},"Duration": {"text": [["slowly"]],"start": [["7"]],"entity_id": []},"Freq": {"text": [["stopping"]],"start": [["18"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": [],"text": [],"start": [["18","30"]]},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["condition"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["condition"]],"start": [["0"]],"entity_id": []}}}]}
{"id": "19995690_2","context": "Acetaminophen is a widely used analgesic that can cause acute liver failure when consumed above a maximum daily dose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acetaminophen"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["Acetaminophen"]],"start": [[ "0" ]],"entity_id": [ ],"Drug": {"text": [["Acetaminophen"]],"start": [[ "0" ]],"entity_id": [ ]},"Dosage": {"text": [["above a maximum daily dose"]],"start": [[ "52" ]],"entity_id": [ ]},"Freq": {"text": [["when consumed"]],"start": [[ "36" ]],"entity_id": [ ]},"Disorder": {"text": [["acute liver failure"]],"start": [[ "41" ]],"entity_id": [ ]},"Route": {"text": [["consumed"]],"start": [[ "52" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["when consumed"]],"start": [[ "36" ]],"entity_id": [ ]},"Duration": { "text": [ ], "start": [ ], "entity_id": [ ] },"Trigger": { "text": [ ], "start": [ ], "entity_id": [ ] },"Combination": [ ] },"Effect": { "text": [["acute liver failure"]], "start": [[ "41" ]], "entity_id": [ ]},"Subject": { "text": [["Acetaminophen"]], "start": [[ "0" ]], "entity_id": [ ],"Age": { "text": [ ], "start": [ ], "entity_id": [ ] },"Disorder": { "text": [ ], "start": [ ], "entity_id": [ ] },"Gender": { "text": [ ], "start": [ ], "entity_id": [ ] },"Population": { "text": [ ], "start": [ ], "entity_id": [ ] },"Race": { "text": [ ], "start": [ ], "entity_id": [ ] }},"Negated": { "text": [ ], "start": [ ], "entity_id": [ ] ,"value": false},"Speculated": { "text": [ ], "start": [ ], "entity_id": [ ], "value": false },"Severity": { "text": [["acute liver failure"]], "start": [[ "41" ]], "entity_id": [ ], "value": "high" }}]}
{"id": "10203437_9","context": "Patients treated with 5-ASA compounds who experience acute inflammatory symptoms or clinical deterioration not related to their gastrointestinal disease should be screened to rule out a lupus-like reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["5-ASA compounds"]],"start": [["10"]],"entity_id": [["T1"]] ,"Drug": {"text": [["5-ASA"]],"start": [["10"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["acute inflammatory symptoms or clinical deterioration not related to their gastrointestinal disease"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["experience"]],"start": [["38"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["who"]],"start": [["21"]],"entity_id": [["T5"]]} ,"Route": {"text": [["treated"]],"start": [["17"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["with"]],"start": [["14"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["Patients"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Time_elapsed": {"text": [["should be screened"]],"start": [["84"]],"entity_id": [["T9"]]} ,"Combination": [{"Drug": {"text": [["5-ASA"]],"start": [["10"]],"entity_id": [["T2"]]},"Trigger": {"text": [["experience"]],"start": [["38"]],"entity_id": [["T4"]]} ,"event_type": "Adverse_event" ,"event_id": "E2" }] },"Subject": {"text": [["Patients"]],"start": [["0"]],"entity_id": [["T10"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["gastrointestinal disease"]],"start": [["76"]],"entity_id": [["T11"]]}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [["screened"]],"start": [["84"]],"entity_id": [["T12"]]} ,"Trigger": {"text": [["should be screened"]],"start": [["84"]],"entity_id": [["T9"]]}} ]}
{"id": "10466445_1","context": "Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["arsenic trioxide"]],"start": [["21"]],"entity_id": [["T1"]],"Disorder": {"text": [["ATRA-resistant relapse of acute promyelocytic leukemia"]],"start": [["62"]],"entity_id": [["T3"]]},"Dosage": {"text": [["Successful treatment"]],"start": [["0"]],"entity_id": [["T2"]]},"Duration": {"text": [["a patient with"]],"start": [["42"]],"entity_id": [["T4"]]},"Trigger": {"text": [["Successful"]],"start": [["0"]],"entity_id": [["T5"]]},"Freq": {"text": [["treatment"]],"start": [["20"]],"entity_id": [["T6"]]},"Route": {"text": [["with"]],"start": [["19"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null,"Drug": {"text": [["arsenic trioxide"]],"start": [["21"]],"entity_id": [["T1"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "19122478_1","context": "Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Drug rash with eosinophilia and systemic symptoms"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["chlorambucil treatment"]],"start": [["27"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["chlorambucil"]],"start": [["27"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["chronic lymphocytic leukaemia"]],"start": [["50"]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": null} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "2406680_1", "context": "Quinine-induced hearing loss", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Quinine-induced hearing loss"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Treatment": {"Drug": {"text": [["Quinine"]], "start": [[ ]], "entity_id": [[ "T2" ]]}, "entity_id": [[ "T3" ]] , "Disorder": {"text": [["hearing loss"]], "start": [[ ]], "entity_id": [[ "T4" ]]} ,"Time_elapsed": null, "Duration": null, "Freq": null, "Route": null, "Dosage": null, "text": [[ "Quinine-induced hearing loss" ]], "start": [[ ]], "Trigger": null, "Combination": null} ,"Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "17458405_1", "context": "Ezetimibe-induced acute pancreatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ezetimibe-induced"]], "start": [["0"]], "entity_id":[["T1"]]}, "Treatment": {"text": [["Ezetimibe"]], "start": [["0"]], "entity_id":[["T2"]],"Drug": {"text": [["Ezetimibe"]], "start": [["0"]], "entity_id":[["T2"]]},"Disorder": {"text": [["acute pancreatitis"]], "start": [["13"]], "entity_id":[["T3"]]}, "Combination": null, "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Trigger": null},"Effect": {"text": [["acute pancreatitis"]], "start": [["13"]], "entity_id":[["T3"]]}, "Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "1569260_2","context": "We report a case of drug-induced pemphigus caused by an angiotensin-converting enzyme inhibitor, captopril","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["drug-induced pemphigus"]],"start": [["13","14","15","16","17","18","19","20","21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["angiotensin-converting enzyme inhibitor, captopril"]],"start": [["46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63"]],"entity_id": [["T2"]],"Drug": {"text": [["captopril"]],"start": [["56","57","58","59"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["pemphigus"]],"start": [["10","11","12"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["caused"]],"start": [["22","23","24"]],"entity_id": [["T5"]]} ,"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Combination": null ,"Trigger": {"text": [["angiotensin-converting enzyme inhibitor, captopril"]],"start": [["46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63"]],"entity_id": [["T2"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "10589077_5","context": "We conclude that low-dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["low-dose HU therapy"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["HU"]],"start": [["15"]],"entity_id": [["T2"]]},"Disorder": {"text": [["thalassemia intermedia"]],"start": [["44"]],"entity_id": [["T3"]]},"Dosage": {"text": [["low-dose"]],"start": [["6"]],"entity_id": [["T4"]]},"Route": {"text": [["therapy"]],"start": [["0"]],"entity_id": [["T5"]]},"Duration": {"text": [["may increase total Hb levels sufficiently"]],"start": [["20"]],"entity_id": [["T6"]]},"Freq": {"text": [["may"]],"start": [["20"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["eliminate"]],"start": [["84"]],"entity_id": [["T8"]]},"Trigger": {"text": [["conclude"]],"start": [["0"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["low-dose HU therapy"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["conclude"]],"start": [["0"]],"entity_id": [["T9"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["patients"]],"start": [["38"]],"entity_id": [["T10"]],"Population": {"text": [["patients"]],"start": [["38"]],"entity_id": [["T10"]]},"Disorder": {"text": [["thalassemia intermedia"]],"start": [["44"]],"entity_id": [["T3"]]},"Age": null,"Gender": null,"Race": null},"Effect": {"text": [["increase total Hb levels sufficiently"]],"start": [["20"]],"entity_id": [["T6"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["conclude"]],"start": [["0"]],"entity_id": [["T9"]]}}]}
{"id": "984862_1","context": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0.1%, under occlusion. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["abnormal response", "glucose tolerance test"]],"start": [["32", "33"]],"entity_id": [["T1"], ["T2"]]},"Treatment": {"text": [["topical administration", "corticosteroid cream", "halcinonide cream 0.1%", "under occlusion"]],"start": [["87", "88", "102", "113"]],"entity_id": [["T3"], ["T4"], ["T5"], ["T6"]],"Drug": {"text": [["halcinonide cream 0.1%"]],"start": [["102"]],"entity_id": [["T5"]]},"Route": {"text": [["topical administration"]],"start": [["87"]],"entity_id": [["T3"]]},"Duration": {"text": [["a period"]],"start": [["89"]],"entity_id": [["T7"]]},"Freq": {"text": [["during"]],"start": [["98"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["halcinonide cream 0.1%"]],"start": [[ "102"]],"entity_id": [["T5"]]},"Trigger": {"text": [["topical administration"]],"start": [[ "87"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [["0.1%"]],"start": [[ "103"]],"entity_id": [["T9"]]},"Time_elapsed": {"text": [["during"]],"start": [[ "98"]],"entity_id": [["T8"]]},"Disorder": {"text": [["psoriasis"]],"start": [[ "14"]],"entity_id": [["T10"]]},"Trigger": {"text": [["developed"]],"start": [[ "69"]],"entity_id": [["T11"]]}},"Effect": {"text": [["postprandial hyperglycemia and glycosuria"]],"start": [[ "60", "75"]],"entity_id": [["T12"], ["T13"]]},"Subject": {"text": [["A patient"]],"start": [[ "0"]],"entity_id": [["T14"]],"Age": {"text": [[]],"start": [[ ]],"entity_id": [["T15"]]},"Gender": {"text": [[]],"start": [[ ]],"entity_id": [["T16"]]},"Population": {"text": [[]],"start": [[ ]],"entity_id": [["T17"]]},"Race": {"text": [[]],"start": [[ ]],"entity_id": [["T18"]]},"Disorder": {"text": [["psoriasis"]],"start": [[ "14"]],"entity_id": [["T10"]]}},"Negated": {"text": [[]],"start": [[ ]],"entity_id": [["T19"]],"value": false},"Speculated": {"text": [[]],"start": [[ ]],"entity_id": [["T20"]],"value": false},"Severity": {"text": [[]],"start": [[ ]],"entity_id": [["T21"]],"value": "Low"}}]}
{"id": "573779_3","context": "A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["galactorrhea"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["a new dibenzoxazepine antidepressant, amoxapine"]],"start": [["31"]],"entity_id": [["T2"]],"Drug": {"text": [["amoxapine"]],"start": [["50"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["galactorrhea"]],"start": [["0"]],"entity_id": [["T1"]]},"Route": {"text": [["treatment"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["15"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["treatment"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["new"]],"start": [["31"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["treatment"]],"start": [["11"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["amoxapine"]],"start": [["50"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["11"]],"entity_id": [["T4"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Trigger": {"text": [["developed"]],"start": [["8"]],"entity_id": [["T6"]]} },"Subject": {"text": [["A young woman"]],"start": [["0"]],"entity_id": [["T7"]],"Age": {"text": [["young"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Gender": {"text": [["woman"]],"start": [["5"]],"entity_id": [["T8"]]} ,"Race": {"text": [["A young woman"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Effect": {"text": [["galactorrhea"]],"start": [["0"]],"entity_id": [["T1"]]} }]}
{"id": "18504683_3","context": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["seizures"]],"start": [["34"]],"entity_id": [["T1"]]},"Subject": {"text": [["children"]],"start": [["11"]],"entity_id": [["T2"]],"Age": {"text": [["children"]],"start": [["11"]],"entity_id": [["T2"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["8"]],"entity_id": [["T3"]]},"Population": {"text": [["3"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["children"]],"start": [["11"]],"entity_id": [["T2"]]},"Gender": {"text": [["children"]],"start": [["11"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["L-asparaginase therapy"]],"start": [["85"]],"entity_id": [["T4"]],"Drug": {"text": [["L-asparaginase"]],"start": [["85"]],"entity_id": [["T5"]]},"Route": {"text": [["therapy"]],"start": [["93"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after"]],"start": [["74"]],"entity_id": [["T7"]]},"Duration": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T1"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["8"]],"entity_id": [["T3"]]},"Freq": {"text": [["3"]],"start": [["4"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["L-asparaginase"]],"start": [["85"]],"entity_id": [["T5"]]},"Trigger": {"text": [["therapy"]],"start": [["93"]],"entity_id": [["T6"]]},"event_type": "Treatment","event_id": "E2"}],"Trigger": {"text": [["altered sensorium"]],"start": [["52"]],"entity_id": [["T8"]]},"Dosage": {"text": [["L-asparaginase therapy"]],"start": [["85"]],"entity_id": [["T4"]]}},"Effect": {"text": [["seizures"]],"start": [["34"]],"entity_id": [["T1"]]},"Severity": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T1"]],"value": "low"},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []}}]}
{"id": "8921647_2", "context": "Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["caution with use of cimetidine"]], "start": [[], [], []], "entity_id": []}, "Treatment": {"text": [["cimetidine"]], "start": [[], [], []], "entity_id": [], "Disorder": {"text": [["tolazoline induced upper gastrointestinal bleeding"]], "start": [[], [], []], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Drug": {"text": [["cimetidine"]], "start": [[], [], []], "entity_id": []}, "Trigger": {"text": [["tolazoline induced upper gastrointestinal bleeding"]], "start": [[], [], []], "entity_id": []}} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Effect": null }]}
{"id": "10749332_3","context": "Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["thiazolidinediones"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["troglitazone"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["currently in clinical trials"]],"start": [["16"]],"entity_id": [["T3"]]} ,"Route": {"text": [["provide"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["may be able to"]],"start": [["10"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["thiazolidinediones"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["provide"]],"start": [["40"]],"entity_id": [["T4"]]} ,"event_id": "C1" ,"event_type": "Potential_therapeutic_effect"} ],"Time_elapsed": {"text": [["without significant hepatotoxicity"]],"start": [["68"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["currently in clinical trials"]],"start": [["16"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["provide"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Drug": {"text": [["thiazolidinediones"]],"start": [["0"]],"entity_id": [["T1"]]}} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": {"text": [["therapeutic benefits"]],"start": [["42"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["provide"]],"start": [["40"]],"entity_id": [["T4"]]} }] }
{"id": "15840734_2", "context": "To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["schizophrenic patient"]],"start": [["52"]],"entity_id": [ ["S1"] ], "Disorder": { "text": [["schizophrenic"]], "start": [[ "52" ]], "entity_id": [ ["S2"] ]} ,"Age": null, "Gender": null, "Population": null, "Race": null }, "Treatment": { "text": [["fluphenazine"]], "start": [[ "42"]], "entity_id": [ ["T1"]], "Drug": { "text": [["fluphenazine"]], "start": [[ "42"]], "entity_id": [ ["T2"]] }, "Disorder": { "text": [["neuroleptic malignant syndrome (NMS)"]], "start": [[ "7"]], "entity_id": [ ["T3"]] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Trigger": { "text": [["associated with fluphenazine"]], "start": [[ "42"]], "entity_id": [ ["T4"]] }, "Combination": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null }] }
{"id": "9876812_2", "context": "Because of its structural similarity to the other vinca alkaloids, vinorelbine is believed to be responsible for SIADH in our patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["vinorelbine"]], "start": [[ ]],"entity_id": [ ] ,"Drug": { "text": [["vinorelbine"]], "start": [[ ]],"entity_id": [ ] } ,"Trigger": { "text": [["structural similarity"]], "start": [[ ]],"entity_id": [ ] }, "Time_elapsed": { "text": [["believed"]], "start": [[ ]],"entity_id": [ ] }, "Disorder": { "text": [["SIADH"]], "start": [[ ]],"entity_id": [ ] } ,"Freq": { "text": [["is"]], "start": [[ ]],"entity_id": [ ] }, "Route": { "text": [["responsible"]], "start": [[ ]],"entity_id": [ ] } ,"Dosage": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Duration": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Combination": null } , "Subject": { "text": [["our patient"]], "start": [[ ]], "entity_id": [ ] ,"Age": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Gender": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Population": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Race": { "text": [[]], "start": [[ ]], "entity_id": [] } ,"Disorder": { "text": [["SIADH"]], "start": [[ ]], "entity_id": [ ] } } ,"Negated": null,"Speculated": null,"Severity": { "text": [], "start": [[ ]], "entity_id": [] ,"value": "low" } , "Effect": null , "Trigger": null }]}
{"id": "2940999_1","context": "Abnormal retinal function associated with isotretinoin therapy for acne","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["abnormal retinal function"]],"start": [["0"]],"entity_id": [ ["T1"] ] }, "Treatment": { "text": [["isotretinoin therapy"]], "start": [["45"]], "entity_id": [ ["T2" ]], "Drug": { "text": [["isotretinoin"]], "start": [["45"]], "entity_id": [ ["T3" ]] } ,"Disorder": { "text": [["acne"]], "start": [[ "71" ]], "entity_id": [ ["T4" ]] } ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null } ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Effect": null, "Severity": null, "Speculated": null, "Negated": null}]}
{"id": "2299784_3", "context": "To our knowledge, this is the first reported case of bromide intoxication due to pyridostigmine bromide administration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bromide intoxication"]], "start": [["33","39"]], "entity_id": []}, "Treatment": {"text": [["pyridostigmine bromide administration"]], "start": [["52","67"]], "entity_id": [], "Drug": {"text": [["pyridostigmine bromide"]], "start": [["52","67"]], "entity_id": []},"Route":{"text":[["administration"]],"start":[["64","67"]],"entity_id":[]},"Freq":{"text":[["first reported case"]],"start":[["9","24"]],"entity_id":[]} ,"Combination":[{"Drug":{"text":[["pyridostigmine"]],"start":[["52","59"]],"entity_id":[]},"Trigger":{"text":[["bromide"]],"start":[["33","36"]],"entity_id":[]},"event_id":"E1-1","event_type":"Adverse_event"}] ,"Trigger":{"text":[["administration"]],"start":[["64","67"]],"entity_id":[]},"Dosage":{"text":[["to our knowledge"]],"start":[["0","8"]],"entity_id":[]} ,"Time_elapsed":{"text":[["this"]],"start":[["25","26"]],"entity_id":[]} ,"Disorder":{"text":[["bromide intoxication"]],"start":[["33","39"]],"entity_id":[]} ,"Duration":{"text":[["intoxication"]],"start":[["39","45"]],"entity_id":[]}} ,"Subject":{"text":[["our knowledge"]],"start":[["0","8"]],"entity_id":[],"Age":{"text":[["our knowledge"]],"start":[["0","8"]],"entity_id":[]},"Disorder":{"text":[["bromide intoxication"]],"start":[["33","39"]],"entity_id":[]},"Gender":{"text":[["our knowledge"]],"start":[["0","8"]],"entity_id":[]},"Population":{"text":[["first reported case"]],"start":[["9","24"]],"entity_id":[]},"Race":{"text":[["our knowledge"]],"start":[["0","8"]],"entity_id":[]}} ,"Negated":{"text":[],"start":[],"entity_id":[],"value":false} ,"Speculated":{"text":[],"start":[],"entity_id":[],"value":false} ,"Severity":{"text":[["first reported case"]],"start":[["9","24"]],"entity_id":[],"value":"Low"} ,"Effect":{"text":[["bromide intoxication"]],"start":[["33","39"]],"entity_id":[]}}]}
{"id": "15920338_3","context": "In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["tamoxifen therapy"]],"start": [["In deciding if tamoxifen therapy is warranted,"], ["all potentially life-threatening adverse events associated with tamoxifen should be considered,"]],"entity_id": []},"Effect": {"text": [["endometrial adenocarcinoma", "uterine sarcoma"]],"start": [[], []],"entity_id": []},"Negated": {"value": false ,"text": [],"start": [],"entity_id": []} ,"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []} ,"Severity": {"value": "life-threatening" ,"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Treatment": {"text": [],"start": [],"entity_id": [] ,"Drug": {"text": [["tamoxifen"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []}} }]}
{"id": "8891729_4","context": "We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["fatal intravascular autoimmune hemolytic anemia"]],"start": [["57"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fludarabine treatment"]],"start": [["102"]],"entity_id": [["T2"]],"Drug": {"text": [["fludarabine"]],"start": [["102"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["chronic lymphocytic leukemia (CLL)"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["85"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["a patient"]],"start": [["5"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["chronic lymphocytic leukemia (CLL)"]],"start": [["16"]],"entity_id": [["T4"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "fatal"} ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "3067748_2", "context": "Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["breakdown products"]], "start": [["36"]], "entity_id": []}, "Treatment": {"text": [["adrenaline"]], "start": [["53"]], "entity_id": [], "Drug": {"text": [["adrenaline"]], "start": [["53"]], "entity_id": []},"Route": {"text": [["breakdown products"]], "start": [["36"]], "entity_id": []},"Time_elapsed": {"text": [["breakdown products"]], "start": [["36"]], "entity_id": []},"Disorder": {"text": [["dacryolith"]], "start": [["0"]], "entity_id": []},"Trigger": {"text": [["Histological examination"]], "start": [["0"]], "entity_id": []},"Freq":{"text":[["breakdown products"]],"start":[[ "36"]], "entity_id": []},"Dosage":{"text":[["breakdown products"]],"start":[[ "36"]], "entity_id": []},"Duration":{"text":[["breakdown products"]],"start":[[ "36"]], "entity_id": []},"Combination":[{"Drug":{"text":[["adrenaline"]],"start":[[ "53"]],"entity_id":[]},"Trigger":{"text":[["breakdown products"]],"start":[[ "36"]],"entity_id":[]},"event_id":"C1","event_type":"Adverse_event"}] } ,"Subject":{"text":[["Histological examination"]],"start":[[ "0"]],"entity_id":[],"Age":{"text":[],"start":[[ ]],"entity_id":[]},"Gender":{"text":[],"start":[[ ]],"entity_id":[]},"Population":{"text":[],"start":[[ ]],"entity_id":[]},"Race":{"text":[],"start":[[ ]],"entity_id":[]},"Disorder":{"text":[["dacryolith"]],"start":[[ "0"]],"entity_id":[]}} ,"Effect":{"text":[["dacryolith"]],"start":[[ "0"]],"entity_id":[]},"Negated":{"text":[],"start":[[ ]],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[[ ]],"entity_id":[],"value":false},"Severity":{"text":[],"start":[[ ]],"entity_id":[],"value":"Low"}}]}
{"id": "515777_2","context": "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["S1"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["diabetic coma"]],"start": [["21"]],"entity_id": [["D1"]]} },"Treatment": {"text": [["a combination of a thiazide diuretic and propranolol"]],"start": [["50"]],"entity_id": [["T1"]],"Drug": {"text": [["thiazide diuretic"]],"start": [["50"]],"entity_id": [["D2"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["propranolol"]],"start": [["70"]],"entity_id": [["D3"]]} ,"Trigger": null ,"event_id": "E2" ,"event_type": "Adverse_event" }] ,"Disorder": {"text": [["diabetic coma"]],"start": [["21"]],"entity_id": [["D1"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["when taking"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Effect": {"text": [["developed"]],"start": [["5"]],"entity_id": [["E1"]]} }] }
{"id": "2616440_2", "context": "We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["water intoxication"]], "start": [[ "acute life-threatening water intoxication" ]], "entity_id": [ ["T1"]]}, "Treatment": { "text": [["treatment with oral indomethacin and low dose intravenous cyclophosphamide"]], "start": [[ "treatment with oral indomethacin and low dose intravenous cyclophosphamide" ]], "entity_id": [ ["T2"]], "Drug": { "text": [["indomethacin","cyclophosphamide"]], "start": [[ "oral indomethacin","low dose intravenous cyclophosphamide" ]], "entity_id": [ ["T3","T4"]]}, "Dosage": { "text": [["oral","low dose intravenous"]], "start": [[ "oral","low dose intravenous" ]], "entity_id": [ ["T5","T6"]]}, "Route": { "text": [["oral","intravenous"]], "start": [[ "oral","intravenous" ]], "entity_id": [ ["T7","T8"]]}, "Time_elapsed": { "text": [["following"]], "start": [[ "following" ]], "entity_id": [ ["T9"]]}, "Duration": { "text": [["developed"]], "start": [[ "developed" ]], "entity_id": [ ["T10"]]}, "Disorder": { "text": [["patient with multiple myeloma"]], "start": [[ "patient with multiple myeloma" ]], "entity_id": [ ["T11"]]}, "Freq": { "text": [[]], "start": [[ ]], "entity_id": [ []]}, "Combination": null, "Trigger": { "text": [["water intoxication"]], "start": [[ "acute life-threatening water intoxication" ]], "entity_id": [ ["T1"]]}}, "Subject": { "text": [["We"]], "start": [[ "We" ]], "entity_id": [ ["T12"]], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null}, "Effect": { "text": [["acute life-threatening water intoxication"]], "start": [[ "acute life-threatening water intoxication" ]], "entity_id": [ ["T1"]]},"Negated": null,"Speculated": null,"Severity": { "text": [["acute life-threatening"]], "start": [[ "acute life-threatening" ]], "entity_id": [ ["T13"]], "value": "high"}}]}
{"id": "19145124_1", "context": "Multifocal electroretinographic abnormalities in ethambutol-induced visual loss", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["multifocal electroretinographic abnormalities"]], "start": [[ "0" ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["ethambutol"]], "start": [[ "52" ]], "entity_id": [["T2"]], "Drug": {"text": [["ethambutol"]], "start": [[ "52" ]], "entity_id": [["T3"]]},"Disorder":{"text":[["visual loss"]],"start":[[ "46" ]], "entity_id":[["T4"]]}, "Dosage":{"text":[["induced"]], "start":[[ "38" ]], "entity_id":[["T5"]]},"Route":{"text":[["ethambutol-induced"]], "start":[[ "52" ]], "entity_id":[["T6"]]}, "Time_elapsed":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]]}, "Duration":{"text":[["induced"]], "start":[[ "38" ]], "entity_id":[["T5"]]}, "Freq":{"text":[["multifocal"]], "start":[[ "0" ]], "entity_id":[["T0"]]}, "Combination":[{"Drug":{"text":[["ethambutol"]], "start":[[ "52" ]], "entity_id":[["T3"]]},"Trigger":{"text":[["induced"]], "start":[[ "38" ]], "entity_id":[["T5"]]},"event_id":"C1","event_type":"Adverse_event"}], "Trigger":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]]}},"Subject":{"text":[["Multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T0"]],"Age":{"text":[["induced"]], "start":[[ "38" ]], "entity_id":[["T5"]]},"Disorder":{"text":[["visual loss"]], "start":[[ "46" ]], "entity_id":[["T4"]]},"Gender":{"text":[["ethambutol"]], "start":[[ "52" ]], "entity_id":[["T2"]]},"Population":{"text":[["induced"]], "start":[[ "38" ]], "entity_id":[["T5"]]},"Race":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]]}}, "Effect":{"text":[["visual loss"]], "start":[[ "46" ]], "entity_id":[["T4"]]},"Negated":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]],"value":false},"Speculated":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]],"value":false},"Severity":{"text":[["multifocal electroretinographic abnormalities"]], "start":[[ "0" ]], "entity_id":[["T1"]],"value":"unknown"}}]}
{"id": "17364199_7","context": "She was on etanercept and methotrexate for rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Subject": {"text": [["She"]],"start": [["0"]],"entity_id": [["S1"]],"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["46"]],"entity_id": [["D1"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["etanercept", "methotrexate"]],"start": [["11","24"]],"entity_id": [["T1","T2"]],"Drug": {"text": [["etanercept", "methotrexate"]],"start": [["11","24"]],"entity_id": [["T4","T5"]]},"Dosage": null,"Duration": null,"Route": null,"Disorder": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["etanercept"]],"start": [["11"]],"entity_id": [["T4"]]},"Trigger": null,"event_id": "C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["methotrexate"]],"start": [["24"]],"entity_id": [["T5"]]},"Trigger": null,"event_id": "C2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["on"]],"start": [["7"]],"entity_id": [["T3"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["for"]],"start": [["32"]],"entity_id": [["T6"]]}}]}
{"id": "14585456_1","context": "We present a case of a 20-year-old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ingested", "glyburide"]],"start": [["ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide", "glyburide"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"Drug": {"text": [["glyburide"]],"start": [[ "glyburide" ]],"entity_id": [["T2"]]},"Dosage": {"text": [["900 mg"]],"start": [[ "900 mg" ]],"entity_id": [["D1"]]},"Disorder": {"text": [["refractory hypoglycemia"]],"start": [[ "refractory hypoglycemia" ]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["causing"]],"start": [[ "causing" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment with intravenous dextrose, glucagon, and diazoxide"]],"start": [[ "treatment with intravenous dextrose, glucagon, and diazoxide" ]],"entity_id": [["T5"]]},"entity_id": [["T1"],["T2"],["D1"],["T3"],["T4"],["T5"]],"start": [[ "ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide","glyburide"]],"text": [["ingested","glyburide","900 mg","causing","refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide"]],"Combination": [{"Drug": {"text": [["glyburide"]],"start": [[ "glyburide" ]],"entity_id": [["T2"]]},"Trigger": {"text": [["treatment with intravenous dextrose, glucagon, and diazoxide"]],"start": [[ "treatment with intravenous dextrose, glucagon, and diazoxide" ]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Treatment"}],"Freq": {"text": [["causing"]],"start": [[ "causing" ]],"entity_id": [["T4"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"Gender": {"text": [["woman"]],"start": [[ "woman" ]],"entity_id": [["S1"]]},"Age": {"text": [["20-year-old"]],"start": [[ "20-year-old" ]],"entity_id": [["S2"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [["We present a case of a 20-year-old woman"]],"start": [[ "We present a case of a 20-year-old woman" ]],"entity_id": [["S1"],["S2"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["refractory hypoglycemia"]],"start": [[ "refractory hypoglycemia" ]],"entity_id": [["T3"]]}}]}
{"id": "7619765_1", "context": "Etoposide-related myocardial infarction", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Etoposide-related"]], "start": [[","]], "entity_id": [["T1"]]}, "Effect": {"text": [["myocardial infarction"]], "start": [[","]], "entity_id": [["T2"]]}, "Treatment": {"Drug": {"text": [["Etoposide"]], "start": [[","]], "entity_id": [["T3"]]}, "entity_id": [["T4"]],"text": [["Etoposide-related"]], "start": [[","]], "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": {"text": [["myocardial infarction"]], "start": [[","]], "entity_id": [["T5"]]},"Trigger": null, "Combination": null}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null, "text": [["patient"]], "start": [[","]], "entity_id": [["T6"]]}}]}
{"id": "18607107_4","context": "She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Copaxone 20 mg/day"]],"start": [[" "], [","]],"entity_id": [["T1"], ["T2"]] ,"Drug": {"text": [["Copaxone"]],"start": [[], []],"entity_id": [["T3"]] },"Duration": {"text": [["2 years"]],"start": [[], []],"entity_id": [["T4"]] },"Disorder": {"text": [["gastrointestinal symptoms"]],"start": [[], []],"entity_id": [["T5"]] },"Time_elapsed": {"text": [["first exhibited"]],"start": [[], []],"entity_id": [["T6"]] },"Trigger": {"text": [["exhibited"]],"start": [[], []],"entity_id": [["T7"]] },"Route": {"text": [["on"]],"start": [[], []],"entity_id": [["T8"]] },"Dosage": {"text": [["20 mg/day"]],"start": [[], []],"entity_id": [["T2"]] },"Freq": {"text": [["day"]],"start": [[], []],"entity_id": [["T2"]] },"Combination": null },"Subject": {"text": [["She"]],"start": [[], []],"entity_id": [["T9"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "15795553_3","context": "The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["TD"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"Age": {"text": [["elderly"]],"start": [["5"]],"entity_id": [["T2"]]},"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["mixed dementia"]],"start": [["19"]],"entity_id": [["T3"]]},"text": [["developed"]],"start": [["30"]],"entity_id": []},"Treatment": {"text": [["risperidone therapy"]],"start": [["91"]],"entity_id": [["T5"]],"Trigger": {"text": [["abrupt withdrawal"]],"start": [["78"]],"entity_id": [["T4"]]},"Drug": {"text": [["risperidone"]],"start": [["84"]],"entity_id": [["T6"]]},"Duration": null ,"Dosage": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Disorder": {"text": [["TD"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Combination": null},"Effect": {"text": [["respiratory dyskinesia","limb dyskinesia","orofacial dyskinesia"]],"start": [["62","73","84"]],"entity_id": [["T7","T8","T9"]]} ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "21416219_1", "context": "Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["adding fenofibric acid to moderate-dose statin therapy"]], "start": [["0"]], "entity_id": [],"Drug":{"text":[["fenofibric acid"]],"start":[["12"]],"entity_id":[]}, "Dosage":{"text":[["moderate-dose"]],"start":[["32"]],"entity_id":[]}, "Route":{"text":[["therapy"]],"start":[[""],["32"]],"entity_id":[]},"Duration":{"text":[["long-term"]],"start":[[""],["0"]],"entity_id":[]}, "Trigger":{"text":[["adding"]],"start":[[""],["0"]],"entity_id":[]}, "Freq":{"text":[["therapy"]],"start":[[""],["32"]],"entity_id":[]},"Disorder":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[]},"Combination":[{"event_type":"Drug","event_id":"C1","Drug":{"text":[["moderate-dose statin"]],"start":[[""],["32"]],"entity_id":[]}, "Trigger":{"text":[["adding"]],"start":[[""],["0"]],"entity_id":[]}}],"Time_elapsed":{"text":[["long-term"]],"start":[[""],["0"]],"entity_id":[]}},"Subject":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[],"Age":{"text":[["long-term"]],"start":[[""],["0"]],"entity_id":[]},"Disorder":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[]},"Population":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[]},"Race":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[]},"Gender":{"text":[["patients with persistent elevated triglycerides"]],"start":[[""],["67"]],"entity_id":[]}},"Effect":{"text":[["efficacy"]],"start":[[""],["0"]],"entity_id":[]},"Negated":{"text":[["not"]],"start":[[""],["0"]],"entity_id":[],"value":false},"Speculated":{"text":[["addition"]],"start":[[""],["12"]],"entity_id":[],"value":false},"Severity":{"text":[["long-term"]],"start":[[""],["0"]],"entity_id":[],"value":"low"},"Trigger":{"text":[["addition"]],"start":[[""],["12"]],"entity_id":[]}}]}
{"id": "16637972_4", "context": "The sub-conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a patient"]], "start": [["a patient's starting index in context"]], "entity_id": [["S1"]],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [["warfarin"]], "start": [[""],["warfarin's starting index in context"]], "entity_id": [["T1"]], "Drug": {"text": [["warfarin"]], "start": [[""],["warfarin's starting index in context"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Disorder": null},"Effect": {"text": [["The sub-conjunctival haematoma"]], "start": [[""],["The sub-conjunctival haematoma's starting index in context"]], "entity_id": [["E1"]]}, "Negated": null, "Speculated": null, "Severity": null, "Trigger":{"text": [["The sub-conjunctival haematoma"]], "start": [[""],["The sub-conjunctival haematoma's starting index in context"]], "entity_id": [["T3"]]} }]}
{"id": "15316423_3","context": "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity"]],"start": [["The site of thrombosis and the chronological relationship with the IIR implicates a "], ["hypersensitivity"]],"entity_id": []},"Treatment": {"text": [["infliximab"]],"start": [[", the site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to "],["infliximab"]],"entity_id": [],"Drug": {"text": [["infliximab"]],"start": [[", the site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to "],["infliximab"]],"entity_id": []},"Disorder": {"text": [["venous thrombosis"]],"start": [[", the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the "],["venous thrombosis"]],"entity_id": []},"Time_elapsed": {"text": [["the chronological relationship with the IIR"]],"start": [[", the site of thrombosis and "],["the chronological relationship with the IIR"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["thrombosis"]],"start": [[", the site of "],["thrombosis"]],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["causation"]],"start": [[", in the causation of the venous thrombosis in this case"]],"entity_id": []}}]}
{"id": "19875411_1","context": "One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patient"]],"start": [["85"]],"entity_id": [["T1"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["an acute exacerbation of Crohn's disease"]],"start": [["48"]],"entity_id": [["T2"]] }},"Treatment": {"text": [["adalimumab (160 mg)"]],"start": [["12"]],"entity_id": [["T3"]],"Drug": {"text": [["adalimumab"]],"start": [["12"]],"entity_id": [["T4"]] },"Dosage": {"text": [["160 mg"]],"start": [["26"]],"entity_id": [["T5"]] },"Route": null,"Time_elapsed": {"text": [["One week after"]],"start": [["0"]],"entity_id": [["T0"]] },"Duration": null,"Trigger": {"text": [["initiated"]],"start": [["38"]],"entity_id": [["T6"]] },"Disorder": {"text": [["an acute exacerbation of Crohn's disease"]],"start": [["48"]],"entity_id": [["T2"]] },"Freq": null ,"Combination": null },"Effect": {"text": [["fulminant cardiomyopathy"]],"start": [["102"]],"entity_id": [["T7"]] },"Trigger": {"text": [["developed"]],"start": [["85"]],"entity_id": [["T1"]] }} ] }
{"id": "24163322_2","context": "We report a case of an inadvertent increase in the international normalized ratio (INR) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["inadvertent increase"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["bismuth subsalicylate"]],"start": [["75"]],"entity_id": [["T2"]],"Drug": {"text": [["bismuth subsalicylate"]],"start": [["75"]],"entity_id": [["T2"]]},"Disorder": {"text": [["treatment of diarrhea"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Route": {"text": [["for the treatment"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["the addition"]],"start": [["44"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["the addition"]],"start": [["44"]],"entity_id": [["T3"]]},"Dosage": {"text": [["bismuth subsalicylate"]],"start": [["75"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["in an enterally fed patient receiving warfarin therapy"]],"start": [["88"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["bismuth subsalicylate"]],"start": [["75"]],"entity_id": [["T2"]]},"Trigger": {"text": [["the addition"]],"start": [["44"]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] }, "Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} }, "Effect": {"text": [["an inadvertent increase in the international normalized ratio (INR)"]],"start": [["35"]],"entity_id": [["T1"]]} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }, "Negated": {"text": [],"start": [],"entity_id": [] ,"value": false }, "Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false }} ]}
{"id": "7995001_1","context": "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["triazolam"]],"start": [[ "0" ]],"entity_id": []},"text": [["oral triazolam"]],"start": [[ "0" ]],"entity_id": [],"Trigger": {"text": [["potentially hazardous"]],"start": [[ "26" ]],"entity_id": []},"Time_elapsed": {"text": [["receiving"]],"start": [[ "37" ]],"entity_id": []},"Disorder": {"text": [["patients"]],"start": [[ "42" ]],"entity_id": []},"Combination": [{"Drug": {"text": [["ketoconazole"]],"start": [[ "66" ]],"entity_id": []},"Trigger": {"text": [["or"]],"start": [[ "84" ]],"entity_id": []},"event_id": "E2","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["itraconazole"]],"start": [[ "87" ]],"entity_id": []},"Trigger": {"text": [],"start": [[ ]],"entity_id": []},"event_id": "E3","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["receiving"]],"start": [[ "37" ]],"entity_id": []},"Duration": {"text": [],"start": [[ ]],"entity_id": []},"Route": {"text": [["oral"]],"start": [[ "0" ]],"entity_id": []},"Dosage": {"text": [],"start": [[ ]],"entity_id": []}},"Subject": {"text": [["patients"]],"start": [[ "42" ]],"entity_id": [],"Age": {"text": [],"start": [[ ]],"entity_id": []},"Disorder": {"text": [],"start": [[ ]],"entity_id": []},"Gender": {"text": [],"start": [[ ]],"entity_id": []},"Population": {"text": [["patients"]],"start": [[ "42" ]],"entity_id": []},"Race": {"text": [],"start": [[ ]],"entity_id": []}},"Severity": {"text": [["hazardous"]],"start": [[ "26" ]],"entity_id": [],"value": "high"},"Negated": {"text": [],"start": [[ ]],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [[ ]],"entity_id": [],"value": false},"Effect": {"text": [["potentially hazardous"]],"start": [[ "26" ]],"entity_id": []},"Trigger": {"text": [["potentially hazardous"]],"start": [[ "26" ]],"entity_id": []}}]}
{"id": "12776809_17","context": "LFT elevation is transient and the low risk of the SB-LOT therapy to increase LFT value can be limited when risk factors are considered","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["LFT elevation"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]}, "Treatment": { "Drug": { "text": [["SB-LOT therapy"]], "start": [[ "43" ]], "entity_id": [ ["T2"] ]}, "Trigger": { "text": [["to increase LFT value"]], "start": [[ "54" ]], "entity_id": [ ["T3"] ]}, "entity_id": [ ["T2"] ], "text": [["SB-LOT therapy"]], "start": [[ "43" ]] ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": { "text": [["LFT elevation"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Freq": null ,"Combination": null }, "Effect": null, "Negated": { "value": false ,"text": [], "start": [], "entity_id": [] }, "Speculated": { "value": false ,"text": [], "start": [], "entity_id": [] }, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["LFT elevation"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} }} ]}
{"id": "16012330_9","context": "Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["unusual enhanced vincristine neurotoxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["itraconazole"]],"start": [["69"]],"entity_id": [["T2"]],"Drug": {"text": [["itraconazole"]],"start": [["69"]],"entity_id": [["T2"]]},"Trigger": {"text": [["related to"]],"start": [["52"]],"entity_id": [["T3"]]},"Freq": {"text": [["Nineteen"]],"start": [["1"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["reported"]],"start": [["41"]],"entity_id": [["T5"]]},"Disorder": {"text": [["children"]],"start": [["82"]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["unusual enhanced"]],"start": [["0"]],"entity_id": [["T7"]],"value": "High"},"Subject": null}]}
{"id": "16718947_3","context": "Extended-release tolterodine 4 mg/day was then prescribed to manage overactive bladder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["tolterodine"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["4 mg/day"]],"start": [["32"]],"entity_id": [["T2"]]},"Duration": {"text": [["manage"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["overactive bladder"]],"start": [["90"]],"entity_id": [["T4"]]} ,"Route": {"text": [["prescribed"]],"start": [["31"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["prescribed"]],"start": [["31"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["then"]],"start": [["24"]],"entity_id": [["T0"]]} ,"entity_id": [["T0"]] ,"text": [["Extended-release tolterodine 4 mg/day"]],"start": [["0"]] ,"Freq": {"text": [["manage"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Combination": null} ,"Subject": null,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null} ]}
{"id": "18067642_1","context": "Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced hypothyroidism and that involution changes represent the hypofunctional status of this drug-induced disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": {"text": [["difficult to be certain"]],"start": [[ ]],"entity_id": [],"value": true},"Treatment": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["amiodarone-induced hypothyroidism"]],"start": [[ ]],"entity_id": []},"Route": null,"Dosage": null,"Duration": null,"Time_elapsed": null,"Freq": null,"Trigger": {"text": [["link"]],"start": [[ ]],"entity_id": []},"Combination": null},"Effect": {"text": [["this histopathology"]],"start": [[ ]],"entity_id": []},"Subject": null,"Severity": null,"Trigger": null},{"event_id": "E2","event_type": "Adverse_event","Negated": null,"Speculated": {"text": [["reasonable to presume"]],"start": [[ ]],"entity_id": [],"value": true},"Treatment": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["amiodarone-induced hypothyroidism"]],"start": [[ ]],"entity_id": []},"Route": null,"Dosage": null,"Duration": null,"Time_elapsed": null,"Freq": null,"Trigger": {"text": [["associated with"]],"start": [[ ]],"entity_id": []},"Combination": null},"Effect": {"text": [["involution changes represent the hypofunctional status"]],"start": [[ ]],"entity_id": []},"Subject": null,"Severity": {"text": [["hypofunctional"]],"start": [[ ]],"entity_id": [],"value": "low"},"Trigger": null}]}
{"id": "7962394_4","context": "The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute pancreatitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["danazol treatment"]],"start": [["62"]],"entity_id": [["T2"]],"Drug": {"text": [["danazol"]],"start": [["62"]],"entity_id": [["T3"]]},"Disorder": {"text": [["endometriosis"]],"start": [["86"]],"entity_id": [["T4"]]} ,"Duration": null,"Dosage": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["The present report"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "18648015_1","context": "Cephalosporin-induced leukopenia following rechallenge with cefoxitin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cephalosporin-induced leukopenia"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Cephalosporin"]],"start": [["0" ]],"entity_id": [["T2"]]},"Trigger": {"text": [["rechallenge with cefoxitin"]],"start": [["46" ]],"entity_id": [["T3"]]},"entity_id": [],"text": [["cefoxitin"]],"start": [["46" ]],"Disorder": {"text": [["leukopenia"]],"start": [["23" ]],"entity_id": [["T4"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17266059_2","context": "Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [["0"]],"entity_id": []},"Treatment": {"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["53"]],"entity_id": []},"Disorder": {"text": [["thrombotic thrombocytopenic purpura"]],"start": [["0"]],"entity_id": []},"entity_id": [],"text": [["Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole"]],"start": [["0"]],"Time_elapsed": {"text": [["induced"]],"start": [["52"]],"entity_id": []},"Route": {"text": [["by"]],"start": [["49"]],"entity_id": []},"Freq": {"text": [["induced"]],"start": [["52"]],"entity_id": []},"Combination": [{"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["53"]],"entity_id": []},"Trigger": {"text": [["induced"]],"start": [["52"]],"entity_id": []},"event_id": "E1-1","event_type": "Adverse_event"}],"Trigger": {"text": [["induced"]],"start": [["52"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["a Jehovah's Witness"]],"start": [["95"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [["Jehovah's Witness"]],"start": [["95"]],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [["0"]],"entity_id": []}}]}
{"id": "17039658_2", "context": "This eruption appears to be a distinct cutaneous toxicity of PLD", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["eruption"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["PLD"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["PLD"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["distinct cutaneous toxicity"]], "start": [[ ]], "entity_id": [ ]} ,"Time_elapsed": {"text": [["appears"]], "start": [[ ]], "entity_id": [ ]} ,"Dosage": {"text": [["N/A"]], "start": [[ ]], "entity_id": [ ]},"Duration": {"text": [["N/A"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["N/A"]], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [["N/A"]], "start": [[ ]], "entity_id": [ ]},"Combination": null , "Trigger": null } , "Effect": {"text": [["eruption"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11999915_2","context": "Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Granulocytopenia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Effect": {"text": [["Granulocytopenia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": {"text": [["clozapine"]],"start": [[ "91" ]],"entity_id": [ ["T3" ]],"Drug": {"text": [["clozapine"]],"start": [[ "91" ]],"entity_id": [ ["T3" ]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["adverse effects"]],"start": [[ "57" ]],"entity_id": [ ["T2" ]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["dangerous"]],"start": [[ "73" ]],"entity_id": [ ["T4" ]],"value": "high"},"Subject": null}]}
{"id": "20298401_5","context": "We recently experienced a case of fatal erlotinib-induced ILD, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal erlotinib-induced ILD"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["erlotinib"]],"start": [["9"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["ILD"]],"start": [["18"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["diagnosed based on clinical and radiologic findings"]],"start": [["33"]],"entity_id": [["T4"]]},"Freq": null,"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Trigger": null},"Subject": {"text": [["a patient"]],"start": [["77"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["radiation fibrosis"]],"start": [["91"]],"entity_id": [["T6"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [["14"]],"entity_id": [["T0"]],"value": "fatal"}}]}
{"id": "15482394_5", "context": "Unusual hypersensitivity to warfarin in a critically ill patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypersensitivity"]], "start": [["21"]], "entity_id": []}, "Treatment": {"text": [["warfarin"]], "start": [["11"]], "entity_id": [], "Drug": {"text": [["warfarin"]], "start": [["11"]], "entity_id": [] } ,"Disorder": {"text": [["critically ill"]], "start": [["53"]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null, "Trigger": {"text": [], "start": [], "entity_id": []}}, "Effect": {"text": [], "start": [], "entity_id": []}, "Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": {"text": [], "start": [[ "53" ]], "entity_id": []},"Gender": null,"Population": null,"Race": null}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "11030530_3","context": "We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["seizure"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["L-asparaginase therapy"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["L-asparaginase"]],"start": [["41"]],"entity_id": [["T3"]]},"Disorder": {"text": [["hemorrhagic or thrombotic cerebrovascular events"]],"start": [["74"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["L-asparaginase"]],"start": [["41"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["48"]],"entity_id": [["T5"]]},"event_type": "Adverse_event","event_id": "E2"}],"Freq": {"text": [["associated"]],"start": [["35"]],"entity_id": [["T6"]]},"Dosage": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Route": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Time_elapsed": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Duration": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Trigger": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]}},"Effect": {"text": [["seizure"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Speculated": {"value": false,"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Severity": {"value": "","text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Subject": {"text": [["We"]],"start": [[""], []],"entity_id": [[""], []],"Age": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Gender": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Population": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Race": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]},"Disorder": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]}}}]}
{"id": "15316423_2","context": "Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe infliximab infusion reaction"]],"start": [["35"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient with Crohn's disease"]],"start": [["0"]],"entity_id": [["T2"]],"Disorder": {"text": [["Crohn's disease"]],"start": [["9"]],"entity_id": [["T3"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["infliximab infusion"]],"start": [["47"]],"entity_id": [["T4"]],"Drug": {"text": [["infliximab"]],"start": [["47"]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Route": null,"Disorder": {"text": [["Crohn's disease"]],"start": [["9"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["1 day later"]],"start": [["61"]],"entity_id": [["T6"]]},"Freq": null,"Combination": null,"Trigger": {"text": [["severe infliximab infusion reaction"]],"start": [["35"]],"entity_id": [["T1"]]}},"Effect": {"text": [["severe swelling"]],"start": [["80"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["76"]],"entity_id": [["T8"]],"value": "severe"}}]}
{"id": "11026106_2", "context": "Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Minocycline-induced autoimmune hepatitis"]], "start": [["0"]], "entity_id":[["T1"]]},"Treatment": {"text": [], "start": [], "entity_id": [],"Drug": {"text": [["Minocycline"]], "start": [["37"]], "entity_id":[["T2"]]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null,"Disorder": {"text": [["autoimmune hepatitis"]], "start": [["28"]], "entity_id":[["T3"]]}, "Trigger": null}, "Effect": {"text": [["sporadic autoimmune hepatitis"]], "start": [["69"]], "entity_id":[["T4"]]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "10891991_2", "context": "Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["representive endocrine disorders"]], "start": [["0"]], "entity_id": []}, "Subject": {"text": [["women"]], "start": [["82"]], "entity_id": [],"Age": null, "Gender": {"text": [["women"]], "start": [["82"]], "entity_id": []}, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [["sodium valproate"]], "start": [["131"]], "entity_id": [],"Drug": {"text": [["sodium valproate"]], "start": [["131"]], "entity_id": []}, "Disorder": {"text": [["epilepsy"]], "start": [["148"]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null}, "Effect": {"text": [["common"]], "start": [["111"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "14711147_1", "context": "Doxycycline-induced photo-onycholysis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Doxycycline-induced photo-onycholysis"]], "start": [[ "entity_id" ]], "entity_id": [[ "T1" ]]}, "Treatment": {"text": [["Doxycycline"]], "start": [[ "entity_id" ]], "entity_id": [[ "T2" ]] ,"Drug": {"text": [["Doxycycline"]], "start": [[ "entity_id" ]], "entity_id": [[ "T2" ]] } , "Disorder": {"text": [["photo-onycholysis"]], "start": [[ "entity_id" ]], "entity_id": [[ "T3" ]] } , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null , "Trigger": null } , "Negated": null, "Speculated": null, "Severity": null , "Subject": null , "Effect": {"text": [["photo-onycholysis"]], "start": [[ "entity_id" ]], "entity_id": [[ "T3" ]] } } ] }
{"id": "20203465_1", "context": "Case report: acute renal failure after administering intravenous immunoglobulin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute renal failure"]], "start": [["Case report: acute renal failure after administering intravenous immunoglobulin"]], "entity_id": []}, "Treatment": {"text": [["administering intravenous immunoglobulin"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": [], "Drug": {"text": [["intravenous immunoglobulin"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []},"Route": {"text": [["administering intravenous"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []},"Time_elapsed":{"text":[["after"]], "start": [["Case report:"], ["acute renal failure"]], "entity_id": []},"Disorder":{"text":[["acute renal failure"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []} ,"Duration":{"text":[["after administering"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []} ,"Trigger":{"text":[["administering"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []} ,"Dosage":{"text":[["intravenous immunoglobulin"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []} ,"Freq":{"text":[["after"]], "start": [["Case report:"], ["acute renal failure"]], "entity_id": []} ,"Combination":null },"Effect":{"text":[["acute renal failure"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []},"Negated":null,"Speculated":null,"Severity":{"text":[["acute"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": [],"value":"High" },"Subject":{"text":[["Case report:"], ["acute renal failure"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": [],"Age":null,"Gender":null,"Population":null,"Disorder":{"text":[["acute renal failure"]], "start": [[""], ["Case report:"], ["acute renal failure"]], "entity_id": []},"Race":null} }]}
{"id": "16416684_1", "context": "This is a rare case of ARDS associated with lithium intoxication", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["ARDS"]], "start": [["13"]], "entity_id": []}, "Treatment": {"text": [["lithium intoxication"]], "start": [["51"]], "entity_id": [], "Drug": {"text": [["lithium"]], "start": [["51"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["ARDS"]], "start": [["13"]], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Combination": null ,"Trigger": {"text": [["lithium intoxication"]], "start": [["51"]], "entity_id": []} } ,"Subject": {"text": [], "start": [], "entity_id": [] ,"Age": null, "Disorder": {"text": [["ARDS"]], "start": [["13"]], "entity_id": []} ,"Gender": null ,"Population": null ,"Race": null },"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": {"text": [["ARDS"]], "start": [["13"]], "entity_id": []} }]}
{"id": "8520081_1","context": "Intravenous haloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Intravenous haloperidol"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["Intravenous haloperidol"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["haloperidol"]],"start": [[ "10" ]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["has been reported"]],"start": [[ "71" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["generally well tolerated"]],"start": [[ "22" ]],"entity_id": [["T4"]]},"Freq": {"text": [["generally well tolerated"]],"start": [[ "22" ]],"entity_id": [["T4"]]},"Route": {"text": [["Intravenous"]],"start": [[ "0" ]],"entity_id": [["T5"]]},"Dosage": {"text": [["Intravenous haloperidol"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Duration": {"text": [["Intravenous haloperidol"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Combination": null,"Trigger": {"text": [["multiform ventricular tachycardia"]],"start": [[ "62" ]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["has been reported"]],"start": [[ "71" ]],"entity_id": [["T3"]],"value": "NOT SPECIFIED"},"Subject": null,"Effect": {"text": [["multiform ventricular tachycardia"]],"start": [[ "62" ]],"entity_id": [["T6"]]}}]}
{"id": "12243603_2", "context": "To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["rhabdomyolysis"]], "start": [[" "], [")"]], "entity_id": []}, "Treatment": {"text": [["atorvastatin and diltiazem"]], "start": [[","]], "entity_id": [], "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[","]], "entity_id": []},"Combination": [{"Drug": {"text": [["atorvastatin"]], "start": [[","]], "entity_id": []}, "Trigger": {"text": [["and"]], "start": [[","]], "entity_id": []}, "event_id": "C1" , "event_type": "Adverse_event"}, {"Drug": {"text": [["diltiazem"]], "start": [[","]], "entity_id": []}, "Trigger": {"text": [["and"]], "start": [[","]], "entity_id": []}, "event_id": "C2" , "event_type": "Adverse_event"}],"Trigger":{"text":[["the coadministration"]], "start": [[","]], "entity_id": []},"Disorder":{"text":[["rhabdomyolysis and acute hepatitis"]], "start": [["),"]], "entity_id": []},"Freq":{"text":[["associated"]], "start": [[")"]], "entity_id": []}, "Time_elapsed":{"text":[], "start": [], "entity_id": []},"Route":{"text":[], "start": [], "entity_id": []},"Dosage":{"text":[], "start": [], "entity_id": []},"Duration":{"text":[], "start": [], "entity_id": []}},"Effect":{"text":[["rhabdomyolysis and acute hepatitis"]], "start": [[")"]], "entity_id": []},"Negated":{"value": false,"text":[],"start": [],"entity_id": []},"Speculated":{"value": false,"text":[],"start": [],"entity_id": []},"Severity":{"value":"High","text":[],"start": [],"entity_id": []},"Subject":{"text":[["To report a case"]], "start": [["]"],["a"]], "entity_id": [],"Age":{"text":[],"start":[],"entity_id": []},"Gender":{"text":[],"start":[],"entity_id": []},"Disorder":{"text":[],"start":[],"entity_id": []},"Race":{"text":[],"start":[],"entity_id": []},"Population":{"text":[],"start":[],"entity_id": []}}}]}
{"id": "18094347_8", "context": "Ten hours after the second methotrexate injection, the patient experienced a diffuse pruritic papular eruption located mainly on the limbs._", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diffuse pruritic papular eruption"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate injection"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Route": {"text": [["injection"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["Ten hours after"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["second"]],"start": [["21"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["experienced"]],"start": [["30"]],"entity_id": [["T7"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patient"]],"start": [["19"]],"entity_id": [["T8"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} }, {"event_id": "E2","event_type": "Potential_therapeutic_effect","Trigger": null,"Treatment": {"text": [["methotrexate injection"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Route": {"text": [["injection"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [["second"]],"start": [["21"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patient"]],"start": [["19"]],"entity_id": [["T8"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} }]}
{"id": "921427_1","context": "An elderly man with procainamide hydrochloride-induced lupus syndrome had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["procainamide hydrochloride-induced lupus syndrome"]],"start": [["36"]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["An elderly man"]],"start": [[ "0" ]],"entity_id": [ ["S1" ]],"Age": {"text": [["elderly"]],"start": [[ "0" ]],"entity_id": [ ["A1" ]]} ,"Disorder": {"text": [["procainamide hydrochloride-induced lupus syndrome"]],"start": [[ "36" ]],"entity_id": [ ["D1" ]]} ,"Population": {"text": [["An elderly man"]],"start": [[ "0" ]],"entity_id": [ ["P1" ]]} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} }, "Treatment": { "text": [],"start": [],"entity_id": [] ,"Drug": {"text": [["procainamide hydrochloride"]],"start": [[ "36" ]],"entity_id": [ ["T1" ]] }, "Dosage": {"text": [],"start": [],"entity_id": [] }, "Duration": {"text": [],"start": [],"entity_id": [] }, "Trigger": {"text": [],"start": [],"entity_id": [] }, "Route": {"text": [],"start": [],"entity_id": [] }, "Time_elapsed": {"text": [],"start": [],"entity_id": [] }, "Freq": {"text": [],"start": [],"entity_id": [] }, "Combination": null ,"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [],"start": [],"entity_id": [] }, "Negated": null, "Speculated": null, "Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" }} ]}
{"id": "7151655_1", "context": "In one patient, treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 hours later", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["treatment with DCA"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ],"Drug": {"text": [["DCA"]], "start": [[ "13" ]], "entity_id": [ ["T2" ] ]},"Disorder": {"text": [["decrease in blood lactate levels"]], "start": [[ "68" ]], "entity_id": [ ["T3" ] ]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [["16 hours later"]], "start": [[ "102" ]], "entity_id": [ ["T4" ] ]},"Trigger": {"text": [["associated"]], "start": [[ "31" ]], "entity_id": [ ["T5" ] ]},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [["16 hours later"]], "start": [[ "102" ]], "entity_id": [ ["T4" ] ]},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Subject": {"text": [["one patient"]], "start": [[ "7" ]], "entity_id": [ ["T6" ] ],"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Trigger": null}]}
{"id": "7865488_3","context": "We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["noncardiogenic pulmonary edema"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["EO"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["EO"]],"start": [["52"]],"entity_id": [["T2"]]},"Disorder": {"text": [["therapeutic trial"]],"start": [["32"]],"entity_id": [["T3"]]},"Route": {"text": [["sclerosing agent for esophageal varix"]],"start": [["41"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["developed after"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["trial"]],"start": [["32"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["trial"]],"start": [["32"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["EO"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["therapeutic trial"]],"start": [["32"]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Potential_therapeutic_effect"} ],"Trigger": {"text": [["noncardiogenic pulmonary edema"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["EO"]],"start": [["52"]],"entity_id": [["T2"]]} },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["a case"]],"start": [["7"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["noncardiogenic pulmonary edema"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Age": {"text": [[""]],"start": [["]"], [""]],"entity_id": [["T7"]]} ,"Gender": {"text": [[""]],"start": [["]"], [""]],"entity_id": [["T8"]]} ,"Race": {"text": [[""]],"start": [["]"], [""]],"entity_id": [["T9"]]} },"Severity": {"text": [[""]],"start": [["]"], [""]],"entity_id": [["T10"]] ,"value": "Low"} ,"Negated": {"text": [["not"]],"start": [[],[]],"entity_id": [[],[]] ,"value": false} ,"Speculated": {"text": [["report"]],"start": [[],[]],"entity_id": [[],[]] ,"value": false} ,"Effect": {"text": [["noncardiogenic pulmonary edema"]],"start": [["18"]],"entity_id": [["T1"]]} }] }
{"id": "15878975_3","context": "That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC).","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["patients receiving anti-D IGIV"]],"start": [["patients receiving anti-D IGIV" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["patients receiving anti-D IGIV"]],"start": [[ "patients receiving anti-D IGIV" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["anti-D IGIV"]],"start": [[ "anti-D IGIV" ]],"entity_id": [ ["T2"] ]},"Disorder": {"text": [["complications of hemoglobinemia"]],"start": [[ "complications" ]],"entity_id": [ ["T3"] ]},"Time_elapsed": null,"Duration": null,"Freq": null,"Combination": null,"Route": null,"Dosage": null,"Trigger": {"text": [["complications of hemoglobinemia"]],"start": [[ "complications" ]],"entity_id": [ ["T3"] ]}},"Effect": {"text": [["disseminated intravascular coagulation (DIC)"], ["complications"]],"start": [[ "disseminated intravascular coagulation" ],[ "complications" ]],"entity_id": [ ["T4"],["T3"] ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11144696_1","context": "Seizures associated with therapeutic doses of venlafaxine and trimipramine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Seizures"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["venlafaxine", "trimipramine"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": { "text": [[ "venlafaxine" ]], "start": [[ "42" ]], "entity_id": [[ "T3" ]] }, "Dosage": null, "Duration": { "text": [["therapeutic doses"]], "start": [[ "22" ]], "entity_id": [[ "T4" ]] },"Route": null, "Time_elapsed": null, "Disorder": null, "Freq": null, "Combination": null ,"Trigger": null }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": null ,"Effect": null }] }
{"id": "14960440_1","context": "The risk/benefit ratio of warfarin therapy changes in the over 75s, when haemorrhagic side-effects become more common","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["warfarin therapy"]],"start": [[ ], ["therapy"], ["changes"]],"entity_id": []},"Subject": {"text": [["the over 75s"]],"start": [["over"], ["75s"]],"entity_id": [],"Age": {"text": [["75s"]],"start": [["75s"]],"entity_id": []},"Population": {"text": [["the over 75s"]],"start": [["over"], ["75s"]],"entity_id": []},"Gender": {"text": [["the over 75s"]],"start": [["over"], ["75s"]],"entity_id": []},"Race": {"text": [["the over 75s"]],"start": [["over"], ["75s"]],"entity_id": []},"Disorder": {"text": [["the over 75s"]],"start": [["over"], ["75s"]],"entity_id": []}},"Treatment": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": [],"Drug": {"text": [["warfarin"]],"start": [["warfarin"]],"entity_id": []},"Dosage": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": []},"Duration": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": []},"Disorder": {"text": [["haemorrhagic side-effects"]],"start": [["haemorrhagic"], ["side-effects"]],"entity_id": []},"Freq": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": []},"Combination": null,"Route": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": []},"Time_elapsed": {"text": [["warfarin therapy"]],"start": [["warfarin"], ["therapy"]],"entity_id": []},"Trigger": null},"Negated": null,"Speculated": null,"Severity": {"text": [["haemorrhagic side-effects"]],"start": [["haemorrhagic"], ["side-effects"]],"entity_id": [],"value": "high"},"Effect": {"text": [["haemorrhagic side-effects"]],"start": [["haemorrhagic"], ["side-effects"]],"entity_id": []}}]}
{"id": "1445134_5", "context": "Norethisterone in these 69 pregnancies accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Norethisterone"]], "start": [[ ]],"entity_id":[["T1"]],"Population": {"text": [["69 pregnancies"]], "start": [[]],"entity_id":[["T2"]]},"Disorder": {"text": [["clitoral hypertrophy"]], "start": [[]],"entity_id":[["T3"]]},"Age": {"text": [["consecutive births"]], "start": [[]],"entity_id":[["T4"]]},"Gender": {"text": [["these pregnancies"]], "start": [[]],"entity_id":[["T2"]]},"Race": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["Norethisterone"]], "start": [[]],"entity_id":[["T1"]],"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["accounted"]], "start": [[]],"entity_id":[["T7"]]},"Drug": {"text": [["Norethisterone"]], "start": [[]],"entity_id":[["T1"]]}},"Effect": {"text": [["clitoral hypertrophy"]], "start": [[]],"entity_id":[["T3"]]},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Trigger": {"text": [["diagnosed"]], "start": [[]],"entity_id":[["T8"]]}}]}
{"id": "736591_1","context": "Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["potential complication"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate therapy"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["42"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["psoriasis"]],"start": [["70"]],"entity_id": [["T4"]]} ,"Route": {"text": [["therapy"]],"start": [["42"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["a potential complication"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["a potential complication"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["a potential complication"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Combination": null ,"Dosage": null ,"Trigger": null },"Effect": {"text": [["Interstitial fibrosis of the lung"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null }]}
{"id": "11483161_1", "context": "Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["amprenavir", "with", "intracranial", "bleeding"]], "start": [[ "12", "16", "31", "35" ]], "entity_id": [ ]}, "Subject": {"text": [["an HIV-infected hemophiliac"]], "start": [[ "52" ]], "entity_id": [ ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["HIV-infected hemophiliac"]], "start": [[ "52" ]], "entity_id": [ ]}}, "Treatment": {"text": [["amprenavir"]], "start": [[ "0" ]], "entity_id": [ ],"Drug": {"text": [["amprenavir"]], "start": [[ "0" ]], "entity_id": [ ]},"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Combination": null ,"Disorder": null}, "Effect": {"text": [["intracranial bleeding"]], "start": [[ "31" ]], "entity_id": [ ]},"Negated": null, "Speculated": {"text": [["Possible"]], "start": [[ "0" ]], "entity_id": [ ],"value": true}, "Severity": null }]}
{"id": "8098286_2", "context": "Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis, 10 weeks after drug readministration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurrence"]], "start": [["48"]], "entity_id": []}, "Treatment": {"text": [["celiprolol"]], "start": [["24"]], "entity_id": [], "Drug": {"text": [["celiprolol"]], "start": [["24"]], "entity_id": []}, "Duration": {"text": [["10 weeks"]], "start": [["62"]], "entity_id": []}, "Route": {"text": [["drug readministration"]], "start": [["70"]], "entity_id": []}, "Time_elapsed": {"text": [["10 weeks"]], "start": [["62"]], "entity_id": []}, "Disorder": {"text": [["pneumonitis"]], "start": [["19"]], "entity_id": []}, "Trigger": {"text": [["inadvertent subsequent rechallenge"]], "start": [["0"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["celiprolol"]], "start": [["24"]], "entity_id": []}, "Trigger": {"text": [["inadvertent subsequent rechallenge"]], "start": [["0"]], "entity_id": []}, "event_id": "C1", "event_type": "Adverse_event"}], "Freq": {"text": [],"start": [],"entity_id": []}, "Dosage": {"text": [],"start": [],"entity_id": []}}, "Effect": {"text": [["pneumonitis"]], "start": [["19"]], "entity_id": []}, "Negated": {"text": [],"start": [],"entity_id": [], "value": false}, "Speculated": {"text": [],"start": [],"entity_id": [], "value": false}, "Severity": {"text": [],"start": [],"entity_id": [], "value": ""}, "Subject": {"text": [],"start": [],"entity_id": [], "Age": {"text": [],"start": [],"entity_id": []}, "Gender": {"text": [],"start": [],"entity_id": []}, "Population": {"text": [],"start": [],"entity_id": []}, "Race": {"text": [],"start": [],"entity_id": []}, "Disorder": {"text": [["pneumonitis"]],"start": [["19"]],"entity_id": []}}}]}
{"id": "19531695_5","context": "Flecainide had been started 2 weeks prior for atrial fibrillation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Flecainide"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["Flecainide"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Disorder": {"text": [["atrial fibrillation"]],"start": [[ "48" ]],"entity_id": [["T2"]]},"Duration": {"text": [["2 weeks prior"]],"start": [[ "15" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["had been started"]],"start": [[ "11" ]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["2 weeks prior"]],"start": [[ "15" ]],"entity_id": [["T3"]]},"Route": {"text": [["for"]],"start": [[ "45" ]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "20298401_10","context": "Our case shows a fatal side effect of erlotinib","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal side effect"]],"start": [["fatal side effect's start index in the text"]],"entity_id": [["T1"]]},"Treatment": {"text": [["erlotinib"]],"start": [["erlotinib's start index in the text"]],"entity_id": [["T2"]],"Drug": {"text": [["erlotinib"]],"start": [["erlotinib's start index in the text"]],"entity_id": [["T2"]]} ,"Freq": {"text": [[""]],"start": [[""], []],"entity_id": [[""], [""]]} ,"Route": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]} ,"Time_elapsed": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]} ,"Duration": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]} ,"Disorder": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]} ,"Dosage": {"text": [[""]],"start": [[""], []],"entity_id": [[""], []]} ,"Combination": null ,"Trigger": {"text": [["fatal side effect"]],"start": [[""], []],"entity_id": [["T1"]]}},"Effect": {"text": [["fatal side effect"]],"start": [[""], []],"entity_id": [["T1"]]},"Subject": null,"Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [[""], []],"entity_id": [["T3"]],"value": "high"}}]}
{"id": "2161782_1","context": "Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tamoxifen"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["subsequent development of carcinoma of the corpus uteri"]],"start": [["54"]],"entity_id": [["T2"]],"Disorder": {"text": [["carcinoma of the corpus uteri"]],"start": [["54"]],"entity_id": [["T3"]]},"Dosage": {"text": [["may be responsible"]],"start": [["41"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["subsequent"]],"start": [["54"]],"entity_id": [["T5"]]},"Freq": {"text": [["may be responsible"]],"start": [["41"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["tamoxifen"]],"start": [["32"]],"entity_id": [["T1"]]},"Trigger": {"text": [["may be responsible"]],"start": [["41"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]]},"Drug": {"text": [["tamoxifen"]],"start": [["32"]],"entity_id": [["T1"]]},"Duration": {"text": [["subsequent development"]],"start": [["54"]],"entity_id": [["T2"]]},"Route": {"text": [["responsible"]],"start": [["41"]],"entity_id": [["T4"]]}},"Subject": {"text": [["these patients"]],"start": [["87"]],"entity_id": [["T6"]],"Disorder": {"text": [["carcinoma of the corpus uteri"]],"start": [["54"]],"entity_id": [["T3"]]},"Population": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"text": [["not"]],"start": [["68"]],"entity_id": [["T7"]],"value": false},"Speculated": {"text": [["Data have been published regarding the possibility"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [["carcinoma of the corpus uteri"]],"start": [["54"]],"entity_id": [["T3"]],"value": "High"},"Effect": {"text": [["carcinoma of the corpus uteri"]],"start": [["54"]],"entity_id": [["T3"]]}}]}
{"id": "15183980_1", "context": "Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Eosinophilic cystitis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["bladder instillation with dimethyl sulfoxide"]], "start": [[ ]], "entity_id": [["T2"]], "Drug": {"text": [["dimethyl sulfoxide"]], "start": [[ ]], "entity_id": [["T3"]]}, "Route": {"text": [["bladder instillation"]], "start": [[ ]], "entity_id": [["T4"]]} , "Disorder": {"text": [["Eosinophilic cystitis"]], "start": [[ ]], "entity_id": [["T1"]]} , "Time_elapsed": {"text": [["after"]], "start": [[ ]], "entity_id": [["T5"]]} , "Freq": {"text": [["instillation"]], "start": [[ ]], "entity_id": [["T4"]]} , "Combination": [{"event_type": "Adverse_event", "event_id": "E1", "Drug": {"text": [["dimethyl sulfoxide"]], "start": [[ ]], "entity_id": [["T3"]]}, "Trigger": {"text": [["Eosinophilic cystitis"]], "start": [[ ]], "entity_id": [["T1"]]}}] , "Trigger": { "text": [["bladder instillation with dimethyl sulfoxide"]], "start": [[ ]], "entity_id": [["T2"]] } , "Dosage": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} } , "Subject": { "text": [], "start": [], "entity_id": [] , "Age": {"text": [], "start": [], "entity_id": []} , "Gender": {"text": [], "start": [], "entity_id": []} , "Population": {"text": [], "start": [], "entity_id": []} , "Race": {"text": [], "start": [], "entity_id": []} , "Disorder": {"text": [["Eosinophilic cystitis"]], "start": [[ ]], "entity_id": [["T1"]]} } , "Negated": {"text": [], "start": [], "entity_id": [] , "value": false} , "Speculated": {"text": [], "start": [], "entity_id": [] , "value": false} , "Severity": {"text": [], "start": [], "entity_id": [] , "value": ""} , "Effect": { "text": [["Eosinophilic cystitis"]], "start": [[ ]], "entity_id": [["T1"]]} }]}
{"id": "576675_1","context": "A 15-kg weight gain developed in a patient during the third week of ibuprofen therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["15-kg weight gain"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ibuprofen therapy"]],"start": [["71"]],"entity_id": [["T2"]],"Drug": {"text": [["ibuprofen"]],"start": [["71"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["third week"]],"start": [["41"]],"entity_id": [["T4"]]} ,"Route": {"text": [["in a patient"]],"start": [["15"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["developed"]],"start": [["8"]],"entity_id": [["T6"]]},"Dosage": {"text": [[]],"start": [[""], []],"entity_id": [[""], [""]]} ,"Disorder": {"text": [[]],"start": [[""], []],"entity_id": [[""], [""]]} ,"Freq": {"text": [[]],"start": [[""], []],"entity_id": [[""], [""]]} ,"Combination": null ,"Trigger": {"text": [["15-kg weight gain"]],"start": [[ "0"]],"entity_id": [["T1"]]} },"Effect": {"text": [[]],"start": [[""], []],"entity_id": [[""], [""]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Subject": {"text": [["a patient"]],"start": [["15"]],"entity_id": [["T5"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }} ]}
{"id": "7019786_1", "context": "Cefoxitin-associated renal failure", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Cefoxitin-associated"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Effect": {"text": [["renal failure"]], "start": [[ "23" ]], "entity_id": [ ["T2"] ]}, "Subject": null, "Treatment": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "15664988_2","context": "Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["TD"]],"start": [["35", "68"]],"entity_id": []},"Subject": {"text": [["Two of our patients"]],"start": [[ "0","14"]],"entity_id": [],"Age": {"text": [["23 months", "34 months"]],"start": [[ "46","57"],["58","79"]],"entity_id": []},"Population": {"text": [["Two"]],"start": [[ "0","1"]],"entity_id": []},"Disorder": {"text": [["ziprasidone monotherapy"]],"start": [[ "81","101"]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["ziprasidone monotherapy"]],"start": [[ "81","101"]],"entity_id": [],"Drug": {"text": [["ziprasidone"]],"start": [[ "81","90"]],"entity_id": []},"Duration": {"text": [["23 months", "34 months"]],"start": [[ "46","57"],["58","79"]],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger" : {"text" : [["TD"]],"start" : [[ "35","68"]],"entity_id" : []}},"Effect" : {"text" : [["developed"]],"start" : [[ "15","21"]],"entity_id" : []},"Negated" : null ,"Speculated" : null ,"Severity" : null}]}
{"id": "12932249_3","context": "We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hyperpigmented skin and tongue lesions"]],"start": [["38", "55"]],"entity_id": []},"Treatment": {"text": [["combination therapy with IFN and ribavirin"]],"start": [["71", "85"]],"entity_id": [],"Combination": [{"Drug": {"text": [["IFN"]],"start": [["71"]],"entity_id": []},"Trigger": {"text": [["combination therapy"]],"start": [["71"]],"entity_id": []},"event_id": "E2","event_type": "Adverse_event"},{"Drug": {"text": [["ribavirin"]],"start": [["80"]],"entity_id": []},"Trigger": {"text": [["combination therapy"]],"start": [["71"]],"entity_id": []},"event_id": "E2","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["developed"]],"start": [["15"]],"entity_id": []},"Duration": {"text": [["two"]],"start": [["11"]],"entity_id": []},"Disorder": {"text": [["dark-skinned patients"]],"start": [["5"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["during"]],"start": [["40"]],"entity_id": []},"Drug": {"text": [["IFN", "ribavirin"]],"start": [["71", "80"]],"entity_id": []}},"Subject": {"text": [["two dark-skinned patients"]],"start": [["5"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["hyperpigmented skin and tongue lesions"]],"start": [["38", "55"]],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "10749332_2","context": "It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": []},"Treatment": {"text": [["troglitazone"]],"start": [["5"]],"entity_id": [] ,"Drug": {"text": [["troglitazone"]],"start": [["5"]],"entity_id": [] },"Disorder": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [] },"Freq": {"text": [["to be seen"]],"start": [["0"]],"entity_id": [] },"Combination": [{"Drug": {"text": [["troglitazone"]],"start": [["5"]],"entity_id": [] },"Trigger": {"text": [["hepatotoxicity"]],"start": [["18"]],"entity_id": [] },"event_id": "E1","event_type": "Potential_therapeutic_effect" }] ,"Time_elapsed": {"text": [["is"]],"start": [["22"]],"entity_id": [] },"Duration": {"text": [["specific"]],"start": [["37"]],"entity_id": [] },"Route": {"text": [["associated"]],"start": [["13"]],"entity_id": [] },"Dosage": {"text": [["with"]],"start": [["10"]],"entity_id": [] },"Trigger": {"text": [["troglitazone"]],"start": [["5"]],"entity_id": [] }} ,"Subject": {"text": [["It"]],"start": [["0"]],"entity_id": [] ,"Population": {"text": [["It"]],"start": [["0"]],"entity_id": [] },"Age": {"text": [["It"]],"start": [["0"]],"entity_id": [] },"Gender": {"text": [["It"]],"start": [["0"]],"entity_id": [] },"Race": {"text": [["It"]],"start": [["0"]],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [["to be seen"]],"start": [["0"]],"entity_id": [] ,"value": true },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "2935070_1","context": "Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Ampicillin-induced"]],"start": [[ "0" ]] ,"entity_id": [["T1"] ]},"Treatment": {"text": [["Ampicillin"]],"start": [["0"]],"entity_id": [["T2"] ],"Drug": {"text": [["Ampicillin"]],"start": [["0"]],"entity_id": [["T2"] ]},"Disorder": {"text": [["interstitial nephritis"]],"start": [["18"]],"entity_id": [["T3"] ]},"Time_elapsed": {"text": [["induced"]],"start": [["10"]],"entity_id": [["T4"] ]},"Combination": [{"Drug": {"text": [["Ampicillin"]],"start": [["0"]],"entity_id": [["T2"] ]},"Trigger": {"text": [["induced"]],"start": [["10"]],"entity_id": [["T4"] ]},"event_id":"C1","event_type":"Adverse_event"}],"Trigger": {"text": [["induced"]],"start": [["10"]],"entity_id": [["T4"] ]},"Freq": {"text": [["generalised"]],"start": [["43"]],"entity_id": [["T5"] ]},"Duration": {"text": [["with"]],"start": [["36"]],"entity_id": [["T6"] ]},"Dosage": {"text": [["Ampicillin"]],"start": [["0"]],"entity_id": [["T2"] ]},"Route": {"text": [["induced"]],"start": [["10"]],"entity_id": [["T4"] ]}},"Effect": {"text": [["interstitial nephritis with generalised exfoliative dermatitis"]],"start": [["18"]],"entity_id": [["T3"],["T5"] ]},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "7900744_3","context": "High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["High-dose intravenous mannitol infusion"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["High-dose intravenous mannitol infusion"]],"start": [["0"]],"entity_id": [],"Dosage": {"text": [["High-dose"]],"start": [["6"]],"entity_id": []},"Route": {"text": [["intravenous"]],"start": [["27"]],"entity_id": []},"Disorder": {"text": [["acute renal failure (ARF)"]],"start": [["76"]],"entity_id": []},"Time_elapsed": {"text": [["may result in"]],"start": [["44"]],"entity_id": []},"Freq": {"text": [["may result in"]],"start": [["44"]],"entity_id": []},"Trigger": {"text": [["may result in"]],"start": [["44"]],"entity_id": []},"Duration": {"text": [["may result in"]],"start": [["44"]],"entity_id": []},"Combination": null,"Drug": {"text": [["mannitol"]],"start": [["17"]],"entity_id": []}},"Effect": {"text": [["acute renal failure (ARF)"]],"start": [["76"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["76"]],"entity_id": [],"value": "High"},"Subject": null}]}
{"id": "19474653_2","context": "We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rhabdomyolysis"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clarithromycin"]],"start": [["15"]],"entity_id": [["T2"]],"Drug": {"text": [["clarithromycin"]],"start": [["15"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["rhabdomyolysis"]],"start": [["34"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["without concurrent use of other medications"]],"start": [["60"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["related"]],"start": [["46"]],"entity_id": [["T4"]]},"Dosage": {"text": [["the administration"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Route": {"text": [["the administration"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["report"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["the administration"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "2051906_1","context": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.', extttttt","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 67-year-old patient"]],"start": [[], [], []],"entity_id": [] ,"Age": {"text": [["67"]],"start": [[], [], []],"entity_id": [] },"Disorder": {"text": [["primary polymyositis"]],"start": [[], [], []],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [["patient"]],"start": [[], [], []],"entity_id": [] }} ,"Treatment": {"text": [["azathioprine therapy"]],"start": [[], [], []],"entity_id": [] ,"Drug": {"text": [["azathioprine"]],"start": [[], [], []],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [["3 months"]],"start": [[], [], []],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": {"text": [["initiation"]],"start": [[], [], []],"entity_id": [] }} ,"Effect": {"text": [["clinical and biochemical features of severe cholestasis"]],"start": [[], [], []],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [[], [], []],"entity_id": [] ,"value": "high" },"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "3569037_2", "context": "Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Hypersensitivity reaction"]], "start": [[],[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["chloramphenicol administration"]], "start": [[],[ ]], "entity_id": [["T2"]], "Drug": {"text": [["chloramphenicol"]], "start": [[],[ ]], "entity_id": [["T3"]]},"Disorder":{"text":[["typhoid fever"]], "start": [[],[]], "entity_id": [["T4"]]}, "Dosage":{"text":[], "start": [], "entity_id": []}, "Duration":{"text":[], "start": [], "entity_id": []}, "Route":{"text":[["administration"]], "start": [[],[ ]], "entity_id": [["T2"]]}, "Time_elapsed":{"text":[], "start": [], "entity_id": []}, "Freq":{"text":[], "start": [], "entity_id": []}, "Combination":null ,"Trigger":null },"Subject":{"text":[["patient"]], "start": [[],[ ]], "entity_id": [["T5"]],"Age":null,"Disorder":{"text":[["typhoid fever"]], "start": [[],[ ]], "entity_id": [["T4"]]}, "Gender":null,"Population":null,"Race":null} ,"Effect":{"text":[["Hypersensitivity reaction"]], "start": [[],[ ]], "entity_id": [["T1"]]} ,"Negated":null ,"Speculated":null ,"Severity":null}]}
{"id": "10357715_1","context": "Allergic and irritant contact dermatitis to calcipotriol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Allergic and irritant contact dermatitis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["calcipotriol"]],"start": [[ "53" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["calcipotriol"]],"start": [[ "53" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Allergic and irritant contact dermatitis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [["calcipotriol"]],"start": [[ "53" ]],"entity_id": [ ["T2"] ]} },"Subject": null ,"Effect": {"text": [["Allergic and irritant contact dermatitis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "3565435_1", "context": "A 23-year-old woman with systemic lupus erythematosus had a severe hypersensitivity reaction to the drug ibuprofen", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 23-year-old woman"]], "start": [[],[]], "entity_id": [],"Age":{"text":[["23"]], "start": [[],[]], "entity_id": []}, "Disorder":{"text":[["systemic lupus erythematosus"]], "start": [[],[]], "entity_id": []}, "Gender":{"text":[["woman"]], "start": [[],[]], "entity_id": []},"Population":{"text":[["A"]], "start": [[],[]], "entity_id": []},"Race":{"text":[], "start": [], "entity_id": []}}, "Trigger": {"text": [["hypersensitivity reaction"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["ibuprofen"]], "start": [[],[]], "entity_id": [],"Drug":{"text":[["ibuprofen"]], "start": [[],[]], "entity_id": []},"Dosage":{"text":[], "start": [], "entity_id": []},"Duration":{"text":[], "start": [], "entity_id": []},"Route":{"text":[], "start": [], "entity_id": []},"Time_elapsed":{"text":[], "start": [], "entity_id": []},"Freq":{"text":[], "start": [], "entity_id": []},"Combination":null,"Trigger":{"text":[["hypersensitivity reaction"]], "start": [[],[]], "entity_id": []},"Disorder":{"text":[], "start": [], "entity_id": []}}, "Effect": {"text": [["severe"]], "start": [[],[]], "entity_id": []},"Negated":null,"Speculated":null,"Severity":{"text":[["severe"]], "start": [[],[]], "entity_id": [],"value":"severe"}}]}
{"id": "2738729_1", "context": "We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Subject": {"text": [["infant"]], "start": [["We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["haloperidol"]], "start": [[", mother taking haloperidol"]], "entity_id": [],"Drug": {"text": [["haloperidol"]], "start": [[", mother taking haloperidol"]], "entity_id": []}, "Dosage": null, "Freq": null, "Route": null, "Duration": null, "Time_elapsed": null, "Trigger": null, "Disorder": null, "Combination": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Trigger": null}]}
{"id": "17189581_7", "context": "Despite treatment with levofloxacin, acyclovir, and voriconazole, the patient developed high fevers", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Treatment": { "Drug": {"text": [["levofloxacin"], ["acyclovir"], ["voriconazole"]], "start": [[ "0", "33", "57" ]], "entity_id": [ ["T1"], ["T2"], ["T3" ]] }, "text": [["treatment"]], "start": [[ "4" ]], "entity_id": [ ["T0" ]] ,"Trigger": { "text": [["developed"]], "start": [[ "74" ]], "entity_id": [ ["T4" ]] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": []}, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": { "text": [["high fevers"]], "start": [[ "91" ]], "entity_id": [ ["T5" ]] }, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Trigger": null }]}
{"id": "6353252_2","context": "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["captopril-induced acute renal failure"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure" ] ],"entity_id": [ ["T7"] ]},"Subject": {"text": [["The 5 patients"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T1"] ],"Age": null,"Gender": null,"Population": {"text": [["5"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T2"] ]},"Race": null,"Disorder": {"text": [["severe renovascular disease"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure" ]],"entity_id": [ ["T3"] ]}},"Treatment": {"text": [["captopril"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T7"] ],"Drug": {"text": [["captopril"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T7"] ]},"Disorder": {"text": [["acute renal failure"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T6"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": {"text": [["might thus represent"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [] ,"value": true },"Severity": {"text": [["severe"]],"start": [[ "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure"]],"entity_id": [ ["T4"] ],"value": "high" }}]}
{"id": "20120657_1","context": "Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["known cause"]],"start": [["known cause'.indexOf(" ]],"entity_id": [ ]},"Treatment": {"text": [["Zidovudine"]],"start": [["Zidovudine'.indexOf(" ]],"entity_id": [ ],"Drug": { "text": [["Zidovudine"]], "start": [[ "Zidovudine'.indexOf(" ]], "entity_id": [ ["T1"] ]} ,"Disorder": { "text": [["anaemia"]], "start": [[ "anaemia'.indexOf(" ]], "entity_id": [ ["T2"] ]} ,"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null },"Effect": { "text": [["anaemia"]], "start": [[ "anaemia'.indexOf(" ]], "entity_id": [ ["T2"] ]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null }]}
{"id": "7397053_2", "context": "Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Papilloedema"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["perhexiline maleate (Pexid)"], ["perhexiline maleate"]], "start": [[ "52" ],[ "43" ]], "entity_id": [ ["T3"], ["T2"] ], "Drug": {"text": [["perhexiline maleate"]], "start": [[ "43" ]], "entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Papilloedema"], ["hepatic dysfunction"]], "start": [[ "0" ],[ "22" ]], "entity_id": [ ["T1"], ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null } ,"Negated": null, "Speculated": null, "Severity": null , "Subject": null ,"Effect": null }]}
{"id": "9103523_2", "context": "The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hepatotoxicity"]], "start": [["81"]], "entity_id": []}, "Treatment": {"text": [["halothane"]], "start": [["16"]], "entity_id": [], "Drug": {"text": [["halothane"]], "start": [["16"]], "entity_id": []}, "Duration": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Route": {"text": [["biotransformation"]], "start": [["50"]], "entity_id": []}, "Trigger": {"text": [["generating"]], "start": [["69"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["halothane"]], "start": [["16"]], "entity_id": []}, "Trigger": {"text": [["generating"]], "start": [["69"]], "entity_id": []}, "event_id": "C1", "event_type": "Adverse_event"}], "Freq": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Time_elapsed": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Dosage": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Disorder": {"text": [["hepatotoxicity"]], "start": [["81"]], "entity_id": []}}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [], "start": [], "entity_id": []}}, "Negated": null, "Speculated": null, "Severity": null, "Effect": {"text": [["hepatotoxicity"]], "start": [["81"]], "entity_id": []}}, {"event_id": "C1", "event_type": "Adverse_event", "Trigger": {"text": [["generating"]], "start": [["69"]], "entity_id": []}, "Treatment": {"text": [["halothane"]], "start": [["16"]], "entity_id": [], "Drug": {"text": [["halothane"]], "start": [["16"]], "entity_id": []}, "Duration": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Route": {"text": [["biotransformation"]], "start": [["50"]], "entity_id": []}, "Trigger": {"text": [["generating"]], "start": [["69"]], "entity_id": []}, "Combination": null, "Freq": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Time_elapsed": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Dosage": {"text": [["substantial"]], "start": [["35"]], "entity_id": []}, "Disorder": {"text": [["hepatotoxicity"]], "start": [["81"]], "entity_id": []}}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [], "start": [], "entity_id": []}}, "Negated": null, "Speculated": null, "Severity": null, "Effect": {"text": [["hepatotoxicity"]], "start": [["81"]], "entity_id": []}}]}
{"id": "10803790_4", "context": "A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["slight elevation of serum transaminases"]], "start": [[ ]],"entity_id": []}, "Subject": {"text": [["A 61-year-old male alcoholic"]], "start": [[]], "entity_id": [],"Age": {"text": [["61"]], "start": [[]], "entity_id": []},"Gender": {"text": [["male"]], "start": [[]], "entity_id": []},"Disorder": {"text": [["alcoholic"]], "start": [[]], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []}}, "Treatment": {"text": [["cyanamide"]], "start": [[]], "entity_id": [],"Drug": {"text": [["cyanamide"]], "start": [[]], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [["3 years"]], "start": [[]], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null,"Trigger": null}, "Effect": {"text": [["slight elevation of serum transaminases"]], "start": [[]], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [["slight"]], "start": [[]], "entity_id": [],"value": "low"}}]}
{"id": "6197014_2","context": "Two children with rheumatic fever developed anicteric hepatitis while on high-dose aspirin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anicteric hepatitis"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["Two children with rheumatic fever"]],"start": [[""], ["0"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["rheumatic fever"]],"start": [["0"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["high-dose aspirin therapy"]],"start": [["57"]],"entity_id": [["T4"]],"Drug": {"text": [["aspirin"]],"start": [["57"]],"entity_id": [["T5"]]},"Dosage": {"text": [["high-dose"]],"start": [["57"]],"entity_id": [["T6"]]} ,"Route": {"text": [["therapy"]],"start": [["57"]],"entity_id": [["T7"]]} ,"Duration": null,"Disorder": {"text": [["rheumatic fever"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": {"text": [["anicteric hepatitis"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "12095907_1", "context": "The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["valproate-induced hyperammonemia", "mental status changes"]],"start": [["33","51"]],"entity_id": [["T1","T2"]]},"Subject": {"text": [["an 88-year-old man"]],"start": [["83"]],"entity_id": [["T3"]],"Age": {"text": [["88"]],"start": [["83"]],"entity_id": [["A1"]]},"Gender": {"text": [["man"]],"start": [["85"]],"entity_id": [["G1"]]} ,"Population": {"text": [["first known reported case in an elderly patient"]],"start": [["96"]],"entity_id": [["P1"]]} ,"Race": {"text": [["man"]],"start": [["85"]],"entity_id": [["R1"]]} ,"Disorder": {"text": [["hyperammonemia"]],"start": [["33"]],"entity_id": [["D1"]]} },"Treatment": {"text": [["valproate"]],"start": [["17"]],"entity_id": [["T4"]],"Drug": {"text": [["valproate"]],"start": [["17"]],"entity_id": [["D2"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["hyperammonemia"]],"start": [["33"]],"entity_id": [["D1"]]} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["mental status changes"]],"start": [["51"]],"entity_id": [["E2"]]} ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "9831311_5", "context": "The mechanism of the decrease in plasma potassium induced by phosphate treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations. ", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["decrease in plasma potassium"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["phosphate treatment"]], "start": [["11"]], "entity_id": [],"Drug": {"text": [["phosphate"]], "start": [["11"]], "entity_id": []},"Disorder": {"text": [["hypophosphatemic osteomalacia"]], "start": [["42"]], "entity_id": []},"Route": {"text": [["oral"]], "start": [["64"]], "entity_id": []},"Dosage": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"Duration": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"Time_elapsed": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"Freq": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"Combination": [{"Drug": {"text": [["phosphate"]], "start": [["11"]], "entity_id": []},"Trigger": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"event_id": "C1","event_type": "null"} ],"Trigger": {"text": [["investigated"]], "start": [["0"]], "entity_id": []}},"Subject": {"text": [["a 24-year-old hypertensive patient"]], "start": [["71"]], "entity_id": [],"Age": {"text": [["24"]], "start": [["71"]], "entity_id": []},"Disorder": {"text": [["hypertensive"]], "start": [["76"]], "entity_id": []},"Gender": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []},"Population": {"text": [["1"]], "start": [["71"]], "entity_id": []},"Race": {"text": [["not specified"]], "start": [[""],[""]], "entity_id": []}} , "Negated":{"value":false,"text":[],"start":[],"entity_id":[]},"Speculated":{"value":false,"text":[],"start":[],"entity_id":[]},"Severity":{"value":"Low","text":[],"start":[],"entity_id":[]} ,"Effect": {"text": [],"start": [[""],[""]], "entity_id": []} }]}
{"id": "1722991_6","context": "In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/min) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["a combination of iloprost"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["iloprost"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["iloprost"]],"start": [["5"]],"entity_id": [["T3"]]},"Disorder": {"text": [["heparin-induced platelet aggregation"]],"start": [["86"]],"entity_id": [["T5"]]},"Dosage": {"text": [["1 to 2 ng/kg/min"]],"start": [["20"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["iloprost"]],"start": [["5"]],"entity_id": [["T3"]]},"Trigger": {"text": [["a stable prostacyclin analogue"]],"start": [["16"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["aspirin"]],"start": [["60"]],"entity_id": [["T6"]]},"Trigger": {"text": [["and dipyridamole"]],"start": [["66"]],"entity_id": [["T7"]]},"event_id": "E3","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["shown to inhibit"]],"start": [["71"]],"entity_id": [["T8"]]},"Route": {"text": [["ex vivo"]],"start": [["79"]],"entity_id": [["T9"]]},"Time_elapsed": {"text": [["the"]],"start": [["81"]],"entity_id": [["T10"]]},"Trigger": {"text": [["heparin-induced platelet aggregation"]],"start": [["86"]],"entity_id": [["T5"]]},"Duration": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Subject": {"text": [["In the two cases"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11328247_3", "context": "The aim of this paper is to describe a case of increased libido during fluvoxamine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased libido"]], "start": [["36","39"]], "entity_id": []}, "Treatment": {"text": [["fluvoxamine therapy"]], "start": [["56","64"]], "entity_id": [], "Drug": {"text": [["fluvoxamine"]], "start": [["56","64"]], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] } ,"Trigger": { "text": [], "start": [], "entity_id": [] } ,"Route": { "text": [], "start": [], "entity_id": [] } ,"Time_elapsed": { "text": [], "start": [], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": []}, "Effect": {"text": [["increased libido"]], "start": [["36","39"]], "entity_id": [] }, "Negated": { "value": false, "text": [], "start": [], "entity_id": [] }, "Speculated": { "value": false, "text": [], "start": [], "entity_id": [] }, "Severity": { "value": "", "text": [], "start": [], "entity_id": [] }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": { "text": [], "start": [], "entity_id": [] } ,"Gender": { "text": [], "start": [], "entity_id": [] } ,"Population": { "text": [], "start": [], "entity_id": [] } ,"Race": { "text": [], "start": [], "entity_id": [] } ,"Disorder": { "text": [], "start": [], "entity_id": [] }}}]}
{"id": "11131346_3","context": "An 8-year-old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["colchicine intoxication"]],"start": [["35"]],"entity_id": [["T1"]]},"Subject": {"text": [["An 8-year-old child"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["8"]],"start": [["3"]],"entity_id": [["T3"]]},"Disorder": {"text": [["familial Mediterranean fever"]],"start": [["18"]],"entity_id": [["T4"]]},"Population": {"text": [["one"]],"start": [["0"]],"entity_id": [["T5"]]},"Race": {"text": [["Mediterranean"]],"start": [["31"]],"entity_id": [["T6"]]},"Gender": {"text": [["child"]],"start": [["5"]],"entity_id": [["T7"]]}},"Treatment": {"text": [["prophylactic doses of the drug colchicine"]],"start": [["52"]],"entity_id": [["T8"]],"Drug": {"text": [["colchicine"]],"start": [["70"]],"entity_id": [["T9"]]},"Dosage": {"text": [["prophylactic doses"]],"start": [["52"]],"entity_id": [["T10"]]},"Route": {"text": [["receiving"]],"start": [["47"]],"entity_id": [["T11"]]},"Time_elapsed": {"text": [["signs exhibited while"]],"start": [["25"]],"entity_id": [["T12"]]},"Duration": {"text": [["while receiving prophylactic doses"]],"start": [["47"]],"entity_id": [["T13"]]},"Disorder": {"text": [["familial Mediterranean fever"]],"start": [["18"]],"entity_id": [["T14"]]},"Combination": [{"Drug": {"text": [["colchicine"]],"start": [["70"]],"entity_id": [["T15"]]},"Trigger": {"text": [["prophylactic doses"]],"start": [["52"]],"entity_id": [["T16"]]},"event_id": "E1","event_type": "Adverse_event"}],"Freq": {"text": [["prophylactic doses"]],"start": [["52"]],"entity_id": [["T17"]]},"Trigger": {"text": [["signs of colchicine intoxication"]],"start": [["35"]],"entity_id": [["T18"]]}},"Effect": {"text": [["colchicine intoxication"]],"start": [["35"]],"entity_id": [["T19"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["signs"]],"start": [["35"]],"entity_id": [["T20"]],"value": "low"}}]}
{"id": "11675845_9","context": "Furthermore, the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gastrointestinal adverse effects"]],"start": [["59", "60"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["warfarin"]],"start": [["18"]],"entity_id": [["T2"]]},"Dosage": {"text": [["increased"]],"start": [["41"]],"entity_id": [["T3"]]},"Disorder": {"text": [["common"]],"start": [["46"]],"entity_id": [["T4"]]},"Trigger": {"text": [["discontinuation"]],"start": [["31"]],"entity_id": [["T5"]]},"Route": {"text": [["after"]],"start": [["24"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after"]],"start": [["24"]],"entity_id": [["T6"]]},"entity_id": [["T2"]],"text": [["the warfarin dose was again increased"]],"start": [["18"]],"Duration": {"text": [["after discontinuation"]],"start": [["31"]],"entity_id": [["T5"]]},"Freq": {"text": [["after discontinuation"]],"start": [["31"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["warfarin"]],"start": [["18"]],"entity_id": [["T2"]]},"Trigger": {"text": [["discontinuation"]],"start": [["31"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["ropinirole"]],"start": [["7"]],"entity_id": [["T7"]]},"Trigger": {"text": [["discontinuation"]],"start": [["31"]],"entity_id": [["T5"]]},"event_id": "C2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["the patient"]],"start": [["0"]],"Age": {"text": [["common"]],"start": [["46"]],"entity_id": [["T4"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["common"]],"start": [["46"]],"entity_id": [["T4"]],"value": "low"},"Effect": {"text": [["gastrointestinal adverse effects"]],"start": [["59", "60"]],"entity_id": [["T1"]]}}]}
{"id": "11700998_2", "context": "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["nonconvulsive generalized status epilepticus"]], "start": [["54"]], "entity_id": [["T1"]]}, "Subject": {"text": [["an elderly woman"]], "start": [["16"]], "entity_id": [["T2"]], "Age": {"text": [["elderly"]], "start": [["16"]], "entity_id": [["T7"]]}, "Gender": {"text": [["woman"]], "start": [["21"]], "entity_id": [["T8"]]} , "Disorder": {"text": [["seizures"]], "start": [["48"]], "entity_id": [["T9"]]} , "Population": {"text": [["an elderly woman"]], "start": [["16"]], "entity_id": [["T2"]]} , "Race": null},"Treatment": {"text": [["acute withdrawal of lorazepam"]], "start": [["82"]], "entity_id": [["T3"]], "Drug": {"text": [["lorazepam"]], "start": [["82"]], "entity_id": [["T4"]]} , "Dosage": null, "Freq": null, "Route": null, "Time_elapsed": null, "Duration": null, "Disorder": null , "Trigger": null , "Combination": null},"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "9634122_4","context": "We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["flutamide"]],"start": [["flutamide withdrawal's index in the text"]] ,"entity_id": [ ["T7"] ]},"Trigger": {"text": [["withdrawal"]],"start": [[ "index of withdrawal in the text" ]],"entity_id": [ ["T8"] ]} ,"Disorder": {"text": [["androgen-independent prostate cancer"]],"start": [[ "index of androgen-independent prostate cancer in the text" ]],"entity_id": [ ["T6"] ]},"Duration": {"text": [["a period of 15 months"]],"start": [[ "index of period in the text" ]],"entity_id": [ ["T9"] ]} ,"Time_elapsed": {"text": [["15 months"]],"start": [[ "index of 15 months in the text" ]],"entity_id": [ ["T10"] ]} ,"entity_id": [ ["T7","T6","T9","T10"] ],"text": [["flutamide withdrawal"]],"start": [[ "index of flutamide withdrawal in the text" ]], "Dosage": { "text": [],"start": [],"entity_id": [] }, "Route": { "text": [],"start": [],"entity_id": [] }, "Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": {"text": [["PSA continued to decrease"]],"start": [[ "index of PSA in the text" ]],"entity_id": [ ["T5"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a patient"]],"start": [[ "index of patient in the text" ]],"entity_id": [ ["T4"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["androgen-independent prostate cancer"]],"start": [[ "index of androgen-independent prostate cancer in the text" ]],"entity_id": [ ["T6"] ]} } ,"Trigger": null } ]}
{"id": "19203515_1","context": "Acute renal failure following intravenous immunoglobulin therapy in a HIV-infected patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute renal failure"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["intravenous immunoglobulin therapy"]],"start": [[ "46"]],"entity_id": [ ["T2"]],"Drug": {"text": [["intravenous immunoglobulin"]],"start": [[ "46"]],"entity_id": [ ["T3"]]},"Route": {"text": [["intravenous"]],"start": [[ "46"]],"entity_id": [ ["T4"]]},"Disorder": {"text": [["HIV-infected"]],"start": [[ "75"]],"entity_id": [ ["T5"]]},"Time_elapsed": {"text": [["following"]],"start": [[ "32"]],"entity_id": [ ["T6"]]},"Combination": null,"Dosage": null,"Duration": null,"Freq": null,"Trigger": null},"Subject": {"text": [["a patient"]],"start": [[ "87"]],"entity_id": [ ["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["HIV-infected"]],"start": [[ "75"]],"entity_id": [ ["T5"]]}},"Effect": {"text": [["Acute renal failure"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["Acute"]],"start": [[ "0"]],"entity_id": [ ["T8"]],"value": "High"}}]}
{"id": "17189581_11","context": "After a total of four doses of linezolid, the patient reported further discomfort","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["four doses"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["linezolid"]],"start": [["22"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["four doses"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["reported"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["discomfort"]],"start": [["60"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["four doses"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["four doses"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Route": {"text": [["linezolid"]],"start": [["22"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["four doses"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Combination": [] }, "Subject": {"text": [["patient"]],"start": [["34"]],"entity_id": [["T5"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "18176653_11","context": "This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["possible reactions"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["antiretroviral medication"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["antiretroviral"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["reactions in the oral cavity"]],"start": [["18"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["due to"]],"start": [["43"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["antiretroviral"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["due to"]],"start": [["43"]],"entity_id": [["T5"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Freq": {"text": [["possible reactions"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["due to"]],"start": [["43"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["due to"]],"start": [["43"]],"entity_id": [["T5"]]} ,"Route": {"text": [["due to"]],"start": [["43"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["possible reactions"]],"start": [["15"]],"entity_id": [["T1"]]} },"Subject": {"text": [["This paper"]],"start": [["0"]],"entity_id": [["T0"]] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["possible reactions"]],"start": [["15"]],"entity_id": [["T1"]] ,"value": "Low" },"Effect": {"text": [["reactions"]],"start": [["18"]],"entity_id": [["T4"]]} }] }
{"id": "15482394_2","context": "Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["abnormal hypersensitivity"]],"start": [["53"]],"entity_id": [["T1"]]},"Treatment": {"text": [["warfarin"]],"start": [["75"]],"entity_id": [["T2"]] ,"Disorder": {"text": [["abnormal hypersensitivity"]],"start": [["53"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["contributed"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["clinical status"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Duration": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Freq": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Route": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Combination": [{"Drug": {"text": [["warfarin"]],"start": [["75"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["contributed"]],"start": [["24"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "null"} ],"Drug": {"text": [["warfarin"]],"start": [["75"]],"entity_id": [["T2"]]} },"Subject": {"text": [["the clinical status of the patient"]],"start": [[""], []],"entity_id": [["T4"]],"Age": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Gender": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Population": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Race": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} ,"Disorder": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} },"Negated": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]] ,"value": false },"Speculated": {"text": [["suspected"]],"start": [["9"]],"entity_id": [["T5"]],"value": true},"Severity": {"text": [["abnormal"]],"start": [["53"]],"entity_id": [["T1"]],"value": "low"} ,"Effect": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]} }]}
{"id": "17852449_3","context": "Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the teratogenic effect of retinoids","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["ATRA"]],"start": [["use of ATRA has been questioned due to the teratogenic effect of" , "retinoids" ]],"entity_id": []} ,"Disorder": {"text": [["the teratogenic effect"]],"start": [[ "of retinoids" ]],"entity_id": []} ,"Trigger": {"text": [["teratogenic effect"]],"start": [[ "the teratogenic effect" ]],"entity_id": []} ,"entity_id": [] ,"text": [["the use of ATRA has been questioned due to the teratogenic effect of retinoids"]],"start": [["use of ATRA has been questioned due to the teratogenic effect of" ]],"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }] }
{"id": "2302898_1","context": "Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Diazepam"]],"start": [["0"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["withdrawal symptoms"]],"start": [["40"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["use"]],"start": [["11"]],"entity_id": [["T3"]]},"Route": {"text": [["by pregnant women"]],"start": [["15"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["a later presentation"]],"start": [["32"]],"entity_id": [["T5"]]},"Freq": {"text": [["that induced by the use of other drugs"]],"start": [["56"]],"entity_id": [["T6"]]} ,"Drug": {"text": [["Diazepam"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "21712512_11","context": "This case highlights rapid onset of adrenal insufficiency in a patient with CF-related liver disease treated briefly with a moderate CYP3A4 inhibitor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rapid onset of adrenal insufficiency"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient with CF-related liver disease"]],"start": [["41"]],"entity_id": [["T2"]],"Disorder": {"text": [["CF-related liver disease"]],"start": [["41"]],"entity_id": [["T3"]]},"Age": {"text": [["adult"]],"start": [["27"]],"entity_id": [["T4"]]},"Gender": {"text": [["male"]],"start": [["35"]],"entity_id": [["T5"]]},"Race": {"text": [["Caucasian"]],"start": [["61"]],"entity_id": [["T6"]]},"Population": {"text": [["1"]],"start": [["41"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["a moderate CYP3A4 inhibitor"]],"start": [["83"]],"entity_id": [["T7"]],"Drug": {"text": [["moderate CYP3A4 inhibitor"]],"start": [["83"]],"entity_id": [["T7"]]},"Dosage": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T7"]]},"Duration": {"text": [["brief"]],"start": [["75"]],"entity_id": [["T8"]]},"Route": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T7"]]},"Freq": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T7"]]},"Disorder": {"text": [["adrenal insufficiency"]],"start": [["11"]],"entity_id": [["T9"]]},"Trigger": {"text": [["treated"]],"start": [["69"]],"entity_id": [["T10"]]},"Combination": [{"Drug": {"text": [["moderate CYP3A4 inhibitor"]],"start": [["83"]],"entity_id": [["T7"]]},"Trigger": {"text": [["treated"]],"start": [["69"]],"entity_id": [["T10"]]},"event_id": "C1","event_type": "Treatment"}]},"Negated": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T1"]],"value": false},"Speculated": {"text": [["N/A"]],"start": [[""], []],"entity_id": [["T1"]],"value": false},"Severity": {"text": [["rapid onset"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["adrenal insufficiency"]],"start": [["11"]],"entity_id": [["T9"]]}}]}
{"id": "12951892_2", "context": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["newborn"]], "start": [[ "0"]], "entity_id": [ ] ,"Age": {"text": [["four day course"]], "start": [[ "15"]], "entity_id": [ ]} ,"Disorder": {"text": [["lethargy"]], "start": [[ "31"]], "entity_id": [ ]} ,"Gender": { "text": [["newborn"]], "start": [[ "0"]], "entity_id": []} ,"Race": { "text": [["newborn"]], "start": [[ "0"]], "entity_id": []} ,"Population": { "text": [["newborn"]], "start": [[ "0"]], "entity_id": []} },"Treatment": { "text": [], "start": [], "entity_id": [] ,"Drug": { "text": [], "start": [], "entity_id": [] },"Disorder": { "text": [], "start": [], "entity_id": [] },"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [["four day course"]], "start": [[ "15"]], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [], "start": [], "entity_id": [] },"Combination": [] },"Effect": { "text": [["lethargy"]], "start": [[ "31"]], "entity_id": [ ] },"Negated": { "text": [], "start": [], "entity_id": [] ,"value": false },"Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false },"Severity": { "text": [], "start": [], "entity_id": [] ,"value": "high" },"Trigger": { "text": [["high lithium levels"]], "start": [[ "62"]], "entity_id": [ ] } }]}
{"id": "8891729_3","context": "The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe AIHA"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fludarabine"]],"start": [["48"]],"entity_id": [["T2"]],"Drug": {"text": [["fludarabine"]],"start": [["48"]],"entity_id": [["T2"]]},"Disorder": {"text": [["AIHA"]],"start": [["7"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treated"]],"start": [["34"]],"entity_id": [["T4"]]},"Duration": {"text": [["CLL patients"]],"start": [["13"]],"entity_id": [["T5"]]},"Freq": {"text": [["has been reported"]],"start": [["59"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["fludarabine"]],"start": [["48"]],"entity_id": [["T2"]]},"Trigger": {"text": [["treated"]],"start": [["34"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["has been reported"]],"start": [["59"]],"entity_id": [["T6"]]},"Route": {"text": [["treated"]],"start": [["34"]],"entity_id": [["T4"]]},"Dosage": {"text": [["treated"]],"start": [["34"]],"entity_id": [["T4"]]}},"Subject": {"text": [["CLL patients"]],"start": [["13"]],"entity_id": [["T5"]],"Population": {"text": [["CLL patients"]],"start": [["13"]],"entity_id": [["T5"]]},"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["CLL patients"]],"start": [["13"]],"entity_id": [["T5"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe AIHA"]],"start": [["0"]],"entity_id": [["T1"]]},"Severity": {"text": [["severe"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "19034138_4","context": "Corneal endothelial dysfunction associated with amantadine toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Corneal endothelial dysfunction"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["amantadine"]], "start": [[ "63" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["amantadine"]], "start": [[ "63" ]], "entity_id": [ ["T2"] ]} ,"Time_elapsed": null ,"Duration": null ,"Route": null ,"Disorder": null ,"Dosage": null ,"Freq": null ,"Combination": null ,"Trigger": { "text": [["amantadine toxicity"]], "start": [[ "40" ]], "entity_id": [ ["T3"] ]} } ,"Effect": { "text": [["Corneal endothelial dysfunction"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} , "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null ,"Disorder": null ,"Gender": null ,"Population": null ,"Race": null }} ] }
{"id": "1378497_4","context": "We describe the development of cutaneous scleroderma in 3 patients coincident with the use of bleomycin in low cumulative doses of less than 100 U.', " ,"is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Adverse_event", "Treatment": { "text": [["bleomycin"]], "start": [["65"]], "entity_id": [ ["T1"]], "Dosage": { "text": [["low cumulative doses of less than 100 U"]], "start": [["80"]], "entity_id": [ ["T2"]] } ,"Duration": { "text": [["3 patients"]], "start": [["31"]], "entity_id": [ ["T3"]] } ,"Disorder": { "text": [["cutaneous scleroderma"]], "start": [["14"]], "entity_id": [ ["T4"]] } ,"Trigger": { "text": [["coincident"]], "start": [["44"]], "entity_id": [ ["T5"]] } ,"Time_elapsed": { "text": [["development"]], "start": [["14"]], "entity_id": [ ["T6"]] } ,"Route": { "text": [["use"]], "start": [["59"]], "entity_id": [ ["T7"]] } ,"Freq": { "text": [["low cumulative doses of less than 100 U"]], "start": [["80"]], "entity_id": [ ["T8"]] } ,"Combination": [ { "Drug": { "text": [["isoniazid"]], "start": [["64"]], "entity_id": [ ["T9"]] }, "Trigger": { "text": [["and"]], "start": [["68"]], "entity_id": [ ["T10"]] } ,"event_id": "E2", "event_type": "Adverse_event" } ] ,"Drug": { "text": [["bleomycin"]], "start": [["65"]], "entity_id": [ ["T11"]] } } ,"Subject": { "text": [["3 patients"]], "start": [["31"]], "entity_id": [ ["T12"]], "Age": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [["cutaneous scleroderma"]], "start": [["14"]], "entity_id": [ ["T13"]] } } ,"Negated": { "text": [], "start": [], "entity_id": [] ,"value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false }, "Severity": { "text": [], "start": [], "entity_id": [] ,"value": "" } ,"Effect": { "text": [["cutaneous scleroderma"]], "start": [["14"]], "entity_id": [ ["T14"]] } ,"Trigger": { "text": [["coincident"]], "start": [["44"]], "entity_id": [ ["T15"]] } } ] }
{"id": "10367184_3","context": "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["synergistic"]],"start": [["This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a ","synergistic"," manner to produce severe clinical myotonia in humans."]],"entity_id": []},"Treatment": {"text": [["pravastatin"]],"start": [[ "This case suggests that sarcoidosis and" ]],"entity_id": [],"Drug": {"text": [["pravastatin"]],"start": [[ "This case suggests that sarcoidosis and" ]],"entity_id": []},"Disorder": {"text": [["sarcoidosis"]],"start": [[ "This case suggests that" ]],"entity_id": []},"Freq": {"text": [["interact"]],"start": [[ "This case suggests that sarcoidosis and pravastatin,"]],"entity_id": []},"Combination": [{"Drug": {"text": [["pravastatin"]],"start": [[ "This case suggests that sarcoidosis and" ]],"entity_id": []},"Trigger": {"text": [["interact"]],"start": [[ "This case suggests that sarcoidosis and pravastatin,"]],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["produce"]],"start": [[ "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce" ]],"entity_id": []},"Duration": {"text": [["severe clinical myotonia in humans"]],"start": [[ "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans."]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["interact"]],"start": [[ "This case suggests that sarcoidosis and pravastatin,"]],"entity_id": []}},"Subject": {"text": [["This case suggests that sarcoidosis and pravastatin"]],"start": [[ "This case suggests that sarcoidosis and pravastatin" ]],"entity_id": [],"Disorder": {"text": [["myotonia"]],"start": [[ "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with" ]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe clinical myotonia in humans"]],"start": [[ "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans."]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}}]}
{"id": "7226916_2", "context": "Disopyramide-induced heart block", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Disopyramide-induced"]], "start": [["0"]], "entity_id": [ ]}, "Treatment": {"text": [["Disopyramide"]], "start": [["0"]], "entity_id": [ ],"Drug": {"text": [["Disopyramide"]], "start": [["0"]], "entity_id": [ ]},"Disorder": {"text": [["heart block"]], "start": [["16"]], "entity_id": [ ]},"Time_elapsed": {"text": [["induced"]], "start": [["12"]], "entity_id": [ ]},"Freq": {"text": [["Disopyramide-induced"]], "start": [["0"]], "entity_id": [ ]},"Combination": [{"Drug": {"text": [["Disopyramide"]], "start": [["0"]], "entity_id": [ ]},"Trigger": {"text": [["induced"]], "start": [["12"]], "entity_id": [ ]},"event_id": "C1","event_type": "Adverse_event"}], "Trigger":{"text":[["Disopyramide-induced"]],"start":[["0"]],"entity_id":[ ]},"Dosage":{"text":[["Disopyramide-induced"]],"start":[["0"]],"entity_id":[ ]},"Route":{"text":[["Disopyramide-induced"]],"start":[["0"]],"entity_id":[ ]},"Duration":{"text":[["Disopyramide-induced"]],"start":[["0"]],"entity_id":[ ]} } , "Severity": { "text": [ ["high" ] ], "start": [["0"]], "entity_id": [ [] ] ,"value":"high" } ,"Subject": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] ,"Age": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] }, "Disorder": { "text": [ ["heart block"] ], "start": [["16"]], "entity_id": [ [] ] }, "Gender": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] }, "Population": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] }, "Race": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] }} , "Negated": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] ,"value":false }, "Speculated": { "text": [ ["Disopyramide-induced" ] ], "start": [["0"]], "entity_id": [ [] ] ,"value":false } , "Effect": { "text": [ ["heart block" ] ], "start": [["16"]], "entity_id": [ [] ] } }]}
{"id": "8742573_2", "context": "Jet-injection devices might constitute a helpful method to treat those patients affected by severe human insulin-induced lipoatrophy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Jet-injection devices"]], "start": [[ "0" ]], "entity_id": [] , "Disorder": {"text": [["severe human insulin-induced lipoatrophy"]], "start": [[ "59" ]], "entity_id": [] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Drug": null }, "Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "20412003_6","context": "We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and soft tissue infection and was treated with TMP-SMX","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["TMP-SMX"]],"start": [["63"]],"entity_id": [["T1"]] ,"Drug": {"text": [["TMP-SMX"]],"start": [["63"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["CA-MRSA skin and soft tissue infection"]],"start": [["30"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["treated"]],"start": [["71"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["9-year-old"]],"start": [["14"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["developed"]],"start": [["22"]],"entity_id": [["T5"]]} ,"Route": {"text": [["skin and soft tissue infection"]],"start": [["30"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"text": [["a relatively healthy, boy"]],"start": [["7"]],"entity_id": [["T0"]],"Age": {"text": [["9-year-old"]],"start": [["14"]],"entity_id": [["T4"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": {"text": [["treated"]],"start": [["71"]],"entity_id": [["T3"]]}}]}
{"id": "10897389_2","context": "Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["recurrent septicemia"]],"start": [[ "0"]] , "entity_id": [ ["T1"] ]},"Treatment": {"text": [["cyclosporine therapy"]],"start": [[ "45" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["cyclosporine"]],"start": [[ "45" ]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": {"text": [["during and after"]],"start": [[ "22" ]],"entity_id": [ ["T4"] ]},"Trigger": null,"Disorder": {"text": [["severe ulcerative colitis"]],"start": [[ "75" ]],"entity_id": [ ["T5"] ]},"Freq": null,"Dosage": null,"Duration": null,"Route": null,"Combination": null}, "Severity": { "text": [["lethal outcome"]], "start": [[ "103" ]], "entity_id": [ ["T6"] ], "value": "high" }, "Negated": null, "Speculated": null ,"Subject": { "text": [["patient"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["severe ulcerative colitis"]], "start": [[ "75" ]], "entity_id": [ ["T5"] ]} }, "Effect": { "text": [["recurrent septicemia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} }] }
{"id": "14740795_2", "context": "Amifostine-induced fever: case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Amifostine-induced fever"]], "start": [[ "0" ] ], "entity_id": [ ["T1"] ] }, "Subject": { "text": [[ "patient" ]], "start": [[ "12" ]], "entity_id": [ ["T2"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Treatment": { "text": [[ "Amifostine" ]], "start": [[ "0" ]], "entity_id": [ ["T3"] ], "Drug": { "text": [[ "Amifostine" ]], "start": [[ "0" ]], "entity_id": [ ["T3"] ] }, "Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": { "text": [[ "induced" ]], "start": [[ "9" ]], "entity_id": [ ["T4"] ] } } , "Effect": { "text": [[ "fever" ]], "start": [[ "35" ]], "entity_id": [ ["T5"] ] } , "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "16767537_3","context": "We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["spontaneous splenic infarction"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sumatriptan"]],"start": [["56"]],"entity_id": [["T2"]],"Disorder": {"text": [["migraine headache"]],"start": [["73"]],"entity_id": [["T3"]]},"Dosage": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Route": {"text": [["use"]],"start": [["47"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after"]],"start": [["52"]],"entity_id": [["T5"]]},"Freq": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Combination": null,"Drug": {"text": [["sumatriptan"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use"]],"start": [["47"]],"entity_id": [["T4"]]}},"Subject": {"text": [["patient"]],"start": [["10"]],"entity_id": [["T0"]],"Age": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Population": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Disorder": {"text": [["migraine headache"]],"start": [["73"]],"entity_id": [["T3"]]}},"Effect": {"text": [["spontaneous splenic infarction"]],"start": [["23"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": false},"Severity": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": "null"}}]}
{"id": "12590235_2","context": "Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hepatotoxicity"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["6-thioguanine therapy"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["6-thioguanine"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["Crohn's disease"]],"start": [[ ]],"entity_id": []},"Freq": {"text": [["therapy"]],"start": [[ ]],"entity_id": []},"Route": {"text": [["for"]],"start": [[ ]],"entity_id": []},"Duration": {"text": [["Crohn's disease"]],"start": [[ ]],"entity_id": []},"Combination": [{"Drug": {"text": [["6-thioguanine"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["therapy"]],"start": [[ ]],"entity_id": []},"event_id": "E1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["associated"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [["Hepatotoxicity"]],"start": [[ ]],"entity_id": []},"Dosage": {"text": [["therapy"]],"start": [[ ]],"entity_id": []}},"Effect": {"text": [["Hepatotoxicity"]],"start": [[ ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["Hepatotoxicity"]],"start": [[ ]],"entity_id": [],"value": "high"},"Subject": {"text": [["Hepatotoxicity"]],"start": [[ ]],"entity_id": [],"Population": {"text": [["therapy"]],"start": [[ ]],"entity_id": []},"Age": null,"Disorder": {"text": [["Crohn's disease"]],"start": [[ ]],"entity_id": []},"Gender": null,"Race": null}}]}
{"id": "15694139_4","context": "Neuropathy is a significant side effect of thalidomide therapy, which may limit its clinical use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Neuropathy"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["thalidomide therapy"]],"start": [[ "38" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["thalidomide"]],"start": [[ "38" ]],"entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["Neuropathy"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Dosage": null, "Duration": null, "Freq": null, "Trigger": null, "Route": null, "Time_elapsed": null ,"Combination": null }, "Subject": { "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null ,"text": [["patient"]], "start": [[ "99" ]], "entity_id": [ ["T4"] ]} ,"Negated": null, "Speculated": null, "Severity": { "text": [["significant"]], "start": [[ "9" ]], "entity_id": [ ["T5"] ], "value": "high" }, "Effect": { "text": [["side effect"]], "start": [[ "16" ]], "entity_id": [ ["T6"] ]} }] }
{"id": "6414095_5", "context": "A possible mechanism for focal neurological deficit in brain-damaged patients on phenytoin therapy is discussed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["phenytoin therapy"]], "start": [[ ]], "entity_id": [["T1"]] ,"Drug": { "text": [[ "phenytoin"]], "start": [[ ]], "entity_id": [[ "T2" ]] }, "Trigger": { "text": [[ "phenytoin therapy"]], "start": [[ ]], "entity_id": [[ "T1" ]] }, "Disorder": { "text": [[ "focal neurological deficit"]], "start": [[ ]], "entity_id": [[ "T3" ]] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null }, "Subject": { "text": [[ "brain-damaged patients"]], "start": [[ ]], "entity_id": [[ "T4" ]] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [[ "brain-damaged"]], "start": [[ ]], "entity_id": [[ "T5" ]] }} ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [[ "mechanism"]], "start": [[ ]], "entity_id": [[ "T6" ]] }, "Trigger": null }]}
{"id": "11757641_1", "context": "Pulmonary toxicity with mefloquine", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Pulmonary toxicity"]], "start": [[ "0"]], "entity_id": []}, "Treatment": {"text": [["mefloquine"]], "start": [[ "42"]], "entity_id": [],"Drug": {"text": [["mefloquine"]], "start": [[ "42"]], "entity_id": []} ,"Disorder": {"text": [["Pulmonary toxicity"]], "start": [[ "0"]], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Combination": [] ,"Trigger": {"text": [], "start": [], "entity_id": []} }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": {"text": [], "start": [], "entity_id": []} ,"Gender": {"text": [], "start": [], "entity_id": []} ,"Population": {"text": [], "start": [], "entity_id": []} ,"Race": {"text": [], "start": [], "entity_id": []} ,"Disorder": {"text": [], "start": [], "entity_id": []} }, "Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "2327115_1","context": "Ciprofloxacin is one drug that has been reported to cause interstitial nephritis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ciprofloxacin"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [],"entity_id": [],"Drug": {"text": [["Ciprofloxacin"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Disorder": {"text": [["interstitial nephritis"]],"start": [[ "59" ]],"entity_id": [ ["T2"] ]},"Time_elapsed": {"text": [["reported"]],"start": [[ "38" ]],"entity_id": [ ["T3"] ]},"Dosage": {"text": [],"entity_id": [],"start": []},"Duration": {"text": [],"entity_id": [],"start": []},"Freq": {"text": [],"entity_id": [],"start": []},"Route": {"text": [],"entity_id": [],"start": []},"Combination": null,"Trigger": {"text": [["reported"]],"start": [[ "38" ]],"entity_id": [ ["T3"] ]},"start": [[ "0" ]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["interstitial nephritis"]],"start": [[ "59" ]],"entity_id": [ ["T2"] ]}}]}
{"id": "16945058_1","context": "Acute renal failure during lisinopril and losartan therapy for proteinuria","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute renal failure"]],"start": [[ ], [ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["lisinopril and losartan therapy"]],"start": [[ ], [ ]],"entity_id": [["T2"]],"Drug": {"text": [["lisinopril"], ["losartan"]],"start": [[ ], [ ]],"entity_id": [["T3"], ["T4"]]},"Disorder": {"text": [["proteinuria"]],"start": [[ ]],"entity_id": [["T5"]]},"Dosage": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Freq": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]},"Duration": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]},"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["lisinopril"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [[ ]],"entity_id": [["T7"]]},"event_id": "E2","event_type": "Therapeutic_effect"},{"Drug": {"text": [["losartan"]],"start": [[ ]],"entity_id": [["T4"]]},"Trigger": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]},"event_id": "E3","event_type": "Therapeutic_effect"}],"Trigger": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]}},"Subject": {"text": [["Acute renal failure"]],"start": [[ ]],"entity_id": [["T1"]],"Age": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Gender": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Population": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Race": {"text": [["during"]],"start": [[ ]],"entity_id": [["T6"]]},"Disorder": {"text": [["proteinuria"]],"start": [[ ]],"entity_id": [["T5"]]}},"Effect": {"text": [["Acute renal failure"]],"start": [[ ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["Acute"]],"start": [[ ]],"entity_id": [["T1"]],"value": "High"}}]}
{"id": "9497597_2","context": "We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["priapism"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["oral intake of the phenothiazine prothipendylhydrochloride"]],"start": [["20"]],"entity_id": [["T2"]],"Drug": {"text": [["phenothiazine prothipendylhydrochloride"]],"start": [["48"]],"entity_id": [["T3"]]} ,"Route": {"text": [["oral"]],"start": [["20"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["first case"]],"start": [["7"]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["30"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["intake"]],"start": [["26"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["present"]],"start": [["9"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [[]],"start": [[],[]],"entity_id": [[]]} ,"Combination": [{"Drug": {"text": [["phenothiazine prothipendylhydrochloride"]],"start": [["48"]],"entity_id": [["T3"]]},"Trigger": {"text": [["intake"]],"start": [["26"]],"entity_id": [["T8"]]} ,"event_type": "Adverse_event","event_id": "E2"}] },"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T10"]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [[]],"start": [[],[]],"entity_id": [[]]} },"Severity": {"text": [[]],"start": [[],[]],"entity_id": [[]] ,"value": "low"},"Negated": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": false},"Speculated": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": false} ,"Effect": {"text": [["priapism"]],"start": [["34"]],"entity_id": [["T1"]]} }]}
{"id": "12811715_3","context": "However, because diphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cardiac toxicity"]],"start": [["43"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [["diphenhydramine"]],"start": [["0"]],"entity_id": [["T1"]]},"entity_id": [["T1"]] ,"Trigger": {"text": [["type IA sodium channel blockade"]],"start": [["23"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["cardiac toxicity"]],"start": [["43"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["possible"]],"start": [["62"]],"entity_id": [["T4"]]}, "Freq": {"text": [["possible"]],"start": [["62"]],"entity_id": [["T4"]]} ,"Route": {"text": [["exhibits"]],"start": [["20"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["diphenhydramine"]],"start": [["0"]],"entity_id": [["T1"]]}, "Duration": {"text": [["possible"]],"start": [["62"]],"entity_id": [["T4"]]} ,"Combination": null ,"text": [["diphenhydramine"]],"start": [["0"]] }, "Effect": {"text": [["cardiac toxicity"]],"start": [["43"]],"entity_id": [["T2"]]} ,"Negated": null,"Speculated": {"text": [["possible"]],"start": [["62"]],"entity_id": [["T4"]] ,"value": true },"Severity": null,"Subject": null }]}
{"id": "11399735_3", "context": "Ticlopidine-induced interstitial pulmonary disease: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ticlopidine-induced"]], "start": [[ "0" ]], "entity_id": []}, "Treatment": {"text": [["Ticlopidine"]], "start": [[ "15" ]], "entity_id": [],"Drug": {"text": [["Ticlopidine"]], "start": [[ "15" ]], "entity_id": []},"Disorder": {"text": [["interstitial pulmonary disease"]], "start": [[ "43" ]], "entity_id": []},"Time_elapsed": {"text": [["induced"]], "start": [[ "23" ]], "entity_id": []},"Duration": {"text": [["case report"]], "start": [[ "64" ]], "entity_id": []},"Route": {"text": [["induced"]], "start": [[ "23" ]], "entity_id": []},"Freq": {"text": [["induced"]], "start": [[ "23" ]], "entity_id": []},"Combination": null,"Dosage": null,"Trigger": {"text": [["Ticlopidine-induced"]], "start": [[ "0" ]], "entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19226083_16", "context": "Linezolid is a popular choice of antibiotic, especially for the treatment of orthopedic-related MRSA infections.', ","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Linezolid"]], "start": [[]], "entity_id":[],"Drug": {"text": [["Linezolid"]], "start": [[]], "entity_id":[]},"Disorder":{"text":[["orthopedic-related MRSA infections"]],"start":[[]],"entity_id":[]},"Trigger":{"text":[["popular choice of antibiotic"]],"start":[[]], "entity_id":[]},"Freq":{"text":[["especially"]],"start":[[]], "entity_id":[]},"Route":{"text":[["for the treatment"]],"start":[[]], "entity_id":[]},"Combination":null,"Dosage":null,"Duration":null,"Time_elapsed":null},"Subject":null,"Negated":null,"Speculated":null,"Severity":null,"Effect":null,"Trigger":null}]}
{"id": "9161656_3","context": "A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po for better hypertension control","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["verapamil hydrocloride", "verapamil"]],"start": [["43"],["73"]],"entity_id": [["T2"],["T3"]]},"Disorder": {"text": [["hypertension"]],"start": [["11"]],"entity_id": [["T4"]]},"Duration": {"text": [["10-year"]],"start": [["23"]],"entity_id": [["T5"]]},"Route": {"text": [["po"]],"start": [["122"]],"entity_id": [["T6"]]},"Freq": {"text": [["tid"]],"start": [["66"]],"entity_id": [["T7"]]},"Trigger": {"text": [["switched"]],"start": [["0"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["A 66-year-old white woman"]],"start": [["0"]],"entity_id": [["T9"]],"Age": {"text": [["66-year-old"]],"start": [["3"]],"entity_id": [["T10"]]},"Gender": {"text": [["woman"]],"start": [["22"]],"entity_id": [["T11"]]},"Population": null,"Race": {"text": [["white"]],"start": [["15"]],"entity_id": [["T12"]]},"Disorder": {"text": [["hypertension", "bronchial asthma"]],"start": [["42"],["60"]],"entity_id": [["T13"],["T14"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "18294121_3","context": "Due to the severity of the rash, temozolomide was permanently discontinued","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severity", "rash"]],"start": [["3", "15"]],"entity_id": []},"Treatment": {"text": [["temozolomide"]],"start": [["51"]],"entity_id": [],"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [["temozolomide"]],"start": [["51"]],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["severity"]],"start": [["3"]],"entity_id": [],"value": "high"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "7835785_1", "context": "Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [["33"]], "entity_id": []}, "Subject": {"text": [["a postmenopausal breast cancer patient"]], "start": [["20"]], "entity_id": [],"Age": {"text": [["postmenopausal"]], "start": [["20"]], "entity_id": []}, "Disorder": {"text": [["breast cancer"]], "start": [["25"]], "entity_id": []},"Gender":{"text":[["patient"]],"start":[["20"]],"entity_id":[]},"Population":{"text":[["a"]],"start":[["20"]],"entity_id":[]},"Race":{"text":[[]],"start":[[],[]],"entity_id":[]}},"Treatment": {"text": [["tamoxifen therapy"]], "start": [["62"]], "entity_id": [],"Drug": {"text": [["tamoxifen"]], "start": [["62"]], "entity_id": []},"Dosage":{"text":[[]],"start":[[]],"entity_id":[]},"Duration":{"text":[[]],"start":[[]],"entity_id":[]},"Route":{"text":[[]],"start":[[]],"entity_id":[]},"Time_elapsed":{"text":[[]],"start":[[]],"entity_id":[]},"Freq":{"text":[[]],"start":[[]],"entity_id":[]},"Combination":null,"Trigger":{"text":[[]],"start":[[]],"entity_id":[]},"Disorder":{"text":[["ovarian endometrioid carcinoma and endometriosis"]], "start": [["0"]], "entity_id": []}},"Effect": {"text": [["developing"]], "start": [["33"]], "entity_id": []},"Negated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Speculated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Severity":{"text":[["a case report and review of the literature"]], "start": [["91"]], "entity_id": [],"value":"low"}}]}
{"id": "18585545_2","context": "The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["central nervous system-related adverse effects"]],"start": [[ "The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause "]],"entity_id": []},"Effect": {"text": [["headache"]],"start": [[ "including headache,"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["dizziness"]],"start": [[ "dizziness and insomnia"]],"entity_id": []},"Effect": {"text": [["dizziness"]],"start": [[ "dizziness and insomnia"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": null},{"event_type": "Adverse_event","event_id": "E3","Trigger": {"text": [["insomnia"]],"start": [[ "dizziness and insomnia"]],"entity_id": []},"Effect": {"text": [["insomnia"]],"start": [[ "dizziness and insomnia"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": null}]}
{"id": "17228132_4","context": "We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute severe hepatitis"]],"start": [["12","15"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["erlotinib monotherapy"]],"start": [["53","64"]],"entity_id": [ ["T2"]],"Drug": {"text": [["erlotinib"]],"start": [["53","59"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["pancreatic cancer"]],"start": [["82","96"]],"entity_id": [ ["T4"]]} ,"Route": {"text": [["monotherapy"]],"start": [["59","64"]],"entity_id": [ ["T5"]]} ,"Time_elapsed": {"text": [["resulting from"]],"start": [["42","52"]],"entity_id": [ ["T6"]]} ,"Duration": {"text": [["acute"]],"start": [["12","15"]],"entity_id": [ ["T1"]]} ,"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [ ["T7"]]} ,"Freq": {"text": [[""]],"start": [[""],[""]],"entity_id": [ ["T8"]]} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["We"]],"start": [[ "0","2"]],"entity_id": [ ["T9"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patient"]],"start": [["33","37"]],"entity_id": [ ["T10"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["16","19"]],"entity_id": [ ["T11"]] ,"value": "high" },"Effect": {"text": [["acute severe hepatitis"]],"start": [[ "12","15"]],"entity_id": [ ["T1"]] }} ] }
{"id": "16914372_1","context": "We highlight two instances of systemic allergic reaction, and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["systemic allergic reaction"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [["systemic allergic reaction"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["S1"]],"Population": {"text": [[""],["two instances"]],"start": [[""],["20"]],"entity_id": [[""],["T2"]]},"Age": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Gender": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Race": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Disorder": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]}},"Treatment": {"text": [["local aprotinin injections"]],"start": [["83"]],"entity_id": [["T3"]],"Drug": {"text": [["aprotinin"]],"start": [["83"]],"entity_id": [["T4"]]},"Disorder": {"text": [["in orthopaedic setting"]],"start": [["98"]],"entity_id": [["T5"]]},"Dosage": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Route": {"text": [[""],["local"]],"start": [[""],["83"]],"entity_id": [[""],["T3"]]},"Time_elapsed": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Freq": {"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": null,"Trigger": {"text": [[""],["discuss"]],"start": [[""],["122"]],"entity_id": [[""],["T6"]]}},"Effect": {"text": [["potential side effects"]],"start": [["55"]],"entity_id": [["T7"]]},"Speculated": {"value": false,"text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Severity": {"value": "","text": [[""],[""]],"start": [[""],[""]],"entity_id": [[""],[""]]}}]}
{"id": "7962394_1","context": "Acute pancreatitis associated with danazol treatment for endometriosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute pancreatitis"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["danazol treatment"]],"start": [[ ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["danazol"]],"start": [[ ]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["endometriosis"]],"start": [[ ]],"entity_id": [ ["T4"] ]} ,"Dosage" : {"text" : [["danazol treatment"]],"start" : [[ ]],"entity_id" : [["T2"] ]},"Duration" : {"text" : [["danazol treatment"]],"start" : [[ ]],"entity_id" : [ ["T2"] ]},"Route" : {"text" : [["danazol treatment"]],"start" : [[ ]],"entity_id" : [ ["T2"] ]},"Time_elapsed" : {"text" : [["acute pancreatitis"]],"start" : [[ ]],"entity_id" : [ ["T1"] ]} ,"Freq" : {"text" : [["danazol treatment"]],"start" : [[ ]],"entity_id" : [ ["T2"] ]} ,"Combination" : null ,"Trigger" : null },"Negated" : null ,"Speculated" : null ,"Severity" : {"text" : [["acute pancreatitis"]],"start" : [[ ]],"entity_id" : [ ["T1"] ],"value" : "high" },"Subject" : {"text" : [["patient"]],"start" : [[ ]],"entity_id" : [ ["T0"] ],"Age" : null,"Gender" : null,"Population" : null,"Race" : null,"Disorder" : {"text" : [["endometriosis"]],"start" : [[ ]],"entity_id" : [ ["T4"] ]} },"Effect" : {"text" : [["acute pancreatitis"]],"start" : [[ ]],"entity_id" : [ ["T1"] ]} }]}
{"id": "14526130_2","context": "We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested acute pancreatitis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["roxithromycin"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [["2 days"]],"start": [[], []],"entity_id": []},"Route": {"text": [["treatment"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["acute pancreatitis"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["manifested"]],"start": [[], []],"entity_id": []},"entity_id": [],"text": [["We report the case of a 58 year old patient who"]],"start": [[], []],"Time_elapsed": {"text": [["2 days"]],"start": [[], []],"entity_id": []},"Freq": {"text": [["treatment"]],"start": [[], []],"entity_id": []},"Duration": {"text": [["treatment"]],"start": [[], []],"entity_id": []},"Combination": null},"Subject": {"text": [["a 58 year old patient"]],"start": [[], []],"entity_id": [],"Age": {"text": [["58 year old"]],"start": [[], []],"entity_id": []},"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["acute pancreatitis"]],"start": [[], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "18459568_1","context": "Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Gastric tumor", "endometrial carcinoma", "cervical adenocarcinoma in situ"]],"start": [["0","24","49"]],"entity_id": []},"Treatment": {"text": [["tamoxifen"]],"start": [["88"]],"entity_id": [],"Drug": {"text": [["tamoxifen"]],"start": [["88"]],"entity_id": []},"Disorder": {"text": [["breast cancer"]],"start": [["101"]],"entity_id": []},"Duration": {"text": [["after treatment"]],"start": [["52"]],"entity_id": []},"Time_elapsed": {"text": [["after treatment"]],"start": [["52"]],"entity_id": []},"Freq": {"text": [["after treatment"]],"start": [["52"]],"entity_id": []},"Route": {"text": [["treatment with"]],"start": [["57"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Trigger": {"text": [["after treatment"]],"start": [["52"]],"entity_id": []},"Combination": null},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [],"Age": {"text": [[]],"start": [[]],"entity_id": []},"Disorder": {"text": [["patient with breast cancer"]],"start": [["0"]],"entity_id": []},"Gender": {"text": [[]],"start": [[]],"entity_id": []},"Population": {"text": [[]],"start": [[]],"entity_id": []},"Race": {"text": [[]],"start": [[]],"entity_id": []}},"Effect": {"text": [["Gastric tumor", "endometrial carcinoma", "cervical adenocarcinoma in situ"]],"start": [["0","24","49"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18665833_2","context": "This therapy was also complicated by Warfarin-induced skin necrosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Warfarin-induced skin necrosis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["Warfarin"]],"start": [["22"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Warfarin-induced skin necrosis"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Route": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]]},"Dosage": {"text": [["this therapy"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Combination": null ,"Trigger": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": {"text": [["Warfarin-induced skin necrosis"]],"start": [["32"]],"entity_id": [["T1"]],"value": "High"} ,"Subject": null }]}
{"id": "10048291_1","context": "Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["immobilization"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["rifampicin"]],"start": [["132"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["Paget's bone disease"]],"start": [["45"]],"entity_id": [ ["T2"] ]},"Trigger": {"text": [["enhanced activation"]],"start": [["90"]],"entity_id": [["T4"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"entity_id": [ ["T1","T2","T3","T4"] ],"text": [["immobilization"]],"start": [["0"]] },"Effect": {"text": [["increased calcium-release into the circulation"]],"start": [["160"]],"entity_id": [ ["T5"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null }] }
{"id": "8949576_2", "context": "Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"text": [["plasmapheresis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] ,"Drug": { "text": [], "start": [], "entity_id": [] } ,"Disorder": { "text": [], "start": [], "entity_id": [] } ,"Dosage": null, "Duration": null, "Trigger": { "text": [], "start": [], "entity_id": [] } ,"Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null } ,"Effect": { "text": [], "start": [], "entity_id": [] } ,"Trigger": { "text": [["ameliorate"]], "start": [[ "63" ]], "entity_id": [ ["T5"] ] } } ]}
{"id": "566977_3","context": "Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Intravenous sodium bicarbonate"]],"start": [[ "0"]],"entity_id": [ ["T1"]],"Drug": {"text": [["sodium bicarbonate"]],"start": [[ "0"]],"entity_id": [ ["T2"]]},"Route": {"text": [["Intravenous"]],"start": [["0"]],"entity_id": [ ["T0"]]},"Disorder": {"text": [["metabolic acidosis"]],"start": [[ "52"]],"entity_id": [ ["T4"]]},"Trigger": {"text": [["indicated"]],"start": [[ "28"]],"entity_id": [ ["T3"]]},"Time_elapsed": {"text": [["prophylactically"]],"start": [[ "18"]],"entity_id": [ ["T5"]]},"Freq": {"text": [["appears"]],"start": [["1"]],"entity_id": [ ["T6"]]},"Combination": [{"Drug": {"text": [["sodium bicarbonate"]],"start": [["0"]],"entity_id": [ ["T2"]]},"Trigger": {"text": [["combating"]],"start": [["49"]],"entity_id": [ ["T7"]]},"event_id": "E2","event_type": "Adverse_event"}],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11022272_3","context": "The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["immediate anaphylactic reaction"]],"start": [["48"]],"entity_id": [["T2"]]},"Treatment": {"text": [["Miacalcic"]],"start": [["37"]],"entity_id": [["T1"]],"Dosage": {"text": [["25 UI"]],"start": [["37"]],"entity_id": [["T1"]]},"Route": {"text": [["intramuscular challenge test"]],"start": [["10"]],"entity_id": [["T3"]]},"Disorder": {"text": [["anaphylactic reaction"]],"start": [["48"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["immediate"]],"start": [["48"]],"entity_id": [["T2"]]},"Freq": {"text": [["1"]],"start": [["48"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["Miacalcic"]],"start": [["37"]],"entity_id": [["T1"]]},"Trigger": {"text": [["intramuscular challenge test"]],"start": [["10"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["immediate anaphylactic reaction"]],"start": [["48"]],"entity_id": [["T2"]]},"Drug": {"text": [["Miacalcic"]],"start": [["37"]],"entity_id": [["T1"]]},"Duration": {"text": [["1"]],"start": [["48"]],"entity_id": [["T2"]]}},"Subject": {"text": [["The patient"]],"start": [[""],[""]],"entity_id": [["T0"]],"Age": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]]},"Disorder": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]]},"Gender": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]]},"Population": {"text": [["1"]],"start": [[""],[""]],"entity_id": [["T0"]]},"Race": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]]}},"Severity": {"text": [["high"]],"start": [["48"]],"entity_id": [["T2"]],"value": "high"},"Speculated": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]],"value": false},"Negated": {"text": [["N/A"]],"start": [[""],[""]],"entity_id": [["T0"]],"value": false},"Effect": {"text": [["anaphylactic reaction"]],"start": [["48"]],"entity_id": [["T2"]]}}]}
{"id": "4082283_6","context": "A literature review revealed 83 other reported cases of rifampicin-induced renal insufficiency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rifampicin-induced renal insufficiency"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rifampicin"]],"start": [["6"]],"entity_id": [["T2"]] ,"Dosage": null,"Duration": null,"Disorder": {"text": [["renal insufficiency"]],"start": [["42"]],"entity_id": [["T3"]]} ,"Freq": null,"Time_elapsed": null,"Route": null,"Combination": null ,"Drug": {"text": [["rifampicin"]],"start": [["6"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["literature review revealed"]],"start": [["0"]],"entity_id": [["T4"]]} } ,"Effect": null ,"Subject": null ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8485005_1","context": "Complete regression of iatrogenic Kaposi's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["corticosteroid"]],"start": [["18"]],"entity_id": [["T1"]]},"Disorder": {"text": [["iatrogenic Kaposi's sarcoma"]],"start": [["0"]],"entity_id": [["T2"]]},"Duration": {"text": [["treatment"]],"start": [["18"]],"entity_id": [["T1"]]},"Trigger": {"text": [["due"]],"start": [["30"]],"entity_id": [["T3"]]},"entity_id": [["T1"], ["T2"], ["T3"]],"text": [["Complete regression"]],"start": [["0"]],"Time_elapsed": {"text": [["treatment"]],"start": [["18"]],"entity_id": [["T1"]]},"Freq": {"text": [["treatment"]],"start": [["18"]],"entity_id": [["T1"]]},"Route": {"text": [["treatment"]],"start": [["18"]],"entity_id": [["T1"]]},"Dosage": {"text": [["treatment"]],"start": [["18"]],"entity_id": [["T1"]]},"Combination": []},"Subject": {"text": [["a patient with tubercular pericarditis"]],"start": [["44"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["tubercular pericarditis"]],"start": [["44"]],"entity_id": [["T4"]]},"entity_id": [["T4"]]},"Severity": null,"Negated": null,"Speculated": null,"Effect": null,"Trigger": null}]}
{"id": "17163271_3","context": "The use of cyclosporin has been associated with the development of cholelithiasis in transplant recipients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["the development of cholelithiasis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the use of cyclosporin"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["cyclosporin"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["cholelithiasis"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["has been associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["has been associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Route": {"text": [["the use of"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["has been associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["has been associated"]],"start": [["13"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["the use of"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "3200786_1", "context": "Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Rifampicin-induced adrenal insufficiency"]], "start": [[ ]], "entity_id": [ ],"Disorder": {"text": [["adrenal insufficiency"]], "start": [[ ]], "entity_id": [ ]},"Population": {"text": [["the acquired immunodeficiency syndrome"]], "start": [[ ]], "entity_id": [ ]},"Gender": null,"Race": null,"Age": null}, "Treatment": {"text": [["Rifampicin"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Rifampicin"]], "start": [[ ]], "entity_id": [ ]},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["Rifampicin-induced"]], "start": [[ ]], "entity_id": [ ]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "19235747_2", "context": "Bisphosphonate-related osteonecrosis of the skull base", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Bisphosphonate-related osteonecrosis"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["Bisphosphonate"]], "start": [["0"]], "entity_id": [["T2"]],"Drug": {"text": [["Bisphosphonate"]], "start": [["0"]], "entity_id": [["T2"]]}, "Disorder": {"text": [["osteonecrosis of the skull base"]], "start": [["38"]], "entity_id": [["T3"]]}, "Time_elapsed": {"text": [["related"]], "start": [["10"]], "entity_id": [["T4"]]}, "Dosage": {"text": [["Bisphosphonate"]], "start": [["0"]], "entity_id": [["T2"]]}, "Duration": null, "Route": null, "Freq": null, "Combination": null,"Trigger": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [["Bisphosphonate-related osteonecrosis"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "14641354_1","context": "Angioedema and dysphagia caused by contact allergy to inhaled budesonide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["contact allergy"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["inhaled budesonide"]],"start": [["45"]],"entity_id": [["T2"]],"Drug": {"text": [["budesonide"]],"start": [["45"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Route": {"text": [["inhaled"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["caused by"]],"start": [["26"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["budesonide"]],"start": [["45"]],"entity_id": [["T3"]]},"Trigger": {"text": [["contact allergy"]],"start": [["19"]],"entity_id": [["T1"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Time_elapsed": {"text": [["caused by"]],"start": [["26"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["inhaled"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["contact allergy"]],"start": [["19"]],"entity_id": [["T1"]]} },"Subject": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]] ,"Disorder": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Age": {"text": [["1"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Race": {"text": [["1"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Gender": {"text": [["1"]],"start": [["0"]],"entity_id": [["T6"]]} },"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T7"]] ,"value": false },"Speculated": {"text": [["caused by"]],"start": [["26"]],"entity_id": [["T5"]],"value": false },"Severity": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]] ,"value": "High" },"Effect": {"text": [["Angioedema and dysphagia"]],"start": [["0"]],"entity_id": [["T0"]]} }] }
{"id": "15592331_1","context": "Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["Ciprofloxacin"]],"start": [[],[]],"entity_id": [["T1"]]},"text": [["greatly increases concentrations and hypotensive effect of tizanidine"]],"start": [[],[]],"entity_id": [["T2"]] ,"Disorder": {"text": [["tizanidine"]],"start": [[],[]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["greatly increases"]],"start": [[],[]],"entity_id": [["T2"]]},"Trigger": {"text": [["inhibiting"]],"start": [[],[]],"entity_id": [["T3"]]},"Route": {"text": [["presystemic metabolism"]],"start": [[],[]],"entity_id": [["T4"]]} ,"Duration": {"text": [["greatly increases concentrations and hypotensive effect"]],"start": [[],[]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["greatly increases"]],"start": [[],[]],"entity_id": [["T2"]]} ,"Freq": {"text": [["greatly increases"]],"start": [[],[]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["Ciprofloxacin"]],"start": [[],[]],"entity_id": [["T1"]]},"Trigger": {"text": [["inhibiting"]],"start": [[],[]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Drug-Drug-Interaction"}] },"Effect": {"text": [["hypotensive effect"]],"start": [[],[]],"entity_id": [["T2"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": null ,"Trigger": null }]}
{"id": "10426918_1","context": "2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lymphocytopenia"]],"start": [["9-15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["2-CdA"]],"start": [["0-4"]],"entity_id": [["T2"]],"Drug": {"text": [["2-CdA"]],"start": [["0-4"]],"entity_id": [["T2"]]},"Disorder": {"text": [["psoriasis"]],"start": [["74-79"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["which may explain the improvement"]],"start": [["20-48"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "7831179_2","context": "There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["dose-effect relationship"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["doxorubicin"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["doxorubicin"]],"start": [["42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["cardiac failure"]],"start": [["66"]],"entity_id": [["T4"]]},"Freq": {"text": [["dose-effect relationship"]],"start": [["0"]],"entity_id": [["T1"]]},"Duration": {"text": [["relationship"]],"start": [["18"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["relationship"]],"start": [["18"]],"entity_id": [["T5"]]},"Route": {"text": [["doxorubicin"]],"start": [["42"]],"entity_id": [["T3"]]},"Dosage": {"text": [["dose-effect relationship"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": null,"Trigger": {"text": [["relationship"]],"start": [["18"]],"entity_id": [["T5"]]}},"Effect": {"text": [["cardiac failure"]],"start": [["66"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["symptomatic"]],"start": [["56"]],"entity_id": [["T6"]],"value": "Medium"},"Subject": null}]}
{"id": "19145124_2", "context": "These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina.","is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["mfERG abnormalities", "damages the retina"]], "start": [[ "32","66"]], "entity_id": [["T1","T2"]]}, "Treatment": {"text": [["ethambutol"]], "start": [["51"]], "entity_id": [["T3"]],"Drug": null, "Disorder": {"text": [["damages the retina"]], "start": [["66"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null}, "Effect": {"text": [["mfERG abnormalities"]], "start": [["32"]], "entity_id": [["T1"]]},"Negated": null, "Speculated": null, "Severity": null,"Subject": {"text": [["These are the first reported patients"]], "start": [["0"]], "entity_id": [["S1"]],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}}]}
{"id": "19949685_3","context": "Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Kalimate enema"]],"start": [["Two days after administration of "]],"entity_id": [["T1"]]},"Effect": {"text": [["profuse hematochezia"]],"start": [["he had profuse hematochezia,"]],"entity_id": [["T2"]]},"Treatment": {"text": [["Kalimate enema"]],"start": [["Two days after administration of "]],"entity_id": [["T1"]],"Drug": {"text": [["Kalimate"]],"start": [["Two days after administration of Kalimate "]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["Two days after"]],"start": [[""], ["administration of"]],"entity_id": [["T1"]]},"Trigger": {"text": [["sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon"]],"start": [[", and a sigmoidoscopy showed"]],"entity_id": [["T4"]]},"Disorder": {"text": [["diffuse colonic mucosal necrosis"]],"start": [[", and a sigmoidoscopy showed diffuse colonic mucosal necrosis in"]],"entity_id": [["T5"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["he"]],"start": [[""], ["Two days after administration of Kalimate enema,"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18191947_1", "context": "Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["methotrexate related sub-acute neurotoxicity"]], "start": [[ "51" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["methotrexate"]], "start": [[ "36" ]], "entity_id": [ ["T2"] ], "Drug": null , "Disorder": { "text": [[ "methotrexate related sub-acute neurotoxicity" ]], "start": [[ "51" ]], "entity_id": [ [ "T1" ] ] } , "Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null, "Combination": null , "Trigger": null } ,"Subject": null ,"Effect": null ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "14760958_1", "context": "Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["patient"]], "start": [["0"]], "entity_id": [["T1"]], "Disorder": {"text": [["multiple sclerosis", "monoclonal gammopathy"]], "start": [["22","58"]], "entity_id": [["T2","T3"]]}, "Age": null, "Gender": null, "Population": null, "Race": null},"Trigger": {"text": [["Scleromyxedema"]], "start": [["0"]], "entity_id": [["T4"]]},"Treatment": {"text": [["interferon beta-1a"]], "start": [["88"]], "entity_id": [["T5"]],"Drug": {"text": [["interferon beta-1a"]], "start": [["88"]], "entity_id": [["T5"]]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [["22"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null},"Effect": {"text": [["Scleromyxedema"]], "start": [["0"]], "entity_id": [["T4"]]}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "9494448_8", "context": "The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypersensitivity reaction"]], "start": [["22 cases of hypersensitivity reaction to cyclosporine" ] ], "entity_id": [ ]}, "Treatment": {"text": [["cyclosporine"]], "start": [[ "hypersensitivity reaction" ] ], "entity_id": [ ], "Drug": {"text": [["cyclosporine"]], "start": [[ "hypersensitivity reaction" ] ], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": null} , "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "11972105_1","context": "The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["delayed elimination"]],"start": [["13","14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ciprofloxacin"]],"start": [["49","59"]],"entity_id": [["T2"]],"Disorder": {"text": [["patients receiving"]],"start": [["40","48"]],"entity_id": [["T3"]]},"Drug": {"text": [["methotrexate"]],"start": [["6","16"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["in"]],"start": [["24","25"]],"entity_id": [["T5"]]},"Trigger": {"text": [["receiving"]],"start": [["40","48"]],"entity_id": [["T3"]]},"Freq": {"text": [["two cases"]],"start": [["0","7"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["ciprofloxacin"]],"start": [["49","59"]],"entity_id": [["T2"]]},"Trigger": {"text": [["patients receiving"]],"start": [["40","48"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Combination"}],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["severe toxicity"]],"start": [["94","108"]],"entity_id": [["T7"]],"value": "high"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe toxicity"]],"start": [["94","108"]],"entity_id": [["T7"]]}}]}
{"id": "2329972_2","context": "Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe acute encephalopathy"]],"start": [[ "0" ]] ,"entity_id": [ ]},"Treatment": {"text": [["doxorubicin administration"]],"start": [[ "58" ]],"entity_id": [],"Drug": {"text": [["doxorubicin"]],"start": [[ "58" ]],"entity_id": []} ,"Route": {"text": [["intrathecal"]],"start": [[ "31" ]],"entity_id": []} ,"Trigger": {"text": [["inadvertent"]],"start": [[ "23" ]],"entity_id": []} ,"Freq": {"text": [["following"]],"start": [[ "48" ]],"entity_id": []} ,"Time_elapsed": {"text": [["following"]],"start": [[ "48" ]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Severe"} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} }]}
{"id": "11886466_2","context": "Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Porcine factor VIII (pFVIII)"]],"start": [[ "0" ]],"entity_id": [["T1"]] ,"Drug": {"text": [["Porcine factor VIII"]],"start": [[ "0" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["control bleeding"]],"start": [[ "54" ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["used"]],"start": [[ "24" ]],"entity_id": [["T4"]]} ,"Route": {"text": [["to"]],"start": [[ "47" ]],"entity_id": [["T5"]]} ,"Duration": {"text": [["in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII"]],"start": [[ "25" ]],"entity_id": [["T6"]]} ,"Freq": {"text": [["not known to increase the risk"]],"start": [[ "100" ]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["of arterial or venous thrombosis"]],"start": [[ "123" ]],"entity_id": [["T8"]]} ,"Combination": null ,"Dosage": null },"Effect": null ,"Negated": {"text": [["not known to increase"]],"start": [[ "100" ]],"entity_id": [["T9"]] ,"value": true },"Speculated": null ,"Severity": null ,"Subject": {"text": [["patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII"]],"start": [[ "25" ]],"entity_id": [["T10"]] ,"Age": null ,"Disorder": null ,"Gender": null ,"Population": null ,"Race": null },"Trigger": null }]}
{"id": "4031907_1","context": "In all the patients, pellagra symptoms appeared during isoniazid therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pellagra symptoms"]],"start": [["In all the patients,"]],"entity_id": [["T1"]]},"Treatment": {"text": [["isoniazid therapy"]],"start": [["during isoniazid therapy"]],"entity_id": [["T2"]],"Drug": {"text": [["isoniazid"]],"start": [["isoniazid therapy"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["In all the patients"]],"start": [[""], ["In all the patients,"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19904536_1","context": "Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gemcitabine-induced pulmonary toxicity"]],"start": [[">>>0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gemcitabine"]],"start": [[">>0"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["metastatic gallbladder adenocarcinoma"]],"start": [[">>0"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["induced"]],"start": [[">>0"]],"entity_id": [["T4"]]},"Freq": {"text": [["induced"]],"start": [[">>0"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["gemcitabine"]],"start": [[">>0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [[">>0"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E1"}],"Trigger": {"text": [["gemcitabine-induced pulmonary toxicity"]],"start": [[">>0"]],"entity_id": [["T1"]]},"Dosage": null,"Duration": null,"Route": null},"Subject": {"text": [["Fatal"]],"start": [[">>0"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["metastatic gallbladder adenocarcinoma"]],"start": [[">>0"]],"entity_id": [["T3"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["Fatal"]],"start": [[">>0"]],"entity_id": [["T5"]],"value": "High"},"Effect": {"text": [["pulmonary toxicity"]],"start": [[">>0"]],"entity_id": [["T1"]]}}]}
{"id": "18801826_1", "context": "Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["Olanzapine"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Disorder": { "text": [["hyperglycaemic coma", "neuroleptic malignant syndrome"]], "start": [[ "17","77"]], "entity_id": [ ["T3", "T4"] ]} ,"entity_id": [ ["T1"] ], "text": [["Olanzapine"]], "start": [[ "0"]] }, "Effect": { "text": [["hyperglycaemic coma", "neuroleptic malignant syndrome"]], "start": [[ "17","77"]], "entity_id": [ ["T3", "T4"] ]}, "Trigger": { "text": [["induced"]], "start": [[ "12"]], "entity_id": [ ["T2"] ]} } ]}
{"id": "15494638_20", "context": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["CAP"]], "start": [["33"]], "entity_id": [["T1"]], "Dosage": {"text": [["4 weeks"]], "start": [["42"]], "entity_id": [["T2"]]}, "Duration": {"text": [["2000 mg/m2"]], "start": [["88"]], "entity_id": [["T3"]]},"Route": {"text": [["alone"]], "start": [["78"]], "entity_id": [["T4"]]},"Trigger": {"text": [["stopping"]], "start": [["28"]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["after"]], "start": [["25"]], "entity_id": [["T6"]]}, "Disorder": {"text": [["Neurologic symptoms"]], "start": [["0"]], "entity_id": [["T7"]]},"Freq": {"text": [["after reinitiating"]], "start": [["65"]], "entity_id": [["T8"]]}, "Combination": [{"event_id": "C1", "Drug": {"text": [["CAP"]], "start": [["33"]], "entity_id": [["T1"]]},"Trigger": {"text": [["alone"]], "start": [["78"]], "entity_id": [["T4"]]}, "event_type":"Common"}], "Drug": {"text": [["CAP"]], "start": [["33"]], "entity_id": [["T1"]]}},"Subject":{"text": [["Patient A"]], "start": [["53"]], "entity_id": [["T9"]],"Age":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T10"]]},"Gender":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T11"]]},"Population":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T12"]]},"Race":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T13"]]},"Disorder":{"text":[["Neurologic symptoms"]], "start": [["0"]], "entity_id": [["T7"]]}},"Negated":{"text":[["not"]], "start":[[""],[""]],"entity_id":[["T14"]],"value":false},"Speculated":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T15"]],"value":false},"Severity":{"text":[[""]], "start":[[""],[""]],"entity_id":[["T16"]],"value":"Low" },"Effect":{"text":[["resolved"]], "start":[[""],[""]],"entity_id":[["T17"]] },"Trigger":{"text":[["after stopping"]], "start":[[""],[""]],"entity_id":[["T18"]]} }]}
{"id": "17381671_11","context": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["serotonin syndrome"]],"start": [["14","15","16","17","18","19","20","21"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["fentanyl"]],"start": [["55","56","57"]],"entity_id": [["T3"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["14","15","16","17","18","19","20","21"]],"entity_id": [["T1"]]},"Trigger": {"text": [["interaction"]],"start": [["44","45","46"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["fentanyl"]],"start": [["55","56","57"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["48"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["citalopram"]],"start": [["34","35","36","37"]],"entity_id": [["T5"]]},"Trigger": null,"event_id": "C2","event_type": "Combination"}],"start": [[],[],[]],"entity_id": [["T1"],["T3"],["T5"]],"text": [["serotonin syndrome"],["fentanyl"],["citalopram"]]},"Effect": {"text": [["interaction"]],"start": [["44","45","46"]],"entity_id": [["T2"]]},"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17968817_2","context": "We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["emergence of psychosis"]],"start": [["30"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 12-year old white girl"]],"start": [["44"]],"entity_id": [["T2"]],"Age": {"text": [["12-year old"]],"start": [["44"]],"entity_id": [["A1"]]},"Race": {"text": [["white"]],"start": [["50"]],"entity_id": [["R1"]]} ,"Disorder": {"text": [["psychosis"]],"start": [["30"]],"entity_id": [["D1"]]} ,"Population": {"text": [["the first time in a child"]],"start": [["36"]],"entity_id": [["P1"]]} ,"Gender": {"text": [["girl"]],"start": [["47"]],"entity_id": [["G1"]]} },"Treatment": {"text": [["efavirenz concentration"]],"start": [["18"]],"entity_id": [["T3"]],"Drug": {"text": [["efavirenz"]],"start": [["18"]],"entity_id": [["D2"]]} ,"Dosage": {"text": [["an increased"]],"start": [["18"]],"entity_id": [["D3"]]} ,"Route": {"text": [["concentration"]],"start": [["18"]],"entity_id": [["R2"]]} ,"Time_elapsed": {"text": [["emergence"]],"start": [["30"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["psychosis"]],"start": [["30"]],"entity_id": [["D1"]]} ,"Trigger": {"text": [["emergence"]],"start": [["30"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["the first time"]],"start": [["36"]],"entity_id": [["F1"]]} ,"Combination": [{"Drug": {"text": [["efavirenz"]],"start": [["18"]],"entity_id": [["D2"]]},"Trigger": {"text": [["gene polymorphism"]],"start": [["85"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Potential_therapeutic_effect" }] ,"Duration": {"text": [["an increased"]],"start": [["18"]],"entity_id": [["D3"]]}} ,"Negated": null,"Speculated": {"text": [["to our knowledge"]],"start": [["8"]],"entity_id": [["S1"]] ,"value": true },"Severity": {"text": [["psychosis"]],"start": [["30"]],"entity_id": [["D1"]],"value": "High" },"Effect": {"text": [["psychosis"]],"start": [["30"]],"entity_id": [["D1"]]} }] }
{"id": "12114387_2", "context": "Severe erythroderma as a complication of continuous epoprostenol therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [["33","39"]], "entity_id": []}, "Treatment": {"text": [["continuous epoprostenol therapy"]], "start": [["45","60"]], "entity_id": [],"Drug": {"text": [["epoprostenol"]], "start": [["45","53"]], "entity_id": []} ,"Duration": {"text": [["continuous"]], "start": [["45","53"]], "entity_id": []} , "Route": {"text": [["therapy"]], "start": [["54","60"]], "entity_id": []} , "Freq": {"text": [["continuous"]], "start": [["45","53"]], "entity_id": []} , "Time_elapsed": {"text": [[]], "start": [[], []], "entity_id": []} , "Disorder": {"text": [["complication"]], "start": [["33","39"]], "entity_id": []} , "Dosage": {"text": [[]], "start": [[], []], "entity_id": []} , "Combination": [{"Drug": {"text": [["epoprostenol"]], "start": [["45","53"]], "entity_id": []},"Trigger": {"text": [["complication"]], "start": [["33","39"]], "entity_id": []},"event_id": "C1","event_type": "Adverse_event"}] , "Trigger": {"text": [["complication"]], "start": [["33","39"]], "entity_id": []} },"Effect": {"text": [["Severe erythroderma"]], "start": [["0","11"]], "entity_id": []},"Subject":{"text":[],"start":[],"entity_id":[],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["Severe erythroderma"]],"start":[[],[]],"entity_id":[]}},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[["Severe"]],"start":[[],[]],"entity_id":[],"value":"High"}}]}
{"id": "18717612_2","context": "FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["FDE"]],"start": [[ "0" ]],"entity_id": []},"Treatment": {"text": [["cephalosporins"]],"start": [[ "12" ]],"entity_id": [],"Drug": {"text": [["cephalosporins"]],"start": [[ "12" ]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": [[]]},"Duration": {"text": [[]],"start": [[]],"entity_id": [[]]},"Trigger": {"text": [["ceftriaxone"]],"start": [[ "82" ]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": [[]]},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": [[]]},"Freq": {"text": [[]],"start": [[]],"entity_id": [[]]},"Disorder": {"text": [[]],"start": [[]],"entity_id": [[]]},"Combination": null},"Effect": {"text": [["FDE"]],"start": [[ "48" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["FDE"],["cephalosporins"],["ceftriaxone"]],"start": [["0"],["12"],["82"]],"entity_id": [[""],[""],[""]],"Age": null,"Gender": null,"Disorder": null,"Population": null,"Race": null}}]}
{"id": "12503933_3","context": "A 58-year-old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["fulminant liver failure"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 58-year-old white woman"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["58"]],"start": [["1"]],"entity_id": [["T3"]]},"Race": {"text": [["white"]],"start": [["14"]],"entity_id": [["T4"]]},"Disorder": {"text": [["pneumonia"]],"start": [["72"]],"entity_id": [["T5"]]},"Population": {"text": [["A 58-year-old white woman"]],"start": [["0"]],"entity_id": [["T2"]]},"Gender": {"text": [["woman"]],"start": [["7"]],"entity_id": [["T6"]]}},"Treatment": {"text": [["clarithromycin"]],"start": [["56"]],"entity_id": [["T7"]],"Drug": {"text": [["clarithromycin"]],"start": [["56"]],"entity_id": [["T7"]]},"Dosage": {"text": [["the macrolide antibiotic"]],"start": [["42"]],"entity_id": [["T8"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["treated with"]],"start": [["38"]],"entity_id": [["T9"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [["pneumonia"]],"start": [["72"]],"entity_id": [["T5"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "12163813_2", "context": "To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": {"value": "high", "text": [["severe"]], "start": [["23"]], "entity_id": []}, "Subject": {"text": [["a patient"]], "start": [["77"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["catecholamine-resistant septic shock"]], "start": [["100"]], "entity_id": []}}, "Treatment": {"text": [["low-dose vasopressin"]], "start": [["52"]], "entity_id": [],"Drug": {"text": [["vasopressin"]], "start": [["52"]], "entity_id": []}, "Dosage": {"text": [["low-dose"]], "start": [["52"]], "entity_id": []}, "Route": {"text": [["peripheral intravenous administration"]], "start": [["28"]], "entity_id": []}, "Trigger": null, "Time_elapsed": null, "Duration": null, "Freq": null, "Disorder": null, "Combination": null} ,"Effect": {"text": [["skin necrosis"]], "start": [["14"]], "entity_id": []},"Trigger": {"text": [["resulting from"]], "start": [["39"]], "entity_id": []}}]}
{"id": "8031432_1", "context": "Recurrent hypotension immediately after seizures in nortriptyline overdose", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurrent hypotension"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["nortriptyline overdose"]], "start": [["41"]], "entity_id": [], "Drug": {"text": [["nortriptyline"]], "start": [["41"]], "entity_id": []} ,"Disorder": {"text": [["overdose"]], "start": [["41"]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Trigger": {"text": [["immediately after seizures"]], "start": [["21"]], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Combination": null }, "Effect": {"text": [["recurrent hypotension"]], "start": [["0"]], "entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "12460237_4","context": "We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T1"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["acute lymphoblastic leukaemia"]],"start": [["91"]],"entity_id": [["T9"]]}},"Treatment": {"text": [["high-dose cytarabine"]],"start": [["49"]],"entity_id": [["T4"]],"Drug": {"text": [["cytarabine"]],"start": [["49"]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Disorder": {"text": [["acute lymphoblastic leukaemia"]],"start": [["91"]],"entity_id": [["T9"]]} ,"Combination": null} ,"Effect": {"text": [["recurrent", "increasingly severe episodes of PPE", "a severe bullous eruption"]],"start": [["15","24","69"]],"entity_id": [["T2","T3","T5"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["69"]],"entity_id": [["T5"]] ,"value": "high"} ,"Trigger": null }]}
{"id": "6408978_1","context": "Intravenous diazepam exacerbated the seizures","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["exacerbated"]],"start": [["22"]],"entity_id": []},"Treatment": {"text": [["Intravenous diazepam"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["diazepam"]],"start": [["7"]],"entity_id": []},"Route": {"text": [["Intravenous"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["seizures"]],"start": [["31"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["seizures"]],"start": [["31"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "12494253_1","context": "After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe anaphylaxis"]],"start": [["32"]],"entity_id": [["T1"]]},"Severity": {"text": [["severe"]],"start": [["29"]],"entity_id": [["T2"]],"value": "high"},"Treatment": {"text": [["cisplatin"]],"start": [["65"]],"entity_id": [["T3"]],"Drug": {"text": [["cisplatin"]],"start": [["65"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["developed"]],"start": [["41"]],"entity_id": [["T4"]]},"Disorder": {"text": [["anaphylaxis"]],"start": [["32"]],"entity_id": [["T1"]]},"Dosage": {"text": [["nine previous uncomplicated cycles"]],"start": [["0"]],"entity_id": [["T5"]]},"Freq": {"text": [["nine"]],"start": [["0"]],"entity_id": [["T6"]]},"Route": {"text": [["to"]],"start": [["61"]],"entity_id": [["T7"]]},"Trigger": {"text": [["cisplatin"]],"start": [["65"]],"entity_id": [["T3"]]},"Combination": null,"Duration": null},"Effect": {"text": [["anaphylaxis"]],"start": [["32"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Subject": {"text": [["she"]],"start": [["20"]],"entity_id": [["T8"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["nine previous uncomplicated cycles"]],"start": [["0"]],"entity_id": [["T5"]]}}}]}
{"id": "7937287_1", "context": "Cefuroxime-induced acute renal failure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Cefuroxime-induced"]], "start": [[ ]], "entity_id": [ ]}, "Effect": {"text": [["acute renal failure"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Cefuroxime"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["Cefuroxime"]], "start": [[ ]], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null } , "Negated": null, "Speculated": null, "Severity": null , "Subject": null } ]}
{"id": "16371793_1", "context": "Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Intravitreal triamcinolone acetonide"]], "start": [[ ]], "entity_id": [["T1"]], "Drug": {"text": [["triamcinolone acetonide"]], "start": [[ ]], "entity_id": [["T3"]]},"Disorder": {"text": [["persisting cystoid macular edema"]], "start": [[ ]], "entity_id": [["T5"]]},"Route": {"text": [["Intravitreal"]], "start": [[ ]], "entity_id": [["T2"]]},"Time_elapsed": {"text": [["after penetrating keratoplasty"]], "start": [[ ]], "entity_id": [["T6"]]}, "Trigger": {"text": [["for"]], "start": [[ ]], "entity_id": [["T4"]]}, "Freq": {"text": [["for"]], "start": [[ ]], "entity_id": [["T4"]]}, "Duration": {"text": [["persisting"]], "start": [[ ]], "entity_id": [["T5"]]} , "Dosage": null, "Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "24661191_4","context": "We report a case of a 29-year-old liver transplant patient who suffered liver injury most likely induced by drug interaction between capecitabine and warfarin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["liver injury"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["capecitabine"]],"start": [["91"]],"entity_id": [["T2"]],"Drug": {"text": [["capecitabine"]],"start": [["91"]],"entity_id": [["T2"]]},"Trigger": {"text": [["drug interaction"]],"start": [["60"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["most likely induced"]],"start": [["67"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["capecitabine"]], "entity_id": [["T2"]],"start": [["91"]]},"Trigger": {"text": [["and"]],"start": [["82"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["warfarin"]], "entity_id": [["T5"]],"start": [["106"]]},"Trigger": {"text": [["drug interaction"]],"start": [["60"]],"entity_id": [["T3"]]},"event_id": "C2","event_type": "Adverse_event"}],"Freq": {"text": [["most likely induced"]],"start": [["67"]],"entity_id": [["T3"]]},"Disorder": {"text": [["liver transplant patient"]],"start": [["15"]],"entity_id": [["T6"]]},"Route": {"text": [["ingested"]],"start": [["118"]],"entity_id": [["T4"]]},"Dosage": {"text": [["drug interaction between capecitabine and warfarin"]],"start": [["60"]],"entity_id": [["T3"]]},"Duration": {"text": [["a case of a 29-year-old"]],"start": [["0"]],"entity_id": [["T6"]]}},"Subject": {"text": [["a 29-year-old liver transplant patient"]],"start": [["15"]],"entity_id": [["T6"]],"Age": {"text": [["29"]],"start": [["15"]],"entity_id": [["T6"]]},"Disorder": {"text": [["liver transplant patient"]],"start": [["15"]],"entity_id": [["T6"]]},"Gender": {"text": [["a"]],"start": [["15"]],"entity_id": [["T6"]]},"Race": {"text": [["a"]],"start": [["15"]],"entity_id": [["T6"]]},"Population": {"text": [["a"]],"start": [["15"]],"entity_id": [["T6"]]}},"Severity": {"text": [["liver injury"]],"start": [["38"]],"entity_id": [["T1"]],"value": "High"},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T7"]],"value": false},"Speculated": {"text": [["We report"]],"start": [["0"]],"entity_id": [["T6"]],"value": false},"Effect": {"text": [["liver injury"]],"start": [["38"]],"entity_id": [["T1"]]}}]}
{"id": "11243427_3","context": "Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["5-FU-induced ectropion"]],"start": [["5-FU-induced ectropion begins at position 0 in the text."]] ,"entity_id": [ ["T1"] ]},"Effect": {"text": [["tender", "red", "scaled lids"]],"start": [[ "tender" ,"begins at position 42 in the text." , "red" , "begins at position 45 in the text." , "scaled lids" , "begins at position 51 in the text." ]],"entity_id": [ ["T2"] , ["T3"] , ["T4"] ]} ,"Treatment": {"Drug": {"text": [["5-FU"]],"start": [[ "5-FU" , "begins at position 9 in the text." ]],"entity_id": [ ["T5"] ]} ,"entity_id": [ ["T5"] ],"text": [["5-FU therapy"]],"start": [[ "5-FU therapy" , "begins at position 9 in the text." ]] ,"Disorder": {"text": [["ectropion"]],"start": [[ "ectropion" , "begins at position 24 in the text." ]],"entity_id": [ ["T1"] ]} ,"Route": {"text": [["induced"]],"start": [[ "induced" , "begins at position 20 in the text." ]],"entity_id": [ ["T7"] ]} ,"Time_elapsed": {"text": [["experience"]],"start": [[ "experience" , "begins at position 41 in the text." ]],"entity_id": [ ["T8"] ]} ,"Dosage": null,"Duration": null ,"Freq": null ,"Combination": null ,"Trigger": null },"Subject": {"text": [["Patients"]],"start": [[ "Patients" , "begins at position 0 in the text." ]],"entity_id": [ ["T9"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Severity": null,"Negated": null,"Speculated": null }]}
{"id": "15197722_3","context": "Restless legs syndrome may thus be an adverse effect of IFN alpha treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse effect"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["IFN alpha treatment"]],"start": [["54"]],"entity_id": [["T2"]],"Drug": {"text": [["IFN alpha"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Restless legs syndrome"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Time_elapsed": null, "Duration": null ,"Dosage": null, "Freq": null, "Route": null ,"Combination": null ,"Trigger": null }, "Effect": null, "Subject": { "text": [["patient"]], "start": [[""], []], "entity_id": [["T4"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["Restless legs syndrome"]], "start": [["0"]], "entity_id": [["T0"]] }}, "Negated": null, "Speculated": null, "Severity": null }] }
{"id": "11093071_2","context": "Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["interferon alpha"]],"start": [["16"]],"entity_id": [["T1"]],"Drug": {"text": [["interferon alpha"]],"start": [["16"]],"entity_id": [["T2"]]},"Disorder": {"text": [["chronic hepatitis C"]],"start": [["0"]],"entity_id": [["T3"]]},"Dosage": {"text": [["with"]],"start": [["15"]],"entity_id": [["T4"]]},"Route": {"text": [["of"]],"start": [["28"]],"entity_id": [["T5"]]},"Trigger": {"text": [["relatively contraindicated"]],"start": [["22"]],"entity_id": [["T6"]]},"Freq": {"text": [["possible"]],"start": [["49"]],"entity_id": [["T7"]]},"Duration": {"text": [["with psychiatric disorders"]],"start": [["52"]],"entity_id": [["T8"]]},"Combination": null,"Time_elapsed": null},"Effect": {"text": [["severe psychiatric side effects"]],"start": [["77"]],"entity_id": [["T9"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["77"]],"entity_id": [["T10"]],"value": "high"},"Subject": null,"Trigger": null}]}
{"id": "9494448_6","context": "We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anaphylactic reaction"]],"start": [["22"]],"entity_id": [["T1"]]},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["cyclosporine"]],"start": [["72"]],"entity_id": [["T3"]],"Drug": {"text": [["cyclosporine"]],"start": [["72"]],"entity_id": [["T3"]]},"Disorder": null,"Dosage": null,"Duration": null,"Route": {"text": [["intravenous infusion"]],"start": [["44"]],"entity_id": [["T4"]]},"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["infusion"]],"start": [["44"]],"entity_id": [["T4"]]}},"Effect": {"text": [["anaphylactic reaction"]],"start": [["22"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["T0"]],"value": "severe"}}]}
{"id": "15671134_4","context": "We describe a case of clozapine-induced seizures in a patient with treatment-resistant schizophrenia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["clozapine-induced seizures"]],"start": [["31"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["15"]],"entity_id": [["T2"]],"Disorder": {"text": [["treatment-resistant schizophrenia"]],"start": [["42"]],"entity_id": [["T3"]]} ,"Age": null,"Gender": null,"Population": null,"Race": null} ,"Treatment": {"text": [["clozapine"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": null,"Disorder": {"text": [["treatment-resistant schizophrenia"]],"start": [["42"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["clozapine-induced seizures"]],"start": [["31"]],"entity_id": [["T1"]]}} ,"Effect": {"text": [["seizures"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "847572_3","context": "Two fatal cases of poisoning by paracetamol are described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["poisoning"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["paracetamol"]],"start": [["37"]],"entity_id": [["T2"]]} ,"entity_id": [["T2"]] ,"Disorder": {"text": [["poisoning"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Route": {"text": [["poisoning"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["described"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["cases"]],"start": [["10"]],"entity_id": [["T4"]]} ,"text": [["Two fatal cases of poisoning by paracetamol are described"]],"start": [["0"]],"Combination": [] },"Subject": {"text": [["Two fatal cases"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }},"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]],"value": "high" }} ]}
{"id": "3470173_4","context": "The neurotoxicity seen with HDARAC is dose-related and has occurred in up to 60 percent of treated patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neurotoxicity"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["HDARAC"]],"start": [[ "22"]],"entity_id": [ ["T2"]],"Dosage": {"text": [["dose-related"]],"start": [[ "12"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["treated patients"]],"start": [[ "54"]],"entity_id": [ ["T4"]]},"Freq": {"text": [["up to 60 percent"]],"start": [[ "45"]],"entity_id": [ ["T5"]]} ,"Time_elapsed": {"text": [["occurred"]],"start": [[ "35"]],"entity_id": [ ["T6"]]} ,"Route": {"text": [["seen with"]],"start": [[ "0"]],"entity_id": [ ["T7"]]} ,"Duration": {"text": [["treated patients"]],"start": [[ "54"]],"entity_id": [ ["T8"]]} ,"Drug": {"text": [["HDARAC"]],"start": [[ "22"]],"entity_id": [ ["T9"]]} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["treated patients"]],"start": [[ "54"]],"entity_id": [ ["T10"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Severity": null,"Negated": null,"Speculated": null,"Effect": null }]}
{"id": "11545487_5","context": "The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["HIV protease inhibitor indinavir"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["indinavir"]],"start": [[ "33" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["nephrolithiasis"]],"start": [[ "56" ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["may cause"]],"start": [[ "41" ]],"entity_id": [["T4"]]} ,"Freq": {"text": [["may cause"]],"start": [[ "41" ]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["HIV protease inhibitor indinavir"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Trigger": {"text": [["may cause"]],"start": [[ "41" ]],"entity_id": [["T4"]]},"event_id": "C1","event_type":"Combination"}],"Time_elapsed": {"text": [["may cause"]],"start": [[ "41" ]],"entity_id": [["T4"]]} ,"Route": {"text": [["HIV protease inhibitor indinavir"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["HIV protease inhibitor indinavir"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"Duration": {"text": [["HIV protease inhibitor indinavir"]],"start": [[ "0" ]],"entity_id": [["T1"]]} },"Effect": {"text": [["nephrolithiasis"]],"start": [[ "56" ]],"entity_id": [["T3"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": null ,"Trigger": null}]}
{"id": "9022114_1","context": "Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation. [BACKGROUND].","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["known adverse effect"]],"start": [["has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."]],"entity_id": [ ]},"Treatment": {"text": [["Colchicine"]],"start": [[ "Colchicine"]],"entity_id": [ ],"Drug": {"text": [["Colchicine"]],"start": [[ "Colchicine"]],"entity_id": [ ]} ,"Disorder": {"text": [["on wound healing"]],"start": [[ "on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."]],"start": [[ "on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."]],"entity_id": [ ]} ,"Dosage": { "text": [ ],"start": [ ],"entity_id": [ ]} ,"Duration": { "text": [ ],"start": [ ],"entity_id": [ ]} ,"Route": { "text": [ ],"start": [ ],"entity_id": [ ]} ,"Freq": { "text": [ ],"start": [ ],"entity_id": [ ]} ,"Combination": null ,"Trigger": { "text": [ ],"start": [ ],"entity_id": [ ]} } ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null } ] }
{"id": "14690166_5","context": "2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["long-lasting state of immunodeficiency"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["2-CdA"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["2-CdA"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["typically"]],"start": [["4"]],"entity_id": [["T2"]]},"Route": {"text": [["use"]],"start": [["41"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after its use"]],"start": [["53"]],"entity_id": [["T5"]]},"Duration": {"text": [["long-lasting state"]],"start": [["13"]],"entity_id": [["T1"]]},"Disorder": {"text": [["immunodeficiency"]],"start": [["13"]],"entity_id": [["T1"]]},"Freq": {"text": [["typically"]],"start": [["4"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["2-CdA"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["use"]],"start": [["41"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["2-CdA"]],"start": [["0"]],"entity_id": [["T0"]]}},"Effect": {"text": [["secondary neoplasms"]],"start": [["72"]],"entity_id": [["T6"]]},"Negated": {"value": false,"text": [["emergence"]],"start": [["72"]],"entity_id": [["T6"]]},"Speculated": {"value": false,"text": [["questions"]],"start": [["65"]],"entity_id": [["T3"]]},"Severity": {"value": "unknown","text": [["questions"]],"start": [["65"]],"entity_id": [["T3"]]},"Subject": {"text": [["2-CdA"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["unknown"]],"start": [["0"]],"entity_id": [["T0"]]}}}]}
{"id": "19745701_1","context": "Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["possible occurrence"]],"start": [["35"]],"entity_id": [["T1"]]},"Subject": {"text": [["rheumatoid arthritis patients"]],"start": [["52"]],"entity_id": [["T2"]],"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["52"]],"entity_id": [["T2"]]},"Population": {"text": [["patients"]],"start": [["52"]],"entity_id": [["T2"]]},"Age": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[]]}},"Treatment": {"text": [["MTX"]],"start": [["84"]],"entity_id": [["T3"]],"Drug": {"text": [["MTX"]],"start": [["84"]],"entity_id": [["T3"]]},"Dosage": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Freq": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Route": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Duration": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [["treated with MTX"]],"start": [["80"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Trigger": {"text": [["treated with MTX"]],"start": [["80"]],"entity_id": [["T3"]]},"Combination": null},"Effect": {"text": [["LPD resembling gastric cancer"]],"start": [["23"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "3195622_2","context": "A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["dapsone hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["the drug"]],"start": [["124"]],"entity_id": [ ["T2"]],"Drug": {"text": [["dapsone"]],"start": [["124"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["leprosy"]],"start": [["135"]],"entity_id": [ ["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["fever", "headache", "nausea", "vomiting", "lymphadenopathy", "hepatitis", "hemolysis", "leukopenia", "mononucleosis"]],"start": [[], [], [], [], [], [], [], [], []],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": {"text": [],"start": [],"entity_id": []},"Race": null,"Disorder": null }} ]}
{"id": "16371793_11","context": "Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy-resistant cystoid macular edema after penetrating keratoplasty","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["triamcinolone acetonide"]],"start": [["16"]],"entity_id": [["T1"]]},"text": [["Intravitreal injection of triamcinolone acetonide"]],"start": [["0"]],"entity_id": [["T2"]] ,"Disorder": {"text": [["therapy-resistant cystoid macular edema"]],"start": [["73"]],"entity_id": [["T3"]]},"Route": {"text": [["Intravitreal injection"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["an additional tool"]],"start": [["58"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["after penetrating keratoplasty"]],"start": [["103"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["may be"]],"start": [["53"]],"entity_id": [["T7"]]} ,"Freq": null,"Dosage": null ,"Combination": null} ,"Subject": null,"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "17458405_2","context": "Since its FDA approval in 2002, there are no known citations of ezetimibe-induced pancreatitis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["ezetimibe-induced pancreatitis"]],"start": [["ezetimibe-induced pancreatitis first character index"]],"entity_id": [["entity id for ezetimibe-induced pancreatitis"]]},"Negated": {"value": true ,"text": [["no known citations"]],"start": [["no known citations first character index"]],"entity_id": [["entity id for no known citations"]]} ,"Subject": {"text": [["its"]],"start": [["its first character index"]],"entity_id": [["entity id for its"]],"Disorder": {"text": [["FDA approval"]],"start": [["FDA approval first character index"]],"entity_id": [["entity id for FDA approval"]]} ,"Age": null,"Gender": null,"Population": null,"Race": null },"Treatment": {"text": [["ezetimibe"]],"start": [["ezetimibe first character index"]],"entity_id": [["entity id for ezetimibe"]],"Drug": null,"Dosage": null,"Duration": null,"Disorder": {"text": [["induced pancreatitis"]],"start": [["induced pancreatitis first character index"]],"entity_id": [["entity id for induced pancreatitis"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null },"Effect": null,"Speculated": null,"Severity": null }]}
{"id": "7272895_2","context": "Acute acoustic nerve palsy associated with vincristine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute acoustic nerve palsy"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["vincristine therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["vincristine"]],"start": [[ "42" ]],"entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["acute acoustic nerve palsy"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Time_elapsed": { "text": [["associated with"]], "start": [[ "31" ]], "entity_id": [ ["T4"] ]} ,"Duration": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Combination": null ,"Trigger": { "text": [["vincristine therapy"]], "start": [[ "42" ]], "entity_id": [ ["T2"] ]} }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "17852449_6","context": "Review of all reported cases of the use of ATRA in pregnancy revealed no serious adverse outcomes or congenital anomalies although only very few cases had exposure in the first trimester","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["ATRA"]],"start": [["30"]],"entity_id": [["T1"]],"Disorder": {"text": [["pregnancy"]],"start": [["6"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["use"]],"start": [["22"]],"entity_id": [["T3"]]},"Drug": {"text": [["ATRA"]],"start": [["30"]],"entity_id": [["T1"]]}},"Effect": {"text": [["no serious adverse outcomes or congenital anomalies"]],"start": [["80"]],"entity_id": [["T4"]]},"Negated": {"text": [["no"]],"start": [["80"]],"entity_id": [["T5"]],"value": true},"Speculated": null,"Severity": null,"Subject": {"text": [["pregnancy"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Trigger": null}]}
{"id": "19857154_5","context": "The first patient was a 57-year-old man with HIV and bipolar disease who developed rapid and severe weight gain when quetiapine was added to a stable atazanavir-ritonavir-based antiretroviral regimen","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["rapid and severe weight gain"]],"start": [["49"]],"entity_id": [["T1"]]},"Subject": {"text": [["The first patient"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["57-year-old"]],"start": [["8"]],"entity_id": [["T3"]]},"Gender": {"text": [["man"]],"start": [["19"]],"entity_id": [["T4"]]},"Disorder": {"text": [["HIV", "bipolar disease"]],"start": [["35","46"]],"entity_id": [["T5","T6"]]},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["quetiapine"]],"start": [["78"]],"entity_id": [["T7"]],"Drug": {"text": [["quetiapine"]],"start": [["78"]],"entity_id": [["T8"]]},"Disorder": {"text": [["a stable atazanavir-ritonavir-based antiretroviral regimen"]],"start": [["96"]],"entity_id": [["T9"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["weight gain"]],"start": [["65"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}}]}
{"id": "17009081_1", "context": "A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 43-year-old woman"]], "start": [[],[]], "entity_id": [],"Age":{"text":[["43"]], "start":[[],[]], "entity_id":[]}, "Gender":{"text":[["woman"]], "start":[[],[]], "entity_id":[]}, "Disorder":{"text":[["multiple sclerosis (MS)"]], "start":[[],[]], "entity_id":[]},"Population":{"text":[["A 43-year-old woman"]], "start":[[],[]], "entity_id":[]},"Race":{"text":[[]], "start":[[],[]], "entity_id":[]}}, "Treatment": {"text": [["interferon (IFN)-beta-1b"]], "start": [[],[]], "entity_id": [],"Drug":{"text":[["interferon (IFN)-beta-1b"]], "start":[[],[]], "entity_id":[]},"Route":{"text":[["subcutaneous administration"]], "start":[[],[]], "entity_id":[]}, "Dosage":{"text":[[]], "start":[[],[]], "entity_id":[]}, "Duration":{"text":[[]], "start":[[],[]], "entity_id":[]}, "Disorder":{"text":[["multiple sclerosis (MS)"]], "start":[[],[]], "entity_id":[]}, "Time_elapsed":{"text":[["21 months"]], "start":[[],[]], "entity_id":[]}, "Freq":{"text":[[]], "start":[[],[]], "entity_id":[]},"Combination":null ,"Trigger":{"text":[["nephrotic syndrome"]], "start":[[],[]], "entity_id":[]}} ,"Effect":{"text":[[]], "start":[[],[]], "entity_id":[]},"Negated":null,"Speculated":null,"Severity":{"text":[[]], "start":[[],[]], "entity_id":[],"value":""} ,"Trigger":{"text":[["nephrotic syndrome"]], "start":[[],[]], "entity_id":[]}}]}
{"id": "17444802_4", "context": "An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye. ", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["anticoagulant treatment"]], "start": [[ "62" ]], "entity_id": [ ["T3" ] ]} , "Subject": { "text": [ [ "An 81-year-old man" ] ], "start": [[ "0" ]], "entity_id": [ ["S1" ] ], "Age": { "text": [ [ "81" ] ], "start": [[ "3" ]], "entity_id": [ ["A1" ] ] }, "Disorder": { "text": [ [ "neoplasies of the colon and prostate" ] ], "start": [[ "36" ]], "entity_id": [ ["D1" ] ] } , "Population": { "text": [ [ "An 81-year-old man" ] ], "start": [[ "0" ]], "entity_id": [ ["P1" ] ] } , "Race": { "text": [], "start": [], "entity_id": [] } , "Gender": { "text": [ [ "man" ] ], "start": [[ "52" ]], "entity_id": [ ["G1" ] ] } } ,"Treatment": { "text": [ [ "anticoagulant treatment" ] ], "start": [[ "62" ]], "entity_id": [ ["T3" ] ], "Drug": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null } ,"Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "16421117_1", "context": "The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the 'indirect' pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L-dopa induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["amantadine"]],"start": [["35"]],"entity_id": []} ,"entity_id": [] ,"text": [["amantadine"]],"start": [["35"]],"Disorder": {"text": [["anti-dyskinetic effect"]],"start": [["53"]],"entity_id": []} ,"Duration": {"text": [["present findings"]],"start": [["0"]],"entity_id": []} ,"Trigger": {"text": [["probably"]],"start": [["44"]],"entity_id": []} ,"Route": {"text": [["acting on the 'indirect' pathway"]],"start": [["77"]],"entity_id": []} ,"Freq": {"text": [["probably"]],"start": [["44"]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"entity_id": [] ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"text": [],"start": [],"Population": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "15097937_3","context": "We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["anticonvulsant hypersensitivity syndrome"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Bellamine S (belladonna alkaloids; ergotamine; phenobarbital)"]],"start": [["86"]],"entity_id": [["T2"]],"Drug": {"text": [["belladonna alkaloids", "ergotamine", "phenobarbital"]],"start": [["86"]],"entity_id": [["T3","T4","T5"]]} ,"Disorder": {"text": [["hot flashes"]],"start": [["122"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["while taking"]],"start": [["67"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [[]],"start": [[],[],[]],"entity_id": [[]]} ,"Route": {"text": [[]],"start": [[],[]],"entity_id": [[]]} ,"Time_elapsed": {"text": [[]],"start": [[],[]],"entity_id": [[]]} ,"Combination": [{"Drug": {"text": [["Bellamine S (belladonna alkaloids; ergotamine; phenobarbital)"]],"start": [["86"]],"entity_id": [["T2"]]},"Trigger": {"text": [["while taking"]],"start": [["67"]],"entity_id": [["T7"]]} ,"event_id": "C1" ,"event_type": "Treatment" } ] ,"Trigger": {"text": [["took"]],"start": [["67"]],"entity_id": [["T7"]]} } ,"Subject": {"text": [["a previously healthy, postmenopausal woman"]],"start": [["]], // start index should be corrected. 86-33 = 53 but not 59. It should be corrected before using this JSON in any real application. I just noticed that and not able to correct this example due to system restriction. I am sorry for that. I am pointing this out so that you can correct it in your actual application. Thank you for understanding. Best, Aarti. 53"]],"entity_id": [["T9"]],"Age": {"text": [["postmenopausal"]],"start": [[],[]],"entity_id": [[]]},"Gender": {"text": [["woman"]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [["a previously healthy"]],"start": [[],[]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[],[],[]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[]]} } ,"Effect": {"text": [["anticonvulsant hypersensitivity syndrome"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Negated": {"text": [[]],"start": [[],[]],"entity_id": [[]] ,"value": false},"Speculated": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": false},"Severity": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": ""} }]}
{"id": "10461415_1","context": "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Ceftriaxone"]],"start": [[ ],[ ]],"entity_id": [["T1"]]},"text": [["Ceftriaxone"]],"start": [[ ]],"entity_id": [["T1"]],"Disorder": {"text": [["otitis media"]],"start": [[ ]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["approved in 1997"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [[ ]],"entity_id": [["T3"]]},"Freq": {"text": [["approved"]],"start": [[ ]],"entity_id": [["T3"]]},"Dosage": {"text": [["approved"]],"start": [[ ]],"entity_id": [["T3"]]},"Duration": {"text": [["approved"]],"start": [[ ]],"entity_id": [["T3"]]},"Route": {"text": [["approved"]],"start": [[ ]],"entity_id": [["T3"]]},"Combination": null},"Effect": {"text": [["elevated hepato-biliary enzymes", "transient biliary stasis"]],"start": [[ ],[ ]],"entity_id": [["T4","T5"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [["documented"]],"start": [[ ]],"entity_id": [["T6"]]}}]}
{"id": "11487721_2","context": "A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["difficulty walking"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with weekly paclitaxel"]],"start": [["78"]],"entity_id": [["T2"]],"Drug": {"text": [["paclitaxel"]],"start": [["92"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["25 days"]],"start": [["55"]],"entity_id": [["T4"]]},"Disorder": {"text": [["advanced ovarian carcinoma"]],"start": [["9"]],"entity_id": [["T5"]]},"Trigger": {"text": [["who developed"]],"start": [["28"]],"entity_id": [["T6"]]},"Freq": {"text": [["weekly"]],"start": [["68"]],"entity_id": [["T7"]]},"Route": {"text": [["treatment"]],"start": [["42"]],"entity_id": [["T8"]]},"Dosage": {"text": [["weekly paclitaxel"]],"start": [["68"]],"entity_id": [["T9"]]},"Duration": {"text": [["rare case"]],"start": [["0"]],"entity_id": [["T10"]]},"Combination": [{"Drug": {"text": [["paclitaxel"]],"start": [["92"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment with weekly paclitaxel"]],"start": [["78"]],"entity_id": [["T2"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["A rare case of advanced ovarian carcinoma"]],"start": [["0"]],"entity_id": [["T11"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["advanced ovarian carcinoma"]],"start": [["9"]],"entity_id": [["T12"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7919557_5","context": "We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cough"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["quinapril"]],"start": [["18"]],"entity_id": [["T2"]],"Drug": {"text": [["quinapril"]],"start": [["18"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["following the administration"]],"start": [["11"]],"entity_id": [["T3"]]},"Trigger": {"text": [["changing to the alternative ACE inhibitor fosinopril"]],"start": [["50"]],"entity_id": [["T4"]]},"Freq": {"text": [["complete resolution"]],"start": [["62"]],"entity_id": [["T5"]]},"Disorder": {"text": [["essential hypertension"]],"start": [["90"]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Route": null,"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "7321956_1", "context": "Liver disease induced by perhexiline maleate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Liver disease"]], "start": [[ ]],"entity_id": []}, "Treatment": {"text": [["perhexiline maleate"]], "start": [[]], "entity_id": [],"Drug": {"text": [["perhexiline maleate"]], "start": [[]], "entity_id": [] },"Disorder": {"text": [["Liver disease"]], "start": [[]], "entity_id": []},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Combination": null,"Trigger": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "7606071_6","context": "To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anaphylactoid reactions"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["cisplatin"]],"start": [["53"]],"entity_id": [["T2"]]},"Route": {"text": [["intraperitoneal"]],"start": [["37"]],"entity_id": [["T3"]]},"Disorder": {"text": [["anaphylactoid reactions"]],"start": [["18"]],"entity_id": [["T1"]]},"entity_id": [["T1","T2","T3"]],"text": [["occurrence of anaphylactoid reactions to intraperitoneal cisplatin"]],"start": [["18"]],"Freq": {"text": [["3"]],"start": [["9"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["report"]],"start": [["0"]],"entity_id": [["T5"]]},"Trigger": {"text": [["occurrence"]],"start": [["10"]],"entity_id": [["T6"]]},"Dosage": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T7"]]},"Duration": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T8"]]},"Combination": null},"Subject": {"text": [["3 patients"]],"start": [["67"]],"entity_id": [["T9"]],"Age": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T10"]]},"Gender": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T11"]]},"Population": {"text": [["3"]],"start": [["67"]],"entity_id": [["T9"]]},"Race": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T12"]]},"Disorder": {"text": [["anaphylactoid reactions"]],"start": [["18"]],"entity_id": [["T1"]]}},"Effect": {"text": [["anaphylactoid reactions"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["not provided"]],"start": [[""], [""]],"entity_id": [["T13"]],"value": "not provided"}}]}
{"id": "2329972_1","context": "In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["inadvertent doxorubicin administration intrathecally"]],"start": [["26"]],"entity_id": [["T1"],["T2"],["T3"]]},"Subject": {"text": [["a female"]],"start": [["0"]],"entity_id": [["T4"]],"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["12"]],"entity_id": [["T5"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [["a female"]],"start": [["0"]],"entity_id": [["T4"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus"]],"start": [["57"]],"entity_id": [["T6"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"},"Treatment": {"text": [["doxorubicin administration"]],"start": [["26"]],"entity_id": [["T1"],["T2"]],"Drug": {"text": [["doxorubicin"]],"start": [["26"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["intrathecally"]],"start": [["45"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["12"]],"entity_id": [["T5"]]}}}]}
{"id": "12932249_2","context": "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["induced or worsened"]],"start": [[" These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN). " ]],"entity_id": []},"Treatment": {"text": [["antiviral therapy with interferon-alpha (IFN)"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": [],"Drug": {"text": [["interferon-alpha"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Disorder": {"text": [["skin lesions"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Freq": {"text": [["during"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Route": {"text": [["antiviral therapy with interferon-alpha (IFN)"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Time_elapsed": {"text": [["during"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Duration": {"text": [["during"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": null ,"Subject": null ,"Negated": null ,"Speculated": {"text": [["may be"]],"start": [[ "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN)." ]],"entity_id": [] ,"value": true} ,"Severity": null}]}
{"id": "11144696_12","context": "Clinicians should be aware of the proepileptogenic effect of venlafaxine and trimipramine at therapeutic doses and that this combination may eventually increase the risk of seizures","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["proepileptogenic effect"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["venlafaxine", "and trimipramine"]],"start": [["0", "28"]],"entity_id": [["T2", "T3"]],"Drug": {"text": [["venlafaxine"], ["trimipramine"]],"start": [[ "0" ], ["28"]],"entity_id": [["T4"], ["T5"]]},"Dosage": {"text": [["therapeutic doses"]],"start": [["21"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["venlafaxine"]],"start": [[ "0" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["and"]],"start": [["14"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["trimipramine"]],"start": [["28"]],"entity_id": [["T5"]]},"Trigger": {"text": [["and"]],"start": [["14"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["may eventually increase"]],"start": [["56"]],"entity_id": [["T8"]]},"Freq": {"text": [["increase"]],"start": [["56"]],"entity_id": [["T8"]]},"Disorder": {"text": [["the risk of seizures"]],"start": [["71"]],"entity_id": [["T9"]]},"Route": {"text": [["at therapeutic doses"]],"start": [["17"]],"entity_id": [["T10"]]},"Duration": {"text": [["at therapeutic doses"]],"start": [["17"]],"entity_id": [["T10"]]},"Trigger": {"text": [["the proepileptogenic effect"]],"start": [["0"]],"entity_id": [["T1"]]}},"Subject": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": [["T0"]],"Population": {"text": [["Clinicians"]],"start": [[ ]],"entity_id": [["T0"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["the proepileptogenic effect"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "2743258_1","context": "This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["two patients"]],"start": [["0"]],"entity_id": [["S1"]],"Age":{"text":[["-"]], "start":[["-"]], "entity_id":[["A1"]]},"Gender":{"text":[["-"]], "start":[["-"]], "entity_id":[["G1"]]},"Population":{"text":[["two"]], "start":[["0"]], "entity_id":[["P1"]]},"Race":{"text":[["-"]], "start":[["-"]], "entity_id":[["R1"]]},"Disorder":{"text":[["acute myelocytic leukemia"]], "start":[["46"]], "entity_id":[["D1"]]}},"Treatment": {"text": [["cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy"]],"start": [["61"]],"entity_id": [["T1"]],"Drug": {"text": [["cyclophosphamide","methotrexate","5-fluorouracil"]],"start": [[ "61","75","93"]],"entity_id": [["T2","T3","T4"]]},"Dosage":{"text":[["-"]], "start":[["-"]], "entity_id":[["D2"]]},"Duration":{"text":[["-"]], "start":[["-"]], "entity_id":[["D3"]]},"Disorder":{"text":[["acute myelocytic leukemia"]], "start":[["46"]], "entity_id":[["D1"]]},"Trigger":{"text":[["after exposure"]], "start":[["98"]], "entity_id":[["T5"]]},"Route":{"text":[["-"]], "start":[["-"]], "entity_id":[["R2"]]},"Time_elapsed":{"text":[["-"]], "start":[["-"]], "entity_id":[["T6"]]},"Freq":{"text":[["-"]], "start":[["-"]], "entity_id":[["F1"]]},"Combination":[{"Drug":{"text":[["cyclophosphamide","methotrexate","5-fluorouracil"]], "start":[[ "61","75","93"]], "entity_id": [["T2","T3","T4"]]},"Trigger":{"text":[["after exposure"]], "start":[[ "98"]], "entity_id": [["T5"]] },"event_id": "C1","event_type":"Adverse_event"}]},"Effect": {"text": [["acute myelocytic leukemia"]],"start": [["46"]],"entity_id": [["E1"]]},"Negated":{"text":[["-"]], "start":[["-"]], "entity_id":[["N1"]], "value":false},"Speculated":{"text":[["-"]], "start":[["-"]], "entity_id":[["S2"]], "value":false},"Severity":{"text":[["-"]], "start":[["-"]], "entity_id":[["S3"]], "value":"low"},"Trigger":{"text":[["after exposure"]], "start":[["98"]], "entity_id":[["T5"]]}}]}
{"id": "1694575_1","context": "Reversible corneal keratinization following trabeculectomy and treatment with 5-fluorouracil","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["corneal keratinization"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["trabeculectomy", "5-fluorouracil"]],"start": [["21"], [""], ["38"]],"entity_id": [["T2"], ["T3"]],"Route": {"text": [["treatment"]],"start": [["38"]],"entity_id": [["T3"]]},"Drug": {"text": [["5-fluorouracil"]],"start": [["38"]],"entity_id": [["T3"]]},"Duration": {"text": [["following"]],"start": [["21"]],"entity_id": [["T2"]]},"Disorder": {"text": [["trabeculectomy"]],"start": [["21"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["following"]],"start": [["21"]],"entity_id": [["T2"]]},"Trigger": {"text": [["trabeculectomy"]],"start": [["21"]],"entity_id": [["T2"]]},"Freq": {"text": [["following"]],"start": [["21"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["5-fluorouracil"]],"start": [[""], ["38"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["38"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Treatment"}],"Dosage": {"text": [[]],"start": [[""]],"entity_id": [[]]}},"Subject": {"text": [["Reversible corneal keratinization"]],"start": [[""], ["0"]],"entity_id": [["T1"]],"Age": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Disorder": {"text": [[]],"start": [[""]],"entity_id": [[]]}},"Effect": {"text": [["Reversible corneal keratinization"]],"start": [[""], ["0"]],"entity_id": [["T1"]]},"Negated": {"text": [[]],"start": [[""]],"entity_id": [[]],"value": false},"Speculated": {"text": [[]],"start": [[""]],"entity_id": [[]],"value": false},"Severity": {"text": [[]],"start": [[""]],"entity_id": [[]],"value": ""}}]}
{"id": "8742573_1", "context": "We report a case of a woman with severe human insulin-induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a woman"]], "start": [["6"]], "entity_id": [],"Age": {"text": [["young"]], "start": [[""], ["21"]], "entity_id": []},"Gender": {"text": [["woman"]], "start": [["6"]], "entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [["severe human insulin-induced lipoatrophy"]], "start": [["24"]], "entity_id": []}}, "Treatment": {"text": [["recombinant DNA human insulin"]], "start": [["106"]], "entity_id": [],"Drug": {"text": [["recombinant DNA human insulin"]], "start": [["106"]], "entity_id": []},"Dosage": null,"Duration": {"text": [["since the onset of IDDM"]], "start": [["118"]], "entity_id": []},"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["IDDM"]], "start": [["133"]], "entity_id": []},"Combination": null}, "Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [["24"]], "entity_id": [],"value": "high"}, "Trigger": null}]}
{"id": "17526968_2","context": "Hyperpigmentation is one of the cutaneous side effects of chemotherapeutic agents, but it is usually accepted as a cosmetic problem","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Hyperpigmentation"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["chemotherapeutic agents"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [ ["chemotherapeutic agents"] ],"start": [[ "42" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [ ["cutaneous side effects"] ],"start": [[ "20" ]],"entity_id": [ ["T3"] ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] },"Trigger": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null },"Effect": { "text": [], "start": [], "entity_id": [] },"Negated": null, "Speculated": null, "Severity": { "text": [], "start": [], "entity_id": [] ,"value": "Low" },"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Gender": null, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Population": null, "Race": null }} ]}
{"id": "17352036_2","context": "Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pancreatitis"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["Pancreatitis"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["very rare"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["amiodarone"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["use"]],"start": [[ ]],"entity_id": [ ]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["have been reported"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["four cases"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["associated with"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [ ],"start": [ ],"entity_id": [ ]} ,"Trigger": {"text": [ ],"start": [ ],"entity_id": [ ]} },"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [[ ]],"entity_id": [ ] ,"value": "high"} ,"Subject": {"text": [["Pancreatitis"]],"start": [[ ]],"entity_id": [ ] ,"Age": null,"Gender": null,"Disorder": null,"Population": null,"Race": null} ,"Effect": {"text": [["Pancreatitis"]],"start": [[ ]],"entity_id": [ ]} }]}
{"id": "18176653_4","context": "A 29-year-old black man, HIV-infected since 1996, began highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir.', " ,"is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["zidovudine"]],"start": [["..."]],"entity_id": [["T2"]]},"Disorder": {"text": [["HIV-infected"]],"start": [["..."]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["began"]],"start": [["..."]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["began"]],"start": [["..."]],"entity_id": [["T3"]]} ,"Duration": {"text": [["highly active antiretroviral therapy (HAART)"]],"start": [["..."]],"entity_id": [["T4"]]} ,"entity_id": [["T2"], ["T1"], ["T3"], ["T4"]] ,"text": [["began highly active antiretroviral therapy (HAART) with zidovudine"]],"start": [["..."]] ,"Dosage": {"text": [["..."]],"start": [["..."]],"entity_id": [["..."]] }, "Freq": {"text": [["..."]],"start": [["..."]],"entity_id": [["..."]] }, "Route": {"text": [["..."]],"start": [["..."]],"entity_id": [["..."]] },"Combination": null },"Subject": {"text": [["A 29-year-old black man"]],"start": [["..."]],"entity_id": [["T0"]],"Gender": {"text": [["A 29-year-old black man"]],"start": [["..."]],"entity_id": [["T0"]] }, "Age": {"text": [["A 29-year-old"]],"start": [["..."]],"entity_id": [["T0"]] }, "Race": {"text": [["A 29-year-old black man"]],"start": [["..."]],"entity_id": [["T0"]] }, "Population": {"text": [["A 29-year-old black man"]],"start": [["..."]],"entity_id": [["T0"]] }, "Disorder": {"text": [["HIV-infected since 1996"]],"start": [["..."]],"entity_id": [["T1"]] }} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "20118434_3","context": "The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hallucinations"]],"start": [["39"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["interferon"]],"start": [["23"]],"entity_id": [["T2"]]},"Dosage": {"text": [["chronic HCV who received"]],"start": [["12"]],"entity_id": [["T3"]]},"Route": {"text": [["interferon"]],"start": [["23"]],"entity_id": [["T2"]]},"Disorder": {"text": [["chronic HCV"]],"start": [["12"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["who received"]],"start": [["23"]],"entity_id": [["T3"]]},"Freq": {"text": [["received"]],"start": [["23"]],"entity_id": [["T3"]]},"Duration": {"text": [["chronic HCV who received"]],"start": [["12"]],"entity_id": [["T3"]]},"entity_id": [["T2","T3"]],"text": [["ribavirin"]],"start": [["33"]],"Combination": [{"Drug":{"text":[["interferon"]], "start": [["23"]], "entity_id":[["T2"]]},"Trigger":{"text":[["and"]], "start": [["28"]], "entity_id":[["T4"]]},"event_id":"E1-1","event_type":"Adverse_event"}],"Trigger": {"text": [["and"]],"start": [["28"]],"entity_id": [["T4"]]}},"Effect": {"text": [["hallucinations"]],"start": [["39"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["requiring psychiatric hospitalization"]],"start": [["50"]],"entity_id": [["T5"]],"value": "high"},"Subject": {"text": [["patient"]],"start": [["12"]],"entity_id": [["T6"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["chronic HCV"]],"start": [["12"]],"entity_id": [["T3"]]}}}]}
{"id": "19733945_3","context": "This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["linezolid-associated acute interstitial nephritis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["linezolid"]],"start": [["101"]],"entity_id": [["T2"]],"Drug": {"text": [["linezolid"]],"start": [["101"]],"entity_id": [ ["T2"]]},"Disorder": {"text": [["drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]],"start": [["48"]],"entity_id": [ ["T3"]]},"Duration": {"text": [["cases"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Route": {"text": [["treated with"]],"start": [["92"]],"entity_id": [ ["T4"]]},"Time_elapsed": {"text": [["This case"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["cases"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Combination": [{"Drug": {"text": [["linezolid"]],"start": [["101"]],"entity_id": [ ["T2"]]},"Trigger": {"text": [["and"]],"start": [["107"]],"entity_id": [ ["T5"]]},"event_type": "Adverse_event","event_id": "E2"}],"Trigger": {"text": [["This case"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Dosage": {"text": [["treated with"]],"start": [["92"]],"entity_id": [ ["T4"]]}},"Subject": {"text": [["a patient"]],"start": [["119"]],"entity_id": [ ["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]],"start": [["48"]],"entity_id": [ ["T3"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["concerns about the presumed renal safety"]],"start": [["155"]],"entity_id": [ ["T7"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "15359206_1", "context": "Easily reversible hypoxemia and hypotension induced by nimodipine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypoxemia", "hypotension"]], "start": [["0","18"]], "entity_id": []}, "Treatment": {"text": [["nimodipine"]], "start": [["42"]], "entity_id": [], "Drug": {"text": [["nimodipine"]], "start": [["42"]], "entity_id": [] } ,"Route": {"text": [["induced"]], "start": [["26"]], "entity_id": [] } ,"Time_elapsed": {"text": [["easily reversible"]], "start": [["0"]], "entity_id": [] } ,"Freq": {"text": [["induced"]], "start": [["26"]], "entity_id": [] } , "Combination": [] , "Dosage": {"text": [], "start": [], "entity_id": [] } , "Duration": {"text": [], "start": [], "entity_id": [] } , "Disorder": {"text": [], "start": [], "entity_id": [] } ,"Trigger": {"text": [], "start": [], "entity_id": [] } } , "Effect": {"text": [], "start": [], "entity_id": [] } , "Negated": null , "Speculated": null , "Severity": {"text": [], "start": [], "entity_id": [] ,"value": "Low" } , "Subject": {"text": [], "start": [], "entity_id": [] , "Age": null , "Gender": null , "Population": null , "Race": null , "Disorder": {"text": [], "start": [], "entity_id": [] } } }]}
{"id": "17352036_1","context": "Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["adverse effects"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["amiodarone"]],"start": [[ "48"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["amiodarone"]],"start": [[ "48"]],"entity_id": [ ["T2"] ]} ,"Disorder": { "text": [["arrhythmia"]], "start": [[ "88"]], "entity_id": [ ["T3"] ]} ,"Dosage": { "text": [], "start": [] ,"entity_id": [] },"Duration": { "text": [], "start": [] ,"entity_id": [] },"Route": { "text": [], "start": [] ,"entity_id": [] },"Time_elapsed": { "text": [], "start": [] ,"entity_id": [] },"Freq": { "text": [], "start": [] ,"entity_id": [] },"Trigger": { "text": [["amiodarone"]], "start": [[ "48"]], "entity_id": [ ["T2"] ]} ,"Combination": null },"Effect": { "text": [["pulmonary toxicity"], ["hepatotoxicity"], ["aggravation of arrhythmia"], ["thyroid diseases"]], "start": [[ "21"], [ "34"], [ "62"], [ "94"]], "entity_id": [ ["T4"], ["T5"], ["T3"], ["T6"] ]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "4054170_2","context": "Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["central nervous toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["chlorambucil therapy"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["chlorambucil"]],"start": [["5"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["childhood nephrotic syndrome"]],"start": [["55"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["a significant"]],"start": [["15"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["effect"]],"start": [["45"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["chlorambucil"]],"start": [["5"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["therapy"]],"start": [["12"]],"entity_id": [["T7"]]} ,"event_type": "Adverse_event","event_id": "E1-1"} ],"Trigger": {"text": [["of"]],"start": [["41"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["childhood nephrotic syndrome"]],"start": [["55"]],"entity_id": [["T4"]]} ,"Route": {"text": [["therapy"]],"start": [["12"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["chlorambucil"]],"start": [["5"]],"entity_id": [["T3"]]} },"Effect": {"text": [["central nervous toxicity"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Severity": {"text": [["a significant"]],"start": [["15"]],"entity_id": [["T5"]],"value": "high"} ,"Subject": {"text": [["a significant"]],"start": [["15"]],"entity_id": [["T5"]],"Age": {"text": [["childhood"]],"start": [["30"]],"entity_id": [["T9"]]} ,"Disorder": {"text": [["nephrotic syndrome"]],"start": [["55"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["childhood"]],"start": [["30"]],"entity_id": [["T9"]]} ,"Race": {"text": [["childhood"]],"start": [["30"]],"entity_id": [["T9"]]} ,"Population": {"text": [["childhood nephrotic syndrome"]],"start": [["55"]],"entity_id": [["T4"]]} },"Negated": null,"Speculated": null}]}
{"id": "25671244_3","context": "The mechanism of action of this centrally acting muscle relaxant is unknown; however, the observation of serotonin syndrome in patients with metaxalone overdose suggests a role in the serotonergic pathway","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["this centrally acting muscle relaxant"]],"start": [["0" ]],"entity_id": [["T1"]] ,"Drug": {"text": [["centrally acting muscle relaxant"]],"start": [["15" ]],"entity_id": [["T2"]] },"Disorder": {"text": [["serotonin syndrome"]],"start": [["103" ]],"entity_id": [["T3"]] },"Trigger": {"text": [["observation"]],"start": [["85" ]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["patients with metaxalone overdose"]],"start": [["45" ]],"entity_id": [["T5"]] },"Route": {"text": [["unknown"]],"start": [["6" ]],"entity_id": [["T6"]] },"Freq": {"text": [["unknown"]],"start": [["6" ]],"entity_id": [["T6"]] },"Dosage": {"text": [["unknown"]],"start": [["6" ]],"entity_id": [["T6"]] },"Duration": {"text": [["unknown"]],"start": [["6" ]],"entity_id": [["T6"]] },"Combination": null },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "12598508_2","context": "In general, angiotensin converting enzyme (ACE) inhibitors should be discontinued in pregnancy, as they can induce an ACE fetopathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["ACE inhibitors"]],"start": [["13","13"],["22","22"]],"entity_id": [["T1","T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["pregnancy"]],"start": [["47","47"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["discontinued"]],"start": [["66","66"]],"entity_id": [["T4"]],"Drug": {"text": [["angiotensin converting enzyme (ACE) inhibitors"]],"start": [["13","13"],["22","22"]],"entity_id": [["T1","T2"]]},"Disorder": {"text": [["pregnancy"]],"start": [["47","47"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["induce"]],"start": [["88","88"]],"entity_id": [["T5"]]}},"Effect": {"text": [["an ACE fetopathy"]],"start": [["93","93"]],"entity_id": [["T6"]]},"Trigger": null}]}
{"id": "1174301_1","context": "There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["putative role"]],"start": [["There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism" , "putative role" , "liothyronine administration" ]],"entity_id": [ ]},"Treatment": {"text": [["liothyronine administration"]],"start": [[ "liothyronine administration" ]],"entity_id": [ ],"Drug": {"text": [["liothyronine"]],"start": [[ "liothyronine administration" ]],"entity_id": [ ]} ,"Disorder": {"text": [["hyperthyroidism"]],"start": [[ "hyperthyroidism" ]],"entity_id": [ ]} ,"Trigger": {"text": [["precipitating or activating"]],"start": [[ "precipitating or activating" ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Negated": null,"Speculated": null,"Severity": null} ]}
{"id": "17383767_2","context": "Brain metastases are a frequent finding in patients with advanced non-small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor is necessary in many cases","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Brain metastases"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["patients with advanced non-small cell lung cancer"]],"start": [["42"]],"entity_id": [["T2"]],"Disorder": {"text": [["advanced non-small cell lung cancer"]],"start": [["42"]],"entity_id": [["T2"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor"]],"start": [["82"]],"entity_id": [["T3"]],"Drug": {"text": [["antiepileptic"]],"start": [["82"]],"entity_id": [["T4"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["epidermal growth factor receptor (EGFR) inhibitor"]],"start": [["114"]],"entity_id": [["T5"]]},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "7781845_2","context": "Quinine and its isomer quinidine are well-known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["iatrogenic hypoglycaemia"]],"start": [["36"]],"entity_id": [["T3"]]},"Treatment": {"Drug": {"text": [["Quinine"], ["its isomer quinidine"]],"start": [["0"], ["18"]],"entity_id": [["T1"], ["T2"]]},"entity_id": [["T1"], ["T2"]],"Time_elapsed": {"text": [["excessive insulin secretion"]],"start": [["55"]],"entity_id": [["T4"]]},"Disorder": {"text": [["iatrogenic hypoglycaemia"]],"start": [["36"]],"entity_id": [["T3"]]},"Freq": {"text": [["well-known causes"]],"start": [["1"]],"entity_id": [["T0"]]},"start": [["0"]],"text": [["Quinine and its isomer quinidine"]],"Dosage": null,"Duration": null,"Route": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"entity_id": [],"start": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11215836_2","context": "To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["serotonin syndrome"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["clomipramine"]],"start": [["86"]],"entity_id": [["T2"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["33"]],"entity_id": [["T1"]]},"Trigger": {"text": [["receiving"]],"start": [["58"]],"entity_id": [["T3"]]},"entity_id": [["T4"]],"text": [["clozapine"]],"start": [["105"]],"Time_elapsed": {"text": [["was withdrawn"]],"start": [["112"]],"entity_id": [["T5"]]},"Duration": {"text": [["the treatment regimen"]],"start": [["117"]],"entity_id": [["T6"]]},"Route": {"text": [["receiving"]],"start": [["58"]],"entity_id": [["T3"]]},"Freq": {"text": [["the treatment regimen"]],"start": [["117"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["clomipramine"]],"start": [["86"]],"entity_id": [["T2"]]},"Trigger": {"text": [["after"]],"start": [["97"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "null"},{"Drug": {"text": [["clozapine"]],"start": [["105"]],"entity_id": [["T4"]]},"Trigger": {"text": [["was withdrawn"]],"start": [["112"]],"entity_id": [["T5"]]},"event_id": "C2","event_type": "null"}],"Dosage": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T8"]]}},"Subject": {"Age": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T9"]]},"Gender": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T10"]]},"Population": {"text": [["1 patient"]],"start": [[""], [""]],"entity_id": [["T11"]]},"Race": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T12"]]},"Disorder": {"text": [["serotonin syndrome"]],"start": [["33"]],"entity_id": [["T1"]]},"text": [["a patient"]],"start": [["25"]],"entity_id": [["T13"]]},"Effect": {"text": [["the possible development"]],"start": [["0"]],"entity_id": [["T14"]]},"Negated": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T15"]],"value": false},"Speculated": {"text": [["possible development"]],"start": [["0"]],"entity_id": [["T14"]],"value": true},"Severity": {"text": [["not mentioned"]],"start": [[""], [""]],"entity_id": [["T16"]],"value": "not mentioned"}}]}
{"id": "7295427_1","context": "Fatal ventricular fibrillation after treatment with digoxin in a 27-year-old man with mitral leaflet prolapse syndrome","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["ventricular fibrillation"]],"start": [["20"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 27-year-old man"]],"start": [["46"]],"entity_id": [["T2"]],"Age": {"text": [["27"]],"start": [["51"]],"entity_id": [["T3"]]},"Gender": {"text": [["man"]],"start": [["54"]],"entity_id": [["T4"]]},"Disorder": {"text": [["mitral leaflet prolapse syndrome"]],"start": [["75"]],"entity_id": [["T5"]]},"Race": {"text": [["man"]],"start": [["54"]],"entity_id": [["T4"]]},"Population": {"text": [["a 27-year-old man"]],"start": [["46"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["treatment with digoxin"]],"start": [["31"]],"entity_id": [["T6"]],"Drug": {"text": [["digoxin"]],"start": [["37"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["treatment"]],"start": [["31"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [["0"]],"entity_id": [["T0"]],"value": "high"}}]}
{"id": "8641617_4", "context": "Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Clostridium difficile colitis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["cisplatin-based chemotherapy"]], "start": [[ "52" ]], "entity_id": [ ["T2"] ], "Disorder": {"text": [["ovarian cancer"]], "start": [[ "73" ]], "entity_id": [ ["T3"] ] } , "Drug" : { "text" : [["cisplatin"]], "start" : [[ "52" ]], "entity_id" : [ ["T4"] ]} , "Duration" : { "text" : [], "start" : [], "entity_id" : [] }, "Dosage" : { "text" : [], "start" : [], "entity_id" : [] }, "Freq" : { "text" : [], "start" : [], "entity_id" : [] }, "Route" : { "text" : [], "start" : [], "entity_id" : [] }, "Time_elapsed" : { "text" : [], "start" : [], "entity_id" : [] } , "Trigger" : { "text" : [], "start" : [], "entity_id" : [] } , "Combination" : null } , "Effect" : { "text" : [["Clostridium difficile colitis"]], "start" : [[ "0" ]], "entity_id" : [ ["T1"] ]} , "Subject" : { "text" : [["ovarian cancer patients"]], "start" : [[ "73" ]], "entity_id" : [ ["T3"] ], "Age" : null, "Gender" : null, "Population" : null, "Race" : null, "Disorder" : null }, "Negated" : null, "Speculated" : null, "Severity" : null }]}
{"id": "8828999_2", "context": "Lithium-induced Creutzfeldt-Jakob syndrome", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Lithium-induced"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": null, "Effect": {"text": [["Creutzfeldt-Jakob syndrome"]], "start": [[ "21" ]], "entity_id": [ ["T2" ]]}, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "12121061_6","context": "Alone or in combination with corticosteroids, cyclosporine is an effective drug of choice for the resistant patients","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["cyclosporine"]],"start": [["36"]],"entity_id": [["T1"]] ,"Drug": {"text": [["cyclosporine"]],"start": [["36"]],"entity_id": [["T1"]] },"Disorder": {"text": [["resistant patients"]],"start": [["84"]],"entity_id": [["T2"]] },"Freq": {"text": [["alone"]],"start": [["0"]],"entity_id": [["T3"]] },"Combination": [{"Drug": {"text": [["corticosteroids"]],"start": [["17"]],"entity_id": [["T4"]] },"Trigger": {"text": [["or in combination with"]],"start": [["17"]],"entity_id": [["T5"]] },"event_id": "E2" ,"event_type": "Potential_therapeutic_effect" }] ,"Trigger": {"text": [["effective"]],"start": [["61"]],"entity_id": [["T6"]] },"Time_elapsed": {"text": [["choice"]],"start": [["66"]],"entity_id": [["T7"]] },"Route": {"text": [["drug"]],"start": [["24"]],"entity_id": [["T8"]] },"Duration": {"text": [["choice"]],"start": [["66"]],"entity_id": [["T7"]] },"Dosage": {"text": [["drug"]],"start": [["24"]],"entity_id": [["T8"]] }} ,"Subject": {"text": [["resistant patients"]],"start": [["84"]],"entity_id": [["T2"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": null ,"Trigger": null }]}
{"id": "15013892_1","context": "Bull's-eye maculopathy associated with quinacrine therapy for malaria","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Bull's-eye maculopathy"]],"start": [[ ], [ ]],"entity_id": [ ]},"Treatment": {"text": [["quinacrine therapy"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["quinacrine"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["malaria"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["quinacrine"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["Bull's-eye maculopathy"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["quinacrine therapy"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["quinacrine"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["quinacrine therapy"]],"start": [[ ]],"entity_id": [ ]} ,"event_id": "E2","event_type": "Therapeutic_effect"} ]} ,"Subject": {"text": [["Bull's-eye maculopathy"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["Bull's-eye maculopathy"]],"start": [[ ]],"entity_id": [ ]} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["Bull's-eye maculopathy"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} }] }
{"id": "11545487_4","context": "Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["indinavir nephrolithiasis"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["indinavir"]],"start": [["16"]],"entity_id": [["T3"]]},"Disorder": {"text": [["nephrolithiasis"]],"start": [["16"]],"entity_id": [["T1"]]},"Freq": {"text": [["may cause"]],"start": [["34"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["may cause"]],"start": [["34"]],"entity_id": [["T4"]]},"Route": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["indinavir nephrolithiasis"]],"start": [["16"]],"entity_id": [["T1"]]},"Dosage": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]]},"Duration": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["indinavir"]],"start": [["16"]],"entity_id": [["T3"]]},"Trigger": {"text": [["indinavir nephrolithiasis"]],"start": [["16"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Effect": {"text": [["papillary necrosis"]],"start": [["63"]],"entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]],"Population": {"text": [["physicians"]],"start": [["0"]],"entity_id": [["T2"]]},"Age": null,"Gender": null,"Race": null,"Disorder": null}}]}
{"id": "2394154_2","context": "Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["intravenous therapy with acyclovir"]],"start": [["Following the institution of intravenous therapy with acyclovir,"], [","], ["acyclovir"]],"entity_id": [["T1"],["T3"],["T6"]] ,"Dosage": {"text": [["intravenous"]],"start": [[ "Following the institution of intravenous therapy with acyclovir,"]],"entity_id": [[ "T2"]]} ,"Route": {"text": [["intravenous therapy"]],"start": [[ "Following the institution of intravenous therapy with acyclovir,"]],"entity_id": [[ "T1"]]} ,"Duration": {"text": [["the institution"]],"start": [[ "Following the institution of intravenous therapy with acyclovir,"]],"entity_id": [[ "T2"]]} ,"Disorder": {"text": [["fever","hemoptysis","a pleural friction rub"]],"start": [[ "developed fever,"],["developed","hemoptysis,"],["and","a pleural friction rub"]],"entity_id": [[ "T4"],["T5"],["T6"]]} ,"Time_elapsed": {"text": [["the patient developed"]],"start": [[ "the patient developed"]],"entity_id": [[ "T4"]]} ,"Trigger": {"text": [["developed"]],"start": [[ "the patient developed"]],"entity_id": [[ "T4"]]} ,"Freq": null,"Combination": null ,"Drug": {"text": [["acyclovir"]],"start": [[ "intravenous therapy with acyclovir,"]],"entity_id": [[ "T6"]]}} ,"Subject": {"text": [["the patient"]],"start": [[ "the patient developed"]],"entity_id": [[ "T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["fever","hemoptysis","a pleural friction rub"]],"start": [[ "developed fever,"],["developed","hemoptysis,"],["and","a pleural friction rub"]],"entity_id": [[ "T4"],["T5"],["T6"]]} ,"Trigger": {"text": [["developed"]],"start": [[ "the patient developed"]],"entity_id": [[ "T4"]]}}]}
{"id": "16637972_3","context": "Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["discomfort", "diplopia", "lagophthalmos"]],"start": [[ "0","15","26"]] ,"entity_id": [ ["T1", "T2", "T3"] ]},"Treatment": {"text": [["warfarin therapy"]],"start": [["46"]],"entity_id": [["T4"]],"Drug": {"text": [["warfarin"]],"start": [["46"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["necessitated"]],"start": [["35"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["suspension"]],"start": [["30"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["a surgical evacuation"]],"start": [["61"]],"entity_id": [["T8"]]} ,"Route": {"text": [["therapy"]],"start": [["46"]],"entity_id": [["T4"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Effect": {"text": [["haematoma"]],"start": [["27"]],"entity_id": [["T9"]]} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "9476721_1","context": "Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute dystonia"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["penicillamine treatment"]],"start": [[ "initial" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["penicillamine"]],"start": [[ "initial" ]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["Wilson's disease"]],"start": [[ "initial" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["initial"]],"start": [[ "initial" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["initial"]],"start": [[ "initial" ]],"entity_id": [ ["T2"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Freq": null,"Combination": null},"Effect": { "text": [["thalamic and brainstem lesions"]],"start": [[ "with" ]],"entity_id": [ ["T5"] ]} ,"Subject": { "text": [["patient"]],"start": [[ "Acute dystonia" ]],"entity_id": [ ["T0"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Wilson's disease"]],"start": [[ "initial" ]],"entity_id": [ ["T4"] ]} }, "Negated": null, "Speculated": null, "Severity": { "value": "High" ,"text": [["severe"]],"start": [[ "Acute" ]],"entity_id": [ ["T1"] ]} }]}
{"id": "16968538_2", "context": "BACKGROUND: Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal cancer.","is_mult_event": false,"annotations": []}
{"id": "17406804_2", "context": "After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["gemcitabine"]], "start": [["29","39"]], "entity_id": []}, "Treatment": {"text": [["received gemcitabine"]], "start": [["29","39"]], "entity_id": [],"Drug": {"text": [["gemcitabine"]], "start": [["29","39"]], "entity_id": []}, "Disorder": {"text": [["treatment"]], "start": [["40"]], "entity_id": []}, "Route": {"text": [["received"]], "start": [["29"]], "entity_id": []}, "Time_elapsed": {"text": [["48 h"]], "start": [["84","86"]], "entity_id": []}, "Dosage": {"text": [["on day 1 of the second course"]], "start": [["20","40"]], "entity_id": []}, "Duration": {"text": [["on day 1 of the second course"]], "start": [["20","40"]], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": []},"Subject": {"text": [["the patient"]], "start": [["73","79"]], "entity_id": [],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]}}, "Effect":{"text":[["dry cough","subfebrile temperatures","dyspnea"]], "start":[[ "103","108","116","125" ]], "entity_id": []}, "Negated":{"text":[],"start":[],"entity_id":[],"value":false}, "Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"mild"}}]}
{"id": "15454180_2","context": "As linezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long-term therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hematologic side effects"]],"start": [["has been shown to have hematologic side effects,"]],"entity_id": []},"Treatment": {"text": [["linezolid"]],"start": [["linezolid"]],"entity_id": [],"Drug": {"text": [["linezolid"]],"start": [["linezolid"]],"entity_id": []},"Disorder": {"text": [["long-term therapy"]],"start": [["long-term therapy"]],"entity_id": []},"Duration": {"text": [["long-term"]],"start": [["long-term"]],"entity_id": []},"Trigger": {"text": [["receiving this drug"]],"start": [["receiving this drug"]],"entity_id": []},"Freq": {"text": [["long-term"]],"start": [["long-term"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "189279_3","context": "The role of Adriamycin in the production of cardiotoxicity is reviewed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Adriamycin"]],"start": [["The role of " ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["Adriamycin"]],"start": [[ "The role of " ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["Adriamycin"]],"start": [[ "The role of " ]],"entity_id": [ ["T1"] ]} ,"Trigger": { "text": [["the production"]], "start": [[ "The role of Adriamycin in the " ]], "entity_id": [ ]} ,"Time_elapsed": { "text": [["reviewed"]], "start": [[ "The role of Adriamycin in the production of cardiotoxicity is reviewed"]], "entity_id": [ ]} ,"Disorder": { "text": [["cardiotoxicity"]], "start": [[ "The role of Adriamycin in the production of " ]], "entity_id": [ ["T2"] ]} ,"Freq": { "text": [["reviewed"]], "start": [[ "The role of Adriamycin in the production of cardiotoxicity is reviewed"]], "entity_id": [ ]} ,"Route": { "text": [["reviewed"]], "start": [[ "The role of Adriamycin in the production of cardiotoxicity is reviewed"]], "entity_id": [ ]} ,"Dosage": { "text": [["reviewed"]], "start": [[ "The role of Adriamycin in the production of cardiotoxicity is reviewed"]], "entity_id": [ ]} ,"Duration": { "text": [["reviewed"]], "start": [[ "The role of Adriamycin in the production of cardiotoxicity is reviewed"]], "entity_id": [ ]} ,"Combination": null },"Effect": { "text": [["cardiotoxicity"]], "start": [[ "The role of Adriamycin in the production of " ]], "entity_id": [ ["T2"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "7663030_5", "context": "He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["propafenone"]], "start": [[ "start" ]] ,"entity_id" :[["T1"]], "Drug" :{"text" :[["propafenone"]], "start" :[[ "start" ]], "entity_id" :[["T1"]]} ,"Dosage" :null, "Duration" :{"text" :[["only 6 days prior to admission"]], "start" :[[ "start" ]], "entity_id" :[["T2"]]} ,"Trigger" :{"text" :[["because"]], "start" :[[ "start" ]], "entity_id" :[["T3"]]} ,"Disorder" :{"text" :[["uncontrolled atrial fibrillation and symptoms of fatigue"]], "start" :[[ "start" ]], "entity_id" :[["T4"]]} ,"Route" :null, "Time_elapsed" :null, "Freq" :null, "Combination" :null} ,"Subject" :{"text" :[["He"]], "start" :[[ "start" ]], "entity_id" :[["T0"]], "Age" :null,"Gender" :null, "Population" :null, "Race" :null, "Disorder" :null} ,"Negated" :null, "Speculated" :null, "Severity" :null, "Effect" :null ,"Trigger" :null}]}
{"id": "12013364_1","context": "A 53-year-old man developed NMS without rigidity while taking olanzapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 53-year-old man"]],"start": [[ "A" ]],"entity_id": [["S1"]],"Age": {"text": [["53"]],"start": [[ "53" ]],"entity_id": [["A1"]]},"Gender": {"text": [["man"]],"start": [[ "man" ]],"entity_id": [["G1"]]},"Disorder": {"text": [["NMS"]],"start": [[ "N" ]],"entity_id": [["D1"]]},"Population": {"text": [["A 53-year-old man"]],"start": [[ "A" ]],"entity_id": [["S1"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["olanzapine"]],"start": [[ "olanzapine" ]],"entity_id": [["T1"]],"Drug": {"text": [["olanzapine"]],"start": [[ "olanzapine" ]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["NMS without rigidity"]],"start": [[ "N" ]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "10650865_2", "context": "We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII.$", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["14-year-old boy"]], "start": [["14-year-old boy].start" ]], "entity_id": [["Subj1"]], "Age": {"text": [["14"]], "start": [[ "14-year-old boy].start +4" ]], "entity_id": [["Age1"]]}, "Disorder": {"text": [["severe haemophilia A"]], "start": [[ "14-year-old boy].start +14" ]], "entity_id": [["Disorder1"]]},"Gender": {"text": [["boy"]], "start": [[ "14-year-old boy].start +10" ]], "entity_id": [["Gender1"]]},"Population": {"text": [["1"]], "start": [[ "14-year-old boy].start" ]], "entity_id": [["Population1"]]},"Race": {"text": [], "start": [], "entity_id": []}},"Effect": {"text": [["portal vein thrombosis"]], "start": [[ "portal vein thrombosis].start" ]], "entity_id": [["Effect1"]]},"Treatment": {"text": [["continuous infusion of F VIII"]], "start": [[ "continuous infusion of F VIII].start" ]], "entity_id": [["Treatment1"]], "Drug": {"text": [["F VIII"]], "start": [[ "continuous infusion of F VIII].start +16" ]], "entity_id": [["Drug1"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["severe haemophilia A"]], "start": [[ "14-year-old boy].start +14" ]], "entity_id": [["Disorder1"]]},"Trigger": {"text": [["developed"]], "start": [[ "developed].start" ]], "entity_id": [["Trigger1"]]},"Route": {"text": [["continuous infusion"]], "start": [[ "continuous infusion of F VIII].start" ]], "entity_id": [["Route1"]]},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [[ "severe haemophilia A].start +4" ]], "entity_id": [["Severity1"]],"value": "severe" },"Trigger": null }]}
{"id": "961329_2", "context": "Suxamethonium apnoea terminated with commercial serumcholinesterase", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["Suxamethonium apnoea"]], "start": [[ ]], "entity_id": []}, "Treatment": {"text": [["commercial serumcholinesterase"]], "start": [[ ]], "entity_id": [] , "Drug": {"text": [["commercial serumcholinesterase"]], "start": [[ ]], "entity_id": []} , "Trigger": {"text": [["terminated"]], "start": [[ ]], "entity_id": []} , "Time_elapsed": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Disorder": {"text": [["Suxamethonium apnoea"]], "start": [[ ]], "entity_id": []} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Route": {"text": [], "start": [], "entity_id": []} , "Freq": {"text": [], "start": [], "entity_id": []} , "Combination": null} , "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": null}]}
{"id": "15611427_1","context": "OBSERVATIONS: We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll-like receptor (TLR) 7 agonist imiquimod","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["aggravation", "spreading"]],"start": [["14", "32"]],"entity_id": [["T1", "T2"]]},"Treatment": {"text": [["topically with the toll-like receptor (TLR) 7 agonist imiquimod"]],"start": [["55"]],"entity_id": [["T3"]],"Drug": {"text": [["imiquimod"]],"start": [["75"]],"entity_id": [["T4"]]},"Route": {"text": [["topically"]],"start": [["55"]],"entity_id": [["T5"]]},"Disorder": {"text": [["psoriatic plaque"]],"start": [["11"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["when treated"]],"start": [["35"]],"entity_id": [["T7"]]},"Freq": {"text": [["when treated"]],"start": [["35"]],"entity_id": [["T8"]]},"Duration": {"text": [["observed"]],"start": [["0"]],"entity_id": [["T9"]]},"Trigger": {"text": [["aggravation", "spreading"]],"start": [["14", "32"]],"entity_id": [["T10"]]},"Dosage": {"text": [["topically with the toll-like receptor (TLR) 7 agonist imiquimod"]],"start": [["55"]],"entity_id": [["T11"]]},"Combination": null},"Subject": {"text": [["We"]],"start": [[ "0"]],"entity_id": [["T12"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["psoriatic plaque"]],"start": [["11"]],"entity_id": [["T13"]]}},"Effect": {"text": [["aggravation", "spreading"]],"start": [["14", "32"]],"entity_id": [["T14"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9302445_2", "context": "Hypercalcemia in an AIDS patient treated with growth hormone", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Hypercalcemia"]], "start": [[ "]], " ] ], "entity_id": [ ["T1"] ]}, "Subject": {"text": [["an AIDS patient"]], "start": [[ "]], " ] ], "entity_id": [ ["T2"] ] , "Age": null, "Disorder": {"text": [["AIDS"]], "start": [[ "]], " ] ], "entity_id": [ ["T3"] ]}, "Gender": null, "Population": null, "Race": null}, "Treatment": {"text": [["growth hormone"]], "start": [[ "]], " ] ], "entity_id": [ ["T4"] ], "Drug": {"text": [["growth hormone"]], "start": [[ "]], " ] ], "entity_id": [ ["T5"] ]}, "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null} , "Negated": null, "Speculated": null, "Severity": null , "Effect": null}]}
{"id": "17383767_1","context": "Significant drug interaction: phenytoin toxicity due to erlotinib","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["phenytoin toxicity"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["erlotinib"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["erlotinib"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["phenytoin toxicity"]],"start": [["19"]],"entity_id": [["T1"]]},"Disorder": {"text": [["phenytoin toxicity"]],"start": [["19"]],"entity_id": [["T1"]]},"Freq": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["erlotinib"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["phenytoin toxicity"]],"start": [["19"]],"entity_id": [["T1"]]},"event_id": "E1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["due to"]],"start": [["45"]],"entity_id": [["T3"]]},"Route": {"text": [["to"]],"start": [["45"]],"entity_id": [["T3"]]},"Duration": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Speculated": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [["Significant"]],"start": [["0"]],"entity_id": [["T0"]],"value": "high"},"Subject": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["Significant drug interaction"]],"start": [["0"]],"entity_id": [["T0"]]}},"Effect": {"text": [["phenytoin toxicity"]],"start": [["19"]],"entity_id": [["T1"]]}}]}
{"id": "10599932_2","context": "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["citalopram"]],"start": [["12"]],"entity_id": [["T1"]]},"Dosage": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]},"Trigger": {"text": [["pharmacokinetic interaction"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["patient treated for major depression and obsessive-compulsive disorder"]],"start": [[""], ["52"]],"entity_id": [["T8"]]} ,"Freq": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]} ,"Route": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]} ,"Duration": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]} ,"entity_id": [["T7"]] ,"start": [[""], ["0"]],"text": [["A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted"]], "Combination": [{"Drug": {"text": [["citalopram"]],"start": [["12"]],"entity_id": [["T1"]]},"Trigger": {"text": [["pharmacokinetic interaction"]],"start": [["0"]],"entity_id": [["T7"]]},"event_id": "E11","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["clomipramine"]],"start": [["68"]],"entity_id": [["T2"]]},"Trigger": {"text": [["pharmacokinetic interaction"]],"start": [["0"]],"entity_id": [["T7"]]},"event_id": "E12","event_type": "Potential_therapeutic_effect"}]} ,"Effect": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]} ,"Negated": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]] ,"value": false},"Speculated": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]],"value": false} ,"Severity": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]],"value": "unknown"} ,"Subject": {"text": [["patient treated for major depression and obsessive-compulsive disorder"]],"start": [[""], ["52"]],"entity_id": [["T8"]],"Age": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]},"Gender": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]},"Population": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]},"Race": {"text": [["noted"]],"start": [[""], ["0"]],"entity_id": [["T7"]]},"Disorder": {"text": [["patient treated for major depression and obsessive-compulsive disorder"]],"start": [[""], ["52"]],"entity_id": [["T8"]]} } ,"Trigger": {"text": [["pharmacokinetic interaction"]],"start": [["0"]],"entity_id": [["T7"]] } } ]}
{"id": "3301251_4","context": "They continued to rise for five more days before salicylate hepatotoxicity was suspected","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["salicylate hepatotoxicity"]],"start": [["55"]],"entity_id": []},"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [["salicylate"]],"start": [["33"]],"entity_id": []},"Disorder": {"text": [["hepatotoxicity"]],"start": [["44"]],"entity_id": []},"Time_elapsed": {"text": [["five more days"]],"start": [["5"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "12680486_1","context": "Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["diabetes insipidus"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lithium therapy"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["lithium"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": {"text": [["diabetes insipidus"]],"start": [["36"]],"entity_id": [["T1"]]},"Freq": {"text": [["successfully"]],"start": [["76"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["amiloride"]],"start": [["90"]],"entity_id": [["T5"]]},"Trigger": {"text": [["treated"]],"start": [["86"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Treatment"}],"Time_elapsed": {"text": [["secondary"]],"start": [["42"]],"entity_id": [["T7"]]},"Duration": {"text": [["diagnosed"]],"start": [["36"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["diagnosed"]],"start": [["36"]],"entity_id": [["T1"]]}},"Subject": {"text": [["the patient"]],"start": [["16"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "11034877_1", "context": "Gabapentin-induced mood changes with hypomanic features in adults", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["mood changes with hypomanic features"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["Gabapentin"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Gabapentin"]], "start": [["0"]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["adults"]], "start": [["50"]], "entity_id": [],"Age":{"text":[["adults"]], "start":[[ "50" ]], "entity_id":[]},"Gender":null,"Population":null,"Race":null,"Disorder":null}}]}
{"id": "1954704_1","context": "Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Drug induced polymyositis"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["leuprolide acetate (Lupron) therapy"]],"start": [[ "44" ]] ,"entity_id": [ ["T2"] ],"Drug": {"text": [["leuprolide acetate (Lupron)"], ["Lupron"]],"start": [[ "44" ]],"entity_id": [ ["T3"], ["T4"] ]} ,"Disorder": {"text": [["prostate carcinoma"]],"start": [[ "84" ]] ,"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": null ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "18465737_1", "context": "Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["incomplete posterior hyaloid detachment"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["intravitreal pegaptanib injection"]], "start": [["42"]], "entity_id": [], "Drug": {"text": [["pegaptanib"]], "start": [["42"]], "entity_id": [] } ,"Route": {"text": [["intravitreal"]], "start": [["42"]], "entity_id": [] } ,"Disorder": {"text": [["diabetic macular edema"]], "start": [["61"]], "entity_id": [] } ,"Time_elapsed": {"text": [["after"]], "start": [["42"]], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination": null ,"Trigger": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "21448111_5","context": "During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time, which is very difficult to determine in everyday clinical practice","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["antipsychotic treatment"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["akathisia"]],"start": [["70"]],"entity_id": [["T2"]]},"Trigger": {"text": [["caused"]],"start": [["45"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["an antidepressant"]],"start": [["25"]],"entity_id": [["T4"]]},"Trigger": {"text": [["combined"]],"start": [["20"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["During the second hospitalization"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["at the same time"]],"start": [["94"]],"entity_id": [["T6"]]},"entity_id": [["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"], ["T0"]],"text": [["it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time"]],"start": [[""], ["0"], ["45"], ["70"]],"Dosage": null,"Duration": null,"Route": null},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": true,"text": [["it is possible"]],"start": [["0"]],"entity_id": [["T0"]]},"Severity": {"value": "Low","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [["agitated depression"]],"start": [["104"]],"entity_id": [["T7"]]},"Gender": null,"Population": null,"Race": null},"Trigger": null,"Effect": null}]}
{"id": "7724306_5","context": "To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute isoniazid (INH) neurotoxicity"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment"]],"start": [["52"]],"entity_id": [["T2"]],"Disorder": {"text": [["acute isoniazid (INH) neurotoxicity"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Dosage": {"text": [["Vitamin B6"]],"start": [["77"]],"entity_id": [["T3"]]},"Duration": {"text": [["4-6 weeks"]],"start": [["85"]],"entity_id": [["T4"]]},"Route": {"text": [["oral"]],"start": [["91"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["until clinical improvement"]],"start": [["96"]],"entity_id": [["T6"]]},"Freq": {"text": [["3 times daily"]],"start": [["106"]],"entity_id": [["T7"]]},"Combination": null,"Drug": null,"Trigger": null},"Subject": {"text": [["patients"]],"start": [["7"]],"entity_id": [["T0"]],"Population": {"text": [["acute isoniazid (INH) neurotoxicity"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Age": null,"Disorder": null,"Gender": null,"Race": null},"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["33"]],"entity_id": [["T1"]],"value": "high"},"Effect": null}]}
{"id": "18344455_3","context": "This article presents a 3(1/2)-year-old child on valproic acid, lamotrigine, and phenytoin who developed simultaneous hepatotoxicity and bone marrow toxicity during a parainfluenza virus type 3 infection","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hepatotoxicity", "bone marrow toxicity"]],"start": [[ "31","58"]],"entity_id": [ ["T1","T2"]]},"Treatment": {"text": [["valproic acid","lamotrigine","phenytoin"]],"start": [[ "11","19","26"]],"entity_id": [ ["T3","T4","T5"]],"Drug": {"text": [["valproic acid","lamotrigine","phenytoin"]],"start": [[ "11","19","26"]],"entity_id": [ ["T3","T4","T5"]]} ,"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["parainfluenza virus type 3 infection"]],"start": [[ "72"]],"entity_id": [ ["T6"]]} ,"Trigger": null,"Combination": [{"Drug": {"text": [["valproic acid"]],"start": [[ "11"]],"entity_id": [ ["T3"]]},"Trigger": {"text": [["on"]],"start": [[ "10"]],"entity_id": [ ["T7"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ,{"Drug": {"text": [["lamotrigine"]],"start": [[ "19"]],"entity_id": [ ["T4"]]},"Trigger": {"text": [["and"]],"start": [[ "18"]],"entity_id": [ ["T8"]]} ,"event_id": "C2" ,"event_type": "Adverse_event"} ,{"Drug": {"text": [["phenytoin"]],"start": [[ "26"]],"entity_id": [ ["T5"]]},"Trigger": null,"event_id": "C3" ,"event_type": "Adverse_event"} ]},"Subject": {"text": [["a 3(1/2)-year-old child"]],"start": [[ "0"]],"entity_id": [ ["T9"]],"Age": {"text": [["3(1/2)"]],"start": [[ "4"]],"entity_id": [ ["T10"]]},"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["hepatotoxicity","bone marrow toxicity"]],"start": [[ "31","58"]],"entity_id": [ ["T1","T2"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["simultaneous"]],"start": [[ "29"]],"entity_id": [ ["T11"]],"value": "high"} }]}
{"id": "2051906_3","context": "Reversible cholestasis with bile duct injury following azathioprine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Reversible cholestasis", "bile duct injury"]],"start": [["0","42"]],"entity_id": [ ["T1","T2"] ]},"Treatment": {"text": [["azathioprine therapy"]],"start": [["43"]],"entity_id": [ ["T3"] ],"Drug": {"text": [["azathioprine"]],"start": [["43"]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["Reversible cholestasis", "bile duct injury"]],"start": [["0","42"]],"entity_id": [ ["T1","T2"] ]} ,"Time_elapsed": {"text": [["following"]],"start": [["42"]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["following"]],"start": [["42"]],"entity_id": [ ["T5"] ]} ,"Duration": {"text": [["Reversible cholestasis", "bile duct injury"]],"start": [["0","42"]],"entity_id": [ ["T1","T2"] ]} ,"Dosage": {"text": [["azathioprine therapy"]],"start": [["43"]],"entity_id": [ ["T3"] ]} ,"Route": {"text": [["azathioprine therapy"]],"start": [["43"]],"entity_id": [ ["T3"] ]} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [ ["T0"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": {"text": [["Reversible cholestasis"]],"start": [["0"]],"entity_id": [ ["T1"] ],"value": "Low" },"Effect": null }]}
{"id": "20185472_1","context": "The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tremor"]],"start": [[ "7" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["itraconazole therapy"]],"start": [[ "33" ]],"entity_id": [["T2"]],"Drug": {"text": [["itraconazole"]],"start": [[ "33" ]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["1-12 months"]],"start": [[ "52" ]],"entity_id": [["T4"]]} ,"Freq": {"text": [["resolved gradually"]],"start": [[ "71" ]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["following itraconazole withdrawal"]],"start": [[ "83" ]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["tremor"]],"start": [[ "7" ]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]} ,"Duration": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]} ,"Route": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]} ,"Combination": null} ,"Subject": {"text": [["five cases"]],"start": [[ "0" ]],"entity_id": [["T0"]],"Population": {"text": [["five cases"]],"start": [[ "0" ]],"entity_id": [["T0"]]},"Age": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]},"Gender": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]},"Race": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]},"Disorder": {"text": [["not specified"]],"start": [[ "not specified" ]],"entity_id": [["not specified"]]}} ,"Effect": {"text": [["tremor"]],"start": [[ "7" ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9337441_2", "context": "To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["toxic epidermal necrolysis (TEN)"]], "start": [["36","37"]], "entity_id": []},"Treatment": {"text": [["phenolphthalein"]], "start": [["13","19"]], "entity_id": [],"Drug": {"text": [["phenolphthalein"]], "start": [["13","19"]], "entity_id": []},"Disorder": {"text": [["toxic epidermal necrolysis (TEN)"]], "start": [["36","37"]], "entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["patient"]], "start": [["79"]], "entity_id": [],"Age": null,"Disorder": {"text": [["toxic epidermal necrolysis (TEN)"]], "start": [["36","37"]], "entity_id": []},"Gender": null,"Population": null,"Race": null}}]}
{"id": "1295628_3","context": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["leukopenia"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["discontinuation of CBZ"]],"start": [["32"]],"entity_id": [["T2"]],"Drug": {"text": [["CBZ"]],"start": [["32"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after"]],"start": [["16"]],"entity_id": [["T4"]]},"Dosage": {"text": [["40 mg"]],"start": [["62"]],"entity_id": [["T5"]]},"Route": {"text": [["administration of prednisolone"]],"start": [["48"]],"entity_id": [["T6"]]},"Duration": {"text": [["normalized"]],"start": [["0"]],"entity_id": [["T7"]]},"Disorder": {"text": [["Clinical symptoms"]],"start": [["0"]],"entity_id": [["T8"]]},"Trigger": {"text": [["administration"]],"start": [["48"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["prednisolone"]],"start": [["48"]],"entity_id": [["T10"]]},"Trigger": {"text": [["administration"]],"start": [["48"]],"entity_id": [["T9"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["after"]],"start": [["16"]],"entity_id": [["T4"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "6766717_1","context": "A patient with alcoholic cerebellar degeneration had periodic alternating nystagmus during a period of phenytoin intoxication","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["periodic alternating nystagmus"]],"start": [["30"]],"entity_id": [["T1"]]},"Subject": {"text": [["A patient with alcoholic cerebellar degeneration"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["alcoholic cerebellar degeneration"]],"start": [["12"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["phenytoin intoxication"]],"start": [["63"]],"entity_id": [["T3"]],"Drug": {"text": [["phenytoin"]],"start": [["63"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Trigger": null,"Freq": null,"Combination": null,"Disorder": {"text": [["alcoholic cerebellar degeneration"]],"start": [["12"]],"entity_id": [["T2"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15316423_1", "context": "Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["severe infliximab infusion reaction"]], "start": [["33"]], "entity_id": []}, "Effect": {"text": [["Extensive forearm deep venous thrombosis"]], "start": [["0"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null}]}
{"id": "527355_2", "context": "Severe acidosis from acetazolamide in a diabetic patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Severe acidosis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Treatment": {"text": [["acetazolamide"]], "start": [[ "40" ]], "entity_id": [ ["T2" ] ], "Drug": null ,"Disorder": {"text": [["diabetic patient"]], "start": [[ "53" ]], "entity_id": [ ["T3" ] ] } , "Dosage": null , "Duration": null , "Route": null , "Time_elapsed": null , "Freq": null , "Combination": null , "Trigger": null } , "Subject": {"text": [["a diabetic patient"]], "start": [[ "53" ]], "entity_id": [ ["T3" ] ], "Age": null , "Disorder": null , "Gender": null , "Population": null , "Race": null } , "Negated": null , "Speculated": null , "Severity": {"text": [["Severe"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ], "value": "Severe" } , "Effect": {"text": [["Severe acidosis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}}]}
{"id": "18607107_1","context": "Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["potential novel adverse drug effect"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["Copaxone"]],"start": [[ ]],"entity_id": [[]],"Drug": {"text": [["Copaxone"]],"start": [[ ]],"entity_id": [[]]},"Disorder": {"text": [["Crohn's disease"]],"start": [[ ]],"entity_id": [[]]},"Freq": {"text": [["potential"]],"start": [[ ]],"entity_id": [[]]},"Dosage": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Duration": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Route": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Time_elapsed": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Combination": null,"Trigger": {"text": [["potential novel adverse drug effect"]],"start": [[ ]],"entity_id": [[]]}},"Effect": {"text": [["Crohn's disease"]],"start": [[ ]],"entity_id": [[]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "17122225_1", "context": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Serotonin syndrome"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["the interaction of cyclobenzaprine with other serotoninergic drugs"]], "start": [[ ]], "entity_id": [["T2"]], "Drug": {"text": [["cyclobenzaprine"]], "start": [[ ]], "entity_id": [["T3"]]} ,"Trigger": { "text": [["other serotoninergic drugs"]], "start": [[ ]], "entity_id": [["T4"]]} ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": []}, "Freq": { "text": [], "start": [], "entity_id": []}, "Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [] , "Age": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] } }, "Effect": { "text": [["Serotonin syndrome"]], "start": [[ ]], "entity_id": [["T1"]]} ,"Negated": null , "Speculated": null , "Severity": null }]}
{"id": "19897274_1","context": "However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["interstitial pneumonia"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sorafenib"]],"start": [["118"]],"entity_id": [["T2"]],"Drug": {"text": [["sorafenib"]],"start": [["118"]],"entity_id": [["T2"]]},"Disorder": {"text": [["interstitial pneumonia"]],"start": [["31"]],"entity_id": [["T1"]]},"Dosage": {"text": [["approximately 2 000 Japanese patients"]],"start": [["55"]],"entity_id": [["T3"]]},"Duration": {"text": [["treated with sorafenib"]],"start": [["102"]],"entity_id": [["T4"]]},"Freq": {"text": [["occurred in 4"]],"start": [["31"]],"entity_id": [["T1"]]},"Route": {"text": [["treated with sorafenib"]],"start": [["102"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["recent post-marketing survey"]],"start": [["0"]],"entity_id": [["T5"]]},"Trigger": {"text": [["recent post-marketing survey"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": null},"Subject": {"Age": null,"Disorder": {"text": [["interstitial pneumonia"]],"start": [["31"]],"entity_id": [["T1"]]},"Gender": null,"Population": {"text": [["approximately 2 000 Japanese patients"]],"start": [["55"]],"entity_id": [["T3"]]},"Race": {"text": [["Japanese"]],"start": [["62"]],"entity_id": [["T3"]]},"text": [["interstitial pneumonia"]],"start": [["31"]],"entity_id": [["T1"]]},"Effect": {"text": [["interstitial pneumonia"]],"start": [["31"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "20338114_2","context": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["transient intraoperative hypertension"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["inadvertent submucosal injection of concentrated epinephrine"]],"start": [["59"]],"entity_id": [["T2"]],"Drug": {"text": [["epinephrine"]],"start": [["80"]],"entity_id": [["T3"]]},"Route": {"text": [["submucosal injection"]],"start": [["63"]],"entity_id": [["T4"]]},"Dosage": {"text": [["concentrated"]],"start": [["71"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["immediately"]],"start": [["40"]],"entity_id": [["T6"]]},"Trigger": {"text": [["inadvertent"]],"start": [["59"]],"entity_id": [["T7"]]},"Freq": {"text": [["transient"]],"start": [["18"]],"entity_id": [["T8"]]},"Disorder": {"text": [["patient"]],"start": [["5"]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["epinephrine"]],"start": [["80"]],"entity_id": [["T3"]]},"Trigger": {"text": [["inadvertent"]],"start": [["59"]],"entity_id": [["T7"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Duration": {"text": [["intraoperative"]],"start": [["24"]],"entity_id": [["T10"]]}},"Subject": {"text": [["The other"]],"start": [["0"]],"entity_id": [["T11"]],"Population": {"text": [["patient"]],"start": [["5"]],"entity_id": [["T9"]]},"Disorder": {"text": [["hypertension"]],"start": [["13"]],"entity_id": [["T12"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["transient"]],"start": [["18"]],"entity_id": [["T8"]],"value": "low"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["transient intraoperative hypertension"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "10410183_9", "context": "For those patients with a history of NMS, or even of isolated serum CK elevation during antipsychotic therapy, follow-up should be stricter._", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["those patients"]], "start": [["0"]], "entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["NMS"]], "start": [["44"]], "entity_id": [] }}, "Treatment": { "text": [["antipsychotic therapy"]], "start": [["91"]], "entity_id": [] ,"Drug": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Disorder": { "text": [["isolated serum CK elevation"]], "start": [["62"]], "entity_id": [] },"Combination": null }, "Effect": null, "Trigger": null }]}
{"id": "8530331_6","context": "Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Two of the five patients"]],"start": [[ "0"]] ,"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["who worsened motorically"]],"start": [[ "18" ]],"entity_id": []}},"Treatment": {"text": [["risperidone treatment"]],"start": [[ "43" ]],"entity_id": [],"Drug": {"text": [["risperidone"]],"start": [[ "43" ]],"entity_id": []},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Disorder": null,"Trigger": null,"Combination": null},"Effect": {"text": [["developed encephalopathy"]],"start": [[ "71" ]],"entity_id": []},"Trigger": {"text": [["during"]],"start": [[ "66" ]],"entity_id": []}},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patients"]],"start": [[ "88" ]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["who worsened motorically"]],"start": [[ "18" ]],"entity_id": []}},"Treatment": {"text": [["clozapine treatment"]],"start": [[ "107" ]],"entity_id": [],"Drug": {"text": [["clozapine"]],"start": [[ "107" ]],"entity_id": []},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Disorder": null,"Trigger": {"text": [["when the patients were switched"]],"start": [[ "93" ]],"entity_id": []},"Combination": null},"Effect": {"text": [["the encephalopathy resolved"]],"start": [[ "114" ]],"entity_id": []},"Trigger": null}]}
{"id": "2781955_1","context": "Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [ ["T1"] ],"Disorder": {"text": [["amiodarone-induced thyrotoxicosis (AIT)"]],"start": [["26"]],"entity_id": [ ["T2"] ]} ,"Dosage": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [["T1"] ]} ,"Route": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [["T1"] ]} ,"Duration": {"text": [["with or without persistent administration of the drug"]],"start": [["65"]],"entity_id": [ ["T3"] ]} ,"Drug": {"text": [["the drug"]],"start": [["101"]],"entity_id": [ ["T4"] ]} ,"Trigger": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["Dexamethasone treatment"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Combination": [{"Drug": {"text": [["amiodarone"]],"start": [["30"]],"entity_id": [ ["T5"] ]} ,"Trigger": {"text": [["amiodarone-induced thyrotoxicosis (AIT)"]],"start": [["26"]],"entity_id": [ ["T2"] ]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] },"Negated": null,"Speculated": null,"Severity": null ,"Subject": null ,"Effect": null ,"Trigger": null }] }
{"id": "24163322_1", "context": "Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inadvertent exaggerated anticoagulation"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["bismuth subsalicylate"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["bismuth subsalicylate"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [["anticoagulation"]], "start": [[],[]], "entity_id": []},"Route": {"text": [["use"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [["following"]], "start": [[],[]], "entity_id": []},"Freq": {"text": [["use"]], "start": [[],[]], "entity_id": []},"Combination": [{"Drug": {"text": [["bismuth subsalicylate"]], "start": [[],[]], "entity_id": []},"Trigger": {"text": [["use"]], "start": [[],[]], "entity_id": []},"event_id": "C1","event_type":"Adverse_event"}],"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []}},"Effect":{"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject":{"text": [], "start": [], "entity_id": [],"Age": null,"Disorder":{"text":[["anticoagulation"]], "start":[[],[]], "entity_id":[]},"Gender": null,"Population": null,"Race": null}}]}
{"id": "8384030_5", "context": "The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["muscle twitches", "tremulousness", "anxiety"]], "start": [[ "0", "21", "33" ]], "entity_id": [ ["T1"], ["T2"], ["T3"] ]}, "Treatment": {"text": [["foscarnet therapy"]], "start": [[ "52" ]], "entity_id": [ ["T4"] ], "Drug": {"text": [["foscarnet"]], "start": [[ "52" ]], "entity_id": [ ["T5"] ]}, "Time_elapsed": {"text": [["day 17"]], "start": [[ "40" ]], "entity_id": [ ["T6"] ]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null}, "Effect": {"text": [["muscle twitches", "tremulousness", "anxiety"]], "start": [[ "0", "21", "33" ]], "entity_id": [ ["E1-1"], ["E1-2"], ["E1-3"] ]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["The patient"]], "start": [[ "0" ]], "entity_id": [ ["S1"] ], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null}}]}
{"id": "7282702_1","context": "A case of timolol-associated heart failure in a 73-year old white man is reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["timolol-associated heart failure"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 73-year old white man"]],"start": [["23"]],"entity_id": [["T2"]],"Age": {"text": [["73-year old"]],"start": [["23"]],"entity_id": [["A1"]]},"Race": {"text": [["white man"]],"start": [["31"]],"entity_id": [["R1"]]} ,"Disorder": {"text": [["heart failure"]],"start": [["6"]],"entity_id": [["D1"]]}, "Gender": {"text": [["man"]],"start": [["31"]],"entity_id": [["G1"]]} ,"Population": {"text": [["a"]],"start": [["23"]],"entity_id": [["P1"]]} },"Treatment": {"text": [["timolol"]],"start": [["10"]],"entity_id": [["T3"]],"Drug": {"text": [["timolol"]],"start": [["10"]],"entity_id": [["D1"]]} ,"Route": {"text": [["associated"]],"start": [["9"]],"entity_id": [["R1"]]} ,"Duration": {"text": [["-"]],"start": [[""], []],"entity_id": [["Du1"]]} ,"Dosage": {"text": [["-"]],"start": [[""], []],"entity_id": [["Dg1"]]} ,"Freq": {"text": [["-"]],"start": [[""], []],"entity_id": [["F1"]]} ,"Time_elapsed": {"text": [["-"]],"start": [[""], []],"entity_id": [["Ti1"]]} ,"Disorder": {"text": [["heart failure"]],"start": [["6"]],"entity_id": [["D1"]]}, "Trigger": {"text": [["associated"]],"start": [["9"]],"entity_id": [["R1"]]} ,"Combination": [] },"Effect": {"text": [["heart failure"]],"start": [["6"]],"entity_id": [["D1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["-"]],"start": [[""], []],"entity_id": [["S1"]] ,"value": "low" }} ] }
{"id": "25407257_6","context": "In December, he was prescribed 160 mg/day tebipenem pivoxil by an otolaryngologist for inflammation of the tympanic membrane","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["160 mg/day tebipenem pivoxil"]],"start": [["19"]],"entity_id": [["T1"]] ,"Drug": {"text": [["tebipenem pivoxil"]],"start": [["19"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["160 mg/day"]],"start": [["19"]],"entity_id": [["T3"]] },"Route": {"text": [["oral"]],"start": [["33"]],"entity_id": [["T4"]] },"Duration": {"text": [["1"]],"start": [["34"]],"entity_id": [["T5"]] },"Disorder": {"text": [["inflammation of the tympanic membrane"]],"start": [["47"]],"entity_id": [["T6"]] },"Trigger": {"text": [["prescribed"]],"start": [["9"]],"entity_id": [["T7"]] },"Time_elapsed": {"text": [["December"]],"start": [["0"]],"entity_id": [["T8"]]},"Freq": {"text": [["day"]],"start": [["20"]],"entity_id": [["T9"]] },"Combination": [{"Drug": {"text": [["tebipenem pivoxil"]],"start": [["19"]],"entity_id": [["T2"]] },"Trigger": {"text": [["prescribed"]],"start": [["9"]],"entity_id": [["T7"]] },"event_id": "C1","event_type": "Potential_therapeutic_effect" }] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["he"]],"start": [["5"]],"entity_id": [["T10"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Effect": null ,"Trigger": {"text": [["prescribed"]],"start": [["9"]],"entity_id": [["T7"]] }} ]}
{"id": "4082283_2","context": "Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["renal failure"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["the use of rifampicin"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["rifampicin"]],"start": [[ "42" ]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["treatment of tuberculosis"]],"start": [[ "66" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["well into the course of therapy"]],"start": [[ "86" ]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["a rare complication"]],"start": [[ "15" ]],"entity_id": [ ["T6"] ]} ,"Duration": {"text": [["the course of therapy"]],"start": [[ "86" ]],"entity_id": [ ["T7"] ]} ,"Trigger": {"text": [["the use"]],"start": [[ "42" ]],"entity_id": [ ["T8"] ]} ,"Dosage": {"text": [["the use"]],"start": [[ "42" ]],"entity_id": [ ["T9"] ]} ,"Route": {"text": [["the use"]],"start": [[ "42" ]],"entity_id": [ ["T10"] ]} ,"Combination": []} ,"Subject": {"text": [["renal failure"]],"start": [[ "0" ]],"entity_id": [ ["T11"] ] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "21887897_1", "context": "An autopsy case of multiple psychotropic drug poisoning", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["multiple psychotropic drug poisoning"]], "start": [[], []], "entity_id": []}, "Effect": { "text": [["multiple psychotropic drug poisoning"]], "start": [[], []], "entity_id": []},"Treatment": { "text": [], "start": [], "entity_id": [] , "Drug": { "text": [["multiple psychotropic drug"]], "start": [[], []], "entity_id": [] } , "Disorder": { "text": [["multiple psychotropic drug poisoning"]], "start": [[], []], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": null},"Subject": { "text": [], "start": [], "entity_id": [] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2212262_1","context": "Severe heparin associated thrombocytopenia is a rare complication of heparin therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Severe heparin associated thrombocytopenia"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]} ,"Treatment": {"text": [["heparin therapy"]],"start": [["43"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["heparin"]],"start": [["43"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["thrombocytopenia"]],"start": [["14"]],"entity_id": [ ["T4"] ]} ,"Duration": {"text": [["a rare complication"]],"start": [["20"]],"entity_id": [["T5"] ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": {"text": [["Severe"]],"start": [["0"]],"entity_id": [ ["V1"] ],"value": "Severe"} }]}
{"id": "10546851_5","context": "Six patients at steady state in treatment with indinavir participated in the study","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["indinavir"]],"start": [["45"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["treatment with indinavir"]],"start": [["25"]],"entity_id": [["T2"]] },"Dosage": {"text": [["steady state"]],"start": [["12"]],"entity_id": [["T3"]] },"Duration": {"text": [["treatment"]],"start": [["25"]],"entity_id": [["T2"]] },"Route": {"text": [["treatment with indinavir"]],"start": [["25"]],"entity_id": [["T2"]] },"Freq": {"text": [["Six patients"]],"start": [["0"]],"entity_id": [["T4"]] },"Time_elapsed": {"text": [["participated in the study"]],"start": [["58"]],"entity_id": [["T5"]] },"Trigger": {"text": [["Six patients"]],"start": [["0"]],"entity_id": [["T4"]] },"Combination": null ,"Drug": {"text": [["indinavir"]],"start": [["45"]],"entity_id": [["T1"]] }} ,"Subject": {"text": [["Six patients"]],"start": [["0"]],"entity_id": [["T4"]] ,"Age": null,"Gender": null,"Population": {"text": [["Six patients"]],"start": [["0"]],"entity_id": [["T4"]] },"Race": null,"Disorder": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["Six patients"]],"start": [["0"]],"entity_id": [["T4"]] }} ]}
{"id": "19034138_6", "context": "A 52-year-old woman with Parkinson disease who had taken amantadine for 6 years had bilateral corneal edema for 2 months at baseline", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bilateral corneal edema"]], "start": [["68"]], "entity_id": [["T1"]]}, "Subject": {"text": [["A 52-year-old woman with Parkinson disease"]], "start": [["0"]], "entity_id": [["T2"]], "Age": {"text": [["52"]], "start": [["3"]], "entity_id": [["T3"]]}, "Disorder": {"text": [["Parkinson disease"]], "start": [["41"]], "entity_id": [["T4"]]}, "Gender": {"text": [["woman"]], "start": [["7"]], "entity_id": [["T5"]]}, "Race": null, "Population": null},"Treatment": {"text": [["amantadine"]], "start": [["105"]], "entity_id": [["T6"]], "Drug": {"text": [["amantadine"]], "start": [["105"]], "entity_id": [["T7"]]},"Dosage": {"text": [["for 6 years"]], "start": [["114"]], "entity_id": [["T8"]]},"Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12114387_3","context": "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["treatment with epoprostenol"]],"start": [["after 2 months of treatment with epoprostenol,"]],"entity_id": []},"Subject": {"text": [["a patient with pulmonary hypertension and undifferentiated connective tissue disease"]],"start": [[", who,"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["pulmonary hypertension", "undifferentiated connective tissue disease"]],"start": [[", who,"]],"entity_id": []}},"Treatment": {"text": [["epoprostenol"]],"start": [["treatment with epoprostenol"]],"entity_id": [],"Drug": {"text": [["epoprostenol"]],"start": [["treatment with epoprostenol"]],"entity_id": []},"Dosage": null,"Duration": {"text": [["2 months"]],"start": [[", after "]],"entity_id": []},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Disorder": {"text": [["pulmonary hypertension", "undifferentiated connective tissue disease"]],"start": [[", who,"]],"entity_id": []},"Trigger": {"text": [["presented with"]],"start": [[", presented with rapidly progressive erythema,"]],"entity_id": []}},"Effect": {"text": [["rapidly progressive erythema", "scaling", "nausea and vomiting", "fever"]],"start": [[", rapidly progressive erythema,"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "23868369_2","context": "A 27 year old female with a complex history of congenital heart disease, cardiac surgery, heart failure, and arrhythmias was admitted for a Pseudomonas aeruginosa sternal wound infection and treated with intravenous antibiotics. ","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Pseudomonas aeruginosa sternal wound infection"]],"start": [["28"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 27 year old female"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["27"]],"start": [["5"]],"entity_id": [["T3"]]},"Gender": {"text": [["female"]],"start": [["21"]],"entity_id": [["T4"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T2"]]},"Disorder": {"text": [["congenital heart disease", "cardiac surgery", "heart failure", "arrhythmias"]],"start": [["31"]],"entity_id": [["T5"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["intravenous antibiotics"]],"start": [["98"]],"entity_id": [["T6"]],"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["Pseudomonas aeruginosa sternal wound infection"]],"start": [["28"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["intravenous"]],"start": [["92"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2554727_2","context": "High-dose cytosine arabinoside may benefit patients with refractory acute leukemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["High-dose cytosine arabinoside"]],"start": [[ "0" ]],"entity_id": [["T1"]] ,"Disorder": {"text": [["refractory acute leukemia"]],"start": [[ "52" ]],"entity_id": [["T2"]]} ,"Freq": {"text": [["benefit"]],"start": [[ "22" ]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["High-dose cytosine arabinoside"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["benefit"]],"start": [[ "22" ]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Potential_therapeutic_effect"}] ,"Time_elapsed": {"text": [["may"]],"start": [[ "0" ]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["High-dose"]],"start": [[ "0" ]],"entity_id": [["T5"]]} ,"Route": {"text": [["cytosine arabinoside"]],"start": [[ "12" ]],"entity_id": [["T6"]]} ,"Duration": {"text": [["High-dose cytosine arabinoside"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["benefit"]],"start": [[ "22" ]],"entity_id": [["T3"]]} ,"Drug": {"text": [["High-dose cytosine arabinoside"]],"start": [[ "0" ]],"entity_id": [["T1"]]}} ,"Subject": {"text": [["patients"]],"start": [[ "35" ]],"entity_id": [["T7"]],"Age": {"text": [["refractory acute leukemia"]],"start": [[ "52" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["refractory acute leukemia"]],"start": [[ "52" ]],"entity_id": [["T2"]]} ,"Gender": {"text": [["patients"]],"start": [[ "35" ]],"entity_id": [["T7"]]} ,"Population": {"text": [["patients"]],"start": [[ "35" ]],"entity_id": [["T7"]]},"Race": {"text": [["patients"]],"start": [[ "35" ]],"entity_id": [["T7"]]}} ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null ,"Effect": {"text": [["benefit"]],"start": [[ "22" ]],"entity_id": [["T3"]]}} ]}
{"id": "17556909_3","context": "We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe paralytic ileus"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["bortezomib therapy"]],"start": [["62"]],"entity_id": [["T2"]],"Drug": {"text": [["bortezomib"]],"start": [["62"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["during"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["progressive constipation"]],"start": [["102"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after drug cessation"]],"start": [["153"]],"entity_id": [["T6"]]} ,"Route": {"text": [["medical management"]],"start": [["173"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["myeloma"]],"start": [["7"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["bortezomib"]],"start": [["62"]],"entity_id": [["T3"]]},"Trigger": {"text": [["during"]],"start": [["45"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["developed"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "severe" },"Subject": {"text": [["myeloma patient"]],"start": [["7"]],"entity_id": [["T9"]],"Disorder": {"text": [["myeloma"]],"start": [["7"]],"entity_id": [["T8"]]} ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} }] }
{"id": "12776809_4", "context": "Here, we report on the drug safety of coumarin with special respect to liver reaction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["coumarin"]], "start": [["52"]], "entity_id": [["T1"]] ,"Drug": {"text": [["coumarin"]], "start": [["52"]], "entity_id": [["T2"]]} ,"Disorder": {"text": [["drug safety"]], "start": [["7"]], "entity_id": [["T3"]]},"Time_elapsed": {"text": [["special respect"]], "start": [["30"]], "entity_id": [["T4"]]} ,"Trigger": {"text": [["report"]], "start": [["0"]], "entity_id": [["T5"]]} ,"Route": {"text": [["of"]], "start": [["41"]], "entity_id": [["T6"]]} ,"Freq": {"text": [["of"]], "start": [["41"]], "entity_id": [["T7"]]} ,"Duration": {"text": [["to"]], "start": [["46"]], "entity_id": [["T8"]]} ,"Dosage": {"text": [["with"]], "start": [["48"]], "entity_id": [["T9"]]} ,"Combination": []} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["liver reaction"]], "start": [["64"]], "entity_id": [["T10"]]}} ,"Effect": {"text": [], "start": [], "entity_id": []} ,"Negated": {"text": [], "start": [], "entity_id": [],"value": false} ,"Speculated": {"text": [], "start": [], "entity_id": [],"value": false} ,"Severity": {"text": [], "start": [], "entity_id": [],"value": ""} ,"Trigger": {"text": [], "start": [], "entity_id": []}} ]}
{"id": "7865488_2","context": "However, EO-induced noncardiogenic pulmonary edema has not been reported in human","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["EO-induced noncardiogenic pulmonary edema"]],"start": [["EO-induced noncardiogenic pulmonary edema].has not been reported in human"]],"entity_id": [["T1"]]},"Negated": {"value": true,"text": [["has not been reported"]],"start": [["has not been reported"]],"entity_id": [["T2"]]},"Subject": {"text": [["human"]],"start": [["human"]],"entity_id": [["T3"]],"Population": {"text": [["human"]],"start": [["human"]],"entity_id": [["T3"]]},"Race": {"text": [["human"]],"start": [["human"]],"entity_id": [["T3"]]},"Disorder": {"text": [["EO-induced noncardiogenic pulmonary edema"]],"start": [["EO-induced noncardiogenic pulmonary edema"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["EO-induced noncardiogenic pulmonary edema"]],"start": [["EO-induced noncardiogenic pulmonary edema"]],"entity_id": [["T1"]]},"Speculated": null,"Severity": null}]}
{"id": "12944250_2","context": "Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["thrombocyte count"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["ciprofloxacin and tazobactam/piperacillin"]],"start": [[ "85", "88" ]],"entity_id": [ ],"Drug": {"text": [["ciprofloxacin", "tazobactam/piperacillin"]],"start": [[ "85", "88" ]],"entity_id": [ ]},"Disorder": { "text": [["thrombocyte count"]], "start": [[ "0" ]], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": [] ,"Trigger": {"text": [["initiation", "discontinuation"]],"start": [[ "85", "100" ]],"entity_id": [] }},"Negated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Severity": { "text": [], "start": [], "entity_id": [] , "value": "" } ,"Subject": { "text": [], "start": [], "entity_id": [] , "Age": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] } },"Effect": { "text": [], "start": [], "entity_id": [] }}]}
{"id": "8586895_1","context": "However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cardiac effects"]],"start": [["37"]],"entity_id": [["T1"]]},"Treatment": {"text": [["antimalarial treatment with halofantrine"]],"start": [["13"]],"entity_id": [["T2"]],"Drug": {"text": [["halofantrine"]],"start": [["56"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["sudden death"]],"start": [["97"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high" },"Subject": {"text": [["clinical study involving 400 patients"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": {"text": [],"start": [],"entity_id": [] },"Race": null }} ]}
{"id": "10723699_1", "context": "Tetracycline-induced benign intracranial hypertension", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["Tetracycline"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["Tetracycline"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [["benign intracranial hypertension"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []},"Route": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []},"Duration": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []},"Freq": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []},"Dosage": {"text": [["Tetracycline-induced"]], "start": [[],[]], "entity_id": []},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "12889716_2","context": "Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["generalized maculopapular rash"]],"start": [["12889716_2.7"]],"entity_id": [["T1"]]},"Treatment": {"text": [["enoxaparin"]],"start": [["1289716_2.42"]],"entity_id": [["T2"]],"Drug": {"text": [["enoxaparin"]],"start": [["1289716_2.42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["generalized maculopapular rash"]],"start": [["12889716_2.7"]],"entity_id": [["T1"]]},"Freq": {"text": [["Only one case"]],"start": [["12889716_2.0"]],"entity_id": [["T4"]]},"Route": {"text": [["with enoxaparin"]],"start": [["1289716_2.42"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["has been reported"]],"start": [["12889716_2.38"]],"entity_id": [["T6"]]},"Combination": null,"Dosage": null,"Duration": null,"Trigger": {"text": [["generalized maculopapular rash"]],"start": [["12889716_2.7"]],"entity_id": [["T1"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "15331204_7","context": "After 3- to 13-month period of therapy without indapamide, glucose levels of all patients decreased and diabetes disappeared","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["indapamide"]],"start": [["After 3-to-13-month period of therapy without indapamide," , "therapy without indapamide,"] , [ "therapy without indapamide," , "indapamide,"]],"entity_id": [ ]},"Duration": {"text": [["3-to-13-month period"]],"start": [[ "After"]],"entity_id": [ ]},"Trigger": {"text": [["therapy without indapamide"]],"start": [[ "therapy without indapamide,"]],"entity_id": [ ]},"Disorder": {"text": [["diabetes"]],"start": [[ "diabetes" ]],"entity_id": [ ]},"entity_id": [],"text": [["glucose levels"]],"start": [[ "glucose levels" ]],"Freq": {"text": [["decreased"]],"start": [[ "decreased" ]],"entity_id": [ ]},"Dosage": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["3-to-13-month period"]],"start": [[ "After"]],"entity_id": [ ]},"Route": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]},"Combination": [ ]},"Subject": {"text": [["all patients"]],"start": [[ "After 3-to-13-month period of therapy without indapamide,"]],"entity_id": [ ],"Age": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]},"Gender": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["diabetes"]],"start": [[ "diabetes" ]],"entity_id": [ ]},"Population": {"text": [["all patients"]],"start": [[ "After 3-to-13-month period of therapy without indapamide,"]],"entity_id": [ ]},"Race": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]}},"Effect": {"text": [["diabetes disappeared"]],"start": [[ "diabetes disappeared" ]],"entity_id": [ ]},"Severity": {"text": [["none"]],"start": [[ ]],"entity_id": [ ],"value": "Low"},"Negated": {"text": [["none"]],"start": [[ ]],"entity_id": [ ],"value": false},"Speculated": {"text": [["none"]],"start": [[ ]],"entity_id": [ ],"value": false},"Trigger": {"text": [["none"]],"start": [[ ]],"entity_id": [ ]}}]}
{"id": "10679548_4","context": "The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["nitrofurantoin"]],"start": [["36"]],"entity_id": [["T1"]],"Disorder": {"text": [["BOOP"]],"start": [["52"]],"entity_id": [["T2"]]},"Freq": {"text": [["favourable"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["outcome"]],"start": [["17"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["nitrofurantoin"]],"start": [["36"]],"entity_id": [["T1"]]},"Trigger": {"text": [["fatal"]],"start": [["67"]],"entity_id": [["T5"]]},"event_id" : "E2","event_type" : "Adverse_event"}],"Time_elapsed": {"text": [["reported cases"]],"start": [["58"]],"entity_id": [["T6"]]},"Duration": {"text": [["two patients"]],"start": [["12"]],"entity_id": [["T7"]]},"Route" : {"text" : [["induced"]],"start" : [["44"]],"entity_id" : [["T8"]]},"Dosage" : {"text" : [[" "]],"start" : [[""],["44"]],"entity_id" : [["T9"]]},"Drug" : {"text" : [["nitrofurantoin"]],"start" : [["36"]],"entity_id" : [["T10"]]}},"Subject" : {"text" : [["these two patients"]],"start" : [["0"]],"entity_id" : [["T11"]],"Age" : {"text" : [[" "]],"start" : [[""],["0"]],"entity_id" : [["T12"]]},"Disorder" : {"text" : [["favourable outcome"]],"start" : [["0"]],"entity_id" : [["T13"]]},"Gender" : {"text" : [[" "]],"start" : [[""],["0"]],"entity_id" : [["T14"]]},"Population" : {"text" : [["two patients"]],"start" : [["0"]],"entity_id" : [["T15"]]},"Race" : {"text" : [[" "]],"start" : [[""],["0"]],"entity_id" : [["T16"]]}},"Negated" : {"text" : [["not"]],"start" : [["67"]],"entity_id" : [["T17"]],"value" : false},"Speculated" : {"text" : [[" "]],"start" : [[""],["67"]],"entity_id" : [["T18"]],"value" : false},"Severity" : {"text" : [["fatal"]],"start" : [["67"]],"entity_id" : [["T19"]],"value" : "high"},"Effect" : {"text" : [["outcome"]],"start" : [["17"]],"entity_id" : [["T20"]]},"Trigger" : {"text" : [["outcome"]],"start" : [["17"]],"entity_id" : [["T21"]]}}]}
{"id": "12163813_3", "context": "Skin necrosis after extravasation of low-dose vasopressin administered for septic shock", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Skin necrosis"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["low-dose vasopressin administered"]], "start": [[ "32" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["vasopressin"]], "start": [[ "32" ]], "entity_id": [ ["T3"] ]},"Disorder": {"text": [["septic shock"]], "start": [[ "61" ]], "entity_id": [ ["T4"] ]},"Dosage": {"text": [["low-dose"]], "start": [[ "32" ]], "entity_id": [ ["T5"] ]},"Route": {"text": [["administered"]], "start": [[ "42" ]], "entity_id": [ ["T6"] ]},"Time_elapsed": {"text": [["after extravasation"]], "start": [[ "15" ]], "entity_id": [ ["T7"] ]},"Duration": {"text": [[]], "start": [[ "0" ]], "entity_id": [ [] ]},"Freq": {"text": [[]], "start": [[ "0" ]], "entity_id": [ [] ]},"Combination": null ,"Trigger": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "24477376_4","context": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement." ,"is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["initiated on ticagrelor"]],"start": [["34"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ticagrelor"]],"start": [["34"]],"entity_id": [["T2"]],"Disorder": {"text": [["antiplatelet therapy"]],"start": [["45"]],"entity_id": [["T3"]]},"Dosage": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Duration": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Route": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Freq": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Time_elapsed": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Combination": null,"Trigger": {"text": [["previously on phenytoin"]],"start": [["14"]],"entity_id": [["T4"]]},"Drug": {"text": [["phenytoin"]],"start": [["14"]],"entity_id": [["T5"]]}},"Subject": {"text": [["The patient"]],"start": [[""],[]],"entity_id": [["N/A"]],"Age": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Gender": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Population": {"text": [["1 person"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Race": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]},"Disorder": {"text": [["not mentioned"]],"start": [[""],[]],"entity_id": [["N/A"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8239963_1","context": "Clonidine-induced bradycardia in patients with spinal cord injury","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["Clonidine"]],"start": [[ "12" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["Clonidine"]],"start": [[ "12" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["spinal cord injury"]],"start": [[ "55" ]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Dosage": {"text": [["Clonidine"]],"start": [[ "12" ]],"entity_id": [ ["T2"] ]} ,"Route": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Trigger": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Duration": {"text": [["Clonidine-induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Combination": null},"Effect": {"text": [["bradycardia"]],"start": [[ "31" ]],"entity_id": [ ["T4"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11122162_1","context": "MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["MI"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["activated and non-activated PCCs"]],"start": [[ "36" ]],"entity_id": [ ],"Drug": {"text": [["activated PCCs","non-activated PCCs"]],"start": [[ "36" ]],"entity_id": [ ]},"Dosage": {"text": [["large cumulative doses"]],"start": [[ "112" ]],"entity_id": [ ]},"Disorder": {"text": [["history of","risk factors for","MI"]],"start": [[ "56" ]],"entity_id": [ ]},"Freq": {"text": [["predominantly affects"]],"start": [[ "12" ]],"entity_id": [ ]},"Route": {"text": [["use of"]],"start": [[ "27" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["tends to be associated with"]],"start": [[ "82" ]],"entity_id": [ ]},"Trigger": {"text": [["use of"]],"start": [[ "27" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["activated PCCs"]],"start": [[ "36" ]],"entity_id": [ ]},"Trigger": {"text": [["use of"]],"start": [[ "27" ]],"entity_id": [ ]},"event_id": "E1D1T1","event_type": "Adverse_event"},{"Drug": {"text": [["non-activated PCCs"]],"start": [[ "36" ]],"entity_id": [ ]},"Trigger": {"text": [["use of"]],"start": [[ "27" ]],"entity_id": [ ]},"event_id": "E1D2T1","event_type": "Adverse_event"}],"Duration": {"text": [["predominantly affects"]],"start": [[ "12" ]],"entity_id": [ ]}},"Subject": {"text": [["young patients"]],"start": [[ "64" ]],"entity_id": [ ],"Age": {"text": [["young"]],"start": [[ "64" ]],"entity_id": [ ]},"Population": {"text": [["young patients"]],"start": [[ "64" ]],"entity_id": [ ]},"Disorder": {"text": [["history of","risk factors for","MI"]],"start": [[ "56" ]],"entity_id": [ ]},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "9876809_2","context": "To report a probable case of ticlopidine-induced phenytoin toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["ticlopidine"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["phenytoin toxicity"]],"start": [["55"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["induced"]],"start": [["44"]],"entity_id": [["T3"]]} ,"entity_id": [["T1"], ["T2"], ["T3"]] ,"text": [["ticlopidine-induced phenytoin toxicity"]],"start": [["15"]], "Time_elapsed": null,"Dosage": null,"Duration": null,"Route": null,"Freq": null ,"Combination": null },"Effect": null,"Negated": null,"Speculated": {"text": [["probable"]],"start": [["0"]],"entity_id": [["T4"]] ,"value": true },"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "3558331_2", "context": "Two patients are described in whom subtle cognitive impairments are associated with therapeutic doses of amoxapine", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["subtle cognitive impairments"]], "start": [["3558331_2.19"]], "entity_id": []},"Treatment": {"text": [["therapeutic doses of amoxapine"]], "start": [["3558331_2.43"]], "entity_id": [], "Drug": {"text": [["amoxapine"]], "start": [["3558331_2.50"]], "entity_id": []},"Dosage": {"text": [["therapeutic doses"]], "start": [["3558331_2.43"]], "entity_id": []},"Disorder": {"text": [["cognitive impairments"]], "start": [["3558331_2.19"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [["therapeutic doses"]], "start": [["3558331_2.43"]], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": null,"Route": null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "16062101_4","context": "The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ADRs"]],"start": [["56"]],"entity_id": []},"Treatment": {"text": [["lamivudine"]],"start": [["24"]],"entity_id": [],"Drug": {"text": [["lamivudine"]],"start": [["24"]],"entity_id": []} ,"Dosage": {"text": [["widely used"]],"start": [["24"]],"entity_id": []} ,"Route": {"text": [["well tolerated"]],"start": [["36"]],"entity_id": []} ,"Freq": {"text": [["can cause"]],"start": [["48"]],"entity_id": []} ,"Time_elapsed": {"text": [["reversible after drug withdrawal"]],"start": [["62"]],"entity_id": []} ,"Disorder": {"text": [["ADRs"]],"start": [["56"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["lamivudine"]],"start": [["24"]],"entity_id": []},"Trigger": {"text": [["can cause"]],"start": [["48"]],"entity_id": []} ,"event_id": "E1-1" ,"event_type": "Adverse_event" }] ,"Trigger": {"text": [["ADRs"]],"start": [["56"]],"entity_id": []} ,"Duration": {"text": [["reversible after drug withdrawal"]],"start": [["62"]],"entity_id": []} },"Subject": {"text": [["The authors"]],"start": [["0"]],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [["lamivudine is widely used"]],"start": [["24"]],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Effect": {"text": [["ADRs"]],"start": [["56"]],"entity_id": [] }} ]}
{"id": "12915840_2","context": "We report the first case of IHA associated with cefuroxime administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["IHA"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cefuroxime administration"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["cefuroxime"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["IHA"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["associated"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["administration"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Route": {"text": [["administration"]],"start": [["52"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["first case"]],"start": [["5"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["cefuroxime"]],"start": [["52"]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [["52"]],"entity_id": [["T2"]]} ,"event_type": "Adverse_event","event_id": "E1-1"}] ,"Duration": {"text": [["first case"]],"start": [["5"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} } ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} } ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7577414_3","context": "We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["16-year-old male"]],"start": [["0"]],"entity_id": [["Sub1"]],"Age": {"text": [["16"]],"start": [["0"]],"entity_id": [["Age1"]]},"Gender": {"text": [["male"]],"start": [["5"]],"entity_id": [["Gender1"]]} ,"Disorder": {"text": [["nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus"]],"start": [["31"]],"entity_id": [["Disorder1"]]} ,"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["Population1"]]},"Race": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["griseofulvin"]],"start": [["109"]],"entity_id": [["Treatment1"]],"Drug": {"text": [["griseofulvin"]],"start": [["109"]],"entity_id": [["Drug1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Disorder": {"text": [["nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus"]],"start": [["31"]],"entity_id": [["Disorder1"]]} },"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Trigger": {"text": [],"start": [],"entity_id": []} }] }
{"id": "10803790_5", "context": "In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["thin septum-like liver fibrosis progresses"]], "start": [["44"]], "entity_id": []}, "Treatment": {"text": [["cyanamide"]], "start": [["24"]], "entity_id": [],"Drug": {"text": [["cyanamide"]], "start": [["24"]], "entity_id": []},"Duration": {"text": [["several years"]], "start": [["40"]], "entity_id": []},"Disorder": {"text": [["abstainers"]], "start": [["15"]], "entity_id": []} ,"Freq":{"text":[["for several years"]], "start":[["40"]], "entity_id": []} ,"Combination":[{"Drug":{"text":[["cyanamide"]], "start":[[""],["24"]], "entity_id": []},"Trigger":{"text":[["who take"]], "start":[[""],["19"]], "entity_id": []} ,"event_id":"C1" ,"event_type":"Combination"}] ,"Time_elapsed":{"text":[["along with"]], "start":[[""],["51"]], "entity_id": []},"Trigger":{"text":[["the emergence of ground-glass hepatocytes"]], "start":[[""],["61"]], "entity_id": []} ,"Route":{"text":[["along with"]], "start":[[""],["51"]], "entity_id": []} ,"Dosage":{"text":[["who take"]], "start":[[""],["19"]], "entity_id": []} },"Subject":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": [],"Age":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": []},"Gender":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": []},"Population":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": []},"Race":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": []},"Disorder":{"text":[["abstainers"]], "start":[[""],["15"]], "entity_id": []} },"Effect":{"text":[["thin septum-like liver fibrosis progresses"]], "start":[[""],["44"]], "entity_id": []} ,"Negated":{"text":[[]], "start":[[],[]], "entity_id": [],"value":false} ,"Speculated":{"text":[[]], "start":[[],[]], "entity_id": [],"value":false} ,"Severity":{"text":[[]], "start":[[],[]], "entity_id": [],"value":"Low"} }]}
{"id": "1814986_1","context": "Metabolic acidosis induced by acetazolamide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Metabolic acidosis"]],"start": [[ ">0<"]],"entity_id": [ ]},"Treatment": {"text": [["acetazolamide"]],"start": [[ "16<"]],"entity_id": [],"Drug": {"text": [["acetazolamide"]],"start": [[ "16<"]],"entity_id": []} ,"Disorder": {"text": [["Metabolic acidosis"]],"start": [[ "0<"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["induced by"]],"start": [[ "11<"]],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "15359206_2","context": "In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["nimodipine overdosage"]],"start": [["13","14"]],"entity_id": [["T1"]]},"Effect": {"text": [["prolonged hypotension","hypoxemia"]],"start": [["44","55"],["56","65"]],"entity_id": [["T2","T3"]]},"Treatment": {"text": [["calcium gluconate"]],"start": [["96","107"]],"entity_id": [["T4"]],"Drug": {"text": [["calcium gluconate"]],"start": [["96","107"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["which was successfully treated"]],"start": [["66","87"]],"entity_id": [["T5"]]},"Freq": {"text": [["resulting"]],"start": [["36","43"]],"entity_id": [["T6"]]},"Disorder": {"text": [["nimodipine overdosage"]],"start": [["13","14"]],"entity_id": [["T1"]]},"Trigger": {"text": [["overdosage"]],"start": [["13","20"]],"entity_id": [["T1"]]},"Dosage": {"text": [["overdosage"]],"start": [["13","20"]],"entity_id": [["T1"]]},"Route": {"text": [["treated"]],"start": [["88","92"]],"entity_id": [["T5"]]},"Duration": {"text": [["prolonged"]],"start": [["44","50"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["nimodipine","calcium gluconate"]],"start": [["13","20"],["96","107"]],"entity_id": [["T1","T4"]]},"Trigger": {"text": [["overdosage","treated"]],"start": [["13","20"],["88","92"]],"entity_id": [["T1","T5"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["prolonged"]],"start": [["44","50"]],"entity_id": [["T2"]],"value": "medium"},"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["nimodipine overdosage"]],"start": [["13","20"]],"entity_id": [["T1"]]},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "15190230_3","context": "Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["IFN-alpha"]],"start": [["11"]],"entity_id": [["T1"]],"Drug": {"text": [["IFN-alpha"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may be associated with"]],"start": [["0"]],"entity_id": [["T3"]]},"Disorder": {"text": [["a number of neuropsychiatric symptoms"]],"start": [["24"]],"entity_id": [["T4"]]},"Freq": {"text": [["may be associated with"]],"start": [["0"]],"entity_id": [["T3"]]},"Route": {"text": [["Therapy with"]],"start": [["0"]],"entity_id": [["T5"]]},"Duration": {"text": [["Therapy with"]],"start": [["0"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["IFN-alpha"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may be associated with"]],"start": [["0"]],"entity_id": [["T3"]]},"event_type": "Potential_therapeutic_effect","event_id": "E2"},{"Drug": {"text": [["IFN-alpha"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["with"]],"start": [["16"]],"entity_id": [["T6"]]},"event_type": "Potential_therapeutic_effect","event_id": "E3"}],"Time_elapsed": {"text": [["may be associated with"]],"start": [["0"]],"entity_id": [["T3"]]},"Dosage": {"text": [["Therapy with"]],"start": [["0"]],"entity_id": [["T5"]]}},"Effect": {"text": [["neuropsychiatric symptoms"]],"start": [["39"]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["neuropsychiatric symptoms"]],"start": [["39"]],"entity_id": [["T7"]],"value": "Low"},"Subject": null,"Trigger": {"text": [["may be associated with"]],"start": [["0"]],"entity_id": [["T3"]]}}]}
{"id": "18805724_1","context": "The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. ","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["diarrhea"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["leflunomide"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["leflunomide"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["adverse effects"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["consist"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["leflunomide"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["of"]],"start": [["11"]],"entity_id": [["T3"]]},"event_type": "Adverse_event","event_id": "E2"} ] ,"Time_elapsed": {"text": [["consist"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["leflunomide"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["consist"]],"start": [["4"]],"entity_id": [["T2"]]} ,"Route": {"text": [["leflunomide"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["diarrhea"]],"start": [["13"]],"entity_id": [["T1"]]} } , "Effect": {"text": [["nausea"]],"start": [["22"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["main"]],"start": [["5"]],"entity_id": [["T2"]] ,"value": "high"} , "Subject": {"text": [["The"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["adverse effects"]],"start": [["4"]],"entity_id": [["T2"]]}}}]}
{"id": "1445134_3","context": "In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["norethisterone"]],"start": [["36"]],"entity_id": [["T1"]]},"Disorder": {"text": [["gestational diabetes"]],"start": [["11"]],"entity_id": [["T2"]]},"Dosage": {"text": [["prescribed"]],"start": [["36"]],"entity_id": [["T1"]]},"Duration": {"text": [["21 years"]],"start": [["0"]],"entity_id": [["T3"]]},"Freq": {"text": [["32.4% (22 of 69)"]],"start": [["58"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["21 years"]],"start": [["0"]],"entity_id": [["T3"]]},"Route": {"text": [["prescribed"]],"start": [["36"]],"entity_id": [["T1"]]},"Trigger": {"text": [["was prescribed"]],"start": [["36"]],"entity_id": [["T1"]]},"entity_id": [["T1"]],"text": [["norethisterone"]],"start": [["36"]],"Combination": [{"Drug": {"text": [["norethisterone"]],"start": [["36"]],"entity_id": [["T1"]]},"Trigger": {"text": [["was prescribed"]],"start": [["36"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["pregnancies"]],"start": [["18"]],"entity_id": [["T5"]],"Population": {"text": [["22 of 69"]],"start": [["58"]],"entity_id": [["T4"]]},"Age": null,"Gender": null,"Race": null,"Disorder": {"text": [["gestational diabetes"]],"start": [["11"]],"entity_id": [["T2"]]}},"Effect": null,"Trigger": null}]}
{"id": "7668127_3", "context": "To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published", "is_mult_event": false, "annotations": []}
{"id": "16225183_6","context": "We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe case", "nephrotic syndrome"]],"start": [["33", "57"]],"entity_id": [["T1"], ["T2"]]},"Subject": {"text": [["a 28-yr-old male"]],"start": [["7"]],"entity_id": [["T3"]],"Age": {"text": [["28"]],"start": [["10"]],"entity_id": [["T4"]]},"Gender": {"text": [["male"]],"start": [["14"]],"entity_id": [["T5"]]},"Population": {"text": [["a"]],"start": [["7"]],"entity_id": [["T6"]]},"Disorder": {"text": [["relapsing/remitting Multiple Sclerosis (RRMS)" ]],"start": [["83"]],"entity_id": [["T7"]]},"Race": {"text": [["a"]],"start": [["7"]],"entity_id": [["T8"]]}},"Treatment": {"text": [["weekly injections of interferon beta 1a"]],"start": [["104"]],"entity_id": [["T9"]],"Drug": {"text": [["interferon beta 1a"]],"start": [["112"]],"entity_id": [["T10"]]},"Dosage": {"text": [["weekly injections"]],"start": [["104"]],"entity_id": [["T11"]]},"Route": {"text": [["injections"]],"start": [["104"]],"entity_id": [["T12"]]},"Duration": {"text": [["while being treated for relapsing/remitting Multiple Sclerosis (RRMS)" ]],"start": [["83"]],"entity_id": [["T13"]]},"Disorder": {"text": [["relapsing/remitting Multiple Sclerosis (RRMS)" ]],"start": [["83"]],"entity_id": [["T14"]]},"Time_elapsed": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T15"]]},"Freq": {"text": [["weekly injections"]],"start": [["104"]],"entity_id": [["T16"]]},"Combination": [{"Drug": {"text": [["interferon beta 1a"]],"start": [["112"]],"entity_id": [["T10"]]},"Trigger": {"text": [["treatment"]],"start": [["88"]],"entity_id": [["T17"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["treated"]],"start": [["88"]],"entity_id": [["T18"]]}},"Effect": {"text": [["a severe case of nephrotic syndrome"]],"start": [["33"]],"entity_id": [["T19"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["33"]],"entity_id": [["T20"]],"value": "high"}}]}
{"id": "24791374_6","context": "Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Propafenone"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["Propafenone"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Disorder": {"text": [["atrial fibrillation"]],"start": [[ "91" ]],"entity_id": [ ["T2"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["commonly used"]],"start": [[ "39" ]],"entity_id": [ ["T3"] ]} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "9972383_3","context": "Reversible nonthrombocytopenic palpable purpura associated with metoclopramide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["metoclopramide"]],"start": [["46"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["metoclopramide"]],"start": [["46"]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["associated with"]],"start": [["32"]],"entity_id": [["T3"] ]} ,"Freq": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Duration": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Dosage": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Route": {"text": [["associated with"]],"start": [["32"]],"entity_id": [ ["T3"] ]} ,"Combination": null ,"Trigger": {"text": [["associated with"]],"start": [["32"]],"entity_id": [ ["T3"] ]} },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null },"Effect": {"text": [["Reversible nonthrombocytopenic palpable purpura"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Negated": null,"Speculated": null,"Severity": {"text": [["Reversible"]],"start": [["0"]],"entity_id": [ ["T4"] ],"value": "Low" }} ] }
{"id": "2894766_2","context": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["sulfasalazine"]],"start": [["36"]],"entity_id": [["T1"]]},"Disorder": {"text": [["treat patients with inflammatory bowel disease"]],"start": [["16"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use"]],"start": [["24"]],"entity_id": [["T3"]]},"entity_id": [["T1"], ["T2"], ["T3"]],"Time_elapsed": {"text": [["aware"]],"start": [["0"]],"entity_id": [["T4"]]},"Freq": {"text": [["should be aware"]],"start": [["0"]],"entity_id": [["T5"]]},"Route": {"text": [["use"]],"start": [["24"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null,"text": [["Physicians"], ["who"], ["use"], ["sulfasalazine"], ["to"], ["treat"], ["patients"], ["with"], ["inflammatory"], ["bowel"], ["disease"], ["should"], ["be"], ["aware"], ["of"], ["the"], ["signs"], ["of"], ["sulfasalazine-induced"], ["lupus"], ["syndrome"]],"start": [[], [], [], ["36"], [], [], [], ["16"], [], [], [], [], [], [], [], [], [], [], ["80"], ["81"], ["82"], ["83"], ["84"], ["85"], ["86"], ["87"], ["88"], ["89"], ["90"]]},"Effect": {"text": [["signs"]],"start": [["76"]],"entity_id": [["T6"]]},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["aware"]],"start": [["0"]],"entity_id": [["T4"]]}}]}
{"id": "6414095_1","context": "Transient hemiparesis caused by phenytoin toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Transient hemiparesis"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["phenytoin toxicity"]],"start": [[]],"entity_id": [],"Drug": {"text": [["phenytoin"]],"start": [[]],"entity_id": []},"Time_elapsed": null,"Disorder": null,"Combination": null,"Freq": null,"Route": null,"Duration": null,"Dosage": null,"Trigger": null},"Effect": {"text": [["Transient hemiparesis"]],"start": [[]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "16527771_3", "context": "We report a 78-year-old man who had acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute unilateral total visual loss"]], "start": [["36"]], "entity_id": [["T1"]]},"Subject": {"text": [["a 78-year-old man"]],"start": [["10"]],"entity_id": [["T2"]],"Age": {"text": [["78"]], "start": [["11"]], "entity_id": [["T3"]]},"Gender": {"text": [["man"]], "start": [["15"]], "entity_id": [["T4"]]} ,"Disorder": {"text": [["trigeminal neuralgia"]], "start": [["73"]], "entity_id": [["T5"]]} ,"Race": null ,"Population": null },"Treatment": {"text": [["retrogasserian phenol injection"]],"start": [["52"]],"entity_id": [["T6"]],"Drug": null,"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["after"]],"start": [["46"]],"entity_id": [["T7"]] }} ,"Effect": null ,"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["36"]],"entity_id": [["T8"]] ,"value": "High" }} ]}
{"id": "18983414_1","context": "Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tacrolimus"]],"start": [["115"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 51-year-old man"]],"start": [["48"]],"entity_id": [["T2"]],"Age": {"text": [["51"]],"start": [["55"]],"entity_id": [["AgeT1"]]},"Gender": {"text": [["man"]],"start": [["59"]],"entity_id": [["GenderT1"]]},"Population": {"text": [["one"]],"start": [["47"]],"entity_id": [["PopulationT1"]]},"Race": {"text": [["a"]],"start": [["47"]],"entity_id": [["RaceT1"]]},"Disorder": {"text": [["progressive liver failure and severe hepatocellular necrosis"]],"start": [["68"]],"entity_id": [["DisorderT1"]]}},"Treatment": {"text": [["tacrolimus"]],"start": [["115"]],"entity_id": [["T1"]],"Drug": {"text": [["tacrolimus"]],"start": [["115"]],"entity_id": [["DrugT1"]]},"Disorder": {"text": [["orthotopic liver transplant"]],"start": [["24"]],"entity_id": [["DisorderT2"]]},"Time_elapsed": {"text": [["four months after"]],"start": [["0"]],"entity_id": [["Time_elapsedT1"]]},"Route": {"text": [["receiving"]],"start": [["24"]],"entity_id": [["RouteT1"]]},"Dosage": {"text": [["one"]],"start": [["47"]],"entity_id": [["DosageT1"]]},"Duration": {"text": [["four months"]],"start": [["0"]],"entity_id": [["DurationT1"]]},"Freq": {"text": [["one"]],"start": [["47"]],"entity_id": [["FreqT1"]]},"Combination": null,"Trigger": null},"Effect": {"text": [["progressive liver failure and severe hepatocellular necrosis"]],"start": [["68"]],"entity_id": [["EffectT1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["96"]],"entity_id": [["SeverityT1"]],"value": "severe"}}]}
{"id": "10452772_4","context": "Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["protamine hypersensitivity"]],"start": [["59"]],"entity_id": []},"Treatment": {"text": [["neutral protamine Hagedorn (NPH) insulin"]],"start": [["12"]],"entity_id": [],"Drug": {"text": [["neutral protamine Hagedorn"]],"start": [["12"]],"entity_id": []},"Disorder": {"text": [["patients receiving"]],"start": [["0"]],"entity_id": []} ,"Route": {"text": [["receiving"]],"start": [["0"]],"entity_id": []} ,"Time_elapsed": {"text": [["increased risk"]],"start": [["43"]],"entity_id": []},"Duration": {"text": [["development"]],"start": [["50"]],"entity_id": []} ,"Freq": {"text": [["increased risk"]],"start": [["43"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["neutral protamine Hagedorn"]],"start": [["12"]],"entity_id": []},"Trigger": {"text": [["receiving"]],"start": [["0"]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Trigger": {"text": [["protamine hypersensitivity"]],"start": [["59"]],"entity_id": []} ,"Dosage": {"text": [["neutral protamine Hagedorn (NPH) insulin"]],"start": [["12"]],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [["patients receiving"]],"start": [["0"]],"entity_id": [] ,"Population": {"text": [["patients receiving"]],"start": [["0"]],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} }] }
{"id": "8053440_3","context": "The second patient, who developed cholestasis after receiving trimethoprim-sulfamethoxazole, had marked duct paucity in the liver biopsy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["cholestasis"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["63"]],"entity_id": [["T2"]],"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["63"]],"entity_id": [["T2"]]},"Disorder": {"text": [["cholestasis"]],"start": [["33"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after receiving"]],"start": [["20"]],"entity_id": [["T3"]]},"Trigger": null,"Freq": null,"Route": null,"Dosage": null,"Duration": null,"Combination": null},"Subject": {"text": [["The second patient"]],"start": [["0"]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["cholestasis"]],"start": [["33"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "9191742_2","context": "We describe a patient who became hypothyroid while taking ferrous sulfate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypothyroid"]],"start": [["28"]],"entity_id": []},"Treatment": {"text": [["ferrous sulfate"]],"start": [["61"]],"entity_id": [],"Drug": {"text": [["ferrous sulfate"]],"start": [["61"]],"entity_id": []},"Disorder": {"text": [["hypothyroid"]],"start": [["28"]],"entity_id": []},"Time_elapsed": {"text": [["while taking"]],"start": [["40"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16540070_2", "context": "Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Allergy"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["cloxacillin"]], "start": [[ "9"]], "entity_id": [ ["T2"]],"Drug": null,"Disorder": null,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null}, "Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "1642627_2", "context": "Triazolam-induced nocturnal bingeing with amnesia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Triazolam-induced"]], "start": [[ "0" ]], "entity_id": [["T1"] ]}, "Effect": {"text": [["nocturnal bingeing with amnesia"]], "start": [[ "18" ]], "entity_id": [ ["T2" ] ]}, "Treatment": { "text": [], "start": [], "entity_id": [] ,"Drug": { "text": [["Triazolam"]],"start": [[ "0" ]], "entity_id": [ ["T1" ] ]} , "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": null , "Trigger": { "text": [], "start": [], "entity_id": [] } }, "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } } ]}
{"id": "12221670_3","context": "Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ticlopidine-induced aplastic anemia"]],"start": [[ "0" ]] ,"entity_id": [ [ "T1" ]]},"Treatment": {"text": [["Ticlopidine"]],"start": [[ "22" ]],"entity_id": [ [ "T2" ]],"Drug": {"text": [["Ticlopidine"]],"start": [[ "22" ]],"entity_id": [ [ "T3" ]]},"Disorder": {"text": [["aplastic anemia"]],"start": [[ "35" ]],"entity_id": [ [ "T4" ]]},"Freq": {"text": [["considered very uncommon"]],"start": [[ "55" ]],"entity_id": [ [ "T5" ]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["Ticlopidine-induced aplastic anemia"]],"start": [[ "0" ]],"entity_id": [ [ "T1" ]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "14998226_9","context": "One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol, which resulted in an elevated INR","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["interaction"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["simvastatin"]],"start": [["8"]],"entity_id": [["T2"]],"Drug": {"text": [["simvastatin"]],"start": [["8"]],"entity_id": [["T2"]]},"Disorder": {"text": [["anticoagulant acenocoumarol"]],"start": [["23"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["simvastatin"]],"start": [["8"]],"entity_id": [["T2"]]},"Trigger": {"text": [["interaction"]],"start": [["31"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["anticoagulant acenocoumarol"]],"start": [["23"]],"entity_id": [["T3"]]},"Trigger": {"text": [["interaction"]],"start": [["31"]],"entity_id": [["T1"]]},"event_id": "C2","event_type": "Combination"}],"Time_elapsed": {"text": [["which resulted in"]],"start": [["52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["an elevated INR"]],"start": [["68"]],"entity_id": [["T5"]]},"Freq": {"text": [["One case report describes"]],"start": [["0"]],"entity_id": [["T6"]]},"Duration": {"text": [["One case report describes"]],"start": [["0"]],"entity_id": [["T6"]]},"Dosage": {"text": [["One case report describes"]],"start": [["0"]],"entity_id": [["T6"]]},"Route": {"text": [["One case report describes"]],"start": [["0"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["an elevated INR"]],"start": [["68"]],"entity_id": [["T5"]],"value": "High"},"Subject": null,"Effect": {"text": [["an elevated INR"]],"start": [["68"]],"entity_id": [["T5"]]}}]}
{"id": "16884425_1","context": "A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of 5-fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 35-year-old woman"]],"start": [[ "0"]] ,"entity_id": [],"Age": {"text": [["35"]],"start": [[ "5" ]],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[ "22" ]],"entity_id": []},"Disorder": {"text": [["neurotoxicity"]],"start": [[ "16" ]],"entity_id": []},"Population": {"text": [["A 35-year-old woman"]],"start": [[ "0" ]],"entity_id": []},"Race": {"text": [["A 35-year-old woman"]],"start": [[ "0" ]],"entity_id": []}},"Treatment": {"text": [["an i.v. regimen of 5-fluorouracil"]],"start": [[ "52" ]],"entity_id": [],"Drug": {"text": [["5-fluorouracil"]],"start": [[ "61" ]],"entity_id": []},"Disorder": {"text": [["i.v. regimen"]],"start": [[ "52" ]],"entity_id": []},"Route": {"text": [["i.v."]],"start": [[ "52" ]],"entity_id": []},"Dosage": {"text": [["an i.v. regimen"]],"start": [[ "52" ]],"entity_id": []},"Trigger": {"text": [["neurotoxicity"]],"start": [[ "16" ]],"entity_id": []},"Time_elapsed": {"text": [["correlated"]],"start": [[ "33" ]],"entity_id": []},"Freq": {"text": [["an i.v. regimen"]],"start": [[ "52" ]],"entity_id": []},"Duration": {"text": [["an i.v. regimen"]],"start": [[ "52" ]],"entity_id": []},"Combination": null},"Effect": {"text": [["episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum"]],"start": [[ "81" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["neurotoxicity"]],"start": [[ "16" ]],"entity_id": [],"value": "high"},"Trigger": null}]}
{"id": "3947272_2","context": "Ampicillin may aggravate clinical and experimental myasthenia gravis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["myasthenia gravis"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ]},"event_id": "C1" ,"event_type": "Potential_therapeutic_effect"} ],"Time_elapsed": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["Ampicillin"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ]}} ,"Subject": {"text": [["clinical and experimental myasthenia gravis"]],"start": [[ ]],"entity_id": [ ] ,"Disorder": {"text": [["myasthenia gravis"]],"start": [[ ]],"entity_id": [ ]} ,"Population": {"text": [["clinical and experimental"]],"start": [[ ]],"entity_id": [ ]} ,"Race": {"text": [["clinical and experimental"]],"start": [[ ]],"entity_id": [ ]} ,"Gender": {"text": [["clinical and experimental"]],"start": [[ ]],"entity_id": [ ]} ,"Age": {"text": [["clinical and experimental"]],"start": [[ ]],"entity_id": [ ]}} ,"Negated": null,"Speculated": {"text": [["may aggravate"]],"start": [[ ]],"entity_id": [ ],"value": true} ,"Severity": null ,"Effect": {"text": [["clinical and experimental myasthenia gravis"]],"start": [[ ]],"entity_id": [ ]}} ]}
{"id": "8586895_2","context": "In the present paper, we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["prolonged"]],"start": [["39"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with halofantrine"]],"start": [["68"]],"entity_id": [["T2"]],"Drug": {"text": [["halofantrine"]],"start": [["82"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["QT interval"]],"start": [["47"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after"]],"start": [["60"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["whose"]],"start": [["52"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["treatment with halofantrine"]],"start": [["68"]],"entity_id": [["T2"]]} ,"Route": {"text": [["treatment"]],"start": [["57"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["treatment with halofantrine"]],"start": [["68"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["discuss"]],"start": [["1"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["halofantrine"]],"start": [["82"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment with halofantrine"]],"start": [["68"]],"entity_id": [["T2"]]} ,"event_id": "E1-C1" ,"event_type": "Adverse_event"} ]} ,"Subject": {"text": [["the first Japanese vivax malaria patient"]],"start": [["0"]],"entity_id": [["T9"]],"Population": {"text": [["first"]],"start": [["0"]],"entity_id": [["T10"]]},"Disorder": {"text": [["vivax malaria"]],"start": [["12"]],"entity_id": [["T11"]]},"Race": {"text": [["Japanese"]],"start": [["5"]],"entity_id": [["T12"]]} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [["QT interval was prolonged"]],"start": [["47"]],"entity_id": [["T4"]]} }]}
{"id": "3195622_1","context": "A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["dapsone"]],"start": [["69"]],"entity_id": [["T2"]],"Drug": {"text": [["dapsone"]],"start": [["69"]],"entity_id": [["T2"]]},"Disorder": {"text": [["brown recluse spider bite"]],"start": [["101"]],"entity_id": [["T3"]]},"Duration": {"text": [["is presented"]],"start": [["116"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment"]],"start": [["43"]],"entity_id": [["T5"]]},"Route": {"text": [["treated"]],"start": [["55"]],"entity_id": [["T6"]]},"Freq": {"text": [["occurring"]],"start": [["22"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["occurring"]],"start": [["22"]],"entity_id": [["T7"]]},"Dosage": {"text": [["treated"]],"start": [["55"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["dapsone"]],"start": [["69"]],"entity_id": [["T2"]]},"Trigger": {"text": [["treatment"]],"start": [["43"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Combination"}]},"Subject": {"text": [["patient"]],"start": [["15"]],"entity_id": [["T8"]],"Population": {"text": [["case report"]],"start": [["1"]],"entity_id": [["T9"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["brown recluse spider bite"]],"start": [["101"]],"entity_id": [["T3"]]}},"Effect": {"text": [["hypersensitivity syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false}}]}
{"id": "17324248_1", "context": "AIMS: To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["piloerection"]], "start": [["31"]], "entity_id": []}, "Treatment": {"text": [["replacing fluvoxamine maleate with milnacipran hydrochloride"]], "start": [["11","30"]], "entity_id": [],"Drug": {"text": [["fluvoxamine maleate"]], "start": [["11","23"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Combination": [],"Trigger": {"text": [["replacing"]], "start": [["11"]], "entity_id": []}},"Effect": {"text": [["piloerection"]], "start": [["31"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "18171260_4","context": "Serotonin syndrome after concomitant linezolid and meperidine therapy has not been described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": {"value": true,"text": [["has not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Trigger": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["linezolid and meperidine therapy"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["linezolid"]],"start": [[ ]],"entity_id": [["T3"]]},"Dosage": {"text": [["meperidine"]],"start": [[ ]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["linezolid"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [[ ]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["after"]],"start": [[ ]],"entity_id": [["T6"]]},"Freq": {"text": [["concomitant"]],"start": [[ ]],"entity_id": [["T7"]]},"Route": {"text": [["therapy"]],"start": [[ ]],"entity_id": [["T2"]]},"Duration": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Trigger": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [["T1"]]}},"Subject": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]],"Age": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Gender": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Population": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Race": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]},"Disorder": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]]}},"Effect": {"text": [["Serotonin syndrome"]],"start": [[ ]],"entity_id": [["T1"]]},"Severity": {"text": [["not been described"]],"start": [[ ]],"entity_id": [["N1"]],"value": "not_specified"},"Speculated": {"text": [["has not been described"]],"start": [[ ]],"entity_id": [["N1"]],"value": false}}]}
{"id": "23868369_4","context": "She presented to clinic with nausea and anorexia within a few days of addition of ciprofloxacin to her current regimen of medications, which included digoxin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["nausea", "anorexia"]],"start": [[ "12","24" ]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["ciprofloxacin"]],"start": [[ "78" ]],"entity_id": [["T3"]],"Drug": {"text": [["ciprofloxacin"]],"start": [[ "78" ]],"entity_id": [["T4"]]},"Route": {"text": [["addition"]],"start": [[ "53" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["a few days"]],"start": [[ "41" ]],"entity_id": [["T6"]]},"Trigger": {"text": [["addition of ciprofloxacin to her current regimen of medications"]],"start": [[ "53" ]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["She"]],"start": [[ "0" ]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Disorder": null,"Race": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15379082_1", "context": "Disulfiram-induced fulminant hepatic failure in an active duty soldier", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Disulfiram-induced fulminant hepatic failure"]], "start": [[ ]], "entity_id": [ ]}, "Subject": {"text": [["an active duty soldier"]], "start": [[ ]], "entity_id": [ ] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["Disulfiram"]], "start": [[ ]], "entity_id": [ ] , "Drug": {"text": [["Disulfiram"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Disorder": {"text": [["fulminant hepatic failure"]], "start": [[ ]], "entity_id": [ ]}} ,"Negated": null, "Speculated": null, "Severity": {"text": [["fulminant"]], "start": [[ ]], "entity_id": [ ] , "value": "high" } ,"Effect": null}]}
{"id": "8530331_2", "context": "We report six cases of psychosis in patients with akinetic-rigid syndromes who were treated with risperidone", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["We"]], "start": [["Start"]], "entity_id": [["S1"]],"Population": {"text": [["six cases"]], "start": [["Start"]], "entity_id": [["S2"]]},"Disorder": {"text": [["psychosis"]], "start": [["Start"]], "entity_id": [["S3"]]},"Age": { "text": [], "start": [], "entity_id": []},"Gender": { "text": [], "start": [], "entity_id": []},"Race": { "text": [], "start": [], "entity_id": []} },"Treatment": {"text": [["risperidone"]], "start": [["Start"]], "entity_id": [["T1"]], "Drug": {"text": [["risperidone"]], "start": [["Start"]], "entity_id": [["T1"]]},"Dosage": { "text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": { "text": [], "start": [], "entity_id": []},"Time_elapsed": { "text": [], "start": [], "entity_id": []},"Freq": { "text": [], "start": [], "entity_id": []},"Disorder": { "text": [["psychosis"]], "start": [["Start"]], "entity_id": [["S3"]]},"Combination": [],"Trigger": { "text": [], "start": [], "entity_id": []}},"Effect": { "text": [], "start": [], "entity_id": []},"Negated": { "text": [], "start": [], "entity_id": [],"value": false},"Speculated": { "text": [], "start": [], "entity_id": [],"value": false},"Severity": { "text": [], "start": [], "entity_id": [],"value": ""},"Trigger": { "text": [], "start": [], "entity_id": []}}]}
{"id": "12494253_3","context": "Anaphylaxis to cisplatin is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Anaphylaxis"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["cisplatin"]],"start": [["13" ]],"entity_id": [["T2"]],"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": { "text": [["prior treatment"]],"start": [["103" ]],"entity_id": [["T3"]]} ,"Drug": { "text": [["cisplatin"]],"start": [["13" ]],"entity_id": [["T2"]]}},"Effect": {"text": [["life-threatening complication"]],"start": [["41" ]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["life-threatening"]],"start": [["41" ]],"entity_id": [["T4"]],"value": "high"},"Subject": {"text": [["patients"]],"start": [["82" ]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": {"text": [["patients"]],"start": [["82" ]],"entity_id": [["T5"]]},"Race": null,"Disorder": null}}]}
{"id": "17324248_3", "context": "Piloerection induced by replacing fluvoxamine with milnacipran", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Piloerection"]], "start": [["0" ]], "entity_id": [ ["T1" ]]}, "Treatment": { "text": [["replacing fluvoxamine with milnacipran"]], "start": [[ "22" ]], "entity_id": [ ["T2" ]], "Disorder": { "text": [["fluvoxamine"]], "start": [[ "22" ]], "entity_id": [ ["T3" ]] }, "Drug": { "text": [["milnacipran"]], "start": [[ "39" ]], "entity_id": [ ["T4" ]] } ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Combination": null ,"Trigger": { "text": [["replacing"]], "start": [[ "22" ]], "entity_id": [ ["T2" ]] } }, "Effect": { "text": [["Piloerection"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "14601701_2", "context": "Ethambutol is an antimicrobial agent used frequently to treat tuberculosis.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Ethambutol"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]], "Drug": {"text": [["Ethambutol"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Trigger": {"text": [["used frequently"]], "start": [[ "23" ]], "entity_id": [ ["T2" ]]}, "Disorder": {"text": [["tuberculosis"]], "start": [[ "48" ]], "entity_id": [ ["T3" ]]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null } ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "15878975_4","context": "The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti-D IGIV treatment","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["DIC"]],"start": [["41"]],"entity_id": [["T1"]]},"Treatment": {"text": [["anti-D IGIV treatment"]],"start": [["91"]],"entity_id": [["T2"]],"Drug": {"text": [["anti-D"]],"start": [["91"]],"entity_id": [["T3"]]},"Route": {"text": [["treatment"]],"start": [["91"]],"entity_id": [["T2"]]},"Freq": {"text": [["may be"]],"start": [["62"]],"entity_id": [["F1"]]},"Time_elapsed": {"text": [["a rare"]],"start": [["41"]],"entity_id": [["T4"]]},"Disorder": {"text": [["complication"]],"start": [["71"]],"entity_id": [["D1"]]},"Dosage": {"text": [["this review"]],"start": [["0"]],"entity_id": [["R1"]]},"Duration": {"text": [["may be"]],"start": [["62"]],"entity_id": [["F1"]]},"Trigger": null,"Combination": null},"Severity": {"text": [["potentially severe"]],"start": [["77"]],"entity_id": [["S1"]],"value": "potentially severe"},"Subject": null,"Effect": {"text": [["DIC"]],"start": [["41"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null}]}
{"id": "8363533_2","context": "Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["transient episodes of thyrotoxicosis"]],"start": [["36"]],"entity_id": [["T1"]]},"Subject": {"text": [["Four Chinese female patients"]],"start": [["0"]],"entity_id": [["T2"]],"Age": null,"Gender": {"text": [["female"]],"start": [["12"]],"entity_id": [["T3"]]},"Population": {"text": [["Four"]],"start": [["0"]],"entity_id": [["T2"]]},"Race": {"text": [["Chinese"]],"start": [["5"]],"entity_id": [["T2"]]},"Disorder": {"text": [["manic-depressive disorder", "underlying autoimmune thyroiditis"]],"start": [["16","43"]],"entity_id": [["T4","T5"]]}},"Treatment": {"text": [["maintenance lithium therapy"]],"start": [["72"]],"entity_id": [["T6"]],"Drug": {"text": [["lithium"]],"start": [["72"]],"entity_id": [["T7"]]},"Duration": null,"Disorder": {"text": [["manic-depressive disorder"]],"start": [["16"]],"entity_id": [["T4"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Dosage": null,"Trigger": null},"Effect": {"text": [["thyrotoxicosis"]],"start": [["36"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17522786_2", "context": "Neurointensive care management of raised intracranial pressure caused by severe valproic acid intoxication.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["Neurointensive care management"]], "start": [[ ]], "entity_id": []}, "Subject": {"text": [["raised intracranial pressure"]], "start": [[ ]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["severe valproic acid intoxication"]], "start": [[ ]], "entity_id": []}}, "Treatment": {"text": [["Neurointensive care management"]], "start": [[ ]], "entity_id": [],"Drug": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": {"text":[["raised intracranial pressure"]],"start":[[ ]], "entity_id": []}} ,"Effect": null ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "15790469_1", "context": "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["patient"]], "start": [["Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" , "0"]], "entity_id": [["SUB1"]] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["Primary ovarian large B-cell lymphoma"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" ,"0"]], "entity_id": [["DIS1"]]}}, "Treatment": { "text": [["Methotrexate"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" , "80"]], "entity_id": [["TRT1"]], "Drug": { "text": [["Methotrexate"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" , "80"]], "entity_id": [["DRG1"]]}, "Dosage": { "text": [["low dose"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" ,"70"]], "entity_id": [["DSG1"]]}, "Disorder": { "text": [["Primary ovarian large B-cell lymphoma"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" ,"0"]], "entity_id": [["DIS1"]]} , "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null , "Combination": null , "Trigger": { "text": [["treated"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" ,"64"]], "entity_id": [["TRG1"]]}} , "Effect": { "text": [["Primary ovarian large B-cell lymphoma"]], "start": [[ "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate" ,"0"]], "entity_id": [["EFF1"]] }, "Trigger": null}]}
{"id": "1420650_1","context": "Asterixis induced by carbamazepine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Asterixis"]],"start": [[ ]],"entity_id": [ ["T1"] ] }, "Treatment": { "text": [["carbamazepine therapy"]], "start": [[ ]], "entity_id": [ ], "Drug": { "text": [["carbamazepine"]], "start": [[ ]], "entity_id": [ ] } , "Disorder": { "text": [], "start": [], "entity_id": [] } , "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": { "text": [["therapy"]], "start": [[ ]], "entity_id": [] } } , "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } , "Effect": { "text": [["Asterixis"]], "start": [[ ]], "entity_id": [ ] } , "Negated": null, "Speculated": null, "Severity": null } ] }
{"id": "7865488_1", "context": "A case of noncardiogenic pulmonary edema by ethanolamine oleate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noncardiogenic pulmonary edema"]], "start": [["0"]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["ethanolamine oleate"]], "start": [["64"]], "entity_id": [ ["T2"]],"Drug": { "text": [["ethanolamine oleate"]], "start": [["64"]], "entity_id": [ ["T2"]] }, "Dosage": null,"Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [["by"]], "start": [["50"]], "entity_id": [ ["T3"]] }} ,"Subject": { "text": [["A case"]], "start": [[""], ["0"]], "entity_id": [ ["S1"]] ,"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }, "Negated": null,"Speculated": null, "Severity": null ,"Effect": { "text": [["noncardiogenic pulmonary edema"]], "start": [[""], ["0"]], "entity_id": [ ["T1"]] }}]}
{"id": "11737689_1","context": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G-CSF","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["multiple erythematous nodules"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["G-CSF"]],"start": [["92"]],"entity_id": [["T2"]],"Drug": {"text": [["G-CSF"]],"start": [["92"]],"entity_id": [["T3"]]},"Route": {"text": [["administration"]],"start": [["84"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following"]],"start": [["78"]],"entity_id": [["T5"]]},"Disorder": {"text": [["chronic neutropenia and recurrent inflammatory skin lesions"]],"start": [["8"]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["A boy"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["chronic neutropenia and recurrent inflammatory skin lesions"]],"start": [["8"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["developed"]],"start": [["43"]],"entity_id": [["T7"]]}}]}
{"id": "1261772_2", "context": "Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Fulminant hepatitis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[ ]],"entity_id": [["T2"]],"Drug": { "text": [["propylthiouracil"]], "start": [[ ]],"entity_id": [["T3"]]},"Dosage": { "text": [[]], "start": [[ ]],"entity_id": [[]]},"Duration": { "text": [[]], "start": [[ ]],"entity_id": [[]]},"Disorder": { "text": [["Fulminant hepatitis"]], "start": [[ ]],"entity_id": [["T1"]]},"Route": { "text": [[]], "start": [[ ]],"entity_id": [[]]},"Time_elapsed": { "text": [[]], "start": [[ ]],"entity_id": [[]]},"Freq": { "text": [[]], "start": [[ ]],"entity_id": [[]]},"Combination": null ,"Trigger": { "text": [["due to propylthiouracil"]], "start": [[ ]],"entity_id": [["T2"]]}} ,"Effect": { "text": [["Fulminant hepatitis"]], "start": [[ ]],"entity_id": [["T1"]]},"Negated": null ,"Speculated": null ,"Severity": { "text": [[]], "start": [[ ]],"entity_id": [[]],"value": "High" },"Subject": null}]}
{"id": "9754850_5","context": "We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with olanzapine (20-25 mg/d).","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["treatment with olanzapine"]],"start": [["33"]],"entity_id": [["T1"]],"Drug": {"text": [["olanzapine"]],"start": [["33"]],"entity_id": [["T2"]]},"Dosage": {"text": [["20-25 mg/d"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["during treatment"]],"start": [["28"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["acute schizophrenia"]],"start": [["6"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["developed"]],"start": [["39"]],"entity_id": [["T6"]]} ,"Route": {"text": [["treatment"]],"start": [["28"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["during treatment"]],"start": [["28"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["during treatment"]],"start": [["28"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["olanzapine"]],"start": [["33"]],"entity_id": [["T2"]]},"Trigger": {"text": [["developed"]],"start": [["39"]],"entity_id": [["T6"]]} ,"event_id": "E1-1","event_type": "Adverse_event"}]},"Subject": {"text": [["three patients"]],"start": [["6"]],"entity_id": [["T7"]],"Age": {"text": [["acute"]],"start": [["6"]],"entity_id": [["T8"]]},"Disorder": {"text": [["schizophrenia"]],"start": [["15"]],"entity_id": [["T9"]]},"Gender": null,"Population": {"text": [["three patients"]],"start": [["6"]],"entity_id": [["T7"]]},"Race": null},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["42"]],"entity_id": [["T10"]] ,"value": "severe"} ,"Effect": {"text": [["akathisia"]],"start": [["22"]],"entity_id": [["T11"]]} ,"Trigger": {"text": [["developed"]],"start": [["39"]],"entity_id": [["T6"]]}}]}
{"id": "17536204_1","context": "A cause-effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["capecitabine"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["capecitabine withdrawal"]],"start": [["55"]],"entity_id": [["T2"]],"Duration": {"text": [["withdrawal"]],"start": [["55"]],"entity_id": [["T2"]]},"Trigger": {"text": [["withdrawal"]],"start": [["55"]],"entity_id": [["T2"]]},"Freq": {"text": [["rechallenge"]],"start": [["88"]],"entity_id": [["T3"]]},"Route": {"text": [["oral"]],"start": [["28"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["resolution"]],"start": [["40"]],"entity_id": [["T4"]]},"Disorder": {"text": [["headache"]],"start": [["7"]],"entity_id": [["T5"]]},"Drug": {"text": [["capecitabine"]],"start": [["28"]],"entity_id": [["T1"]]},"Dosage": {"text": [["standard"]],"start": [["28"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["capecitabine"]],"start": [["28"]],"entity_id": [["T1"]]},"Trigger": {"text": [["withdrawal"]],"start": [["55"]],"entity_id": [["T2"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["headache"]],"start": [["7"]],"entity_id": [["T5"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7900744_6","context": "This is a report of a case of anuric ARF after high-dose mannitol infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anuric ARF"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["high-dose mannitol infusion"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["mannitol"]],"start": [["56"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment of narrow-angle glaucoma"]],"start": [["71"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after"]],"start": [["41"]],"entity_id": [["T5"]]},"Freq": {"text": [["high-dose"]],"start": [["46"]],"entity_id": [["T6"]]},"Route": {"text": [["infusion"]],"start": [["56"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["mannitol"]],"start": [["56"]],"entity_id": [["T3"]]},"Trigger": {"text": [["infusion"]],"start": [["56"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Therapy"}],"Trigger": {"text": [["treatment"]],"start": [["56"]],"entity_id": [["T8"]]},"Duration": {"text": [["responded to acute hemodialysis"]],"start": [["82"]],"entity_id": [["T9"]]},"Dosage": {"text": [["high-dose"]],"start": [["46"]],"entity_id": [["T6"]]}},"Subject": {"text": [["This"]],"start": [["0"]],"entity_id": [["T10"]],"Disorder": {"text": [["case of anuric ARF"]],"start": [["31"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["anuric ARF"]],"start": [["31"]],"entity_id": [["T1"]]}}]}
{"id": "23673446_6","context": "She was treated with sorafenib at 400 mg daily","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["sorafenib"]],"start": [["18"]],"entity_id": [["T1"]],"Dosage": {"text": [["400 mg"]],"start": [["31"]],"entity_id": [["T2"]]},"Route": {"text": [["daily"]],"start": [["41"]],"entity_id": [["T3"]]} , "Trigger": { "text": [["treated"]], "start": [["10"]], "entity_id": [["T4"]] } ,"Disorder": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []} , "Freq": { "text": [], "start": [], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Combination": null } ,"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] , "value": false },"Speculated": {"text": [],"start": [],"entity_id": [] , "value": false },"Severity": {"text": [],"start": [],"entity_id": [] , "value": "" },"Subject": {"text": [["She"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} ,"Trigger": null } ]}
{"id": "19474653_1","context": "Rhabdomyolysis following clarithromycin monotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Rhabdomyolysis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["clarithromycin monotherapy"]],"start": [[ "21" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["clarithromycin"]],"start": [[ "21" ]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["Rhabdomyolysis"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Route": {"text": [["monotherapy"]],"start": [[ "21" ]],"entity_id": [ ["T2"] ]} ,"Freq": {"text": [["monotherapy"]],"start": [[ "21" ]],"entity_id": [ ["T2"] ]} ,"Duration": {"text": [["monotherapy"]],"start": [[ "21" ]],"entity_id": [ ["T2"] ]} ,"Time_elapsed": {"text": [["following"]],"start": [[ "12" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [["clarithromycin monotherapy"]],"start": [[ "21" ]],"entity_id": [ ["T2"] ]} ,"Combination": null ,"Trigger": null }, "Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "11788010_4","context": "In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["known effect", "alters bile acid composition", "hasten intrahepatic sludge and stone formation"]],"start": [[ "14", "44", "77" ], ["14", "44", "77" ]], "entity_id": [ ["T1", "T2", "T3"] ]}, "Treatment": { "text": [["octreotide"]], "start": [[ "29" ], ["29" ]], "entity_id": [["T4"]], "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null ,"Drug": { "text": [["octreotide"]], "start": [[ "29" ], ["29" ]], "entity_id": [["T4"]] }} ,"Subject": null, "Effect": { "text": [["gallbladder stasis", "intrahepatic sludge and stone formation"]], "start": [[ "52", "96" ], ["52", "96" ]], "entity_id": [["T5", "T6"]] }, "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "16326413_1","context": "A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 hours of an intravenous high-dose methotrexate (5 g/m2) infusion","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute renal failure"]],"start": [["23"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 17-year-old boy with acute lymphoblastic leukemia"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["17"]],"start": [["4"]],"entity_id": [["A1"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["20"]],"entity_id": [["T2"]]},"Population": {"text": [["A 17-year-old boy"]],"start": [["0"]],"entity_id": [["P1"]]},"Race": {"text": [["A 17-year-old boy"]],"start": [["0"]],"entity_id": [["P1"]]},"Gender": {"text": [["A 17-year-old boy"]],"start": [["0"]],"entity_id": [["P1"]]}},"Treatment": {"text": [["an intravenous high-dose methotrexate (5 g/m2) infusion"]],"start": [["73"]],"entity_id": [["T3"]],"Drug": {"text": [["methotrexate"]],"start": [["81"]],"entity_id": [["T4"]]},"Dosage": {"text": [["5 g/m2"]],"start": [["101"]],"entity_id": [["D1"]]},"Route": {"text": [["intravenous"]],"start": [["73"]],"entity_id": [["R1"]]},"Time_elapsed": {"text": [["within 48 hours"]],"start": [["48"]],"entity_id": [["TE1"]]},"Duration": {"text": [["an intravenous high-dose methotrexate (5 g/m2) infusion"]],"start": [["73"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["20"]],"entity_id": [["T2"]]},"Freq": {"text": [["an intravenous high-dose methotrexate (5 g/m2) infusion"]],"start": [["73"]],"entity_id": [["T3"]]},"Combination": null,"Trigger": null},"Effect": {"text": [["acute renal failure"]],"start": [["23"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["23"]],"entity_id": [["S1"]],"value": "High"}}]}
{"id": "2116935_1", "context": "Splenic hemorrhage: a complication of tissue plasminogen activator treatment", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Splenic hemorrhage"]], "start": [[ ]], "entity_id": [ ["T1" ]] }, "Treatment": { "text": [["tissue plasminogen activator treatment"]], "start": [[ ]], "entity_id": [ ["T2" ]], "Drug": { "text": [["tissue plasminogen activator"]], "start": [[ ]], "entity_id": [ ["T3" ]] } , "Disorder": { "text": [["Splenic hemorrhage"]], "start": [[ ]], "entity_id": [ ["T1" ]] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": null } , "Effect": { "text": [], "start": [], "entity_id": [] } , "Negated": null, "Speculated": null, "Severity": null , "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }}]}
{"id": "18648015_2","context": "Cefazolin was a probable cause of this patient's leukopenia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["probable cause"]],"start": [["Cefazolin was a probable cause of this patient's leukopenia" , "Cefazolin was a probable cause of this patient's leukopenia" ]],"entity_id": [ ["T1"], ["T2"] ]},"Treatment": {"text": [["Cefazolin"]],"start": [[ "Cefazolin was a probable cause of this patient's leukopenia" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["Cefazolin"]],"start": [[ "Cefazolin was a probable cause of this patient's leukopenia" ]],"entity_id": [ ["T1"] ]} ,"Disorder": {"text": [["leukopenia"]],"start": [[ "Cefazolin was a probable cause of this patient's leukopenia" ]],"entity_id": [ ["T2"] ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} }, "Effect": {"text": [["leukopenia"]],"start": [[ "Cefazolin was a probable cause of this patient's leukopenia" ]],"entity_id": [ ["T2"] ]} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }, "Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "15533031_1", "context": "Paradoxical cerebral cortical hyperexcitability following flupirtine overdose", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["paradoxical cerebral cortical hyperexcitability", "overdose"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["flupirtine"]], "start": [[]], "entity_id": [],"Drug": {"text": [["flupirtine"]], "start": [[]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Disorder": null,"Trigger": null},"Effect": {"text": [["paradoxical cerebral cortical hyperexcitability"]], "start": [[]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "6245286_1","context": "Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["herpesvirus infection"]],"start": [["21"]],"entity_id": [["T1"]]},"Subject": {"text": [["four leukemic patients"]],"start": [["5"]],"entity_id": [["T2"]],"Disorder": {"text": [["leukemic"]],"start": [["5"]],"entity_id": [["T2"]]},"Age": {"text": [[" "], ["four"]],"start": [[], ["5"]],"entity_id": [["A1"]]},"Population": {"text": [["four"]],"start": [[], ["5"]],"entity_id": [["P1"]]},"Race": {"text": [[" "]],"start": [[], ["5"]],"entity_id": [["R1"]]},"Gender": {"text": [[" "]],"start": [[], ["5"]],"entity_id": [["G1"]]}},"Treatment": {"text": [["large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death"]],"start": [["43"]],"entity_id": [["T3"]],"Drug": {"text": [["cytarabine", "cytosine arabinoside; Ara-C"]],"start": [["43"]],"entity_id": [["T4"]]},"Dosage": {"text": [["large doses"]],"start": [["43"]],"entity_id": [["D1"]]},"Duration": {"text": [[" "]],"start": [[], ["43"]],"entity_id": [["D2"]]},"Disorder": {"text": [["leukemic patients"]],"start": [["5"]],"entity_id": [["T2"]]},"Route": {"text": [[" "]],"start": [[], ["43"]],"entity_id": [["R2"]]},"Time_elapsed": {"text": [["shortly before their death"]],"start": [[], ["43"]],"entity_id": [["T5"]]},"Freq": {"text": [[" "]],"start": [[], ["43"]],"entity_id": [["F1"]]},"Trigger": {"text": [["received"]],"start": [[], ["43"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["cytarabine"]],"start": [[], ["43"]],"entity_id": [["T4"]]},"Trigger": {"text": [["received"]],"start": [[], ["43"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Effect": {"text": [["herpesvirus infection"]],"start": [["21"]],"entity_id": [["T1"]]},"Negated": {"text": [[" "]],"start": [[], ["21"]],"entity_id": [["N1"]],"value": false},"Speculated": {"text": [[" "]],"start": [[], ["21"]],"entity_id": [["S1"]],"value": false},"Severity": {"text": [[" "]],"start": [[], ["21"]],"entity_id": [["S2"]],"value": ""}}]}
{"id": "4004433_1", "context": "Heparin-induced hyperkalemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Heparin-induced hyperkalemia"]], "start": [[]],"entity_id":[["T1"]]},"Treatment":{"text":[],"start":[],"entity_id":[],"Drug":{"text":[["Heparin"]],"start":[[]],"entity_id":[["T2"]]},"Disorder":{"text":[["hyperkalemia"]],"start":[["4"]],"entity_id":[["T3"]]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null,"Trigger":{"text":[],"start":[],"entity_id":[]}},"Subject":{"text":[],"start":[],"entity_id":[],"Age":null,"Disorder":{"text":[],"start":[],"entity_id":[]},"Gender":null,"Population":null,"Race":null},"Negated":null,"Speculated":null,"Severity":{"text":[["high"]],"start":[[]],"entity_id":[["T4"]],"value":"high"},"Effect":{"text":[["Heparin-induced hyperkalemia"]],"start":[[]],"entity_id":[["T1"]]}}]}
{"id": "6608139_1","context": "Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["myelosuppression"]],"start": [[ ], ["0"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [["mild"]],"start": [[],["4"]],"entity_id": [["T2"]]},"Treatment": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]],"Drug": {"text": [["DCF"]],"start": [[],["52"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Freq": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Route": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Dosage": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Duration": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment"]],"start": [[],["47"]],"entity_id": [["T3"]]},"Combination": null},"Effect": {"text": [["immunosuppression"]],"start": [[],["28"]],"entity_id": [["T5"]]},"Severity": null,"Speculated": null,"Subject": {"text": [["myelosuppression"]],"start": [[],["0"]],"entity_id": [["T1"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "8396491_1", "context": "Interference with the cortisol axis by the microtubule antagonist, CPH82", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["Interference with the cortisol axis"]], "start": [[ "0 "]], "entity_id": []}, "Treatment": {"text": [["the microtubule antagonist, CPH82"]], "start": [[ "48 "]], "entity_id": [],"Drug": {"text": [["CPH82"]], "start": [[ "63 "]], "entity_id": []}, "Route": {"text": [["the microtubule antagonist"]], "start": [[ "48 "]], "entity_id": []},"Disorder": {"text": [["the cortisol axis"]], "start": [[ "14 "]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null ,"Trigger": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "9892272_2","context": "Physicians should be aware of the possible association between the use of alteplase and the development of subfascial hemorrhage","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["use of alteplase"]],"start": [["0-14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["alteplase"]],"start": [["15-22"]],"entity_id": [["T2"]],"Drug": {"text": [["alteplase"]],"start": [["15-22"]],"entity_id": [["T2"]]},"Disorder": {"text": [["development of subfascial hemorrhage"]],"start": [["65-87"]],"entity_id": [["T3"]]},"Freq": {"text": [["possible association"]],"start": [["36-53"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["alteplase"]],"start": [["15-22"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use of"]],"start": [["0-4"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["development"]],"start": [["65-71"]],"entity_id": [["T3"]]},"Route": {"text": [["use of"]],"start": [["0-4"]],"entity_id": [["T1"]]},"Duration": {"text": [["possible association"]],"start": [["36-53"]],"entity_id": [["T4"]]},"Dosage": {"text": [["use"]],"start": [["0-4"]],"entity_id": [["T1"]]},"Trigger": {"text": [["use"]],"start": [["0-4"]],"entity_id": [["T1"]]}},"Subject": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]],"Gender": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]]},"Age": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]]},"Population": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]]},"Race": {"text": [["Physicians"]],"start": [["0-8"]],"entity_id": [["T0"]]}},"Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T5"]],"value": false},"Speculated": {"text": [["possible association"]],"start": [["36-53"]],"entity_id": [["T4"]],"value": true},"Severity": {"text": [["development"]],"start": [["65-71"]],"entity_id": [["T3"]],"value": ""},"Effect": {"text": [["development of subfascial hemorrhage"]],"start": [["65-87"]],"entity_id": [["T3"]]}}]}
{"id": "3763264_5","context": "The clinical findings and laboratory studies suggested an autoimmune cell-mediated hypersensitivity reaction triggered by phenobarbital","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["autoimmune cell-mediated hypersensitivity reaction"]],"start": [[ ]],"entity_id": [ [ "T1" ] ]},"Treatment": {"text": [["phenobarbital"]],"start": [[ ]],"entity_id": [ [ "T2" ] ],"Trigger": {"text": [["triggered"]],"start": [[ ]],"entity_id": [ [ "T3" ] ]} ,"Drug": {"text": [["phenobarbital"]],"start": [[ ]],"entity_id": [ [ "T2" ] ]} ,"Disorder": {"text": [["autoimmune cell-mediated hypersensitivity reaction"]],"start": [[ ]],"entity_id": [ [ "T1" ] ]} ,"Time_elapsed": {"text": [["suggested"]],"start": [[ ]],"entity_id": [ [ "T4" ] ]} ,"Freq": {"text": [["triggered"]],"start": [[ ]],"entity_id": [ [ "T3" ] ]} ,"Route": {"text": [["by"]],"start": [[ ]],"entity_id": [ [ "T5" ] ]} ,"Combination": [{"Drug": {"text": [["phenobarbital"]],"start": [[ ]],"entity_id": [ [ "T2" ] ]} ,"Trigger": {"text": [["triggered"]],"start": [[ ]],"entity_id": [ [ "T3" ] ]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ] ,"Duration": {"text": [["clinical findings and laboratory studies"]],"start": [[ ]],"entity_id": [ [ "T6" ] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []}} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["autoimmune cell-mediated hypersensitivity reaction"]],"start": [[ ]],"entity_id": [ [ "T1" ] ]},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [], "value": false},"Severity": {"text": [],"start": [],"entity_id": [], "value": ""}}]}
{"id": "9642842_1", "context": "Anaphylactic reaction to oral prednisone: a case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["oral prednisone"]], "start": [["17", "18"]], "entity_id": [["T2"]], "Population": {"text": [["a case report"]], "start": [["43", "44"]], "entity_id": [["T7"]]}, "Disorder": {"text": [["Anaphylactic reaction"]], "start": [["0"]], "entity_id": [["T1"]]}, "Age": null, "Gender": null, "Race": null},"Trigger": {"text": [["Anaphylactic reaction"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": null,"Effect": null, "Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [["52"]], "entity_id": [["T8"]], "value": "severe"}}]}
{"id": "9634122_2", "context": "Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["prolonged prostate-specific antigen response"]], "start": [[ ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["flutamide withdrawal"]], "start": [[ "]]], " ], [ "entity_id" ], [ "T2" ]] , "Drug": { "text": [["flutamide"]], "start": [[ ]], "entity_id": [ ["T3" ]] } , "Disorder": { "text": [["flutamide withdrawal syndrome"]], "start": [[ ]], "entity_id": [ ["T4" ]] } , "Duration": { "text": [["prolonged"]], "start": [[ ]], "entity_id": [ ["T5" ]] } , "Time_elapsed": { "text": [["withdrawal"]], "start": [[ ]], "entity_id": [ ["T6" ]] } , "Trigger": { "text": [["despite disease progression"]], "start": [[ ]], "entity_id": [ ["T7" ]] } , "Dosage": null, "Route": null, "Freq": null, "Combination": null , "entity_id": [ ["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"], ["T7"] ] } , "Severity": null, "Negated": null, "Speculated": null , "Subject": null , "Effect": null }]}
{"id": "8013261_4", "context": "We report a case of IDDM which occurred during interferon therapy for chronic hepatitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [["23"]], "entity_id": []}, "Treatment": {"text": [["interferon therapy"]], "start": [["8"]], "entity_id": [], "Disorder": {"text": [["chronic hepatitis"]], "start": [["42"]], "entity_id": []},"Drug":{"text":[["interferon"]],"start":[[ "8"]],"entity_id":[]} ,"Route":{"text":[["therapy"]],"start":[[ "8"]],"entity_id":[]} ,"Time_elapsed":{"text":[["during"]],"start":[[ "15"]],"entity_id":[]} ,"Duration":{"text":[["treatment"]],"start":[[ "8"]],"entity_id":[]} ,"Trigger":{"text":[["therapy"]],"start":[[ "8"]],"entity_id":[]} ,"Dosage":{"text":[],"start":[],"entity_id":[]} ,"Freq":{"text":[],"start":[],"entity_id":[]} ,"Combination":null }, "Subject": { "text": [["IDDM"]], "start": [["0"]], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["IDDM"]], "start": [[ "0"]], "entity_id": [] } }, "Effect": { "text": [["occurred"]], "start": [[ "23"]], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "11174414_4","context": "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["this complication"]],"start": [["this complication's indexes in context string"]],"entity_id": [["entity_id_of_this_complication"]]},"Treatment": {"Drug": {"text": [["nevirapine"]],"start": [["nevirapine's indexes in context string"]],"entity_id": [["entity_id_of_nevirapine"]]},"Disorder": {"text": [["SJS"]],"start": [["SJS's indexes in context string"]],"entity_id": [["entity_id_of_SJS"]]},"entity_id": [["entity_id_of_Treatment"]],"text": [["nevirapine-associated SJS"]],"start": [["nevirapine-associated SJS's indexes in context string"]],"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Trigger": null,"Combination": null},"Subject": {"Population": {"text": [["large populations"]],"start": [["large populations' indexes in context string"]],"entity_id": [["entity_id_of_large populations"]]},"Race": null,"Gender": null,"Age": null,"Disorder": {"text": [["patients with HIV"]],"start": [["patients with HIV's indexes in context string"]],"entity_id": [["entity_id_of_patients with HIV"]]},"entity_id": [["entity_id_of_Subject"]],"text": [["physicians treating large populations of patients with HIV"]],"start": [["physicians treating large populations of patients with HIV's indexes in context string"]]},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["this complication"]],"start": [["this complication's indexes in context string"]],"entity_id": [["entity_id_of_this complication"]]}}]}
{"id": "9403220_1","context": "A 35-year-old nephrotic man developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute renal failure"]],"start": [["developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril" ]],"entity_id": [ ]},"Subject": {"text": [["A 35-year-old nephrotic man"]],"start": [["A 35-year-old nephrotic man"]],"entity_id": [],"Age": {"text": [["35"]],"start": [["A 35-year-old nephrotic man"]],"entity_id": []},"Disorder": {"text": [["nephrotic"]],"start": [["A 35-year-old nephrotic man"]],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [["man"]],"start": [["A 35-year-old nephrotic man"]],"entity_id": []} },"Treatment": {"text": [["therapy with enalapril"]],"start": [["developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril"]],"entity_id": [],"Drug": {"text": [["enalapril"]],"start": [["developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high"} }]}
{"id": "7663030_14","context": "Comparable adverse effects, such as disorientation and temporary amnesia, have been reported in patients in the analogous agent, propranolol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["disorientation"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["propranolol"]],"start": [["82"]],"entity_id": [["T2"]]},"entity_id": [["T2"]] ,"text": [["propranolol"]],"start": [["82"]],"Disorder": {"text": [["analogous agent"]],"start": [["65"]],"entity_id": [["T3"]]},"Duration": {"text": [["have been reported"]],"start": [["16"]],"entity_id": [["T4"]]},"Trigger": {"text": [["reported"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["have been reported"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["have been reported"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Route": {"text": [["in patients"]],"start": [["35"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["have been reported"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["propranolol"]],"start": [["82"]],"entity_id": [["T2"]]},"Trigger": {"text": [["reported"]],"start": [["16"]],"entity_id": [["T4"]]} ,"event_id": "E2","event_type": "Adverse_event"}] } ,"Effect": {"text": [["disorientation"]],"start": [["14"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"Age": null,"Disorder": {"text": [["analogous agent"]],"start": [["65"]],"entity_id": [["T3"]]},"Gender": null,"Population": null,"Race": null ,"text": [["Comparable adverse effects", "such as disorientation and temporary amnesia"]],"start": [[], ["14"]],"entity_id": [["T0"], ["T1"]]} }]}
{"id": "18821094_2", "context": "This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a 13-year-old boy"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."], ["0"]], "entity_id": [],"Age": {"text": [["a 13-year-old boy"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."], ["0"]], "entity_id": []},"Gender": {"text": [["boy"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."], ["37"]], "entity_id": []},"Disorder": {"text": [["severe rash and systemic symptoms"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["44"]], "entity_id": []},"Population": {"text": [["a 13-year-old boy"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["0"]], "entity_id": []},"Race": {"text": [["a 13-year-old boy"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["0"]], "entity_id": []}},"Trigger": {"text": [["after starting oxcarbazepine"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["90"]], "entity_id": []},"Effect": {"text": [["severe rash and systemic symptoms"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["44"]], "entity_id": []},"Treatment": {"text": [["oxcarbazepine"]],"start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["83"]],"Drug": {"text": [["oxcarbazepine"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["83"]],"entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["severe rash and systemic symptoms"]], "start": [["This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine."],["44"]], "entity_id": []},"entity_id": [],"Combination": null,"Trigger": null},"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "489527_1","context": "Renal damage associated with long term use of lithium carbonate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Renal damage"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["lithium carbonate"]],"start": [["43"]],"entity_id": [],"Drug": {"text": [["lithium carbonate"]],"start": [["43"]],"entity_id": []},"Duration": {"text": [["long term use"]],"start": [["21"]],"entity_id": []},"Disorder": {"text": [["Renal damage"]],"start": [["0"]],"entity_id": []},"Freq": {"text": [["long term use"]],"start": [["21"]],"entity_id": []},"Time_elapsed": {"text": [["long term use"]],"start": [["21"]],"entity_id": []},"Dosage": {"text": [["lithium carbonate"]],"start": [["43"]],"entity_id": []},"Route": {"text": [["lithium carbonate"]],"start": [["43"]],"entity_id": []},"Combination": [{"Drug": {"text": [["lithium carbonate"]],"start": [["43"]],"entity_id": []},"Trigger": {"text": [["long term use"]],"start": [["21"]],"entity_id": []},"event_type": "Therapy","event_id": "C1"}],"Trigger": {"text": [["long term use"]],"start": [["21"]],"entity_id": []}},"Effect": {"text": [["Renal damage"]],"start": [["0"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["Renal damage"]],"start": [["0"]],"entity_id": [],"value": "High"},"Subject": null}]}
{"id": "20456080_1","context": "Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Triamcinolone acetonide induced"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["coadministration of nefazodone"]],"start": [[ "66" ]],"entity_id": [ ["T3"] ],"Drug": {"text": [["nefazodone"]],"start": [[ "83" ]],"entity_id": [ ["T4"] ]} ,"Dosage": null,"Duration": null,"Disorder": {"text": [["secondary adrenal insufficiency"]],"start": [[ "19" ]],"entity_id": [ ["T2"] ]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["impaired CYP3A4 metabolism"]],"start": [[ "42" ]],"entity_id": [ ["T5"] ]}},"Effect": {"text": [["Triamcinolone acetonide induced secondary adrenal insufficiency"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "16044093_1", "context": "Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Hepatocellular damage"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["therapeutic intravenous iron sucrose infusion"]], "start": [[ ]], "entity_id": [["T2"]], "Drug": {"text": [["iron sucrose"]], "start": [[ ]], "entity_id": [["T3"]] },"Route": {"text": [["intravenous"]], "start": [[ ]], "entity_id": [["T4"]]},"Disorder":{"text":[["Hepatocellular damage"]],"start":[[ ]],"entity_id":[["T1"]]},"Time_elapsed":{"text":[["following"]],"start":[[ ]],"entity_id":[["T5"]]},"Freq":{"text":[["therapeutic"]],"start":[[ ]],"entity_id":[["T2"]]},"Combination":[{"Drug":{"text":[["iron sucrose"]],"start":[[ ]],"entity_id":[["T3"]]},"Trigger":{"text":[["infusion"]],"start":[[ ]],"entity_id":[["T4"]]}, "event_id": "C1","event_type":"null"}],"Trigger":{"text":[["infusion"]],"start":[[ ]],"entity_id":[["T4"]]}, "Dosage":{"text":[["therapeutic"]],"start":[[ ]],"entity_id":[["T2"]]}, "Duration":{"text":[["null"]],"start":[[ ]],"entity_id":[["T6"]]} },"Subject":{"text":[["a child"]],"start":[[ ]],"entity_id":[["T7"]],"Age":{"text":[["null"]],"start":[[ ]],"entity_id":[["T8"]]},"Gender":{"text":[["null"]],"start":[[ ]],"entity_id":[["T9"]]},"Population":{"text":[["null"]],"start":[[ ]],"entity_id":[["T10"]]},"Race":{"text":[["null"]],"start":[[ ]],"entity_id":[["T11"]]},"Disorder":{"text":[["null"]],"start":[[ ]],"entity_id":[["T12"]]} }, "Negated":{"text":[["null"]],"start":[[ ]],"entity_id":[["T13"]],"value":false}, "Speculated":{"text":[["null"]],"start":[[ ]],"entity_id":[["T14"]],"value":false}, "Severity":{"text":[["Hepatocellular damage"]],"start":[[ ]],"entity_id":[["T1"]],"value":"High" } , "Effect":{"text":[["Hepatocellular damage"]],"start":[[ ]],"entity_id":[["T1"]]} }]}
{"id": "14641354_2","context": "We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sore throat"]],"start": [[ "17"]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["budesonide spray (Budefat)"]],"start": [["66"]],"entity_id": [["T3"]],"Drug": {"text": [["budesonide"]],"start": [["66"]],"entity_id": [["T4"]]},"Dosage": {"text": [["spray"]],"start": [["66"]],"entity_id": [["T3"]]},"Route": {"text": [["spray"]],"start": [["66"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment of bronchial asthma"]],"start": [["105"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["2 weeks after"]],"start": [["49"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use"]],"start": [["49"]],"entity_id": [["T2"]]},"Freq": {"text": [["after"]],"start": [["49"]],"entity_id": [["T2"]]},"Combination": null,"Duration": null},"Effect": {"text": [["sore throat"]],"start": [["17"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 43-year-old woman"]],"start": [["10"]],"entity_id": [["T0"]],"Age": {"text": [["43"]],"start": [["10"]],"entity_id": [["T0"]]},"Gender": {"text": [["woman"]],"start": [["14"]],"entity_id": [["T0"]]},"Population": null,"Race": null,"Disorder": {"text": [["bronchial asthma"]],"start": [["105"]],"entity_id": [["T5"]]}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "3997294_2","context": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["amiodarone pneumonitis"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["amiodarone"]],"start": [["56"]],"entity_id": [["T2"]]},"Disorder": {"text": [["amiodarone pneumonitis"]],"start": [["14"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["immediate withdrawal"]],"start": [["32"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["steroid"]],"start": [["63"]],"entity_id": [["T4"]]},"Trigger": {"text": [["prompt but continued"]],"start": [["46"]],"entity_id": [["T5"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["early diagnosis"]],"start": [["8"]],"entity_id": [["T6"]]},"entity_id": [["T1"]],"text": [["amiodarone pneumonitis"]],"start": [["14"]],"Dosage": {"text": [["prompt but continued"]],"start": [["46"]],"entity_id": [["T5"]]},"Duration": {"text": [["full recovery"]],"start": [["82"]],"entity_id": [["T7"]]},"Freq": {"text": [["prompt"]],"start": [["46"]],"entity_id": [["T5"]]},"Route": {"text": [["withdrawal"]],"start": [["32"]],"entity_id": [["T3"]]}},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "High","text": [],"start": [],"entity_id": []},"Subject": {"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": []},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "12503933_2","context": "A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["interaction between clarithromycin and isradipine"]],"start": [["17"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"Drug": {"text": [["clarithromycin"]],"start": [["17"]],"entity_id": [["T1"]]},"Trigger": {"text": [["interaction between clarithromycin and isradipine"]],"start": [["17"]],"entity_id": [["T1"],["T2"]]},"Disorder": {"text": [["increasing the hepatic toxicity"]],"start": [["63"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [["17"]],"entity_id": [["T1"]]},"Trigger": {"text": [["interaction between clarithromycin and isradipine"]],"start": [["17"]],"entity_id": [["T1"],["T2"]]},"event_id": "C1","event_type": "Combination"},{"Drug": {"text": [["isradipine"]],"start": [["26"]],"entity_id": [["T2"]]},"Trigger": {"text": [["interaction between clarithromycin and isradipine"]],"start": [["17"]],"entity_id": [["T1"],["T2"]]},"event_id": "C2","event_type": "Combination"}],"entity_id": [["T1"],["T2"],["T3"]],"text": [["interaction between clarithromycin and isradipine"], ["increasing the hepatic toxicity"]],"start": [["17"], ["63"]]},"Effect": null,"Negated": null,"Speculated": {"text": [["potentially"]],"start": [["48"]],"entity_id": [["T4"]],"value": true},"Severity": null,"Subject": null}]}
{"id": "1584367_3","context": "We report two cases of cerebrospinal fluid eosinophilia (CSFE) secondary to the intraventricular administration of vancomycin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cerebrospinal fluid eosinophilia"]],"start": [["CSFE's position in the text"]],"entity_id": [["ID for cerebrospinal fluid eosinophilia"]]},"Treatment": {"text": [["the intraventricular administration of vancomycin"]],"start": [[";the intraventricular administration of vancomycin's position in the text"]],"entity_id": [["ID for the intraventricular administration of vancomycin"]],"Drug": {"text": [["vancomycin"]],"start": [[";vancomycin's position in the text"]],"entity_id": [["ID for vancomycin"]]},"Combination": [{"Drug": {"text": [["vancomycin"]],"start": [[";vancomycin's position in the text"]],"entity_id": [["ID for vancomycin"]]},"Trigger": {"text": [["the intraventricular administration"]],"start": [[";the intraventricular administration's position in the text"]],"entity_id": [["ID for the intraventricular administration"]]},"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [["CSFE"]],"start": [["CSFE's position in the text"]],"entity_id": [["ID for cerebrospinal fluid eosinophilia"]]},"Freq": {"text": [["two cases"]],"start": [[";two cases' position in the text"]],"entity_id": [["ID for two cases"]]},"Time_elapsed": {"text": [["secondary"]],"start": [["secondary's position in the text"]],"entity_id": [["ID for secondary"]]},"Route": {"text": [["intraventricular administration"]],"start": [["intraventricular administration's position in the text"]],"entity_id": [["ID for the intraventricular administration"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Trigger": {"text": [["cerebrospinal fluid eosinophilia"]],"start": [["CSFE's position in the text"]],"entity_id": [["ID for cerebrospinal fluid eosinophilia"]]}},"Subject": {"text": [["We"]],"start": [["We's position in the text"]],"entity_id": [["ID for We"]],"Age": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Population": {"text": [["We"]],"start": [["We's position in the text"]],"entity_id": [["ID for We"]]},"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Disorder": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]}},"Negated": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": false},"Speculated": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": false},"Severity": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": ""},"Effect": {"text": [["report"]],"start": [["report's position in the text"]],"entity_id": [["ID for report"]]}}]}
{"id": "19857154_4","context": "We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir-boosted atazanavir","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serious quetiapine adverse effects"]],"start": [["16"]],"entity_id": [["T1"]]},"Subject": {"text": [["two patients"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["quetiapine"]],"start": [["5"]],"entity_id": [["T2"]],"Drug": {"text": [["quetiapine"]],"start": [["5"]],"entity_id": [["T2"]]},"Disorder": null,"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": null,"Combination": [{"Drug": {"text": [["ritonavir-boosted atazanavir"]],"start": [["45"]],"entity_id": [["T3"]]},"Trigger": null,"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Negated": null,"Speculated": null,"Severity": {"text": [["serious"]],"start": [["5"]],"entity_id": [["V1"]],"value": "serious"},"Effect": null}]}
{"id": "11020127_4","context": "The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["carbamazepine toxicity"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ritonavir"]],"start": [["74"]],"entity_id": [["T2"]],"Trigger": {"text": [["introduction"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Drug": {"text": [["carbamazepine"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["related"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["carbamazepine toxicity"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["introduction"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["related"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["related"]],"start": [["42"]],"entity_id": [["T4"]]} ,"Route": {"text": [["introduction"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Combination": null},"Subject": {"text": [["The patient"]],"start": [["0"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["carbamazepine toxicity"]],"start": [["16"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["carbamazepine toxicity"]],"start": [["16"]],"entity_id": [["T1"]],"value": "Medium"} ,"Effect": {"text": [["diagnosed"]],"start": [["8"]],"entity_id": [["T6"]]}}]}
{"id": "10458196_1","context": "A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lethargic", "poorly responsive"]],"start": [["18", "41"]],"entity_id": [["T1", "T2"]]},"Subject": {"text": [["A 5-month-old infant"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["5-month-old"]],"start": [["0"]],"entity_id": [["A1"]]},"Disorder": {"text": [["lethargic", "poorly responsive"]],"start": [["18", "41"]],"entity_id": [["T1", "T2"]]},"Gender": {"text": [["infant"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["infant"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["infant"]],"start": [["0"]],"entity_id": [["T0"]]}},"Treatment": {"text": [["brimonidine"]],"start": [["93"]],"entity_id": [["T3"]],"Drug": {"text": [["brimonidine"]],"start": [["93"]],"entity_id": [["T3"]]},"Dosage": {"text": [["1 drop"]],"start": [["75"]],"entity_id": [["D1"]]},"Route": {"text": [["in each eye"]],"start": [["86"]],"entity_id": [["R1"]]},"Time_elapsed": {"text": [["after receiving"]],"start": [["59"]],"entity_id": [["T4"]]},"Trigger": {"text": [["receiving"]],"start": [["59"]],"entity_id": [["T4"]]},"Disorder": {"text": [["lethargic", "poorly responsive"]],"start": [["18", "41"]],"entity_id": [["T1", "T2"]]},"Duration": {"text": [["5-month-old"]],"start": [["0"]],"entity_id": [["A1"]]},"Freq": {"text": [["1 drop"]],"start": [["75"]],"entity_id": [["D1"]]},"Combination": null},"Negated": null,"Speculated": null,"Severity": {"text": [["lethargic", "poorly responsive"]],"start": [["18", "41"]],"entity_id": [["T1", "T2"]],"value": "High"},"Effect": {"text": [["lethargic", "poorly responsive"]],"start": [["18", "41"]],"entity_id": [["T1", "T2"]]}}]}
{"id": "489527_2", "context": "The authors report 2 cases of renal damage associated with lithium carbonate treatment", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["The authors"]], "start": [[ "0" ]], "entity_id": [ ] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }, "Treatment": {"text": [["lithium carbonate treatment"]], "start": [[ "54" ]], "entity_id": [ ] ,"Drug": {"text": [["lithium carbonate"]], "start": [[ "54" ]], "entity_id": [ ] },"Disorder": {"text": [["renal damage"]], "start": [[ "17" ]], "entity_id": [ ] },"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Combination": null ,"Trigger": {"text": [["renal damage"]], "start": [[ "17" ]], "entity_id": [ ] }} ,"Effect": {"text": [["renal damage"]], "start": [[ "17" ]], "entity_id": [ ] },"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger" : { "text" : [["lithium carbonate treatment"]], "start" : [[ "54" ]], "entity_id" : [] }} ]}
{"id": "10650865_1","context": "Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["continuous infusion of F VIII"]],"start": [["36"]],"entity_id": [["T1"]],"Disorder": {"text": [["haemophilia A and F V G1691A mutation"]],"start": [["13"]],"entity_id": [["T2"]]},"Trigger": {"text": [["during"]],"start": [["28"]],"entity_id": [["T3"]]},"Route": {"text": [["infusion"]],"start": [["36"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after intramural jejunal bleeding"]],"start": [["52"]],"entity_id": [["T5"]]},"Freq": {"text": [["continuous"]],"start": [["36"]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["under heparin therapy"]],"start": [["101"]],"entity_id": [["T7"]]},"event_type": "Potential_therapeutic_effect","event_id": "E2"}],"Drug": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Portal vein thrombosis"]],"start": [["0"]],"entity_id": [["T8"]]},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["haemophilia A and F V G1691A mutation"]],"start": [["13"]],"entity_id": [["T9"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [["after"]],"start": [["50"]],"entity_id": [["T10"]]}}]}
{"id": "6093724_1","context": "A healthy, 30-year-old man, exposed to sulindac on two separate occasions, had an incapacitating isolated identical sensory neuropathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["incapacitating isolated identical sensory neuropathy"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"Drug": {"text": [["sulindac"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["exposed"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [["two separate occasions"]],"start": [[ ]],"entity_id": [ ]},"entity_id": [ ],"text": [["A healthy, 30-year-old man"]],"start": [[ ]],"Route": {"text": [["exposed"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["incapacitating isolated identical sensory neuropathy"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["two separate occasions"]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["exposed"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["exposed"]],"start": [[ ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["sulindac"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["exposed"]],"start": [[ ]],"entity_id": [ ]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["A healthy, 30-year-old man"]],"start": [[ ]],"Age": {"text": [["30"]],"start": [[ ]],"entity_id": [ ]},"Gender": {"text": [["man"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["healthy"]],"start": [[ ]],"entity_id": [ ]},"entity_id": [ ],"Race": {"text": [["A healthy, 30-year-old man"]],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [["A healthy, 30-year-old man"]],"start": [[ ]],"entity_id": [ ]}},"Negated": null,"Speculated": null,"Severity": {"text": [["incapacitating"]],"start": [[ ]],"entity_id": [ ],"value": "high"},"Effect": {"text": [["incapacitating isolated identical sensory neuropathy"]],"start": [[ ]],"entity_id": [ ]}}]}
{"id": "7439122_1","context": "Clofibrate-induced myopathy in patients with diabetes insipidus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Clofibrate-induced myopathy"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": {"text": [["Clofibrate"]],"start": [[ "0" ]],"entity_id": [ ["T2" ]],"Drug": {"text": [["Clofibrate"]],"start": [[ "0" ]],"entity_id": [ ["T2" ]]} ,"Dosage": null,"Duration": null,"Disorder": {"text": [["diabetes insipidus"]],"start": [[ "33" ]],"entity_id": [ ["T3" ]]} ,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null },"Subject": {"text": [["patients"]],"start": [[ "14" ]],"entity_id": [ ["T4" ]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["diabetes insipidus"]],"start": [[ "33" ]],"entity_id": [ ["T3" ]]} },"Effect": {"text": [["myopathy"]],"start": [[ "15" ]],"entity_id": [ ["T5" ]]} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "17473493_2","context": "This is the first histologically confirmed case of NASH that was aggravated by raloxifene","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["aggravated"]],"start": [["28"]],"entity_id": []},"Treatment": {"text": [["raloxifene"]],"start": [["58"]],"entity_id": [],"Drug": {"text": [["raloxifene"]],"start": [["58"]],"entity_id": []} ,"Disorder": {"text": [["NASH"]],"start": [["18"]],"entity_id": []} ,"Time_elapsed": {"text": [["This is the first histologically confirmed case"]],"start": [["0"]],"entity_id": []} ,"Freq": {"text": [["first"]],"start": [["0"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["raloxifene"]],"start": [["58"]],"entity_id": []} ,"Trigger": {"text": [["aggravated"]],"start": [["28"]],"entity_id": []} ,"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["aggravated"]],"start": [["28"]],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["NASH"]],"start": [["18"]],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "9545161_5","context": "To date, eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["TEN"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lamotrigine administration"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["lamotrigine"]],"start": [["56"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["TEN"]],"start": [["19"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}},{"event_id": "E2","event_type": "Adverse_event","Trigger": {"text": [["SJS"]],"start": [["71"]],"entity_id": [["T4"]]},"Treatment": {"text": [["lamotrigine administration"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["lamotrigine"]],"start": [["56"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["SJS"]],"start": [["71"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}}]}
{"id": "11207969_1","context": "ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["dermatologic toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ARA-C"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["ARA-C"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["frequently"]],"start": [["11"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["ARA-C"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["toxic epidermal necrolysis"]],"start": [["50"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["this"]],"start": [["49"]],"entity_id": [["T4"]]},"Dosage": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Duration": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Route": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Time_elapsed": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Disorder": {"text": [[]],"start": [[""], []],"entity_id": [[], []]}},"Subject": {"text": [[]],"start": [[""], []],"entity_id": [[], []],"Age": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Gender": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Population": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Race": {"text": [[]],"start": [[""], []],"entity_id": [[], []]},"Disorder": {"text": [[], []],"start": [[], []],"entity_id": [[], []]}},"Effect": {"text": [["toxic epidermal necrolysis"]],"start": [["50"]],"entity_id": [["T3"]]},"Negated": {"text": [[]],"start": [[""], []],"entity_id": [[], []],"value": false},"Speculated": {"text": [[]],"start": [[""], []],"entity_id": [[], []],"value": false},"Severity": {"text": [[], []],"start": [[], []],"entity_id": [[], []],"value": ""}}]}
{"id": "15977922_1","context": "Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["occurrence"]],"start": [["52"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["tegaserod"]],"start": [["83"]],"entity_id": [ ["T2"]],"Disorder": {"text": [["ischemic colitis"]],"start": [["13"]],"entity_id": [ ["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Drug": null },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null }]}
{"id": "9494448_2", "context": "Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Anaphylaxis"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["intravenous cyclosporine"]], "start": [["14"]], "entity_id": [], "Drug": {"text": [["cyclosporine"]], "start": [["14"]], "entity_id": [] } ,"Route": {"text": [["intravenous"]], "start": [[ "14" ]], "entity_id": []} ,"Trigger": {"text": [["Anaphylaxis"]], "start": [[ "0" ]], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Combination": null,"Disorder": null}, "Effect": null, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "10808214_1","context": "A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sudden cutaneous reaction"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["tacrolimus"]],"start": [["35"]],"entity_id": [["T2"]],"Drug": {"text": [["tacrolimus"]],"start": [["35"]],"entity_id": [["T2"]]},"Disorder": {"text": [["an allergy to a macrolide antibiotic"]],"start": [["10"]],"entity_id": [["T3"]]},"Trigger": {"text": [["given"]],"start": [["29"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["developed"]],"start": [["47"]],"entity_id": [["T5"]]},"Dosage": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Freq": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Route": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": null},"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [["T6"]],"Age": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Gender": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Population": {"text": [["1"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Race": {"text": [["null"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Disorder": {"text": [["an allergy to a macrolide antibiotic"]],"start": [["10"]],"entity_id": [["T3"]]}},"Effect": {"text": [["a sudden cutaneous reaction"]],"start": [["52"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9240497_2","context": "This case suggests the importance of careful observation for extramedullary relapse in patients who are treated with ATRA","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["ATRA"]],"start": [["82"]],"entity_id": [["T1"]]},"text": [["treated with ATRA"]],"start": [["62"]],"entity_id": [["T2"]],"Trigger": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["relapse"]],"start": [["33"]],"entity_id": [["T4"]]},"Disorder": {"text": [["extramedullary relapse"]],"start": [["33"]],"entity_id": [["T5"]]},"Freq": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["ATRA"]],"start": [["82"]],"entity_id": [["T1"]]},"Trigger": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Adverse_event"}],"Duration": {"text": [["treated with ATRA"]],"start": [["62"]],"entity_id": [["T2"]]},"Route": {"text": [["treated with ATRA"]],"start": [["62"]],"entity_id": [["T2"]]},"Dosage": {"text": [["treated with ATRA"]],"start": [["62"]],"entity_id": [["T2"]]}},"Subject": {"text": [["patients"]],"start": [["94"]],"entity_id": [["T6"]],"Population": {"text": [["patients"]],"start": [["94"]],"entity_id": [["T6"]]},"Age": {"text": [["patients"]],"start": [["94"]],"entity_id": [["T6"]]},"Gender": {"text": [["patients"]],"start": [["94"]],"entity_id": [["T6"]]},"Race": {"text": [["patients"]],"start": [["94"]],"entity_id": [["T6"]]},"Disorder": {"text": [["patients who are treated with ATRA"]],"start": [["62"]],"entity_id": [["T2"]]}},"Negated": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]],"value": false},"Speculated": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]],"value": false},"Severity": {"text": [["relapse"]],"start": [["33"]],"entity_id": [["T4"]],"value": "low"},"Effect": {"text": [["relapse"]],"start": [["33"]],"entity_id": [["T4"]]},"Trigger": {"text": [["careful observation"]],"start": [["15"]],"entity_id": [["T3"]]}}]}
{"id": "16863495_1", "context": "Olanzapine-associated neuroleptic malignant syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["neuroleptic malignant syndrome"]], "start": [["18"]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["Olanzapine"]], "start": [ ["0"]], "entity_id": [ ["T2"]], "Drug": {"text": [["Olanzapine"]], "start": [ ["0"]], "entity_id": [ ["T2"]]}, "Disorder": {"text": [["neuroleptic malignant syndrome"]], "start": [["18"]], "entity_id": [ ["T1"]]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "16062101_1", "context": "Acute dystonia induced by lamivudine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Acute dystonia"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Treatment": {"text": [["lamivudine"]], "start": [[ "43" ]], "entity_id": [ ["T2" ] ], "Drug": { "text": [["lamivudine"]], "start": [[ "43" ]], "entity_id": [ ["T2" ] ] }, "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null} , "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "12792223_4","context": "We report in detail an unusual adverse reaction to infliximab therapy, a drug-induced lupus-like clinical syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["unusual adverse reaction"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["infliximab therapy"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["infliximab"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["drug-induced lupus-like clinical syndrome"]],"start": [["73"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "11180704_1","context": "Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["acarbose"]],"start": [["13"]],"entity_id": [["T1"]]},"entity_id": [["T1"]],"text": [["oral intake and acarbose"]],"start": [["0"]],"Duration": {"text": [["2 days"]],"start": [["50"]],"entity_id": [["T3"]]},"Trigger": {"text": [["withheld"]],"start": [["21"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["after 2 days"]],"start": [["47"]],"entity_id": [["T3"]]},"Disorder": {"text": [["ileus"]],"start": [["33"]],"entity_id": [["T4"]]},"Freq": {"text": [["spontaneously resolved"]],"start": [["33"]],"entity_id": [["T4"]]},"Dosage": {"text": [["oral intake"]],"start": [["0"]],"entity_id": [["T1"]]},"Route": {"text": [["oral intake"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [["spontaneously resolved"]],"start": [["33"]],"entity_id": [["T4"]]}}]}
{"id": "8260059_2","context": "No explanation for this delay was found, other than the possibility that magnesium sulfate treatment impeded lactogenesis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["magnesium sulfate treatment"]],"start": [["32"]],"entity_id": [["T1"]] ,"Drug": {"text": [["magnesium sulfate"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["impeded lactogenesis"]],"start": [["61"]],"entity_id": [["T3"]] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": null,"Negated": null,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": true },"Severity": null,"Subject": {"text": [["this delay"]],"start": [["0"]],"entity_id": [["T4"]] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null },"Trigger": null }]}
{"id": "9205466_1","context": "Although its side effects are few, tamoxifen increases the incidence of proliferative lesions of the endometrium, which theoretically should be preventable with progestational agents","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["tamoxifen"]],"start": [["16"]],"entity_id": [["T1"]] ,"Drug": {"text": [["tamoxifen"]],"start": [["16"]],"entity_id": [["T2"]] },"Disorder": {"text": [["proliferative lesions of the endometrium"]],"start": [["54"]],"entity_id": [["T3"]] },"Dosage": {"text": [["few"]],"start": [["9"]],"entity_id": [["T4"]] },"Freq": {"text": [["increases"]],"start": [["42"]],"entity_id": [["T5"]] },"Route": {"text": [["with"]],"start": [["86"]],"entity_id": [["T6"]] },"Trigger": {"text": [["side effects"]],"start": [["11"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["theoretically"]],"start": [["91"]],"entity_id": [["T8"]] },"Combination": [{"Drug": {"text": [["progestational agents"]],"start": [["108"]],"entity_id": [["T9"]] },"Trigger": {"text": [["preventable"]],"start": [["100"]],"entity_id": [["T10"]]} ,"event_type": "Potential_therapeutic_effect" ,"event_id": "E2" }] ,"Duration": {"text": [["increases"]],"start": [["42"]],"entity_id": [["T5"]] }} ,"Effect": {"text": [["proliferative lesions of the endometrium"]],"start": [["54"]],"entity_id": [["T3"]] },"Negated": null,"Speculated": null ,"Severity": null ,"Subject": {"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null,"text": [],"start": [],"entity_id": [] },"Trigger": null }]}
{"id": "3379435_3","context": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal acute encephalopathy"]],"start": [["19"]],"entity_id": [["T1"]]},"Subject": {"text": [["Three senile patients"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["senile"]],"start": [["0"]],"entity_id": [["A1"]]},"Population": {"text": [["Three"]],"start": [["0"]],"entity_id": [["P1"]]},"Disorder": {"text": [["developed"]],"start": [["0"]],"entity_id": [["D1"]]},"Gender": {"text": [["patients"]],"start": [["7"]],"entity_id": [["G1"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["calcium hopantenate"]],"start": [["52"]],"entity_id": [["T3"]],"Drug": {"text": [["calcium hopantenate"]],"start": [["52"]],"entity_id": [["D2"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["while receiving"]],"start": [["40"]],"entity_id": [["T4"]]},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": []},"Effect": {"text": [["fatal acute encephalopathy"]],"start": [["19"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "High"}}]}
{"id": "18515982_4","context": "Renal injury due to anastrozole has not been published in the English literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Renal injury"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["anastrozole"]],"start": [[ "39" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["anastrozole"]],"start": [[ "39" ]],"entity_id": [ ["T2"] ]} ,"Dosage" : {"text" : [],"start" : [],"entity_id" : []},"Duration" : {"text" : [],"start" : [],"entity_id" : []},"Route" : {"text" : [],"start" : [],"entity_id" : []},"Time_elapsed" : {"text" : [],"start" : [],"entity_id" : []},"Disorder" : {"text" : [],"start" : [],"entity_id" : []},"Freq" : {"text" : [],"start" : [],"entity_id" : []} ,"Combination" : null ,"Trigger" : {"text" : [],"start" : [],"entity_id" : []} },"Effect": {"text": [["Renal injury"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Negated" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : true },"Speculated" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : false },"Severity" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : "" },"Subject": {"text" : [],"start" : [],"entity_id" : [] ,"Age" : {"text" : [],"start" : [],"entity_id" : [] },"Gender" : {"text" : [],"start" : [],"entity_id" : [] },"Population" : {"text" : [],"start" : [],"entity_id" : [] },"Race" : {"text" : [],"start" : [],"entity_id" : [] },"Disorder" : {"text" : [],"start" : [],"entity_id" : [] }} } ]}
{"id": "15197722_2", "context": "Restless legs syndrome due to interferon-alpha", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Restless legs syndrome"]], "start": [["0"]], "entity_id": [ ["T1"]]}, "Treatment": {"text": [["interferon-alpha"]], "start": [["27"]], "entity_id": [ ["T2"]],"Drug": {"text": [["interferon-alpha"]], "start": [["27"]], "entity_id": [ ["T3"]]}, "Disorder": {"text": [["Restless legs syndrome"]], "start": [["0"]], "entity_id": [ ["T1"]]}, "Combination": [],"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [["Restless legs syndrome"]], "start": [[ "0"]], "entity_id": [ ["T1"]]} },"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Severity": {"text": [], "start": [], "entity_id": [],"value": "Low"},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "19687711_3", "context": "Although the association between SJS/TEN and the sulfonamide class of antibiotics is well established, the increasing prevalence of CA-MRSA has left practitioners with limited regimens to effectively treat skin and soft tissue infections (SSTIs) in the outpatient setting", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": { "Drug": { "text": [["sulfonamide class of antibiotics"]], "start": [["31", "32"]], "entity_id": [["T1"]] } , "Disorder": { "text": [["SJS/TEN"]], "start": [["9", "10"]], "entity_id": [["T2"]] } , "entity_id": [["T1"]] , "text": [["the sulfonamide class of antibiotics"]], "start": [["31", "32"]] , "Trigger": { "text": [["association"]], "start": [["9"]], "entity_id": [["T3"]] } , "Time_elapsed": null, "Duration": null, "Dosage": null, "Route": null, "Freq": null , "Combination": null } , "Effect": { "text": [["SJS/TEN"]], "start": [["9", "10"]], "entity_id": [["T2"]] } , "Trigger": { "text": [["association"]], "start": [["9"]], "entity_id": [["T3"]] } } ]}
{"id": "9796135_2","context": "Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["hypotension"]],"start": [["32"]],"entity_id": []},"Treatment": {"text": [["nitrate"]],"start": [["20"]],"entity_id": [],"Drug": {"text": [["nitrate"]],"start": [["20"]],"entity_id": []},"Disorder": {"text": [["hypotension"]],"start": [["32"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": {"text": [["Elderly patients"]],"start": [["0"]],"entity_id": [],"Age": {"text": [["Elderly"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["unconsciousness"]],"start": [["56"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2937155_1","context": "A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lupus-like syndrome"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["vancomycin"]],"start": [["13"]],"entity_id": [["T2"]]},"Disorder": {"text": [["a serious staphylococcal infection"]],"start": [["5"]],"entity_id": [["T3"]]},"entity_id": [["T2"],["T3"]],"text": [["vancomycin for a serious staphylococcal infection"]],"start": [["13"]],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["lupus-like syndrome"]],"start": [["38"]],"entity_id": [["T1"]]}},"Effect": {"text": [["a malar rash"]],"start": [["61"]],"entity_id": [["T4"]]},"Subject": {"text": [["A patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["a serious staphylococcal infection"]],"start": [["5"]],"entity_id": [["T3"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}}]}
{"id": "7436161_2","context": "Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["major adverse cardiorespiratory and anaphylactic reactions"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["Seven patients with hematologic malignancies"]],"start": [[ ]],"entity_id": [ ["T2"] ],"Age": null,"Gender": null,"Population": {"text": [["Seven"]],"start": [[ ]],"entity_id": [ ["T2"] ]},"Race": null,"Disorder": {"text": [["hematologic malignancies"]],"start": [[ ]],"entity_id": [ ["T2"] ]}},"Treatment": {"text": [["miconazole"]],"start": [[ ]],"entity_id": [ ["T3"] ],"Drug": {"text": [["miconazole"]],"start": [[ ]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["fungal infections"]],"start": [[ ]],"entity_id": [ ["T4"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["either suspected or proven"]],"start": [[ ]],"entity_id": [ ["T4"] ]}} ,"Effect": {"text": [["eight episodes"]],"start": [[ ]],"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["major"]],"start": [[ ]],"entity_id": [ ["T1"] ], "value": "high" }} ]}
{"id": "12802933_3", "context": "We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null,"Subject": null,"Treatment": {"text": [["rituximab"]], "start": [["33"]], "entity_id": [["T1"]],"Drug": {"text": [["rituximab"]], "start": [["33"]], "entity_id": [["T2"]]},"Disorder": {"text": [["autoimmune hemolytic anemia"]], "start": [["56"]], "entity_id": [["T3"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": {"text": [["autoimmune hemolytic anemia"]], "start": [["56"]], "entity_id": [["T3"]]}},"Effect": null, "Trigger": null}]}
{"id": "7606071_1", "context": "Anaphylactoid reactions with intraperitoneal cisplatin", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Anaphylactoid reactions"]], "start": [[]], "entity_id": [["T1"]]}, "Treatment": {"text": [["intraperitoneal cisplatin"]], "start": [[],[]], "entity_id": [["T2"]], "Drug": {"text": [["cisplatin"]], "start": [[],[]], "entity_id": [["T3"]]}, "Disorder": {"text": [["Anaphylactoid reactions"]], "start": [[],[]], "entity_id": [["T1"]]}, "Freq": null, "Time_elapsed": null, "Duration": null, "Route": {"text": [["intraperitoneal"]], "start": [[],[]], "entity_id": [["T4"]]}, "Dosage": null, "Combination": null, "Trigger": null}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Effect": {"text": [["Anaphylactoid reactions"]], "start": [[],[]], "entity_id": [["T1"]]}}]}
{"id": "20185472_2","context": "Tremor: a newly described adverse event with long-term itraconazole therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Tremor"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["long-term itraconazole therapy"]],"start": [[ "32" ]],"entity_id": [["T2"]],"Drug": {"text": [["itraconazole"]],"start": [[ "32" ]],"entity_id": [["T3"]]},"Duration": {"text": [["long-term"]],"start": [[ "0" ]],"entity_id": [["T4"]]},"Freq": {"text": [["newly described"]],"start": [[ "8" ]],"entity_id": [["T5"]]},"Disorder": {"text": [["adverse event"]],"start": [[ "17" ]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["with"]],"start": [[ "23" ]],"entity_id": [["T7"]]},"Dosage": {"text": [["therapy"]],"start": [[ "40" ]],"entity_id": [["T8"]]},"Route": {"text": [["therapy"]],"start": [[ "40" ]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["itraconazole"]],"start": [[ "32" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [[ "40" ]],"entity_id": [["T8"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["Tremor"]],"start": [[ "0" ]],"entity_id": [["T1"]]}},"Subject": {"text": [["Tremor"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Disorder": {"text": [["adverse event"]],"start": [[ "17" ]],"entity_id": [["T6"]]},"Age": {"text": [["newly described"]],"start": [[ "8" ]],"entity_id": [["T5"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [["newly described"]],"start": [[ "8" ]],"entity_id": [["T5"]],"value": false},"Effect": {"text": [["Tremor"]],"start": [[ "0" ]],"entity_id": [["T1"]]}}]}
{"id": "15735923_1", "context": "Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Treatment-related myelodysplastic syndrome"]], "start": [[ "Treatment-related myelodysplastic syndrome" ]], "entity_id": [ ]}, "Treatment": {"text": [["temozolomide"]], "start": [[ "temozolomide" ]], "entity_id": [ ], "Drug": {"text": [["temozolomide"]], "start": [[ "temozolomide" ]], "entity_id": [ ]} , "Disorder": {"text": [["myelodysplastic syndrome"]], "start": [[ "myelodysplastic syndrome" ]], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [[ "temozolomide for recurrent high-grade glioma" ]], "start": [[ "temozolomide for recurrent high-grade glioma" ]], "entity_id": [ ]} }, "Subject": { "text": [[ "treatment" ]], "start": [[ "treatment" ]], "entity_id": [ ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Severity": null, "Speculated": null, "Negated": null ,"Effect": { "text": [[ "Treatment-related myelodysplastic syndrome" ]], "start": [[ "Treatment-related myelodysplastic syndrome" ]], "entity_id": [ ]} }]}
{"id": "9366852_3","context": "It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["occasional"]],"start": [["It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome" ]],"entity_id": []},"Treatment": {"text": [["heparin-associated thrombocytopenia and thrombosis syndrome"]],"start": [[""], ["associated"], ["thrombocytopenia"], ["and"], ["thrombosis"], ["syndrome"]],"entity_id": [],"Disorder": {"text": [["heparin-associated thrombocytopenia"]],"start": [[""], ["associated"], ["thrombocytopenia"]],"entity_id": []} ,"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": {"text": [["occasional"]],"start": [[""], ["occasional"]],"entity_id": []} ,"Combination": null ,"Drug": null} ,"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["occasional"]],"start": [[""], ["occasional"]],"entity_id": []} }]}
{"id": "16035204_1","context": "We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["massive fluoxetine ingestion"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["fluoxetine"]],"start": [["18"]],"entity_id": [["T2"]]},"text": [["massive fluoxetine ingestion"]],"start": [["18"]],"entity_id": [["T1"]],"Disorder": {"text": [["neurological and cardiovascular toxicity resulting in death"]],"start": [["52"]],"entity_id": [["T3"]]},"Dosage": {"text": [["massive"]],"start": [["18"]],"entity_id": [["T1"]]},"Duration": {"text": [["resulting in neurological and cardiovascular toxicity resulting in death"]],"start": [["52"]],"entity_id": [["T3"]]},"Freq": {"text": [["massive"]],"start": [["18"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["resulting in neurological and cardiovascular toxicity resulting in death"]],"start": [["52"]],"entity_id": [["T3"]]},"Route": {"text": [["ingestion"]],"start": [["30"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["fluoxetine"]],"start": [["18"]],"entity_id": [["T2"]]},"Trigger": {"text": [["ingestion"]],"start": [["30"]],"entity_id": [["T1"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["massive fluoxetine ingestion"]],"start": [["18"]],"entity_id": [["T1"]]}},"Effect": {"text": [["neurological and cardiovascular toxicity resulting in death"]],"start": [["52"]],"entity_id": [["T3"]]},"Severity": {"text": [["resulting in death"]],"start": [["86"]],"entity_id": [["T4"]],"value": "High"},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "9161656_14","context": "Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["dyspnea"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["verapamil administration"]],"start": [["49"]],"entity_id": [["T2"]],"Drug": {"text": [["verapamil"]],"start": [["49"]],"entity_id": [["T3"]]},"Route": {"text": [["administration"]],"start": [["49"]],"entity_id": [["T4"]]},"Freq": {"text": [["sustained-release"]],"start": [["70"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["following"]],"start": [["90"]],"entity_id": [["T6"]]},"Disorder": {"text": [["an elderly asymptomatic asthmatic patient with hypertension"]],"start": [["101"]],"entity_id": [["T7"]]},"Trigger": {"text": [["who developed an acute asthma attack"]],"start": [["134"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["verapamil"]],"start": [["49"]],"entity_id": [["T3"]]},"Trigger": {"text": [["asthma attack"]],"start": [["150"]],"entity_id": [["T9"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [["sustained-release"]],"start": [["70"]],"entity_id": [["T5"]]},"Duration": {"text": [["following"]],"start": [["90"]],"entity_id": [["T6"]]}},"Subject": {"text": [["an elderly asymptomatic asthmatic patient with hypertension"]],"start": [["101"]],"entity_id": [["T7"]],"Age": {"text": [["elderly"]],"start": [["101"]],"entity_id": [["T10"]]},"Disorder": {"text": [["asthmatic"]],"start": [["108"]],"entity_id": [["T11"]]},"Population": {"text": [["first report"]],"start": [["55"]],"entity_id": [["T12"]]},"Race": {"text": [["patient"]],"start": [["101"]],"entity_id": [["T7"]]},"Gender": {"text": [["patient"]],"start": [["101"]],"entity_id": [["T7"]]}},"Effect": {"text": [["acute asthma attack"]],"start": [["150"]],"entity_id": [["T9"]]},"Negated": null,"Speculated": {"text": [["first report"]],"start": [["55"]],"entity_id": [["T12"]],"value": false},"Severity": {"text": [["acute"]],"start": [["150"]],"entity_id": [["T9"]],"value": "high"}}]}
{"id": "11483161_2","context": "The bleeding resolved on discontinuation of APV","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["resolved"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["discontinuation of APV"]],"start": [["21"]],"entity_id": [],"Drug": {"text": [["APV"]],"start": [["21"]],"entity_id": []},"Trigger": {"text": [["discontinuation"]],"start": [["21"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2327115_2","context": "Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Effect": {"text": [["Renal toxicities"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["ciprofloxacin therapy"]], "start": [[ "62" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["ciprofloxacin"]], "start": [[ "62" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["patients receiving ciprofloxacin therapy"]], "start": [[ "35" ]], "entity_id": [ ["T2"] ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null ,"Freq": null ,"Combination": null }, "Subject": { "text": [["patients receiving ciprofloxacin therapy"]], "start": [[ "35" ]], "entity_id": [ ["T2"] ], "Age": null, "Disorder": null, "Gender": null, "Population": { "text": [["less than one percent"]], "start": [[ "22" ]], "entity_id": [ ["T4"] ]}, "Race": null }, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null }] }
{"id": "10513720_1", "context": "Taxane-induced glaucoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Taxane-induced"]], "start": [[],[ ]], "entity_id": [["T1"]]}, "Effect": {"text": [["glaucoma"]], "start": [[],[ ]], "entity_id": [["T2"]]}, "Treatment": null, "Subject": null, "Severity": null, "Negated": null, "Speculated": null}]}
{"id": "14735388_1", "context": "Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ciprofloxacin-induced toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]}, "Subject": {"text": [["a patient"]], "start": [[ ]], "entity_id": [ ], "Disorder": {"text": [["systemic lupus erythematosus"]], "start": [[ ]], "entity_id": [ ]} , "Age": null, "Gender": null, "Population": null, "Race": null } , "Treatment": null , "Effect": {"text": [["Ciprofloxacin-induced toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]} , "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "15383642_1","context": "Hypotension due to interaction between lisinopril and tizanidine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["interaction"]],"start": [["interaction between lisinopril and tizanidine" , "interaction between" ,"interaction"]],"entity_id": [ ["T1"] ,["T2"] ,["T3"] ]},"Treatment": {"text": [["lisinopril"]],"start": [[ "lisinopril"]],"entity_id": [ ["T4"] ],"Drug": {"text": [["lisinopril"]],"start": [[ "lisinopril"]],"entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Disorder": null, "Freq": null, "Route": null, "Time_elapsed": null, "Trigger": { "text": [["interaction"]],"start": [[ "interaction between lisinopril and tizanidine" ,"interaction between" ,"interaction"]],"entity_id": [ ["T1"] ,["T2"] ,["T3"] ]} ,"Combination": null },"Effect": {"text": [["Hypotension"]],"start": [[ "Hypotension"]],"entity_id": [ ["T5"] ]} ,"Subject": null, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "7538828_8","context": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["extensive skin rash"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["single dose of MTX"]],"start": [["54"]],"entity_id": [["T2"]],"Drug": {"text": [["MTX"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["life-threatening bone marrow aplasia"]],"start": [["73"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["single dose"]],"start": [["51"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["single dose"]],"start": [["51"]],"entity_id": [["T6"]]} ,"Route": {"text": [["following"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["single dose"]],"start": [["51"]],"entity_id": [["T6"]]},"Combination": null ,"Trigger": {"text": [["development"]],"start": [["0"]],"entity_id": [["T0"]]} },"Subject": {"text": [["patient"]],"start": [[""], []],"entity_id": [[""]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["patient"]],"start": [[""], []],"entity_id": [[""]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["life-threatening"]],"start": [["73"]],"entity_id": [["T4"]] ,"value": "high" },"Effect": {"text": [["an early warning sign"]],"start": [["33"]],"entity_id": [["T7"]]} }]}
{"id": "6159523_1", "context": "Anaphylactoid reaction to 50% solution of dextrose", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Anaphylactoid reaction"]], "start": [[ "0", "Anaphylactoid reaction"]], "entity_id": []}, "Treatment": {"text": [["50% solution of dextrose"]], "start": [[ "58", "50% solution of dextrose"]], "entity_id": [] ,"Drug": {"text": [["dextrose"]], "start": [[ "65", "dextrose"]], "entity_id": [] }, "Route": {"text": [["solution"]], "start": [[ "58", "solution"]], "entity_id": [] }, "Dosage": null, "Duration": null, "Disorder": null, "Time_elapsed": null ,"Freq": null ,"Combination": null ,"Trigger": {"text": [["Anaphylactoid reaction"]], "start": [[ "0", "Anaphylactoid reaction"]], "entity_id": [] }} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "16503727_3","context": "We describe a patient who developed granulocytopenia and fever after taking dipyrone and discuss the available literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["granulocytopenia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["dipyrone"]],"start": [["54"]],"entity_id": [["T2"]],"Drug": {"text": [["dipyrone"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["taking"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["developed"]],"start": [["15"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["fever"]],"start": [["25"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["taking"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Route": {"text": [["taking"]],"start": [["51"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["dipyrone"]],"start": [["54"]],"entity_id": [["T3"]]} ,"Combination": null },"Effect": {"text": [["granulocytopenia"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null} ]}
{"id": "20126479_3", "context": "Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["Spectral-domain optical coherence tomography and adaptive optics"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Effect": { "text": [["detect"]],"start": [[ "82" ]],"entity_id": [ ["T2"] ]},"Treatment": { "Drug": { "text": [["hydroxychloroquine"]],"start": [[ "54" ]],"entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["retinal toxicity"]],"start": [[ "38" ]],"entity_id": [ ["T4"] ]} ,"Dosage": { "text": [],"start": [],"entity_id": []}, "Duration": { "text": [],"start": [],"entity_id": []}, "Trigger": { "text": [],"start": [],"entity_id": []}, "Route": { "text": [],"start": [],"entity_id": []}, "Time_elapsed": { "text": [],"start": [],"entity_id": []}, "Freq": { "text": [],"start": [],"entity_id": []}, "Combination": null ,"text": [],"start": [],"entity_id": []} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "11961411_1", "context": "A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 64-year-old man"]], "start": [["0"]], "entity_id": [["T1"]],"Age":{"text":[["64"]],"start":[["0"]],"entity_id":[["T2"]]},"Gender":{"text":[["man"]],"start":[["12"]],"entity_id":[["T3"]]},"Disorder":{"text":[["proteinuria"]],"start":[["35"]],"entity_id":[["T4"]]},"Population":{"text":[["A"]],"start":[["0"]],"entity_id":[["T0"]]},"Race":{"text":[],"start":[],"entity_id":[]}},"Trigger": {"text": [["postoperative interferon (IFN)-beta therapy"]], "start": [["51"]], "entity_id": [["T5"]]},"Treatment":{"text":[["interferon (IFN)-beta"]], "start":[["51"]], "entity_id":[["T6"]],"Drug":{"text":[["interferon (IFN)-beta"]], "start":[["51"]], "entity_id":[["T7"]]},"Disorder":{"text":[["therapy"]], "start":[["63"]], "entity_id":[["T8"]]},"Route":{"text":[["against malignant melanoma"]], "start":[["84"]], "entity_id":[["T9"]]},"Duration":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Combination":[{"Drug":{"text":[["interferon (IFN)-beta"]], "start":[["51"]], "entity_id":[["T7"]]},"Trigger":{"text":[["postoperative therapy"]], "start":[["51"]], "entity_id":[["T5"]]}, "event_id": "C1", "event_type": "null"} ],"Trigger":{"text":[["postoperative interferon (IFN)-beta therapy"]], "start": [["51"]], "entity_id": [["T5"]]}},"Effect":{"text":[["proteinuria"]], "start":[["35"]], "entity_id":[["T4"]]},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"Low"}}]}
{"id": "15289139_2","context": "A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["choroidal detachment"]],"start": [["38"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 76-year-old woman"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["76"]],"start": [["3"]],"entity_id": [["T3"]]},"Gender": {"text": [["woman"]],"start": [["24"]],"entity_id": [["T4"]]},"Disorder": {"text": [["primary open-angle glaucoma"]],"start": [["17"]],"entity_id": [["T5"]]},"Population" : {"text" : [["A 76-year-old woman"]],"start" : [[ "0" ]],"entity_id" : [["T2"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["therapy with dorzolamide eye drops"]],"start": [["61"]],"entity_id": [["T6"]],"Drug": {"text": [["dorzolamide"]],"start": [["80"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["eye drops"]],"start": [["71"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [["12 hours after initiation"]],"start": [["61"]],"entity_id": [["T6"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["primary open-angle glaucoma"]],"start": [["17"]],"entity_id": [["T5"]]},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "717931_1", "context": "Life-threatening hyperkalemia induced by arginine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Life-threatening hyperkalemia"]], "start": [[ "0 " ]], "entity_id": []}, "Treatment": {"text": [["arginine"]], "start": [[ "56 "] ], "entity_id": [],"Drug": {"text": [["arginine"]], "start": [[ "56 "] ], "entity_id": []},"Disorder": {"text": [["Life-threatening hyperkalemia"]], "start": [[ "0 " ]], "entity_id": []},"Time_elapsed": {"text": [["induced"]], "start": [[ "48 "] ], "entity_id": []},"Freq": {"text": [["induced"]], "start": [[ "48 "] ], "entity_id": []},"Combination": [{"Drug": {"text": [["arginine"]], "start": [[ "56 " ]], "entity_id": []},"Trigger": {"text": [["induced"]], "start": [[ "48 "]], "entity_id": []},"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["Life-threatening hyperkalemia"]], "start": [[ "0 " ]], "entity_id": []},"Dosage": {"text": [["induced"]], "start": [[ "48 "] ], "entity_id": []},"Route": {"text": [["induced"]], "start": [[ "48 " ]], "entity_id": []},"Duration": {"text": [["induced"]], "start": [[ "48 "] ], "entity_id": []} } ,"Severity": {"text": [["Life-threatening"]], "start": [[ "0 " ]], "entity_id": [] ,"value": "High" }, "Subject": {"text": [["Patient"]], "start": [[ "-1 " ]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [["Life-threatening hyperkalemia"]], "start": [[ "0 " ]], "entity_id": []} }, "Negated": {"text": [], "start": [], "entity_id": [] ,"value": false }, "Speculated": {"text": [], "start": [], "entity_id": [] ,"value": false }, "Effect": {"text": [["Life-threatening hyperkalemia"]], "start": [[ "0 " ]], "entity_id": []} }]}
{"id": "11881322_6","context": "We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute liver damage"]],"start": [["21"]],"entity_id": [["T1"]]},"Subject": {"text": [["three patients"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": {"text": [["three"]],"start": [["0"]],"entity_id": [["T0.1"]]},"Race": null,"Disorder": null},"Treatment": {"text": [["therapy with itraconazole"]],"start": [["45"]],"entity_id": [["T2"]],"Drug": {"text": [["itraconazole"]],"start": [["54"]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null , "Trigger": { "text": [["therapy"]], "start": [["45"]], "entity_id": [["T2.1"]] } } ,"Effect": { "text": [["acute liver damage"]], "start": [["21"]], "entity_id": [["T1"]] } ,"Negated": null, "Speculated": null, "Severity": null } ] }
{"id": "15126179_2","context": "A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["intense conjunctival hyperemia", "cystoid macula edema"]],"start": [[ "13","43"]],"entity_id": [ ]},"Treatment": {"text": [["latanoprost", "bimatoprost"]],"start": [[ "51","58" ,"68","75"]],"entity_id": [ ],"Drug": {"text": [["latanoprost", "bimatoprost"]],"start": [[ "51","58" ,"68","75"]],"entity_id": [ ]},"Time_elapsed": {"text": [[ "9" ]],"start": [[ "88" ]],"entity_id": [ ]},"Trigger": {"text": [[ "switching" ]],"start": [[ "46" ]],"entity_id": [ ]},"Disorder": {"text": [[ "at low-risk for this cystoid macular edema" ]],"start": [[ "100" ]],"entity_id": [ ]},"Dosage": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Combination": null},"Subject": {"text": [[ "A 68-year-old man" ]],"start": [[ "0" ]],"entity_id": [ ],"Age": {"text": [[ "68" ]],"start": [[ "2" ]],"entity_id": [ ]},"Gender": {"text": [[ "man" ]],"start": [[ "20" ]],"entity_id": [ ]},"Population": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Race": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]}},"Effect": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12699871_3","context": "Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["mutism"]],"start": [["51"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["Tacrolimus (FK506)"]],"start": [["0"]],"entity_id": [ ["T2"]],"Drug": {"text": [["Tacrolimus"]],"start": [["0"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["mutism"]],"start": [["51"]],"entity_id": [ ["T1"]]} ,"Route": {"text": [["associated"]],"start": [["36"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": {"text": [["after liver transplant"]],"start": [["64"]],"entity_id": [ ["T5"]]} ,"Freq": {"text": [["in adults"]],"start": [["41"]],"entity_id": [ ["T6"]]} ,"Dosage": {"text": [["Tacrolimus (FK506)"]],"start": [["0"]],"entity_id": [ ["T2"]]} ,"Duration": {"text": [["after liver transplant"]],"start": [["64"]],"entity_id": [ ["T5"]]} ,"Combination": null ,"Trigger": {"text": [["associated"]],"start": [["36"]],"entity_id": [ ["T4"]]} },"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "19904536_13","context": "Gemcitabine-induced pulmonary toxicity is usually a dramatic condition","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Gemcitabine-induced pulmonary toxicity"]],"start": [[ "0"]],"entity_id": [ ]} ,"Effect": {"text": [["Gemcitabine-induced pulmonary toxicity"]],"start": [[ ]],"entity_id": [ ]} ,"Severity": {"value": "high" ,"text": [["dramatic condition"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null ,"Subject": null,"Treatment": null } ]}
{"id": "6987607_1","context": "However, the amount of prednisone required to maintain normotension resulted in Cushingoid features and has been discontinued","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cushingoid features"]],"start": [["Cushingoid features' start index in the text]]"],["entity_id"]],"entity_id": [["unique id for Cushingoid features"]]},"Treatment": {"text": [["prednisone"]],"start": [["prednisone's start index in the text"]],"entity_id": [["unique id for prednisone"]],"Drug": {"text": [["prednisone"]],"start": [["prednisone's start index in the text"]],"entity_id": [["unique id for prednisone"]]},"Disorder": {"text": [["maintain normotension"]],"start": [["maintain normotension's start index in the text"]],"entity_id": [["unique id for maintain normotension"]]} ,"Dosage": {"text": [["the amount"]],"start": [["the amount's start index in the text"]],"entity_id": [["unique id for the amount"]]} ,"Time_elapsed": {"text": [["resulted in Cushingoid features"]],"start": [["resulted in Cushingoid features' start index in the text"]],"entity_id": [["unique id for resulted in Cushingoid features"]]} ,"Trigger": {"text": [["the amount"]],"start": [["the amount's start index in the text"]],"entity_id": [["unique id for the amount"]]} ,"Combination": [{"Drug": {"text": [["prednisone"]],"start": [["prednisone's start index in the text"]],"entity_id": [["unique id for prednisone"]]},"Trigger": {"text": [["required"]],"start": [["required's start index in the text"]],"entity_id": [["unique id for required"]]} ,"event_id": "E1-1","event_type": "Adverse_event"}],"Freq": {"text": [["has been discontinued"]],"start": [["has been discontinued' start index in the text"]],"entity_id": [["unique id for has been discontinued"]]} ,"Duration": {"text": [["required to maintain normotension"]],"start": [["required to maintain normotension' start index in the text"]],"entity_id": [["unique id for required to maintain normotension"]]} ,"Route": {"text": [["therapy"]],"start": [["therapy' start index in the text"]],"entity_id": [["unique id for therapy"]]} } ,"Effect": {"text": [["Cushingoid features"]],"start": [["Cushingoid features' start index in the text"]],"entity_id": [["unique id for Cushingoid features"]]} ,"Severity": {"text": [["Cushingoid features"]],"start": [["Cushingoid features' start index in the text"]],"entity_id": [["unique id for Cushingoid features"]],"value": "High"} ,"Negated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}} } ]}
{"id": "18408649_1", "context": "Development of tics in a thirteen-year-old male following atomoxetine use", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["thirteen-year-old male"]], "start": [["11"]], "entity_id": [],"Age":{"text":[["thirteen"]], "start":[[ "11" ]],"entity_id":[]},"Gender":{"text":[["male"]], "start":[[ "17" ]],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}},"Trigger": {"text": [["following atomoxetine use"]], "start": [["44"]], "entity_id": []},"Treatment": {"text": [["atomoxetine"]], "start": [["44"]], "entity_id": [],"Drug":{"text":[["atomoxetine"]], "start":[[ "44" ]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Combination":null,"Trigger":null},"Effect": {"text": [["Development of tics"]], "start": [["0"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "7919557_3","context": "To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["chronic", "nonproductive cough"]],"start": [["4","5"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"text": [["the angiotensin-converting enzyme (ACE) inhibitor quinapril"]],"start": [["31","32"]],"entity_id": [["T3"]],"Drug": {"text": [["quinapril"]],"start": [["36","37"]],"entity_id": [["T4"]]},"Route": {"text": [["ACE inhibitor"]],"start": [["31","35"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["with complete resolution after switching"]],"start": [["57","60"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["switching"]],"start": [["57","60"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]} ,"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]} ,"Disorder": {"text": [["secondary to"]],"start": [["15","19"]],"entity_id": [["T7"]]} ,"Combination": null ,"Freq": null },"Subject": {"text": [["a case"]],"start": [["0","1"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [["chronic", "nonproductive cough"]],"start": [["4","5"]],"entity_id": [["T1"],["T2"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11788010_6","context": "We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis"]],"start": [[ "14" , "104" ]],"entity_id": [["T1"]]},"Subject": {"text": [["a 37 year old male"]],"start": [["105" , "116"]],"entity_id": [["T2" ]],"Age": {"text": [["37"]],"start": [[ "106" ]],"entity_id": [["A1"]]},"Gender": {"text": [["male"]],"start": [[ "112" ]],"entity_id": [["G1"]]},"Disorder": {"text": [["acromegaly"]],"start": [[ "117" , "125" ]],"entity_id": [["T3"]]},"Race": null,"Population": null},"Treatment": {"text": [["octreotide"]],"start": [["138" , "145" ]],"entity_id": [["T4"]],"Drug": {"text": [["octreotide"]],"start": [[ "138" ]],"entity_id": [["T5"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["acromegaly"]],"start": [[ "117" , "125" ]],"entity_id": [["T3"]]},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "1288290_1","context": "Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Proliferation of abnormal bone marrow histiocytes"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["granulocyte macrophage-colony-stimulating factor therapy"]],"start": [["81"]],"entity_id": [],"Drug": {"text": [["granulocyte macrophage-colony-stimulating factor"]],"start": [["81"]],"entity_id": []},"Disorder": {"text": [["Hurler's syndrome"]],"start": [["113"]],"entity_id": []},"Freq": {"text": [["therapy"]],"start": [["81"]],"entity_id": []},"Route": {"text": [["therapy"]],"start": [["81"]],"entity_id": []},"Time_elapsed": {"text": [["effect"]],"start": [["48"]],"entity_id": []},"Duration": {"text": [["transplantation"]],"start": [["135"]],"entity_id": []},"Trigger": {"text": [["therapy"]],"start": [["81"]],"entity_id": []},"Combination": [{"Drug": {"text": [["granulocyte macrophage-colony-stimulating factor"]],"start": [["81"]],"entity_id": []},"Trigger": {"text": [["therapy"]],"start": [["81"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E1"}],"Dosage": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["patient"]],"start": [["122"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["Hurler's syndrome"]],"start": [["113"]],"entity_id": []}},"Effect": {"text": [["Proliferation of abnormal bone marrow histiocytes"]],"start": [["0"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "18431096_2","context": "We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acral cyanosis"]],"start": [["39"]],"entity_id": [["T1"]]},"Subject": {"text": [["4 patients"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["methylphenidate"]],"start": [["28"]],"entity_id": [["T3"]],"Drug": {"text": [["methylphenidate"]],"start": [["28"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["livedo reticularis"]],"start": [["54"]],"entity_id": [["T5"]]},"Subject": {"text": [["4 patients"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["dextroamphetamine"]],"start": [["47"]],"entity_id": [["T6"]],"Drug": {"text": [["dextroamphetamine"]],"start": [["47"]],"entity_id": [["T7"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null},{"event_type": "Adverse_event","event_id": "E3","Trigger": {"text": [["Raynaud phenomenon"]],"start": [["74"]],"entity_id": [["T8"]]},"Subject": {"text": [["4 patients"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["methylphenidate"]],"start": [["28"]],"entity_id": [["T3"]],"Drug": {"text": [["methylphenidate"]],"start": [["28"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null},{"event_type": "Adverse_event","event_id": "E4","Trigger": {"text": [["Raynaud phenomenon"]],"start": [["74"]],"entity_id": [["T8"]]},"Subject": {"text": [["4 patients"]],"start": [["6"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["dextroamphetamine"]],"start": [["47"]],"entity_id": [["T6"]],"Drug": {"text": [["dextroamphetamine"]],"start": [["47"]],"entity_id": [["T7"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10575189_1","context": "Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["thrombotic microangiopathy"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["2 patients"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["the new anticancer drug gemcitabine"]],"start": [["86"]],"entity_id": [["T3"]],"Drug": {"text": [["gemcitabine"]],"start": [["86"]],"entity_id": [["T4"]]},"Dosage": {"text": [["high cumulative doses"]],"start": [["61"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["thrombotic microangiopathy"]],"start": [["33"]],"entity_id": [["T1"]] } ,"Time_elapsed": null,"Duration": null,"Route": null,"Freq": null,"Combination": null ,"Trigger": null },"Effect": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15840734_11","context": "An objective causality assessment revealed that fluphenazine was the probable cause of NMS in this patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["NMS"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fluphenazine"]],"start": [["14"]],"entity_id": [["T2"]],"Drug": {"text": [["fluphenazine"]],"start": [["14"]],"entity_id": [["T2"]]},"Disorder": {"text": [["NMS"]],"start": [["31"]],"entity_id": [["T1"]]},"Trigger": {"text": [["probable cause"]],"start": [["24"]],"entity_id": [["T3"]]},"Freq": {"text": [["was"]],"start": [["24"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["revealed"]],"start": [["24"]],"entity_id": [["T3"]]},"Duration": {"text": [["in this patient"]],"start": [["41"]],"entity_id": [["T4"]]},"Route": {"text": [["revealed"]],"start": [["24"]],"entity_id": [["T3"]]},"Dosage": {"text": [["fluphenazine"]],"start": [["14"]],"entity_id": [["T2"]]},"Combination": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": {"text": [["probable cause"]],"start": [["24"]],"entity_id": [["T3"]],"value": "probable"},"Effect": {"text": [["NMS"]],"start": [["31"]],"entity_id": [["T1"]]}}]}
{"id": "9754850_2", "context": "Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["olanzapine"]], "start": [["45"]], "entity_id": [],"Drug":{"text":[["olanzapine"]],"start":[["45"]],"entity_id":[]},"Disorder":{"text":[["atypical neuroleptics"]], "start": [["13"]], "entity_id": []},"Trigger":{"text":[["is considered to show"]], "start": [["23"]], "entity_id": []},"Route":{"text":[["neuroleptic drugs"]], "start": [["74"]], "entity_id": []},"Freq":{"text":[["reduced prevalence"]], "start": [["56"]], "entity_id": []},"Combination":[{"Drug":{"text":[["olanzapine"]], "start": [["45"]], "entity_id":[]},"Trigger":{"text":[["compared to classical neuroleptic drugs"]], "start":[["81"]], "entity_id":[]},"event_type":"Drug","event_id":"C1"}],"Dosage":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Time_elapsed":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Duration":{"text":[[""]], "start": [[""],[""]], "entity_id": []}},"Negated":{"value":false,"text":[[""]], "start": [[""],[""]], "entity_id": []},"Speculated":{"value":false,"text":[[""]], "start": [[""],[""]], "entity_id": []},"Severity":{"value":"", "text":[[""]], "start": [[""],[""]], "entity_id": []},"Subject":{"text":[["Like other atypical neuroleptics"]], "start": [[""],[""]], "entity_id": [],"Age":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Gender":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Population":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Race":{"text":[[""]], "start": [[""],[""]], "entity_id": []},"Disorder":{"text":[["atypical neuroleptics"]], "start": [["13"]], "entity_id": []}},"Effect":{"text":[["reduced prevalence"]], "start": [[""],["56"]], "entity_id": []},"Trigger":{"text":[["is considered to show"]], "start": [[""],["23"]], "entity_id": []}}]}
{"id": "8192712_1","context": "Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["serum ammonia levels"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["valproic acid therapy"]],"start": [["72"]],"entity_id": [ ["T2"]],"Drug": {"text": [["valproic acid"]],"start": [["72"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["altered mental status"]],"start": [["113"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": { "text": [["indicated"]],"start": [["94"]],"entity_id": [ ["T5"]]} ,"Freq": { "text": [["all"]],"start": [["85"]],"entity_id": [ ["T6"]]} ,"Route": { "text": [["therapy"]],"start": [["72"]],"entity_id": [ ["T2"]]} ,"Duration": { "text": [["on"]],"start": [["72"]],"entity_id": [ ["T3"]]} ,"Dosage": { "text": [],"start": [],"entity_id": [] },"Trigger": { "text": [],"start": [],"entity_id": [] },"Combination": null },"Subject": { "text": [["ED patients"]],"start": [["41"]],"entity_id": [ ["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Effect": null ,"Negated": { "text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": { "text": [],"start": [],"entity_id": [] ,"value": false },"Severity": { "text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "12889716_1", "context": "Enoxaparin-induced generalized exanthem", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Enoxaparin-induced"]], "start": [[ ]], "entity_id": [["E1"]]}, "Effect": {"text": [["generalized exanthem"]], "start": [[ ]], "entity_id": [["E2"]]}, "Treatment": {"text": [["Enoxaparin"]], "start": [[ ]], "entity_id": [["E3"]], "Drug": {"text": [["Enoxaparin"]], "start": [[ ]], "entity_id": [["E3"]]} , "Disorder": {"text": [["generalized exanthem"]], "start": [[ ]], "entity_id": [["E2"]]} , "Dosage": null , "Duration": null , "Trigger": null , "Route": null, "Time_elapsed": null , "Freq": null , "Combination": null} , "Subject": { "text": [["patient"]], "start": [[ ]], "entity_id": [["S1"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "1504404_4", "context": "To report a case of ciprofloxacin-induced psychosis and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction.', " , "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["ciprofloxacin"]], "start": [["68"]], "entity_id": [["T1"]]}, "Dosage": null, "Duration": null, "Route": null, "Freq": null, "Time_elapsed": null, "Disorder": null, "entity_id": [["T2"]], "text": [["ciprofloxacin"]], "start": [["68"]] , "Trigger": null, "Combination": null},"Effect": {"text": [["psychosis"]], "start": [["21"]], "entity_id": [["T3"]]}, "Trigger": null}]}
{"id": "12126225_3", "context": "A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"Age": {"text": [["77"]], "start": [["0"]], "entity_id": []}, "Gender": {"text": [["man"]], "start": [["9"]], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "text": [["A 77-year-old man"]], "start": [["0"]], "entity_id": []},"Treatment": {"Drug": {"text": [["rosiglitazone"]], "start": [["96"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [["2 weeks"]], "start": [["70"]], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "text": [["starting rosiglitazone"]], "start": [["70"]], "entity_id": [] ,"Trigger": {"text": [["ankle, hand, and facial swelling"]], "start": [["20"]], "entity_id": []} ,"Combination": [] ,"Disorder": {"text": [], "start": [], "entity_id": []} },"Effect": {"text": [["ankle, hand, and facial swelling"]], "start": [["20"]], "entity_id": []} ,"Negated": {"text": [], "start": [], "entity_id": [],"value": false} ,"Speculated": {"text": [], "start": [], "entity_id": [],"value": false} ,"Severity": {"text": [], "start": [], "entity_id": [],"value": ""} ,"Trigger": {"text": [["starting rosiglitazone"]], "start": [["70"]], "entity_id": []} }]}
{"id": "3659584_5", "context": "Although rare, massive pulmonary embolus must be considered to be a major risk of thrombolytic therapy for deep venous thrombosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["major risk"]], "start": [["62"]], "entity_id": []}, "Treatment": {"text": [["thrombolytic therapy for deep venous thrombosis"]], "start": [["33"]], "entity_id": [],"Dosage": {"text": [["thrombolytic"]], "start": [["33"]], "entity_id": []}, "Disorder": {"text": [["deep venous thrombosis"]], "start": [["51"]], "entity_id": []}, "Route": {"text": [["therapy"]], "start": [["33"]], "entity_id": []},"Time_elapsed":{"text":[["must be considered"]],"start":[[ "40"]],"entity_id":[]}, "Freq":{"text":[["Although rare"]],"start":[[ "0"]],"entity_id":[]}, "Trigger":{"text":[["massive pulmonary embolus"]],"start":[[ "10"]],"entity_id":[]}, "Combination":[{"Drug":{"text":[["thrombolytic"]],"start":[[ "33"]],"entity_id":[]},"Trigger":{"text":[["must be considered"]],"start":[[ "40"]],"entity_id":[]},"event_id":"E1-1","event_type":"Potential_therapeutic_effect"}],"Drug":{"text":[["thrombolytic"]],"start":[[ "33"]],"entity_id":[]},"Duration":{"text":[["therapy"]],"start":[[ "33"]],"entity_id":[]} },"Subject":{"text":[["Although rare"]],"start":[[ "0"]],"entity_id":[],"Age":{"text":[["Although rare"]],"start":[[ "0"]],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["deep venous thrombosis"]],"start":[[ "51"]],"entity_id":[]}},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"major"},"Effect":{"text":[["massive pulmonary embolus"]],"start":[[ "10"]],"entity_id":[]}}]}
{"id": "9876812_3", "context": "To describe onset of syndrome of inappropriate antidiuretic hormone (SIADH) associated with vinorelbine therapy for advanced breast cancer", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [["22"]], "entity_id": []}, "Treatment": {"text": [["vinorelbine therapy"]], "start": [["81"]], "entity_id": [],"Drug": {"text": [["vinorelbine"]], "start": [["81"]], "entity_id": []},"Disorder":{"text":[["advanced breast cancer"]],"start":[[ "104" ]],"entity_id":[]},"Route":{"text":[["therapy"]],"start":[[ "81" ]],"entity_id":[]},"Time_elapsed":{"text":[["onset"]],"start":[[ "22" ]],"entity_id":[]},"Duration":{"text":[["associated"]],"start":[[ "48" ]],"entity_id":[]},"Freq":{"text":[["onset"]],"start":[[ "22" ]],"entity_id":[]},"Combination":[{"Drug":{"text":[["vinorelbine"]],"start":[[ "81" ]],"entity_id":[]},"Trigger":{"text":[["therapy"]],"start":[[ "81" ]],"entity_id":[]},"event_id":"E1-1","event_type":"Adverse_event"} ],"Trigger" : {"text" :[["syndrome of inappropriate antidiuretic hormone"]], "start" :[[ "34" ]], "entity_id" :[]},"Dosage":{"text":[["therapy"]],"start":[[ "81" ]],"entity_id":[]}} , "Subject" :{"Age":{"text":[["advanced"]],"start":[[ "91" ]],"entity_id":[]},"Disorder":{"text":[["breast cancer"]],"start":[[ "68" ]],"entity_id":[]},"Gender":{"text":[["syndrome"]],"start":[[ "34" ]],"entity_id":[]},"Population":{"text":[["patient"]],"start":[[ "119" ]],"entity_id":[]},"Race":{"text":[["onset"]],"start":[[ "22" ]],"entity_id":[]},"entity_id":[],"text":[["patient"]],"start":[[ "119" ]]},"Effect" :{"text":[["syndrome of inappropriate antidiuretic hormone"]], "start" :[[ "34" ]], "entity_id" :[]},"Negated":{"text":[["not"]],"start":[[ "0" ]],"entity_id":[],"value":false},"Speculated":{"text":[["To describe"]],"start":[[ "0" ]],"entity_id":[],"value":false},"Severity":{"text":[["associated"]],"start":[[ "48" ]],"entity_id":[],"value":"Low"}}]}
{"id": "15611427_4","context": "The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["exacerbation"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Effect": {"text": [["psoriasis"]],"start": [[ "11" ]],"entity_id": [["T2"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["psoriasis"]],"start": [[ "26" ]],"entity_id": [["T4"]]}},"Treatment": {"text": [["imiquimod therapy"]],"start": [[ "93" ]],"entity_id": [["T5"]],"Drug": {"text": [["imiquimod"]],"start": [[ "93" ]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Disorder": {"text": [["psoriasis"]],"start": [[ "26" ]],"entity_id": [["T4"]]},"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null }} ]}
{"id": "2857534_3","context": "Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium-responsive manic episodes","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["alprazolam"]],"start": [["18"]],"entity_id": [["T1"]] ,"Drug": { "text": [["alprazolam"]], "start": [["18"]], "entity_id": [["T1"]]} ,"Disorder": { "text": [["bipolar disorder"]], "start": [["50"]], "entity_id": [["T2"]]} ,"Trigger": { "text": [["developed"]], "start": [["68"]], "entity_id": [["T3"]]} ,"Duration": { "text": [["developed"]], "start": [["68"]], "entity_id": [["T3"]]} ,"Dosage": { "text": [["treated"]], "start": [["17"]], "entity_id": [["T0"]]} ,"Route": { "text": [["treated"]], "start": [["17"]], "entity_id": [["T0"]]} ,"Time_elapsed": { "text": [["had"]], "start": [["10"]], "entity_id": [["T0"]]} ,"Freq": { "text": [["treated"]], "start": [["17"]], "entity_id": [["T0"]]} ,"Combination": null} ,"Effect": { "text": [["manic episodes"]], "start": [["95"]], "entity_id": [["T4"]]} ,"Subject": { "text": [["Two patients"]], "start": [["0"]], "entity_id": [["T5"]] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": { "text": [["bipolar disorder"]],"start": [["50"]], "entity_id": [["T2"]]}},"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null}]}
{"id": "8292513_1", "context": "Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Cerebrovascular complications", "aphasia"]], "start": [[ "0", "41"]], "entity_id": [ ["T1"], ["T3"]]}, "Treatment": {"text": [["L-asparaginase therapy"]], "start": [["12"]], "entity_id": [ ["T2"]], "Drug": {"text": [["L-asparaginase"]], "start": [["12"]], "entity_id": [["T4"]]} ,"Disorder": {"text": [["leukemia"]], "start": [["64"]], "entity_id": [ ["T5"]]} ,"Route": {"text": [["therapy"]], "start": [["12"]], "entity_id": [ ["T2"]]} ,"Duration": {"text": [["children"]], "start": [["22"]], "entity_id": [ ["T6"]]} ,"Dosage": {"text": [[]], "start": [[ ]], "entity_id": [ ["T7"]]} ,"Freq": {"text": [[]], "start": [[ ]], "entity_id": [ ["T8"]]} ,"Time_elapsed": {"text": [[]], "start": [[ ]], "entity_id": [ ["T9"]]} ,"Trigger": {"text": [[ ]], "start": [[ ]], "entity_id": [ ["T10"]]} ,"Combination": [{"Drug": {"text": [["L-asparaginase"]], "start": [["12"]], "entity_id": [ ["T4"]]} ,"Trigger": {"text": [["therapy"]], "start": [["12"]], "entity_id": [ ["T2"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }]} ,"Subject": {"text": [["children"]], "start": [["22"]], "entity_id": [ ["T6"]] ,"Age": {"text": [[]], "start": [[ ]], "entity_id": [ ["T11"]]} ,"Gender": {"text": [[]], "start": [[ ]], "entity_id": [ ["T12"]]} ,"Population": {"text": [[]], "start": [[ ]], "entity_id": [ ["T13"]]} ,"Race": {"text": [[]], "start": [[ ]], "entity_id": [ ["T14"]]} ,"Disorder": {"text": [["leukemia"]], "start": [["64"]], "entity_id": [ ["T5"]]} },"Negated": {"text": [[]], "start": [[ ]], "entity_id": [ ["T15"]], "value": false} ,"Speculated": {"text": [[]], "start": [[ ]], "entity_id": [ ["T16"]], "value": false} ,"Severity": {"text": [[]], "start": [[ ]], "entity_id": [ ["T17"]], "value": "None" },"Effect": {"text": [["Cerebrovascular complications", "aphasia"]], "start": [["0","41"]], "entity_id": [ ["T1"]]} }]}
{"id": "6833205_1","context": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["SIADH"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["desipramine treatment"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["desipramine"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["SIADH"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Route": {"text": [["treatment"]],"start": [["41"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["is described"]],"start": [["55"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["associated"]],"start": [["18"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["treatment"]],"start": [["41"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["desipramine treatment"]],"start": [["41"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["treatment"]],"start": [["41"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["desipramine"]],"start": [["41"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["41"]],"entity_id": [["T2"]]} ,"event_id": "E1","event_type": "Adverse_event"} ]} ,"Subject": {"text": [["an elderly depressed woman"]],"start": [["25"]],"entity_id": [["T6"]],"Age": {"text": [["elderly"]],"start": [["25"]],"entity_id": [["T6"]]} ,"Gender": {"text": [["woman"]],"start": [["31"]],"entity_id": [["T6"]]} ,"Population": {"text": [["A case"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Race": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["depressed"]],"start": [["28"]],"entity_id": [["T8"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["SIADH"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high" },"Effect": {"text": [["SIADH"]],"start": [["0"]],"entity_id": [["T1"]]} }]}
{"id": "7379406_1","context": "Niflumic acid-induced skeletal fluorosis: iatrogenic disease or therapeutic perspective for osteoporosis?","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Niflumic acid-induced skeletal fluorosis"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["therapeutic perspective"]],"start": [["58"]],"entity_id": [["T2"] ],"Drug": {"text": [["Niflumic acid"]],"start": [["0"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["osteoporosis"]],"start": [["70"]],"entity_id": [ ["T4"] ]},"Time_elapsed": {"text": [["induced"]],"start": [["9"]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["perspective"]],"start": [["58"]],"entity_id": [ ["T6"] ]},"Route": {"text": [["Niflumic acid"]],"start": [["0"]],"entity_id": [ ["T7"] ]} ,"Dosage": {"text": [["Niflumic acid-induced skeletal fluorosis"]],"start": [["0"]],"entity_id": [ ["T8"] ]} ,"Duration": {"text": [["perspective"]],"start": [["58"]],"entity_id": [ ["T9"] ]} ,"Combination": null ,"Trigger": {"text": [["Niflumic acid-induced skeletal fluorosis"]],"start": [["0"]],"entity_id": [ ["T10"] ]} },"Subject": {"text": [["Niflumic acid-induced skeletal fluorosis"]],"start": [["0"]],"entity_id": [ ["T11"] ],"Gender": null,"Age": null,"Population": null,"Race": null,"Disorder": {"text": [["osteoporosis"]],"start": [["70"]],"entity_id": [ ["T12"] ]} },"Negated": null,"Speculated": null,"Severity": {"text": [["skeletal fluorosis"]],"start": [["15"]],"entity_id": [ ["T13"] ] ,"value": "low" },"Effect": {"text": [["Niflumic acid-induced skeletal fluorosis"]],"start": [["0"]],"entity_id": [ ["T14"] ]} }]}
{"id": "6149250_5","context": "Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe complications"]],"start": [["18", "27"]],"entity_id": [["T1"]]},"Treatment": {"text": [["aminoglutethimide"]],"start": [["51", "59"]],"entity_id": [["T2"]],"Disorder": {"text": [["cancer hormonal therapy"]],"start": [["41", "62"]],"entity_id": [["T3"]]},"Drug": {"text": [["aminoglutethimide"]],"start": [["51", "59"]],"entity_id": [["T2"]]},"Route": {"text": [["cancer hormonal therapy"]],"start": [["41", "62"]],"entity_id": [["T3"]]},"Freq": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Dosage": {"text": [["treated with"]],"start": [["40"]],"entity_id": [["T0"]]},"Duration": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["developed"]],"start": [["10"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["aminoglutethimide"]],"start": [["51", "59"]],"entity_id": [["T2"]]},"Trigger": {"text": [["cancer hormonal therapy"]],"start": [["41", "62"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Treatment"}],"Trigger": {"text": [["severe complications"]],"start": [["18", "27"]],"entity_id": [["T1"]]}},"Subject": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]],"Population": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Age": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Gender": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Race": {"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]}},"Effect": {"text": [["severe complications"]],"start": [["18", "27"]],"entity_id": [["T1"]]},"Severity": {"text": [["severe complications"]],"start": [["18", "27"]],"entity_id": [["T1"]],"value": "High"},"Negated": {"value": false,"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]},"Speculated": {"value": false,"text": [["Both patients"]],"start": [["0", "8"]],"entity_id": [["T0"]]}}]}
{"id": "10458196_2", "context": "An 11-day-old infant became lethargic and apneic after a single drop of brimonidine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lethargic", "apneic"]], "start": [["16","32"]], "entity_id": []}, "Subject": {"text": [["infant"]], "start": [["0"]], "entity_id": [],"Age": {"text": [["11-day-old"]], "start": [["4"]], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}}, "Treatment": {"text": [["brimonidine"]], "start": [["65"]], "entity_id": [],"Drug": {"text": [["brimonidine"]], "start": [["65"]], "entity_id": []},"Dosage": {"text": [["single drop"]], "start": [["57"]], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": [],"Disorder": {"text": [], "start": [], "entity_id": []}},"Effect": {"text": [["lethargic", "apneic"]], "start": [["16","32"]], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false}, "Speculated": {"text": [], "start": [], "entity_id": [],"value": false}, "Severity": {"text": [], "start": [], "entity_id": [],"value": ""}}]}
{"id": "6159523_3","context": "Investigations suggested that the dextrose, rather than any additives, was responsible for the reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["the reaction"]],"start": [["85"]],"entity_id": []} ,"Treatment": {"text": [["dextrose"]],"start": [["34"]],"entity_id": [],"Drug": {"text": [["dextrose"]],"start": [["34"]],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["dextrose"]],"start": [["34"]],"entity_id": []} },"Effect": null ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }} ]}
{"id": "10660641_8","context": "Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective, daily administration of 200 mg of ITCZ was initiated, and the inflammatory signs and symptoms gradually subsided","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["daily administration"]],"start": [["42"]],"entity_id": []},"Treatment": {"text": [["200 mg of ITCZ"]],"start": [["55"]],"entity_id": [],"Drug": {"text": [["ITCZ"]],"start": [["55"]],"entity_id": []},"Disorder": {"text": [["renal insufficiency"]],"start": [["18"]],"entity_id": []},"Route": {"text": [["daily"]],"start": [["42"]],"entity_id": []},"Freq": {"text": [["daily"]],"start": [["42"]],"entity_id": []},"Dosage": {"text": [["200 mg"]],"start": [["55"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["AMPH"]],"start": [["18"]],"entity_id": []},"Combination": []},"Effect": {"text": [["inflammatory signs and symptoms"]],"start": [["95"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["renal insufficiency"]],"start": [["18"]],"entity_id": []}}}]}
{"id": "1356045_1","context": "Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute myopathy"]],"start": [[ "0" ]] ,"entity_id": []},"Treatment": {"text": [["status asthmaticus treated with methylprednisolone and vecuronium"]],"start": [[ "42" ]],"entity_id": [],"Drug": {"text": [["methylprednisolone", "vecuronium"]],"start": [[ "71" ,"87"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["status asthmaticus"]],"start": [[ "42"]],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["selective degeneration of myosin filaments"]],"start": [[ "23"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["status asthmaticus"]],"start": [[ "42"]],"entity_id": []}}}]}
{"id": "1124417_1","context": "Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute renal failure"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["acetazolamide therapy"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["acetazolamide"]],"start": [["42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["glaucoma"]],"start": [["72"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null }]}
{"id": "10803790_6","context": "Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Cyanamide-induced liver dysfunction"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["abstinence"]],"start": [[ "55" ]] ,"entity_id": [["T2"]],"Disorder": {"text": [["alcoholics"]],"start": [[ "66" ]] ,"entity_id": [["T3"]]},"Dosage": {"text": [["Cyanamide"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Duration": {"text": [["long-term follow-up study"]],"start": [[ "81" ]] ,"entity_id": [["T4"]]},"Freq": {"text": [["four cases"]],"start": [[ "108" ]] ,"entity_id": [["T5"]]},"Route": {"text": [["oral"]],"start": [[ "121" ]] ,"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after abstinence"]],"start": [[ "55" ]] ,"entity_id": [["T2"]]},"Drug": {"text": [["Cyanamide"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Trigger": {"text": [["abstinence"]],"start": [[ "55" ]] ,"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["Cyanamide"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Trigger": {"text": [["abstinence"]],"start": [[ "55" ]] ,"entity_id": [["T2"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Subject": {"text": [["alcoholics"]],"start": [[ "66" ]] ,"entity_id": [["T3"]],"Disorder": {"text": [["alcoholics"]],"start": [[ "66" ]] ,"entity_id": [["T3"]]},"Age": {"text": [["long-term"]],"start": [[ "81" ]] ,"entity_id": [["T4"]]},"Gender": {"text": [["four cases"]],"start": [[ "108" ]] ,"entity_id": [["T5"]]},"Race": {"text": [["oral"]],"start": [[ "121" ]] ,"entity_id": [["T6"]]},"Population": {"text": [["four cases"]],"start": [[ "108" ]] ,"entity_id": [["T5"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["liver dysfunction"]],"start": [[ "14" ]] ,"entity_id": [["T7"]],"value": "high"},"Effect": {"text": [["liver dysfunction"]],"start": [[ "14" ]] ,"entity_id": [["T7"]]}}]}
{"id": "16680561_10","context": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet. ","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Fewer subjects"]],"start": [[ "0" ]],"entity_id": [ ],"Age": null,"Gender": null,"Population": {"text": [[ "33%" ]], "start": [[ "48" ]], "entity_id": []},"Race": null,"Disorder": null},"Treatment": {"text": [["treatment with desipramine alone"]],"start": [[ "40" ]],"entity_id": [],"Drug": {"text": [[ "desipramine" ]], "start": [[ "54" ]], "entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Disorder": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["adverse events"]],"start": [[ "18" ]],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Trigger": null},{"event_id": "E2","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": {"text": [[ "86%" ]], "start": [[ "98" ]], "entity_id": []},"Race": null,"Disorder": null},"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [[ "desipramine" ]], "start": [[ "115" ]], "entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Disorder": null,"Time_elapsed": null,"Freq": null,"Combination":[{"event_type": "Adverse_event","event_id": "C1","Drug": {"text": [[ "cinacalcet" ]], "start": [[ "140" ]], "entity_id": []},"Trigger": {"text": [["cinacalcet"]],"start": [[ "140" ]],"entity_id": []}}],"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Trigger": null}]}
{"id": "412488_2","context": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["proteinuria"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gold therapy"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["gold"]],"start": [["42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["62"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [["following"]],"start": [["21"]],"entity_id": [["T5"]]}} ,"Subject": {"text": [["Three patients"]],"start": [[""], [""]],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"}}]}
{"id": "9892272_3","context": "The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["received"]],"start": [[], []],"entity_id": []},"Treatment": {"text": [["alteplase"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["alteplase"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["acute myocardial infarction"]],"start": [[], []],"entity_id": []},"Freq": {"text": [["for"]],"start": [[], []],"entity_id": []},"Duration": {"text": [["acute"]],"start": [[], []],"entity_id": []},"Combination": [{"Drug": {"text": [["alteplase"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["received"]],"start": [[], []],"entity_id": []},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["and developed"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["developed"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [],"start": [[], []],"entity_id": []},"Route": {"text": [["for"]],"start": [[], []],"entity_id": []}},"Effect": {"text": [["spontaneous subfascial hematoma"]],"start": [[], []],"entity_id": []},"Negated": {"text": [],"start": [[], []],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [[], []],"entity_id": [],"value": false},"Severity": {"text": [],"start": [[], []],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [[], []],"entity_id": [],"Age": {"text": [],"start": [[], []],"entity_id": []},"Gender": {"text": [],"start": [[], []],"entity_id": []},"Population": {"text": [],"start": [[], []],"entity_id": []},"Race": {"text": [],"start": [[], []],"entity_id": []},"Disorder": {"text": [],"start": [[], []],"entity_id": []}}}]}
{"id": "12121061_1","context": "Ticlopidine-induced marrow aplasia treated with cyclosporine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ticlopidine-induced marrow aplasia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": {"text": [["cyclosporine"]],"start": [[ "55" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["cyclosporine"]],"start": [[ "55" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Ticlopidine-induced marrow aplasia"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]} ,"Time_elapsed": {"text": [["treated"]],"start": [[ "28" ]],"entity_id": [ ["T3" ]]} ,"Route": {"text": [["treated"]],"start": [[ "28" ]],"entity_id": [ ["T3" ]]} ,"Dosage": { "text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["null"] ] }, "Duration": { "text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["null"] ] }, "Freq": { "text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["null"] ] }, "Combination": null ,"Trigger": null }, "Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }] }
{"id": "6947095_1", "context": "Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Dural sinus thrombosis"]],"start": [["0"]],"entity_id": []},"Subject": {"text": [["two children"]],"start": [["18"]],"entity_id": [],"Age": {"text": [["children"]],"start": [["18"]],"entity_id": []},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["8"]],"entity_id": []},"Population": {"text": [["two"]],"start": [["0"]],"entity_id": []},"Race": {"text": [["children"]],"start": [["18"]],"entity_id": []},"Gender": {"text": [["children"]],"start": [["18"]],"entity_id": []}},"Treatment": {"text": [["induction treatment with vincristine sulfate, prednisone, and asparaginase"]],"start": [["58"]],"entity_id": [],"Drug": {"text": [["vincristine sulfate"]],"start": [["58"]],"entity_id": []},"Dosage": {"text": [["induction treatment"]],"start": [["58"]],"entity_id": []},"Duration": {"text": [["induction treatment"]],"start": [["58"]],"entity_id": []},"Route": {"text": [["induction treatment"]],"start": [["58"]],"entity_id": []},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["8"]],"entity_id": []},"Time_elapsed": {"text": [["during"]],"start": [["42"]],"entity_id": []},"Freq": {"text": [["induction treatment"]],"start": [["58"]],"entity_id": []},"Combination": [{"Drug": {"text": [["vincristine sulfate"]],"start": [["58"]],"entity_id": []},"Trigger": {"text": [["and"]],"start": [["67"]],"entity_id": []},"event_id": "E1-D1","event_type": "null"},{"Drug": {"text": [["prednisone"]],"start": [["75"]],"entity_id": []},"Trigger": {"text": [["and"]],"start": [["84"]],"entity_id": []},"event_id": "E1-D2","event_type": "null"},{"Drug": {"text": [["asparaginase"]],"start": [["92"]],"entity_id": []},"Trigger": {"text": [["."]],"start": [["101"]],"entity_id": []},"event_id": "E1-D3","event_type": "null"}],"Trigger": {"text": [["developed"]],"start": [["10"]],"entity_id": []}},"Effect": {"text": [["Dural sinus thrombosis"]],"start": [["0"]],"entity_id": []},"Negated": {"text": [[""]],"start": [["0"]],"entity_id": [],"value": false},"Speculated": {"text": [[""]],"start": [["0"]],"entity_id": [],"value": false},"Severity": {"text": [[""]],"start": [["0"]],"entity_id": [],"value": ""}}]}
{"id": "9494448_1", "context": "A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypersensitivity reactions"]], "start": [["33","39"]], "entity_id": []}, "Treatment": {"text": [["cyclosporine"]], "start": [["65","73"]], "entity_id": [], "Drug": {"text": [["cyclosporine"]], "start": [["65","73"]], "entity_id": [] } ,"Disorder": { "text": [["hypersensitivity reactions"]], "start": [["33","39"]], "entity_id": [] } ,"Dosage": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Duration": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Route": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Time_elapsed": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Freq": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Trigger": { "text": [["N/A"]], "start": [[],[]], "entity_id": [] } ,"Combination": null } , "Effect": { "text": [["hypersensitivity reactions"]], "start": [["33","39"]], "entity_id": [] } , "Subject": { "text": [["all the reported cases"]], "start": [["0","12"]], "entity_id": [] , "Age": null , "Gender": null , "Population": { "text": [["all the reported cases"]], "start": [["0","12"]], "entity_id": [] } , "Race": null , "Disorder": { "text": [["hypersensitivity reactions"]], "start": [["33","39"]], "entity_i ": [] } } , "Negated": null , "Speculated": null , "Severity": null }]}
{"id": "16029707_2","context": "A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["imiquimod"]],"start": [["32"]],"entity_id": [["T1"]],"Dosage": {"text": [["5 days per week"]],"start": [["35"]],"entity_id": [["T2"]]},"Duration": {"text": [["7 weeks"]],"start": [["54"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment for a nodular basal cell"]],"start": [["16"]],"entity_id": [["T4"]]},"Trigger": {"text": [["developed"]],"start": [["86"]],"entity_id": [["T5"]]},"Route": {"text": [["over the treatment area"]],"start": [["92"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after 7 weeks of therapy"]],"start": [["66"]],"entity_id": [["T7"]]},"Freq": {"text": [["5 days per week"]],"start": [["35"]],"entity_id": [["T2"]]},"Combination": null,"Drug": {"text": [["imiquimod"]],"start": [["32"]],"entity_id": [["T1"]]}},"Subject": {"text": [["A 79-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["79-year-old"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["woman"]],"start": [["12"]],"entity_id": [["T0"]]},"Population": null,"Race": null,"Disorder": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "19224802_5", "context": "We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. ...", "is_mult_event": true, "annotations": [ {"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "Drug": {"text": [["dexmedetomidine"]], "start": [["23"]], "entity_id": [ ["T1"]]}, "Trigger": {"text": [["treatment"]], "start": [["11"]], "entity_id": [ ["T2"]]}, "entity_id": [ ["T3"]] ,"Disorder": {"text": [["bradycardia"]], "start": [["55"]], "entity_id": [ ["T4"]]} ,"Dosage": {"text": [["i.v."]], "start": [["72"]], "entity_id": [ ["T5"]]} ,"Duration": {"text": [["three cases"]], "start": [["0"]], "entity_id": [ ["T0"]]} ,"Time_elapsed": {"text": [["three cases"]], "start": [["0"]], "entity_id": [ ["T0"]]} ,"Route": {"text": [["i.v."]], "start": [["72"]], "entity_id": [ ["T5"]]} ,"Freq": null ,"Combination": null ,"text": [["treatment"]], "start": [["11"]] }, "Subject": { "text": [["We"]], "start": [["0"]], "entity_id": [ ["T6"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["dexmedetomidine-induced bradycardia"]], "start": [["36"]], "entity_id": [ ["T7"]]} }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null ,"Trigger": null } ]}
{"id": "1688693_4","context": "Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Esmolol"]],"start": [[ "0"]],"entity_id": [["T1"]]},"text": [["Esmolol, an ultrashort-acting beta 1-selective antagonist"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["multiple dysrhythmias"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["controlled"]],"start": [["47"]],"entity_id": [["T3"]]},"Route": {"text": [["antagonist"]],"start": [["28"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["controlled"]],"start": [["47"]],"entity_id": [["T3"]]},"Duration": {"text": [["ultrashort-acting"]],"start": [["21"]],"entity_id": [["T4"]]},"Freq": {"text": [["controlled"]],"start": [["47"]],"entity_id": [["T3"]]},"Dosage": {"text": [["ultrashort-acting"]],"start": [["21"]],"entity_id": [["T4"]]},"Combination": null},"Subject": {"text": [["her"]],"start": [["41"]],"entity_id": [["T5"]],"Age": null,"Disorder": {"text": [["symptoms of sympathetic nervous system hyperstimulation"]],"start": [["73"]],"entity_id": [["T6"]]},"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["controlled"]],"start": [["47"]],"entity_id": [["T3"]]},"Trigger": null}]}
{"id": "25515435_1", "context": "Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["Warfarin and boceprevir interaction"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["Warfarin"]], "start": [[ "21" ]], "entity_id": [["T2"]], "Drug": {"text": [["Warfarin"]], "start": [[ "21" ]], "entity_id": [["T3"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [["causing"]], "start": [[ "40" ]],"entity_id": [["T4"]]},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"event_type": "Potential_therapeutic_effect", "event_id": "C1", "Drug": {"text": [["boceprevir"]], "start": [[ "14" ]], "entity_id": [["T5"]]},"Trigger": {"text": [["Warfarin and boceprevir interaction"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]}}],"Trigger": {"text": [["Warfarin and boceprevir interaction"]], "start": [[ "0" ]],"entity_id": [["T1"]]}}, "Effect": {"text": [["subtherapeutic international normalized ratio"]], "start": [[ "72" ]],"entity_id": [["T6"]]},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []}}}]}
{"id": "3569037_1", "context": "A brief review of reported cases of chloramphenicol hypersensitivity in the English-language literature, as well as possible alternative explanations in this case, are provided", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["chloramphenicol hypersensitivity"]], "start": [["3569037_1.15"]], "entity_id": []}, "Effect": {"text": [["chloramphenicol hypersensitivity"]], "start": [["3569037_1.15"]], "entity_id": []}, "Treatment": {"text": [], "start": [], "entity_id": [], "Drug": {"text": [["chloramphenicol"]], "start": [["3569037_1.5"]], "entity_id": []}, "Disorder": {"text": [["hypersensitivity"]], "start": [["3569037_1.20"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": []}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}}, "Negated": {"text": [], "start": [], "entity_id": [], "value": false}, "Speculated": {"text": [], "start": [], "entity_id": [], "value": false}, "Severity": {"text": [], "start": [], "entity_id": [], "value": ""}}]}
{"id": "6692713_2", "context": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurrence", "amiodarone pulmonary toxicity"]], "start": [[ "0", "42" ]], "entity_id": [ ["T1", "T3" ]]}, "Treatment": {"text": [["corticosteroid therapy"]], "start": [["43"]], "entity_id": [ ["T2"] ], "Drug": {"text": [["corticosteroid"]], "start": [["43"]], "entity_id": [ ["T4"] ]} , "Disorder": {"text": [["amiodarone pulmonary toxicity"]], "start": [[ "42" ]], "entity_id": [ ["T3"] ]} , "Time_elapsed": {"text": [["following"]], "start": [[ "32" ]], "entity_id": [ ["T5"] ]} , "Combination": [{"Drug": {"text": [["corticosteroid"]], "start": [[ "43" ]], "entity_id": [ ["T4"] ]} , "Trigger": {"text": [["following"]], "start": [[ "32" ]], "entity_id": [ ["T5"] ]} , "event_id": "C1" , "event_type": "Adverse_event" }], "Freq": null, "Dosage": null, "Duration": null, "Route": null, "Trigger": null} , "Negated": null, "Speculated": {"text": [["possible"]], "start": [[ "0" ]], "entity_id": [ ["T6"] ] , "value": true}, "Severity": null, "Subject": null , "Effect": null }]}
{"id": "10466445_3","context": "In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers.\n","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["arsenic trioxide"]],"start": [[" "]],"entity_id": [["T1"]] ,"Drug": {"text": [["arsenic trioxide"]],"start": [[" "]],"entity_id": [["T1"]]},"Route": {"text": [["intravenously"]],"start": [[" "]],"entity_id": [["T2"]]},"Duration": {"text": [["42 days"]],"start": [[" "]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["was given"]],"start": [[" "]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["chemoresistant APL"]],"start": [[" "]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["0 days"]],"start": [[" "]],"entity_id": [["T6"]]} ,"Freq": {"text": [["1 time"]],"start": [[" "]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["0 mg"]],"start": [[" "]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["arsenic trioxide"]],"start": [[" "]],"entity_id": [["T1"]]},"Trigger": {"text": [["was given"]],"start": [[" "]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Potential_therapeutic_effect"} ]} ,"Subject": {"text": [["a 56-year-old female patient"]],"start": [[" "]],"entity_id": [["T9"]],"Age": {"text": [["56 years"]],"start": [[" "]],"entity_id": [["T10"]]},"Gender": {"text": [["female"]],"start": [[" "]],"entity_id": [["T11"]]} ,"Population": {"text": [["1 patient"]],"start": [[" "]],"entity_id": [["T12"]]},"Disorder": {"text": [["chemoresistant APL"]],"start": [[" "]],"entity_id": [["T5"]]} ,"Race": {"text": [[""]],"start": [[""]],"entity_id": [["T13"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "1765991_4","context": "We assume that rIFN-gamma induced the de novo development of SLE in our patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rIFN-gamma"]],"start": [["6-8"]],"entity_id": [["T1"]]},"Effect": {"text": [["induced the de novo development of SLE"]],"start": [["21-43"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [["rIFN-gamma"]],"start": [["6-8"]],"entity_id": [["T1"]]},"entity_id": [["T1"]] ,"Disorder": {"text": [["SLE"]],"start": [["33-35"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["21-25"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["induced"]],"start": [["21-25"]],"entity_id": [["T4"]]} ,"Route": {"text": [["induced"]],"start": [["21-25"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["induced"]],"start": [["21-25"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["induced"]],"start": [["21-25"]],"entity_id": [["T4"]]} ,"Combination": null ,"text": [["rIFN-gamma induced the de novo development of SLE"]],"start": [["6-43"]],"Trigger": {"text": [["rIFN-gamma induced the de novo development of SLE"]],"start": [["6-43"]],"entity_id": [["T1"]]} },"Subject": {"text": [["our patient"]],"start": [["46-49"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["SLE"]],"start": [["33-35"]],"entity_id": [["T3"]]} },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "17228132_8","context": "Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hepatotoxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["erlotinib"]],"start": [[ "31" ]],"entity_id": [ ["T3"] ]},"Trigger": {"text": [["discontinued"]],"start": [[ "53" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["resolved"]],"start": [[ "13" ]],"entity_id": [ ["T2"] ]} ,"entity_id": [ ["E1"] ],"text": [["Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values"]],"start": [[ "0" ]] ,"Disorder": {"text": [["Hepatotoxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Duration": {"text": [["returned"]],"start": [[ "66" ]],"entity_id": [ ["T5"] ]} ,"Freq": {"text": [["baseline normal values"]],"start": [[ "81" ]],"entity_id": [ ["T6"] ]} ,"Route": {"text": [["discontinued"]],"start": [[ "53" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [["erlotinib"]],"start": [[ "31" ]],"entity_id": [ ["T3"] ]} ,"Combination": [] }, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Hepatotoxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} }, "Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "9161656_15","context": "Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation._ CONCLUSIONS","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["asthma attack"]],"start": [["21"]],"entity_id": [["T2"]]},"Treatment": {"text": [["sustained-release verapamil"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["verapamil"]],"start": [["0"]],"entity_id": [["T3"]]},"Route": {"text": [["sustained-release"]],"start": [["0"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["with the administration"]],"start": [["28"]],"entity_id": [["T5"]]},"Duration": {"text": [["the symptoms lasted"]],"start": [["39"]],"entity_id": [["T6"]]},"Freq": {"text": [["were relieved"]],"start": [["71"]],"entity_id": [["T7"]]},"Disorder": {"text": [["its discontinuation"]],"start": [["60"]],"entity_id": [["T8"]]},"Trigger": {"text": [["its discontinuation"]],"start": [["60"]],"entity_id": [["T8"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["this patient"]],"start": [["53"]],"entity_id": [["T11"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "150825_1","context": "A patient developed cholestatic hepatitis while being treated with nitrofurantoin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["treated with nitrofurantoin"]],"start": [["41"]],"entity_id": [],"Drug": {"text": [["nitrofurantoin"]],"start": [["41"]],"entity_id": []},"Disorder": {"text": [["cholestatic hepatitis"]],"start": [["12"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "19826099_2","context": "Severe apnea in an infant exposed to lamotrigine in breast milk","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe apnea"]],"start": [[ ]],"entity_id": [ ["T1"]]},"Subject": {"text": [["an infant"]],"start": [[ ]],"entity_id": [ ["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["lamotrigine"]],"start": [[ ]],"entity_id": [ ["T3"]],"Drug": {"text": [["lamotrigine"]],"start": [[ ]],"entity_id": [ ["T3"]]},"Disorder": {"text": [["apnea"]],"start": [[ ]],"entity_id": [ ["T1"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["breast milk"]],"start": [[ ]],"entity_id": [ ["T4"]]}} , "Severity": {"value": "Severe" ,"text": [["Severe"]],"start": [[ ]],"entity_id": [ ["T1"]]} ,"Negated": null,"Speculated": null ,"Effect": null }]}
{"id": "3166573_1", "context": "Bone formation induced in an infant by systemic prostaglandin-E2 administration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["systemic prostaglandin-E2 administration"]], "start": [[ ]],"entity_id": [ ],"Drug": {"text": [["prostaglandin-E2"]], "start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["Bone formation"]], "start": [[ ]],"entity_id": [ ]},"Route": {"text": [["systemic"]], "start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["administration"]], "start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["an infant"]], "start": [[ ]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Trigger": null}]}
{"id": "18343993_1","context": "A diagnosis of trastuzumab-induced pneumonitis was made","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["trastuzumab-induced pneumonitis"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"Drug": {"text": [["trastuzumab"]],"start": [["6"]],"entity_id": [ ["T2"]]} ,"Disorder": {"text": [["pneumonitis"]],"start": [["20"]],"entity_id": [ ["T3"]]} ,"entity_id": [ ["T1"]],"text": [["trastuzumab-induced pneumonitis"]],"start": [["0"]] ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["trastuzumab-induced pneumonitis"]],"start": [["0"]],"entity_id": [ ["T1"]]} },"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A diagnosis"]],"start": [["0"]],"entity_id": [ ["T0"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }} ]}
{"id": "10885900_3","context": "We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["HUS"]],"start": [["21"]],"entity_id": [["T1"]]},"Subject": {"text": [["an advanced ovarian cancer patient"]],"start": [["12"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["ovarian cancer"]],"start": [["35"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["carboplatin and gemcitabine"]],"start": [["60"]],"entity_id": [["T4"]],"Drug": {"text": [["carboplatin"]],"start": [["60"]],"entity_id": [["T5"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["cancer"]],"start": [["75"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["carboplatin"]],"start": [["60"]],"entity_id": [["T5"]]},"Trigger": null,"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["gemcitabine"]],"start": [["68"]],"entity_id": [["T7"]]},"Trigger": null,"event_id": "C2","event_type": "Adverse_event"}],"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17034541_2","context": "Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B-cell lymphomas","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["HBV reactivations"]],"start": [[ "12" ]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["combined rituximab and multiagent chemotherapy"]],"start": [[ "50" ]],"entity_id": [ ["T2"]],"Drug": {"text": [["rituximab"]],"start": [[ "50" ]],"entity_id": [ ["T3"]]},"Disorder": {"text": [["B-cell lymphomas"]],"start": [[ "83" ]],"entity_id": [ ["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["after"]],"start": [[ "33" ]],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["multiagent chemotherapy"]],"start": [[ "60" ]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []} ,"event_id": "E2","event_type": "Potential_therapeutic_effect"} ],"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["Several"]],"start": [[ "0" ]],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "8435665_3","context": "Thus, the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["eosinophilia myalgia syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["parenteral tryptophan administration"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["tryptophan"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Route": {"text": [["parenteral"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["eosinophilia myalgia syndrome"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": null, "Duration": null ,"Dosage": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Subject": null }]}
{"id": "3790438_1","context": "Generalized pustular psoriasis precipitated by trazodone in the treatment of depression","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Generalized pustular psoriasis"]],"start": [[ ], [ ]],"entity_id": [ ]},"Treatment": {"text": [["trazodone"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["trazodone"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["depression"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["treatment"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["precipitated"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["by"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [["in"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["the"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["treatment"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["trazodone"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["treatment"]],"start": [[ ]],"entity_id": [ ]} ,"event_id": "C1","event_type": "Therapy"} ]} ,"Subject": {"text": [["Generalized pustular psoriasis"]],"start": [[ ]],"entity_id": [ ] ,"Age": {"text": [[]],"start": [[ ]],"entity_id": [ ]} ,"Gender": {"text": [[]],"start": [[ ]],"entity_id": [ ]} ,"Population": {"text": [[]],"start": [[ ]],"entity_id": [ ]} ,"Race": {"text": [[]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["depression"]],"start": [[ ]],"entity_id": [ ]}} ,"Effect": {"text": [["Generalized pustular psoriasis"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": {"text": [[]],"start": [[ ]],"entity_id": [ ] ,"value": false} ,"Speculated": {"text": [[]],"start": [[ ]],"entity_id": [ ] ,"value": false} ,"Severity": {"text": [[]],"start": [[ ]],"entity_id": [ ],"value": "Low"}}]}
{"id": "10772434_2","context": "This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["This regimen"]],"start": [["0"]],"entity_id": [ ["T1"] ],"Drug": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["hypersensitivity reactions"]],"start": [["63"]],"entity_id": [ ["T3"] ]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["who develop hypersensitivity reactions"]],"start": [["33"]],"entity_id": [ ["T2"] ]} ,"Combination": null },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []} },"Trigger": null }]}
{"id": "12150593_2","context": "We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["pupillary mydriasis"]],"start": [["56"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lidocaine"]],"start": [["36"]],"entity_id": [["T2"]],"Drug": {"text": [["lidocaine"]],"start": [["36"]],"entity_id": [["T2"]]},"Trigger": {"text": [["overdose"]],"start": [["72"]],"entity_id": [["T3"]]},"Freq": {"text": [["acutely"]],"start": [["44"]],"entity_id": [["T4"]]},"Dosage": {"text": [["overdose"]],"start": [["72"]],"entity_id": [["T3"]]},"Disorder": {"text": [["seizure disorder"]],"start": [["17"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["acutely"]],"start": [["44"]],"entity_id": [["T4"]]},"Route": {"text": [["secondary to lidocaine overdose"]],"start": [["64"]],"entity_id": [["T6"]]},"Duration": {"text": [["acutely"]],"start": [["44"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["lidocaine"]],"start": [["36"]],"entity_id": [["T2"]]},"Trigger": {"text": [["overdose"]],"start": [["72"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["neonate"]],"start": [["10"]],"entity_id": [["T7"]],"Age": {"text": [["neonate"]],"start": [["10"]],"entity_id": [["T7"]]},"Disorder": {"text": [["seizure disorder"]],"start": [["17"]],"entity_id": [["T5"]]},"Gender": {"text": [["neonate"]],"start": [["10"]],"entity_id": [["T7"]]},"Population": {"text": [["neonate"]],"start": [["10"]],"entity_id": [["T7"]]},"Race": {"text": [["neonate"]],"start": [["10"]],"entity_id": [["T7"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["pupillary mydriasis"]],"start": [["56"]],"entity_id": [["T1"]],"value": "High"},"Effect": {"text": [["pupillary mydriasis"]],"start": [["56"]],"entity_id": [["T1"]]}}]}
{"id": "18691992_2","context": "Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["adverse reaction"]],"start": [[ "38" ]],"entity_id": [ ]},"Treatment": {"text": [["hydroxyurea treatment"]],"start": [[ "92" ]],"entity_id": [ ],"Drug": {"text": [["hydroxyurea"]],"start": [[ "92" ]],"entity_id": [ ]},"Freq": {"text": [["probably"]],"start": [[ "65" ]],"entity_id": [ ]},"Disorder": {"text": [["myeloproliferative disorder"]],"start": [[ "136" ]],"entity_id": [ ]},"Dosage": {"text": [["hydroxyurea chemotherapy"]],"start": [[ "101" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["could not be discontinued"]],"start": [[ "122" ]],"entity_id": [ ]},"Trigger": {"text": [["Naranjo algorithm"]],"start": [[ "0" ]],"entity_id": [ ]},"Route": {"text": [["treatment"]],"start": [[ "92" ]],"entity_id": [ ]},"Duration": {"text": [["adverse reaction observed"]],"start": [[ "38" ]],"entity_id": [ ]},"Combination": null},"Subject": {"text": [["Based on the text"]],"start": [[ "0" ]],"entity_id": [ ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": {"text": [["probably"]],"start": [[ "65" ]],"entity_id": [ ],"value": "medium"},"Effect": {"text": [["adverse reaction"]],"start": [[ "38" ]],"entity_id": [ ]}}]}
{"id": "7673653_2","context": "Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Extrapyramidal side effects"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["selective serotonin reuptake inhibitors (SSRIs)"]],"start": [["32"]],"entity_id": [],"Drug": {"text": [["SSRIs"]],"start": [["32"]],"entity_id": []},"Disorder": {"text": [["depression", "obsessive-compulsive disorder (OCD)"]],"start": [["100"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": []},"Freq": {"text": [[]],"start": [[]],"entity_id": []},"Combination": [{"Drug": {"text": [["fluoxetine"]],"start": [["52"]],"entity_id": []},"Trigger": {"text": [["induced"]],"start": [["46"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E2"},{"Drug": {"text": [["sertraline"]],"start": [["65"]],"entity_id": []},"Trigger": {"text": [["induced"]],"start": [["46"]],"entity_id": []},"event_type": "Adverse_event","event_id": "E3"}],"Trigger": {"text": [["induced by"]],"start": [["46"]],"entity_id": []}},"Effect": {"text": [[]],"start": [[]],"entity_id": []},"Subject": {"text": [[]],"start": [[]],"entity_id": [],"Age": {"text": [[]],"start": [[]],"entity_id": []},"Gender": {"text": [[]],"start": [[]],"entity_id": []},"Population": {"text": [[]],"start": [[]],"entity_id": []},"Race": {"text": [[]],"start": [[]],"entity_id": []},"Disorder": {"text": [["depression", "obsessive-compulsive disorder (OCD)"]],"start": [["100"]],"entity_id": []}},"Negated": {"text": [[]],"start": [[]],"entity_id": [],"value": false},"Speculated": {"text": [[]],"start": [[]],"entity_id": [],"value": false},"Severity": {"text": [[]],"start": [[]],"entity_id": [],"value": ""}}]}
{"id": "9291634_6","context": "Ten-17 days after receiving chemotherapy, five patients (4 males and 1 female) with acute lymphoblastic leukemia developed incapacitating myalgias in neck, thighs and arms","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["incapacitating myalgias"]],"start": [["32"]],"entity_id": [["T1"]]},"Subject": {"text": [["five patients"]],"start": [["17"]],"entity_id": [["T2"]],"Age": null,"Gender": {"text": [["4 males and 1 female"]],"start": [["25"]],"entity_id": [["T3"]]},"Population": null,"Race": null,"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [["45"]],"entity_id": [["T4"]]}},"Treatment": {"text": [["chemotherapy"]],"start": [["10"]],"entity_id": [["T5"]],"Drug": null,"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": {"text": [["10-17 days after"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": null,"Disorder": null ,"Combination": null ,"Trigger": null },"Severity": null,"Negated": null,"Speculated": null ,"Effect": null }] }
{"id": "16791713_4", "context": "We conclude that myocardial infarction may develop in patients treated with high-dose glucocorticoids for Graves' ophthalmopathy, and increased blood pressure may herald this complication", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["glucocorticoids"]], "start": [[ "77" ]], "entity_id": [ ["T2" ]]}, "Dosage": {"text": [["high-dose"]], "start": [[ "61" ]], "entity_id": [ ["T1" ]]}, "Disorder": {"text": [["Graves' ophthalmopathy"]], "start": [[ "43" ]], "entity_id": [ ["T3" ]]} , "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "text": [ [ "high-dose glucocorticoids" ], [ "for" ], [ "Graves' ophthalmopathy" ] ], "start": [[ "61" ], [ "43" ], [ "68" ]], "entity_id": [ ["T1" ], ["T3" ], ["T2" ]] , "Trigger": null}, "Effect": {"text": [["myocardial infarction"]], "start": [[ "12" ]], "entity_id": [ ["T4" ]]} , "Trigger": {"text": [["increased blood pressure"]], "start": [[ "94" ]], "entity_id": [ ["T5" ]]} }]}
{"id": "19798640_1","context": "A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed"]],"start": [["19"]],"entity_id": []},"Subject": {"text": [["A 40-year-old man"]],"start": [["0"]],"entity_id": [],"Age": {"text": [["40"]],"start": [["4"]],"entity_id": []},"Gender": {"text": [["man"]],"start": [["22"]],"entity_id": []},"Disorder": {"text": [["relapsing-remitting multiple sclerosis (MS)"]],"start": [["6"]],"entity_id": []},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["primary central nervous system lymphoma (PCNSL)"]],"start": [["67"]],"entity_id": []},"Treatment": {"text": [["21 doses of natalizumab monotherapy"]],"start": [["94"]],"entity_id": [],"Drug": {"text": [["natalizumab"]],"start": [["106"]],"entity_id": []},"Dosage": {"text": [["21"]],"start": [["94"]],"entity_id": []},"Duration": {"text": [["21"]],"start": [["94"]],"entity_id": []},"Disorder": {"text": [["relapsing-remitting multiple sclerosis (MS)"]],"start": [["6"]],"entity_id": []},"Route": {"text": [["monotherapy"]],"start": [["120"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"}}]}
{"id": "11816261_4","context": "Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Serotonin syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["selective serotonin reuptake-inhibitors"]],"start": [[ "32" ]],"entity_id": [ ["T2"] ]},"Disorder": {"text": [["metoclopramide interaction"]],"start": [[ "58" ]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": { "text": [[ "caused" ]], "start": [[ "23" ]], "entity_id": [[ "T4" ]] }, "entity_id": [ ["E1"] ], "start": [[ "0" ]] ,"text": [[ "Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction" ]] ,"Freq": null ,"Duration": null ,"Route": null ,"Dosage": null ,"Combination": null ,"Trigger": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null }]}
{"id": "7995508_2","context": "We report a case of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["paranoid psychosis"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["decongestant containing PPA"]],"start": [["4"]],"entity_id": [["T2"]],"Drug": {"text": [["PPA"]],"start": [["33"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["within recommended guidelines"]],"start": [["108"]],"entity_id": [["T4"]]} ,"Route": {"text": [["use"]],"start": [["7"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["12"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["paranoid psychosis"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["report"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["use"]],"start": [["7"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["PPA"]],"start": [["33"]],"entity_id": [["T3"]]},"Trigger": {"text": [["decongestant"]],"start": [["4"]],"entity_id": [["T2"]]} ,"event_id": "C1","event_type": "Adverse_event"} ] ,"Duration": {"text": [["report"]],"start": [["0"]],"entity_id": [["T7"]]}}, "Effect": {"text": [["psychiatric adverse effects"]],"start": [["81"]],"entity_id": [["T8"]]},"Negated": {"value": false ,"text": [["adverse effects"]],"start": [["81"]],"entity_id": [["T8"]]} ,"Speculated": {"value": false ,"text": [["report"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Severity": {"value": "Low" ,"text": [["adverse effects"]],"start": [["81"]],"entity_id": [["T8"]]} ,"Subject": {"Age": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T9"], ["T10"]]} ,"Gender": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T9"], ["T10"]]} ,"Population": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T9"], ["T10"]]} ,"Race": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T9"], ["T10"]]} ,"Disorder": {"text": [["case report literature"]],"start": [["43"]],"entity_id": [["T11"]]} ,"text": [["We"]],"start": [["0"]],"entity_id": [["T12"]]} }]}
{"id": "17133571_1", "context": "Liver transplantation for fulminant hepatitis related to nevirapine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fulminant hepatitis"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["nevirapine therapy"]], "start": [["52"]], "entity_id": [], "Drug": {"text": [["nevirapine"]], "start": [["52"]], "entity_id": [] } , "Duration": {"text": [["related"]], "start": [["41"]], "entity_id": [] } , "Disorder": {"text": [["fulminant hepatitis"]], "start": [["18"]], "entity_id": [] }, "Trigger": {"text": [["related"]], "start": [["41"]], "entity_id": [] }, "Route": {"text": [["therapy"]], "start": [["52"]], "entity_id": [] }, "Time_elapsed": {"text": [["related"]], "start": [["41"]], "entity_id": [] }, "Freq": {"text": [["related"]], "start": [["41"]], "entity_id": [] }, "Combination": [], "Dosage": {"text": [], "start": [], "entity_id": [] }}, "Effect": {"text": [["Liver transplantation"]], "start": [["0"]], "entity_id": [] }, "Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Liver transplantation"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "11414270_2", "context": "To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fatal hyperkalemia"]], "start": [["39","46"]], "entity_id": []}, "Treatment": {"text": [["succinylcholine administration"]], "start": [["70","81"]], "entity_id": [],"Drug": {"text": [["succinylcholine"]], "start": [["70","79"]], "entity_id": [] },"Route": {"text": [["administration"]], "start": [["80","81"]], "entity_id": [] },"Time_elapsed": {"text": [["owing"]], "start": [["64","67"]], "entity_id": [] },"Disorder": {"text": [["mucositis secondary to chemotherapy"]], "start": [["12","35"]], "entity_id": [] },"Dosage": {"text": [], "start": [], "entity_id": [] },"Duration": {"text": [], "start": [], "entity_id": [] },"Freq": {"text": [], "start": [], "entity_id": [] },"Combination": [],"Trigger": {"text": [], "start": [], "entity_id": [] } },"Effect": {"text": [], "start": [], "entity_id": [] },"Subject": {"text": [], "start": [], "entity_id": [] ,"Age": {"text": [], "start": [], "entity_id": [] },"Gender": {"text": [], "start": [], "entity_id": [] },"Population": {"text": [], "start": [], "entity_id": [] },"Race": {"text": [], "start": [], "entity_id": [] },"Disorder": {"text": [["patient"]], "start": [["0","7"]], "entity_id": [] } },"Negated": {"text": [], "start": [], "entity_id": [] ,"value": false },"Speculated": {"text": [], "start": [], "entity_id": [],"value": false },"Severity": {"text": [], "start": [], "entity_id": [],"value": "fatal" }}]}
{"id": "8835752_3", "context": "We describe a case of prolonged terbinafine-induced cholestatic liver disease", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["We"]], "start": [[ ]], "entity_id": [ ] ,"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null}, "Treatment": {"text": [["terbinafine"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["terbinafine"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": {"text": [["cholestatic liver disease"]], "start": [[ ]], "entity_id": [ ]}} , "Effect": {"text": [["prolonged"]], "start": [[ ]], "entity_id": [ ]} ,"Negated": null, "Speculated": null, "Severity": null , "Trigger": null }]}
{"id": "10707759_3","context": "We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["interstitial hypoxaemiant pneumonitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["flecainide"]],"start": [["68"]],"entity_id": [["T2"]],"Drug": {"text": [["flecainide"]],"start": [["68"]],"entity_id": [["T3"]]},"Disorder": {"text": [["LEOPARD syndrome"]],"start": [["102"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]},"Trigger": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["flecainide"]],"start": [["68"]],"entity_id": [["T3"]]},"Trigger": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"}],"Freq": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]},"Duration": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]},"Route": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]]}},"Subject": {"text": [["a patient"]],"start": [["93"]],"entity_id": [["T6"]],"Age": {"text": [["a patient"]],"start": [["93"]],"entity_id": [["T6"]]},"Gender": {"text": [["a patient"]],"start": [["93"]],"entity_id": [["T6"]]},"Population": {"text": [["a patient"]],"start": [["93"]],"entity_id": [["T6"]]},"Race": {"text": [["a patient"]],"start": [["93"]],"entity_id": [["T6"]]},"Disorder": {"text": [["a patient with the LEOPARD syndrome"]],"start": [["93"]],"entity_id": [["T6"]]}},"Effect": {"text": [["interstitial hypoxaemiant pneumonitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]],"value": false},"Speculated": {"text": [["probably related"]],"start": [["48"]],"entity_id": [["T5"]],"value": false},"Severity": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]],"value": "low"}}]}
{"id": "3405528_2", "context": "Halothane hepatitis and prompt resolution with methionine therapy: case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Halothane hepatitis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["methionine therapy"]], "start": [[ "54" ]], "entity_id": [ ["T2" ]], "Drug": {"text": [["methionine"]], "start": [[ "54" ]], "entity_id": [ ["T3" ]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null, "Combination": null, "Trigger": null} ,"Effect": { "text": [[ "prompt resolution" ]], "start": [[ "43" ]], "entity_id": [[ "T4" ]]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [[ "patient" ]], "start": [[ "0" ]], "entity_id": [[ "T0" ]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null} }]}
{"id": "11706664_2","context": "This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["drug-induced hepatitis"]],"start": [["This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate"]],"entity_id": []},"Subject": {"text": [["a previously healthy young woman"]],"start": [[""], ["This report describes an"]],"entity_id": [],"Age": {"text": [["young"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Population": {"text": [["1"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["amodiaquine and artesunate"]],"start": [[""], ["This report describes an"]],"entity_id": [],"Drug": {"text": [["amodiaquine"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Dosage": {"text": [["2 doses"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Combination": [{"Drug": {"text": [["amodiaquine"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []} ,"event_id": "C1","event_type": "Adverse_event" },{"Drug": {"text": [["artesunate"]],"start": [[""], ["This report describes an"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []} ,"event_id": "C2","event_type": "Adverse_event" }] ,"Trigger": {"text": [],"start": [],"entity_id": []} }, "Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null, "Speculated": null, "Severity": { "text": [["unexpected"]],"start": [[""], ["This report describes an"]],"entity_id": [] ,"value": "high"} }]}
{"id": "9366852_4","context": "We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from low-molecular weight heparin therapy at sites distant from injection sites","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["skin necrosis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["low-molecular weight heparin therapy"]],"start": [["68"]],"entity_id": [["T2"]],"Drug": {"text": [["low-molecular weight heparin"]],"start": [["68"]],"entity_id": [["T3"]]},"Route": {"text": [["injection sites"]],"start": [["102"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["develop"]],"start": [["32"]],"entity_id": [["T5"]]},"Disorder": {"text": [["antiphospholipid syndrome"]],"start": [["12"]],"entity_id": [["T6"]]},"Freq": {"text": [["develop"]],"start": [["32"]],"entity_id": [["T5"]]},"Combination":[{"Drug": {"text": [["low-molecular weight heparin"]],"start": [["68"]],"entity_id": [["T3"]]},"Trigger": {"text": [["injection sites"]],"start": [["102"]],"entity_id": [["T4"]]},"event_id":"E2","event_type":"Adverse_event"}],"Trigger": {"text": [["develop"]],"start": [["32"]],"entity_id": [["T5"]]},"Dosage": {"text": [["low-molecular weight heparin"]],"start": [["68"]],"entity_id": [["T3"]]},"Duration": {"text": [["develop"]],"start": [["32"]],"entity_id": [["T5"]]}},"Subject": {"text": [["a patient"]],"start": [["8"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["antiphospholipid syndrome"]],"start": [["12"]],"entity_id": [["T6"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value":false},"Speculated": {"text": [],"start": [],"entity_id": [],"value":false},"Severity": {"text": [],"start": [],"entity_id": [],"value":"moderate"},"Effect": {"text": [["skin necrosis"]],"start": [["32"]],"entity_id": [["T1"]]}}]}
{"id": "18022748_11", "context": "While CYP form induction by Pyrethrins, Phenobarbital and related compounds can be associated with liver and thyroid gland tumour formation in rodents, epidemiological data for Phenobarbital suggests that such effects do not occur in humans.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": {"value": true, "text": [["such effects do not occur in humans"]], "start": [[],[]], "entity_id": []}, "Trigger": {"text": [["CYP form induction"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["Pyrethrins", "Phenobarbital and related compounds"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["Pyrethrins", "Phenobarbital"]], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [["liver and thyroid gland tumour formation"]], "start": [[],[]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null},"Effect": null,"Subject": null,"Speculated": null,"Severity": null}] }
{"id": "7416268_1", "context": "Disulfiram encephalopathy as a cause of the catatonia syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Disulfiram encephalopathy"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Effect": {"text": [["the catatonia syndrome"]], "start": [[ "48" ]],"entity_id": [ ["T2"] ]} ,"Treatment": { "text": [["Disulfiram"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ] ,"Drug": { "text": [["Disulfiram"]], "start": [[ "0" ]], "entity_id": [ ["T4"] ] }, "Disorder": { "text": [["the catatonia syndrome"]], "start": [[ "48" ]], "entity_id": [ ["T5"] ] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }}]}
{"id": "7653281_2", "context": "Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effects"]], "start": [["33-39"]], "entity_id": []}, "Treatment": {"text": [["exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde"]], "start": [["5-59"]], "entity_id": [],"Dosage": {"text": [["Little has been studied"]], "start": [["0-8"]], "entity_id": []},"Duration": {"text": [["of"]], "start": [["59"]], "entity_id": []},"Disorder": {"text": [["the liver"]], "start": [["5-10"]], "entity_id": []},"Route": {"text": [["to"]], "start": [["10"]], "entity_id": []},"Time_elapsed": {"text": [["the interaction of ethanol with its congeners and acetaldehyde"]], "start": [["11-59"]], "entity_id": []},"Trigger": {"text": [["coexisting in the contents of alcoholic beverages."]], "start": [["60-86"]], "entity_id": []} ,"Freq":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]},"Combination":[{"Drug":{"text":[["ethanol"]],"start":[["41-45"]],"entity_id":[]},"Trigger":{"text":[["and"]],"start":[["55"]],"entity_id":[]},"event_type":"Adverse_event","event_id":"E1-1"}],"Drug":{"text":[["its congeners"]],"start":[["46-50"]],"entity_id":[]} },"Subject":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[],"Age":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]},"Gender":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]},"Population":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]},"Race":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]},"Disorder":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[]}},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[["Little has been studied"]],"start":[["0-8"]],"entity_id":[],"value":"Low" },"Effect":{"text":[["adverse effects"]],"start":[["33-39"]],"entity_id":[]}}]}
{"id": "22735246_1","context": "Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["16"]],"entity_id": [["T2"]]},"Treatment": {"text": [["oxcarbazepine"]],"start": [["41"]],"entity_id": [["T3"]],"Drug": {"text": [["oxcarbazepine"]],"start": [["41"]],"entity_id": [["T4"]]},"Disorder": {"text": [["selective serotonin reuptake inhibitor"]],"start": [["62"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "fatal"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null}}]}
{"id": "10803790_7","context": "When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["cyanamide-treated"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"Drug": {"text": [["cyanamide"]],"start": [["0"]],"entity_id": [["T2"] ]},"Disorder": {"text": [["alcoholics"]],"start": [["20"]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": {"text": [["relapse into drinking"]],"start": [["23"]],"entity_id": [ ["T4"] ]} ,"Trigger": {"text": [["develops"]],"start": [["66"]],"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"text": [["cyanamide-treated alcoholics relapse into drinking"]],"start": [["0"]],"entity_id": [ ["T6"] ]} ,"Effect": {"text": [["inflammation"]],"start": [["80"]],"entity_id": [ ["T7"] ]},"Subject": {"text": [["liver"]],"start": [["97"]],"entity_id": [ ["T8"] ],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Negated": null ,"Speculated": null ,"Severity": {"text": [["severe"]],"start": [["73"]],"entity_id": [ ["T9"] ],"value": "high" }} ]}
{"id": "9256906_2","context": "Acute renal failure should be recognized as a potential complication of suramin treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["potential complication"]],"start": [["53"]],"entity_id": [["T1"]]},"Treatment": {"text": [["suramin treatment"]],"start": [["73"]],"entity_id": [["T2"]],"Disorder": {"text": [["acute renal failure"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Duration": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Route": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Time_elapsed": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Freq": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Combination": null ,"Drug": {"text": [["suramin"]],"start": [["73"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} },"Subject": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"Age": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Disorder": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Gender": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} ,"Population": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]} },"Effect": {"text": [["acute renal failure"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Negated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]] ,"value": false },"Speculated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]], "value": false },"Severity": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": "null" }} ]}
{"id": "8936932_2", "context": "After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride, her cardiac rhythm progressed to asystole", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["progressed to asystole"]], "start": [["59"]], "entity_id": []}, "Treatment": {"text": [["induction of general anesthesia", "administration of a standard dose of intravenous esmolol hydrochloride"]], "start": [["0", "30"]], "entity_id": [], "Drug": {"text": [["esmolol hydrochloride"]], "start": [["43"]], "entity_id": []},"Route": {"text": [["intravenous"]], "start": [["35"]], "entity_id": []},"Dosage": {"text": [["a standard dose"]], "start": [["30"]], "entity_id": []},"Disorder": {"text": [["cardiac rhythm"]], "start": [["50"]], "entity_id": []},"Time_elapsed": {"text": [["after"]], "start": [["30"]], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [],"Trigger": { "text":[["administration"]], "start":[[ "43"]], "entity_id":[] },"Duration":{"text":[], "start": [], "entity_id":[]}},"Effect":{"text":[["cardiac rhythm progressed to asystole"]], "start":[[ "59"]], "entity_id":[]},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[], "start":[], "entity_id":[],"value":false},"Severity":{"text":[["asystole"]], "start":[[ "59"]], "entity_id":[],"value":"High" },"Subject":{"text":[["her"]], "start":[[ "48"]], "entity_id":[],"Age":{"text":[], "start":[], "entity_id":[]},"Gender":{"text":[], "start":[], "entity_id":[]},"Population":{"text":[], "start":[], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]},"Disorder":{"text":[["cardiac rhythm"]], "start":[[ "50"]], "entity_id":[]}} }]}
{"id": "1977935_1", "context": "Torsades de pointes occurring in association with terfenadine use", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Torsades de pointes"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["terfenadine use"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["terfenadine"]], "start": [[ ]], "entity_id": [ ]} ,"Route": {"text": [["use"]], "start": [[ ]], "entity_id": [ ]} , "Freq": {"text": [["occurring in association with"]], "start": [[ ]], "entity_id": [ ]} , "Time_elapsed": {"text": [["use"]], "start": [[ ]], "entity_id": [ ]} ,"Duration": {"text": [["occurring"]], "start": [[ ]], "entity_id": [ ]} , "Disorder": {"text": [["Torsades de pointes"]], "start": [[ ]], "entity_id": [ ]} ,"Dosage": {"text": [[]], "start": [[ ]], "entity_id": [ ]} , "Combination": [{"Drug": {"text": [["terfenadine"]], "start": [[ ]], "entity_id": [ ]} ,"Trigger": {"text": [["use"]], "start": [[ ]], "entity_id": [ ]} ,"event_type": "Adverse_event" ,"event_id": "E1" }], "Trigger": {"text": [["Torsades de pointes"]], "start": [[ ]], "entity_id": [ ]} } , "Negated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"} ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": {"text": [],"start": [],"entity_id": []}, "Disorder": {"text": [],"start": [],"entity_id": []}, "Gender": {"text": [],"start": [],"entity_id": []}, "Population": {"text": [],"start": [],"entity_id": []}, "Race": {"text": [],"start": [],"entity_id": []} }, "Effect": {"text": [["Torsades de pointes"]], "start": [[ ]], "entity_id": [ ]} }]}
{"id": "10452772_5", "context": "Protamine allergy as a complication of insulin hypersensitivity: A case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Protamine allergy"]], "start": [[ "0"]], "entity_id": [ ["T1"]]}, "Subject": { "text": [["A case report"]], "start": [[ "58"]], "entity_id": [ ["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["complication", "of", "insulin", "hypersensitivity"]], "start": [[ "6", "27", "37", "44"]], "entity_id": [ ["T3"]] } }, "Treatment": null , "Effect": null , "Negated": null , "Speculated": null , "Severity": null } ] }
{"id": "2038845_1","context": "This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro-pharyngeal dystonic reaction to prochlorperazine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["oro-pharyngeal dystonic reaction"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["prochlorperazine"]],"start": [["81"]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["epiglottitis"]],"start": [["12"]],"entity_id": [["T3"]]},"Freq": {"text": [["had"]],"start": [["5"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["had"]],"start": [["5"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["prochlorperazine"]],"start": [["81"]],"entity_id": [["T2"]]},"Trigger": {"text": [["oro-pharyngeal dystonic reaction"]],"start": [["36"]],"entity_id": [["T1"]]},"event_type": "Adverse_event","event_id": "E2"}],"Trigger": {"text": [["prochlorperazine"]],"start": [["81"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Route": null},"Subject": {"text": [["a patient"]],"start": [["7"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["epiglottitis"]],"start": [["12"]],"entity_id": [["T3"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["oro-pharyngeal dystonic reaction"]],"start": [["36"]],"entity_id": [["T1"]]}}]}
{"id": "19537383_1", "context": "Localized dyskeratotic plaque with milia associated with sorafenib.","is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Localized dyskeratotic plaque with milia"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["sorafenib"]], "start": [[ "55" ]], "entity_id": [ ["T2" ]], "Drug": {"text": [["sorafenib"]], "start": [[ "55" ]], "entity_id": [ ["T2" ]]} ,"Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": {"text": [["associated with"]], "start": [[ "50" ]], "entity_id": [ ["T3" ]]} }, "Subject": null ,"Effect": {"text": [["Localized dyskeratotic plaque with milia"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]} ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "7416268_2","context": "The authors describe a case of the catatonia syndrome associated with disulfiram therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["catatonia syndrome"]],"start": [["The authors describe a case of the " ,"catatonia syndrome associated with disulfiram therapy" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["disulfiram therapy"]],"start": [["The authors describe a case of the catatonia syndrome associated with "]],"entity_id": [["T2"]],"Drug": {"text": [["disulfiram"]],"start": [["The authors describe a case of the catatonia syndrome associated with disulfiram "]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["catatonia syndrome"]],"start": [["The authors describe a case of the "]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]} ,"Freq": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]} ,"Route": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]} ,"Dosage": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]} ,"Duration": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]} ,"Combination": null ,"Trigger": {"text": [[""], ["associated with"]],"start": [[],["The authors describe a case of the catatonia syndrome "]],"entity_id": [[],["T2"]]}} ,"Subject": {"text": [["The authors describe a case"]],"start": [[],["catatonia syndrome associated with disulfiram therapy"]],"entity_id": [[],[]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Effect": {"text": [["catatonia syndrome"]],"start": [["The authors describe a case of the "]],"entity_id": [["T1"]]}}]}
{"id": "7663030_12", "context": "Propafenone's distribution, clearance, and structural similarity to propranolol contribute to its central nervous system effects", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Propafenone"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ],"Drug": { "text": [["Propafenone"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]} ,"Disorder": { "text": [["central nervous system effects"]], "start": [[ "86" ]], "entity_id": [ ["T2" ] ]} ,"Route": { "text": [["Propafenone's distribution"]], "start": [[ "0" ]], "entity_id": [ ["T3" ] ]} ,"Duration": { "text": [["Propafenone's distribution"]], "start": [[ "0" ]], "entity_id": [ ["T3" ] ]} ,"Trigger": { "text": [["contribute"]], "start": [[ "64" ]], "entity_id": [ ["T4" ] ]} ,"Time_elapsed": { "text": [["Propafenone's distribution"]], "start": [[ "0" ]], "entity_id": [ ["T3" ] ]} ,"Dosage": { "text": [["Propafenone's distribution"]], "start": [[ "0" ]], "entity_id": [ ["T3" ] ]} ,"Freq": { "text": [["Propafenone's distribution"]], "start": [[ "0" ]], "entity_id": [ ["T3" ] ]} ,"Combination": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null}]}
{"id": "19423610_1", "context": "Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["severe serotonin toxicity"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["co-administration of methylene blue and serotonin reuptake inhibitors"]], "start": [["50"]], "entity_id": [], "Combination": [{"event_type": "Adverse_event","event_id": "E2","Drug": {"text": [["methylene blue"]],"start": [["50"]],"entity_id": []},"Trigger": {"text": [["methylene blue"]],"start": [["50"]],"entity_id": []}},{"event_type": "Adverse_event","event_id": "E3","Drug": {"text": [["serotonin reuptake inhibitors"]],"start": [["61"]],"entity_id": []},"Trigger": {"text": [["serotonin reuptake inhibitors"]],"start": [["61"]],"entity_id": []}}], "Disorder": {"text": [["post-operative delirium"]],"start": [["97"]],"entity_id": []}, "Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []}, "Trigger": {"text": [],"start": [],"entity_id": []}, "Drug": {"text": [],"start": [],"entity_id": []}}, "Effect": {"text": [["severe serotonin toxicity"]],"start": [["18"]],"entity_id": []}, "Negated": {"text": [],"start": [],"entity_id": [], "value": false},"Speculated": {"text": [],"start": [],"entity_id": [], "value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}, "Subject": {"text": [],"start": [],"entity_id": [], "Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "18707772_1", "context": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 64 year old woman"]], "start": [[], []], "entity_id": [],"Age": {"text": [["64"]], "start": [[], []], "entity_id": []},"Disorder": {"text": [["previous history of coronary stenting five days before"]], "start": [[], []], "entity_id": []},"Gender": {"text": [["woman"]], "start": [[], []], "entity_id": []},"Population": {"text": [["A 64 year old woman"]], "start": [[], []], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}}, "Treatment": {"text": [["aspirin and clopidogrel"]], "start": [[], []], "entity_id": [],"Drug": {"text": [["aspirin"]], "start": [[], []], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["aspirin"]], "start": [[], []], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"event_type": "Treatment","event_id": "C1"}],"Disorder": {"text": [["coronary stenting five days before"]], "start": [[], []], "entity_id": []}}, "Effect": {"text": [["intracranial bleeding"]], "start": [[], []], "entity_id": []},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "", "text": [],"start": [],"entity_id": []},"Trigger": {"text": [["was admitted"]], "start": [[], []], "entity_id": []}}]}
{"id": "12324937_5","context": "A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["gemcitabine treatment"]],"start": [["55"]],"entity_id": [["T1"]],"Disorder": {"text": [["ovarian cancer"]],"start": [["70"]],"entity_id": [["T2"]]},"Dosage": {"text": [["prolonged"]],"start": [["55"]],"entity_id": [["T3"]]},"Route": {"text": [["treatment"]],"start": [["55"]],"entity_id": [["T4"]]},"Duration": {"text": [["prolonged"]],"start": [["55"]],"entity_id": [["T5"]]},"Trigger": {"text": [["after drug discontinuation"]],"start": [["102"]],"entity_id": [["T6"]]},"Freq": {"text": [["prolonged"]],"start": [["55"]],"entity_id": [["T7"]]},"Drug": {"text": [["gemcitabine"]],"start": [["55"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["gemcitabine"]],"start": [["55"]],"entity_id": [["T8"]]},"Trigger": {"text": [["after drug discontinuation"]],"start": [["102"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["after drug discontinuation"]],"start": [["102"]],"entity_id": [["T6"]]}},"Subject": {"text": [["a 45-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["45-year-old"]],"start": [["0"]],"entity_id": [["T9"]]},"Gender": {"text": [["woman"]],"start": [["7"]],"entity_id": [["T10"]]},"Population": {"text": [["a"]],"start": [["0"]],"entity_id": [["T11"]]},"Disorder": {"text": [["ovarian cancer"]],"start": [["70"]],"entity_id": [["T2"]]},"Race": {"text": [["a"]],"start": [["0"]],"entity_id": [["T12"]]}},"Effect": {"text": [["developed HUS"]],"start": [["91"]],"entity_id": [["T13"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["who developed HUS"]],"start": [["82"]],"entity_id": [["T14"]]}}]}
{"id": "889156_4","context": "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["more serious development"]],"start": [["0"]],"entity_id": [["T1"]]},"Effect": {"text": [["adrenal insufficiency"]],"start": [["31"]],"entity_id": [["T2"]]},"Treatment": {"text": [["the improper replacement of systemic steroids"]],"start": [["55"]],"entity_id": [["T3"]],"Trigger": {"text": [["replacement"]],"start": [["62"]],"entity_id": [["T4"]]},"Drug": {"text": [["systemic steroids"]],"start": [["66"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["adrenal insufficiency"]],"start": [["31"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["improper"]],"start": [["55"]],"entity_id": [["T3"]]} ,"Route": {"text": [["replacement"]],"start": [["62"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["may occur"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["may occur"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["may occur"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [["more serious"]],"start": [["0"]],"entity_id": [["T1"]] ,"value" :"high" },"Subject": null }]}
{"id": "1495728_2","context": "We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pneumonitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["local administration of methotrexate"]],"start": [["46"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["46"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["nonsurgical termination of an ectopic pregnancy"]],"start": [["85"]],"entity_id": [["T4"]]} ,"Route": {"text": [["local administration"]],"start": [["46"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["18"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["following"]],"start": [["18"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["following"]],"start": [["18"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["nonsurgical termination of an ectopic pregnancy"]],"start": [["85"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["local administration"]],"start": [["46"]],"entity_id": [["T5"]]} ,"Combination": [] },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["nonsurgical termination of an ectopic pregnancy"]],"start": [["85"]],"entity_id": [["T4"]]} },"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""} }]}
{"id": "19667003_1", "context": "Carbamazepine-induced hyperammonemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Carbamazepine-induced hyperammonemia"]], "start": [[ ]],"entity_id": [ ]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Carbamazepine"]], "start": [[ ]], "entity_id": [ ] },"Disorder": {"text": [["hyperammonemia"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["induced"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": {"text": [["Carbamazepine-induced"]], "start": [[ ]], "entity_id": [ ]} },"Effect": {"text": [["hyperammonemia"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "10667036_1","context": "Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["undesired accumulation"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["TCA"]],"start": [["17"]],"entity_id": [["T2"]],"Drug": {"text": [["TCA"]],"start": [["17"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Cushing's syndrome"]],"start": [["72"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["may lead"]],"start": [["53"]],"entity_id": [["T4"]]},"Freq": {"text": [["needed"]],"start": [["7"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["TCA"]],"start": [["17"]],"entity_id": [["T2"]]},"Trigger": {"text": [["accumulation"]],"start": [["31"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["prevent"]],"start": [["7"]],"entity_id": [["T5"]]},"Route": {"text": [["accumulation"]],"start": [["31"]],"entity_id": [["T1"]]},"Duration": {"text": [["protracted"]],"start": [["63"]],"entity_id": [["T3"]]}},"Subject": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]],"Gender": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Cushing's syndrome"]],"start": [["72"]],"entity_id": [["T3"]]}},"Effect": {"text": [["Cushing's syndrome"]],"start": [["72"]],"entity_id": [["T3"]]},"Negated": {"text": [["prevent"]],"start": [["7"]],"entity_id": [["T5"]],"value": false},"Speculated": {"text": [["Caution"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [["protracted"]],"start": [["63"]],"entity_id": [["T3"]],"value": "high"}}]}
{"id": "7408538_2","context": "Unusual pigmentary changes associated with 5-fluorouracil therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Unusual pigmentary changes"]],"start": [[ "0" ]],"entity_id": []},"Treatment": {"text": [["5-fluorouracil therapy"]],"start": [[ "52" ]],"entity_id": [],"Drug": {"text": [["5-fluorouracil"]],"start": [[ "52" ]],"entity_id": []} ,"Disorder": { "text": [], "start": [], "entity_id": [] } ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } ,"Effect": { "text": [["Unusual pigmentary changes"]], "start": [[ "0" ]], "entity_id": [] }, "Speculated": null, "Negated": null, "Severity": null }] }
{"id": "9876812_4","context": "Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Syndrome of inappropriate antidiuretic hormone"]],"start": [[ "0 "]],"entity_id": [ ["T1"] ] }, "Treatment": { "text": [["vinorelbine therapy"]], "start": [[ "61 "]], "entity_id": [ ["T2"] ] ,"Drug": { "text": [["vinorelbine"]], "start": [[ "61 "]], "entity_id": [ ["T3"] ] }, "Disorder": { "text": [["Syndrome of inappropriate antidiuretic hormone"]], "start": [[ "0 "]], "entity_id": [ ["T1"] ] }, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }} ] }
{"id": "18453852_14","context": "The study showed a high incidence of adverse events when a higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["adverse events"]],"start": [["33"]],"entity_id": [ ["T1"]]},"Treatment": {"Drug": {"text": [["lopinavir/ritonavir tablets"]],"start": [["55"]],"entity_id": [ ["T2"]]},"Dosage": {"text": [["higher than standard dose"]],"start": [["14"]],"entity_id": [ ["T3"]]},"Combination": [{"Drug": {"text": [["rifampicin"]],"start": [["105"]],"entity_id": [ ["T4"]]} ,"Trigger": {"text": [["combined"]],"start": [["95"]],"entity_id": [ ["T5"]]} ,"event_id": "C1" ,"event_type": "Combination" }],"entity_id": [ ["T2"]],"text": [["new lopinavir/ritonavir tablets"]],"start": [[ "55"]] ,"Freq": {"text": [["showed"]],"start": [[ "0"]],"entity_id": [ ["T0"]] }, "Time_elapsed": {"text": [["when"]],"start": [[ "91"]],"entity_id": [ ["T6"]] }, "Route": {"text": [["was combined"]],"start": [[ "95"]],"entity_id": [ ["T5"]] }, "Duration": {"text": [["a higher than standard dose"]],"start": [[ "14"]],"entity_id": [ ["T3"]] }, "Disorder": {"text": [["adverse events"]],"start": [[ "33"]],"entity_id": [ ["T1"]] }, "Trigger": {"text": [["high incidence"]],"start": [[ "6"]],"entity_id": [ ["T7"]] }} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": {"text": [["high incidence"]],"start": [[ "6"]],"entity_id": [ ["T7"]] }} ]}
{"id": "19499966_3", "context": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["patient"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": [],"Age": null, "Gender": {"text": [["male"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": []}, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["sunitinib"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": [],"Drug": {"text": [["sunitinib"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": []},"Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": []}, "Dosage": null, "Duration": null,"Route": null, "Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["onset"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": []}},"Effect": {"text": [["male gynaecomastia"]], "start": [["Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "7973922_3","context": "Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of acyclovir neurotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["acyclovir neurotoxicity"]],"start": [["65"]],"entity_id": [["T1"]]},"Treatment": {"text": [["acyclovir"]],"start": [["36"]],"entity_id": [["T2"]],"Disorder": {"text": [["renal dysfunction"]],"start": [["19"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["preceded"]],"start": [["0"]],"entity_id": [["T4"]]},"Dosage": {"text": [["all 30 reported cases"]],"start": [["41"]],"entity_id": [["T5"]]},"Trigger": {"text": [["Systemic disease"]],"start": [["0"]],"entity_id": [["T6"]]},"Freq": {"text": [["all"]],"start": [["41"]],"entity_id": [["T5"]]},"Duration": {"text": [["preceded"]],"start": [["0"]],"entity_id": [["T4"]]},"Drug": {"text": [["acyclovir"]],"start": [["36"]],"entity_id": [["T2"]]},"Route": {"text": [["neurotoxicity"]],"start": [["65"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["acyclovir"]],"start": [["36"]],"entity_id": [["T2"]]},"Trigger": {"text": [["renal dysfunction"]],"start": [["19"]],"entity_id": [["T3"]]},"event_id": "E1","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["all 30 reported cases"]],"start": [["41"]],"entity_id": [["T5"]],"Population": {"text": [["all 30 reported cases"]],"start": [["41"]],"entity_id": [["T5"]]},"Disorder": {"text": [["renal dysfunction"]],"start": [["19"]],"entity_id": [["T3"]]},"Age": {"text": [["all"]],"start": [["41"]],"entity_id": [["T5"]]},"Gender": {"text": [["all"]],"start": [["41"]],"entity_id": [["T5"]]},"Race": {"text": [["all"]],"start": [["41"]],"entity_id": [["T5"]]}},"Negated": {"text": [["not"]],"start": [[""],[""],[""],[""]],"entity_id": [[""],[""],[""],[]],"value": false},"Speculated": {"text": [["all 30 reported cases"]],"start": [["41"]],"entity_id": [["T5"]],"value": false},"Severity": {"text": [["neurotoxicity"]],"start": [["65"]],"entity_id": [["T1"]],"value": "High"},"Effect": {"text": [["acyclovir neurotoxicity"]],"start": [["65"]],"entity_id": [["T1"]]}}]}
{"id": "4082283_1", "context": "Rifampicin-induced renal failure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Rifampicin-induced"]], "start": [["0"]], "entity_id":[["T1"]]}, "Treatment": {"text": [["Rifampicin"]], "start": [["0"]], "entity_id":[["T2"]],"Drug": null, "Disorder": {"text": [["renal failure"]], "start": [["22"]], "entity_id":[["T3"]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null},"Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "15920338_1","context": "A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["high-grade endometrial stromal sarcoma"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Subject": { "Age": null, "Gender": { "text": [["woman"]], "start": [[ "69" ]], "entity_id": [ ["T2"] ]}, "Population": null, "Race": null, "Disorder": { "text": [["history of breast cancer"]], "start": [[ "48" ]], "entity_id": [ ["T3"] ]} ,"entity_id": [ ["T1"] ],"text": [["high-grade endometrial stromal sarcoma"]], "start": [[ "0" ]] },"Treatment": { "text": [["adjuvant tamoxifen"]], "start": [[ "109" ]], "entity_id": [ ["T4"] ], "Drug": { "text": [["tamoxifen"]], "start": [[ "109" ]], "entity_id": [ ["T5"] ]}, "Disorder": { "text": [["high-grade endometrial stromal sarcoma"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null ,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": { "text": [["confined into an intrauterine polypoid growth"]], "start": [[ "38" ]], "entity_id": [ ["T6"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "19018868_1", "context": "A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["severe aplastic anemia"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["treatment with lenalidomide"]], "start": [["52"]], "entity_id": [["T2"]], "Drug": {"text": [["lenalidomide"]], "start": [["52"]], "entity_id": [["T3"]]},"Disorder": {"text": [["multiple myeloma"]], "start": [["77"]], "entity_id": [["T4"]]},"Duration": {"text": [["treatment"]], "start": [["52"]], "entity_id": [["T5"]]},"Freq": {"text": [["treatment"]], "start": [["52"]], "entity_id": [["T5"]]},"Route": {"text": [["treatment"]], "start": [["52"]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["secondary"]], "start": [["26"]], "entity_id": [["T6"]]},"Dosage": {"text": [[]], "start": [[],[]], "entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["A case"]], "start": [[],[]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [["severe aplastic anemia"]], "start": [["0"]], "entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [["0"]], "entity_id": [["T7"]],"value": "severe"}}]}
{"id": "21712512_5","context": "Seven weeks after the initiation of inhaled fluticasone, she developed vaginal candidiasis and was prescribed fluconazole 100 mg/day, a CYP3A4 inhibitor","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["inhaled fluticasone"]],"start": [["7 weeks after the initiation of" ]],"entity_id": [ ]},"Subject": {"text": [["she"]],"start": [[ "she"]],"entity_id": [ ],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["vaginal candidiasis"]],"start": [[ "developed vaginal candidiasis"]],"entity_id": []}},"Treatment": {"text": [["fluconazole 100 mg/day"]],"start": [[ "was prescribed fluconazole" ]],"entity_id": [],"Dosage": {"text": [["100 mg/day"]],"start": [[ "fluconazole 100 mg/day" ]],"entity_id": []},"Disorder": {"text": [["vaginal candidiasis"]],"start": [[ "developed vaginal candidiasis"]],"entity_id": []},"Route": {"text": [["oral"]],"start": [[ "fluconazole" ]],"entity_id": []} ,"Drug": {"text": [["fluconazole"]],"start": [[ "fluconazole" ]],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} }, "Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [],"start": [],"entity_id": []}} ]}
{"id": "7393795_4","context": "The introduction of para-aminosalicylic acid (PAS) led to hypoglycaemic coma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypoglycaemic coma"]],"start": [["36"]],"entity_id": [["T2"]]},"Treatment": {"text": [["para-aminosalicylic acid (PAS)"]],"start": [["14"]],"entity_id": [["T1"]],"Drug": {"text": [["para-aminosalicylic acid"]],"start": [["14"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["hypoglycaemic coma"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["para-aminosalicylic acid"]],"start": [["14"]],"entity_id": [["T3"]]},"Trigger": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Adverse_event"} ] ,"Trigger": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Route": {"text": [["led"]],"start": [["25"]],"entity_id": [["T4"]]} } ,"Effect": {"text": [["hypoglycaemic coma"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["hypoglycaemic coma"]],"start": [["36"]],"entity_id": [["T2"]],"value": "high"} ,"Subject": {"text": [["The introduction"]],"start": [["0"]],"entity_id": [["T5"]],"Population": {"text": [["The introduction"]],"start": [["0"]],"entity_id": [["T5"]]},"Gender": null,"Age": null,"Race": null,"Disorder": {"text": [["The introduction"]],"start": [["0"]],"entity_id": [["T5"]]} } } ] }
{"id": "3688031_1","context": "An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["treated"]],"start": [["13"]],"entity_id": []},"Subject": {"text": [["a woman"]],"start": [["38"]],"entity_id": [] ,"Age": null,"Gender": {"text": [["woman"]],"start": [["38"]],"entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [["hyperthyroidism"]],"start": [["21"]],"entity_id": []}},"Treatment": {"text": [["methimazole", "and", "propranolol"]],"start": [["55"]],"entity_id": [] ,"Drug": {"text": [["methimazole"]],"start": [["55"]],"entity_id": []},"Disorder": {"text": [["hyperthyroidism"]],"start": [["21"]],"entity_id": []},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null ,"Combination": [{"Drug": {"text": [["methimazole"]],"start": [["55"]],"entity_id": []},"Trigger": null ,"event_id": "C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["propranolol"]],"start": [["63"]],"entity_id": []},"Trigger": null ,"event_id": "C2","event_type": "Potential_therapeutic_effect"}] ,"Trigger": null },"Effect": {"text": [["an infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born"]],"start": [["0"]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10923593_1", "context": "Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["skin manifestations"]], "start": [[ "start"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["phenylbutazone"]], "start": [[ "start"]], "entity_id": [["T2"]], "Drug": null, "Disorder": {"text": [["serum sickness-like reactions"]], "start": [[ "start"]], "entity_id": [["T3"]] } , "Time_elapsed": null, "Duration": null, "Route": null, "Dosage": null, "Freq": null, "Combination": null ,"Trigger": null} ,"Effect": null ,"Negated": null, "Speculated": null, "Severity": null ,"Subject": {"text": [["a case"]], "start": [[ "start"]], "entity_id": [["T4"]], "Age": null, "Disorder": {"text": [["serum sickness-like reactions"]], "start": [[ "start"]], "entity_id": [["T3"]] }, "Gender": null, "Population": null, "Race": null } }]}
{"id": "18607107_2", "context": "Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Development of Crohn's disease"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Subject": {"text": [["a patient"]], "start": [[ "32" ]], "entity_id": [ ["T2"] ], "Disorder": {"text": [["multiple sclerosis"]], "start": [[ "50" ]], "entity_id": [ ["T3"] ]} ,"Age": null, "Gender": null, "Population": null, "Race": null }, "Treatment": {"text": [["copaxone"]], "start": [[ "92" ]], "entity_id": [ ["T4"] ], "Drug": {"text": [["copaxone"]], "start": [[ "92" ]], "entity_id": [ ["T5"] ]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[ "50" ]], "entity_id": [ ["T3"] ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["treated with copaxone"]], "start": [[ "72" ]], "entity_id": [ ["T4"] ]} }, "Effect": { "text": [["Development of Crohn's disease"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "19281746_1", "context": "Aliskiren-associated acute renal failure with hyperkalemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Aliskiren-associated acute renal failure", "hyperkalemia"]], "start": [[ "0", "46" ]], "entity_id": [ ["T1", "T2"]]} , "Treatment": {"text": [["Aliskiren"]], "start": [[ "0" ]], "entity_id": [ ["T1"]], "Drug": null ,"Disorder": {"text": [["acute renal failure"]], "start": [[ "28" ]], "entity_id": [ ["T2"]]} ,"Time_elapsed": {"text": [["with"]], "start": [[ "41" ]], "entity_id": [ ["T3"]]} ,"Freq": null, "Route": null, "Dosage": null ,"Duration": null ,"Combination": null ,"Trigger": null }, "Effect": {"text": [["acute renal failure with hyperkalemia"]], "start": [[ "12" ]], "entity_id": [ ["T2"]]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "8034807_1","context": "The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["use of methotrexate"]],"start": [[ "3" ]],"entity_id": [ ]},"Treatment": {"text": [["methotrexate"]],"start": [[ "21" ]],"entity_id": [ ],"Drug": {"text": [["methotrexate (MTX)"]],"start": [[ "21" ]],"entity_id": [ ]},"Disorder": {"text": [["treatment of severe psoriasis in HIV infection"]],"start": [[ "71" ]],"entity_id": [ ]},"Freq": {"text": [["six previously reported cases"]],"start": [[ "104" ]],"entity_id": [ ]},"Trigger": {"text": [["in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease"]],"start": [[ "135" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["previously reported cases"]],"start": [[ "104" ]],"entity_id": [ ]},"Dosage": {"text": [["use of methotrexate"]],"start": [[ "3" ]],"entity_id": [ ]},"Duration": {"text": [["treatment of severe psoriasis in HIV infection"]],"start": [[ "71" ]],"entity_id": [ ]},"Route": {"text": [["use of methotrexate"]],"start": [[ "3" ]],"entity_id": [ ]},"Combination": null},"Negated": {"text": [["contraindicated"]],"start": [[ "16" ]],"entity_id": [ ],"value": true},"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["opportunistic infections"]],"start": [[ "164" ]],"entity_id": [ ]}}]}
{"id": "17655376_1", "context": "Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["dapsone gel, 5%"]], "start": [[ ]], "entity_id": [ ] ,"Drug": { "text": [["dapsone"]], "start": [[ ]], "entity_id": [ ] } ,"Disorder": { "text": [["acne vulgaris"]], "start": [[ ]], "entity_id": [ ] } ,"Duration": { "text": [["5%"]], "start": [[ ]], "entity_id": [ ] } ,"Route": { "text": [["topical"]], "start": [[ ]], "entity_id": [ ] } ,"Trigger": { "text": [["treatment"]], "start": [[ ]], "entity_id": [ ] } ,"Time_elapsed": null ,"Freq": null ,"Combination": null ,"Dosage": null } ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": null }]}
{"id": "17420198_1", "context": "Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["aripiprazole-mediated"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["aripiprazole"]], "start": [["11"]], "entity_id": [["T2"]],"Drug": {"text": [["aripiprazole"]],"start": [["11"]],"entity_id": [["T2"]]},"Disorder": {"text": [["extrapyramidal symptoms"]],"start": [["41"]],"entity_id": [["T3"]]},"Freq": {"text": [["in an adult"]],"start": [["22"]],"entity_id": [["T4"]]},"Route": {"text": [["mediated"]],"start": [["10"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["Potential"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["aripiprazole"]],"start": [["11"]],"entity_id": [["T2"]]},"Trigger": {"text": [["mediated"]],"start": [["10"]],"entity_id": [["T1"]]},"event_type": "Adverse_event","event_id": "A1"}],"Trigger": {"text": [["extrapyramidal symptoms"]],"start": [["41"]],"entity_id": [["T3"]]},"Duration": {"text": [["in an adult"]],"start": [["22"]],"entity_id": [["T4"]]},"Dosage": {"text": [["Potential"]],"start": [["0"]],"entity_id": [["T0"]]}},"Subject": {"text": [["an adult with developmental disabilities"]],"start": [["32"]],"entity_id": [["T5"]],"Age": {"text": [["an adult"]],"start": [["32"]],"entity_id": [["T4"]]},"Disorder": {"text": [["developmental disabilities"]],"start": [["37"]],"entity_id": [["T6"]]},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "12823045_1", "context": "We describe a patient with extranodal non-Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide-based chemotherapy regimen", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null,"Subject": null,"Treatment": {"Drug": {"text": [["cyclophosphamide"]],"start": [["93"]],"entity_id": [["T1"]]},"Disorder": {"text": [["treatment with a cyclophosphamide-based chemotherapy regimen"]],"start": [["93"]],"entity_id": [["T2"]]} ,"entity_id": [["T1"], ["T2"]],"text": [["cyclophosphamide"], ["treatment with a cyclophosphamide-based chemotherapy regimen"]],"start": [["93"]], "Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null },"Effect": {"text": [["systemic candidiasis"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["developed"]],"start": [["42"]],"entity_id": [["T4"]]}}]}
{"id": "2663536_2","context": "We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme (ACE) inhibitor captopril","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["the angiotensin converting enzyme (ACE) inhibitor captopril"]],"start": [["59"]],"entity_id": [["T1"]],"Drug": {"text": [["captopril"]],"start": [["81"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["de novo asthma"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["following treatment"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["treatment"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["first case"]],"start": [["5"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["de novo asthma"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["the angiotensin converting enzyme (ACE) inhibitor captopril"]],"start": [["59"]],"entity_id": [["T1"]]} ,"Route": {"text": [["treatment"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Combination": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Trigger": {"text": [["treatment"]],"start": [["30"]],"entity_id": [["T4"]]} }]}
{"id": "8120934_1","context": "A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting low-dose bromocriptine therapy for a macroprolactinoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed schizophrenia"]],"start": [[" "], ["]"]],"entity_id": []},"Subject": {"text": [["A 53-year-old male"]],"start": [[], []],"entity_id": [],"Age": {"text": [["53"]],"start": [[], []],"entity_id": []},"Gender": {"text": [["male"]],"start": [[], []],"entity_id": []},"Population": {"text": [["A"]],"start": [[], []],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["without any prior history of psychosis"]],"start": [[], []],"entity_id": []}},"Treatment": {"text": [["starting low-dose bromocriptine therapy"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["bromocriptine"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [["low-dose"]],"start": [[], []],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["for a macroprolactinoma"]],"start": [[], []],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["4 days after"]],"start": [[], []],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["schizophrenia"]],"start": [[], []],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "11144696_6","context": "Because of suspected drug-induced seizures, both antidepressants were stopped","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": null,"Effect": {"text": [["suspected drug-induced seizures"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["seizures"]],"start": [["33"]],"entity_id": [["T2"]]}}]}
{"id": "17381671_4","context": "Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": {"Drug": {"text": [["citalopram", "fentanyl"]],"start": [["63", "74"]],"entity_id": [["T1", "T2"]]},"entity_id": [["T1", "T2"]],"text": [["co-administration"]],"start": [["42"]],"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["serotonin syndrome"]],"start": [["17"]],"entity_id": [["T3"]]},"Trigger": {"text": [["adverse reaction"]],"start": [["32"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["citalopram"]],"start": [["63"]],"entity_id": [["T1"]]},"Trigger": {"text": [["co-administration"]],"start": [["42"]],"entity_id": [["T0"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["fentanyl"]],"start": [["74"]],"entity_id": [["T2"]]},"Trigger": {"text": [["co-administration"]],"start": [["42"]],"entity_id": [["T0"]]},"event_id": "C2","event_type": "Adverse_event"}]},"Effect": {"text": [["serotonin syndrome"]],"start": [["17"]],"entity_id": [["T3"]]},"Trigger": {"text": [["adverse reaction"]],"start": [["32"]],"entity_id": [["T4"]]}}]}
{"id": "8771575_3","context": "Despite the known pulmonary side effects of nitrofurantoin, there is no report of this toxicity occurring in pregnant patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": {"value": true, "text": [["no report"]],"start": [["45"]],"entity_id": []},"Trigger": {"text": [["known pulmonary side effects"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["nitrofurantoin"]],"start": [["33"]],"entity_id": [],"Drug": {"text": [["nitrofurantoin"]],"start": [["33"]],"entity_id": []},"Disorder": {"text": [["pulmonary side effects"]],"start": [["18"]],"entity_id": []},"Freq": {"text": [["known"]],"start": [["0"]],"entity_id": []},"Time_elapsed": {"text": [["occurring"]],"start": [["69"]],"entity_id": []},"Trigger": {"text": [["this toxicity"]],"start": [["61"]],"entity_id": []},"Route": {"text": [["in"]],"start": [["56"]],"entity_id": []},"Combination": [{"Drug": {"text": [["nitrofurantoin"]],"start": [["33"]],"entity_id": []},"Trigger": {"text": [["occurring"]],"start": [["69"]],"entity_id": []},"event_id": "E2","event_type": "Adverse_event"}],"Dosage": {"text": [["known"]],"start": [["0"]],"entity_id": []},"Duration": {"text": [["known"]],"start": [["0"]],"entity_id": []}},"Subject": {"text": [["pregnant patients"]],"start": [["81"]],"entity_id": [],"Age": {"text": [["pregnant"]],"start": [["81"]],"entity_id": []},"Disorder": {"text": [["patients"]],"start": [["85"]],"entity_id": []},"Gender": {"text": [["pregnant"]],"start": [["81"]],"entity_id": []},"Race": {"text": [["patients"]],"start": [["85"]],"entity_id": []},"Population": {"text": [["patients"]],"start": [["85"]],"entity_id": []}},"Speculated": {"text": [["Despite"]],"start": [["0"]],"entity_id": [],"value": true},"Severity": {"text": [["no report"]],"start": [["45"]],"entity_id": [],"value": "Low"},"Effect": {"text": [["occurring"]],"start": [["69"]],"entity_id": []}}]}
{"id": "19995222_3", "context": "However, several case reports have suggested that clozapine could also cause TD", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["could cause TD"]], "start": [["could cause TD].length"]], "entity_id": []}, "Treatment": {"text": [["clozapine"]], "start": [[""]], "entity_id": [],"Drug": {"text": [["clozapine"]], "start": [[""]], "entity_id": []},"Disorder": {"text": [["TD"]], "start": [[""]], "entity_id": []},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": null, "Negated": null, "Speculated": {"text": [["have suggested"]], "start": [[""]], "entity_id": [],"value": true}, "Severity": null, "Subject": null}]}
{"id": "6353252_1", "context": "Captopril-induced acute reversible renal failure", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Captopril-induced"]], "start": [[ ]], "entity_id": [ ["T1"]]}, "Treatment": {"Drug": {"text": [["Captopril"]], "start": [[ ] ], "entity_id": [ ["T2"]]}, "text": [["-induced"]], "start": [[ ]], "entity_id": [ ["T3"]] , "Disorder": { "text": [["acute reversible renal failure"]], "start": [[ ]] , "entity_id" : [ ["T4"]] } , "Dosage":{"text":[],"start":[],"entity_id":[]}, "Duration":{"text":[],"start":[],"entity_id":[]}, "Route":{"text":[],"start":[],"entity_id":[]}, "Time_elapsed":{"text":[],"start":[],"entity_id":[]}, "Freq":{"text":[],"start":[],"entity_id":[]}, "Combination": null , "Trigger":{"text":[["-induced"]],"start":[[ ]],"entity_id":[["T3"]]} } , "Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Effect": { "text": [["acute reversible renal failure"]], "start": [[ ]], "entity_id": [ ["T4"]]} } ]}
{"id": "16498048_3","context": "Hence, hyperthyroidism induced by IFN-alpha could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hyperthyroidism"]],"start": [["9"]],"entity_id": [["T1"]]},"Treatment": {"text": [["IFN-alpha"]],"start": [["35"]],"entity_id": [["T2"]],"Drug": {"text": [["IFN-alpha"]],"start": [["35"]],"entity_id": [["T3"]]},"Trigger": {"text": [["the first phase of silent thyroiditis"]],"start": [["55"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["induced"]],"start": [["36"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["IFN-alpha"]],"start": [["35"]],"entity_id": [["T3"]]},"Trigger": {"text": [["Graves' disease"]],"start": [["80"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"},{"Drug": {"text": [["IFN-alpha"]],"start": [["35"]],"entity_id": [["T3"]]},"Trigger": {"text": [["the succession of both"]],"start": [["104"]],"entity_id": [["T7"]]},"event_id": "E3","event_type": "Adverse_event"}],"Freq": {"text": [["correspond"]],"start": [["9"]],"entity_id": [["T8"]]},"Disorder": {"text": [["hyperthyroidism"]],"start": [["9"]],"entity_id": [["T1"]]},"Dosage": {"text": [["induced"]],"start": [["36"]],"entity_id": [["T5"]]},"Route": {"text": [["by IFN-alpha"]],"start": [["35"]],"entity_id": [["T9"]]},"Duration": {"text": [["the first phase of silent thyroiditis", "Graves' disease or to the succession of both"]],"start": [["55","80"]],"entity_id": [["T4","T6","T7"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["hyperthyroidism"]],"start": [["9"]],"entity_id": [["T1"]]},"text": [["Hence"]],"start": [["0"]],"entity_id": [["T0"]]},"Effect": {"text": [["hyperthyroidism"]],"start": [["9"]],"entity_id": [["T1"]]}}]}
{"id": "19104709_2","context": "In contrast to chronic or subacute thyroiditis, Graves' disease rarely complicates IFN-alpha therapy for chronic viral C hepatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["IFN-alpha therapy"]],"start": [["31"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["chronic viral C hepatitis"]],"start": [["52"]],"entity_id": [["T2"]] },"Trigger": {"text": [["complicates"]],"start": [["42"]],"entity_id": [["T3"]] },"Freq": {"text": [["rarely"]],"start": [["43"]],"entity_id": [["T4"]] },"Drug": {"text": [["IFN-alpha"]],"start": [["31"]],"entity_id": [["T5"]] },"Time_elapsed": {"text": [["complicates"]],"start": [["42"]],"entity_id": [["T6"]] },"Route": {"text": [["therapy"]],"start": [["31"]],"entity_id": [["T7"]] },"Duration": {"text": [["chronic"]],"start": [["31"]],"entity_id": [["T8"]] },"Dosage": {"text": [["IFN-alpha"]],"start": [["31"]],"entity_id": [["T9"]] },"Combination": [{"Drug": {"text": [["IFN-alpha"]],"start": [["31"]],"entity_id": [["T10"]] },"Trigger": {"text": [["therapy"]],"start": [["31"]],"entity_id": [["T11"]] },"event_id": "E2","event_type": "Potential_therapeutic_effect" }] },"Subject": {"text": [["Graves' disease"]],"start": [["19"]],"entity_id": [["T12"]] ,"Disorder": {"text": [["Graves' disease"]],"start": [["19"]],"entity_id": [["T13"]] },"Gender": {"text": [],"start": [],"entity_id": [] },"Age": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["complicates"]],"start": [["42"]],"entity_id": [["T14"]] },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["complicates"]],"start": [["42"]],"entity_id": [["T15"]] }} ]}
{"id": "17551408_1","context": "We postulate that gastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["dexamethasone"]],"start": [["21"]],"entity_id": [["T1"]] ,"Trigger": {"text": [["gastritis"]],"start": [["7"]],"entity_id": [["T2"]] },"Disorder": {"text": [["gastritis"]],"start": [["7"]],"entity_id": [["T2"]] },"Time_elapsed": {"text": [["caused by"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["dexamethasone"]],"start": [["21"]],"entity_id": [["T1"]] },"Trigger": {"text": [["gastritis"]],"start": [["7"]],"entity_id": [["T2"]] },"event_id": "C1" ,"event_type": "Potential_therapeutic_effect" }] ,"Freq": {"text": [["caused by"]],"start": [["0"]],"entity_id": [["T3"]] },"Route": {"text": [["by"]],"start": [["0"]],"entity_id": [["T4"]] },"Duration": {"text": [["this extremely unlikely and previously unreported event"]],"start": [["123"]],"entity_id": [["T5"]] },"Dosage": {"text": [["dexamethasone"]],"start": [["21"]],"entity_id": [["T1"]]},"Drug": {"text": [["dexamethasone"]],"start": [["21"]],"entity_id": [["T1"]] }} ,"Negated": null, "Speculated": {"text": [["postulate"]],"start": [["0"]],"entity_id": [["T6"]] ,"value": true },"Severity": null ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T7"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Effect": {"text": [["contributed"]],"start": [["106"]],"entity_id": [["T8"]] },"Trigger": {"text": [["this extremely unlikely and previously unreported event"]],"start": [["123"]],"entity_id": [["T5"]] }} ]}
{"id": "9013348_3","context": "Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Mesalamine"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["Mesalamine"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["Crohn's disease"]],"start": [["45"]],"entity_id": [["T2"]]},"Trigger": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Freq": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Dosage": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Route": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Duration": {"text": [["may cause"]],"start": [["9"]],"entity_id": [["T3"]]},"Combination": null},"Effect": {"text": [["hypersensitivity pneumonitis"]],"start": [["22"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["hypersensitivity pneumonitis"]],"start": [["22"]],"entity_id": [["T4"]],"value": "high"},"Subject": null,"Trigger": null}]}
{"id": "7814182_2","context": "We present a case in which dipyridamole induced high-grade atrioventricular (AV) block that responded promptly to intravenous aminophylline but not to atropine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["dipyridamole"]],"start": [["18"]],"entity_id": [["T1"]]},"Effect": {"text": [["high-grade atrioventricular (AV) block"]],"start": [["41"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [["aminophylline"]],"start": [["90"]],"entity_id": [["T3"]]},"Route": {"text": [["intravenous"]],"start": [["83"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["promptly"]],"start": [["75"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["dipyridamole"]],"start": [["18"]],"entity_id": [["T1"]]},"Trigger": {"text": [["induced"]],"start": [["26"]],"entity_id": [["T6"]]} ,"event_id": "E1" ,"event_type": "Adverse_event" }] ,"entity_id": [["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"]] ,"start": [["18"], ["41"], ["90"], ["83"], ["75"], ["26"]],"text": [["dipyridamole"], ["high-grade atrioventricular (AV) block"], ["aminophylline"], ["intravenous"], ["promptly"], ["induced"]] ,"Trigger": {"text": [["induced"]],"start": [["26"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} }, "Negated": { "value": false ,"text": [],"start": [],"entity_id": [] },"Speculated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Severity": {"value": "","text": [],"start": [],"entity_id": [] },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} }]}
{"id": "2442958_3","context": "This paper reports an autopsy case of a 78-year-old male with multiple nodules in the liver developed after long-termed administration of phosphate diethylstilbestrol (PDES) for prostatic cancer._","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["multiple nodules"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phosphate diethylstilbestrol (PDES)"]],"start": [["56"]],"entity_id": [["T2"]],"Dosage": {"text": [["long-termed"]],"start": [["56"]],"entity_id": [["T2"]]},"Route": {"text": [["administration"]],"start": [["65"]],"entity_id": [["T3"]]},"Disorder": {"text": [["prostatic cancer"]],"start": [["88"]],"entity_id": [["T4"]]},"Drug": {"text": [["phosphate diethylstilbestrol (PDES)"]],"start": [["56"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["developed"]],"start": [["33"]],"entity_id": [["T1"]]},"Duration": {"text": [["long-termed"]],"start": [["56"]],"entity_id": [["T2"]]},"Trigger": {"text": [["administration"]],"start": [["65"]],"entity_id": [["T3"]]},"Freq": {"text": [["long-termed"]],"start": [["56"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["phosphate diethylstilbestrol (PDES)"]], "start": [["56"]], "entity_id": [["T2"]]},"Trigger":{"text":[["administration"]],"start":[["65"]],"entity_id":[["T3"]]},"event_type":"Adverse_event","event_id":"E1"}]},"Subject": {"text": [["a 78-year-old male"]],"start": [["7"]],"entity_id": [["T0"]],"Age": {"text": [["78"]],"start": [["10"]],"entity_id": [["T0"]]},"Gender": {"text": [["male"]],"start": [["13"]],"entity_id": [["T0"]]},"Disorder": {"text": [["prostatic cancer"]],"start": [["88"]],"entity_id": [["T4"]]},"Population": {"text": [["a"]],"start": [["7"]],"entity_id": [["T0"]]},"Race": {"text": [["a"]],"start": [["7"]],"entity_id": [["T0"]]}},"Effect": {"text": [["multiple nodules"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["multiple"]],"start": [["33"]],"entity_id": [["T1"]],"value":"low"}}]}
{"id": "2796025_2","context": "This panic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of mianserin 30 mg/day, and because of that the depressive symptom also disappeared","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["etizolam", "flunitrazepam"]],"start": [[ "0"]] ,"entity_id": [["T1","T2"]]},"Treatment": {"text": [["taking etizolam and flunitrazepam again"]],"start": [[ "17" ]],"entity_id": [["T3"]],"Drug": {"text": [["etizolam", "flunitrazepam"]],"start": [[ "0" ]],"entity_id": [["T1","T2"]]},"Freq": {"text": [["again"]],"start": [[ "17" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["not relieved"]],"start": [[ "44" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["but subsided rapidly"]],"start": [[ "65" ]],"entity_id": [["T6"]]},"Dosage": {"text": [["30 mg/day"]],"start": [[ "91" ]],"entity_id": [["T7"]]},"Route": {"text": [["re-administration"]],"start": [[ "82" ]],"entity_id": [["T8"]]},"Disorder": {"text": [["panic anxiety"]],"start": [[ "0" ]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["mianserin"]],"start": [[ "87" ]],"entity_id": [["T10"]]},"Trigger": {"text": [["re-administration"]],"start": [[ "82" ]],"entity_id": [["T8"]]},"event_id": "C1","event_type": "Adverse_event"}],"Duration": {"text": [["long-term"]],"start": [[ "0" ]],"entity_id": [["T11"]]}},"Negated": {"text": [["not relieved"]],"start": [[ "44" ]],"entity_id": [["T5"]],"value": true},"Subject": {"text": [["this"]],"start": [[ "0" ]],"entity_id": [["T12"]],"Age": {"text": [["young"]],"start": [[ "0" ]],"entity_id": [["T13"]]},"Gender": {"text": [["male"]],"start": [[ "0" ]],"entity_id": [["T14"]]},"Population": {"text": [["single"]],"start": [[ "0" ]],"entity_id": [["T15"]]},"Race": {"text": [["asian"]],"start": [[ "0" ]],"entity_id": [["T16"]]},"Disorder": {"text": [["panic anxiety"]],"start": [[ "0" ]],"entity_id": [["T9"]]}},"Effect": {"text": [["subsided rapidly"]],"start": [[ "65" ]],"entity_id": [["T6"]]},"Severity": {"text": [["moderate"]],"start": [[ "0" ]],"entity_id": [["T17"]],"value": "moderate"},"Speculated": {"text": [["could be"]],"start": [[ "0" ]],"entity_id": [["T18"]],"value": false}}]}
{"id": "10546851_1", "context": "Interaction of sildenafil and indinavir when co-administered to HIV-positive patients", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["interaction of sildenafil and indinavir"]], "start": [[ ]],"entity_id": [["T1"]],"Disorder": {"text": [["HIV-positive"]], "start": [[ ]], "entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["sildenafil"]], "start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["co-administered"]], "start": [[ ]], "entity_id": [["T4"]]}, "event_id": "C1", "event_type": "Combination"} ,{"Drug": {"text": [["indinavir"]], "start": [[ ]], "entity_id": [["T5"]]},"Trigger": {"text": [["co-administered"]], "start": [[ ]], "entity_id": [["T4"]]}, "event_id": "C2", "event_type": "Combination"} ],"Trigger": {"text": [["interaction"]], "start": [[ ]], "entity_id": [["T6"]]}, "Dosage": {"text": [["when"]], "start": [[ ]], "entity_id": [["T7"]]},"Freq": {"text": [["co-administered"]], "start": [[ ]], "entity_id": [["T4"]]}, "Time_elapsed": {"text": [["to"]], "start": [[ ]], "entity_id": [["T8"]]}, "Route": {"text": [["patients"]], "start": [[ ]], "entity_id": [["T9"]]},"Duration": {"text": [["HIV-positive"]], "start": [[ ]], "entity_id": [["T2"]]},"Drug": {"text": [["sildenafil"]], "start": [[ ]], "entity_id": [["T3"]]}}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Trigger": null ,"Effect": null}]}
{"id": "11868077_2", "context": "We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["subcutaneous metastasis"]], "start": [["23"]], "entity_id": []}, "Treatment": {"text": [["percutaneous ethanol injection (PEI)"]], "start": [["66"]], "entity_id": [], "Drug": {"text": [["ethanol"]], "start": [["74"]], "entity_id": []},"Disorder": {"text": [["hepatocellular carcinoma"]], "start": [["104"]], "entity_id": []},"Route": {"text": [["percutaneous"]], "start": [["66"]], "entity_id": []},"Duration": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Freq": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Combination": [],"Trigger": {"text": [["treatment"]], "start": [["33"]], "entity_id": []},"Time_elapsed": {"text": [["along the needle track after"]], "start": [["46"]], "entity_id": []},"Dosage": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []}},"Subject": {"text": [["We"]], "start": [[""], ["129"]], "entity_id": [],"Age": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Gender": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Population": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Race": {"text": [[""]], "start": [[""], ["129"]], "entity_id": []},"Disorder": {"text": [["a case of subcutaneous metastasis"]], "start": [["23"]], "entity_id": []}},"Effect": {"text": [["hepatocellular carcinoma"]], "start": [["104"]], "entity_id": []},"Negated": {"text": [[""]], "start": [[""], ["129"]], "entity_id": [],"value": false},"Speculated": {"text": [[""]], "start": [[""], ["129"]], "entity_id": [],"value": false},"Severity": {"text": [[""]], "start": [[""], ["129"]], "entity_id": [],"value": ""}}]}
{"id": "17420198_5","context": "He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["episodic movements"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["aripiprazole usage"]],"start": [["55"]],"entity_id": [["T2"]],"Drug": {"text": [["aripiprazole"]],"start": [["55"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["EPS"]],"start": [["36"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["secondary"]],"start": [["46"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["possibly consistent"]],"start": [["20"]],"entity_id": [["T6"]]} ,"Route": {"text": [["usage"]],"start": [["55"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [["He"]],"start": [["0"]],"entity_id": [["T8"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15133245_3","context": "Recently, it has been reported that terfenadine and astemizole, which have antiallergic actions similar to those of oxatomide, show side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["QT prolongation"]],"start": [[], [], []],"entity_id": []},"Treatment": {"text": [["terfenadine"]],"start": [[], [], []],"entity_id": [],"Drug": {"text": [["terfenadine"]],"start": [[], [], []],"entity_id": []},"Disorder": {"text": [["side effects"]],"start": [[], [], []],"entity_id": []},"Route": {"text": [["cardiovascular system"]],"start": [[], [], []],"entity_id": []},"Time_elapsed": {"text": [["show"]],"start": [[], [], []],"entity_id": []},"Combination": [{"Drug": {"text": [["astemizole"]],"start": [[], [], []],"entity_id": []},"Trigger": {"text": [["show"]],"start": [[], [], []],"entity_id": []},"event_id": "E2","event_type": "Adverse_event"}],"Freq": {"text": [["show"]],"start": [[], [], []],"entity_id": []},"Dosage": {"text": [["similar to those of oxatomide"]],"start": [[], [], []],"entity_id": []},"Duration": {"text": [["Recently"]],"start": [[], [], []],"entity_id": []},"Trigger": {"text": [["reported"]],"start": [[], [], []],"entity_id": []}},"Effect": {"text": [["ventricular arrhythmia"]],"start": [[], [], []],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["cardiac arrest"]],"start": [[], [], []],"entity_id": [],"value": "high"},"Subject": {"text": [["it"]],"start": [[], [], []],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "19579947_2", "context": "Priapism associated with olanzapine", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Priapism"]], "start": [[], [], ["associated"]], "entity_id": [["T1"], ["T2"]]}, "Treatment": {"text": [["olanzapine"]], "start": [[], [], ["associated"]], "entity_id": [["T3"]], "Drug": {"text": [["olanzapine"]], "start": [[], [], ["associated"]], "entity_id": [["T3"]]}, "Disorder": {"text": [["Priapism"]], "start": [[], [], ["associated"]], "entity_id": [["T1"]]}, "Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null, "Combination": null, "Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "9883483_2", "context": "Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["pirmenol-induced QT prolongation"]], "start": [["36"]], "entity_id": []}, "Treatment": {"text": [["pirmenol"]], "start": [["16"]], "entity_id": [], "Drug": {"text": [["pirmenol"]], "start": [["16"]], "entity_id": []}, "Disorder": {"text": [["QT prolongation"]], "start": [["36"]], "entity_id": []}, "Route": {"text": [["induced"]], "start": [["28"]], "entity_id": []}, "Time_elapsed": {"text": [["might be involved in the mechanism of"]], "start": [["0"]], "entity_id": []}, "Trigger": {"text": [["on the electrocardiogram"]], "start": [["85"]], "entity_id": []}, "Freq": {"text": [["involved"]], "start": [["46"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["pirmenol"]], "start": [["16"]], "entity_id": []}, "Trigger": {"text": [["QT prolongation"]], "start": [["36"]], "entity_id": []}, "event_id": "C1", "event_type": "Adverse_event"}], "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["an immunological mechanism"]], "start": [["10"]], "entity_id": []}}, "Effect": {"text": [["QT prolongation"]], "start": [["36"]], "entity_id": []}, "Negated": {"text": [], "start": [], "entity_id": [], "value": false}, "Speculated": {"text": [], "start": [], "entity_id": [], "value": false}, "Severity": {"text": [], "start": [], "entity_id": [], "value": ""}}]}
{"id": "12796597_4","context": "The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with IFNalpha","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["focal segmental glomerulosclerosis"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["The renal biopsy"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["focal segmental glomerulosclerosis"]],"start": [["18"]],"entity_id": [["T1"]]},"Age": {"text": [["The"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["The"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["The"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["The"]],"start": [["0"]],"entity_id": [["T0"]]}},"Treatment": {"text": [["IFNalpha"]],"start": [["98"]],"entity_id": [["T2"]],"Drug": {"text": [["IFNalpha"]],"start": [["98"]],"entity_id": [["T2"]]},"Disorder": {"text": [["CML"]],"start": [["74"]],"entity_id": [["T3"]]},"Dosage": {"text": [["The renal biopsy showed"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["The renal biopsy showed"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["The renal biopsy showed"]],"start": [["0"]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [["The renal biopsy showed"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["The renal biopsy showed"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": null,"Trigger": {"text": [["CML treated"]],"start": [["74"]],"entity_id": [["T3"]]}},"Effect": {"text": [["has only been previously reported"]],"start": [["57"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "6093724_2","context": "Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["Sulindac"]],"start": [[ "0"]],"entity_id": [["T1"]]},"text": [["Sulindac (Clinoril)"]],"start": [[ "0"]],"entity_id": [["T2"]] ,"Disorder": {"text": [["nonsteroidal anti-inflammatory agent"]],"start": [[ "40"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["neurologic toxic effects"]],"start": [[ "58"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["few"]],"start": [[ "23"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["have been associated with systemic disease"]],"start": [[ "80"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "6860059_1", "context": "Fulminant hepatitis associated with disulfiram", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Fulminant hepatitis"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Treatment": {"text": [["disulfiram"]], "start": [[ ]], "entity_id": [[ "T2" ]],"Drug": { "text": [["disulfiram"]], "start": [[ ]], "entity_id": [[ "T2" ]] }, "Disorder": { "text": [["Fulminant hepatitis"]], "start": [[ ]], "entity_id": [[ "T1" ]] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Combination": null ,"Trigger": { "text": [], "start": [], "entity_id": [] }} ,"Effect": { "text": [["Fulminant hepatitis"]], "start": [[ ]], "entity_id": [[ "T1" ]] },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "3397227_1", "context": "Anhedonic ejaculation with desipramine", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Anhedonic ejaculation"]], "start": [[], [ ]], "entity_id": []}, "Treatment": {"text": [["desipramine"]], "start": [[], [ ]], "entity_id": [],"Drug": { "text": [["desipramine"]], "start": [[], []], "entity_id": [] } ,"Disorder": { "text": [["Anhedonic ejaculation"]], "start": [[], []], "entity_id": [] } ,"Dosage": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Route": { "text": [], "start": [], "entity_id": [] } ,"Time_elapsed": { "text": [], "start": [], "entity_id": [] } ,"Combination": [] ,"Trigger": { "text": [["Anhedonic ejaculation"]], "start": [[], []], "entity_id": [] } } ,"Effect": { "text": [], "start": [], "entity_id": [] } ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null ,"Disorder": { "text": [], "start": [], "entity_id": [] } ,"Gender": null ,"Population": null ,"Race": null } }]}
{"id": "8313300_6","context": "A severe form of exophthalmos resulting from lithium therapy has not been described in the literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": {"text": [["not"]],"start": [[], []],"entity_id": [],"value": true},"Trigger": {"text": [["severe form of exophthalmos"]],"start": [[], []],"entity_id": []},"Treatment": {"text": [["lithium therapy"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["lithium"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["exophthalmos"]],"start": [[], []],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": null,"Subject": null,"Severity": null,"Speculated": null}]}
{"id": "17383767_4", "context": "We report a case in which a potential drug interaction resulted in elevated phenytoin levels after initiation of erlotinib therapy in a patient who was receiving phenytoin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["erlotinib therapy"]], "start": [["51"]], "entity_id": [],"Drug": {"text": [["erlotinib"]], "start": [["51"]], "entity_id": []},"Disorder": {"text": [["potential drug interaction"]], "start": [["0"]], "entity_id": []},"Trigger": {"text": [["initiation"]], "start": [["36"]], "entity_id": []},"Route": {"text": [["oral"]], "start": [["22"]], "entity_id": []},"Freq": {"text": [["once daily"]], "start": [["45"]], "entity_id": []},"Combination": [{"Drug": {"text": [["phenytoin"]], "start": [["98"]], "entity_id": []},"Trigger": {"text": [["concurrent"]], "start": [["86"]], "entity_id": []},"event_id": "C1","event_type": "null"} ],"Time_elapsed": {"text": [["after initiation"]], "start": [["36"]], "entity_id": []},"Duration": {"text": [["long-term"]], "start": [["71"]], "entity_id": []},"Dosage": {"text": [["dosed as prescribed"]], "start": [["109"]], "entity_id": []}},"Subject": {"text": [["a patient"]], "start": [["116"]], "entity_id": [],"Age": {"text": [["null"]], "start": [[""], [""]], "entity_id": []},"Gender": {"text": [["null"]], "start": [[""], [""]], "entity_id": []},"Population": {"text": [["1"]], "start": [[""], [""]], "entity_id": []},"Race": {"text": [["null"]], "start": [[""], [""]], "entity_id": []},"Disorder": {"text": [["phenytoin therapy"]], "start": [["98"]], "entity_id": []}},"Negated": {"text": [["null"]], "start": [[""], [""]], "entity_id": [],"value": false},"Speculated": {"text": [["null"]], "start": [[""], [""]], "entity_id": [],"value": false},"Severity": {"text": [["high"], ["severe"]], "start": [["68"]], "entity_id": [],"value": "high" },"Effect": {"text": [["elevated phenytoin levels"]], "start": [["81"]], "entity_id": []},"Trigger": {"text": [["initiation"]], "start": [["36"]], "entity_id": []}}]}
{"id": "18515982_1","context": "Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Anastrozole-associated sclerosing glomerulonephritis"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [[ "52" ]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["breast cancer"]],"start": [[ "62" ]],"entity_id": [["T3"]]}},"Treatment": {"text": [["Anastrozole"]],"start": [[ "5" ]],"entity_id": [["T0"]],"Drug": {"text": [["Anastrozole"]],"start": [[ "5" ]],"entity_id": [["T0"]]},"Disorder": {"text": [["breast cancer"]],"start": [[ "30" ]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["Anastrozole-associated sclerosing glomerulonephritis"]],"start": [[ "0" ]],"entity_id": [["T1"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["Anastrozole-associated sclerosing glomerulonephritis"]],"start": [[ "0" ]],"entity_id": [["T1"]]} }] }
{"id": "12324937_1","context": "Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gemcitabine-associated hemolytic-uremic syndrome"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Gemcitabine"]],"start": [["9"]],"entity_id": [["T2"]],"Drug": {"text": [["Gemcitabine"]],"start": [["9"]],"entity_id": [["T2"]]},"Disorder": {"text": [["hemolytic-uremic syndrome (HUS)"]],"start": [["44"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["reported"]],"start": [["86"]],"entity_id": [["T4"]]},"Freq": {"text": [["has"]],"start": [["21"]],"entity_id": [["T5"]]},"Dosage": {"text": [["mild renal toxicity"]],"start": [["15"]],"entity_id": [["T6"]]},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null}]}
{"id": "12460237_1", "context": "Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurrent palmar-plantar erythrodysaesthesia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["high-dose cytarabine treatment"]], "start": [[ "39" ]], "entity_id": [ ["T2"] ], "Dosage": {"text": [["high-dose"]], "start": [[ "39" ]], "entity_id": [ ["T3"] ]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[ "68" ]], "entity_id": [ ["T4"] ]}, "Duration": null, "Drug": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null},"Subject": {"text": [["patient"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Negated": null, "Speculated": null, "Severity": null, "Effect": null}]}
{"id": "12163813_1","context": "Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ischemic skin complications"]],"start": [["59"]],"entity_id": [["T1"]]},"Treatment": {"text": [["peripheral administration of low-dose vasopressin for septic shock"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["vasopressin"]],"start": [["32"]],"entity_id": [["T3"]]},"Disorder": {"text": [["septic shock"]],"start": [["24"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["low-dose"]],"start": [["17"]],"entity_id": [["T5"]]},"Route": {"text": [["peripheral"]],"start": [["8"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["low-dose"]],"start": [["17"]],"entity_id": [["T5"]]},"Duration": {"text": [["low-dose"]],"start": [["17"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["of"]],"start": [["46"]],"entity_id": [["T7"]]},"Combination": null ,"Trigger": {"text": [["risk"]],"start": [["52"]],"entity_id": [["T8"]]} } ,"Negated": null,"Speculated": null,"Severity": {"text": [["ischemic skin complications"]],"start": [["59"]],"entity_id": [["T1"]],"value": "high"} ,"Subject": null ,"Effect": null } ]}
{"id": "17039658_3","context": "We report the case of a 60-year-old woman who developed erythema and erosions in the axilla and groin while on PLD for breast cancer","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["erythema", "erosions"]],"start": [["15", "33"]],"entity_id": [["T1", "T2"]]},"Subject": {"text": [["a 60-year-old woman"]],"start": [["5"]],"entity_id": [["T3"]],"Age": {"text": [["60"]],"start": [[ "5" ]],"entity_id": [["T7"]]},"Gender": {"text": [["woman"]],"start": [[ "12" ]],"entity_id": [["T8"]]},"Disorder": {"text": [["breast cancer"]],"start": [["83"]],"entity_id": [["T9"]]},"Population": {"text": [["a"]],"start": [[ "5" ]],"entity_id": [["T10"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["PLD"]],"start": [["66"]],"entity_id": [["T4"]],"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["for breast cancer"]],"start": [["75"]],"entity_id": [["T11"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["erythema", "erosions"]],"start": [[ "15", "33"]],"entity_id": [["T12", "T13"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "18171260_2","context": "Serotonin syndrome has been reported with administration of linezolid and serotonin reuptake inhibitors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Serotonin syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] }, "Treatment": { "text": [["linezolid", "serotonin reuptake inhibitors"]], "start": [[ "42" ], [ "63" ]], "entity_id": [ ["T2", "T3" ]] ,"Drug": { "text": [["linezolid"]], "start": [[ "42" ]], "entity_id": [ ["T2" ]] }, "Dosage": null,"Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [["administration"]], "start": [[ "25" ]], "entity_id": [ ["T4" ]] }} ,"Effect": { "text": [["Serotonin syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }} ]}
{"id": "18585545_4", "context": "Levofloxacin-induced delirium with psychotic features", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Levofloxacin-induced"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]] }, "Effect": { "text": [["delirium with psychotic features"]], "start": [[ "19" ]], "entity_id": [[ "T2" ]] } ,"Treatment": { "text": [["Levofloxacin"]], "start": [[ "0" ]], "entity_id": [[ "T3" ]] ,"Drug": { "text": [["Levofloxacin"]], "start": [[ "0" ]], "entity_id": [[ "T4" ]] }, "Dosage": null, "Freq": null, "Route": null, "Duration": null, "Time_elapsed": null, "Disorder": null ,"Combination": null ,"Trigger": { "text": [["Levofloxacin-induced"]], "start": [[ "0" ]], "entity_id": [[ "T5" ]] }} ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "8007037_2","context": "Methemoglobinemia: an occupational hazard of phenylpropanolamine production","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Methemoglobinemia"]],"start": [[ ], [ ]],"entity_id": []},"Treatment": {"Drug": {"text": [["phenylpropanolamine"]],"start": [[ ]],"entity_id": []} ,"text": [["production"]],"start": [[]],"entity_id": [] ,"Trigger": {"text": [["an occupational hazard"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [["production"]],"start": [[]],"entity_id": []} ,"Disorder": {"text": [["Methemoglobinemia"]],"start": [[]],"entity_id": []} ,"Freq": {"text": [["an"]],"start": [[]],"entity_id": []} ,"Route": {"text": [["of"]],"start": [[]],"entity_id": []} ,"Dosage": {"text": [["production"]],"start": [[]],"entity_id": []} ,"Duration": {"text": [["an occupational hazard"]],"start": [[]],"entity_id": []},"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "9220046_1","context": "In each case, the patients were treated over 5 years with lovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["lovastatin"]],"start": [["21"]],"entity_id": [["T1"]],"Duration": {"text": [["5 years"]],"start": [["25"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["rhabdomyolysis"]],"start": [["55"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["completion"]],"start": [["85"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["coincided"]],"start": [["73"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["newer macrolide antibiotic"]],"start": [["100"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["prescribed regimen"]],"start": [["91"]],"entity_id": [["T7"]]} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect" }] ,"Freq": {"text": [["each case"]],"start": [["5"]],"entity_id": [["T0"]]} ,"Route": {"text": [["treated"]],"start": [["21"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Drug": {"text": [["lovastatin"]],"start": [["21"]],"entity_id": [["T1"]]} },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["the patients"]],"start": [["0"]],"entity_id": [["T9"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["rhabdomyolysis"]],"start": [["55"]],"entity_id": [["T3"]]} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Trigger": null }] }
{"id": "16371793_2", "context": "The intravitreal application of triamcinolone acetonide as treatment of long-standing, therapy-resistant cystoid macular edema after penetrating keratoplasty is reported", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["triamcinolone acetonide"]], "start": [["31"]], "entity_id": [],"Drug":{"text":[["triamcinolone acetonide"]],"start":[["31"]],"entity_id":[]},"Route":{"text":[["intravitreal application"]],"start":[["0"]],"entity_id":[]},"Disorder":{"text":[["treatment of long-standing, therapy-resistant cystoid macular edema after penetrating keratoplasty"]],"start":[["51"]],"entity_id":[]},"Time_elapsed":{"text":[["is reported"]],"start":[["101"]],"entity_id":[]},"Duration":{"text":[["long-standing"]],"start":[["51"]],"entity_id":[]},"Dosage":{"text":[[]],"start":[[]],"entity_id":[]},"Freq":{"text":[[]],"start":[[]],"entity_id":[]},"Trigger":{"text":[[]],"start":[[]],"entity_id":[]},"Combination":[{"Drug":{"text":[["triamcinolone acetonide"]],"start":[["31"]],"entity_id":[]},"Trigger":{"text":[["intravitreal application"]],"start":[["0"]],"entity_id":[]},"event_id":"C1","event_type":"Combination"}]},"Subject":{"text":[["is reported"]],"start":[["101"]],"entity_id":[],"Age":{"text":[[]],"start":[[]],"entity_id":[]},"Gender":{"text":[[]],"start":[[]],"entity_id":[]},"Population":{"text":[[]],"start":[[]],"entity_id":[]},"Race":{"text":[[]],"start":[[]],"entity_id":[]},"Disorder":{"text":[["treatment of long-standing, therapy-resistant cystoid macular edema after penetrating keratoplasty"]],"start":[["51"]],"entity_id":[]}},"Negated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Speculated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Severity":{"text":[[]],"start":[[]],"entity_id":[],"value":""},"Effect":{"text":[[]],"start":[[]],"entity_id":[]},"Trigger":{"text":[[]],"start":[[]],"entity_id":[]}}]}
{"id": "23868369_8", "context": "Patients receiving ciprofloxacin and digoxin should be monitored closely for the risk of digoxin toxicity", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["monitored closely for the risk"]], "start": [["31","32"]], "entity_id": []}, "Treatment": {"text": [["ciprofloxacin and digoxin"]], "start": [["8","19"]], "entity_id": [], "Drug": {"text": [["ciprofloxacin","digoxin"]], "start": [["8","13","15","19"]], "entity_id": []},"Disorder": {"text": [["digoxin toxicity"]], "start": [["52","58"]], "entity_id": []},"Freq": {"text": [["receiving"]], "start": [["0","7"]], "entity_id": []},"Route": {"text": [["orally"]], "start": [["27","30"]], "entity_id": []},"Combination": [{"Drug": {"text": [["ciprofloxacin"]], "start": [["8","13"]], "entity_id": []},"Trigger": {"text": [["and"]], "start": [["14"]], "entity_id": []},"event_id": "C1","event_type": "Treatment"} ,{"Drug": {"text": [["digoxin"]], "start": [["15","19"]], "entity_id": []},"Trigger": {"text": [["and"]], "start": [["14"]], "entity_id": []},"event_id": "C2","event_type": "Treatment"} ],"Time_elapsed": {"text": [["receiving"]], "start": [["0","7"]], "entity_id": []},"Dosage": {"text": [["close"]], "start": [["31","32"]], "entity_id": []},"Duration": {"text": [["close"]], "start": [["31","32"]], "entity_id": []},"Trigger": {"text": [["monitored closely for the risk"]], "start": [["31","51"]], "entity_id": []}} ,"Subject": {"text": [["Patients"]], "start": [["0"]], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []}} ,"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""} , "Effect": {"text": [], "start": [], "entity_id": []} }]}
{"id": "11443640_2","context": "To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["MMI"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["MMI"]],"start": [["51"]],"entity_id": [["T2"]]},"Disorder": {"text": [["pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["due"]],"start": [["22"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["MMI"]],"start": [["51"]],"entity_id": [["T2"]]} ,"Route": {"text": [["due"]],"start": [["22"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["first report"]],"start": [["5"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["first report"]],"start": [["5"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["first report"]],"start": [["5"]],"entity_id": [["T4"]]},"Combination": null} ,"Subject": {"text": [["To our knowledge"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["pancytopenia"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["massive plasmocytosis"]],"start": [["83"]],"entity_id": [["T5"]],"value": "high"}}]}
{"id": "4082283_3","context": "The following is a report of 2 cases of rifampicin-induced renal insufficiency","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rifampicin-induced renal insufficiency"]],"start": [["33","43"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["rifampicin"]],"start": [["7","13"]],"entity_id": [["T2"]]},"entity_id": [["T3"]],"Disorder": {"text": [["renal insufficiency"]],"start": [["27","36"]],"entity_id": [["T4"]]},"start": [["0"]],"Freq": {"text": [["2"]],"start": [["5"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["rifampicin"]],"start": [["7","13"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["14","18"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["cases"]],"start": [["0"]],"entity_id": [["T7"]]},"Duration": {"text": [["report"]],"start": [["5","11"]],"entity_id": [["T8"]]},"text": [["The following is a report"]],"Trigger": {"text": [["of"]],"start": [["22"]],"entity_id": [["T9"]]},"Route": {"text": [["cases"]],"start": [["5"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["renal insufficiency"]],"start": [["27","36"]],"entity_id": [["T4"]]}}]}
{"id": "14601701_4","context": "We describe a 43-year-old man who developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bilateral optic neuropathy"]],"start": [["developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol" ],[ "bilateral optic neuropathy" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["ethambutol"]],"start": [["treatment with ethambutol"]],"entity_id": [ ["T2"]],"Drug": {"text": [["ethambutol"]],"start": [["treatment with ethambutol"]],"entity_id": [ ["T3"]]},"Duration": {"text": [["during treatment with ethambutol"]],"start": [["during treatment with ethambutol"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": { "text": [["developed"]], "start": [[ "developed" ]], "entity_id": [ ["T5"] ] } , "Dosage": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T6"],["T7"] ] } ,"Route": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T8"],["T9"] ] } , "Freq": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T10"],["T11"] ] } , "Disorder": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T12"],["T13"] ] } , "Combination": null , "Trigger" : { "text" : [["during treatment with ethambutol"]], "start" : [[ "during treatment with ethambutol" ]], "entity_id" : [ ["T14"] ] } } , "Subject": {"text": [["a 43-year-old man"]],"start": [[ "a 43-year-old man" ]],"entity_id": [ ["T15"] ],"Age": { "text": [[ "43" ]], "start": [[ "43" ]], "entity_id": [ ["T16"] ] } , "Gender": { "text": [[ "man" ]], "start": [[ "man" ]], "entity_id": [ ["T17"] ] } ,"Population": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T18"],["T19"] ] } , "Race": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T20"],["T21"] ] } , "Disorder": { "text": [[""],[""]], "start": [[],[]], "entity_id": [ ["T22"],["T23"] ] } } , "Effect": { "text": [["signs and symptoms"]], "start": [[ "signs and symptoms" ]], "entity_id": [ ["T24"] ] } , "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "8445549_3","context": "The patient described in this paper was a 78-year-old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["oral lesions"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["glibenclamide therapy"]],"start": [["86"]],"entity_id": [["T2"]],"Drug": {"text": [["glibenclamide"]],"start": [["86"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["diabetic"]],"start": [["48"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["following institution"]],"start": [["63"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["78-year-old"]],"start": [["12"]],"entity_id": [["T6"]]},"Route": {"text": [["therapy"]],"start": [["86"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["following institution"]],"start": [["63"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["PV"]],"start": [["55"]],"entity_id": [["T7"]]} ,"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["78-year-old"]],"start": [["12"]],"entity_id": [["T6"]]},"Gender": {"text": [["man"]],"start": [["50"]],"entity_id": [["T8"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["diabetic"]],"start": [["48"]],"entity_id": [["T4"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "16146480_2","context": "Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["propofol administration"]],"start": [["98"]],"entity_id": [["T2"]]},"Subject": {"text": [["patients with Cushing's disease"]],"start": [["55"]],"entity_id": [["T1"]],"Population": {"text": [["patients with Cushing's disease"]],"start": [["55"]],"entity_id": [["T1"]]},"Disorder": {"text": [["Cushing's disease"]],"start": [["27"]],"entity_id": [["T0"]]},"Age": null,"Gender": null,"Race": null},"Treatment": null,"Effect": {"text": [["acute pancreatitis"]],"start": [["79"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": {"text": [["might be more prone"]],"start": [["88"]],"entity_id": [["T4"]],"value": true},"Severity": null}]}
{"id": "21715267_2", "context": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections._2", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["Moxifloxacin"]],"start": [[ ], ["Moxifloxacin"], ["and"], ["lomefloxacin"]],"entity_id": []},"text": [["Moxifloxacin and lomefloxacin"]],"start": [["Moxifloxacin"], ["and"], ["lomefloxacin"], ["are"]],"entity_id": [],"Time_elapsed": null,"Duration": null,"Disorder": null,"Dosage": null,"Route": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "9337441_14", "context": "To our knowledge, this case report represents only the third description of laxative-induced TEN", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["laxative-induced TEN"]], "start": [["laxative-induced TEN's starting index in context"]], "entity_id": []}, "Treatment": {"text": [], "start": [], "entity_id": [],"Drug": {"text": [["laxative"]], "start": [["laxative's starting index in context"]], "entity_id": []},"Disorder": {"text": [["TEN"]], "start": [["" ]], "entity_id": []},"Route": {"text": [["induced"]], "start": [["" ]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [],"Dosage": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [["laxative-induced TEN"]], "start": [["" ]], "entity_id": []}},"Effect": {"text": [], "start": [], "entity_id": []},"Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []}},"Negated": {"value": false,"text": [], "start": [], "entity_id": []},"Speculated": {"value": false,"text": [], "start": [], "entity_id": []},"Severity": {"value": "severe","text": [], "start": [], "entity_id": []}}]}
{"id": "21417793_2","context": "Prompted by the advent of potentially life-threatening neuromuscular symptoms following initiation of linezolid therapy in two patients receiving treatment with a serotonin reuptake inhibitor antidepressant, an evaluation was conducted to determine the incidence and characteristics of symptomatic serotonin toxicity among hospitalized patients receiving combined treatment with these medications." ,"is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neuromuscular symptoms"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["linezolid therapy"]],"start": [["15"]],"entity_id": [["T2"]],"Drug": {"text": [["linezolid"]],"start": [["15"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["treatment with a serotonin reuptake inhibitor antidepressant"]],"start": [["60"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["following initiation"]],"start": [["22"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["following initiation"]],"start": [["22"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]} ,"Duration": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]} ,"Route": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]} ,"Freq": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]} ,"Combination": null} ,"Effect": {"text": [["symptomatic serotonin toxicity"]],"start": [["119"]],"entity_id": [["T6"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["potentially life-threatening"]],"start": [["42"]],"entity_id": [["T7"]] ,"value": "High"} ,"Subject": {"text": [["patients"]],"start": [["95"]],"entity_id": [["T8"]],"Age": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]] },"Gender": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]] },"Population": {"text": [["hospitalized"]],"start": [["95"]],"entity_id": [["T8"]] },"Race": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]] },"Disorder": {"text": [["receiving treatment with a serotonin reuptake inhibitor antidepressant"]],"start": [["60"]],"entity_id": [["T4"]] }} } ]}
{"id": "8244201_3","context": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hyperkalaemia"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["sulfamethoxazole-trimethoprim"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["Pneumocystis carinii pneumonia"]],"start": [[ ]],"entity_id": [ ]} ,"Drug": {"text": [["sulfamethoxazole-trimethoprim"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": [] },"Effect": {"text": [["renal tubular dysfunction"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": {"text": [],"start": [],"entity_id": [] },"Race": null,"Disorder": {"text": [["lymphoid malignancy"]],"start": [[ ]],"entity_id": [ ]} }} ]}
{"id": "19540093_2","context": "Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe abdominal pain"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["tigecycline"]],"start": [["16"]],"entity_id": [["T2"]],"Drug": {"text": [["tigecycline"]],"start": [["16"]],"entity_id": [["T2"]]},"Duration": {"text": [["7 days"]],"start": [["16"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["7 days"]],"start": [["16"]],"entity_id": [["T3"]]},"Freq": {"text": [["days"]],"start": [["23"]],"entity_id": [["T4"]]},"Disorder": {"text": [["acute pancreatitis"]],"start": [["56"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [["30"]],"entity_id": [["T6"]]},"Route": {"text": [["days"]],"start": [["23"]],"entity_id": [["T4"]]},"Dosage": {"text": [[]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": [{"Drug": {"text": [["tigecycline"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Trigger": {"text": [["7 days"]],"start": [[""],[""]],"entity_id": [[""],[""]]},"event_id": "","event_type": ""}]},"Subject": {"text": [["she"]],"start": [["27"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe abdominal pain"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}}]}
{"id": "11850606_4","context": "To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["interferon alpha"]],"start": [[" "], [")"]],"entity_id": [["T1"], ["T2"]],"Disorder": {"text": [["hepatitis B"]],"start": [[","]],"entity_id": [["T3"]]},"Dosage": {"text": [["administered"]],"start": [[","]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["until"]],"start": [[","]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [[")"]],"entity_id": [["T6"]]},"Freq": {"text": [["until"]],"start": [[","]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["interferon alpha"]],"start": [[")"]],"entity_id": [["T2"]]},"Trigger": {"text": [["developed"]],"start": [[")"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Duration": {"text": [["until"]],"start": [[","]],"entity_id": [["T5"]]},"Route": {"text": [["administered"]],"start": [[","]],"entity_id": [["T4"]]},"Drug": {"text": [["interferon alpha"]],"start": [[")"]],"entity_id": [["T2"]]}},"Subject": {"text": [["To treat hepatitis B"]],"start": [[], ["To"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["hepatitis B"]],"start": [[","]],"entity_id": [["T3"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["developed"]],"start": [[")"]],"entity_id": [["T6"]]}}]}
{"id": "16882112_4","context": "We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["lithium"]],"start": [["12"]],"entity_id": [["T2"]]},"Dosage": {"text": [["dual selective re-uptake inhibition mechanism"]],"start": [["43"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treatment"]],"start": [["16"]],"entity_id": [["T4"]]},"Route": {"text": [["during"]],"start": [["20"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["20"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["lithium"]],"start": [["12"]],"entity_id": [["T2"]]},"Trigger": {"text": [["and"]],"start": [["28"]],"entity_id": [["T6"]]},"event_id": "E1-1","event_type": "Adverse_event"}] ,"Trigger": {"text": [["treatment"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["during"]],"start": [["20"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["during"]],"start": [["20"]],"entity_id": [["T5"]]} ,"entity_id": [["T2","T3","T4","T5"]] ,"start": [["12","43","16","20"]] ,"text": [["lithium","dual selective re-uptake inhibition mechanism","treatment","during"]] },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]] ,"Age": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Gender": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Population": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Race": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["treatment"]],"start": [["16"]],"entity_id": [["T4"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["serotonin syndrome"]],"start": [["23"]],"entity_id": [["T1"]],"value": "High"} ,"Effect": {"text": [["serotonin syndrome"]],"start": [["23"]],"entity_id": [["T1"]]} }]}
{"id": "19531695_13","context": "Supratherapeutic flecainide plasma concentrations may cause delirium","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Supratherapeutic flecainide plasma concentrations"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["flecainide"]],"start": [[ "49" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["flecainide"]],"start": [[ "49" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["delirium"]],"start": [[ "88" ]],"entity_id": [ ["T3"] ]} ,"Dosage": { "text": [["Supratherapeutic"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Route": { "text": [["plasma concentrations"]], "start": [[ "31" ]], "entity_id": [ ["T1"] ]} ,"Time_elapsed": null ,"Duration": null ,"Freq": null ,"Combination": null ,"Trigger": null },"Effect": { "text": [["delirium"]], "start": [[ "88" ]], "entity_id": [ ["T3"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "18644535_2","context": "This is a case report of possible association of methylphenidate and enuresis in an 11-year-old boy with attention deficit hyperactivity disorder","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["possible association"]],"start": [["26"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methylphenidate"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["methylphenidate"]],"start": [["42"]],"entity_id": [["T3"]]},"Disorder": {"text": [["enuresis"]],"start": [["51"]],"entity_id": [["T4"]]},"Freq": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Dosage": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Duration": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Route": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Trigger": {"text": [["-"]],"start": [[],[]],"entity_id": [["T5"]]},"Combination": null},"Subject": {"text": [["an 11-year-old boy"]],"start": [["64"]],"entity_id": [["T6"]],"Age": {"text": [["11"]],"start": [[],[]],"entity_id": [["T7"]]},"Disorder": {"text": [["attention deficit hyperactivity disorder"]],"start": [["78"]],"entity_id": [["T8"]]},"Gender": {"text": [["boy"]],"start": [[],[]],"entity_id": [["T9"]]},"Population": {"text": [["-"]],"start": [[],[]],"entity_id": [["T10"]]},"Race": {"text": [["-"]],"start": [[],[]],"entity_id": [["T10"]]}},"Effect": {"text": [["enuresis"]],"start": [["51"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": {"text": [["possible"]],"start": [[],[]],"entity_id": [["T1"]],"value": true},"Severity": null}]}
{"id": "19331262_4","context": "This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neuroleptic malignant syndrome"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["risperidone"]],"start": [["58"]],"entity_id": [["T2"]],"Drug": {"text": [["risperidone"]],"start": [["58"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Joubert syndrome"]],"start": [["86"]],"entity_id": [["T3"]]},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Route": {"text": [[]],"start": [],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [],"entity_id": []},"Freq": {"text": [[]],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [[]],"start": [],"entity_id": []}},"Effect": {"text": [[]],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [[]],"start": [],"entity_id": [],"value": "high"},"Subject": {"text": [["a child"]],"start": [["35"]],"entity_id": [["T4"]],"Age": {"text": [[]],"start": [],"entity_id": []},"Gender": {"text": [[]],"start": [],"entity_id": []},"Population": {"text": [[]],"start": [],"entity_id": []},"Race": {"text": [[]],"start": [],"entity_id": []},"Disorder": {"text": [["Joubert syndrome"]],"start": [["86"]],"entity_id": [["T3"]]}}}]}
{"id": "7724306_1","context": "Acute INH neurotoxicity was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["acute INH neurotoxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"value": true,"text": [["not suspected"]],"start": [["31"]],"entity_id": [["T2"]]},"Treatment": {"text": [["INH"]],"start": [["22"]],"entity_id": [["T3"]],"Drug": {"text": [["INH"]],"start": [["22"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute INH neurotoxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["4 weeks later"]],"start": [["55"]],"entity_id": [["T4"]]},"Trigger": {"text": [["readmitted"]],"start": [["55"]],"entity_id": [["T4"]]},"Freq": {"text": [["another seizure"]],"start": [["64"]],"entity_id": [["T5"]]},"Dosage": {"text": [["not suspected"]],"start": [["31"]],"entity_id": [["T2"]]},"Route": {"text": [["not suspected"]],"start": [["31"]],"entity_id": [["T2"]]},"Duration": {"text": [["not suspected"]],"start": [["31"]],"entity_id": [["T2"]]},"Combination": null},"Effect": {"text": [["the diagnosis of acute INH neurotoxicity"]],"start": [["112"]],"entity_id": [["T6"]]},"Subject": null,"Severity": null,"Speculated": null}]}
{"id": "12066972_1", "context": "Levofloxacin-induced toxic epidermal necrolysis in an elderly patient", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Levofloxacin-induced toxic epidermal necrolysis"]], "start": [[ "0" ] ], "entity_id": [ ["T1"] ]}, "Subject": { "text": [["an elderly patient"]], "start": [[ "66" ] ], "entity_id": [ ["T2"] ], "Age": { "text": [["elderly"]], "start": [[ "66" ] ], "entity_id": [ ["T7"] ]} , "Disorder": { "text": [["toxic epidermal necrolysis"]], "start": [[ "31" ] ], "entity_id": [ ["T3"] ]} , "Gender": { "text": [["patient"]], "start": [[ "66" ] ], "entity_id": [ ["T8"] ]} , "Race": null , "Population": null }, "Treatment": { "text": [["Levofloxacin"]], "start": [[ "0" ] ], "entity_id": [ ["T4"] ], "Drug": { "text": [["Levofloxacin"]], "start": [[ "0" ] ], "entity_id": [ ["T4"] ]} , "Dosage": null , "Duration": null , "Disorder": { "text": [["toxic epidermal necrolysis"]], "start": [[ "31" ] ], "entity_id": [ ["T3"] ]} , "Route": null , "Time_elapsed": null , "Freq": null , "Combination": null , "Trigger": null } , "Effect": { "text": [["toxic epidermal necrolysis"]], "start": [[ "31" ] ], "entity_id": [ ["T3"] ]} , "Negated": null , "Speculated": null , "Severity": null }]}
{"id": "7582710_2","context": "The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["mild nitritoid symptoms"]],"start": [[ "0" ]],"entity_id": [ ]},"Treatment": {"text": [["gold sodium thiomalate (GSTM)"]],"start": [[ "84" ]],"entity_id": [ ],"Drug": {"text": [["gold sodium thiomalate"]],"start": [[ "84" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["shortly"]],"start": [[ "60" ]],"entity_id": [ ]},"Disorder": {"text": [["T10-T12 dermatomes"]],"start": [[ "40" ]],"entity_id": [ ]},"Trigger": {"text": [["injection"]],"start": [[ "102" ]],"entity_id": [ ]},"Duration": {"text": [["mild"]],"start": [[ "0" ]],"entity_id": [ ]},"Freq": {"text": [["first patient"]],"start": [[ "0" ]],"entity_id": [ ]},"Route": {"text": [["injection"]],"start": [[ "102" ]],"entity_id": [ ]},"Dosage": {"text": [["gold sodium thiomalate (GSTM)"]],"start": [[ "84" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["gold sodium thiomalate"]],"start": [[ "84" ]],"entity_id": [ ]},"Trigger": {"text": [["injection"]],"start": [[ "102" ]],"entity_id": [ ]},"event_type": "Adverse_event","event_id": "E1"}]},"Subject": {"text": [["first patient"]],"start": [[ "0" ]],"entity_id": [ ],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["mild nitritoid symptoms"]],"start": [[ "0" ]],"entity_id": [ ]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["mild"]],"start": [[ "0" ]],"entity_id": [],"value": "low"}}]}
{"id": "9824032_3","context": "Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["intense dental and gingival pain"]],"start": [["32", "33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["niacin therapy"]],"start": [["62", "63"]],"entity_id": [["T2"]],"Drug": {"text": [["niacin"]],"start": [["62", "63"]],"entity_id": [["T3"]]},"Duration": {"text": [["5 months"]],"start": [["59", "60"]],"entity_id": [["T4"]]},"Disorder": {"text": [["dyslipidemia"]],"start": [["47", "48"]],"entity_id": [["T5"]]},"Freq": {"text": [["increases in dose"]],"start": [["78", "79"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["that was associated with"]],"start": [["72"]],"entity_id": [["T7"]]},"Route": {"text": [["given"]],"start": [["41"]],"entity_id": [["T8"]]},"Trigger": {"text": [["given"]],"start": [["41"]],"entity_id": [["T8"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["Two 65-year-old white men with coronary heart disease"]],"start": [["0"]],"entity_id": [["T9"]],"Age": {"text": [["65-year-old"]],"start": [["0"]],"entity_id": [["T10"]]},"Gender": {"text": [["men"]],"start": [["15"]],"entity_id": [["T11"]]},"Race": {"text": [["white"]],"start": [["12"]],"entity_id": [["T12"]]},"Population": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["coronary heart disease"]],"start": [["23"]],"entity_id": [["T13"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "3335488_2", "context": "Two patients are described who developed testicular swelling and pain during treatment with desipramine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["testicular swelling and pain"]], "start": [["developed testicular swelling and pain's index"]],"entity_id": [["T1"]]}, "Treatment": {"text": [["treatment with desipramine"]], "start": [["treatment with desipramine's index"]], "entity_id": [["T2"]], "Drug": {"text": [["desipramine"]], "start": [["desipramine's index"]], "entity_id": [["T3"]] },"Duration": { "text": [["during treatment"]], "start": [["during treatment's index"]], "entity_id": [["T4"]]},"Disorder": { "text": [["testicular swelling and pain"]], "start": [["developed testicular swelling and pain's index"]], "entity_id": [["T1"]] },"Time_elapsed": { "text": [["during treatment"]], "start": [["during treatment's index"]], "entity_id": [["T4"]]},"Freq": { "text": [["during treatment"]], "start": [["during treatment's index"]], "entity_id": [["T4"]]},"Combination": [{ "Drug": { "text": [["desipramine"]], "start": [["desipramine's index"]], "entity_id": [["T3"]] },"Trigger": { "text": [["treatment with desipramine"]], "start": [["treatment with desipramine's index"]], "entity_id": [["T2"]]},"event_id": "C1" , "event_type": "Treatment" }],"Trigger": { "text": [["treatment with desipramine"]], "start": [["treatment with desipramine's index"]], "entity_id": [["T2"]]},"Dosage": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] } },"Subject": { "text": [["Two patients"]], "start": [[ "Two patients' index"]], "entity_id": [[ "T0"]],"Age": { "text": [], "start": [], "entity_id": [] },"Gender": { "text": [], "start": [], "entity_id": [] },"Population": { "text": [["Two patients"]], "start": [[ "Two patients' index"]], "entity_id": [[ "T0"]] },"Race": { "text": [], "start": [], "entity_id": [] },"Disorder": { "text": [], "start": [], "entity_id": [] } },"Effect": { "text": [["testicular swelling and pain"]], "start": [[ "testicular swelling and pain's index"]], "entity_id": [[ "T1"]]},"Negated": { "text": [], "start": [], "entity_id": [],"value": false },"Speculated": { "text": [], "start": [], "entity_id": [],"value": false },"Severity": { "text": [], "start": [], "entity_id": [],"value": "" } }]}
{"id": "6635723_1","context": "Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide-induced hyponatremia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["rechallenge"]],"start": [["36"]],"entity_id": []},"Treatment": {"text": [["hydrochlorothiazide"]],"start": [["27"]],"entity_id": [],"Disorder": {"text": [["thiazide-induced hyponatremia"]],"start": [["74"]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [["rechallenge"]],"start": [["36"]],"entity_id": []} ,"Drug": {"text": [["hydrochlorothiazide"]],"start": [["27"]],"entity_id": []} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }} ]}
{"id": "17675030_2", "context": "Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["oxcarbazepine-related angioneurotic edema"]], "start": [["0"]], "entity_id": [["T1"]]},"Subject": {"text": [["case report"]], "start": [["55"]], "entity_id": [["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Effect": {"text": [["angioneurotic edema"]], "start": [["15"]], "entity_id": [["T3"]]},"Severity": null, "Negated": null, "Speculated": null ,"Treatment": { "text": [["oxcarbazepine"]], "start": [["7"]], "entity_id": [["T4"]], "Drug": null, "Disorder": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null }}]}
{"id": "8253700_1","context": "Fluoxetine, a highly specific serotonin reuptake inhibitor, has been reported to cause sexual dysfunction in a minority of patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["sexual dysfunction"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Fluoxetine"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["Fluoxetine"]],"start": [["0"]],"entity_id": [["T2"]]},"Disorder": {"text": [["sexual dysfunction"]],"start": [["52"]],"entity_id": [["T1"]]},"Freq": {"text": [["a minority of patients"]],"start": [["70"]],"entity_id": [["T3"]]},"Route": {"text": [["reported"]],"start": [["41"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["has been reported"]],"start": [["34"]],"entity_id": [["T5"]]},"Dosage": {"text": [["a highly specific serotonin reuptake inhibitor"]],"start": [["21"]],"entity_id": [["T6"]]},"Duration": {"text": [["has been reported"]],"start": [["34"]],"entity_id": [["T5"]]},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["sexual dysfunction"]],"start": [["52"]],"entity_id": [["T1"]]}}]}
{"id": "18362995_4", "context": "We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure.$", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["imatinib treatment"]], "start": [["63", "64"]], "entity_id": []}, "Treatment": {"text": [["imatinib treatment"]], "start": [["63", "64"]], "entity_id": [], "Drug": {"text": [["imatinib"]], "start": [["63", "64"]], "entity_id": []}, "Disorder": {"text": [["CML"]], "start": [["21"]], "entity_id": []},"Duration":{"text":[["45-year-old"]],"start":[[ "6","7"]],"entity_id":[]}, "Route":{"text":[["oral"]],"start":[["63"]], "entity_id":[]},"Freq":{"text":[["chronic"]],"start":[["41","42"]],"entity_id":[]}, "Combination":[{"Drug":{"text":[["imatinib"]],"start":[["63","64"]],"entity_id":[]},"Trigger":{"text":[["treatment"]],"start":[["63"]],"entity_id":[]},"event_id":"C1","event_type":"Treatment"}],"Trigger":{"text":[["presenting with herpetic rash and acute liver failure"]],"start":[["93"]],"entity_id":[]},"Dosage":{"text":[[]],"start":[[]],"entity_id":[]},"Time_elapsed":{"text":[[]],"start":[[]],"entity_id":[]}},"Subject":{"text":[["We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection"]],"start":[[],[],[],[],[],[],[],[],[],[]],"entity_id":[],"Age":{"text":[["45-year-old"]],"start":[[ "6","7"]],"entity_id":[]},"Gender":{"text":[["man"]],"start":[[ "51"]],"entity_id":[]},"Population":{"text":[["We report"]],"start":[[],[]],"entity_id":[]},"Race":{"text":[["Chinese"]],"start":[[ "36"]],"entity_id":[]},"Disorder":{"text":[["CML and chronic hepatitis B virus infection"]], "start":[[ "21","22"],["28","29"]],"entity_id":[]}},"Effect":{"text":[["herpetic rash and acute liver failure"]],"start":[["93"]],"entity_id":[]},"Negated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Speculated":{"text":[[]],"start":[[]],"entity_id":[],"value":false},"Severity":{"text":[[]],"start":[[]],"entity_id":[],"value":"low"}}]}
{"id": "3947272_4","context": "One patient had severe temporary weakness after an ampicillin sodium challenge","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe temporary weakness"]],"start": [["18","19"]],"entity_id": []},"Treatment": {"text": [["ampicillin sodium challenge"]],"start": [["52","53"]],"entity_id": [],"Drug": {"text": [["ampicillin sodium"]],"start": [["52","53"]],"entity_id": []} ,"Disorder": {"text": [["challenge"]],"start": [["56"]],"entity_id": []} ,"Route": {"text": [["after"]],"start": [["42"]],"entity_id": []} ,"Time_elapsed": {"text": [["after"]],"start": [["42"]],"entity_id": []} ,"Freq": {"text": [["after"]],"start": [["42"]],"entity_id": []} ,"Duration": {"text": [["temporary"]],"start": [["17"]],"entity_id": []} ,"Trigger": {"text": [["after"]],"start": [["42"]],"entity_id": []} ,"Combination": [] ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["One patient"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["severe temporary weakness"]],"start": [["18","19"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}}]}
{"id": "11142491_1","context": "Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Acute myeloid leukemia", "lung cancer"]],"start": [[ ], []],"entity_id": [["T1"],["T2"]]},"Subject": {"text": [["a chronic lymphocytic leukemia patient"]],"start": [[ ]],"entity_id": [["T3"]],"Disorder": {"text": [["chronic lymphocytic leukemia"]],"start": [[ ]],"entity_id": [["T4"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["fludarabine and autologous peripheral blood stem-cell transplantation"]],"start": [[]],"entity_id": [["T5"]],"Drug": {"text": [["fludarabine"]],"start": [[]],"entity_id": [["T6"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "16960880_1","context": "Despite a very low complication rate, several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["several severe arterial thrombotic events"]],"start": [["26"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["26"]],"entity_id": [["T2"]] ,"value": "high" }, "Subject": null ,"Treatment": { "Drug": { "text": [["thrombin"]], "start": [["75"]], "entity_id": [ ["T3"] ]}, "Route": { "text": [["injection"]], "start": [["83"]], "entity_id": [ ["T4"] ]} ,"Disorder": { "text": [["pseudoaneurysms"]], "start": [["96"]], "entity_id": [ ["T5"] ]} ,"entity_id": [ ["T1"] ], "Dosage": null ,"Duration": null ,"Freq": null ,"Time_elapsed": null ,"Trigger": null ,"Combination": null ,"text": [["thrombin injection"]], "start": [["75"]] }, "Effect": { "text": [["several severe arterial thrombotic events"]], "start": [["26"]], "entity_id": [ ["T1"] ]} } ]}
{"id": "17060191_2","context": "Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["may cause"]],"start": [["34"]],"entity_id": []},"Treatment": {"text": [["administration of the drug to the mother"]],"start": [["21"]],"entity_id": [],"Drug": {"text": [["indomethacin"]],"start": [["21"]],"entity_id": []},"Disorder": {"text": [["side effects"]],"start": [["40"]],"entity_id": []},"Duration": {"text": [["many"]],"start": [["36"]],"entity_id": []},"Time_elapsed": {"text": [["may cause"]],"start": [["34"]],"entity_id": []},"Route": {"text": [["administration of the drug to the mother"]],"start": [["21"]],"entity_id": []},"Combination": [{"Drug": {"text": [["indomethacin"]],"start": [["21"]],"entity_id": []},"Trigger": {"text": [["may cause"]],"start": [["34"]],"entity_id": []},"event_type": "Potential_therapeutic_effect","event_id": "E1"}],"Freq": {"text": [["may cause"]],"start": [["34"]],"entity_id": []},"Trigger": {"text": [["may cause"]],"start": [["34"]],"entity_id": []},"Dosage": {"text": [["administration of the drug to the mother"]],"start": [["21"]],"entity_id": []}},"Effect": {"text": [["premature closure of the ductus arteriosus"]],"start": [["62"]],"entity_id": []},"Subject": {"text": [["Exposure of the fetus to indomethacin"]],"start": [["0"]],"entity_id": [],"Population": {"text": [["many"]],"start": [["36"]],"entity_id": []},"Disorder": {"text": [["side effects"]],"start": [["40"]],"entity_id": []},"Gender": {"text": [["the fetus"]],"start": [["0"]],"entity_id": []},"Race": {"text": [["the fetus"]],"start": [["0"]],"entity_id": []},"Age": {"text": [["the fetus"]],"start": [["0"]],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"}}]}
{"id": "19745701_3","context": "She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["immunodeficiency"]],"start": [["27"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["MTX administration"]],"start": [["55"]],"entity_id": [ ["T2"]],"Drug": {"text": [["MTX"]],"start": [["55"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD)"]],"start": [["11"]],"entity_id": [ ["T4"]]} ,"Time_elapsed": {"text": [["due"]],"start": [["34"]],"entity_id": [ ["T5"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["She"]],"start": [[ "0"]],"entity_id": [ ["T0"]],"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "18682542_1", "context": "Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here, especially vancomycin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["vancomycin"]], "start": [["especially vancomycin''.start()]], " ] , ["entity_id"] ] ,"entity_id": [["T1"]]},"Dosage": null, "Duration" : null, "Disorder" : null, "Freq" : null, "Route" : null, "Time_elapsed" : null ,"text" : [["antibiotic treatment"]], "start" : [[ "especially vancomycin''.start()]]," ,"entity_id" ,"entity_id" ] ], "Trigger" : { "text" : [["adverse reaction"]], "start" : [[ "this adverse reaction''.start()]], " ,"entity_id" ,"entity_id" ] ] ,"entity_id" : [["T2"]]},"entity_id" : [["E1"]] ,"Combination" : null} ,"Effect" : { "text" : [["similar complex neurologic symptoms"]], "start" : [[ "facing similar complex neurologic symptoms''.start()]], " ,"entity_id" ,"entity_id" ] ] ,"entity_id" : [["T3"]]},"Trigger" : { "text" : [["this adverse reaction"]], "start" : [[ "this adverse reaction''.start()]], " ,"entity_id" ,"entity_id" ] ] ,"entity_id" : [["T2"]]} }]}
{"id": "24661191_5","context": "Vitamin K1 caused skin rash possibly because of the distribution and metabolism characteristic of the drug in this patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["skin rash"]],"start": [["19"]],"entity_id": [["T2"]]},"Treatment": {"text": [["Vitamin K1"]],"start": [["0"]],"entity_id": [["T1"]] ,"Drug": {"text": [["Vitamin K1"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["skin rash"]],"start": [["19"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["possibly"]],"start": [["12"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["Vitamin K1"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["distribution and metabolism"]],"start": [["40"]],"entity_id": [["T4"]]} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect"}] ,"Freq": {"text": [["because"]],"start": [["32"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["because"]],"start": [["32"]],"entity_id": [["T5"]]} ,"Route": {"text": [["the distribution and metabolism"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["the distribution and metabolism"]],"start": [["40"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["Vitamin K1"]],"start": [["0"]],"entity_id": [["T1"]]} },"Subject": {"text": [["this patient"]],"start": [["67"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [["possibly"]],"start": [["12"]],"entity_id": [["T3"]] ,"value": true },"Severity": {"text": [["skin rash"]],"start": [["19"]],"entity_id": [["T2"]] ,"value": "Low" },"Effect": {"text": [["skin rash"]],"start": [["19"]],"entity_id": [["T2"]]} }]}
{"id": "14601701_3","context": "The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["toxic effect"]],"start": [["11"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["ethambutol"]],"start": [["36"]],"entity_id": [["T2"]]} ,"text": [["ethambutol"]],"start": [["36"]],"entity_id": [["T2"]] ,"Disorder": {"text": [["optic neuropathy"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["commonly recognized"]],"start": [["7"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["toxic effect"]],"start": [["11"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["commonly recognized"]],"start": [["7"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["uncommon"]],"start": [["81"]],"entity_id": [["T5"]]} ,"Combination": null ,"Route": null ,"Dosage": null }, "Effect": {"text": [["optic neuropathy"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "189279_1", "context": "A case of congestive heart failure in a child with Wilms' tumor treated Adriamycin is presented and discussed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["congestive heart failure"]], "start": [[ "0" ]],"entity_id": [ ]}, "Treatment": {"text": [["Adriamycin"]], "start": [[ "47" ]], "entity_id": [ ], "Drug": {"text": [["Adriamycin"]], "start": [[ "47" ]], "entity_id": [ ]} ,"Trigger": {"text": [["treated"]], "start": [[ "22" ]], "entity_id": [ ]} ,"Disorder": {"text": [["Wilms' tumor"]], "start": [[ "10" ]], "entity_id": [ ]} ,"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Combination": null }, "Subject": { "text": [["a child"]], "start": [[ "16" ]],"entity_id": [ ], "Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": {"text": [["Wilms' tumor"]], "start": [[ "10" ]], "entity_id": [ ]} },"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }]}
{"id": "9494448_3","context": "Hypersensitivity reactions to cyclosporine are rare","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hypersensitivity reactions"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["cyclosporine"]],"start": [["35"]],"entity_id": [["T2"]]},"entity_id": [["T2"]] ,"start": [["35"]],"text": [["cyclosporine"]] ,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["Hypersensitivity reactions"]],"start": [["0"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": {"text": [["are rare"]],"start": [["42"]],"entity_id": []}}]}
{"id": "24318743_15", "context": "In addition, single-agent weekly AUC2-carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["single-agent weekly AUC2-carboplatin"]], "start": [["0"]], "entity_id": [],"Drug": {"text": [["carboplatin"]], "start": [["32"]], "entity_id": [] },"Disorder": {"text": [["Inactive"]], "start": [["59"]], "entity_id": [] },"Dosage": {"text": [["weekly AUC2"]], "start": [["15"]], "entity_id": [] },"Route": {"text": [["single-agent"]], "start": [["0"]], "entity_id": [] },"Duration": {"text": [], "start": [], "entity_id": [] },"Trigger": {"text": [], "start": [], "entity_id": [] },"Time_elapsed": {"text": [], "start": [], "entity_id": [] },"Freq": {"text": [], "start": [], "entity_id": [] },"Combination": []}, "Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a homogenously defined population of PROC"]], "start": [["82"]], "entity_id": [],"Age": null,"Gender": null,"Population": {"text": [["a homogenously defined population"]], "start": [["82"]], "entity_id": []},"Race": null,"Disorder": {"text": [["PROC"]], "start": [["107"]], "entity_id": []}},"Trigger": null}]}
{"id": "18533420_1","context": "Intrathecal baclofen can impair sexual function and ejaculation in some patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["impair"]],"start": [["Intrathecal baclofen can impair sexual function and ejaculation in some patients" , "Intrathecal baclofen can impair sexual function and ejaculation in some patients" , "Intrathecal baclofen can impair sexual function and ejaculation in some patients" , "Intrathecal baclofen can impair sexual function and ejaculation in some patients" , "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ], [ "0" ], [ "0" ], [ "0" ] ],"entity_id": [ ["E1"] ]} ,"Subject": {"text": [["some patients"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E2"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }, "Treatment": {"text": [["Intrathecal baclofen"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E3"]],"Drug": {"text": [["baclofen"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E4"]] }, "Dosage": null,"Duration": null,"Route": null,"Disorder": {"text": [["sexual function"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E5"]] }, "Freq": null, "Time_elapsed": null, "Combination": null ,"Trigger": {"text": [["impair"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E6"]] }} ,"Effect": {"text": [["sexual function"]],"start": [[ "Intrathecal baclofen can impair sexual function and ejaculation in some patients" ]],"entity_id": [["E7"]] }, "Negated": null, "Speculated": null, "Severity": null }] }
{"id": "15671134_1", "context": "A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["A case"]], "start": [[ "0" ]], "entity_id": [ ["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["clozapine-induced tonic-clonic seizures"]], "start": [[ "20" ]], "entity_id": [ ["S2"]]}},"Treatment": {"text": [["valproate"]], "start": [[ "101" ]], "entity_id": [ ["T1"]],"Drug": {"text": [["valproate"]], "start": [[ "101" ]], "entity_id": [ ["T2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["clozapine-induced tonic-clonic seizures"]], "start": [[ "20" ]], "entity_id": [ ["S2"]]},"Freq": null ,"Combination": null ,"Trigger": { "text": [[ "managed" ]], "start": [[ "66" ]], "entity_id": [ ["T3"]] }},"Effect": {"text": [["clozapine-induced tonic-clonic seizures"]], "start": [[ "20" ]], "entity_id": [ ["S2"]]} ,"Trigger": null }]}
{"id": "8276031_5", "context": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre, is also discussed", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["symptomatology"]],"start": [[ ], ["symptomatology"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["naphthylimidazoline exposure"]],"start": [[ ], ["naphthylimidazoline exposure"]],"entity_id": [ ["T2"]] ,"Disorder": { "text": [["naphthylimidazoline exposure"]], "start": [[ ], ["naphthylimidazoline exposure"]], "entity_id": [ ["T2"]] } ,"Dosage": { "text": [["other paediatric cases"]], "start": [[ ], ["other paediatric cases"]], "entity_id": [ ["T3"]] } ,"Duration": { "text": [["18"]], "start": [[ ], ["18"]], "entity_id": [ ["T4"]] } ,"Route": { "text": [["reported to the Belgian National Poison Centre"]], "start": [[ ], ["reported to the Belgian National Poison Centre"]], "entity_id": [ ["T5"]] } ,"Time_elapsed": { "text": [["also discussed"]], "start": [[ ], ["also discussed"]], "entity_id": [ ["T6"]] } ,"Freq": null ,"Combination": null ,"Trigger": { "text": [["symptomatology"]], "start": [[ ], ["symptomatology"]], "entity_id": [ ["T1"]] } ,"Drug": { "text": [["naphthylimidazoline"]], "start": [[ ], ["naphthylimidazoline"]], "entity_id": [ ["T7"]] } } ,"Subject": { "text": [["18 other paediatric cases"]], "start": [[ ], ["18 other paediatric cases"]], "entity_id": [ ["T3"]], "Age": { "text": [["18"]], "start": [[ ], ["18"]], "entity_id": [ ["T4"]] } ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": { "text": [["naphthylimidazoline exposure"]], "start": [[ ], ["naphthylimidazoline exposure"]], "entity_id": [ ["T2"]] } } ,"Severity": null ,"Negated": null ,"Speculated": null ,"Effect": null } ]}
{"id": "11020127_1", "context": "Protease inhibitor-induced carbamazepine toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Protease inhibitor-induced carbamazepine toxicity"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]]}, "Treatment": {"text": [["carbamazepine"]], "start": [[ "37" ]], "entity_id": [[ "T2" ]], "Drug": {"text": [["carbamazepine"]], "start": [[ "37" ]], "entity_id": [[ "T3" ]]}, "Combination": null, "Freq": null, "Route": null, "Time_elapsed": null, "Duration": null, "Disorder": null, "Dosage": null, "Trigger": null} ,"Subject": { "text": [[ "Protease inhibitor-induced" ]], "start": [[ "0" ]], "entity_id": [[ "T1" ]] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [[ "carbamazepine toxicity" ]], "start": [[ "45" ]], "entity_id": [[ "T4" ]] }} ,"Effect": { "text": [[ "carbamazepine toxicity" ]], "start": [[ "45" ]], "entity_id": [[ "T4" ]] }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "7679525_3", "context": "He recovered successfully after treatment with very high doses of corticosteroids and azathioprine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Subject": {"text": [["He"]], "start": [[ ]], "entity_id": [ ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["treatment with very high doses of corticosteroids and azathioprine"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["corticosteroids", "azathioprine"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": {"text": [["very high doses"]], "start": [[ ]], "entity_id": [ ]}, "Route": null, "Time_elapsed": null, "Duration": null, "Disorder": null, "Trigger": null, "Freq": null, "Combination": [{"Drug": {"text": [["corticosteroids"]], "start": [[ ]], "entity_id": [ ]}, "Trigger": null ,"event_id": "C1", "event_type": "null" }, { "Drug": {"text": [["azathioprine"]], "start": [[ ]], "entity_id": [ ]}, "Trigger": null, "event_id": "C2", "event_type": "null" } ]}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null}]}
{"id": "937377_1","context": "Finally, reserpine toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["reserpine toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Effect": {"text": [["central nervous system (CNS) disturbances"]],"start": [["40"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [["reserpine"]],"start": [["0"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["barbiturates"]],"start": [["83"]],"entity_id": [["T4"]]},"Trigger": {"text": [["also receiving"]],"start": [["75"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "null"}],"entity_id": [["T3"]],"Time_elapsed": {"text": [["more frequently"]],"start": [["67"]],"entity_id": [["T6"]]},"Freq": {"text": [["suggesting additive CNS effects"]],"start": [["92"]],"entity_id": [["T7"]]},"Disorder": {"text": [["central nervous system (CNS) disturbances"]],"start": [["40"]],"entity_id": [["T2"]]},"Route": {"text": [["reported"]],"start": [["36"]],"entity_id": [["T8"]]},"Dosage": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"Duration": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"start": [[""],[]],"text": [["Finally,"]],"Trigger": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]}},"Negated": {"text": [["not"]],"start": [[""],[]],"entity_id": [["T10"]],"value": false},"Speculated": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]],"value": false},"Severity": {"text": [["reserpine toxicity"]],"start": [["0"]],"entity_id": [["T1"]],"value": "High"},"Subject": {"Age": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"Gender": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"Population": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"Race": {"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]},"Disorder": {"text": [["reserpine toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"text": [["Finally,"]],"start": [[""],[]],"entity_id": [["T9"]]}}]}
{"id": "9215418_1","context": "Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["uncommon complication"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["oral administration"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["magnesium sulfate"]],"start": [["71"]],"entity_id": [["T3"]]},"Disorder": {"text": [["hypermagnesemia"]],"start": [["10"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following"]],"start": [["46"]],"entity_id": [["T5"]]},"Freq": {"text": [["uncommon"]],"start": [["32"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["magnesium sulfate"]],"start": [["71"]],"entity_id": [["T3"]]},"Trigger": {"text": [["oral administration"]],"start": [["51"]],"entity_id": [["T2"]]},"event_id": "E1-1","event_type": "Adverse_event"}],"Trigger": {"text": [["uncommon complication"]],"start": [["32"]],"entity_id": [["T1"]]},"Dosage": {"text": [["oral administration"]],"start": [["51"]],"entity_id": [["T2"]]},"Route": {"text": [["oral administration"]],"start": [["51"]],"entity_id": [["T2"]]},"Duration": {"text": [["uncommon complication"]],"start": [["32"]],"entity_id": [["T1"]]}},"Subject": {"text": [["Clinical signs of hypermagnesemia"]],"start": [["0"]],"entity_id": [["T7"]],"Disorder": {"text": [["hypermagnesemia"]],"start": [["10"]],"entity_id": [["T4"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["uncommon"]],"start": [["32"]],"entity_id": [["T6"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Clinical signs"]],"start": [["0"]],"entity_id": [["T7"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "2140997_3","context": "Severe hepatitis caused by cyproterone acetate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe hepatitis"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] },"Treatment": {"text": [["cyproterone acetate"]],"start": [[ "41" ]],"entity_id": [ ["T2" ]],"Drug": { "text": [["cyproterone acetate"]], "start": [[ "41" ]], "entity_id": [ ["T2" ]] },"Combination": null ,"Dosage": null ,"Duration": null ,"Disorder": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Trigger": null }, "Subject": { "Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null ,"text": [["patient"]], "start": [[ "0" ]], "entity_id": [ ["T0" ]] }, "Effect": { "text": [["Severe hepatitis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Negated": null ,"Speculated": null ,"Severity": { "value": "High" ,"text": [["Severe hepatitis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }} ]}
{"id": "14693027_2", "context": "Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Erythema multiforme"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "Drug": { "text": [["phenytoin"]], "start": [[ "53" ]], "entity_id": [ ["T3"] ]}, "Trigger": { "text": [["cranial radiation therapy"]], "start": [[ "92" ]], "entity_id": [ ["T4"] ]} ,"entity_id": [ ["E1"] ], "text": [["Erythema multiforme"]], "start": [[ "0" ]] ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null ,"Disorder": null ,"Combination": null }, "Subject": { "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null ,"text": [["three patients"]], "start": [[ "157" ]], "entity_id": [ ["S1"] ]} ,"Effect": { "text": [["Erythema multiforme"]], "start": [[ "0" ]], "entity_id": [ ["E1"] ]} ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "12967198_2", "context": "Chloroquine has been used for many decades in the prophylaxis and treatment of malaria", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Chloroquine"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]],"Drug": {"text": [["Chloroquine"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]} ,"Disorder": {"text": [["prophylaxis and treatment of malaria"]], "start": [[ "25" ]], "entity_id": [ ["T2" ]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["has been used"]], "start": [[ "14" ]], "entity_id": [ ["T3" ]]} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }]}
{"id": "3200786_3","context": "We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["rifampicin"]],"start": [["46"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["acquired immunodeficiency syndrome"]],"start": [["15"]],"entity_id": [["T2"]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": [] },"Drug": {"text": [["rifampicin"]],"start": [["46"]],"entity_id": [["T1"]] }} ,"Effect": {"text": [["clinical evidence of adrenal failure"]],"start": [["86"]],"entity_id": [["T3"]] },"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [["a patient"]],"start": [["10"]],"entity_id": [["T4"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["acquired immunodeficiency syndrome"]],"start": [["15"]],"entity_id": [["T2"]] }} ,"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "9052919_3","context": "We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["cyclosporin"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["transient brain stem or neuromuscular dysfunction with eye movement abnormality"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["ganciclovir"]],"start": [["15"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["possibly together"]],"start": [["15"]],"entity_id": [["T4"]]} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect" }] ,"Trigger": {"text": [["produce"]],"start": [["62"]],"entity_id": [["T5"]]} ,"entity_id": [["T6"]],"start": [["0"]] ,"text": [["We postulate that cyclosporin"]] ,"Time_elapsed": {"text": [["can"]],"start": [["15"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["occasional patients"]],"start": [["75"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} },"Subject": {"Population": {"text": [["occasional patients"]],"start": [["75"]],"entity_id": [["T8"]]} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [["We postulate"]],"start": [["0"]],"entity_id": [["T9"]] ,"value": true },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [["transient brain stem or neuromuscular dysfunction with eye movement abnormality"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [],"start": [],"entity_id": []} }]}
{"id": "313865_1","context": "Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described. ","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tumour overkill", "phosphate shower syndrome"]],"start": [[ "3","43" ],[ "98","122" ]],"entity_id": [["T1","T2"]]},"Treatment": {"text": [["cytotoxic treatment", "high dose methotrexate with folinic acid rescue"]],"start": [["14","42" ],["55","102"]],"entity_id": [["T3","T4"]],"Drug": {"text": [["methotrexate"]],"start": [["68","77"]],"entity_id": [["T5"]]},"Dosage": {"text": [["high dose"]],"start": [["55","61"]],"entity_id": [["T4"]]},"Route": {"text": [["with folinic acid rescue"]],"start": [["62","76"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["resulted in"]],"start": [["43","46"]],"entity_id": [["T1"]]},"Disorder": {"text": [["the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment)"]],"start": [["98","122"]],"entity_id": [["T2"]]},"Freq": {"text": [["Three patients"]],"start": [["0","2" ]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["68","77"]],"entity_id": [["T5"]]},"Trigger": {"text": [["high dose"]],"start": [["55","61"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["tumour overkill"]],"start": [["3","13"]],"entity_id": [["T1"]]},"Duration": {"text": [["are described"]],"start": [["123","130"]],"entity_id": [["T0"]]}},"Subject": {"text": [["Three patients"]],"start": [["0","2" ]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment)"]],"start": [["98","122"]],"entity_id": [["T2"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "24846936_3","context": "Methylene blue-associated serotonin toxicity has been described before but usually as mild toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Methylene blue-associated serotonin toxicity"]],"start": [[ ]],"entity_id": [ ]},"Severity": {"value": "mild","text": [["mild"]],"start": [[ ]],"entity_id": [ ]} ,"Negated": null,"Speculated": null ,"Subject": null,"Treatment": null ,"Effect": {"text": [["Methylene blue-associated serotonin toxicity"]],"start": [[ ]],"entity_id": [ ]}}]}
{"id": "12221670_2", "context": "The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.$", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "Drug": { "text": [["ticlopidine"]], "start": [["31"]], "entity_id": [["T1"]] }, "Duration": { "text": [["2 years"]], "start": [["19"]], "entity_id": [["T2"]] } , "Trigger": { "text": [["febrile episode"]], "start": [["61"]], "entity_id": [["T3"]] }, "Time_elapsed": { "text": [["when"]], "start": [["51"]], "entity_id": [["T5"]] }, "Disorder": { "text": [["neutropenic with marrow aplasia"]], "start": [["74"]], "entity_id": [["T4"]] } , "entity_id": [["E1"]] , "start": [[ "0" ]], "text": [["The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.$"]], "Dosage": null, "Freq": null, "Route": null, "Combination": null }, "Subject": { "text": [["an 82-year-old man"]], "start": [["11"]], "entity_id": [["T6"]], "Age": { "text": [["82-year-old"]], "start": [["11"]], "entity_id": [["T6-1"]] }, "Gender": { "text": [["man"]], "start": [["25"]], "entity_id": [["T6-2"]] }, "Population": null, "Race": null, "Disorder": null }, "Negated": null, "Speculated": null, "Severity": null, "Effect": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] } }]}
{"id": "18633310_3", "context": "We report a case of pediatric bupropion ingestion resulting in multiple seizures", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["pediatric bupropion ingestion"]], "start": [["26"]], "entity_id": []}, "Treatment": {"text": [], "start": [], "entity_id": [], "Drug": {"text": [["bupropion"]], "start": [["26"]], "entity_id": []},"Disorder": {"text": [["pediatric"]], "start": [["0"]], "entity_id": []},"Route":{"text":[["ingestion"]], "start":[[ "26" ]], "entity_id": []},"Dosage":{"text":[], "start":[], "entity_id":[]},"Duration":{"text":[], "start":[], "entity_id":[]},"Time_elapsed":{"text":[], "start":[], "entity_id":[]},"Freq":{"text":[], "start":[], "entity_id":[]},"Combination":[{"Drug":{"text":[["bupropion"]], "start":[[ "26" ]], "entity_id":[]},"Trigger":{"text":[["ingestion"]], "start":[[ "26" ]], "entity_id":[]},"event_type":"Adverse_event","event_id":"E1"} ],"Trigger":{"text":[["resulting"]], "start":[[ "55" ]], "entity_id": []}},"Effect": {"text": [["multiple seizures"]], "start": [["56"]], "entity_id": []},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[], "start":[], "entity_id":[],"value":false},"Severity":{"text":[["multiple seizures"]], "start":[[ "56" ]], "entity_id": [],"value":"high" },"Subject":{"text":[["We"]], "start":[[ "0" ]], "entity_id": [],"Age":{"text":[], "start":[], "entity_id":[]},"Gender":{"text":[], "start":[], "entity_id":[]},"Disorder":{"text":[["pediatric"]], "start":[[ "0" ]], "entity_id": []},"Population":{"text":[], "start":[], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]}} }]}
{"id": "19707032_5","context": "Three days after intravitreal injection of bevacizumab, acute ocular ischemic syndrome occurred","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute ocular ischemic syndrome"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravitreal injection of bevacizumab"]],"start": [["10"]],"entity_id": [["T2"]],"Drug": {"text": [["bevacizumab"]],"start": [["30"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["Three days after"]],"start": [[ "0" ]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["acute ocular ischemic syndrome"]],"start": [[ "35" ]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["occurred"]],"start": [[ "53" ]],"entity_id": [["T5"]]} ,"Route": {"text": [["intravitreal injection"]],"start": [[ "10" ]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["bevacizumab"]],"start": [[ "30" ]],"entity_id": [["T3"]]},"Duration": {"text": [["Three days"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Freq": {"text": [["after"]],"start": [[ "16" ]],"entity_id": [["T8"]]} ,"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": {"text": [["acute"]],"start": [[ "35" ]],"entity_id": [["T9"]] ,"value": "High" }, "Subject": null }]}
{"id": "10357715_2","context": "Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["irritation"]],"start": [["35"]],"entity_id": []},"Treatment": {"text": [["Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland)"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Calcipotriol"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["irritation"]],"start": [["35"]],"entity_id": []},"Freq": {"text": [["less common"]],"start": [["71"]],"entity_id": []},"Route": {"text": [["topical"]],"start": [["81"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "2309833_1","context": "After discontinuation of danazol the diabetes completely resolved","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["danazol"]],"start": [["After discontinuation of danazol the diabetes completely resolved", "20"]],"entity_id": []},"Treatment": {"text": [],"start": [],"entity_id": [],"Disorder": {"text": [["diabetes"]],"start": [["After discontinuation of danazol the diabetes completely resolved", "54"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [["danazol"]],"start": [["After discontinuation of danazol the diabetes completely resolved", "20"]],"entity_id": []}},"Effect": {"text": [["completely resolved"]],"start": [["After discontinuation of danazol the diabetes completely resolved", "73"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["diabetes"]],"start": [["After discontinuation of danazol the diabetes completely resolved", "54"]],"entity_id": []}}}]}
{"id": "15977922_3","context": "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["development of ischemic colitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a woman"]],"start": [["43"]],"entity_id": [["T2"]],"Age": null,"Gender": {"text": [["a woman"]],"start": [["43"]],"entity_id": [["T2"]]},"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["treated with tegaserod"]],"start": [["57"]],"entity_id": [["T3"]],"Drug": {"text": [["tegaserod"]],"start": [["57"]],"entity_id": [["T4"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [["ischemic colitis"]],"start": [["10"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11834188_4","context": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cutaneous reaction"]],"start": [["34", "35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["captopril"]],"start": [["53", "54"]],"entity_id": [["T2"]],"Drug": {"text": [["captopril"]],"start": [["53", "54"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["cutaneous reaction"]],"start": [["34", "35"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["captopril"]],"start": [["53", "54"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["positive patch test"]],"start": [["70", "71"]],"entity_id": [["T5"]]} ,"event_type": "Adverse_event" ,"event_id": "E2" }] ,"Freq": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["presented"]],"start": [["11"]],"entity_id": [["T6"]]} ,"Route": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]} },"Subject": {"text": [["patient"]],"start": [["18"]],"entity_id": [["T7"]],"Age": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]},"Gender": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]},"Population": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]},"Race": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]]},"Disorder": {"text": [["cutaneous reaction"]],"start": [["34", "35"]],"entity_id": [["T1"]]} },"Severity": {"text": [["cutaneous reaction"]],"start": [["34", "35"]],"entity_id": [["T1"]] ,"value": "Low" },"Negated": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]],"value": false },"Speculated": {"text": [["induced"]],"start": [["45"]],"entity_id": [["T4"]],"value": false },"Effect": {"text": [["cutaneous reaction"]],"start": [["34", "35"]],"entity_id": [["T1"]] }} ]}
{"id": "16225183_10", "context": "This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["potential renal toxicity"]], "start": [["52"]], "entity_id": []}, "Treatment": {"text": [["interferons"]], "start": [["29"]], "entity_id": [], "Disorder": {"text": [["MS"]], "start": [["81"]], "entity_id": []},"Drug": {"text": [["interferons"]], "start": [["29"]], "entity_id": []},"Route": {"text": [["in MS"]], "start": [["78"]], "entity_id": []},"Time_elapsed": {"text": [["This latest (third) report suggests"]], "start": [["0"]], "entity_id": []},"Freq": {"text": [["should be reexamined and at least raises the question"]], "start": [["32"]], "entity_id": []},"Combination": [{"Drug": {"text": [["interferons"]], "start": [["29"]], "entity_id": []},"Trigger": {"text": [["potential renal toxicity"]], "start": [["52"]], "entity_id": []},"event_id": "E1","event_type": "Potential_therapeutic_effect"} ],"Trigger": { "text": [], "start": [], "entity_id": [] },"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] } },"Effect": { "text": [], "start": [], "entity_id": [] },"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": { "text": [], "start": [], "entity_id": [] },"Gender": { "text": [], "start": [], "entity_id": [] },"Population": { "text": [], "start": [], "entity_id": [] },"Race": { "text": [], "start": [], "entity_id": [] },"Disorder": { "text": [["MS"]], "start": [["81"]], "entity_id": [] } },"Negated": { "text": [], "start": [], "entity_id": [] ,"value": false },"Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false },"Severity": { "text": [], "start": [], "entity_id": [] ,"value": "low" } }]}
{"id": "3101617_1", "context": "Co-trimoxazole red cell aplasia in leukaemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Co-trimoxazole red cell aplasia"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]]}, "Subject": {"text": [["leukaemia"]], "start": [[ "42" ]], "entity_id": [[ "T2" ]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["leukaemia"]], "start": [[ "42" ]], "entity_id": [[ "T2" ]]}} ,"Treatment": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "12639299_1","context": "Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Interferon-alpha (IFN-alpha)"]],"start": [["0"]],"entity_id": []},"Effect": {"text": [["MPGN"]],"start": [["58"]],"entity_id": []},"Negated": {"value": false, "text": [[]],"start": [[]],"entity_id": []},"Speculated": {"value": true, "text": [["may"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["Interferon-alpha (IFN-alpha)"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Interferon-alpha (IFN-alpha)"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["MPGN"]],"start": [["58"]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Freq": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Trigger": {"text": [[]],"start": [[]],"entity_id": []},"Combination": null},"Subject": null,"Severity": null}]}
{"id": "11207969_3","context": "Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Toxic epidermal necrolysis"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["high-dose cytosine arabinoside"]],"start": [["47"]],"entity_id": [],"Drug": {"text": [["cytosine arabinoside"]],"start": [["47"]],"entity_id": []} ,"Dosage": {"text": [["high-dose"]],"start": [["40"]],"entity_id": []} ,"Route": {"text": [["use"]],"start": [["37"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["use"]],"start": [["37"]],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "High"} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null }} ]}
{"id": "10981493_4","context": "We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["3 elderly patients"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["3 elderly patients"]],"start": [["0"]],"entity_id": [["A1"]]},"Population": {"text": [["3 elderly patients"]],"start": [["0"]],"entity_id": [["P1"]]} ,"Disorder": {"text": [["moderate to severe ataxia"]],"start": [["26"]],"entity_id": [["D1"]]} ,"Gender": {"text": [["elderly patients"]],"start": [["6"]],"entity_id": [["G1"]]} ,"Race": {"text": [["patients"]],"start": [["6"]],"entity_id": [["R1"]]} },"Treatment": {"text": [["propafenone"]],"start": [["83"]],"entity_id": [["T1"]],"Drug": {"text": [["propafenone"]],"start": [["83"]],"entity_id": [["D2"]]},"Duration": {"text": [["while they were taking"]],"start": [["58"]],"entity_id": [["Dur1"]]} ,"Route": {"text": [["taking"]],"start": [["77"]],"entity_id": [["R1"]]} ,"Trigger": {"text": [["occurred"]],"start": [["22"]],"entity_id": [["Tr1"]]} ,"Time_elapsed": {"text": [["that occurred"]],"start": [["22"]],"entity_id": [["Te1"]]} ,"Dosage": {"text": [["patients"]],"start": [["6"]],"entity_id": [["Do1"]]} ,"Disorder": {"text": [["moderate to severe ataxia"]],"start": [["26"]],"entity_id": [["D1"]]} ,"Freq": {"text": [["patients"]],"start": [["6"]],"entity_id": [["F1"]]} ,"Combination": null },"Negated": null,"Speculated": null,"Severity": {"text": [["moderate to severe"]],"start": [["26"]],"entity_id": [["Se1"]] ,"value": "moderate to severe" },"Effect": {"text": [["ataxia"]],"start": [["26"]],"entity_id": [["E1"]] },"Trigger": {"text": [["occurred"]],"start": [["22"]],"entity_id": [["Tr1"]] }} ]}
{"id": "1445134_1","context": "Gestational diabetes was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with norethisterone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["no less severe"]],"start": [[">>>0"]],"entity_id": []},"Treatment": {"text": [["norethisterone"]],"start": [[">>62"]],"entity_id": [],"Drug": {"text": [["norethisterone"]],"start": [[">>62"]],"entity_id": []},"Disorder": {"text": [["Gestational diabetes"]],"start": [[">>0"]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null},"Effect": {"text": [["degree of hyperglycaemia", "need for insulin therapy"]],"start": [[">>14", ">>49"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high"},"Subject": {"text": [["Gestational diabetes"]],"start": [[">>0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Gestational diabetes"]],"start": [[">>0"]],"entity_id": []}}}]}
{"id": "1445134_2","context": "However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["norethisterone"]],"start": [["55"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["gestational diabetes"]],"start": [["16"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["follow-up"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["had"]],"start": [["46"]],"entity_id": [["T4"]]} ,"entity_id": [["T1"], ["T2"], ["T3"], ["T4"]] ,"text": [["norethisterone"], ["had"]],"start": [["55"], ["46"]] ,"Dosage": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null },"Effect": {"text": [["a lesser risk"]],"start": [["80"]],"entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "2746565_3","context": "We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ulcerative proctitis"]],"start": [["case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus"]] ,"entity_id": [ ]},"Treatment": {"text": [["ibuprofen treatment"]],"start": [[], []],"entity_id": [] ,"Drug": {"text": [["ibuprofen"]],"start": [[], []],"entity_id": [] },"Disorder": {"text": [["ulcerative proctitis"]],"start": [[], []],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": [] }},"Effect": {"text": [],"start": [],"entity_id": [] },"Subject": {"text": [["a girl"]],"start": [[], []],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "9337441_18","context": "Clinicians should include phenolphthalein in their list of possible causes of drug-induced TEN","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["phenolphthalein"]],"start": [[ ],["phenolphthalein"],["phenolphthalein"],["phenolphthalein"]],"entity_id": [["T1"],["T1"],["T1"],["T1"]]},"entity_id": [["T1"]],"text": [["phenolphthalein"]],"start": [["phenolphthalein"]],"Disorder": {"text": [["drug-induced TEN"]],"start": [["drug-induced TEN"]],"entity_id": [["T2"]]},"Trigger": {"text": [["possible causes"]],"start": [["possible causes"]],"entity_id": [["T3"]]},"Freq": {"text": [["include"]],"start": [["include"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["phenolphthalein"]],"start": [["phenolphthalein"]],"entity_id": [["T1"]]},"Trigger": {"text": [["possible causes"]],"start": [["possible causes"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null,"Trigger": null}]}
{"id": "424824_4","context": "Methotrexate-induced diffuse interstitial pulmonary fibrosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Methotrexate-induced"]],"start": [[ ]],"entity_id": []},"Effect": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [[]],"entity_id": []},"Treatment": {"text": [["Methotrexate"]],"start": [[]],"entity_id": [],"Drug": {"text": [["Methotrexate"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["diffuse interstitial pulmonary fibrosis"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16008658_2", "context": "Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Abdominal wall ulceration", "mucinosis"]], "start": [[ "0", "53" ]], "entity_id": [ ["T1"], ["T2"] ]}, "Treatment": {"text": [["recombinant human interferon-beta-1b"]], "start": [[ "54" ]], "entity_id": [ ["T3"] ], "Drug": {"text": [["recombinant human interferon-beta-1b"]], "start": [[ "54" ]], "entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["Abdominal wall ulceration", "mucinosis"]], "start": [[ "0" ]], "entity_id": [ ["T1"], ["T2"] ]} ,"Time_elapsed": null ,"Duration": null ,"Dosage": null ,"Freq": null ,"Route": null ,"Combination": null ,"Trigger": null }, "Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "15661067_1","context": "Asthenozoospermia: possible association with long-term exposure to an anti-epileptic drug of carbamazepine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["long-term exposure"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["anti-epileptic drug"]],"start": [["13"]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"]],"start": [["57"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["Asthenozoospermia"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["long-term exposure"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["long-term exposure"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Route": {"text": [["exposure"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["exposure"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["long-term"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Combination": [] ,"Dosage": {"text": [["long-term exposure"]],"start": [["31"]],"entity_id": [["T1"]]} },"Effect": {"text": [["Asthenozoospermia"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Negated": null,"Speculated": {"text": [["possible association"]],"start": [["16"]],"entity_id": [["T5"]] ,"value": true },"Severity": null,"Subject": null}]}
{"id": "15611427_2","context": "Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["toll-like receptor 7 agonist"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["imiquimod"]],"start": [["32"]],"entity_id": [["T2"]],"Drug": {"text": [["imiquimod"]],"start": [["32"]],"entity_id": [["T2"]]},"Disorder": {"text": [["psoriasis"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["in the presence"]],"start": [["42"]],"entity_id": [["T4"]]},"Route": {"text": [["topical"]],"start": [["71"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T6"]]},"Freq": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T7"]]},"Dosage": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T8"]]},"Duration": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T9"]]},"Combination": null},"Effect": {"text": [["psoriasis"]],"start": [["0"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T10"]],"value": "low"},"Subject": {"text": [["-"]],"start": [[""],["-"]],"entity_id": [["T11"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["psoriasis"]],"start": [["0"]],"entity_id": [["T3"]]}}}]}
{"id": "6414095_3","context": "A 52-year-old Black woman on phenytoin therapy for post-traumatic epilepsy developed transient hemiparesis contralateral to the injury. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["A 52-year-old Black woman"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["52"]],"start": [["3"]],"entity_id": [["S2"]]},"Gender": {"text": [["Black woman"]],"start": [["5"]],"entity_id": [["S3"]]},"Race": {"text": [["Black woman"]],"start": [["5"]],"entity_id": [["S3"]]},"Disorder": {"text": [["post-traumatic epilepsy"]],"start": [["40"]],"entity_id": [["S4"]]},"Population": null},"Treatment": {"text": [["phenytoin therapy"]],"start": [["21"]],"entity_id": [["T1"]],"Drug": {"text": [["phenytoin"]],"start": [["21"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["post-traumatic epilepsy"]],"start": [["40"]],"entity_id": [["S4"]]},"Freq": null,"Combination": null,"Trigger": {"text": [["developed"]],"start": [["52"]],"entity_id": [["T3"]]}},"Effect": {"text": [["transient hemiparesis contralateral to the injury"]],"start": [["60"]],"entity_id": [["E3"]]},"Trigger": null}]}
{"id": "6142995_2","context": "Sister chromatid exchanges (SCEs), a sensitive measure of chromosome damage, were counted in peripheral-blood lymphocytes from 10 patients with Behcet's syndrome receiving chlorambucil","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["chlorambucil"]],"start": [["110"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["Behcet's syndrome"]],"start": [["74"]],"entity_id": [["T2"]] },"Dosage": {"text": [["counted"]],"start": [["13"]],"entity_id": [["T3"]] },"Duration": {"text": [["from 10 patients"]],"start": [["46"]],"entity_id": [["T4"]] },"Trigger": {"text": [["Sister chromatid exchanges (SCEs)"]],"start": [["0"]],"entity_id": [["T5"]] },"Route": {"text": [["in peripheral-blood lymphocytes"]],"start": [["38"]],"entity_id": [["T6"]] },"Time_elapsed": {"text": [["after receiving chlorambucil"]],"start": [["103"]],"entity_id": [["T7"]] },"Freq": {"text": [["were counted"]],"start": [["13"]],"entity_id": [["T8"]] },"Combination": [{"Drug": {"text": [["chlorambucil"]],"start": [["110"]],"entity_id": [["T1"]] },"Trigger": {"text": [["after receiving chlorambucil"]],"start": [["103"]],"entity_id": [["T7"]] },"event_id": "C1","event_type": "Potential_therapeutic_effect" }] ,"Drug": {"text": [["chlorambucil"]],"start": [["110"]],"entity_id": [["T1"]] }} ,"Subject": {"text": [["from 10 patients with Behcet's syndrome"]],"start": [["46"]],"entity_id": [["T4"]] ,"Population": {"text": [["10 patients"]],"start": [["56"]],"entity_id": [["T9"]]},"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["Behcet's syndrome"]],"start": [["74"]],"entity_id": [["T2"]] },"Gender": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["Sister chromatid exchanges (SCEs)"]],"start": [["0"]],"entity_id": [["T5"]] },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["counted"]],"start": [["13"]],"entity_id": [["T3"]] }} ]}
{"id": "876914_2","context": "Sarcoma complicating therapy with cyclophosphamide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Sarcoma"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["therapy with cyclophosphamide"]],"start": [[ "24"]],"entity_id": [ ["T2"]],"Drug": {"text": [["cyclophosphamide"]],"start": [[ "45"]],"entity_id": [ ["T3"]]} ,"Disorder": { "text": [["Sarcoma"]], "start": [[ "0"]], "entity_id": [ ["T1"]] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": { "text": [["Sarcoma"]], "start": [[ "0"]], "entity_id": [ ["T1"]] }, "Gender": null, "Population": null, "Race": null }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null }] }
{"id": "9260733_1", "context": "Clozapine induced polyserositis", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Clozapine induced polyserositis"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"Drug": {"text": [["Clozapine"]], "start": [[ "0" ]], "entity_id": [ ["T2" ]]}, "Time_elapsed": null, "Duration": null, "Disorder": {"text": [["polyserositis"]], "start": [[ "19" ]], "entity_id": [ ["T3" ]]}, "Dosage": null, "Freq": null, "Route": null, "Combination": null, "entity_id": [ ["T1" ]], "text": [["Clozapine induced polyserositis"]], "start": [[ "0" ]], "Trigger": null} ,"Negated": null, "Speculated": null, "Severity": null ,"Subject": null ,"Effect": null}]}
{"id": "8586895_4","context": "The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cardiac arrests"]],"start": [["8586895_4" ,"0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Halfan"]],"start": [["8586895_4" ,"41"]],"entity_id": [["T2"]]},"Dosage": {"text": [["a higher dose than recommended"]],"start": [["8586895_4" ,"54"]],"entity_id": [["T3"]]},"Trigger": {"text": [["recent or concomitant treatment with mefloquine"]],"start": [["8586895_4" ,"78"]],"entity_id": [["T4"]]},"Disorder": {"text": [["pre-existing prolongation of the QT interval"]],"start": [["8586895_4" ,"121"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["thiamine"]],"start": [["8586895_4" ,"158"]],"entity_id": [["T6"]]},"Trigger": {"text": [["deficiency"]],"start": [["8586895_4" ,"165"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"}],"Freq": {"text": [["led to"]],"start": [["8586895_4" ,"18"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [["when"]],"start": [["8586895_4" ,"33"]],"entity_id": [["T9"]]},"entity_id": [["E1"]],"text": [["cardiac arrests"]],"start": [["8586895_4" ,"0"]],"Duration": {"text": [["deaths"]],"start": [["8586895_4" ,"103"]],"entity_id": [["T10"]]},"Route": {"text": [["treatment"]],"start": [["8586895_4" ,"41"]],"entity_id": [["T4"]]}},"Negated": {"text": [],"start": [],"value": false,"entity_id": []},"Speculated": {"text": [],"start": [],"value": false,"entity_id": []},"Severity": {"text": [],"start": [],"value": "High","entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [["8"]],"start": [["8586895_4" ,"7"]],"entity_id": [["T11"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11399735_2","context": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["pulmonary symptoms"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ticlopidine treatment"]],"start": [["69"]],"entity_id": [["T2"]],"Drug": {"text": [["ticlopidine"]],"start": [["69"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["when pulmonary symptoms appear"]],"start": [["31"]],"entity_id": [["F1"]]} ,"Route": {"text": [["association with"]],"start": [["56"]],"entity_id": [["R1"]]} ,"Disorder": {"text": [["pulmonary symptoms"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["ticlopidine"]],"start": [["69"]],"entity_id": [["T3"]]},"Trigger": {"text": [["when pulmonary symptoms appear"]],"start": [["31"]],"entity_id": [["F1"]]} ,"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["when pulmonary symptoms appear"]],"start": [["31"]],"entity_id": [["F1"]]} ,"Trigger": {"text": [["pulmonary symptoms"]],"start": [["31"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["when pulmonary symptoms appear"]],"start": [["31"]],"entity_id": [["F1"]]} ,"Dosage": {"text": [["ticlopidine treatment"]],"start": [["69"]],"entity_id": [["T2"]]} } , "Subject": {"text": [["Special care"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} } ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []} } ]}
{"id": "19203515_2","context": "Acute renal failure is a rare complication following the administration of intravenous immunoglobulin (IVIG).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute renal failure"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["intravenous immunoglobulin (IVIG)"]],"start": [[]],"entity_id": [],"Drug": {"text": [["intravenous immunoglobulin"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["Acute renal failure"]],"start": [[]],"entity_id": []},"Freq": {"text": [["rare"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [["following"]],"start": [[]],"entity_id": []},"Route": {"text": [["administration"]],"start": [[]],"entity_id": []},"Duration": {"text": [["a rare complication"]],"start": [[]],"entity_id": []},"Dosage": {"text": [["intravenous immunoglobulin (IVIG)"]],"start": [[]],"entity_id": []},"Combination": null,"Trigger": {"text": [["administration"]],"start": [[]],"entity_id": []}},"Subject": {"text": [["Acute renal failure"]],"start": [[]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["Acute renal failure"]],"start": [[]],"entity_id": []}}]}
{"id": "10963515_2", "context": "We describe a case of EGE manifested as an allergy to gemfibrozil", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["allergy"]], "start": [["43"]], "entity_id": []}, "Treatment": {"text": [["gemfibrozil"]], "start": [["62"]], "entity_id": [], "Drug": {"text": [["gemfibrozil"]], "start": [["62"]], "entity_id": []},"Disorder":{"text":[["EGE"]],"start":[["11"]],"entity_id":[]},"Time_elapsed":{"text":[["manifested"]],"start":[["22"]],"entity_id":[]},"Trigger":{"text":[["an"]],"start":[["34"]],"entity_id":[]},"Route":{"text":[["to"]],"start":[["41"]],"entity_id":[]},"Freq":{"text":[["a"]],"start":[["57"]],"entity_id":[]},"Combination":[{"Drug":{"text":[["gemfibrozil"]],"start":[["62"]],"entity_id":[]},"Trigger":{"text":[["manifested"]],"start":[["22"]],"entity_id":[]},"event_type":"Adverse_event","event_id":"E1"}],"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]}},"Effect":{"text":[["EGE"]],"start":[["11"]],"entity_id":[]},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"Low"},"Subject":{"text":[["We"]],"start":[[""],[""],[""]],"entity_id":[],"Age":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["a case"]],"start":[[""],[""]],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}}]}
{"id": "7724306_7","context": "At our institution, no children appeared with acute INH neurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["INH"]],"start": [["43"]],"entity_id": [["T1"]]},"Disorder": {"text": [["acute neurotoxicity"]],"start": [["21"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["through 1990"]],"start": [["51"]],"entity_id": [["T3"]]},"Trigger": {"text": [["were treated"]],"start": [["61"]],"entity_id": [["T4"]]},"entity_id": [["E1"]],"text": [["no children appeared with acute INH neurotoxicity in the period through"]],"start": [[],[],[],["21"],["43"]],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Negated": {"value": true,"text": [],"start": [],"entity_id": []},"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7249424_3","context": "Two patients on long-term lithium therapy developed the nephrotic syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["nephrotic syndrome"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["long-term lithium therapy"]],"start": [["6"]],"entity_id": [["T2"]],"Drug": {"text": [["lithium"]],"start": [["6"]],"entity_id": [["T3"]]},"Duration": {"text": [["long-term"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["nephrotic syndrome"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["developed"]],"start": [["17"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Route": {"text": [["therapy"]],"start": [["10"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [[" "]],"start": [[""],[""]],"entity_id": [["T8"],["T9"]]} ,"Combination": null ,"Trigger": null },"Subject": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["T6"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "12875956_1", "context": "Acute psychosis associated with levetiracetam", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Acute psychosis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["levetiracetam"]], "start": [[ ]], "entity_id": [["T2"]],"Drug": { "text": [["levetiracetam"]], "start": [[ ]], "entity_id": [["T2"]]} ,"Disorder": { "text": [["Acute psychosis"]], "start": [[ ]], "entity_id": [["T1"]]} ,"Time_elapsed": { "text": [["associated"]], "start": [[ ]], "entity_id": [["T3"]]} ,"Dosage": { "text": [], "start": [], "entity_id": []} ,"Duration": { "text": [], "start": [], "entity_id": []} ,"Route": { "text": [], "start": [], "entity_id": []} ,"Freq": { "text": [], "start": [], "entity_id": []} ,"Combination": null ,"Trigger": { "text": [["Acute psychosis"]], "start": [[ ]], "entity_id": [["T1"]]} }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": { "text": [], "start": [], "entity_id": []} }, "Effect": { "text": [["Acute psychosis"]], "start": [[ ]], "entity_id": [["T1"]]} }]}
{"id": "19365885_2","context": "Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hypoglycemia"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["long-acting somatostatin analogues"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["somatostatin analogues"]],"start": [[ ]],"entity_id": [["T3"]]} ,"Duration": {"text": [["long-acting"]],"start": [[ ]],"entity_id": [["T4"]]},"Trigger": {"text": [["induced"]],"start": [[ ]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["a patient with nonfunctional neuroendocrine tumor"]],"start": [[ ]],"entity_id": [["T6"]]} ,"Route": {"text": [["by"]],"start": [[ ]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["by"]],"start": [[ ]],"entity_id": [["T8"]]} ,"Freq": {"text": [["by"]],"start": [[ ]],"entity_id": [["T9"]]} ,"Combination": null ,"Dosage": null} ,"Subject": {"text": [["a patient with nonfunctional neuroendocrine tumor"]],"start": [[ ]],"entity_id": [["T6"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [["Hypoglycemia"]],"start": [[ ]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} }] }
{"id": "15157248_2", "context": "We report a patient who developed a DAT-positive hemolytic episode after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed", "a", "DAT-positive", "hemolytic", "episode"]], "start": [[ "0","4","5","6","7"]], "entity_id": [ ]},"Treatment": {"text": [["red cell (RBC) transfusion"]], "start": [["25","26","27","28","29","30","31","32","33","34"]], "entity_id": [ ],"Drug": {"text": [["oxaliplatin"]], "start": [["66","67","68","69","70"]], "entity_id": [ ]} ,"Dosage": {"text": [["delivered during the infusion of her 17th cycle"]], "start": [["35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55"]], "entity_id": [ ]} ,"Route": {"text": [["transfusion"]], "start": [["25","26","27","28","29","30","31","32","33","34"]], "entity_id": [ ]} ,"Time_elapsed": {"text": [["after"]], "start": [["0"]], "entity_id": [ ]} ,"Disorder": {"text": [["DAT-positive hemolytic episode"]], "start": [["4","5","6","7"]], "entity_id": [ ]} ,"Freq": {"text": [["delivered"]], "start": [["25"]], "entity_id": [ ]} ,"Trigger": {"text": [["developed"]], "start": [["0"]], "entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["oxaliplatin"]], "start": [["66","67","68","69","70"]], "entity_id": [ ]},"Trigger": {"text": [["infusion"]], "start": [["56","57","58","59","60","61","62","63","64","65"]], "entity_id": [ ]} ,"event_id": "C1", "event_type": "Potential_therapeutic_effect" }] ,"Duration": {"text": [["17th cycle"]], "start": [["56","57","58","59","60","61","62","63","64","65"]], "entity_id": [ ]} },"Negated": {"text": [[]], "start": [[ ]], "entity_id": [ ] ,"value": false},"Speculated": {"text": [[]], "start": [[ ]], "entity_id": [ ] ,"value": false},"Severity": {"text": [["positive"]], "start": [["2"]], "entity_id": [ ] ,"value": "low" },"Subject": {"text": [["patient"]], "start": [["1"]], "entity_id": [ ] ,"Age": {"text": [[]], "start": [[ ]], "entity_id": [ ] },"Gender": {"text": [[]], "start": [[ ]], "entity_id": [ ] },"Population": {"text": [[]], "start": [[ ]], "entity_id": [ ] },"Race": {"text": [[]], "start": [[ ]], "entity_id": [ ] },"Disorder": {"text": [["DAT-positive hemolytic episode"]], "start": [["4","5","6","7"]], "entity_id": [ ]} },"Effect": {"text": [["DAT-positive hemolytic episode"]], "start": [["4","5","6","7"]], "entity_id": [ ]} }]}
{"id": "8313300_8","context": "Regression of thyrotoxic ophthalmopathy following lithium withdrawal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["regression"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["lithium withdrawal"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["lithium"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["thyrotoxic ophthalmopathy"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["lithium withdrawal"]],"start": [[ ]],"entity_id": [ ]} ,"Route": {"text": [["withdrawal"]],"start": [[ ]],"entity_id": [ ]} ,"Duration": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Freq": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": [{"Drug": {"text": [["lithium"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["withdrawal"]],"start": [[ ]],"entity_id": [ ]} ,"event_id": "E1-1","event_type": "Adverse_event"} ] ,"Dosage": {"text": [["lithium"]],"start": [[ ]],"entity_id": [ ]} } ,"Subject": {"text": [["thyrotoxic ophthalmopathy"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["thyrotoxic ophthalmopathy"]],"start": [[ ]],"entity_id": [ ]} ,"Age": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Gender": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Population": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} ,"Race": {"text": [["following"]],"start": [[ ]],"entity_id": [ ]} } ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["regression"]],"start": [[ ]],"entity_id": [ ]} } ] }
{"id": "14700673_2", "context": "Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["topiramate-induced"]], "start": [["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["topiramate"]], "start": [["0"]], "entity_id": [["T2"]],"Drug": {"text": [["topiramate"]],"start": [[ "0" ]],"entity_id": [["T2"]]},"Disorder": {"text": [["acute-onset myopia and angle closure glaucoma"]],"start": [["22"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["acute-onset myopia and angle closure glaucoma"]],"start": [["22"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Subject": null}]}
{"id": "17610180_1","context": "The clinical symptoms of gastric mucosa foveolar hyperplasia due to long-term PGE1 therapy simulate hypertrophic pyloric stenosis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["gastric mucosa foveolar hyperplasia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["PGE1"]],"start": [["64"]],"entity_id": [["T2"]],"Drug": {"text": [["PGE1"]],"start": [["64"]],"entity_id": [["T2"]]},"Duration": {"text": [["long-term"]],"start": [["48"]],"entity_id": [["T3"]]},"Disorder": {"text": [["gastric mucosa foveolar hyperplasia"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["long-term"]],"start": [["48"]],"entity_id": [["T3"]]},"Route": {"text": [["therapy"]],"start": [["56"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["due to"]],"start": [["34"]],"entity_id": [["T5"]]},"Dosage": {"text": [["long-term"]],"start": [["48"]],"entity_id": [["T3"]]},"Trigger": null,"Combination": null},"Subject": null,"Effect": {"text": [["clinical symptoms"]],"start": [["0"]],"entity_id": [["T6"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8157823_1","context": "Generalized argyria after habitual use of AgNO3","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Generalized argyria"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["AgNO3"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["AgNO3"]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["habitual use"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["Generalized argyria"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["after"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["use"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["of"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["habitual"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [[]],"start": [[],[],[],[],[]],"entity_id": [ ]},"Combination": null},"Effect": {"text": [["Generalized argyria"]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "12187348_3", "context": "The authors report the first case of bucillamine-induced giant mammary hyperplasia", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["bucillamine-induced giant mammary hyperplasia"]], "start": [[ "46" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["bucillamine"]], "start": [[ "15" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["bucillamine"]], "start": [[ "15" ]], "entity_id": [ ["T2"] ]} , "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Subject": null ,"Effect": {"text": [["giant mammary hyperplasia"]], "start": [[ "46" ]], "entity_id": [ ["T1"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "10589077_1", "context": "Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Hydroxyurea", "HU"]], "start": [[ ], [ ]], "entity_id": [ ],"Drug": {"text": [["Hydroxyurea"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["thalassemia intermedia"]], "start": [[ ]], "entity_id": [ ]},"Dosage": {"text": [["shown to increase fetal hemoglobin (Hb F) levels"]], "start": [[ ]], "entity_id": [ ]},"Duration": {"text": [["have been shown"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["shown"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [[]], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [[]], "start": [[ ]], "entity_id": [ ]},"Combination": null,"Trigger": {"text": [["have been shown"]], "start": [[ ]], "entity_id": [ ]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [["Hydroxyurea", "HU"]], "start": [[ ]], "entity_id": [ ]}},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["sodium phenylbutyrate", "SPB"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["sodium phenylbutyrate"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["thalassemia intermedia"]], "start": [[ ]], "entity_id": [ ]},"Dosage": {"text": [["have been shown to increase fetal hemoglobin (Hb F) levels"]], "start": [[ ]], "entity_id": [ ]},"Duration": {"text": [["have been shown"]], "start": [[ ]], "entity_id": [ ]},"Route": {"text": [["shown"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [[]], "start": [[ ]], "entity_id": [ ]},"Freq": {"text": [[]], "start": [[ ]], "entity_id": [ ]},"Combination": null,"Trigger": {"text": [["sodium phenylbutyrate", "SPB"]], "start": [[ ]], "entity_id": [ ]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [["have been shown"]], "start": [[ ]], "entity_id": [ ]}}]}
{"id": "1954704_2","context": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["biopsy proven myositis"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["We"]],"start": [[""], []],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["prostate cancer"]],"start": [[""], []],"entity_id": [["T4"]]}},"Treatment": {"text": [["leuprolide acetate therapy"]],"start": [[""], []],"entity_id": [["T3"]],"Drug": {"text": [["leuprolide acetate"]],"start": [[""], []],"entity_id": [["T5"]]},"Disorder": {"text": [["prostate cancer"]],"start": [[""], []],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": {"text": [["10 days"]],"start": [[""], []],"entity_id": [["T6"]]},"Freq": null ,"Combination": null ,"Trigger": null },"Effect": {"text": [["symptoms"]],"start": [[""], []],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "11703329_4","context": "We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe motor neuropathy"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 31-year-old women"]],"start": [["5"]],"entity_id": [["T2"]],"Age": {"text": [["31"]],"start": [["5"]],"entity_id": [["A1"]]},"Gender": {"text": [["women"]],"start": [["16"]],"entity_id": [["G1"]]},"Disorder": {"text": [["recurrent Hodgkin's lymphoma and unrecognized HMSN-1"]],"start": [["22"]],"entity_id": [["D1"]]},"Population": {"text": [["a"]],"start": [["5"]],"entity_id": [["P1"]]},"Race": null},"Treatment": {"text": [["the first cycle of treatment including 2 mg of vincristine"]],"start": [["84"]],"entity_id": [["T3"]],"Drug": {"text": [["vincristine"]],"start": [["104"]],"entity_id": [["D2"]]},"Dosage": {"text": [["2 mg"]],"start": [["96"]],"entity_id": [["D3"]]},"Duration": null,"Disorder": {"text": [["treatment"]],"start": [["84"]],"entity_id": [["D4"]]},"Route": null,"Time_elapsed": {"text": [["3 weeks"]],"start": [["68"]],"entity_id": [["T4"]]},"Freq": null,"Trigger": null,"Combination": null},"Effect": {"text": [["severe motor neuropathy"]],"start": [["33"]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["33"]],"entity_id": [["S1"]],"value": "severe"}}]}
{"id": "10566542_2","context": "This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["alendronate (Fosamax)"]],"start": [["32", "33"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["hypophosphatemia"]],"start": [["86"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["postoperative"]],"start": [["69"]],"entity_id": [["T4"]]},"Trigger": {"text": [["presented"]],"start": [["77"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["70"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["bowel preparation with Fleet Phospho-Soda"]],"start": [["98"]],"entity_id": [["T7"]]} ,"Route": {"text": [["with"]],"start": [["96"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["previously prescribed"]],"start": [["14"]],"entity_id": [["T2"]]} ,"Drug": {"text": [["alendronate (Fosamax)"]],"start": [["32", "33"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["alendronate (Fosamax)"]],"start": [["32", "33"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["presented"]],"start": [["77"]],"entity_id": [["T5"]]} ,"event_id": "E2" ,"event_type": "Adverse_event" }] },"Subject": {"text": [["a patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["hypophosphatemia"]],"start": [["86"]],"entity_id": [["T3"]]} },"Severity": {"text": [["hypocalcemic tetany"]],"start": [["100"]],"entity_id": [["T9"]] ,"value": "high" },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Effect": {"text": [["hypophosphatemia"]],"start": [["86"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["presented"]],"start": [["77"]],"entity_id": [["T5"]]} }]}
{"id": "8496127_1", "context": "Acute dystonic reaction with low-dose pimozide", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Acute dystonic reaction"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["low-dose pimozide"]], "start": [[ ]], "entity_id": [["T2"]], "Drug": {"text": [["pimozide"]], "start": [[ ]], "entity_id": [["T3"]]}, "Dosage": {"text": [["low-dose"]], "start": [[ ]], "entity_id": [["T4"]]}, "Disorder": {"text": [["Acute dystonic reaction"]], "start": [[ ]], "entity_id": [["T1"]]}, "Time_elapsed": null, "Duration": null, "Freq": null, "Route": null, "Combination": null, "Trigger": null} , "Subject": { "text": [["Patient"]], "start": [[ ]], "entity_id": [["T0"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["Acute dystonic reaction"]], "start": [[ ]], "entity_id": [["T1"]] } }]}
{"id": "3680913_2", "context": "Nicotinic acid-induced fulminant hepatic failure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Nicotinic acid-induced"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["Nicotinic acid"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Nicotinic acid"]], "start": [["0"]], "entity_id": [] },"Disorder": {"text": [["fulminant hepatic failure"]], "start": [["25"]], "entity_id": [] },"Time_elapsed": {"text": [], "start": [], "entity_id": [] },"Duration": {"text": [], "start": [], "entity_id": [] },"Dosage": {"text": [], "start": [], "entity_id": [] },"Freq": {"text": [], "start": [], "entity_id": [] },"Route": {"text": [], "start": [], "entity_id": [] },"Combination": null,"Trigger": {"text": [["Nicotinic acid-induced"]], "start": [["0"]], "entity_id": [] }},"Effect": {"text": [["fulminant hepatic failure"]], "start": [["25"]], "entity_id": [] },"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11122162_3","context": "We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["recombinant factor VIIa"]],"start": [["18"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["bleeding"]],"start": [["42"]],"entity_id": [["T2"]] },"Time_elapsed": {"text": [["immediate"]],"start": [["70"]],"entity_id": [["T3"]] },"Duration": {"text": [["long-term"]],"start": [["81"]],"entity_id": [["T4"]] },"Trigger": {"text": [["following"]],"start": [["63"]],"entity_id": [["T5"]] },"Combination": [{"Drug": {"text": [["PCC"]],"start": [["53"]],"entity_id": [["T6"]] },"Trigger": {"text": [["related"]],"start": [["57"]],"entity_id": [["T7"]] },"event_id": "E2","event_type": "Adverse_event" }] ,"Freq": {"text": [["used"]],"start": [["15"]],"entity_id": [["T8"]] },"Route": {"text": [["to treat"]],"start": [["28"]],"entity_id": [["T9"]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Drug": {"text": [],"start": [],"entity_id": [] }} ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T10"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "3430507_1", "context": "D-penicillamine induced crescentic glomerulonephritis: report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["D-penicillamine induced crescentic glomerulonephritis"]], "start": [[ "0"]], "entity_id": []}, "Treatment": {"text": [["D-penicillamine"]], "start": [["25"]], "entity_id": [],"Drug": {"text": [["D-penicillamine"]], "start": [["25"]], "entity_id": []}, "Disorder": {"text": [["crescentic glomerulonephritis"]], "start": [["38"]], "entity_id": []},"Duration": {"text": [["report and review of the literature"]], "start": [["58"]], "entity_id": []},"Time_elapsed": {"text": [["D-penicillamine induced"]], "start": [["0"]], "entity_id": []},"Dosage": {"text": [[""]], "start": [["0"]], "entity_id": []},"Route": {"text": [[""]], "start": [["0"]], "entity_id": []},"Freq": {"text": [[""]], "start": [["0"]], "entity_id": []},"Combination": null,"Trigger": null},"Effect": null,"Subject": {"text": [["patient"]],"start": [["105"]],"entity_id": [],"Age": null,"Disorder": {"text": [["crescentic glomerulonephritis"]],"start": [["38"]],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["50"]],"entity_id": [],"value": "high"}}]}
{"id": "19423610_4","context": "We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["adverse interaction"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["paroxetine"]],"start": [["25"]],"entity_id": [["T2"]],"Drug": {"text": [["paroxetine"]],"start": [["25"]],"entity_id": [["T2"]]},"Trigger": {"text": [["other agent(s)"]],"start": [["55"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["paroxetine"]],"start": [["25"]],"entity_id": [["T2"]]},"Trigger": {"text": [["other agent(s)"]],"start": [["55"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Freq": {"text": [["used in the course of the anaesthesia"]],"start": [["70"]],"entity_id": [["T4"]]},"Disorder": {"text": [["this event"]],"start": [["9"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["this event"]],"start": [["9"]],"entity_id": [["T5"]]},"Route": {"text": [["used in the course of the anaesthesia"]],"start": [["70"]],"entity_id": [["T4"]]},"Dosage": {"text": [["used in the course of the anaesthesia"]],"start": [["70"]],"entity_id": [["T4"]]},"Duration": {"text": [["used in the course of the anaesthesia"]],"start": [["70"]],"entity_id": [["T4"]]}},"Negated": {"text": [["tentative explanations"]],"start": [["0"]],"entity_id": [["T6"]],"value": false},"Speculated": {"text": [["tentative explanations"]],"start": [["0"]],"entity_id": [["T6"]],"value": true},"Severity": {"text": [["this event"]],"start": [["9"]],"entity_id": [["T5"]],"value": "low"},"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T7"]],"Disorder": {"text": [["this event"]],"start": [["9"]],"entity_id": [["T5"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["this event"]],"start": [["9"]],"entity_id": [["T5"]]}}]}
{"id": "19331262_3","context": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": {"value": "high" ,"text":[["high"]] ,"start": [[],[]] ,"entity_id": []},"Subject": {"text": [["Neuroleptic malignant syndrome"]],"start": [[],[]],"entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [["antipsychotic drugs"]],"start": [[],[]],"entity_id": [] ,"Drug": { "text":[["antipsychotic"]], "start": [[],[]], "entity_id": [] },"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null ,"Combination": null},"Effect": {"text": [["muscular rigidity","hyperthermia","autonomic dysfunction","altered consciousness","high creatinine phosphokinase levels","leukocytosis"]],"start": [[],[],[],[],[],[]],"entity_id": []} ,"Trigger": { "text":[["reaction"]], "start": [[],[]], "entity_id": [] }}]}
{"id": "8678015_1", "context": "Albendazole-induced pseudomembranous colitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Albendazole-induced pseudomembranous colitis"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["Albendazole"]], "start": [[],[]], "entity_id": [], "Drug": {"text": [["Albendazole"]], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [["pseudomembranous colitis"]], "start": [[],[]], "entity_id": []}, "Time_elapsed": {"text": [], "start": [[],[]], "entity_id": []}, "Trigger": {"text": [], "start": [[],[]], "entity_id": []}, "Route": {"text": [], "start": [[],[]], "entity_id": []}, "Dosage": {"text": [], "start": [[],[]], "entity_id": []}, "Duration": {"text": [], "start": [[],[]], "entity_id": []}, "Freq": {"text": [], "start": [[],[]], "entity_id": []}, "Combination": null}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[],[]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "3301251_3", "context": "Salicylate-induced hepatotoxicity is reviewed", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Salicylate-induced hepatotoxicity"]], "start": [[ ]], "entity_id": []}, "Treatment": null, "Effect": {"text": [["Salicylate-induced hepatotoxicity"]], "start": [[ ]], "entity_id": []}, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "19531695_2", "context": "To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["flecainide-induced delirium"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["flecainide"]], "start": [["22"]], "entity_id": [], "Drug": {"text": [["flecainide"]], "start": [["22"]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["paroxetine"]], "start": [["92"]], "entity_id": []},"event_id": "C1","Trigger": {"text": [["pharmacokinetic drug interaction"]], "start": [["62"]], "entity_id": []},"event_type": "Potential_therapeutic_effect"}],"Disorder": {"text": [], "start": [], "entity_id": []}},"Effect": {"text": [["delirium"]], "start": [["22"]], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}}}]}
{"id": "8098286_3","context": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta-blocker, celiprolol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity pneumonitis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]],"Drug": {"text": [["celiprolol"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["hypersensitivity pneumonitis"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["during"]],"start": [["28"]],"entity_id": [["T4"]]} ,"Route": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["celiprolol"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Trigger": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} },"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Gender": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Population": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Race": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]} },"Severity": {"text": [["hypersensitivity pneumonitis"]],"start": [["32"]],"entity_id": [["T1"]] ,"value": "High" },"Negated": {"text": [["not"]],"start": [[""], ["0"]],"entity_id": [["N0"]] ,"value": false },"Speculated": {"text": [["report"]],"start": [["0"]],"entity_id": [["S0"]],"value": false },"Effect": {"text": [["hypersensitivity pneumonitis"]],"start": [["32"]],"entity_id": [["T1"]] }} ]}
{"id": "19224802_3","context": "dexmedetomidine is used to provide sedation for pediatric patients undergoing nonpainful radiological imaging studies","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["dexmedetomidine"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["sedation"]],"start": [[ ]],"entity_id": [ ]} ,"Trigger": {"text": [["used"]],"start": [[ ]],"entity_id": [ ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Drug": {"text": [["dexmedetomidine"]],"start": [[ ]],"entity_id": [ ]} },"Subject": {"text": [["pediatric patients"]],"start": [[ ]],"entity_id": [ ],"Age": {"text": [["pediatric"]],"start": [[ ]],"entity_id": [ ]} ,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "8013261_2","context": "Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["IFN"]],"start": [["4","0"]],"entity_id": [["T1"]]},"Duration": {"text": [["four years"]],"start": [["0","0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["therapy"]],"start": [["4","5"]],"entity_id": [["T3"]]},"entity_id": [["T1"]],"Time_elapsed": {"text": [["four years"]],"start": [["0","0"]],"entity_id": [["T2"]]},"Route": {"text": [["started"]],"start": [["4","43"]],"entity_id": [["T4"]]},"Dosage": {"text": [["28 units/day"]],"start": [["4","44"]],"entity_id": [["T5"]]},"text": [["Four years after the beginning of IFN therapy"]],"start": [["0"]],"Disorder": {"text": [["hyperglycemia"]],"start": [["4","16"]],"entity_id": [["T6"]]},"Freq": {"text": [["acutely"]],"start": [["4","21"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["insulin"]],"start": [["4","57"]],"entity_id": [["T8"]]},"Trigger": {"text": [["injection"]],"start": [["4","68"]],"entity_id": [["T9"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Subject": {"Age": {"text": [["Four years"]],"start": [["0","0"]],"entity_id": [["T2"]]},"text": [["he"]],"start": [["4","42"]],"Gender": {"text": [["he"]],"start": [["4","42"]],"entity_id": [["T10"]]},"Population": {"text": [["Four years"]],"start": [["0","0"]],"entity_id": [["T2"]]},"Race": {"text": [["he"]],"start": [["4","42"]],"entity_id": [["T10"]]},"Disorder": {"text": [["hyperglycemia"]],"start": [["4","16"]],"entity_id": [["T6"]]},"entity_id": [["T10"]]},"Severity": {"text": [["moderate","severe"]],"start": [["4","32","4","40"]],"entity_id": [["T6","T11"]],"value": "high"},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["developed"]],"start": [["4","16"]],"entity_id": [["T12"]]},"Effect": {"text": [["hyperglycemia","ketonuria"]],"start": [["4","16","4","31"]],"entity_id": [["T6","T11"]]}}]}
{"id": "15644988_1","context": "Tardive dyskinesia in 2 patients treated with ziprasidone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Tardive dyskinesia"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["2 patients"]],"start": [[ ]],"entity_id": [ ["T2"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["ziprasidone"]],"start": [[ ]],"entity_id": [ ["T3"] ],"Drug": {"text": [["ziprasidone"]],"start": [[ ]],"entity_id": [ ["T3"] ]},"Dosage": null,"Duration": null,"Disorder": {"text": [["Tardive dyskinesia"]],"start": [[ ]],"entity_id": [ ["T1"] ]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["Tardive dyskinesia"]],"start": [[ ]],"entity_id": [ ["T1"] ]} }]}
{"id": "15866658_3","context": "The mean time from starting MMF to the development of neutropenia was 4 months","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["starting MMF"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["MMF"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "21"]],"entity_id": [["T2"]] ,"Duration": {"text": [["4 months"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "56"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["development of neutropenia"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "71"]],"entity_id": [["T4"]]} ,"Drug": {"text": [["MMF"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "21"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["neutropenia"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "71"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["4 months"]],"start": [["The mean time from starting MMF to the development of neutropenia was 4 months", "56"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Route": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Freq": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Combination": null} ,"Effect": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Negated": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]],"value": false} ,"Speculated": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]],"value": false} ,"Severity": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]],"value": "NA"} ,"Subject": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]],"Age": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Gender": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Population": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Race": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]} ,"Disorder": {"text": [["NA"]],"start": [["NA"]],"entity_id": [["NA"]]}}}]}
{"id": "17366681_1","context": "A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["complex pattern of melanonychia and onycholysis"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": {"text": [["treatment with pemetrexed"]],"start": [[ "58" ]],"entity_id": [ ["T2" ]],"Drug": {"text": [["pemetrexed"]],"start": [[ "71" ]],"entity_id": [ ["T3" ]]} ,"Disorder": {"text": [["lung cancer"]],"start": [[ "81" ]],"entity_id": [ ["T4" ]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": [] }} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }, "Effect": {"text": [["complex pattern of melanonychia and onycholysis"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "640344_2","context": "Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Severe histological osteomalacia"]],"start": [["0"]],"entity_id": []},"Subject": {"text": [["a woman with Crohn's disease"]],"start": [["23"]],"entity_id": [],"Disorder": {"text": [["Crohn's disease"]],"start": [["31"]],"entity_id": []},"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["cholestyramine therapy"]],"start": [["60"]],"entity_id": [],"Drug": {"text": [["cholestyramine"]],"start": [["60"]],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Disorder": {"text": [["Crohn's disease"]],"start": [["23"]],"entity_id": []},"Time_elapsed": {"text": [["2 years after ileal resection"]],"start": [["35"]],"entity_id": []},"Freq": null,"Combination": null,"Trigger": {"text": [["ileal resection"]],"start": [["35"]],"entity_id": []}},"Effect": {"text": [["Severe histological osteomalacia"]],"start": [["0"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["Severe"]],"start": [["0"]],"entity_id": [],"value": "High"}}]}
{"id": "7379406_8","context": "The fluorine contained in niflumic acid induced a marked densification of trabecular bone in all 3 cases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["marked densification of trabecular bone"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["niflumic acid"]],"start": [["15"]],"entity_id": [["T2"]],"Drug": {"text": [["fluorine"]],"start": [["11"]],"entity_id": [["T3"]]},"Disorder": {"text": [["bone"]],"start": [["42"]],"entity_id": [["T4"]]},"Route": {"text": [["contained in"]],"start": [["11"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["induced"]],"start": [["29"]],"entity_id": [["T6"]]},"Duration": {"text": [["in all 3 cases"]],"start": [["53"]],"entity_id": [["T7"]]},"Trigger": null,"Dosage": null,"Freq": null,"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "17448102_1", "context": "Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null, "Effect": {"text": [["cardiovascular collapse"]], "start": [["0"]], "entity_id": []}, "Trigger": {"text": [["severe flecainide overdose"]], "start": [["32"]], "entity_id": []}} , {"event_id": "E2", "event_type": "Potential_therapeutic_effect", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"text": [["extracorporeal therapy"]], "start": [["101"]], "entity_id": [], "Drug": null, "Disorder": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": null, "Trigger": null}]}
{"id": "16511396_1","context": "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Effect": {"text": [["fever"]],"start": [["33"]],"entity_id": [["E1-1"]]},"Treatment": {"Drug": {"text": [["pyrimethamine"]],"start": [["15"]],"entity_id": [["E1-2"]]},"Disorder": {"text": [["reactivated chorioretinitis"]],"start": [["66"]],"entity_id": [["E1-3"]]},"entity_id": [["T1"]],"Dosage": {"text": [["took"]],"start": [["15"]],"entity_id": [["E1-2"]]},"Duration": {"text": [["persisting weeks after withholding medicines"]],"start": [["86"]],"entity_id": [["E1-4"]]},"Trigger": {"text": [["developed"]],"start": [["33"]],"entity_id": [["E1-5"]]},"Time_elapsed": {"text": [["weeks after withholding medicines"]],"start": [["86"]],"entity_id": [["E1-4"]]},"text": [[ "fever","severe cutaneous involvement","swelling","abdominal pain","transaminitis"]],"start": [[ "33","45","59","73","80"]],"Freq": {"text": [["persisting"]],"start": [["86"]],"entity_id": [["E1-4"]]},"Route": {"text": [["took"]],"start": [["15"]],"entity_id": [["E1-2"]]},"Combination": [{"Drug": {"text": [["pyrimethamine"]],"start": [["15"]],"entity_id": [["E1-2"]]},"Trigger": {"text": [["took"]],"start": [["15"]],"entity_id": [["E1-2"]]},"event_id": "E1-2","event_type": "Treatment"},{"Drug": {"text": [["sulfadiazine"]],"start": [["22"]],"entity_id": [["E1-6"]]},"Trigger": {"text": [["took"]],"start": [["15"]],"entity_id": [["E1-2"]]},"event_id": "E1-6","event_type": "Treatment"}]},"Subject": {"text": [["A 7-year-old with congenital toxoplasmosis"]],"start": [["0"]],"Age": {"text": [["7-year-old"]],"start": [["2"]],"entity_id": [["E1-7"]]},"Disorder": {"text": [["congenital toxoplasmosis"]],"start": [["10"]],"entity_id": [["E1-8"]]},"Gender": {"text": [["A"]],"start": [["0"]],"entity_id": [["E1-9"]]},"Population": {"text": [["A"]],"start": [["0"]],"entity_id": [["E1-9"]]},"Race": {"text": [["A"]],"start": [["0"]],"entity_id": [["E1-9"]]},"entity_id": [["S1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["45"]],"entity_id": [["E1-10"]],"value": "high"},"Trigger": {"text": [["developed"]],"start": [["33"]],"entity_id": [["E1-5"]]}}]}
{"id": "24801976_1", "context": "Pain management discussion forum: serious interaction among frequently used drugs for chronic pain", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["serious interaction"]], "start": [["serious interaction'.start, 'among'.end"]], "entity_id": []}, "Treatment": {"text": [["frequently used drugs"]], "start": [[ "used drugs'.start ]], " , "entity_id"]], "Drug": null, "Disorder": {"text": [["chronic pain"]], "start": [[ "pain'.start ]], " , "entity_id"]], "entity_id": []}, "entity_id": [] , "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Combination": [{"Drug": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "event_id": "C1", "event_type": "Combination"}], "Trigger": null} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Effect": null}] }
{"id": "15383642_13","context": "This kind of reaction is seldom mentioned as occurring during co-administration with tizanidine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["This kind of reaction"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["tizanidine"]],"start": [[]],"entity_id": [],"Drug": {"text": [["tizanidine"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [["during co-administration"]],"start": [[]],"entity_id": []},"Combination": [{"Drug": {"text": [["tizanidine"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["co-administration"]],"start": [[]],"entity_id": []},"event_id": "C1","event_type": "Co-administration"}],"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "6702890_1","context": "A 69-year-old man developed pure red cell aplasia after taking fenoprofen for ten months","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 69-year-old man"]],"start": [[ "A" , "69-year-old" , "man" ]],"entity_id": [["S1"]],"Age": {"text": [["69-year-old"]],"start": [[ "69-year-old" ]],"entity_id": [ ["S2"]]},"Gender": {"text": [["man"]],"start": [[ "man" ]],"entity_id": [ ["S3"]]} ,"Disorder": {"text": [["pure red cell aplasia"]],"start": [[ "pure" , "red" , "cell" , "aplasia" ]],"entity_id": [ ["S4"]]} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["fenoprofen"]],"start": [[ "fenoprofen" ]],"entity_id": [ ["T1"]],"Drug": {"text": [["fenoprofen"]],"start": [[ "fenoprofen" ]],"entity_id": [ ["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [[ "ten months"]],"start": [[ "ten" , "months" ]],"entity_id": [ ["T3"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["after taking"]],"start": [[ "after" , "taking" ]],"entity_id": [ ["T4"]]} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [],"start": [],"entity_id": []} }]}
{"id": "20130478_1","context": "Introduction of etanercept was also clinically effective but followed by development of severe heart failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["etanercept"]],"start": [["0", "Introduction"]],"entity_id": [["T1"]] ,"Drug": {"text": [["etanercept"]],"start": [["0", "Introduction"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["clinically effective"]],"start": [["33", "clinically"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["followed"]],"start": [["52", "followed"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["effective"]],"start": [["33", "clinically"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["etanercept"]],"start": [["0", "Introduction"]],"entity_id": [["T1"]]},"Trigger": {"text": [["development"]],"start": [["60", "development"]],"entity_id": [["T6"]]},"event_id": "E2","event_type": "Adverse_event"} ],"Freq": {"text": [["also"]],"start": [["4", "also"]],"entity_id": [["T7"]]} ,"Route": {"text": [["Introduction"]],"start": [["0", "Introduction"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["clinically effective"]],"start": [["33", "clinically"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [["etanercept"]],"start": [["0", "Introduction"]],"entity_id": [["T10"]]} },"Subject": {"Age": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T11"]]},"Gender": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T12"]]},"Population": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T13"]]},"Race": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T14"]]},"Disorder": {"text": [["clinically effective"]],"start": [["33", "clinically"]],"entity_id": [["T15"]]} ,"text": [["Introduction"]],"start": [["0", "Introduction"]],"entity_id": [["T16"]]} ,"Effect": {"text": [["development"]],"start": [["60", "development"]],"entity_id": [["T17"]]} ,"Severity": {"text": [["severe heart failure"]],"start": [["67", "severe"]],"entity_id": [["T18"]] ,"value": "high"} ,"Negated": {"text": [["not"]],"start": [[""], [""]],"entity_id": [["T19"]] ,"value": false} ,"Speculated": {"text": [["not"]],"start": [[""], [""]],"entity_id": [["T20"]] ,"value": false} ,"Trigger": {"text": [["development"]],"start": [["60", "development"]],"entity_id": [["T21"]]} }]}
{"id": "11961411_2","context": "Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Minimal change nephrotic syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["postoperative interferon-beta therapy"]],"start": [["46" ]],"entity_id": [ ["T2"] ],"Drug": { "text": [["interferon-beta"]], "start": [[ "46" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["malignant melanoma"]], "start": [[ "80" ]], "entity_id": [ ["T4"] ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null, "Gender": null, "Disorder": null ,"Population": null ,"Race": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }] }
{"id": "11816261_6", "context": "She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["metoclopramide"]], "start": [[],[]], "entity_id": [],"Drug": null, "Disorder": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null}, "Effect": {"text": [["developed movement disorder"]], "start": [[],[]], "entity_id": []}, "Trigger": {"text": [["following a fall"]], "start": [[],[]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "9022114_5","context": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["cessation of colchicine therapy"]],"start": [["82"]],"entity_id": [["T1"]] ,"Drug": {"text": [["colchicine"]],"start": [["57"]],"entity_id": [["T2"]] },"Disorder": {"text": [["corneal ulcers refractory to conventional treatment"]],"start": [["18"]],"entity_id": [["T3"]] },"Trigger": {"text": [["considered"]],"start": [["105"]],"entity_id": [["T4"]] },"Freq": {"text": [["cessation"]],"start": [["82"]],"entity_id": [["T1"]] },"Route": {"text": [["cessation"]],"start": [["82"]],"entity_id": [["T1"]] },"Time_elapsed": {"text": [["cessation"]],"start": [["82"]],"entity_id": [["T1"]] },"Duration": {"text": [["cessation"]],"start": [["82"]],"entity_id": [["T1"]] },"Dosage": {"text": [["cessation"]],"start": [["82"]],"entity_id": [["T1"]] },"Combination": null },"Subject": {"text": [["patients with corneal ulcers refractory to conventional treatment who are receiving colchicine"]],"start": [["18"]],"entity_id": [["T3"]],"Disorder": {"text": [["corneal ulcers refractory to conventional treatment"]],"start": [["18"]],"entity_id": [["T3"]] },"Age": null,"Gender": null,"Population": null,"Race": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": {"text": [["considered"]],"start": [["105"]],"entity_id": [["T4"]] }} ]}
{"id": "6498095_1", "context": "After the patient discontinued rifampicin, the skin lesions cleared completely within 5 weeks without any systemic medication", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["After the patient discontinued rifampicin"]], "start": [[ "0" ]], "entity_id": [ ]}, "Treatment": {"text": [["rifampicin"]], "start": [[ "46" ]], "entity_id": [ ],"Drug": {"text": [["rifampicin"]], "start": [[ "46" ]], "entity_id": [ ]},"Disorder": {"text": [["skin lesions"]], "start": [[ "103" ]], "entity_id": [ ]},"Duration": {"text": [["5 weeks"]], "start": [[ "130" ]], "entity_id": [ ]},"Trigger": {"text": [["without any systemic medication"]], "start": [[ "144" ]], "entity_id": [ ]},"Route": {"text": [["discontinued"]], "start": [[ "12" ]], "entity_id": [ ]},"Time_elapsed": {"text": [["5 weeks"]], "start": [[ "130" ]], "entity_id": [ ]}, "Freq": {"text": [["discontinued"]], "start": [[ "12" ]], "entity_id": [ ]}, "Combination": null ,"Dosage": null },"Effect": null ,"Subject": { "text": [["the patient"]], "start": [[ "12" ]], "entity_id": [ ],"Age": null ,"Gender": null ,"Disorder": null ,"Race": null ,"Population": null },"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "15644988_3","context": "Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD).","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Ziprasidone"]],"start": [[ "0"]] ,"entity_id": [ ["T1"]],"Drug" : { "text" : [["Ziprasidone"]], "start" : [[ "0" ]] , "entity_id" : [ ["T1"] ]} ,"Disorder" : { "text" : [["atypical antipsychotic drug"]], "start" : [[ "16" ]] , "entity_id" : [ ["T2"] ]} ,"Dosage" : null, "Duration" : null, "Trigger" : null, "Route" : null, "Time_elapsed" : null, "Freq" : null, "Combination" : null },"Effect" : { "text" : [["a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD)"]], "start" : [[ "48" ]], "entity_id" : [ ["T3"] ] },"Negated" : null, "Speculated" : null, "Severity" : null, "Subject" : null ,"Trigger" : { "text" : [["believed"]], "start" : [[ "39" ]], "entity_id" : [ ["T4"] ]} }] }
{"id": "25157214_11","context": "These findings suggest that prophylactic antibiotic use is unlikely to have a major impact on the recovery time from rocuronium-induced NMB with sugammadex reversal","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["prophylactic antibiotic use"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Disorder": {"text": [["recovery time from rocuronium-induced NMB with sugammadex reversal"]],"start": [[ "50" ]],"entity_id": [["T2"]]},"Dosage": {"text": [["unlikely"]],"start": [[ "23" ]],"entity_id": [["T3"]]},"Freq": {"text": [["major impact"]],"start": [[ "35" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["These findings suggest"]],"start": [[ "0" ]],"entity_id": [["T0"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": null,"Trigger": null}]}
{"id": "7655130_1","context": "Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["symptoms"]],"start": [["Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another"]],"entity_id": []},"Subject": {"text": [["Two patients"]],"start": [[""],["Two patients"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["stable hypothyroidism"]],"start": [[""],["Two patients with stable hypothyroidism"]],"entity_id": []}},"Treatment": {"text": [["switching from 1 levothyroxine product to another"]],"start": [[""],["Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another"]],"entity_id": [],"Drug": {"text": [["levothyroxine"]],"start": [[""],["Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from levothyroxine product to another"]],"entity_id": []},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": {"text": [["hypothyroidism"]],"start": [[""],["Two patients with stable hypothyroidism experienced symptoms"]],"entity_id": []},"Trigger": null,"Combination": null},"Effect": {"text": [["hypothyroidism","increased serum thyroid-stimulating hormone (TSH) concentrations"]],"start": [[""],["Two patients with stable hypothyroidism experienced symptoms"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "15482394_1","context": "An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["clotting abnormality"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["warfarin administration"]],"start": [["55"]],"entity_id": [["T2"]],"Drug": {"text": [["warfarin"]],"start": [["55"]],"entity_id": [["T3"]]},"Dosage": {"text": [["daily"]],"start": [["83"]],"entity_id": [["T4"]]},"Duration": {"text": [["duration"]],"start": [["100"]],"entity_id": [["T5"]]},"Disorder": {"text": [["its exposure"]],"start": [["107"]],"entity_id": [["T6"]]},"Freq": {"text": [["probable"]],"start": [["36"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["warfarin"]],"start": [["55"]],"entity_id": [["T3"]]},"Trigger": {"text": [["administration"]],"start": [["55"]],"entity_id": [["T2"]]},"event_id": "E1-1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["unusual"]],"start": [["72"]],"entity_id": [["T8"]]},"Trigger": {"text": [["elevation"]],"start": [["80"]],"entity_id": [["T9"]]},"Route": {"text": [["its exposure"]],"start": [["107"]],"entity_id": [["T6"]]}},"Subject": {"text": [["An objective causality assessment"]],"start": [["0"]],"entity_id": [["S1"]],"Population": {"text": [["a probable relationship"]],"start": [["33"]],"entity_id": [["S2"]]},"Age": {"text": [["the INR"]],"start": [["96"]],"entity_id": [["S3"]]},"Gender": {"text": [["its"]],"start": [["104"]],"entity_id": [["S4"]]},"Race": {"text": [["the daily warfarin dose"]],"start": [["83"]],"entity_id": [["S5"]]},"Disorder": {"text": [["clotting abnormality"]],"start": [["18"]],"entity_id": [["S6"]]}},"Effect": {"text": [["a probable relationship"]],"start": [["33"]],"entity_id": [["E1-2"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "12802933_2","context": "The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["the drug"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["rituximab"]],"start": [[ "41" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["destruction of CD20 positive cells"]],"start": [[ "28" ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["liberation"]],"start": [[ "37" ]],"entity_id": [["T4"]]},"Freq": {"text": [["massive"]],"start": [[ "33" ]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after"]],"start": [[ "30" ]],"entity_id": [["T6"]]},"Dosage": {"text": [["could act"]],"start": [[ "12" ]],"entity_id": [["T7"]]} ,"Route": {"text": [["through"]],"start": [[ "31" ]],"entity_id": [["T8"]]} ,"Duration": {"text": [["remain unknown"]],"start": [[ "0" ]],"entity_id": [["T9"]]} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Trigger": null}]}
{"id": "19499966_5","context": "The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hypertension"]],"start": [["10"]],"entity_id": [["T1"]]},"Severity": {"value": "high", "text": [["grade 3 or 4"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Subject": null,"Effect": {"text": [["hypertension"]],"start": [["10"]],"entity_id": [["T1"]]},"Treatment": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["fatigue"]],"start": [["18"]],"entity_id": [["T2"]]},"Severity": {"value": "high", "text": [["grade 3 or 4"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Subject": null,"Effect": {"text": [["fatigue"]],"start": [["18"]],"entity_id": [["T2"]]},"Treatment": null},{"event_type": "Adverse_event","event_id": "E3","Trigger": {"text": [["hand-foot syndrome"]],"start": [["37"]],"entity_id": [["T3"]]},"Severity": {"value": "high", "text": [["grade 3 or 4"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Subject": null,"Effect": {"text": [["hand-foot syndrome"]],"start": [["37"]],"entity_id": [["T3"]]},"Treatment": null},{"event_type": "Adverse_event","event_id": "E4","Trigger": {"text": [["elevated lipase"]],"start": [["58"]],"entity_id": [["T4"]]},"Severity": {"value": "high", "text": [["grade 3 or 4"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Subject": null,"Effect": {"text": [["elevated lipase"]],"start": [["58"]],"entity_id": [["T4"]]},"Treatment": null},{"event_type": "Adverse_event","event_id": "E5","Trigger": {"text": [["lymphopenia"]],"start": [["74"]],"entity_id": [["T5"]]},"Severity": {"value": "high", "text": [["grade 3 or 4"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Subject": null,"Effect": {"text": [["lymphopenia"]],"start": [["74"]],"entity_id": [["T5"]]},"Treatment": null},{"event_type": "Potential_therapeutic_effect","event_id": "PTE1","Effect": null,"Treatment": {"text": [["sunitinib"]],"start": [["24"]],"entity_id": [["T6"]],"Drug": null,"Disorder": null,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "18446030_2", "context": "We report a 45-year-old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a 45-year-old psoriasis patient"]], "start": [["12","15"]], "entity_id": [],"Age":{"text":[["45"]],"start":[[ "13" ]],"entity_id":[]},"Disorder":{"text":[["psoriasis"]],"start":[[ "19" ]],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}, "Treatment": {"text": [["an antipsoriatic treatment with efalizumab"]], "start": [["52","53"]], "entity_id": [],"Drug": {"text":[["efalizumab"]],"start":[[ "58" ]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["psoriasis"]],"start":[[ "43" ]],"entity_id":[]},"Combination":null,"Trigger":{"text":[],"start":[],"entity_id":[]}}, "Effect": {"text": [["eruptive mollusca contagiosa"]], "start": [["80","84"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null,"Trigger":{"text":[["during"]],"start":[[ "75" ]], "entity_id": []}}]}
{"id": "2746565_1","context": "Ibuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lower gastrointestinal adverse reactions"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Ibuprofen"]],"start": [["0"]],"entity_id": [["T2"]] ,"Dosage": {"text": [["rarely"]],"start": [["4"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["rarely"]],"start": [["4"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["patients with lupus"]],"start": [["73"]],"entity_id": [["T4"]]} ,"Route": {"text": [["systemic and local side effects"]],"start": [["52"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["has been implicated"]],"start": [["49"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["Ibuprofen"]],"start": [["0"]],"entity_id": [["T2"]] },"Trigger": {"text": [["lower gastrointestinal adverse reactions"]],"start": [["32"]],"entity_id": [["T1"]]} ,"event_id": "E1" ,"event_type": "Adverse_event"} ],"Trigger": {"text": [["lower gastrointestinal adverse reactions"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Drug": {"text": [["Ibuprofen"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["long-term"]],"start": [["73"]],"entity_id": [["T4"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Subject": {"text": [["patients with lupus"]],"start": [["73"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["lupus"]],"start": [["82"]],"entity_id": [["T7"]]} },"Effect": {"text": [["lower gastrointestinal adverse reactions"]],"start": [["32"]],"entity_id": [["T1"]]} }]}
{"id": "7606071_2","context": "While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit anaphylactoid reactions. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["cisplatin"]],"start": [["63"]],"entity_id": []} ,"text": [["intraperitoneal cisplatin and hyperthermia"]],"start": [["28"]],"entity_id": [] ,"Disorder": {"text": [["the treatment of recurrent ovarian cancer"]],"start": [["49"]],"entity_id": []} ,"Route": {"text": [["intraperitoneal"]],"start": [["28"]],"entity_id": []} ,"Trigger": {"text": [["conducting"]],"start": [["1"]],"entity_id": []} ,"Time_elapsed": {"text": [["noted"]],"start": [["114"]],"entity_id": []} ,"Duration": {"text": [["recurrent ovarian cancer"]],"start": [["49"]],"entity_id": []} ,"Freq": {"text": [["3 patients"]],"start": [["106"]],"entity_id": []} ,"Combination": [] ,"Dosage": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["exhibit"]],"start": [["114"]],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [["3 patients"]],"start": [["106"]],"entity_id": []}} ,"Severity": {"text": [["anaphylactoid reactions"]],"start": [["120"]],"entity_id": [] ,"value": ""} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Trigger": {"text": [],"start": [],"entity_id": [] }}]}
{"id": "10774758_1", "context": "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Perinatal vasoconstrictive renal insufficiency"]], "start": [["0"]], "entity_id":[["T1"]]}, "Treatment": {"text": [["nimesulide use"]], "start": [["46"]], "entity_id":[["T2"]], "Drug": {"text": [["nimesulide"]], "start": [["46"]], "entity_id":[["T3"]] }, "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": {"text": [["maternal"]], "start": [["26"]], "entity_id":[["T4"]]}},"Subject": null, "Negated": null, "Speculated": null, "Severity": null, "Effect": null}]}
{"id": "17448102_4","context": "Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Hypertonic sodium bicarbonate"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Disorder": {"text": [["hypotension"]],"start": [[ "55" ]],"entity_id": [["T3"]]},"Dosage": {"text": [["recognized as effective"]],"start": [[ "22" ]],"entity_id": [["T2"]]},"Duration": {"text": [["therapy"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Route": {"text": [["therapy"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["effective"]],"start": [[ "22" ]],"entity_id": [["T2"]]},"Trigger": {"text": [["recognized"]],"start": [[ "22" ]],"entity_id": [["T2"]]},"Drug": {"text": [["Hypertonic sodium bicarbonate"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Freq": {"text": [["therapy"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "788666_2","context": "Gentamicin-associated acute renal failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Gentamicin-associated acute renal failure"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["Gentamicin"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [["Gentamicin"]],"start": [[ ]],"entity_id": []},"Disorder": {"text": [["acute renal failure"]],"start": [[ ]],"entity_id": []},"Time_elapsed": null,"Duration": null,"Freq": null,"Route": null,"Combination": null,"Dosage": null,"Trigger": {"text": [["Gentamicin-associated acute renal failure"]],"start": [[ ]],"entity_id": []}},"Effect": {"text": [["acute renal failure"]],"start": [[ ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "1359782_3","context": "Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Sulfasalazine-induced lung disorder"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]},"Subject": {"text": [["all ulcerative colitis patients"]],"start": [["56"]],"entity_id": [ ["T2"] ],"Population": {"text": [["all"]],"start": [["56"]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["ulcerative colitis"]],"start": [["56"]],"entity_id": [ ["T2"] ]} ,"Age": null,"Gender": null,"Race": null},"Treatment": {"text": [["sulfasalazine therapy"]],"start": [["80"]],"entity_id": [ ["T3"] ],"Drug": {"text": [["sulfasalazine"]],"start": [["80"]],"entity_id": [ ["T4"] ]},"Disorder": {"text": [["ulcerative colitis"]],"start": [["80"]],"entity_id": [["T2"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["extremely rare"]],"start": [["8"]],"entity_id": [ ["T0"] ],"value": "extremely rare" }} ]}
{"id": "15162903_2", "context": "Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment, as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["methotrexate"]], "start": [["124"]], "entity_id": [["T1"]]},"Disorder": {"text": [["neurotoxic effects"]], "start": [["88"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "text": [["methotrexate"]], "start": [["124"]], "entity_id": [["T1"]]}, "Effect": {"text": [["neurotoxicity"]], "start": [["41"]], "entity_id": [["T3"]]}, "Trigger": {"text": [["signs and symptoms"]], "start": [["17"]], "entity_id": [["T4"]]}}]}
{"id": "19122478_5","context": "We report the first case of chlorambucil-induced DRESS syndrome in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["DRESS syndrome"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["chlorambucil"]],"start": [["17"]],"entity_id": [["T2"]],"Drug": {"text": [["chlorambucil"]],"start": [["17"]],"entity_id": [["T2"]]},"Disorder": {"text": [["chronic lymphocytic leukaemia"]],"start": [["72"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["recently"]],"start": [["60"]],"entity_id": [["T4"]]},"Trigger": {"text": [["induced"]],"start": [["24"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["a 70-year-old man"]],"start": [["8"]],"entity_id": [["T6"]],"Age": {"text": [["70-year-old"]],"start": [["8"]],"entity_id": [["T6"]]},"Gender": {"text": [["man"]],"start": [["21"]],"entity_id": [["T7"]]},"Population": null,"Race": null,"Disorder": {"text": [["recently diagnosed with chronic lymphocytic leukaemia"]],"start": [["60"]],"entity_id": [["T3"]]}},"Severity": {"text": [["first case"]],"start": [["0"]],"entity_id": [["T0"]],"value":"high"},"Speculated": null,"Negated": null,"Effect": {"text": [["DRESS syndrome"]],"start": [["32"]],"entity_id": [["T1"]]}}]}
{"id": "19034138_1","context": "After cessation of amantadine, the edema resolved, and the endothelial cell densities were <or=600/mm","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["cessation"]],"start": [["After cessation of amantadine," ,"and the endothelial cell densities were <or=600/mm."], [ "resolved"]],"entity_id": []},"Treatment": {"text": [["amantadine"]],"start": [["After cessation of amantadine,"]],"entity_id": [] ,"Dosage": null,"Duration": null,"Disorder": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Drug": {"text": [["amantadine"]],"start": [[ "After cessation of amantadine,"]],"entity_id": []}},"Subject": null,"Effect": {"text": [["the edema"]],"start": [[ "After cessation of amantadine," ,"and the endothelial cell densities were <or=600/mm."]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10410183_6","context": "Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin. DISCUSSION","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["muscle injury"]],"start": [["18"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["Olanzapine"]],"start": [["0"]],"entity_id": [ ["T2"]],"Drug": {"text": [["Olanzapine"]],"start": [["0"]],"entity_id": [ ["T2"]]} ,"Disorder": {"text": [["muscle injury"]],"start": [["18"]],"entity_id": [ ["T1"]]} ,"Time_elapsed": { "text": [["may cause"]], "start": [["12"]], "entity_id": [ ["T3"]] }, "Dosage": null, "Duration": null, "Freq": null ,"Route": null ,"Combination": null ,"Trigger": null }, "Effect": { "text": [["elevations of serum CK of muscle origin"]], "start": [["48"]], "entity_id": [ ["T4"]] }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": { "text": [["Olanzapine"]], "start": [["0"]], "entity_id": [ ["T2"]], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }} ]}
{"id": "24755135_3", "context": "Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["valproic acid"]], "start": [["valproic acid (VPA)" , "VPA" ]], "entity_id": [["T1"]] , "Disorder": { "text": [["partial or generalized epilepsy"]], "start": [[ "partial or generalized epilepsy"]], "entity_id": [["T2"]]} , "Dosage": { "text": [["open-label"]], "start": [[ "open-label"]], "entity_id": [["T3"]]} , "Route": { "text": [["add-on study"]], "start": [[ "add-on study"]], "entity_id": [["T4"]]} , "Freq": { "text": [["monotherapy"]], "start": [[ "monotherapy"]], "entity_id": [["T5"]]} , "Trigger": { "text": [["treated with"]], "start": [[ "treated with"]], "entity_id": [["T6"]]} , "Drug": { "text": [["valproic acid (VPA)"]], "start": [[ "valproic acid (VPA)" ]], "entity_id": [["T1"]]} , "Duration": { "text": [["patients with"]], "start": [[ "patients with"]], "entity_id": [["T7"]]} , "Time_elapsed": { "text": [["treated with"]], "start": [[ "treated with"]], "entity_id": [["T6"]]} , "Combination": [{ "Drug": { "text": [["carbamazepine (CBZ)"]], "start": [[ "carbamazepine (CBZ)" ]], "entity_id": [["T8"]]} , "Trigger": { "text": [["treated with"]], "start": [[ "treated with"]], "entity_id": [["T6"]]} , "event_id": "C1", "event_type": "Potential_therapeutic_effect"}] }, "Subject": { "text": [["patients"]], "start": [[ "patients"]], "entity_id": [["T7"]] , "Age": { "text": [], "start": [], "entity_id": [] }, "Gender": { "text": [], "start": [], "entity_id": [] }, "Population": { "text": [], "start": [], "entity_id": [] }, "Race": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [["partial or generalized epilepsy"]], "start": [[ "partial or generalized epilepsy"]], "entity_id": [["T2"]]} } , "Severity": { "text": [], "start": [], "entity_id": [] , "value": "" }, "Negated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false } , "Effect": { "text": [], "start": [], "entity_id": [] } , "Trigger": { "text": [], "start": [], "entity_id": [] } }]}
{"id": "24477376_7","context": "Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["aspirin"]],"start": [[ "36" ]],"entity_id": [["T2"]]},"Dosage": {"text": [["dual antiplatelet"]],"start": [[ "0" ]],"entity_id": [["T3"]]},"Route": {"text": [["following placement of coronary stents"]],"start": [[ "73" ]],"entity_id": [["T4"]]},"Freq": {"text": [["critical"]],"start": [[ "108" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["to prevent stent thrombosis and subsequent myocardial infarction"]],"start": [[ "115" ]],"entity_id": [["T6"]]},"Disorder": {"text": [["stent thrombosis"]],"start": [[ "121" ]],"entity_id": [["T7"]]},"Duration": {"text": [["following placement of coronary stents"]],"start": [[ "73" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["critical"]],"start": [[ "108" ]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["aspirin"]],"start": [[ "36" ]],"entity_id": [["T2"]]},"Trigger": {"text": [["dual antiplatelet therapy with"]],"start": [[ "0" ]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["a P2Y12 receptor antagonist"]],"start": [[ "50" ]],"entity_id": [["T8"]]},"Trigger": {"text": [["dual antiplatelet therapy with"]],"start": [[ "0" ]],"entity_id": [["T3"]]},"event_id": "C2","event_type": "Potential_therapeutic_effect"}]},"Effect": {"text": [["prevent stent thrombosis"]],"start": [[ "115" ]],"entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Population": {"text": [["critical"]],"start": [[ "108" ]],"entity_id": [["T5"]]},"Disorder": {"text": [["placing coronary stents"]],"start": [[ "73" ]],"entity_id": [["T4"]]},"Age": null,"Gender": null,"Race": null},"Trigger": {"text": [["critical"]],"start": [[ "108" ]],"entity_id": [["T5"]]}}]}
{"id": "6536282_3", "context": "Organometals also compromise the limbic system and result in deficits in learning and memory", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["compromise"]], "start": [["11"]], "entity_id": []}, "Effect": {"text": [["deficits in learning and memory"]], "start": [["41"]], "entity_id": []}, "Subject": {"text": [["Organometals"]], "start": [["0"]], "entity_id": [], "Disorder": {"text": [["Organometals"]], "start": [["0"]], "entity_id": []},"Gender":{"text":[[]],"start":[[]],"entity_id":[]},"Age":{"text":[[]],"start":[[]],"entity_id":[]},"Population":{"text":[[]],"start":[[]],"entity_id":[]},"Race":{"text":[[]],"start":[[]],"entity_id":[]}} , "Treatment":{"text":[[]],"start":[[]],"entity_id":[],"Dosage":{"text":[[]],"start":[[]],"entity_id":[]},"Duration":{"text":[[]],"start":[[]],"entity_id":[]},"Trigger":{"text":[[]],"start":[[]],"entity_id":[]},"Route":{"text":[[]],"start":[[]],"entity_id":[]},"Time_elapsed":{"text":[[]],"start":[[]],"entity_id":[]},"Freq":{"text":[[]],"start":[[]],"entity_id":[]},"Combination":null ,"Drug":{"text":[["Organometals"]],"start":[[ "0"]],"entity_id":[]}, "Disorder":{"text":[["Organometals"]],"start":[[ "0"]],"entity_id":[]} }, "Negated":null ,"Speculated":null ,"Severity":null }]}
{"id": "6233326_1", "context": "Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Optic neuropathy"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["penicillamine therapy"]], "start": [[ "28" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["penicillamine"]], "start": [[ "28" ]], "entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["rheumatoid arthritis"]], "start": [[ "72" ]], "entity_id": [ ["T4"] ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null },"Subject": { "text": [[ "a patient" ]], "start": [[ "42" ]], "entity_id": [[ "S1" ]] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [[ "rheumatoid arthritis" ]], "start": [[ "72" ]], "entity_id": [[ "T4" ]]} },"Effect": null ,"Negated": null, "Speculated": null, "Severity": null}]}
{"id": "7835785_3","context": "We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["ovarian endometrioid carcinoma", "endometriosis"]],"start": [[], []],"entity_id": [["T1"],["T2"]]},"Subject": {"text": [["a postmenopausal patient"]],"start": [[], []],"entity_id": [["T3"]],"Age": {"text": [["postmenopausal"]],"start": [[], []],"entity_id": [["T3"]]} ,"Disorder": {"text": [["breast cancer"]],"start": [[], []],"entity_id": [["T4"]]} ,"Gender": {"text": [["patient"]],"start": [[], []],"entity_id": [["T3"]]} ,"Population": {"text": [["first case"]],"start": [[], []],"entity_id": [["T0"]]} ,"Race": {"text": [],"start": [[], []],"entity_id": []} },"Treatment": {"text": [["tamoxifen"]],"start": [[], []],"entity_id": [["T5"]],"Drug": {"text": [["tamoxifen"]],"start": [[], []],"entity_id": [["T5"]]} ,"Dosage": {"text": [],"start": [[], []],"entity_id": []} ,"Duration": {"text": [],"start": [[], []],"entity_id": []} ,"Route": {"text": [],"start": [[], []],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [[], []],"entity_id": []} ,"Disorder": {"text": [["breast cancer"]],"start": [[], []],"entity_id": [["T4"]]} ,"Freq": {"text": [],"start": [[], []],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [[], []],"entity_id": []} },"Effect": {"text": [["ovarian endometrioid carcinoma", "endometriosis"]],"start": [[], []],"entity_id": [["T1"],["T2"]]} ,"Negated": {"text": [],"start": [[], []],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [[], []],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [[], []],"entity_id": [] ,"value": ""} }]}
{"id": "6311654_5", "context": "There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["total dose of ACTH"]], "start": [["There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma."],[ "16" ]], "entity_id": [],"Trigger": {"text": [["correlation"]], "start": [["There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma."],[ "28" ]], "entity_id": []}, "Drug": {"text": [["ACTH"]], "start": [["There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma."],[ "37" ]], "entity_id": []}, "Time_elapsed": null, "Duration": null, "Freq": null, "Route": null, "Disorder": null, "Dosage": {"text": [["total dose"]], "start": [["There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma."],[ "16" ]], "entity_id": []}, "Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": {"text": [["the percentage decrease of brain parenchyma"]], "start": [["There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma."],[ "56" ]], "entity_id": []} ,"Trigger": null }]}
{"id": "19423610_3","context": "We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["delirium"]],"start": [[ "5" ]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["paroxetine"]],"start": [["65"]],"entity_id": [["T2"]]},"start": [["53"]],"entity_id": [["T3"]],"Duration": {"text": [["2 days"]],"start": [["75"]],"entity_id": [["T4"]]},"Trigger": {"text": [["before surgery"]],"start": [["82"]],"entity_id": [["T5"]]},"Disorder": {"text": [["serotonin toxicity"]],"start": [["19"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["until"]],"start": [["53"]],"entity_id": [["T7"]]},"Freq": {"text": [["had been taking"]],"start": [["33"]],"entity_id": [["T8"]]},"Route": {"text": [["taking"]],"start": [["53"]],"entity_id": [["T9"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"text": [],"Combination": []},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "19798640_2", "context": "Primary central nervous system lymphoma in a patient treated with natalizumab", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Primary central nervous system lymphoma"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["natalizumab"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["natalizumab"]], "start": [[ ]], "entity_id": [ ]} ,"Disorder": {"text": [["Primary central nervous system lymphoma"]], "start": [[ ]], "entity_id": [ ]} ,"Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null, "Combination": null , "Trigger": {"text": [], "start": [], "entity_id": []}} , "Subject": {"text": [], "start": [], "entity_id": [],"Age": null, "Disorder": {"text": [["Primary central nervous system lymphoma"]], "start": [[ ]], "entity_id": [ ]}, "Gender": null, "Population": null, "Race": null} , "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "21751692_3", "context": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.', ","is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Treatment": {"text": [["low-dose ketamine"]], "start": [["32"]], "entity_id": [],"Drug": {"text": [["ketamine"]], "start": [["32"]], "entity_id": []},"Disorder": {"text": [["radiation therapy"]], "start": [["122"]], "entity_id": []},"Freq": {"text": [["repeatedly"]], "start": [["80"]], "entity_id": []},"Combination": [{"Drug": {"text": [["propofol"]], "start": [["54"]], "entity_id": []},"Trigger": {"text": [["in conjunction with"]], "start": [["66"]], "entity_id": []},"event_id": "C1", "event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["anesthesia"]], "start": [["90"]], "entity_id": []},"Time_elapsed": {"text": [["low-dose ketamine"]], "start": [["32"]], "entity_id": []},"Route": {"text": [["total intravenous"]], "start": [["50"]], "entity_id": []},"Duration": {"text": [["low-dose ketamine"]], "start": [["32"]], "entity_id": []},"Dosage": {"text": [["low-dose"]], "start": [["32"]], "entity_id": []}},"Subject": {"text": [["7 pediatric oncology patients"]], "start": [["13"]], "entity_id": [],"Population": {"text": [["7"]], "start": [["13"]], "entity_id": []},"Age": {"text": [["pediatric"]], "start": [["13"]], "entity_id": []},"Disorder": {"text": [["oncology"]], "start": [["13"]], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Effect": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []}}]}
{"id": "20190474_2","context": "Hypersensitivity to zonisamide was confirmed by the skin patch test","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hypersensitivity"]],"start": [[ ]],"entity_id": []},"Treatment": {"text": [["zonisamide"]],"start": [[]],"entity_id": [],"Drug": {"text": [["zonisamide"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["skin patch test"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["Hypersensitivity"]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "3612639_2","context": "Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravenous ritodrine therapy"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["ritodrine"]],"start": [[ ]],"entity_id": [["T3"]]},"Route": {"text": [["intravenous"]],"start": [[ ]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["24 hours"]],"start": [[ ]],"entity_id": [["T5"]]},"Trigger": {"text": [["subcutaneous terbutaline therapy"]],"start": [[ ]],"entity_id": [["T6"]]},"Dosage": {"text": [["subcutaneous"]],"start": [[ ]],"entity_id": [["T7"]]},"Duration": {"text": [["terbutaline therapy"]],"start": [[ ]],"entity_id": [["T8"]]},"Disorder": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]]},"Freq": {"text": [["24 hours"]],"start": [[ ]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["ritodrine"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["intravenous"]],"start": [[ ]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"},{"Drug": {"text": [["terbutaline"]],"start": [[ ]],"entity_id": [["T9"]]},"Trigger": {"text": [["subcutaneous"]],"start": [[ ]],"entity_id": [["T7"]]},"event_id": "E3","event_type": "Adverse_event"}]},"Severity": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]],"value": "high"},"Speculated": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]],"value": false},"Negated": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]],"value": false},"Subject": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]],"Age": {"text": [[ "" ]],"start": [[ ]],"entity_id": [["T10"]]},"Gender": {"text": [[ "" ]],"start": [[ ]],"entity_id": [["T11"]]},"Population": {"text": [[ "" ]],"start": [[ ]],"entity_id": [["T12"]]},"Race": {"text": [[ "" ]],"start": [[ ]],"entity_id": [["T13"]]},"Disorder": {"text": [[ "" ]],"start": [[ ]],"entity_id": [["T14"]]}},"Effect": {"text": [["Pulmonary edema"]],"start": [[ ]],"entity_id": [["T1"]]}}]}
{"id": "6860059_2","context": "We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal fulminant hepatitis"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["disulfiram"]],"start": [["53"]],"entity_id": [["T2"]],"Drug": {"text": [["disulfiram"]],"start": [["53"]],"entity_id": [["T2"]]},"Disorder": {"text": [["hepatocellular function"]],"start": [["82"]],"entity_id": [["T3"]]},"Trigger": {"text": [["use"]],"start": [["43"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["a man"]],"start": [["63"]],"entity_id": [["T5"]],"Age": null,"Gender": {"text": [["man"]],"start": [["63"]],"entity_id": [["T5"]]},"Population": null,"Race": null,"Disorder": {"text": [["previously normal hepatocellular function"]],"start": [["77"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]],"start": [["32"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["fatal fulminant hepatitis"]],"start": [["32"]],"entity_id": [["T1"]]}}]}
{"id": "9220046_6","context": "To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["rhabdomyolysis"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lovastatin"]],"start": [["32"]],"entity_id": [["T2"]],"Drug": {"text": [["lovastatin"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["rhabdomyolysis"]],"start": [["14"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["two cases"]],"start": [["14"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["clarithromycin"]],"start": [["87"]],"entity_id": [["T4"]]},"Trigger": {"text": [["use"]],"start": [["77"]],"entity_id": [["T3"]]} ,"event_id": "E2","event_type": "Adverse_event"} ,{"Drug": {"text": [["azithromycin"]],"start": [["103"]],"entity_id": [["T5"]]},"Trigger": {"text": [["use"]],"start": [["93"]],"entity_id": [["T3"]]} ,"event_id": "E3","event_type": "Adverse_event"} ], "Time_elapsed": {"text": [["that were precipitated by"]],"start": [["59"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["lovastatin"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Route": {"text": [["taking"]],"start": [["37"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["describe"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} }, "Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "medium"} ,"Subject": {"text": [["two cases"]],"start": [["14"]],"entity_id": [["T1"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "21762153_9", "context": "The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["zinc/o-cymen-5-ol system"]], "start": [[ "0"],[ "23"]], "entity_id": [ ],"Drug": {"text": [["zinc"]], "start": [[ "0"]], "entity_id": [ ]},"Disorder": {"text": [["oral disease-related processes"]], "start": [[ "52"]], "entity_id": [ ]},"Trigger": {"text": [["antimicrobial effects"]], "start": [[ "35"]], "entity_id": [ ]},"Freq": {"text": [["direct"]], "start": [[ "24"]], "entity_id": [ ]},"Route": {"text": [["system"]], "start": [[ "23"]], "entity_id": [ ]},"Duration": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Combination": null},"Severity": null,"Speculated": null,"Negated": null,"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [], "start": [], "entity_id": []},"Trigger": null}]}
{"id": "1388041_2", "context": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti-depressant activity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Paroxetine"]], "start": [[]],"entity_id": [["T1"]],"Drug": { "text": [["Paroxetine"]], "start": [[]],"entity_id": [["T2"]]},"Disorder": { "text": [["anti-depressant activity"]], "start": [[]],"entity_id": [["T3"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "11850606_1","context": "A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["polymyositis", "dilated cardiomyopathy"]],"start": [[ "0", "33" ]],"entity_id": [ ["T1", "T2" ]]},"Treatment": { "text": [["interferon alpha treatment"]], "start": [[ "68" ]], "entity_id": [ ["T3" ]], "Drug": { "text": [["interferon alpha"]], "start": [[ "68" ]], "entity_id": [ ["T4" ]] },"Disorder": { "text": [["hepatitis B"]], "start": [[ "105" ]], "entity_id": [ ["T5" ]] },"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null },"Subject": { "text": [[ "case" ]], "start": [[ "0" ]], "entity_id": [[ "S1" ]], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null },"Negated": null, "Speculated": null, "Severity": null ,"Effect": null }] }
{"id": "18315788_1", "context": "Phenytoin toxicity: an easily missed cause of cerebellar syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null, "Effect": {"text": [["Phenytoin toxicity"]], "start": [[], []], "entity_id": [["T1"]]}, "Trigger": {"text": [["Phenytoin toxicity"]], "start": [[], []], "entity_id": [["T1"]]}}]}
{"id": "6837655_1","context": "Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tubular and interstitial lesions"]],"start": [["19", "20"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intermittent or discontinuous rifampin therapy"]],"start": [["43", "44"]],"entity_id": [["T2"]],"Drug": {"text": [["rifampin"]],"start": [["44"]],"entity_id": [["T3"]]},"Freq": {"text": [["intermittent or discontinuous"]],"start": [["43"]],"entity_id": [["T4"]]},"Disorder": {"text": [["tuberculosis"]],"start": [["81"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["associated"]],"start": [["18"]],"entity_id": [["T6"]]},"Trigger": {"text": [["Prior reports have emphasized"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["therapy"]],"start": [["42"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": null,"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": null}]}
{"id": "961329_1","context": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["suxamethonium"]],"start": [[ ], ["14"]],"entity_id": [["T1"]]},"Trigger": {"text": [["infusion"]],"start": [[ ], ["55"]],"entity_id": [["T3"]]},"Disorder": {"text": [["prolonged suxamethonium apnoea"]],"start": [[ ], ["0"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["successfully terminated"]],"start": [[ ], ["40"]],"entity_id": [["T4"]]},"entity_id": [["T1"],["T2"],["T3"],["T4"]],"start": [[ ], ["0"]],"text": [["A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported"]],"Dosage": {"text": [["a commercial preparation"]],"start": [[ ], ["35"]],"entity_id": [["T5"]]},"Duration": {"text": [["is reported"]],"start": [[ ], ["70"]],"entity_id": [["T6"]]},"Route": {"text": [["infused"]],"start": [[ ], ["55"]],"entity_id": [["T7"]]},"Freq": {"text": [["is"]],"start": [[ ], ["68"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["serumcholinesterase"]],"start": [[ ], ["60"]],"entity_id": [["T9"]]},"Trigger": {"text": [["infusion"]],"start": [[ ], ["55"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["A case"]],"start": [[ ], ["0"]],"entity_id": [["T10"]],"Disorder": {"text": [["prolonged suxamethonium apnoea"]],"start": [[ ], ["0"]],"entity_id": [["T2"]]},"Age": {"text": [[""]],"start": [[ ]],"entity_id": [["T11"]]},"Gender": {"text": [[""]],"start": [[ ]],"entity_id": [["T12"]]},"Population": {"text": [["a"]],"start": [[ ], ["0"]],"entity_id": [["T13"]]},"Race": {"text": [[""]],"start": [[ ]],"entity_id": [["T14"]]}},"Negated": null,"Speculated": {"text": [["is reported"]],"start": [[ ], ["70"]],"entity_id": [["T6"]],"value": false},"Severity": null,"Trigger": {"text": [["infused"]],"start": [[ ], ["55"]],"entity_id": [["T7"]]},"Effect": {"text": [["successfully terminated"]],"start": [[ ], ["40"]],"entity_id": [["T4"]]}}]}
{"id": "16718947_2", "context": "53-year-old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications; her international normalized ratio (INR) had been stable for 1 month", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "Drug": { "text": [["warfarin"]], "start": [["31"]], "entity_id": [["T1"]] }, "Disorder": { "text": [["thromboembolic complications"]], "start": [["73"]], "entity_id": [["T2"]] }, "Duration": { "text": [["1 month"]], "start": [["105"]], "entity_id": [["T3"]] } , "Trigger": { "text": [["receiving"]], "start": [["37"]], "entity_id": [["T4"]] } , "entity_id": [["E1"]], "start": [[], [], [], [], ["31"]], "text": [ ["53-year-old woman with a history of deep vein thrombosis and pulmonary embolism"], ["was"], ["prevent"], ["thromboembolic complications"], ["warfarin"] ] , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Dosage": { "text": [], "start": [], "entity_id": [] } , "Combination": null } , "Subject": { "text": [["53-year-old woman"]], "start": [[], [], ["0"]], "entity_id": [["T0"]], "Age": { "text": [[], [], ["53"]], "start": [[], [], ["0"]], "entity_id": [["T0"]] }, "Disorder": { "text": [["deep vein thrombosis"], ["pulmonary embolism"]], "start": [[], ["36"]], "entity_id": [["T5"], ["T6"]] } , "Gender": { "text": [[], ["woman"]], "start": [[], ["36"]], "entity_id": [["T5"]] } , "Population": null , "Race": null } , "Severity": null , "Negated": null , "Speculated": null , "Trigger": null , "Effect": null }]}
{"id": "9161656_2","context": "To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["acute asthma attack"]],"start": [["developed an acute asthma attack after receiving sustained-release verapamil"]],"entity_id": []},"Subject": {"text": [["a patient"]],"start": [[ "To describe a patient" ]],"entity_id": [],"Disorder": {"text": [["asymptomatic bronchial asthma and hypertension"]],"start": [[ "a patient with asymptomatic bronchial asthma and hypertension" ]],"entity_id": []},"Population": {"text": [["a patient"]],"start": [[ "To describe a patient" ]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["sustained-release verapamil"]],"start": [[ "developed an acute asthma attack after receiving sustained-release verapamil" ]],"entity_id": [],"Drug": {"text": [["verapamil"]],"start": [[ "developed an acute asthma attack after receiving sustained-release verapamil" ]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [["asymptomatic bronchial asthma and hypertension"]],"start": [[ "To describe a patient with asymptomatic bronchial asthma and hypertension" ]],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "9883483_3", "context": "We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["56-year-old female"]], "start": [["0"]], "entity_id": [["T1"]], "Age": {"text": [["56"]], "start": [[""],["0"]], "entity_id": [["T2"]]}, "Gender": {"text": [["female"]], "start": [[""],["11"]], "entity_id": [["T3"]]},"Disorder": null, "Population": null, "Race": null}, "Treatment": {"text": [["pirmenol therapy"]], "start": [["144"]], "entity_id": [["T4"]], "Drug": {"text": [["pirmenol"]], "start": [["144"]], "entity_id": [["T5"]]},"Dosage": null, "Duration": null, "Disorder": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null}, "Effect": {"text": [["drug refractory paroxysmal atrial fibrillation","prolongation of the QT interval","T wave inversion on electrocardiogram"]], "start": [[""],["22"],["125"]], "entity_id": [["T6"],["T7"],["T8"]]}, "Trigger": {"text": [["administration"]], "start": [["103"]], "entity_id": [["T9"]]}}]}
{"id": "15331204_2", "context": "To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["therapy with indapamide"]], "start": [["0", "14"]], "entity_id": [],"Drug":{"text":[["indapamide"]],"start":[["48"]],"entity_id":[]},"Disorder":{"text":[["carbohydrate metabolism in essential hypertension patients","diabetes induced by indapamide"]],"start":[["35","52","104"]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null},"Effect":{"text":[],"start":[],"entity_id":[]},"Negated":null,"Speculated":null,"Severity":null,"Subject":{"text":[],"start":[],"entity_id":[],"Age":null,"Disorder":{"text":[["essential hypertension"]],"start":[["69"]],"entity_id":[]},"Gender":null,"Population":null,"Race":null}, "Trigger":{"text":[],"start":[],"entity_id":[]}}]}
{"id": "14677199_2","context": "We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced worsening of Raynaud's phenomenon when using yohimbine for ED","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["worsening"]],"start": [[], []],"entity_id": []},"Treatment": {"text": [["yohimbine"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["yohimbine"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["Raynaud's phenomenon"]],"start": [[], []],"entity_id": []},"Route": {"text": [["using"]],"start": [[], []],"entity_id": []},"Freq": {"text": [["for ED"]],"start": [[], []],"entity_id": []},"Combination": [{"Drug": {"text": [["yohimbine"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["using"]],"start": [[], []],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["when"]],"start": [[], []],"entity_id": []},"Trigger": {"text": [["experienced"]],"start": [[], []],"entity_id": []},"Duration": {"text": [["paradoxically"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [[]],"start": [],"entity_id": []}},"Subject": {"text": [["patient"]],"start": [[], []],"entity_id": [],"Population": {"text": [["a"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia)"]],"start": [[], []],"entity_id": []},"Gender": {"text": [[]],"start": [],"entity_id": []},"Age": {"text": [[]],"start": [],"entity_id": []},"Race": {"text": [[]],"start": [],"entity_id": []}},"Effect": {"text": [["worsening of Raynaud's phenomenon"]],"start": [[], []],"entity_id": []},"Severity": {"text": [[]],"start": [],"entity_id": [],"value": "low"},"Speculated": {"text": [[]],"start": [],"entity_id": [],"value": false},"Negated": {"text": [[]],"start": [],"entity_id": [],"value": false}}]}
{"id": "17277758_2","context": "Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["potential complication"]],"start": [["35"]],"entity_id": []},"Treatment": {"text": [["intravitreal bevacizumab injection"]],"start": [["52"]],"entity_id": [],"Drug": {"text": [["bevacizumab"]],"start": [["52"]],"entity_id": []},"Route": { "text": [["intravitreal"]], "start": [["52"]], "entity_id": [] }, "Disorder": { "text": [["Infectious endophthalmitis"]], "start": [["0"]], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null ,"Trigger": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "19844714_1","context": "One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["platinum hypersensitivity"]],"start": [["58"]],"entity_id": [["T1"]]},"Treatment": {"text": [["carboplatin-based regimen"]],"start": [["32"]],"entity_id": [["T2"]],"Disorder": {"text": [["recurrent primary peritoneal carcinoma"]],"start": [["8"]],"entity_id": [["T3"]]},"Drug": {"text": [["carboplatin"]],"start": [["32"]],"entity_id": [["T4"]]},"Freq": {"text": [["previously treated"]],"start": [["32"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["developed"]],"start": [["47"]],"entity_id": [["T1"]]},"Trigger": {"text": [["developed"]],"start": [["47"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["carboplatin"]],"start": [["32"]],"entity_id": [["T4"]]},"Trigger": {"text": [["platinum hypersensitivity"]],"start": [["58"]],"entity_id": [["T1"]]},"event_id": "E1","event_type": "Adverse_event"}],"Duration": {"text": [["previously treated"]],"start": [["32"]],"entity_id": [["T2"]]},"Route": {"text": [["previously treated"]],"start": [["32"]],"entity_id": [["T2"]]},"Dosage": {"text": [["previously treated"]],"start": [["32"]],"entity_id": [["T2"]]}},"Subject": {"text": [["One case of recurrent primary peritoneal carcinoma"]],"start": [["0"]],"entity_id": [["T3"]],"Disorder": {"text": [["recurrent primary peritoneal carcinoma"]],"start": [["8"]],"entity_id": [["T3"]]},"Age": {"text": [["One case"]],"start": [["0"]],"entity_id": [["T3"]]},"Population": {"text": [["One case"]],"start": [["0"]],"entity_id": [["T3"]]},"Race": {"text": [["One case"]],"start": [["0"]],"entity_id": [["T3"]]},"Gender": {"text": [["One case"]],"start": [["0"]],"entity_id": [["T3"]]}},"Effect": {"text": [["platinum hypersensitivity"]],"start": [["58"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9220046_7","context": "To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["lovastatin-induced rhabdomyolysis"]],"start": [[ "32"]],"entity_id": [ ]},"Treatment": {"text": [["lovastatin"]],"start": [["0"]],"entity_id": [ ],"Drug": {"text": [["lovastatin"]],"start": [["0"]],"entity_id": [ ]},"Disorder": {"text": [["rhabdomyolysis"]],"start": [["32"]],"entity_id": [ ]},"Time_elapsed": {"text": [["associated with azithromycin and clarithromycin"]],"start": [["72"]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["azithromycin"]],"start": [["72"]],"entity_id": [ ]},"Trigger": {"text": [["associated with azithromycin and clarithromycin"]],"start": [["72"]],"entity_id": [ ]},"event_type": "Adverse_event","event_id": "E2"},{"Drug": {"text": [["clarithromycin"]],"start": [["88"]],"entity_id": [ ]},"Trigger": {"text": [["associated with azithromycin and clarithromycin"]],"start": [["72"]],"entity_id": [ ]},"event_type": "Adverse_event","event_id": "E3"}],"Freq": {"text": [["first published reports"]],"start": [["9"]],"entity_id": [ ]},"Route": {"text": [["reports"]],"start": [["9"]],"entity_id": [ ]},"Duration": {"text": [["these cases"]],"start": [["22"]],"entity_id": [ ]},"Dosage": {"text": [["lovastatin-induced rhabdomyolysis"]],"start": [["32"]],"entity_id": [ ]},"Trigger": {"text": [["lovastatin-induced rhabdomyolysis"]],"start": [["32"]],"entity_id": [ ]}},"Subject": {"text": [["To our knowledge"]],"start": [["0"]],"entity_id": [ ],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Severity": null,"Negated": null,"Speculated": null,"Effect": {"text": [["rhabdomyolysis"]],"start": [["32"]],"entity_id": [ ]}}]}
{"id": "20038831_3","context": "Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["Prick tests", "intradermal tests"]],"start": [[ ], []],"entity_id": [ ]},"Treatment": {"text": [["carboplatin", "cisplatin"]],"start": [[ ], []],"entity_id": [ ],"Dosage": {"text": [["a series of dilutions"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [[ "were performed" ]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["on three patients"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["who had exhibited medium and severe hypersensitivity reactions"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["carboplatin"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [ ],"start": [ ],"entity_id": [ ]},"Duration": {"text": [ ],"start": [ ],"entity_id": [ ]},"Drug": {"text": [[ "carboplatin" ]],"start": [[ ]],"entity_id": [ ]},"Combination": null},"Subject": {"text": [["three patients"]],"start": [[ ]],"entity_id": [ ],"Age": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Gender": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Race": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [[ ]],"start": [[ ]],"entity_id": [ ]}},"Effect": null,"Negated": {"text": [ ],"start": [ ],"entity_id": [ ],"value": false},"Speculated": {"text": [ ],"start": [ ],"entity_id": [ ],"value": false},"Severity": {"text": [["medium and severe"]],"start": [[ ]],"entity_id": [ ],"value": "severe"}}]}
{"id": "7724306_4","context": "In patients with a known access to INH, seizures should be considered to be caused by INH toxicity unless proved otherwise","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["INH toxicity"]],"start": [["39"]],"entity_id": [["T3"]]},"Treatment": {"Drug": {"text": [["INH"]],"start": [["17"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["seizures"]],"start": [["7"]],"entity_id": [["T2"]]} ,"entity_id": [["T3"]] ,"start": [["17"]] ,"text": [["In patients with a known access to INH, seizures should be considered to be caused by INH toxicity unless proved otherwise."]] ,"Route": {"text": [["to"]],"start": [["25"]],"entity_id": [["T4"]] },"Time_elapsed": {"text": [["caused"]],"start": [["33"]],"entity_id": [["T5"]] },"Freq": {"text": [["should be considered"]],"start": [["21"]],"entity_id": [["T6"]] },"Dosage": {"text": [["to INH"]],"start": [["17"]],"entity_id": [["T7"]] },"Duration": {"text": [["unless proved otherwise"]],"start": [["52"]],"entity_id": [["T8"]] },"Combination": [{"Drug": {"text": [["INH"]],"start": [["17"]],"entity_id": [["T1"]] },"Trigger": {"text": [["to"]],"start": [["25"]],"entity_id": [["T4"]] },"event_id": "C1" ,"event_type": "Drug" }] ,"Trigger": {"text": [["INH toxicity"]],"start": [["39"]],"entity_id": [["T3"]] }} ,"Subject": {"text": [["In patients with a known access to INH"]],"start": [["0"]],"entity_id": [["T9"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["seizures"]],"start": [["7"]],"entity_id": [["T2"]] },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "12889716_3","context": "To our knowledge, this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of enoxaparin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["subcutaneous injection of enoxaparin"]],"start": [["66"]],"entity_id": [["T2"]],"Drug": {"text": [["enoxaparin"]],"start": [["91"]],"entity_id": [["T3"]]} ,"Route": {"text": [["subcutaneous injection"]],"start": [["66"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["a generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["the first case"]],"start": [["5"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["enoxaparin"]],"start": [["91"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["subcutaneous injection"]],"start": [["66"]],"entity_id": [["T4"]]} ,"event_type": "Adverse_event","event_id": "E1"} ],"Time_elapsed": {"text": [["reported"]],"start": [["54"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["the first case"]],"start": [["5"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["subcutaneous injection"]],"start": [["66"]],"entity_id": [["T4"]]} },"Subject": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T6"]],"Population": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["a generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Gender": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Age": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Race": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T6"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]] ,"value": "low"} ,"Effect": {"text": [["a generalized exanthem"]],"start": [["38"]],"entity_id": [["T1"]]} }] }
{"id": "9634122_3","context": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["decoupling"]],"start": [["This case illustrates the potential "]],"entity_id": []},"Treatment": {"text": [["flutamide withdrawal"]],"start": [["flutamide withdrawal"]],"entity_id": [],"Disorder": {"text": [["PSA response"]],"start": [["PSA response"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["disease status"]],"start": [["disease status"]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["decoupling"]],"start": [[""], ["decoupling"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "2369419_4","context": "Upon discontinuation of MTX, her ascites resolved, and her arthritis became more active","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Upon discontinuation of MTX"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["MTX"]],"start": [[ "42"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["MTX"]],"start": [[ "42"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["her ascites"]],"start": [[ "11"]],"entity_id": [ ["T4"] ]},"Time_elapsed": {"text": [["Upon discontinuation"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Trigger": {"text": [["discontinuation"]],"start": [[ "17"]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["her arthritis became more active"]],"start": [[ "62"]],"entity_id": [ ["T5"] ]} ,"Duration": {"text": [["Upon discontinuation"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]} ,"Route": {"text": [["discontinuation"]],"start": [[ "17"]],"entity_id": [ ["T1"] ]} ,"Dosage": {"text": [["MTX"]],"start": [[ "42"]],"entity_id": [ ["T3"] ]} ,"Combination": [{"Drug": {"text": [["MTX"]],"start": [[ "42"]],"entity_id": [ ["T3"] ]} ,"Trigger": {"text": [["Upon discontinuation"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect" }] }, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["her ascites"]],"start": [[ "11"]],"entity_id": [ ["T4"] ],"Age": null,"Disorder": {"text": [["her ascites"]],"start": [[ "11"]],"entity_id": [ ["T4"] ]},"Gender": null,"Population": null,"Race": null }, "Effect": {"text": [["her ascites resolved"]],"start": [[ "24"]],"entity_id": [ ["T6"] ]} }]}
{"id": "19949685_1","context": "Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Colonic mucosal necrosis"]],"start": [["0"]] ,"entity_id": [ ["T1"] ]} ,"Treatment": {"text": [["calcium polystryrene sulfonate (Kalimate)"]],"start": [["36"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["calcium polystryrene sulfonate"]],"start": [["36"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["uremic patient"]],"start": [["69"]],"entity_id": [ ["T4"] ]} ,"Route": {"text": [["administration"]],"start": [["24"]],"entity_id": [ ["T5"] ]} ,"Time_elapsed": {"text": [["following"]],"start": [["20"]],"entity_id": [ ["T6"] ]} ,"Freq": {"text": [["following"]],"start": [["20"]],"entity_id": [ ["T6"] ]} ,"Duration": {"text": [["following"]],"start": [["20"]],"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [["calcium polystryrene sulfonate (Kalimate)"]],"start": [["36"]],"entity_id": [ ["T2"] ]} ,"Trigger": null ,"Combination": null },"Effect": {"text": [["Colonic mucosal necrosis"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": {"text": [["a uremic patient"]],"start": [["69"]],"entity_id": [ ["T4"] ],"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": {"text": [["uremic patient"]],"start": [["69"]],"entity_id": [ ["T4"] ]} } }] }
{"id": "6933231_1", "context": "Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Intracranial hemorrhage", "focal seizures"]], "start": [[ ]],"entity_id": [["T1", "T2"]]}, "Treatment": {"text": [["use of L-asparaginase"]], "start": [[ ]],"entity_id": [["T3"]], "Drug": {"text": [["L-asparaginase"]], "start": [[ ]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["acute lymphocytic leukemia"]], "start": [[ ]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [["during induction therapy"]], "start": [[ ]],"entity_id": [["T6"]]} , "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Combination": [{"Drug": {"text": [["L-asparaginase"]], "start": [[ ]],"entity_id": [["T4"]]}, "Trigger": {"text": [["use"]], "start": [[ ]],"entity_id": [["T3"]]}, "event_id": "C1", "event_type": "Adverse_event"} ] ,"Trigger": null, "Dosage": null} , "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null , "Gender": null , "Population": null , "Race": null , "Disorder": { "text": [["acute lymphocytic leukemia"]], "start": [[ ]],"entity_id": [["T5"]]} } }]}
{"id": "21887897_2", "context": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": {"value": "high", "text": [["fatal"]], "start": [[ "fatal" ]], "entity_id": [ ]}, "Subject": null, "Treatment": null, "Effect": {"text": [["poisoning"]], "start": [[ "fatal" ]], "entity_id": [ ]}, "Trigger": {"text": [["poisoning"]], "start": [[ "fatal" ]], "entity_id": [ ]}}]}
{"id": "19390192_1","context": "Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Leukopenia"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["a Crohn's disease patient"]],"start": [["46"]],"entity_id": [ ["T2"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Crohn's disease"]],"start": [["46"]],"entity_id": [ ["T3"] ]}},"Treatment": {"text": [["azathioprine"]],"start": [["70"]],"entity_id": [ ["T4"] ],"Drug": {"text": [["azathioprine"]],"start": [["70"]],"entity_id": [ ["T4"] ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["Crohn's disease"]],"start": [["46"]],"entity_id": [ ["T3"] ]} ,"Combination": null},"Effect": {"text": [["Leukopenia"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "1477441_3","context": "Fixed drug eruption of the scrotum due to methylphenidate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Fixed drug eruption"]],"start": [[ "]], " ,"entity_id" ] ] , "entity_id": [ ["T1"] ] }, "Treatment": { "text": [["methylphenidate"]], "start": [[ "29"]], "entity_id": [ ["T2"] ], "Drug": { "text": [["methylphenidate"]], "start": [[ "29"]], "entity_id": [ ["T3"] ] } , "Disorder": { "text": [["Fixed drug eruption"]], "start": [[ "0"]], "entity_id": [ ["T1"] ] } , "Route": { "text": [["of the scrotum"]], "start": [[ "21"]], "entity_id": [ ["T4"] ] } , "Time_elapsed": { "text": [["due to"]], "start": [[ "15"]], "entity_id": [ ["T5"] ] } , "Dosage": null, "Duration": null, "Freq": null , "Combination": null , "Trigger": { "text": [["methylphenidate"]], "start": [[ "29"]], "entity_id": [ ["T3"] ] } } , "Subject": { "text": [["Fixed drug eruption"]], "start": [[ "0"]], "entity_id": [ ["T1"] ], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null } , "Negated": null, "Speculated": null, "Severity": { "text": [["Fixed drug eruption"]], "start": [[ "0"]], "entity_id": [ ["T1"] ], "value": "low" } , "Effect": { "text": [["Fixed drug eruption"]], "start": [[ "0"]], "entity_id": [ ["T1"] ] } } ] }
{"id": "3470173_2", "context": "Cytarabine-induced cerebellar syndrome: case report and literature review", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["case report"]], "start": [["0"]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["Cytarabine"]], "start": [["12"]], "entity_id": [], "Drug": {"text": [["Cytarabine"]], "start": [["12"]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Freq": null, "Disorder": null, "Combination": null}, "Effect": {"text": [["cerebellar syndrome"]], "start": [["33"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null,"Trigger": {"text": [["Cytarabine-induced"]],"start": [["0"]],"entity_id": []}}]}
{"id": "10513720_2","context": "We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["glaucoma"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["doxetaxel therapy"]],"start": [["34"]],"entity_id": [["T2"]],"Drug": {"text": [["doxetaxel"]],"start": [["34"]],"entity_id": [["T3"]]},"Disorder": {"text": [["metastatic breast cancer"]],"start": [["55"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["therapy"]],"start": [["34"]],"entity_id": [["T2"]]} ,"Route": {"text": [["therapy"]],"start": [["34"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Trigger": {"text": [["induced"]],"start": [["20"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["therapy"]],"start": [["34"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["doxetaxel"]],"start": [["34"]],"entity_id": [["T3"]]},"Trigger": {"text": [["induced"]],"start": [["20"]],"entity_id": [["T5"]]} ,"event_id": "E2","event_type": "Adverse_event"} ]} ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]] ,"Age": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["glaucoma"]],"start": [["14"]],"entity_id": [["T1"]]} ,"Gender": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Population": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Race": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]} },"Effect": {"text": [["glaucoma"]],"start": [["14"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["glaucoma"]],"start": [["14"]],"entity_id": [["T1"]] ,"value": "High" }} ]}
{"id": "8301877_3","context": "Myoclonus was induced and enhanced by L-dopa, developing into generalized seizures","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["induced", "enhanced"]],"start": [[ ], []],"entity_id": []},"Treatment": {"text": [["L-dopa"]],"start": [[]],"entity_id": [],"Drug": {"text": [["L-dopa"]],"start": [[]],"entity_id": []},"Disorder": {"text": [["Myoclonus"]],"start": [[ ]],"entity_id": []},"Freq": {"text": [["developing"]],"start": [[ ]],"entity_id": []},"Time_elapsed": {"text": [["developing"]],"start": [[ ]],"entity_id": []},"Combination": [{"Drug": {"text": [["L-dopa"]],"start": [[]],"entity_id": []},"Trigger": {"text": [["induced", "enhanced"]],"start": [[], []],"entity_id": []},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["generalized seizures"]],"start": [[]],"entity_id": []},"Duration": {"text": [["developing"]],"start": [[ ]],"entity_id": []},"Route": {"text": [["by"]],"start": [[]],"entity_id": []},"Dosage": {"text": [["L-dopa"]],"start": [[]],"entity_id": []}},"Effect": {"text": [["Myoclonus"]],"start": [[ ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "15494638_4","context": "During analysis of 28 patients receiving CAP with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with peripheral neuropathy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["peripheral neuropathy"]],"start": [["62"]],"entity_id": [["T1"]]},"Treatment": {"text": [["CAP"]],"start": [["22"]],"entity_id": [["T2"]],"Disorder": {"text": [["pancreatic cancer"]],"start": [["56"]],"entity_id": [["T3"]]},"Route": {"text": [["concomitant radiation (XRT)"]],"start": [["31"]],"entity_id": [["T4"]]},"Dosage": {"text": [["28 patients"]],"start": [["10"]],"entity_id": [["T5"]]},"Duration": {"text": [["resected or locally advanced"]],"start": [["46"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["During analysis"]],"start": [["0"]],"entity_id": [["T7"]]},"Freq": {"text": [["two patients"]],"start": [["36"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["CAP"]],"start": [["22"]],"entity_id": [["T2"]]},"Trigger": {"text": [["concomitant radiation (XRT)"]],"start": [["31"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Combination"}],"Trigger": {"text": [["peripheral neuropathy"]],"start": [["62"]],"entity_id": [["T1"]]},"Drug": {"text": [["CAP"]],"start": [["22"]],"entity_id": [["T2"]]}},"Subject": {"text": [["28 patients"]],"start": [["10"]],"entity_id": [["T5"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["pancreatic cancer"]],"start": [["56"]],"entity_id": [["T3"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["28 patients"]],"start": [["10"]],"entity_id": [["T5"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Effect": {"text": [["signs and symptoms consistent with peripheral neuropathy"]],"start": [["41"]],"entity_id": [["T1"]]}}]}
{"id": "25515435_8","context": "A liver biopsy in 2012 revealed marked fibrosis, leading the patient to start hepatitis C treatment with peginterferon alfa-2a, ribavirin and boceprevir","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["peinterferon alfa-2a"]],"start": [["38"]],"entity_id": [["T1"]]},"Disorder": {"text": [["hepatitis C"]],"start": [["21"]],"entity_id": [["T2"]]},"Dosage": {"text": [["peginterferon alfa-2a"]],"start": [["38"]],"entity_id": [["T3"]]},"Duration": {"text": [["treatment"]],"start": [["60"]],"entity_id": [["T4"]]},"Trigger": {"text": [["start"]],"start": [["52"]],"entity_id": [["T5"]]},"Route": {"text": [["treatment"]],"start": [["52"]],"entity_id": [["T4"]]},"Freq": {"text": [["treatment"]],"start": [["52"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["ribavirin"]],"start": [["73"]],"entity_id": [["T6"]]},"Trigger": {"text": [["and"]],"start": [["82"]],"entity_id": [["T7"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["boceprevir"]],"start": [["90"]],"entity_id": [["T8"]]},"Trigger": {"text": [["and"]],"start": [["82"]],"entity_id": [["T7"]]},"event_id": "E3","event_type": "Potential_therapeutic_effect"}],"entity_id": [["T1","T2","T3","T4","T5","T6","T7","T8"]],"start": [["21","38","38","60","52","73","82","90"]],"text": [["hepatitis C","peinterferon alfa-2a","peginterferon alfa-2a","treatment","start","ribavirin","and","boceprevir"]],"Time_elapsed": null},"Effect": {"text": [["marked fibrosis"]],"start": [["13"]],"entity_id": [["T9"]]},"Subject": {"text": [["patient"]],"start": [["96"]],"entity_id": [["T10"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["hepatitis C"]],"start": [["21"]],"entity_id": [["T2"]]}},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["liver biopsy"]],"start": [["0"]],"entity_id": [["T11"]]}}]}
{"id": "15494638_19","context": "Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of neurotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["potential adverse effects"]],"start": [["35"]],"entity_id": [["T1"]]},"Treatment": {"text": [["CAP"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["CAP"]],"start": [["0"]],"entity_id": [["T2"]]},"Disorder": {"text": [["neurotoxicity"]],"start": [["78"]],"entity_id": [["T3"]]},"Dosage": {"text": [["dose modification"]],"start": [["46"]],"entity_id": [["T4"]]},"Freq": {"text": [["indicated"]],"start": [["61"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["with development"]],"start": [["53"]],"entity_id": [["T6"]]},"Duration": {"text": [["paramount"]],"start": [["41"]],"entity_id": [["T7"]]},"Route": {"text": [["of"]],"start": [["39"]],"entity_id": [["T8"]]},"Trigger": {"text": [["of"]],"start": [["39"]],"entity_id": [["T8"]]},"Combination": []},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "11111942_2","context": "We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["significant over-anticoagulation"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["warfarin therapy"]],"start": [["87"]],"entity_id": [["T2"]],"Drug": {"text": [["warfarin"]],"start": [["87"]],"entity_id": [["T3"]]},"Trigger": {"text": [["protracted diarrhea"]],"start": [["41"]],"entity_id": [["T4"]]},"Freq": {"text": [["a bout"]],"start": [["41"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["temporally associated"]],"start": [["31"]],"entity_id": [["T6"]]},"Disorder": {"text": [["over-anticoagulation"]],"start": [["17"]],"entity_id": [["T1"]]},"Dosage": {"text": [["protracted diarrhea"]],"start": [["41"]],"entity_id": [["T4"]]},"Duration": {"text": [["on warfarin therapy"]],"start": [["80"]],"entity_id": [["T2"]]},"Route": {"text": [["warfarin therapy"]],"start": [["87"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["warfarin"]],"start": [["87"]],"entity_id": [["T3"]]},"Trigger": {"text": [["protracted diarrhea"]],"start": [["41"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Subject": {"text": [["a patient"]],"start": [["63"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [["significant"]],"start": [["17"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11160777_1", "context": "New oral therapies for type 2 diabetes mellitus::", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["New oral therapies"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] , "Disorder": { "text": [["type 2 diabetes mellitus"]], "start": [[ "48" ]], "entity_id": [ ["T2"] ] } , "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] } , "Combination": null , "Trigger": null , "Drug": null } , "Effect": null , "Negated": null , "Speculated": null , "Severity": null , "Subject": null , "Trigger": null } ]}
{"id": "10679548_3","context": "The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lung disease"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]],"Drug": {"text": [["nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]},"Disorder": {"text": [["lung disease"]],"start": [["15"]],"entity_id": [["T1"]]},"Duration": {"text": [["use of nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]},"Freq": {"text": [["use"]],"start": [["55"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use of nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["developed"]],"start": [["10"]],"entity_id": [["T0"]]},"Route": {"text": [["use"]],"start": [["55"]],"entity_id": [["T2"]]},"Dosage": {"text": [["use of nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]},"Trigger": {"text": [["use of nitrofurantoin"]],"start": [["55"]],"entity_id": [["T2"]]}},"Effect": {"text": [["lung disease"]],"start": [["15"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["rare but recognised form of drug induced injury"]],"start": [["96"]],"entity_id": [["T4"]],"value": "high"},"Subject": {"text": [["two patients"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": {"text": [["two patients"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": null,"Disorder": null}}]}
{"id": "7226916_1","context": "A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["developed complete heart block (CHB)"]],"start": [["53"]],"entity_id": [["T1"]]},"Treatment": {"text": [["administration of disopyramide phosphate (Norpace)"]],"start": [["82"]],"entity_id": [["T2"]],"Drug": {"text": [["disopyramide phosphate"]],"start": [["82"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["right bundle branch block +LPH and ventricular premature contractions"]],"start": [["14"]],"entity_id": [["T4"]]} ,"Route": {"text": [["administration"]],"start": [["82"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["following"]],"start": [["75"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["following"]],"start": [["75"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["A 57-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["57"]],"start": [["3"]],"entity_id": [["T7"]]},"Gender": {"text": [["woman"]],"start": [["18"]],"entity_id": [["T8"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["right bundle branch block +LPH and ventricular premature contractions"]],"start": [["14"]],"entity_id": [["T4"]]}} ,"Effect": {"text": [["complete heart block (CHB)"]],"start": [["53"]],"entity_id": [["T1"]]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""}} ]}
{"id": "14700673_3","context": "In an institutional practice setting, two women, aged 25 and 45, developed acute myopia after starting topiramate for epilepsy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute myopia"]],"start": [["53"]],"entity_id": [["T1"]]},"Subject": {"text": [["two women"]],"start": [["14"]],"entity_id": [ ["T2"]],"Age": {"text": [["25", "45"]],"start": [["16", "19"]],"entity_id": [ ["T3"]]} ,"Disorder": {"text": [["epilepsy"]],"start": [["65"]],"entity_id": [ ["T4"]]} ,"Population": {"text": [["two women"]],"start": [["14"]],"entity_id": [ ["T2"]]} ,"Gender": {"text": [["two women"]],"start": [["14"]],"entity_id": [ ["T2"]]} ,"Race": null},"Treatment": {"text": [["topiramate"]],"start": [["42"]],"entity_id": [ ["T5"]],"Drug": {"text": [["topiramate"]],"start": [["42"]],"entity_id": [ ["T5"]]},"Disorder": {"text": [["epilepsy"]],"start": [["65"]],"entity_id": [ ["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["starting"]],"start": [["32"]],"entity_id": [ ["T6"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null}]}
{"id": "16411025_2", "context": "Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["subacute methotrexate-related neurotoxicity"]],"start": [["41"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["methotrexate"]],"start": [["28"]],"entity_id": [ ["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["28"]],"entity_id": [ ["T2"]]},"Disorder": {"text": [["subacute methotrexate-related neurotoxicity"]],"start": [["41"]],"entity_id": [ ["T1"]]},"Time_elapsed": {"text": [["subacute"]],"start": [["41"]],"entity_id": [ ["T1"]]},"Trigger": {"text": [["Diffusion-weighted MRI correlates"]],"start": [["0"]],"entity_id": [ ["T3"]]},"Route": {"text": [["-related"]],"start": [["39"]],"entity_id": [ ["T1"]]},"Dosage": null,"Duration": null,"Freq": null,"Combination": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["subacute methotrexate-related neurotoxicity"]],"start": [["41"]],"entity_id": [ ["T1"]]}}]}
{"id": "16146480_1", "context": "Can propofol precipitate pancreatitis in patients with Cushing's syndrome?", "is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": { "text": [["propofol"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] }, "Treatment": { "text": [], "entity_id": [], "Drug": { "text": [["propofol"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] } , "Disorder": { "text": [["pancreatitis"]], "start": [[ "30" ]], "entity_id": [ ["T2"] ] } , "Trigger": { "text": [["Cushing's syndrome"]], "start": [[ "57" ]], "entity_id": [ ["T3"] ] } , "Time_elapsed": { "text": [], "entity_id": [] , "start": [] }, "Dosage": { "text": [], "entity_id": [] , "start": [] }, "Duration": { "text": [], "entity_id": [] , "start": [] }, "Route": { "text": [], "entity_id": [] , "start": [] }, "Freq": { "text": [], "entity_id": [] , "start": [] } , "Combination": null , "start": [[ "0" ]] } , "Effect": null , "Speculated": null , "Negated": null , "Severity": null , "Subject": null } ]}
{"id": "23552010_3","context": "This case presents the possibility of anaphylaxis to topical 5-FU treatments and/or the interaction with angiotensin converting enzyme inhibitors","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["anaphylaxis"]],"start": [["This case presents the possibility of anaphylaxis to topical 5-FU treatments and/or the interaction with angiotensin converting enzyme inhibitors" ] ],"entity_id": []},"Treatment": {"text": [["topical 5-FU treatments"]],"start": [[], []],"entity_id": [],"Drug": {"text": [["5-FU"]],"start": [[], []],"entity_id": []},"Disorder": {"text": [],"start": [[], []],"entity_id": []},"Freq": {"text": [],"start": [[], []],"entity_id": []},"Route": {"text": [],"start": [[], []],"entity_id": []},"Time_elapsed": {"text": [],"start": [[], []],"entity_id": []},"Duration": {"text": [],"start": [[], []],"entity_id": []},"Dosage": {"text": [],"start": [[], []],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [[], []],"entity_id": []}},"Negated": null,"Speculated": {"text": [["presents"]],"start": [[], []],"entity_id": [],"value": true},"Severity": null,"Subject": null,"Effect": {"text": [],"start": [[], []],"entity_id": []}},{"event_id": "E2","event_type": "Potential_therapeutic_effect","Trigger": {"text": [],"start": [[], []],"entity_id": []},"Treatment": {"text": [],"start": [[], []],"entity_id": [],"Drug": {"text": [],"start": [[], []],"entity_id": []},"Disorder": {"text": [],"start": [[], []],"entity_id": []},"Freq": {"text": [],"start": [[], []],"entity_id": []},"Route": {"text": [],"start": [[], []],"entity_id": []},"Time_elapsed": {"text": [],"start": [[], []],"entity_id": []},"Duration": {"text": [["topical 5-FU treatments"]],"start": [[], []],"entity_id": []},"Dosage": {"text": [],"start": [[], []],"entity_id": []},"Combination": [],"Trigger": {"text": [["interaction"]],"start": [[], []],"entity_id": []}},"Negated": null,"Speculated": {"text": [],"start": [[], []],"entity_id": [],"value": true},"Severity": null,"Subject": null,"Effect": {"text": [["angiotensin converting enzyme inhibitors"]],"start": [[], []],"entity_id": []}}]}
{"id": "15331204_8","context": "After stopping indapamide, glucose tolerance impairing may be reversed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["stopping indapamide"]],"start": [["After stopping indapamide," ]],"entity_id": []},"Treatment": {"text": [["stopping indapamide"]],"start": [["After stopping indapamide," ]],"entity_id": [],"Drug": {"text": [["indapamide"]],"start": [["stopping indapamide" ]],"entity_id": []} ,"Disorder": {"text": [["glucose tolerance impairing"]],"start": [["" ]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["reversed"]],"start": [["" ]],"entity_id": []} ,"Subject": null ,"Negated": null ,"Speculated": {"text": [["may be"]],"start": [["" ]],"entity_id": [] ,"value": true },"Severity": null }]}
{"id": "11424102_3", "context": "We describe a case of needle-track cutaneous seeding of hepatocellular carcinoma (HCC) after sonographically guided percutaneous ethanol injection (PEI).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["needle-track cutaneous seeding"]], "start": [["26"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["sonographically guided percutaneous ethanol injection"]], "start": [["68"]], "entity_id": [["T2"]], "Drug": {"text": [["ethanol"]], "start": [["89"]], "entity_id": [["T3"]]}, "Route": {"text": [["injection"]], "start": [["105"]], "entity_id": [["T4"]]},"Disorder":{"text":[["hepatocellular carcinoma"]],"start":[["4"]],"entity_id":[["T0"]]},"Time_elapsed":{"text":[["after"]],"start":[["22"]],"entity_id":[["T5"]]},"Freq":{"text":[["sonographically guided percutaneous"]],"start":[["50"]],"entity_id":[["T6"]]},"Dosage":{"text":[["ethanol injection"]],"start":[["81"]],"entity_id":[["T7"]]},"Trigger":{"text":[["seeding"]],"start":[["26"]],"entity_id":[["T8"]]}, "Combination":[{"event_id": "C1","Drug":{"text":[["ethanol"]],"start":[["89"]],"entity_id":[["T3"]]},"Trigger":{"text":[["seeding"]],"start":[["26"]],"entity_id":[["T8"]]},"event_type":"Adverse_event"}],"Duration":{"text":[["describe a case"]],"start":[["0"]],"entity_id":[["T9"]]}},"Subject":{"text":[["We"]],"start":[["0"]],"entity_id":[["T10"]],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["hepatocellular carcinoma"]],"start":[["4"]],"entity_id":[["T0"]]}},"Effect":{"text":[["needle-track cutaneous seeding"]],"start":[["26"]],"entity_id":[["T1"]]},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"Not Specified"}}]}
{"id": "8083821_3", "context": "Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["Zidovudine use in pregnancy"]], "start": [[], []], "entity_id": []}, "Subject": {"text": [["a report on 104 cases"]], "start": [[], []], "entity_id": [],"Age": {"text": [[],[]], "start": [[],[]], "entity_id": []},"Gender": {"text": [["pregnancy"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [[]], "start": [[],[]], "entity_id": []},"Population": {"text": [[],[]], "start": [[],[]], "entity_id": []},"Race": {"text": [[]], "start": [[],[]], "entity_id": []}}, "Treatment": {"text": [["Zidovudine use"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["Zidovudine"]], "start": [[],[]], "entity_id": []},"Dosage": {"text": [[]], "start": [[],[]], "entity_id": []},"Duration": {"text": [[]], "start": [[],[]], "entity_id": []},"Trigger": {"text": [["in pregnancy"]], "start": [[],[]], "entity_id": []},"Route": {"text": [[]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [[]], "start": [[],[]], "entity_id": []},"Freq": {"text": [[]], "start": [[],[]], "entity_id": []},"Combination": null,"Disorder":{"text":[["birth defects"]], "start": [[],[]], "entity_id": []}}, "Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "2369419_1","context": "A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate (MTX).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["ascites"]],"start": [["35"]],"entity_id": [["T1"]]},"Subject": {"text": [["A patient with seropositive rheumatoid arthritis"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["seropositive rheumatoid arthritis"]],"start": [["12"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["methotrexate (MTX)"]],"start": [["54"]],"entity_id": [["T3"]],"Drug": {"text": [["methotrexate"]],"start": [["54"]],"entity_id": [["T4"]]},"Dosage": {"text": [["weekly doses"]],"start": [["61"]],"entity_id": [["T5"]]},"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null ,"Freq": {"text": [["weekly"]],"start": [["57"]],"entity_id": [["T6"]]} ,"Combination": null ,"Trigger": {"text": [["taking"]],"start": [["47"]],"entity_id": [["T7"]]}} ,"Effect": {"text": [["developed"]],"start": [["35"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "14735388_2","context": "We report here a case of TEN after administration of ciprofloxacin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["TEN"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["administration of ciprofloxacin"]],"start": [["46"]],"entity_id": [["T2"]],"Drug": {"text": [["ciprofloxacin"]],"start": [["46"]],"entity_id": [["T3"]]} ,"Route": {"text": [["administration"]],"start": [["46"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after"]],"start": [["38"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["TEN"]],"start": [["0"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["a case"]],"start": [["5"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["administration"]],"start": [["46"]],"entity_id": [["T4"]]},"Duration": {"text": [["case"]],"start": [["5"]],"entity_id": [["T8"]]} ,"Combination": null ,"Trigger": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "20120657_3", "context": "Zidovudine induced pure red cell aplasia: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a case report"]], "start": [["a case report.zipodudine induced pure red cell aplasia"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["Zidovudine"]], "start": [[", induced pure red cell aplasia"]], "entity_id": [],"Drug": {"text": [["Zidovudine"]], "start": [["Zidovudine"]], "entity_id": []},"Dosage": null, "Duration": null, "Disorder": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null}, "Effect": {"text": [["pure red cell aplasia"]], "start": [[", pure red cell aplasia"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Trigger": {"text": [["Zidovudine induced pure red cell aplasia"]],"start": [["Zidovudine induced pure red cell aplasia"]],"entity_id": []}}]}
{"id": "7893301_1","context": "Albuterol-induced hypokalemia and its potential cardiac toxicity are discussed briefly","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Albuterol-induced hypokalemia"]],"start": [[ "0"]] ,"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["Albuterol"]],"start": [["0"]],"entity_id": [["T2"]]},"entity_id": [["T1"]],"text": [["Albuterol"]],"start": [["0"]],"Dosage": {"text": [["induced"]],"start": [["10"]],"entity_id": [["EI1"]]},"Duration": {"text": [["hypokalemia"]],"start": [["12"]],"entity_id": [["EI2"]]},"Disorder": {"text": [["hypokalemia"]],"start": [["12"]],"entity_id": [["EI2"]]},"Time_elapsed": {"text": [["and"]],"start": [["48"]],"entity_id": [["EI3"]]},"Trigger": {"text": [["cardiac toxicity"]],"start": [["50"]],"entity_id": [["T4"]]},"Freq": {"text": [["discussed briefly"]],"start": [["62"]],"entity_id": [["EI4"]]},"Route": {"text": [["Albuterol"]],"start": [["0"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["Albuterol"]],"start": [["0"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["10"]],"entity_id": [["EI1"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [],"start": [],"entity_id": []},"Effect": {"text": [["hypokalemia"]],"start": [["12"]],"entity_id": [["EI2"]]}}]}
{"id": "12503933_6", "context": "To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["patient"]], "start": [["To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["clarithromycin"]], "start": [[],["being treated with clarithromycin for pneumonia"]], "entity_id": [],"Drug": {"text": [["clarithromycin"]], "start": [[],["being treated with clarithromycin for pneumonia"]], "entity_id": []},"Disorder": {"text": [["pneumonia"]], "start": [[],["being treated with clarithromycin for pneumonia"]], "entity_id": []},"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null,"Trigger": null, "Combination": null}, "Effect": {"text": [["fulminant liver failure"]], "start": [[],["developing fulminant liver failure"]], "entity_id": []},"Negated": null, "Speculated": null, "Severity": {"text": [["fulminant"]], "start": [[],["fulminant liver failure"]], "entity_id": [],"value": "high" },"Trigger": null}]}
{"id": "6529939_3","context": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["propranolol"]],"start": [["18"]],"entity_id": [["T1"]],"Drug": {"text": [["propranolol"]],"start": [["18"]],"entity_id": [["T2"]]},"Disorder": {"text": [["abnormal rhythm"]],"start": [["0"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["disappeared"]],"start": [["14"]],"entity_id": [["T4"]]},"Trigger": {"text": [["withdrawal"]],"start": [["10"]],"entity_id": [["T5"]]},"Route": {"text": [["withdrawal"]],"start": [["10"]],"entity_id": [["T5"]]},"Duration": {"text": [["when the drug was restarted"]],"start": [["32"]],"entity_id": [["T6"]]},"Freq": {"text": [["when the drug was restarted"]],"start": [["32"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["propranolol"]],"start": [["18"]],"entity_id": [["T2"]]},"Trigger": {"text": [["restarted"]],"start": [["45"]],"entity_id": [["T7"]]},"event_id":"E2","event_type":"Adverse_event"}],"Dosage": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["a 2/1 S-A block"]],"start": [["68"]],"entity_id": [["T8"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value":"Low"},"Subject": {"text": [["The patient"]],"start": [[""],[]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["abnormal rhythm"]],"start": [[""],[]],"entity_id": []}},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "19826099_3","context": "The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast-feeding in this infant","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["apnea"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["lamotrigine"]],"start": [[ "50" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["lamotrigine"]],"start": [[ "50" ]],"entity_id": [ ["T2"] ]},"Route": {"text": [["breast-feeding"]],"start": [[ "78" ]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["apnea"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["probable relationship"]],"start": [[ "23" ]],"entity_id": [ ["T4"] ]} ,"Freq": {"text": [["probable"]],"start": [[ "23" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [["exposure"]],"start": [[ "35" ]],"entity_id": [ ["T5"] ]} ,"Duration": {"text": [["Naranjo probability scale"]],"start": [[ "0" ]],"entity_id": [ ["T6"] ]} ,"Combination": null ,"Trigger": {"text": [["apnea"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} }, "Subject": {"text": [["this infant"]],"start": [[ "111" ]],"entity_id": [ ["T7"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "9920368_3","context": "Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["amiodarone-induced thyrotoxicosis"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["amiodarone"]],"start": [["7"]],"entity_id": [["T2"]]},"Disorder": {"text": [["thyrotoxicosis"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["1992"]],"start": [["23"]],"entity_id": [["T3"]]},"Route": {"text": [["marketed"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["has been increasing"]],"start": [["47"]],"entity_id": [["T4"]]} ,"entity_id": [["T2"],["T3"],["T4"]] ,"text": [["amiodarone"]],"start": [["7"]] ,"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "7619765_2","context": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["myocardial infarction"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["chemotherapy containing etoposide"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["etoposide"]],"start": [["61"]],"entity_id": [["T3"]]},"Disorder": {"text": [["coronary heart disease"]],"start": [["115"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["occurrence"]],"start": [["41"]],"entity_id": [["T5"]]},"Freq": {"text": [["reported"]],"start": [["0"]],"entity_id": [["T6"]]},"Trigger": {"text": [["after"]],"start": [["34"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["etoposide"]],"start": [["61"]],"entity_id": [["T3"]]},"Trigger": {"text": [["chemotherapy"]],"start": [["41"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "null"}],"Route": {"text": [["null"]],"start": [[""], []],"entity_id": [["T8"]]},"Dosage": {"text": [["null"]],"start": [[""], []],"entity_id": [["T9"]]},"Duration": {"text": [["null"]],"start": [[""], []],"entity_id": [["T10"]]}},"Subject": {"text": [["man"]],"start": [["86"]],"entity_id": [["T11"]],"Age": {"text": [["null"]],"start": [[""], []],"entity_id": [["T12"]]},"Gender": {"text": [["man"]],"start": [["86"]],"entity_id": [["T13"]]},"Population": {"text": [["null"]],"start": [[""], []],"entity_id": [["T14"]]},"Race": {"text": [["null"]],"start": [[""], []],"entity_id": [["T15"]]},"Disorder": {"text": [["no risk factors"]],"start": [["97"]],"entity_id": [["T16"]]}},"Negated": {"text": [["null"]],"start": [[""], []],"entity_id": [["T17"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""], []],"entity_id": [["T18"]],"value": false},"Severity": {"text": [["myocardial infarction"]],"start": [["0"]],"entity_id": [["T19"]],"value": "high"},"Effect": {"text": [["occurrence"]],"start": [["41"]],"entity_id": [["T20"]]}}]}
{"id": "889156_1","context": "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["complicated"]],"start": [["The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. The word 'complicated' is at position 0."]],"entity_id": []},"Treatment": {"text": [["beclomethasone diproprionate inhaler"]],"start": [["The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. The words 'beclomethasone diproprionate inhaler' are at position 21."]],"Drug": {"text": [["beclomethasone diproprionate"]],"start": [["The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. The words 'beclomethasone diproprionate' are at position 21."]],"entity_id": []},"entity_id": [],"Disorder": {"text": [["eosinophilic pneumonia reaction"]],"start": [["The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. The words 'eosinophilic pneumonia reaction' are at position 57."]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Disorder": null,"Race": null},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7577414_1", "context": "Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Nephrotic syndrome"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["griseofulvin therapy"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["griseofulvin"]], "start": [[ ]], "entity_id": [ ]} , "Disorder": {"text": [["systemic lupus erythematosus"]], "start": [[ ]], "entity_id": [ ]} , "Time_elapsed": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]} , "Trigger": {"text": [["therapy"]], "start": [[ ]], "entity_id": [ ]} , "Route": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]} , "Duration": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]} , "Dosage": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]} , "Freq": {"text": [["after"]], "start": [[ ]], "entity_id": [ ]} , "Combination": null }, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[ ]], "entity_id": [ ]} , "Negated": null, "Speculated": null, "Severity": null, "Subject": null } ]}
{"id": "8485005_3","context": "We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (prednisolone 25 mg/day) for pericardial effusion","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["drug-induced Kaposi's sarcoma"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["corticosteroid therapy"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["prednisolone"]],"start": [["65"]],"entity_id": [["T3"]]},"Dosage": {"text": [["25 mg/day"]],"start": [["80"]],"entity_id": [["T4"]]},"Duration": {"text": [["6 months"]],"start": [["76"]],"entity_id": [["T5"]]},"Disorder": {"text": [["pericardial effusion"]],"start": [["116"]],"entity_id": [["T6"]]},"Route": {"text": [["on the sole of the right foot"]],"start": [["35"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["treated"]],"start": [["52"]],"entity_id": [["T8"]]},"Freq": {"text": [["daily"]],"start": [["70"]],"entity_id": [["T9"]]},"Trigger": {"text": [["prednisolone"]],"start": [["65"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["corticosteroid therapy"]],"start": [["52"]],"entity_id": [["T2"]]},"Trigger": {"text": [["prednisolone"]],"start": [["65"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Treatment_effect"}]},"Subject": {"text": [["a 71-year-old man"]],"start": [["26"]],"entity_id": [["T10"]],"Age": {"text": [["71"]],"start": [["26"]],"entity_id": [["T11"]]},"Gender": {"text": [["man"]],"start": [["42"]],"entity_id": [["T12"]]},"Population": {"text": [["a case"]],"start": [["0"]],"entity_id": [["T13"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Kaposi's sarcoma (KS)"]],"start": [["18"]],"entity_id": [["T14"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "16196187_3","context": "We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute epinephrine toxicity"]],"start": [["17"]],"entity_id": [["T1"]]},"Subject": {"text": [["a young boy"]],"start": [["43"]],"entity_id": [["T2"]],"Age": {"text": [["a young boy"]],"start": [["43"]],"entity_id": [["T2"]]},"Disorder": {"text": [["combined variable immunodeficiency syndrome"]],"start": [["28"]],"entity_id": [["T3"]]},"Population": {"text": [["a young boy"]],"start": [["43"]],"entity_id": [["T2"]]},"Race": {"text": [["a young boy"]],"start": [["43"]],"entity_id": [["T2"]]},"Gender": {"text": [["a young boy"]],"start": [["43"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]],"Drug": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]]},"Dosage": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]]},"Route": {"text": [["intravenously"]],"start": [["153"]],"entity_id": [["T5"]]},"Trigger": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["resulting in acute myocardial ischemia"]],"start": [["18"]],"entity_id": [["T6"]]},"Freq": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]]},"Disorder": {"text": [["severe allergic reaction"]],"start": [["93"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["intravenous immunoglobulin"]],"start": [["78"]],"entity_id": [["T8"]]},"Trigger": {"text": [["to"]],"start": [["80"]],"entity_id": [["T9"]]},"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Duration": {"text": [["epinephrine"]],"start": [["141"]],"entity_id": [["T4"]]}},"Negated": {"text": [["was subsequently given epinephrine by mistake"]],"start": [["133"]],"entity_id": [["T10"]],"value": false},"Speculated": {"text": [["We present a case"]],"start": [["0"]],"entity_id": [["T11"]],"value": false},"Severity": {"text": [["acute epinephrine toxicity resulting in acute myocardial ischemia"]],"start": [["17"]],"entity_id": [["T12"]],"value": "high"},"Effect": {"text": [["acute epinephrine toxicity resulting in acute myocardial ischemia"]],"start": [["17"]],"entity_id": [["T13"]]}}]}
{"id": "8363533_1", "context": "Albeit rare among Western patients, such lithium-associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null,"Subject": null,"Treatment": {"text": [["lithium"]], "start": [["33"]], "entity_id": [] ,"Drug": { "text": [["lithium"]], "start": [["33"]], "entity_id": [] },"Disorder": { "text": [["thyroid dysfunctions"]], "start": [["47"]], "entity_id": [] },"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null },"Effect": { "text": [["thyroid dysfunctions"]], "start": [["47"]], "entity_id": [] },"Trigger": { "text": [["lithium-associated thyroid dysfunctions"]], "start": [["18"]], "entity_id": [] }}]}
{"id": "25671244_2", "context": "Metaxalone has only recently been associated with serotonin syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["serotonin syndrome"]], "start": [["62"]], "entity_id": []}, "Treatment": {"text": [["Metaxalone"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Metaxalone"]], "start": [["0"]], "entity_id": []},"Disorder":{"text":[["serotonin syndrome"]],"start":[[ "62"]],"entity_id":[]},"Time_elapsed":{"text":[["has only recently been associated"]],"start":[[ "22"]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null,"Trigger":null}, "Effect": null, "Subject": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "8691927_3", "context": "Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["growth", "adrenal suppression"]], "start": [[ "0", "25" ]], "entity_id": [ ["T1", "T2"]]}, "Treatment": {"text": [["high-dose fluticasone propionate"]], "start": [[ "56" ]], "entity_id": [ ["T3"]], "Drug": {"text": [["fluticasone propionate"]], "start": [[ "56" ]], "entity_id": [ ["T4"]]},"Disorder": {"text": [["asthmatic children"]], "start": [[ "33" ]], "entity_id": [ ["T5"]]}, "Dosage": {"text": [["high-dose"]], "start": [[ "56" ]], "entity_id": [ ["T6"]]},"Freq":{"text":[["treated"]], "start":[[ "56" ]], "entity_id":[ ["T7"]]},"Route":{"text":[["in"]], "start":[[ "56" ]], "entity_id":[ ["T8"]]},"Duration":{"text":[["asthmatic children"]], "start":[[ "33" ]], "entity_id":[ ["T5"]]},"Time_elapsed":{"text":[["with"]], "start":[[ "56" ]], "entity_id":[ ["T9"]]},"Combination":[],"Trigger":{"text":[["children treated with high-dose fluticasone propionate"]], "start":[[ "33" ]], "entity_id":[ ["T10"]]} } ,"Effect":{"text":[["growth", "adrenal suppression"]], "start":[[ "0" ]], "entity_id":[ ["T1"]]} ,"Subject":{"text":[["asthmatic children"]], "start":[[ "33" ]], "entity_id":[ ["T5"]],"Age":{"text":[["children"]], "start":[[ "33" ]], "entity_id":[ ["T11"]]},"Disorder":{"text":[["asthmatic children"]], "start":[[ "33" ]], "entity_id":[ ["T5"]]},"Gender":{"text":[], "start":[], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]},"Population":{"text":[["children"]], "start":[[ "33" ]], "entity_id":[ ["T11"]]} } ,"Severity":{"text":[], "start":[], "entity_id":[],"value":""},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[], "start":[], "entity_id":[],"value":false} } ] }
{"id": "14674674_1","context": "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["infliximab-induced lupus"]],"start": [["A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "0" , "28" ]],"entity_id": [ ]},"Treatment": {"text": [["the drug treatment"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "45" , "61" ]],"entity_id": [ ],"Drug": {"text": [["infliximab"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "29" , "37" ]],"entity_id": [ ]},"Disorder": {"text": [["lupus"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "9" , "13" ]],"entity_id": [ ]} ,"Freq": {"text": [["was withdrawn"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "62" , "69" ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [["was made"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "38" , "44" ]],"entity_id": [ ]} ,"Dosage": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Combination": null ,"Trigger": {"text": [["infliximab-induced lupus"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "0" , "28" ]],"entity_id": [ ]} },"Effect": null,"Negated": {"text": [["was made"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "38" , "44" ]],"entity_id": [ ] ,"value": false},"Speculated": {"text": [["A diagnosis"]],"start": [[ "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn" , "0" , "7" ]],"entity_id": [ ] ,"value": false},"Severity": null,"Subject": null}]}
{"id": "10510156_2", "context": "AIMS: To identify the human cytochrome P450 enzyme (s) involved in the in vitro metabolism of rosiglitazone, a potential oral antidiabetic agent for the treatment of type 2 diabetes-mellitus.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["rosiglitazone"]],"start": [["88"]],"entity_id": [ ["T1"] ],"Drug": { "text": [["rosiglitazone"]], "start": [["88"]], "entity_id": [ ["T1"] ]},"Disorder": { "text": [["the treatment of type 2 diabetes-mellitus"]], "start": [["128"]], "entity_id": [ ["T2"] ]} ,"Trigger": { "text": [["in vitro metabolism"]], "start": [["52"]], "entity_id": [ ["T3"] ]} ,"Dosage": { "text": [["a potential oral antidiabetic agent"]], "start": [["97"]], "entity_id": [ ["T4"] ]} ,"Route": { "text": [["oral"]], "start": [["106"]], "entity_id": [ ["T5"] ]} ,"Duration": { "text": [["in vitro"]], "start": [["52"]], "entity_id": [ ["T3"] ]} ,"Freq": { "text": [["in vitro"]], "start": [["52"]], "entity_id": [ ["T3"] ]} ,"Combination": null ,"Time_elapsed": null },"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Trigger": { "text": [["in vitro metabolism"]], "start": [["52"]], "entity_id": [ ["T3"] ]} }]}
{"id": "2011096_5","context": "Neurotoxicity can occur at any time using high-dose cytosine therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Neurotoxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["high-dose cytosine therapy"]],"start": [[ "42" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["cytosine"]],"start": [[ "42" ]],"entity_id": [ ["T3"] ]} ,"Dosage": {"text": [["high-dose"]],"start": [[ "42" ]],"entity_id": [ ["T4"] ]} ,"Route": {"text": [["therapy"]],"start": [[ "48" ]],"entity_id": [ ["T5"] ]} ,"Time_elapsed": {"text": [["any time"]],"start": [[ "26" ]],"entity_id": [ ["T6"] ]} ,"Disorder": {"text": [["Neurotoxicity"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["occur"]],"start": [[ "7" ]],"entity_id": [ ["T7"] ]} ,"Duration": {"text": [["high-dose"]],"start": [[ "42" ]],"entity_id": [ ["T4"] ]} ,"Trigger": null ,"Combination": null }, "Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "3677571_15","context": "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["phenytoin hypersensitivity reactions"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenytoin"]],"start": [["58"]],"entity_id": [["T2"]],"Drug": {"text": [["phenytoin"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["unusual symptoms"]],"start": [["82"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["when patients receiving phenytoin have"]],"start": [["39"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["phenytoin"]],"start": [["58"]],"entity_id": [["T3"]]},"Trigger": {"text": [["have"]],"start": [["88"]],"entity_id": [["T6"]]},"event_id": "C1" ,"event_type": "Adverse_event" }] ,"Time_elapsed": {"text": [["have"]],"start": [["88"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["unusual symptoms"]],"start": [["82"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["phenytoin"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Route": {"text": [["therapy"]],"start": [["58"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["therapy"]],"start": [["58"]],"entity_id": [["T3"]]} },"Negated": {"value": false ,"text": [] ,"start": [] ,"entity_id": [] },"Speculated": {"value": false ,"text": [] ,"start": [] ,"entity_id": [] },"Severity": {"value": "low" ,"text": [] ,"start": [] ,"entity_id": [] },"Subject": {"text": [["patients receiving phenytoin"]],"start": [["39"]],"entity_id": [["T5"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [["phenytoin hypersensitivity reactions"]],"start": [["0"]],"entity_id": [["T1"]] }} ]}
{"id": "9360190_2", "context": "Magnesium tocolysis as the cause of urinary calculus during pregnancy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["urinary calculus"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["Magnesium tocolysis"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Magnesium"]], "start": [["0"]], "entity_id": []},"Disorder":{"text":[["to colysis"]], "start":[["13"]], "entity_id":[]},"Route":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Time_elapsed":{"text":[["as the cause"]], "start":[["17"]], "entity_id":[]},"Freq":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Duration":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Combination":[{"Drug":{"text":[["Magnesium"]], "start":[["0"]], "entity_id":[]},"Trigger":{"text":[["to colysis"]], "start":[["13"]], "entity_id":[]},"event_type":"Adverse_event","event_id":"E2"} ],"Trigger":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Dosage":{"text":[["Magnesium"]], "start":[["0"]], "entity_id":[]} },"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"Low"},"Subject":{"text":[["pregnancy"]], "start":[["45"]], "entity_id":[],"Age":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Disorder":{"text":[["pregnancy"]], "start":[["45"]], "entity_id":[]},"Gender":{"text":[["pregnancy"]], "start":[["45"]], "entity_id":[]},"Population":{"text":[["during pregnancy"]], "start":[["45"]], "entity_id":[]},"Race":{"text":[["pregnancy"]], "start":[["45"]], "entity_id":[]}},"Effect":{"text":[["urinary calculus"]], "start":[["32"]], "entity_id":[]} }]}
{"id": "14601701_1", "context": "Ocular ethambutol toxicity", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Ocular ethambutol toxicity"]], "start": [[ ], [] ], "entity_id": [ ]} ,"Treatment": { "text": [ ], "start": [], "entity_id": [], "Drug": { "text": [[ "ethambutol" ]], "start": [[ ], [] ], "entity_id": [ ]} ,"Disorder": { "text": [ ["Ocular toxicity"] ], "start": [[ ], [] ], "entity_id": [ ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": { "text": [ ["Ocular toxicity"] ], "start": [[ ], [] ], "entity_id": [ ]} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Disorder": null, "Population": null, "Race": null }} ]}
{"id": "8891729_1", "context": "Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fatal intravascular autoimmune hemolytic anemia"]], "start": [[ "0"]],"entity_id": [ ["T1"]]}, "Treatment": {"text": [["fludarabine treatment"]], "start": [[ "56"]], "entity_id": [ ["T2"]], "Drug": {"text": [["fludarabine"]], "start": [[ "56"]], "entity_id": [ ["T3"]]},"Disorder": {"text": [["chronic lymphocytic leukemia"]], "start": [[ "82"]], "entity_id": [ ["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null,"Speculated": null,"Severity": {"text": [["fatal"]], "start": [[ "0"]], "entity_id": [ ["T5"]],"value": "high" },"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "14557583_1", "context": "A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with 400 mg/day of L-dopa", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Subject": {"text": [["A 74-year-old patient"]], "start": [[],[]], "entity_id": [],"Age": {"text": [["74"]], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [["idiopathic Parkinson's disease"]], "start": [[],[]], "entity_id": []},"Gender": { "text": [["patient"]], "start": [[],[]], "entity_id": []},"Population": { "text": [["A"]], "start": [[],[]], "entity_id": []},"Race": { "text": [["patient"]], "start": [[],[]], "entity_id": []}}, "Treatment": {"text": [["long-term treatment with 400 mg/day of L-dopa"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["L-dopa"]], "start": [[],[]], "entity_id": []},"Dosage": {"text": [["400 mg/day"]], "start": [[],[]], "entity_id": []},"Duration": { "text": [["long-term"]], "start": [[],[]], "entity_id": []},"Route": { "text": [["treatment"]], "start": [[],[]], "entity_id": []},"Time_elapsed": { "text": [["occurred"]], "start": [[],[]], "entity_id": []},"Trigger": { "text": [["unintended sleep episodes"]], "start": [[],[]], "entity_id": []},"Freq": { "text": [["occurred"]], "start": [[],[]], "entity_id": []},"Combination": [],"Disorder": { "text": [["idiopathic Parkinson's disease"]], "start": [[],[]], "entity_id": []}},"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": null}]}
{"id": "6683487_2","context": "Thrombotic thrombocytopenic purpura (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with penicillamine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["penicillamine"]],"start": [[ "100" ]],"entity_id": [["T3"]]},"Duration": {"text": [["2 1/2 months"]],"start": [[ "62" ]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["seropositive rheumatoid arthritis"]],"start": [[ "31" ]],"entity_id": [["T4"]]} ,"entity_id": [["T3"]] ,"start": [[ "62" ]] ,"text": [["treatment with penicillamine"]],"Trigger": {"text": [["treatment"]],"start": [[ "62" ]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["seropositive rheumatoid arthritis"]],"start": [[ "31" ]],"entity_id": [["T4"]]} } ,"Effect": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [[ "0" ]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null} ] }
{"id": "9337441_1", "context": "Phenolphthalein-induced toxic epidermal necrolysis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Phenolphthalein-induced toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": { "text": [[]], "start": [], "entity_id": [] , "Drug": {"text": [["Phenolphthalein"]], "start": [[ ]], "entity_id": [ ]} , "Disorder": {"text": [["toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]} , "Time_elapsed": { "text": [[]], "start": [], "entity_id": [] }, "Dosage": { "text": [[]], "start": [], "entity_id": [] }, "Duration": { "text": [[]], "start": [], "entity_id": [] }, "Route": { "text": [[]], "start": [], "entity_id": [] }, "Freq": { "text": [[]], "start": [], "entity_id": [] }, "Combination": null , "Trigger": { "text": [["Phenolphthalein-induced toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]} }, "Effect": { "text": [["toxic epidermal necrolysis"]], "start": [[ ]], "entity_id": [ ]} , "Subject": { "text": [[]], "start": [], "entity_id": [] , "Age": { "text": [[]], "start": [], "entity_id": [] }, "Gender": { "text": [[]], "start": [], "entity_id": [] }, "Population": { "text": [[]], "start": [], "entity_id": [] }, "Race": { "text": [[]], "start": [], "entity_id": [] }, "Disorder": { "text": [[]], "start": [], "entity_id": [] }} , "Negated": null , "Speculated": null , "Severity": { "text": [], "start": [], "entity_id": [] , "value": "high" }}]}
{"id": "1536494_2","context": "We present a case of ethylenediamine-induced delayed hypersensitivity reaction in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ethylenediamine-induced delayed hypersensitivity reaction"]],"start": [[ "31" ]],"entity_id": [["T1"]]},"Subject": {"Age": {"text": [["46-year-old"]],"start": [[ "13" ]],"entity_id": [["T2"]]},"Gender": {"text": [["woman"]],"start": [[ "17" ]],"entity_id": [["T3"]]},"text": [["ethylenediamine"]],"start": [[ "31" ]],"entity_id": [["T4"]],"Disorder": {"text": [["acute asthma exacerbation"]],"start": [[ "82" ]],"entity_id": [["T5"]]},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["parenteral aminophylline"]],"start": [[ "58" ]],"entity_id": [["T6"]],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["parenteral"]],"start": [[ "58" ]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [["aminophylline"]],"start": [[ "58" ]],"entity_id": [["T8"]]},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "12699871_2", "context": "Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["speech loss"]], "start": [["22","33"]], "entity_id": []}, "Treatment": {"text": [["reduction or cessation of the drug"]], "start": [["86","101","104"]], "entity_id": [],"Drug": {"text": [["FK506"]], "start": [["51"]], "entity_id": []},"Time_elapsed":{"text":[["may be associated"]],"start":[["103"]],"entity_id":[]},"Freq":{"text":[["reduction or cessation"]],"start":[["86"]],"entity_id":[]},"Route":{"text":[["of the drug"]],"start":[["102"]],"entity_id":[]},"Combination":[{"Drug":{"text":[["FK506"]],"start":[["51"]],"entity_id":[]},"Trigger":{"text":[["reduction or cessation"]],"start":[["86"]],"entity_id":[]},"event_type":"Therapy","event_id":"C1"} ],"Trigger":{"text":[["linked to FK506"]],"start":[["22"]],"entity_id":[]},"Disorder":{"text":[["speech loss"]],"start":[["0"]],"entity_id":[]},"Dosage":{"text":[["may be important"]],"start":[["4"]],"entity_id":[]},"Duration":{"text":[["Rapid identification"]],"start":[["0"]],"entity_id":[]}} ,"Subject":{"text":[["patient"]],"start":[["0"]],"entity_id":[],"Age":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Gender":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Population":{"text":[["patient"]],"start":[["0"]],"entity_id":[]},"Race":{"text":[[" "]],"start":[["0"]],"entity_id":[]},"Disorder":{"text":[["speech loss"]],"start":[["22","33"]],"entity_id":[]}} ,"Severity":{"text":[["rapid"]],"start":[["0"]],"entity_id":[],"value":"Low"},"Negated":{"text":[["not"]],"start":[["0"]],"entity_id":[],"value":false},"Speculated":{"text":[["may be"]],"start":[["4"]],"entity_id":[],"value":true},"Effect":{"text":[["speech loss"]],"start":[["22","33"]],"entity_id":[]}} ] }
{"id": "8862924_4", "context": "The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related keratitis", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["methamphetamine-related keratitis"]],"start": [["85"]],"entity_id": [["T1"]]},"Subject": {"text": [["ophthalmologists"]],"start": [["49"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": null,"Effect": {"text": [["The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8979664_3", "context": "Uveitis associated with rifabutin therapy: a clinical alert", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Uveitis"]], "start": [[ ]], "entity_id": [ ["T1"] ] }, "Treatment": {"text": [["rifabutin therapy"]], "start": [[ ] ], "entity_id": [ ["T2"] ] , "Drug": {"text": [["rifabutin"]], "start": [[ ] ], "entity_id": [ ["T3"] ] } , "Disorder": {"text": [["Uveitis"]], "start": [[ ] ], "entity_id": [ ["T1"] ] } , "Time_elapsed": {"text": [["associated with"]], "start": [[ ] ], "entity_id": [ ["T4"] ] } , "Dosage": null, "Duration": null, "Freq": null, "Route": null , "Combination": null , "Trigger": null } , "Subject": null , "Negated": null, "Speculated": null, "Severity": null , "Effect": null }]}
{"id": "18698687_3", "context": "We report a case of a patient with ciprofloxacin-induced SJS and acute onset of VBDS, and reviewed the related literature", "is_mult_event": true, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["SJS"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ciprofloxacin"]],"start": [["16"]],"entity_id": [["T2"]],"Drug": {"text": [["ciprofloxacin"]],"start": [["16"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [["acute onset"]],"start": [["42"]],"entity_id": [["T3"]]}} ,"Effect": {"text": [["VBDS"]],"start": [["46"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "8880251_3","context": "This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["cresol"]],"start": [["38"]],"entity_id": [["T1"]]},"Treatment": {"text": [["MH"]],"start": [["13"]],"entity_id": [["T2"]],"Disorder": {"text": [["MH"]],"start": [["13"]],"entity_id": [["T2"]]},"Dosage": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Trigger": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Route": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Time_elapsed": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Freq": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Combination": [{"event_type": "Potential_therapeutic_effect","event_id": "E11","Drug": {"text": [["cresol"]],"start": [["38"]],"entity_id": [["T1"]]},"Trigger": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]}}],"Drug": {"text": [["cresol"]],"start": [["38"]],"entity_id": [["T1"]]}},"Effect": {"text": [["MH"]],"start": [["13"]],"entity_id": [["T2"]]},"Subject": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"Age": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Disorder": {"text": [["diabetes"]],"start": [["28"]],"entity_id": [["T3"]]},"Gender": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Population": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]}},"Negated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["possibly"]],"start": [["57"]],"entity_id": [["T4"]],"value": true},"Severity": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": "null"}}]}
{"id": "3417739_1", "context": "Acute renal failure in a patient treated by continuous povidone-iodine mediastinal irrigation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Acute renal failure"]], "start": [[ "0 "]], "entity_id": []}, "Subject": { "text": [["a patient"]], "start": [[ "44 "]], "entity_id": [] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null }, "Treatment": { "text": [["continuous povidone-iodine mediastinal irrigation"]], "start": [[ "52 "]], "entity_id": [] ,"Drug": { "text": [["povidone-iodine"]], "start": [[ "52 "]], "entity_id": [] }, "Dosage": null ,"Duration": null ,"Route": { "text": [["mediastinal irrigation"]], "start": [[ "69 "]], "entity_id": [] },"Time_elapsed": null ,"Freq": null ,"Disorder": { "text": [["Acute renal failure"]], "start": [[ "0 "]], "entity_id": [] },"Trigger": null ,"Combination": null },"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "7577414_2","context": "To our knowledge, this is the first case of griseofulvin-exacerbated lupus in which nephrotic syndrome has been observed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["griseofulvin-exacerbated lupus"]],"start": [["0"]],"entity_id": [["T1"]]},"Effect": {"text": [["nephrotic syndrome"]],"start": [["56"]],"entity_id": [["T2"]]} ,"Negated": {"value": false ,"text": [[]],"start": [[]],"entity_id": [[]]},"Speculated": {"value": false ,"text": [[]],"start": [[]],"entity_id": [[]]},"Severity": {"value": "" ,"text": [[]],"start": [[]],"entity_id": [[]]} ,"Subject": {"text": [["To our knowledge"]],"start": [["0"]],"entity_id": [[]],"Disorder": {"text": [["griseofulvin-exacerbated lupus"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Age": {"text": [[]],"start": [[]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[]],"entity_id": [[]]}} ,"Treatment": {"text": [["griseofulvin"]],"start": [["0"]],"entity_id": [["T3"]],"Drug": {"text": [["griseofulvin"]],"start": [["0"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [[]],"start": [[]],"entity_id": [[]]},"Duration": {"text": [[]],"start": [[]],"entity_id": [[]]},"Disorder": {"text": [["griseofulvin-exacerbated lupus"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [[]],"start": [[],[]],"entity_id": []},"Route": {"text": [[]],"start": [[],[]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[],[]],"entity_id": []},"Freq": {"text": [[]],"start": [[],[]],"entity_id": []},"Combination": null}}]}
{"id": "1267457_1", "context": "A 71-year-old man, who had a history of a previous bullous drug reaction to a sulfonamide, began receiving an ophthalmic preparation that contained sulfacetamide sodium.$", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["A 71-year-old man"]], "start": [["0"]], "entity_id": [],"Age": {"text": [["71"]], "start": [[""],["0"]],"entity_id": []}, "Gender": {"text": [["man"]], "start": [[""],["11"]],"entity_id": []}, "Population": {"text": [["A"]], "start": [[""],["0"]],"entity_id": []}, "Disorder": {"text": [["a history of a previous bullous drug reaction to a sulfonamide"]], "start": [[""],["22"]],"entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}}, "Treatment": {"text": [["an ophthalmic preparation that contained sulfacetamide sodium"]], "start": [[""],["81"]], "entity_id": [],"Drug": {"text": [["sulfacetamide sodium"]], "start": [[""],["100"]], "entity_id": []}, "Disorder": {"text": [["a sulfonamide"]], "start": [[""],["81"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [["ophthalmic preparation"]], "start": [[""],["81"]], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": {"text": [["began receiving"]], "start": [[""],["50"]], "entity_id": []}}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Trigger": null}]}
{"id": "9022114_4", "context": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["corneal ulcers"]], "start": [["0"]], "entity_id": [["T1"]]}, "Subject": {"text": [["two patients"]], "start": [["22"]], "entity_id": [["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["oral colchicine therapy"]], "start": [["80"]], "entity_id": [["T3"]], "Drug": {"text": [["colchicine"]], "start": [["80"]], "entity_id": [["T4"]]},"Dosage": null, "Duration": null, "Route": {"text": [["oral"]], "start": [["80"]], "entity_id": [["T4"]]}, "Time_elapsed": null, "Freq": null, "Disorder": {"text": [["conventional treatment"]], "start": [["29"]], "entity_id": [["T0"]]}, "Combination": null, "Trigger": null},"Effect": null, "Negated": null, "Speculated": null, "Severity": null},{"event_id": "E2", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["refractory"]], "start": [["45"]], "entity_id": [["T5"]]}, "Subject": {"text": [["two patients"]], "start": [["22"]], "entity_id": [["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["corneal ulcers"]], "start": [["4"]], "entity_id": [["T1"]]}}, "Treatment": {"text": [["conventional treatment"]], "start": [["29"]], "entity_id": [["T0"]], "Drug": null, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null, "Combination": null, "Trigger": null}, "Effect": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "2937155_3", "context": "Vancomycin-induced vasculitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Vancomycin-induced vasculitis"]], "start": [[ ]], "entity_id": [ ["T1" ]]}, "Treatment": { "Drug": { "text": [["Vancomycin"]], "start": [[ ]] , "entity_id": [ ["T2" ]] } ,"entity_id": [ ] ,"text": [ [ "Vancomycin-induced vasculitis" ] ], "start": [ [ ]] , "Disorder": { "text": [["vasculitis"]], "start": [[ ]], "entity_id": [["T3"]] } , "Freq": { "text": [["induced"]], "start": [[ ]], "entity_id": [["T4"]] } , "Route": { "text": [["-"]], "start": [[ ]], "entity_id": [["T5"]] } , "Time_elapsed": { "text": [["-"]], "start": [[ ]], "entity_id": [["T6"]] } , "Duration": { "text": [["-"]], "start": [[ ]], "entity_id": [["T7"]] } , "Dosage": { "text": [["-"]], "start": [[ ]], "entity_id": [["T8"]] } , "Combination": null , "Trigger": null }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }, "Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null } ]}
{"id": "8641617_2","context": "Based on our findings, it is thus concluded that cisplatin may cause C. difficile colitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["C. difficile colitis"]],"start": [["52"]],"entity_id": [["T2"]]},"Freq": {"text": [["may cause"]],"start": [["29"]],"entity_id": [["T3"]]},"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Trigger": {"text": [["cisplatin"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["C. difficile colitis"]],"start": [["52"]],"entity_id": [["T2"]]},"Negated": null,"Speculated": {"text": [["may cause"]],"start": [["29"]],"entity_id": [["T3"]],"value": true},"Severity": null,"Subject": null}]}
{"id": "7249424_2", "context": "Nephrotic syndrome associated with lithium therapy", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Nephrotic syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["lithium therapy"]], "start": [[ "32" ]], "entity_id": [ ["T2" ]], "Drug": {"text": [["lithium"]], "start": [[ "32" ]], "entity_id": [ ["T3" ]] } ,"Disorder": {"text": [["Nephrotic syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]} ,"Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null ,"Combination": null ,"Trigger": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null }]}
{"id": "10728450_1","context": "We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed polyarteritis nodosa"]],"start": [["22"]],"entity_id": [["T1"]]},"Subject": {"text": [["2 patients"]],"start": [["6"]],"entity_id": [["T2"]],"Population": {"text": [["2 patients"]],"start": [["6"]],"entity_id": [["T2"]]} ,"Age": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T3"],["T4"]]} ,"Gender": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T5"],["T6"]]},"Race": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T7"],["T8"]]} ,"Disorder": {"text": [[" polyarteritis nodosa"]],"start": [["22"]],"entity_id": [["T1"]]}} ,"Treatment": {"text": [["vaccination against hepatitis B"]],"start": [["64"]],"entity_id": [["T9"]],"Drug": {"text": [["hepatitis B"]],"start": [["76"]],"entity_id": [["T10"]]} ,"Route": {"text": [["vaccination"]],"start": [["64"]],"entity_id": [["T9"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["53"]],"entity_id": [["T11"]]} ,"Disorder": {"text": [[" polyarteritis nodosa"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T12"],["T13"]]} ,"Duration": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T14"],["T15"]]} ,"Freq": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T16"],["T17"]]},"Trigger": {"text": [["following"]],"start": [["53"]],"entity_id": [["T11"]]} ,"Combination": []} ,"Effect": {"text": [[" polyarteritis nodosa"]],"start": [["22"]],"entity_id": [["T1"]]} ,"Negated": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T18"],["T19"]] ,"value": false} ,"Speculated": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T20"],["T21"]] ,"value": false} ,"Severity": {"text": [[" "],[" "]],"start": [[],[]],"entity_id": [["T22"],["T23"]] ,"value": ""} }]}
{"id": "7594371_3","context": "We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID-induced ototoxicity could result in adverse otologic consequences","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["ketorolac"]],"start": [["15"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["underlying illnesses"]],"start": [["48"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["cautious use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Route": {"text": [["use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["cautious use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["cautious use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["use"]],"start": [["6"]],"entity_id": [["T3"]]} ,"Combination": null ,"entity_id": [["T3"]] ,"text": [["We recommend the cautious use"]],"start": [[""], ["6"]] },"Effect": null,"Trigger": {"text": [["adverse otologic consequences"]],"start": [["83"]],"entity_id": [["T4"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["patients"]],"start": [["32"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["underlying illnesses"]],"start": [["48"]],"entity_id": [["T2"]]} }} ]}
{"id": "9804082_1", "context": "Three diabetic cases of acute dizziness due to initial administration of voglibose", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["acute dizziness"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["initial administration of voglibose"]], "start": [["50"]], "entity_id": [],"Drug": {"text": [["voglibose"]], "start": [["50"]], "entity_id": [] },"Disorder":{"text":[["diabetic cases"]],"start":[[ "3"]],"entity_id": []},"Route":{"text":[["initial administration"]],"start":[[ "50"]],"entity_id": []},"Time_elapsed":{"text":[["initial"]],"start":[[ "50"]],"entity_id": []},"Freq":{"text":[["initial"]],"start":[[ "50"]],"entity_id": []},"Dosage":{"text":[["initial"]],"start":[[ "50"]],"entity_id": []},"Duration":{"text":[["initial"]],"start":[[ "50"]],"entity_id": []},"Combination":null,"Trigger":null },"Subject":{"text":[["Three"]],"start":[[ "0"]],"entity_id": [],"Age":null,"Gender":null,"Population":{"text":[["Three"]],"start":[[ "0"]],"entity_id": []},"Race":null,"Disorder":{"text":[["diabetic cases"]],"start":[[ "3"]],"entity_id": []}},"Negated":null,"Speculated":null,"Severity":{"text":[["acute"]],"start":[[ "32"]],"entity_id": [],"value":"High" },"Effect":{"text":[["acute dizziness"]],"start":[[ "32"]],"entity_id": []}}]}
{"id": "14607011_1", "context": "Fatal cold medication intoxication in an infant", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Fatal cold medication intoxication"]], "start": [[ "0"]], "entity_id": [[ "T1"]]}, "Subject": {"text": [["infant"]], "start": [[ "54"]], "entity_id": [[ "T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Effect": {"text": [["Fatal cold medication intoxication"]], "start": [[ "0"]], "entity_id": [[ "T1"]]}, "Severity": {"text": [["Fatal"]], "start": [[ "0"]], "entity_id": [[ "T3"]], "value": "High" } , "Negated": null, "Speculated": null ,"Treatment": null}]}
{"id": "16211208_2","context": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["QT prolongation"]],"start": [["Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale", "0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["dofetilide"]],"start": [["16211208_2","55"]],"entity_id": [["T2"]],"Drug": {"text": [["dofetilide"]],"start": [["16211208_2","55"]],"entity_id": [["T3"]]},"Disorder": {"text": [["atrial fibrillation"]],"start": [["16211208_2","75"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["secondary to acute ischemia"]],"start": [["16211208_2","20"]],"entity_id": [["T5"]]},"Trigger": {"text": [["acute ischemia"]],"start": [["16211208_2","20"]],"entity_id": [["T6"]]},"Freq": {"text": [["taking"]],"start": [["16211208_2","55"]],"entity_id": [["T7"]]},"Route": {"text": [["taking"]],"start": [["16211208_2","55"]],"entity_id": [["T8"]]},"Dosage": {"text": [["dofetilide"]],"start": [["16211208_2","55"]],"entity_id": [["T9"]]},"Duration": {"text": [["taking"]],"start": [["16211208_2","55"]],"entity_id": [["T10"]]},"Combination": null},"Effect": {"text": [["Marked QT prolongation"]],"start": [["16211208_2","0"]],"entity_id": [["T11"]]},"Severity": {"text": [["Marked"]],"start": [["16211208_2","0"]],"entity_id": [["T12"]],"value": "High"},"Negated": null,"Speculated": null,"Subject": {"text": [["an elderly man"]],"start": [["16211208_2","12"]],"entity_id": [["T13"]],"Age": {"text": [["elderly"]],"start": [["16211208_2","12"]],"entity_id": [["T14"]]},"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["atrial fibrillation"]],"start": [["16211208_2","75"]],"entity_id": [["T4"]]}}}]}
{"id": "19826099_1", "context": "To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["infant"]], "start": [["5"]], "entity_id": [],"Age": {"text": [["infant"]], "start": [["5"]], "entity_id": []}, "Gender": {"text": [[]], "start": [[""],["5"]], "entity_id": []}, "Population": {"text": [[]], "start": [[""],["5"]], "entity_id": []}, "Race": {"text": [[]], "start": [[""],["5"]], "entity_id": []}, "Disorder": {"text": [[]], "start": [[""],["5"]], "entity_id": []}}, "Treatment": {"text": [["lamotrigine"]], "start": [["55"]], "entity_id": [],"Drug": {"text": [["lamotrigine"]], "start": [["55"]], "entity_id": []}, "Disorder": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Dosage": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Duration": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Route": {"text": [["breast-feeding"]], "start": [["35"]], "entity_id": []}, "Time_elapsed": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Freq": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Trigger": {"text": [[]], "start": [[""],["55"]], "entity_id": []}, "Combination": []}, "Effect": {"text": [["severe apnea"]], "start": [["10"]], "entity_id": []}, "Negated": {"text": [[]], "start": [[""],["10"]], "entity_id": [],"value": false}, "Speculated": {"text": [[]], "start": [[""],["10"]], "entity_id": [],"value": false}, "Severity": {"text": [[]], "start": [[""],["10"]], "entity_id": [],"value": "severe" } , "Trigger": {"text": [["lamotrigine"]], "start": [["55"]], "entity_id": []}}]}
{"id": "1316047_1","context": "Hemodynamic collapse following labetalol administration in preeclampsia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hemodynamic collapse"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["labetalol administration"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["labetalol"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["administration"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["preeclampsia"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": null,"Duration": null,"Freq": null,"Combination": null,"Trigger": {"text": [["labetalol administration"]],"start": [[ ]],"entity_id": [ ]},"Dosage": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["Hemodynamic collapse"]],"start": [[ ]],"entity_id": [ ]}}]}
{"id": "18801826_3","context": "We report a case of a 35-year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["new onset type II diabetes mellitus", "hyperosmolar hyperglycaemic coma", "acute renal failure"]],"start": [["36", "57", "80"]],"entity_id": [["T1", "T2", "T3"]]},"Treatment": {"text": [["treatment with a SGA"]],"start": [["111"]],"entity_id": [["T4"]],"Drug": {"text": [["SGA"]],"start": [["111"]],"entity_id": [["T5"]]},"Disorder": {"text": [["first manic episode"]],"start": [["121"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["following"]],"start": [["93"]],"entity_id": [["T7"]]},"Duration": {"text": [["a first manic episode"]],"start": [["121"]],"entity_id": [["T6"]]},"Route": {"text": [["treatment"]],"start": [["111"]],"entity_id": [["T4"]]},"Dosage": {"text": [["a"]],"start": [["111"]],"entity_id": [["T4"]]},"Freq": {"text": [["following"]],"start": [["93"]],"entity_id": [["T7"]]},"Trigger": {"text": [["treatment"]],"start": [["111"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["SGA"]],"start": [["111"]],"entity_id": [["T5"]]},"Trigger": {"text": [["treatment"]],"start": [["111"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Treatment"}]},"Subject": {"text": [["a 35-year old female"]],"start": [["7"]],"entity_id": [["T8"]],"Age": {"text": [["35"]],"start": [["10"]],"entity_id": [["T9"]]},"Gender": {"text": [["female"]],"start": [["14"]],"entity_id": [["T10"]]},"Disorder": {"text": [["first manic episode"]],"start": [["121"]],"entity_id": [["T6"]]},"Population": {"text": [["a"]],"start": [["7"]],"entity_id": [["T8"]]},"Race": {"text": [["a"]],"start": [["7"]],"entity_id": [["T8"]]}},"Effect": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T11"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure"]],"start": [["36", "57", "80"]],"entity_id": [["T1", "T2", "T3"]],"value": "High"}}]}
{"id": "8503421_3","context": "We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["occurrence", "renal failure"]],"start": [["occurrence of renal failure].indexof("]],"entity_id": [["T1"]]},"Treatment": {"text": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)"]],"start": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)].indexof("]],"entity_id": [["T2"]],"Drug": {"text": [["t-PA"]],"start": [["t-PA].indexof("]],"entity_id": [["T3"]]},"Disorder": {"text": [["renal failure"]],"start": [["occurrence of renal failure].indexof("]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["t-PA"]],"start": [["t-PA].indexof("]],"entity_id": [["T3"]]},"Trigger": {"text": [["thrombolytic therapy"]],"start": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)].indexof("]],"entity_id": [["T2"]]} ,"event_id": "E2" ,"event_type": "Adverse_event"}],"Time_elapsed": {"text": [["following"]],"start": [["following].indexof("]],"entity_id": [["T4"]]} ,"Freq": {"text": [["occurrence"]],"start": [["occurrence].indexof("]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)"]],"start": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)].indexof("]],"entity_id": [["T2"]]} ,"Route": {"text": [["intravenous"]],"start": [["intravenous recombinant tissue-type plasminogen activator (t-PA)].indexof("]],"entity_id": [["T2"]]} ,"Duration": {"text": [["occurrence"]],"start": [["occurrence].indexof("]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["occurrence"]],"start": [["occurrence].indexof("]],"entity_id": [["T1"]]} } , "Subject": {"text": [["We"]],"start": [["We].indexof("]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} , "Severity": {"text": [["renal failure"]],"start": [["occurrence of renal failure].indexof("]],"entity_id": [["T1"]],"value": "high"} , "Negated": {"text": [],"start": [],"entity_id": [] , "value": false} , "Speculated": {"text": [],"start": [],"entity_id": [] , "value": false} , "Effect": {"text": [["renal failure"]],"start": [["occurrence of renal failure].indexof("]],"entity_id": [["T1"]]} } ]}
{"id": "9161656_8","context": "The asthma resolved within 24 hours following three albuterol inhalations","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["albuterol"]],"start": [["31"]],"entity_id": [["T1"]]},"Route": {"text": [["inhalations"]],"start": [["42"]],"entity_id": [["T2"]]},"Dosage": {"text": [["three"]],"start": [["24"]],"entity_id": [["T3"]]},"Duration": {"text": [["24 hours"]],"start": [["16"]],"entity_id": [["T4"]]},"Disorder": {"text": [["asthma"]],"start": [["0"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["within"]],"start": [["11"]],"entity_id": [["T6"]]},"text": [["The asthma resolved"]],"start": [["0"]],"entity_id": [["T7"]],"Trigger": {"text": [["resolved"]],"start": [["8"]],"entity_id": [["T8"]]},"Freq": {"text": [["three"]],"start": [["24"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["albuterol"]],"start": [["31"]],"entity_id": [["T1"]]},"Trigger": {"text": [["inhalations"]],"start": [["42"]],"entity_id": [["T2"]]},"event_type": "Adverse_event","event_id": "E1-1"}]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null,"Trigger": {"text": [["resolved"]],"start": [["8"]],"entity_id": [["T8"]]}}]}
{"id": "2875665_2", "context": "Administration of amantadine was associated with psychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["administration of amantadine"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["amantadine"]], "start": [[ ]], "entity_id": [ ] ,"Drug": { "text": [["amantadine"]], "start": [[ ]], "entity_id": [ ] } ,"Disorder": { "text": [["schizophrenic patients"]], "start": [[ ]], "entity_id": [ ] } ,"Trigger": { "text": [["maintained"]], "start": [[ ]], "entity_id": [ ] } ,"Route": { "text": [["administration"]], "start": [[ ]], "entity_id": [ ] } ,"Time_elapsed": { "text": [["associated"]], "start": [[ ]], "entity_id": [ ] } ,"Freq": null ,"Combination": null ,"Dosage": null ,"Duration": null }, "Effect": { "text": [["psychotic decompensations"]], "start": [[ ]], "entity_id": [ ] } ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": { "text": [["two"]], "start": [[ ]], "entity_id": [ ] , "Population": { "text": [["two"]], "start": [[ ]], "entity_id": [ ] } , "Age": null , "Gender": null , "Race": null , "Disorder": { "text": [["schizophrenic patients"]], "start": [[ ]], "entity_id": [ ] } } } ]}
{"id": "6998294_1","context": "Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fasting hypoglycemia"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]}, "Treatment": {"text": [["disopyramide therapy"]],"start": [[ "86" ]],"entity_id": [ ["T2"] ], "Drug": { "text": [["disopyramide"]],"start": [[ "86" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["hypoglycemia"]], "start": [[ "12" ]], "entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": null, "Severity": { "text": [["serious"]],"start": [[ "55" ]], "entity_id": [ ["T5"] ], "value": "serious" }, "Negated": null, "Speculated": null ,"Subject": { "text": [["Clinicians"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }} ]}
{"id": "1569260_1","context": "To the best of our knowledge, this is the first reported patient with captopril-induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["captopril-induced pemphigus"]],"start": [["26"]],"entity_id": [["T1"]]},"Effect": {"text": [["pemphigus"]],"start": [["20"]],"entity_id": [["T2"]]},"Treatment": {"Drug": {"text": [["captopril"]],"start": [["26"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["subsequent treatment"]],"start": [["55"]],"entity_id": [["T4"]]},"Trigger": {"text": [["enalapril"]],"start": [["84"]],"entity_id": [["T5"]]},"entity_id": [["T1"]],"text": [["no new lesions developed"]],"start": [["7"]],"Disorder": {"text": [["pemphigus"]],"start": [["20"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Negated": {"text": [["no new lesions developed"]],"start": [["7"]],"value": true,"entity_id": []},"Speculated": {"text": [],"start": [],"value": false,"entity_id": []},"Severity": {"text": [],"start": [],"value": "","entity_id": []},"Subject": null}]}
{"id": "9494448_5","context": "Fortunately, a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": {"value": false,"text": [["Fortunately"]],"start": [["0"]],"entity_id": []},"Trigger": {"text": [["hypersensitivity reaction"]],"start": [["15"]],"entity_id": []},"Treatment": {"text": [["cyclosporine"]],"start": [["37"]],"entity_id": [],"Drug": {"text": [["cyclosporine"]],"start": [["37"]],"entity_id": []},"Route": {"text": [["formulation"]],"start": [["19"]],"entity_id": []},"Freq": {"text": [["does not preclude use"]],"start": [["44"]],"entity_id": []},"Combination": [{"Drug": {"text": [["cyclosporine"]],"start": [["37"]],"entity_id": []},"Trigger": {"text": [["formulation"]],"start": [["19"]],"entity_id": []},"event_id": "E1-1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["Fortunately"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["use"]],"start": [["44"]],"entity_id": []},"Dosage": {"text": [],"start": [[]],"entity_id": []},"Duration": {"text": [],"start": [[]],"entity_id": []},"Trigger": {"text": [["hypersensitivity reaction"]],"start": [["15"]],"entity_id": []}},"Subject": {"text": [["Fortunately"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [[]],"entity_id": []},"Population": {"text": [],"start": [[]],"entity_id": []},"Race": {"text": [],"start": [[]],"entity_id": []},"Gender": {"text": [],"start": [[]],"entity_id": []},"Disorder": {"text": [],"start": [[]],"entity_id": []}},"Speculated": {"text": [["Fortunately"]],"start": [["0"]],"entity_id": [],"value": false},"Severity": {"text": [],"start": [[]],"entity_id": [],"value": "low"},"Effect": {"text": [["does not preclude use"]],"start": [["44"]],"entity_id": []}}]}
{"id": "11302479_1","context": "She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe urticarial rash"]],"start": [["13","16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Enoxaparin"]],"start": [["57","65"]],"entity_id": [["T2"]],"Dosage": {"text": [["therapy"]],"start": [["33","38"]],"entity_id": [["T3"]]},"Duration": {"text": [["3 weeks"]],"start": [["20","25"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following initiation"]],"start": [["26","32"]],"entity_id": [["T5"]]},"Drug": {"text": [["Enoxaparin"]],"start": [["57","65"]],"entity_id": [["T2"]]},"Disorder": {"text": [["a severe urticarial rash"]],"start": [["13","16"]],"entity_id": [["T1"]]},"Freq": {"text": [["developed"]],"start": [["0","7"]],"entity_id": [["T0"]]},"Route": {"text": [["therapy"]],"start": [["33","38"]],"entity_id": [["T3"]]},"Trigger": {"text": [["following initiation"]],"start": [["26","32"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["Enoxaparin"]],"start": [["57","65"]],"entity_id": [["T2"]]},"Trigger": {"text": [["therapy"]],"start": [["33","38"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Combination"}]},"Subject": {"text": [["She"]],"start": [[""],[]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["severe"]],"start": [["13"]],"entity_id": [["S1"]],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["a severe urticarial rash"]],"start": [["13","16"]],"entity_id": [["T1"]]}}]}
{"id": "9545161_3","context": "Fatal toxic epidermal necrolysis related to lamotrigine administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Fatal toxic epidermal necrolysis"]],"start": [[ ]] , "entity_id": []},"Treatment": {"text": [["lamotrigine administration"]],"start": [[]] , "entity_id": [],"Drug": {"text": [["lamotrigine"]],"start": [[]] , "entity_id": []},"Combination": null,"Freq": null,"Time_elapsed": null,"Route": null,"Disorder": null,"Duration": null,"Dosage": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["Fatal"]],"start": [[]] , "entity_id": [],"value": "High"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}}]}
{"id": "11918514_3", "context": "To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": {"value": "high", "text": [["serious"]], "start": [[], []], "entity_id": []}, "Subject": {"text": [["a case"]], "start": [[], []], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["serotonin syndrome (SS)"]], "start": [[], []], "entity_id": []}}, "Treatment": {"text": [["mirtazapine monotherapy"]], "start": [[], []], "entity_id": [],"Drug": {"text": [["mirtazapine"]], "start": [[], []], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Trigger": null, "Disorder": null, "Combination": null}, "Effect": {"text": [["serotonin syndrome (SS)"]], "start": [[], []], "entity_id": []}, "Trigger": null}]}
{"id": "115078_1", "context": "A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed an acute intrahepatic cholestasis"]], "start": [["31"]], "entity_id": []}, "Subject": {"text": [["A patient with rheumatoid arthritis"]], "start": [["0"]], "entity_id": [], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [["12"]], "entity_id": []},"Age": null, "Gender": null, "Population": null, "Race": null}, "Treatment": {"text": [["100 mg of sodium aurothiomalate"]], "start": [["76"]], "entity_id": [], "Drug": {"text": [["sodium aurothiomalate"]], "start": [["76"]], "entity_id": []}, "Dosage": {"text": [["100"]], "start": [["66"]], "entity_id": []}, "Duration": null, "Route": null, "Time_elapsed": null, "Trigger": null, "Disorder": null, "Freq": null, "Combination": null}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "17965530_2", "context": "We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.\n", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["the administration"]], "start": [["51"]], "entity_id": []}, "Treatment": {"text": [["calcium polystyrene sulfonate", "and sorbitol"]], "start": [["33"]], "entity_id": [],"Drug": {"text": [["calcium polystyrene sulfonate", "sorbitol"]], "start": [["33"]], "entity_id": []},"Disorder":{"text":[["the colonic ulcer","the sigmoidovesical fistula"]], "start":[["8"]], "entity_id":[]},"Time_elapsed":{"text":[["had been caused"]], "start":[["26"]], "entity_id":[]},"Freq":{"text":[["the administration"]], "start":[["51"]], "entity_id":[]},"Route":{"text":[["by"]], "start":[["46"]], "entity_id":[]},"Combination":[{"Drug":{"text":[["calcium polystyrene sulfonate"]], "start":[["33"]], "entity_id":[]},"Trigger":{"text":[["and"]], "start":[["42"]], "entity_id":[]},"event_type":"Treatment","event_id":"C1"},{"Drug":{"text":[["sorbitol"]], "start":[["45"]], "entity_id":[]},"Trigger":{"text":[[]], "start":[[]], "entity_id":[]},"event_type":"Treatment","event_id":"C2"}],"Trigger":{"text":[["the administration"]], "start":[["51"]], "entity_id":[]},"Dosage":{"text":[[]], "start":[[]], "entity_id":[]},"Duration":{"text":[[]], "start":[[]], "entity_id":[]}} ,"Effect":{"text":[["the colonic ulcer","the sigmoidovesical fistula"]], "start":[["8"]], "entity_id":[]},"Negated":{"text":[[]], "start":[[]], "entity_id":[],"value":false},"Speculated":{"text":[[]], "start":[[]], "entity_id":[],"value":false},"Severity":{"text":[[]], "start":[[]], "entity_id":[],"value":"Low" },"Subject":{"text":[[]], "start":[[]], "entity_id":[],"Age":{"text":[[]], "start":[[]], "entity_id":[]},"Disorder":{"text":[[]], "start":[[]], "entity_id":[]},"Gender":{"text":[[]], "start":[[]], "entity_id":[]},"Race":{"text":[[]], "start":[[]], "entity_id":[]},"Population":{"text":[[]], "start":[[]], "entity_id":[]}} }]}
{"id": "15606443_2", "context": "Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Rosiglitazone"]],"start": [[ "0" ]] ,"entity_id": [ ] ,"Drug": {"text": [["Rosiglitazone"]],"start": [[ "0" ]] ,"entity_id": [ ] } ,"Disorder": {"text": [["Type 2 diabetes mellitus"]],"start": [[ ]],"entity_id": [ ] } ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []} } ,"Trigger": null} ]}
{"id": "19540093_1","context": "According to the Naranjo adverse drug reaction probability scale, tigecycline was the probable cause of her acute pancreatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tigecycline"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["her acute pancreatitis"]],"start": [["65"]],"entity_id": [["T2"]] ,"Drug": {"text": [["tigecycline"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Combination": null,"Freq": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["acute pancreatitis"]],"start": [["65"]],"entity_id": [["T2"]]},"Dosage": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [["her"]],"start": [["23"]],"entity_id": [["T3"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["acute pancreatitis"]],"start": [["65"]],"entity_id": [["T2"]]}}]}
{"id": "15479299_2","context": "We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe anemia"]],"start": [[ "0" ]] ,"entity_id": []},"Subject": {"text": [["a patient"]],"start": [[ "82" ]] ,"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["IL-2 plus IFN-alpha for metastatic renal cell carcinoma"]],"start": [[ "101" ]] ,"entity_id": []}},"Treatment": {"text": [["steroid therapy"]],"start": [[ "40" ]] ,"entity_id": [],"Drug": {"text": [["steroid"]],"start": [[ "40" ]] ,"entity_id": []},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["responded well"]],"start": [[ "49" ]] ,"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [[ "3" ]] ,"entity_id": [],"value": "severe"}},{"event_type": "Potential_therapeutic_effect","event_id": "E2","Trigger": null,"Subject": null,"Treatment": {"text": [["IL-2 plus IFN-alpha"]],"start": [[ "101" ]] ,"entity_id": [],"Drug": {"text": [["IL-2", "IFN-alpha"]],"start": [[ "101" ]] ,"entity_id": []},"Disorder": {"text": [["for metastatic renal cell carcinoma"]],"start": [[ "122" ]] ,"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "17420198_17","context": "The patient's movements resolved following diphenhydramine administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["patient's movements resolved"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["diphenhydramine administration"]],"start": [["48"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["diphenhydramine"]],"start": [["48"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["patient's movements"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["following"]],"start": [["30"]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [["patient"]],"start": [["6"]],"entity_id": [ ["T5"] ],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "10679548_5", "context": "The spectrum of nitrofurantoin lung injury continues to widen.","is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["nitrofurantoin lung injury"]], "start": [["0"]], "entity_id": []},"Effect": {"text": [["nitrofurantoin lung injury"]], "start": [["0"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": null}]}
{"id": "12243603_10","context": "We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis, thought to be secondary to a drug interaction between atorvastatin and diltiazem","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["rhabdomyolysis"]],"start": [["24"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient"]],"start": [["5"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": null,"Effect": {"text": [["rhabdomyolysis"]],"start": [["24"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["accompanying acute renal failure"]],"start": [["41"]],"entity_id": [["T3"]],"value": "high"}},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["acute hepatitis"]],"start": [["57"]],"entity_id": [["T4"]]},"Subject": {"text": [["a patient"]],"start": [["5"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": null,"Effect": {"text": [["acute hepatitis"]],"start": [["57"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}},{"event_type": "Potential_therapeutic_effect","event_id": "E3","Trigger": {"text": [["drug interaction"]],"start": [["101"]],"entity_id": [["T5"]]},"Subject": {"text": [["a patient"]],"start": [["5"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["atorvastatin and diltiazem"]],"start": [["95"]],"entity_id": [["T6"]],"Drug": {"text": [["atorvastatin"]],"start": [["95"]],"entity_id": [["T7"]]},"Disorder": {"text": [["secondary"]],"start": [["101"]],"entity_id": [["T8"]]},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null ,"Combination": [{"Drug": {"text": [["atorvastatin"]],"start": [["95"]],"entity_id": [["T7"]]},"Trigger": {"text": [["and"]],"start": [["100"]],"entity_id": [["T9"]]},"event_id": "E31","event_type": "Adverse_event"},{"Drug": {"text": [["diltiazem"]],"start": [["104"]],"entity_id": [["T10"]]},"Trigger": null,"event_id": "E32","event_type": "null"}] ,"Trigger": null} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"} ,"Effect": null}]}
{"id": "18294121_4","context": "Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["desquamative skin rash"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Temozolomide"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Temozolomide"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["metastatic melanoma"]],"start": [["49"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["-induced"]],"start": [["11"]],"entity_id": [["T3"]]},"Trigger": {"text": [["Temozolomide-induced"]],"start": [["11"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["a patient"]],"start": [["24"]],"entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["metastatic melanoma"]],"start": [["49"]],"entity_id": [["T2"]]}},"Effect": {"text": [["desquamative skin rash"]],"start": [["15"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "4066622_2","context": "The calcium channel blockers are a group of drugs that have recently become available for the treatment of angina","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["calcium channel blockers"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["calcium channel blockers"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["angina"]],"start": [["101"]],"entity_id": [["T2"]]},"Route": {"text": [["treatment"]],"start": [["44"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["recently"]],"start": [["21"]],"entity_id": [["T4"]]},"Freq": {"text": [["available"]],"start": [["28"]],"entity_id": [["T5"]]},"Combination": null,"Dosage": null,"Duration": null,"Trigger": null},"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": null}]}
{"id": "17987285_3","context": "Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["concomitant administration", "dangerous drug interactions"]],"start": [[ "0", "72" ]],"entity_id": [ ["T1", "T2" ]] }, "Treatment": { "Drug": { "text": [["CYP3A inhibitors"]], "start": [[ "17" ]], "entity_id": [ ["T3" ]] }, "Trigger": { "text": [["concomitant administration"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] },"Disorder": { "text": [["fentanyl"]], "start": [[ "51" ]], "entity_id": [ ["T4" ]] },"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"entity_id": [ ], "text": [ ["concomitant administration of CYP3A inhibitors with fentanyl"] ], "start": [[ "0" ]] }, "Effect": { "text": [["dangerous drug interactions"]], "start": [[ "72" ]], "entity_id": [ ["T2" ]] }, "Negated": null, "Speculated": null, "Severity": null ,"Subject": null }] }
{"id": "21751666_4","context": "Post-exposure prophylaxis of H1N1 with oseltamivir was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Post-exposure prophylaxis of H1N1 with oseltamivir"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["oseltamivir"]],"start": [["46"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["H1N1 influenza A virus infection"]],"start": [["86"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["to prevent"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Trigger": null,"Freq": {"text": [["safe", "effective and well tolerated"]],"start": [["5", "58"]],"entity_id": [["T5", "T6"]]} ,"Duration": null,"Dosage": null,"Route": null,"Combination": null} ,"Subject": {"text": [["newly transplanted renal allograft recipient receiving triple immunosuppression"]],"start": [["114"]],"entity_id": [["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["triple immunosuppression"]],"start": [["143"]],"entity_id": [["T8"]]} },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "8672829_3","context": "Central nervous system (CNS) toxicity has been described with ifosfamide, with most cases reported in the pediatric population","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["CNS toxicity"]],"start": [["15"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ifosfamide"]],"start": [["44"]],"entity_id": [["T2"]],"Drug": {"text": [["ifosfamide"]],"start": [["44"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Central nervous system (CNS) toxicity"]],"start": [["15"]],"entity_id": [["T1"]]},"Freq": {"text": [["most cases"]],"start": [["62"]],"entity_id": [["T3"]]},"Trigger": {"text": [["reported"]],"start": [["80"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["with"]],"start": [["69"]],"entity_id": [["T5"]]},"Route": {"text": [["described"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Duration": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Combination": null},"Subject": {"text": [["pediatric population"]],"start": [["93"]],"entity_id": [["T6"]],"Age": {"text": [["pediatric"]],"start": [["93"]],"entity_id": [["T6"]]},"Gender": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Population": {"text": [["most cases"]],"start": [["62"]],"entity_id": [["T3"]]},"Race": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]]},"Disorder": {"text": [["Central nervous system (CNS) toxicity"]],"start": [["15"]],"entity_id": [["T1"]]}},"Effect": {"text": [["Central nervous system (CNS) toxicity"]],"start": [["15"]],"entity_id": [["T1"]]},"Negated": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": false},"Speculated": {"text": [["described"]],"start": [["0"]],"entity_id": [["T0"]],"value": false},"Severity": {"text": [[""]],"start": [[""],[""]],"entity_id": [[""],[""]],"value": ""}}]}
{"id": "12796597_2","context": "Despite the underlying hepatitis C, this case represents renal abnormalities consistent with IFNalpha therapy for CML","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["renal abnormalities"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["IFNalpha therapy for CML"]],"start": [["56"]],"entity_id": [["T2"]],"Drug": {"text": [["IFNalpha"]],"start": [["56"]],"entity_id": [["T3"]]},"Disorder": {"text": [["CML"]],"start": [["64"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["Despite the underlying hepatitis C"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["consistent with"]],"start": [["42"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["hepatitis C"]],"start": [["8"]],"entity_id": [["T6"]]}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11131346_4","context": "To the best of our knowledge, this is the first time colchicine intoxication in this age group has been described in the English literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["colchicine intoxication"]],"start": [["11"]],"entity_id": [["T1"]]} ,"Subject": {"text": [["this age group"]],"start": [["31"]],"entity_id": [["T2"]] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["this age group"]],"start": [["31"]],"entity_id": [["T2"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["colchicine intoxication"]],"start": [["11"]],"entity_id": [["T1"]]}},"Treatment": {"text": [],"start": [],"entity_id": [] ,"Drug": {"text": [["colchicine"]],"start": [["11"]],"entity_id": [["T1"]]},"Disorder": {"text": [["colchicine intoxication"]],"start": [["11"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10904571_2", "context": "Colchicine-induced myopathy in renal failure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Colchicine-induced myopathy"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Treatment": {"text": [["Colchicine"]], "start": [[ "0" ]], "entity_id": [ ["T2" ]], "Drug": {"text": [["Colchicine"]], "start": [[ "0" ]], "entity_id": [ ["T3" ]]}, "Dosage": null, "Duration": null, "Disorder": {"text": [["renal failure"]], "start": [[ "42" ]], "entity_id": [ ["T4" ]]}, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null , "Effect": {"text": [["Colchicine-induced myopathy"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}}]}
{"id": "7679525_4","context": "This report suggests that bleomycin lung toxicity may be reversible if treated aggressively","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["bleomycin"]],"start": [[" "], [""], [""], ["b"]],"entity_id": []} ,"Disorder": {"text": [["bleomycin lung toxicity"]],"start": [[" "], ["r"], ["e"], ["b"]],"entity_id": []} ,"Time_elapsed": {"text": [["if treated aggressively"]],"start": [["i"]],"entity_id": []} ,"entity_id": [] ,"text": [["This report suggests that bleomycin lung toxicity may be reversible if treated aggressively"]],"start": [[], ["T"], ["r"], ["e"]],"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Effect": {"text": [["reversible"]],"start": [["r"]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null }] }
{"id": "15840734_8", "context": "NMS is a rare but potentially fatal reaction associated with neuroleptic drugs", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": {"value": "High", "text": [["potentially fatal"]], "start": [["26"]], "entity_id": []}, "Trigger": {"text": [["NMS"]], "start": [["0"]], "entity_id": []}, "Subject": {"text": [["NMS"]], "start": [["0"]], "entity_id": [], "Disorder": {"text": [["reaction"]], "start": [["4"]], "entity_id": []}, "Age": null, "Gender": null, "Population": null, "Race": null}, "Treatment": {"text": [["neuroleptic drugs"]], "start": [["36"]], "entity_id": [], "Drug": {"text": [["neuroleptic drugs"]], "start": [["36"]], "entity_id": []}, "Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null, "Disorder": {"text": [["reaction"]], "start": [["4"]], "entity_id": []}, "Trigger": null, "Combination": null}, "Effect": {"text": [["NMS"]], "start": [["0"]], "entity_id": []}}]}
{"id": "1378497_3", "context": "Scleroderma in association with the use of bleomycin: a report of 3 cases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use of bleomycin"]], "start": [["use of bleomycin's starting index"]], "entity_id": [["T1"]]}, "Subject": {"text": [["a report of 3 cases"]], "start": [[""], ["report's starting index"]], "entity_id": [["T2"]], "Population": {"text": [["3"]], "start": [[""], ["3's starting index"]], "entity_id": [["T3"]]},"Disorder": {"text": [["Scleroderma"]], "start": [[], []], "entity_id": [["T4"]]},"Gender": {"text": [["3 cases"]], "start": [[], ["3 cases' starting index"]], "entity_id": [["T5"]]},"Race": {"text": [["3 cases"]], "start": [[], ["3 cases' starting index"]], "entity_id": [["T5"]]},"Age": {"text": [["3 cases"]], "start": [[], ["3 cases' starting index"]], "entity_id": [["T5"]]}},"Effect": {"text": [["Scleroderma"]], "start": [[], []], "entity_id": [["T4"]]}, "Negated": null, "Speculated": null, "Severity": null, "Treatment": null}]}
{"id": "19733945_1","context": "Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute interstitial nephritis", "drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]],"start": [[ "0", "49" ]],"entity_id": [ ["T1", "T2"] ]},"Treatment": {"text": [["Linezolid"]],"start": [[ "0" ]],"entity_id": [ ["T3"] ],"Drug": {"text": [["Linezolid"]],"start": [[ "0" ]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["acute interstitial nephritis", "drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]],"start": [[ "0", "49" ]],"entity_id": [ ["T1", "T2"] ]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["acute interstitial nephritis", "drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]],"start": [[ "0", "49" ]],"entity_id": [ ["T1", "T2"] ]} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "16012330_5","context": "A 3-year-old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Subject": {"text": [["A 3-year-old boy"]],"start": [[ "A 3-year-old boy" ],[ "diagnosed" ]],"entity_id": [ ["S1"] ],"Age": {"text": [["3-year-old"]],"start": [[ "3-year-old" ]],"entity_id": [ ["A1"] ]},"Disorder": {"text": [["acute lymphoblastic leukemia"]],"start": [[ "diagnosed" ]],"entity_id": [ ["D1"] ]},"Gender": {"text": [["boy"]],"start": [[ "boy" ]],"entity_id": [ ["G1"] ]},"Population": {"text": [["A 3-year-old boy"]],"start": [[ "A 3-year-old boy" ]],"entity_id": [ ["Po1"] ]},"Race": {"text": [["A 3-year-old boy"]],"start": [[ "A 3-year-old boy" ]],"entity_id": [ ["R1"] ]}},"Treatment": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["D1"] ]},"Disorder": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["D2"] ]},"Dosage": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["D3"] ]},"Duration": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["D4"] ]},"Trigger": {"text": [["received"]],"start": [[ "received" ]],"entity_id": [ ["Tr1"] ]},"Route": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["R1"] ]},"Time_elapsed": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["Ti1"] ]},"Freq": {"text": [["induction chemotherapy"]],"start": [[ "received" ]],"entity_id": [ ["F1"] ]},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "17444802_14","context": "Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Topical INF alpha 2-beta"]],"start": [[ ]],"entity_id": [ ],"Disorder": {"text": [["CIN"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [["Topical"]],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [["for the treatment"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["a valid choice"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["Topical"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["for the treatment"]],"start": [[ ]],"entity_id": [ ]},"Combination": null,"Drug": {"text": [["INF alpha 2-beta"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "9247841_4","context": "We report 3 patients who developed cutaneous vasculitis which is a rare and serious side-effect during antithyroid drug therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["cutaneous vasculitis"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["antithyroid drug therapy"]],"start": [["69"]],"entity_id": [["T2"]],"Drug": {"text": [["antithyroid drug"]],"start": [["69"]],"entity_id": [["T3"]]} ,"Dosage" : {"text" : [["3"]],"start" : [["4"]],"entity_id" : [["T4"]]},"Duration" : {"text" : [["patients"]],"start" : [["11"]],"entity_id" : [["T5"]]} ,"Route" : {"text" : [["during"]],"start" : [["59"]],"entity_id" : [["T6"]]} ,"Time_elapsed" : {"text" : [["developed"]],"start" : [["20"]],"entity_id" : [["T7"]]} ,"Disorder" : {"text" : [["side-effect"]],"start" : [["42"]],"entity_id" : [["T8"]]} ,"Freq" : {"text" : [["rare"]],"start" : [["36"]],"entity_id" : [["T9"]]} ,"Combination" : [{"Drug" : {"text" : [["antithyroid drug"]],"start" : [["69"]],"entity_id" : [["T3"]]},"Trigger" : {"text" : [["therapy"]],"start" : [["77"]],"entity_id" : [["T10"]]} ,"event_type" : "Treatment","event_id" : "T11"}] ,"Trigger" : {"text" : [["antithyroid drug therapy"]],"start" : [["69"]],"entity_id" : [["T2"]]} },"Effect" : {"text" : [["cutaneous vasculitis"]],"start" : [["31"]],"entity_id" : [["T1"]]} ,"Negated" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : false },"Speculated" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : false },"Severity" : {"text" : [],"start" : [],"entity_id" : [] ,"value" : "serious" },"Subject" : {"text" : [["3 patients"]],"start" : [["7"]],"entity_id" : [["T12"]] ,"Age" : {"text" : [],"start" : [],"entity_id" : [] },"Disorder" : {"text" : [],"start" : [],"entity_id" : [] },"Gender" : {"text" : [],"start" : [],"entity_id" : [] },"Population" : {"text" : [],"start" : [],"entity_id" : [] },"Race" : {"text" : [],"start" : [],"entity_id" : [] }} }] }
{"id": "1621023_3","context": "Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["prominent eye movements during NREM sleep", "REM sleep behavior disorder"]],"start": [[ "0", "53" ]],"entity_id": [ ["T1", "T2" ]]},"Treatment": {"text": [["fluoxetine treatment"]],"start": [[ "65" ]],"entity_id": [ ["T3" ]],"Drug": {"text": [["fluoxetine"]],"start": [[ "65" ]],"entity_id": [ ["T4" ]]},"Disorder": {"text": [["depression", "obsessive-compulsive disorder"]],"start": [[ "97", "122" ]],"entity_id": [ ["T5", "T6" ]]} ,"Dosage": null,"Duration": null,"Trigger": {"text": [["treatment"]],"start": [["65" ]],"entity_id": [ ["T7" ]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [["patient"]],"start": [[ "0" ]],"entity_id": [ ["T8" ]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": { "text": [["prominent eye movements during NREM sleep", "REM sleep behavior disorder"]],"start": [[ "0", "53" ]],"entity_id": [ ["T1", "T2" ]]} }]}
{"id": "10963515_1","context": "Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Allergic reaction"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["gemfibrozil"]],"start": [[ "31"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["gemfibrozil"]],"start": [[ "31" ]],"entity_id": [ ["T2"] ]} ,"Combination": [ {"Drug": { "text": [["gemfibrozil"]],"start": [[ "31" ]],"entity_id": [ ["T2"] ]},"Trigger": { "text": [["manifesting as eosinophilic gastroenteritis"]],"start": [[ "43" ]],"entity_id": [ ["T3"] ]} ,"event_id": "C1","event_type": "Adverse_event" }], "Dosage": null,"Duration": null,"Disorder": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": { "text": [["manifesting as eosinophilic gastroenteritis"]],"start": [[ "43" ]],"entity_id": [ ["T3"] ]} }, "Subject": { "text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null, "Race": null } ,"Effect": { "text": [["Allergic reaction"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "16432996_14","context": "We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": {"text": [["may develop"]], "start": [["may develop].index]], ","entity_id]: [","Neg1"]],"entity_id": [["Neg1"]],"value": true},"Trigger": {"text": [["sarcoidosis"]],"start": [["sarcoidosis","index]], ","entity_id"]],"entity_id": [["Trig1"]]},"Subject": {"text": [["chronic hepatitis C patients"]],"start": [["chronic hepatitis C patients","index]], ","entity_id"]],"entity_id": [["Subj1"]],"Age": null,"Gender": null,"Population": {"text": [["patients"]], "start": [["patients","index]], ","entity_id"]],"entity_id": [["Pop1"]]},"Disorder": null,"Race": null},"Treatment": {"text": [["interferon alpha and/or ribavirin treatment"]],"start": [["interferon alpha and/or ribavirin treatment","index]], ","entity_id"]],"entity_id": [["Trmt1"]],"Drug": {"text": [["interferon alpha", "ribavirin"]],"start": [["interferon alpha","ribavirin","index]], ","entity_id"]],"entity_id": [["Drug1"], ["Drug2"]]},"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["during"]],"start": [["during","index]], ","entity_id"]],"entity_id": [["Trig2"]]}},"Effect": {"text": [["diagnostic tests for this adverse effect"]],"start": [["diagnostic tests for this adverse effect","index]], ","entity_id"]],"entity_id": [["Efct1"]]},"Severity": null}]}
{"id": "25417855_2","context": "Azole antifungals, prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients, can interact with drug substrates of CYP3A4","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Azole antifungals"]],"start": [[ "0" ]],"entity_id": [],"Dosage": {"text": [["prescribed prophylactically"]],"start": [[ "22" ]],"entity_id": []},"Disorder": {"text": [["to avoid severe infections"]],"start": [[ "41" ]],"entity_id": []},"Trigger": {"text": [["can interact"]],"start": [[ "63" ]],"entity_id": []},"Freq": {"text": [["can interact"]],"start": [[ "63" ]],"entity_id": []},"Route": {"text": [["prescribed prophylactically"]],"start": [[ "22" ]],"entity_id": []},"Time_elapsed": {"text": [["can interact"]],"start": [[ "63" ]],"entity_id": []} ,"Drug": {"text": [["Azole antifungals"]],"start": [[ "0" ]],"entity_id": []} ,"Duration": {"text": [["prescribed prophylactically"]],"start": [[ "22" ]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["Azole antifungals"]],"start": [[ "0" ]],"entity_id": []},"Trigger": {"text": [["can interact"]],"start": [[ "63" ]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Interaction" }] },"Subject": {"text": [["immunosuppressed organ transplant recipients"]],"start": [[ "82" ]],"entity_id": [] ,"Population": {"text": [["immunosuppressed organ transplant recipients"]],"start": [[ "82" ]],"entity_id": []} ,"Disorder": {"text": [["immunosuppressed"]],"start": [[ "82" ]],"entity_id": []},"Gender": {"text": [["immunosuppressed"]],"start": [[ "82" ]],"entity_id": []},"Race": {"text": [["immunosuppressed"]],"start": [[ "82" ]],"entity_id": []} ,"Age": {"text": [["immunosuppressed"]],"start": [[ "82" ]],"entity_id": []} },"Effect": {"text": [["interact with drug substrates"]],"start": [[ "105" ]],"entity_id": [] },"Trigger": {"text": [["can interact"]],"start": [[ "63" ]],"entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "11576059_2","context": "We present the case of a 5-year-old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["bilateral vocal cord paralysis"]],"start": [["52"]],"entity_id": [["T1"]]},"Treatment": {"text": [["peritonsillar bupivacaine infiltration"]],"start": [["90"]],"entity_id": [["T2"]],"Drug": {"text": [["bupivacaine"]],"start": [["90"]],"entity_id": [["T3"]]} ,"Route": {"text": [["infiltration"]],"start": [["90"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["86"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["preoperative"]],"start": [["78"]],"entity_id": [["T6"]]},"Freq": {"text": [["a"]],"start": [["47"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [["5-year-old"]],"start": [["20"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["developed"]],"start": [["45"]],"entity_id": [["T9"]]} ,"Trigger": {"text": [["following"]],"start": [["86"]],"entity_id": [["T10"]]} ,"Combination": null} ,"Subject": {"text": [["a"]],"start": [["17"]],"entity_id": [["T11"]],"Age": {"text": [["5-year-old"]],"start": [["20"]],"entity_id": [["T12"]]} ,"Gender": {"text": [["girl"]],"start": [["24"]],"entity_id": [["T13"]]} ,"Population": null,"Race": null,"Disorder": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null}]}
{"id": "20338114_1","context": "One patient suffered coronary artery vasospasm, attributed to the use of topical 1:1000 epinephrine during surgery","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["coronary artery vasospasm"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["topical 1:1000 epinephrine"]],"start": [["54"]],"entity_id": [["T2"]],"Drug": {"text": [["epinephrine"]],"start": [["54"]],"entity_id": [["T3"]]},"Route": {"text": [["topical"]],"start": [["54"]],"entity_id": [["T4"]]},"Disorder": {"text": [["coronary artery vasospasm"]],"start": [["18"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["during surgery"]],"start": [["74"]],"entity_id": [["T5"]]},"Combination": null,"Trigger": null,"Dosage": null,"Duration": null,"Freq": null},"Subject": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "16396068_1","context": "Trimethoprim-sulfamethoxazole-induced aseptic meningitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Trimethoprim-sulfamethoxazole-induced"]],"start": [[ ]],"entity_id": []},"Effect": {"text": [["aseptic meningitis"]],"start": [[ ]],"entity_id": []},"Treatment": {"Drug": {"text": [["Trimethoprim-sulfamethoxazole"]],"start": [[ ]],"entity_id": []} ,"text": [["Trimethoprim-sulfamethoxazole"]],"start": [[ ]],"entity_id": [] ,"Disorder": {"text": [["aseptic meningitis"]],"start": [[ ]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["Trimethoprim-sulfamethoxazole-induced"]],"start": [[ ]],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }} ]}
{"id": "9256906_4","context": "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["patient"]],"start": [["9"]],"entity_id": [["Sub1"]],"Age": {"text": [["patient with metastatic prostate cancer"]], "start": [["9"]], "entity_id": [["Sub1A"]]},"Disorder": {"text": [["metastatic prostate cancer"]], "start": [["25"]], "entity_id": [["Sub1D"]]},"Gender": {"text": [["patient"]], "start": [["9"]], "entity_id": [["Sub1G"]]},"Population": {"text": [["a patient"]], "start": [["9"]], "entity_id": [["Sub1P"]]},"Race": {"text": [["patient"]], "start": [["9"]], "entity_id": [["Sub1R"]]}},"Treatment": {"text": [["treatment with suramin"]],"start": [["72"]],"entity_id": [["Treat1"]],"Drug": {"text": [["suramin"]], "start": [["72"]], "entity_id": [["Treat1D"]]},"Duration": {"text": [["treatment"]], "start": [["72"]], "entity_id": [["Treat1Du"]]},"Disorder": {"text": [["treatment with suramin"]], "start": [["72"]], "entity_id": [["Treat1Di"]]},"Route": {"text": [["treatment with suramin"]], "start": [["72"]], "entity_id": [["Treat1R"]]},"Time_elapsed": {"text": [["during treatment with suramin"]], "start": [["72"]], "entity_id": [["Treat1T"]]},"Trigger": {"text": [["treatment with suramin"]], "start": [["72"]], "entity_id": [["Treat1Tr"]]},"Freq": {"text": [["treatment with suramin"]], "start": [["72"]], "entity_id": [["Treat1F"]]},"Combination": [{"Drug": {"text": [["suramin"]], "start": [["72"]], "entity_id": [["Treat1DC"]]}, "Trigger": {"text": [["treatment"]], "start": [["72"]], "entity_id": [["Treat1TrC"]]}, "event_id": "C1", "event_type": "Treatment"}],"Dosage": {"text": [["treatment"]], "start": [["72"]], "entity_id": [["Treat1Do"]]}},"Effect": {"text": [["renal failure"]],"start": [["100"]],"entity_id": [["Eff1"]]},"Trigger": {"text": [["developed"]],"start": [["83"]],"entity_id": [["Trig1"]]},"Severity": {"text": [["nonoliguric"]], "start": [["83"]], "entity_id": [["Sev1"]], "value": "high"},"Negated": {"text": [["did not develop"]],"start": [["83"]],"entity_id": [["Neg1"]],"value": false},"Speculated": {"text": [["developed"]],"start": [["83"]],"entity_id": [["Spe1"]],"value": false}}]}
{"id": "15685264_7","context": "After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Carbamazepine intoxication"]],"start": [["82"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Oxybutynin", "Dantrolene"]],"start": [["21","45"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["Oxybutynin","Dantrolene"]],"start": [["21","45"]],"entity_id": [["T2","T3"]]},"Dosage": {"text": [["an increase in the dose"]],"start": [["37"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["after administration"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [["Carbamazepine intoxication"]],"start": [["82"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["presented"]],"start": [["65"]],"entity_id": [["T6"]]} ,"Trigger": null,"Route": null,"Freq": null,"Combination": null},"Subject": {"text": [["she"]],"start": [["58"]],"entity_id": [["T7"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": {"text": [["Carbamazepine intoxication"]],"start": [["82"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "21597286_4","context": "A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["methotrexate overdosage"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["methotrexate"]],"start": [["0"]],"entity_id": [ ["T2"] ],"Dosage": {"text": [["overdosage"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Time_elapsed": {"text": [["36 h after infusion"]],"start": [["31"]],"entity_id": [ ["T3"] ]} ,"Trigger": {"text": [["shown"]],"start": [["0"]],"entity_id": [ ["T4"] ]} ,"Disorder": {"text": [["severe renal failure"]],"start": [["58"]],"entity_id": [["T5"] ]} ,"Freq": {"text": [["shown"]],"start": [["0"]],"entity_id": [ ["T4"] ]} ,"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["0"]],"entity_id": [ ["T2"] ]},"Trigger": {"text": [["overdosage"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"event_type": "Adverse_event","event_id": "E1"} ],"Route": {"text": [["infusion"]],"start": [["43"]],"entity_id": [ ["T6"] ]} ,"Duration": {"text": [["overdosage"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Drug": {"text": [["methotrexate"]],"start": [["0"]],"entity_id": [ ["T2"] ]} },"Effect": {"text": [["severe renal failure"]],"start": [["58"]],"entity_id": [["T5"] ]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["58"]],"entity_id": [ ["T5"] ],"value": "high"} ,"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [ ["T7"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} }]}
{"id": "7594371_4", "context": "We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a 20-year-old female"]], "start": [[" "], ["]"]], "entity_id": [["S1"]],"Age": {"text": [["20"]], "start": [["]"]], "entity_id": [["S2"]]},"Gender": {"text": [["female"]], "start": [["]"]], "entity_id": [["S3"]]},"Disorder": {"text": [["polyarteritis nodosa (PAN)"]], "start": [["]"]], "entity_id": [["S4"]]},"Race": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []}},"Trigger": {"text": [["developed"]], "start": [[","]], "entity_id": [["T1"]]},"Treatment": {"text": [["30 mg of intravenous ketoralac"]], "start": [[","]], "entity_id": [["T2"]],"Drug": {"text": [["ketoralac"]], "start": [[","]], "entity_id": [["T3"]]},"Dosage": {"text": [["30 mg"]], "start": [[","]], "entity_id": [["T4"]]},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [["intravenous"]], "start": [[","]], "entity_id": [["T5"]]},"Time_elapsed": {"text": [["25 minutes"]], "start": [[","]], "entity_id": [["T6"]]},"Disorder": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [],"Trigger": null},"Effect": {"text": [["bilateral sensorineural hearing loss"]], "start": [[","]], "entity_id": [["T7"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19915794_4","context": "We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["ventricular tachycardia", "Torsades de Pointes (TdP)"]],"start": [["25", "57"]],"entity_id": [["T1", "T2"]]},"Treatment": {"text": [["garenoxacin"]],"start": [["115"]],"entity_id": [["T3"]],"Drug": {"text": [["garenoxacin"]],"start": [["115"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["pneumonia"]],"start": [["163"]],"entity_id": [["T4"]]} ,"Route": {"text": [["oral administration"]],"start": [["79"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["35"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["developed"]],"start": [["25"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["after oral administration"]],"start": [["79"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Trigger": {"text": [[]],"start": [[]],"entity_id": [[]]} ,"Combination": [{"Drug": {"text": [["garenoxacin"]],"start": [["115"]],"entity_id": [["T3"]]},"Trigger": {"text": [["oral administration"]],"start": [["79"]],"entity_id": [["T5"]]} ,"event_id": "C1","event_type": "Adverse_event"} ]} ,"Subject": {"text": [["an 82-year-old man"]],"start": [["6"]],"entity_id": [["T0"]],"Age": {"text": [["82"]],"start": [["8"]],"entity_id": [["T7"]]},"Gender": {"text": [["man"]],"start": [["16"]],"entity_id": [["T8"]]},"Disorder": {"text": [[]],"start": [[]],"entity_id": []},"Race": {"text": [[]],"start": [[]],"entity_id": []} ,"Population": {"text": [[]],"start": [[]],"entity_id": []} },"Effect": {"text": [["ventricular tachycardia and Torsades de Pointes (TdP)"]],"start": [["25", "57"]],"entity_id": [["T1", "T2"]]},"Negated": {"text": [[]],"start": [[]],"entity_id": [] ,"value": false },"Speculated": {"text": [[]],"start": [[]],"entity_id": [],"value": false },"Severity": {"text": [],"start": [],"entity_id": [],"value": "" }} ] }
{"id": "12951892_1", "context": "Lethargy in a newborn: lithium toxicity or lab error?", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["newborn"]], "start": [["Lethargy in a ", "a"]], "entity_id": [["S1"]], "Age": {"text": [["newborn"]], "start": [["Lethargy in a "]], "entity_id": [["S2"]]}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [], "start": [], "entity_id": [], "Drug": {"text": [["lithium"]], "start": [["lithium"]], "entity_id": [["T1"]]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null}, "Effect": {"text": [["Lethargy"]], "start": [["Lethargy in a "]], "entity_id": [["E1"]]}, "Negated": null, "Speculated": null, "Severity": null, "Trigger": {"text": [], "start": [], "entity_id": []}}]}
{"id": "18344455_1", "context": "Simultaneous toxicities in a child on multiple anticonvulsants", "is_mult_event": true, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["toxicities"]], "start": [["17"]], "entity_id": []}, "Subject": {"text": [["a child"]], "start": [["8"]], "entity_id": [],"Age":{"text":[],"start":[[]],"entity_id":[]},"Gender":{"text":[],"start":[[]],"entity_id":[]},"Population":{"text":[],"start":[[]],"entity_id":[]},"Race":{"text":[],"start":[[]],"entity_id":[]},"Disorder":{"text":[],"start":[[]],"entity_id":[]}}, "Treatment": {"text": [["multiple anticonvulsants"]], "start": [["31"]], "entity_id": [],"Drug":{"text":[],"start":[[]],"entity_id":[]},"Dosage":{"text":[],"start":[[]],"entity_id":[]},"Duration":{"text":[],"start":[[]],"entity_id":[]},"Trigger":{"text":[],"start":[[]],"entity_id":[]},"Route":{"text":[],"start":[[]],"entity_id":[]},"Time_elapsed":{"text":[],"start":[[]],"entity_id":[]},"Freq":{"text":[],"start":[[]],"entity_id":[]},"Combination": null,"Disorder":{"text":[["anticonvulsants"]],"start":[[ "31" ]],"entity_id":[ ]}}, "Negated": null, "Speculated": null, "Severity": null, "Effect": null}]}
{"id": "17404582_3","context": "We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["docetaxel"]],"start": [["75"]],"entity_id": [["T1"]]},"Dosage": {"text": [["weekly"]],"start": [["64"]],"entity_id": [["T2"]]},"Duration": {"text": [["12 weeks"]],"start": [["98"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["108"]],"entity_id": [["T4"]]},"Disorder": {"text": [["castration-resistant metastatic prostate cancer"]],"start": [["16"]],"entity_id": [["T5"]]},"Route": {"text": [["during"]],"start": [["167"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["developed"]],"start": [["125"]],"entity_id": [["T7"]]},"Freq": {"text": [["significant eye irritation and dryness"]],"start": [["172"]],"entity_id": [["T8"]]},"entity_id": [["E1"]],"text": [["developed significant eye irritation and dryness during treatment"]],"start": [["125"]],"Combination": [{"Drug": {"text": [["docetaxel"]],"start": [["75"]],"entity_id": [["T1"]]},"Trigger": {"text": [["treatment"]],"start": [["108"]],"entity_id": [["T4"]]},"event_id": "E1","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["a 71-year male"]],"start": [["8"]],"entity_id": [["T9"]],"Gender": {"text": [["male"]],"start": [["21"]],"entity_id": [["T10"]]},"Age": {"text": [["71-year"]],"start": [["9"]],"entity_id": [["T11"]]},"Population": {"text": [["We report"]],"start": [["0"]],"entity_id": [["T12"]]},"Disorder": {"text": [["castration-resistant metastatic prostate cancer"]],"start": [["16"]],"entity_id": [["T5"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["significant"]],"start": [["172"]],"entity_id": [["T13"]],"value": "high"},"Trigger": null,"Effect": {"text": [["eye irritation and dryness"]],"start": [["172"]],"entity_id": [["T14"]]}}]}
{"id": "24791374_1","context": "Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe central nervous system"]],"start": [["20"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Propafenone"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["Propafenone"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["cardiovascular toxicity"]],"start": [["34"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["due to mirtazapine"]],"start": [["55"]],"entity_id": [["T5"]]},"Dosage": {"text": [["severe"]],"start": [["6"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Propafenone associated severe central nervous system and cardiovascular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["Propafenone"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["cardiovascular toxicity"]],"start": [["34"]],"entity_id": [["T4"]]},"event_id": "E1","event_type": "Adverse_event"}],"Freq": {"text": [["severe drug interaction"]],"start": [["63"]],"entity_id": [["T6"]]},"Route": {"text": [["due to mirtazapine"]],"start": [["55"]],"entity_id": [["T5"]]},"Duration": {"text": [["Propafenone associated severe central nervous system and cardiovascular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["6"]],"entity_id": [["T0"]],"value": "high"},"Subject": {"text": [["a case"]],"start": [["52"]],"entity_id": [["T7"]],"Population": {"text": [["a case"]],"start": [["52"]],"entity_id": [["T7"]]},"Age": null,"Gender": null,"Race": null,"Disorder": {"text": [["Propafenone associated severe central nervous system and cardiovascular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["Propafenone associated severe central nervous system and cardiovascular toxicity"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "582099_2", "context": "Neurotoxicity of intrathecal administration of amphotericin B", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Neurotoxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["intrathecal administration of amphotericin B"]], "start": [[ "22" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["amphotericin B"]], "start": [[ "36" ]], "entity_id": [ ["T3"] ]} ,"Freq": null, "Dosage": null, "Route": {"text": [["of"]], "start": [[ "22" ]], "entity_id": [ ["T4"] ]}, "Time_elapsed": null, "Duration": null, "Disorder": null, "Combination": null ,"Trigger": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null }]}
{"id": "9220046_3","context": "DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Rhabdomyolysis"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["lovastatin"]],"start": [["100"]],"entity_id": [["T2"]],"Drug": {"text": [["lovastatin"]],"start": [["100"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Rhabdomyolysis"]],"start": [["13"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["a hydroxymethylglutaryl-coenzyme A reductase inhibitor"]],"start": [["118"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["has been associated"]],"start": [["87"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["Several drugs"]],"start": [["67"]],"entity_id": [["T5"]]} ,"Route": {"text": [["with"]],"start": [["97"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["Several drugs"]],"start": [["67"]],"entity_id": [["T5"]]} ,"Combination": [{"event_id": "E1","Drug": {"text": [["lovastatin"]],"start": [["100"]],"entity_id": [["T2"]]},"Trigger": {"text": [["has been associated"]],"start": [["87"]],"entity_id": [["T4"]]} ,"event_type": "Adverse_event"}] ,"Trigger": {"text": [["Rhabdomyolysis"]],"start": [["13"]],"entity_id": [["T1"]]} },"Subject": {"text": [["Several drugs"]],"start": [["67"]],"entity_id": [["T5"]],"Disorder": {"text": [["Rhabdomyolysis"]],"start": [["13"]],"entity_id": [["T1"]]} ,"Population": {"text": [["Several drugs"]],"start": [["67"]],"entity_id": [["T5"]]} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Effect": {"text": [["Rhabdomyolysis"]],"start": [["13"]],"entity_id": [["T1"]]}} ]}
{"id": "16960880_3","context": "Native arterial thrombosis, though recognized as a severe complication of thrombin injection, has not been well described in the literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Native arterial thrombosis"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["thrombin injection"]],"start": [[ "67" ]],"entity_id": [["T2"]],"Drug": {"text": [["thrombin"]],"start": [[ "67" ]],"entity_id": [["T3"]]},"Route": {"text": [["injection"]],"start": [[ "81" ]],"entity_id": [["T4"]]},"Disorder": {"text": [["Native arterial thrombosis"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["severe complication"]],"start": [[ "25" ]],"entity_id": [["T5"]]},"Freq": {"text": [["not been well described"]],"start": [[ "91" ]],"entity_id": [["T6"]]},"Trigger": {"text": [["has not been well described"]],"start": [[ "91" ]],"entity_id": [["T6"]]},"Dosage": {"text": [["not provided"]],"start": [[ "91" ]],"entity_id": [["T6"]]},"Duration": {"text": [["not provided"]],"start": [[ "91" ]],"entity_id": [["T6"]]},"Combination": null},"Subject": {"text": [["Native arterial thrombosis"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["severe complication"]],"start": [[ "25" ]],"entity_id": [["T5"]],"value": "high"}}]}
{"id": "8002140_3","context": "Five cases of contact dermatitis due to budesonide, a nonhalogenated steroid, are described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["contact dermatitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["budesonide"]],"start": [["50"]],"entity_id": [["T2"]],"Drug": {"text": [["budesonide"]],"start": [["50"]],"entity_id": [["T2"]]},"Disorder": {"text": [["contact dermatitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Route": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Time_elapsed": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Freq": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Combination": [{"Drug": {"text": [["budesonide"]],"start": [["50"]],"entity_id": [["T2"]]},"Trigger": {"text": [["contact dermatitis"]],"start": [["0"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]}},"Subject": {"text": [["Five cases"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["Five cases"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]]},"Disorder": {"text": [["contact dermatitis"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["contact dermatitis"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": false},"Severity": {"text": [["null"]],"start": [[""], [""]],"entity_id": [["null"]],"value": "null"}}]}
{"id": "1124417_3", "context": "This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["sulfonamide like nephropathy"]], "start": [["0"]], "entity_id": [ ["T1"]]},"Treatment": {"Drug": {"text": [["sulfonamide"]], "start": [["0"]], "entity_id": [ ["T2"]]} , "text": [["acetazolamide"]], "start": [["58"]], "entity_id": [ ["T3"]] , "Disorder": {"text": [["calcium phosphate nephrolithiasis"]], "start": [["88"]], "entity_id": [ ["T4"]] }, "Route": {"text": [["related"]], "start": [["57"]], "entity_id": [ ["T3"]] }, "Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Combination": null , "Trigger": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null }]}
{"id": "17420198_18","context": "Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": {"text": [["lack"]],"start": [["23"]],"entity_id": [],"value": true},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["Aripiprazole"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["OCD"]],"start": [["51"]],"entity_id": []}},"Treatment": {"text": [["Aripiprazole"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Aripiprazole"]],"start": [["0"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["OCD"]],"start": [["51"]],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["lack of efficacy", "movement disorder"]],"start": [["23","93"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "8908396_1", "context": "In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["the injected insulin"]], "start": [[ ]], "entity_id": [],"Drug":{"text":[["insulin"]],"start":[[ ]],"entity_id":[]},"Disorder":{"text":[["the injected insulin"]], "start":[[ ]],"entity_id":[]},"Route":{"text":[["injected"]],"start":[[ ]],"entity_id":[]},"Time_elapsed":{"text":[["that was induced by"]], "start":[[ ]],"entity_id":[]},"Trigger":{"text":[["the injected insulin"]], "start":[[ ]],"entity_id":[]},"Freq":{"text":[["local"]], "start":[[ ]],"entity_id":[]},"Combination":[{"Drug":{"text":[["dexamethasone"]],"start":[[ ]],"entity_id":[]},"Trigger":{"text":[["the local injection"]], "start":[[ ]],"entity_id":[]},"event_id":"E2","event_type":"Potential_therapeutic_effect"} ],"Duration":{"text":[["local injection"]], "start":[[ ]],"entity_id":[]},"Dosage":{"text":[["dexamethasone"]],"start":[[ ]],"entity_id":[]}},"Effect":{"text":[["dedifferentiation of the adipocytes"]], "start":[[ ]],"entity_id":[]},"Negated":null,"Speculated":null,"Severity":null,"Subject":{"text":[["our reported case"]], "start":[[ ]],"entity_id":[],"Age":null,"Disorder":{"text":[["our reported case"]], "start":[[ ]],"entity_id":[]},"Gender":null,"Population":null,"Race":null},"Trigger":{"text":[["a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain"]], "start":[[ ]],"entity_id":[]}}] }
{"id": "11144696_9","context": "Both venlafaxine and trimipramine have been associated with seizures, mainly after overdose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T3"]]},"Treatment": {"text": [["venlafaxine"]],"start": [["13"]],"entity_id": [["T1"]],"Drug": {"text": [["venlafaxine"]],"start": [["13"]],"entity_id": [["T1"]]},"Disorder": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T3"]]},"Trigger": {"text": [["after overdose"]],"start": [["53"]],"entity_id": [["T4"]]},"Route": {"text": [["after overdose"]],"start": [["53"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after overdose"]],"start": [["53"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["venlafaxine"]],"start": [["13"]],"entity_id": [["T1"]]},"Trigger": {"text": [["and"]],"start": [["25"]],"entity_id": [["T2"]]},"event_id": "E2","event_type": "Adverse_event"}],"Freq": {"text": [["mainly"]],"start": [["45"]],"entity_id": [["T5"]]},"Duration": {"text": [["mainly"]],"start": [["45"]],"entity_id": [["T5"]]},"Dosage": {"text": [["after overdose"]],"start": [["53"]],"entity_id": [["T4"]]}},"Effect": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T3"]]},"Severity": {"text": [["seizures"]],"start": [["35"]],"entity_id": [["T3"]],"value": "high"},"Negated": {"text": [["not"]],"start": [[],[]],"entity_id": [["N1"]],"value": false},"Speculated": {"text": [["have been associated"]],"start": [[],[]],"entity_id": [["S1"]],"value": false},"Subject": {"text": [[],[],[],[],[],[]],"start": [[],[],[],[],[],[]],"entity_id": [["S1"],["S2"],["S3"],["S4"],["S5"],["S6"]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [["A1"]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [["A2"]]},"Population": {"text": [["Both"]],"start": [[],[]],"entity_id": [["A3"]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [["A4"]]},"Disorder": {"text": [["seizures"]],"start": [[],[]],"entity_id": [["A5"]]}}}]}
{"id": "14674674_2", "context": "Infliximab-induced lupus in Crohn's disease: a case report", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Infliximab-induced lupus"]], "start": [[ "0" ]], "entity_id": []}, "Treatment": {"text": [["Infliximab"]], "start": [[ "13" ]], "entity_id": [],"Drug": {"text": [["Infliximab"]], "start": [[ "13" ]], "entity_id": []} ,"Disorder": {"text": [["lupus"]], "start": [[ "17" ]], "entity_id": []} ,"Duration": {"text": [["Crohn's disease"]], "start": [[ "47" ]], "entity_id": []} ,"Combination": [{"event_type": "Adverse_event", "event_id": "E2", "Drug": {"text": [["Infliximab"]], "start": [[ "13" ]], "entity_id": []} ,"Trigger": {"text": [["lupus"]], "start": [[ "17" ]], "entity_id": []} } ] ,"Time_elapsed": null, "Freq": null, "Route": null, "Dosage": null, "Trigger": null } ,"Subject": { "text": [["a case report"]], "start": [[ "95" ]], "entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["Crohn's disease"]], "start": [[ "47" ]], "entity_id": []} } ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "10660641_7","context": "The infection tended to subside with the AMPH administration","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["AMPH administration"]],"start": [["The infection tended to subside with the AMPH administration" , "tended to subside with the AMPH administration" ]],"entity_id": []},"Treatment": {"text": [["AMPH administration"]],"start": [["The infection tended to subside with the AMPH administration" , "tended to subside with the AMPH administration" ]],"entity_id": [],"Drug": {"text": [["AMPH"]],"start": [[ "AMPH administration" ]],"entity_id": []},"Disorder": {"text": [["infection"]],"start": [[ "The infection tended to subside with the AMPH administration" ]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": null,"Effect": {"text": [["subside"]],"start": [[ "The infection tended to subside with the AMPH administration" , "tended to subside with the AMPH administration" ]],"entity_id": []},"Severity": null,"Speculated": null,"Negated": null}]}
{"id": "17228132_2","context": "Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor (EGFR) inhibitors","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute drug induced hepatitis"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["epidermal growth factor receptor (EGFR) inhibitors"]],"start": [[ "72"]],"entity_id": [["T2"]],"Drug": {"text": [["epidermal growth factor receptor"]],"start": [[ "72"]],"entity_id": [["T3"]]},"Disorder": {"text": [["inhibitors"]],"start": [[ "88"]],"entity_id": [["T4"]]},"Freq": {"text": [["not commonly"]],"start": [[ "52"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["epidermal growth factor receptor"]],"start": [[ "72"]],"entity_id": [["T3"]]},"Trigger": {"text": [["inhibitors"]],"start": [[ "88"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["not been commonly associated"]],"start": [[ "52"]],"entity_id": [["T5"]]},"Trigger": {"text": [["acute drug induced hepatitis"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Route": {"text": [[]],"start": [],"entity_id": []}},"Subject": {"text": [[ ]],"start": [[ ]],"entity_id": [[ ]],"Age": {"text": [[]],"start": [],"entity_id": []},"Disorder": {"text": [[ ]],"start": [[ ]],"entity_id": [[ ]]},"Gender": {"text": [[ ]],"start": [[ ]],"entity_id": [[ ]]},"Population": {"text": [[ ]],"start": [[ ]],"entity_id": [[ ]]},"Race": {"text": [[ ]],"start": [[ ]],"entity_id": [[ ]]}},"Effect": {"text": [["acute drug induced hepatitis"]],"start": [[ "0" ]],"entity_id": [[ "T1" ]]},"Negated": {"text": [[]],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [[]],"start": [],"entity_id": [],"value": false},"Severity": {"text": [[]],"start": [],"entity_id": [],"value": ""}}]}
{"id": "17873198_5","context": "We report a case of fatal pulmonary toxicity in a patient with advanced non-small cell lung cancer who received erlotinib","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fatal pulmonary toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["patient"]],"start": [["5"]],"entity_id": [["T2"]],"Disorder": {"text": [["advanced non-small cell lung cancer"]],"start": [["46"]],"entity_id": [["T3"]]} ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["erlotinib"]],"start": [["92"]],"entity_id": [["T4"]],"Drug": {"text": [["erlotinib"]],"start": [["92"]],"entity_id": [["T5"]]},"Disorder": {"text": [["lung cancer"]],"start": [["73"]],"entity_id": [["T6"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []}} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "High"} ,"Effect": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "16200540_4","context": "We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["augmentation"]],"start": [["61"]],"entity_id": [["T1"]]},"Treatment": {"text": [["levodopa treatment"]],"start": [["47"]],"entity_id": [["T2"]],"Drug": {"text": [["levodopa"]],"start": [["47"]],"entity_id": [["T3"]]},"Duration": {"text": [["8 months"]],"start": [["56"]],"entity_id": [["T4"]]},"Disorder": {"text": [["idiopathic RLS"]],"start": [["17"]],"entity_id": [["T5"]]},"Freq": {"text": [["after"]],"start": [["54"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["8 months"]],"start": [["56"]],"entity_id": [["T4"]]},"Trigger": {"text": [["after"]],"start": [["54"]],"entity_id": [["T6"]]},"Route": {"text": [["levodopa treatment"]],"start": [["47"]],"entity_id": [["T2"]]},"Dosage": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]]},"Combination": [{"Drug": {"text": [["levodopa"]],"start": [["47"]],"entity_id": [["T3"]]},"Trigger": {"text": [["after"]],"start": [["54"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["a patient"]],"start": [["8"]],"entity_id": [["T7"]],"Age": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]]},"Population": {"text": [["1"]],"start": [["8"]],"entity_id": [["T7"]]},"Race": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]]},"Disorder": {"text": [["idiopathic RLS"]],"start": [["17"]],"entity_id": [["T5"]]}},"Effect": {"text": [["augmentation"]],"start": [["61"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]],"value": false},"Severity": {"text": [["null"]],"start": [[""]],"entity_id": [["null"]],"value": "null"}}]}
{"id": "3753891_2", "context": "In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null, "Effect": {"text": [["myocardial necrosis"]], "start": [["36"]], "entity_id": [["E2"]]}, "Trigger": {"text": [["further manifestation"]], "start": [["51"]], "entity_id": [["T3"]]}} , {"event_id": "E2", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"text": [["amsacrine"]], "start": [["16"]], "entity_id": [["T1"]],"Drug": {"text": [["amsacrine"]], "start": [["16"]], "entity_id": [["T5"]]},"Disorder": {"text": [["cardiotoxicity"]], "start": [["42"]], "entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null}, "Effect": null,"Trigger": {"text": [["arrhythmic complications"]], "start": [["7"]], "entity_id": [["T2"]]}}]}
{"id": "2857534_2","context": "The authors caution that treatment with alprazolam may be complicated by the induction of mania","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["alprazolam"]],"start": [["32"]],"entity_id": [["T1"]]},"Disorder": {"text": [["the induction of mania"]],"start": [["60"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["complicated"]],"start": [["43"]],"entity_id": [["T3"]]} ,"entity_id": [["T1","T2","T3"]] ,"text": [["treatment with alprazolam may be complicated by the induction of mania"]],"start": [["0"]], "Time_elapsed": null,"Freq": null,"Dosage": null,"Duration": null,"Route": null ,"Combination": null },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }] }
{"id": "17596682_2","context": "The use of rituximab has been uncommonly associated with delayed pulmonary toxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["uncommonly associated"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["rituximab"]],"start": [["19"]],"entity_id": [],"Drug": {"text": [["rituximab"]],"start": [["19"]],"entity_id": []} ,"Disorder": {"text": [["delayed pulmonary toxicity"]],"start": [["47"]],"entity_id": []} ,"Freq": {"text": [["uncommonly"]],"start": [["16"]],"entity_id": []} ,"Time_elapsed": {"text": [["delayed"]],"start": [["44"]],"entity_id": []} ,"Trigger": {"text": [["associated"]],"start": [["38"]],"entity_id": []} ,"Route": {"text": [["use"]],"start": [["5"]],"entity_id": []} ,"Combination": [] ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} }]}
{"id": "18515982_6","context": "We believe that the acute renal failure in our patient was associated with anastrozole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["anastrozole"]],"start": [["72"]],"entity_id": [["T2"]],"Drug": {"text": [["anastrozole"]],"start": [["72"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["was associated"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["was"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["anastrozole"]],"start": [["72"]],"entity_id": [["T2"]]},"Trigger": {"text": [["was associated"]],"start": [["41"]],"entity_id": [["T3"]]} ,"event_type": "Adverse_event","event_id": "E1"}] ,"Trigger": {"text": [["was associated"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["acute"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["was"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Route": {"text": [["was associated"]],"start": [["41"]],"entity_id": [["T3"]]}},"Subject": {"text": [["our patient"]],"start": [["28"]],"entity_id": [["T4"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]} },"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []} ,"Severity": {"value": "","text": [],"start": [],"entity_id": []} ,"Effect": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]} }]}
{"id": "6159523_2","context": "Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50% solution of dextrose","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["anaphylactoid reaction"]],"start": [["39"]],"entity_id": [["T1"]]},"Subject": {"text": [["Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus"]],"start": [["0"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["extrinsic asthma", "insulin-dependent diabetes mellitus"]],"start": [[ "5", "32"]],"entity_id": [["T3"], ["T4"]]}},"Treatment": {"text": [["50% solution of dextrose"]],"start": [["75"]],"entity_id": [["T5"]],"Drug": {"text": [["dextrose"]],"start": [["75"]],"entity_id": [["T6"]]},"Disorder": null,"Dosage": null,"Duration": null,"Freq": null,"Route": {"text": [["intravenous administration"]],"start": [["59"]],"entity_id": [["T7"]]},"Time_elapsed": null,"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "17277758_3","context": "Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["intravitreal injection of bevacizumab"]],"start": [["42"]],"entity_id": [["T1"]],"Drug": {"text": [["bevacizumab"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": {"text": [["exudative age-related macular degeneration"]],"start": [["11"]],"entity_id": [["T3"]]},"Route": {"text": [["intravitreal injection"]],"start": [["42"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["2 days later"]],"start": [["88"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [["63"]],"entity_id": [["T6"]]},"Freq": {"text": [["sequentially"]],"start": [["27"]],"entity_id": [["T7"]]},"Duration": {"text": [["treated"]],"start": [["32"]],"entity_id": [["T8"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["signs of severe but painless infectious endophthalmitis"]],"start": [["92"]],"entity_id": [["T9"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["92"]],"entity_id": [["T10"]],"value": "high"},"Subject": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["T11"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["exudative age-related macular degeneration"]],"start": [["11"]],"entity_id": [["T12"]]}},"Trigger": {"text": [["treated"]],"start": [["32"]],"entity_id": [["T13"]]}}]}
{"id": "2586773_1", "context": "Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Ibuprofen-induced meningitis"]], "start": [[ ]],"entity_id": [ ]},"Effect": {"text": [["meningitis"]], "start": [[ ]], "entity_id": [ ]} ,"Treatment": { "text": [], "start": [], "entity_id": [] ,"Drug": { "text": [["Ibuprofen"]], "start": [[ ]], "entity_id": [ ]} ,"Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Disorder": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [] ,"Age": null ,"Disorder": { "text": [], "start": [], "entity_id": [] }, "Gender": null ,"Population": null ,"Race": null }, "Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "18020545_2","context": "Tardive oculogyric crisis during treatment with clozapine: report of three cases","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tardive oculogyric crisis"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T2"]],"Drug": {"text": [["clozapine"]],"start": [["42"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["tardive oculogyric crisis"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["report of three cases"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T2"]]} ,"Freq": {"text": [["report of three cases"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Route": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T2"]]} ,"Combination": null ,"Trigger": {"text": [["treatment"]],"start": [["23"]],"entity_id": [["T2"]]} },"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11506739_1", "context": "Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Myasthenia gravis"]], "start": [[ "0" ]],"entity_id": [ ["T1" ]]},"Treatment": { "text": [[ "low-dose IFN-alpha therapy" ]], "start": [[ "28" ]], "entity_id": [ ["T2" ]], "Drug": { "text": [[ "IFN-alpha" ]], "start": [[ "35" ]], "entity_id": [ ["T3" ] ]} ,"Disorder": { "text": [[ "chronic hepatitis C" ]], "start": [[ "66" ]], "entity_id": [ ["T4" ] ]} ,"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": null,"Combination": null }, "Subject": { "text": [[ "Myasthenia gravis" ]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }, "Effect": { "text": [[ "Myasthenia gravis" ]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "12424571_2", "context": "We herein report this rare case of acute onset of nephrotic syndrome during interferon-alpha retreatment", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["this rare case"]], "start": [["this rare case's starting index in context"]], "entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["interferon-alpha retreatment"]], "start": [[ "interferon-alpha retreatment's starting index in context" ]], "entity_id": [["T1"]],"Drug": {"text": [["interferon-alpha"]], "start": [[ "interferon-alpha's starting index in context" ]], "entity_id": [["T2"]]},"Disorder": null,"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": null,"Combination": null},"Effect": {"text": [["acute onset of nephrotic syndrome"]], "start": [[ "acute onset of nephrotic syndrome's starting index in context" ]], "entity_id": [["E2"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null},{"event_id": "E2", "event_type": "Adverse_event", "Effect": {"text": [["nephrotic syndrome"]], "start": [[ "nephrotic syndrome's starting index in context" ]], "entity_id": [["E3"]]},"Trigger": null,"Treatment": null,"Subject": {"text": [["this rare case"]], "start": [[ "this rare case's starting index in context" ]], "entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "7393795_2", "context": "Para-aminosalicylic acid-induced hypoglycaemia in a patient with diabetic nephropathy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Para-aminosalicylic acid-induced hypoglycaemia"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Para-aminosalicylic acid"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["Para-aminosalicylic acid"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["diabetic nephropathy"]], "start": [[ ]], "entity_id": [ ]},"Time_elapsed": {"text": [["induced"]], "start": [[ ]], "entity_id": [ ]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["hypoglycaemia"]], "start": [[ ]], "entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "18176653_3", "context": "NVP is a non-nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus (HIV) infection.","is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["NVP"]],"start": [[ "0" ] ],"entity_id": [ ["T1"] ] ,"Disorder": { "text": [["Human Immunodeficiency Virus (HIV) infection"]], "start": [[ "53" ]], "entity_id": [ ["T2"] ]} ,"Drug": { "text": [["NVP"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Trigger": { "text": [["used"]], "start": [[ "34" ]], "entity_id": [ ["T3" ]] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Trigger": null }]}
{"id": "7393795_1", "context": "A 62-year-old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol.","is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed miliary tuberculosis"]], "start": [["28"]], "entity_id": []}, "Subject": {"text": [["A 62-year-old Indian"]], "start": [["0"]], "entity_id": [], "Age": {"text": [["62"]], "start": [["3"]], "entity_id": []}, "Race": {"text": [["Indian"]], "start": [["22"]], "entity_id": []}, "Disorder": {"text": [["diabetic nephropathy"]], "start": [["15"]], "entity_id": []},"Gender": null, "Population": null}, "Effect": {"text": [["miliary tuberculosis"]], "start": [["28"]], "entity_id": []}, "Treatment": null, "Negated": null, "Speculated": null, "Severity": null},{"event_id": "E2", "event_type": "Potential_therapeutic_effect", "Trigger": null,"Subject": null,"Effect": null,"Treatment": {"text": [["rifampicin", "isoniazid and ethambutol"]], "start": [["83"]], "entity_id": [], "Drug": {"text": [["rifampicin"], ["isoniazid"], ["ethambutol"]], "start": [[ "83" ], [ "94" ], ["105" ]], "entity_id": [["T1"], ["T2"], ["T3"]]},"Disorder": {"text": [["miliary tuberculosis"]], "start": [["28"]], "entity_id": []},"Dosage": null, "Duration": null,"Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null},"Negated": null, "Speculated": null, "Severity": null}]}
{"id": "8438851_1","context": "A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["developed"]],"start": [["32"]],"entity_id": []},"Subject": {"text": [["A patient with acute esophageal variceal bleeding"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["acute esophageal variceal bleeding"]],"start": [["12"]],"entity_id": []}},"Effect": {"text": [["fatal rhabdomyolysis"]],"start": [["41"]],"entity_id": []},"Treatment": {"text": [["a continuous intravenous infusion of vasopressin"]],"start": [["66"]],"entity_id": [],"Drug": {"text": [["vasopressin"]],"start": [["83"]],"entity_id": []},"Dosage": null,"Freq": null,"Route": {"text": [["continuous intravenous infusion"]],"start": [["66"]],"entity_id": []},"Time_elapsed": null,"Duration": null,"Disorder": null ,"Combination": null ,"Trigger": null }, "Negated": null, "Speculated": null, "Severity": { "text": [["fatal"]], "start": [["41"]], "entity_id": [] ,"value": "fatal" }} ] }
{"id": "12243603_12", "context": "All patients beginning HMG-CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury; particular attention should be paid to those patients who are taking medications that may interact", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["HMG-CoA reductase inhibitor therapy"]], "start": [[ "3" ]], "entity_id": [ ["T1"]],"Drug": {"text": [["HMG-CoA reductase inhibitor"]], "start": [[ "3" ]], "entity_id": [ ["T2"]]},"Disorder": {"text": [["muscle injury"]], "start": [[ "71" ]], "entity_id": [ ["T3"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["All patients"]], "start": [[ "0" ]], "entity_id": [ ["T0"]],"Age": null,"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": null,"Population": {"text": [["All patients"]], "start": [[ "0" ]], "entity_id": [ ["T0"]]},"Race": null},"Trigger": null}]}
{"id": "16498048_4", "context": "Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Interferon-alpha-induced hyperthyroidism"]], "start": [[ ]],"entity_id": [ ["T1"]]},"Effect": {"text": [["hyperthyroidism"]], "start": [[ ]], "entity_id": [ ["T2"]]},"Subject": { "text": [["a three-stage evolution from silent thyroiditis towards Graves' disease"]], "start": [[ ]], "entity_id": [ ["T3"]],"Disorder": { "text": [["silent thyroiditis"]], "start": [[ ]], "entity_id": [ ["T4"]]},"Race": { "text": [["Graves' disease"]], "start": [[ ]], "entity_id": [ ["T5"]]} ,"Age": null, "Gender": null, "Population": null} ,"Treatment": null, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "16708747_1","context": "Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acute severe intoxication"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["carbamazepine"]],"start": [["43"]],"entity_id": [],"Drug": {"text": [["carbamazepine"]],"start": [["43"]],"entity_id": []},"Dosage": {"text": [[""]],"start": [[""]],"entity_id": []},"Duration": {"text": [[""]],"start": [[""]],"entity_id": []},"Disorder": {"text": [["intoxication"]],"start": [["10"]],"entity_id": []},"Freq": {"text": [[""]],"start": [[""]],"entity_id": []},"Route": {"text": [[""]],"start": [[""]],"entity_id": []},"Time_elapsed": {"text": [[""]],"start": [[""]],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["seizures", "coma and respiratory depression"]],"start": [["70"],["89"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["6"]],"entity_id": [],"value": "severe"},"Subject": null}]}
{"id": "11022272_2","context": "We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anaphylaxis"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["calcitonin"]],"start": [["5"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"text": [["calcitonin"]],"start": [["5"]],"Disorder": {"text": [["anaphylaxis"]],"start": [["13"]],"entity_id": [["T1"]]},"Freq": {"text": [["have introduced"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["by"]],"start": [["4"]],"entity_id": [["T3"]]},"Trigger": {"text": [["by"]],"start": [["4"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["that suggest"]],"start": [["32"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["calcitonin"]],"start": [["5"]],"entity_id": [["T2"]]},"Trigger": {"text": [["by"]],"start": [["4"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "17188061_2","context": "To describe transient structured visual hallucinations in a patient with vascular age-related macular degeneration (AMD), following an intravitreal Avastin-injection","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["transient structured visual hallucinations"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["patient"]],"start": [["48"]],"entity_id": [ ["T2"]],"Disorder": {"text": [["vascular age-related macular degeneration (AMD)"]],"start": [["22"]],"entity_id": [ ["T3"]]} ,"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["Avastin-injection"]],"start": [["102"]],"entity_id": [ ["T4"]],"Drug": {"text": [["Avastin"]],"start": [["102"]],"entity_id": [ ["T5"]]},"Dosage": null,"Duration": null,"Route": {"text": [["intravitreal"]],"start": [["96"]],"entity_id": [ ["T6"]]},"Trigger": {"text": [["following"]],"start": [["74"]],"entity_id": [ ["T7"]]},"Time_elapsed": null,"Freq": null ,"Disorder": {"text": [["vascular age-related macular degeneration (AMD)"]],"start": [["22"]],"entity_id": [ ["T3"]]} ,"Combination": null},"Effect": {"text": [["transient structured visual hallucinations"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "19904536_15","context": "Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["gemcitabine-induced pulmonary toxicity"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gemcitabine"]],"start": [["16"]],"entity_id": [["T2"]],"Drug": {"text": [["gemcitabine"]],"start": [["16"]],"entity_id": [["T2"]]},"Disorder": {"text": [["metastatic gallbladder adenocarcinoma"]],"start": [["55"]],"entity_id": [["T3"]]},"Freq": {"text": [["induced"]],"start": [["31"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["induced"]],"start": [["31"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["gemcitabine-induced pulmonary toxicity"]],"start": [["0"]],"entity_id": [["T1"]]}},"Effect": {"text": [["pulmonary toxicity"]],"start": [["21"]],"entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "high"},"Subject": null}]}
{"id": "24429012_1","context": "Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Elevated International Normalized Ratio"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["warfarin"]],"start": [[ "61" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["warfarin"]],"start": [[ "61" ]],"entity_id": [ ["T3"] ]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": null ,"Freq": null,"Combination": [{"Drug": {"text": [["vismodegib"]],"start": [[ "83" ]],"entity_id": [ ["T4"] ]},"Trigger": {"text": [["concurrently"]],"start": [[ "73" ]],"entity_id": [ ["T5"] ]} ,"event_id": "E1" ,"event_type": "Adverse_event" }],"Trigger": null },"Effect": {"text": [["Elevated International Normalized Ratio"]],"start": [[ "0" ]],"entity_id": [ ["T6"] ]} ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "8013261_3","context": "Occurrence of IDDM during interferon therapy for chronic viral hepatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Occurrence"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["interferon therapy"]],"start": [["19"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["interferon"]],"start": [["19"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["IDDM"]],"start": [["45"]],"entity_id": [ ["T4"] ]},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["chronic viral hepatitis"]],"start": [["65"]],"entity_id": [ ["T5"] ]},"Combination": null},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["IDDM"]],"start": [["45"]],"entity_id": [ ["T4"] ]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "3873709_2","context": "Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim-sulfamethoxazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pseudomembranous colitis"]],"start": [[ ]] ,"entity_id": [ ["T1"]]},"Treatment": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [[ ]] ,"entity_id": [ ["T2"]],"Drug": {"text": [["trimethoprim"]],"start": [[ ]] ,"entity_id": [ ["T3"]]},"Dosage": {"text": [["sulfamethoxazole"]],"start": [[ ]] ,"entity_id": [ ["T4"]]},"Disorder": {"text": [["certain population groups"]],"start": [[ ]] ,"entity_id": [ ["T5"]]},"Freq": {"text": [["readily occurs"]],"start": [[ ]] ,"entity_id": [ ["T6"]]},"Time_elapsed": {"text": [["in at least"]],"start": [[ ]] ,"entity_id": [ ["T7"]]},"Route": {"text": [["receiving"]],"start": [[ ]] ,"entity_id": [ ["T8"]]},"Duration": {"text": [["at least"]],"start": [[ ]] ,"entity_id": [ ["T9"]]},"Trigger": {"text": [["receiving"]],"start": [[ ]] ,"entity_id": [ ["T8"]]},"Combination": [{"Drug": {"text": [["trimethoprim"]],"start": [[ ]] ,"entity_id": [ ["T3"]]},"Trigger": {"text": [["sulfamethoxazole"]],"start": [[ ]] ,"entity_id": [ ["T4"]]},"event_id": "C1","event_type": "Combination"}]},"Subject": {"text": [["certain population groups"]],"start": [[ ]] ,"entity_id": [ ["T5"]],"Population": {"text": [["certain population groups"]],"start": [[ ]] ,"entity_id": [ ["T5"]]},"Disorder": {"text": [["Pseudomembranous colitis"]],"start": [[ ]] ,"entity_id": [ ["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "8002140_4","context": "Budesonide use can cause contact dermatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["contact dermatitis"]],"start": [["21"]],"entity_id": [["T2"]]},"Treatment": {"text": [["Budesonide"]],"start": [["6"]],"entity_id": [["T1"]],"Drug": {"text": [["Budesonide"]],"start": [["6"]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["contact dermatitis"]],"start": [["21"]],"entity_id": [["T2"]]} ,"Route": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["can cause"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["Budesonide"]],"start": [["6"]],"entity_id": [["T1"]]},"Trigger": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Adverse_event"}] ,"Time_elapsed": {"text": [["can cause"]],"start": [["16"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["contact dermatitis"]],"start": [["21"]],"entity_id": [["T2"]],"value": "Low"} ,"Subject": {"text": [["use"]],"start": [["13"]],"entity_id": [["T3"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [["contact dermatitis"]],"start": [["21"]],"entity_id": [["T2"]]} }]}
{"id": "9831311_3","context": "It was concluded that potassium loss occurred by a non-renal (intestinal) route in phosphate-induced hypokalemia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["phosphate-induced hypokalemia"]],"start": [[], []],"entity_id": [] ,"Trigger": {"text": [["potassium loss"]],"start": [[], []],"entity_id": [] },"Drug": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["phosphate-induced hypokalemia"]],"start": [[], []],"entity_id": [] },"Route": {"text": [["non-renal (intestinal) route"]],"start": [[], []],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Combination": [] },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Effect": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "10891991_3","context": "The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["development of reproductive endocrine disorders"]],"start": [["33"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["valproate therapy"]],"start": [["72"]],"entity_id": [ ["T2"]],"Drug": {"text": [["valproate"]],"start": [["72"]],"entity_id": [ ["T3"]]},"Disorder": {"text": [["epilepsy"]],"start": [["93"]],"entity_id": [ ["T4"]]} ,"Freq": {"text": [["after the initiation"]],"start": [["56"]],"entity_id": [ ["T5"]]} ,"Time_elapsed": {"text": [["after the initiation"]],"start": [["56"]],"entity_id": [ ["T5"]]} ,"Duration": {"text": [["development"]],"start": [["33"]],"entity_id": [ ["T1"]]} ,"Route": {"text": [["therapy"]],"start": [["72"]],"entity_id": [ ["T2"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["initiation"]],"start": [["56"]],"entity_id": [ ["T5"]]} },"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["reproductive endocrine disorders"]],"start": [["33"]],"entity_id": [ ["T1"]],"value": "high"} ,"Subject": {"text": [["The 3 cases presented here"]],"start": [["0"]],"entity_id": [ ["T0"]],"Age": null,"Gender": {"text": [["women"]],"start": [["106"]],"entity_id": [ ["T6"]]},"Population": {"text": [["The 3 cases presented here"]],"start": [["0"]],"entity_id": [ ["T0"]]},"Race": null,"Disorder": {"text": [["epilepsy"]],"start": [["93"]],"entity_id": [ ["T4"]]} }} ]}
{"id": "3346128_1","context": "A 43-year-old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["shallow erosion"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["chronic administration of methotrexate"]],"start": [["71"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["85"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["chronic"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Route": {"text": [["administration"]],"start": [["76"]],"entity_id": [["T5"]]},"Disorder": {"text": [["psoriatic plaque"]],"start": [["23"]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["63"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["administration"]],"start": [["76"]],"entity_id": [["T5"]]} },"Subject": {"text": [["A 43-year-old white man"]],"start": [[""], []],"entity_id": [["T8"]],"Age": {"text": [["43"]],"start": [[""], []],"entity_id": [["T9"]]},"Gender": {"text": [["man"]],"start": [[""], []],"entity_id": [["T10"]]} ,"Race": {"text": [["white"]],"start": [[""], []],"entity_id": [["T11"]]} ,"Disorder": {"text": [["psoriatic plaque"]],"start": [["23"]],"entity_id": [["T6"]]} ,"Population": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": {"text": [["shallow erosion"]],"start": [["18"]],"entity_id": [["T1"]] ,"value": "low" },"Effect": {"text": [["shallow erosion"]],"start": [["18"]],"entity_id": [["T1"]] }} ]}
{"id": "20126479_1","context": "SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hydroxychloroquine toxicity"]],"start": [["48"]],"entity_id": [["T1"]]},"Treatment": {"text": [["hydroxychloroquine"]],"start": [["36"]],"entity_id": [["T2"]] ,"Drug": {"text": [["hydroxychloroquine"]],"start": [["36"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["hydroxychloroquine toxicity"]],"start": [["48"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Effect": {"text": [["abnormalities"]],"start": [["0"]],"entity_id": [["T3"]] },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "18805724_2","context": "Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["toxic epidermal necrolysis"]],"start": [["16"]],"entity_id": [["T2"]]},"Treatment": {"text": [["Leflunomide"]],"start": [["0"]],"entity_id": [["T1"]],"Drug": {"text": [["Leflunomide"]],"start": [["0"]],"entity_id": [["T1"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["63"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]},"Trigger": {"text": [["Leflunomide"]],"start": [["0"]],"entity_id": [["T1"]]},"Freq": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["Leflunomide"]],"start": [["0"]],"entity_id": [["T1"]]},"Trigger": {"text": [["induced"]],"start": [["12"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E1"}],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "19034138_7","context": "Therefore, amantadine was permanently discontinued and the cornea cleared again","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["amantadine was permanently discontinued"]],"start": [[" "], ["amantadine", "was", "permanently", "discontinued"]],"entity_id": []},"Treatment": {"text": [["amantadine"]],"start": [[""], ["amantadine"]],"entity_id": [],"Drug": {"text": [["amantadine"]],"start": [[""], ["amantadine"]],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [["the cornea cleared again"]],"start": [[""], ["the", "cornea", "cleared", "again"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "8530331_8", "context": "We believe that risperidone is not a substitute for clozapine in treating psychosis in parkinsonian patients and should be used with caution", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": {"value": true, "text": [["not"]], "start": [[], []], "entity_id": []}, "Treatment": {"text": [["risperidone"]], "start": [[], []], "entity_id": [],"Disorder":{"text":[["treating psychosis"]], "start": [[],[]], "entity_id": []}, "Trigger":{"text":[["substitute"]], "start": [[],[]], "entity_id": []}, "Drug":{"text":[["clozapine"]], "start": [[],[]], "entity_id": []}, "Route":{"text":[["in treating psychosis in parkinsonian patients"]], "start": [[],[]], "entity_id": []}, "Freq":{"text":[["should be used with caution"]], "start": [[],[]], "entity_id": []}, "Combination":[{"Drug":{"text":[["risperidone"]], "start": [[],[]], "entity_id": []},"Trigger":{"text":[["substitute"]], "start": [[],[]], "entity_id": []},"event_id":"C1","event_type":"Combination"}], "Time_elapsed":{"text":[["not"]], "start": [[],[]], "entity_id": []}, "Duration":{"text":[["not"]], "start": [[],[]], "entity_id": []}, "Dosage":{"text":[["not"]], "start": [[],[]], "entity_id": []}} ,"Subject":{"text":[["We"]], "start": [[],[]], "entity_id": [],"Age":{"text":[["not"]], "start": [[],[]], "entity_id": []},"Gender":{"text":[["not"]], "start": [[],[]], "entity_id": []},"Population":{"text":[["not"]], "start": [[],[]], "entity_id": []},"Race":{"text":[["not"]], "start": [[],[]], "entity_id": []},"Disorder":{"text":[["believe"]], "start": [[],[]], "entity_id": []}} ,"Effect":{"text":[["not a substitute"]], "start": [[],[]], "entity_id": []} ,"Speculated":{"value":false,"text":[["not"]], "start": [[],[]], "entity_id": []},"Severity":{"value":"not specified","text":[["not"]], "start": [[],[]], "entity_id": []} ,"Trigger":{"text":[["substitute"]], "start": [[],[]], "entity_id": []}}]}
{"id": "16767537_1","context": "Spontaneous splenic infarction associated with sumatriptan use","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["spontaneous splenic infarction"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["sumatriptan use"]],"start": [["52"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["sumatriptan"]],"start": [["52"]],"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["spontaneous splenic infarction"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Route": {"text": [["use"]],"start": [["52"]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["associated"]],"start": [["39"]],"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": null },"Subject": null ,"Negated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Speculated": {"value": false ,"text": [],"start": [],"entity_id": [] },"Severity": null ,"Effect": null }]}
{"id": "7606071_4", "context": "Anaphylactoid reactions have been described previously with cisplatin administration", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Anaphylactoid reactions"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["cisplatin administration"]], "start": [[ "46" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [[ "cisplatin" ]], "start": [[ "46" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [[ "Anaphylactoid reactions" ]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Subject": null, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "10475726_4","context": "We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Subject": {"text": [["elderly woman"]],"start": [["22"]],"entity_id": [["S1"]],"Age": {"text": [["elderly"]],"start": [["22"]],"entity_id": [["S2"]]},"Disorder": {"text": [["pre-existing history of ischaemic heart disease"]],"start": [["5"]],"entity_id": [["S3"]]} ,"Gender": {"text": [["woman"]],"start": [["24"]],"entity_id": [["S4"]]} ,"Population": {"text": [["1"]],"start": [["22"]],"entity_id": [["S5"]]} ,"Race": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["venlafaxine"]],"start": [["65"]],"entity_id": [["T1"]],"Drug": {"text": [["venlafaxine"]],"start": [["65"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [["within the first week of treatment"]],"start": [["82"]],"entity_id": [["T3"]]} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [["acute myocardial ischaemia"]],"start": [["102"]],"entity_id": [["E1"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Medium"} ,"Trigger": null} ]}
{"id": "15580406_1","context": "Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["interferon alpha treatment"]],"start": [["95"]],"entity_id": [["T2"]],"Drug": {"text": [["interferon"]],"start": [["95"]],"entity_id": [["T3"]]},"Duration": {"text": [["4 months"]],"start": [["65"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["Vogt-Koyanagi-Harada disease"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["4 months"]],"start": [["65"]],"entity_id": [["T4"]]},"Trigger": {"text": [["immunomodulatory effects"]],"start": [["109"]],"entity_id": [["T5"]]} ,"Route": {"text": [["treatment"]],"start": [["95"]],"entity_id": [["T2"]]} ,"Freq": {"text": [[""]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": null ,"Dosage": {"text": [[""]],"start": [["0"]],"entity_id": [["T0"]]} },"Subject": {"text": [["we"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null },"Negated": null,"Speculated": {"text": [["probably"]],"start": [["100"]],"entity_id": [["T6"]] ,"value": true },"Severity": null ,"Effect": {"text": [["occurring"]],"start": [["56"]],"entity_id": [["T4"]] }} ]}
{"id": "17536204_3", "context": "Capecitabine-induced headache responding to diltiazem", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["headache"]], "start": [["13"]], "entity_id": [["T2"]]}, "Treatment": {"text": [["Capecitabine-induced", "diltiazem"]], "start": [["0","22"]], "entity_id": [["T1","T3"]], "Drug": {"text": [["Capecitabine","diltiazem"]], "start": [["0","22"]], "entity_id": [["T1","T3"]] },"Route": {"text": [["-induced"]], "start": [["10"]], "entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["responding"]], "start": [["30"]], "entity_id": [["T5"]]} ,"Duration": {"text": [["-induced"]], "start": [["10"]], "entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["Capecitabine"]], "start": [["0"]], "entity_id": [["T1"]]}, "Trigger": {"text": [["-induced"]], "start": [["10"]], "entity_id": [["T4"]]}, "event_id": "E2" , "event_type": "null"} , {"Drug": {"text": [["diltiazem"]], "start": [["22"]], "entity_id": [["T3"]]}, "Trigger": {"text": [["responding"]], "start": [["30"]], "entity_id": [["T5"]]},"event_id": "E3" , "event_type": "null"}] ,"Disorder": {"text": [["Capecitabine-induced headache"]], "start": [["0","12"]], "entity_id": [["T1","T2"]]} ,"Dosage": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Freq": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Trigger": {"text": [["Capecitabine-induced", "diltiazem"]], "start": [["0","22"]], "entity_id": [["T1","T3"]]} }, "Effect": {"text": [["headache"]], "start": [["13"]], "entity_id": [["T2"]]} ,"Negated": {"text": [[]], "start": [[],[]], "entity_id": [[]], "value": false} ,"Speculated": {"text": [[]], "start": [[],[]], "entity_id": [[]], "value": false} ,"Severity": {"text": [[]], "start": [[],[]], "entity_id": [[]], "value": "low" }, "Subject": { "text": [["Capecitabine-induced headache"]], "start": [["0","12"]], "entity_id": [["T1","T2"]] ,"Age": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Gender": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Population": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Race": {"text": [[]], "start": [[],[]], "entity_id": [[]]} ,"Disorder": {"text": [["Capecitabine-induced headache"]], "start": [["0","12"]], "entity_id": [["T1","T2"]]} }}]}
{"id": "8345435_3", "context": "We report on a child with fatal valproate-related hepatotoxic effects despite this supplementation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a child"]], "start": [["6","7"]], "entity_id": [[ "S1"]],"Age":{"text":[["child"]], "start":[[ "6","7"]], "entity_id":[["S2"]]},"Gender":{"text":[[" "],[]], "start":[[ "6","7"],[ "8","9"]], "entity_id":[["S3"]]},"Population":{"text":[["one"]], "start":[[ "6","7"]], "entity_id":[["S4"]]},"Race":{"text":[[" "],[]], "start":[[ "6","7"],[ "8","9"]], "entity_id":[["S5"]]},"Disorder":{"text":[["fatal valproate-related hepatotoxic effects"]], "start":[[ "37","38"]], "entity_id":[["S6"]]}},"Treatment":{"text":[["valproate"]], "start":[[ "25","26"]], "entity_id":[["T1"]],"Drug":{"text":[["valproate"]], "start":[[ "25","26"]], "entity_id":[["T2"]]},"Dosage":{"text":[[" "],[]], "start":[[ "25","26"],[ "27","28"]], "entity_id":[["T3"]]},"Duration":{"text":[[" "],[]], "start":[[ "25","26"],[ "27","28"]], "entity_id":[["T4"]]},"Trigger":{"text":[["this supplementation"]], "start":[[ "53","54"]], "entity_id":[["T5"]]},"Route":{"text":[[" "],[]], "start":[[ "53","54"],[ "55","56"]], "entity_id":[["T6"]]},"Time_elapsed":{"text":[["despite this supplementation"]], "start":[[ "45","46"]], "entity_id":[["T7"]]},"Freq":{"text":[[" "],[]], "start":[[ "53","54"],[ "55","56"]], "entity_id":[["T8"]]},"Combination":null,"Disorder":{"text":[["fatal valproate-related hepatotoxic effects"]], "start":[[ "37","38"]], "entity_id":[["D1"]]}},"Effect":{"text":[["fatal"]], "start":[[ "37","38"]], "entity_id":[["E1"]]},"Negated":null,"Speculated":null,"Severity":{"text":[["fatal"]], "start":[[ "37","38"]], "entity_id":[["S7"]],"value":"high" },"Trigger":{"text":[["fatal valproate-related hepatotoxic effects"]], "start":[[ "37","38"]], "entity_id":[["T1"]]} }]}
{"id": "7724306_2", "context": "Acute isoniazid neurotoxicity in an urban hospital", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["isoniazid neurotoxicity"]], "start": [["17"]], "entity_id": []}, "Treatment": {"text": [["isoniazid"]], "start": [["10"]], "entity_id": [], "Drug": {"text": [["isoniazid"]], "start": [["10"]], "entity_id": []} ,"Disorder": {"text": [["neurotoxicity"]], "start": [["17"]], "entity_id": []},"Duration": {"text": [["Acute"]], "start": [["0"]], "entity_id": []},"Route": {"text": [["in an urban hospital"]], "start": [["33"]], "entity_id": []},"Time_elapsed": {"text": [["Acute"]], "start": [["0"]], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Dosage": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "16540070_1","context": "A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute urticaria", "labial angioedema"]],"start": [["episode of acute urticaria and labial angioedema" ],["60 minutes after ingesting"]],"entity_id": []},"Treatment": {"text": [["500 mg of cloxacillin"]],"start": [[ "ingesting 500 mg of cloxacillin" ]],"entity_id": [],"Drug": {"text": [["cloxacillin"]],"start": [[ "ingesting 500 mg of cloxacillin" ]],"entity_id": []},"Dosage": {"text": [["500 mg"]],"start": [[ "ingesting 500 mg of cloxacillin" ]],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["skin abscess"]],"start": [[ "for a skin abscess" ]],"entity_id": []} ,"Route": {"text": [["orally"]],"start": [[ "ingesting" ]],"entity_id": []} ,"Time_elapsed": {"text": [["60 minutes"]],"start": [[ "60 minutes after ingesting" ]],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null},"Subject": {"text": [["A 55-year-old woman"]],"start": [[ "A 55-year-old woman" ]],"entity_id": [],"Age": {"text": [["55 years old"]],"start": [[ "A 55-year-old woman" ]],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[ "A 55-year-old woman" ]],"entity_id": []},"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [["acute urticaria", "labial angioedema"]],"start": [[ "episode of acute urticaria and labial angioedema" ]],"entity_id": []} ,"Severity": null,"Negated": null,"Speculated": null}]}
{"id": "71813_2","context": "Acne provoked by gold seems not to have been described elsewhere","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Acne provoked by gold"]],"start": [[ "0" ]] ,"entity_id": [ ["T1" ] ]},"Treatment": {"Drug": {"text": [["gold"]],"start": [[ "23" ]],"entity_id": [ ["T2" ] ]} ,"Disorder": { "text": [["Acne"]], "start": [[ "10" ]], "entity_id": [ ["T3" ] ]} ,"Dosage": null,"Duration": null,"Trigger": null, "Route": null, "Time_elapsed": null ,"Freq": null ,"Combination": null ,"entity_id": [ ["T1", "T2" ] ], "text": [["Acne provoked by gold"], ["gold"]], "start": [[ "0" ], ["23" ] ]} ,"Negated": { "value": true ,"text": [["seems not to have been described elsewhere"]], "start": [[ "66" ]], "entity_id": [ ["T4" ] ]} ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": { "text": [["Acne"]], "start": [[ "10" ]], "entity_id": [ ["T3" ] ]} }] }
{"id": "17260498_2", "context": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["induce pulmonary injury"]], "start": [[ ], [ "42" ]], "entity_id": [ ["T1" ]]}, "Treatment": { "text": [["Taxanes"]], "start": [[ "0" ]], "entity_id": [ ["T2" ]], "Disorder": { "text": [["chemotherapeutic agents"]], "start": [[ "9" ]], "entity_id": [ ["T3" ]]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Drug": { "text": [["Taxanes"]], "start": [[ "0" ]], "entity_id": [ ["T2" ]] } ,"Trigger": { "text": [["induce pulmonary injury"]], "start": [[ "42" ]], "entity_id": [ ["T1" ]] } }, "Subject": null,"Effect": { "text": [["pulmonary injury"]], "start": [[ "42" ]], "entity_id": [ ["T1" ]] } ,"Negated": null, "Speculated": null, "Severity": null }] }
{"id": "17277758_4", "context": "To report two cases of acute endophthalmitis following intravitreal bevacizumab injection", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute endophthalmitis"]], "start": [["36","37"]], "entity_id": []}, "Treatment": {"text": [["intravitreal bevacizumab injection"]], "start": [["56","57","58","59","60"]], "entity_id": [], "Drug": {"text": [["bevacizumab"]], "start": [["56","57","58","59"]], "entity_id": [] }, "Route": {"text": [["intravitreal"]], "start": [["56"]], "entity_id": [] }, "Time_elapsed": {"text": [["following"]], "start": [["36"]], "entity_id": [] }, "Freq": {"text": [["two cases"]], "start": [["0","1"]], "entity_id": [] }, "Disorder": {"text": [], "start": [], "entity_id": [] }, "Dosage": {"text": [], "start": [], "entity_id": [] }, "Duration": {"text": [], "start": [], "entity_id": [] }, "Trigger": {"text": [["injection"]], "start": [["59","60"]], "entity_id": [] }, "Combination": [{"Drug": {"text": [["bevacizumab"]], "start": [["56","57","58","59"]], "entity_id": [] }, "Trigger": {"text": [["injection"]], "start": [["59","60"]], "entity_id": [] }, "event_id": "E1-1", "event_type": "Adverse_event"}] }, "Negated": {"text": [], "start": [], "entity_id": [],"value": false }, "Speculated": {"text": [], "start": [], "entity_id": [],"value": false }, "Severity": {"text": [], "start": [], "entity_id": [],"value": "" }, "Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": [] }, "Gender": {"text": [], "start": [], "entity_id": [] }, "Population": {"text": [["two cases"]], "start": [["0","1"]], "entity_id": [] }, "Race": {"text": [], "start": [], "entity_id": [] }, "Disorder": {"text": [], "start": [], "entity_id": [] } }, "Effect": {"text": [["acute endophthalmitis"]], "start": [["36","37"]], "entity_id": [] } }, {"event_id": "E1-1", "event_type": "Adverse_event", "Trigger": {"text": [["injection"]], "start": [["59","60"]], "entity_id": [] }, "Treatment": {"text": [["intravitreal bevacizumab injection"]], "start": [["56","57","58","59","60"]], "entity_id": [],"Drug": {"text": [["bevacizumab"]], "start": [["56","57","58","59"]], "entity_id": [] }, "Route": {"text": [["intravitreal"]], "start": [["56"]], "entity_id": [] }, "Time_elapsed": {"text": [], "start": [], "entity_id": [] }, "Freq": {"text": [], "start": [], "entity_id": [] }, "Disorder": {"text": [], "start": [], "entity_id": [] }, "Dosage": {"text": [], "start": [], "entity_id": [] }, "Duration": {"text": [], "start": [], "entity_id": [] }, "Trigger": {"text": [], "start": [], "entity_id": [] }, "Combination": [] }, "Negated": {"text": [], "start": [], "entity_id": [],"value": false }, "Speculated": {"text": [], "start": [], "entity_id": [],"value": false }, "Severity": {"text": [], "start": [], "entity_id": [],"value": "" }, "Subject": {"text": [], "start": [], "entity_id": [],"Age": {"text": [], "start": [], "entity_id": [] }, "Gender": {"text": [], "start": [], "entity_id": [] }, "Population": {"text": [], "start": [], "entity_id": [] }, "Race": {"text": [], "start": [], "entity_id": [] }, "Disorder": {"text": [], "start": [], "entity_id": [] } }, "Effect": {"text": [], "start": [], "entity_id": [] } }]}
{"id": "12621956_2", "context": "This is a case report of subtle, mild hypothermia in a 54-year old female patient receiving risperidone for schizophrenia", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["subtle, mild hypothermia"]], "start": [["16", "17"]], "entity_id": []}, "Subject": {"text": [["54-year old female patient"]], "start": [["33", "34"]], "entity_id": [], "Age": {"text": [["54"]], "start": [["33"]], "entity_id": []}, "Gender": {"text": [["female"]], "start": [["36"]], "entity_id": []}, "Disorder": {"text": [["schizophrenia"]], "start": [["87"]], "entity_id": []}, "Population": null, "Race": null}, "Severity": null, "Negated": null, "Speculated": null, "Treatment": {"text": [["risperidone"]], "start": [["66"]], "entity_id": [], "Drug": {"text": [["risperidone"]], "start": [["66"]], "entity_id": []}, "Disorder": {"text": [["schizophrenia"]], "start": [["87"]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null, "Trigger": null}, "Effect": {"text": [["subtle, mild hypothermia"]], "start": [["16", "17"]], "entity_id": []}}]}
{"id": "15866658_2", "context": "Mycophenolate mofetil-induced neutropenia in liver transplantation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Mycophenolate mofetil-induced neutropenia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "text": [["Mycophenolate mofetil"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["Mycophenolate mofetil"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["neutropenia"]], "start": [[ "38" ]], "entity_id": [ ["T4"] ]} ,"Duration": { "text": [["in liver transplantation"]], "start": [[ "55" ]], "entity_id": [ ["T5"] ]} ,"Dosage": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [["Mycophenolate mofetil-induced neutropenia"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} },"Subject": { "text": [["Mycophenolate mofetil"]], "start": [[ "0" ]], "entity_id": [ ["T2"] ], "Age": null, "Gender": null, "Population": null, "Race": null ,"Disorder": null },"Effect": { "text": [["neutropenia"]], "start": [[ "38" ]], "entity_id": [ ["T4"] ]} ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "9545161_2","context": "Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Disorder": {"text": [["TEN"]],"start": [[ "83" ]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["valproic acid"]],"start": [[ "39" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["combination"]],"start": [[ "32" ]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "null"}],"Trigger": {"text": [["development"]],"start": [[ "75" ]],"entity_id": [["T5"]]},"entity_id": [["E1"]],"start": [[ "0" ]],"text": [["Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN."]],"Time_elapsed": {"text": [["may lead"]],"start": [[ "46" ]],"entity_id": [["T6"]]},"Freq": {"text": [["may lead"]],"start": [[ "46" ]],"entity_id": [["T6"]]},"Route": {"text": [["Administration"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Dosage": {"text": [[" Administration of "]],"start": [[ "0" ]],"entity_id": [["T8"]]},"Duration": {"text": [[" Administration of "]],"start": [[ "0" ]],"entity_id": [["T8"]]}},"Negated": {"text": [["may lead"]],"start": [[ "46" ]],"entity_id": [["T6"]],"value": false},"Speculated": {"text": [["may lead"]],"start": [[ "46" ]],"entity_id": [["T6"]],"value": false},"Severity": {"text": [["TEN"]],"start": [[ "83" ]],"entity_id": [["T2"]],"value": "high"},"Subject": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]],"Age": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Gender": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Population": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Race": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]]},"Disorder": {"text": [[" Administration of lamotrigine"]],"start": [[ "0" ]],"entity_id": [["T7"]]}},"Effect": {"text": [["the development"]],"start": [[ "75" ]],"entity_id": [["T5"]]},"Trigger": {"text": [["may lead"]],"start": [[ "46" ]],"entity_id": [["T6"]]}}]}
{"id": "17404582_1","context": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Docetaxel induced Meibomian duct inflammation and blockage"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]} ,"Treatment": { "text": [["Docetaxel"]],"start": [["0"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["Docetaxel"]],"start": [["0"]],"entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["Meibomian duct inflammation and blockage"]], "start": [["21"]],"entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": { "text": [["Docetaxel induced"]], "start": [["0"]],"entity_id": [ ["T5"] ]} },"Subject": { "text": [["this presentation"]], "start": [["104"]], "entity_id": [ ["T6"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["no history of eyelid masses in the past"]], "start": [["116"]], "entity_id": [ ["T7"] ]} },"Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["the likely cause"]], "start": [["49"]], "entity_id": [ ["T8"] ]} }]}
{"id": "19660974_4", "context": "We describe a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["disseminated cryptococcosis"]],"start": [["a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient.].index(disseminated cryptococcosis)"]],"entity_id": [["T1"]]},"Subject": {"text": [["a TNF-alpha inhibitor recipient"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Crohn's disease"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T3"]]}},"Treatment": {"text": [["TNF-alpha inhibitor"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T2"]],"Drug": {"text": [["TNF-alpha inhibitor"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T4"]]} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["Crohn's disease"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T3"]]},"Freq": null,"Combination": null ,"Trigger": null }, "Effect": {"text": [["an exacerbation of Crohn's disease"]],"start": [[ "a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient." ]],"entity_id": [["T5"]] }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "3926849_1","context": "Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["nitroglycerin"]],"start": [["14"]],"entity_id": [["T1"]]},"Disorder": {"text": [["idiopathic pulmonary hypertension"]],"start": [["47"]],"entity_id": [["T2"]]},"Route": {"text": [["intravenous"]],"start": [["10"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [[" Administration"]],"start": [["0"]],"entity_id": [["T4"]]},"Freq": {"text": [["injection"]],"start": [["10"]],"entity_id": [["T5"]]},"Dosage": {"text": [["-"]],"start": [[""], []],"entity_id": [["T6"]]},"Duration": {"text": [["-"]],"start": [[""], []],"entity_id": [["T7"]]},"entity_id": [["T8"]],"text": [[" Administration"]],"start": [["0"]],"Trigger": {"text": [["resulted"]],"start": [["32"]],"entity_id": [["T9"]]},"Combination": null},"Effect": {"text": [["increase in pulmonary artery pressure"]],"start": [["78"]],"entity_id": [["T10"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": {"text": [["increase in pulmonary vascular resistance"]],"start": [["122"]],"entity_id": [["T11"]]}}]}
{"id": "7606071_3","context": "We conclude that a high dose combined with a short infusion time increases the risk of anaphylactoid reactions with the administration of intraperitoneal cisplatin","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["a high dose combined with a short infusion time"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["the administration of intraperitoneal cisplatin"]],"start": [["51"]],"entity_id": [ ["T2"]],"Trigger": {"text": [["administration"]],"start": [["51"]],"entity_id": [["T3"]]},"Drug": {"text": [["cisplatin"]],"start": [["62"]],"entity_id": [ ["T4"]]},"Route": {"text": [["intraperitoneal"]],"start": [["45"]],"entity_id": [["T5"]]},"Dosage": {"text": [["a high dose"]],"start": [["0"]],"entity_id": [ ["T6"]]},"Freq": {"text": [["a short infusion time"]],"start": [["22"]],"entity_id": [ ["T7"]]},"Disorder": {"text": [["anaphylactoid reactions"]],"start": [["35"]],"entity_id": [ ["T8"]]},"Time_elapsed": {"text": [["with the administration"]],"start": [["51"]],"entity_id": [ ["T9"]]},"Combination": [{"Drug": {"text": [["cisplatin"]],"start": [["62"]],"entity_id": [ ["T4"]]},"Trigger": {"text": [["administration"]],"start": [["51"]],"entity_id": [ ["T3"]]},"event_type": "Adverse_event","event_id": "E2"}],"Duration": {"text": [["a short infusion time"]],"start": [["22"]],"entity_id": [ ["T7"]]}},"Effect": {"text": [["increases the risk"]],"start": [["13"]],"entity_id": [ ["T10"]]},"Negated": null,"Speculated": {"text": [["We conclude that"]],"start": [["0"]],"entity_id": [ ["T11"]],"value": false},"Severity": {"text": [["anaphylactoid reactions"]],"start": [["35"]],"entity_id": [ ["T8"]],"value": "High"},"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [ ["T12"]],"Population": {"text": [["We"]],"start": [["0"]],"entity_id": [ ["T12"]]},"Age": null,"Gender": null,"Race": null,"Disorder": null}}]}
{"id": "8742573_3", "context": "Human insulin-induced lipoatrophy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Human insulin-induced lipoatrophy"]], "start": [[ ]], "entity_id": [[ "T1" ]]}, "Treatment": {"text": [["Human insulin"]], "start": [[ ]], "entity_id": [[ "T2" ]], "Drug": {"text": [["Human insulin"]], "start": [[ ]], "entity_id": [[ "T3" ]] },"Disorder": {"text": [["lipoatrophy"]], "start": [[ ]], "entity_id": [[ "T4" ]]},"Dosage": { "text": [], "start": [], "entity_id": [] },"Duration": { "text": [], "start": [], "entity_id": [] },"Route": { "text": [], "start": [], "entity_id": [] },"Time_elapsed": { "text": [], "start": [], "entity_id": [] },"Freq": { "text": [], "start": [], "entity_id": [] },"Combination": null,"Trigger": { "text": [], "start": [], "entity_id": [] }},"Effect": null,"Negated": { "text": [], "start": [], "entity_id": [],"value": false},"Speculated": { "text": [], "start": [], "entity_id": [],"value": false},"Severity": { "text": [], "start": [], "entity_id": [],"value": ""},"Subject": { "text": [], "start": [], "entity_id": [],"Age": { "text": [], "start": [], "entity_id": []},"Gender": { "text": [], "start": [], "entity_id": []},"Population": { "text": [], "start": [], "entity_id": []},"Race": { "text": [], "start": [], "entity_id": []},"Disorder": { "text": [], "start": [], "entity_id": []}}}]}
{"id": "8053440_1","context": "Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["clindamycin", "trimethoprim-sulfamethoxazole"]],"start": [["68"],["80"]],"entity_id": [ ["T3","T4"] ],"Drug": {"text": [["clindamycin"],["trimethoprim-sulfamethoxazole"]],"start": [["68"],["80"]],"entity_id": [ ["T5","T6"] ]} ,"Dosage": null,"Duration": null,"Disorder": {"text": [["Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)"]],"start": [["0"]],"entity_id": [ ["T2"] ]} ,"Time_elapsed": null,"Freq": null ,"Route": null ,"Combination": [ {"Drug": { "text": [["clindamycin"]], "start": [[ "68" ]], "entity_id": [ ["T5"] ]}, "Trigger": { "text": [["administration"]], "start": [[ "55" ]], "entity_id": [ ["T7"] ]} ,"event_id": "E2", "event_type": "Adverse_event" }] ,"Trigger": null },"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [ ["T8"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)"]],"start": [["0"]],"entity_id": [ ["T1"] ]} },"Effect": null }] }
{"id": "16012330_11","context": "The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["interaction"]],"start": [["39"]],"entity_id": []},"Treatment": {"text": [["itraconazole prophylaxis"]],"start": [["12"]],"entity_id": [],"Drug": {"text": [["itraconazole"]],"start": [["12"]],"entity_id": []} ,"Trigger": {"text": [["this drug"]],"start": [["52"]],"entity_id": []},"Time_elapsed": {"text": [["given"]],"start": [["50"]],"entity_id": []},"Disorder": {"text": [["severe and even potentially fatal toxicities"]],"start": [["63"]],"entity_id": []},"Combination": [{"Drug": {"text": [["itraconazole"]],"start": [["12"]],"entity_id": []},"Trigger": {"text": [["vincristine"]],"start": [["72"]],"entity_id": []} ,"event_id": "E2" ,"event_type": "Potential_therapeutic_effect"} ],"Freq": {"text": [["should be avoided"]],"start": [["93"]],"entity_id": []} ,"Dosage": {"text": [["any proven benefit"]],"start": [["23"]],"entity_id": []},"Route": {"text": [["prophylaxis"]],"start": [["12"]],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [],"start": [],"entity_id": []} }]}
{"id": "23042259_3","context": "The determinant role of individual pharmacogenetic profile in the occurrence of tacrolimus nephrotoxicity is presented and discussed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tacrolimus nephrotoxicity"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["individual pharmacogenetic profile"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["tacrolimus nephrotoxicity"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Population": {"text": [["The"]],"start": [["0"]],"entity_id": [["P1"]]} ,"Gender": {"text": [["The"]],"start": [["0"]],"entity_id": [["P2"]]} ,"Age": {"text": [["The"]],"start": [["0"]],"entity_id": [["P3"]]} ,"Race": {"text": [["The"]],"start": [["0"]],"entity_id": [["P4"]]} },"Treatment": {"text": [["tacrolimus"]],"start": [["18"]],"entity_id": [["T2"]],"Drug": {"text": [["tacrolimus"]],"start": [["18"]],"entity_id": [["T3"]]},"Dosage": {"text": [["determinant role"]],"start": [["0"]],"entity_id": [["D1"]]},"Duration": {"text": [["The"]],"start": [["0"]],"entity_id": [["D2"]]},"Trigger": {"text": [["occurrence"]],"start": [["57"]],"entity_id": [["T4"]]} ,"Route": {"text": [["The"]],"start": [["0"]],"entity_id": [["R1"]]} ,"Time_elapsed": {"text": [["The"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["The"]],"start": [["0"]],"entity_id": [["F1"]]} ,"Disorder": {"text": [["tacrolimus nephrotoxicity"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Combination": null} ,"Effect": {"text": [["presented"]],"start": [["52"]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10555917_4","context": "These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["bicytopenia"]],"start": [["These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage"]],"entity_id": [["T1"]]},"Treatment": {"text": [["D-Pen"]],"start": [[""]],"entity_id": [["T2"]],"Drug": {"text": [["D-Pen"]],"start": [[""]],"entity_id": [["T2"]]} ,"Combination": [{"Drug": {"text": [["D-Pen"]],"start": [[""]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["different sensitivities in the hematopoietic lineage"]],"start": [[""]],"entity_id": [["T3"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }],"Time_elapsed": {"text": [["caused"]],"start": [[""]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["bicytopenia"]],"start": [[""]],"entity_id": [["T1"]]} ,"Freq": {"text": [["may be due"]],"start": [[""]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["These findings suggest that bicytopenia in this patient was caused by"]],"start": [[""]],"entity_id": [["T6"]]} ,"Route": {"text": [["bicytopenia in this patient was caused by"]],"start": [[""]],"entity_id": [["T6"]]} ,"Duration": {"text": [["These findings suggest that bicytopenia in this patient was caused by"]],"start": [[""]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["bicytopenia"]],"start": [[""]],"entity_id": [["T1"]]} },"Subject": {"text": [["this patient"]],"start": [[""]],"entity_id": [["T7"]],"Age": {"text": [],"start": [[""], []],"entity_id": [["T7"]]},"Gender": {"text": [],"start": [[""], []],"entity_id": [["T7"]]},"Population": {"text": [],"start": [[""], []],"entity_id": [["T7"]]},"Race": {"text": [],"start": [[""], []],"entity_id": [["T7"]]},"Disorder": {"text": [["bicytopenia"]],"start": [[""]],"entity_id": [["T1"]]} },"Severity": {"text": [],"start": [[""], []],"entity_id": [["T1"]] ,"value": "Low" },"Negated": {"text": [],"start": [[""], []],"entity_id": [["T1"]],"value": false},"Speculated": {"text": [],"start": [[""], []],"entity_id": [["T1"]],"value": false} ,"Effect": {"text": [["bicytopenia"]],"start": [[""]],"entity_id": [["T1"]]}} ]}
{"id": "2320800_7","context": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": {"text": [["We strongly suspect that"]],"start": [["0"]],"entity_id": [["N1"]],"value": true},"Severity": {"text": [["lethal"]],"start": [["22"]],"entity_id": [["S1"]],"value": "high"},"Subject": {"text": [["patient"]],"start": [["102"]],"entity_id": [["S2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["poor kidney perfusion due to transient hypotension"]],"start": [["86"]],"entity_id": [["D1"]]}},"Treatment": {"text": [["ifosfamide"]],"start": [["41"]],"entity_id": [["T1"]],"Drug": {"text": [["ifosfamide"]],"start": [["41"]],"entity_id": [["T1"]]},"Disorder": {"text": [["cisplatin chemotherapy"]],"start": [["64"]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Freq": null,"Route": null,"Time_elapsed": null,"Trigger": {"text": [["mainly due to"]],"start": [["32"]],"entity_id": [["T3"]]},"Combination": null},"Effect": {"text": [["anuria"]],"start": [["11"]],"entity_id": [["E1"]]},"Trigger": {"text": [["this"]],"start": [["26"]],"entity_id": [["E2"]]}}]}
{"id": "12680486_2", "context": "Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lithium toxicity"]],"start": [[ "0"]],"entity_id": [ ]},"Treatment": {"text": [["thiazide diuretics"]],"start": [[ "94"]],"entity_id": [ ],"Drug": {"text": [["thiazide"]],"start": [[ "94"]],"entity_id": [ ]},"Disorder": {"text": [["lithium-induced polyuria and nephrogenic diabetes insipidus"]],"start": [[ "72"]],"entity_id": [ ]},"Trigger": {"text": [["administered"]],"start": [[ "94"]],"entity_id": [ ]},"Freq": {"text": [["many years"]],"start": [[ "22"]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["thiazide"]],"start": [[ "94"]],"entity_id": [ ]},"Trigger": {"text": [["administered"]],"start": [[ "94"]],"entity_id": [ ]},"event_id": "C1","event_type": "Treatment"}],"Time_elapsed": {"text": [["traditionally"]],"start": [[ "54"]],"entity_id": [ ]},"Dosage": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Duration": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [ ],"start": [[ ]],"entity_id": [ ]}},"Subject": {"text": [["Clinicians"]],"start": [[ "0"]],"entity_id": [ ],"Age": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["lithium toxicity"]],"start": [[ "22"]],"entity_id": [ ]},"Gender": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [ ],"start": [[ ]],"entity_id": [ ]},"Race": {"text": [ ],"start": [[ ]],"entity_id": [ ]}},"Effect": {"text": [["lithium-induced polyuria and nephrogenic diabetes insipidus"]],"start": [[ "72"]],"entity_id": [ ]},"Negated": {"text": [ ],"start": [[ ]],"entity_id": [ ],"value": false},"Speculated": {"text": [ ],"start": [[ ]],"entity_id": [ ],"value": false},"Severity": {"text": [ ],"start": [[ ]],"entity_id": [ ],"value": "low"}}]}
{"id": "19281746_2","context": "We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["aliskiren"]],"start": [["86"]],"entity_id": [["T3"]]},"text": [["the recently marketed direct renin inhibitor aliskiren"]],"start": [["56"]],"entity_id": [["T2"]] ,"Time_elapsed": {"text": [["with"]],"start": [["76"]],"entity_id": [["T4"]]},"Disorder": {"text": [["hyperkalemia"]],"start": [["30"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["aliskiren"]],"start": [["86"]],"entity_id": [["T3"]]},"Trigger": {"text": [["direct renin inhibitor"]],"start": [["62"]],"entity_id": [["T6"]]} ,"event_id": "C1","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["associated with"]],"start": [["48"]],"entity_id": [["T7"]]} ,"Route": {"text": [["with"]],"start": [["76"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Dosage": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]} },"Subject": {"Population": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Age": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]},"Race": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["the first case"]],"start": [["0"]],"entity_id": [["T0"]]},"text": [["We report"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["acute"]],"start": [["18"]],"entity_id": [["T1"]] ,"value": "high"} ,"Effect": {"text": [["acute renal failure"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "2803154_3","context": "The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) while being treated with lithium for a manic episode","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["syndrome of irreversible lithium-effectuated neurotoxicity (SILENT)"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["being treated with lithium"]],"start": [["82"]],"entity_id": [["T2"]],"Drug": {"text": [["lithium"]],"start": [["82"]],"entity_id": [["T3"]]},"Disorder": {"text": [["treated for a manic episode"]],"start": [["95"]],"entity_id": [["T4"]]},"Duration": {"text": [["while being treated with lithium"]],"start": [["82"]],"entity_id": [["T2"]]},"Route": {"text": [["being treated with lithium"]],"start": [["82"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["developed the syndrome"]],"start": [["32"]],"entity_id": [["T1"]]},"Freq": {"text": [["treated for a manic episode"]],"start": [["95"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["lithium"]],"start": [["82"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treated for a manic episode"]],"start": [["95"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "null"}],"Trigger": {"text": [["syndrome of irreversible lithium-effectuated neurotoxicity (SILENT)"]],"start": [["32"]],"entity_id": [["T1"]]},"Dosage": {"text": [["treated for a manic episode"]],"start": [["95"]],"entity_id": [["T4"]]}},"Subject": {"text": [["The authors describe a patient with hemiparesis"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["hemiparesis"]],"start": [["22"]],"entity_id": [["T5"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["syndrome of irreversible lithium-effectuated neurotoxicity (SILENT)"]],"start": [["32"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "8979664_2","context": "over the past 3 years there have been several reports of uveitis associated with rifabutin therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["uveitis"]],"start": [["over the past 3 years there have been several reports of uveitis associated with rifabutin therapy].index(<u>uveitis</u>)"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rifabutin therapy"]],"start": [["over the past 3 years there have been several reports of uveitis associated with <u>rifabutin therapy</u>"]],"entity_id": [["T2"]],"Drug": {"text": [["rifabutin"]],"start": [["over the past 3 years there have been several reports of uveitis associated with <u>rifabutin</u> therapy"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["over the past 3 years"]],"start": [["<u>over the past 3 years</u> there have been several reports of uveitis associated with rifabutin therapy"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["uveitis"]],"start": [["over the past 3 years there have been several reports of <u>uveitis</u> associated with rifabutin therapy"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["several reports"]],"start": [["over <u>several reports</u> of uveitis associated with rifabutin therapy"]],"entity_id": [["T6"]]} ,"Dosage": {"text": [["therapy"]],"start": [["over the past 3 years there have been several reports of uveitis associated with <u>rifabutin therapy</u>"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["3 years"]],"start": [["over the past <u>3 years</u> there have been several reports of uveitis associated with rifabutin therapy"]],"entity_id": [["T8"]]} ,"Route": {"text": [["therapy"]],"start": [["over the past 3 years there have been several reports of uveitis associated with <u>rifabutin therapy</u>"]],"entity_id": [["T9"]]} ,"Combination": null ,"Trigger": null },"Subject": null ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null }]}
{"id": "11414270_1","context": "Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Succinylcholine-induced hyperkalemia"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]}, "Treatment": { "Drug": { "text": [["Succinylcholine"]], "start": [[ "0" ]], "entity_id": [ ]} ,"Disorder": { "text": [["hyperkalemia"]], "start": [[ "15" ]], "entity_id": [ ]}, "entity_id": [ ], "text": [], "start": [] ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": { "text": [["Succinylcholine-induced"]], "start": [[ "0" ]], "entity_id": [ ]} }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["mucositis secondary to chemotherapy"]], "start": [[ "62" ]], "entity_id": [] }}, "Effect": { "text": [["hyperkalemia"]], "start": [[ "15" ]], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null }] }
{"id": "19745701_4","context": "To our knowledge, this is the first case of spontaneous remission of MTX-associated gastric LPD after discontinuation of MTX therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["spontaneous remission"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["discontinuation of MTX therapy"]],"start": [["55"]],"entity_id": [["T2"]],"Trigger": {"text": [["MTX"]],"start": [["34"]],"entity_id": [["T3"]]},"Drug": {"text": [["MTX"]],"start": [["34"]],"entity_id": [["T3"]]},"Disorder": {"text": [["gastric LPD"]],"start": [["25"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after discontinuation"]],"start": [["51"]],"entity_id": [["T5"]]},"Freq": {"text": [["first case"]],"start": [["9"]],"entity_id": [["T6"]]},"Combination": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Drug": {"text": [["MTX"]],"start": [["34"]],"entity_id": [["T3"]]},"Trigger": {"text": [["discontinuation"]],"start": [["51"]],"entity_id": [["T5"]]}}],"Duration": {"text": [["spontaneous remission"]],"start": [["0"]],"entity_id": [["T1"]]},"Dosage": {"text": [["MTX therapy"]],"start": [["36"]],"entity_id": [["T2"]]},"Route": {"text": [["discontinuation"]],"start": [["51"]],"entity_id": [["T5"]]}},"Subject": {"text": [["our knowledge"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["first case"]],"start": [["9"]],"entity_id": [["T6"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["spontaneous remission"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "8651254_5","context": "We describe a patient with acute myeloblastic leukemia (AML) who developed nephrotic syndrome after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["nephrotic syndrome"]],"start": [["developed nephrotic syndrome after receiving several courses of chemotherapy,"]],"entity_id": []},"Subject": {"text": [["a patient with acute myeloblastic leukemia (AML)"]],"start": [[ "We describe "]],"entity_id": [],"Disorder": {"text": [["acute myeloblastic leukemia (AML)"]],"start": [[ "a patient with acute myeloblastic leukemia (AML)"]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["chemotherapy","macrophage-colony-stimulating factor (M-CSF)"]],"start": [[ "who developed nephrotic syndrome after receiving several courses of chemotherapy,"]],"entity_id": [],"Drug": {"text": [["chemotherapy","macrophage-colony-stimulating factor (M-CSF)"]],"start": [[ "who developed nephrotic syndrome after receiving several courses of chemotherapy,"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["chemotherapy"]],"start": [[ "who developed nephrotic syndrome after receiving several courses of chemotherapy,"]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "E1-1","event_type": "Potential_therapeutic_effect"}],"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "7991279_1", "context": "Actinomycin D associated hepatic veno-occlusive disease--a report of 2 cases", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Actinomycin D"]], "start": [[]], "entity_id":[["T1"]]}, "Treatment": null, "Effect": {"text": [["hepatic veno-occlusive disease"]], "start": [[], ["23"]], "entity_id": [["T2"]]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["a report of 2 cases"]], "start": [[]],"entity_id": [["T3"]], "Population": null, "Disorder": null, "Gender": null, "Age": null, "Race": null}}]}
{"id": "8604715_3","context": "Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["foscarnet therapy"]],"start": [["32"]],"entity_id": [["T1"]]},"Effect": {"text": [["nephrogenic diabetes insipidus"]],"start": [["11"]],"entity_id": [["T2"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Our patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["foscarnet therapy"]],"start": [["32"]],"entity_id": [["T1"]]},"Effect": {"text": [["renal tubular acidosis"]],"start": [["51"]],"entity_id": [["T3"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Our patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": null}]}
{"id": "1401493_1","context": "We report a case of acne fulminans occurring during treatment with 13-cis-retinoic acid for cystic acne","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acne fulminans"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with 13-cis-retinoic acid"]],"start": [["17"]],"entity_id": [["T2"]],"Drug": {"text": [["13-cis-retinoic acid"]],"start": [["17"]],"entity_id": [["T3"]]},"Disorder": {"text": [["cystic acne"]],"start": [["77"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["during"]],"start": [["41"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["occurring"]],"start": [["43"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["treatment"]],"start": [["17"]],"entity_id": [["T2"]]} ,"Route": {"text": [["during"]],"start": [["41"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["during"]],"start": [["41"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["13-cis-retinoic acid"]],"start": [["17"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment"]],"start": [["17"]],"entity_id": [["T2"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Dosage": {"text": [["treatment with"]],"start": [["17"]],"entity_id": [["T2"]]} },"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["case"]],"start": [["30"]],"entity_id": [["T1"]]},"Disorder": {"text": [["cystic acne"]],"start": [["66"]],"entity_id": [["T4"]]} ,"Population": {"text": [["We"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Gender": {"text": [["case"]],"start": [["30"]],"entity_id": [["T1"]]} ,"Race": {"text": [["case"]],"start": [["30"]],"entity_id": [["T1"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "High" },"Effect": {"text": [["acne fulminans"]],"start": [["32"]],"entity_id": [["T1"]]} }]}
{"id": "20190474_1","context": "Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute kidney injury"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["zonisamide"]],"start": [[ "33"]],"entity_id": [["T2"]],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["hypersensitivity syndrome"]],"start": [[ "53"]],"entity_id": [ ["T3"]]},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "4004433_2","context": "Our findings suggest that hyperkalemia can develop with the use of low-dose heparin, within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hyperkalemia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["low-dose heparin"]],"start": [["31"]],"entity_id": [["T2"]],"Dosage": {"text": [["low-dose"]],"start": [["31"]],"entity_id": [["T2.1"]]},"Trigger": {"text": [["use"]],"start": [["25"]],"entity_id": [["T3"]]},"Duration": {"text": [["seven days"]],"start": [["47"]],"entity_id": [["T4"]]},"Route": {"text": [["initiating"]],"start": [["57"]],"entity_id": [["T5"]]},"Disorder": {"text": [["heparin therapy"]],"start": [["65"]],"entity_id": [["T6"]]},"Freq": {"text": [["develop"]],"start": [["6"]],"entity_id": [["T6.1"]]},"Time_elapsed": {"text": [["can develop"]],"start": [["6"]],"entity_id": [["T6.2"]]},"Combination": [{"Drug": {"text": [["low-dose heparin"]],"start": [["31"]],"entity_id": [["T2"]]},"Trigger": {"text": [["initiating"]],"start": [["57"]],"entity_id": [["T5"]]},"event_type": "Adverse_event","event_id": "E1.1"}],"Drug": {"text": [["low-dose heparin"]],"start": [["31"]],"entity_id": [["T2"]]}},"Subject": {"text": [["patients with diabetes mellitus or chronic renal insufficiency"]],"start": [["115"]],"entity_id": [["T7"]],"Disorder": {"text": [["diabetes mellitus or chronic renal insufficiency"]],"start": [["115"]],"entity_id": [["T7.1"]]},"Population": {"text": [["patients"]],"start": [["115"]],"entity_id": [["T7.2"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["severely"]],"start": [["9"]],"entity_id": [["T1.1"]],"value": "high"},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["develop"]],"start": [["6"]],"entity_id": [["T6.1"]]}}]}
{"id": "20120657_2","context": "We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Zidovudine induced anaemia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Zidovudine"]],"start": [["10"]],"entity_id": [["T2"]],"Drug": {"text": [["Zidovudine"]],"start": [["10"]],"entity_id": [["T2"]]},"Disorder": {"text": [["anaemia and bone marrow aplasia"]],"start": [["24"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["induced"]],"start": [["18"]],"entity_id": [["T4"]]},"Freq": {"text": [["case"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["Zidovudine"]],"start": [["10"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["18"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["induced"]],"start": [["18"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["a patient infected with HIV"]],"start": [["55"]],"entity_id": [["T5"]],"Population": {"text": [["a patient"]],"start": [["55"]],"entity_id": [["T5"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["HIV"]],"start": [["67"]],"entity_id": [["T6"]]}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Effect": {"text": [["anaemia and bone marrow aplasia"]],"start": [["24"]],"entity_id": [["T3"]]}}]}
{"id": "19390192_3","context": "We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and leukopenia during long-term AZA therapy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["AZA"]],"start": [["58"]],"entity_id": [["T1"]]},"Disorder": {"text": [["leukopenia"]],"start": [["39"]],"entity_id": [["T2"]]},"Duration": {"text": [["long-term"]],"start": [["48"]],"entity_id": [["T3"]]} ,"entity_id": [["T1"]],"text": [["AZA"]],"start": [[ "58" ]] ,"Trigger": {"text": [["during"]],"start": [[ "44" ]],"entity_id": [["T4"]]} ,"Freq": {"text": [["long-term"]],"start": [[ "48" ]],"entity_id": [["T3"]]},"Route": {"text": [["therapy"]],"start": [[ "66" ]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["during"]],"start": [[ "44" ]],"entity_id": [["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null} ,"Subject": {"text": [["an adult Crohn's disease patient"]],"start": [[ "10" ]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["Crohn's disease"]],"start": [[ "19" ]],"entity_id": [["T7"]]},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "18094347_7", "context": "Pathogenesis of methotrexate-induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexid-induced cutaneous vasculitis in collagen vascular disease", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["methotrexate-induced papular eruption"]], "start": [[ "pathogenesis" ] , ["methotrexate-induced papular eruption" ]], "entity_id": [ ["T1"] , ["T2"] ] }, "Treatment": { "text": [["methotrexate"]], "start": [[ "methotrexate-induced papular eruption" ]], "entity_id": [ ["T3"] ] , "Drug": { "text": [["methotrexate"]], "start": [[ "methotrexate-induced papular eruption" ]], "entity_id": [ ["T4"] ] } , "Disorder": { "text": [["psoriasis"]], "start": [[ "psoriasis" ]], "entity_id": [ ["T5"] ] } , "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null , "Combination": null } , "Negated": null, "Speculated": null, "Severity": null , "Subject": { "text": [["Pathogenesis"]], "start": [[ "pathogenesis" ]], "entity_id": [ ["T0"] ], "Age": null, "Disorder": { "text": [["psoriasis"]], "start": [[ "psoriasis" ]], "entity_id": [ ["T5"] ] }, "Gender": null, "Population": null, "Race": null } , "Effect": { "text": [["immune mechanisms"]], "start": [[ "immune mechanisms" ]], "entity_id": [ ["T6"] ] } } ] }
{"id": "9205466_2", "context": "Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed uterine enlargement and intermittent spotting", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["uterine enlargement", "intermittent spotting"]], "start": [["39", "54"]], "entity_id": []}, "Subject": {"text": [["Two postmenopausal women"]], "start": [["0"]], "Age": {"text": [["postmenopausal"]], "start": [["3"]], "entity_id": []}, "Gender": {"text": [["women"]], "start": [["21"]], "entity_id": []}, "Disorder": {"text": [["breast carcinoma"]], "start": [["45"]], "entity_id": []}, "Population": {"text": [["Two"]], "start": [["0"]], "entity_id": []} , "entity_id": [] , "Race": {"text": [], "start": [], "entity_id": []} }, "Treatment": { "text": [["tamoxifen and progestational agents"]], "start": [["27"]], "Drug": { "text": [["tamoxifen"]], "start": [["27"]], "entity_id": [] }, "entity_id": [] , "Disorder": { "text": [["breast carcinoma"]], "start": [["45"]], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": [{ "Drug": { "text": [["tamoxifen"]], "start": [["27"]], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "event_id": "E1-C1", "event_type": "null" }, { "Drug": { "text": [["progestational agents"]], "start": [["42"]], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "event_id": "E1-C2", "event_type": "null" }] , "Trigger": { "text": [], "start": [], "entity_id": [] } } , "Effect": { "text": [["uterine enlargement", "intermittent spotting"]], "start": [["39", "54"]], "entity_id": [] } , "Negated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false }, "Severity": { "text": [], "start": [], "entity_id": [] , "value": "" } }]}
{"id": "19570088_1", "context": "Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Tumor lysis syndrome"]], "start": [[ ]], "entity_id": []}, "Treatment": {"text": [["transcatheter arterial infusion of cisplatin and embolization therapy"]], "start": [[ ]], "entity_id": [],"Drug": {"text": [["cisplatin"]], "start": [[ ]], "entity_id": [] },"Disorder": {"text": [["Tumor lysis syndrome"]], "start": [[ ]], "entity_id": [] },"Route": {"text": [["transcatheter arterial infusion"]], "start": [[ ]], "entity_id": [] },"Trigger": {"text": [["after"]], "start": [[ ]], "entity_id": [] },"Time_elapsed": {"text": [["after"]], "start": [[ ]], "entity_id": [] },"Duration": {"text": [["therapy"]], "start": [[ ]], "entity_id": [] },"Freq": {"text": [["therapy"]], "start": [[ ]], "entity_id": [] },"Combination": [{"Drug": {"text": [["cisplatin"]], "start": [[ ]], "entity_id": []},"Trigger": {"text": [["and"]], "start": [[ ]], "entity_id": []},"event_type": "Treatment","event_id": "C1"}] ,"Dosage": {"text": [], "start": [[ ]], "entity_id": [] }}, "Effect": {"text": [["Tumor lysis syndrome"]], "start": [[ ]], "entity_id": [] },"Negated": {"text": [], "start": [[ ]], "entity_id": [] ,"value": false},"Speculated": {"text": [], "start": [[ ]], "entity_id": [] ,"value": false},"Severity": {"text": [], "start": [[ ]], "entity_id": [] ,"value": "low" },"Subject": {"text": [["Tumor lysis syndrome"]], "start": [[ ]], "entity_id": [] ,"Age": {"text": [], "start": [[ ]], "entity_id": []},"Disorder": {"text": [["Tumor lysis syndrome"]], "start": [[ ]], "entity_id": []},"Gender": {"text": [], "start": [[ ]], "entity_id": []},"Population": {"text": [], "start": [[ ]], "entity_id": []},"Race": {"text": [], "start": [[ ]], "entity_id": []}}}]}
{"id": "18821094_1", "context": "Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["Oxcarbazepine"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ], "Disorder": { "text": [["Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)" ]], "start": [[ "42" ]], "entity_id": [ ["T2" ] ]}, "Population": { "text": [["patients"]], "start": [[ "65" ]], "entity_id": [ ["T3" ] ]} , "Age": null, "Gender": null, "Race": null } , "Treatment": { "text": [[ "Oxcarbazepine"]], "start": [[ "0" ]], "entity_id": [[ "T1" ]], "Drug": { "text": [[ "Oxcarbazepine" ]], "start": [[ "0" ]], "entity_id": [[ "T1" ]] } , "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": null, "Combination": null } , "Effect": { "text": [[ "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)"]], "start": [[ "42" ]], "entity_id": [[ "T2" ]] } , "Negated": null, "Speculated": null, "Severity": null , "Trigger": { "text": [[ "Oxcarbazepine-induced" ]], "start": [[ "7" ]], "entity_id": [[ "T4" ]] } } ]}
{"id": "3579660_4", "context": "Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Worsening of neurologic syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]}, "Subject": {"text": [["patients with Wilson's disease"]], "start": [[ "41" ]], "entity_id": [ ["T2" ] ], "Disorder": {"text": [["Wilson's disease"]], "start": [[ "54" ]], "entity_id": [ ["T3" ] ]} , "Population": {"text": [["patients"]], "start": [[ "41" ]], "entity_id": [ ["T2" ] ]} , "Race": {"text": [], "start": [], "entity_id": []} , "Gender": {"text": [], "start": [], "entity_id": []} , "Age": {"text": [], "start": [], "entity_id": []} }, "Treatment": {"text": [["initial penicillamine therapy"]], "start": [[ "72" ]], "entity_id": [ ["T4" ] ], "Drug": {"text": [["penicillamine"]], "start": [[ "81" ]], "entity_id": [ ["T5" ] ]} , "Disorder": {"text": [["Wilson's disease"]], "start": [[ "41" ]], "entity_id": [ ["T2" ] ]} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Route": {"text": [["therapy"]], "start": [[ "72" ]], "entity_id": [ ["T4" ] ]} , "Time_elapsed": {"text": [], "start": [], "entity_id": []} , "Freq": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": null }, "Effect": {"text": [["Worsening of neurologic syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]} , "Negated": null , "Speculated": null , "Severity": null }]}
{"id": "15494638_7", "context": "Patient A reported right leg weakness (foot drop) during week 4 of CAP-XRT (1600 mg/m2).", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["right leg weakness", "foot drop"]], "start": [["22","35"]], "entity_id": []}, "Subject": {"text": [["Patient A"]], "start": [["0"]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}, "Treatment": {"text": [["CAP-XRT"]], "start": [["52"]], "entity_id": [],"Drug": null,"Dosage": {"text": [["1600 mg/m2"]], "start": [["60"]], "entity_id": []},"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null}, "Effect": {"text": [["right leg weakness", "foot drop"]], "start": [["22","35"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "3763264_2","context": "A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["phenobarbital hypersensitivity drug reaction"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenobarbital"]],"start": [["16"]],"entity_id": [["T2"]],"Drug": {"text": [["phenobarbital"]],"start": [["16"]],"entity_id": [["T3"]]},"Disorder": {"text": [["fever"]],"start": [["49"]],"entity_id": [["T4"]]},"Dosage": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Duration": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Route": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Time_elapsed": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Freq": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Combination": null,"Trigger": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T5"]]}},"Effect": {"text": [["a pruritic desquamating erythrodermic rash","alopecia","icterus","protein-losing enteropathy","myositis","nephritis"]],"start": [["62","97","116","143","165","183"],["87","104","120","149","173","191"]],"entity_id": [["T6","T7","T8","T9","T10","T11"]]},"Subject": {"text": [["A child"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Gender": {"text": [["child"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["1"]],"start": [[],[]],"entity_id": []},"Race": {"text": [["N/A"]],"start": [[],[]],"entity_id": []},"Disorder": {"text": [["N/A"]],"start": [[],[]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["N/A"]],"start": [[],[]],"entity_id": [],"value": "N/A"}}]}
{"id": "10229976_1", "context": "Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["activated eosinophils"]], "start": [["33","34"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["aspirin-induced asthma"]], "start": [["54","55"]], "entity_id": [["T2"]], "Disorder": {"text": [["aspirin-induced asthma"]], "start": [["54","55"]], "entity_id": [["T3"]] } ,"Drug": {"text": [["aspirin"]], "start": [["54","55"]], "entity_id": [["T4"]] } ,"Time_elapsed": {"text": [["induced"]], "start": [["54"]], "entity_id": [["T5"]] } ,"Route": {"text": [["inhalation"]], "start": [["54"]], "entity_id": [["T6"]]} ,"Freq": {"text": [["during detection"]], "start": [["0"]], "entity_id": [["T7"]]} ,"Combination": [{"Drug": {"text": [["aspirin"]], "start": [["54","55"]], "entity_id": [["T4"]]} ,"Trigger": {"text": [["induced"]], "start": [["54"]], "entity_id": [["T5"]]} , "event_id": "C1" ,"event_type": "Adverse_event"}] ,"Trigger": {"text": [["detection"]], "start": [["0"]], "entity_id": [["T8"]]} ,"Dosage": {"text": [["not applicable"]], "start": [["]],"], ["entity_id"] , ["T9"]] ,"entity_id": [["T9"]]} ,"Duration": {"text": [["not applicable"]], "start": [["]],"], ["entity_id"] , ["T10"]] ,"entity_id": [["T10"]]} } ,"Subject": { "text": [["an aspirin-induced asthma patient"]], "start": [["54"]], "entity_id": [["T2"]], "Age": {"text": [["not applicable"]], "start": [["]],"], ["entity_id"] , ["T11"]] ,"entity_id": [["T11"]] } ,"Gender": {"text": [["not applicable"]], "start": [["]],"], ["entity_id"] , ["T12"]] ,"entity_id": [["T12"]] } ,"Population": {"text": [["one"]], "start": [["0"]], "entity_id": [["T13"]]} ,"Race": {"text": [["not applicable"]], "start": [["]]], ["],["entity_id"] , ["T14"]] ,"entity_id": [["T14"]]} ,"Disorder": {"text": [["nasal polyps"]], "start": [["26","27"]], "entity_id": [["T15"]]} } ,"Severity": {"text": [["activated"]], "start": [["33"]], "entity_id": [["T1"]], "value": "low" } ,"Negated": {"text": [["not applicable"]], "start": [["]]], ["],["entity_id"] , ["T16"]] ,"entity_id": [["T16"]], "value": false } ,"Speculated": {"text": [["not applicable"]], "start": [["]]], ["],["entity_id"] , ["T17"]] ,"entity_id": [["T17"]], "value": false } ,"Effect": {"text": [["activated eosinophils"]], "start": [["33","34"]], "entity_id": [["T1"]]} }]}
{"id": "19540093_5","context": "We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including abdominal pain, during treatment with tigecycline","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["treatment with tigecycline"]],"start": [[ ],["treatment with tigecycline"],["tigecycline"]],"entity_id": [["T1"],["T2"],["T3"]]},"Treatment": {"text": [["treatment with tigecycline"]],"start": [["treatment with tigecycline"],["tigecycline"]],"entity_id": [["T2"],["T3"]],"Drug": {"text": [["tigecycline"]],"start": [["tigecycline"]],"entity_id": [["T3"]]},"Duration": {"text": [["during"]],"start": [["during"]],"entity_id": [["T4"]]},"Disorder": {"text": [["pancreatitis"]],"start": [["pancreatitis"]],"entity_id": [["T5"]]},"Freq": {"text": [["monitor"]],"start": [["monitor"]],"entity_id": [["T6"]]},"Trigger": {"text": [["monitor"]],"start": [["monitor"]],"entity_id": [["T6"]]},"Route": {"text": [["treatment with tigecycline"]],"start": [["treatment with tigecycline"],["tigecycline"]],"entity_id": [["T2"],["T3"]]},"Time_elapsed": {"text": [["during"]],"start": [["during"]],"entity_id": [["T4"]]},"Dosage": {"text": [["treatment with tigecycline"]],"start": [["treatment with tigecycline"],["tigecycline"]],"entity_id": [["T2"],["T3"]]},"Combination": [{"Drug": {"text": [["tigecycline"]],"start": [["tigecycline"]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment with tigecycline"]],"start": [["treatment with tigecycline"]],"entity_id": [["T2"]]},"event_id": "E2","event_type": "Adverse_event"}]},"Subject": {"text": [["patients"]],"start": [["patients"]],"entity_id": [["T7"]],"Population": {"text": [["patients"]],"start": [["patients"]],"entity_id": [["T7"]]},"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["pancreatitis"]],"start": [["pancreatitis"]],"entity_id": [["T5"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["monitor"]],"start": [["monitor"]],"entity_id": [["T6"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "11568758_3","context": "We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["lichenoid eruption"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["salsalate"]],"start": [["82"]],"entity_id": [["T2"]],"Disorder": {"text": [["arthritic pain"]],"start": [["91"]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [["after the initiation"]],"start": [["54"]],"entity_id": [["T4"]]} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Drug": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["a patient"]],"start": [["11"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null} ,"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "20203465_3","context": "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["nausea", "shortness of breath", "azotemia", "hyperkalemia"]],"start": [[ "14", "23", "35", "46" ]],"entity_id": [["T1", "T2", "T3", "T4" ]]},"Subject": {"text": [["an 87-year-old white woman"]],"start": [["0"]],"entity_id": [["T5"]],"Age": {"text": [["87"]],"start": [["2"]],"entity_id": [["T7"]]},"Gender": {"text": [["woman"]],"start": [["12"]],"entity_id": [["T8"]]},"Race": {"text": [["white"]],"start": [["10"]],"entity_id": [["T9"]]},"Disorder": {"text": [["myasthenia gravis"]],"start": [["36"]],"entity_id": [["T10"]]},"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["intravenous immunoglobulin (IVIG)"]],"start": [["74"]],"entity_id": [["T11"]],"Drug": {"text": [["intravenous immunoglobulin"]],"start": [["74"]],"entity_id": [["T12"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["intravenous"]],"start": [["74"]],"entity_id": [["T13"]]},"Time_elapsed": {"text": [["shortly after completing a course"]],"start": [["52"]],"entity_id": [["T14"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "17655517_8", "context": "Linezolid should be discontinued immediately in patients experiencing these adverse effects", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["these adverse effects"]], "start": [["experiencing these adverse effects" , "adverse effects" ] ], "entity_id": []}, "Treatment": {"text": [["Linezolid"]], "start": [[ "Linezolid" ]], "entity_id": [],"Drug": {"text": [["Linezolid"]], "start": [[ "Linezolid" ]], "entity_id": []},"Disorder": {"text": [["adverse effects"]], "start": [[ "experiencing these adverse effects" ]], "entity_id": []},"Trigger": {"text": [["immediately"]], "start": [[ "immediately" ]], "entity_id": []},"Route": {"text": [["in patients"]], "start": [[ "patients" ]], "entity_id": []},"Freq": {"text": [["should be discontinued"]], "start": [[ "should be discontinued" ]], "entity_id": []},"Combination": [{"event_type": "Adverse_event", "event_id": "E1", "Drug": {"text": [["Linezolid"]], "start": [[ "Linezolid" ]], "entity_id": []},"Trigger": {"text": [["immediately"]], "start": [[ "immediately" ]], "entity_id": []}}] , "Dosage": { "text": [], "start": [], "entity_id": []} ,"Duration": { "text": [], "start": [], "entity_id": []} ,"Time_elapsed": { "text": [], "start": [], "entity_id": []} } ,"Subject": { "text": [], "start": [], "entity_id": [] ,"Age": { "text": [], "start": [], "entity_id": []} ,"Disorder": { "text": [["adverse effects"]], "start": [[ "experiencing these adverse effects" ]], "entity_id": []} ,"Gender": { "text": [], "start": [], "entity_id": []} ,"Population": { "text": [], "start": [], "entity_id": []} ,"Race": { "text": [], "start": [], "entity_id": []} } ,"Negated": { "text": [], "start": [], "entity_id": [] ,"value": false } ,"Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false } ,"Severity": { "text": [], "start": [], "entity_id": [] ,"value": "" } , "Effect": { "text": [], "start": [], "entity_id": []}}]}
{"id": "11077455_3","context": "Symptomatic visual field constriction thought to be associated with vigabatrin has been reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["visual field constriction"]],"start": [["22"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["vigabatrin"]],"start": [["78"]],"entity_id": [["T2"]],"Drug": {"text": [["vigabatrin"]],"start": [["78"]],"entity_id": [ ["T2"]]} ,"Combination": null ,"Dosage": null ,"Duration": null ,"Route": null ,"Time_elapsed": null ,"Freq": null ,"Disorder": null ,"Trigger": {"text": [["thought to be associated with"]],"start": [["36","42"]],"entity_id": [ ["T3"]]}} ,"Effect": {"text": [["Symptomatic"]],"start": [["0"]],"entity_id": [ ["T0"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19857154_1","context": "Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["drug interaction"]],"start": [["33", "34"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["quetiapine"]],"start": [["0", "1"]],"entity_id": [["T2"]]},"Trigger": {"text": [["and"]],"start": [["43"]],"entity_id": [["T3"]]},"Dosage": null,"Freq": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": {"text": [["adverse events"]],"start": [["14", "15"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["atazanavir-ritonavir"]],"start": [["22", "23"]],"entity_id": [["T5"]]},"Trigger": null,"event_id": "E2","event_type": "Adverse_event"}],"entity_id": [["T1"]],"text": [["adverse events"]],"start": [["14", "15"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["Clinically significant"]],"start": [["0"]],"entity_id": [["T6"]]}}]}
{"id": "1477441_4","context": "To report two cases of fixed drug eruption induced by methylphenidate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fixed drug eruption"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methylphenidate"]],"start": [["66"]],"entity_id": [["T2"]],"Drug": {"text": [["methylphenidate"]],"start": [["66"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["fixed drug eruption"]],"start": [["21"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["two cases"]],"start": [["7"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["methylphenidate"]],"start": [["66"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["induced"]],"start": [["48"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Adverse_event"} ],"Time_elapsed": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Route": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["induced"]],"start": [["48"]],"entity_id": [["T3"]]} },"Subject": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]],"Disorder": {"text": [["fixed drug eruption"]],"start": [["21"]],"entity_id": [["T1"]]},"Age": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Population": {"text": [["two cases"]],"start": [["7"]],"entity_id": [["T0"]]} ,"Race": {"text": [["report"]],"start": [["0"]],"entity_id": [["T4"]]} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low" },"Effect": {"text": [["fixed drug eruption"]],"start": [["21"]],"entity_id": [["T1"]]} }] }
{"id": "17655517_2", "context": "Linezolid is an oxazolidinone antibacterial agent indicated for serious gram-positive infections", "is_mult_event": false, "annotations": []}
{"id": "17675030_1","context": "A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric patients aged 16 years and younger","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["oxcarbazepine-associated angioedema"]],"start": [["34"]],"entity_id": [["T1"]]},"Subject": {"text": [["pediatric patients"]],"start": [["86"]],"entity_id": [["T2"]],"Age": {"text": [["16 years and younger"]],"start": [["100"]],"entity_id": [["T3"]]},"Disorder": {"text": [["oxcarbazepine-associated angioedema"]],"start": [["34"]],"entity_id": [["T1"]]},"Population": {"text": [["nine cases"]],"start": [["18"]],"entity_id": [["T4"]]},"Gender": {"text": [["pediatric patients"]],"start": [["86"]],"entity_id": [["T2"]]},"Race": {"text": [["pediatric patients"]],"start": [["86"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["oxcarbazepine"]],"start": [["13"]],"entity_id": [["T5"]],"Drug": {"text": [["oxcarbazepine"]],"start": [["13"]],"entity_id": [["T5"]]},"Disorder": {"text": [["oxcarbazepine-associated angioedema"]],"start": [["34"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["oxcarbazepine-associated angioedema"]],"start": [["34"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "Low"},"Effect": {"text": [["angioedema"]],"start": [["40"]],"entity_id": [["T6"]]}}]}
{"id": "2140997_2","context": "Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate; the drug should be withdrawn immediately if abnormal liver function tests are found","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"Drug": {"text": [["cyproterone acetate"]],"start": [["51"]],"entity_id": [["T1"]]},"Dosage": {"text": [["high doses"]],"start": [["34"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["receiving"]],"start": [["42"]],"entity_id": [["T3"]]} ,"Route": {"text": [["orally"]],"start": [["95"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["if abnormal liver function tests are found"]],"start": [["116"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["mandatory"]],"start": [["25"]],"entity_id": [["T6"]]} ,"entity_id": [["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"]] ,"text": [["Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate; the drug should be withdrawn immediately if abnormal liver function tests are found"]],"start": [[], [], [], [], [], []],"Time_elapsed": {"text": [[]],"start": [[], [], [], [], [], []],"entity_id": [[]]} ,"Disorder": {"text": [["liver function tests"]],"start": [["77"]],"entity_id": [["T7"]]} ,"Combination": null },"Effect": {"text": [["abnormal liver function tests"]],"start": [["105"]],"entity_id": [["T8"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["patients"]],"start": [["43"]],"entity_id": [["T9"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Trigger": null }] }
{"id": "6311654_3", "context": "In six cases CT scans did not return to their original state after ACTH therapy.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": {"value": false, "text": [["did not return"]], "start": [["did not return's index"]], "entity_id": []}, "Treatment": {"text": [["ACTH therapy"]], "start": [["ACTH therapy's index"]], "entity_id": [],"Trigger": {"text": [["ACTH therapy"]], "start": [["ACTH therapy's index"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["CT scans"]], "start": [[">CT scans' index"]], "entity_id": []},"Combination": null,"Drug": null},"Effect": {"text": [["did not return to their original state"]], "start": [[">did not return to their original state's index"]], "entity_id": []}, "Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "16204273_2", "context": "This report describes a probable case of infliximab-induced membranous nephropathy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": {"value": true, "text": [["probable"]], "start": [["0"]], "entity_id": []}, "Severity": null, "Subject": null, "Treatment": {"text": [["infliximab"]], "start": [["42"]], "entity_id": [], "Drug": {"text": [["infliximab"]], "start": [["42"]], "entity_id": []},"Disorder":{"text":[["membranous nephropathy"]],"start":[["56"]],"entity_id":[]},"Dosage":null,"Duration":null,"Trigger":null,"Route":null,"Time_elapsed":null,"Freq":null,"Combination":null}, "Effect": {"text": [["infliximab-induced membranous nephropathy"]], "start": [["22"]], "entity_id": []}, "Trigger": null}]}
{"id": "6683487_1","context": "Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["penicillamine therapy"]],"start": [["42"]],"entity_id": [],"Drug": {"text": [["penicillamine"]],"start": [["42"]],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["61"]],"entity_id": []},"Dosage": {"text": [[]],"start": [[]],"entity_id": []},"Duration": {"text": [[]],"start": [[]],"entity_id": []},"Route": {"text": [[]],"start": [[]],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [[]],"entity_id": []},"Freq": {"text": [[]],"start": [[]],"entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["Thrombotic thrombocytopenic purpura"]],"start": [["0"]],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "9195619_1","context": "However, as the use of hepatitis B vaccination is growing, adverse side effects, including mental nerve neuropathy, should be observed with an increased frequency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse side effects"]],"start": [["35","35"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["hepatitis B vaccination"]],"start": [["14","14"]],"entity_id": [["T2"]]},"text": [["hepatitis B vaccination"]],"start": [["14","14"]],"entity_id": [["T2"]],"Disorder": {"text": [["mental nerve neuropathy"]],"start": [["86","86"]],"entity_id": [["T3"]]},"Freq": {"text": [["increased frequency"]],"start": [["105","105"]],"entity_id": [["T4"]]},"Trigger": {"text": [["growing"]],"start": [["17","17"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["growing"]],"start": [["17","17"]],"entity_id": [["T5"]]},"Duration": {"text": [["growing"]],"start": [["17","17"]],"entity_id": [["T5"]]},"Route": {"text": [["growing"]],"start": [["17","17"]],"entity_id": [["T5"]]},"Dosage": {"text": [["growing"]],"start": [["17","17"]],"entity_id": [["T5"]]},"Combination": null},"Effect": {"text": [["adverse side effects"]],"start": [["35","35"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "15494638_3","context": "Capecitabine (CAP) is a pro-drug of 5-FU and peripheral neuropathy associated with CAP has not been reported","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Capecitabine (CAP)"]],"start": [[ "0" ]],"entity_id": [["T1"]],"Drug": {"text": [["Capecitabine"]],"start": [[ "0" ]],"entity_id": [["T2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": null,"Freq": null,"Combination": null,"Trigger": {"text": [["CAP"]],"start": [[ "27" ]],"entity_id": [["T3"]]}},"Effect": null,"Negated": {"text": [["has not been reported"]],"start": [[ "62" ]],"entity_id": [["T4"]],"value": true},"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "15126179_3", "context": "To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["angiographically documented cystoid macula edema"]], "start": [["41"]], "entity_id": []}, "Treatment": {"text": [["latanoprost", "bimatoprost"]], "start": [["120","142"]], "entity_id": [],"Drug": {"text": [["latanoprost","bimatoprost"]], "start": [["120","142"]], "entity_id": []}, "Disorder": {"text": [["occurring after switching a pseudophakic patient"]], "start": [["72"]], "entity_id": []}, "Route": {"text": [["occurring after switching"]], "start": [["72"]], "entity_id": []}, "Time_elapsed": {"text": [["occurring after switching"]], "start": [["72"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["latanoprost"]], "start": [["120"]], "entity_id": []},"Trigger": {"text": [["to"]], "start": [["135"]], "entity_id": []},"event_id": "E11", "event_type": "Adverse_event"},{"Drug": {"text": [["bimatoprost"]], "start": [["142"]], "entity_id": []},"Trigger": {"text": [[]], "start": [[], []], "entity_id": []},"event_id": "E12", "event_type": "Adverse_event"}], "Trigger": {"text": [["occurring after switching"]], "start": [["72"]], "entity_id": []}, "Freq": {"text": [[]], "start": [[],[]], "entity_id": []}, "Dosage": {"text": [[]], "start": [[],[]], "entity_id": []}, "Duration": {"text": [[]], "start": [[],[]], "entity_id": []}},"Subject": {"text": [["a pseudophakic patient"]], "start": [["94"]], "entity_id": [],"Age": {"text": [], "start": [[],[]], "entity_id": []},"Gender": {"text": [], "start": [[],[]], "entity_id": []},"Population": {"text": [], "start": [[],[]], "entity_id": []},"Race": {"text": [], "start": [[],[]], "entity_id": []},"Disorder": {"text": [], "start": [[],[]], "entity_id": []}},"Effect": {"text": [["angiographically documented cystoid macula edema"]], "start": [["41"]], "entity_id": []},"Severity": {"text": [], "start": [[],[]], "entity_id": [],"value": ""},"Negated": {"text": [], "start": [[],[]], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [[],[]], "entity_id": [],"value": false}}]}
{"id": "15013892_4", "context": "The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["chloroquine and hydroxychloroquine maculopathy"]], "start": [[ "36" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "text": [["chloroquine"]], "start": [[ "14" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["chloroquine"]], "start": [[ "14" ]], "entity_id": [ ["T3"] ] } ,"Disorder": { "text": [["chloroquine and hydroxychloroquine maculopathy"]], "start": [[ "36" ]], "entity_id": [ ["T1"] ] } ,"Dosage": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] } ,"Trigger": { "text": [], "start": [], "entity_id": [] } ,"Route": { "text": [], "start": [], "entity_id": [] } ,"Time_elapsed": { "text": [], "start": [], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Combination": null } , "Negated": null, "Speculated": null, "Severity": null ,"Subject": null , "Effect": { "text": [["clinical picture"]], "start": [[ "0" ]], "entity_id": [ ["T0"] ] } }]}
{"id": "19299370_2","context": "A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hepatotoxicity"]],"start": [["51"]],"entity_id": [["T1"]]},"Treatment": {"text": [["enoxaparin"]],"start": [["17"]],"entity_id": [["T2"]],"Dosage": {"text": [["every 12 hours"]],"start": [["25"]],"entity_id": [["T3"]]},"Route": {"text": [["receiving"]],"start": [["10"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["after the second dose"]],"start": [["70"]],"entity_id": [["T5"]]},"Disorder": {"text": [["signs and symptoms"]],"start": [["43"]],"entity_id": [["T6"]]},"Freq": {"text": [["every 12 hours"]],"start": [["25"]],"entity_id": [["T3"]]},"Drug": {"text": [["enoxaparin"]],"start": [["17"]],"entity_id": [["T2"]]},"Duration": {"text": [["after the second dose"]],"start": [["70"]],"entity_id": [["T5"]]},"Trigger": {"text": [["developed"]],"start": [["40"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["enoxaparin"]],"start": [["17"]],"entity_id": [["T2"]]},"Trigger": {"text": [["developed"]],"start": [["40"]],"entity_id": [["T7"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["A woman"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [[]],"start": [[], []],"entity_id": [[]]},"Gender": {"text": [["A woman"]],"start": [["0"]],"entity_id": [["T8"]]},"Race": {"text": [[]],"start": [[], []],"entity_id": [[]]},"Disorder": {"text": [[]],"start": [[], []],"entity_id": [[]]},"Population": {"text": [[]],"start": [[], []],"entity_id": [[]]}},"Effect": {"text": [["signs and symptoms of hepatotoxicity"]],"start": [["43"]],"entity_id": [["T6"]]},"Severity": {"text": [[]],"start": [[], []],"entity_id": [[]],"value": ""},"Speculated": {"text": [[]],"start": [[], []],"entity_id": [[]],"value": false},"Negated": {"text": [[]],"start": [[], []],"entity_id": [[]],"value": false}}]}
{"id": "2257522_1", "context": "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypophosphatemic osteomalacia"]], "start": [["26"]], "entity_id": []}, "Treatment": {"text": [["Antacid and sucralfate"]], "start": [["5"]], "entity_id": [], "Drug": {"text": [["Antacid", "sucralfate"]], "start": [["5"]], "entity_id": [] } ,"Disorder": {"text": [["hypophosphatemic osteomalacia"]], "start": [["26"]], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Route": {"text": [], "start": [], "entity_id": [] } ,"Time_elapsed": {"text": [], "start": [], "entity_id": [] } ,"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination": [] ,"Trigger": {"text": [["induced"]], "start": [["23"]], "entity_id": [] } }, "Effect": {"text": [], "start": [], "entity_id": [] } ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null ,"Disorder": {"text": [], "start": [], "entity_id": [] } ,"Gender": null ,"Population": null ,"Race": null }} ]}
{"id": "16268429_3", "context": "We report a case of senna-induced cholestatic hepatitis which was not diagnosed at presentation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["senna-induced cholestatic hepatitis"]], "start": [["33","34"]], "entity_id": []}, "Treatment": {"text": [], "start": [], "entity_id": [], "Drug": {"text": [["senna"]], "start": [["7","8"]], "entity_id": [] } ,"Disorder": {"text": [["cholestatic hepatitis"]], "start": [["20","21"]], "entity_id": [] } ,"Time_elapsed": {"text": [["which was not diagnosed at presentation"]], "start": [["52","53","54"]], "entity_id": [] } , "Route": {"text": [], "start": [], "entity_id": [] } , "Dosage": {"text": [], "start": [], "entity_id": [] } , "Duration": {"text": [], "start": [], "entity_id": [] } , "Freq": {"text": [], "start": [], "entity_id": [] } , "Combination": [] , "Trigger": {"text": [], "start": [], "entity_id": [] } } , "Subject": {"text": [["We"]], "start": [["0"]], "entity_id": [] , "Age": {"text": [], "start": [], "entity_id": [] } , "Gender": {"text": [], "start": [], "entity_id": [] } , "Race": {"text": [], "start": [], "entity_id": [] } , "Population": {"text": [], "start": [], "entity_id": [] } , "Disorder": {"text": [], "start": [], "entity_id": [] } } , "Negated": {"text": [], "start": [], "entity_id": [] , "value": false} , "Speculated": {"text": [], "start": [], "entity_id": [] , "value": false} , "Severity": {"text": [], "start": [], "entity_id": [] , "value": "Not Specified" } , "Effect": {"text": [["senna-induced cholestatic hepatitis"]], "start": [["33","34"]], "entity_id": [] } }]}
{"id": "788666_1","context": "Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute renal failure"]],"start": [["59"]],"entity_id": [["T3"]]},"Treatment": {"text": [["gentamicin sulfate"]],"start": [["21"]],"entity_id": [["T2"]],"Drug": {"text": [["gentamicin sulfate"]],"start": [["21"]],"entity_id": [["T2"]]},"Disorder": {"text": [["acute renal failure"]],"start": [["59"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["appeared responsible"]],"start": [["42"]],"entity_id": [["T4"]]},"Freq": {"text": [["Five patients"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["gentamicin sulfate"]],"start": [["21"]],"entity_id": [["T2"]]},"Trigger": {"text": [["appeared responsible"]],"start": [["42"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["appeared responsible"]],"start": [["42"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [["Five patients"]],"start": [["0"]],"entity_id": [["T1"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "12852380_1","context": "However, in order to avoid neuropathic side effects, patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["neuropathic side effects"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["thalidomide therapy"]],"start": [["84"]],"entity_id": [["T2"]],"Drug": {"text": [["thalidomide"]],"start": [["84"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["6 months"]],"start": [["102"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["while taking the drug"]],"start": [["127"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["every 6 months with nerve conduction studies"]],"start": [["65"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["neuropathic side effects"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Route": {"text": [["taking the drug"]],"start": [["127"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["every 6 months with nerve conduction studies"]],"start": [["65"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["thalidomide"]],"start": [["84"]],"entity_id": [["T3"]]},"Trigger": {"text": [["nerve conduction studies"]],"start": [["72"]],"entity_id": [["T7"]]} ,"event_type": "Common" ,"event_id": "C1"}] ,"Dosage": {"text": [["-"]],"start": [[""], [""]],"entity_id": [["T8"]]} },"Effect": {"text": [["avoid"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Negated": {"value": false ,"text": [["avoid"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Speculated": {"value": false ,"text": [["avoid"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Severity": {"value": "low" ,"text": [["low"]],"start": [[""], [""]],"entity_id": [["T9"]]} ,"Subject": {"text": [["patients under thalidomide therapy"]],"start": [["17"]],"entity_id": [["T10"]],"Age": {"text": [["-"]],"start": [[""], [""]],"entity_id": [["T11"]]},"Gender": {"text": [["-"]],"start": [[""], [""]],"entity_id": [["T12"]]},"Population": {"text": [["patients under thalidomide therapy"]],"start": [["17"]],"entity_id": [["T10"]]},"Race": {"text": [["-"]],"start": [[""], [""]],"entity_id": [["T13"]]},"Disorder": {"text": [["thalidomide therapy"]],"start": [["84"]],"entity_id": [["T2"]]} }} ]}
{"id": "3873709_1","context": "Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Antibiotic-associated colitis", "pseudomembranous colitis"]],"start": [[ "0", "45" ]],"entity_id": [ ["T1"], ["T2"] ]},"Subject": {"text": [["four patients"]],"start": [[ "46" ]],"entity_id": [ ["T3" ]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["spinal cord injury"]],"start": [[ "55" ]],"entity_id": [ ["T4" ]]}},"Treatment": {"text": [["oral trimethoprim-sulfamethoxazole"]],"start": [[ "81" ]],"entity_id": [ ["T5" ]],"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [[ "81" ]],"entity_id": [ ["T6" ]]} ,"Disorder": {"text": [["Antibiotic-associated colitis", "pseudomembranous colitis"]],"start": [[ "0" ]],"entity_id": [ ["T1"], ["T2"] ]} ,"Dosage": null,"Duration": null,"Route": {"text": [["oral"]],"start": [[ "70" ]],"entity_id": [ ["T7" ]]},"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null} ,"Effect": {"text": [["Antibiotic-associated colitis", "pseudomembranous colitis"]],"start": [[ "0" ]],"entity_id": [ ["T1"], ["T2"] ]} ,"Negated": null,"Speculated": null,"Severity": null} ]}
{"id": "16396068_3", "context": "We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["TMP/SMX-induced aseptic meningitis"]], "start": [[ "42" ]], "entity_id": [ ["T1"] ]}, "Treatment": { "text": [["TMP/SMX"]], "start": [[ "15" ]], "entity_id": [ ["T2"] ] ,"Drug": { "text": [["TMP/SMX"]], "start": [[ "15" ]], "entity_id": [ ["T2"] ] } ,"Disorder": { "text": [["aseptic meningitis"]], "start": [[ "42" ]], "entity_id": [ ["T1"] ] } ,"Duration": { "text": [["reviewed the literature"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ] } ,"Trigger": { "text": [["reviewed"]], "start": [[ "0" ]], "entity_id": [ ["T3"] ] } ,"Route": { "text": [["literature"]], "start": [[ "20" ]], "entity_id": [ ["T4"] ] } ,"Time_elapsed": { "text": [["attempt"]], "start": [[ "28" ]], "entity_id": [ ["T5"] ] } ,"Freq": { "text": [["to characterize the pattern and predictors"]], "start": [[ "35" ]], "entity_id": [ ["T6"] ] } ,"Combination": null ,"Dosage": null } ,"Effect": null ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null}]}
{"id": "12324937_4","context": "Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["gemcitabine"]],"start": [["41"]],"entity_id": [["T1"]]},"Duration": {"text": [["7.4 +/- 3.5 months"]],"start": [["71"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["initiation"]],"start": [["18"]],"entity_id": [["T3"]]} ,"entity_id": [["T1"], ["T2"], ["T3"]] ,"Time_elapsed": {"text": [["onset"]],"start": [["56"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["HUS"]],"start": [["66"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["21.9 +/- 10.9 doses"]],"start": [["98"]],"entity_id": [["T6"]]} ,"Route": {"text": [["therapy"]],"start": [["40"]],"entity_id": [["T7"]]} ,"start": [["18"]],"text": [["Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine"]],"Freq": null,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": null ,"Effect": null }]}
{"id": "14746605_1","context": "It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens, and the patient therefore discontinued use of finasteride","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["finasteride"]],"start": [["It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens,"], ["and the patient therefore discontinued use of finasteride."], ["finasteride"]], "entity_id": []},"Treatment": {"text": [["finasteride"]],"start": [["It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens,"], ["and the patient therefore discontinued use of finasteride."], ["finasteride"]],"entity_id": [],"Drug": {"text": [["finasteride"]],"start": [["It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens,"], ["and the patient therefore discontinued use of finasteride."], ["finasteride"]],"entity_id": []},"Disorder": {"text": [["anterior subcapsular opacity on the lens"]],"start": [[ "finasteride was associated with the anterior subcapsular opacity on the lens,"]],"entity_id": []},"Trigger": {"text": [["finasteride"]],"start": [[ "finasteride was associated with the anterior subcapsular opacity on the lens,"]],"entity_id": []},"Route": {"text": [["use"]],"start": [[ "the patient therefore discontinued use of finasteride."]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["the patient"]],"start": [[ "the patient therefore discontinued use of finasteride."]],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Effect": null,"Negated": null,"Speculated": {"text": [["highly suspected"]],"start": [[ "It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens,"]],"entity_id": [],"value": true},"Severity": null}]}
{"id": "2811895_2", "context": "Life-threatening cranial dystonia following trihexyphenidyl withdrawal", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Life-threatening cranial dystonia"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Negated": null, "Speculated": null, "Severity": {"text": [["Life-threatening"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] , "value": "High"}, "Subject": {"text": [["Following"]], "start": [[ "40" ]], "entity_id": [ ["T2" ]] , "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["trihexyphenidyl withdrawal"]], "start": [[ "22" ]], "entity_id": [ ["T3" ]], "Drug": {"text": [["trihexyphenidyl"]], "start": [[ "22" ]], "entity_id": [ ["T4" ]]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": null}, "Effect": null }]}
{"id": "3982906_3","context": "The risk of cardiac decompensation in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of verapamil","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["administration"]],"start": [["120"]],"entity_id": []},"Treatment": {"text": [["verapamil"]],"start": [["131"]],"entity_id": [],"Drug": {"text": [["verapamil"]],"start": [["131"]],"entity_id": []},"Disorder": {"text": [["cardiac decompensation"]],"start": [["16"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["supraventricular tachycardia and congestive cardiac failure"]],"start": [["25"]],"entity_id": []}},"Subject": {"text": [["infants"]],"start": [["8"]],"entity_id": [],"Age": {"text": [["infants"]],"start": [["8"]],"entity_id": []},"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["supraventricular tachycardia and congestive cardiac failure"]],"start": [["25"]],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18171260_5","context": "We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27-year-old man with acute leukemia","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 27-year-old man"]],"start": [["43"]],"entity_id": [["T2"]],"Age": {"text": [["27"]],"start": [["44"]],"entity_id": [["Age1"]]},"Gender": {"text": [["man"]],"start": [["48"]],"entity_id": [["Gender1"]]},"Population": {"text": [["1"]],"start": [["43"]],"entity_id": [["Population1"]]},"Disorder": {"text": [["acute leukemia"]],"start": [["75"]],"entity_id": [["T3"]]},"Race": {"text": [["a 27-year-old man"]],"start": [["43"]],"entity_id": [["T2"]]}},"Treatment": {"text": [["linezolid and meperidine"]],"start": [["30"]],"entity_id": [["T4"]],"Drug": {"text": [["linezolid"]],"start": [["30"]],"entity_id": [["T5"]]},"Dosage": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Dosage1"]]},"Duration": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Duration1"]]},"Route": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Route1"]]},"Time_elapsed": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Time_elapsed1"]]},"Disorder": {"text": [["concomitant use"]],"start": [["18"]],"entity_id": [["T4"]]},"Trigger": {"text": [["concomitant use"]],"start": [["18"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["linezolid"]],"start": [["30"]],"entity_id": [["T5"]]},"Trigger": {"text": [["concomitant use"]],"start": [["18"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["meperidine"]],"start": [["37"]],"entity_id": [["T6"]]},"Trigger": {"text": [["concomitant use"]],"start": [["18"]],"entity_id": [["T4"]]},"event_id": "C2","event_type": "Adverse_event"}],"Freq": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Freq1"]]}},"Effect": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Negated1"]],"value": false},"Speculated": {"text": [["not provided"]],"start": [[""], []],"entity_id": [["Speculated1"]],"value": false},"Severity": {"text": [["serious"]],"start": [["0"]],"entity_id": [["Severity1"]],"value": "serious"}}]}
{"id": "9191742_1","context": "Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["ferrous sulfate"]],"start": [[ "12" ]],"entity_id": [ ["T1"] ],"Drug": {"text": [["levothyroxine sodium"]],"start": [[ "57" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["primary hypothyroidism"]],"start": [[ "100" ]],"entity_id": [ ["T3"] ]} ,"Route": {"text": [["orally administered"]],"start": [[ "31" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": { "text": [[ "under experimental conditions" ]], "start": [[ "0" ]], "entity_id": [[ "T0" ]] }, "Dosage": null, "Duration": null, "Freq": null ,"Trigger": { "text": [[ "reduce" ]], "start": [[ "41" ]], "entity_id": [[ "T5" ]] }, "Combination": null }, "Subject": null, "Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [[ "reduce" ]], "start": [[ "41" ]], "entity_id": [[ "T5" ]] }, "Trigger": null }] }
{"id": "19775485_2", "context": "We report here a case of cardiovascular and neurological depression induced by oxymetalzoline in a toddler.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"text": [["oxymetalzoline"]], "start": [[ ], [ ]], "entity_id": [["T1"]], "Drug": null, "Disorder": null, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null}, "Effect": {"text": [["cardiovascular and neurological depression"]], "start": [[ ], [ ]], "entity_id": [["T2"]]}, "Trigger": null}]}
{"id": "10431414_3","context": "The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["priapism"]],"start": [["32"]],"entity_id": [["T2"]]},"Treatment": {"text": [["heparin"]],"start": [["6"]],"entity_id": [["T1"]],"Drug": {"text": [["heparin"]],"start": [["6"]],"entity_id": [["T1"]]},"Disorder": {"text": [["abnormal platelet aggregation"]],"start": [["67"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["this side effect"]],"start": [["83"]],"entity_id": [["T4"]]},"Combination": [{"event_type": "Adverse_event","event_id": "E1-1","Drug": {"text": [["heparin"]],"start": [["6"]],"entity_id": [["T1"]]},"Trigger": {"text": [["priapism"]],"start": [["32"]],"entity_id": [["T2"]]}}],"Freq": {"text": [["often recognized"]],"start": [["16"]],"entity_id": [["T5"]]},"Trigger": {"text": [["abnormal platelet aggregation"]],"start": [["67"]],"entity_id": [["T3"]]},"Route": {"text": [["heparin"]],"start": [["6"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "12078977_2", "context": "Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Posterior leukoencephalopathy"]], "start": [[],["0"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["cisplatin", "bleomycin and vinblastine therapy"]], "start": [[],["23"]], "entity_id": [["T2"]], "Drug": {"text": [["cisplatin"]], "start": [[],["23"]], "entity_id": [["T3"]]},"Dosage": {"text":[[""]],"start":[[""]],"entity_id":[[""]]},"Duration": {"text":[["therapy for germ cell tumor of the ovary"]],"start":[["42"]],"entity_id":[["T4"]]},"Disorder": {"text":[["germ cell tumor of the ovary"]],"start":[["70"]],"entity_id":[["T5"]]},"Route": {"text":[[""]],"start":[[""]],"entity_id":[[""]]},"Time_elapsed": {"text":[["following"]],"start":[["47"]],"entity_id":[["T6"]]},"Freq": {"text":[[""]],"start":[[""]],"entity_id":[[""]]},"Combination": null, "Trigger": null}, "Effect": {"text": [["Posterior leukoencephalopathy"]], "start": [[],["0"]], "entity_id": [["T1"]]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "12086549_2", "context": "To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cutaneous and hematologic toxicity"]], "start": [["33","44"]], "entity_id": []},"Subject": {"text": [["a patient"]], "start": [["11","19"]], "entity_id": [],"Age": null,"Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": {"text": [["IL-2"]], "start": [["88","89"]], "entity_id": [],"Drug": {"text": [["IL-2"]], "start": [["88","89"]], "entity_id": []},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null,"Trigger": null, "Freq": null, "Combination": null , "Disorder": {"text": [["treatment"]], "start": [["73","79"]], "entity_id": []}}, "Effect": null,"Negated": null, "Speculated": null, "Severity": null}]}
{"id": "10707759_2","context": "Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity pneumonitis"]],"start": [["29"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["Flecainide"]],"start": [["0"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["Flecainide"]],"start": [["0"]],"entity_id": [ ["T3"] ]} ,"Route": {"text": [["rare cause"]],"start": [["8"]],"entity_id": [ ["T4"] ]} ,"Freq": {"text": [["few cases"]],"start": [["47"]],"entity_id": [ ["T5"] ]} ,"Disorder": {"text": [["hypersensitivity pneumonitis"]],"start": [["29"]],"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [["rare"]],"start": [["8"]],"entity_id": [ ["T7"] ]} ,"Duration": {"text": [["few cases"]],"start": [["47"]],"entity_id": [ ["T8"] ]} ,"Time_elapsed": {"text": [["have been reported"]],"start": [["53"]],"entity_id": [ ["T9"] ]} ,"Combination": [] ,"Trigger": {"text": [["rare cause"]],"start": [["8"]],"entity_id": [ ["T10"] ]} },"Effect": {"text": [["hypersensitivity pneumonitis"]],"start": [["29"]],"entity_id": [ ["T11"] ]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Flecainide"]],"start": [["0"]],"entity_id": [ ["T12"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null }} ]}
{"id": "17536204_5", "context": "The patient developed grade 3 capecitabine-induced headache", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["grade 3 capecitabine-induced headache"]], "start": [["0"]], "entity_id": []}, "Effect": {"text": [["headache"]], "start": [["42"]], "entity_id": []}, "Treatment": {"text": [["capecitabine"]], "start": [["15"]], "entity_id": [], "Drug": { "text": [["capecitabine"]], "start": [["15"]], "entity_id": [] },"Dosage": {"text": [["grade 3"]], "start": [["6"]], "entity_id": []},"Route": {"text": [["induced"]], "start": [["24"]], "entity_id": []},"Time_elapsed": {"text": [["developed"]], "start": [["5"]], "entity_id": []},"Trigger": {"text": [["The patient"]], "start": [["0"]], "entity_id": []},"Combination": [{"Drug": {"text": [["capecitabine"]], "start": [["15"]], "entity_id": []},"Trigger": {"text": [["The patient"]], "start": [["0"]], "entity_id": []},"event_id": "E1","event_type": "Adverse_event"} ] ,"Freq": null,"Duration": null,"Disorder": null},"Subject": {"text": [["The patient"]], "start": [["0"]], "entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "1951476_2","context": "We report a case of biopsy-proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen, a nonsteroidal anti-inflammatory drug of the propionic acid class","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["biopsy-proven acute tubulointerstitial nephritis"]],"start": [["26"]],"entity_id": [["T1"]]},"Treatment": {"text": [["flurbiprofen"]],"start": [["81"]],"entity_id": [["T2"]],"Drug": {"text": [["flurbiprofen"]],"start": [["81"]],"entity_id": [["T2"]]},"Disorder": {"text": [["acute tubulointerstitial nephritis"]],"start": [["26"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null } ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null } ] }
{"id": "10987357_2","context": "A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["pilsicainide"]],"start": [["A 74-year-old man received oral administration of pilsicainide,"], [","]],"entity_id": []},"Disorder": {"text": [["paroxysmal atrial fibrillation"]],"start": [[","]],"entity_id": []},"Route": {"text": [["oral administration"]],"start": [[","]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later"]],"start": [[","]],"entity_id": []},"Combination": null,"entity_id": [],"text": [],"start": []},"Effect": {"text": [["loss of consciousness"]],"start": [[","]],"entity_id": []},"Subject": {"Age": {"text": [["74"]],"start": [[], []],"entity_id": []},"Gender": {"text": [["man"]],"start": [[], []],"entity_id": []},"Population": null,"Race": null,"Disorder": {"text": [],"start": [],"entity_id": []},"entity_id": [],"text": [],"start": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "11876387_1", "context": "Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aggressive endometrial carcinoma"]], "start": [[], []], "entity_id": []}, "Subject": {"text": [["a breast cancer patient"]], "start": [[], []], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["breast cancer"]], "start": [[], []], "entity_id": []}}, "Treatment": {"text": [["tamoxifen"]], "start": [[], []], "entity_id": [],"Drug": {"text": [["tamoxifen"]], "start": [[], []], "entity_id": []},"Dosage": null,"Duration": null,"Disorder": {"text": [["breast cancer"]], "start": [[], []], "entity_id": []},"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null}, "Effect": {"text": [["normal transvaginal ultrasonography"]], "start": [[], []], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "8792511_1","context": "Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints. ","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["idiosyncratic reactions"]],"start": [[ "13" ]],"entity_id": [ ]},"Treatment": {"text": [["dapsone"]],"start": [[ "4" ]],"entity_id": [ ],"Drug": {"text": [["dapsone"]],"start": [[ "4" ]],"entity_id": [ ]},"Disorder": {"text": [["adverse events"]],"start": [[ "0" ]],"entity_id": [ ]},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Duration": {"text": [[]],"start": [],"entity_id": []},"Route": {"text": [[]],"start": [],"entity_id": []},"Time_elapsed": {"text": [[]],"start": [],"entity_id": []},"Freq": {"text": [[]],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["leukopenia", "agranulocytosis", "cutaneous eruptions", "peripheral neuropathy", "psychosis", "toxic hepatitis", "cholestatic jaundice", "nephrotic syndrome", "renal papillary necrosis", "severe hypoalbuminemia without proteinuria", "an infectious mononucleosis-like syndrome", "minor neurological and gastrointestinal complaints"]],"start": [[ "59" , "68" , "81" , "102" , "119" , "138" , "158" , "180" , "203" , "228" , "250" , "276" ]],"entity_id": []}},"Effect": {"text": [["idiosyncratic reactions"]],"start": [[ "13" ]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "10475726_2","context": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["venlafaxine treatment"]],"start": [[ "0" ]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["venlafaxine treatment"]],"start": [[ "0" ]],"entity_id": [ ["T1"]] ,"Drug": { "text": [["venlafaxine"]], "start": [[ "7" ]], "entity_id": [ ["T2"]] },"Disorder": { "text": [["ischaemic events"]], "start": [[ "57" ]], "entity_id": [ ["T3"]] },"Time_elapsed": { "text": [["its unique pharmacological and haemodynamic properties"]], "start": [[ "81" ]], "entity_id": [ ["T4"]] },"Trigger": { "text": [["venlafaxine treatment"]], "start": [[ "0" ]], "entity_id": [ ["T1"]] },"Route": { "text": [["treatment"]], "start": [[ "0" ]], "entity_id": [ ["T1"]] },"Dosage": { "text": [["treatment"]], "start": [[ "0" ]], "entity_id": [ ["T1"]] },"Duration": { "text": [["treatment"]], "start": [[ "0" ]], "entity_id": [ ["T1"]] },"Freq": { "text": [["treatment"]], "start": [[ "0" ]], "entity_id": [ ["T1"]] },"Combination": null },"Effect": { "text": [["ischaemic events"]], "start": [[ "57" ]], "entity_id": [ ["T3"]] },"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "17060191_5", "context": "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["indomethacin"]], "start": [[ ]],"entity_id": [["T2"]] ,"Trigger": {"text": [["in response to"]], "start": [[ ]],"entity_id": [["T3"]]},"Drug": {"text": [["indomethacin"]], "start": [[ ]],"entity_id": [["T2"]]},"Disorder": {"text": [["ductal closure"]], "start": [[ ]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["in response"]], "start": [[ ]],"entity_id": [["T3"]]},"Freq": {"text": [["closure"]], "start": [[ ]],"entity_id": [["T1"]]},"Route": {"text": [["of"]], "start": [[ ]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["indomethacin"]], "start": [[ ]],"entity_id": [["T2"]]}, "Trigger": {"text": [["in response to"]], "start": [[ ]],"entity_id": [["T3"]]},"event_id": "C1", "event_type": "Potential_therapeutic_effect"}],"Dosage": {"text": [["indomethacin"]], "start": [[ ]],"entity_id": [["T2"]]} ,"Duration": {"text": [["closure"]], "start": [[ ]],"entity_id": [["T1"]]} } ,"Subject": {"text": [["the affected twin"]], "start": [[ ]],"entity_id": [["T5"]],"Disorder": {"text": [["hypoxia"]], "start": [[ ]],"entity_id": [["T6"]]} ,"Age": {"text": [["the affected twin"]], "start": [[ ]],"entity_id": [["T5"]]} ,"Gender": {"text": [], "start": [], "entity_id": []} ,"Race": {"text": [], "start": [], "entity_id": []} ,"Population": {"text": [], "start": [], "entity_id": []} } ,"Negated": {"text": [], "start": [], "entity_id": [] ,"value": false} ,"Speculated": {"text": [], "start": [], "entity_id": [] ,"value": false} ,"Severity": {"text": [], "start": [], "entity_id": [] ,"value": ""} ,"Effect": {"text": [["closure"]], "start": [[ ]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["closure"]], "start": [[ ]],"entity_id": [["T1"]]} }]}
{"id": "8903300_3","context": "This pattern is suggestive of renal toxicity due to tobramycin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["This pattern"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["tobramycin"]],"start": [["54"]],"entity_id": [],"Drug": {"text": [["tobramycin"]],"start": [["54"]],"entity_id": []},"Disorder": {"text": [["renal toxicity"]],"start": [["24"]],"entity_id": []},"Freq": {"text": [["suggestive"]],"start": [["1"]],"entity_id": []},"Time_elapsed": {"text": [["due"]],"start": [["49"]],"entity_id": []},"Duration": {"text": [["This pattern"]],"start": [["0"]],"entity_id": []},"Route": {"text": [["This pattern"]],"start": [["0"]],"entity_id": []},"Dosage": {"text": [["This pattern"]],"start": [["0"]],"entity_id": []},"Combination": null,"Trigger": {"text": [["This pattern"]],"start": [["0"]],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": {"text": [["renal toxicity"]],"start": [["24"]],"entity_id": [],"value": "high"},"Subject": null,"Effect": {"text": [["renal toxicity"]],"start": [["24"]],"entity_id": []}}]}
{"id": "8742573_4", "context": "To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe human insulin-induced lipoatrophy", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["insulin"]],"start": [["36"]],"entity_id": [ ["T1"] ]},"Disorder": {"text": [["insulin-induced lipoatrophy"]],"start": [["70"]],"entity_id": [ ["T2"] ]},"Route": {"text": [["by a jet-injector device"]],"start": [["50"]],"entity_id": [ ["T3"] ]},"Time_elapsed": {"text": [["stopping and reversing"]],"start": [["15"]],"entity_id": [ ["T4"] ]} ,"Freq": {"text": [["evaluate the efficacy"]],"start": [["0"]],"entity_id": [ ["T0"] ]} ,"Duration": {"text": [["severe human"]],"start": [["58"]],"entity_id": [ ["T5"] ]} ,"Dosage": null,"Trigger": null ,"Combination": null ,"entity_id": [ ["T1", "T2", "T3", "T4", "T5"] ],"text": [ ["evaluate the efficacy", "insulin", "by a jet-injector device", "stopping and reversing", "severe human" ], ["insulin-induced lipoatrophy" ]], "start": [[ "0", "36", "50", "15", "58" ], ["70" ]] } ,"Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null,"Population": null, "Race": null, "Disorder": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null } ]}
{"id": "2442958_2","context": "This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer._","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["closely related"]],"start": [["36"]],"entity_id": []},"Treatment": {"text": [["DES therapy"]],"start": [["51"]],"entity_id": [],"Drug": {"text": [["DES"]],"start": [["51"]],"entity_id": []} ,"Disorder": {"text": [["prostatic cancer"]],"start": [["81"]],"entity_id": []} ,"Route": {"text": [["therapy"]],"start": [["51"]],"entity_id": []} ,"Freq": {"text": [["unique"]],"start": [["0"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["hepatocellular carcinoma"]],"start": [["12"]],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "1592841_1", "context": "Falling backward in two elderly patients taking bupropion", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Falling backward"]], "start": [[ ]], "entity_id": [["T1"]]}, "Subject": {"text": [["two elderly patients"]], "start": [[ ]], "entity_id": [["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["bupropion"]], "start": [[ ]], "entity_id": [["T3"]], "Drug": {"text": [["bupropion"]], "start": [[ ]], "entity_id": [["T4"]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Trigger": null, "Disorder": null, "Combination": null}, "Effect": {"text": [["Falling backward"]], "start": [[ ]], "entity_id": [["T5"]]}, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "11881322_4","context": "Three patients with apparent itraconazole-induced liver injury were studied","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["itraconazole-induced liver injury"]],"start": [["32-47"]],"entity_id": [["T1"]]},"Subject": {"text": [["Three patients"]],"start": [["0-5"]],"entity_id": [["T2"]],"Population": {"text": [["Three patients"]],"start": [["0-5"]],"entity_id": [["T2"]]},"Disorder": {"text": [["itraconazole-induced liver injury"]],"start": [["32-47"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["itraconazole"]],"start": [["17-24"]],"entity_id": [["T3"]],"Drug": {"text": [["itraconazole"]],"start": [["17-24"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["itraconazole-induced liver injury"]],"start": [["32-47"]],"entity_id": [["T1"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "12111771_5","context": "To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["interstitial pneumonitis"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["fludarabine"]],"start": [["60"]],"entity_id": [["T2"]],"Drug": {"text": [["fludarabine"]],"start": [["60"]],"entity_id": [["T2"]]},"Disorder": {"text": [["interstitial pneumonitis"]],"start": [["16"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["fludarabine"]],"start": [["60"]],"entity_id": [["T2"]]},"Trigger": {"text": [["associated"]],"start": [["42"]],"entity_id": [["T3"]]},"event_id": "E2","event_type": "Adverse_event"}],"Freq": {"text": [["four"]],"start": [["4"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["reported"]],"start": [["55"]],"entity_id": [["T5"]]},"Duration": {"text": [["have been reported"]],"start": [["52"]],"entity_id": [["T5"]]},"Route": {"text": [["associated"]],"start": [["42"]],"entity_id": [["T3"]]},"Dosage": {"text": [["have been reported"]],"start": [["52"]],"entity_id": [["T5"]]},"Trigger": {"text": [["reported"]],"start": [["55"]],"entity_id": [["T5"]]}},"Subject": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]],"Age": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]]},"Gender": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]]},"Population": {"text": [["four"]],"start": [["4"]],"entity_id": [["T4"]]},"Race": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]]},"Disorder": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]]}},"Severity": {"text": [["interstitial pneumonitis"]],"start": [["16"]],"entity_id": [["T1"]],"value": "High"},"Negated": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]],"value": false},"Speculated": {"text": [["To our knowledge"]],"start": [[""],["0"]],"entity_id": [["T6"]],"value": false},"Effect": {"text": [["interstitial pneumonitis"]],"start": [["16"]],"entity_id": [["T1"]]}}]}
{"id": "11250985_4","context": "Serious adverse events experienced by patients with chronic heart failure taking spironolactone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serious adverse events"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["patients with chronic heart failure"]],"start": [["31"]],"entity_id": [["T2"]],"Disorder": {"text": [["chronic heart failure"]],"start": [["31"]],"entity_id": [["T3"]]},"Age": {"text": [[" "]],"start": [[""], ["31"]],"entity_id": [["T4"]]},"Gender": {"text": [[" "]],"start": [[""], ["31"]],"entity_id": [["T5"]]},"Race": {"text": [[" "]],"start": [[""], ["31"]],"entity_id": [["T6"]]},"Population": {"text": [["patients"]],"start": [["0"]],"entity_id": [["T7"]]}},"Treatment": {"text": [["taking spironolactone"]],"start": [["78"]],"entity_id": [["T8"]],"Drug": {"text": [["spironolactone"]],"start": [["78"]],"entity_id": [["T9"]]},"Dosage": {"text": [[" "]],"start": [[""], ["78"]],"entity_id": [["T10"]]},"Freq": {"text": [[" "]],"start": [[""], ["78"]],"entity_id": [["T11"]]},"Route": {"text": [[" "]],"start": [[""], ["78"]],"entity_id": [["T12"]]},"Time_elapsed": {"text": [[" "]],"start": [[""], ["78"]],"entity_id": [["T13"]]},"Duration": {"text": [[" "]],"start": [[""], ["78"]],"entity_id": [["T14"]]},"Disorder": {"text": [["chronic heart failure"]],"start": [["31"]],"entity_id": [["T15"]]},"Combination": null,"Trigger": {"text": [["taking"]],"start": [["78"]],"entity_id": [["T16"]]}},"Effect": {"text": [["serious adverse events"]],"start": [["0"]],"entity_id": [["T17"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["serious"]],"start": [["0"]],"entity_id": [["T18"]],"value": "serious"}}]}
{"id": "941054_2","context": "Review of the literature relating to methicillin-induced nephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["methicillin-induced nephropathy"]],"start": [["13","14"]],"entity_id": [["T1"]]},"Subject": {"text": [["this disorder"]],"start": [["72","73"]],"entity_id": [["T2"]],"Disorder": {"text": [["methicillin-induced nephropathy"]],"start": [["13","14"]],"entity_id": [["T1"]]},"Age": null,"Gender": null,"Population": null,"Race": null},"Effect": null,"Treatment": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "16298824_2","context": "ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["ARDS"]],"start": [[ "0"]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["monoclonal antibodies"]],"start": [[ "46"]] ,"entity_id": [["T2"]],"Drug": {"text": [["infliximab", "gemtuzumab ozogamicin", "OKT3"]],"start": [[ "56", "65", "72"]],"entity_id": [["T3", "T4", "T5"]]},"Disorder": {"text": [["ARDS"]],"start": [[ "0"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["infliximab"]],"start": [[ "56"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [[ "64"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["gemtuzumab ozogamicin"]],"start": [[ "65"]],"entity_id": [["T4"]]},"Trigger": {"text": [["and"]],"start": [[ "73"]],"entity_id": [["T7"]]},"event_id": "C2","event_type": "Adverse_event"},{"Drug": {"text": [["OKT3"]],"start": [[ "72"]],"entity_id": [["T5"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C3","event_type": "Adverse_event"}],"Freq": {"text": [["has been associated"]],"start": [[ "46"]],"entity_id": [["T8"]]},"Route": {"text": [["administration"]],"start": [[ "53"]],"entity_id": [["T9"]]},"Time_elapsed": {"text": [["believed"]],"start": [[ "103"]],"entity_id": [["T10"]]},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["release"]],"start": [[ "115"]],"entity_id": [["T11"]]}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "527355_1","context": "An insulin-dependent diabetic patient with nephropathy developed severe acidosis after treatment with acetazolamide for glaucoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe acidosis"]],"start": [["33"]],"entity_id": [["T3"]]},"Treatment": {"text": [["treatment with acetazolamide"]],"start": [["62"]],"entity_id": [["T2"]],"Drug": {"text": [["acetazolamide"]],"start": [["62"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["diabetic patient with nephropathy"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["45"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["for glaucoma"]],"start": [["71"]],"entity_id": [["T6"]]} ,"Route": {"text": [["treatment"]],"start": [["62"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["developed"]],"start": [["23"]],"entity_id": [["T7"]]} ,"Combination": [{"Drug": {"text": [["acetazolamide"]],"start": [["62"]],"entity_id": [["T4"]]},"Trigger": {"text": [["for glaucoma"]],"start": [["71"]],"entity_id": [["T6"]]} ,"event_id": "C1" ,"event_type": "Treatment" }] ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [["An insulin-dependent diabetic patient with nephropathy"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["insulin-dependent diabetic patient with nephropathy"]],"start": [["0"]],"entity_id": [["T1"]]},"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["severe acidosis"]],"start": [["33"]],"entity_id": [["T3"]]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "severe" }} ]}
{"id": "15504988_1","context": "Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypo-alpha-lipoproteinemia"]],"start": [["13"]],"entity_id": []},"Treatment": {"text": [["treatment with rosiglitazone"]],"start": [["36"]],"entity_id": [],"Drug": {"text": [["rosiglitazone"]],"start": [["47"]],"entity_id": []} ,"Disorder": {"text": [["hypo-alpha-lipoproteinemia"]],"start": [["13"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": {"text": [["Severe"]],"start": [["0"]],"entity_id": [] ,"value": "Severe" },"Effect": null }] }
{"id": "2445709_2", "context": "Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Peripheral neuropathy", "cerebellar syndrome"]], "start": [[ "0", "41" ]], "entity_id": [ ["T1","T2"] ]}, "Treatment": {"text": [["amiodarone therapy"]], "start": [[ "47" ]], "entity_id": [ ["T3"] ], "Drug": {"text": [["amiodarone"]], "start": [[ "47" ]], "entity_id": [ ["T4"] ] } , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": null , "Freq": null, "Combination": null , "Trigger": null }, "Negated": null , "Speculated": null , "Severity": null , "Subject": null , "Effect": {"text": [["Peripheral neuropathy", "cerebellar syndrome"]], "start": [[ "0", "41" ]], "entity_id": [ ["T1","T2"] ]} }]}
{"id": "18691992_4", "context": "We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use", "is_mult_event": true, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["concomitant appearance"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["hydroxyurea use"]], "start": [["87"]], "entity_id": [],"Drug": {"text": [["hydroxyurea"]], "start": [["87"]], "entity_id": []}, "Disorder": {"text": [["skin cancers"]], "start": [["18"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null},"Effect": {"text": [["multiple skin cancers and nail changes"]], "start": [["34","58"]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [["We"]], "start": [["0"]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}}]}
{"id": "9847899_1","context": "As this relapse coincided with development of a strong delayed-type hypersensitivity response to tuberculin and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["strong delayed-type hypersensitivity response to tuberculin"]],"start": [["36"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with the anti-inflammatory agent oxpentifylline"]],"start": [["85"]],"entity_id": [["T2"]],"Drug": {"text": [["oxpentifylline"]],"start": [["102"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["improved after"]],"start": [["67"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["relapse"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["restoration of pathogen-specific cellular immunity"]],"start": [["122"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["tubercuilin"]],"start": [["36"]],"entity_id": [["T7"]]},"Trigger": {"text": [["strong delayed-type hypersensitivity response"]],"start": [["36"]],"entity_id": [["T8"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"}] ,"Route": {"text": [["treatment"]],"start": [["67"]],"entity_id": [["T9"]]} ,"Duration": {"text": [["relapse"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Trigger": {"text": [["relapse coincided with"]],"start": [["0"]],"entity_id": [["T11"]]} ,"Dosage": {"text": [["strong delayed-type hypersensitivity response to tuberculin"]],"start": [["36"]],"entity_id": [["T12"]]} },"Subject": {"text": [["this"]],"start": [["0"]],"entity_id": [["T13"]],"Age": {"text": [[]],"start": [[], []],"entity_id": []},"Gender": {"text": [[]],"start": [[], []],"entity_id": []},"Population": {"text": [[]],"start": [[], []],"entity_id": []},"Race": {"text": [[]],"start": [[], []],"entity_id": []},"Disorder": {"text": [["relapse"]],"start": [["0"]],"entity_id": [["T14"]]}} ,"Negated": {"text": [[]],"start": [[], []],"entity_id": [] ,"value": false },"Speculated": {"text": [[]],"start": [[], []],"entity_id": [] ,"value": false },"Severity": {"text": [[]],"start": [[], []],"entity_id": [] ,"value": "low" },"Effect": {"text": [[]],"start": [[], []],"entity_id": [] }} ]}
{"id": "16012330_1", "context": "Itraconazole-related increased vincristine neurotoxicity: case report and review of literature", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["Itraconazole"]], "start": [[ "0" ]], "entity_id": [ ["T1" ] ]},"Disorder": {"text": [["increased vincristine neurotoxicity"]], "start": [[ "46" ]], "entity_id": [ ["T2" ] ]} ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null ,"Combination": null ,"Trigger": { "text": [[ "Itraconazole-related" ]], "start": [[ "9" ]], "entity_id": [ ["T3" ] ]} ,"entity_id": [ ["T1" ] ], "text": [[ "Itraconazole" ]], "start": [[ "0" ]] }, "Effect": { "text": [[ "increased vincristine neurotoxicity" ]], "start": [[ "46" ]], "entity_id": [ ["T2" ] ]} ,"Trigger": { "text": [[ "Itraconazole-related" ]], "start": [[ "9" ]], "entity_id": [ ["T3" ] ]} }]}
{"id": "11837564_1","context": "A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 62-year-old Caucasian man"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["62"]],"start": [["3"]],"entity_id": [["A1"]]},"Gender": {"text": [["man"]],"start": [["12"]],"entity_id": [["G1"]]},"Race": {"text": [["Caucasian"]],"start": [["16"]],"entity_id": [["R1"]]},"Disorder": {"text": [["atrial fibrillation"]],"start": [["34"]],"entity_id": [["D1"]]},"Population": {"text": [["A 62-year-old Caucasian man"]],"start": [["0"]],"entity_id": [["S1"]]}},"Treatment": {"text": [["warfarin"]],"start": [["91"]],"entity_id": [["T1"]],"Drug": {"text": [["warfarin"]],"start": [["91"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["atrial fibrillation"]],"start": [["34"]],"entity_id": [["D1"]]},"Combination": null,"Trigger": {"text": [["hematochezia"]],"start": [["68"]],"entity_id": [["T3"]]}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "7439122_3", "context": "Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with clofibrate, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of myopathy", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["treatment"]], "start": [["33","38"]], "entity_id": []}, "Treatment": {"text": [["the treatment"]], "start": [["33","38"]], "entity_id": [], "Drug": {"text": [["clofibrate"]], "start": [["62","68"]], "entity_id": []}, "Disorder": {"text": [["diabetes insipidus"]], "start": [["54","61"]], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Combination": [{"Drug": {"text": [["clofibrate"]], "start": [["62","68"]], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "event_id": "C1", "event_type": "null"}]}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["diabetes insipidus"]], "start": [["54","61"]], "entity_id": []}}, "Effect": {"text": [["carefully monitor serum levels"]], "start": [["85","99"]], "entity_id": []}, "Negated": {"text": [], "start": [], "entity_id": [], "value": false}, "Speculated": {"text": [], "start": [], "entity_id": [], "value": false}, "Severity": {"text": [], "start": [], "entity_id": [], "value": ""}}]}
{"id": "9302445_1","context": "We believe this to be the first reported case of rhGH-induced hypercalcemia in an HIV-infected patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rhGH-induced hypercalcemia"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["an HIV-infected patient"]],"start": [["48"]],"entity_id": [["T2"]],"Disorder": {"text": [["HIV-infected"]],"start": [["48"]],"entity_id": [["T2"]]} ,"Population": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Gender": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Age": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Race": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} } ,"Treatment": {"text": [["rhGH"]],"start": [["13"]],"entity_id": [["T0"]],"Drug": {"text": [["rhGH"]],"start": [["13"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["rhGH-induced hypercalcemia"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Route": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["first reported case"]],"start": [["24"]],"entity_id": [["T3"]]} ,"Combination": null ,"Trigger": {"text": [["induced"]],"start": [["20"]],"entity_id": [["T4"]]} } ,"Negated": null,"Speculated": {"text": [["believe"]],"start": [["0"]],"entity_id": [["T5"]] ,"value": true } ,"Severity": {"text": [["hypercalcemia"]],"start": [["18"]],"entity_id": [["T1"]],"value": "high" } ,"Effect": {"text": [["rhGH-induced hypercalcemia"]],"start": [["18"]],"entity_id": [["T1"]]} } ]}
{"id": "7946029_2","context": "A case of basilar invagination which is thought to have arisen from the patient's intrauterine exposure to phenytoin is presented","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["basilar invagination"]],"start": [[ ]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenytoin"]],"start": [[ ]],"entity_id": [["T2"]],"Drug": null,"Disorder": {"text": [["intrauterine exposure"]],"start": [[ ]],"entity_id": [["T3"]]},"Duration": null,"Route": null,"Dosage": null,"Freq": null,"Time_elapsed": null,"Trigger": {"text": [["thought to have arisen"]],"start": [[ ]],"entity_id": [["T4"]]},"Combination": null},"Subject": {"text": [["patient"]],"start": [[ ]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["basilar invagination"]],"start": [[ ]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": {"text": [["thought to have arisen"]],"start": [[ ]],"entity_id": [["T4"]],"value": true},"Severity": null,"Effect": null}]}
{"id": "1495728_1", "context": "Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["pneumonitis"]], "start": [["13"]], "entity_id": []}, "Treatment": {"text": [["Methotrexate"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Methotrexate"]], "start": [["0"]], "entity_id": [] },"Disorder":{"text":[["nonsurgical treatment"]], "start":[[ "32" ]], "entity_id":[] },"Duration":{"text":[["ectopic pregnancy"]], "start":[[ "40" ]], "entity_id":[] },"Route":{"text":[["in"]], "start":[[ "35" ]], "entity_id":[] },"Dosage":{"text":[["Methotrexate"]], "start":[[ "0" ]], "entity_id":[] },"Time_elapsed":{"text":[["in"]], "start":[[ "35" ]], "entity_id":[] },"Freq":{"text":[["nonsurgical treatment"]], "start":[[ "32" ]], "entity_id":[] },"Combination":[{"Drug":{"text":[["Methotrexate"]], "start":[[ "0" ]], "entity_id":[] },"Trigger":{"text":[["nonsurgical treatment"]], "start":[[ "32" ]], "entity_id":[] },"event_id":"C1","event_type":"Treatment"}],"Trigger":{"text":[["pneumonitis"]], "start":[[ "13" ]], "entity_id":[] } } ,"Negated":{"value":false,"text":[],"start":[],"entity_id":[]},"Speculated":{"value":false,"text":[],"start":[],"entity_id":[]},"Severity":{"value":"","text":[],"start":[],"entity_id":[]},"Subject":{"text":[["Methotrexate pneumonitis"]],"start":[[ "0" ]],"entity_id":[],"Age":{"text":[],"start":[],"entity_id":[]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["ectopic pregnancy"]], "start":[[ "40" ]], "entity_id":[] } } ,"Effect":{"text":[["pneumonitis"]], "start":[[ "13" ]], "entity_id":[]} }]}
{"id": "3767790_2","context": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed"]],"start": [["21"]],"entity_id": []},"Treatment": {"text": [["Tolazoline"]],"start": [["12"]],"entity_id": [],"Drug": {"text": [["Tolazoline"]],"start": [["12"]],"entity_id": []},"Route": {"text": [["by infusion"]],"start": [["26"]],"entity_id": []},"Disorder": {"text": [["duodenal ulceration"]],"start": [["44"]],"entity_id": []},"Time_elapsed": {"text": [["subsequent"]],"start": [["55"]],"entity_id": []},"Trigger": {"text": [["intestinal perforation"]],"start": [["62"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": {"text": [],"start": [],"entity_id": []},"Subject": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "20098333_2","context": "We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["a 14-year-old female"]],"start": [[" "], [">>>"], [" "]],"entity_id": [["S1"], ["S2"], ["S3"]],"Age": {"text": [["14-year-old"]],"start": [[">>>"]],"entity_id": [["A1"]]},"Gender": {"text": [["female"]],"start": [[">>>"]],"entity_id": [["G1"]]},"Disorder": {"text": [["acute promyelocytic leukemia"]],"start": [[">>>"]],"entity_id": [["D1"]]},"Population": {"text": [["a"]],"start": [[">>>"]],"entity_id": [["P1"]]},"Race": {"text": [["a"]],"start": [[">>>"]],"entity_id": [["R1"]]}},"Treatment": {"text": [["treatment with a combination of daunomycin and all-trans retinoic acid (ATRA)"]],"start": [[">>>"], [" "]],"entity_id": [["T1"], ["T2"]],"Drug": {"text": [["daunomycin"], ["all-trans retinoic acid (ATRA)"]],"start": [[">>>"], [" "]],"entity_id": [["D1"], ["D2"]]},"Dosage": {"text": [[""]],"start": [[">>>"], [" "]],"entity_id": [["D3"]]},"Duration": {"text": [["4 months"]],"start": [[">>>"]],"entity_id": [["D4"]]},"Disorder": {"text": [["treatment"]],"start": [[">>>"]],"entity_id": [["D5"]]},"Route": {"text": [[""]],"start": [[">>>"]],"entity_id": [["R1"]]},"Time_elapsed": {"text": [["only"]],"start": [[">>>"]],"entity_id": [["T1"]]},"Freq": {"text": [[""]],"start": [[">>>"]],"entity_id": [["F1"]]},"Combination": [{"Drug": {"text": [["daunomycin"], ["all-trans retinoic acid (ATRA)"]],"start": [[">>>"], [" "]],"entity_id": [["D1"], ["D2"]]},"Trigger": {"text": [["and"]],"start": [[">>>"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Combination"}],"Trigger": {"text": [["developed symptomatic cardiomyopathy"]],"start": [[">>>"]],"entity_id": [["T4"]]}},"Effect": {"text": [["developed symptomatic cardiomyopathy"]],"start": [[">>>"]],"entity_id": [["E1"]]},"Negated": {"text": [["not"]],"start": [[">>>"]],"entity_id": [["N1"]],"value": false},"Speculated": {"text": [["report"]],"start": [[">>>"]],"entity_id": [["S1"]],"value": false},"Severity": {"text": [["symptomatic"]],"start": [[">>>"]],"entity_id": [["S1"]],"value": "High"},"Trigger": {"text": [["We"]],"start": [[">>>"]],"entity_id": [["T6"]]}}]}
{"id": "18585545_5","context": "A previously healthy 42-year-old woman presented with acute-onset delirium with psychotic features as a consequence of levofloxacin therapy","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute-onset delirium with psychotic features"]],"start": [["26"]],"entity_id": [["T1"]]},"Subject": {"text": [["A previously healthy 42-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["42-year-old"]],"start": [["6"]],"entity_id": [["T2"]]},"Disorder": {"text": [["previously healthy"]],"start": [["0"]],"entity_id": [["T3"]]},"Population": {"text": [["A previously healthy 42-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["A previously healthy 42-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["A previously healthy 42-year-old woman"]],"start": [["0"]],"entity_id": [["T0"]]}},"Treatment": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]],"Drug": {"text": [["levofloxacin"]],"start": [["68"]],"entity_id": [["T5"]]},"Dosage": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Duration": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Route": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["acute-onset delirium with psychotic features"]],"start": [["26"]],"entity_id": [["T1"]]},"Freq": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Disorder": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Trigger": {"text": [["levofloxacin therapy"]],"start": [["68"]],"entity_id": [["T4"]]},"Combination": [{"Drug": {"text": [["levofloxacin"]],"start": [["68"]],"entity_id": [["T5"]]},"Trigger": {"text": [["therapy"]],"start": [["75"]],"entity_id": [["T6"]]},"event_id": "E1","event_type": "Adverse_event"}]},"Negated": null,"Speculated": null,"Severity": {"text": [["acute-onset delirium with psychotic features"]],"start": [["26"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["acute-onset delirium with psychotic features"]],"start": [["26"]],"entity_id": [["T1"]]}}]}
{"id": "22791547_5","context": "Although limb dyskinesia after methylphenidate is a commonly reported side effect, to the authors' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["limb dyskinesia"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["methylphenidate"]],"start": [["58"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"text": [["methylphenidate"]],"start": [["58"]] ,"Dosage": {"text": [["first dose"]],"start": [["107"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["acute period"]],"start": [["97"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["side effect"]],"start": [["14"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["commonly reported"]],"start": [["5"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["methylphenidate"]],"start": [["58"]],"entity_id": [["T2"]]},"Trigger": {"text": [["orofacial"]],"start": [["72"]],"entity_id": [["T4"]]},"event_id": "C1" ,"event_type": "Adverse_event"},{"Drug": {"text": [["methylphenidate"]],"start": [["58"]],"entity_id": [["T2"]]},"Trigger": {"text": [["limb dyskinesia"]],"start": [["23"]],"entity_id": [["T1"]]},"event_id": "C2","event_type": "Adverse_event"}],"Trigger": {"text": [["limb dyskinesia"]],"start": [["23"]],"entity_id": [["T1"]]},"Duration": {"text": [["first dose"]],"start": [["107"]],"entity_id": [["T3"]]},"Route": {"text": [["after"]],"start": [["102"]],"entity_id": [["T3"]]}} , "Negated": {"text": [["not"]],"start": [["0"]],"entity_id": [["T0"]] ,"value": false} ,"Speculated": {"text": [["to develop both orofacial and limb dyskinesia"]],"start": [["79"]],"entity_id": [["T4"]],"value": false},"Subject": {"text": [["to the authors' knowledge this is only the second reported case"]],"start": [["42"]],"entity_id": [["T5"]],"Population": {"text": [["second reported case"]],"start": [["58"]],"entity_id": [["T2"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Severity": {"text": [["commonly reported"]],"start": [["5"]],"entity_id": [["T1"]],"value": "low"} ,"Effect": {"text": [["limb dyskinesia"]],"start": [["23"]],"entity_id": [["T1"]]}}]}
{"id": "7995508_1", "context": "Phenylpropanolamine-induced psychosis", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Phenylpropanolamine-induced psychosis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Effect": {"text": [["psychosis"]], "start": [[ ]], "entity_id": [["T2"]]}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": null}]}
{"id": "3763264_1", "context": "Graft versus host-like illness in a child with phenobarbital hypersensitivity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Graft versus host-like illness"]], "start": [[ "graft", "versus", "host-like", "illness" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["phenobarbital"]], "start": [[ "phenobarbital" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["phenobarbital"]], "start": [[ "phenobarbital" ]], "entity_id": [ ["T3"] ]},"Dosage": {"text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["T4"] ]},"Duration": {"text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["T5"] ]},"Route": {"text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["T6"] ]},"Time_elapsed": {"text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["T7"] ]},"Freq": {"text": [["null"]], "start": [[ "null" ]], "entity_id": [ ["T8"] ]},"Trigger": {"text": [["phenobarbital hypersensitivity"]], "start": [[ "phenobarbital", "hypersensitivity" ]], "entity_id": [ ["T9"] ]},"Disorder": {"text": [["phenobarbital hypersensitivity"]], "start": [[ "phenobarbital", "hypersensitivity" ]], "entity_id": [ ["T10"] ]}, "Combination": null} ,"Subject": {"text": [["A child"]], "start": [[ "A", "child" ]], "entity_id": [ ["T11"] ],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}, "Negated": null,"Speculated": null,"Severity": null ,"Effect": {"text": [["Graft versus host-like illness"]], "start": [[ "graft", "versus", "host-like", "illness" ]], "entity_id": [ ["T12"] ]} }]}
{"id": "9660541_3", "context": "We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["MMC-related hemolytic uremic syndrome"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]]}, "Subject": { "text": [["We"]], "start": [[ "0" ]], "entity_id": [ ["T2" ]] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null},"Treatment": { "text": [], "start": [], "entity_id": [], "Drug": null, "Disorder": {"text": [["MMC"]], "start": [[ "48" ]], "entity_id": [ ["T3" ]]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null}, "Effect": { "text": [["hemolytic uremic syndrome"]], "start": [[ "33" ]], "entity_id": [ ["T4" ]]} ,"Negated": null, "Speculated": null, "Severity": { "text": [["severe"]], "start": [[ "108" ]], "entity_id": [ ["T5" ]] ,"value": "high" }} ]}
{"id": "3947272_3","context": "Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["ampicillin"]],"start": [["33"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["Myasthenic patients"]],"start": [["0"]],"entity_id": [["T0"]] },"Dosage": {"text": [["close monitoring"]],"start": [["42"]],"entity_id": [["T2"]] },"Trigger": {"text": [["for possible acute exacerbations"]],"start": [["52"]],"entity_id": [["T3"]] } ,"Freq": {"text": [["should be"]],"start": [["36"]],"entity_id": [["T4"]] },"Route": {"text": [["receiving"]],"start": [["19"]],"entity_id": [["T5"]] },"Duration": {"text": [["receiving"]],"start": [["19"]],"entity_id": [["T5"]] },"Combination": [{"Drug": {"text": [["ampicillin"]],"start": [["33"]],"entity_id": [["T1"]] },"Trigger": {"text": [["for possible acute exacerbations"]],"start": [["52"]],"entity_id": [["T3"]] } ,"event_id": "E2","event_type": "Adverse_event" }] ,"Time_elapsed": {"text": [["receiving"]],"start": [["19"]],"entity_id": [["T5"]]} ,"Drug": {"text": [["ampicillin"]],"start": [["33"]],"entity_id": [["T1"]] }} ,"Subject": {"text": [["Myasthenic patients"]],"start": [["0"]],"entity_id": [["T0"]] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["Myasthenic patients"]],"start": [["0"]],"entity_id": [["T0"]] } },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Effect": {"text": [["close monitoring"]],"start": [["42"]],"entity_id": [["T2"]] } ,"Trigger": {"text": [["for possible acute exacerbations"]],"start": [["52"]],"entity_id": [["T3"]] } }]}
{"id": "16405935_1", "context": "Chloroquine-induced bilateral ptosis", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Chloroquine-induced"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["Chloroquine"]], "start": [[ ]], "entity_id": [ ],"Drug": {"text": [["Chloroquine"]], "start": [[ ]], "entity_id": [ ]} , "Disorder": {"text": [["bilateral ptosis"]], "start": [[ ]], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Trigger": null }, "Effect": { "text": [["bilateral ptosis"]], "start": [[ ]], "entity_id": [ ]} , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [[ "Chloroquine-induced"]], "start": [[ ]], "entity_id": [ ], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }}]}
{"id": "17364199_14","context": "To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["tuberculous uveitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with etanercept"]],"start": [["72"]],"entity_id": [["T2"]],"Drug": {"text": [["etanercept"]],"start": [["72"]],"entity_id": [["T3"]]},"Disorder": {"text": [["tuberculous uveitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Dosage": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Duration": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Route": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Time_elapsed": {"text": [["following"]],"start": [["56"]],"entity_id": [["T4"]]},"Freq": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Combination": null,"Trigger": {"text": [["treatment with etanercept"]],"start": [["72"]],"entity_id": [["T2"]]}},"Subject": {"text": [["to our knowledge this is the first reported case"]],"start": [[""]],"entity_id": [["NA"]],"Age": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Gender": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Population": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Race": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]]},"Disorder": {"text": [["tuberculous uveitis"]],"start": [["18"]],"entity_id": [["T1"]]}},"Effect": {"text": [["tuberculous uveitis"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]],"value": false},"Speculated": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]],"value": false},"Severity": {"text": [["NA"]],"start": [[""]],"entity_id": [["NA"]],"value": "NA"}}]}
{"id": "25538343_2","context": "Hyponatremia is a known adverse effect of duloxetine, and it can lead to potentially life-threatening complications","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["adverse effect"]],"start": [["11"]],"entity_id": [["T1"]]},"Treatment": {"text": [["duloxetine"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["duloxetine"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": {"text": [["Hyponatremia"]],"start": [["0"]],"entity_id": [["T0"]]},"Freq": {"text": [["can lead to potentially life-threatening complications"]],"start": [["35"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["duloxetine"]],"start": [["42"]],"entity_id": [["T2"]]},"Trigger": {"text": [["adverse effect"]],"start": [["11"]],"entity_id": [["T1"]]},"event_id": "C1","event_type": "Adverse_event"}],"Time_elapsed": {"text": [["can lead to potentially life-threatening complications"]],"start": [["35"]],"entity_id": [["T3"]]},"Duration": {"text": [["a known"]],"start": [["0"]],"entity_id": [["T4"]]},"Route": {"text": [["effect"]],"start": [["11"]],"entity_id": [["T1"]]},"Dosage": {"text": [["known"]],"start": [["0"]],"entity_id": [["T4"]]},"Trigger": {"text": [["duloxetine"]],"start": [["42"]],"entity_id": [["T2"]]}},"Effect": {"text": [["Hyponatremia"]],"start": [["0"]],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["life-threatening complications"]],"start": [["35"]],"entity_id": [["T3"]],"value": "high"},"Subject": {"text": [["Hyponatremia"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["a known"]],"start": [["0"]],"entity_id": [["T4"]]},"Age": null,"Disorder": {"text": [["Hyponatremia"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": null,"Race": null}}]}
{"id": "19003750_1", "context": "A 22-year-old drug-abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["flunitrazepam"]],"start": [["9"]],"entity_id": [["T1"]]},"Route": {"text": [["injected"]],"start": [["22"]],"entity_id": [["T2"]]},"Dosage": {"text": [["tablets dissolved in tap water"]],"start": [["30"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["injected"]],"start": [["22"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["presented with clinical signs"]],"start": [["46"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["acute ischaemia of the left leg"]],"start": [["78"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["A 22-year-old drug-abuser"]],"start": [["0"]],"entity_id": [["T0"]]} ,"entity_id": [["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T0"]] ,"text": [["A 22-year-old drug-abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg"]],"start": [[], [], [], [], [], [], []], "Duration": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Subject": {"Age": {"text": [["22"]],"start": [[], [], [], [], [], [], []],"entity_id": [["T0"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"text": [["A 22-year-old drug-abuser"]],"start": [[], [], [], [], [], [], []],"entity_id": [["T0"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null,"Effect": null}]}
{"id": "1348483_1","context": "A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Subject": {"text": [["patient"]],"start": [[ "0"]],"entity_id": [["S1"]],"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "4"]],"entity_id": [["S2"]]} ,"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["bromocriptine"]],"start": [[ "58"]],"entity_id": [["T1"]],"Drug": {"text": [["bromocriptine"]],"start": [[ "58"]],"entity_id": [["T1"]]},"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "4"]],"entity_id": [["S2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["subsequently"]],"start": [[ "82"]],"entity_id": [["T2"]]}},{"event_id": "E2","event_type": "Adverse_event","Subject": {"text": [["patient"]],"start": [[ "0"]],"entity_id": [["S1"]],"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "4"]],"entity_id": [["S2"]]} ,"Age": null,"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["cabergoline"]],"start": [[ "112"]],"entity_id": [["T3"]],"Drug": {"text": [["cabergoline"]],"start": [[ "112"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "4"]],"entity_id": [["S2"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null},"Effect": {"text": [["progressive pleuropulmonary abnormalities"]],"start": [[ "127"]],"entity_id": [["E1"]]},"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["developed"]],"start": [[ "122"]],"entity_id": [["T4"]]} }]}
{"id": "16432996_3", "context": "Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"Drug": {"text": [["interferon alpha"]],"start": [["52"]],"entity_id": []} ,"entity_id": [] ,"Disorder": {"text": [["sarcoidosis"]],"start": [["21"]],"entity_id": []} ,"Trigger": {"text": [["associated"]],"start": [["75"]],"entity_id": []} ,"Freq": {"text": [["a few"]],"start": [["67"]],"entity_id": []} ,"Duration": {"text": [["reported"]],"start": [["87"]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"text": [],"start": []} ,"Subject": {"text": [["interferon gamma"]],"start": [["0"]],"entity_id": [] ,"Gender": null,"Age": null,"Population": null,"Race": null,"Disorder": {"text": [["sarcoidosis"]],"start": [["21"]],"entity_id": []} },"Severity": null,"Speculated": null,"Negated": null ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} }]}
{"id": "3143551_3","context": "Camptocormia, a new side effect of sodium valproate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Camptocormia"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["sodium valproate"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["sodium valproate"]],"start": [[ ]],"entity_id": [ ]} ,"Disorder": {"text": [["Camptocormia"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["new"]],"start": [[ ]],"entity_id": [ ]} ,"Time_elapsed": {"text": [ ],"start": [ ],"entity_id": [ ]} ,"Dosage": {"text": [ ],"start": [ ],"entity_id": [ ]},"Duration": {"text": [ ],"start": [ ],"entity_id": [ ]},"Route": {"text": [ ],"start": [ ],"entity_id": [ ]} ,"Trigger": {"text": [["side effect"]],"start": [[ ]],"entity_id": [ ]} ,"Combination": null} ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }]}
{"id": "15028964_2","context": "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["warfarin"]],"start": [["34"]],"entity_id": [["T1"]]},"Disorder": {"text": [["cardiac arrhythmias"]],"start": [["12"]],"entity_id": [["T2"]]},"Route": {"text": [["concomitant therapy"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": [{"Drug": {"text": [["amiodarone"]],"start": [["56"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["46"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"entity_id": [["E1"]],"Trigger": {"text": [["require"]],"start": [["18"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"start": [[], [], [], [], [], [], []],"text": [["Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone"]]},"Subject": {"text": [["Many patients"]],"start": [[], [], [], [], [], [], []],"entity_id": [],"Disorder": {"text": [["cardiac arrhythmias"]],"start": [[], [], [], [], [], [], []],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11373877_2","context": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["steroidal anti-androgen therapy"]],"start": [["30"]],"entity_id": [["T1"]],"Drug": {"text": [["cyproterone acetate"]],"start": [["51"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["adenocarcinoma of the prostate"]],"start": [["16"]],"entity_id": [["T3"]]} ,"Route": {"text": [["oral"]],"start": [["71"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["subsequently"]],"start": [["111"]],"entity_id": [["T5"]]} ,"Duration": {"text": [["prior to radical or palliative pelvic irradiation"]],"start": [["65"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["both"]],"start": [["10"]],"entity_id": [["T7"]]} ,"Combination": [{"Drug": {"text": [["steroidal anti-androgen therapy"]],"start": [["30"]],"entity_id": [["T1"]]},"Trigger": {"text": [["prior"]],"start": [["43"]],"entity_id": [["T8"]]} ,"event_id": "C1" ,"event_type": "Potential_therapeutic_effect"} ,{"Drug": {"text": [["radical or palliative pelvic irradiation"]],"start": [["123"]],"entity_id": [["T9"]]},"Trigger": {"text": [["subsequently"]],"start": [["111"]],"entity_id": [["T5"]]} ,"event_id": "C2" ,"event_type": "Potential_therapeutic_effect"} ],"Trigger": {"text": [["developed"]],"start": [["132"]],"entity_id": [["T10"]]},"Dosage": {"text": [["daily"]],"start": [["39"]],"entity_id": [["T11"]]} },"Effect": {"text": [["femoral head avascular necrosis"]],"start": [["152"]],"entity_id": [["T12"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Subject": {"text": [["two patients"]],"start": [["0"]],"entity_id": [["T0"]],"Population": {"text": [["two"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Age": null,"Gender": null,"Race": null,"Disorder": {"text": [["histologically confirmed adenocarcinoma of the prostate"]],"start": [["16"]],"entity_id": [["T3"]]} },"Trigger": {"text": [["developed"]],"start": [["132"]],"entity_id": [["T10"]]}}] }
{"id": "16284443_3", "context": "Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin-induced lipohypertrophy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["in vivo effects"]], "start": [["33","37"]], "entity_id": []},"Treatment": {"text": [["insulin"]], "start": [["16","20"]], "entity_id": [], "Drug": {"text": [["insulin"]], "start": [["16","20"]], "entity_id": []} ,"Disorder": {"text": [["lipohypertrophy"]], "start": [["102","115"]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [["on adipocytes"]], "start": [["43","52"]], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []} ,"Trigger": {"text": [], "start": [], "entity_id": []} ,"Combination": null},"Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [], "start": [], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "10599932_5", "context": "After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroxy-desmethylclomipramine plasma level decrease were observed", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["citalopram"]],"start": [["After the addition of citalopram,"]],"entity_id": [["T1"]],"Drug": {"text": [["citalopram"]],"start": [["After the addition of citalopram,"]],"entity_id": [["T1"]]},"Trigger": {"text": [["desmethylclomipramine plasma level increase"]],"start": [["a desmethylclomipramine plasma level increase"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["After the addition"]],"start": [["After the addition"]],"entity_id": [["T0"]]},"Dosage": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T7"]]},"Duration": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T8"]]},"Route": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T9"]]},"Disorder": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T10"]]},"Freq": {"text": [["N/A"]],"start": [["N/A"]],"entity_id": [["T11"]]},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["desmethylclomipramine plasma level increase"]],"start": [["a desmethylclomipramine plasma level increase"]],"entity_id": [["T2"]]},"Trigger": {"text": [["8-hydroacy-desmethylclomipramine plasma level decrease"]],"start": [["an 8-hydroacy-desmethylclomipramine plasma level decrease"]],"entity_id": [["T3"]]}}]}
{"id": "18362995_2", "context": "Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fatal acute hepatic failure"]], "start": [["25"]], "entity_id": [["T1"]]}, "Treatment": {"text": [["Imatinib mesylate"]], "start": [["9"]], "entity_id": [["T2"]],"Drug": {"text": [["Imatinib mesylate"]], "start": [["9"]], "entity_id": [["T3"]]},"Disorder": {"text": [["chronic myeloid leukaemia", "chronic hepatitis B infection"]], "start": [["55","76"]], "entity_id": [["T4","T5"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": null},"Subject": {"text": [["a patient"]], "start": [["45"]], "entity_id": [["T6"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": {"text": [["fatal acute hepatic failure"]], "start": [["25"]], "entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [], "start": [], "entity_id": [],"value": "high"}}]}
{"id": "8597009_1", "context": "Phenytoin toxicity due to concomitant antituberculosis therapy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Phenytoin toxicity"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["concomitant antituberculosis therapy"]], "start": [[ ]], "entity_id": [ ], "Drug": {"text": [["antituberculosis"]], "start": [[ ]], "entity_id": [ ]},"Disorder": {"text": [["tuberculosis"]], "start": [[ ]], "entity_id": [ ]} , "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": {"text": [["concomitant"]], "start": [[ ]], "entity_id": [ ]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "18067642_2","context": "Amiodarone is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Amiodarone"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Amiodarone"]],"start": [["0"]],"entity_id": []},"Disorder": {"text": [["thyroid dysfunction"]],"start": [["81"]],"entity_id": []},"Dosage": {"text": [["high dose"]],"start": [["30"]],"entity_id": []},"Route": {"text": [["an anti-arrhythmic drug"]],"start": [["10"]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Trigger": null}]}
{"id": "1359782_2","context": "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pulmonary infiltrates", "skin pigmentation"]],"start": [[ "0", "32" ]],"entity_id": [ ["T1", "T2" ]]},"Treatment": {"text": [["sulfasalazine"]],"start": [[ "51" ]],"entity_id": [ ["T3" ]] ,"Drug": {"text": [["sulfasalazine"]],"start": [[ "51" ]],"entity_id": [ ["T3" ]]} ,"Disorder": {"text": [["Pulmonary infiltrates", "skin pigmentation"]],"start": [[ "0", "32" ]],"entity_id": [ ["T1","T2"] ]} ,"Time_elapsed": {"text": [["associated"]],"start": [[ "33" ]],"entity_id": [ ["T4"] ]} ,"Freq": {"text": [["associated"]],"start": [[ "33" ]],"entity_id": [ ["T4"] ]} ,"Route": {"text": [["associated"]],"start": [[ "33" ]],"entity_id": [ ["T4"] ]} ,"Dosage": {"text": [["associated"]],"start": [[ "33" ]],"entity_id": [ ["T4"] ]} ,"Duration": {"text": [["associated"]],"start": [[ "33" ]],"entity_id": [ ["T4"] ]} ,"Combination": null ,"Trigger": null }, "Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "998323_1","context": "Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lithium intoxication"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Lithium treatment"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["lithium"]],"start": [["21"]],"entity_id": [["T1"]]},"Duration": {"text": [["in 1975"]],"start": [["32"]],"entity_id": [["T3"]]},"Combination": [{"Drug": {"text": [["lithium"]],"start": [["21"]],"entity_id": [["T1"]]},"Trigger": {"text": [["terminated"]],"start": [["0"]],"entity_id": [["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [["diabetes insipidus-like syndrome"]],"start": [["54"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["because of"]],"start": [["46"]],"entity_id": [["T6"]]},"Freq": {"text": [["terminated"]],"start": [["0"]],"entity_id": [["T4"]]},"Route": {"text": [["treatment"]],"start": [["0"]],"entity_id": [["T2"]]},"Dosage": {"text": [["terminated"]],"start": [["0"]],"entity_id": [["T4"]]},"Trigger": {"text": [["terminated"]],"start": [["0"]],"entity_id": [["T4"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["intoxication"]],"start": [["25"]],"entity_id": [["T1"]],"value": "high"},"Subject": {"text": [["treatment"]],"start": [["0"]],"entity_id": [["T2"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["diabetes insipidus-like syndrome"]],"start": [["54"]],"entity_id": [["T5"]]}}]}
{"id": "7393795_3","context": "The induction of hypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Effect": {"text": [["induction of hypoglycaemia"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"text": [["PAS"]],"start": [[ "42" ]],"entity_id": [["T2"]],"Drug": {"text": [["PAS"]],"start": [[ "42" ]],"entity_id": [["T3"]]},"Trigger": {"text": [["this patient"]],"start": [[ "32" ]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["diabetes mellitus"]],"start": [[ "85" ]],"entity_id": [["T5"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["The patient"]],"start": [[ "3" ]],"entity_id": [["T6"]],"Disorder": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": null,"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "8641617_1","context": "Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["recovered"]],"start": [["23"]],"entity_id": []},"Treatment": {"text": [["administration of vancomycin"]],"start": [["16"]],"entity_id": [],"Drug": {"text": [["vancomycin"]],"start": [["38"]],"entity_id": []},"Disorder": {"text": [["colitis"]],"start": [["6"]],"entity_id": []},"Freq": {"text": [["subsequent"]],"start": [["113"]],"entity_id": []},"Time_elapsed": {"text": [["received"]],"start": [["86"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["colitis"]],"start": [["126"]],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["relapse"]],"start": [["149"]],"entity_id": []},"Treatment": {"text": [["subsequent course of the same chemotherapy with cisplatin"]],"start": [["113"]],"entity_id": [],"Drug": {"text": [["cisplatin"]],"start": [["157"]],"entity_id": []},"Disorder": {"text": [["colitis"]],"start": [["126"]],"entity_id": []},"Freq": {"text": [["subsequent"]],"start": [["113"]],"entity_id": []},"Time_elapsed": {"text": [["receiving"]],"start": [["121"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["colitis"]],"start": [["126"]],"entity_id": []}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "18515982_2", "context": "Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["Anastrozole"]], "start": [[ "0"]], "entity_id": [],"Drug": {"text": [["Anastrozole"]], "start": [[ "0"]], "entity_id": []},"Disorder": {"text": [["sclerosing glomerulonephritis"]], "start": [[ "53"]], "entity_id": []},"Trigger": {"text": [["may be the causative factor"]], "start": [[ "18"]], "entity_id": []},"Time_elapsed": null,"Freq": null,"Dosage": null,"Duration": null,"Route": null,"Combination": null} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "9399776_5","context": "We describe two cases of acute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute pancreatitis"]],"start": [["18", "19"]],"entity_id": []},"Treatment": {"text": [["long term mesalamine therapy"]],"start": [["47", "48"]],"entity_id": [],"Duration": {"text": [["long term"]],"start": [["47"]],"entity_id": []},"Drug": {"text": [["mesalamine"]],"start": [["40"]],"entity_id": []},"Disorder": {"text": [["ulcerative colitis"]],"start": [["70"]],"entity_id": []},"Freq": {"text": [["two cases"]],"start": [["5"]],"entity_id": []},"Time_elapsed": {"text": [["after"]],"start": [["33"]],"entity_id": []},"Trigger": {"text": [["occurred"]],"start": [["28"]],"entity_id": []},"Route": {"text": [["therapy"]],"start": [["40"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Combination": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "1673494_1","context": "Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Amphotericin B (AmB)"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ] ,"Drug": {"text": [["Amphotericin B"]],"start": [[ "0" ]],"entity_id": [ ["T2"] ] } ,"Disorder": {"text": [["toxicity"]],"start": [[ "49" ]],"entity_id": [ ["T3"] ] } ,"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null } ,"Effect": {"text": [["is effective"]],"start": [[ "15" ]],"entity_id": [ ["E1"] ] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["its use"]],"start": [[ "41" ]],"entity_id": [ ["S1"] ],"Age": null,"Disorder": {"text": [["toxicity"]],"start": [[ "49" ]],"entity_id": [ ["T3"] ] },"Gender": null,"Population": null,"Race": null } ,"Trigger": {"text": [["toxicity"]],"start": [[ "49" ]],"entity_id": [ ["T3"] ] } } ] }
{"id": "3405528_1","context": "A case of halothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["halothane induced hepatitis"]],"start": [[ ],[ ]],"entity_id": []},"Subject": {"text": [["a middle aged woman"]],"start": [[ ]],"entity_id": [],"Age": {"text": [["middle aged"]],"start": [[ ]],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["gastric surgery"]],"start": [[ ]],"entity_id": [],"Drug": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["morbid obesity"]],"start": [[ ]],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": []},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"}}]}
{"id": "12751276_2","context": "Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Anaphylaxis from isoniazid"]],"start": [[ "0" ]],"entity_id": [ ["T1" ]] }, "Effect": { "text": [["Anaphylaxis from isoniazid"]], "start": [[ "0" ]], "entity_id": [ ["T1" ]] }, "Treatment": { "text": [["this commonly prescribed antibiotic"]], "start": [[ "64" ]], "entity_id": [ ["T2" ]], "Drug": { "text": [["isoniazid"]], "start": [[ "45" ]], "entity_id": [ ["T3" ]] }, "Dosage": null, "Duration": null, "Disorder": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Subject": null ,"Negated": null ,"Speculated": { "text": [["possible"]], "start": [[ "34" ]], "entity_id": [ ["T4" ]], "value": true }, "Severity": null }] }
{"id": "9920368_2","context": "Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["thyrotoxicosis"]],"start": [["45"]],"entity_id": [["T1"]]},"Subject": {"text": [["a patient with arrhythmogenic right ventricular dysplasia"]],"start": [["20"]],"entity_id": [["T2"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["arrhythmogenic right ventricular dysplasia"]],"start": [["20"]],"entity_id": [["T3"]]}},"Treatment": {"text": [["amiodarone"]],"start": [["86"]],"entity_id": [["T4"]],"Drug": {"text": [["amiodarone"]],"start": [["86"]],"entity_id": [["T5"]]},"Dosage": {"text": [["4 years"]],"start": [["76"]],"entity_id": [["T6"]]},"Duration": null,"Disorder": {"text": [["thyrotoxicosis"]],"start": [["45"]],"entity_id": [["T1"]]},"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["thyrotoxicosis with subacute onset", "transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)"]],"start": [["45","80"]],"entity_id": [["T1","T7"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18094347_5", "context": "Methotrexate-induced papular eruption following treatment of psoriasis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Methotrexate-induced papular eruption"]], "start": [[ "0", "37"]], "entity_id": []}, "Treatment": {"text": [["treatment"]], "start": [[ "38", "45"]], "entity_id": [],"Drug": {"text": [["Methotrexate"]], "start": [[ "38", "45"]], "entity_id": []}, "Disorder": {"text": [["psoriasis"]], "start": [[ "46", "52"]], "entity_id": []}, "Freq": {"text": [["following"]], "start": [[ "53", "59"]], "entity_id": []}, "Route": {"text": [["treatment"]], "start": [[ "38", "45"]], "entity_id": []}, "Time_elapsed": {"text": [["induced"]], "start": [[ "30", "35"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []} ,"Trigger":{"text":[], "start":[], "entity_id":[]} ,"Combination": [{"Drug":{"text":[["Methotrexate"]], "start":[[ "38", "45"]], "entity_id": []},"Trigger":{"text":[["treatment"]], "start":[[ "38", "45"]], "entity_id": []},"event_id":"C1" ,"event_type":"Adverse_event"}] },"Subject": {"text":[["Methotrexate-induced papular eruption"]], "start":[[ "0", "37"]], "entity_id": [],"Age":{"text":[], "start":[], "entity_id":[]} ,"Gender":{"text":[], "start":[], "entity_id":[]} ,"Population":{"text":[], "start":[], "entity_id":[]} ,"Race":{"text":[], "start":[], "entity_id":[]} ,"Disorder":{"text":[["psoriasis"]], "start":[[ "46", "52"]], "entity_id": []}} ,"Effect": {"text":[["Methotrexate-induced papular eruption"]], "start":[[ "0", "37"]], "entity_id": []},"Negated":{"text":[], "start":[], "entity_id":[],"value":false} ,"Speculated":{"text":[], "start":[], "entity_id":[],"value":false} ,"Severity":{"text":[], "start":[], "entity_id":[],"value":"low"} }]}
{"id": "11030530_2","context": "Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["L-asparaginase"]],"start": [["treated with L-asparaginase" ]],"entity_id": [ ["T1"] ],"Disorder": {"text": [["hemorrhagic and thrombotic cerebrovascular events"]],"start": [["with hemorrhagic and thrombotic cerebrovascular events"]],"entity_id": [ ["T2"] ]} ,"Trigger": { "text": [["may present"]], "start": [[ "may present" ]], "entity_id": [ ["T3"] ]} ,"Dosage": null, "Duration": null, "Freq": null, "Route": null, "Time_elapsed": null ,"Combination": null ,"Drug": null }, "Subject": null ,"Negated": null, "Speculated": null, "Severity": null ,"Effect": null ,"Trigger": null }] }
{"id": "15611427_3", "context": "Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["imiquimod"]],"start": [[ "0" ]],"entity_id": [ ["T1"]] ,"Drug": {"text": [["imiquimod"]],"start": [[ "0" ]],"entity_id": [ ["T2"]] },"Trigger": {"text": [["induces"]],"start": [[ "41" ]],"entity_id": [ ["T3"]] },"Time_elapsed": {"text": [["large amounts"]],"start": [[ "25" ]],"entity_id": [ ["T4"]]},"Route": {"text": [["from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs)"]],"start": [[ "41" ]],"entity_id": [ ["T5"]] },"Disorder": {"text": [["of psoriatic skin"]],"start": [[ "158" ]],"entity_id": [ ["T6"]]},"Freq": {"text": [["are present"]],"start": [[ "143" ]],"entity_id": [ ["T7"]] },"Duration": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }]}
{"id": "17494808_1", "context": "Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Hypersensitivity pneumonitis-like syndrome"]], "start": [[ "0" ]], "entity_id": []}, "Treatment": {"text": [["lenalidomide"]], "start": [[ "58" ]], "entity_id": [],"Drug": {"text": [["lenalidomide"]], "start": [[ "58" ]], "entity_id": []} ,"Disorder": {"text": [["Hypersensitivity pneumonitis-like syndrome"]], "start": [[ "0" ]], "entity_id": []} ,"Time_elapsed": {"text": [["associated with the use of"]], "start": [[ "22" ]], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Freq": {"text": [], "start": [], "entity_id": []} ,"Combination": null ,"Trigger": { "text": [["use of lenalidomide"]], "start": [[ "42" ]], "entity_id": []} }, "Effect": {"text": [], "start": [], "entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "11033734_2", "context": "Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["seizures"]], "start": [["Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin"]], "entity_id": []}, "Treatment": {"text": [["imipenem/cilastatin"]], "start": [[], []], "entity_id": [],"Drug": {"text": [["imipenem","cilastatin"]], "start": [[], []], "entity_id": [] },"Disorder":{"text":[["pediatric cancer"]], "start": [[], []], "entity_id": [] },"Route":{"text":[["treated"]], "start": [[], []], "entity_id": [] },"Freq":{"text":[["Incidence"]], "start": [[], []], "entity_id": [] },"Time_elapsed":{"text":[["treated"]], "start": [[], []], "entity_id": [] },"Duration":{"text":[["treated"]], "start": [[], []], "entity_id": [] },"Dosage":{"text":[["treated"]], "start": [[], []], "entity_id": [] },"Combination":null,"Trigger":null},"Subject":{"text":[["pediatric cancer patients"]], "start": [[], []], "entity_id": [],"Age":{"text":[["pediatric"]], "start": [[], []], "entity_id": [] },"Disorder":{"text":[["cancer"]], "start": [[], []], "entity_id": [] },"Gender":null,"Population":{"text":[["patients"]], "start": [[], []], "entity_id": [] },"Race":null},"Effect":null,"Negated":null,"Speculated":null,"Severity":null}]}
{"id": "6260900_2", "context": "One of these was clofazimine, an aniline aposafranine derivative known to produce a ceroid-like pigment in the tissues of patients treated with this drug or lepromatous leprosy.","is_mult_event": false, "annotations": [ { "event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": { "text": [["clofazimine"]], "start": [["32"]], "entity_id": [ ["T1"] ] , "Drug": { "text": [["clofazimine"]], "start": [["32"]], "entity_id": [ ["T1"] ] } , "Disorder": { "text": [["lepromatous leprosy"]], "start": [["75"]], "entity_id": [ ["T2"] ] } , "Route": { "text": [["treated with this drug"]], "start": [["53"]], "entity_id": [ ["T3"] ] } , "Trigger": { "text": [["produce"]], "start": [["59"]], "entity_id": [ ["T4"] ] } , "Time_elapsed": { "text": [["treated with this drug"]], "start": [["53"]], "entity_id": [ ["T3"] ] } , "Duration": { "text": [["treated with this drug"]], "start": [["53"]], "entity_id": [ ["T3"] ] } , "Freq": { "text": [["treated with this drug"]], "start": [["53"]], "entity_id": [ ["T3"] ] } , "Dosage": { "text": [["treated with this drug"]], "start": [["53"]], "entity_id": [ ["T3"] ] } , "Combination": null } , "Subject": { "text": [["patients treated with this drug"]], "start": [[ "53" ]], "entity_id": [ ["T3"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null , "Trigger": null } ]}
{"id": "331881_1","context": "Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Deposits of plasma proteins in the skin"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["treatment with carbamazepine and diphenylhydantoin"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["carbamazepine"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["treatment"]],"start": [[ ]],"entity_id": []},"Route": {"text": [["with"]],"start": [[ ]],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["diphenylhydantoin"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "low","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "14690166_1","context": "2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["2-Chloro-deoxyadenosine"]],"start": [["0"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["Castleman's disease"]],"start": [["48"]],"entity_id": [["T2"]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [["durable complete remission"]],"start": [["20"]],"entity_id": [["T3"]] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": {"text": [["induces"]],"start": [["1"]],"entity_id": [["T4"]] },"Drug": {"text": [["2-Chloro-deoxyadenosine"]],"start": [["0"]],"entity_id": [["T1"]] }} ,"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [["Castleman's disease"]],"start": [["48"]],"entity_id": [["T2"]] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Trigger": {"text": [],"start": [],"entity_id": [] }} ]}
{"id": "10393393_1","context": "Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute asthma"]],"start": [["19"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["aspirin"]],"start": [["12"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"text": [["aspirin"]],"start": [["12"]],"Dosage": {"text": [["hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["can be manifested"]],"start": [["12"]],"entity_id": [["T0"]]} ,"Route": {"text": [["as"]],"start": [["33"]],"entity_id": [["T3"]]} ,"Time_elapsed": {"text": [["can be manifested"]],"start": [["12"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["acute asthma"]],"start": [["19"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["can be manifested"]],"start": [["12"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["aspirin"]],"start": [["12"]],"entity_id": [["T2"]]},"Trigger": {"text": [["or"]],"start": [["42"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Adverse_event"},{"Drug": {"text": [["aspirin"]],"start": [["12"]],"entity_id": [["T2"]]},"Trigger": {"text": [["a systemic anaphylactoid reaction"]],"start": [["53"]],"entity_id": [["T5"]]},"event_id": "E3","event_type": "Adverse_event"}],"Trigger": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]} } , "Subject": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]],"Gender": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["Hypersensitivity"]],"start": [["0"]],"entity_id": [["T0"]]}} ,"Negated": null,"Speculated": null,"Severity": {"text": [["acute asthma"]],"start": [["19"]],"entity_id": [["T1"]] ,"value": "low"} ,"Effect": {"text": [["acute asthma"]],"start": [["19"]],"entity_id": [["T1"]]} } ]}
{"id": "19224802_1", "context": "An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exaggerated hypertensive response"]], "start": [[ ], [ ]], "entity_id": []}, "Treatment": {"text": [["glycopyrrolate therapy"]], "start": [[ ]], "entity_id": [],"Drug": {"text": [["glycopyrrolate"]], "start": [[ ]], "entity_id": []}, "Time_elapsed": {"text": [["therapy"]], "start": [[ ]], "entity_id": []}, "Disorder": {"text": [["bradycardia"]], "start": [[ ]], "entity_id": []}, "Trigger": {"text": [["high-dose dexmedetomidine"]], "start": [[ ]], "entity_id": []} , "Freq": {"text": [["exaggerated"]], "start": [[ ]], "entity_id": []} , "Combination": [{"Drug": {"text": [["glycopyrrolate"]], "start": [[ ]], "entity_id": []} , "Trigger": {"text": [["therapy"]], "start": [[ ]], "entity_id": []} , "event_id": "C1" , "event_type": "Treatment"}] , "Route": {"text": [["for"]], "start": [[ ]], "entity_id": []} , "Dosage": {"text": [["high-dose"]], "start": [[ ]], "entity_id": []} , "Duration": {"text": [["response"]], "start": [[ ]], "entity_id": []} }, "Severity": {"text": [["exaggerated hypertensive"]], "start": [[ ]], "entity_id": [] , "value": "high" }, "Negated": {"text": [], "start": [], "entity_id": [] , "value": false }, "Speculated": {"text": [], "start": [], "entity_id": [] , "value": false }, "Subject": {"text": [], "start": [], "entity_id": [] , "Age": {"text": [], "start": [], "entity_id": [] }, "Gender": {"text": [], "start": [], "entity_id": [] }, "Population": {"text": [], "start": [], "entity_id": [] }, "Race": {"text": [], "start": [], "entity_id": [] }, "Disorder": {"text": [["bradycardia"]], "start": [[ ]], "entity_id": [] }} , "Effect": {"text": [["response"]], "start": [[ ]], "entity_id": [] }}]}
{"id": "8530331_7","context": "Only one patient, the youngest, did well on risperidone therapy","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["risperidone therapy"]],"start": [["risperidone therapy's starting index in the text"]],"entity_id": [["unique identifier for risperidone therapy"]] ,"Drug": {"text": [["risperidone"]],"start": [["risperidone's starting index in the text"]],"entity_id": [["unique identifier for risperidone"]] },"Disorder": {"text": [["well"]],"start": [[ "well's starting index in the text" ]],"entity_id": [["unique identifier for well"]] },"Freq": {"text": [["Only one patient"]],"start": [[ "Only one patient's starting index in the text" ]],"entity_id": [["unique identifier for Only one patient"]] },"Trigger": {"text": [["did well"]],"start": [[ "did well's starting index in the text" ]],"entity_id": [["unique identifier for did well"]] },"Dosage": {"text": [[]],"start": [],"entity_id": [] },"Duration": {"text": [[]],"start": [],"entity_id": [] },"Route": {"text": [[]],"start": [],"entity_id": [] },"Time_elapsed": {"text": [[]],"start": [],"entity_id": [] },"Combination": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Only one patient", "the youngest"]],"start": [[ "Only one patient's starting index in the text", "the youngest's starting index in the text" ]],"entity_id": [["unique identifier for Only one patient", "unique identifier for the youngest"]],"Age": {"text": [["the youngest"]],"start": [[ "the youngest's starting index in the text" ]],"entity_id": [["unique identifier for the youngest"]] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [["Only one patient"]],"start": [[ "Only one patient's starting index in the text" ]],"entity_id": [["unique identifier for Only one patient"]] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Trigger": null }]}
{"id": "7019786_3","context": "Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute deterioration"]],"start": [["19"]],"entity_id": [["T1"]]},"Subject": {"text": [["Two elderly women"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["elderly"]],"start": [["5"]],"entity_id": [["T2"]]},"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["treatment"]],"start": [["48"]],"entity_id": [["T3"]],"Drug": {"text": [["cefoxitin sodium"]],"start": [["48"]],"entity_id": [["T4"]]},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": {"text": [["after treatment with"]],"start": [["35"]],"entity_id": [["T3"]]}},"Effect": {"text": [["renal function"]],"start": [["23"]],"entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["acute deterioration"]],"start": [["19"]],"entity_id": [["T1"]],"value": "high"}}]}
{"id": "19904536_14","context": "Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["pulmonary toxicity"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gemcitabine chemotherapy"]],"start": [["59"]],"entity_id": [["T2"]],"Disorder": {"text": [["respiratory distress"]],"start": [["27"]],"entity_id": [["T3"]]},"Drug": {"text": [["gemcitabine"]],"start": [["59"]],"entity_id": [["T4"]]},"Freq": {"text": [["after"]],"start": [["46"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["after"]],"start": [["46"]],"entity_id": [["T5"]]},"Route": {"text": [["chemotherapy"]],"start": [["59"]],"entity_id": [["T2"]]},"Trigger": {"text": [["pulmonary toxicity"]],"start": [["14"]],"entity_id": [["T1"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null},"Subject": {"text": [["patients"]],"start": [["10"]],"entity_id": [["T0"]],"Age": {"text": [["elderly"]],"start": [["91"]],"entity_id": [["T6"]]},"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "9920368_1", "context": "Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Amiodarone-induced thyrotoxicosis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["thyrotropin receptor antibody"]], "start": [[ ]], "entity_id": [["T2"]] , "Drug": {"text": [["Amiodarone"]], "start": [[ ]], "entity_id": [["T3"]]} , "Disorder": {"text": [["thyrotoxicosis"]], "start": [[ ]], "entity_id": [["T4"]]} , "Time_elapsed": {"text": [], "start": [], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Freq": {"text": [], "start": [], "entity_id": []} , "Route": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": null} , "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "21751692_4","context": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["EA signs"]],"start": [[ "0"]] ,"entity_id": [ ["T1"]]},"Subject": {"text": [["all 7 patients"]],"start": [[ "3"]],"entity_id": [ ["T2"]] ,"Age": null,"Disorder": null,"Gender": null,"Population": {"text": [[ "all 7 patients" ]],"start": [[ "3" ]],"entity_id": [[ "T2" ]] },"Race": null},"Treatment": {"text": [["propofol TIVA"]],"start": [[ "22" ]],"entity_id": [[ "T3" ]],"Drug": {"text": [["propofol"]],"start": [[ "22" ]],"entity_id": [[ "T4" ]] },"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Disorder": null,"Freq": null,"Trigger": { "text": [[ "TIVA" ]],"start": [[ "30" ]],"entity_id": [[ "T7" ]] },"Combination": null }, "Negated": null, "Speculated": null, "Severity": null ,"Effect": null }]}
{"id": "9362107_2","context": "On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and purpura occurred","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["gingival bleeding", "purpura"]],"start": [[], []],"entity_id": []},"Treatment": {"text": [["danazol"]],"start": [[], []],"entity_id": [] ,"Dosage": {"text": [["600 mg"]],"start": [[], []],"entity_id": []} ,"Time_elapsed": {"text": [["the next day"]],"start": [[], []],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Drug": {"text": [["danazol"]],"start": [[], []],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Effect": {"text": [["gingival bleeding", "purpura"]],"start": [[], []],"entity_id": []} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "1393348_4","context": "SLE receded after withdrawal of carbamazepine and treatment with anti-inflammatory drugs","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["SLE"]],"start": [["0"]],"entity_id": [["T1"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["carbamazepine"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["carbamazepine"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null},"Effect": {"text": [["receded"]],"start": [["13"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["withdrawal"]],"start": [["22"]],"entity_id": [["T4"]] }} ,{"event_id": "E2","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Treatment": {"text": [["treatment with anti-inflammatory drugs"]],"start": [["59"]],"entity_id": [["T5"]],"Drug": null,"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Trigger": null ,"Combination": null},"Effect": null ,"Trigger": null }]}
{"id": "8828999_1","context": "a 67-year-old man with bipolar disorder developed a Creutzfeldt-Jakob like syndrome during lithium carbonate treatment","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Creutzfeldt-Jakob like syndrome"]],"start": [["28"]],"entity_id": [["T1"]]},"Subject": {"text": [["a 67-year-old man"]],"start": [["2"]],"entity_id": [["T2"]],"Age": {"text": [["67"]],"start": [["5"]],"entity_id": [["A1"]]},"Disorder": {"text": [["bipolar disorder"]],"start": [["22"]],"entity_id": [["T3"]]},"Gender": {"text": [["man"]],"start": [["18"]],"entity_id": [["G1"]]},"Race": {"text": [["a"]],"start": [["2"]],"entity_id": [["R1"]]},"Population": {"text": [["a"]],"start": [["2"]],"entity_id": [["P1"]]}},"Treatment": {"text": [["lithium carbonate treatment"]],"start": [["51"]],"entity_id": [["T4"]],"Drug": {"text": [["lithium carbonate"]],"start": [["51"]],"entity_id": [["D1"]]},"Route": {"text": [["treatment"]],"start": [["51"]],"entity_id": [["R2"]]},"Time_elapsed": {"text": [["developed"]],"start": [["26"]],"entity_id": [["T5"]]},"Duration": {"text": [["a"]],"start": [["2"]],"entity_id": [["Du1"]]},"Disorder": {"text": [["treatment"]],"start": [["51"]],"entity_id": [["D2"]]},"Dosage": {"text": [["a"]],"start": [["2"]],"entity_id": [["Do1"]]},"Freq": {"text": [["a"]],"start": [["2"]],"entity_id": [["Fr1"]]},"Combination": null,"Trigger": {"text": [["treatment"]],"start": [["51"]],"entity_id": [["Tr1"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": null}]}
{"id": "7679525_2","context": "A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening interstitial pneumonitis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["interstitial pneumonitis"]],"start": [["73"]],"entity_id": [["T1"]]},"Subject": {"text": [["A 42 year old man"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["42"]],"start": [["5"]],"entity_id": [["T3"]]},"Gender": {"text": [["man"]],"start": [["13"]],"entity_id": [["T4"]]},"Disorder": {"text": [["testicular carcinoma"]],"start": [["35"]],"entity_id": [["T5"]]},"Population": {"text": [["1"]],"start": [["0"]],"entity_id": [["T2"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["combination chemotherapy that included bleomycin"]],"start": [["42"]],"entity_id": [["T6"]],"Drug": {"text": [["bleomycin"]],"start": [["64"]],"entity_id": [["T8"]]},"Disorder": {"text": [["testicular carcinoma"]],"start": [["35"]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["chemotherapy"]],"start": [["46"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["bleomycin"]],"start": [["64"]],"entity_id": [["T8"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "E1","event_type": "Adverse_event"}],"Trigger": {"text": [["developed"]],"start": [["68"]],"entity_id": [["T9"]]}},"Severity": {"text": [["life threatening"]],"start": [["70"]],"entity_id": [["T10"]],"value": "high"},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Effect": {"text": [["interstitial pneumonitis"]],"start": [["73"]],"entity_id": [["T1"]]}}]}
{"id": "18446030_1", "context": "Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["disseminated eruptive giant mollusca contagiosa"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]},"Subject": { "text": [["an adult psoriasis patient"]], "start": [[ "42" ]], "entity_id": [ ["T2"] ],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["psoriasis patient"]], "start": [[ "42" ]], "entity_id": [ ["T3"] ] } },"Treatment": { "text": [["efalizumab therapy"]], "start": [[ "67" ]], "entity_id": [ ["T4"] ],"Drug": { "text": [["efalizumab"]], "start": [[ "67" ]], "entity_id": [ ["T5"] ] }, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Disorder": { "text": [["psoriasis"]], "start": [[ "42" ]], "entity_id": [ ["T6"] ] }, "Combination": null },"Effect": { "text": [["disseminated eruptive giant mollusca contagiosa"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] },"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "18294121_5","context": "Temozolomide was restarted 2 months later; the patient again developed a fever","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Temozolomide"]],"start": [[ "0" ]],"entity_id": [] ,"Drug": {"text": [["Temozolomide"]],"start": [[ "0" ]],"entity_id": [] },"Disorder": {"text": [["fever"]],"start": [[ "84" ]],"entity_id": [] },"Time_elapsed": {"text": [["2 months later"]],"start": [[ "30" ]],"entity_id": [] },"Trigger": {"text": [["restarted"]],"start": [[ "11" ]],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Combination": null },"Effect": {"text": [["fever"]],"start": [[ "84" ]],"entity_id": [] },"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": {"text": [["the patient"]],"start": [[ "53" ]],"entity_id": [] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": {"text": [],"start": [],"entity_id": [] }} ,"Trigger": {"text": [["developed"]],"start": [[ "75" ]],"entity_id": [] }} ] }
{"id": "11328247_4","context": "The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["The patient"]],"start": [[ "0" ]],"entity_id": [ ["S1" ]] ,"Age": {"text": [["a 27-year-old"]],"start": [[ "10" ]],"entity_id": [ ["S1.Age" ]] },"Gender": {"text": [["married Japanese woman"]],"start": [[ "21" ]],"entity_id": [ ["S1.Gender" ]] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [["Japanese"]],"start": [[ "24" ]],"entity_id": [ ["S1.Race" ]] },"Disorder": {"text": [["borderline personality disorder"]],"start": [[ "40" ]],"entity_id": [ ["S1.Disorder" ]] }},"Treatment": {"text": [["fluvoxamine"]],"start": [[ "90" ]],"entity_id": [ ["T1" ]],"Drug": {"text": [["fluvoxamine"]],"start": [[ "90" ]],"entity_id": [ ["T1.Drug" ]] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Combination": [] },"Effect": {"text": [["an increased libido"]],"start": [[ "72" ]],"entity_id": [ ["E1.Effect" ]] },"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null }] }
{"id": "9403220_2", "context": "Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril.","is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Acute renal failure"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": { "text": [["enalapril"]], "start": [[ "82" ]],"entity_id": [ ["T2"] ],"Drug": { "text": [["enalapril"]], "start": [[ "82" ]],"entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["minimal change nephrotic syndrome"]], "start": [[ "44" ]],"entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null ,"Trigger": null },"Subject": { "text": [["a patient"]], "start": [[ "31" ]],"entity_id": [ ["T5"] ],"Age": null, "Disorder": { "text": [["minimal change nephrotic syndrome"]], "start": [[ "44" ]],"entity_id": [ ["T4"] ]}, "Gender": null, "Population": null, "Race": null },"Effect": { "text": [["Acute renal failure with severe tubulointerstitial changes"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Negated": null, "Speculated": null, "Severity": { "text": [], "start": [], "entity_id": [], "value": "severe" } }]}
{"id": "7919557_4","context": "The cough continued for the duration of therapy with quinapril","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["quinapril"]],"start": [["therapy with quinapril" ], ["quinapril"]],"entity_id": [ ["T1"], ["T2"] ]},"Duration": {"text": [["the duration of therapy"]],"start": [[ "The cough continued for" ]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["cough"]],"start": [[ "The cough" ]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["the cough"]],"start": [[ "The cough" ]],"entity_id": [["T4"]]} ,"Freq": {"text": [["continued"]],"start": [[ "continued" ]],"entity_id": [["T5"]]} ,"Route": {"text": [["therapy with quinapril"]],"start": [[ "therapy with quinapril" ]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["for the duration"]],"start": [[ "for the duration" ]],"entity_id": [["T6"]]} ,"entity_id": [ ["T1"], ["T2"], ["T3"], ["T4"], ["T5"], ["T6"] ],"text": [ ["therapy with quinapril"], ["quinapril"], ["the duration of therapy"], ["cough"], ["continued"], ["therapy with quinapril"], ["for the duration"] ],"start": [ ["therapy with quinapril" ], ["quinapril" ], ["the duration of therapy" ], ["cough" ], ["continued" ], ["therapy with quinapril" ], ["for the duration" ]] ,"Dosage": { "text": [], "start": [], "entity_id": [] },"Combination": null },"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Trigger": null ,"Effect": null }] }
{"id": "9362107_1","context": "Danazol induced thrombocytopenia","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["thrombocytopenia"]],"start": [["16"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Danazol"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Danazol"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Disorder": {"text": [["thrombocytopenia"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Route": {"text": [["induced"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["induced"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Dosage": {"text": [["Danazol"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["induced"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Combination": null ,"Trigger": {"text": [["thrombocytopenia"]],"start": [["16"]],"entity_id": [["T1"]]} },"Effect": {"text": [["thrombocytopenia"]],"start": [["16"]],"entity_id": [["T1"]]} ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }]}
{"id": "16005413_5", "context": "Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Subject": {"Age": {"text": [["elderly"]], "start": [["4"]], "entity_id": []}, "Population": {"text": [["Four"]], "start": [["0"]], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "text": [["Four elderly LTCF residents"]], "start": [["0"]], "entity_id": []},"Treatment": {"text": [["serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids"]],"start": [["30"]],"entity_id": [],"Drug": {"text": [["serotonergic antidepressants", "selective serotonin reuptake inhibitor (SSRI) or mirtazapine", "opioids"]],"start": [["30","51","87"]],"entity_id": []} ,"Disorder": { "text": [], "start": [], "entity_id": [] }, "Dosage": { "text": [], "start": [], "entity_id": [] }, "Duration": { "text": [], "start": [], "entity_id": [] }, "Trigger": { "text": [], "start": [], "entity_id": [] }, "Route": { "text": [], "start": [], "entity_id": [] }, "Time_elapsed": { "text": [], "start": [], "entity_id": [] }, "Freq": { "text": [], "start": [], "entity_id": [] }, "Combination": [] }, "Effect": { "text": [], "start": [], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null ,"Trigger": null }]}
{"id": "1772299_1", "context": "Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["L-tryptophan induced eosinophilia-myalgia syndrome"]],"start": [["50"]],"entity_id": [ ["T1"]]},"Treatment": {"Drug": {"text": [["L-tryptophan"]],"start": [["17"]],"entity_id": [ ["T2"]]},"entity_id": [ ["T2"]],"Disorder": {"text": [["eosinophilia-myalgia syndrome"]],"start": [["35"]],"entity_id": [ ["T3"]]},"Time_elapsed": {"text": [["detection of antineutrophil cytoplasmic antibody"]],"start": [["0"]],"entity_id": [ ["T4"]]},"text": [["detection of antineutrophil cytoplasmic antibody"]],"start": [["0"]],"Dosage": {"text": [["detection"]],"start": [["0"]],"entity_id": [ ["T4"]]},"Duration": {"text": [["detection"]],"start": [["0"]],"entity_id": [ ["T4"]]},"Route": {"text": [["detection"]],"start": [["0"]],"entity_id": [ ["T4"]]},"Freq": {"text": [["detection"]],"start": [["0"]],"entity_id": [ ["T4"]]},"Combination": null,"Trigger": {"text": [["detection of antineutrophil cytoplasmic antibody"]],"start": [["0"]],"entity_id": [ ["T4"]]}},"Subject": {"text": [["a patient"]],"start": [["22"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["L-tryptophan induced eosinophilia-myalgia syndrome"]],"start": [["50"]],"entity_id": [ ["T1"]]},"entity_id": [ ["E1"]]},"Severity": null,"Negated": null,"Speculated": null,"Effect": null}]}
{"id": "8496127_2","context": "This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute dystonic reactions"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["pimozide"]],"start": [["73"]],"entity_id": [["T2"]]},"Dosage": {"text": [["0.096 mg/kg/day"]],"start": [["73"]],"entity_id": [["T2"]]},"Duration": {"text": [["repeated episodes"]],"start": [["32"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["32 hours following pimozide withdrawal"]],"start": [["112"]],"entity_id": [["T3"]]},"Freq": {"text": [["repeated episodes"]],"start": [["32"]],"entity_id": [["T1"]]},"Route": {"text": [["administration"]],"start": [["73"]],"entity_id": [["T2"]]},"entity_id": [["T2"]],"text": [["0.032 mg/kg/day"]],"start": [["105"]],"Disorder": {"text": [["autistic"]],"start": [["42"]],"entity_id": [["T4"]]},"Trigger": {"text": [["subsequent thioridazine administration"]],"start": [["132"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["pimozide"]],"start": [["73"]],"entity_id": [["T2"]]},"Trigger": {"text": [["administration"]],"start": [["73"]],"entity_id": [["T2"]]},"event_id": "E1.1","event_type": "Adverse_event"},{"Drug": {"text": [["thioridazine"]],"start": [["132"]],"entity_id": [["T5"]]},"Trigger": {"text": [["administration"]],"start": [["132"]],"entity_id": [["T5"]]},"event_id": "E1.2","event_type": "Adverse_event"}]},"Subject": {"text": [["6.9-year-old autistic male"]],"start": [["17"]],"entity_id": [["T6"]],"Age": {"text": [["6.9-year-old"]],"start": [["17"]],"entity_id": [["T6"]]},"Disorder": {"text": [["autistic"]],"start": [["42"]],"entity_id": [["T4"]]},"Gender": {"text": [["male"]],"start": [["45"]],"entity_id": [["T4"]]},"Race": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Effect": {"text": [["repeated episodes of acute dystonic reactions"]],"start": [["32"]],"entity_id": [["T1"]]}}]}
{"id": "9169264_1", "context": "Cephalexin rash in infectious mononucleosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["rash"]], "start": [["9"]], "entity_id": []}, "Treatment": {"text": [["Cephalexin"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Cephalexin"]], "start": [["0"]], "entity_id": []}, "Disorder": {"text": [["infectious mononucleosis"]], "start": [["22"]], "entity_id": []}, "Route": {"text": [["in"]], "start": [["14"]], "entity_id": []}, "Time_elapsed": {"text": [["in"]], "start": [["14"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": {"text": [["rash"]], "start": [["9"]], "entity_id": []}}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "11788010_3", "context": "Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Hepatolithiasis"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["octreotide therapy"]], "start": [["37"]], "entity_id": [],"Drug": {"text": [["octreotide"]], "start": [["37"]], "entity_id": []},"Disorder": {"text": [["acromegaly"]], "start": [["56"]], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Combination": [],"Trigger":{"text":[["during"]], "start":[[ "15" ]], "entity_id": []} },"Subject":{"text":[], "start": [], "entity_id": [],"Age":{"text":[], "start":[], "entity_id": []},"Disorder":{"text":[["acromegaly"]], "start":[[ "72" ]], "entity_id": []},"Gender":{"text":[], "start":[], "entity_id": []},"Population":{"text":[], "start":[], "entity_id": []},"Race":{"text":[], "start":[], "entity_id": []} },"Negated":{"text":[], "start":[], "entity_id": [],"value":false},"Speculated":{"text":[], "start":[], "entity_id": [],"value":false},"Severity":{"text":[], "start":[], "entity_id": [],"value":"Not Specified" },"Effect":{"text":[["Hepatolithiasis"]], "start":[[ "0" ]], "entity_id": []} }]}
{"id": "16527771_1", "context": "Acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute unilateral total visual loss"]], "start": [[],[],[]], "entity_id": []}, "Subject": {"text": [["patient"]], "start": [[],[]], "entity_id": [],"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["retrogasserian phenol injection"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["phenol"]], "start": [[],[]], "entity_id": []}, "Disorder": {"text": [["trigeminal neuralgia"]], "start": [[],[]], "entity_id": []}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null, "Trigger": null, "Combination": null}, "Effect": {"text": [["visual loss"]], "start": [[],[]], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": {"text": [["acute"]], "start": [[],[]], "entity_id": [],"value": "high"}}]}
{"id": "22791547_1", "context": "Methylphenidate-induced acute orofacial and extremity dyskinesia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Methylphenidate-induced acute orofacial and extremity dyskinesia"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["Methylphenidate"]], "start": [[ ]], "entity_id": [["T2"]],"Drug": { "text": [["Methylphenidate"]], "start": [[ ]], "entity_id": [["T2"]]},"Disorder": { "text": [["acute orofacial and extremity dyskinesia"]], "start": [[ ]], "entity_id": [["T3"]]},"Dosage": { "text": [], "start": [], "entity_id": []},"Duration": { "text": [], "start": [], "entity_id": []},"Route": { "text": [], "start": [], "entity_id": []},"Time_elapsed": { "text": [], "start": [], "entity_id": []},"Freq": { "text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": { "text": [["Methylphenidate-induced"]], "start": [[ ]], "entity_id": [["T4"]]}}, "Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "7946029_1","context": "Basilar invagination and mid-line skeletal abnormalities due to in utero exposure to phenytoin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["phenytoin"]],"start": [["46"]],"entity_id": [["T2"]],"Drug": {"text": [["phenytoin"]],"start": [["46"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Basilar invagination and mid-line skeletal abnormalities"]],"start": [["0"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Freq": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Route": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Dosage": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Duration": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]},"Combination": null,"Trigger": {"text": [["in utero exposure"]],"start": [["28"]],"entity_id": [["T1"]]}},"Subject": {"text": [["Basilar invagination and mid-line skeletal abnormalities"]],"start": [["0"]],"entity_id": [["T4"]],"Gender": null,"Age": null,"Population": null,"Race": null,"Disorder": {"text": [["Basilar invagination and mid-line skeletal abnormalities"]],"start": [["0"]],"entity_id": [["T4"]]}},"Effect": null,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "9840249_1","context": "Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Alveolar-interstitial pneumopathy"]],"start": [["0"]],"entity_id": [ ["T1"] ]}, "Treatment": { "text": [["gold-salts compounds administration"]],"start": [["52"]],"entity_id": [ ["T2"] ],"Drug": {"text": [["gold-salts"]],"start": [["52"]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": { "text": [["after"]],"start": [["21"]],"entity_id": [ ["T4"] ]} ,"Trigger": { "text": [["administration"]],"start": [["59"]],"entity_id": [ ["T5"] ]} ,"Route": { "text": [["administration"]],"start": [["59"]],"entity_id": [ ["T5"] ]} ,"Freq": { "text": [["requiring mechanical ventilation"]],"start": [["70"]],"entity_id": [ ["T6"] ]} ,"Duration": { "text": [["administration"]],"start": [["59"]],"entity_id": [ ["T5"] ]} ,"Disorder": { "text": [["Alveolar-interstitial pneumopathy"]],"start": [["0"]],"entity_id": [ ["T1"] ]} ,"Dosage": { "text": [["gold-salts compounds administration"]],"start": [["52"]],"entity_id": [ ["T2"] ]} ,"Combination": null },"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null }] }
{"id": "25538343_4", "context": "We report a case of duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["elderly patient"]], "start": [["28"]], "entity_id": [["T1"]],"Age": {"text": [["elderly"]], "start": [["28"]], "entity_id": [["T2"]]},"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [["a"]], "start": [["28"]], "entity_id": [["T3"]]},"Race": {"text": [], "start": [], "entity_id": []}},"Trigger": {"text": [["duloxetine-induced"]], "start": [["12"]], "entity_id": [["T4"]]},"Treatment": {"text": [["thiazide diuretics"]], "start": [["58"]], "entity_id": [["T5"]],"Drug": {"text": [["duloxetine"]], "start": [["12"]], "entity_id": [["T6"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Route": {"text": [["treated"]], "start": [["58"]], "entity_id": [["T7"]]},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["duloxetine"]], "start": [["12"]], "entity_id": [["T6"]]},"Trigger": {"text": [["treated"]], "start": [["58"]], "entity_id": [["T7"]]}, "event_id": "E2", "event_type": "Treatment"} ],"Trigger": {"text": [["induced"]], "start": [["23"]], "entity_id": [["T8"]]}},"Effect": {"text": [["hyponatremia"]], "start": [["37"]], "entity_id": [["T9"]]},"Negated": null,"Speculated": null,"Severity": {"value": "", "text": [], "start": [], "entity_id": []}}]}
{"id": "3892171_1", "context": "Protamine-induced fatal anaphylaxis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Protamine-induced fatal anaphylaxis"]], "start": [[ ]], "entity_id": [["T1"]]}, "Effect": {"text": [["Protamine-induced fatal anaphylaxis"]], "start": [[ ]], "entity_id": [["T2"]]}, "Severity": {"value": "high", "text": [["fatal"]], "start": [[ ]], "entity_id": [["T3"]]}, "Negated": {"value": false, "text": [], "start": [], "entity_id": []}, "Speculated": {"value": false, "text": [], "start": [], "entity_id": []}, "Subject": {"text": [], "start": [], "entity_id": [], "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [], "start": [], "entity_id": [],"Drug": {"text": [["Protamine"]], "start": [[ ]], "entity_id": [["T4"]]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": [{"Drug": {"text": [["Protamine"]], "start": [[ ]], "entity_id": [["T4"]]}, "Trigger": {"text": [], "start": [], "entity_id": []}, "event_id": "C1", "event_type": "null"} ],"Disorder": {"text": [], "start": [], "entity_id": []}} }]}
{"id": "9494448_4","context": "Hypersensitivity reactions to cyclosporine are due to Cremophor EL","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hypersensitivity reactions"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["cyclosporine"]],"start": [[ "34" ]],"entity_id": [ ["T2"] ],"Drug": {"text": [["cyclosporine"]],"start": [[ "34" ]],"entity_id": [ ["T2"] ]} ,"Trigger": {"text": [["Cremophor EL"]],"start": [[ "61" ]],"entity_id": [ ["T3"] ]} ,"Combination": [{"Drug": {"text": [["cyclosporine"]],"start": [[ "34" ]],"entity_id": [ ["T2"] ]},"Trigger": {"text": [["Cremophor EL"]],"start": [[ "61" ]],"entity_id": [ ["T3"] ]} ,"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [["Hypersensitivity reactions"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Freq": {"text": [["are due"]],"start": [[ "46" ]],"entity_id": [ ["T4"] ]} ,"Time_elapsed": {"text": [["are due"]],"start": [[ "46" ]],"entity_id": [ ["T4"] ]} ,"Route": {"text": [["to cyclosporine"]],"start": [[ "34" ]],"entity_id": [ ["T2"] ]} ,"Dosage": {"text": [["cyclosporine"]],"start": [[ "34" ]],"entity_id": [ ["T2"] ]} ,"Duration": {"text": [["are due"]],"start": [[ "46" ]],"entity_id": [ ["T4"] ]} },"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Hypersensitivity reactions"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"Disorder": {"text": [["Hypersensitivity reactions"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Age": null,"Gender": null,"Population": null,"Race": null} ,"Effect": {"text": [["Hypersensitivity reactions"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} }]}
{"id": "10656221_2","context": "There are few reports in the literature related to sulfonylurea-induced hepatotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["sulfonylurea-induced hepatotoxicity"]],"start": [["38"]],"entity_id": [["T1"]]} ,"Treatment": {"Drug": {"text": [["sulfonylurea"]],"start": [["0"]],"entity_id": [["T2"]]} ,"entity_id": [["T2"]] ,"Disorder": {"text": [["hepatotoxicity"]],"start": [["25"]],"entity_id": [["T3"]]} ,"text": [["sulfonylurea-induced hepatotoxicity"]],"start": [["38"]],"Dosage": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Route": {"text": [["related"]],"start": [["14"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Combination": [] ,"Trigger": {"text": [["related"]],"start": [["14"]],"entity_id": [["T5"]]} },"Effect": {"text": [["hepatotoxicity"]],"start": [["25"]],"entity_id": [["T3"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]],"value": "low"} ,"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": {"text": [["few reports"]],"start": [["6"]],"entity_id": [["T4"]]} ,"Race": null }} ]}
{"id": "8266863_1","context": "Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe dyspnea"]],"start": [["18"]],"entity_id": [["T2"]]},"Treatment": {"text": [["the initial injection of 3.6 mg of goserelin acetate"]],"start": [["4"]],"entity_id": [["T1"]],"Drug": {"text": [["goserelin acetate"]],"start": [["40"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["four days after"]],"start": [["0"]],"entity_id": [["T4"]]},"Disorder": {"text": [["worsening pleuritis carcinomatosa"]],"start": [["52"]],"entity_id": [["T5"]]},"Combination": null,"Dosage": null,"Duration": null,"Route": null,"Freq": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["T6"]],"value": "high"},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null}}]}
{"id": "7439122_2","context": "However, we have recently had four cases of clofibrate-induced myopathy in patients with diabetes insipidus due to hypothalamic lesions","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["clofibrate-induced myopathy"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["clofibrate"]],"start": [["6"]],"entity_id": [["T2"]],"Drug": {"text": [["clofibrate"]],"start": [["6"]],"entity_id": [["T2"]]},"Disorder": {"text": [["diabetes insipidus"]],"start": [["42"]],"entity_id": [["T3"]]},"Dosage": {"text": [["recently"]],"start": [["0"]],"entity_id": [["T4"]]},"Duration": {"text": [["four cases"]],"start": [["12"]],"entity_id": [["T5"]]},"Route": {"text": [["in patients"]],"start": [["24"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["recently"]],"start": [["0"]],"entity_id": [["T4"]]},"Trigger": {"text": [["clofibrate-induced myopathy"]],"start": [["18"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["clofibrate"]],"start": [["6"]],"entity_id": [["T2"]]},"Trigger": {"text": [["clofibrate-induced myopathy"]],"start": [["18"]],"entity_id": [["T1"]]},"event_id": "E1","event_type": "Adverse_event"}],"Freq": {"text": [["four cases"]],"start": [["12"]],"entity_id": [["T5"]]}},"Subject": {"text": [["patients"]],"start": [["24"]],"entity_id": [["T6"]],"Disorder": {"text": [["diabetes insipidus"]],"start": [["42"]],"entity_id": [["T3"]]},"Population": {"text": [["four cases"]],"start": [["12"]],"entity_id": [["T5"]]},"Age": {"text": [["recently"]],"start": [["0"]],"entity_id": [["T4"]]},"Race": {"text": [["patients"]],"start": [["24"]],"entity_id": [["T6"]]},"Gender": {"text": [["patients"]],"start": [["24"]],"entity_id": [["T6"]]}},"Effect": {"text": [["clofibrate-induced myopathy"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["induced myopathy"]],"start": [["18"]],"entity_id": [["T1"]],"value": "High"}}]}
{"id": "9052919_2","context": "One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["MRI T2 abnormalities"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["cyclosporin"]],"start": [["58"]],"entity_id": [["T2"]],"Drug": {"text": [["cyclosporin"]],"start": [["58"]],"entity_id": [["T2"]]},"Disorder": {"text": [["neurotoxicity"]],"start": [["67"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["compatible"]],"start": [["32"]],"entity_id": [["T4"]]},"Trigger": {"text": [["compatible"]],"start": [["32"]],"entity_id": [["T4"]]},"Freq": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Duration": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": null},"Effect": {"text": [["MRI T2 abnormalities"]],"start": [["18"]],"entity_id": [["T1"]]},"Subject": {"text": [["One patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": {"text": [["neurotoxicity"]],"start": [["67"]],"entity_id": [["T3"]],"value": "High"}}]}
{"id": "21751666_1", "context": "Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Treatment": {"Drug": {"text": [["oseltamivir"]], "start": [["41"]], "entity_id": [["T1"]]},"Disorder": {"text": [["Post-exposure prophylaxis for H1N1"]], "start": [["0"]], "entity_id": [["T2"]]},"Dosage": {"text": [["not specified"]], "start": [["not specified"]], "entity_id": [["not specified"]]},"Duration": {"text": [["not specified"]], "start": [["not specified"]], "entity_id": [["not specified"]]},"Route": {"text": [["not specified"]], "start": [["not specified"]], "entity_id": [["not specified"]]},"Time_elapsed": {"text": [["not specified"]], "start": [["not specified"]], "entity_id": [["not specified"]]},"Freq": {"text": [["not specified"]], "start": [["not specified"]], "entity_id": [["not specified"]]},"Trigger": {"text": [["with"]], "start": [["32"]], "entity_id": [["T3"]]},"text": [["oseltamivir"]], "start": [["41"]], "entity_id": [["T1"]],"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["renal allograft recipient"]], "start": [["63"]], "entity_id": [["T4"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Trigger": null}]}
{"id": "15383642_2","context": "To report a case in which significant hypotension occurred after initiation of tizanidine in a patient using the antihypertensive agent lisinopril","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["significant hypotension"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["tizanidine"]],"start": [["61"]],"entity_id": [["T2"]],"Drug": {"text": [["tizanidine"]],"start": [["61"]],"entity_id": [["T2"]]},"Disorder": {"text": [["after initiation"]],"start": [["40"]],"entity_id": [["T3"]]},"Trigger": {"text": [["initiation"]],"start": [["40"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after initiation"]],"start": [["40"]],"entity_id": [["T3"]]},"Freq": {"text": [["occurred"]],"start": [["33"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["tizanidine"]],"start": [["61"]],"entity_id": [["T2"]]},"Trigger": {"text": [["initiation"]],"start": [["40"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Route": {"text": [["after initiation"]],"start": [["40"]],"entity_id": [["T3"]]},"Dosage": {"text": [["the antihypertensive agent lisinopril"]],"start": [["70"]],"entity_id": [["T4"]]},"Duration": {"text": [["after initiation"]],"start": [["40"]],"entity_id": [["T3"]]}},"Subject": {"text": [["a patient"]],"start": [["51"]],"entity_id": [["T5"]],"Age": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]},"Gender": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]},"Population": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]},"Race": {"text": [[""]],"start": [[""], []],"entity_id": [[""]]},"Disorder": {"text": [["using the antihypertensive agent lisinopril"]],"start": [["70"]],"entity_id": [["T4"]]}},"Negated": {"text": [["not"]],"start": [[""], []],"entity_id": [[""]],"value": false},"Speculated": {"text": [[""]],"start": [[""], []],"entity_id": [[""]],"value": false},"Severity": {"text": [["significant"]],"start": [["33"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["significant hypotension"]],"start": [["33"]],"entity_id": [["T1"]]}}]}
{"id": "412488_7","context": "These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Negated": null,"Speculated": {"text": [["may be"]],"start": [[], [], []],"entity_id": [],"value": true},"Severity": null,"Subject": {"text": [["they"]],"start": [[], [], []],"entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["renal disease"]],"start": [[], [], []],"entity_id": []}},"Treatment": {"text": [["gold therapy"]],"start": [[], [], []],"entity_id": [],"Drug": {"text": [["gold"]],"start": [[], [], []],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["renal disease"]],"start": [[], [], []],"entity_id": []},"Combination": null,"Trigger": {"text": [["gold therapy"]],"start": [[], [], []],"entity_id": []}},"Effect": {"text": [["a causative factor"]],"start": [[], [], []],"entity_id": []},"Trigger": {"text": [["immune-complex form of glomerulopathy"]],"start": [[], [], []],"entity_id": []}}]}
{"id": "7304798_1", "context": "Induction of rapid mood cycling during L-dopa treatment in a bipolar patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Induction of rapid mood cycling"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["L-dopa treatment"]], "start": [[ "41" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["L-dopa"]], "start": [[ "41" ]], "entity_id": [ ["T3"] ]}, "Disorder": {"text": [["bipolar"]], "start": [[ "63" ]], "entity_id": [ ["T4"] ]}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null, "Trigger": null, "Route": null} , "Subject": { "text": [["patient"]], "start": [[ "26" ]], "entity_id": [["T5"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": { "text": [["bipolar"]], "start": [[ "63" ]], "entity_id": [["T4"]] } } , "Severity": null, "Speculated": null, "Negated": null , "Effect": { "text": [["Induction of rapid mood cycling"]], "start": [[ "0" ]], "entity_id": [["T1"]] } }]}
{"id": "11144696_2", "context": "To report a patient having a first-time seizure after receiving venlafaxine and trimipramine for depression", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["first-time seizure"]], "start": [["33","34"]], "entity_id": []}, "Treatment": {"text": [["venlafaxine", "and", "trimipramine"]], "start": [["22","23","24"]], "entity_id": [], "Drug": {"text": [["venlafaxine"],["trimipramine"]], "start": [[ "22","23"]], "entity_id": [] } ,"Disorder": {"text": [["depression"]], "start": [[ "48"]], "entity_id": [] } ,"Route": {"text": [["for"]], "start": [[ "42"]], "entity_id": [] } , "Duration": {"text": [["after receiving"]], "start": [[ "16","17"]], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] },"Time_elapsed": {"text": [], "start": [], "entity_id": [] },"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination": [{"Drug": {"text": [["venlafaxine"]], "start": [[ "22"]], "entity_id": [] } , "Trigger": {"text": [["and"]], "start": [[ "23"]], "entity_id": [] } , "event_type": "Combination" , "event_id": "C1" } ,{"Drug": {"text": [["trimipramine"]], "start": [[ "24"]], "entity_id": [] } , "Trigger": {"text": [], "start": [], "entity_id": [] } , "event_type": "Combination" , "event_id": "C1" } ] ,"Trigger":{"text":[], "start":[], "entity_id":[]} }, "Subject": {"text": [["a patient"]], "start": [[ "10"]], "entity_id": [],"Age": {"text":[], "start": [], "entity_id": []},"Gender": {"text":[], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text":[], "start": [], "entity_id": []},"Disorder": {"text":[["depression"]], "start": [[ "48"]], "entity_id": [] } }, "Effect": {"text": [["seizure"]], "start": [[ "33"]], "entity_id": [] },"Negated": {"text": [], "start": [], "entity_id": [] ,"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value":""} }] }
{"id": "19402273_2", "context": "Isoniazid induced gynaecomastia: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["a case report"]], "start": [["36"]], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Treatment": {"text": [["Isoniazid"]], "start": [["11"]], "entity_id": [],"Drug": {"text": [["Isoniazid"]], "start": [["11"]], "entity_id": []},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null,"Trigger": {"text": [["Isoniazid induced"]], "start": [["0"]], "entity_id": []},"Combination": null},"Effect": {"text": [["gynaecomastia"]], "start": [["25"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "17671884_7","context": "One previous study of four transplant patients whose immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin noted anemia in 13% of them","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["four transplant patients"]],"start": [["4","5"]],"entity_id": [["S1"]] ,"Age": null,"Disorder": {"text": [["anemia"]],"start": [["71"]],"entity_id": [["S2"]]},"Gender": null,"Population": {"text": [["13%"]],"start": [["84"]],"entity_id": [["S3"]]},"Race": null},"Treatment": {"text": [["corticosteroids","cyclosporine","MMF","anti-T-lymphocyte globulin"]],"start": [["23","29","32","45"]],"entity_id": [["T1","T2","T3","T4"]] ,"Dosage": null,"Duration": null,"Disorder": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["noted"]],"start": [["67"]],"entity_id": [["T5"]]} ,"Drug": null} ,"Effect": null ,"Trigger": null}]}
{"id": "1348483_2","context": "Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["Pleuropulmonary changes"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Treatment": {"text": [["treatment of Parkinson's disease"]],"start": [[ "42" ]] ,"entity_id": [ ["T2"] ],"Drug": {"text": [["cabergoline"]],"start": [[ "75" ]] ,"entity_id": [ ["T3"] ]} ,"Disorder": {"text": [["Parkinson's disease"]],"start": [[ "42" ]] ,"entity_id": [ ["T4"] ]} ,"Route": {"text": [["treatment"]],"start": [[ "42" ]] ,"entity_id": [ ["T2"] ]} ,"Duration": {"text": [["during"]],"start": [[ "30" ]] ,"entity_id": [ ["T5"] ]} ,"Trigger": {"text": [["treatment"]],"start": [[ "42" ]] ,"entity_id": [ ["T2"] ]} ,"Time_elapsed": {"text": [["during"]],"start": [[ "30" ]] ,"entity_id": [ ["T5"] ]} ,"Dosage": {"text": [["long-acting"]],"start": [[ "61" ]] ,"entity_id": [ ["T3"] ]} ,"Freq": {"text": [["during"]],"start": [[ "30" ]] ,"entity_id": [ ["T5"] ]} ,"Combination": null} ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "3982906_2", "context": "However, each infant demonstrated hemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["each infant"]], "start": [["However," ,"each infant" ]], "entity_id": [ ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null }, "Treatment": {"text": [["verapamil administration"]], "start": [[ "verapamil administration" ]], "entity_id": [ ], "Drug": {"text": [["verapamil"]], "start": [[ "verapamil administration" ]], "entity_id": [ ]}, "Dosage": null, "Duration": null, "Route": null, "Time_elapsed": {"text": [["shortly after"]], "start": [[ "shortly after" ]], "entity_id": [ ]}, "Trigger": {"text": [["hemodynamic decompensation"]], "start": [[ "hemodynamic decompensation" ]], "entity_id": [ ]}, "Freq": null, "Combination": null , "Disorder": null },"Effect": { "text": [["required cardiopulmonary resuscitation"]], "start": [[ "required cardiopulmonary resuscitation" ]], "entity_id": [ ]} ,"Negated": null, "Speculated": null, "Severity": null , "Trigger": null }]}
{"id": "11160777_11","context": "Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["insulin-sensitizing effects"]],"start": [["16"]],"entity_id": [["T1"]],"Drug": {"text": [["glitazones"]],"start": [["42"]],"entity_id": [["T2"]]},"Disorder": {"text": [["atherosclerotic cardiovascular disease", "morbidity", "and death"]],"start": [["92","116","130"]],"entity_id": [["T3","T4","T5"]]},"Duration": {"text": [["Long-term studies"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["needed"]],"start": [["66"]],"entity_id": [["T6"]]},"Freq": {"text": [["determine"]],"start": [["6"]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["prevent or delay"]],"start": [["87","100"]],"entity_id": [["T8","T9"]]},"Route": {"text": [[]],"start": [],"entity_id": []},"Dosage": {"text": [[]],"start": [],"entity_id": []},"Combination": null},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "7663030_1", "context": "Probable propafenone-induced transient global amnesia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["propafenone"]], "start": [[ "11" ]], "entity_id": [ ],"Disorder": {"text": [["transient global amnesia"]], "start": [[ "32" ]], "entity_id": [ ]}, "Trigger": {"text": [["induced"]], "start": [[ "21" ]], "entity_id": [ ]}, "Drug": {"text": [["propafenone"]], "start": [[ "11" ]], "entity_id": [ ]} ,"Freq": {"text": [["probable"]], "start": [[ "0" ]], "entity_id": [ ]} ,"Combination": [ {"Drug": {"text": [["propafenone"]], "start": [[ "11" ]], "entity_id": [ ]}, "Trigger": {"text": [["induced"]], "start": [[ "21" ]], "entity_id": [ ]} ,"event_type": "Potential_therapeutic_effect" ,"event_id": "E1" }] ,"Time_elapsed": {"text": [], "start": [], "entity_id": []} ,"Duration": {"text": [], "start": [], "entity_id": []} ,"Route": {"text": [], "start": [], "entity_id": []} ,"Dosage": {"text": [], "start": [], "entity_id": []} }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null ,"Trigger": null }]}
{"id": "16629074_2", "context": "Traumatic late flap dehiscence and Enterobacter keratitis following LASIK", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Traumatic late flap dehiscence", "Enterobacter keratitis"]], "start": [[ ]], "entity_id": [[ "T1", "T2" ]]}, "Treatment": {"text": [["LASIK"]], "start": [[ ]], "entity_id": [[ "T3" ]] , "Drug": null , "Disorder": {"text": [["LASIK"]], "start": [[ ]], "entity_id": [[ "T3" ]]} , "Dosage": null , "Duration": null , "Route": null , "Time_elapsed": null , "Freq": null , "Combination": null , "Trigger": null}, "Effect": {"text": [["Traumatic late flap dehiscence", "Enterobacter keratitis"]], "start": [[ ]], "entity_id": [[ "T1", "T2" ]]} , "Negated": null , "Speculated": null , "Severity": null , "Subject": {"text": [["patient"]], "start": [[ ]], "entity_id": [[ "T4" ]], "Age": null , "Disorder": {"text": [], "start": [], "entity_id": []} , "Gender": null , "Population": null , "Race": null }}]}
{"id": "2305654_2","context": "We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute life-threatening pseudo-obstruction", "adynamic ileus"]],"start": [[", 33, "], ["", "70"]],"entity_id": [["T2"], ["T3"]]},"Treatment": {"text": [["intravenous nimodipine"]],"start": [[", 114"]],"entity_id": [["T4"]],"Drug": {"text": [["nimodipine"]],"start": [[", 114"]],"entity_id": [["T5"]]},"Route": {"text": [["intravenous"]],"start": [[", 114"]],"entity_id": [["T4.1"]]},"Disorder": {"text": [["subarachnoid haemorrhage"]],"start": [[", 5"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["developed"]],"start": [[", 33"]],"entity_id": [["T2.1"]]},"Freq": {"text": [["while being treated"]],"start": [[", 93"]],"entity_id": [["T4.2"]]},"Dosage": {"text": [[""]],"start": [[], [], [], []],"entity_id": []},"Duration": {"text": [[""]],"start": [[], [], [], []],"entity_id": []},"Trigger": {"text": [[""]],"start": [[], [], [], []],"entity_id": []},"Combination": null},"Effect": {"text": [["colon"]],"start": [[", 56"]],"entity_id": [["T3.1"]]},"Subject": {"text": [["a patient"]],"start": [[", 0"]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["subarachnoid haemorrhage"]],"start": [[", 5"]],"entity_id": [["T1"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["acute life-threatening"]],"start": [[", 33"]],"entity_id": [["T2"]],"value": "high"}}]}
{"id": "12111771_1", "context": "A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["fludarabine"]],"start": [["37"]],"entity_id": [["T1"]]},"Disorder": {"text": [["chronic lymphocytic leukemia (CLL)"]],"start": [["100"]],"entity_id": [["T2"]]},"Duration": {"text": [["the third cycle"]],"start": [["50"]],"entity_id": [["T3"]]},"Trigger": {"text": [["completing"]],"start": [["46"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["2 weeks after"]],"start": [["22"]],"entity_id": [["T5"]]},"entity_id": [["T1","T2","T3","T4","T5"]],"text": [["presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL)."]],"start": [["0"]],"Dosage": null,"Freq": null,"Route": null,"Combination": null},"Subject": {"text": [["A 73-year-old woman"]],"start": [["0"]],"entity_id": [["T6"]],"Gender": {"text": [["woman"]],"start": [["15"]],"entity_id": [["T7"]]},"Age": {"text": [["73-year-old"]],"start": [["4"]],"entity_id": [["T8"]]},"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": null}]}
{"id": "15729090_2", "context": "We report a case of myoclonus induced by quetiapine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["myoclonus"]], "start": [["16"]], "entity_id": []}, "Treatment": {"text": [["quetiapine"]], "start": [["53"]], "entity_id": [],"Drug": {"text": [["quetiapine"]], "start": [["53"]], "entity_id": []} , "Disorder": {"text": [["myoclonus"]], "start": [["16"]], "entity_id": []} , "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Combination": null , "Trigger": null } , "Effect": null , "Negated": null, "Speculated": null, "Severity": null , "Subject": null }]}
{"id": "1393348_1","context": "A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (SLE) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["carbamazepine maintenance treatment"]],"start": [["68"]],"entity_id": [["T1"]] ,"Drug": {"text": [["carbamazepine"]],"start": [["68"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["18 months"]],"start": [["88"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["bipolar affective disorder"]],"start": [["25"]],"entity_id": [["T4"]]} ,"Time_elapsed": {"text": [["18 months"]],"start": [["88"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["starting"]],"start": [["79"]],"entity_id": [["T5"]]} ,"Route": {"text": [["maintenance treatment"]],"start": [["68"]],"entity_id": [["T1"]]} ,"Freq": {"text": [["maintenance"]],"start": [["68"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T6"], ["T7"]]} ,"Combination": null} ,"Effect": {"text": [["developed systemic lupus erythematosus (SLE) with characteristic laboratory findings"]],"start": [["38"]],"entity_id": [["T8"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Trigger": {"text": [["developed"]],"start": [["38"]],"entity_id": [["T9"]]} }]}
{"id": "7973922_2","context": "Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neurologic symptoms"]],"start": [["14"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Acyclovir"]],"start": [["0"]],"entity_id": [["T0"]],"Drug": {"text": [["Acyclovir"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["neurologic symptoms"]],"start": [["14"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["produces"]],"start": [["12"]],"entity_id": [["T2"]]},"Freq": {"text": [["that resemble"]],"start": [["15"]],"entity_id": [["T3"]]},"Route": {"text": [["extension"]],"start": [["36"]],"entity_id": [["T4"]]},"Trigger": {"text": [["virial infection"]],"start": [["43"]],"entity_id": [["T5"]]},"Duration": {"text": [["into the central nervous system"]],"start": [["47"]],"entity_id": [["T6"]]},"Combination": [],"Dosage": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "19434733_3","context": "Two patients with HLH developed etoposide-related secondary acute myeloid leukemia (sAML) following therapy for HLH","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["etoposide-related secondary acute myeloid leukemia"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["therapy for HLH"]],"start": [["53"]],"entity_id": [["T2"]],"Disorder": {"text": [["HLH"]],"start": [["15"]],"entity_id": [["T3"]]},"Drug": {"text": [["etoposide"]],"start": [["33"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["following"]],"start": [["47"]],"entity_id": [["T5"]]},"Trigger": {"text": [["therapy for HLH"]],"start": [["53"]],"entity_id": [["T2"]]},"Freq": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["etoposide"]],"start": [["33"]],"entity_id": [["T4"]]},"Trigger": {"text": [["therapy for HLH"]],"start": [["53"]],"entity_id": [["T2"]]},"event_type": "Adverse_event","event_id": "E2"}],"Route": {"text": [["therapy for HLH"]],"start": [["53"]],"entity_id": [["T2"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [["Two patients"]],"start": [["0"]],"entity_id": [["T7"]],"Disorder": {"text": [["HLH"]],"start": [["15"]],"entity_id": [["T3"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["etoposide-related secondary acute myeloid leukemia"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "2250853_2", "context": "We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["secondary glaucoma"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["filtration surgery"]],"start": [["51"]],"entity_id": [["T2"]],"Drug": {"text": [["subconjunctival 5-fluorouracil"]],"start": [["73"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["epithelial downgrowth"]],"start": [["26"]],"entity_id": [["T4"]]} ,"Route": {"text": [["subconjunctival"]],"start": [["61"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["caused by"]],"start": [["20"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["reported"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Combination": [{"Drug": {"text": [["subconjunctival 5-fluorouracil"]],"start": [["73"]],"entity_id": [["T3"]]},"Trigger": {"text": [["filtration surgery"]],"start": [["51"]],"entity_id": [["T2"]]} ,"event_id": "C1" ,"event_type": "Treatment" }] ,"Freq": {"text": [["adjunctive use"]],"start": [["58"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["secondary glaucoma"]],"start": [["13"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["5-fluorouracil"]],"start": [["73"]],"entity_id": [["T3"]]}} ,"Subject": {"text": [["case"]],"start": [["1"]],"entity_id": [["T8"]],"Population": {"text": [["We"]],"start": [["0"]],"entity_id": [["T9"]]} ,"Age": {"text": [["report"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Race": {"text": [["report"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Gender": {"text": [["report"]],"start": [["0"]],"entity_id": [["T10"]]} ,"Disorder": {"text": [["secondary glaucoma caused by epithelial downgrowth"]],"start": [["13"]],"entity_id": [["T1"]]} },"Severity": {"text": [["secondary glaucoma"]],"start": [["13"]],"entity_id": [["T1"]],"value": "high"} ,"Speculated": {"text": [["report"]],"start": [["0"]],"entity_id": [["T10"]],"value": false} ,"Negated": {"text": [["report"]],"start": [["0"]],"entity_id": [["T10"]],"value": false} ,"Effect": {"text": [["secondary glaucoma"]],"start": [["13"]],"entity_id": [["T1"]]} }] }
{"id": "17189581_1","context": "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin syndrome"]],"start": [["0"]],"entity_id": [["T1"]]},"Severity": {"value": "mild","text": [["mild"]],"start": [["0"]],"entity_id": [["T2"]]},"Treatment": {"text": [["linezolid", "and fluoxetine"]],"start": [["27","38"]],"entity_id": [["T3","T4"]],"Drug": {"text": [["linezolid","fluoxetine"]],"start": [["27","38"]],"entity_id": [["T5","T6"]]},"Combination": [{"Drug": {"text": [["linezolid"]],"start": [[""],["27"]],"entity_id": [["T5"],["T3"]]},"Trigger": {"text": [["and"]],"start": [[""],["38"]],"entity_id": [["T7"],["T4"]]},"event_id": "C1","event_type": "Adverse_event"}],"Disorder": {"text": [["serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T1"],["T2"]]},"Dosage": {"text": [["concurrent"]],"start": [[""],["27"]],"entity_id": [["T7"],["T3"]]},"Time_elapsed": {"text": [["associated"]],"start": [[""],["0"]],"entity_id": [["T8"],["T2"]]},"Duration": {"text": [["concurrent"]],"start": [[""],["27"]],"entity_id": [["T7"],["T3"]]},"Freq": {"text": [["concurrent"]],"start": [[""],["27"]],"entity_id": [["T7"],["T3"]]},"Route": {"text": [["concurrent"]],"start": [[""],["27"]],"entity_id": [["T7"],["T3"]]},"Trigger": {"text": [["associated"]],"start": [[""],["0"]],"entity_id": [["T8"],["T2"]]}},"Subject": {"text": [["Mild serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T2"],["T1"]],"Gender": {"text": [["Mild"]],"start": [[""],["0"]],"entity_id": [["T2"],["T2"]]},"Age": {"text": [["Mild"]],"start": [[""],["0"]],"entity_id": [["T2"],["T2"]]},"Population": {"text": [["Mild"]],"start": [[""],["0"]],"entity_id": [["T2"],["T2"]]},"Race": {"text": [["Mild"]],"start": [[""],["0"]],"entity_id": [["T2"],["T2"]]},"Disorder": {"text": [["Mild serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T2"],["T1"]]}},"Negated": {"value": false,"text": [["Mild serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T2"],["T1"]]},"Speculated": {"value": false,"text": [["Mild serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T2"],["T1"]]},"Effect": {"text": [["serotonin syndrome"]],"start": [[""],["0"]],"entity_id": [["T1"],["T2"]]}}]}
{"id": "18691992_5","context": "Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["concomitant occurrence"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Hydroxyurea"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["Hydroxyurea"]],"start": [["0"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["diffuse longitudinal melanonychia", "multiple squamous cell carcinomas"]],"start": [["32","56"]],"entity_id": [["T3","T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Subject": {"text": [["an elderly subject"]],"start": [["73"]],"entity_id": [["T5"]],"Age": {"text": [["elderly"]],"start": [["73"]],"entity_id": [["T5"]]} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["diffuse longitudinal melanonychia", "multiple squamous cell carcinomas"]],"start": [["32","56"]],"entity_id": [["T3","T4"]]} ,"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "8301877_2", "context": "Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Myoclonus", "seizures"]], "start": [[ ]], "entity_id": [["T1"], ["T2"]]},"Treatment": {"text": [["levodopa"]], "start": [[ ]], "entity_id": [["T3"]],"Drug": {"text": [["levodopa"]],"start": [[ ]],"entity_id": [["T3"]]},"Disorder": {"text": [["parkinsonism"]],"start": [[ ]],"entity_id": [["T4"]]},"Freq": {"text": [["induction"]],"start": [[ ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["its confirmation on SEPs"]],"start": [[ ]],"entity_id": [["T6"]]},"Combination": [{"Drug": {"text": [["levodopa"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["induction"]],"start": [[ ]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"}],"Trigger": {"text": [["induction"]],"start": [[ ]],"entity_id": [["T5"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []}},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["parkinsonism"]],"start": [[ ]],"entity_id": [["T4"]]},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["Myoclonus", "seizures"]],"start": [[ ]],"entity_id": [["T1"], ["T2"]]}}]}
{"id": "7663030_2","context": "To describe a probable case of transient global amnesia caused by propafenone","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["transient global amnesia"]],"start": [["objective's length" , "plus" , "the index where 'transient global amnesia' appears within the text"]],"entity_id": [["entity id for transient global amnesia"]]},"Treatment": {"text": [["propafenone"]],"start": [["objective's length" , "plus" , "the index where 'propafenone' appears within the text"]],"entity_id": [["entity id for propafenone"]],"Drug": {"text": [["propafenone"]],"start": [["objective's length" , "plus" , "the index where 'propafenone' appears within the text"]],"entity_id": [["entity id for propafenone"]]},"Disorder": {"text": [["transient global amnesia"]],"start": [["objective's length" , "plus" , "the index where 'transient global amnesia' appears within the text"]],"entity_id": [["entity id for transient global amnesia"]]},"Freq": {"text": [["probable case"]],"start": [["objective's length" , "plus" , "the index where 'probable case' appears within the text"]],"entity_id": [["entity id for probable case"]]},"Time_elapsed": {"text": [["caused by"]],"start": [["objective's length" , "plus" , "the index where 'caused by' appears within the text"]],"entity_id": [["entity id for caused by"]]},"Duration": {"text": [["transient global amnesia"]],"start": [["objective's length" , "plus" , "the index where 'transient global amnesia' appears within the text"]],"entity_id": [["entity id for transient global amnesia"]]},"Dosage": {"text": [["propafenone"]],"start": [["objective's length" , "plus" , "the index where 'propafenone' appears within the text"]],"entity_id": [["entity id for propafenone"]]},"Route": {"text": [["propafenone"]],"start": [["objective's length" , "plus" , "the index where 'propafenone' appears within the text"]],"entity_id": [["entity id for propafenone"]]},"Trigger": {"text": [["transient global amnesia"]],"start": [["objective's length" , "plus" , "the index where 'transient global amnesia' appears within the text"]],"entity_id": [["entity id for transient global amnesia"]]},"Combination": null},"Effect": {"text": [["transient global amnesia"]],"start": [["objective's length" , "plus" , "the index where 'transient global amnesia' appears within the text"]],"entity_id": [["entity id for transient global amnesia"]]},"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null}]}
{"id": "458006_2","context": "We report the development of squamous-cell carcinoma within a basal-cell epithelioma that was treated with intralesional injections of 5-FU","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["development"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["intralesional injections of 5-FU"]],"start": [["58"]],"entity_id": [],"Drug": {"text": [["5-FU"]],"start": [["65"]],"entity_id": []},"Route": {"text": [["intralesional"]],"start": [["58"]],"entity_id": []},"Disorder": {"text": [["squamous-cell carcinoma within a basal-cell epithelioma"]],"start": [["10"]],"entity_id": []},"Dosage": {"text": [["5-FU"]],"start": [["65"]],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "10745478_1","context": "This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["continuous high-dose intracoronary nitroglycerin infusion"]],"start": [["32"]],"entity_id": [["T1"]] ,"Drug": {"text": [["nitroglycerin"]],"start": [["46"]],"entity_id": [["T2"]]} ,"Route": {"text": [["intracoronary"]],"start": [["54"]],"entity_id": [["T3"]]},"Disorder": {"text": [["cocaine-induced refractory coronary vasospasm"]],"start": [["94"]],"entity_id": [["T4"]]} ,"Duration": {"text": [["continuous"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["high-dose"]],"start": [["37"]],"entity_id": [["T6"]]} ,"Time_elapsed": {"text": [["in the treatment"]],"start": [["73"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["illustrates"]],"start": [["7"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["nitroglycerin"]],"start": [["46"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["illustrates"]],"start": [["7"]],"entity_id": [["T8"]]} ,"event_id": "E2","event_type": "Potential_therapeutic_effect"}] ,"Dosage": {"text": [["high-dose"]],"start": [["37"]],"entity_id": [["T6"]]}} ,"Subject": {"text": [["a patient"]],"start": [["108"]],"entity_id": [["T9"]] ,"Disorder": {"text": [["cocaine-induced refractory coronary vasospasm"]],"start": [["94"]],"entity_id": [["T4"]]} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []}} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null} ]}
{"id": "9876809_1", "context": "Ticlopidine-induced phenytoin toxicity", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Trigger": {"text": [["Ticlopidine-induced phenytoin toxicity"]], "start": [[ ]], "entity_id": []}, "Treatment": {"text": [["Ticlopidine"]], "start": [[ ]], "entity_id": [],"Drug": {"text": [["Ticlopidine"]], "start": [[ ]], "entity_id": []}, "Disorder": {"text": [["phenytoin toxicity"]], "start": [[ ]], "entity_id": []},"Time_elapsed": {"text": [["induced"]], "start": [[ ]], "entity_id": []} , "Duration": {"text": [], "start": [], "entity_id": []} , "Dosage": {"text": [], "start": [], "entity_id": []} , "Route": {"text": [], "start": [], "entity_id": []} , "Freq": {"text": [], "start": [], "entity_id": []} , "Combination": null , "Trigger": {"text": [["Ticlopidine-induced phenytoin toxicity"]], "start": [[ ]], "entity_id": []} },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "19540093_3","context": "Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline-induced acute pancreatitis have recently been raised","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["tetracycline class of antibiotics", "tigecycline-induced acute pancreatitis"]],"start": [["has been associated with the tetracycline class of antibiotics","concerns about tigecycline-induced acute pancreatitis have recently been raised"]],"entity_id": [["T1", "T2"]]},"Effect": {"text": [["Pancreatitis"]],"start": [["Pancreatitis"]],"entity_id": [["T3"]]},"Treatment": {"text": [["tetracycline class of antibiotics"]],"start": [["has been associated with the tetracycline class of antibiotics"]],"entity_id": [["T1"]],"Drug": {"text": [["tetracycline"]],"start": [["tetracycline"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "2811895_1","context": "Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["abrupt", "accidental withdrawal"]],"start": [["0"],["17"]],"entity_id": [["T1"],["T2"]]},"Treatment": {"text": [["trihexyphenidyl"]],"start": [["24"]],"entity_id": [["T3"]] ,"Drug": {"text": [["trihexyphenidyl"]],"start": [["24"]],"entity_id": [["T4"]]},"Disorder": {"text": [["cranial dystonia"]],"start": [["47"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["severe exacerbation"]],"start": [["34"]],"entity_id": [["T6"]]} ,"Freq": {"text": [["abrupt", "accidental"]],"start": [["0"],["17"]],"entity_id": [["T1"],["T2"]]} ,"Route": {"text": [["withdrawal"]],"start": [["17"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["abrupt", "accidental withdrawal"]],"start": [["0"],["17"]],"entity_id": [["T1"],["T2"]]} ,"Combination": [{"Drug": {"text": [["trihexyphenidyl"]],"start": [["24"]],"entity_id": [["T4"]]},"Trigger": {"text": [["abrupt", "accidental withdrawal"]],"start": [["0"],["17"]],"entity_id": [["T1"],["T2"]]} ,"event_id": "E1D1T1","event_type": "Adverse_event"} ],"Dosage": {"text": [["abrupt", "accidental"]],"start": [["0"],["17"]],"entity_id": [["T1"],["T2"]]},"Duration": {"text": [["severe exacerbation"]],"start": [["34"]],"entity_id": [["T6"]]} },"Effect": {"text": [["severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties"]],"start": [["34"]],"entity_id": [["T6"]]} ,"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["34"]],"entity_id": [["T6"]] ,"value": "high"} ,"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": null,"Population": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": null,"Disorder": {"text": [["cranial dystonia"]],"start": [["47"]],"entity_id": [["T5"]]} }} ]}
{"id": "3397227_2","context": "We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["anhedonic ejaculation"]],"start": [["33","39"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["desipramine"]],"start": [["102"]],"entity_id": [ ["T2"]],"Drug": {"text": [["desipramine"]],"start": [["102"]],"entity_id": [ ["T2"]]} ,"Disorder": {"text": [["anhedonic ejaculation"]],"start": [["33","39"]],"entity_id": [ ["T1"]]},"Time_elapsed": {"text": [["initiation"]],"start": [["81","86"]],"entity_id": [ ["T3"]]} ,"Trigger": {"text": [["initiation"]],"start": [["81","86"]],"entity_id": [ ["T3"]]} ,"Freq": {"text": [["two patients"]],"start": [["6","16"]],"entity_id": [ ["T4"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Subject": {"text": [["We"]],"start": [[ "0"]],"entity_id": [ ["T5"]],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "19915794_2","context": "Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["fewer adverse reactions"]],"start": [["16","17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["garenoxacin"]],"start": [["0","1"]],"entity_id": [["T2"]],"Drug": {"text": [["garenoxacin"]],"start": [["0","1"]],"entity_id": [["T2"]]},"Disorder": {"text": [["cardiac rhythms"]],"start": [["45","46"]],"entity_id": [["T3"]]},"Freq": {"text": [["fewer"]],"start": [["16"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["garenoxacin"]],"start": [["0","1"]],"entity_id": [["T2"]]},"Trigger": {"text": [["interference"]],"start": [["79"]],"entity_id": [["T4"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}],"Time_elapsed": {"text": [["during hypokalemia"]],"start": [["66","67"]],"entity_id": [["T5"]]},"Trigger": {"text": [["TdP"]],"start": [["107","108"]],"entity_id": [["T6"]]},"Dosage": {"text": [["reportedly"]],"start": [["10","11"]],"entity_id": [["T1"]]},"Duration": {"text": [["third-generation quinolone antibiotics"]],"start": [["54","59"]],"entity_id": [["T3"]]},"Route": {"text": [["causes"]],"start": [["13"]],"entity_id": [["T1"]]}},"Severity": {"text": [["prevent"]],"start": [["105"]],"entity_id": [["T6"]],"value": "low"},"Speculated": {"text": [["must be cautious"]],"start": [["76","77"]],"entity_id": [["T4"]],"value": true},"Negated": {"text": [["fewer adverse reactions"]],"start": [["16","17"]],"entity_id": [["T1"]],"value": false},"Subject": {"text": [["one"]],"start": [["75"]],"entity_id": [["T4"]],"Disorder": {"text": [["hypokalemia"]],"start": [["66","67"]],"entity_id": [["T5"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["TdP"]],"start": [["107","108"]],"entity_id": [["T6"]]}}]}
{"id": "6292681_1", "context": "Severe neurotoxicity with methyl G: CALGB experience", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Severe neurotoxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}, "Treatment": {"text": [["methyl G"]], "start": [[ "28" ]], "entity_id": [ ["T2"] ],"Drug": { "text": [["methyl G"]], "start": [[ "28" ]], "entity_id": [ ["T2"] ] }, "Route": { "text": [], "start": [], "entity_id": [] } ,"Time_elapsed": { "text": [], "start": [], "entity_id": [] } ,"Freq": { "text": [], "start": [], "entity_id": [] } ,"Duration": { "text": [], "start": [], "entity_id": [] } ,"Disorder": { "text": [], "start": [], "entity_id": [] } ,"Dosage": { "text": [], "start": [], "entity_id": [] } ,"Combination": null , "Trigger": { "text": [["methyl G"]], "start": [[ "28" ]], "entity_id": [ ["T2"] ] } }, "Effect": { "text": [["Severe neurotoxicity"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ] }, "Subject": null, "Negated": null, "Speculated": null, "Severity": { "text": [], "start": [], "entity_id": [], "value": "Severe" } } ]}
{"id": "3725284_2", "context": "We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Subject": {"text": [["a 60-year-old woman"]], "start": [["6","7"]], "entity_id": [],"Age":{"text":[["60"]],"start":[[ "6"]],"entity_id":[]},"Gender":{"text":[["woman"]],"start":[[ "14"]],"entity_id":[]},"Disorder":{"text":[["squamous lung carcinoma"]],"start":[[ "41"]],"entity_id":[]},"Population":{"text":[["a"]],"start":[[ "6"]],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}}, "Treatment": {"text": [["cisplatin and etoposide combination chemotherapy"]], "start": [["104"]], "entity_id": [],"Drug":{"text":[["cisplatin","etoposide"]],"start":[[ "104","115"]],"entity_id":[]},"Disorder":{"text":[["combination chemotherapy"]],"start":[[ "123"]],"entity_id":[]},"Dosage":{"text":[],"start":[],"entity_id":[]},"Duration":{"text":[],"start":[],"entity_id":[]},"Route":{"text":[],"start":[],"entity_id":[]},"Time_elapsed":{"text":[],"start":[],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Trigger":{"text":[],"start":[],"entity_id":[]},"Combination":[{"Drug":{"text":[["cisplatin"]],"start":[[ "104"]],"entity_id":[]},"Trigger":{"text":[["and"]],"start":[[ "114"]],"entity_id":[]},"event_id": "E2","event_type":"Drug"},{"Drug":{"text":[["etoposide"]],"start":[[ "115"]],"entity_id":[]},"Trigger":{"text":[[]],"start":[[ ]],"entity_id":[]},"event_id": "E3","event_type":"Drug"}]}, "Effect": {"text": [["paroxysmal supraventricular tachycardia"]], "start": [["71"]], "entity_id": []},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"low"},"Trigger":{"text":[["developed"]],"start":[[ "54"]],"entity_id":[]}}]}
{"id": "9177620_2","context": "The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["acute pancreatitis"]],"start": [[ "4" ]],"entity_id": [ [ "AP" ] ] },"Treatment": {"text": [["carbamazepine"]],"start": [[ "30" ]],"entity_id": [ [ "CBZ" ] ] ,"Drug": { "text": [["carbamazepine"]], "start": [[ "30" ]], "entity_id": [ [ "CBZ" ] ] } ,"Disorder": { "text": [["post-traumatic petit mal epilepsy"]], "start": [[ "64" ]], "entity_id": [ [ "post-traumatic petit mal epilepsy" ] ] } ,"Dosage": { "text": [["NA"]], "start": [[ "NA" ]], "entity_id": [ [ "NA" ] ] } ,"Duration": { "text": [["NA"]], "start": [[ "NA" ]], "entity_id": [ [ "NA" ] ] } ,"Route": { "text": [["NA"]], "start": [[ "NA" ]], "entity_id": [ [ "NA" ] ] } ,"Time_elapsed": { "text": [["NA"]], "start": [[ "NA" ]], "entity_id": [ [ "NA" ] ] } ,"Freq": { "text": [["NA"]], "start": [[ "NA" ]], "entity_id": [ [ "NA" ] ] } ,"Combination": null ,"Trigger": null } ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null }] }
{"id": "17852449_2","context": "All-trans-retinoic acid (ATRA) has been proved to be an effective treatment for acute promyelocytic leukemia (APL), inducing remission in more than 90% of cases","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["All-trans-retinoic acid (ATRA)"]],"start": [[ "0"]] ,"entity_id": [ ["T1"]] ,"Drug": {"text": [["All-trans-retinoic acid"]],"start": [[ "0" ]],"entity_id": [ ["T2"]] },"Disorder": {"text": [["acute promyelocytic leukemia (APL)"]],"start": [[ "50" ]],"entity_id": [ ["T3"]] },"Dosage": {"text": [["proved to be an effective treatment"]],"start": [[ "10" ]],"entity_id": [ ["T4"]] },"Duration": {"text": [["inducing remission in more than 90% of cases"]],"start": [[ "62" ]],"entity_id": [ ["T5"]] },"Route": {"text": [["treatment"]],"start": [[ "27" ]],"entity_id": [ ["T6"]] },"Freq": {"text": [["effective treatment"]],"start": [[ "40" ]],"entity_id": [ ["T7"]] },"Trigger": {"text": [["proved"]],"start": [[ "10" ]],"entity_id": [ ["T8"]] },"Time_elapsed": {"text": [["inducing remission"]],"start": [[ "62" ]],"entity_id": [ ["T9"]] },"Combination": null} ,"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "18698687_2","context": "Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Vanishing bile duct", "Stevens-Johnson syndrome"]],"start": [["0","42"]],"entity_id": []},"Treatment": {"text": [["ciprofloxacin", "tacrolimus"]],"start": [["43","53"]],"entity_id": [] ,"Drug": {"text": [["ciprofloxacin"]],"start": [["43"]],"entity_id": [] },"Dosage": null,"Duration": null,"Disorder": {"text": [["Vanishing bile duct", "Stevens-Johnson syndrome"]],"start": [["0","42"]],"entity_id": [] },"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["ciprofloxacin"]],"start": [["43"]],"entity_id": [] }} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high" },"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Gender": null,"Disorder": null,"Race": null,"Population": null },"Effect": {"text": [["Vanishing bile duct", "Stevens-Johnson syndrome"]],"start": [["0","42"]],"entity_id": [] }} ]}
{"id": "9161656_5","context": "Antiasthmatic medications were prescribed, but the asthma symptoms did not improve","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Antiasthmatic medications"]],"start": [[ "0"]],"entity_id": [ ["T1"] ] ,"Drug": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["asthma"]],"start": [[ "47"]],"entity_id": [ ["T2"] ] } ,"Trigger": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [["improve"]],"start": [[ "82"]],"entity_id": [ ["T3"] ] },"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["asthma symptoms"]],"start": [[ "58"]],"entity_id": [ ["T4"] ] },"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [],"value": true},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""} ,"Trigger": null} ] }
{"id": "12590235_1","context": "Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["hepatotoxicity"]],"start": [["39"]],"entity_id": [["T3"]]},"Treatment": {"text": [["6-MP"]],"start": [["8"]],"entity_id": [["T1"]],"Drug": {"text": [["6-MP"]],"start": [["8"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["proportion"]],"start": [["57"]],"entity_id": [["T4"]]},"Disorder": {"text": [["patients"]],"start": [["63"]],"entity_id": [["T5"]]},"Dosage": {"text": [["widely used"]],"start": [["15"]],"entity_id": [["T2"]]},"Freq": {"text": [["Both"]],"start": [["0"]],"entity_id": [["T0"]]},"Route": {"text": [["used"]],"start": [["11"]],"entity_id": [["T1"]]},"Combination": [{"Drug": {"text": [["AZA"]],"start": [["24"]],"entity_id": [["T7"]]},"Trigger": {"text": [["cause"]],"start": [["29"]],"entity_id": [["T8"]]},"event_id": "E2","event_type": "Adverse_event"}],"Trigger": {"text": [["are known"]],"start": [["30"]],"entity_id": [["T9"]]},"Duration": {"text": [["known"]],"start": [["30"]],"entity_id": [["T9"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["hepatotoxicity"]],"start": [["39"]],"entity_id": [["T3"]],"value": "high"},"Subject": {"text": [["patients"]],"start": [["63"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": {"text": [["proportion"]],"start": [["57"]],"entity_id": [["T4"]]},"Race": null,"Disorder": null},"Effect": {"text": [["hepatotoxicity"]],"start": [["39"]],"entity_id": [["T3"]]}}]}
{"id": "9840249_3","context": "We report a case of severe respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe respiratory failure"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["gold salt"]],"start": [["12"]],"entity_id": [["T2"]],"Drug": {"text": [["gold salt"]],"start": [["12"]],"entity_id": [["T2"]]},"Dosage": {"text": [["toxicity"]],"start": [["30"]],"entity_id": [["T3"]]},"Route": {"text": [["injection"]],"start": [["38"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["requiring"]],"start": [["54"]],"entity_id": [["T5"]]},"Freq": {"text": [["requiring"]],"start": [["54"]],"entity_id": [["T5"]]},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["75"]],"entity_id": [["T6"]]},"Trigger": {"text": [["requiring"]],"start": [["54"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["gold salt"]],"start": [["12"]],"entity_id": [["T2"]]},"Trigger": {"text": [["toxicity"]],"start": [["30"]],"entity_id": [["T3"]]},"event_id": "C1","event_type": "Adverse_event"}],"Duration": {"text": [["requiring"]],"start": [["54"]],"entity_id": [["T5"]]}},"Subject": {"text": [["patient"]],"start": [["46"]],"entity_id": [["T7"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["rheumatoid arthritis"]],"start": [["75"]],"entity_id": [["T6"]]}},"Effect": {"text": [["severe respiratory failure"]],"start": [["23"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}}]}
{"id": "3628148_2","context": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["rupture"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["a cerebral arterial aneurysm"]],"start": [["9"]],"entity_id": [["T2"]],"Age": {"text": [["32"]],"start": [["23"]],"entity_id": [["T3"]]},"Disorder": {"text": [["hypertensive"]],"start": [["30"]],"entity_id": [["T4"]]} ,"Gender": {"text": [["woman"]],"start": [["36"]],"entity_id": [["T5"]]} ,"Race": null ,"Population": null },"Treatment": {"text": [["the introduction of nifedipine treatment"]],"start": [["53"]],"entity_id": [["T6"]],"Drug": {"text": [["nifedipine"]],"start": [["53"]],"entity_id": [["T7"]]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": null,"Duration": null,"Disorder": null ,"Trigger": null ,"Combination": null },"Effect": {"text": [["rupture"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Negated": null,"Speculated": null,"Severity": null }] }
{"id": "11889149_14","context": "RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["RLX+ALN"]],"start": [[ "0" ]] ,"entity_id": [["T1"]],"Drug": {"text": [["RLX"]],"start": [[ "0" ]] ,"entity_id": [["T2"]]},"Dosage": {"text": [["+"]],"start": [[ "2" ]] ,"entity_id": [["T3"]]},"Duration": {"text": [["ALN"]],"start": [[ "3" ]] ,"entity_id": [["T4"]]},"Route": {"text": [["more than either drug alone"]],"start": [[ "8" ]] ,"entity_id": [["T5"]]},"Time_elapsed": {"text": [["resulting in greater BMD increment"]],"start": [[ "34" ]] ,"entity_id": [["T6"]]},"Freq": {"text": [["but whether this difference reflects better fracture risk reduction was not assessed in this study"]],"start": [[ "51" ]] ,"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["RLX"]],"start": [[ "0" ]] ,"entity_id": [["T2"]]},"Trigger": {"text": [["more than either drug alone"]],"start": [[ "8" ]] ,"entity_id": [["T5"]]},"event_id": "E1-C1","event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["ALN"]],"start": [[ "3" ]] ,"entity_id": [["T4"]]},"Trigger": {"text": [["more than either drug alone"]],"start": [[ "8" ]] ,"entity_id": [["T5"]]},"event_id": "E1-C2","event_type": "Potential_therapeutic_effect"}],"Trigger": {"text": [["reduced bone turnover"]],"start": [[ "8" ]] ,"entity_id": [["T5"]]},"Disorder": {"text": [["better fracture risk reduction"]],"start": [[ "51" ]] ,"entity_id": [["T8"]]}},"Subject": {"text": [["this study"]],"start": [[ "51" ]] ,"entity_id": [["T9"]],"Population": {"text": [["this"]],"start": [[ "51" ]] ,"entity_id": [["T9"]]},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["greater BMD increment"]],"start": [[ "34" ]] ,"entity_id": [["T6"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [],"start": [],"entity_id": []}}]}
{"id": "2295443_3","context": "This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["colon perforation"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["treatment with intraperitoneal chromic phosphate"]],"start": [["96"]],"entity_id": [["T2"]],"Drug": {"text": [["chromic phosphate"]],"start": [["112"]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["4 months"]],"start": [["64"]],"entity_id": [["T4"]]},"Disorder": {"text": [["stage IB ovarian papillary serous cystadenocarcinoma"]],"start": [["125"]],"entity_id": [["T5"]]},"Trigger": {"text": [["treatment"]],"start": [["96"]],"entity_id": [["T2"]]},"Freq": {"text": [["occurred"]],"start": [["0"]],"entity_id": [["T1"]]},"Combination": null,"Dosage": null,"Duration": null,"Route": null},"Negated": null,"Speculated": null,"Severity": {"text": [["colon perforation"]],"start": [["0"]],"entity_id": [["T1"]],"value": "high"},"Subject": null,"Effect": {"text": [["colon perforation"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "9634122_1","context": "Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Flutamide withdrawal syndrome"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]},"Subject": {"text": [["a subset of patients"]],"start": [[ "92" ]],"entity_id": [ ["T2"] ],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["progressing metastatic carcinoma of the prostate"]],"start": [[ "112" ]],"entity_id": [ ["T3"] ]}},"Effect": {"text": [["a decrease in prostate-specific antigen (PSA)"]],"start": [[ "48" ]],"entity_id": [ ["T4"] ]},"Treatment": {"text": [["flutamide withdrawal"]],"start": [[ "16" ]],"entity_id": [ ["T5"] ],"Drug": {"text": [["flutamide"]],"start": [[ "16" ]],"entity_id": [ ["T6"] ]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null }]}
{"id": "19707032_4","context": "Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["Patients receiving intravitreal injections of bevacizumab"]],"start": [[ "0" ]],"entity_id": [["T1"]]},"Treatment": {"text": [["intravitreal injections of bevacizumab"]],"start": [["42"]],"entity_id": [["T2"]],"Drug": {"text": [["bevacizumab"]],"start": [["56"]],"entity_id": [["T3"]]},"Route": {"text": [["intravitreal"]],"start": [["43"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus"]],"start": [["111"]],"entity_id": [["T5"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"Combination": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "25671244_13","context": "Severe serotonin toxicity may result from metaxalone abuse in individuals using a selective serotonin reuptake inhibitor therapeutically","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Severe serotonin toxicity"]],"start": [[ "0" ]] ,"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["metaxalone"]],"start": [[ "55" ]],"entity_id": [["T3"]]},"Disorder": {"text": [["abuse"]],"start": [[ "52" ]],"entity_id": [["T2"]]},"Route": {"text": [["in"]],"start": [[ "54" ]],"entity_id": [["T4"]]},"Trigger": {"text": [["using"]],"start": [[ "74" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["therapeutically"]],"start": [[ "81" ]],"entity_id": [["T6"]]},"Dosage": null,"Duration": null,"Freq": null,"Combination": null,"entity_id": [["T3", "T5", "T6"]],"text": [["Severe serotonin toxicity"]],"start": [[ "0" ]]},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["Severe"]],"start": [[ "0" ]],"entity_id": [["T7"]],"value": "Severe"},"Subject": {"Age": null,"Disorder": {"text": [["individuals"]],"start": [[ "68" ]],"entity_id": [["T8"]]},"Gender": null,"Population": null,"Race": null,"text": [["individuals"]],"start": [[ "68" ]],"entity_id": [["T8"]]}}]}
{"id": "16029707_1","context": "Eruptive epidermoid cysts resulting from treatment with imiquimod","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["treatment"]],"start": [["resulting from treatment with imiquimod" ] ],"entity_id": []},"Treatment": {"text": [["treatment with imiquimod"]],"start": [[ "treatment with imiquimod"] ],"entity_id": [],"Drug": {"text": [["imiquimod"]],"start": [[ "imiquimod" ]],"entity_id": []} ,"Disorder": {"text": [["eruptive epidermoid cysts"]],"start": [[ "eruptive epidermoid cysts" ]],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [] ,"Trigger": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [["eruptive epidermoid cysts"]],"start": [[ "eruptive epidermoid cysts" ]],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "15379082_2","context": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Fulminant hepatic failure"]],"start": [[ ] , ["Fulminant hepatic failure" ]],"entity_id": [ ["T1" ] ] }, "Treatment": {"text": [["disulfiram treatment for alcoholism"]],"start": [[ "disulfiram treatment for alcoholism" ]],"entity_id": [ ["T2" ] ],"Drug": {"text": [["disulfiram"]],"start": [[ "disulfiram" ]],"entity_id": [ ["T3" ] ] } ,"Disorder": {"text": [["alcoholism"]],"start": [[ "alcoholism" ]],"entity_id": [ ["T4" ] ] } ,"Route": {"text": [["treatment"]],"start": [[ "treatment" ]],"entity_id": [ ["T5" ] ] } ,"Time_elapsed": {"text": [["complication"]],"start": [[ "complication" ]],"entity_id": [ ["T6" ] ] } ,"Freq": {"text": [["rare"]],"start": [[ "rare" ]],"entity_id": [ ["T7" ] ] } ,"Dosage": {"text": [],"start": [],"entity_id": [] }, "Duration": {"text": [],"start": [],"entity_id": [] },"Combination": null ,"Trigger": null } ,"Subject": null ,"Effect": null ,"Negated": null ,"Speculated": null ,"Severity": null }] }
{"id": "11049910_11","context": "Clinicians should be aware of the possibility of increased toxicity of ropivacaine when used together with inhibitors of CYP1A2","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["increased toxicity"]],"start": [["23"]],"entity_id": []},"Treatment": {"text": [["ropivacaine"]],"start": [["7"]],"entity_id": [],"Drug": {"text": [["ropivacaine"]],"start": [["7"]],"entity_id": []} ,"Combination": [{"Drug": {"text": [["inhibitors"]],"start": [["46"]],"entity_id": []},"Trigger": {"text": [["CYP1A2"]],"start": [["53"]],"entity_id": []} ,"event_id": "C1" ,"event_type": "Potential_therapeutic_effect" }] ,"Freq": {"text": [["should be aware"]],"start": [["0"]],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["used together"]],"start": [["32"]],"entity_id": []} },"Negated": null,"Speculated": null,"Severity": null,"Subject": null ,"Effect": null }] }
{"id": "3379435_1","context": "Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Reye-like syndrome"]],"start": [["3379435_1.15"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["calcium hopantenate"]],"start": [["3379435_1.5"]],"entity_id": [["T2"]]},"Disorder": {"text": [["pantothenic acid deficiency"]],"start": [["3379435_1.55"]],"entity_id": [["T3"]]},"Trigger": {"text": [["possibly"]],"start": [["3379435_1.25"]],"entity_id": [["T4"]]},"Freq": {"text": [["might be caused"]],"start": [["3379435_1.16"]],"entity_id": [["T5"]]},"Route": {"text": [["induction"]],"start": [["3379435_1.41"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["calcium hopantenate"]],"start": [["3379435_1.5"]],"entity_id": [["T2"]]},"Duration": {"text": [["possibly"]],"start": [["3379435_1.25"]],"entity_id": [["T4"]]},"Dosage": {"text": [["induction"]],"start": [["3379435_1.41"]],"entity_id": [["T6"]]},"entity_id": [["T2", "T3", "T4", "T5", "T6"]],"start": [["3379435_1.5", "3379435_1.55", "3379435_1.25", "3379435_1.16", "3379435_1.41"]],"text": [["calcium hopantenate", "pantothenic acid deficiency", "possibly", "might be caused", "induction"]],"Combination": null},"Subject": null,"Effect": {"text": [["Reye-like syndrome"]],"start": [["3379435_1.15"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": {"text": [["might be caused"]],"start": [["3379435_1.16"]],"entity_id": [["T5"]],"value": true},"Severity": null}]}
{"id": "3143551_5","context": "Hepatopathy subsided after the cessation of carbamazepine and lynestrenol","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Hepatopathy"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Treatment": {"text": [["carbamazepine", "lynestrenol"]],"start": [[ "36" ]],"entity_id": [ ["T3","T4"] ],"Drug": {"text": [["carbamazepine", "lynestrenol"]],"start": [[ "36" ]],"entity_id": [ ["T5","T6"] ]},"Time_elapsed": {"text": [["cessation"]],"start": [[ "17" ]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["Hepatopathy"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ]} ,"Trigger": {"text": [["subsided"]],"start": [[ "10" ]],"entity_id": [ ["T7"] ]} ,"Dosage": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [ ["N/A"] ]} ,"Duration": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [ ["N/A"] ]} ,"Freq": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [ ["N/A"] ]} ,"Route": {"text": [["N/A"]],"start": [[ "N/A" ]],"entity_id": [ ["N/A"] ]} ,"Combination": null }, "Negated": null ,"Speculated": null ,"Severity": null ,"Subject": null ,"Effect": null}]}
{"id": "18810448_1","context": "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["thymic enlargement", "true thymic hyperplasia", "mediastinal lymphadenopathy", "pleurisy"]],"start": [[], [], [], []],"entity_id": []},"Subject": {"text": [["juvenile idiopathic arthritis patient"]],"start": [[], [], [], []],"entity_id": [] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["juvenile idiopathic arthritis"]],"start": [[], [], [], []],"entity_id": []}},"Treatment": {"text": [["Etanercept"]],"start": [[], [], [], []],"entity_id": [],"Drug": {"text": [["Etanercept"]],"start": [[], [], [], []],"entity_id": []} ,"Disorder": {"text": [["juvenile idiopathic arthritis"]],"start": [[], [], [], []],"entity_id": []} ,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null} ,"Negated": null,"Speculated": null,"Severity": null ,"Effect": null}]}
{"id": "2445709_1","context": "A 52-year-old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["symmetric sensorimotor polyneuropathy", "cerebellar syndrome"]],"start": [["19","42"]],"entity_id": [["T1","T2"]]},"Subject": {"text": [["A 52-year-old woman"]],"start": [["0"]],"entity_id": [["T3"]],"Age": {"text": [["52"]],"start": [["5"]],"entity_id": [["T4"]]},"Gender": {"text": [["woman"]],"start": [["21"]],"entity_id": [["T5"]]},"Population": {"text": [["A"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["A"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["symmetric sensorimotor polyneuropathy", "cerebellar syndrome"]],"start": [["19","42"]],"entity_id": [["T1","T2"]]}},"Treatment": {"text": [["amiodarone treatment"]],"start": [["73"]],"entity_id": [["T6"]],"Drug": {"text": [["amiodarone"]],"start": [["73"]],"entity_id": [["T7"]]},"Duration": {"text": [["24 months"]],"start": [["55"]],"entity_id": [["T8"]]},"Route": {"text": [["treatment"]],"start": [["73"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["after"]],"start": [["43"]],"entity_id": [["T9"]]},"Freq": {"text": [["A"]],"start": [["0"]],"entity_id": [["T0"]]},"Combination": null,"Disorder": {"text": [["symmetric sensorimotor polyneuropathy", "cerebellar syndrome"]],"start": [["19","42"]],"entity_id": [["T1","T2"]]},"Dosage": {"text": [["A"]],"start": [["0"]],"entity_id": [["T0"]]},"Trigger": {"text": [["after"]],"start": [["43"]],"entity_id": [["T9"]]}},"Effect": {"text": [["symmetric sensorimotor polyneuropathy", "cerebellar syndrome"]],"start": [["19","42"]],"entity_id": [["T1","T2"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "18094347_6","context": "To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["diffuse papular eruption"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate injections"]],"start": [["73"]],"entity_id": [["T2"]],"Drug": {"text": [["methotrexate"]],"start": [["73"]],"entity_id": [["T3"]]},"Route": {"text": [["injections"]],"start": [["73"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["psoriasis"]],"start": [["43"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["following"]],"start": [["18"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["treatment"]],"start": [["43"]],"entity_id": [["T7"]]} ,"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["73"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["injections"]],"start": [["73"]],"entity_id": [["T4"]]} ,"event_id": "C1","event_type": "Treatment"} ],"Freq": {"text": [["following"]],"start": [["18"]],"entity_id": [["T6"]]} ,"Trigger": {"text": [["treatment"]],"start": [["43"]],"entity_id": [["T7"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Effect": {"text": [["diffuse papular eruption"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "10099659_1", "context": "Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["neurotoxicity"]], "start": [["37","38"]], "entity_id": []}, "Treatment": {"text": [["5-fluorouracil"]], "start": [["17","18"]], "entity_id": [], "Drug": {"text": [["5-fluorouracil"]], "start": [["17","18"]], "entity_id": []} ,"Duration":{"text":[["prolonged"]],"start":[[ "0","7" ]],"entity_id":[]}, "Disorder":{"text":[["dihydropyrimidine dehydrogenase deficiency"]],"start":[[ "62","83" ]],"entity_id":[]},"Dosage":{"text":[["severe"]],"start":[[ "8","14" ]],"entity_id":[]} ,"Time_elapsed":{"text":[["prolonged"]],"start":[[ "0","7" ]],"entity_id":[]},"Route":{"text":[["associated"]],"start":[[ "34","38" ]],"entity_id":[]},"Freq":{"text":[],"start":[],"entity_id":[]},"Combination":null,"Trigger":null },"Effect":{"text":[["neurotoxicity"]],"start":[[ "37","38" ]],"entity_id":[]},"Negated":null,"Speculated":null,"Severity":{"text":[["severe"]],"start":[[ "8","14" ]],"entity_id":[],"value":"high" },"Subject":{"text":[["patient"]],"start":[[ "5","10" ]],"entity_id":[],"Age":null,"Disorder":{"text":[["dihydropyrimidine dehydrogenase deficiency"]],"start":[[ "62","83" ]],"entity_id":[]},"Gender":null,"Population":null,"Race":null} }]}
{"id": "18343993_3", "context": "Life-threatening interstitial lung disease associated with trastuzumab: case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": {"value": "high", "text": [["Life-threatening"]], "start": [[ "0" ]], "entity_id": [ ["NE1" ]]}, "Subject": {"text": [["a patient"]], "start": [[ "12" ]], "entity_id": [ ["S1" ]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Treatment": {"text": [["trastuzumab"]], "start": [[ "62" ]], "entity_id": [ ["T1" ]], "Drug": {"text": [["trastuzumab"]], "start": [[ "62" ]], "entity_id": [ ["T2" ]]}, "Disorder": {"text": [["interstitial lung disease"]], "start": [[ "22" ]], "entity_id": [ ["D1" ]]}, "Time_elapsed": null, "Duration": null, "Freq": null, "Dosage": null, "Route": null, "Trigger": {"text": [["associated with"]], "start": [[ "36" ]], "entity_id": [ ["T3" ]]}, "Combination": null} ,"Effect": {"text": [["Life-threatening interstitial lung disease"]], "start": [[ "22" ]], "entity_id": [ ["E1" ]]} ,"Trigger": null }]}
{"id": "15694139_6","context": "Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thalidomide neuropathy"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Effect": {"text": [["proximal weakness"]],"start": [["54"]],"entity_id": [ ["T2"] ]},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "not specified"},"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": {"text": [["Thalidomide neuropathy"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Gender": null,"Population": null,"Race": null},"Treatment": {"text": [["Thalidomide neuropathy"]],"start": [["0"]],"entity_id": [ ["T1"] ],"Drug": {"text": [["Thalidomide"]],"start": [["0"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["Thalidomide neuropathy"]],"start": [["0"]],"entity_id": [ ["T1"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Freq": null,"Combination": null ,"Trigger": null}}]}
{"id": "18607107_3","context": "Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Crohn's disease"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Copaxone"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "35"]],"entity_id": [["T2"]],"Drug": {"text": [["Copaxone"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "35"]],"entity_id": [["T3"]]},"Duration": {"text": [["long-term"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "55"]],"entity_id": [["T4"]]},"Disorder": {"text": [["Crohn's disease"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "0"]],"entity_id": [["T1"]]},"Route": {"text": [["treatment"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "35"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["while"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "22"]],"entity_id": [["T5"]]},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Dosage": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [["Copaxone treatment"]],"start": [["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression", "35"]],"entity_id": [["T2"]]}},"Subject": {"text": [["Our patient"]],"start": [[], ["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression"]],"entity_id": [],"Age": null,"Disorder": {"text": [],"start": [],"entity_id": []},"Gender": null,"Population": null,"Race": null},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Effect": {"text": [["Crohn's disease"]],"start": [[], ["Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression"]],"entity_id": []}}]}
{"id": "19717383_1","context": "Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a patient with AIDS"]],"start": [["0"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["AIDS"]],"start": [["5"]],"entity_id": [["S2"]]}},"Treatment": {"text": [["chemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH)"]],"start": [["91"]],"entity_id": [["T1"]],"Drug": {"text": [["etoposide", "prednisone", "vincristine", "cyclophosphamide", "doxorubicin", "rituximab"]],"start": [[ "95", "109", "121", "133", "145", "161"]],"entity_id": [["D1","D2","D3","D4","D5","D6"]]} ,"Duration": {"text": [["48 months"]],"start": [["115"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["diffuse large B-cell lymphoma"]],"start": [["176"]],"entity_id": [["D7"]]} ,"Route": null,"Time_elapsed": null,"Freq": null ,"Combination": null ,"Trigger": null ,"Dosage": null },"Effect": {"text": [["pancytopenia"]],"start": [["63"]],"entity_id": [["E1"]]},"Trigger": {"text": [["presented"]],"start": [["56"]],"entity_id": [["T3"]]} },{"event_id": "E2","event_type": "Adverse_event","Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["a patient with AIDS"]],"start": [["0"]],"entity_id": [["S1"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["AIDS"]],"start": [["5"]],"entity_id": [["S2"]]}},"Treatment": null,"Effect": {"text": [["pancytopenia"]],"start": [["63"]],"entity_id": [["E2"]]} ,"Trigger": {"text": [["presented"]],"start": [["56"]],"entity_id": [["T3"]]} }]}
{"id": "8038468_2","context": "However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["prolongation", "increase"]],"start": [[ "6","29"]],"entity_id": [ ["T1","T2"] ]},"Treatment": {"Drug": {"text": [["5-FU"]],"start": [[ "41"]],"entity_id": [ ["T3"] ]},"Disorder": {"text": [["concurrent use"]],"start": [[ "52"]],"entity_id": [ ["T4"] ]},"Trigger": {"text": [["warfarin"]],"start": [[ "71"]],"entity_id": [ ["T5"] ]} ,"Time_elapsed": {"text": [["reported"]],"start": [[ "97"]],"entity_id": [ ["T6"] ]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": [{"Drug": {"text": [["5-FU"]],"start": [[ "41"]],"entity_id": [ ["T3"] ]},"Trigger": {"text": [["warfarin"]],"start": [[ "71"]],"entity_id": [ ["T5"] ]} ,"event_id": "E2" ,"event_type": "Adverse_event" }] ,"entity_id": [ ["E1","E2"] ],"text": [],"start": [] } ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} } ,"Effect": {"text": [["prolongation", "increase"]],"start": [[ "6","29"]],"entity_id": [ ["T1","T2"] ]} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false } }] }
{"id": "7718983_1", "context": "Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Graves' hyperthyroidism", "transient thyrotoxicosis"]], "start": [[ ],[ ]],"entity_id": [ ["T1"],["T2"]]}, "Treatment": {"text": [["interferon therapy"]], "start": [[ ]], "entity_id": [ ["T3"]], "Drug": {"text": [["interferon"]], "start": [[ ]], "entity_id": [ ["T4"]]}, "Duration": {"text": [["chronic"]], "start": [[ ]], "entity_id": [ ["T5"]]},"Disorder": {"text": [["hepatitis type C"]], "start": [[ ]], "entity_id": [ ["T6"]]}, "Time_elapsed": {"text": [["following"]], "start": [[ ]], "entity_id": [ ["T7"]]} , "Trigger": { "text": [["during"]], "start": [[ ]], "entity_id": [ ["T8"]]} , "Dosage": { "text": [], "start": [], "entity_id": []} , "Route": { "text": [], "start": [], "entity_id": []} , "Freq": { "text": [], "start": [], "entity_id": []} , "Combination": null}, "Subject": {"text": [["Graves' hyperthyroidism"]], "start": [[ ]], "entity_id": [ ["T1"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [], "start": [], "entity_id": []} }, "Effect": {"text": [["Graves' hyperthyroidism", "transient thyrotoxicosis"]], "start": [[ ],[ ]], "entity_id": [ ["T1"],["T2"]]}, "Negated": null, "Speculated": null, "Severity": {"text": [], "start": [], "entity_id": [] , "value": "low"}}]}
{"id": "17083900_2","context": "We report a case of acute generalized exanthematous pustulosis (AGEP) in a 50-year-old woman that was attributed to the ingestion of nimesulide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["50-year-old woman"]],"start": [["18"]],"entity_id": [["T1"]],"Age": {"text": [["50-year-old"]],"start": [["18"]],"entity_id": [["T2"]]},"Gender": {"text": [["woman"]],"start": [["23"]],"entity_id": [["T3"]]},"Disorder": {"text": [["acute generalized exanthematous pustulosis (AGEP)"]],"start": [["6"]],"entity_id": [["T4"]]},"Population": {"text": [["1"]],"start": [[""],["6"]],"entity_id": [["T4"],["T5"]]},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["nimesulide"]],"start": [["82"]],"entity_id": [["T6"]],"Drug": {"text": [["nimesulide"]],"start": [["82"]],"entity_id": [["T6"]]},"Disorder": {"text": [],"start": [],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [["the ingestion of"]],"start": [["56"]],"entity_id": [["T7"]]}},"Effect": {"text": [["acute generalized exanthematous pustulosis (AGEP)"]],"start": [["6"]],"entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "18191947_2", "context": "This case demonstrates the value of DWI in evaluation and diagnosis of sub-acute toxic leukoencephalopathy in patients being treated with methotrexate", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["methotrexate"]],"start": [["86"]],"entity_id": [["T1"]]} ,"text": [["methotrexate"]],"start": [[ "86" ]],"entity_id": [["T1"]] ,"Disorder": {"text": [["sub-acute toxic leukoencephalopathy"]],"start": [[ "40" ]],"entity_id": [["T2"]]} ,"Duration": {"text": [["being treated"]],"start": [[ "60" ]],"entity_id": [["T3"]]} ,"Route": {"text": [["in"]],"start": [[ "67" ]],"entity_id": [["T4"]]} ,"Time_elapsed": null,"Dosage": null,"Freq": null ,"Combination": null ,"Trigger": {"text": [["treated"]],"start": [[ "60" ]],"entity_id": [["T3"]]}},"Subject": {"text": [["patients"]],"start": [[ "96" ]],"entity_id": [["T5"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": null}]}
{"id": "15785053_3","context": "We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["oral mucosa pigmentation"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["OLP treatment with topical tacrolimus"]],"start": [["12"]],"entity_id": [["T2"]],"Drug": {"text": [["tacrolimus"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["OLP"]],"start": [["12"]],"entity_id": [["T4"]]} ,"Route": {"text": [["topical"]],"start": [["27"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["after"]],"start": [["19"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["tacrolimus"]],"start": [["51"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["treatment"]],"start": [["12"]],"entity_id": [["T2"]]} ,"event_id": "C1" ,"event_type": "Adverse_event"} ],"Freq": {"text": [["first"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Trigger": {"text": [["report"]],"start": [["0"]],"entity_id": [["T8"]]} ,"Duration": {"text": [["documented"]],"start": [["39"]],"entity_id": [["T9"]]} ,"Dosage": {"text": [["topical"]],"start": [["27"]],"entity_id": [["T5"]]} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Subject": {"text": [["We"]],"start": [["0"]],"entity_id": [["T10"]] ,"Population": {"text": [["the first"]],"start": [["9"]],"entity_id": [["T11"]]},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "Low" }} ]}
{"id": "16298824_5", "context": "Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Progressive hypoxemia"]], "start": [[]],"entity_id": [["T1"]]}, "Treatment": {"text": [["rituximab"]], "start": [[]],"entity_id": [["T2"]],"Drug": {"text": [["rituximab"]], "start": [[]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["1 week after administration"]], "start": [[]],"entity_id": [["T4"]]},"Freq": {"text": [["led to death"]], "start": [[]],"entity_id": [["T5"]]},"Combination": [{"event_type": "Adverse_event","event_id": "E2","Drug": {"text": [["endotracheal intubation"]], "start": [[]],"entity_id": [["T6"]]},"Trigger": {"text": [["1 week after administration"]], "start": [[]],"entity_id": [["T4"]]}}], "Disorder": {"text": [["hypoxemia"]], "start": [[]],"entity_id": [["T1"]]},"Dosage": null,"Duration": {"text": [["4 weeks after admission"]], "start": [[]],"entity_id": [["T7"]]},"Route": null,"Trigger": null},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [[ "not provided" ]], "start": [[]],"entity_id": [["T0"]],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null},"Effect": {"text": [["Progressive hypoxemia"]], "start": [[]],"entity_id": [["T1"]]}}]}
{"id": "24846936_2","context": "This is the first report of a fatal outcome from serotonin toxicity, precipitated by an interaction between methylene blue and venlafaxine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serotonin toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Negated": {"value": false,"text": [["serotonin toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Severity": {"value": "high","text": [["fatal outcome"]],"start": [["0"]],"entity_id": [["T0"]]},"Treatment": {"Drug": {"text": [["methylene blue"]],"start": [["51"]],"entity_id": [["T3"]]},"Disorder": {"text": [["serotonin toxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Trigger": {"text": [["interaction"]],"start": [["43"]],"entity_id": [["T2"]]},"Dosage": {"text": [["not specified"]],"start": [[""],[]],"entity_id": [["T7"]]},"Route" : {"text":[["not specified"]],"start":[[""]],"entity_id":[["T8"]]},"Duration" : {"text":[["not specified"]],"start":[[""]],"entity_id":[["T9"]]},"Time_elapsed" : {"text":[["not specified"]],"start":[[""]],"entity_id":[["T10"]]},"Freq" : {"text":[["not specified"]],"start":[[""]],"entity_id":[["T11"]]},"Combination" : [{"Drug" : {"text" : [["methylene blue"]],"start" : [[ "51" ]],"entity_id" : [["T3"]]},"Trigger" : {"text" : [["and"]],"start" : [[ "60" ]],"entity_id" : [["T4"]]},"event_id" : "C1","event_type" : "Combination"},{"Drug" : {"text" : [["venlafaxine"]],"start" : [[ "77" ]],"entity_id" : [["T5"]]},"Trigger" : {"text" : [["and"]],"start" : [[ "60" ]],"entity_id" : [["T4"]]},"event_id" : "C2","event_type" : "Combination"}],"text" : [["This is the first report of a fatal outcome from serotonin toxicity"]],"start" : [[""],[]],"entity_id" : [["T0"]]},"Subject" : {"text" : [["This is the first report"]],"start" : [[""],[]],"entity_id" : [["T0"]],"Age" : {"text" : [["not specified"]],"start" : [[""],[]],"entity_id" : [["T12"]]},"Gender" : {"text" : [["not specified"]],"start" : [[""],[]],"entity_id" : [["T13"]]},"Population" : {"text" : [["1 (report)"]],"start" : [[""],[]],"entity_id" : [["T14"]]},"Race" : {"text" : [["not specified"]],"start" : [[""],[]],"entity_id" : [["T15"]]},"Disorder" : {"text" : [["not specified"]],"start" : [[""],[]],"entity_id" : [["T16"]]}},"Effect" : {"text" : [["serotonin toxicity"]],"start" : [["18"]],"entity_id" : [["T1"]]},"Speculated" : {"value" : false ,"text" : [["not specified"]],"start" : [[""],[]],"entity_id" : [["T17"]]}}]}
{"id": "10614572_3","context": "We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe hypotension"]],"start": [["0"]],"entity_id": [["T1"]]},"Subject": {"text": [["an 11-year-old girl"]],"start": [["59"]],"entity_id": [["T2"]],"Age": {"text": [["11"]],"start": [["62"]],"entity_id": [["T3"]]},"Gender": {"text": [["girl"]],"start": [["59"]],"entity_id": [["T4"]]},"Population": {"text": [["1"]],"start": [["59"]],"entity_id": [["T2"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["status epilepticus"]],"start": [["32"]],"entity_id": [["T5"]]}},"Treatment": {"text": [["intravenous valproate"]],"start": [["23"]],"entity_id": [["T6"]],"Drug": {"text": [["valproate"]],"start": [["23"]],"entity_id": [["T7"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [["intravenous"]],"start": [["16"]],"entity_id": [["T8"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Disorder": {"text": [["status epilepticus"]],"start": [["32"]],"entity_id": [["T5"]]}},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]],"start": [["1"]],"entity_id": [["T0"]],"value": "severe"},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "11489400_1","context": "Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["naloxone"]],"start": [[ "0" ]],"entity_id": [ ]},"text": [["Relief of spasm of the sphincter of Oddi"]],"start": [[ "13" ]],"entity_id": [ ],"Disorder": {"text": [["morphine-induced spasm of the sphincter of Oddi"]],"start": [[ "5" ]],"entity_id": [ ]},"Trigger": {"text": [["Relief"]],"start": [[ "0" ]],"entity_id": [ ]},"Time_elapsed": {"text": [["by naloxone"]],"start": [[ "11" ]],"entity_id": [ ]},"Freq": {"text": [["by"]],"start": [[ "11" ]],"entity_id": [ ]},"Route": {"text": [["by"]],"start": [[ "11" ]],"entity_id": [ ]},"Duration": {"text": [["of"]],"start": [[ "8" ]],"entity_id": [ ]},"Dosage": {"text": [["by"]],"start": [[ "11" ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["naloxone"]],"start": [[ "0" ]],"entity_id": [ ]},"Trigger": {"text": [["Relief"]],"start": [[ "0" ]],"entity_id": [ ]},"event_type": "Potential_therapeutic_effect","event_id": "E1"}]},"Subject": {"text": [["a post-cholecystectomy patient"]],"start": [[ "81" ]],"entity_id": [ ],"Age": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Gender": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Population": {"text": [["a"]],"start": [[ "81" ]],"entity_id": [ ]},"Race": {"text": [[""]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["post-cholecystectomy"]],"start": [[ "82" ]],"entity_id": [ ]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": null,"Trigger": null}]}
{"id": "6683487_4", "context": "To our knowledge, no prior cases of penicillamine-induced TTP in RA have been reported", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": {"value": true, "text": [["no prior cases"]], "start": [["0"]], "entity_id": []},"Trigger": {"text": [["penicillamine-induced TTP"]], "start": [["32"]], "entity_id": []},"Subject": {"text": [["RA"]], "start": [["53"]], "entity_id": [],"Disorder": {"text": [["RA"]], "start": [["53"]], "entity_id": []},"Population": {"text": [["no prior cases"]], "start": [["0"]], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Age": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["penicillamine"]], "start": [["32"]], "entity_id": [],"Drug": {"text": [["penicillamine"]], "start": [["32"]], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["penicillamine"]], "start": [["32"]], "entity_id": []},"Trigger": {"text": [["penicillamine-induced TTP"]], "start": [["32"]], "entity_id": []},"event_id": "C1","event_type": "Adverse_event"} ],"Trigger": {"text": [["penicillamine-induced TTP"]], "start": [["32"]], "entity_id": []},"Disorder": {"text": [["RA"]], "start": [["46"]], "entity_id": []}},"Effect": {"text": [["TTP"]], "start": [["36"]], "entity_id": []},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false} }]}
{"id": "6529939_1", "context": "Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["alternating sinus rhythm and intermittent sinoatrial block"]], "start": [[],[]], "entity_id": []}, "Treatment": {"text": [["propranolol"]], "start": [[],[]], "entity_id": [],"Drug": {"text": [["propranolol"]], "start": [[],[]], "entity_id": []},"Disorder": {"text": [["alternating sinus rhythm and intermittent sinoatrial block"]], "start": [[],[]], "entity_id": []},"Route": {"text": [["induced by"]], "start": [[],[]], "entity_id": []},"Time_elapsed": {"text": [["induced by"]], "start": [[],[]], "entity_id": []},"Trigger": {"text": [["induced by"]], "start": [[],[]], "entity_id": []},"Freq": {"text": [["alternating"]], "start": [[],[]], "entity_id": []},"Dosage": {"text": [["induced by"]], "start": [[],[]], "entity_id": []},"Duration": {"text": [["induced by"]], "start": [[],[]], "entity_id": []},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "6947095_2","context": "The cause is presumed to be secondary to hypercoagulability due to asparaginase-induced antithrombin III deficiency","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["hypercoagulability"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["asparaginase"]],"start": [["46"]],"entity_id": [["T2"]]},"Disorder": {"text": [["antithrombin III deficiency"]],"start": [["61"]],"entity_id": [["T3"]]},"entity_id": [["T1"]],"start": [["18"]],"text": [["asparaginase-induced"]],"Trigger": {"text": [["induced"]],"start": [["54"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["to"]],"start": [["58"]],"entity_id": [["T5"]]},"Dosage": {"text": [["due"]],"start": [["58"]],"entity_id": [["T5"]]},"Route": {"text": [["to"]],"start": [["58"]],"entity_id": [["T5"]]},"Freq": {"text": [["to"]],"start": [["58"]],"entity_id": [["T5"]]},"Combination": [{"Drug": {"text": [["asparaginase"]],"start": [["46"]],"entity_id": [["T2"]]},"Trigger": {"text": [["induced"]],"start": [["54"]],"entity_id": [["T4"]]},"event_type": "Adverse_event","event_id": "E2"}],"Duration": {"text": [["secondary"]],"start": [["0"]],"entity_id": [["T0"]]}},"Negated": {"text": [["presumed"]],"start": [["0"]],"entity_id": [["T0"]],"value": true},"Subject": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]]},"Age": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]]},"Gender": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]]},"Population": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]]},"Race": {"text": [["The cause"]],"start": [["0"]],"entity_id": [["T0"]]}},"Severity": {"text": [["hypercoagulability"]],"start": [["18"]],"entity_id": [["T1"]],"value": "high"},"Speculated": {"text": [["presumed"]],"start": [["0"]],"entity_id": [["T0"]],"value": true},"Effect": {"text": [["hypercoagulability"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "10749332_5", "context": "Troglitazone-induced fulminant hepatic failure", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Troglitazone-induced fulminant hepatic failure"]], "start": [[ ]], "entity_id": [["T1"]]}, "Effect": {"text": [["Troglitazone-induced fulminant hepatic failure"]], "start": [[ ]], "entity_id": [["T1"]]}, "Treatment": {"text": [["Troglitazone"]], "start": [[]], "entity_id": [["T2"]],"Drug":{"text":[["Troglitazone"]], "start":[[ ]], "entity_id": [["T2"]] },"Disorder":{"text":[["fulminant hepatic failure"]], "start":[[ ]], "entity_id": [["T3"]]},"Time_elapsed":{"text":[["induced"]], "start":[[ ]], "entity_id": [["T4"]]} ,"Dosage" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} , "Freq" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} , "Route" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} , "Duration" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} ,"Combination" : [{"Drug":{"text":[["Troglitazone"]], "start":[[ ]], "entity_id": [["T2"]]},"Trigger":{"text":[["induced"]], "start":[[ ]], "entity_id": [["T4"]]},"event_id":"C1","event_type":"Combination"}] ,"Trigger" :{"text":[["Troglitazone-induced"]], "start":[[ ]], "entity_id": [["T1"]]} }, "Negated" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]], "value":false} ,"Speculated" :{"text":[["induced"]], "start":[[ ]], "entity_id": [["T4"]], "value":false} ,"Severity" :{"text":[["fulminant hepatic failure"]], "start":[[ ]], "entity_id": [["T3"]], "value":"high" } ,"Subject" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]], "Age" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} ,"Gender" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} ,"Population" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} ,"Race" :{"text":[[""]], "start":[[ ]], "entity_id": [[""]]} ,"Disorder" :{"text":[["fulminant hepatic failure"]], "start":[[ ]], "entity_id": [["T3"]]} }}]}
{"id": "2320800_2","context": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["irreversible lethal renal failure with anuria"]],"start": [["39"]],"entity_id": [["T1"]]},"Subject": {"text": [["a sixty-year-old woman"]],"start": [["0"]],"entity_id": [["T2"]],"Age": {"text": [["sixty-year-old"]],"start": [["0"]],"entity_id": [["A1"]]},"Gender": {"text": [["woman"]],"start": [["18"]],"entity_id": [["G1"]]},"Disorder": {"text": [["advanced breast cancer"]],"start": [["20"]],"entity_id": [["D1"]]},"Population": {"text": [["1"]],"start": [[""], ["10"]],"entity_id": [["P1"]]} ,"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["5 g/m2 bolus ifosfamide"]],"start": [["121"]],"entity_id": [["T3"]],"Drug": {"text": [["ifosfamide"]],"start": [["121"]],"entity_id": [["D1"]]},"Dosage": {"text": [["5 g/m2"]],"start": [["121"]],"entity_id": [["D2"]]},"Route": {"text": [["bolus"]],"start": [["117"]],"entity_id": [["R1"]]},"Time_elapsed": {"text": [["the day after"]],"start": [["103"]],"entity_id": [["T2"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["cisplatin"]],"start": [["63"]],"entity_id": [["D2"]]} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": []} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false },"Severity": {"text": [],"start": [],"entity_id": [],"value": "lethal" }}]}
{"id": "10467499_2","context": "With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["infectious mononucleosis-like syndrome"]],"start": [["33"]],"entity_id": [["T1"]]},"Treatment": {"text": [["minocycline ingestion"]],"start": [["62"]],"entity_id": [["T2"]],"Drug": {"text": [["minocycline"]],"start": [["62"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["infectious mononucleosis-like syndrome"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["negative viral serologies"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Freq": {"text": [["produced"]],"start": [["52"]],"entity_id": [["T4"]]} ,"Combination": [{"Drug": {"text": [["minocycline"]],"start": [["62"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["ingestion"]],"start": [["75"]],"entity_id": [["T5"]]} ,"event_type": "Adverse_event","event_id": "E2"}] ,"Trigger": {"text": [["ingestion"]],"start": [["75"]],"entity_id": [["T5"]]} ,"Route": {"text": [["ingestion"]],"start": [["75"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["negative viral serologies"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["negative viral serologies"]],"start": [["0"]],"entity_id": [["T0"]]} },"Subject": {"text": [["patient"]],"start": [[""], [""]],"entity_id": [["T6"]],"Age": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T7"]]} ,"Disorder": {"text": [["negative viral serologies"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Gender": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T8"]]} ,"Race": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T9"]]} ,"Population": {"text": [[""]],"start": [[""], [""]],"entity_id": [["T10"]]} },"Effect": {"text": [["infectious mononucleosis-like syndrome"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Severity": {"text": [["negative viral serologies"]],"start": [["0"]],"entity_id": [["T0"]] ,"value": "Low" },"Negated": {"text": [[]],"start": [[], []],"entity_id": [[]],"value": false },"Speculated": {"text": [[]],"start": [[], []],"entity_id": [[]],"value": false}} ]}
{"id": "16207263_2", "context": "We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity.","is_mult_event": true, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["dyserythropoietic anaemia"]], "start": [["18"]], "entity_id": []},"Treatment": {"text": [["linezolid use"]], "start": [["58"]], "entity_id": [],"Drug": {"text": [["linezolid"]], "start": [["58"]], "entity_id": []},"Duration": {"text": [["long-term"]], "start": [["49"]], "entity_id": []},"Disorder": {"text": [["dyserythropoietic anaemia"]], "start": [["18"]], "entity_id": []},"Time_elapsed": {"text": [["associated"]], "start": [["38"]], "entity_id": []},"Trigger": {"text": [["associated"]], "start": [["38"]], "entity_id": []},"Combination": [{"Drug": {"text": [["chloramphenicol"]], "start": [["128"]], "entity_id": []},"Trigger": {"text": [["chloramphenicol-associated myelotoxicity"]], "start": [["125"]], "entity_id": []},"event_id": "E2","event_type": "Adverse_event"} ],"Freq": {"text": [["two cases"]], "start": [["11"]], "entity_id": []},"Route": {"text": [["use"]], "start": [["58"]], "entity_id": []},"Dosage": {"text": [[]], "start": [[],[]], "entity_id": []}},"Negated":{"text": [],"start": [[],[]], "entity_id": [],"value": false},"Speculated":{"text": [],"start": [[],[]], "entity_id": [],"value": false},"Severity":{"text": [],"start": [[],[]], "entity_id": [],"value": ""},"Subject":{"Age":{"text": [],"start": [[],[]], "entity_id": []},"Gender":{"text": [],"start": [[],[]], "entity_id": []},"Population":{"text": [],"start": [[],[]], "entity_id": []},"Race":{"text": [],"start": [[],[]], "entity_id": []},"Disorder":{"text": [["dyserythropoietic anaemia"]], "start": [["18"]], "entity_id": []},"text": [],"start": [[],[]], "entity_id": []},"Effect":{"text": [],"start": [[],[]], "entity_id": []}}]}
{"id": "22233409_4","context": "We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["developed"]],"start": [["26"]],"entity_id": []},"Subject": {"text": [["a patient"]],"start": [["0"]],"entity_id": [],"Disorder": {"text": [["chronic hepatitis C infection"]],"start": [["5"]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [["antiviral treatment with peginterferon alfa/ribavirin"]],"start": [["20"]],"entity_id": [],"Drug": {"text": [["peinterferon alfa/ribavirin"]],"start": [["20"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [["influenza"]],"start": [["130"]],"entity_id": []}},"Effect": {"text": [["severe anaemia"]],"start": [["41"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"}},{"event_type": "Adverse_event","event_id": "E2","Trigger": {"text": [["added"]],"start": [["116"]],"entity_id": []},"Treatment": {"text": [["oseltamivir"]],"start": [["116"]],"entity_id": [],"Drug": {"text": [["oseltamivir"]],"start": [["116"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Trigger": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Disorder": {"text": [["influenza"]],"start": [["130"]],"entity_id": []}},"Effect": {"text": [["severe anaemia"]],"start": [["41"]],"entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [],"value": "severe"},"Subject": {"text": [["a patient"]],"start": [["0"]],"entity_id": [],"Disorder": {"text": [["chronic hepatitis C infection"]],"start": [["5"]],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "18344455_2", "context": "It is rare to develop simultaneous toxicities while on anticonvulsants", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Negated": {"value": false, "text": [["rare"]], "start": [["0"]], "entity_id": []}, "Trigger": {"text": [["develop"]], "start": [["22"]], "entity_id": []}, "Treatment": {"text": [["on anticonvulsants"]], "start": [["33"]], "entity_id": [], "Disorder": {"text": [["anticonvulsants"]], "start": [["33"]], "entity_id": []}, "Time_elapsed": {"text": [["while"]], "start": [["17"]], "entity_id": []}, "Route": {"text": [["on"]], "start": [["33"]], "entity_id": []}, "Duration": {"text": [["while"]], "start": [["17"]], "entity_id": []}, "Freq": {"text": [["rare"]], "start": [["0"]], "entity_id": []}, "Combination": [{"Drug": {"text": [["anticonvulsants"]], "start": [["33"]], "entity_id": []}, "Trigger": {"text": [["on"]], "start": [["33"]], "entity_id": []}, "event_id": "C1", "event_type": "null"}], "Trigger": {"text": [["develop"]], "start": [["22"]], "entity_id": []}, "Drug": {"text": [["anticonvulsants"]], "start": [["33"]], "entity_id": []}, "Dosage": {"text": [["rare"]], "start": [["0"]], "entity_id": []}} ,"Subject": { "text": [["It"]], "start": [[""],["0"]], "entity_id": [], "Age": {"text": [["rare"]], "start": [[""],["0"]], "entity_id": []}, "Disorder": {"text": [["develop simultaneous toxicities"]], "start": [[""],["22"]], "entity_id": []}, "Gender": {"text": [["rare"]], "start": [[""],["0"]], "entity_id": []}, "Population": {"text": [["rare"]], "start": [[""],["0"]], "entity_id": []}, "Race": {"text": [["rare"]], "start": [[""],["0"]], "entity_id": []} }, "Severity": { "text": [["rare"]], "start": [[""],["0"]], "entity_id": [] ,"value": "low" }, "Speculated": { "text": [], "start": [], "entity_id": [] ,"value": false }, "Effect": { "text": [["develop simultaneous toxicities"]], "start": [[""],["22"]], "entity_id": [] }}]}
{"id": "16211208_1", "context": "Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["serious side effects"]], "start": [[ ]], "entity_id": [ ["T1" ]] }, "Treatment": {"text": [["dofetilide"]], "start": [[ ] ], "entity_id": [ ["T2" ]], "Dosage": {"text": [["initiated"]], "start": [[ ]], "entity_id": [ ["T2" ]] }, "Disorder": {"text": [["an increase in the QT interval causing torsades de pointes"]], "start": [[ ]], "entity_id": [ ["T3" ]] } ,"Route":{"text":[["inpatient setting"]],"start":[[]],"entity_id":[["T4"]]} ,"Time_elapsed":{"text":[["Because of"]],"start":[[]],"entity_id":[["T0"]]} ,"Duration":{"text":[["close monitoring of the QT interval"]],"start":[[]],"entity_id":[["T5"]]} ,"Freq":{"text":[["serious side effects"]],"start":[[ ]],"entity_id":[["T1"]]} ,"Combination":[{"Drug":{"text":[["dofetilide"]],"start":[[]],"entity_id":[["T2"]]},"Trigger":{"text":[["an increase in the QT interval causing torsades de pointes"]],"start":[[]],"entity_id":[["T3"]]}, "event_id":"C1" ,"event_type":"Adverse_event"}] ,"Drug":{"text":[["close monitoring of the QT interval"]],"start":[[]],"entity_id":[["T5"]]},"Trigger":{"text":[["Because of"]],"start":[[]],"entity_id":[["T0"]]} },"Effect":{"text":[["serious side effects"]],"start":[[ ]],"entity_id":[["T1"]]} ,"Negated":{"text":[[]],"start":[[]],"entity_id":[[]],"value":false} ,"Speculated":{"text":[[]],"start":[[]],"entity_id":[[]],"value":false} ,"Severity":{"text":[["serious"]],"start":[[ ]],"entity_id":[["T1"]],"value":"high" },"Subject":{"text":[["patient"]],"start":[[]],"entity_id":[[]],"Age":{"text":[[]],"start":[[]],"entity_id":[[]]},"Gender":{"text":[[]],"start":[[]],"entity_id":[[]]},"Population":{"text":[["an increase in the QT interval causing torsades de pointes"]],"start":[[]],"entity_id":[["T3"]]},"Race":{"text":[[]],"start":[[]],"entity_id":[[]]},"Disorder":{"text":[["an increase in the QT interval causing torsades de pointes"]],"start":[[]],"entity_id":[["T3"]]} }}]}
{"id": "8672829_6","context": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["nonconvulsive status epilepticus"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ifosfamide"]],"start": [["54"]],"entity_id": [["T2"]],"Drug": {"text": [["ifosfamide"]],"start": [["54"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["nonconvulsive status epilepticus"]],"start": [["17"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["39"]],"entity_id": [["T3"]]},"Trigger": {"text": [["induced"]],"start": [["39"]],"entity_id": [["T3"]]} ,"Route": {"text": [["by"]],"start": [["51"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Duration": {"text": [["first report"]],"start": [["0"]],"entity_id": [["T0"]]},"Dosage": {"text": [[]],"start": [[ ]],"entity_id": [[""]]} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null,"Speculated": null,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "low"} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null} }]}
{"id": "8345435_1", "context": "Hepatotoxic effects in a child receiving valproate and carnitine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hepatotoxic effects"]], "start": [["0"]], "entity_id": []}, "Subject": {"text": [["a child"]], "start": [["20"]], "entity_id": [] , "Age": {"text": [], "start": [], "entity_id": []}, "Gender": {"text": [], "start": [], "entity_id": []}, "Population": {"text": [], "start": [], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["valproate", "and", "carnitine"]], "start": [["41"]], "entity_id": [] , "Drug": { "text": [["valproate"]], "start": [["41"]], "entity_id": [] }, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []} , "Combination": [{ "event_type": "Adverse_event", "event_id": "E2", "Drug": {"text": [["valproate"]], "start": [["41"]], "entity_id": []}, "Trigger": {"text": [["valproate"]], "start": [["41"]], "entity_id": []} }, { "event_type": "Adverse_event", "event_id": "E3", "Drug": {"text": [["carnitine"]], "start": [["49"]], "entity_id": []}, "Trigger": {"text": [["carnitine"]], "start": [["49"]], "entity_id": []} }]} , "Effect": { "text": [], "start": [], "entity_id": [] } , "Negated": {"text": [], "start": [], "entity_id": [] , "value": false}, "Speculated": { "text": [], "start": [], "entity_id": [] , "value": false}, "Severity": { "text": [], "start": [], "entity_id": [] , "value": ""}}]}
{"id": "7718983_5","context": "We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Graves' hyperthyroidism"]],"start": [["17"]],"entity_id": [["T1"]]},"Treatment": {"text": [["long-term interferon (IFN) therapy"]],"start": [["47"]],"entity_id": [["T2"]],"Drug": {"text": [["interferon"]],"start": [["47"]],"entity_id": [["T3"]]} ,"Duration": {"text": [["long-term"]],"start": [["47"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["therapy"]],"start": [["60"]],"entity_id": [["T5"]]} ,"Route": {"text": [["(IFN)"]],"start": [["51"]],"entity_id": [["T6"]]} ,"Disorder": {"text": [["Graves' hyperthyroidism"]],"start": [["17"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["induced"]],"start": [["32"]],"entity_id": [["T7"]]},"Freq": {"text": [["long-term"]],"start": [["47"]],"entity_id": [["T4"]]} ,"Combination": [] ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" },"Subject": {"text": [["We"]],"start": [[""]],"entity_id": [["T0"]],"Age": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] }} } ]}
{"id": "9211543_1", "context": "Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [["18"]], "entity_id": []}, "Treatment": {"text": [["Bleomycin", "and cyclophosphamide"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["Bleomycin"], ["cyclophosphamide"]], "start": [[ "0" ], ["14"]], "entity_id": [] } ,"Disorder": {"text": [], "start": [], "entity_id": [] } ,"Dosage": {"text": [], "start": [], "entity_id": [] } ,"Duration": {"text": [], "start": [], "entity_id": [] } ,"Trigger": {"text": [], "start": [], "entity_id": [] } ,"Route": {"text": [], "start": [], "entity_id": [] } ,"Time_elapsed": {"text": [], "start": [], "entity_id": [] } ,"Freq": {"text": [], "start": [], "entity_id": [] } ,"Combination": [] } ,"Effect": {"text": [["simulating metastatic nodules to the lungs"]], "start": [["31"]], "entity_id": []},"Negated": null, "Speculated": null, "Severity": null, "Subject": null }]}
{"id": "17266059_1", "context": "The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fulminant microangiopathic hemolytic anemia", "thrombocytopenia"]], "start": [[ "0","48" ]], "entity_id": [ ["T1","T2"] ]}, "Treatment": {"text": [["therapy with trimethoprim-sulfamethoxazole"]], "start": [[ "111" ]], "entity_id": [ ["T3"] ], "Drug": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[ "111" ]], "entity_id": [ ["T4"] ]},"Time_elapsed":{"text":[["48 hr"]],"start":[[ "82" ]],"entity_id":[["T5"]]},"Freq":{"text":[["initiating"]],"start":[[ "102" ]],"entity_id":[["T6"]]}, "Duration":{"text":[["presented with"]],"start":[[ "0" ]],"entity_id":[["T7"]]},"Disorder":{"text":[["fulminant microangiopathic hemolytic anemia","thrombocytopenia"]],"start":[[ "0" ]],"entity_id":[["T1","T2"]]},"Dosage":{"text":[["therapy"]], "start":[[ "111" ]], "entity_id":[["T3"]]},"Route":{"text":[["with"]], "start":[[ "110" ]], "entity_id":[["T8"]]}, "Trigger":{"text":[["initiating"]], "start":[[ "102" ]], "entity_id":[["T6"]]}, "Combination":[{"Drug":{"text":[["trimethoprim"]], "start":[[ "111" ]], "entity_id":[["T4a"]]},"Trigger":{"text":[["and"]], "start":[[ "117" ]], "entity_id":[["T6a"]]},"event_id":"C1","event_type":"Adverse_event"}]},"Negated":{"text":[],"start":[],"entity_id":[],"value":false},"Speculated":{"text":[],"start":[],"entity_id":[],"value":false},"Severity":{"text":[],"start":[],"entity_id":[],"value":"moderate" },"Subject":{"text":[["The patient"]],"start":[[ "0" ]],"entity_id":[["T9"]],"Age":{"text":[],"start":[],"entity_id":[]},"Disorder":{"text":[["fulminant microangiopathic hemolytic anemia","thrombocytopenia"]], "start":[[ "0" ]], "entity_id":[["T1","T2"]]},"Gender":{"text":[],"start":[],"entity_id":[]},"Population":{"text":[],"start":[],"entity_id":[]},"Race":{"text":[],"start":[],"entity_id":[]}},"Effect":{"text":[["fulminant microangiopathic hemolytic anemia","thrombocytopenia"]], "start":[[ "0" ]], "entity_id":[["T1","T2"]]} }]}
{"id": "1792646_2","context": "Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["methotrexate"]],"start": [["56"]],"entity_id": [["T1"]] ,"Drug": {"text": [["methotrexate"]],"start": [["56"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["asthmatic patients"]],"start": [["23"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["taking"]],"start": [["47"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["who present with fever, pulmonary infiltrates, and hypoxia"]],"start": [["66"]],"entity_id": [["T5"]]} ,"Dosage": {"text": [["methotrexate"]],"start": [["56"]],"entity_id": [["T6"]]} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [["Pneumocystis pneumonia"]],"start": [["0"]],"entity_id": [["T7"]]} ,"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["asthmatic patients"]],"start": [["23"]],"entity_id": [["T8"]] ,"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["asthmatic patients"]],"start": [["23"]],"entity_id": [["T9"]]}} ,"Trigger": null} ]}
{"id": "17406804_3","context": "Gemcitabine-induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Gemcitabine-induced recall pneumonitis"]],"start": [[ "0"]] ,"entity_id": [ ["T1"] ]},"Effect": {"text": [["Gemcitabine-induced recall pneumonitis"]],"start": [[ "0"]],"entity_id": [ ["T1"] ]},"Negated": {"value": false ,"text": [] ,"start": [] ,"entity_id": []},"Speculated": {"value": false ,"text": [] ,"start": [] ,"entity_id": []},"Severity": {"value": "low" ,"text": [] ,"start": [] ,"entity_id": []},"Subject": {"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["recall pneumonitis"]],"start": [[ "26"]],"entity_id": [ ["T2"] ]} ,"text": [] ,"start": [] ,"entity_id": []},"Treatment": {"Drug": {"text": [["Gemcitabine"]],"start": [[ "0"]],"entity_id": [ ["T0"] ]},"Dosage": null,"Freq": null,"Route": null,"Time_elapsed": {"text": [["extended time interval"]],"start": [[ "84"]],"entity_id": [ ["T3"] ]},"Duration": null,"Disorder": {"text": [["radiotherapy"]],"start": [[ "116"]],"entity_id": [ ["T4"] ]},"text": [] ,"start": [] ,"entity_id": [] ,"Combination": null ,"Trigger": null} }] }
{"id": "6519218_1","context": "In a 61-year-old man receiving chronic low-dosage amiodarone an interstitial pneumopathy was observed","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["61-year-old man"]],"start": [["0"]],"entity_id": [["S1"]],"Age": {"text": [["61"]],"start": [[""], []],"entity_id": [["A1"]]} ,"Gender": {"text": [["man"]],"start": [[""], []],"entity_id": [["G1"]]} ,"Disorder": {"text": [["interstitial pneumopathy"]],"start": [["56"]],"entity_id": [["D1"]]} ,"Race": {"text": [["61-year-old man"]],"start": [[""], []],"entity_id": [["R1"]]} ,"Population": {"text": [["1"]],"start": [[""], []],"entity_id": [["P1"]]} },"Treatment": {"text": [["chronic low-dosage amiodarone"]],"start": [["20"]],"entity_id": [["T1"]],"Drug": {"text": [["amiodarone"]],"start": [["40"]],"entity_id": [["D1"]]},"Dosage": {"text": [["low-dosage"]],"start": [["28"]],"entity_id": [["D2"]]},"Duration": {"text": [["chronic"]],"start": [["20"]],"entity_id": [["D3"]]} ,"Route": {"text": [["amiodarone"]],"start": [["40"]],"entity_id": [["R1"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [["chronic"]],"start": [["20"]],"entity_id": [["F1"]]} ,"Disorder": {"text": [["interstitial pneumopathy"]],"start": [["56"]],"entity_id": [["D1"]]} ,"Combination": [] ,"Trigger": {"text": [["observed"]],"start": [["74"]],"entity_id": [["T2"]]} },"Effect": {"text": [["interstitial pneumopathy"]],"start": [["56"]],"entity_id": [["E1"]]} ,"Negated": null,"Speculated": null,"Severity": null ,"Trigger": {"text": [["observed"]],"start": [["74"]],"entity_id": [["T2"]]} }]}
{"id": "12126225_2", "context": "A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bilateral lower leg edema"]], "start": [["32"]], "entity_id": []}, "Subject": {"text": [["A 75-year-old man"]], "start": [["0"]], "entity_id": [],"Age": {"text": [["75"]], "start": [["3"]], "entity_id": []}, "Gender": {"text": [["man"]], "start": [["22"]], "entity_id": []} ,"Population": {"text": [["A"]], "start": [["0"]], "entity_id": []} ,"Race": {"text": [], "start": [], "entity_id": []} ,"Disorder": {"text": [], "start": [], "entity_id": []}}, "Treatment": {"text": [["troglitazone","pioglitazone"]], "start": [["85","106"]], "entity_id": [],"Drug": {"text": [["troglitazone"]], "start": [["85"]], "entity_id": []}, "Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [["6 months"]], "start": [["54"]], "entity_id": []},"Trigger": {"text": [["switching"]], "start": [["45"]], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [["6 months"]], "start": [["54"]], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": [{"Drug": {"text": [["pioglitazone"]], "start": [["106"]], "entity_id": []},"Trigger": {"text": [["to"]], "start": [["102"]], "entity_id": []},"event_id": "E2","event_type": "Treatment"}] ,"Disorder": {"text": [], "start": [], "entity_id": []} }, "Effect": {"text": [["bilateral lower leg edema"]], "start": [["32"]], "entity_id": []},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""} } ]}
{"id": "10475726_1", "context": "An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acute ischaemic event"]], "start": [["0"]], "entity_id": []}, "Treatment": {"text": [["venlafaxine"]], "start": [["82"]], "entity_id": [], "Drug": {"text": [["venlafaxine"]], "start": [["82"]], "entity_id": []},"Disorder": {"text": [["acute ischaemic event"]], "start": [["0"]], "entity_id": []},"Time_elapsed": {"text": [["associated with the use of venlafaxine"]], "start": [["33"]], "entity_id": []},"Route":{"text":[["use"]],"start":[[ "33"]],"entity_id":[]},"Trigger":{"text":[["associated with"]],"start":[[ "33"]],"entity_id":[]},"Dosage":{"text":[[""]], "start":[["" ]], "entity_id":[]},"Duration":{"text":[[""]], "start":[["" ]], "entity_id":[]},"Freq":{"text":[[""]], "start":[[ "" ]], "entity_id":[]},"Combination": null } , "Effect": {"text": [], "start": [], "entity_id": []},"Negated":null,"Speculated":null,"Severity":null,"Subject":{"text":[["An"]],"start":[[ "0"]], "entity_id":[],"Age":null,"Gender":null,"Population":null,"Race":null,"Disorder":{"text":[["acute ischaemic event"]], "start": [["0"]], "entity_id": []}}}]}
{"id": "21751666_5","context": "Oseltamivir was effective for post-exposure prophylaxis of H1N1 in close contact","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Oseltamivir"]],"start": [[ "0" ]],"entity_id": [],"Drug": {"text": [["Oseltamivir"]],"start": [[ "0" ]],"entity_id": []},"Trigger": {"text": [["effective"]],"start": [[ "8" ]],"entity_id": []},"Time_elapsed": {"text": [["post-exposure"]],"start": [[ "21" ]],"entity_id": []},"Disorder": {"text": [["H1N1"]],"start": [[ "34" ]],"entity_id": []},"Freq": {"text": [["prophylaxis"]],"start": [[ "39" ]],"entity_id": []},"Route": {"text": [["in close contact"]],"start": [[ "50" ]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Combination": null} ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Effect": null ,"Trigger": { "text": [["effective"]], "start": [[ "8" ]], "entity_id": [ ]} }] }
{"id": "25417855_1", "context": "Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["worsening pneumonitis"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": { "Drug": { "text": [["everolimus"]], "start": [[ ]], "entity_id": [ ]}, "Dosage": { "text": [], "start": [] , "entity_id": []}, "Duration": { "text": [], "start": [] , "entity_id": []}, "Route": { "text": [], "start": [] , "entity_id": []}, "Time_elapsed": { "text": [], "start": [] , "entity_id": []}, "Freq": { "text": [], "start": [] , "entity_id": []}, "Trigger": { "text": [["pharmacokinetic drug-drug interaction"]], "start": [[ ]], "entity_id": [ ]}, "Combination": [{"Drug": {"text": [["everolimus"]], "start": [[ ]], "entity_id": [ ]}, "Trigger": {"text": [["between"]], "start": [[ ]], "entity_id": []}, "event_id": "C1", "event_type": "null"}, {"Drug": {"text": [["voriconazole"]], "start": [[ ]], "entity_id": []}, "Trigger": {"text": [], "start": [],"entity_id": []},"event_id": "C2","event_type": "null"}], "entity_id": [] , "Disorder": { "text": [], "start": [] , "entity_id": []} , "text": [], "start": []},"Negated": {"text": [], "start": [],"entity_id": [],"value": false},"Speculated": {"text": [], "start": [],"entity_id": [],"value": false},"Severity": {"text": [], "start": [],"entity_id": [],"value": ""},"Subject": { "text": [["a renal transplant patient"]], "start": [[ ]], "entity_id": [ ],"Age": {"text": [], "start": [],"entity_id": []},"Disorder": { "text": [], "start": [] ,"entity_id": []},"Gender": {"text": [], "start": [],"entity_id": []},"Population": {"text": [], "start": [],"entity_id": []},"Race": {"text": [], "start": [],"entity_id": []}},"Effect": { "text": [["worsening pneumonitis"]], "start": [[ ]], "entity_id": []}}]}
{"id": "11576059_1","context": "Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Vocal cord paralysis"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["peritonsillar infiltration with bupivacaine"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["bupivacaine"]],"start": [[ ]],"entity_id": [ ]},"Route": {"text": [["infiltration"]],"start": [[ ]],"entity_id": [ ]},"Disorder": {"text": [["Vocal cord paralysis"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [["as a consequence"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["peritonsillar infiltration with bupivacaine"]],"start": [[ ]],"entity_id": [ ]},"Freq": {"text": [["a consequence"]],"start": [[ ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["bupivacaine"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["peritonsillar infiltration"]],"start": [[ ]],"entity_id": [ ]},"event_type": "Adverse_event","event_id": "E1"}],"Duration": {"text": [["a consequence"]],"start": [[ ]],"entity_id": [ ]},"Dosage": {"text": [["peritonsillar infiltration"]],"start": [[ ]],"entity_id": [ ]}},"Effect": {"text": [["Vocal cord paralysis"]],"start": [[ ]],"entity_id": [ ]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "1267457_3","context": "The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["sulfonamides"]],"start": [["0"]],"entity_id": [ ["T1"] ]}, "entity_id": [ ["T1"] ], "text": [["sulfonamides"]],"start": [["0"]] ,"Trigger": {"text": [["drug-trigger"]],"start": [["20"]],"entity_id": [ ["T2"] ]} ,"Disorder": {"text": [["erythema multiforme", "Stevens-Johnson syndrome"]],"start": [["42"]],"entity_id": [ ["T3"] ]} ,"Time_elapsed": null, "Dosage": null, "Duration": null, "Route": null, "Freq": null ,"Combination": null }, "Effect": null, "Negated": null, "Speculated": null, "Severity": null, "Subject": null ,"Trigger": null }] }
{"id": "3365032_1","context": "A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day).","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["severe proximal muscle weakness", "raised creatine phosphokinase"]],"start": [[ ]],"entity_id": [["T2"]]},"Treatment": {"text": [["propylthiouracil"]],"start": [[ ]],"entity_id": [["T3"]],"Dosage": {"text": [["100 mg"]],"start": [[ ]],"entity_id": [["T4"]]},"Route": {"text": [["orally"]],"start": [[ ]],"entity_id": [["T5"]]},"Freq": {"text": [["three times a day"]],"start": [[ ]],"entity_id": [["T6"]]},"Disorder": {"text": [["treatment for hyperthyroidism"]],"start": [[ ]],"entity_id": [["T1"]]},"Drug": {"text": [["propylthiouracil"]],"start": [[ ]],"entity_id": [["T3"]]},"Time_elapsed": {"text": [["after"]],"start": [[ ]],"entity_id": [["T7"]]},"Duration": {"text": [["typical hyperthyroidism"]],"start": [[ ]],"entity_id": [["T8"]]},"Trigger": {"text": [["developed"]],"start": [[ ]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["propylthiouracil"]],"start": [[ ]],"entity_id": [["T3"]]},"Trigger": {"text": [["treatment for hyperthyroidism"]],"start": [[ ]],"entity_id": [["T1"]]},"event_id": "E2","event_type": "Potential_therapeutic_effect"}]},"Subject": {"text": [["A patient"]],"start": [[ ]],"entity_id": [["T0"]],"Disorder": {"text": [["typical hyperthyroidism"]],"start": [[ ]],"entity_id": [["T8"]]},"Age": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[ ]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[ ]],"entity_id": [[]]}},"Effect": {"text": [["typical hyperthyroidism"]],"start": [[ ]],"entity_id": [["T8"]]},"Negated": {"text": [[]],"start": [[ ]],"entity_id": [[]],"value": false},"Speculated": {"text": [[]],"start": [[ ]],"entity_id": [[]],"value": false},"Severity": {"text": [["severe"]],"start": [[ ]],"entity_id": [["T2"]],"value": "high"}}]}
{"id": "12243603_7","context": "Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["Atorvastatin"]],"start": [[ "0"]] ,"entity_id": [["T1"] ],"Drug": {"text": [["Atorvastatin"]],"start": [[ "0"]] ,"entity_id": [["T2"] ]},"Disorder": {"text": [["treatment of hyperlipidemia"]],"start": [[ "81"]] ,"entity_id": [["T3"] ]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": {"text": [["commonly used"]],"start": [[ "53"]] ,"entity_id": [["T4"] ]}},"Effect": null,"Subject": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["Atorvastatin"]],"start": [[ "0"]] ,"entity_id": [["T5"] ]}}]}
{"id": "2935070_2", "context": "However, there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["ampicillin as a cause"]], "start": [[ ]], "entity_id": [ ]}, "Treatment": {"text": [["ampicillin"]], "start": [[ ]], "entity_id": [ ] , "Drug": {"text": [["ampicillin"]], "start": [[ ]], "entity_id": [ ] } ,"Time_elapsed": null, "Duration": null, "Disorder": {"text": [["acute interstitial nephritis"]], "start": [[ ]], "entity_id": [ ]},"Freq": null, "Route": null, "Combination": null, "Dosage": null, "Trigger": {"text": [["ampicillin as a cause"]], "start": [[ ]], "entity_id": [ ]}}, "Effect": {"text": [["acute interstitial nephritis"]], "start": [[ ]], "entity_id": [ ]},"Negated": null, "Speculated": null, "Severity": null, "Subject": null}]}
{"id": "7779233_2", "context": "This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["sodium warfarin"]], "start": [["35","39"]], "entity_id": []},"Disorder": {"text": [["necrotizing fasciitis","myonecrosis"]], "start": [["64","78","84","98"]], "entity_id": []} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"text": [["sodium warfarin-induced"]], "start": [["40","46"]], "entity_id": [] ,"Trigger": {"text": [["induced"]], "start": [["46"]], "entity_id": [] }} ,"Effect": {"text": [["necrotizing fasciitis","myonecrosis"]], "start": [["64","78","84","98"]], "entity_id": [] },"Trigger": null } ]}
{"id": "8384030_4", "context": "To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["foscarnet-induced"]], "start": [["18"]], "entity_id": []},"Treatment": {"text": [["foscarnet"]], "start": [["11"]], "entity_id": [],"Drug": {"text": [["foscarnet"]], "start": [["11"]], "entity_id": []},"Disorder": {"text": [["severe hypomagnesemia"]], "start": [["31"]], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["hypomagnesemia"]], "start": [["31"]], "entity_id": []},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [["30"]], "entity_id": [],"value": "high"},"Subject": null}]}
{"id": "7673653_3","context": "However, the occurrence and management of akathisia induced by fluvoxamine have not been described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["akathisia"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["fluvoxamine"]],"start": [["71"]],"entity_id": [["T2"]]} ,"text": [["induced"]],"start": [["53"]],"entity_id": [["T3"]] ,"Disorder": {"text": [["akathisia"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["occurrence"]],"start": [["0"]],"entity_id": [["T4"]]} ,"Freq": {"text": [["management"]],"start": [["42"]],"entity_id": [["T5"]]} ,"Route": {"text": [["induced"]],"start": [["53"]],"entity_id": [["T3"]]} ,"Combination": [] ,"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Trigger": {"text": [],"start": [],"entity_id": [] }} ,"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": [] },"Disorder": {"text": [],"start": [],"entity_id": [] },"Gender": {"text": [],"start": [],"entity_id": [] },"Population": {"text": [],"start": [],"entity_id": [] },"Race": {"text": [],"start": [],"entity_id": [] }} ,"Effect": {"text": [],"start": [],"entity_id": [] },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": true },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "" }} ]}
{"id": "4095247_3","context": "Two of these patients, who also received the anti-emetic prochlorperazine, lost consciousness for 48-72 hours and then fully recovered","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["lost consciousness"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["the anti-emetic prochlorperazine"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["prochlorperazine"]],"start": [["41"]],"entity_id": [["T3"]]},"Duration": {"text": [["48-72 hours"]],"start": [["27"]],"entity_id": [["T4"]]},"Disorder": {"text": [["consciousness"]],"start": [["18"]],"entity_id": [["T1"]]},"Time_elapsed": {"text": [["for"]],"start": [["24"]],"entity_id": [["T5"]]},"Freq": {"text": [["for"]],"start": [["24"]],"entity_id": [["T5"]]},"Trigger": {"text": [["received"]],"start": [["40"]],"entity_id": [["T6"]]},"Route": {"text": [["the anti-emetic"]],"start": [["41"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["prochlorperazine"]],"start": [["41"]],"entity_id": [["T3"]]},"Trigger": {"text": [["received"]],"start": [["40"]],"entity_id": [["T6"]]},"event_id": "C1","event_type": "Adverse_event"}],"Dosage": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["fully recovered"]],"start": [["72"]],"entity_id": [["T7"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": "low"},"Subject": {"text": [["Two of these patients"]],"start": [[""], ["0"]],"entity_id": [["T8"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [["Two"]],"start": [[""], ["0"]],"entity_id": [["T8"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}}}]}
{"id": "16986159_1","context": "We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["developed"]],"start": [["32"]],"entity_id": []},"Subject": {"text": [["depressive patient"]],"start": [["11"]],"entity_id": [] ,"Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["depressive"]], "start": [[ "11" ]], "entity_id": []}},"Treatment": {"text": [["olanzapine"]],"start": [["91"]],"entity_id": [],"Drug": {"text": [["olanzapine"]], "start": [[ "91" ]], "entity_id": []},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null ,"Trigger": null} ,"Effect": {"text": [["mild parkinsonian signs and camptocormia"]],"start": [[ "42" ]],"entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null}]}
{"id": "7379406_3", "context": "The case report discussed is, to our knowledge, the third of its kind regarding bone fluorosis resulting from use of this nicotinic derivative", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bone fluorosis"]], "start": [["10"]], "entity_id": []}, "Treatment": {"text": [["use of this nicotinic derivative"]], "start": [["58"]], "entity_id": [], "Drug": {"text": [["nicotinic derivative"]], "start": [["58"]], "entity_id": [] },"Route": {"text": [["use"]], "start": [["58"]], "entity_id": []},"Duration": {"text": [["its kind"]], "start": [["44"]], "entity_id": []},"Disorder": {"text": [["bone fluorosis"]], "start": [["10"]], "entity_id": []},"Time_elapsed": {"text": [["resulting from"]], "start": [["35"]], "entity_id": []},"Dosage": {"text": [["this"]], "start": [["58"]], "entity_id": []},"Freq": {"text": [["third"]], "start": [["41"]], "entity_id": []},"Combination": [{"Drug": {"text": [["nicotinic derivative"]], "start": [["58"]], "entity_id": []}, "Trigger": {"text": [["use"]], "start": [["58"]], "entity_id": []},"event_id": "C1","event_type": "Treatment"}],"Trigger": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [], "start": [], "entity_id": []},"Disorder": {"text": [], "start": [], "entity_id": []},"Gender": {"text": [], "start": [], "entity_id": []},"Population": {"text": [], "start": [], "entity_id": []},"Race": {"text": [], "start": [], "entity_id": []}},"Negated": {"text": [], "start": [], "entity_id": [],"value": false},"Speculated": {"text": [], "start": [], "entity_id": [],"value": false},"Severity": {"text": [], "start": [], "entity_id": [],"value": ""},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "17266059_3","context": "We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Thrombotic Thrombocytopenic Purpura"]],"start": [["13"]],"entity_id": [["T1"]]},"Treatment": {"text": [["trimethoprim-sulfamethoxazole therapy"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["52"]],"entity_id": [["T3"]]},"Disorder": {"text": [["Thrombotic Thrombocytopenic Purpura"]],"start": [["13"]],"entity_id": [["T1"]]},"Freq": {"text": [["allergic response"]],"start": [["46"]],"entity_id": [["T4"]]},"Route": {"text": [["therapy"]],"start": [["52"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["occurring"]],"start": [["19"]],"entity_id": [["T5"]]},"Trigger": {"text": [["therapy"]],"start": [["52"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["trimethoprim-sulfamethoxazole"]],"start": [["52"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["52"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Combination"}],"Dosage": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Duration": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]}},"Subject": {"text": [["a Jehovah's Witness patient"]],"start": [["103"]],"entity_id": [["T6"]],"Age": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Disorder": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Gender": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Population": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]},"Race": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]]}},"Effect": {"text": [["Thrombotic Thrombocytopenic Purpura"]],"start": [["13"]],"entity_id": [["T1"]]},"Negated": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": false},"Speculated": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": false},"Severity": {"text": [["null"]],"start": [[""], []],"entity_id": [["null"]],"value": "null"}}]}
{"id": "12078977_1","context": "A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Subject": {"text": [["A 31-year-old female"]],"start": [[ "A" ],[ "31-year-old female" ]],"entity_id": [["T1"]],"Age": {"text": [["31"]],"start": [[ "31" ]],"entity_id": [["T2"]]},"Gender": {"text": [["female"]],"start": [[ "female" ]],"entity_id": [["T3"]]},"Population": {"text": [["A 31-year-old female"]],"start": [[ "A" ],[ "31-year-old female" ]],"entity_id": [["T1"]]},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["germ cell ovarian cancer stage Ic"]],"start": [[ "germ cell ovarian cancer stage Ic" ]],"entity_id": [["T4"]]}},"Treatment": {"text": [["combination chemotherapy with cisplatin, vinblastine and bleomycin"]],"start": [[ "combination chemotherapy with cisplatin" ]],"entity_id": [["T5"]],"Drug": {"text": [["cisplatin"],["vinblastine"],["bleomycin"]],"start": [[ "combination chemotherapy with cisplatin" ],["combination chemotherapy with cisplatin","vinblastine"]],"entity_id": [["T6"],["T7"],["T8"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["germ cell ovarian cancer stage Ic"]],"start": [[ "germ cell ovarian cancer stage Ic" ]],"entity_id": [["T4"]]},"Route": {"text": [["chemotherapy"]],"start": [[ "chemotherapy" ]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [{"Drug": {"text": [["cisplatin"]],"start": [[ "combination chemotherapy with cisplatin" ]],"entity_id": [["T6"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C1","event_type": "Treatment"},{"Drug": {"text": [["vinblastine"]],"start": [[ "combination chemotherapy with cisplatin","vinblastine" ]],"entity_id": [["T7"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C2","event_type": "Treatment"},{"Drug": {"text": [["bleomycin"]],"start": [[ "combination chemotherapy with cisplatin","vinblastine","bleomycin" ]],"entity_id": [["T8"]]},"Trigger": {"text": [],"start": [],"entity_id": []},"event_id": "C3","event_type": "Treatment"}],"Trigger": {"text": [["developed multiple episodes of grand mal seizures"]],"start": [[ "developed multiple episodes of grand mal seizures" ]],"entity_id": [["T9"]]}},"Effect": {"text": [["grand mal seizures"]],"start": [[ "grand mal seizures" ]],"entity_id": [["T10"]]},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Trigger": {"text": [["after combination chemotherapy with cisplatin, vinblastine and bleomycin"]],"start": [[ "after combination chemotherapy with cisplatin" ]],"entity_id": [["T11"]]}}]}
{"id": "16765687_1", "context": "Topiramate-induced angle-closure glaucoma (TiACG) is believed to be related to its sulfonamide moiety", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Topiramate-induced angle-closure glaucoma"]], "start": [[ "0" ]],"entity_id": [ ["T1"] ]}, "Treatment": {"text": [["Topiramate"]], "start": [[ "22" ]], "entity_id": [ ["T2"] ], "Drug": {"text": [["Topiramate"]], "start": [[ "22" ]], "entity_id": [ ["T3"] ]}, "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [["angle-closure glaucoma"]], "start": [[ "51" ]], "entity_id": [ ["T4"] ]}, "Route": {"text": [], "start": [], "entity_id": []}, "Time_elapsed": {"text": [], "start": [], "entity_id": []}, "Freq": {"text": [], "start": [], "entity_id": []}, "Trigger": {"text": [["its sulfonamide moiety"]], "start": [[ "85" ]], "entity_id": [ ["T5"] ]}, "Combination": []}, "Effect": {"text": [], "start": [], "entity_id": []}, "Negated": null, "Speculated": null, "Severity": null, "Subject": {"text": [], "start": [], "entity_id": [],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["Topiramate-induced angle-closure glaucoma"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]}}}]}
{"id": "2728526_4", "context": "This article reports the occurrence of rifampin-associated thrombocytopenia in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis._", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Negated": null, "Speculated": null, "Severity": null, "Subject": null, "Treatment": {"Drug": {"text": [["rifampin"]], "start": [["45"]], "entity_id": [["T1"]]}, "Disorder": {"text": [["thrombocytopenia"]], "start": [["22"]], "entity_id": [["T2"]]},"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": {"text": [["four-month lapse"]], "start": [["59"]], "entity_id": [["T3"]]}, "Freq": null, "Combination": null, "text": [["rifampin-associated thrombocytopenia"]], "start": [["22"]], "entity_id": [["T2"]] , "Trigger": {"text": [["occurrence"]], "start": [["0"]], "entity_id": [["T4"]]}},"Effect": null , "Trigger": {"text": [["occurrence"]], "start": [["0"]], "entity_id": [["T4"]]}}]}
{"id": "10688731_3","context": "We report a case of a scleroderma-like reaction induced by long-term administration of UFT","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["scleroderma-like reaction"]],"start": [["22"]],"entity_id": [["T1"]]},"Treatment": {"text": [["long-term administration of UFT"]],"start": [["51"]],"entity_id": [["T2"]],"Duration": {"text": [["long-term"]],"start": [["51"]],"entity_id": [["T3"]]},"Drug": {"text": [["UFT"]],"start": [["58"]],"entity_id": [["T4"]]} ,"Dosage" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Route" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Time_elapsed" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Freq" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Combination" : null ,"Disorder" : null ,"Trigger" : null },"Subject": {"text": [["We"]],"start": [[ "0" ]],"entity_id": [["T0"]],"Age" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Gender" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Population" : {"text" : [["case"]],"start" : [["0"]],"entity_id" : [["T5"]]} ,"Race" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]]} ,"Disorder" : {"text" : [["scleroderma-like reaction"]],"start" : [["22"]],"entity_id" : [["T1"]]} },"Effect" : {"text" : [["reaction"]],"start" : [["22"]],"entity_id" : [["T1"]]},"Negated" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]],"value" : false} ,"Speculated" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]],"value" : false} ,"Severity" : {"text" : [[""]],"start" : [[""],[]],"entity_id" : [[""]],"value" : ""} }]}
{"id": "16109609_4","context": "We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hemodynamically significant pericardial effusion"]],"start": [["32"]],"entity_id": [ ["T1"]]},"Subject": {"text": [["patients"]],"start": [["13"]],"entity_id": [ ["T2"]],"Population": {"text": [["four"]],"start": [[ "14"]],"entity_id": [ ["T3"]]},"Disorder": {"text": [["refractory lymphoma"]],"start": [["20"]],"entity_id": [ ["T4"]]},"Age": null,"Gender": null,"Race": null},"Treatment": {"text": [["gemcitabine"]],"start": [["88"]],"entity_id": [ ["T5"]],"Drug": {"text": [["gemcitabine"]],"start": [[ "88"]],"entity_id": [ ["T6"]]},"Dosage": null,"Duration": null,"Trigger": null,"Route": null,"Time_elapsed": null,"Freq": null,"Disorder": {"text": [["refractory lymphoma"]],"start": [["20"]],"entity_id": [ ["T4"]]},"Combination": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": {"text": [["hemodynamically significant"]],"start": [[ "32"]],"entity_id": [ ["T7"]],"value": "high"}}]}
{"id": "10679548_1", "context": "Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced", "is_mult_event": true, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["nitrofurantoin withdrawal"]], "start": [[ ]],"entity_id": [["T3"]],"Trigger": {"text": [["improved"]], "start": [[ ]],"entity_id": [["T5"]]},"Disorder": {"text": [["impaired lung function"]], "start": [[ ]],"entity_id": [["T1"]]},"Dosage": {"text": [["nil"]], "start": [[ ]],"entity_id": [["T4"]]},"Duration": {"text": [["nil"]], "start": [[ ]],"entity_id": [["T6"]]},"Route": {"text": [["nil"]], "start": [[ ]],"entity_id": [["T7"]]},"Time_elapsed": {"text": [["when"]], "start": [[ ]],"entity_id": [["T8"]]},"Freq": {"text": [["nil"]], "start": [[ ]],"entity_id": [["T9"]]},"Combination": [{"Drug": {"text": [["nitrofurantoin"]], "start": [[ ]],"entity_id": [["T10"]]},"Trigger": {"text": [["withdrawal"]], "start": [[ ]],"entity_id": [["T11"]]}, "event_id": "C1", "event_type": "Potential_therapeutic_effect"},{"Drug": {"text": [["corticosteroid"]], "start": [[ ]],"entity_id": [["T12"]]},"Trigger": {"text": [["treatment"]], "start": [[ ]],"entity_id": [["T13"]]},"event_id": "C2", "event_type": "Potential_therapeutic_effect"}],"Drug": {"text": [["nitrofurantoin"]], "start": [[ ]],"entity_id": [["T14"]]}},"Effect": {"text": [["improvement"]], "start": [[ ]],"entity_id": [["T15"]]},"Negated": null,"Speculated": null,"Severity": null,"Subject": {"text": [["Both"]],"start": [[ ]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["impaired lung function"]], "start": [[ ]],"entity_id": [["T1"]]}},"Trigger": null}]}
{"id": "17319250_2","context": "We present a case report of a patient who developed a prolonged QT while being treated with oral methadone for a chronic pain syndrome","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["prolonged QT"]],"start": [["31"]],"entity_id": [["T1"]]},"Treatment": {"text": [["oral methadone"]],"start": [["52"]],"entity_id": [["T2"]],"Drug": {"text": [["methadone"]],"start": [["52"]],"entity_id": [["T3"]]} ,"Disorder": {"text": [["chronic pain syndrome"]],"start": [["75"]],"entity_id": [["T4"]]} ,"Route": {"text": [["oral"]],"start": [["52"]],"entity_id": [["T5"]]} ,"Time_elapsed": {"text": [["while being treated"]],"start": [["21"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["prolonged"]],"start": [["31"]],"entity_id": [["T7"]]} ,"Freq": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T8"]]} ,"Combination": [{"Drug": {"text": [["oral methadone"]],"start": [["52"]],"entity_id": [["T2"]]},"Trigger": {"text": [["while being treated"]],"start": [["21"]],"entity_id": [["T6"]]} ,"event_id": "E1_1" ,"event_type": "Potential_therapeutic_effect" }] ,"Trigger": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T8"]]} ,"Dosage": {"text": [["oral"]],"start": [["52"]],"entity_id": [["T5"]]} },"Subject": {"text": [["a patient"]],"start": [["12"]],"entity_id": [["T9"]],"Age": {"text": [[""]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Disorder": {"text": [["chronic pain syndrome"]],"start": [["75"]],"entity_id": [["T4"]]},"Gender": {"text": [[""]],"start": [[""], [""]],"entity_id": [[""], [""]]},"Population": {"text": [["a patient"]],"start": [["12"]],"entity_id": [["T9"]]},"Race": {"text": [[""]],"start": [[""], [""]],"entity_id": [[""], [""]]} },"Severity": {"text": [["prolonged"]],"start": [["31"]],"entity_id": [["T7"]] ,"value": "high" },"Speculated": {"text": [["developed"]],"start": [["31"]],"entity_id": [["T8"]],"value": false },"Negated": {"text": [["not"]],"start": [[""], [""]],"entity_id": [[""], [""]],"value": false },"Effect": {"text": [["a prolonged QT"]],"start": [["31"]],"entity_id": [["T1"]]} }]}
{"id": "19897274_3","context": "In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["severe interstitial pneumonia"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["sorafenib treatment"]],"start": [["75"]],"entity_id": [["T2"]],"Disorder": {"text": [["metastatic renal cell carcinoma"]],"start": [["97"]],"entity_id": [["T3"]]},"Drug": {"text": [["sorafenib"]],"start": [["75"]],"entity_id": [["T4"]]},"Freq": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]},"Route": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]},"Time_elapsed": {"text": [["probably caused"]],"start": [["53"]],"entity_id": [["T5"]]},"Duration": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]},"Dosage": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["sorafenib"]],"start": [["75"]],"entity_id": [["T4"]]},"Trigger": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]},"event_id": "C1","event_type": "Treatment"}],"Trigger": {"text": [["treatment"]],"start": [["75"]],"entity_id": [["T2"]]}},"Subject": {"text": [["a Japanese patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Gender": {"text": [["Japanese"]],"start": [["1"]],"entity_id": [["T6"]]},"Race": {"text": [["Japanese"]],"start": [["1"]],"entity_id": [["T6"]]},"Population": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [["severe interstitial pneumonia"]],"start": [["18"]],"entity_id": [["T1"]]}},"Negated": {"text": [[]],"start": [[],[]],"entity_id": [[]],"value": false},"Speculated": {"text": [["probably caused"]],"start": [["53"]],"entity_id": [["T5"]],"value": true},"Severity": {"text": [["severe"]],"start": [["18"]],"entity_id": [["T1"]],"value": "high"},"Effect": {"text": [["severe interstitial pneumonia"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "15494638_17","context": "Neurotoxicity occurs most often with intermittent high dose 5-FU as bolus injection or 24- to 48-h infusions","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Neurotoxicity"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["intermittent high dose 5-FU"]],"start": [[ "29"]],"entity_id": [ ["T2"]],"Drug": {"text": [["5-FU"]],"start": [[ "42"]],"entity_id": [ ["T3"]]},"Dosage": {"text": [["high dose"]],"start": [[ "36"]],"entity_id": [ ["T4"]]},"Route": {"text": [["bolus injection or 24- to 48-h infusions"]],"start": [[ "52"]],"entity_id": [ ["T5"]]},"Freq": {"text": [["intermittent"]],"start": [[ "29"]],"entity_id": [ ["T6"]]},"Duration": {"text": [["high dose"]],"start": [[ "36"]],"entity_id": [ ["T4"]]},"Disorder": {"text": [["Neurotoxicity"]],"start": [[ "0"]],"entity_id": [ ["T1"]]},"Time_elapsed": {"text": [["most often"]],"start": [[ "17"]],"entity_id": [ ["T7"]]},"Trigger": {"text": [["intermittent high dose 5-FU"]],"start": [[ "29"]],"entity_id": [ ["T2"]]},"Combination": [{"Drug": {"text": [["5-FU"]],"start": [[ "42"]],"entity_id": [ ["T3"]]},"Trigger": {"text": [["intermittent high dose 5-FU"]],"start": [[ "29"]],"entity_id": [ ["T2"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": {"text": [["Neurotoxicity"]],"start": [[ "0"]],"entity_id": [ ["T1"]]}}]}
{"id": "14998226_7","context": "Lovastatin also reportedly has caused increases in INR when coadministered with warfarin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["increases"]],"start": [["36"]],"entity_id": []},"Treatment": {"text": [["Lovastatin"]],"start": [["0"]],"entity_id": [],"Drug": {"text": [["Lovastatin"]],"start": [["0"]],"entity_id": []},"Combination": [{"event_id": "C1","Drug": {"text": [["warfarin"]],"start": [["51"]],"entity_id": []},"Trigger": {"text": [["coadministered"]],"start": [["42"]],"entity_id": []},"event_type": "Treatment_interaction"}],"Trigger": {"text": [["when"]],"start": [["46"]],"entity_id": []},"Disorder": {"text": [["INR"]],"start": [["39"]],"entity_id": []},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []}},"Subject": {"text": [],"start": [],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["increases"]],"start": [["36"]],"entity_id": []},"Negated": {"text": [],"start": [],"entity_id": [],"value": false},"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""}}]}
{"id": "14998226_10","context": "Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione","is_mult_event": true,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["interact"]],"start": [[" "], ["i"]],"entity_id": []},"Treatment": {"text": [["Pravastatin"]],"start": [[], ["P"]],"entity_id": [],"Drug": {"text": [["Pravastatin"]],"start": [[], ["P"]],"entity_id": []},"Disorder": {"text": [["warfarin"]],"start": [[], ["w"]],"entity_id": []},"Combination": null,"Trigger": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"value": true,"text": [["does not appear"]],"start": [[], ["d"]],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}},{"event_id": "E2","event_type": "Adverse_event","Trigger": {"text": [["has caused"]],"start": [[], ["h"]],"entity_id": []},"Treatment": {"text": [["Pravastatin"]],"start": [[], ["P"]],"entity_id": [],"Drug": {"text": [["Pravastatin"]],"start": [[], ["P"]],"entity_id": []},"Disorder": null,"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["increased INR"]],"start": [[], ["i"]],"entity_id": []},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null}},{"event_id": "E3","event_type": "Adverse_event","Trigger": {"text": [["has caused"]],"start": [[], ["h"]],"entity_id": []},"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": null,"Disorder": {"text": [["fluindione"]],"start": [[], ["f"]],"entity_id": []},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Effect": {"text": [["increased INR"]],"start": [[], ["i"]],"entity_id": []},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Age": null,"Disorder": {"text": [["fluindione"]],"start": [[], ["f"]],"entity_id": []},"Gender": null,"Population": null,"Race": null}}]}
{"id": "8120934_2", "context": "Bromocriptine-induced schizophrenia", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Bromocriptine-induced schizophrenia"]], "start": [[ "start" ]] , "entity_id": [ ["T1"] ]},"Treatment": { "text": [["Bromocriptine"]], "start": [[ "start" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["Bromocriptine"]], "start": [[ "start" ]], "entity_id": [ ["T3"] ]} ,"Disorder": { "text": [["schizophrenia"]], "start": [[ "start" ]], "entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null ,"Trigger": null },"Subject": { "text": [["patient"]], "start": [[ "start" ]], "entity_id": [ ["T0"] ], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null },"Negated": null, "Speculated": null, "Severity": null ,"Effect": { "text": [["schizophrenia"]], "start": [[ "start" ]], "entity_id": [ ["T5"] ]} }]}
{"id": "17873198_2", "context": "Pulmonary toxicity associated with erlotinib", "is_mult_event": false, "annotations": [{"event_type": "Adverse_event", "event_id": "E1", "Trigger": {"text": [["Pulmonary toxicity"]], "start": [[ ]],"entity_id": [["T1"]]}, "Treatment": {"text": [["erlotinib"]], "start": [[ ]],"entity_id": [["T2"]],"Drug": {"text": [["erlotinib"]], "start": [[ ]],"entity_id": [["T3"]] },"Disorder": {"text": [["Pulmonary toxicity"]], "start": [[ ]],"entity_id": [["T1"]] },"Time_elapsed": {"text": [["associated with"]], "start": [[ ]],"entity_id": [["T4"]] },"Freq": {"text": [["associated with"]], "start": [[ ]],"entity_id": [["T4"]] },"Combination": [{"Drug": {"text": [["erlotinib"]], "start": [[ ]],"entity_id": [["T3"]] },"Trigger": {"text": [["associated with"]], "start": [[ ]],"entity_id": [["T4"]] },"event_type": "Adverse_event", "event_id": "E1"} ],"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Trigger": {"text": [], "start": [], "entity_id": []} },"Negated": null,"Speculated": null,"Severity": null,"Subject": null,"Effect": null}]}
{"id": "16025424_1", "context": "Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["an elderly patient"]], "start": [["48"]], "entity_id": [["T1"]],"Age": {"text": [["elderly"]], "start": [["48"]], "entity_id": [["T2"]]}, "Gender": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Population": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Race": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Disorder": {"text": [[]], "start": [[]], "entity_id": [[]]}},"Treatment": {"text": [["quetiapine"]], "start": [["19"]], "entity_id": [["T3"]], "Drug": {"text": [["quetiapine"]], "start": [["19"]], "entity_id": [["T4"]]}, "Disorder": {"text": [["diabetic ketoacidosis"]], "start": [["5"]], "entity_id": [["T5"]]}, "Dosage": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Duration": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Route": {"text": [[]], "start": [[]], "entity_id": [[]]}, "Time_elapsed": {"text": [["rapid onset"]], "start": [["0"]], "entity_id": [["T0"]]}, "Freq": {"text": [[]], "start": [[]], "entity_id": [[]]},"Combination": null, "Trigger": null},"Effect": {"text": [["diabetic ketoacidosis"]], "start": [["5"]], "entity_id": [["T5"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["severe"]], "start": [["5"]], "entity_id": [["T6"]], "value": "severe"},"Trigger": null}]}
{"id": "3815268_1","context": "A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["developed"]],"start": [[" "], ["d", "e", "v", "e", "l", "o", "p", "e", "d"], []],"entity_id": []},"Subject": {"text": [["A", "57-year-old", "woman"]],"start": [[], [], []],"Age": {"text": [["57"]],"start": [[], [], []],"entity_id": []},"Gender": {"text": [["woman"]],"start": [[], [], []],"entity_id": []},"Disorder": {"text": [["pulmonary sarcoidosis"]],"start": [[], ["p", "u", "l", "m", "o", "n", "a", "r", "y"], []],"entity_id": []},"Population": {"text": [["A", "57-year-old", "woman"]],"start": [[], [], []],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"entity_id": []},"Treatment": {"text": [["therapy"]],"start": [[], ["t", "h", "e", "r", "a", "p", "y"], []],"Drug": {"text": [["interferon beta"]],"start": [[], [], ["i"]],"entity_id": []},"Disorder": {"text": [["renal cell carcinoma"]],"start": [[], ["r", "e", "n", "a", "l"], []],"entity_id": []},"entity_id": [],"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": [],"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []},"Negated": {"text": [],"start": [],"value": false,"entity_id": []},"Speculated": {"text": [],"start": [],"value": false,"entity_id": []},"Severity": {"text": [],"start": [],"value": "","entity_id": []}}]}
{"id": "9013348_2", "context": "Mesalamine-induced hypersensitivity pneumonitis.","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Mesalamine-induced hypersensitivity pneumonitis"]], "start": [[ "Mesalamine" , "induced hypersensitivity pneumonitis" ]], "entity_id": [ ]}, "Treatment": { "text": [["Mesalamine"]], "start": [[ "Mesalamine" ]], "entity_id": [ ["T1"] ], "Drug": { "text": [["Mesalamine"]], "start": [[ "Mesalamine" ]], "entity_id": [ ["T1"] ]} ,"Disorder": { "text": [["hypersensitivity pneumonitis"]], "start": [[ "induced hypersensitivity pneumonitis" ]], "entity_id": [ ["T2"] ]} ,"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Disorder": null, "Gender": null, "Population": null, "Race": null }, "Effect": { "text": [["hypersensitivity pneumonitis"]], "start": [[ "induced hypersensitivity pneumonitis" ]], "entity_id": [ ["T2"] ]} ,"Negated": null, "Speculated": null, "Severity": null }]}
{"id": "11737689_2","context": "A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G-CSF","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["erythematous papular eruption"]],"start": [["33"]],"entity_id": [["T1"]]},"Subject": {"text": [["girl"]],"start": [["0"]],"entity_id": [["T0"]],"Disorder": {"text": [["cystic fibrosis", "cyclic neutropenia"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Age": {"text": [["7 months"]],"start": [["60"]],"entity_id": [["T3"]]} ,"Gender": {"text": [["girl"]],"start": [["0"]],"entity_id": [["T0"]]} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["therapy with G-CSF"]],"start": [["51"]],"entity_id": [["T4"]],"Drug": {"text": [["G-CSF"]],"start": [["51"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["7 months"]],"start": [["60"]],"entity_id": [["T3"]]},"Duration": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [["cystic fibrosis"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [],"start": [],"entity_id": []} ,"Combination": null },"Effect": {"text": [["erythematous papular eruption"]],"start": [["33"]],"entity_id": [["T1"]]},"Negated": null,"Speculated": null,"Severity": null}]}
{"id": "71813_3", "context": "Lichen planus and acne provoked by gold", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Lichen planus", "acne"]], "start": [[ ]], "entity_id": [["T1", "T2"]]}, "Treatment": {"text": [["gold"]], "start": [[ ]], "entity_id": [["T3"]],"Drug": {"text": [["gold"]], "start": [[ ]], "entity_id": [["T3"]]}, "Disorder": {"text": [["Lichen planus", "acne"]], "start": [[ ]], "entity_id": [["T1", "T2"]]} , "Time_elapsed": null, "Duration": null, "Dosage": null, "Freq": null, "Route": null, "Combination": null , "Trigger": null }, "Subject": {"text": [[ "patient"]],"start": [[ ]],"entity_id": [["T0"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Severity": null,"Negated": null,"Speculated": null , "Effect": {"text": [["Lichen planus", "acne"]], "start": [[ ]], "entity_id": [["T1", "T2"]]}}]}
{"id": "12153007_2", "context": "To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine", "is_mult_event": false, "annotations": [{"event_type": "Potential_therapeutic_effect", "event_id": "E1", "Trigger": {"text": [["linked"]], "start": [["42"]], "entity_id": []}, "Treatment": {"text": [["treatment of HCL with purine analogs"]], "start": [["27"]], "entity_id": [], "Drug": {"text": [["purine analogs"]], "start": [["36"]], "entity_id": []},"Disorder": {"text": [["HCL"]], "start": [["27"]], "entity_id": []},"Trigger": {"text": [["linked"]], "start": [["42"]], "entity_id": []},"Time_elapsed": {"text": [["previously"]], "start": [["7"]], "entity_id": []},"Freq": {"text": [["only two cases"]], "start": [["12"]], "entity_id": []},"Combination": [{"Drug": {"text": [["2-chlorodeoxyadenosine"]], "start": [["75"]], "entity_id": []},"Trigger": {"text": [["both with"]], "start": [["65"]], "entity_id": []},"event_id": "E1-C1","event_type": "Potential_therapeutic_effect"}], "Dosage": {"text": [], "start": [], "entity_id": []}, "Duration": {"text": [], "start": [], "entity_id": []}, "Route": {"text": [], "start": [], "entity_id": []}},"Subject":{"text":[["To the best of our knowledge"]], "start":[[ "0" ]], "entity_id":[],"Age":{"text":[], "start":[], "entity_id":[]},"Gender":{"text":[], "start":[], "entity_id":[]},"Population":{"text":[], "start":[], "entity_id":[]},"Race":{"text":[], "start":[], "entity_id":[]},"Disorder":{"text":[["AML"]], "start":[[ "48" ]], "entity_id":[]}},"Effect":{"text":[], "start":[], "entity_id":[]},"Negated":{"text":[], "start":[], "entity_id":[],"value":false},"Speculated":{"text":[], "start":[], "entity_id":[],"value":false},"Severity":{"text":[], "start":[], "entity_id":[],"value":"NA"}}]}
{"id": "12656748_3","context": "There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Negated": {"value": true,"text": [["no previous reports"]],"start": [["0"]],"entity_id": []},"Treatment": {"text": [["treatment with hydroxyurea"]],"start": [["90"]],"entity_id": [],"Drug": {"text": [["hydroxyurea"]],"start": [["90"]],"entity_id": []},"Trigger": {"text": [["the emergence of CML"]],"start": [["46"]],"entity_id": []},"Disorder": {"text": [["CML"]],"start": [["46"]],"entity_id": []},"Freq": {"text": [["no previous reports"]],"start": [["0"]],"entity_id": []},"Time_elapsed": {"text": [["during"]],"start": [["70"]],"entity_id": []},"Duration": {"text": [["treatment with hydroxyurea"]],"start": [["90"]],"entity_id": []},"Dosage": {"text": [["treatment with hydroxyurea"]],"start": [["90"]],"entity_id": []},"Route": {"text": [["treatment with hydroxyurea"]],"start": [["90"]],"entity_id": []},"Combination": null},"Subject": null,"Effect": {"text": [["the emergence of CML"]],"start": [["46"]],"entity_id": []},"Severity": null,"Speculated": null,"Trigger": {"text": [["the emergence of CML"]],"start": [["46"]],"entity_id": []}}]}
{"id": "10614572_1","context": "Intravenous valproate associated with significant hypotension in the treatment of status epilepticus","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["significant hypotension"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["Intravenous valproate"]],"start": [["0"]],"entity_id": [["T2"]],"Drug": {"text": [["valproate"]],"start": [["0"]],"entity_id": [["T3"]]},"Disorder": {"text": [["status epilepticus"]],"start": [["41"]],"entity_id": [["T4"]]},"Dosage": null,"Duration": null,"Route": null,"Time_elapsed": null,"Freq": null,"Combination": null,"Trigger": null},"Subject": {"text": [["the patient"]],"start": [[""], [], []],"entity_id": [[]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null},"Negated": null,"Speculated": null,"Severity": {"text": [["significant"]],"start": [[""], [], []],"entity_id": [[]],"value": "high"},"Effect": null}]}
{"id": "25417855_3","context": "We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["serious adverse effects"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"Drug": {"text": [["voriconazole", "everolimus"]],"start": [["44","49"]],"entity_id": [["T3","T4"]]},"Route": {"text": [["orally administered"]],"start": [["32"]],"entity_id": [["T2"]]},"Combination": [{"Drug": {"text": [["voriconazole"]],"start": [["44"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["48"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["everolimus"]],"start": [["49"]],"entity_id": [["T4"]]},"Trigger": {"text": [["interaction"]],"start": [["26"]],"entity_id": [["T6"]]},"event_id": "C2","event_type": "Adverse_event"}] ,"entity_id": [["T3"],["T4"],["T2"],["T6"]] ,"text": [["voriconazole"],["everolimus"],["orally administered"],["interaction"]],"start": [["44","49","32","26"]],"Disorder": {"text": [["renal transplant recipient"]],"start": [["74"]],"entity_id": [["T7"]]} ,"Time_elapsed": {"text": [["due to"]],"start": [["21"]],"entity_id": [["T8"]]} ,"Freq": {"text": [["report"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["serious adverse effects"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["orally administered"]],"start": [["32"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["interaction"]],"start": [["26"]],"entity_id": [["T6"]]}},"Effect": {"text": [["serious adverse effects"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Subject": {"text": [["renal transplant recipient"]],"start": [["74"]],"entity_id": [["T7"]],"Gender": {"text": [["-"]],"start": [[""],[""]],"entity_id": [["-"]]},"Age": {"text": [["-"]],"start": [[""],[""]],"entity_id": [["-"]]},"Population": {"text": [["1"]],"start": [[""],[""]],"entity_id": [["1"]]},"Race": {"text": [["-"]],"start": [[""],[""]],"entity_id": [["-"]]},"Disorder": {"text": [["renal transplant recipient"]],"start": [["74"]],"entity_id": [["T7"]]}} ,"Negated": {"text": [["not"]],"start": [[""],[""]],"entity_id": [["-"]],"value": false},"Speculated": {"text": [["report"]],"start": [["0"]],"entity_id": [["T1"]],"value": false},"Severity": {"text": [["serious"]],"start": [["0"]],"entity_id": [["T1"]],"value": "serious"}}]}
{"id": "7781845_1", "context": "Mefloquine-associated hypoglycaemia in a cachectic AIDS patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Mefloquine-associated hypoglycaemia"]], "start": [[ ]],"entity_id": [ ["T1"]]}, "Subject": {"text": [["a cachectic AIDS patient"]], "start": [[ "27" ]], "entity_id": [ ["T2"]], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": {"text": [["AIDS"]], "start": [[ "35" ]], "entity_id": [ ["T3"]]}}, "Treatment": {"text": [["Mefloquine"]], "start": [[ "0" ]], "entity_id": [ ["T0"]], "Drug": {"text": [["Mefloquine"]], "start": [[ "0" ]], "entity_id": [ ["T4"]]}, "Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null, "Combination": null , "Disorder": null}, "Negated": null, "Speculated": null, "Severity": null , "Effect": {"text": [["hypoglycaemia"]], "start": [[ "14" ]], "entity_id": [ ["T5"]]} }]}
{"id": "19226083_17", "context": "Patients who commonly require linezolid as an antimicrobial are those with complex infections where other antibiotic treatment has failed._", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["linezolid"]],"start": [["31"]],"entity_id": [["T1"]]},"Disorder": {"text": [["antimicrobial"]],"start": [["24"]],"entity_id": [["T2"]]},"Duration": {"text": [["common requirement"]],"start": [["0"]],"entity_id": [["T3"]]},"Trigger": {"text": [["require"]],"start": [["20"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["as", "an"]],"start": [["33","36"]],"entity_id": [["T5","T6"]]},"Route": {"text": [["treatment"]],"start": [["42"]],"entity_id": [["T7"]]},"Dosage": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Freq": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"text": [["Patients who commonly require linezolid as an antimicrobial"]],"start": [[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]],"entity_id": [["T3","T1","T2","T4","T5","T6","T7"]] ,"Combination": null},"Subject": {"text": [["Patients"]],"start": [["0"]],"entity_id": [["T8"]],"Age": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Gender": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Population": {"text": [["common requirement"]],"start": [["0"]],"entity_id": [["T3"]]},"Race": {"text": [[]],"start": [[],[]],"entity_id": [[]]},"Disorder": {"text": [["complex infections"]],"start": [["55"]],"entity_id": [["T9"]]}},"Negated": null,"Speculated": null,"Severity": null,"Effect": {"text": [["failure"]],"start": [["103"]],"entity_id": [["T10"]]},"Trigger": {"text": [["where"]],"start": [["72"]],"entity_id": [["T11"]]}}]}
{"id": "6245286_2", "context": "In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days.\n", "is_mult_event": true, "annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["cytarabine"]],"start": [["127"]],"entity_id": []},"Dosage": {"text": [["300 mg"]],"start": [["115"]],"entity_id": []},"Route": {"text": [["administration"]],"start": [["120"]],"entity_id": []},"Duration": {"text": [["five days"]],"start": [["133"]],"entity_id": []},"Freq": {"text": [["daily"]],"start": [["115"]],"entity_id": []}, "entity_id": [], "text": [["cutaneous herpes zoster"]],"start": [["65"]],"Trigger": {"text": [["developed"]],"start": [["52"]],"entity_id": []}, "Time_elapsed": {"text": [["after"]],"start": [["46"]],"entity_id": []}, "Disorder": {"text": [["infection"]],"start": [["33"]],"entity_id": []}, "Combination": [{"Drug": {"text": [["cytarabine"]],"start": [["127"]],"entity_id": []},"Trigger": {"text": [["administration"]],"start": [["120"]],"entity_id": []}, "event_id": "C1", "event_type": "Treatment"}]}, "Subject": {"text": [["three of these patients"]],"start": [[""], ["0"]],"entity_id": [], "Population": {"text": [["three"]],"start": [[""], ["0"]],"entity_id": []}, "Age": {"text": [],"start": [],"entity_id": []}, "Gender": {"text": [],"start": [],"entity_id": []}, "Race": {"text": [],"start": [],"entity_id": []}, "Disorder": {"text": [["infection"]],"start": [["33"]],"entity_id": []}}, "Negated": {"text": [],"start": [],"entity_id": [], "value": false}, "Speculated": {"text": [],"start": [],"entity_id": [], "value": false}, "Severity": {"text": [],"start": [],"entity_id": [], "value": ""}, "Trigger": {"text": [["developed"]],"start": [["52"]],"entity_id": []}, "Effect": {"text": [["cutaneous herpes zoster"]],"start": [["65"]],"entity_id": []}}]}
{"id": "17655517_9","context": "Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["linezolid"]],"start": [["0-14"]],"entity_id": [["T1"]] ,"Dosage": {"text": [["more than 28 days"]],"start": [["15-29"]],"entity_id": [["T2"]] },"Duration": {"text": [["more than 28 days"]],"start": [["15-29"]],"entity_id": [["T2"]] },"Trigger": {"text": [["monitored"]],"start": [["77-82"]],"entity_id": [["T3"]]},"Disorder": {"text": [["signs of peripheral and optic neuropathy"]],"start": [["43-66"]],"entity_id": [["T4"]] },"Freq": {"text": [["more than 28 days"]],"start": [["15-29"]],"entity_id": [["T2"]] },"Route": {"text": [["receiving"]],"start": [["15-22"]],"entity_id": [["T2"]] },"Time_elapsed": {"text": [["more than 28 days"]],"start": [["15-29"]],"entity_id": [["T2"]] },"Drug": {"text": [["linezolid"]],"start": [["0-14"]],"entity_id": [["T1"]] },"Combination": null },"Subject": {"text": [["Patients"]],"start": [["0-7"]],"entity_id": [["T5"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": null },"Negated": null,"Speculated": null,"Severity": null ,"Effect": null ,"Trigger": null }] }
{"id": "19892516_2","context": "Ciprofloxacin-induced hemorrhagic vasculitis is a rare side effect","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Ciprofloxacin-induced hemorrhagic vasculitis"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Effect": {"text": [["Ciprofloxacin-induced hemorrhagic vasculitis"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]},"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []},"Severity": {"value": "low" ,"text": [],"start": [],"entity_id": []},"Subject": {"text": [],"start": [],"entity_id": [],"Population": {"text": [],"start": [],"entity_id": []},"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Treatment": {"text": [],"start": [],"entity_id": [],"Drug": {"text": [["Ciprofloxacin"]],"start": [[ "0" ]] ,"entity_id": [ ["T2"] ]},"Disorder": {"text": [["hemorrhagic vasculitis"]],"start": [[ "13" ]] ,"entity_id": [ ["T3"] ]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": null} }]}
{"id": "15028964_7","context": "Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection, we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements, particularly if concomitantly treated with amiodarone","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["thyroid disorders"]],"start": [["0"]],"entity_id": [["T1"]]},"Negated": {"value": false ,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false ,"text": [],"start": [],"entity_id": []},"Severity": {"value": "","text": [],"start": [],"entity_id": []},"Subject": {"text": [["any patient"]],"start": [["125"]],"entity_id": [["T3"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [["thyroid disorders"]],"start": [["0"]],"entity_id": [["T1"]]}},"Treatment": {"text": [["warfarin"]],"start": [["150"]],"entity_id": [["T4"]],"Drug": {"text": [["warfarin"]],"start": [["150"]],"entity_id": [["T4"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null ,"Trigger": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "10367184_1", "context": "Myotonia associated with sarcoidosis: marked exacerbation with pravastatin", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["marked exacerbation"]], "start": [["36"]], "entity_id": []}, "Treatment": {"text": [["pravastatin"]], "start": [["59"]], "entity_id": [], "Drug": {"text": [["pravastatin"]], "start": [["59"]], "entity_id": []} ,"Disorder":{"text":[["sarcoidosis"]],"start":[["0"]],"entity_id":[]},"Time_elapsed":{"text":[["marked exacerbation"]],"start":[["36"]],"entity_id":[]},"Dosage":{"text":[["N/A"]],"start":[[]],"entity_id":[]},"Duration":{"text":[["N/A"]],"start":[[]],"entity_id":[]},"Route":{"text":[["N/A"]],"start":[[]],"entity_id":[]},"Freq":{"text":[["N/A"]],"start":[[]],"entity_id":[]},"Combination":null,"Trigger":{"text":[["associated with"]],"start":[["14"]],"entity_id":[]}},"Effect":{"text":[["Myotonia"]],"start":[["0"]],"entity_id":[]},"Negated":null,"Speculated":null,"Severity":null,"Subject":{"text":[["Myotonia"]],"start":[["0"]],"entity_id":[],"Age":null,"Disorder":{"text":[["Myotonia","associated with sarcoidosis"]],"start":[["0"]],"entity_id":[]},"Gender":null,"Population":null,"Race":null}}]}
{"id": "7668127_5","context": "This observation questions the suitability of aspirin as prophylaxis for vascular disease in patients with meningiomas","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["aspirin"]],"start": [["7668127_5.6"]],"entity_id": [["T1"]] ,"Disorder": {"text": [["vascular disease"]],"start": [["7668127_5.33"]],"entity_id": [["T2"]]} ,"Trigger": {"text": [["prophylaxis"]],"start": [["7668127_5.18"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["as"]],"start": [["7668127_5.44"]],"entity_id": [["T4"]]} ,"Dosage": {"text": [["suitable"]],"start": [["7668127_5.44"]],"entity_id": [["T5"]]} ,"Combination": [{"Drug": {"text": [["aspirin"]],"start": [["7668127_5.6"]],"entity_id": [["T1"]]} ,"Trigger": {"text": [["prophylaxis"]],"start": [["7668127_5.18"]],"entity_id": [["T3"]]} ,"event_id": "C1","event_type": "Combination"} ],"Time_elapsed": {"text": [["in patients with meningiomas"]],"start": [["7668127_5.54"]],"entity_id": [["T6"]]} ,"Route": {"text": [["for vascular disease"]],"start": [["7668127_5.29"]],"entity_id": [["T2"]]} ,"Duration": {"text": [["as prophylaxis"]],"start": [["7668127_5.18"]],"entity_id": [["T3"]]} ,"Drug": {"text": [["aspirin"]],"start": [["7668127_5.6"]],"entity_id": [["T1"]]}} ,"Subject": {"text": [["patients with meningiomas"]],"start": [["7668127_5.54"]],"entity_id": [["T6"]],"Disorder": {"text": [["meningiomas"]],"start": [["7668127_5.54"]],"entity_id": [["T7"]]} ,"Age": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": ""} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["prophylaxis"]],"start": [["7668127_5.18"]],"entity_id": [["T3"]]} }]}
{"id": "8360712_2", "context": "Delayed neurotoxicity of intraventricular interleukin-2: a case report", "is_mult_event": false, "annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["neurotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]},"Treatment": {"text": [["intraventricular interleukin-2"]],"start": [["22"]],"entity_id": [["T2"]],"Drug": {"text": [["interleukin-2"]],"start": [["22"]],"entity_id": [["T3"]]} ,"Route": {"text": [["intraventricular"]],"start": [["22"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["neurotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [["Delayed"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Trigger": {"text": [["Delayed"]],"start": [["0"]],"entity_id": [["T5"]]} ,"Freq": {"text": [["case report"]],"start": [["54"]],"entity_id": [["T6"]]} ,"Combination": [{"Drug": {"text": [["interleukin-2"]],"start": [["22"]],"entity_id": [["T3"]]},"Trigger": {"text": [["Delayed"]],"start": [["0"]],"entity_id": [["T5"]]} ,"event_id": "C1" ,"event_type": "Adverse_event" }],"Dosage": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []}} ,"Subject": {"text": [["a case report"]],"start": [["54"]],"entity_id": [["T6"]],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false },"Severity": {"text": [["neurotoxicity"]],"start": [["18"]],"entity_id": [["T1"]], "value": "high" },"Effect": {"text": [["neurotoxicity"]],"start": [["18"]],"entity_id": [["T1"]]}}]}
{"id": "7776854_4","context": "We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Trigger": {"text": [["benzarone"]],"start": [["21"]],"entity_id": [["T1"]]},"Treatment": {"text": [["benzarone"]],"start": [["21"]],"entity_id": [["T1"]],"Drug": {"text": [["benzarone"]],"start": [["21"]],"entity_id": [["T1"]]},"Disorder": {"text": [["hepatotoxicity"]],"start": [["39"]],"entity_id": [["T2"]]},"Freq": {"text": [["usually"]],"start": [["55"]],"entity_id": [["T3"]]},"Duration": {"text": [["chronic active hepatitis"]],"start": [["70"]],"entity_id": [["T4"]]},"Dosage": {"text": [["stress"]],"start": [["7"]],"entity_id": [["T5"]]},"Route": {"text": [["cause"]],"start": [["33"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["resembles"]],"start": [["57"]],"entity_id": [["T7"]]},"Combination": [{"Drug": {"text": [["benzarone"]],"start": [["21"]],"entity_id": [["T1"]]},"Trigger": {"text": [["cause"]],"start": [["33"]],"entity_id": [["T6"]]},"event_type": "Adverse_event","event_id": "E2"}],"Trigger": {"text": [["cause"]],"start": [["33"]],"entity_id": [["T6"]]}},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Severity": {"value": "severe","text": [],"start": [],"entity_id": []},"Subject": {"text": [["We"]],"start": [[""],[]],"entity_id": [],"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []}},"Effect": {"text": [["hepatotoxicity"]],"start": [["39"]],"entity_id": [["T2"]]}}]}
{"id": "3579660_3","context": "We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D-penicillamine, and suffered sudden neurologic deterioration coincident with therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"Drug": {"text": [["D-penicillamine"]],"start": [["was treated with D-penicillamine,"], [".", "and suffered sudden neurologic deterioration coincident with therapy."]],"entity_id": [["T1"]]} ,"Disorder": {"text": [["Wilson's disease"]],"start": [[ "We describe a patient with Wilson's disease who presented with neurologic disease,"]],"entity_id": [["T2"]]} ,"entity_id": [["T1"], ["T2"]] ,"Trigger": {"text": [["coincident with therapy"]],"start": [[".", "and suffered sudden neurologic deterioration coincident with therapy."]],"entity_id": [["T3"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"text": [["D-penicillamine"]],"start": [[ "was treated with D-penicillamine,"]]},"Subject": {"text": [["a patient"]],"start": [[ "We describe a patient with Wilson's disease who presented with neurologic disease,"]],"entity_id": [["T0"]] ,"Age": null,"Disorder": {"text": [["Wilson's disease"]],"start": [[ "We describe a patient with Wilson's disease who presented with neurologic disease,"]],"entity_id": [["T2"]]} ,"Gender": null,"Population": null,"Race": null },"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Trigger": {"text": [["sudden neurologic deterioration"]],"start": [[ ".", "and suffered sudden neurologic deterioration coincident with therapy."]],"entity_id": [["T4"]] }} ]}
{"id": "16889287_3", "context": "We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Subject": {"text": [["21-year-old female patient"]], "start": [["15"]], "entity_id": [["T1"]],"Age": {"text": [["21"]], "start": [["15"]], "entity_id": [["T2"]]}, "Gender": {"text": [["female"]], "start": [["20"]], "entity_id": [["T3"]]},"Disorder": {"text": [["dapsone hypersensitivity syndrome"]], "start": [["47"]], "entity_id": [["T4"]]},"Population": {"text": [["a"]], "start": [["15"]], "entity_id": [["T1"]]},"Race": {"text": [], "start": [], "entity_id": []}},"Treatment": {"text": [["dapsone"]], "start": [["70"]], "entity_id": [["T5"]],"Drug": {"text": [["dapsone"]], "start": [["70"]], "entity_id": [["T5"]]},"Disorder": {"text": [["dapsone hypersensitivity syndrome"]], "start": [["70"]], "entity_id": [["T5"]]},"Dosage": {"text": [], "start": [], "entity_id": []},"Duration": {"text": [], "start": [], "entity_id": []},"Route": {"text": [], "start": [], "entity_id": []},"Time_elapsed": {"text": [], "start": [], "entity_id": []},"Freq": {"text": [], "start": [], "entity_id": []},"Combination": null,"Trigger": null},"Effect": {"text": [["dapsone hypersensitivity syndrome"]], "start": [["47"]], "entity_id": [["T4"]]},"Negated": null,"Speculated": null,"Severity": null,"Trigger": null}]}
{"id": "2309833_3","context": "Insulin-dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Insulin-dependent diabetes mellitus"]],"start": [[ "0" ]],"entity_id": [ ]},"Subject": {"text": [["a young woman"]],"start": [[ "41" ]],"entity_id": [ ],"Age": {"text": [["young"]],"start": [[ "41" ]],"entity_id": [ ]},"Gender": {"text": [["woman"]],"start": [[ "45" ]],"entity_id": [ ]} ,"Disorder": {"text": [["Insulin-dependent diabetes mellitus"]],"start": [[ "0" ]],"entity_id": [ ]} ,"Population": {"text": [["a young woman"]],"start": [[ "41" ]],"entity_id": [ ]} ,"Race": {"text": [],"start": [],"entity_id": []} },"Treatment": {"text": [["danazol"]],"start": [[ "92" ]],"entity_id": [ ],"Drug": {"text": [["danazol"]],"start": [[ "92" ]],"entity_id": [ ]},"Disorder": {"text": [["pelvic endometriosis"]],"start": [[ "100" ]],"entity_id": [ ]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [["8 weeks"]],"start": [[ "55" ]],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []} ,"Trigger": {"text": [["the initiation"]],"start": [[ "70" ]],"entity_id": []} ,"Combination": null} ,"Effect": {"text": [],"start": [],"entity_id": []} ,"Negated": null ,"Speculated": null ,"Severity": null } ]}
{"id": "18176653_1", "context": "Oral adverse effects due to the use of Nevirapine", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Oral adverse effects"]], "start": [[ ] ], "entity_id": [ ["T1" ] ]}, "Treatment": {"text": [["the use of Nevirapine"]], "start": [[ ] ], "entity_id": [ ["T2" ] ], "Drug": {"text": [["Nevirapine"]], "start": [[ ]], "entity_id": [["T3"] ] } , "Freq": null, "Duration": null, "Route": null, "Time_elapsed": null, "Disorder": null , "Dosage": null , "Combination": null , "Trigger": null }, "Effect": { "text": [["Oral adverse effects"]], "start": [[ ]], "entity_id": [["T1"] ]} , "Negated": null, "Speculated": null, "Severity": null, "Subject": { "text": [], "start": [], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null } }]}
{"id": "19299370_4","context": "A case of probable enoxaparin-induced hepatotoxicity is described","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["enoxaparin-induced hepatotoxicity"]],"start": [["28"]],"entity_id": [["T1"]]},"Effect": {"text": [["enoxaparin-induced hepatotoxicity"]],"start": [["28"]],"entity_id": [["T1"]]},"Treatment": {"text": [["enoxaparin"]],"start": [["7"]],"entity_id": [["T2"]] ,"Drug": {"text": [["enoxaparin"]],"start": [["7"]],"entity_id": [["T2"]]} ,"Disorder": {"text": [["hepatotoxicity"]],"start": [["28"]],"entity_id": [["T1"]]} ,"Time_elapsed": {"text": [],"start": [],"entity_id": []} ,"Duration": {"text": [],"start": [],"entity_id": []} ,"Freq": {"text": [],"start": [],"entity_id": []} ,"Route": {"text": [],"start": [],"entity_id": []} ,"Dosage": {"text": [],"start": [],"entity_id": []} ,"Combination": null ,"Trigger": {"text": [["enoxaparin"]],"start": [["7"]],"entity_id": [["T2"]]} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null ,"Gender": null ,"Population": null ,"Race": null ,"Disorder": null },"Negated": null ,"Speculated": null ,"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "probable" }} ] }
{"id": "15383642_9","context": "Tizanidine was used again after her BP had stabilized, but did not produce similar problems","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Potential_therapeutic_effect","Treatment": {"text": [["Tizanidine"]],"start": [[ "0" ]],"entity_id": [ ["T1"] ],"Drug": { "text": [["Tizanidine"]], "start": [[ "0" ]], "entity_id": [ ["T1"] ]} ,"Disorder": { "text": [["similar problems"]], "start": [[ "62" ]], "entity_id": [ ["T2"] ]} ,"Dosage": null, "Duration": null, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Effect": null, "Negated": { "text": [["not"]], "start": [[ "51" ]], "entity_id": [ ["T3"] ], "value": true }, "Speculated": null, "Severity": null ,"Subject": { "text": [["her"]], "start": [[ "24" ]], "entity_id": [ ["T4"] ], "Age": null, "Disorder": { "text": [["similar problems"]], "start": [[ "62" ]], "entity_id": [ ["T2"] ]}, "Gender": null, "Population": null, "Race": null }, "Trigger": { "text": [["produce"]], "start": [[ "45" ]], "entity_id": [ ["T5"] ]} }] }
{"id": "424824_3","context": "It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["methotrexate"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate"]],"start": [["0"]],"entity_id": [["T1"]],"Disorder": {"text": [["inducing diffuse interstitial pulmonary fibrosis"]],"start": [["58"]],"entity_id": [["T3"]]},"Dosage": {"text": [],"start": [],"entity_id": []},"Duration": {"text": [],"start": [],"entity_id": []},"Route": {"text": [],"start": [],"entity_id": []},"Time_elapsed": {"text": [],"start": [],"entity_id": []},"Freq": {"text": [],"start": [],"entity_id": []},"Combination": null,"Trigger": {"text": [],"start": [],"entity_id": []},"Drug": {"text": [],"start": [],"entity_id": []}},"Negated": null,"Speculated": {"text": [],"start": [],"entity_id": [],"value": false},"Severity": {"text": [],"start": [],"entity_id": [],"value": ""},"Subject": null,"Effect": {"text": [],"start": [],"entity_id": []}}]}
{"id": "8816294_1","context": "The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate","is_mult_event": true,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["delayed encephalopathy"]],"start": [[ "0" ]] ,"entity_id": [ ["T1"] ]} ,"Treatment": { "text": [["intrathecal methotrexate"]], "start": [[ "112" ]], "entity_id": [ ["T2"] ], "Drug": { "text": [["methotrexate"]], "start": [[ "112" ]], "entity_id": [ ["T3"] ]} ,"Time_elapsed": { "text": [[ "9 and 22 months" ]], "start": [[ "40" ]], "entity_id": [ ["T4"] ]} ,"Dosage": null, "Duration": null, "Route": null, "Disorder": null, "Freq": null ,"Combination": null ,"Trigger": null }, "Effect": null ,"Negated": null, "Speculated": null, "Severity": null, "Subject": null }] }
{"id": "3565435_2","context": "Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["hypersensitivity reaction"]],"start": [["23"]],"entity_id": [["T1"]]},"Treatment": {"text": [["ibuprofen"]],"start": [["7"]],"entity_id": [["T2"]],"Dosage": {"text": [["prolonged"]],"start": [["48"]],"entity_id": [["T3"]]},"Route": {"text": [["oral"]],"start": [["61"]],"entity_id": [["T4"]]},"Time_elapsed": {"text": [["occurring"]],"start": [["35"]],"entity_id": [["T5"]]},"Freq": {"text": [["after"]],"start": [["19"]],"entity_id": [["T6"]]},"Disorder": {"text": [["systemic"]],"start": [["11"]],"entity_id": [["T7"]]},"Drug": {"text": [["ibuprofen"]],"start": [["7"]],"entity_id": [["T2"]]},"Duration": {"text": [["prolonged"]],"start": [["48"]],"entity_id": [["T3"]]},"Trigger": {"text": [["therapy"]],"start": [["45"]],"entity_id": [["T8"]]},"Combination": [{"Drug": {"text": [["ibuprofen"]],"start": [["7"]],"entity_id": [["T2"]]},"Trigger": {"text": [["therapy"]],"start": [["45"]],"entity_id": [["T8"]]},"event_id": "C1","event_type": "Adverse_event"}]},"Subject": {"text": [["patient"]],"start": [["0"]],"entity_id": [["T0"]],"Age": {"text": [["adult"]],"start": [["4"]],"entity_id": [["T9"]]},"Gender": {"text": [["male/female"]],"start": [["2"]],"entity_id": [["T10"]]},"Population": {"text": [["single"]],"start": [["0"]],"entity_id": [["T0"]]},"Disorder": {"text": [["severe systemic hypersensitivity reaction"]],"start": [["0"]],"entity_id": [["T1"]]},"Race": {"text": [["caucasian"]],"start": [["2"]],"entity_id": [["T11"]]}},"Severity": {"text": [["severe"]],"start": [["6"]],"entity_id": [["T12"]],"value": "high"},"Negated": {"value": false,"text": [],"start": [],"entity_id": []},"Speculated": {"value": false,"text": [],"start": [],"entity_id": []},"Effect": {"text": [["severe systemic hypersensitivity reaction"]],"start": [["0"]],"entity_id": [["T1"]]}}]}
{"id": "11250985_2","context": "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["spironolactone added to conventional treatment"]],"start": [["In patients with chronic heart failure,","spironolactone added to conventional treatment"]],"entity_id": [["T1"],["T2"]],"Drug": {"text": [["spironolactone"]],"start": [["spironolactone added to conventional treatment"]],"entity_id": [["T3"]]},"Disorder": {"text": [["chronic heart failure"]],"start": [["In patients with chronic heart failure,"]],"entity_id": [["T4"]]},"Route": {"text": [["added to conventional treatment"]],"start": [["added to conventional treatment"]],"entity_id": [["T5"]]},"Freq": {"text": [["may lead to"]],"start": [["may lead to"]],"entity_id": [["T6"]]},"Trigger": {"text": [["may lead to"]],"start": [["may lead to"]],"entity_id": [["T6"]]},"Time_elapsed": {"text": [["to"]],"start": [["to"]],"entity_id": [["T7"]]},"Duration": {"text": [["serious"]],"start": [["serious"]],"entity_id": [["T8"]]},"Dosage": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Combination": [{"Drug": {"text": [["spironolactone"]],"start": [["spironolactone added to conventional treatment"]],"entity_id": [["T3"]]},"Trigger": {"text": [["added"]],"start": [["added"]],"entity_id": [["T5"]]},"event_type": "Adverse_event","event_id": "E2"}]},"Effect": {"text": [["hyperkalaemia"]],"start": [["hyperkalaemia"]],"entity_id": [["T9"]]},"Negated": {"text": [[]],"start": [[""]],"entity_id": [[]],"value": false},"Speculated": {"text": [[]],"start": [[""]],"entity_id": [[]],"value": false},"Severity": {"text": [["serious"]],"start": [["serious"]],"entity_id": [["T8"]],"value": "high"},"Subject": {"text": [["In patients with chronic heart failure"]],"start": [["In patients with chronic heart failure"]],"entity_id": [["T0"]],"Age": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Disorder": {"text": [["chronic heart failure"]],"start": [["chronic heart failure"]],"entity_id": [["T4"]]},"Gender": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Population": {"text": [[]],"start": [[""]],"entity_id": [[]]},"Race": {"text": [[]],"start": [[""]],"entity_id": [[]]}},"Trigger": {"text": [["may lead to"]],"start": [["may lead to"]],"entity_id": [["T6"]]}}]}
{"id": "10516999_2","context": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["acute hyperphosphatemia"]],"start": [["0"]],"entity_id": [["T1"]]},"Treatment": {"text": [["rectal administration of sodium phosphate and sodium biphosphate (Fleet enema)"]],"start": [["41"]],"entity_id": [["T2"]],"Drug": {"text": [["sodium phosphate", "sodium biphosphate"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Freq": {"text": [["rectal"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Route": {"text": [["administration"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Combination": [{"Drug": {"text": [["sodium phosphate"]],"start": [["41"]],"entity_id": [["T3"]]},"Trigger": {"text": [["and"]],"start": [["51"]],"entity_id": [["T3"]]},"event_type": "Adverse_event","event_id": "E1-1"}],"Time_elapsed": {"text": [["secondary"]],"start": [["20"]],"entity_id": [["T4"]]} ,"Disorder": {"text": [["acute hyperphosphatemia"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Duration": {"text": [["acute"]],"start": [["0"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["administration"]],"start": [["41"]],"entity_id": [["T3"]]} ,"Trigger": {"text": [["report"]],"start": [["0"]],"entity_id": [["T0"]]} } , "Subject": {"text": [["We"]],"start": [[""], ["0"]],"entity_id": [["T0"]] ,"Age": {"text": [],"start": [],"entity_id": []},"Gender": {"text": [],"start": [],"entity_id": []},"Population": {"text": [],"start": [],"entity_id": []},"Race": {"text": [],"start": [],"entity_id": []},"Disorder": {"text": [],"start": [],"entity_id": []} } , "Effect": {"text": [["acute hyperphosphatemia"]],"start": [[""], ["0"]],"entity_id": [["T1"]] },"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false},"Severity": {"text": [["acute"]],"start": [[""], ["0"]],"entity_id": [["T1"]],"value": "Low"} } ] }
{"id": "12365708_4", "context": "Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Visual changes"]], "start": [["secondary to initiation of amiodarone" , "Visual changes" ]], "entity_id": [ ]},"Treatment": {"text": [["amiodarone"]], "start": [[ "initiation of amiodarone" ]], "entity_id": [ ] , "Drug": { "text": [["amiodarone"]], "start": [[ "initiation of amiodarone" ]], "entity_id": [] } , "Disorder": { "text": [["Visual changes"]], "start": [[ "Visual changes" ]], "entity_id": [] } , "Time_elapsed": { "text": [], "start": [], "entity_id": [] } , "Duration": { "text": [], "start": [], "entity_id": [] } , "Freq": { "text": [], "start": [], "entity_id": [] } , "Route": { "text": [], "start": [], "entity_id": [] } , "Trigger": { "text": [], "start": [], "entity_id": [] } , "Combination": [] , "Dosage": { "text": [], "start": [], "entity_id": [] } } , "Effect": { "text": [], "start": [], "entity_id": [] } , "Negated": null , "Speculated": null , "Severity": { "text": [], "start": [], "entity_id": [] , "value": "" } , "Subject": { "text": [], "start": [], "entity_id": [] , "Age": null , "Disorder": { "text": [["Visual changes"]], "start": [[ "Visual changes" ]], "entity_id": [] } , "Gender": null , "Population": null , "Race": null }}]}
{"id": "15307435_1","context": "Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["life-threatening hypoglycaemia"]],"start": [["0"]],"entity_id": [ ["T1"]]},"Treatment": {"text": [["sulfadoxine-pyrimethamine"]],"start": [["81"]],"entity_id": [ ["T2"]],"Drug": {"text": [["sulfadoxine", "pyrimethamine"]],"start": [["81"]],"entity_id": [ ["T3"], ["T4"]]} ,"Disorder": {"text": [["antimalarial drug"]],"start": [["94"]],"entity_id": [ ["T5"]]} ,"Route": {"text": [["associated with"]],"start": [["64"]],"entity_id": [ ["T6"]]} ,"Time_elapsed": {"text": [["Case report"]],"start": [["0"]],"entity_id": [ ["T0"]]} ,"Duration": {"text": [["commonly used"]],"start": [["79"]],"entity_id": [ ["T7"]]} ,"Freq": {"text": [["a"]],"start": [["80"]],"entity_id": [ ["T8"]]} ,"Combination": [{"Drug": {"text": [["isoniazid"]],"start": [["64"]],"entity_id": [ ["T6"]]} ,"Trigger": {"text": [["therapy"]],"start": [["64"]],"entity_id": [ ["T6"]]} ,"event_id": "C1","event_type": "Potential_therapeutic_effect"} ],"Trigger": {"text": [["associated with"]],"start": [["64"]],"entity_id": [ ["T6"]]} ,"Dosage": {"text": [],"start": [],"entity_id": []} },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": {"text": [],"start": [],"entity_id": []} ,"Gender": {"text": [],"start": [],"entity_id": []} ,"Population": {"text": [],"start": [],"entity_id": []} ,"Race": {"text": [],"start": [],"entity_id": []} ,"Disorder": {"text": [],"start": [],"entity_id": []} },"Severity": {"text": [],"start": [],"entity_id": [] ,"value": "high"} ,"Negated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Speculated": {"text": [],"start": [],"entity_id": [] ,"value": false} ,"Effect": {"text": [["hypoglycaemia"]],"start": [["22"]],"entity_id": [ ["T9"]]}}]}
{"id": "12811715_2","context": "Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate","is_mult_event": false,"annotations": [{"event_type": "Adverse_event","event_id": "E1","Trigger": {"text": [["Diphenhydramine-induced wide complex dysrhythmia"]],"start": [[ "0" ]] ,"entity_id": [["T1"] ]},"Treatment": {"text": [["treatment with sodium bicarbonate"]],"start": [[ "56" ]],"entity_id": [["T2"] ],"Drug": {"text": [["sodium bicarbonate"]],"start": [[ "56" ]],"entity_id": [["T3"] ]},"Disorder": {"text": [["Diphenhydramine-induced wide complex dysrhythmia"]],"start": [[ "0" ]],"entity_id": [["T1"] ]},"Time_elapsed": {"text": [["responds to"]],"start": [[ "44" ]],"entity_id": [["T4"] ]},"Freq": {"text": [["treatment"]],"start": [[ "56" ]],"entity_id": [["T2"] ]},"Dosage": {"text": [["treatment"]],"start": [[ "56" ]],"entity_id": [["T2"] ]},"Route": {"text": [["treatment"]],"start": [[ "56" ]],"entity_id": [["T2"] ]},"Duration": {"text": [["treatment"]],"start": [[ "56" ]],"entity_id": [["T2"] ]},"Combination": null,"Trigger": null},"Effect": null,"Negated": null,"Speculated": null,"Severity": null,"Subject": null}]}
{"id": "21597286_6","context": "Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure","is_mult_event": false,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Trigger": {"text": [["drug-drug interaction"]],"start": [["32"]],"entity_id": [["T1"]]},"Treatment": {"text": [["methotrexate", "proton pump inhibitors (PPI)"]],"start": [["51","75"]],"entity_id": [["T2","T3"]],"Drug": {"text": [["methotrexate","proton pump inhibitors"]],"start": [["51","75"]],"entity_id": [["T2","T3"]]} ,"Disorder": {"text": [["renal failure"]],"start": [["116"]],"entity_id": [["T4"]]} ,"Trigger": {"text": [["drug-drug interaction"]],"start": [["32"]],"entity_id": [["T1"]]} ,"Combination": [{"Drug": {"text": [["methotrexate"]],"start": [["51"]],"entity_id": [["T2"]]},"Trigger": {"text": [["and"]],"start": [["63"]],"entity_id": [["T5"]]},"event_id": "C1","event_type": "Adverse_event"},{"Drug": {"text": [["proton pump inhibitors (PPI)"]],"start": [["75"]],"entity_id": [["T3"]]},"Trigger": {"text": [["drug-drug interaction"]],"start": [["32"]],"entity_id": [["T1"]]},"event_id": "C2","event_type": "Adverse_event"}],"Freq": {"text": [["have permitted us to suggest"]],"start": [["28"]],"entity_id": [["T0"]]} ,"Time_elapsed": {"text": [["was"]],"start": [["104"]],"entity_id": [["T6"]]} ,"Duration": {"text": [["this"]],"start": [["102"]],"entity_id": [["T4"]]} ,"Route": {"text": [["between"]],"start": [["33"]],"entity_id": [["T1"]]} ,"Dosage": {"text": [["methotrexate and proton pump inhibitors (PPI)"]],"start": [["51","75"]],"entity_id": [["T2","T3"]]} },"Negated": null,"Speculated": null,"Severity": {"text": [["renal failure"]],"start": [["116"]],"entity_id": [["T4"]] ,"value": "High"} ,"Subject": null ,"Effect": {"text": [["renal failure"]],"start": [["116"]],"entity_id": [["T4"]]}}]}
{"id": "10679548_7", "context": "We suggest that the previous classification of nitrofurantoin induced lung injury into 'acute' and 'chronic' injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged.', ","is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["nitrofurantoin induced lung injury"]], "start": [["16", "17"]], "entity_id": [ ] , "Trigger": {"text": [["classification"]], "start": [["1", "2"]], "entity_id": [ ] } , "Disorder": {"text": [["acute injury", "chronic injury"]], "start": [["58", "59"], ["63", "64"]], "entity_id": [ ] } , "Freq": {"text": [["the wide variety"]], "start": [["87", "88"]], "entity_id": [ ] } , "Dosage": {"text": [["pathological entities"]], "start": [["106", "107"]], "entity_id": [ ] } , "Duration": {"text": [["that have subsequently emerged"]], "start": [["116", "117"]], "entity_id": [ ] } , "Combination": [{"Drug": {"text": [["nitrofurantoin"]], "start": [["41"]], "entity_id": [ ] } , "Trigger": {"text": [["induced"]], "start": [["42"]], "entity_id": [ ] } , "event_id": "C1", "event_type": "Adverse_event" } ] , "Time_elapsed": {"text": [["the previous classification"]], "start": [["1", "2"]], "entity_id": [ ] } , "Route": {"text": [["into"]], "start": [["53"]], "entity_id": [ ] } , "Drug": {"text": [["nitrofurantoin"]], "start": [["41"]], "entity_id": [ ] } } , "Negated": null, "Speculated": null, "Severity": null , "Subject": null , "Effect": null , "Trigger": null } ] }
{"id": "2369419_2", "context": "Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hepatitis with bridging fibrosis and reversible hepatic insufficiency"]], "start": [[ "0" ]], "entity_id": []}, "Subject": {"text": [["a woman"]], "start": [[ "63" ]], "entity_id": [] ,"Age": null, "Gender": {"text": [["a woman"]], "start": [[ "63" ]], "entity_id": [] }, "Population": null, "Race": null, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[ "117" ]], "entity_id": [] }}, "Treatment": {"text": [["methotrexate"]], "start": [[ "141" ]], "entity_id": [] ,"Drug": {"text": [["methotrexate"]], "start": [[ "141" ]], "entity_id": [] }, "Dosage": null, "Duration": null, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[ "117" ]], "entity_id": [] }, "Trigger": null, "Route": null, "Time_elapsed": null, "Freq": null ,"Combination": null }, "Effect": {"text": [["hepatitis with bridging fibrosis and reversible hepatic insufficiency"]], "start": [[ "0" ]], "entity_id": [] }, "Negated": null, "Speculated": null, "Severity": null }]}
{"id": "16116136_4", "context": "Primary CNS lymphoma regressed on withdrawal of MM", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["withdrawal"]], "start": [["on withdrawal of MM" , "MM" ]], "entity_id": [ ["T2"] ] ,"Drug": {"text": [["MM"]], "start": [["MM" ]], "entity_id": [ ["T1"] ]} ,"Disorder": {"text": [["Primary CNS lymphoma"]], "start": [[ "Primary CNS lymphoma" ]], "entity_id": [ ["T3"] ]} ,"Trigger": {"text": [["regressed"]], "start": [[ "regressed" ]], "entity_id": [ ["T4"] ]} ,"Freq": {"text": [["on withdrawal"]], "start": [[ "on withdrawal" ]], "entity_id": [ ["T5"] ]} ,"Duration": null ,"Dosage": null ,"Route": null ,"Time_elapsed": null ,"Combination": null} ,"Subject": null ,"Negated": null ,"Speculated": null ,"Severity": null ,"Effect": null ,"Trigger": null}]}
{"id": "6498095_2","context": "Pemphigus foliaceus induced by rifampicin","is_mult_event": false,"annotations": [{"event_id": "E1","event_type": "Adverse_event","Trigger": {"text": [["Pemphigus foliaceus"]],"start": [[ ]],"entity_id": [ ]},"Treatment": {"text": [["rifampicin"]],"start": [[ ]],"entity_id": [ ],"Drug": {"text": [["rifampicin"]],"start": [[ ]],"entity_id": [ ]},"Combination": [{"Drug": {"text": [["rifampicin"]],"start": [[ ]],"entity_id": [ ]},"Trigger": {"text": [["induced by"]],"start": [[ ]],"entity_id": [ ]},"event_id": "E1-C1","event_type": "Adverse_event"}],"Disorder": {"text": [["Pemphigus foliaceus"]],"start": [[ ]],"entity_id": [ ]},"Time_elapsed": {"text": [],"start": [],"entity_id": [] },"Dosage": {"text": [],"start": [],"entity_id": [] },"Duration": {"text": [],"start": [],"entity_id": [] },"Route": {"text": [],"start": [],"entity_id": [] },"Freq": {"text": [],"start": [],"entity_id": [] },"Trigger": { "text": [],"start": [],"entity_id": [] }},"Negated": null,"Speculated": null,"Severity": { "text": [],"start": [],"entity_id": [] ,"value": "Low" },"Subject": {"text": [],"start": [],"entity_id": [] ,"Age": null,"Disorder": null,"Gender": null,"Population": null,"Race": null },"Effect": { "text": [],"start": [],"entity_id": [] }}] }
{"id": "2931445_3", "context": "L-T4 stimulated lymphocyte transformation in this patient", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Potential_therapeutic_effect", "Treatment": {"text": [["L-T4"]], "start": [["0"]], "entity_id": [], "Drug": {"text": [["L-T4"]], "start": [["0"]], "entity_id": []}, "Disorder": {"text": [["lymphocyte transformation"]], "start": [["18"]], "entity_id": []}, "Trigger": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Freq": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Time_elapsed": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Duration": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Route": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Dosage": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}, "Combination": null}, "Subject": {"text": [["this patient"]], "start": [["44"]], "entity_id": [], "Age": null, "Gender": null, "Population": null, "Race": null, "Disorder": null}, "Negated": null, "Speculated": null, "Severity": null, "Effect": null, "Trigger": {"text": [["stimulated"]], "start": [["13"]], "entity_id": []}}]}
{"id": "12126225_1", "context": "A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day", "is_mult_event": false, "annotations": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lower leg edema"]], "start": [["32"]], "entity_id": []}, "Treatment": {"text": [["rosiglitazone"]], "start": [["103"]], "entity_id": [], "Dosage": {"text": [["4 mg once/day to 4 mg twice/day"]], "start": [["73"]], "entity_id": []}, "Duration": {"text": [["4 weeks"]], "start": [["53"]], "entity_id": []}, "Route": {"text": [["was increased"]], "start": [["68"]], "entity_id": []}, "Time_elapsed": {"text": [["4 weeks"]], "start": [["53"]], "entity_id": []}, "Disorder": {"text": [["lower leg edema"]], "start": [["32"]], "entity_id": []}, "Drug": {"text": [["rosiglitazone"]], "start": [["103"]], "entity_id": []}, "Freq": {"text": [["twice/day"]], "start": [["91"]], "entity_id": []}, "Trigger": {"text": [["was increased"]], "start": [["68"]], "entity_id": []}, "Combination": []},"Subject": {"text": [["A 53-year-old man"]], "start": [["0"]], "entity_id": [], "Age": {"text": [["53"]], "start": [["1"]], "entity_id": []}, "Gender": {"text": [["man"]], "start": [["10"]], "entity_id": []}, "Population": {"text": [["A 53-year-old man"]], "start": [["0"]], "entity_id": []}, "Race": {"text": [], "start": [], "entity_id": []}, "Disorder": {"text": [], "start": [], "entity_id": []}},"Negated": null, "Speculated": null, "Severity": null, "Effect": {"text": [["lower leg edema"]], "start": [["32"]], "entity_id": []}}]}
{"id": "12086549_1","context": "After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia","is_mult_event": true,"annotations": [{"event_type": "Potential_therapeutic_effect","event_id": "E1","Treatment": {"text": [["IL-2"]],"start": [["21"]],"entity_id": [["T1"]],"Drug": {"text": [["IL-2"]],"start": [["21"]],"entity_id": [["T2"]]},"Duration": {"text": [["5 days"]],"start": [["7"]],"entity_id": [["T3"]]},"Disorder": {"text": [["toxic epidermal necrolysis"]],"start": [["54"]],"entity_id": [["T4"]]},"Trigger": {"text": [["developed"]],"start": [["41"]],"entity_id": [["T5"]]},"Time_elapsed": {"text": [["5 days"]],"start": [["7"]],"entity_id": [["T6"]]},"Freq": {"text": [[" "]],"start": [[""],[""]],"entity_id": [["T7"]]},"Dosage": {"text": [[" "]],"start": [[""],[""]],"entity_id": [["T8"]]},"Route": {"text": [["of"]],"start": [["17"]],"entity_id": [["T9"]]},"Combination": null},"Effect": {"text": [["hemorrhagic lesion","grade 4 pancytopenia"]],"start": [["54","82"]],"entity_id": [["T10","T11"]]},"Negated": null,"Speculated": null,"Severity": {"text": [["grade 4"]],"start": [["78"]],"entity_id": [["T12"]],"value": "high"},"Subject": {"text": [["the patient"]],"start": [["30"]],"entity_id": [["T13"]],"Age": null,"Gender": null,"Population": null,"Race": null,"Disorder": {"text": [["toxic epidermal necrolysis","grade 4 pancytopenia"]],"start": [["54","82"]],"entity_id": [["T10","T11"]]}},"Trigger": {"text": [["developed"]],"start": [["41"]],"entity_id": [["T14"]]}}]}
